The	O
saline	O
lavage	O
procedure	O
caused	O
progressive	O
development	B-PROC
of	O
shunt	O
flow	O
(	O
approximately	O
22	O
%)	O
and	O
perfusion	O
of	O
low	O
V	O
A	O
/	O
Q	O
areas	O
(	O
approximately	O
7	O
%),	O
associated	O
with	O
severe	O
V	O
A	O
/	O
Q	O
mismatch	O
.	O

The	O
contributions	O
of	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	O
in	O
the	O
pathogenesis	B-PROC
of	O
the	O
disease	O
were	O
investigated	O
.	O

Both	O
chimeric	O
S	O
proteins	O
appeared	O
to	O
cause	O
cell	B-PROC
fusion	I-PROC
when	O
expressed	B-PROC
individually	O
,	O
suggesting	O
that	O
they	O
were	O
biologically	O
fully	O
active	O
.	O

CONCLUSIONS	O
:	O
Respiratory	B-PROC
mechanics	I-PROC
during	O
PLV	O
for	O
dependent	O
lung	O
-	O
dominant	O
lung	O
injury	O
were	O
optimal	O
at	O
a	O
PFC	O
dose	O
less	O
than	O
the	O
FRC	B-PROC
.	O

TITLE	O
:	O
Pregnancy	O
outcomes	O
in	O
healthy	O
nulliparas	B-PROC
who	O
developed	O
hypertension	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
maternal	O
and	O
perinatal	O
outcomes	O
in	O
nulliparas	B-PROC
with	O
pregnancy	O
-	O
associated	O
hypertension	O
or	O
preeclampsia	O
.	O

It	O
associates	O
with	O
both	O
viral	O
genomic	O
RNA	O
and	O
subgenomic	O
mRNAs	O
and	O
has	O
structural	O
and	O
non	O
-	O
structural	O
roles	O
in	O
replication	O
including	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
transcription	B-PROC
,	O
genome	O
replication	O
,	O
encapsidation	O
and	O
translation	B-PROC
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
cleavage	B-PROC
activity	O
of	O
the	O
first	O
papain	O
-	O
like	O
proteinase	B-PROC
domain	O
encoded	O
by	O
open	O
reading	O
frame	O
1a	O
of	O
the	O
coronavirus	O
Avian	O
infectious	O
bronchitis	O
virus	O
and	O
characterization	O
of	O
the	O
cleavage	B-PROC
products	O
.	O

Previously	O
we	O
identified	O
the	O
first	O
cleavage	B-PROC
event	O
as	O
proteolysis	B-PROC
at	O
the	O
Gly	O
(	O
673	O
)-	O
Gly	O
(	O
674	O
)	O
dipeptide	O
bond	O
mediated	O
by	O
the	O
first	O
papain	O
-	O
like	O
proteinase	B-PROC
domain	O
(	O
PLPD	O
-	O
1	O
)	O
to	O
release	O
an	O
87	O
-	O
kDa	O
mature	O
protein	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
a	O
novel	O
cleavage	B-PROC
activity	O
of	O
PLPD	O
-	O
1	O
.	O

Expression	B-PROC
,	O
deletion	O
,	O
and	O
mutagenesis	B-PROC
studies	O
showed	O
that	O
the	O
product	O
encoded	O
between	O
nucleotides	O
2548	O
and	O
8865	O
was	O
further	O
cleaved	O
by	O
PLPD	O
-	O
1	O
at	O
the	O
Gly	O
(	O
2265	O
)-	O
Gly	O
(	O
2266	O
)	O
dipeptide	O
bond	O
to	O
release	O
an	O
N	O
-	O
terminal	O
195	O
-	O
kDa	O
and	O
a	O
C	O
-	O
terminal	O
41	O
-	O
kDa	O
cleavage	B-PROC
product	O
.	O

Glycosidase	O
digestion	B-PROC
and	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
studies	O
of	O
the	O
41	O
-	O
kDa	O
protein	O
demonstrated	O
that	O
it	O
is	O
modified	O
by	O
N	O
-	O
linked	O
glycosylation	B-PROC
at	O
the	O
Asn	O
(	O
2313	O
)	O
residue	O
encoded	O
by	O
nucleotides	O
7465	O
to	O
7467	O
.	O

The	O
parental	O
virus	O
was	O
found	O
to	O
have	O
an	O
increased	O
resistance	B-PROC
to	O
the	O
detergent	O
octylglucoside	O
compared	O
to	O
the	O
HAD	O
mutants	O
.	O

Even	O
when	O
feline	O
macrophages	O
were	O
pretreated	O
with	O
MAb	O
FK50	O
-	O
4	O
prior	O
to	O
FIPV	O
inoculation	O
,	O
this	O
antibody	B-PROC
prevented	O
FIPV	O
infection	O
.	O

Finally	O
,	O
electron	O
microscopic	O
studies	O
demonstrated	O
that	O
expression	B-PROC
of	O
the	O
E	O
protein	O
in	O
cells	O
induced	O
the	O
formation	B-PROC
of	O
characteristic	O
membrane	O
structures	O
also	O
observed	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
cells	O
,	O
apparently	O
consisting	O
of	O
masses	O
of	O
tubular	O
,	O
smooth	O
,	O
convoluted	O
membranes	O
.	O

TITLE	O
:	O
Initial	O
severity	O
of	O
metabolic	B-PROC
acidosis	O
predicts	O
the	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
in	O
severely	O
traumatized	O
patients	O
.	O

Parameters	O
of	O
oxygenation	B-PROC
,	O
lung	O
mechanics	O
,	O
and	O
hemodynamics	B-PROC
were	O
determined	O
in	O
both	O
the	O
supine	O
and	O
prone	O
positions	O
.	O

Analysis	O
was	O
performed	O
in	O
bronchoalveolar	O
lavage	O
fluids	O
(	O
BALF	O
)	O
of	O
patients	O
with	O
ARDS	O
triggered	O
by	O
nonpulmonary	O
underlying	O
events	O
in	O
the	O
absence	O
of	O
lung	O
infection	O
(	O
ARDS	O
;	O
n	O
=	O
25	O
),	O
pneumonia	O
demanding	O
mechanical	O
ventilation	O
(	O
PNEU	O
-	O
vent	O
;	O
n	O
=	O
114	O
),	O
spontaneously	O
breathing	B-PROC
patients	O
with	O
pneumonia	O
(	O
PNEU	O
-	O
spon	O
;	O
n	O
=	O
40	O
),	O
and	O
ARDS	O
in	O
combination	O
with	O
lung	O
infection	O
(	O
ARDS	O
+	O
PNEU	O
;	O
n	O
=	O
43	O
);	O
comparison	O
with	O
healthy	O
control	O
subjects	O
(	O
n	O
=	O
35	O
)	O
was	O
performed	O
.	O

We	O
conclude	O
that	O
inhaled	B-PROC
NO	O
is	O
effective	O
in	O
improving	O
oxygenation	B-PROC
in	O
patients	O
with	O
ARDS	O
.	O

ECLS	O
provides	O
life	O
support	O
in	O
severe	O
respiratory	O
failure	O
in	O
children	O
,	O
allowing	O
time	O
for	O
injured	O
lungs	O
to	O
recover	B-PROC
.	O

Severe	O
facial	O
or	O
upper	O
chest	O
wall	O
pressure	O
necrosis	B-PROC
developed	O
in	O
two	O
patients	O
,	O
despite	O
extensive	O
padding	O
and	O
careful	O
attention	O
to	O
skin	O
care	O
.	O

A	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
secretion	B-PROC
of	O
IFN	O
by	O
both	O
Mphi	O
and	O
L929	O
cells	O
incubated	O
with	O
cocaine	O
,	O
with	O
a	O
concomitant	O
decrease	O
in	O
virus	B-PROC
replication	I-PROC
,	O
is	O
also	O
reported	O
.	O

Charts	O
of	O
consecutive	O
ARDS	O
patients	O
(	O
lung	O
injury	O
score	O
>	O
2	O
)	O
during	O
a	O
2	O
-	O
yr	O
period	O
,	O
tested	O
for	O
both	O
inhaled	B-PROC
NO	O
and	O
prone	O
positioning	O
efficacy	O
were	O
retrospectively	O
reviewed	O
.	O

An	O
increase	O
in	O
variations	O
in	O
the	O
Pao2	O
/	O
Fio2	O
ratio	O
of	O
>	O
15	O
torr	O
was	O
associated	O
with	O
prone	O
positioning	O
in	O
16	O
patients	O
(	O
59	O
%)	O
and	O
with	O
NO	O
inhalation	B-PROC
in	O
13	O
patients	O
(	O
48	O
%)	O
(	O
not	O
significant	O
).	O

Neutrophils	O
and	O
platelets	O
are	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
acute	O
respiratory	O
failure	O
.	O

The	O
combination	O
of	O
PLA2	O
and	O
trypsin	O
decreased	O
Pao2	O
,	O
lung	B-PROC
compliance	I-PROC
,	O
and	O
peripheral	O
counts	O
of	O
neutrophils	O
and	O
platelets	O
and	O
increased	O
alveolar	O
/	O
arterial	O
oxygen	B-PROC
tension	I-PROC
difference	O
,	O
lung	O
resistance	B-PROC
,	O
wet	O
weight	O
/	O
dry	O
weight	O
ratio	O
,	O
and	O
the	O
number	O
of	O
neutrophils	O
in	O
the	O
lung	O
.	O

The	O
polyproteins	O
are	O
cotranslationally	O
processed	O
by	O
viral	O
proteinases	O
into	O
at	O
least	O
15	O
mature	O
proteins	O
,	O
including	O
four	O
predicted	O
cleavage	B-PROC
products	O
of	O
less	O
than	O
25	O
kDa	O
that	O
together	O
would	O
comprise	O
the	O
final	O
59	O
kDa	O
of	O
protein	O
translated	O
from	O
open	O
reading	O
frame	O
1a	O
.	O

No	O
patient	O
demonstrated	O
normal	O
sleep	B-PROC
.	O

Severe	O
sleep	B-PROC
fragmentation	O
was	O
reflected	O
by	O
a	O
high	O
frequency	O
of	O
arousals	O
(	O
20	O
+/-	O

ABSTRACT	O
:	O
Various	O
strains	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
cause	O
respiratory	O
,	O
kidney	O
,	O
enteric	O
and	O
reproductive	B-PROC
illnesses	O
in	O
chickens	O
,	O
especially	O
in	O
newly	O
hatched	O
chicks	O
.	O

In	O
vitro	O
expression	B-PROC
of	O
ORF	O
3b	O
from	O
Purdue	O
mRNA	O
3	O
-	O
like	O
transcripts	O
did	O
not	O
fully	O
conform	O
to	O
a	O
predicted	O
leaky	O
scanning	O
pattern	O
,	O
suggesting	O
ribosomes	O
might	O
also	O
be	O
entering	O
internally	O
.	O

There	O
was	O
no	O
variation	O
in	O
the	O
isotype	O
-	O
specific	O
BCV	O
antibody	B-PROC
titres	O
between	O
healthy	O
quarters	O
of	O
the	O
same	O
udder	O
,	O
but	O
subclinical	O
mastitis	O
was	O
associated	O
with	O
higher	O
levels	O
of	O
IgA	O
antibodies	O
and	O
weak	O
false	O
IgM	O
positive	O
reactions	O
in	O
undiluted	O
milk	O
.	O

The	O
activation	O
of	O
specific	O
and	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
T	O
lymphocytes	O
by	O
both	O
virus	O
and	O
anti	O
-	O
Id	O
in	O
immunized	O
mice	O
and	O
the	O
absence	O
of	O
adoptive	O
transfer	O
of	O
protection	O
by	O
splenocytes	O
suggested	O
the	O
participation	O
of	O
T	O
helper	O
activity	O
in	O
the	O
induction	O
of	O
protective	O
virus	O
-	O
neutralizing	O
Ab3	O
.	O

Reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
and	O
cycle	O
sequencing	O
techniques	O
were	O
used	O
to	O
elucidate	O
the	O
genetic	O
and	O
deduced	O
amino	O
acid	O
relationships	O
among	O
the	O
isolates	O
.	O

One	O
died	B-PROC
of	O
sepsis	O
,	O
and	O
the	O
other	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
without	O
a	O
recovery	O
in	O
bone	O
marrow	O
.	O

A	O
low	O
concentration	O
of	O
mature	O
neutrophils	O
in	O
the	O
systemic	O
circulation	B-PROC
of	O
premature	O
infants	O
within	O
2	O
hours	O
of	O
birth	B-PROC
is	O
associated	O
with	O
more	O
severe	O
respiratory	O
distress	O
during	O
the	O
first	O
postnatal	O
week	O
and	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
complications	O
of	O
prematurity	O
.	O

CONCLUSIONS	O
:	O
A	O
low	O
concentration	O
of	O
mature	O
neutrophils	O
in	O
the	O
systemic	O
circulation	B-PROC
of	O
premature	O
infants	O
within	O
2	O
hours	O
of	O
birth	B-PROC
is	O
associated	O
with	O
more	O
severe	O
respiratory	O
distress	O
during	O
the	O
first	O
postnatal	O
week	O
and	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
complications	O
of	O
prematurity	O
.	O

We	O
have	O
explored	O
the	O
caspase	B-PROC
activation	I-PROC
events	O
that	O
are	O
initiated	O
upon	O
infection	O
of	O
the	O
human	O
rectal	O
tumor	O
cell	O
line	O
HRT18	O
with	O
TGEV	O
.	O

TITLE	O
:	O
Subgenomic	O
negative	O
-	O
strand	O
RNA	O
function	O
during	O
mouse	O
hepatitis	O
virus	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Programmed	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
has	O
become	O
the	O
subject	O
of	O
increasing	O
interest	O
over	O
the	O
last	O
several	O
years	O
,	O
due	O
in	O
part	O
to	O
the	O
ubiquitous	O
nature	O
of	O
this	O
translational	B-PROC
recoding	O
mechanism	O
in	O
pathogenic	O
animal	O
and	O
plant	O
viruses	O
.	O

These	O
studies	O
are	O
summarized	O
here	O
and	O
provide	O
new	O
insights	O
into	O
the	O
structural	O
requirements	O
and	O
mechanism	O
of	O
programmed	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
.	O

The	O
majority	O
of	O
scientists	O
consider	O
disorders	O
in	O
the	O
ventilation	O
-	O
perfusion	O
function	O
of	O
the	O
lungs	O
the	O
main	O
factor	O
in	O
the	O
pathogenesis	B-PROC
of	O
burn	O
shock	O
.	O

Comparison	O
of	O
the	O
main	O
and	O
control	O
groups	O
demonstrated	O
the	O
efficiency	O
of	O
early	O
respiratory	O
therapy	O
in	O
children	O
with	O
severe	O
burns	O
,	O
because	O
such	O
therapy	O
normalizes	O
the	O
blood	O
oxygen	O
transporting	O
function	O
and	O
hemodynamic	B-PROC
parameters	O
sooner	O
and	O
with	O
less	O
strain	O
for	O
the	O
compensatory	O
potential	O
of	O
the	O
organism	O
.	O

Comparison	O
with	O
a	O
first	O
-	O
generation	O
adenovirus	O
carrying	O
the	O
same	O
mIFN	O
-	O
alpha2	O
expression	B-PROC
cassette	O
indicates	O
that	O
at	O
certain	O
HD	O
-	O
IFN	O
doses	O
,	O
induction	O
of	O
antiviral	O
genes	O
can	O
be	O
achieved	O
in	O
the	O
absence	O
of	O
detectable	O
circulating	O
mIFN	O
-	O
alpha2	O
.	O

ABSTRACT	O
:	O
Swine	O
influenza	O
virus	O
(	O
SIV	O
),	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
and	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
are	O
enzootic	O
viruses	O
causing	O
pulmonary	O
infections	O
in	O
pigs	O
.	O

Individual	O
assessments	O
showed	O
no	O
relationship	O
between	O
the	O
PaO2	O
/	O
FIO2	O
evolution	B-PROC
at	O
any	O
time	O
and	O
the	O
quantity	O
of	O
secretions	O
obtained	O
during	O
the	O
first	O
2	O
hours	O
in	O
the	O
prone	O
position	O
.	O

Admission	O
and	O
serial	O
carboxyhemoglobin	O
levels	O
,	O
blood	B-PROC
gases	I-PROC
,	O
and	O
computerized	O
tomography	O
of	O
the	O
chest	O
were	O
obtained	O
.	O

Smoke	O
inhalation	B-PROC
and	O
carbon	O
monoxide	O
poisoning	O
may	O
lead	O
to	O
life	O
-	O
threatening	O
hypoxemia	O
associated	O
with	O
resultant	O
cardiovascular	O
instability	O
.	O

There	O
are	O
trends	O
toward	O
decreases	O
in	O
CLD	O
in	O
survivors	O
at	O
28	O
-	O
30	O
days	O
,	O
'	B-PROC
death	I-PROC
or	O
CLD	O
at	O
28	O
-	O
30	O
days	O
'	O
and	O
CLD	O
in	O
survivors	O
at	O
36	O
-	O
37	O
weeks	O
postmenstrual	O
age	O
or	O
discharge	O
in	O
the	O
HFOV	O
group	O
.	O

A	O
trend	O
toward	O
risk	O
reduction	O
for	O
bronchopulmonary	O
dysplasia	O
or	O
death	B-PROC
at	O
28	O
days	O
was	O
also	O
evident	O
(	O
Typical	O
RR	O
0	O
.	O
94	O
,	O
95	O
%	O
CI	O
0	O
.	O
88	O
,	O
1	O
.	O
00	O
;	O
Typical	O
RD	O
-	O
0	O
.	O
04	O
,	O
95	O
%	O
CI	O
-	O
0	O
.	O
07	O
,	O
-	O
0	O
.	O
00	O
).	O

ABSTRACT	O
:	O
Rapid	O
progressive	O
encephalopathy	O
with	O
a	O
high	O
fever	B-PROC
,	O
consciousness	O
loss	O
and	O
recurrent	O
convulsions	O
has	O
been	O
occasionally	O
reported	O
in	O
children	O
during	O
influenza	O
pandemics	O
in	O
Japan	O
since	O
1995	O
.	O

The	O
cattle	O
with	O
HI	O
antibody	B-PROC
titers	O
of	O
>	O
or	O
=	O
160	O
and	O
the	O
SN	O
titers	O
of	O
>	O
or	O
=	O
640	O
showed	O
no	O
clinical	O
signs	O
,	O
but	O
the	O
cattle	O
with	O
the	O
HI	O
antibody	B-PROC
titer	O
<	O
80	O
and	O
the	O
SN	O
antibody	B-PROC
titer	O
<	O
160	O
developed	O
watery	O
diarrhea	O
and	O
fever	B-PROC
after	O
challenge	O
.	O

Two	O
classical	O
models	O
of	O
acute	B-PROC
inflammatory	I-PROC
response	I-PROC
induced	O
in	O
laboratory	O
animals	O
,	O
the	O
Arthus	O
and	O
Shwartzman	O
reactions	O
,	O
could	O
explain	O
the	O
pathogenesis	B-PROC
of	O
the	O
severe	O
lung	O
lesions	O
that	O
characterize	O
PP	O
.	O

ABSTRACT	O
:	O
To	O
present	O
the	O
use	O
of	O
a	O
novel	O
high	O
-	O
pressure	O
recruitment	O
maneuver	O
followed	O
by	O
high	O
levels	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
a	O
patient	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

A	O
total	O
of	O
1295	O
adults	O
who	O
died	B-PROC
during	O
hospitalization	O
for	O
ARF	O
or	O
MOSF	O
.	O

SUPPORT	O
enrolled	O
2956	O
patients	O
with	O
ARF	O
or	O
MOSF	O
,	O
and	O
44	O
%	O
died	B-PROC
during	O
enrollment	O
hospitalization	O
.	O

The	O
average	O
time	O
from	O
the	O
DNR	O
order	O
to	O
death	B-PROC
was	O
2	O
days	O
.	O

Surrogates	O
indicated	O
that	O
one	O
out	O
of	O
four	O
patients	O
died	B-PROC
with	O
severe	O
pain	O
and	O
one	O
out	O
of	O
three	O
with	O
severe	O
confusion	O
.	O

The	O
99	O
nt	O
overlap	O
between	O
ORF1a	O
and	O
ORF1b	O
contains	O
a	O
putative	O
AAAUUUU	O
'	O
slippery	O
'	O
sequence	O
associated	O
with	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
.	O

ECMO	O
was	O
used	O
for	O
183	O
hours	O
,	O
at	O
which	O
point	O
the	O
boy	O
was	O
weaned	B-PROC
without	O
complications	O
.	O

Nasal	O
swab	O
specimens	O
were	O
submitted	O
for	O
virus	O
isolation	O
and	O
bacterial	O
culture	O
;	O
blood	O
samples	O
were	O
submitted	O
for	O
measurement	O
of	O
respiratory	O
bovine	O
coronavirus	O
(	O
RBCV	O
)	O
hemagglutinin	O
inhibition	B-PROC
titers	O
.	O

Further	O
,	O
we	O
found	O
an	O
increased	O
number	O
of	O
PLM	O
(	O
368	O
),	O
PLM	O
/	O
h	O
of	O
time	O
in	O
bed	O
(	O
49	O
/	O
h	O
),	O
PLM	O
/	O
h	O
of	O
REM	B-PROC
sleep	B-PROC
(	O
11	O
),	O
PLM	O
/	O
h	O
of	O
non	O
-	O
REM	B-PROC
sleep	B-PROC
(	O
46	O
)	O
and	O
PLM	O
/	O
h	O
awake	O
(	O
61	O
).	O

Vaporisation	O
of	O
perfluorohexane	O
in	O
a	O
concentration	O
of	O
18	O
Vol	O
.%	O
of	O
inspired	B-PROC
gas	O
improved	O
significantly	O
oxygenation	B-PROC
and	O
lung	B-PROC
compliance	I-PROC
.	O

TITLE	O
:	O
Expression	B-PROC
of	O
reporter	O
genes	O
from	O
the	O
defective	O
RNA	O
CD	O
-	O
61	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
defective	O
RNA	O
(	O
D	O
-	O
RNA	O
)	O
CD	O
-	O
61	O
,	O
derived	O
from	O
the	O
Beaudette	O
strain	O
of	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
was	O
used	O
as	O
an	O
RNA	O
vector	O
for	O
the	O
expression	B-PROC
of	O
two	O
reporter	O
genes	O
,	O
luciferase	O
and	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
).	O

D	O
-	O
RNAs	O
expressing	O
the	O
CAT	O
gene	O
were	O
demonstrated	O
to	O
be	O
capable	O
of	O
producing	O
CAT	O
protein	O
in	O
a	O
helper	O
-	O
dependent	O
expression	B-PROC
system	O
to	O
about	O
1	O
.	O
6	O
microgram	O
per	O
10	O
(	O
6	O
)	O
cells	O
.	O

Samples	O
of	O
blood	O
and	O
respiratory	O
tract	O
secretions	O
were	O
sent	O
to	O
central	O
laboratories	O
for	O
antibody	B-PROC
testing	O
,	O
culture	O
,	O
DNA	O
testing	O
,	O
and	O
histopathological	O
analyses	O
.	O

Eighteen	O
patients	O
died	B-PROC
,	O
and	O
the	O
most	O
common	O
causes	O
of	O
death	B-PROC
were	O
pulmonary	O
emboli	O
and	O
infectious	O
bronchopneumonia	O
.	O

The	O
nucleocapsid	O
protein	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
was	O
dissected	O
into	O
12	O
fragments	O
and	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
.	O

Sera	O
against	O
Australia	O
T	O
,	O
China	O
Ch5	O
,	O
Singapore	O
P4	O
,	O
USA	O
M41	O
and	O
China	O
T3	O
isolates	O
were	O
used	O
to	O
study	O
the	O
conservation	O
and	O
localization	B-PROC
of	O
the	O
antigenic	O
region	O
on	O
the	O
IBV	O
nucleocapsid	O
protein	O
.	O

Thirty	O
-	O
one	O
(	O
31	O
)	O
formalin	O
-	O
fixed	O
hearts	O
from	O
domestic	O
cats	O
who	O
died	B-PROC
of	O
idiopathic	O
cardiomyopathy	O
were	O
randomly	O
selected	O
from	O
pathology	O
archives	O
.	O

PEEP	O
by	O
itself	O
does	O
not	O
have	O
a	O
consistent	O
effect	O
on	O
splanchnic	O
blood	B-PROC
flow	I-PROC
and	O
metabolism	B-PROC
when	O
cardiac	O
index	O
is	O
stable	O
and	O
patients	O
are	O
ventilated	O
within	O
the	O
linear	O
part	O
of	O
the	O
pv	O
curve	O
.	O

RESULTS	O
:	O
Respiratory	O
,	O
renal	O
,	O
and	O
hemodynamic	B-PROC
function	O
improved	O
immediately	O
in	O
all	O
3	O
patients	O
after	O
decompression	O
.	O

In	O
our	O
previous	O
studies	O
,	O
the	O
proteinase	B-PROC
was	O
identified	O
as	O
a	O
33	O
-	O
kDa	O
protein	O
in	O
IBV	O
-	O
infected	O
cells	O
,	O
and	O
its	O
catalytic	O
center	O
was	O
shown	O
to	O
consist	O
of	O
H	O
(	O
2820	O
)	O
and	O
C	O
(	O
2922	O
)	O
residues	O
.	O

Analysis	O
of	O
the	O
autoprocessing	O
kinetics	O
in	O
vitro	O
reveals	O
that	O
proteolysis	B-PROC
at	O
the	O
Q	O
(	O
2779	O
)-	O
S	O
(	O
2780	O
)	O
site	O
is	O
the	O
first	O
cleavage	B-PROC
event	O
mediated	O
by	O
this	O
proteinase	B-PROC
.	O

Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
represent	O
a	O
group	O
of	O
enzymes	O
involved	O
in	O
the	O
degradation	O
of	O
most	O
of	O
the	O
components	O
of	O
the	O
ECM	O
and	O
therefore	O
participate	O
in	O
tissue	B-PROC
remodeling	I-PROC
associated	O
with	O
pathological	O
situations	O
such	O
as	O
acute	O
lung	O
injury	O
.	O

Porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
),	O
a	O
spike	O
(	O
S	O
)	O
gene	O
natural	O
deletion	O
mutant	O
of	O
TGEV	O
,	O
has	O
a	O
respiratory	O
tissue	B-PROC
tropism	B-PROC
and	O
causes	O
mild	O
or	O
subclinical	O
respiratory	O
infections	O
.	O

The	O
study	O
identified	O
1617	O
English	O
-	O
and	O
Spanish	O
-	O
speaking	O
patients	O
with	O
cancer	O
or	O
human	O
immunodeficiency	O
virus	B-PROC
infection	I-PROC
or	O
acquired	O
immunodeficiency	O
syndrome	O
who	O
participated	O
in	O
a	O
multisite	O
validation	O
of	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
Scale	O
.	O

TITLE	O
:	O
Terbutaline	O
prevents	O
circulatory	B-PROC
failure	O
and	O
mitigates	O
mortality	O
in	O
rodents	O
with	O
endotoxemia	O
.	O

A	O
histidine	O
-	O
tagged	O
form	O
of	O
this	O
protein	O
,	O
HEL	O
,	O
was	O
expressed	B-PROC
using	O
baculovirus	O
vectors	O
in	O
insect	O
cells	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
p38	O
mitogen	O
activate	O
kinase	O
attenuates	O
the	O
severity	O
of	O
pancreatitis	O
-	O
induced	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

Pulmonary	O
TNF	O
-	O
alpha	B-PROC
protein	I-PROC
was	O
detected	O
by	O
immunohistochemistry	O
.	O

Patient	O
developed	O
rigor	O
,	O
chill	O
and	O
elevated	B-PROC
temperature	I-PROC
approximately	O
100	O
min	O
into	O
the	O
infusion	O
.	O

TITLE	O
:	O
Lactogenic	O
immunity	B-PROC
following	O
vaccination	O
of	O
cattle	O
with	O
bovine	O
coronavirus	O
.	O

To	O
date	O
,	O
two	O
of	O
the	O
MHV	O
replicase	O
-	O
encoded	O
proteinases	O
,	O
papain	O
-	O
like	O
proteinase	B-PROC
1	O
(	O
PLP1	O
)	O
and	O
the	O
poliovirus	O
3C	O
-	O
like	O
proteinase	B-PROC
(	O
3CLpro	O
),	O
have	O
been	O
shown	O
to	O
process	O
the	O
replicase	O
polyprotein	O
.	O

Pulse	B-PROC
-	O
chase	O
experiments	O
showed	O
that	O
p150	O
is	O
rapidly	O
generated	O
in	O
MHV	O
-	O
infected	O
cells	O
and	O
that	O
p44	O
is	O
processed	O
from	O
the	O
p150	O
precursor	O
.	O

The	O
M	O
protein	O
-	O
nucleocapsid	O
interaction	O
,	O
which	O
occurred	O
near	O
or	O
at	O
the	O
MHV	O
budding	B-PROC
site	O
,	O
most	O
probably	O
represented	O
the	O
process	O
of	O
specific	O
packaging	O
of	O
the	O
MHV	O
genome	O
into	O
MHV	O
particles	O
.	O

TITLE	O
:	O
The	O
T	O
cell	O
chemoattractant	O
IFN	O
-	O
inducible	O
protein	O
10	O
is	O
essential	O
in	O
host	B-PROC
defense	I-PROC
against	O
viral	O
-	O
induced	O
neurologic	O
disease	O
.	O

Recently	O
,	O
outbreaks	O
of	O
TGE	O
of	O
reduced	O
virulence	B-PROC
were	O
reported	O
in	O
the	O
field	O
.	O

TITLE	O
:	O
Down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
Bgp1	O
(	O
a	O
)	O
viral	O
receptor	O
by	O
interferon	O
-	O
gamma	O
is	O
related	O
to	O
the	O
antiviral	O
state	O
and	O
resistance	B-PROC
to	O
mouse	O
hepatitis	O
virus	O
3	O
infection	O
.	O

ABSTRACT	O
:	O
Together	O
with	O
the	O
evidence	O
that	O
the	O
reduced	O
virus	O
growth	B-PROC
and	O
the	O
antiviral	O
state	O
induced	O
by	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
,	O
occurring	O
only	O
in	O
macrophages	O
from	O
resistant	O
animals	O
,	O
correlated	O
with	O
the	O
decrease	O
of	O
MHV3	O
binding	O
to	O
macrophage	O
membrane	O
proteins	O
,	O
we	O
show	O
here	O
the	O
expression	B-PROC
of	O
cellular	O
and	O
viral	O
genes	O
in	O
resistant	O
(	O
A	O
/	O
J	O
)	O
and	O
susceptible	O
(	O
BALB	O
/	O
c	O
)	O
mouse	O
macrophages	O
after	O
IFN	O
-	O
gamma	O
activation	O
/	O
infection	O
.	O

The	O
expression	B-PROC
of	O
interferon	O
response	O
gene	O
47	O
and	O
interferon	O
regulatory	O
factor	O
1	O
genes	O
takes	O
place	O
after	O
IFN	O
-	O
gamma	O
activation	O
in	O
both	O
macrophages	O
,	O
indicating	O
their	O
activation	O
.	O

Nasal	O
swab	O
and	O
serum	O
samples	O
were	O
collected	O
prior	O
to	O
onset	O
of	O
the	O
epizootics	O
,	O
during	O
disease	O
progression	O
,	O
and	O
after	O
death	B-PROC
,	O
when	O
necropsies	O
were	O
performed	O
and	O
lung	O
samples	O
were	O
collected	O
.	O

TITLE	O
:	O
Heterogeneous	O
nuclear	O
ribonucleoprotein	O
A1	O
regulates	O
RNA	B-PROC
synthesis	I-PROC
of	O
a	O
cytoplasmic	O
virus	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
hnRNP	O
A1	O
also	O
participates	O
in	O
the	O
transcription	B-PROC
and	O
replication	O
of	O
a	O
cytoplasmic	O
RNA	O
virus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

The	O
hnRNP	O
A1	O
mutant	O
caused	O
a	O
global	O
inhibition	B-PROC
of	O
viral	O
mRNA	B-PROC
transcription	B-PROC
and	O
genomic	O
replication	O
,	O
and	O
also	O
a	O
preferential	O
inhibition	B-PROC
of	O
the	O
replication	O
of	O
defective	O
-	O
interfering	O
RNAs	O
.	O

Correction	O
of	O
the	O
metabolic	B-PROC
acidosis	O
by	O
insulin	O
therapy	O
resulted	O
in	O
intracellular	O
penetration	O
of	O
phosphate	O
and	O
potassium	O
,	O
causing	O
severe	O
hypophosphataemia	O
and	O
hypokaliaemia	O
responsible	O
for	O
ARD	O
.	O

The	O
28S	O
rRNA	O
cleavage	B-PROC
occurred	O
as	O
early	O
as	O
4	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.)	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
,	O
with	O
the	O
appearance	O
of	O
subsequent	O
cleavage	B-PROC
products	O
and	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
intact	O
28S	O
rRNA	O
with	O
increasing	O
times	O
of	O
infection	O
;	O
almost	O
all	O
of	O
the	O
intact	O
28S	O
rRNA	O
disappeared	O
by	O
24	O
h	O
p	O
.	O
i	O
.	O

Furthermore	O
,	O
28S	O
rRNA	O
cleavage	B-PROC
occurred	O
in	O
an	O
MHV	O
-	O
infected	O
mouse	O
embryonic	O
fibroblast	O
cell	O
line	O
derived	O
from	O
RNase	O
L	O
knockout	O
mice	O
.	O

In	O
MHV	O
-	O
infected	O
17Cl	O
-	O
1	O
cells	O
,	O
28S	O
rRNA	O
cleavage	B-PROC
preceded	O
DNA	B-PROC
fragmentation	I-PROC
by	O
at	O
least	O
18	O
h	O
.	O
Blockage	O
of	O
apoptosis	B-PROC
in	O
MHV	O
-	O
infected	O
17Cl	O
-	O
1	O
cells	O
by	O
treatment	O
with	O
a	O
caspase	O
inhibitor	O
did	O
not	O
block	O
28S	O
rRNA	O
cleavage	B-PROC
.	O

Based	O
on	O
similarities	O
in	O
genome	O
organization	O
and	O
protein	B-PROC
expression	B-PROC
,	O
the	O
arteriviruses	O
have	O
recently	O
been	O
grouped	O
together	O
with	O
the	O
coronaviruses	O
and	O
toroviruses	O
in	O
the	O
newly	O
established	O
order	O
Nidovirales	O
.	O

TITLE	O
:	O
The	O
arterivirus	O
replicase	O
is	O
the	O
only	O
viral	O
protein	O
required	O
for	O
genome	O
replication	O
and	O
subgenomic	O
mRNA	B-PROC
transcription	B-PROC
.	O

TITLE	O
:	O
[	O
Changes	O
in	O
emergency	O
visits	O
of	O
patients	O
infected	O
by	O
human	O
immunodeficiency	O
virus	O
since	O
the	O
widespread	O
use	O
of	O
protease	B-PROC
inhibitors	I-PROC
].	O

Sera	O
were	O
tested	O
for	O
antibodies	O
to	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
swine	O
influenza	O
virus	O
(	O
SIV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
pseudorabies	O
virus	O
,	O
Mycoplasma	O
hyopneumoniae	O
,	O
and	O
Actinobacillus	O
pleuropneumoniae	O
.	O

TITLE	O
:	O
Nascent	O
synthesis	B-PROC
of	O
leader	O
sequence	O
-	O
containing	O
subgenomic	O
mRNAs	O
in	O
coronavirus	O
genome	O
-	O
length	O
replicative	O
intermediate	O
RNA	O
.	O

Goat	O
anti	O
-	O
turkey	O
immunoglobulin	B-PROC
G	O
(	O
light	O
plus	O
heavy	O
chains	O
)	O
conjugated	O
with	O
horseradish	O
peroxidase	O
was	O
used	O
as	O
detector	O
antibody	B-PROC
.	O

Serum	O
samples	O
of	O
turkeys	O
experimentally	O
infected	O
with	O
TCV	O
collected	O
sequentially	O
from	O
1	O
to	O
63	O
days	O
postinfection	O
were	O
applied	O
to	O
the	O
established	O
antibody	B-PROC
-	O
capture	O
ELISA	O
using	O
IBV	O
antigens	O
.	O

The	O
nonfumigated	O
and	O
vaccinated	O
birds	O
(	O
NFV	O
)	O
revealed	O
less	O
injury	O
on	O
the	O
epithelial	O
surface	O
and	O
a	O
more	O
rapid	O
response	O
to	O
epithelial	O
regeneration	B-PROC
than	O
the	O
in	O
only	O
fumigated	O
animals	O
(	O
FNV	O
).	O

These	O
flocks	O
(	O
14	O
chicken	O
and	O
1	O
quail	O
)	O
were	O
experiencing	O
a	O
variety	O
of	O
IB	O
-	O
like	O
conditions	O
including	O
respiratory	O
disease	O
,	O
digestive	B-PROC
and	O
kidney	O
problems	O
,	O
and	O
drops	O
in	O
egg	O
production	O
.	O

TITLE	O
:	O
Hypoproteinemia	O
predicts	O
acute	O
respiratory	O
distress	O
syndrome	O
development	B-PROC
,	O
weight	O
gain	O
,	O
and	O
death	B-PROC
in	O
patients	O
with	O
sepsis	O
.	O

The	O
identification	O
of	O
water	O
channels	O
expressed	B-PROC
in	O
lung	O
,	O
together	O
with	O
the	O
high	O
water	O
permeabilities	O
,	O
suggest	O
a	O
potential	O
role	O
for	O
channel	O
-	O
mediated	O
water	O
movement	B-PROC
between	O
the	O
air	O
space	O
and	O
capillary	O
compartments	O
,	O
although	O
definitive	O
evidence	O
will	O
depend	O
on	O
the	O
results	O
of	O
transgenic	O
mouse	O
knock	O
-	O
out	O
studies	O
.	O

The	O
application	O
of	O
this	O
new	O
knowledge	O
regarding	O
salt	O
and	O
water	B-PROC
transport	B-PROC
in	O
alveolar	O
epithelium	O
in	O
relation	O
to	O
pathologic	O
conditions	O
has	O
been	O
successful	O
in	O
clinically	O
relevant	O
experimental	O
studies	O
,	O
as	O
well	O
as	O
in	O
a	O
few	O
clinical	O
studies	O
.	O

More	O
clinical	O
research	O
is	O
needed	O
to	O
evaluate	O
the	O
strategies	O
that	O
can	O
upregulate	O
alveolar	O
epithelial	B-PROC
fluid	I-PROC
transport	B-PROC
with	O
both	O
short	O
-	O
term	O
therapy	O
(	O
i	O
.	O
e	O
.,	O
beta	O
-	O
agonists	O
)	O
and	O
more	O
sustained	O
,	O
longer	O
-	O
term	O
effects	O
of	O
epithelial	O
mitogens	O
such	O
as	O
keratinocyte	O
growth	B-PROC
factor	O
.	O

ABSTRACT	O
:	O
Fibroblast	O
growth	B-PROC
factor	O
2	O
(	O
FGF2	O
)	O
is	O
an	O
excellent	O
candidate	O
to	O
regulate	O
remyelination	B-PROC
based	O
on	O
its	O
proposed	O
actions	O
in	O
oligodendrocyte	O
lineage	O
cell	B-PROC
development	B-PROC
in	O
conjunction	O
with	O
its	O
involvement	O
in	O
CNS	O
regeneration	B-PROC
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
possible	O
differences	O
between	O
Far	O
-	O
East	O
Asian	O
men	O
and	O
white	O
men	O
in	O
obstructive	O
sleep	B-PROC
apnea	O
syndrome	O
(	O
OSAS	O
).	O

This	O
deletion	O
effectively	O
eliminated	O
the	O
replication	O
of	O
the	O
DI	O
-	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)-	O
reporter	O
,	O
as	O
demonstrated	O
by	O
the	O
sensitive	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
.	O

The	O
approximately	O
30	O
-	O
kb	O
genome	O
,	O
coupled	O
with	O
regions	O
of	O
genomic	O
instability	O
,	O
has	O
hindered	O
the	O
development	B-PROC
of	O
a	O
full	O
-	O
length	O
infectious	O
cDNA	O
construct	O
.	O

The	O
most	O
frequent	O
symptom	O
was	O
oral	O
allergy	B-PROC
syndrome	O
(	O
n	O
=	O
14	O
),	O
but	O
two	O
patients	O
experienced	O
life	O
-	O
threatening	O
reactions	O
,	O
including	O
respiratory	O
symptoms	O
and	O
hypotension	O
.	O

The	O
most	O
common	O
foods	O
associated	O
with	O
melon	O
allergy	B-PROC
were	O
avocado	O
(	O
n	O
=	O
7	O
),	O
banana	O
(	O
n	O
=	O
7	O
),	O
kiwi	O
(	O
n	O
=	O
6	O
),	O
watermelon	O
(	O
n	O
=	O
6	O
),	O
and	O
peach	O
(	O
n	O
=	O
5	O
).	O

CONCLUSIONS	O
:	O
About	O
one	O
third	O
of	O
reported	O
reactions	O
to	O
melon	O
are	O
confirmed	O
by	O
means	O
of	O
DBPCFC	O
,	O
which	O
has	O
been	O
proven	O
to	O
be	O
the	O
most	O
reliable	O
procedure	O
in	O
the	O
diagnosis	O
of	O
clinical	O
fruit	O
allergy	B-PROC
.	O

Cells	O
were	O
co	O
-	O
infected	O
simultaneously	O
with	O
IBV	O
,	O
the	O
recombinant	O
FPV	O
(	O
rFPV	O
)	O
containing	O
the	O
D	O
-	O
RNA	O
sequence	O
and	O
a	O
second	O
rFPV	O
expressing	O
T7	O
RNA	O
polymerase	O
for	O
the	O
initial	O
expression	B-PROC
of	O
the	O
D	O
-	O
RNA	O
transcript	O
,	O
subsequently	O
rescued	O
by	O
helper	O
IBV	O
.	O

ABSTRACT	O
:	O
The	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
)	O
5B19	O
.	O
2	O
,	O
which	O
has	O
virus	O
-	O
neutralizing	O
and	O
fusion	O
inhibition	B-PROC
activities	O
,	O
binds	O
to	O
an	O
epitope	O
(	O
S2A	O
)	O
consisting	O
of	O
nine	O
hydrophobic	O
amino	O
acids	O
in	O
the	O
S2	O
subunit	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
.	O

Using	O
previously	O
described	O
BCV	O
primers	O
,	O
the	O
N	O
protein	O
gene	O
of	O
isolate	O
NC99	O
was	O
amplified	O
by	O
a	O
reverse	O
transcriptase	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
.	O

In	O
vitro	O
translation	B-PROC
study	O
confirmed	O
that	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
was	O
translated	O
from	O
mRNA5	O
-	O
1	O
,	O
which	O
encodes	O
the	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
5b	O
at	O
its	O
5	O
'-	O
end	O
,	O
indicating	O
that	O
mRNA5	O
-	O
1	O
is	O
a	O
functional	O
message	O
.	O

We	O
examined	O
by	O
confocal	O
microscopy	O
the	O
subcellular	O
localization	B-PROC
of	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
N	O
protein	O
both	O
in	O
the	O
absence	O
and	O
in	O
the	O
context	O
of	O
an	O
infected	O
cell	O
and	O
found	O
that	O
N	O
protein	O
localizes	O
both	O
to	O
the	O
cytoplasmic	O
and	O
nucleolar	O
compartments	O
.	O

Sixty	O
-	O
four	O
patients	O
with	O
either	O
the	O
HELLP	O
syndrome	O
(	O
n	O
=	O
32	O
)	O
or	O
severe	O
preeclampsia	O
but	O
absent	O
HELLP	O
syndrome	O
laboratory	O
test	O
results	O
(	O
n	O
=	O
32	O
),	O
admitted	O
at	O
<	O
or	O
=	O
28	O
.	O
0	O
weeks	O
'	O
gestation	B-PROC
between	O
July	O
1	O
,	O
1992	O
,	O
and	O
April	O
30	O
,	O
1999	O
,	O
were	O
studied	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
2	O
groups	O
with	O
respect	O
to	O
neonatal	O
death	B-PROC
(	O
11	O
%	O
vs	O
17	O
%),	O
respiratory	O
distress	O
syndrome	O
(	O
78	O
%	O
vs	O
86	O
%),	O
or	O
composite	O
neonatal	O
morbidity	O
.	O

ABSTRACT	O
:	O
Five	O
recombinant	O
porcine	O
adenoviruses	O
of	O
serotype	O
5	O
(	O
PAdV	O
-	O
5	O
)	O
carrying	O
the	O
full	O
-	O
length	O
or	O
the	O
5	O
'	O
2	O
.	O
2	O
kb	O
half	O
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
spike	O
(	O
S	O
)	O
gene	O
were	O
generated	O
by	O
homologous	B-PROC
recombination	B-PROC
in	O
E	O
.	O
coli	O
strain	O
BJ5183	O
cells	O
and	O
subsequent	O
transfection	B-PROC
of	O
swine	O
testicle	O
cells	O
.	O

The	O
HE	O
genes	O
of	O
wild	O
-	O
type	O
EBCV	O
strain	O
LY138	O
and	O
RBCV	O
strains	O
OK	O
-	O
0514	O
(	O
OK	O
)	O
and	O
LSU	O
-	O
94LSS	O
-	O
051	O
(	O
LSU	O
)	O
were	O
cloned	O
,	O
sequenced	O
and	O
transiently	O
expressed	B-PROC
in	O
COS	O
-	O
7	O
cells	O
.	O

Time	O
-	O
dependent	O
determination	O
of	O
the	O
AE	O
activity	O
of	O
purified	O
RBCV	O
OK	O
and	O
LSU	O
particles	O
showed	O
lower	O
AE	O
activity	O
at	O
39	O
degrees	O
C	O
than	O
at	O
37	O
degrees	O
C	O
,	O
whereas	O
the	O
purified	O
EBCV	O
LY	O
particles	O
retained	O
full	O
AE	O
activity	O
at	O
both	O
37	O
degrees	O
C	O
and	O
39	O
degrees	O
C	O
.	O
Transiently	O
expressed	B-PROC
RBCV	O
HE	O
exhibited	O
a	O
marked	O
reduction	O
of	O
AE	O
activity	O
after	O
40	O
min	O
of	O
assay	O
time	O
at	O
37	O
degrees	O
C	O
.	O
In	O
contrast	O
,	O
the	O
AE	O
activity	O
of	O
the	O
transiently	O
expressed	B-PROC
EBCV	O
HE	O
remained	O
stable	O
beyond	O
40	O
min	O
.	O

This	O
high	O
density	O
was	O
observed	O
only	O
when	O
TGEV	O
with	O
a	O
functional	O
sialic	O
acid	O
binding	B-PROC
activity	I-PROC
was	O
analyzed	O
.	O

However	O
,	O
when	O
neuraminidase	O
-	O
treated	O
virions	O
or	O
mutants	O
with	O
a	O
defective	O
sialic	O
acid	O
binding	B-PROC
activity	I-PROC
were	O
analyzed	O
,	O
the	O
S	O
protein	O
remained	O
in	O
the	O
supernatant	O
rather	O
than	O
in	O
the	O
pellet	O
fraction	O
.	O

Hemodynamic	B-PROC
evaluation	O
was	O
performed	O
5	O
to	O
60	O
minutes	O
after	O
the	O
VAI	O
was	O
initiated	O
or	O
after	O
the	O
MAE	O
.	O

Improved	O
prognosis	O
of	O
lung	O
transplantation	O
requires	O
the	O
development	B-PROC
of	O
new	O
immunosuppressive	O
agents	O
with	O
lower	O
risk	O
of	O
infection	O
and	O
chronic	O
rejection	O
observed	O
with	O
current	O
treatments	O
.	O

Although	O
of	O
interest	O
in	O
their	O
own	O
right	O
,	O
an	O
understanding	O
of	O
the	O
diverse	O
mechanisms	O
used	O
by	O
viruses	O
to	O
induce	O
demyelination	O
may	O
shed	O
light	O
into	O
the	O
etiology	O
and	O
pathogenesis	B-PROC
of	O
the	O
common	O
demyelinating	O
disorder	O
multiple	O
sclerosis	O
(	O
MS	O
).	O

This	O
suggests	O
that	O
demyelination	O
induced	O
by	O
viral	B-PROC
infections	I-PROC
can	O
result	O
from	O
:	O
1	O
)	O
a	O
direct	O
viral	B-PROC
infection	I-PROC
of	O
oligodendroglia	O
resulting	O
in	O
cell	B-PROC
death	I-PROC
with	O
degeneration	O
of	O
myelin	O
and	O
its	O
subsequent	O
removal	O
;	O
2	O
)	O
a	O
persistent	O
viral	B-PROC
infection	I-PROC
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
infectious	O
virus	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
normal	O
cellular	B-PROC
homeostasis	I-PROC
and	O
subsequent	O
oligodendroglial	O
death	B-PROC
;	O
3	O
)	O
a	O
vigorous	O
virus	O
-	O
specific	O
inflammatory	B-PROC
response	I-PROC
wherein	O
the	O
virus	O
replicates	O
in	O
a	O
cell	O
type	O
other	O
than	O
oligodendroglia	O
,	O
but	O
cytokines	O
and	O
other	O
immune	O
mediators	O
directly	O
damage	O
the	O
oligodendroglia	O
or	O
the	O
myelin	O
sheath	O
;	O
or	O
4	O
)	O
infection	O
initiates	O
activation	O
of	O
an	O
immune	B-PROC
response	I-PROC
specific	O
for	O
either	O
oligodendroglia	O
or	O
myelin	O
components	O
.	O

Alternatively	O
,	O
antigenic	O
epitopes	O
derived	O
from	O
the	O
viral	O
proteins	O
may	O
exhibit	O
sufficient	O
homology	O
to	O
host	O
components	O
that	O
the	O
immune	B-PROC
response	I-PROC
to	O
the	O
virus	O
activates	O
autoreactive	O
T	O
cells	O
,	O
i	O
.	O
e	O
.	O
molecular	B-PROC
mimicry	I-PROC
.	O

Our	O
study	O
suggests	O
that	O
increased	O
concentrations	O
of	O
vWf	O
:	O
Ag	O
in	O
plasma	O
are	O
predictive	O
of	O
the	O
development	B-PROC
of	O
ARDS	O
and	O
signal	O
poor	O
prognosis	O
in	O
patients	O
following	O
severe	O
trauma	O
.	O

Three	O
of	O
four	O
placebo	O
-	O
treated	O
patients	O
had	O
persistent	O
bacterial	O
growth	B-PROC
on	O
bronchoscopy	O
repeated	O
after	O
48	O
h	O
compared	O
with	O
2	O
of	O
10	O
filgrastim	O
-	O
treated	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
high	O
-	O
dose	O
almitrine	O
infusion	O
on	O
gas	O
exchange	O
and	O
right	B-PROC
ventricular	I-PROC
function	I-PROC
in	O
patients	O
with	O
severe	O
hypoxemia	O
related	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
decrease	O
in	O
right	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
induced	O
by	O
almitrine	O
was	O
correlated	O
with	O
the	O
baseline	O
MPAP	O
.	O

Astroviruses	O
are	O
often	O
shed	O
in	O
stools	O
during	O
long	O
periods	B-PROC
and	O
can	O
be	O
detected	O
by	O
electron	O
microscopy	O
.	O

These	O
vaccines	O
induced	O
sustained	O
antibody	B-PROC
responses	I-PROC
against	O
ND	O
and	O
IB	O
.	O

Patients	O
who	O
had	O
received	O
inhaled	B-PROC
nitric	O
oxide	O
as	O
part	O
of	O
their	O
intensive	O
care	O
treatment	O
for	O
severe	O
hypoxaemia	O
and	O
/	O
or	O
pulmonary	O
hypertension	O
,	O
and	O
in	O
whom	O
6	O
mo	O
had	O
elapsed	O
since	O
treatment	O
,	O
were	O
included	O
for	O
evaluation	O
.	O

Thus	O
36	O
paediatric	O
or	O
neonatal	O
patients	O
were	O
examined	O
for	O
circulatory	B-PROC
,	O
respiratory	O
or	O
neurological	O
disorders	O
with	O
clinical	O
examination	O
,	O
echocardiography	O
,	O
chest	O
X	O
-	O
ray	O
and	O
a	O
capillary	O
blood	O
sample	O
.	O

The	O
few	O
residual	O
circulatory	B-PROC
and	O
respiratory	O
symptoms	O
could	O
be	O
related	O
to	O
the	O
initial	O
condition	O
.	O

In	O
nine	O
cases	O
,	O
Hellp	O
occurred	O
before	O
32	O
weeks	O
of	O
gestation	B-PROC
and	O
later	O
in	O
two	O
other	O
cases	O
.	O

Six	O
perinatal	O
deaths	B-PROC
were	O
related	O
to	O
abruptio	O
placenta	O
,	O
intrauterine	O
asphyxia	O
and	O
extreme	O
prematurity	O
.	O

Six	O
perinatal	O
deaths	B-PROC
were	O
related	O
to	O
abruptio	O
placenta	O
,	O
intrauterine	O
asphyxia	O
and	O
extreme	O
prematurity	O
.	O

Viral	B-PROC
shedding	I-PROC
may	O
be	O
intermittent	O
.	O

The	O
absence	O
of	O
PMN	B-PROC
in	O
the	O
peritoneum	O
was	O
due	O
in	O
part	O
to	O
lysis	B-PROC
of	O
intraperitoneal	O
PMN	B-PROC
,	O
because	O
the	O
peritoneal	O
fluids	O
contained	O
free	O
myeloperoxidase	O
and	O
induced	O
rapid	O
death	B-PROC
of	O
normal	O
rabbit	O
PMN	B-PROC
in	O
vitro	O
.	O

This	O
virus	O
encodes	O
spike	O
(	O
S	O
)	O
glycoproteins	O
that	O
are	O
extraordinarily	O
effective	O
mediators	O
of	O
intercellular	O
membrane	B-PROC
fusion	I-PROC
,	O
unique	O
in	O
their	O
ability	O
to	O
initiate	O
fusion	O
even	O
without	O
prior	O
interaction	O
with	O
the	O
primary	O
MHV	O
receptor	O
,	O
a	O
murine	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecule	O
(	O
CEACAM	O
).	O

TITLE	O
:	O
Virus	O
-	O
neutralizing	O
monoclonal	O
antibody	B-PROC
expressed	B-PROC
in	O
milk	O
of	O
transgenic	O
mice	O
provides	O
full	O
protection	O
against	O
virus	O
-	O
induced	O
encephalitis	O
.	O

This	O
demonstrates	O
that	O
a	O
single	O
neutralizing	O
antibody	B-PROC
expressed	B-PROC
in	O
the	O
milk	O
of	O
transgenic	O
mice	O
is	O
sufficient	O
to	O
completely	O
protect	O
suckling	O
offspring	O
against	O
MHV	O
-	O
JHM	O
-	O
induced	O
encephalitis	O
.	O

ABSTRACT	O
:	O
Archived	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
25	O
pigs	O
naturally	O
infected	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
were	O
examined	O
by	O
in	O
situ	O
hybridization	B-PROC
for	O
TGEV	O
nucleic	O
acid	O
using	O
a	O
nonradioactive	O
digoxigenin	O
-	O
labeled	O
cDNA	O
probe	O
that	O
targeted	B-PROC
the	O
nucleocapsid	O
sequence	O
of	O
TGEV	O
strains	O
.	O

TITLE	O
:	O
[	O
10	O
years	O
experience	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
].	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
member	O
of	O
the	O
Coronaviridae	O
,	O
contains	O
a	O
polyadenylated	O
positive	O
-	O
sense	B-PROC
single	O
-	O
stranded	O
genomic	O
RNA	O
which	O
is	O
31	O
kb	O
long	O
.	O

Serum	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
were	O
assayed	O
at	O
1	O
and	O
4	O
hours	O
after	O
the	O
injury	O
stimuli	O
.	O

Among	O
the	O
colloids	O
,	O
albumin	O
offers	O
several	O
advantages	O
compared	O
with	O
artificial	O
colloids	O
,	O
including	O
less	O
restrictive	O
dose	O
limitations	O
,	O
lower	O
risk	O
of	O
impaired	O
haemostasis	B-PROC
,	O
absence	O
of	O
tissue	O
deposition	O
leading	O
to	O
severe	O
prolonged	O
pruritus	O
,	O
reduced	O
incidence	O
of	O
anaphylactoid	O
reactions	O
,	O
and	O
ease	O
of	O
monitoring	O
to	O
prevent	O
fluid	O
overload	O
.	O

The	O
recombinant	O
proteins	O
induce	O
immune	B-PROC
responses	I-PROC
and	O
have	O
several	O
benefits	O
over	O
current	O
vaccine	O
technologies	O
,	O
including	O
increased	O
safety	O
,	O
economy	O
,	O
stability	O
,	O
versatility	O
and	O
efficacy	O
.	O

ABSTRACT	O
:	O
Development	B-PROC
of	O
complications	O
is	O
very	O
common	O
among	O
the	O
patients	O
suffering	O
from	O
Plasmodium	O
falciparum	O
infection	O
.	O

However	O
,	O
IFN	O
-	O
gamma	O
is	O
essential	O
for	O
controlling	O
virus	B-PROC
replication	I-PROC
in	O
oligodendrocytes	O
.	O

A	O
chronic	O
drinking	B-PROC
water	O
study	O
showed	O
an	O
apparent	O
increase	O
,	O
in	O
females	O
only	O
,	O
of	O
large	O
granular	O
cell	O
lymphocytic	O
leukemia	O
but	O
this	O
was	O
not	O
dosage	O
related	O
.	O

Developmental	O
toxicity	O
studies	O
show	O
GA	O
not	O
to	O
be	O
teratogenic	O
,	O
and	O
a	O
two	O
-	O
generation	O
study	O
showed	O
no	O
adverse	O
reproductive	B-PROC
effects	O
.	O

At	O
median	O
time	O
of	O
6	O
.	O
0	O
years	O
after	O
ICU	O
discharge	O
,	O
forty	O
-	O
six	O
ARDS	O
survivors	O
were	O
tested	O
with	O
SKT	O
,	O
a	O
short	O
cognitive	O
performance	O
test	O
for	O
assessing	O
deficits	O
of	O
memory	B-PROC
and	O
attention	O
.	O

ABSTRACT	O
:	O
Faecal	O
samples	O
from	O
suckling	O
(	O
n	O
=	O
205	O
)	O
and	O
weaned	B-PROC
piglets	O
(	O
n	O
=	O
82	O
)	O
with	O
diarrhoea	O
from	O
24	O
farms	O
in	O
Southern	O
Germany	O
were	O
examined	O
for	O
shedding	O
of	O
important	O
metazoic	O
parasitic	O
,	O
viral	O
and	O
bacterial	O
pathogens	O
using	O
culture	O
,	O
microscopic	O
and	O
electronmicroscopic	O
methods	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
was	O
amplified	O
by	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
,	O
cloned	O
,	O
and	O
expressed	B-PROC
in	O
the	O
baculovirus	O
expression	B-PROC
system	O
.	O

A	O
recombinant	O
baculovirus	O
containing	O
the	O
TCV	O
N	O
gene	O
(	O
rBTCV	O
/	O
N	O
)	O
was	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
expression	B-PROC
of	O
TCV	O
N	O
protein	O
as	O
determined	O
by	O
western	O
immunoblot	O
analysis	O
.	O

We	O
developed	O
a	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
analysis	O
that	O
can	O
differentiate	O
this	O
new	O
serotype	O
from	O
all	O
other	O
serotypes	O
of	O
IBV	O
.	O

TITLE	O
:	O
The	O
exacerbating	O
effect	O
of	O
infectious	O
bronchitis	O
virus	B-PROC
infection	I-PROC
on	O
the	O
infectious	O
bursal	O
disease	O
virus	O
-	O
induced	O
suppression	B-PROC
of	O
opsonization	B-PROC
by	O
Escherichia	O
coil	O
antibody	B-PROC
in	O
chickens	O
.	O

Macrophages	O
from	O
the	O
peripheral	O
blood	O
and	O
the	O
respiratory	O
tracts	O
of	O
chickens	O
infected	O
with	O
IBV	O
or	O
IBDV	O
plus	O
IBV	O
efficiently	O
performed	O
in	O
vitro	O
phagocytosis	B-PROC
of	O
E	O
.	O
coli	O
in	O
the	O
presence	O
of	O
positive	O
-	O
control	O
serum	O
(	O
i	O
.	O
e	O
.,	O
E	O
.	O
coli	O
antiserum	O
produced	O
in	O
normal	O
chickens	O
).	O

ABSTRACT	O
:	O
The	O
3	O
'-	O
untranslated	O
region	O
(	O
3	O
'-	O
UTR	O
)	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
regulates	O
the	O
replication	O
of	O
and	O
transcription	B-PROC
from	O
the	O
viral	O
RNA	O
.	O

These	O
studies	O
suggest	O
that	O
hnRNP	O
A1	O
-	O
PTB	O
interactions	O
provide	O
a	O
molecular	O
mechanism	O
for	O
potential	O
5	O
'-	O
3	O
'	O
cross	O
talks	O
in	O
MHV	O
RNA	O
,	O
which	O
may	O
be	O
important	O
for	O
RNA	B-PROC
replication	I-PROC
and	O
transcription	B-PROC
.	O

This	O
pattern	O
of	O
decreased	O
food	B-PROC
intake	I-PROC
is	O
similar	O
to	O
that	O
occurring	O
during	O
indomethacin	O
-	O
induced	O
ulcerative	O
ileitis	O
,	O
where	O
we	O
previously	O
measured	O
an	O
increase	O
in	O
plasma	O
tumor	O
-	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)-	O
alpha	O
.	O

The	O
differences	O
in	O
the	O
decrease	O
in	O
the	O
feeding	O
pattern	O
between	O
the	O
SDA	O
viral	O
and	O
a	O
bacterial	O
infection	O
suggest	O
that	O
factors	O
other	O
than	O
TNF	O
-	O
alpha	O
alone	O
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
anorexia	O
during	O
a	O
viral	B-PROC
infection	I-PROC
.	O

Many	O
viral	B-PROC
infections	I-PROC
develop	O
in	O
an	O
epidemiological	O
way	O
(	O
influenza	O
,	O
VRS	O
bronchiolitis	O
,	O
rhinovirus	O
infections	O
...)	O
and	O
several	O
epidemics	O
by	O
different	O
viruses	O
overlap	O
from	O
September	O
-	O
October	O
to	O
March	O
-	O
April	O
making	O
it	O
very	O
difficult	O
to	O
decide	O
the	O
precise	O
cause	O
.	O

Parasitized	O
erythrocytes	O
,	O
which	O
can	O
form	O
rosettes	O
or	O
auto	O
-	O
agglutinate	O
,	O
are	O
sequestrated	O
in	O
the	O
deep	O
microvasculature	B-PROC
and	O
stick	O
to	O
activated	O
endothelium	O
by	O
the	O
mean	O
of	O
various	O
receptors	O
.	O

These	O
studies	O
indicate	O
,	O
first	O
,	O
that	O
both	O
gelatinase	O
B	O
and	O
stromelysin	O
1	O
are	O
involved	O
in	O
the	O
development	B-PROC
of	O
experimental	O
acute	O
lung	O
injury	O
,	O
and	O
second	O
,	O
that	O
the	O
mechanisms	O
by	O
which	O
these	O
individual	O
MMPs	O
function	O
appear	O
to	O
differ	O
.	O

1	O
.	O
7	O
mmHg	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
index	O
(	O
from	O
314	O
+/-	O

ABSTRACT	O
:	O
Severe	O
cutaneous	O
hemorrhages	O
with	O
dermal	O
and	O
subcutaneous	O
capillary	O
angioplasia	O
were	O
seen	O
in	O
aborted	O
and	O
stillborn	O
piglets	O
,	O
concurrently	O
with	O
an	O
acute	O
outbreak	O
of	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
abortions	O
.	O

CMV	O
and	O
rotating	O
dosing	O
both	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
the	O
oxygenation	B-PROC
index	O
after	O
a	O
15	O
mL	O
/	O
kg	O
dose	O
of	O
perflubron	O
.	O

Because	O
local	O
PaCO2	O
-	O
related	O
changes	O
in	O
bronchomotor	O
tone	O
promote	O
VA	B-PROC
/	I-PROC
Q	I-PROC
matching	O
,	O
this	O
mechanism	O
should	O
be	O
impaired	O
by	O
anesthetics	O
that	O
cause	O
bronchodilation	B-PROC
.	O

It	O
begins	O
as	O
noncardiogenic	O
pulmonary	O
edema	O
and	O
develops	O
into	O
a	O
neutrophilic	B-PROC
alveolitis	O
,	O
and	O
,	O
later	O
,	O
pulmonary	O
fibrosis	O
.	O

RESULTS	O
:	O
Venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
was	O
successful	O
in	O
75	O
%	O
patients	O
who	O
survived	O
.	O

In	O
patients	O
who	O
died	B-PROC
necropsy	O
confirmed	O
irreversible	O
multiorgan	O
failure	O
.	O

CONCLUSIONS	O
:	O
In	O
indicated	O
cases	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
remains	O
the	O
method	O
of	O
choice	O
in	O
critically	O
ill	O
mature	O
neonates	O
.	O

The	O
mechanism	O
of	O
injury	O
produced	O
by	O
inflicted	O
head	O
injuries	O
in	O
these	O
children	O
is	O
most	O
often	O
rotational	O
movement	B-PROC
of	O
the	O
brain	O
within	O
the	O
cranial	O
cavity	O
.	O

TITLE	O
:	O
Echinococcal	O
hydatid	O
cyst	O
at	O
the	O
right	O
ventricle	O
outlet	O
with	O
leakage	O
to	O
the	O
pulmonary	O
artery	O
outflow	O
causing	O
follicular	O
airway	O
disease	O
and	O
sudden	O
death	B-PROC
.	O

TITLE	O
:	O
Effect	O
of	O
an	O
acute	O
increase	O
in	O
PCO2	O
on	O
splanchnic	O
perfusion	O
and	O
metabolism	B-PROC
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
acute	O
effects	O
of	O
an	O
increase	O
in	O
PCO2	O
on	O
splanchnic	O
tissue	O
perfusion	O
and	O
metabolism	B-PROC
.	O

All	O
patients	O
had	O
bilateral	O
infiltrates	O
on	O
chest	O
radiography	O
,	O
a	O
PaO2	O
/	O
FIO2	O
ratio	O
less	O
than	O
200	O
mmHg	O
,	O
and	O
stable	O
hemodynamics	B-PROC
without	O
vasoactive	O
drugs	O
.	O

PCO2	O
was	O
increased	O
5	O
-	O
20	O
%	O
by	O
an	O
added	O
dead	B-PROC
space	O
from	O
baseline	O
,	O
followed	O
by	O
a	O
return	O
to	O
baseline	O
.	O

Such	O
integration	B-PROC
is	O
essential	O
for	O
the	O
production	O
of	O
progeny	O
viruses	O
,	O
and	O
therefore	O
therapeutic	O
agents	O
that	O
can	O
inhibit	O
this	O
process	O
should	O
be	O
effective	O
anti	O
-	O
HIV	O
agents	O
.	O

The	O
results	O
show	O
that	O
both	O
necrosis	B-PROC
and	O
apoptosis	B-PROC
may	O
contribute	O
to	O
the	O
death	B-PROC
of	O
infected	O
cells	O
in	O
lytic	O
IBV	O
infection	O
.	O

In	O
addition	O
,	O
nephropathogenic	O
strains	O
had	O
the	O
same	O
cleavage	B-PROC
recognition	O
site	O
sequence	O
as	O
many	O
nonnephropathogenic	O
isolates	O
.	O

Pre	O
-	O
operatively	O
,	O
predicted	O
mean	O
of	O
PaO	B-PROC
(	O
2	O
),	O
PaCO	O
(	O
2	O
)	O
and	O
%	O
FEV1	O
were	O
72	O
mmHg	O
(	O
57	O
--	O
86	O
),	O
37	O
mmHg	O
(	O
33	O
--	O
42	O
)	O
and	O
80	O
%	O
(	O
37	O
--	O
114	O
),	O
respectively	O
.	O

Gas	B-PROC
exchange	I-PROC
,	I-PROC
pulmonary	I-PROC
mechanic	O
,	O
and	O
haemodynamic	O
parameters	O
were	O
obtained	O
at	O
regular	O
intervals	O
.	O

PFC	O
aerosol	O
increased	O
oxygenation	B-PROC
(	O
PaO2	O
)	O
15	O
min	O
after	O
the	O
initiation	O
of	O
treatment	O
up	O
to	O
120	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
The	O
autocatalytic	O
release	O
of	O
a	O
putative	O
RNA	O
virus	O
transcription	B-PROC
factor	O
from	O
its	O
polyprotein	O
precursor	O
involves	O
two	O
paralogous	O
papain	O
-	O
like	O
proteases	O
that	O
cleave	O
the	O
same	O
peptide	O
bond	O
.	O

By	O
using	O
comparative	O
sequence	O
analysis	O
,	O
we	O
now	O
show	O
that	O
the	O
respective	O
proteins	O
of	O
all	O
sequenced	O
coronaviruses	O
are	O
flanked	O
by	O
two	O
conserved	O
PLpro	O
cleavage	B-PROC
sites	O
and	O
share	O
a	O
complex	O
(	O
multi	O
)	O
domain	O
organization	O
with	O
PL1pro	O
being	O
inactivated	O
in	O
IBV	O
.	O

A	O
large	O
subset	O
of	O
coronaviruses	O
may	O
employ	O
two	O
proteases	O
to	O
cleave	O
the	O
same	O
site	O
(	O
s	O
)	O
and	O
thus	O
regulate	O
the	O
expression	B-PROC
of	O
the	O
viral	O
genome	O
in	O
a	O
unique	O
way	O
.	O

All	O
60	O
sera	O
positive	O
for	O
NT	O
antibody	B-PROC
were	O
positive	O
for	O
IP	O
antibody	B-PROC
,	O
and	O
all	O
180	O
sera	O
negative	O
for	O
NT	O
antibody	B-PROC
were	O
negative	O
for	O
IP	O
antibody	B-PROC
in	O
the	O
healthy	O
dogs	O
.	O

The	O
possibility	O
of	O
engineering	O
the	O
tissue	O
and	O
species	O
tropism	B-PROC
to	O
target	O
expression	B-PROC
to	O
different	O
organs	O
and	O
animal	O
species	O
,	O
including	O
humans	O
,	O
increases	O
the	O
potential	O
of	O
coronaviruses	O
as	O
vectors	O
.	O

Thus	O
,	O
coronaviruses	O
are	O
promising	O
virus	O
vectors	O
for	O
vaccine	O
development	B-PROC
and	O
,	O
possibly	O
,	O
for	O
gene	O
therapy	O
.	O

routes	O
died	B-PROC
,	O
but	O
all	O
those	O
inoculated	O
by	O
other	O
routes	O
survived	O
.	O

The	O
large	O
spike	O
(	O
S	O
)	O
glycoprotein	O
is	O
an	O
important	O
determinant	O
of	O
species	O
specificity	B-PROC
,	I-PROC
tissue	I-PROC
tropism	B-PROC
and	O
virulence	B-PROC
of	O
coronavirus	O
infection	O
.	O

These	O
data	O
suggest	O
that	O
B	O
cells	O
may	O
function	O
as	O
antibody	B-PROC
-	O
independent	O
innate	B-PROC
immune	I-PROC
response	I-PROC
during	O
JHMV	O
infection	O
in	O
vivo	O
.	O

Infections	O
accounted	O
for	O
the	O
greatest	O
number	O
of	O
deaths	B-PROC
(	O
bacterial	O
pneumonia	O
,	O
four	O
patients	O
;	O
catheter	O
-	O
related	O
bacteremia	O
,	O
one	O
patient	O
).	O

L	O
-	O
Selectin	B-PROC
levels	O
did	O
not	O
differ	O
between	O
survivors	O
and	O
nonsurvivors	O
.	O

At	O
least	O
6	O
months	O
weaning	B-PROC
from	O
alcohol	O
is	O
a	O
commonly	O
accepted	O
selection	O
criterion	O
for	O
transplantation	O
candidates	O
.	O

Liver	O
transplantation	O
in	O
this	O
subpopulation	O
of	O
often	O
young	O
patient	O
who	O
have	O
not	O
achieved	O
weaning	B-PROC
merits	O
further	O
evaluation	O
.	O

Recent	O
evidence	O
suggests	O
that	O
this	O
final	O
stage	O
need	O
not	O
be	O
protracted	O
,	O
and	O
if	O
certain	O
criteria	O
are	O
fulfilled	O
,	O
rapid	O
weaning	B-PROC
is	O
feasible	O
.	O

TITLE	O
:	O
Targeted	B-PROC
disruption	O
of	O
the	O
Ceacam1	O
(	O
MHVR	O
)	O
gene	O
leads	O
to	O
reduced	O
susceptibility	O
of	O
mice	O
to	O
mouse	O
hepatitis	O
virus	B-PROC
infection	I-PROC
.	O

Ceacam1a	O
-	O
targeted	B-PROC
mice	O
provide	O
a	O
new	O
model	O
to	O
study	O
the	O
effects	O
of	O
modulation	O
of	O
receptor	B-PROC
expression	B-PROC
on	O
susceptibility	O
to	O
MHV	O
infection	O
in	O
vivo	O
.	O

Injury	O
Severity	O
Score	O
was	O
similar	O
in	O
the	O
severe	O
and	O
moderate	O
groups	O
(	O
23	O
.	O
3	O
vs	O
.	O
26	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
33	O
),	O
as	O
were	O
admission	O
Glasgow	O
Coma	O
Scale	O
score	O
(	O
12	O
vs	O
.	O
13	O
,	O
p	O
=	O
0	O
.	O
30	O
),	O
admission	O
blood	B-PROC
pressure	I-PROC
(	O
131	O
vs	O
.	O
129	O
mm	O
Hg	O
,	O
p	O
=	O
0	O
.	O
90	O
),	O
and	O
admission	O
Pao2	O
/	O
Fio2	O
(	O
197	O
vs	O
.	O
255	O
,	O
p	O
=	O
0	O
.	O
14	O
).	O

CONCLUSIONS	O
:	O
Extent	O
of	O
contusion	O
volumes	O
measured	O
using	O
three	O
-	O
dimensional	O
reconstruction	O
allows	O
identification	O
of	O
patients	O
at	O
high	O
risk	O
of	O
pulmonary	O
dysfunction	O
as	O
characterized	O
by	O
development	B-PROC
of	O
ARDS	O
.	O

ABSTRACT	O
:	O
Stunted	O
growth	B-PROC
of	O
poults	O
afflicted	O
by	O
enteritis	O
mortality	O
syndrome	O
(	O
PEMS	O
)	O
may	O
be	O
associated	O
with	O
depressed	O
digestive	B-PROC
capabilities	O
.	O

ABSTRACT	O
:	O
The	O
Fas	O
/	O
Fas	O
ligand	B-PROC
(	O
FasL	O
)	O
system	O
has	O
been	O
implicated	O
in	O
alveolar	O
epithelial	O
cell	O
apoptosis	B-PROC
during	O
pulmonary	O
fibrosis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
conclude	O
that	O
the	O
Fas	O
/	O
FasL	O
system	O
contributes	O
to	O
the	O
development	B-PROC
of	O
permeability	O
changes	O
and	O
tissue	O
injury	O
during	O
-	O
gram	O
negative	O
bacterial	O
pneumonia	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
basis	O
of	O
neurotropism	O
of	O
MHVs	O
,	O
we	O
compared	O
the	O
pathogenesis	B-PROC
and	O
genomic	O
sequence	O
of	O
MHV	O
-	O
2	O
with	O
that	O
of	O
MHV	O
-	O
A59	O
.	O

Concomitantly	O
,	O
pulmonary	O
shunt	O
fraction	O
,	O
alveolar	O
-	O
arterial	O
oxygen	B-PROC
tension	I-PROC
difference	O
[	O
P	O
(	O
a	O
-	O
a	O
)	O
o2	O
]/	O
Pao2	O
,	O
and	O
cardiac	O
index	O
increased	O
as	O
well	O
,	O
whereas	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
and	O
Pao2	O
/	O
Fio2	O
declined	O
.	O

The	O
most	O
frequent	O
signs	O
were	O
meiosis	B-PROC
,	O
change	O
in	O
mental	O
status	O
,	O
hypersalivation	O
and	O
fasciculations	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
demonstrates	O
the	O
use	O
of	O
stochastic	O
genetic	O
epidemiological	O
models	O
for	O
quantifying	O
the	O
consequences	O
of	O
selecting	O
animals	O
for	O
resistance	B-PROC
to	O
a	O
microparasitic	O
infectious	O
disease	O
.	O

The	O
model	O
is	O
relevant	O
for	O
many	O
classes	O
of	O
infectious	O
diseases	O
where	O
sporadic	O
epidemics	O
occur	O
,	O
and	O
it	O
is	O
a	O
powerful	O
tool	O
for	O
investigating	O
the	O
costs	O
,	O
benefits	O
,	O
and	O
risks	O
associated	O
with	O
breeding	B-PROC
for	O
resistance	B-PROC
to	O
specific	O
diseases	O
.	O

The	O
second	O
involves	O
selection	O
with	O
the	O
assumption	O
of	O
introgression	O
of	O
a	O
major	O
recessive	O
gene	O
that	O
confers	O
resistance	B-PROC
(	O
the	O
gene	O
introgression	O
model	O
).	O

However	O
,	O
the	O
expressed	B-PROC
negative	O
-	O
strand	O
DI	O
RNA	O
transcripts	O
are	O
poor	O
templates	O
for	O
positive	O
-	O
strand	O
DI	O
RNA	B-PROC
synthesis	I-PROC
.	O

Thus	O
,	O
we	O
observed	O
that	O
approximately	O
30	O
%	O
of	O
cells	O
transfected	O
with	O
the	O
N	O
protein	O
appeared	O
to	O
be	O
undergoing	O
cell	B-PROC
division	I-PROC
.	O

The	O
most	O
likely	O
explanation	O
for	O
this	O
is	O
that	O
the	O
N	O
protein	O
induced	O
a	O
cell	B-PROC
cycle	I-PROC
delay	O
or	O
arrest	O
,	O
most	O
likely	O
in	O
the	O
G	O
(	O
2	O
)/	O
M	B-PROC
phase	I-PROC
.	O

ABSTRACT	O
:	O
Studies	O
were	O
performed	O
to	O
investigate	O
the	O
contributions	O
of	O
the	O
CC	O
chemokine	O
receptor	O
CCR5	O
in	O
host	B-PROC
defense	I-PROC
and	O
disease	O
development	B-PROC
following	O
intracranial	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

However	O
,	O
by	O
day	O
12	O
pi	O
,	O
T	O
cell	O
infiltration	O
into	O
the	O
CNS	O
of	O
infected	O
CCR5	O
(-/-)	O
and	O
CCR5	O
(+/+)	O
mice	O
was	O
similar	O
and	O
both	O
strains	O
exhibited	O
comparable	O
viral	O
titers	O
,	O
indicating	O
that	O
CCR5	O
expression	B-PROC
is	O
not	O
essential	O
for	O
host	B-PROC
defense	I-PROC
.	O

The	O
majority	O
of	O
our	O
cases	O
resulted	O
from	O
severe	O
trauma	O
with	O
infected	O
and	O
necrotic	B-PROC
soft	O
tissues	O
,	O
disseminated	O
tumor	O
disease	O
,	O
or	O
ulcers	O
in	O
elderly	O
,	O
multimorbid	O
patients	O
.	O

RESULTS	O
:	O
Eight	O
patients	O
were	O
healed	O
and	O
1	O
died	B-PROC
of	O
septic	O
shock	O
and	O
multiple	O
organ	O
failure	O
.	O

ABSTRACT	O
:	O
The	O
complete	O
sequence	O
(	O
28580	O
nt	O
)	O
of	O
the	O
PUR46	O
-	O
MAD	B-PROC
clone	O
of	O
the	O
Purdue	O
cluster	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
has	O
been	O
determined	O
and	O
compared	O
with	O
members	O
of	O
this	O
cluster	O
and	O
other	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
)	O
and	O
sepsis	O
exhibit	O
decreased	O
plasma	O
selenium	O
and	O
glutathione	O
peroxidase	O
activity	O
.	O

11	O
immediately	O
before	O
death	B-PROC
.	O

Ventilator	O
inspiratory	B-PROC
flow	O
(	O
V	O
(	O
I	O
))	O
and	O
trigger	O
sensitivity	O
settings	O
should	O
be	O
optimized	O
to	O
limit	O
the	O
increase	O
in	O
work	B-PROC
of	I-PROC
breathing	B-PROC
and	O
dyspnea	O
.	O

Most	O
of	O
the	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
locate	O
in	O
the	O
putative	O
signal	O
sequence	O
and	O
two	O
short	O
hypervariable	O
regions	O
at	O
the	O
amino	O
terminus	O
.	O

ABSTRACT	O
:	O
Viral	O
respiratory	O
tract	O
infections	O
may	O
cause	O
both	O
harmless	O
common	O
colds	O
and	O
severe	O
asthma	O
exacerbations	O
;	O
the	O
differences	O
in	O
disease	O
expression	B-PROC
probably	O
depend	O
on	O
the	O
allergic	O
status	O
of	O
the	O
patient	O
.	O

In	O
general	O
,	O
lymphoid	O
tissues	O
showed	O
T	O
-	O
and	O
B	O
-	O
cell	O
depletion	O
,	O
often	O
including	O
massive	O
to	O
complete	O
thymic	O
involution	B-PROC
or	O
atrophy	O
.	O

The	O
findings	O
indicated	O
that	O
the	O
major	O
difference	O
in	O
lymphatic	O
tissues	O
between	O
FIPV	O
-	O
infected	O
cats	O
with	O
FIP	O
and	O
those	O
without	O
FIP	O
was	O
the	O
development	B-PROC
of	O
lymphocyte	O
depletion	O
in	O
the	O
first	O
group	O
and	O
lymphocyte	B-PROC
proliferation	I-PROC
in	O
the	O
second	O
.	O

This	O
is	O
the	O
first	O
report	O
that	O
compares	O
the	O
neurovirulence	O
and	O
pathogenesis	B-PROC
of	O
isogenic	O
viruses	O
with	O
defined	O
alterations	O
in	O
the	O
MHV	O
spike	O
protein	O
.	O

We	O
found	O
that	O
three	O
encephalitis	O
-	O
positive	O
,	O
demyelination	O
-	O
negative	O
,	O
hepatitis	O
-	O
negative	O
recombinant	O
viruses	O
have	O
an	O
MHV	O
-	O
A59	O
-	O
derived	O
S	O
gene	O
,	O
which	O
contains	O
three	O
identical	O
point	B-PROC
mutations	I-PROC
(	O
I375M	O
,	O
L652I	O
,	O
and	O
T1087N	O
).	O

Resistance	B-PROC
was	O
noted	O
to	O
both	O
chloroquine	O
and	O
artesunate	O
.	O

Further	O
,	O
peripheral	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	O
from	O
immunized	O
CCR2	O
(-/-)	O
mice	O
displayed	O
a	O
marked	O
reduction	O
in	O
IFN	O
-	O
gamma	O
production	O
in	O
response	O
to	O
viral	O
Ag	O
and	O
did	O
not	O
migrate	O
into	O
the	O
CNS	O
of	O
MHV	O
-	O
infected	O
recombination	B-PROC
-	O
activating	O
gene	O
(	O
RAG	O
)	O
1	O
(-/-)	O
mice	O
following	O
adoptive	O
transfer	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
regular	O
inhalation	B-PROC
of	O
cannabis	O
has	O
the	O
same	O
consequences	O
as	O
tobacco	O
smoking	O
.	O

ABSTRACT	O
:	O
Viral	O
upper	O
respiratory	O
infections	O
are	O
the	O
most	O
common	O
cause	O
of	O
clinical	O
olfactory	B-PROC
dysfunction	O
,	O
but	O
the	O
pathogenesis	B-PROC
of	O
dysosmia	O
after	O
viral	B-PROC
infection	I-PROC
is	O
poorly	O
understood	O
.	O

TITLE	O
:	O
Origin	O
and	O
evolution	B-PROC
of	O
Georgia	O
98	O
(	O
GA98	O
),	O
a	O
new	O
serotype	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
immune	B-PROC
response	I-PROC
to	O
a	O
naked	O
plasmid	O
DNA	O
encoding	O
the	O
nucleoprotein	O
(	O
N	O
protein	O
)	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
was	O
investigated	O
in	O
this	O
study	O
.	O

An	O
optimal	O
antibody	B-PROC
response	I-PROC
was	O
achieved	O
with	O
100	O
microg	O
of	O
pcDNA	O
/	O
N	O
.	O
The	O
response	O
lasted	O
at	O
least	O
11	O
weeks	O
after	O
primary	O
immunization	O
.	O

TITLE	O
:	O
Humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
in	O
turkey	O
poults	O
infected	O
with	O
turkey	O
coronavirus	O
.	O

The	O
IgM	O
isotype	O
antibody	B-PROC
response	I-PROC
to	O
TCV	O
was	O
1	O
.	O
40	O
and	O
0	O
.	O
91	O
at	O
7	O
and	O
14	O
d	O
PI	O
,	O
respectively	O
.	O

Turkeys	O
infected	O
with	O
TCV	O
had	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
antibody	B-PROC
response	I-PROC
to	O
sheep	O
erythrocytes	O
than	O
noninfected	O
controls	O
at	O
7	O
d	O
PI	O
.	O

Immunofluorescent	O
staining	O
of	O
IBV	O
-	O
infected	O
cells	O
and	O
cells	O
expressing	O
individual	O
cleavage	B-PROC
products	O
showed	O
that	O
the	O
100	O
-,	O
68	O
-,	O
and	O
58	O
-	O
kDa	O
proteins	O
were	O
associated	O
with	O
the	O
membranes	O
of	O
the	O
endoplasmic	O
reticulum	O
,	O
and	O
the	O
39	O
-	O
and	O
35	O
-	O
kDa	O
proteins	O
displayed	O
diffuse	O
distribution	O
patterns	O
.	O

TITLE	O
:	O
Neurovirulence	O
in	O
mice	O
of	O
soluble	O
receptor	O
-	O
resistant	O
(	O
srr	O
)	O
mutants	O
of	O
mouse	O
hepatitis	O
virus	O
:	O
intensive	O
apoptosis	B-PROC
caused	O
by	O
less	O
virulent	O
srr	O
mutant	O
.	O

In	O
the	O
brain	O
and	O
spinal	O
cord	O
,	O
the	O
growth	B-PROC
of	O
srr7	O
was	O
more	O
than	O
2	O
log10	O
lower	O
than	O
that	O
of	O
the	O
wt	O
virus	O
.	O

Swine	O
initially	O
were	O
placed	O
on	O
mechanical	O
ventilation	O
(	O
zero	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
,	O
21	O
%	O
FiO2	O
).	O

To	O
determine	O
the	O
role	O
of	O
RNA	O
secondary	O
structures	O
within	O
these	O
two	O
host	O
protein	O
binding	O
elements	O
in	O
viral	B-PROC
replication	I-PROC
,	O
we	O
explored	O
the	O
secondary	O
structure	O
of	O
the	O
3	O
'-	O
terminal	O
166	O
nucleotides	O
of	O
the	O
MHV	O
strain	O
JHM	O
genome	O
using	O
limited	O
RNase	O
digestion	B-PROC
assays	O
.	O

Acute	O
hypoxia	O
also	O
increased	O
rabbit	O
alveolar	O
macrophage	O
IL	O
-	O
8	O
expression	B-PROC
.	O

Hypoxia	O
increased	O
DNA	O
binding	B-PROC
activity	I-PROC
of	O
AP	O
-	O
1	O
and	O
C	O
/	O
EBP	O
but	O
not	O
NF	O
-	O
kappaB	O
.	O
Hypoxia	O
induced	O
HIF	O
-	O
1	O
expression	B-PROC
,	O
but	O
cobaltous	O
ions	O
and	O
desferrioxamine	O
did	O
not	O
mimic	O
hypoxic	O
IL	O
-	O
8	O
induction	O
.	O

Both	O
the	O
pattern	O
of	O
cytokine	O
expression	B-PROC
and	O
transcription	B-PROC
factor	O
activation	O
by	O
hypoxia	O
was	O
different	O
to	O
that	O
seen	O
with	O
endotoxin	O
.	O

ABSTRACT	O
:	O
During	O
routine	O
investigations	O
on	O
fish	O
,	O
a	O
virus	O
(	O
isolate	O
DF	O
24	O
/	O
00	O
)	O
with	O
novel	O
morphological	O
features	O
and	O
hitherto	O
undescribed	O
morphogenesis	B-PROC
was	O
isolated	O
from	O
a	O
white	O
bream	O
(	O
Blicca	O
bjoerkna	O
L	O
.;	O
Teleostei	O
,	O
order	O
Cypriniformes	O
).	O

ABSTRACT	O
:	O
The	O
complete	O
genome	O
sequences	O
are	O
reported	O
here	O
of	O
two	O
field	O
isolates	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
),	O
which	O
were	O
isolated	O
from	O
respiratory	O
and	O
intestinal	O
samples	O
of	O
the	O
same	O
animal	O
experiencing	O
fatal	O
pneumonia	O
during	O
a	O
bovine	O
shipping	O
fever	B-PROC
epizootic	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
provides	O
an	O
excellent	O
animal	O
model	O
for	O
the	O
study	O
of	O
the	O
immunopathological	O
mechanisms	O
involved	O
in	O
hepatic	O
viral	B-PROC
diseases	I-PROC
.	O

Among	O
the	O
different	O
processes	O
contributing	O
to	O
the	O
continuous	O
generation	O
of	O
new	O
viral	O
variants	O
RNA	O
recombination	B-PROC
is	O
of	O
special	O
importance	O
.	O

As	O
a	O
consequence	O
,	O
BMV	O
is	O
the	O
virus	O
for	O
which	O
the	O
structural	O
requirements	O
for	O
genetic	O
RNA	O
recombination	B-PROC
have	O
been	O
most	O
precisely	O
established	O
.	O

Because	O
Arg	O
and	O
Lys	O
are	O
similar	O
in	O
structure	O
and	O
are	O
known	O
to	O
compete	O
in	O
intestinal	B-PROC
absorption	I-PROC
,	O
dietary	O
Lys	O
treatments	O
[	O
near	O
NRC	O
(	O
1994	O
)	O
recommendations	O
]	O
were	O
evaluated	O
to	O
determine	O
if	O
Arg	O
and	O
Lys	O
interact	O
to	O
affect	O
broiler	O
immunity	B-PROC
.	O

Antibody	B-PROC
levels	O
to	O
SRBC	O
were	O
higher	O
in	O
birds	O
supplemented	O
with	O
50	O
IU	O
of	O
VE	O
/	O
kg	O
compared	O
to	O
those	O
supplemented	O
with	O
0	O
or	O
200	O
IU	O
/	O
kg	O
of	O
VE	O
.	O

TITLE	O
:	O
Immediate	O
effects	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
and	O
low	O
and	O
high	O
tidal	O
volume	O
ventilation	O
upon	O
gas	O
exchange	O
and	O
compliance	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

Low	O
tidal	O
volume	O
ventilation	O
with	O
PEEP	O
set	O
at	O
5	O
cmH2O	O
results	O
in	O
poor	O
oxygenation	B-PROC
and	O
compliance	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
acute	O
lung	O
injury	O
.	O

for	O
2	O
h	O
)	O
provoked	O
pulmonary	O
hemorrhage	O
and	O
edema	O
,	O
protein	O
leakage	O
and	O
massive	O
neutrophil	O
infiltration	O
,	O
resulted	O
in	O
severe	O
hypoxemia	O
and	O
impaired	O
lung	B-PROC
compliance	I-PROC
,	O
accompanying	O
the	O
increase	O
of	O
phospholipase	B-PROC
A	I-PROC
(	O
2	O
)	O
activity	O
and	O
interleukin	O
-	O
8	O
,	O
and	O
degradation	O
of	O
surfactant	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

Concomitantly	O
,	O
surfactant	O
proteins	O
and	O
Clara	O
cell	O
secretory	B-PROC
protein	O
mRNA	B-PROC
expression	B-PROC
decreased	O
.	O

These	O
candidates	O
,	O
in	O
turn	O
,	O
can	O
be	O
directed	O
to	O
the	O
lung	O
epithelium	O
in	O
transgenic	O
mice	O
or	O
abated	O
in	O
inducible	O
and	O
constitutive	O
gene	O
-	O
targeted	B-PROC
mice	O
.	O

Therapies	O
targeting	B-PROC
specific	O
pathophysiologic	O
steps	O
in	O
the	O
development	B-PROC
or	O
persistence	O
of	O
this	O
syndrome	O
are	O
in	O
various	O
stages	O
of	O
laboratory	O
and	O
clinical	O
testing	O
.	O

ABSTRACT	O
:	O
The	O
transcription	B-PROC
regulatory	O
sequences	O
(	O
TRSs	O
)	O
of	O
the	O
coronavirus	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
have	O
been	O
characterized	O
by	O
using	O
a	O
helper	O
virus	O
-	O
dependent	O
expression	B-PROC
system	O
based	O
on	O
coronavirus	O
-	O
derived	O
minigenomes	O
to	O
study	O
the	O
synthesis	B-PROC
of	O
subgenomic	O
mRNAs	O
.	O

The	O
presence	O
of	O
an	O
appropriate	O
Kozak	O
context	O
led	O
to	O
a	O
higher	O
level	O
of	O
protein	B-PROC
expression	B-PROC
.	O

The	O
development	B-PROC
of	O
infectious	O
TGEV	O
replicon	O
particles	O
should	O
assist	O
studies	O
of	O
TGEV	O
replication	O
and	O
assembly	O
as	O
well	O
as	O
facilitate	O
the	O
production	O
of	O
novel	O
swine	O
candidate	O
vaccines	O
.	O

Patients	O
who	O
died	B-PROC
before	O
or	O
on	O
admission	O
and	O
those	O
with	O
prior	O
chronic	O
renal	O
disease	O
were	O
excluded	O
from	O
the	O
study	O
.	O

When	O
proper	O
dialysis	O
and	O
intensive	O
care	O
facilities	O
together	O
with	O
around	O
the	O
clock	O
dedicated	O
human	O
effort	B-PROC
are	O
available	O
,	O
crush	O
injury	O
-	O
related	O
ARF	O
patients	O
have	O
a	O
lower	O
mortality	O
.	O

In	O
this	O
sense	B-PROC
they	O
are	O
similar	O
to	O
the	O
pH	O
-	O
dependent	O
MHV	O
-	O
4	O
variant	O
OBLV60	O
.	O

IFN	O
at	O
100	O
U	O
/	O
ml	O
reduced	O
viral	B-PROC
replication	I-PROC
by	O
50	O
%	O
as	O
measured	O
by	O
syncytia	O
formation	B-PROC
.	O

Increasing	O
viral	O
load	O
did	O
not	O
enhance	O
frequencies	O
or	O
effector	O
function	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
within	O
the	O
CNS	O
,	O
indicating	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
T	O
cell	O
responses	O
.	O

Although	O
an	O
Ab	O
-	O
independent	O
antiviral	O
function	O
of	O
B	O
cells	O
was	O
not	O
evident	O
during	O
acute	O
infection	O
,	O
the	O
presence	O
of	O
B	O
cells	O
altered	O
CNS	O
cellular	B-PROC
tropism	B-PROC
during	O
viral	O
recrudescence	O
.	O

Altered	O
tropism	B-PROC
coincided	O
with	O
distinct	O
regulation	B-PROC
of	O
CNS	O
virus	O
-	O
specific	O
CD4	O
+	O
T	O
cells	O
.	O

B	O
cells	O
themselves	O
may	O
also	O
play	O
a	O
subtle	O
role	O
in	O
modulating	O
pathogenesis	B-PROC
by	O
influencing	O
tropism	B-PROC
.	O

The	O
disease	O
progressed	O
rapidly	O
and	O
all	O
patients	O
died	B-PROC
within	O
24	O
-	O
48	O
hours	O
after	O
admission	O
from	O
complications	O
such	O
as	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
),	O
acute	O
renal	O
failure	O
(	O
ARF	O
)	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Moreover	O
,	O
clinical	O
presentation	O
of	O
interstitial	O
lung	O
disease	O
can	O
be	O
dichotomized	O
,	O
according	O
to	O
patients	O
'	O
pulmonary	O
manifestations	O
,	O
into	O
:	O
1	O
)	O
both	O
acute	O
and	O
aggressive	B-PROC
lung	O
disease	O
similar	O
to	O
Hamman	O
-	O
Rich	O
syndrome	O
;	O
2	O
)	O
slowly	O
progressive	O
lung	O
disease	O
;	O
and	O
3	O
)	O
an	O
asymptomatic	O
pattern	O
.	O

Transcriptional	B-PROC
activation	I-PROC
of	O
mIFN	O
(	O
alpha	O
)	O
induced	O
by	O
doxycycline	O
resulted	O
in	O
prolonged	O
survival	O
and	O
reduced	O
liver	O
damage	O
in	O
HD	O
-	O
TET	O
-	O
IFN	O
-	O
injected	O
mice	O
challenged	O
with	O
a	O
lethal	O
dose	O
of	O
coronavirus	O
.	O

The	O
memory	B-PROC
B	O
cell	O
response	O
was	O
prominent	O
at	O
PID	O
21	O
and	O
25	O
and	O
consisted	O
in	O
IgG	O
and	O
IgA	O
ASC	O
.	O

Confocal	O
microscopy	O
revealed	O
that	O
the	O
majority	O
of	O
cells	O
(>	O
70	O
%)	O
undergoing	O
apoptosis	B-PROC
were	O
neurons	O
.	O

These	O
studies	O
indicate	O
that	O
NOS2	O
-	O
generated	O
NO	O
contributes	O
to	O
apoptosis	B-PROC
of	I-PROC
neurons	I-PROC
but	O
not	O
demyelination	O
following	O
MHV	O
infection	O
.	O

Treatment	O
with	O
CY	O
mainly	O
induced	O
B	O
cell	O
deficiency	O
as	O
indicated	O
by	O
significant	O
reductions	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
antibody	B-PROC
responses	I-PROC
to	O
sheep	O
erythrocytes	O
7	O
days	O
after	O
injection	O
.	O

Changes	O
in	O
the	O
neural	B-PROC
control	I-PROC
of	O
the	O
airways	O
contribute	O
to	O
bronchoconstriction	B-PROC
,	O
which	O
is	O
reflected	O
in	O
an	O
increased	O
efficacy	O
of	O
anticholinergic	O
medications	O
during	O
acute	O
asthma	O
attacks	O
.	O

Lungs	O
of	O
hyperoxic	O
rats	O
showed	O
increase	O
in	O
the	O
expression	B-PROC
of	O
CYP1A1	O
in	O
airway	O
epithelial	O
cells	O
,	O
type	O
II	O
pneumocytes	O
,	O
and	O
endothelial	O
cells	O
.	O

The	O
results	O
show	O
that	O
the	O
S	O
-	O
fg	O
fusion	O
protein	O
is	O
highly	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
among	O
different	O
IBV	O
serotypes	O
,	O
and	O
the	O
S	O
-	O
fg	O
ELISA	O
is	O
found	O
to	O
be	O
a	O
convenient	O
,	O
economical	O
,	O
and	O
efficient	O
method	O
for	O
antibody	B-PROC
detection	O
against	O
IBV	O
.	O

Administration	O
of	O
exogenous	O
IFN	O
-	O
gamma	O
to	O
BALB	O
-	O
GKO	O
partially	O
inhibited	O
the	O
acute	O
death	B-PROC
.	O

Isotype	O
-	O
specific	O
antibody	B-PROC
responses	I-PROC
in	O
serum	O
were	O
investigated	O
by	O
ELISA	O
.	O

A	O
strong	O
positive	O
correlation	O
was	O
established	O
between	O
protection	O
and	O
the	O
ASC	O
responses	O
detected	O
in	O
gut	O
associated	O
lymphoid	O
tissues	O
and	O
blood	O
at	O
the	O
challenge	O
day	O
and	O
also	O
between	O
protection	O
and	O
serum	O
isotype	O
-	O
specific	O
antibody	B-PROC
titers	O
on	O
that	O
day	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
association	O
between	O
antibody	B-PROC
(	O
Ab	O
)	O
production	O
and	O
disease	B-PROC
resistance	I-PROC
.	O

ABSTRACT	O
:	O
Lead	O
,	O
a	O
ubiquitous	O
environmental	O
contaminant	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
various	O
functions	O
of	O
the	O
immune	O
system	O
and	O
decrease	O
host	O
resistance	B-PROC
to	O
infectious	O
disease	O
.	O

Rapid	O
recruitment	O
of	O
B	O
cells	O
in	O
the	O
absence	O
of	O
specific	O
Ab	O
secretion	B-PROC
supports	O
a	O
potential	O
Ab	O
-	O
independent	O
effector	O
function	O
involving	O
lysis	B-PROC
of	O
virus	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Sleep	B-PROC
apnea	O
is	O
one	O
of	O
the	O
most	O
frequent	O
manifestations	O
of	O
respiratory	O
obstruction	O
.	O

Mandibular	O
distraction	O
is	O
a	O
safe	O
and	O
reliable	O
procedure	O
for	O
treating	O
patients	O
with	O
obstructive	O
sleep	B-PROC
apnea	O
.	O

CONCLUSIONS	O
:	O
Mandibular	O
distraction	O
is	O
a	O
safe	O
and	O
reliable	O
procedure	O
for	O
treating	O
patients	O
with	O
obstructive	O
sleep	B-PROC
apnea	O
.	O

Oxygen	O
plus	O
nitric	O
oxide	O
inhalation	B-PROC
compared	O
with	O
oxygen	O
alone	O
increased	O
recruitment	O
of	O
alveolar	O
neutrophils	O
(	O
32	O
.	O
5	O
+/-	O

The	O
ex	O
vivo	O
alveolar	O
neutrophil	O
functions	O
were	O
similar	O
regardless	O
of	O
whether	O
rats	O
previously	O
inhaled	B-PROC
nitric	O
oxide	O
.	O

ABSTRACT	O
:	O
In	O
Mediterranean	O
areas	O
,	O
oral	O
allergy	B-PROC
syndrome	O
(	O
OAS	O
)	O
occurs	O
independently	O
of	O
an	O
associated	O
birch	O
pollinosis	O
;	O
moreover	O
,	O
on	O
occasions	O
it	O
presents	O
with	O
no	O
other	O
associated	O
pollinosis	O
.	O

Enzyme	O
allergosorbent	O
(	O
EAST	O
)-	O
inhibition	B-PROC
showed	O
high	O
inhibition	B-PROC
values	O
when	O
P	O
.	O
acerifolia	O
pollen	O
extract	O
was	O
used	O
as	O
free	O
phase	O
.	O

Finally	O
,	O
viral	O
RNA	B-PROC
synthesis	I-PROC
was	O
detected	O
by	O
labeling	O
with	O
5	O
-	O
bromouridine	O
5	O
'-	O
triphosphate	O
.	O

Northern	O
hybridization	B-PROC
using	O
probes	O
to	O
the	O
four	O
putative	O
GAV	O
ORFs	O
and	O
either	O
total	O
or	O
poly	O
(	O
A	O
)-	O
selected	O
RNA	O
identified	O
two	O
3	O
'-	O
coterminal	O
subgenomic	O
(	O
sg	O
)	O
mRNAs	O
of	O
approximately	O
6	O
kb	O
and	O
approximately	O
5	O
.	O
5	O
kb	O
.	O

Once	O
on	O
the	O
surface	O
of	O
infected	O
cells	O
and	O
virions	O
,	O
peripheral	O
S1	O
fragments	O
bind	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecule	O
(	O
CEACAM	O
)	O
receptors	O
,	O
and	O
this	O
triggers	O
membrane	B-PROC
fusion	I-PROC
reactions	O
mediated	O
by	O
integral	O
membrane	O
S2	O
fragments	O
.	O

7	O
%,	O
and	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
index	O
(	O
PVRI	O
)	O
from	O
(	O
16	O
+/-	O

Liver	O
Dialysis	O
employs	O
hemodiabsorption	O
(	O
dialysis	O
of	O
blood	O
against	O
powdered	O
sorbents	O
including	O
charcoal	O
and	O
cation	O
exchanger	B-PROC
)	O
to	O
remove	O
selectively	O
numerous	O
small	O
-	O
molecular	O
-	O
weight	O
toxins	O
of	O
hepatic	O
failure	O
.	O

Sorbent	O
columns	O
of	O
charcoal	O
and	O
an	O
anion	O
exchanger	B-PROC
remove	O
hepatic	O
toxins	O
from	O
the	O
albumin	O
dialysate	O
,	O
and	O
a	O
second	O
dialyzer	O
removes	O
water	O
-	O
soluble	O
toxins	O
,	O
such	O
as	O
ammonium	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
role	O
of	O
sPLA	O
(	O
2	O
)	O
in	O
chemokine	B-PROC
production	I-PROC
in	O
human	O
lung	O
microvascular	O
endothelial	O
cells	O
(	O
LMVEC	O
)	O
stimulated	O
with	O
the	O
endotoxins	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
lipoteichoic	O
acid	O
(	O
LTA	O
).	O

We	O
report	O
two	O
clinical	O
cases	O
characterized	O
by	O
late	O
onset	O
central	O
hypoventilation	O
syndrome	O
(	O
three	O
years	O
--	O
six	O
months	O
,	O
and	O
five	O
years	O
old	O
):	O
in	O
the	O
first	O
case	O
the	O
diagnosis	O
was	O
made	O
after	O
general	B-PROC
anesthesia	I-PROC
and	O
the	O
second	O
one	O
presented	O
with	O
acute	O
nocturnal	O
comatose	O
state	O
.	O

Nine	O
sera	O
from	O
uninfected	O
pigs	O
,	O
34	O
sera	O
from	O
16	O
pigs	O
experimentally	O
infected	O
with	O
TGEV	O
,	O
and	O
sera	O
from	O
10	O
pigs	O
experimentally	O
infected	O
with	O
PRCV	O
were	O
evaluated	O
using	O
both	O
the	O
TGEV	O
/	O
PRCV	O
blocking	O
ELISA	O
and	O
a	O
virus	B-PROC
neutralization	I-PROC
(	O
VN	O
)	O
assay	O
.	O

When	O
sera	O
from	O
specific	O
age	O
groups	O
were	O
compared	O
,	O
the	O
ELISA	O
identified	O
a	O
greater	O
proportion	O
(	O
0	O
.	O
83	O
)	O
of	O
pigs	O
in	O
herds	O
with	O
TGEV	O
antibody	B-PROC
when	O
suckling	O
piglets	O
were	O
used	O
.	O

Hemodynamics	B-PROC
,	O
pulmonary	O
mechanics	O
and	O
gas	O
exchange	O
were	O
observed	O
before	O
,	O
during	O
,	O
and	O
2	O
min	O
,	O
5	O
min	O
after	O
applying	O
SI	O
.	O

As	O
his	O
clinical	O
situation	O
deteriorated	O
rapidly	O
,	O
BMT	O
was	O
performed	O
with	O
unmanipulated	O
marrow	O
stem	O
cells	O
from	O
his	O
EBV	O
-	O
positive	O
HLA	O
-	O
identical	O
sister	O
after	O
conditioning	O
with	O
dexamethasone	O
(	O
1	O
.	O
75	O
mg	O
/	O
kg	O
/	O
day	O
),	O
cyclophosphamide	O
(	O
114	O
mg	O
/	O
kg	O
)	O
and	O
etoposide	O
(	O
10	O
mg	O
/	O
kg	O
),	O
with	O
no	O
immunosuppression	B-PROC
given	O
post	O
transplant	O
.	O

Engraftment	B-PROC
occurred	O
on	O
day	O
6	O
with	O
explosive	O
proliferation	O
of	O
donor	O
CD8	O
(+)	O
T	O
cells	O
.	O

The	O
carboxy	O
terminus	O
of	O
MHV	O
M	O
has	O
previously	O
been	O
shown	O
to	O
be	O
extremely	O
sensitive	O
to	O
mutation	O
,	O
both	O
in	O
a	O
virus	O
-	O
like	O
particle	O
expression	B-PROC
system	O
and	O
in	O
the	O
intact	O
virion	O
.	O

Electromyography	O
revealed	O
pronounced	O
denervation	O
activity	O
and	O
markedly	O
slow	O
nerve	O
conduction	B-PROC
velocity	I-PROC
(	O
3	O
m	O
/	O
s	O
)	O
with	O
evidence	O
of	O
conduction	B-PROC
block	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
experimental	O
virus	B-PROC
infection	I-PROC
may	O
induce	O
host	O
responses	O
that	O
provoke	O
enhanced	O
immunoglobulin	B-PROC
E	O
(	O
IgE	O
)	O
synthesis	B-PROC
.	O

Because	O
resistance	B-PROC
of	O
viridans	O
streptococci	O
to	O
a	O
variety	O
of	O
antimicrobial	O
agents	O
is	O
increasingly	O
recognized	O
,	O
penicillin	O
susceptibility	O
cannot	O
be	O
assumed	O
,	O
and	O
empirical	O
vancomycin	O
therapy	O
should	O
be	O
used	O
to	O
treat	O
neutropenic	O
patients	O
with	O
cancer	O
who	O
have	O
shock	O
or	O
are	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
reduced	O
MHV	O
production	O
in	O
SB	O
203580	O
-	O
treated	O
cells	O
was	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
a	O
decrease	O
in	O
virus	O
-	O
specific	O
protein	B-PROC
synthesis	I-PROC
and	O
virus	O
-	O
specific	O
mRNA	O
accumulation	O
.	O

Fluorogenic	O
nuclease	O
RT	O
-	O
PCR	O
assays	O
combine	O
RT	O
-	O
PCR	O
with	O
an	O
internal	O
fluorogenic	O
hybridization	B-PROC
probe	O
,	O
thereby	O
eliminating	O
post	O
-	O
PCR	O
processing	O
and	O
potentially	O
enhancing	O
specificity	O
.	O

The	O
patients	O
were	O
ventilated	O
with	O
a	O
mean	O
tidal	O
volume	O
of	O
11	O
.	O
0	O
+/-	O
0	O
.	O
5	O
mL	O
x	O
kg	O
(-	O
1	O
)	O
body	O
weight	O
(	O
bw	O
),	O
either	O
volume	O
or	O
pressure	O
controlled	O
,	O
with	O
16	O
.	O
3	O
+/-	O
2	O
.	O
8	O
cmH2O	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
,	O
for	O
an	O
average	O
of	O
3	O
.	O
5	O
+/-	O
0	O
.	O
3	O
days	O
at	O
study	O
entry	O
.	O

IPP	O
was	O
used	O
in	O
all	O
patients	O
including	O
those	O
with	O
recent	O
tracheostomy	O
,	O
open	O
abdomens	O
,	O
laparotomy	O
,	O
thoracotomy	O
,	O
leg	O
external	O
fixators	O
,	O
central	O
nervous	O
system	O
injury	O
,	O
continuous	O
venovenous	O
hemofiltration	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
cannulae	O
,	O
vasopressor	O
therapy	O
,	O
recent	O
chest	O
wall	O
open	O
reduction	O
and	O
internal	O
fixation	O
,	O
and	O
facial	O
fractures	O
.	O

Respiration	B-PROC
rates	O
were	O
recorded	O
hourly	O
.	O

Ergotamine	O
reduced	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
plasma	O
LH	O
and	O
increased	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
growth	B-PROC
hormone	O
concentrations	O
in	O
Brahman	O
.	O

The	O
individual	O
SNAP	O
items	O
that	O
contributed	O
most	O
to	O
SNAP	O
moderate	O
and	O
severe	O
categories	O
were	O
blood	B-PROC
gas	I-PROC
items	O
,	O
creatinine	O
,	O
urine	O
output	O
,	O
blood	O
glucose	O
,	O
and	O
seizures	O
.	O

Sensitivity	O
and	O
specificity	O
of	O
the	O
cELISA	O
for	O
detection	O
of	O
TCV	O
antibodies	O
were	O
determined	O
by	O
comparison	O
with	O
the	O
indirect	O
fluorescent	O
antibody	B-PROC
test	O
(	O
IFAT	O
)	O
with	O
1269	O
reference	O
,	O
experimentally	O
derived	O
,	O
and	O
field	O
-	O
origin	O
sera	O
.	O

The	O
remaining	O
two	O
isolates	O
,	O
N	O
-	O
M24	O
and	O
N	O
-	O
M39	O
,	O
that	O
did	O
not	O
react	O
with	O
Mass	O
-	O
specific	O
Mab	O
,	O
resisted	O
neutralization	O
by	O
Mass	O
-	O
specific	O
chicken	O
serum	O
,	O
and	O
were	O
neutralized	O
only	O
by	O
homologous	O
chicken	O
antibody	B-PROC
were	O
identified	O
as	O
non	O
-	O
Mass	O
IBV	O
.	O

We	O
report	O
two	O
new	O
cases	O
of	O
documented	O
grade	O
III	O
anaphylaxis	O
,	O
leading	O
to	O
death	B-PROC
in	O
one	O
patient	O
.	O

Despite	O
immediate	O
life	O
support	O
,	O
the	O
postoperative	O
period	O
was	O
complicated	O
by	O
persistent	O
low	O
systolic	O
pressure	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
renal	O
failure	O
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
and	O
pancreatitis	O
,	O
leading	O
to	O
the	O
death	B-PROC
of	O
the	O
patient	O
.	O

RESULTS	O
:	O
All	O
patients	O
showed	O
at	O
least	O
a	O
25	O
%	O
reduction	O
in	O
oxygenation	B-PROC
index	O
within	O
2	O
h	O
of	O
HFO	O
,	O
with	O
return	O
to	O
conventional	O
ventilation	O
after	O
27	O
-	O
65	O
h	O
.	O

This	O
review	O
concentrates	O
on	O
in	O
vivo	O
studies	O
of	O
cytokine	O
involvement	O
in	O
infectious	O
respiratory	O
diseases	O
of	O
swine	O
,	O
with	O
an	O
emphasis	O
on	O
viral	B-PROC
infections	I-PROC
.	O

Staphylococcal	O
enterotoxin	O
B	O
produces	O
a	O
syndrome	O
of	O
fever	B-PROC
,	O
nausea	O
,	O
and	O
diarrhea	O
and	O
may	O
produce	O
a	O
pulmonary	O
syndrome	O
if	O
aerosolized	O
.	O

The	O
molecular	O
mechanisms	O
governing	O
leukocyte	B-PROC
trafficking	B-PROC
and	O
accumulation	O
within	O
the	O
CNS	O
of	O
MHV	O
-	O
infected	O
mice	O
are	O
just	O
now	O
being	O
understood	O
and	O
recent	O
studies	O
indicate	O
that	O
chemokines	O
and	O
chemokine	O
receptors	O
have	O
an	O
important	O
role	O
in	O
this	O
process	O
.	O

Differentiation	B-PROC
of	O
turkey	O
anti	O
-	O
TCoV	O
antiserum	O
from	O
normal	O
turkey	O
serum	O
was	O
better	O
achieved	O
by	O
ELISA	O
plates	O
coated	O
with	O
TCoV	O
preparation	O
purified	O
by	O
size	O
-	O
exclusion	O
chromatography	O
than	O
that	O
purified	O
by	O
sucrose	O
density	O
gradient	O
.	O

TITLE	O
:	O
Failure	O
to	O
spread	O
bovine	O
virus	O
diarrhoea	O
virus	B-PROC
infection	I-PROC
from	O
primarily	O
infected	O
calves	O
despite	O
concurrent	O
infection	O
with	O
bovine	O
coronavirus	O
.	O

This	O
finding	O
supports	O
the	O
principle	O
of	O
the	O
Scandinavian	O
BVDV	O
control	O
programmes	O
that	O
elimination	B-PROC
of	O
BVDV	O
infection	O
from	O
cattle	O
populations	O
can	O
be	O
achieved	O
by	O
identifying	O
and	O
removing	O
persistently	O
infected	O
(	O
PI	O
)	O
animals	O
,	O
i	O
.	O
e	O
.	O
that	O
long	O
-	O
term	O
circulation	B-PROC
of	O
the	O
virus	O
without	O
the	O
presence	O
of	O
PI	O
animals	O
is	O
highly	O
unlikely	O
.	O

Increased	O
induction	O
of	O
MMP	O
,	O
TIMP	O
,	O
and	O
chemokine	O
expression	B-PROC
correlated	O
with	O
increased	O
virus	B-PROC
replication	I-PROC
but	O
not	O
with	O
inflammatory	O
cell	O
infiltration	O
.	O

In	O
addition	O
,	O
GM	O
-	O
CSF	O
therapy	O
was	O
not	O
associated	O
with	O
worsened	O
acute	O
respiratory	O
distress	O
syndrome	O
or	O
the	O
multiple	O
organ	O
dysfunction	O
syndrome	O
,	O
suggesting	O
a	O
homeostatic	B-PROC
role	O
for	O
GM	O
-	O
CSF	O
in	O
sepsis	O
-	O
related	O
pulmonary	O
dysfunction	O
.	O

Coagulation	B-PROC
becomes	O
activated	O
by	O
circulating	O
endotoxin	O
or	O
bacteria	O
,	O
and	O
a	O
procoagulant	O
state	O
develops	O
in	O
the	O
vascular	O
and	O
the	O
alveolar	O
compartments	O
of	O
the	O
lung	O
.	O

Eleven	O
percent	O
of	O
cattle	O
had	O
antibody	B-PROC
titers	O
against	O
BCV	O
at	O
0	O
DPA	O
and	O
91	O
%	O
of	O
cattle	O
seroconverted	O
to	O
BCV	O
by	O
21	O
DPA	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
a	O
case	O
of	O
severe	O
skin	O
necrosis	B-PROC
resulting	O
from	O
peripheral	O
intravenous	O
administration	O
of	O
low	O
-	O
dose	O
vasopressin	O
in	O
a	O
patient	O
with	O
catecholamine	O
-	O
resistant	O
septic	O
shock	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
antibody	B-PROC
response	I-PROC
to	O
canine	O
coronavirus	O
infection	O
in	O
dogs	O
by	O
Western	O
Blotting	O
analysis	O
.	O

The	O
cell	B-PROC
proliferation	I-PROC
response	O
detected	O
in	O
blood	O
mirrored	O
that	O
detected	O
in	O
the	O
mesenteric	O
lymph	O
nodes	O
,	O
and	O
showed	O
also	O
good	O
correlation	O
with	O
protection	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
systemic	O
arterial	B-PROC
pressure	I-PROC
or	O
arterial	O
methaemoglobin	O
concentration	O
after	O
DETA	O
/	O
NO	O
inhalation	B-PROC
.	O

The	O
most	O
relevant	O
applications	O
of	O
inhaled	B-PROC
NO	O
are	O
in	O
infants	O
with	O
primary	O
pulmonary	O
hypertension	O
or	O
hypoxia	O
.	O

Attempts	O
to	O
improve	O
CO	O
(	O
2	O
)	O
elimination	B-PROC
by	O
a	O
decrease	O
in	O
the	O
HFOV	O
oscillatory	O
frequency	O
and	O
an	O
increase	O
in	O
the	O
amplitude	O
pressure	O
failed	O
.	O

Of	O
the	O
10	O
U	O
of	O
plasma	O
used	O
,	O
one	O
was	O
from	O
a	O
multiparous	O
female	O
donor	O
with	O
HLA	O
antibodies	O
reactive	O
with	O
patient	O
'	O
s	O
granulocytes	O
in	O
immunofluorescence	O
and	O
agglutination	B-PROC
assays	O
.	O

Eighty	O
-	O
eight	O
patients	O
with	O
severe	O
multiple	O
trauma	O
were	O
admitted	O
into	O
Department	O
of	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
and	O
the	O
cardiovascular	O
,	O
respiratory	O
,	O
renal	O
,	O
and	O
coagulation	B-PROC
functions	O
,	O
milieu	O
interieur	O
,	O
and	O
infectious	O
sources	O
were	O
monitored	O
.	O

Lung	O
tissues	O
were	O
analyzed	O
for	O
activation	B-PROC
of	I-PROC
NF	I-PROC
-	I-PROC
kappaB	I-PROC
,	O
myeloperoxidase	O
activity	O
,	O
and	O
wet	O
/	O
dry	O
weight	O
ratio	O
.	O

The	O
underlying	O
pathological	O
events	O
were	O
respectively	O
pulmonary	O
tuberculosis	O
and	O
upper	O
respiratory	O
infection	O
in	O
the	O
two	O
monophasic	O
cases	O
;	O
in	O
the	O
22	O
recurrent	O
ONM	O
patients	O
:	O
pulmonary	O
tuberculosis	O
(	O
3	O
),	O
neurocysticercosis	O
(	O
1	O
),	O
polyarteritis	O
nodosa	O
(	O
1	O
),	O
antinuclear	O
antibody	B-PROC
and	O
rheumatoid	O
factor	O
(	O
1	O
),	O
antiphospholipid	O
antibody	B-PROC
primary	O
syndrome	O
(	O
1	O
),	O
diabetes	O
mellitus	O
(	O
1	O
),	O
hypothyroidism	O
(	O
1	O
),	O
and	O
amenorrhea	O
-	O
galactorrhea	O
(	O
4	O
).	O

These	O
marked	O
-	O
NDV	O
recombinants	O
,	O
in	O
conjunction	O
with	O
a	O
diagnostic	O
test	O
,	O
enable	O
serological	O
differentiation	B-PROC
of	O
vaccinated	O
animals	O
from	O
infected	O
animals	O
and	O
may	O
be	O
useful	O
tools	O
in	O
ND	O
eradication	O
programs	O
.	O

TITLE	O
:	O
Tissue	O
distribution	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
following	O
in	O
ovo	O
inoculation	O
of	O
chicken	O
embryos	O
examined	O
by	O
in	O
situ	O
hybridization	B-PROC
with	O
antisense	O
digoxigenin	O
-	O
labeled	O
universal	O
riboprobe	O
.	O

In	O
situ	O
hybridization	B-PROC
with	O
this	O
probe	O
will	O
be	O
useful	O
for	O
understanding	O
the	O
tissue	B-PROC
tropism	B-PROC
and	O
the	O
pathogenesis	B-PROC
of	O
IBV	O
in	O
vivo	O
.	O

This	O
dramatic	O
result	O
indicated	O
that	O
the	O
absence	O
of	O
FGF2	O
promoted	O
oligodendrocyte	O
regeneration	B-PROC
,	O
possibly	O
by	O
enhancing	O
oligodendrocyte	B-PROC
progenitor	I-PROC
proliferation	I-PROC
and	O
/	O
or	O
differentiation	B-PROC
.	O

We	O
used	O
leukocyte	O
uptake	O
of	O
the	O
glucose	O
analog	O
[	O
18F	O
]	O
fluorodeoxyglucose	O
(	O
18FDG	O
),	O
which	O
indicates	O
postmigrational	O
neutrophil	O
activity	O
,	O
to	O
identify	O
and	O
quantify	O
the	O
relationship	O
between	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
neutrophil	B-PROC
activation	I-PROC
in	O
experimental	O
pancreatitis	O
in	O
rats	O
.	O

The	O
sheep	O
developed	O
a	O
hyperkinetic	O
cardiovascular	O
response	O
concomitant	O
with	O
a	O
decrease	O
in	O
Pao	B-PROC
similar	O
to	O
severe	O
sepsis	O
in	O
human	O
patients	O
who	O
meet	O
the	O
criteria	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO2	O
/	O
FIO2	O
<	O
200	O
).	O

These	O
changes	O
were	O
more	O
severe	O
than	O
in	O
animals	O
exposed	O
to	O
smoke	O
inhalation	B-PROC
alone	O
.	O

We	O
report	O
what	O
we	O
believe	O
to	O
be	O
the	O
first	O
case	O
of	O
posterior	O
ischemic	O
optic	O
neuropathy	O
due	O
to	O
perioperative	O
hypotension	O
in	O
a	O
patient	O
who	O
had	O
a	O
penetrating	O
thoracoabdominal	O
injury	O
with	O
massive	O
hemorrhage	O
,	O
severe	O
hypotension	O
,	O
massive	O
microcapillary	O
circulatory	B-PROC
leak	O
,	O
multiple	O
system	O
organ	O
failure	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
examined	O
the	O
contribution	O
of	O
differences	O
in	O
cellular	B-PROC
tropism	B-PROC
,	O
viral	O
spread	O
,	O
and	O
the	O
immune	B-PROC
response	I-PROC
to	O
infection	O
to	O
the	O
differential	O
neurovirulence	O
of	O
S	O
(	O
4	O
)	O
R	O
and	O
S	O
(	O
A59	O
)	O
R	O
.	O
MHV	O
-	O
4	O
spike	O
-	O
mediated	O
neurovirulence	O
was	O
associated	O
with	O
extensive	O
viral	O
spread	O
in	O
the	O
brain	O
in	O
both	O
neurons	O
and	O
astrocytes	O
.	O

FIo2	O
,	O
arterial	O
blood	B-PROC
gases	I-PROC
,	O
mean	O
airway	O
pressure	O
(	O
mean	O
Paw	O
),	O
blood	B-PROC
pressure	I-PROC
,	O
heart	O
rate	O
and	O
central	O
venous	B-PROC
pressure	I-PROC
were	O
recorded	O
by	O
4	O
,	O
8	O
,	O
12	O
,	O
24	O
,	O
48	O
and	O
72	O
h	O
of	O
HFOV	O
and	O
compared	O
to	O
conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
)	O
at	O
baseline	O
(	O
4	O
h	O
prior	O
to	O
HFOV	O
).	O

All	O
were	O
ventilated	O
by	O
HFOV	O
as	O
the	O
primary	O
mode	O
of	O
ventilation	O
using	O
the	O
high	O
volume	O
strategy	O
aimed	O
at	O
optimizing	O
lung	B-PROC
volume	I-PROC
.	O

ABSTRACT	O
:	O
A	O
segment	O
of	O
genomic	O
RNA	O
extending	O
from	O
the	O
3	O
'-	O
end	O
of	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
gene	O
to	O
the	O
5	O
'-	O
end	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
gene	O
of	O
Turkey	O
coronavirus	O
(	O
TCV	O
)	O
was	O
amplified	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

ABSTRACT	O
:	O
The	O
observation	O
that	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
develop	O
autoantibodies	O
directed	O
mainly	O
to	O
liver	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
)	O
enabled	O
the	O
development	B-PROC
of	O
an	O
ELISA	O
applicable	O
to	O
the	O
detection	O
of	O
MHV	O
-	O
infection	O
.	O

ABSTRACT	O
:	O
Targeted	B-PROC
recombination	B-PROC
was	O
used	O
to	O
select	O
mouse	O
hepatitis	O
virus	O
isolates	O
with	O
stable	O
and	O
efficient	O
expression	B-PROC
of	O
the	O
gene	O
encoding	O
the	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
).	O

They	O
caused	O
encephalitis	O
and	O
demyelination	O
in	O
animals	O
as	O
wild	O
-	O
type	O
virus	O
;	O
however	O
,	O
they	O
were	O
somewhat	O
attenuated	O
in	O
virulence	B-PROC
.	O

Thus	O
,	O
EGFP	O
-	O
expressing	O
viruses	O
will	O
be	O
useful	O
in	O
the	O
studies	O
of	O
murine	O
coronavirus	O
pathogenesis	B-PROC
in	O
mice	O
.	O

TITLE	O
:	O
Differential	O
induction	B-PROC
of	I-PROC
apoptosis	I-PROC
in	O
demyelinating	O
and	O
nondemyelinating	O
infection	O
by	O
mouse	O
hepatitis	O
virus	O
.	O

The	O
presence	O
of	O
TUNEL	O
staining	O
in	O
oligodendrocytes	O
suggests	O
that	O
apoptosis	B-PROC
may	O
play	O
an	O
important	O
role	O
in	O
MHV	O
-	O
induced	O
demyelination	O
.	O

ABSTRACT	O
:	O
Elimination	B-PROC
of	O
an	O
enzootic	O
infection	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
from	O
a	O
large	O
population	O
of	O
genetically	O
engineered	O
mice	O
was	O
accomplished	O
by	O
selecting	O
seropositive	O
,	O
non	O
-	O
infective	O
breeders	O
for	O
a	O
newly	O
restored	O
MHV	O
-	O
free	O
breeding	B-PROC
colony	O
.	O

An	O
ELISA	O
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
MHV	O
-	O
specific	O
antibody	B-PROC
,	O
and	O
TaqMan	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
was	O
used	O
to	O
detect	O
MHV	O
in	O
the	O
feces	O
.	O

TITLE	O
:	O
In	O
vitro	O
detection	O
of	O
apoptosis	B-PROC
in	O
monocytes	O
/	O
macrophages	O
infected	O
with	O
human	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
strain	O
229E	O
infection	O
,	O
but	O
not	O
HCoV	O
strain	O
OC43	O
infection	O
,	O
of	O
monocytes	O
/	O
macrophages	O
from	O
healthy	O
donors	O
and	O
patients	O
with	O
multiple	O
sclerosis	O
in	O
remission	O
resulted	O
in	O
increased	O
apoptosis	B-PROC
,	O
as	O
measured	O
by	O
DNA	O
changes	O
and	O
annexin	O
V	O
staining	O
.	O

Its	O
origins	O
are	O
during	O
fetal	B-PROC
development	B-PROC
.	O

However	O
,	O
this	O
period	O
demonstrates	O
much	O
less	O
instability	O
than	O
does	O
the	O
neonatal	O
period	O
,	O
when	O
most	O
deaths	B-PROC
from	O
congenital	O
defects	O
and	O
severe	O
maternal	O
anemia	O
occur	O
.	O

The	O
best	O
cutoff	O
point	O
for	O
urinary	O
PROP	O
to	O
predict	O
overall	O
severity	O
was	O
>	O
1	O
nmol	O
/	O
l	O
<	O
or	O
=	O
48	O
h	O
after	O
symptom	O
onset	O
(	O
negative	O
predictive	O
value	O
=	O
88	O
%),	O
but	O
the	O
PROP	O
levels	O
failed	O
to	O
predict	O
the	O
development	B-PROC
of	O
multi	O
-	O
organ	O
dysfunction	O
.	O

There	O
were	O
18	O
,	O
133	O
patients	O
identified	O
,	O
and	O
544	O
were	O
excluded	O
because	O
of	O
early	O
death	B-PROC
.	O

ABSTRACT	O
:	O
Despite	O
their	O
high	O
frequency	O
of	O
RNA	O
recombination	B-PROC
,	O
the	O
plus	O
-	O
strand	O
coronaviruses	O
have	O
a	O
characteristic	O
,	O
strictly	O
conserved	O
genome	O
organization	O
with	O
the	O
essential	O
genes	O
occurring	O
in	O
the	O
order	O
5	O
'-	O
polymerase	O
(	O
pol	O
)-	O
S	O
-	O
E	O
-	O
M	O
-	O
N	O
-	O
3	O
'.	O

An	O
increase	O
in	O
the	O
amount	O
of	O
Fas	O
(	O
APO	O
-	O
1	O
/	O
CD95	O
),	O
caspase	O
-	O
8	O
activation	O
,	O
caspase	O
-	O
8	O
-	O
mediated	O
Bid	O
cleavage	B-PROC
,	O
and	O
subsequent	O
translocation	B-PROC
of	O
truncated	O
Bid	O
to	O
mitochondria	O
,	O
all	O
of	O
which	O
relate	O
to	O
the	O
Fas	O
-	O
mediated	O
pathway	B-PROC
,	O
also	O
occurred	O
in	O
MHV	O
-	O
infected	O
17Cl	O
-	O
1	O
cells	O
,	O
whereas	O
the	O
formation	B-PROC
of	O
the	O
death	B-PROC
-	O
inducing	O
signaling	B-PROC
complex	O
,	O
a	O
direct	O
indication	O
of	O
the	O
activation	O
of	O
Fas	O
-	O
mediated	O
pathway	B-PROC
,	O
was	O
undetectable	O
.	O

This	O
study	O
redirects	O
our	O
current	O
approach	O
of	O
utilizing	O
the	O
MHV	O
targeted	B-PROC
RNA	O
recombination	B-PROC
as	O
a	O
means	O
to	O
study	O
bovine	O
coronavirus	O
genetics	O
towards	O
the	O
construction	O
of	O
an	O
infectious	O
cDNA	O
clone	O
.	O

The	O
use	O
of	O
HFOV	O
improves	O
oxygenation	B-PROC
by	O
increasing	O
lung	O
recruitment	O
.	O

TITLE	O
:	O
Discontinuous	O
and	O
non	O
-	O
discontinuous	O
subgenomic	O
RNA	O
transcription	B-PROC
in	O
a	O
nidovirus	O
.	O

Apparently	O
,	O
BEV	O
combines	O
discontinuous	O
and	O
non	O
-	O
discontinuous	O
RNA	B-PROC
synthesis	I-PROC
to	O
produce	O
its	O
sg	O
mRNAs	O
.	O

Transgenic	O
plants	O
are	O
now	O
recognized	O
as	O
legitimate	O
sources	O
for	O
these	O
proteins	O
,	O
especially	O
in	O
the	O
developing	O
area	O
of	O
oral	O
vaccines	O
,	O
because	O
antigens	O
have	O
been	O
shown	O
to	O
be	O
correctly	O
processed	O
in	O
plants	O
into	O
forms	O
that	O
elicit	O
immune	B-PROC
responses	I-PROC
when	O
fed	O
to	O
animals	O
or	O
humans	O
.	O

Antigens	O
expressed	B-PROC
in	O
maize	O
(	O
Zea	O
mays	O
)	O
are	O
particularly	O
attractive	O
since	O
they	O
can	O
be	O
deposited	O
in	O
the	O
natural	O
storage	B-PROC
vessel	O
,	O
the	O
corn	O
seed	O
,	O
and	O
can	O
be	O
conveniently	O
delivered	O
to	O
any	O
organism	O
that	O
consumes	O
grain	O
.	O

To	O
clarify	O
the	O
precise	O
function	O
of	O
PTB	O
in	O
MHV	O
replication	O
,	O
we	O
dissociated	O
the	O
processes	O
of	O
viral	B-PROC
transcription	B-PROC
from	O
translation	B-PROC
by	O
transfecting	O
different	O
types	O
of	O
MHV	O
defective	O
-	O
interfering	O
(	O
DI	O
)	O
RNA	O
that	O
contain	O
various	O
reporter	O
genes	O
into	O
these	O
stable	O
cell	O
lines	O
.	O

Transcription	B-PROC
of	O
the	O
DI	O
RNA	O
during	O
MHV	O
infection	O
was	O
greatly	O
inhibited	O
in	O
these	O
cell	O
lines	O
,	O
indicating	O
that	O
PTB	O
modulates	O
MHV	O
transcription	B-PROC
.	O

Perforin	O
-	O
mediated	O
cytolysis	B-PROC
controls	O
virus	O
in	O
microglia	O
/	O
macrophages	O
and	O
astrocytes	O
,	O
whereas	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
regulates	O
viral	B-PROC
replication	I-PROC
in	O
oligodendroglia	O
.	O

That	O
the	O
recombinant	O
virus	O
elicited	O
anti	O
-	O
IBV	O
protective	O
immunity	B-PROC
was	O
indicated	O
by	O
the	O
manifested	O
,	O
relatively	O
mild	O
clinical	O
signs	O
of	O
disease	O
,	O
decreased	O
titers	O
of	O
recovered	O
challenge	O
virus	O
,	O
and	O
less	O
severe	O
histologic	O
changes	O
of	O
the	O
tracheas	O
in	O
virulent	O
IBV	O
Mass	O
41	O
-	O
challenged	O
chickens	O
previously	O
receiving	O
rFPV	O
-	O
S1	O
as	O
compared	O
with	O
parental	O
fowl	O
poxvirus	O
(	O
FPV	O
)-	O
vaccinated	O
control	O
birds	O
.	O

Serum	O
IBV	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
antibody	B-PROC
geometric	O
mean	O
titers	O
(	O
GMTs	O
)	O
after	O
vaccination	O
with	O
the	O
combinations	O
of	O
live	O
attenuated	O
strains	O
were	O
low	O
,	O
ranging	O
from	O
184	O
to	O
1	O
,	O
354	O
,	O
prior	O
to	O
NIBV	O
challenge	O
at	O
10	O
wk	O
of	O
age	O
.	O

Mice	O
deficient	O
in	O
IL	O
-	O
2	O
,	O
IL	O
-	O
2Ralpha	O
,	O
and	O
IL	O
-	O
2Rbeta	O
are	O
each	O
characterized	O
by	O
a	O
rapid	O
lethal	O
autoimmune	O
lymphoproliferative	O
disorder	O
that	O
complicates	O
their	O
use	O
in	O
studies	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
these	O
cytokines	O
and	O
receptors	O
for	O
immune	B-PROC
responses	I-PROC
in	O
vivo	O
.	O

Thus	O
,	O
although	O
T	O
effector	O
function	O
is	O
somewhat	O
impaired	O
,	O
T	O
cell	O
immunity	B-PROC
is	O
largely	O
functional	O
in	O
the	O
absence	O
of	O
IL	O
-	O
2	O
-	O
and	O
IL	O
-	O
15	O
-	O
induced	O
signaling	B-PROC
through	O
IL	O
-	O
2Rbeta	O
.	O

TITLE	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-PROC
of	O
an	O
invertebrate	O
nidovirus	O
links	O
coronavirus	O
and	O
potyvirus	O
homologs	O
.	O

Neurofilament	O
immunostaining	O
of	O
spinal	O
cord	O
sections	O
demonstrates	O
that	O
axonal	O
injury	O
with	O
oligodendrocyte	B-PROC
apoptosis	I-PROC
also	O
precedes	O
demyelination	O
in	O
an	O
animal	O
model	O
for	O
MS	O
,	O
Theiler	O
'	O
s	O
murine	O
encephalomyelitis	O
virus	B-PROC
infection	I-PROC
.	O

In	O
a	O
10	O
-	O
month	O
period	O
eight	O
(	O
three	O
gestational	O
,	O
five	O
pre	O
-	O
gestational	O
)	O
women	O
received	O
antenatal	O
corticosteroids	O
from	O
a	O
total	O
of	O
37	O
diabetic	O
pregnancies	B-PROC
.	O

TITLE	O
:	O
M	O
gene	O
evolution	B-PROC
of	O
canine	O
coronavirus	O
in	O
naturally	O
infected	O
dogs	O
.	O

The	O
virus	O
was	O
detected	O
intermittently	O
in	O
the	O
pups	O
'	O
faeces	O
by	O
PCR	O
for	O
periods	B-PROC
of	O
156	O
and	O
146	O
days	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-PROC
1alpha	O
(	O
STAT1	O
alpha	O
)	O
is	O
reported	O
to	O
be	O
essential	O
for	O
IFN	O
-	O
gamma	O
and	O
IFN	O
-	O
alpha	O
regulated	O
gene	B-PROC
expression	I-PROC
,	O
while	O
STAT1	O
beta	O
,	O
an	O
alternate	O
splice	O
-	O
form	O
,	O
mediates	O
only	O
IFN	O
-	O
alpha	O
-	O
dependent	O
gene	B-PROC
expression	I-PROC
.	O

The	O
pathogenesis	B-PROC
,	O
transmission	O
,	O
and	O
/	O
or	O
population	O
-	O
level	O
influences	O
of	O
M	O
.	O
gallisepticum	O
,	O
M	O
.	O
synoviae	O
,	O
and	O
REV	O
in	O
Rio	O
Grande	O
wild	O
turkeys	O
deserves	O
further	O
study	O
.	O

ABSTRACT	O
:	O
Acute	O
demyelination	O
of	O
adult	O
CNS	O
,	O
resulting	O
from	O
trauma	O
or	O
disease	O
,	O
is	O
initially	O
followed	O
by	O
remyelination	B-PROC
.	O

We	O
cultured	O
glial	O
cells	O
directly	O
from	O
demyelinating	O
and	O
remyelinating	O
spinal	O
cords	O
using	O
conditions	O
that	O
maintain	O
the	O
dramatically	O
enhanced	O
OP	O
proliferative	O
response	O
prior	O
to	O
CNS	O
remyelination	B-PROC
.	O

This	O
was	O
associated	O
with	O
an	O
increase	O
in	O
PaO	B-PROC
(	O
2	O
)	O
and	O
a	O
decrease	O
in	O
total	O
static	O
compliance	O
.	O

ARDS	O
is	O
a	O
biphasic	O
disease	O
that	O
includes	O
an	O
acute	O
phase	O
,	O
consisting	O
of	O
severe	O
leukocyte	O
infiltration	O
,	O
edema	O
,	O
hemorrhage	O
,	O
and	O
the	O
formation	B-PROC
of	O
hyaline	O
membranes	O
,	O
and	O
a	O
chronic	O
phase	O
,	O
which	O
is	O
characterized	O
by	O
persistent	O
intra	O
-	O
alveolar	O
and	O
interstitial	O
fibrosis	O
.	O

These	O
trials	O
showed	O
consistently	O
that	O
,	O
in	O
these	O
patients	O
,	O
the	O
use	O
of	O
low	O
dose	O
of	O
corticosteroids	O
alleviated	O
inflammation	O
,	O
restored	O
cardiovascular	O
homeostasis	B-PROC
,	O
reduced	O
organ	O
dysfunction	O
,	O
improved	O
survival	O
and	O
was	O
safe	O
.	O

Hemodynamic	B-PROC
alterations	O
,	O
immune	B-PROC
response	I-PROC
,	O
and	O
direct	O
nephrotoxicity	O
are	O
responsible	O
for	O
the	O
development	B-PROC
of	O
renal	O
lesions	O
.	O

Distinct	O
positive	O
signals	O
for	O
PEDV	O
and	O
TGEV	O
were	O
also	O
detected	O
in	O
the	O
same	O
jejunal	O
tissues	O
by	O
in	O
situ	O
hybridization	B-PROC
.	O

TITLE	O
:	O
Acute	O
oxygenation	B-PROC
response	O
to	O
inhaled	B-PROC
nitric	O
oxide	O
when	O
combined	O
with	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
adults	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
To	O
prospectively	O
evaluate	O
the	O
oxygenation	B-PROC
effect	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
INO	O
)	O
delivered	O
during	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
adult	O
patients	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
oxygenation	B-PROC
failure	O
.	O

In	O
addition	O
,	O
specific	O
markers	O
may	O
be	O
useful	O
for	O
predicting	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
or	O
for	O
assessing	O
prognosis	O
.	O

In	O
this	O
report	O
we	O
show	O
that	O
expressed	B-PROC
coronavirus	O
envelope	O
protein	O
M	O
specifically	O
interacted	O
with	O
coexpressed	O
noncoronavirus	O
RNA	O
transcripts	O
containing	O
the	O
short	O
viral	B-PROC
packaging	I-PROC
signal	O
in	O
the	O
absence	O
of	O
coronavirus	O
N	O
protein	O
.	O

Positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
averaged	O
16	O
.	O
6	O
+/-	O
4	O
mbar	O
in	O
the	O
high	O
PEEP	O
and	O
7	O
.	O
6	O
+/-	O
2	O
.	O
2	O
mbar	O
in	O
the	O
low	O
PEEP	O
group	O
.	O

Nevertheless	O
,	O
PDT	O
did	O
not	O
significantly	O
decrease	O
oxygenation	B-PROC
in	O
either	O
group	O
1	O
and	O
24	O
h	O
after	O
PDT	O
(	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
):	O
223	O
+/-	O
83	O
and	O
260	O
+/-	O
86	O
mmHg	O
in	O
the	O
high	O
PEEP	O
group	O
and	O
280	O
+/-	O
88	O
and	O
302	O
+/-	O
82	O
mmHg	O
in	O
the	O
low	O
PEEP	O
group	O
,	O
respectively	O
).	O

Furthermore	O
,	O
oxygenation	B-PROC
did	O
not	O
deteriorate	O
with	O
PDT	O
even	O
in	O
patients	O
with	O
gravely	O
impaired	O
gas	O
exchange	O
(	O
lowest	O
quartile	O
)	O
with	O
a	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
averaging	O
130	O
+/-	O
42	O
mmHg	O
(	O
range	O
45	O
-	O
192	O
mmHg	O
)	O
at	O
a	O
PEEP	O
of	O
17	O
+/-	O
4	O
mbar	O
.	O

Molecular	O
modeling	O
studies	O
led	O
to	O
the	O
synthesis	B-PROC
of	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)-	O
N	O
-(	O
p	O
-	O
substituted	O
phenyl	O
)-	O
N	O
-	O
acylthiocarbamates	O
,	O
which	O
showed	O
in	O
vitro	O
activities	O
against	O
HIV	O
-	O
1	O
in	O
the	O
low	O
nanomolar	O
range	O
.	O

Oxygenation	B-PROC
improved	O
rapidly	O
,	O
and	O
early	O
operative	O
stabilization	O
was	O
possible	O
.	O

As	O
judged	O
from	O
the	O
pattern	O
of	O
soluble	O
cytokines	O
in	O
plasma	O
and	O
the	O
effect	O
of	O
the	O
plasma	O
on	O
monocyte	B-PROC
activation	I-PROC
by	O
LPS	O
,	O
mild	O
,	O
localized	O
infection	O
can	O
induce	O
a	O
systemic	O
response	O
that	O
is	O
predominantly	O
anti	O
-	O
inflammatory	O
.	O

TITLE	O
:	O
Early	O
alterations	O
in	O
neutrophil	B-PROC
activation	I-PROC
are	O
associated	O
with	O
outcome	O
in	O
acute	O
lung	O
injury	O
.	O

After	O
PTE	O
,	O
he	O
developed	O
severe	O
RPE	O
,	O
PH	O
,	O
hypoxia	O
and	O
bronchial	O
bleeding	O
,	O
resulting	O
in	O
failed	O
weaning	B-PROC
from	O
cardiopulmonary	O
bypass	O
.	O

Moreover	O
,	O
these	O
molecules	O
also	O
regulate	O
T	B-PROC
-	I-PROC
cell	I-PROC
activation	I-PROC
and	O
differentiation	B-PROC
following	O
antigenic	O
stimulation	O
.	O

TITLE	O
:	O
Differences	O
between	O
BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6	O
mice	O
in	O
mouse	O
hepatitis	O
virus	B-PROC
replication	I-PROC
in	O
primary	O
hepatocyte	O
culture	O
.	O

Memory	B-PROC
immune	O
T	O
cells	O
collected	O
at	O
3	O
to	O
6	O
weeks	O
p	O
.	O
i	O
.	O

Despite	O
this	O
improvement	O
in	O
early	O
survival	O
,	O
delayed	O
graft	O
failure	O
related	O
to	O
chronic	O
graft	B-PROC
rejection	I-PROC
continues	O
to	O
limit	O
the	O
survival	O
and	O
function	O
of	O
lung	O
transplant	O
recipients	O
.	O

Chronic	O
lung	O
transplant	B-PROC
rejection	I-PROC
Bronchiolitis	O
obliterans	O
(	O
BO	O
)	O
is	O
an	O
inflammatory	O
process	O
that	O
leads	O
to	O
fibrous	O
scarring	O
of	O
the	O
terminal	O
and	O
respiratory	O
bronchioles	O
and	O
subsequent	O
total	O
occlusion	B-PROC
of	O
the	O
airways	O
.	O

Better	O
understanding	O
of	O
the	O
pathophysiology	O
,	O
and	O
earlier	O
recognition	O
of	O
BO	O
may	O
result	O
in	O
improved	O
long	O
term	O
patient	O
and	O
graft	B-PROC
survival	I-PROC
and	O
function	O
.	O

As	O
monitored	O
by	O
RT	O
-	O
PCR	O
,	O
mRNA	O
for	O
the	O
2	O
splice	O
variants	O
,	O
VEGF	O
(	O
121	O
)	O
and	O
VEGF	O
(	O
165	O
),	O
and	O
for	O
VEGFR	O
-	O
2	O
/	O
KDR	O
were	O
expressed	B-PROC
in	O
both	O
groups	O
,	O
the	O
yields	O
being	O
lower	O
in	O
the	O
sepsis	O
group	O
.	O

Patients	O
were	O
randomized	O
for	O
conventional	O
therapy	O
(	O
control	O
)	O
or	O
continuous	O
treatment	O
with	O
10	O
parts	O
per	O
million	O
(	O
ppm	O
)	O
inhaled	B-PROC
NO	O
until	O
weaning	B-PROC
was	O
initiated	O
.	O

The	O
results	O
provide	O
definitive	O
evidence	O
that	O
iNOS	O
is	O
a	O
key	O
mediator	O
of	O
pulmonary	O
pathology	O
in	O
sheep	O
with	O
ARDS	O
resulting	O
from	O
combined	O
burn	O
and	O
smoke	O
inhalation	B-PROC
injury	O
.	O

We	O
describe	O
here	O
the	O
development	B-PROC
and	O
use	O
of	O
a	O
reverse	O
genetics	O
strategy	O
for	O
FIPV	O
based	O
on	O
targeted	B-PROC
RNA	O
recombination	B-PROC
that	O
is	O
analogous	O
to	O
what	O
has	O
been	O
described	O
for	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
(	O
L	O
.	O
Kuo	O
et	O
al	O
.,	O
J	O
.	O
Virol	O
.	O
74	O
:	O
1393	O
-	O
1406	O
,	O
2000	O
).	O

Expression	B-PROC
of	O
the	O
E	O
protein	O
alone	O
results	O
in	O
its	O
incorporation	O
into	O
vesicles	O
that	O
are	O
released	O
from	O
cells	O
,	O
and	O
the	O
coexpression	O
of	O
the	O
E	O
protein	O
with	O
the	O
membrane	O
protein	O
M	O
leads	O
to	O
the	O
assembly	O
of	O
coronavirus	O
-	O
like	O
particles	O
.	O

However	O
,	O
following	O
initial	O
clearance	O
,	O
virus	O
reactivates	O
in	O
the	O
absence	O
of	O
humoral	B-PROC
immunity	I-PROC
.	O

Ab	O
-	O
mediated	O
protection	O
was	O
not	O
associated	O
with	O
alterations	O
in	O
virus	O
-	O
specific	O
T	O
-	O
cell	B-PROC
function	I-PROC
or	O
inflammation	O
.	O

Lung	O
protective	O
ventilation	O
is	O
accepted	O
as	O
a	O
proven	O
therapy	O
and	O
the	O
use	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
as	O
well	O
as	O
spontaneous	O
breathing	B-PROC
during	O
controlled	O
ventilation	O
are	O
common	O
therapies	O
.	O

Fever	B-PROC
and	O
exanthema	O
were	O
observed	O
in	O
all	O
patients	O
,	O
and	O
an	O
eschar	O
was	O
pointed	O
out	O
in	O
20	O
(	O
71	O
%)	O
patients	O
.	O

Although	O
the	O
data	O
support	O
a	O
key	O
role	O
for	O
neutrophil	O
elastase	O
in	O
the	O
pathogenesis	B-PROC
of	O
ARDS	O
,	O
further	O
study	O
is	O
needed	O
to	O
fully	O
define	O
the	O
actions	O
of	O
neutrophil	O
elastase	O
,	O
and	O
how	O
these	O
actions	O
affect	O
host	O
functions	O
,	O
before	O
we	O
can	O
exploit	O
this	O
knowledge	O
for	O
therapeutic	O
benefit	O
.	O

The	O
mechanisms	O
that	O
contribute	O
to	O
this	O
fibrin	O
deposition	O
are	O
bronchoalveolar	O
tissue	O
factor	O
-	O
mediated	O
thrombin	O
generation	O
and	O
localized	O
depression	O
of	O
urokinase	O
plasminogen	O
activator	O
-	O
mediated	O
fibrinolysis	B-PROC
,	O
caused	O
by	O
the	O
increase	O
of	O
plasminogen	O
activator	O
inhibitors	O
.	O

Coagulation	B-PROC
and	O
fibrinolytic	O
proteins	O
may	O
have	O
an	O
additional	O
role	O
beyond	O
fibrin	O
turnover	O
and	O
inflammation	O
,	O
e	O
.	O
g	O
.,	O
in	O
mechanisms	O
mediating	O
cell	O
recruitment	O
and	O
migration	B-PROC
.	O

It	O
is	O
also	O
unclear	O
whether	O
such	O
a	O
response	O
,	O
if	O
present	O
,	O
predisposes	O
patients	O
to	O
ongoing	O
lung	O
inflammation	O
and	O
the	O
development	B-PROC
of	O
late	O
fibroproliferative	O
ARDS	O
,	O
or	O
if	O
it	O
is	O
predictive	O
of	O
a	O
beneficial	O
response	O
to	O
steroids	O
.	O

Increased	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
and	O
leukocyte	O
accumulation	O
have	O
been	O
successfully	O
prevented	O
in	O
animals	O
treated	O
with	O
tissue	O
factor	O
/	O
activated	O
factor	O
VII	O
pathway	B-PROC
inhibitor	O
.	O

Finally	O
,	O
plasminogen	B-PROC
activators	I-PROC
may	O
improve	O
gas	O
exchange	O
in	O
ALI	O
,	O
but	O
studies	O
in	O
humans	O
are	O
limited	O
.	O

Arterial	O
blood	B-PROC
gases	I-PROC
,	O
cardiovascular	O
hemodynamics	B-PROC
,	O
dynamic	O
lung	B-PROC
compliance	I-PROC
,	O
and	O
total	O
lung	O
injury	O
scores	O
were	O
measured	O
.	O

Consensus	O
coronavirus	O
primers	O
designed	O
to	O
amplify	O
a	O
fragment	O
of	O
the	O
polymerase	O
gene	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
used	O
to	O
obtain	O
a	O
sequence	O
that	O
clearly	O
identified	O
the	O
isolate	O
as	O
a	O
unique	O
coronavirus	O
only	O
distantly	O
related	O
to	O
previously	O
sequenced	O
coronaviruses	O
.	O

Establishment	O
of	O
coronavirus	O
NS2	O
-	O
specific	O
,	O
HLA	O
-	O
A2	O
-	O
restricted	O
CD8	O
(+)-	O
T	O
-	O
cell	O
clones	O
and	O
ex	O
vivo	O
analysis	O
of	O
HPV16	O
E7	O
specific	O
T	O
cells	O
obtained	O
by	O
HLA	O
-	O
A2	O
tetramer	O
-	O
guided	O
sorting	B-PROC
from	O
PBL	O
or	O
tumor	O
-	O
infiltrating	O
lymphocytes	O
obtained	O
from	O
patients	O
with	O
cervical	O
cancer	O
showed	O
that	O
cross	O
-	O
reactivity	O
with	O
HPV16	O
E7	O
(	O
11	O
-	O
19	O
(	O
20	O
))	O
and	O
coronavirus	O
NS2	O
(	O
52	O
-	O
60	O
)	O
represents	O
a	O
common	O
feature	O
of	O
this	O
antiviral	O
immune	B-PROC
response	I-PROC
defined	O
by	O
cytokine	B-PROC
production	I-PROC
.	O

Paired	O
serum	O
samples	O
obtained	O
from	O
blood	O
collected	O
on	O
days	O
0	O
and	O
35	O
were	O
analyzed	O
for	O
BoTV	O
antibodies	O
with	O
a	O
hemagglutination	B-PROC
inhibition	B-PROC
assay	O
.	O

Calves	O
that	O
were	O
seronegative	O
or	O
had	O
low	O
antibody	B-PROC
titers	O
against	O
BoTV	O
(<	O
or	O
=	O
1	O
:	O
10	O
hemagglutination	B-PROC
inhibition	B-PROC
units	O
)	O
at	O
arrival	O
seroconverted	O
to	O
BoTV	O
(>	O
4	O
-	O
fold	O
increase	O
in	O
titer	O
);	O
these	O
calves	O
were	O
more	O
likely	O
to	O
shed	O
virus	O
than	O
calves	O
that	O
were	O
seropositive	O
against	O
BoTV	O
at	O
arrival	O
.	O

Interestingly	O
,	O
in	O
vivo	O
infections	O
with	O
rTGEV	O
-	O
delta7	O
showed	O
an	O
additional	O
reduction	O
in	O
virus	B-PROC
replication	I-PROC
in	O
the	O
lung	O
and	O
gut	O
,	O
and	O
in	O
virulence	B-PROC
,	O
indicating	O
that	O
TGEV	O
gene	O
7	O
influences	O
virus	O
pathogenesis	B-PROC
.	O

Cohorts	O
were	O
compared	O
for	O
mortality	O
or	O
the	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
pneumonia	O
,	O
and	O
systemic	O
sepsis	O
using	O
standard	O
definitions	O
.	O

There	O
have	O
been	O
three	O
deaths	B-PROC
.	O

The	O
genome	O
sequence	O
will	O
aid	O
in	O
the	O
diagnosis	O
of	O
SARS	O
virus	B-PROC
infection	I-PROC
in	O
humans	O
and	O
potential	O
animal	O
hosts	O
(	O
using	O
polymerase	O
chain	O
reaction	O
and	O
immunological	O
tests	O
),	O
in	O
the	O
development	B-PROC
of	O
antivirals	O
(	O
including	O
neutralizing	O
antibodies	O
),	O
and	O
in	O
the	O
identification	O
of	O
putative	O
epitopes	O
for	O
vaccine	O
development	B-PROC
.	O

A	O
persistent	O
elevation	O
of	O
the	O
intra	O
-	O
abdominal	O
pressure	O
beyond	O
20	O
-	O
25	O
cmH2O	O
,	O
with	O
significant	O
respiratory	O
,	O
hemodynamic	B-PROC
and	O
renal	O
dysfunction	O
is	O
an	O
indication	O
for	O
abdominal	O
decompression	O
,	O
before	O
the	O
manifestations	O
of	O
abdominal	O
compartment	O
syndrome	O
became	O
clinically	O
evident	O
.	O

TITLE	O
:	O
Haemorrhagic	O
-	O
fever	B-PROC
-	O
like	O
changes	O
and	O
normal	O
chest	O
radiograph	O
in	O
a	O
doctor	O
with	O
SARS	O
.	O

In	O
all	O
patients	O
admitted	O
for	O
eclampsia	O
between	O
January	O
1997	O
et	O
December	O
1999	O
,	O
the	O
following	O
parameters	O
were	O
studied	O
:	O
age	O
,	O
parity	O
,	O
interval	O
between	O
disease	O
et	O
admission	O
,	O
post	O
-	O
eclampsia	O
Glasgow	O
Coma	O
Scale	O
(	O
GCS	O
),	O
time	O
of	O
occurrence	O
of	O
eclampsia	O
during	O
pregnancy	O
,	O
delivery	O
route	O
,	O
blood	B-PROC
pressure	I-PROC
data	O
at	O
admission	O
,	O
the	O
occurrence	O
of	O
complications	O
at	O
admission	O
or	O
during	O
hospital	O
stay	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
contagious	O
viral	B-PROC
illness	I-PROC
first	O
recognized	O
in	O
late	O
2002	O
.	O

ABSTRACT	O
:	O
A	O
2	O
-	O
month	O
-	O
old	O
male	O
infant	O
with	O
severe	O
dyspnea	O
was	O
diagnosed	O
as	O
having	O
right	O
pulmonary	O
agenesis	O
at	O
birth	B-PROC
and	O
was	O
admitted	O
to	O
our	O
hospital	O
after	O
tracheal	O
intubation	O
with	O
an	O
endotracheal	O
tube	O
of	O
3	O
mm	O
in	O
diameter	O
.	O

Percutaneous	O
cardiopulmonary	O
support	O
(	O
PCPS	O
)	O
was	O
used	O
to	O
maintain	O
his	O
pulmonary	B-PROC
function	I-PROC
,	O
and	O
pericardial	O
tracheoplasty	O
was	O
performed	O
.	O

Secretion	B-PROC
of	O
a	O
coronavirus	O
could	O
be	O
detected	O
in	O
respiratory	O
samples	O
during	O
the	O
febrile	B-PROC
phase	O
and	O
in	O
feces	O
for	O
a	O
longer	O
time	O
.	O

CONCLUSIONS	O
:	O
The	O
ER	O
lakes	O
are	O
involved	O
in	O
the	O
maturation	B-PROC
of	O
the	O
viruses	O
,	O
and	O
the	O
envelop	O
and	O
nuclear	O
capsid	O
of	O
the	O
virus	O
entering	O
the	O
cells	O
from	O
extracellular	O
space	O
are	O
removed	O
and	O
degraded	O
in	O
the	O
endosome	O
/	O
lysosome	O
.	O

This	O
catheter	O
was	O
effective	O
in	O
protecting	O
the	O
visceral	O
organs	O
and	O
the	O
spinal	O
cord	O
in	O
the	O
repair	B-PROC
of	O
an	O
aortic	O
arch	O
aneurysm	O
.	O

With	O
the	O
use	O
of	O
detailed	O
epidemiologic	O
data	O
from	O
Singapore	O
and	O
epidemic	O
curves	O
from	O
other	O
settings	O
,	O
we	O
estimated	O
the	O
reproductive	B-PROC
number	O
for	O
SARS	O
in	O
the	O
absence	O
of	O
interventions	O
and	O
in	O
the	O
presence	O
of	O
control	O
efforts	O
.	O

These	O
results	O
indicate	O
that	O
stem	O
-	O
loop	O
III	O
in	O
the	O
BCoV	O
5	O
'	O
UTR	O
is	O
a	O
cis	O
-	O
acting	O
element	O
for	O
DI	O
RNA	B-PROC
replication	I-PROC
and	O
that	O
its	O
associated	O
intra	O
-	O
5	O
'	O
UTR	O
ORF	O
may	O
function	O
to	O
enhance	O
replication	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
is	O
a	O
frequent	O
complication	O
of	O
severe	O
sepsis	O
or	O
blood	O
loss	O
and	O
is	O
often	O
associated	O
with	O
an	O
excessive	O
inflammatory	B-PROC
response	I-PROC
requiring	O
mechanical	O
ventilation	O
.	O

Rats	O
were	O
subjected	O
to	O
either	O
hemorrhage	O
or	O
endotoxemia	O
for	O
1	O
hr	O
,	O
followed	O
by	O
resuscitation	O
to	O
a	O
controlled	O
mean	O
blood	B-PROC
pressure	I-PROC
with	O
Ringer	O
'	O
s	O
lactate	O
,	O
5	O
%	O
albumin	O
,	O
or	O
25	O
%	O
albumin	O
for	O
1	O
hr	O
.	O

We	O
concluded	O
that	O
the	O
DeltaStream	O
blood	O
pump	O
may	O
be	O
used	O
for	O
veno	O
-	O
venous	O
ECMO	O
without	O
major	O
blood	O
damage	O
or	O
hemodynamic	B-PROC
impairment	O
.	O

Fever	B-PROC
and	O
pneumonia	O
initially	O
improved	O
but	O
64	O
(	O
85	O
%)	O
patients	O
developed	O
recurrent	O
fever	B-PROC
after	O
a	O
mean	O
of	O
8	O
.	O
9	O
(	O
SD	O
3	O
.	O
1	O
)	O
days	O
,	O
55	O
(	O
73	O
%)	O
had	O
watery	O
diarrhoea	O
after	O
7	O
.	O
5	O
(	O
2	O
.	O
3	O
)	O
days	O
,	O
60	O
(	O
80	O
%)	O
had	O
radiological	O
worsening	O
after	O
7	O
.	O
4	O
(	O
2	O
.	O
2	O
)	O
days	O
,	O
and	O
respiratory	O
symptoms	O
worsened	O
in	O
34	O
(	O
45	O
%)	O
after	O
8	O
.	O
6	O
(	O
3	O
.	O
0	O
)	O
days	O
.	O

The	O
patient	O
was	O
successfully	O
treated	O
with	O
cardiac	O
resuscitation	O
,	O
extra	O
corporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
),	O
NO	O
,	O
kinetic	O
therapy	O
,	O
surfactant	O
,	O
urodilatin	O
,	O
and	O
other	O
standard	O
intensive	O
care	O
regimens	O
.	O

In	O
a	O
patient	O
with	O
severe	O
ARDS	O
,	O
oxygenation	B-PROC
failure	O
under	O
maximized	O
ventilatory	O
settings	O
,	O
and	O
subsequent	O
five	O
-	O
organ	O
system	O
failure	O
,	O
an	O
integrated	O
therapeutical	O
approach	O
comprising	O
ECMO	O
,	O
NO	O
,	O
kinetic	O
therapy	O
,	O
surfactant	O
,	O
and	O
urodilatin	O
did	O
cross	O
-	O
bridge	O
respiratory	O
and	O
vital	O
functions	O
,	O
enabling	O
overall	O
survival	O
.	O

Nutrient	O
provision	O
was	O
adjusted	O
daily	O
to	O
account	O
for	O
organ	O
and	O
metabolic	B-PROC
changes	O
including	O
hepatic	O
,	O
pulmonary	O
,	O
and	O
renal	O
dysfunction	O
.	O

The	O
patient	O
did	O
well	O
and	O
was	O
eventually	O
extubated	O
and	O
eating	B-PROC
a	O
regular	O
diet	O
.	O

TITLE	O
:	O
Detection	O
of	O
sendai	O
virus	O
and	O
pneumonia	O
virus	O
of	O
mice	O
by	O
use	O
of	O
fluorogenic	O
nuclease	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
have	O
proven	O
useful	O
for	O
detection	O
of	O
Sendai	O
virus	O
and	O
PVM	O
immunodeficient	O
animals	O
and	O
contaminated	O
biomaterials	O
.	O

ABSTRACT	O
:	O
Anti	O
-	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
(	O
anti	O
-	O
MHC	B-PROC
)	O
antibodies	O
(	O
Abs	O
)	O
and	O
antipolymorphonuclear	O
neutrophil	O
(	O
anti	O
-	O
PMN	B-PROC
)	O
Abs	O
are	O
generally	O
considered	O
as	O
the	O
main	O
causes	O
of	O
the	O
development	B-PROC
of	O
transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
(	O
TRALI	O
),	O
which	O
is	O
one	O
of	O
the	O
most	O
severe	O
and	O
sometimes	O
lethal	O
side	O
effects	O
of	O
transfusion	O
.	O

We	O
observed	O
that	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
markedly	O
enhances	O
the	O
expression	B-PROC
of	O
MHC	B-PROC
class	O
II	O
DR	O
in	O
PMNs	O
.	O

The	O
binding	O
for	O
one	O
protein	B-PROC
-	I-PROC
protein	I-PROC
interaction	I-PROC
pair	O
(	O
D757	O
-	O
R761	O
motif	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
to	O
P585	O
-	O
A653	O
domain	O
of	O
CD13	O
)	O
has	O
been	O
simulated	O
by	O
molecular	O
modeling	O
and	O
docking	B-PROC
simulation	O
methods	O
.	O

ABSTRACT	O
:	O
To	O
constructed	O
a	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
model	O
for	O
the	O
3C	O
like	O
(	O
3CL	O
)	O
proteinase	B-PROC
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
to	O
design	O
inhibitors	O
of	O
the	O
3CL	O
proteinase	B-PROC
based	O
on	O
the	O
3D	O
model	O
.	O

Screening	O
the	O
known	O
proteinase	B-PROC
inhibitors	O
may	O
be	O
an	O
appreciated	O
shortcut	O
to	O
discover	O
anti	O
-	O
SARS	O
drugs	O
.	O

Percutaneous	O
transluminal	O
angioplasty	O
of	O
the	O
left	O
renal	O
artery	O
normalized	O
kidney	B-PROC
function	I-PROC
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
use	O
hypergravity	O
to	O
further	O
investigate	O
the	O
mechanisms	O
behind	O
the	O
differences	O
in	O
arterial	O
oxygenation	B-PROC
between	O
the	O
prone	O
and	O
the	O
supine	O
posture	O
.	O

At	O
the	O
same	O
time	O
,	O
functional	B-PROC
residual	I-PROC
capacity	I-PROC
decreased	O
by	O
33	O
and	O
23	O
%,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
for	O
supine	O
vs	O
.	O
prone	O
),	O
and	O
cardiac	O
output	O
by	O
40	O
and	O
31	O
%	O
(	O
P	O
=	O
0	O
.	O
007	O
for	O
supine	O
vs	O
.	O
prone	O
),	O
despite	O
an	O
increase	O
in	O
heart	O
rate	O
of	O
16	O
and	O
28	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
for	O
supine	O
vs	O
.	O
prone	O
),	O
respectively	O
.	O

Expression	B-PROC
of	O
the	O
S1	O
gene	O
in	O
the	O
recombinants	O
was	O
confirmed	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
by	O
20h	O
post	O
-	O
infection	O
.	O

Commercial	O
broiler	O
chickens	O
were	O
orally	O
vaccinated	O
at	O
day	O
0	O
or	O
day	O
6	O
post	O
-	O
hatch	B-PROC
and	O
challenged	O
at	O
day	O
35	O
post	O
-	O
hatch	B-PROC
.	O

FAV	O
antibody	B-PROC
ELISA	O
confirmed	O
that	O
maternal	O
antibody	B-PROC
directed	O
against	O
inclusion	O
body	O
hepatitis	O
(	O
serotype	O
8	O
)	O
had	O
decayed	O
in	O
control	O
birds	O
and	O
that	O
FAV	O
specific	O
serum	O
IgG	O
responses	O
were	O
produced	O
in	O
vaccinated	O
birds	O
at	O
the	O
time	O
of	O
challenge	O
.	O

This	O
review	O
mainly	O
focuses	O
upon	O
the	O
pathogenic	O
contribution	O
of	O
NE	O
to	O
these	O
neutrophil	O
-	O
predominant	O
inflammatory	O
lung	O
diseases	O
,	O
and	O
evaluates	O
the	O
experimental	O
and	O
clinical	O
efficacies	O
of	O
the	O
two	O
-	O
types	O
of	O
appropriate	O
small	O
molecular	O
weight	O
human	O
neutrophil	O
elastase	O
(	O
HNE	O
)	O
inhibitors	O
:	O
acyl	O
-	O
enzyme	B-PROC
inhibitors	I-PROC
and	O
transition	O
-	O
state	O
inhibitors	O
.	O

Provoked	O
by	O
infection	O
,	O
transitory	O
non	O
-	O
specific	O
inflammatory	O
muscular	O
reaction	O
and	O
functional	O
disorders	O
of	O
nerve	O
conductivity	O
and	O
excitability	O
may	O
be	O
considered	O
as	O
one	O
of	O
the	O
possible	O
mechanisms	O
of	O
NMS	O
development	B-PROC
.	O

The	O
World	O
Health	O
Organization	O
has	O
received	O
reports	O
of	O
4	O
,	O
836	O
cases	O
,	O
of	O
which	O
293	O
persons	O
have	O
died	B-PROC
.	O

The	O
investigation	O
underscores	O
the	O
need	O
for	O
monitoring	O
fever	B-PROC
and	O
respiratory	O
symptoms	O
in	O
hospitalized	O
patients	O
and	O
visitors	O
,	O
particularly	O
after	O
a	O
decline	O
in	O
the	O
number	O
of	O
reported	O
SARS	O
cases	O
.	O

The	O
amino	O
acid	O
sequence	O
contained	O
seven	O
potential	O
sites	O
for	O
threonine	O
(	O
T	O
)-	O
or	O
serine	O
(	O
S	O
)-	O
linked	O
phosphorylation	B-PROC
by	O
each	O
protein	O
kinase	O
C	O
and	O
casein	O
kinase	O
II	O
.	O

We	O
found	O
that	O
the	O
construct	O
extending	O
from	O
the	O
putative	O
PLP2	O
cleavage	B-PROC
site	O
at	O
glycine	O
2840	O
-	O
alanine	O
2841	O
was	O
most	O
similar	O
in	O
size	O
to	O
the	O
processed	O
MP1	O
replicase	O
product	O
generated	O
in	O
a	O
trans	O
-	O
cleavage	B-PROC
assay	O
.	O

We	O
found	O
that	O
substitutions	O
at	O
phenylalanine	O
2835	O
,	O
glycine	O
2839	O
,	O
or	O
glycine	O
2840	O
resulted	O
in	O
a	O
reduction	O
in	O
cleavage	B-PROC
of	O
MP1	O
.	O

Finally	O
,	O
to	O
unequivocally	O
identify	O
this	O
cleavage	B-PROC
site	O
,	O
we	O
isolated	O
radiolabeled	O
MP1	O
protein	O
and	O
determined	O
the	O
position	O
of	O
[(	O
35	O
)	O
S	O
]	O
methionine	O
residues	O
released	O
by	O
Edman	O
degradation	O
reaction	O
.	O

This	O
study	O
is	O
the	O
first	O
report	O
of	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
cleavage	B-PROC
site	O
recognized	O
by	O
murine	O
coronavirus	O
PLP2	O
activity	O
.	O

ABSTRACT	O
:	O
To	O
report	O
cases	O
of	O
neonates	O
successfully	O
treated	O
with	O
both	O
exogenous	O
surfactant	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
INO	O
).	O

The	O
clinical	O
presentation	O
is	O
unspecific	O
and	O
includes	O
fever	B-PROC
,	O
respiratory	O
symptoms	O
,	O
lymphopenia	O
and	O
pulmonary	O
infiltrates	O
on	O
X	O
-	O
ray	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
as	O
a	O
new	O
viral	B-PROC
disease	I-PROC
is	O
causing	O
a	O
great	O
concern	O
for	O
health	O
authorities	O
and	O
general	O
population	O
.	O

Proinflammatory	O
cytokines	O
released	O
by	O
stimulated	O
macrophages	O
in	O
the	O
alveoli	O
could	O
have	O
a	O
prominent	O
role	O
in	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

PTX	O
would	O
feature	O
a	O
possible	O
antiviral	O
activity	O
along	O
with	O
a	O
well	O
-	O
known	O
cytokine	O
-	O
modulating	O
activity	O
not	O
as	O
immunosuppressant	O
as	O
that	O
of	O
the	O
corticoids	O
,	O
down	O
-	O
regulating	O
proinflammatory	O
cytokines	O
but	O
leaving	O
functional	O
the	O
rest	O
of	O
the	O
immune	B-PROC
response	I-PROC
.	O

Other	O
effects	O
of	O
PTX	O
are	O
discussed	O
,	O
as	O
bronchodilation	B-PROC
.	O

Detection	O
of	O
sgmRNAs	O
in	O
virions	O
by	O
specific	O
reverse	B-PROC
transcription	B-PROC
-	O
PCRs	O
(	O
RT	O
-	O
PCRs	O
)	O
was	O
related	O
to	O
the	O
purity	O
of	O
virus	O
preparations	O
.	O

Venoarterial	O
patients	O
had	O
significantly	O
greater	O
alveolar	O
-	O
arterial	O
oxygen	O
gradients	O
and	O
lower	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratios	O
than	O
venovenous	O
patients	O
(	O
p	O
<.	O
03	O
).	O

Venovenous	O
ECMO	O
can	O
effectively	O
provide	O
adequate	O
oxygenation	B-PROC
for	O
pediatric	O
patients	O
with	O
severe	O
acute	O
respiratory	O
failure	O
receiving	O
ECMO	O
support	O
.	O

Immunofluorescent	O
studies	O
revealed	O
that	O
the	O
normal	O
3b	O
protein	O
was	O
localized	O
to	O
the	O
nucleus	O
and	O
the	O
truncated	O
product	O
showed	O
a	O
""""	O
free	O
""""	O
distribution	O
pattern	O
,	O
indicating	O
that	O
the	O
C	O
-	O
terminal	O
portion	O
of	O
3b	O
was	O
responsible	O
for	O
its	O
nuclear	O
localization	B-PROC
.	O

Further	O
characterization	O
of	O
the	O
two	O
isolates	O
demonstrated	O
that	O
p36c12	O
showed	O
growth	B-PROC
advantage	O
over	O
p20c22	O
in	O
both	O
Vero	O
cells	O
and	O
chicken	O
embryos	O
and	O
was	O
more	O
virulent	O
in	O
chicken	O
embryos	O
than	O
p20c22	O
.	O

ABSTRACT	O
:	O
Chemical	O
modification	O
of	O
the	O
proteins	O
bovine	O
serum	O
albumin	O
,	O
alpha	O
-	O
lactalbumin	O
,	O
beta	O
-	O
lactoglobulin	O
and	O
chicken	O
lysozyme	O
by	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
(	O
3	O
-	O
HP	O
)	O
yielded	O
compounds	O
which	O
exerted	B-PROC
antiviral	O
activity	O
in	O
vitro	O
as	O
compared	O
with	O
the	O
native	O
unmodified	O
proteins	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
possible	O
death	B-PROC
risk	O
factors	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

More	O
attention	O
should	O
be	O
paid	O
to	O
deal	O
with	O
these	O
risk	O
factors	O
and	O
to	O
prevent	O
the	O
development	B-PROC
of	O
serious	O
complications	O
associated	O
with	O
SARS	O
.	O

CONCLUSIONS	O
:	O
More	O
attention	O
should	O
be	O
paid	O
to	O
deal	O
with	O
these	O
risk	O
factors	O
and	O
to	O
prevent	O
the	O
development	B-PROC
of	O
serious	O
complications	O
associated	O
with	O
SARS	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
appeared	O
that	O
corticosteroid	O
therapy	O
has	O
no	O
marked	O
effect	O
on	O
the	O
development	B-PROC
of	O
chest	O
radiogram	O
in	O
patients	O
with	O
SARS	O
.	O

Systemic	O
toxic	O
changes	O
included	O
degeneration	O
and	O
necrosis	B-PROC
of	O
the	O
parenchyma	O
cells	O
in	O
the	O
lung	O
,	O
liver	O
,	O
kidney	O
,	O
heart	O
,	O
and	O
adrenal	O
gland	O
.	O

RESULTS	O
:	O
On	O
25th	O
March	O
2003	O
,	O
a	O
91	O
year	O
old	O
man	O
was	O
admitted	O
to	O
Hospital	O
J	O
in	O
Beijing	O
with	O
stroke	O
and	O
fever	B-PROC
.	O

The	O
main	O
symptoms	O
and	O
signs	O
of	O
the	O
SARS	O
patients	O
would	O
include	O
fever	B-PROC
,	O
cough	O
and	O
chest	O
X	O
-	O
ray	O
changes	O
.	O

All	O
patients	O
presented	O
fever	B-PROC
,	O
and	O
some	O
of	O
them	O
complained	O
of	O
rigor	O
,	O
dry	O
cough	O
,	O
dyspnea	O
,	O
malaise	O
,	O
headache	O
,	O
and	O
hypoxemia	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
serum	O
antibody	B-PROC
responses	I-PROC
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
nucleocapsid	O
(	O
N	O
)	O
antigen	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

In	O
13	O
patients	O
with	O
SARS	O
,	O
the	O
antibody	B-PROC
responses	I-PROC
to	O
N	O
antigen	O
were	O
not	O
detectable	O
in	O
the	O
first	O
week	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

The	O
IgM	O
and	O
IgG	O
seroprotection	O
rates	O
were	O
83	O
.	O
3	O
%	O
and	O
66	O
.	O
7	O
%	O
respectively	O
in	O
the	O
second	O
week	O
,	O
both	O
reaching	B-PROC
100	O
%	O
at	O
the	O
third	O
week	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
report	O
on	O
the	O
preparation	O
of	O
mAb	O
that	O
is	O
specific	O
to	O
the	O
SARS	O
-	O
Cov	O
,	O
and	O
the	O
high	O
-	O
specificity	O
and	O
high	O
-	O
affinity	O
mAb	O
produced	O
by	O
the	O
4	O
strains	O
of	O
hybridomas	O
provide	O
a	O
basis	O
for	O
further	O
researches	O
on	O
the	O
pathogenesis	B-PROC
and	O
early	O
diagnosis	O
of	O
SARS	O
.	O

Two	O
of	O
these	O
patients	O
had	O
died	B-PROC
by	O
8	O
weeks	O
'	O
follow	O
-	O
up	O
.	O

ABSTRACT	O
:	O
This	O
report	O
updates	O
reported	O
cases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
worldwide	O
and	O
in	O
the	O
United	O
States	O
,	O
describes	O
a	O
change	O
in	O
the	O
recommended	O
timing	O
of	O
collection	O
of	O
a	O
convalescent	O
-	O
phase	O
serum	O
specimen	O
to	O
test	O
for	O
antibody	B-PROC
to	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
introduces	O
a	O
new	O
case	O
exclusion	O
criterion	O
based	O
on	O
negative	O
SARS	O
-	O
CoV	O
serology	O
.	O

Alimentotherapy	O
,	O
respiratory	O
auxiliaring	O
ventilation	O
,	O
anti	O
-	O
infective	O
and	O
glucocorticoid	O
methods	O
were	O
used	O
in	O
western	O
medicine	O
;	O
Chinese	O
herbal	O
medicine	O
was	O
used	O
according	O
to	O
syndrome	O
differentiation	B-PROC
in	O
traditional	O
Chinese	O
medicine	O
.	O

Seven	O
patients	O
who	O
developed	O
ARDS	O
complicated	O
with	O
multiple	O
organs	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
died	B-PROC
.	O

The	O
time	O
between	O
the	O
onset	O
of	O
fever	B-PROC
and	O
leukopenia	O
was	O
(	O
4	O
.	O
4	O
+/-	O
2	O
.	O
3	O
)	O
days	O
,	O
with	O
the	O
lowest	O
white	O
blood	O
cell	O
count	O
of	O
(	O
2	O
.	O
80	O
+/-	O

0	O
.	O
72	O
)	O
x	O
10	O
(	O
9	O
)/	O
L	O
.	O
(	O
6	O
)	O
The	O
lowest	O
arterial	B-PROC
oxygen	I-PROC
saturation	I-PROC
was	O
(	O
94	O
.	O
8	O
+/-	O

In	O
conclusion	O
,	O
in	O
regard	O
to	O
the	O
pre	O
-	O
and	O
post	O
-	O
red	O
cell	O
-	O
exchange	O
clinical	O
and	O
laboratory	O
data	O
,	O
we	O
can	O
say	O
that	O
red	O
cell	O
-	O
exchange	O
provides	O
a	O
dramatic	O
resolution	O
of	O
the	O
episode	O
of	O
ACS	O
,	O
minimizes	O
the	O
development	B-PROC
of	O
iron	O
overload	O
,	O
and	O
rapidly	O
decreases	O
HbS	O
and	O
hematocrit	O
levels	O
.	O

SARS	O
is	O
a	O
recently	O
recognized	O
infectious	O
disease	O
that	O
may	O
lead	O
to	O
death	B-PROC
and	O
severe	O
pulmonary	O
sequelae	O
.	O

Gefitinib	O
acts	O
by	O
inhibition	B-PROC
of	O
the	O
epidermal	O
growth	B-PROC
factor	O
receptor	O
tyrosine	O
kinase	O
.	O

RESULTS	O
:	O
Eleven	O
patients	O
died	B-PROC
during	O
the	O
hospital	O
stay	O
with	O
an	O
early	O
operative	O
mortality	O
of	O
8	O
.	O
8	O
%.	O

Extensive	O
consolidation	O
of	O
lungs	O
,	O
formation	B-PROC
of	O
hyaline	O
membrane	O
to	O
a	O
large	O
extent	O
,	O
respiratory	O
distress	O
and	O
decrease	O
of	O
immune	B-PROC
function	I-PROC
are	O
the	O
main	O
causes	O
of	O
death	B-PROC
.	O

Meanwhile	O
,	O
haemorrhagic	O
necrosis	B-PROC
was	O
showed	O
in	O
lymph	O
nodes	O
and	O
spleen	O
with	O
attenuation	O
of	O
lymphocytes	O
.	O

Mouse	O
eyes	O
were	O
evaluated	O
for	O
infiltrating	O
cells	O
and	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
(	O
MHC	B-PROC
)	O
expression	B-PROC
by	O
immunocytochemical	O
staining	O
.	O

Isolated	O
retinas	O
were	O
analyzed	O
for	O
IFN	O
-	O
gamma	O
mRNA	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
sera	O
were	O
evaluated	O
for	O
IFN	O
-	O
gamma	B-PROC
protein	I-PROC
by	O
ELISA	O
assays	O
.	O

Limited	O
proteolysis	B-PROC
in	O
combination	O
with	O
mass	O
spectrometry	O
indicated	O
that	O
HR1	O
and	O
HR2	O
occur	O
in	O
the	O
complex	O
in	O
an	O
antiparallel	O
fashion	O
.	O

Since	O
the	O
novel	O
Chlamydia	O
-	O
like	O
agent	O
was	O
found	O
co	O
-	O
existing	O
with	O
a	O
coronavirus	O
-	O
like	O
agent	O
in	O
the	O
dead	B-PROC
cases	O
of	O
SARS	O
,	O
it	O
looks	O
most	O
likely	O
that	O
both	O
the	O
agents	O
play	O
some	O
roles	O
in	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
raises	O
questions	O
about	O
the	O
appropriate	O
infection	O
control	O
measures	O
to	O
use	O
when	O
conducting	B-PROC
maintenance	O
procedures	O
on	O
medical	O
devices	O
that	O
may	O
have	O
been	O
exposed	O
to	O
the	O
SARS	O
virus	O
--	O
that	O
is	O
,	O
devices	O
that	O
have	O
been	O
used	O
on	O
,	O
or	O
located	O
in	O
the	O
same	O
room	O
as	O
,	O
a	O
patient	O
with	O
(	O
or	O
suspected	O
to	O
have	O
)	O
SARS	O
.	O

Fever	B-PROC
and	O
lymphopenia	O
are	O
occasionally	O
followed	O
by	O
rapidly	O
progressive	O
respiratory	O
compromise	O
.	O

RESULTS	O
:	O
The	O
rate	O
of	O
anomaly	O
liver	B-PROC
function	I-PROC
in	O
the	O
common	O
SARS	O
patients	O
group	O
was	O
68	O
.	O
1	O
%,	O
which	O
was	O
higher	O
than	O
that	O
in	O
the	O
common	O
pneumonia	O
patients	O
group	O
(	O
24	O
.	O
6	O
%),	O
chi2	O
=	O
27	O
.	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
.	O

RESULTS	O
:	O
Fever	B-PROC
was	O
found	O
in	O
97	O
.	O
8	O
%	O
of	O
the	O
patients	O
.	O

Published	O
experience	O
in	O
adults	O
suggests	O
that	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
successfully	O
support	O
trauma	O
victims	O
with	O
pulmonary	O
failure	O
.	O

Our	O
genomic	O
analyses	O
strongly	O
suggest	O
that	O
the	O
new	O
SARS	O
-	O
coronavirus	O
did	O
not	O
emerge	O
through	O
mutation	O
or	O
recombination	B-PROC
and	O
that	O
it	O
has	O
probably	O
been	O
transmitted	O
from	O
a	O
so	O
far	O
not	O
identified	O
animal	O
species	O
to	O
humans	O
.	O

The	O
potential	O
danger	O
of	O
such	O
vaccines	O
should	O
not	O
be	O
neglected	O
during	O
the	O
process	O
of	O
vaccine	O
development	B-PROC
.	O

Fever	B-PROC
,	O
lymphopenia	O
,	O
low	O
serum	O
iron	O
and	O
chest	O
radiograph	O
are	O
helpful	O
to	O
diagnose	O
SARS	O
early	O
;	O
age	O
is	O
the	O
independent	O
predictor	O
of	O
an	O
outcome	O
.	O

Management	O
with	O
corticosteroids	O
effectively	O
ameliorated	O
and	O
suppressed	O
the	O
development	B-PROC
of	O
pulmonary	O
fibrosis	O
.	O

Clinical	O
symptoms	O
of	O
these	O
patients	O
were	O
fever	B-PROC
(	O
100	O
%),	O
coughing	O
(	O
88	O
%),	O
and	O
dyspnea	O
(	O
80	O
%).	O

All	O
the	O
five	O
patients	O
who	O
died	B-PROC
had	O
CD	O
(	O
4	O
)(+)	O
counts	O
less	O
than	O
200	O
/	O
microl	O
.	O

All	O
the	O
patients	O
had	O
a	O
fever	B-PROC
(	O
temperature	O
>	O
38	O
degrees	O
C	O
for	O
over	O
24	O
hours	O
)	O
and	O
other	O
manifestations	O
as	O
reported	O
before	O
.	O

Two	O
patients	O
died	B-PROC
of	O
progressive	O
acute	O
respiratory	O
distress	O
disease	O
.	O

The	O
first	O
onset	O
symptom	O
of	O
the	O
27	O
cases	O
is	O
high	O
fever	B-PROC
accompany	O
with	O
toxic	O
symptom	O
such	O
as	O
muscular	O
soreness	O
,	O
headache	O
,	O
etc	O
.	O

The	O
lung	O
of	O
SARS	O
from	O
autopsy	O
is	O
characterized	O
by	O
edema	O
,	O
intra	O
-	O
alveolar	O
fibrin	O
exudates	O
,	O
hyaline	O
membrane	O
formation	B-PROC
,	O
organization	O
of	O
intra	O
-	O
alveolar	O
exudates	O
and	O
fibrosis	O
,	O
which	O
lead	O
to	O
the	O
obliteration	O
of	O
alveoli	O
and	O
consolidation	O
of	O
lungs	O
.	O

TITLE	O
:	O
Novel	O
synthesis	B-PROC
of	O
polymorphous	O
nanocrystalline	O
KNbO3	O
by	O
a	O
low	O
temperature	O
solution	O
method	O
.	O

Viruses	O
of	O
viral	O
hepatitis	O
B	O
,	O
C	O
,	O
D	O
and	O
HIV	O
,	O
CMV	O
,	O
EBV	O
may	O
be	O
the	O
source	O
of	O
nosocomial	O
viral	B-PROC
infections	I-PROC
transmitted	O
by	O
blood	O
(	O
transfusions	O
).	O

Birth	B-PROC
weights	O
of	O
eleven	O
babies	O
(	O
30	O
%)	O
were	O
below	O
1500	O
g	O
.	O

The	O
disease	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
spread	O
quickly	O
and	O
caused	O
numerous	O
deaths	B-PROC
,	O
as	O
well	O
as	O
public	O
panic	O
.	O

Those	O
of	O
nonresponsiveness	O
had	O
higher	O
dosage	O
and	O
needed	O
longer	O
time	O
to	O
reach	B-PROC
stable	O
.	O

Serum	O
antibody	B-PROC
was	O
not	O
detected	O
until	O
on	O
the	O
9th	O
day	O
of	O
the	O
course	O
of	O
illness	O
;	O
CT	O
is	O
a	O
more	O
sensitive	O
method	O
for	O
detection	O
of	O
the	O
abnormal	O
chest	O
radiographs	O
than	O
regular	O
X	O
-	O
ray	O
test	O
.	O

ABSTRACT	O
:	O
To	O
primarily	O
investigate	O
the	O
changing	O
mode	O
of	O
anti	O
-	O
SARS	O
coronavirus	O
IgG	O
antibody	B-PROC
in	O
clinically	O
diagnosed	O
SARS	O
patients	O
and	O
the	O
possibility	O
of	O
subclinical	O
infection	O
in	O
physicians	O
and	O
nurses	O
through	O
close	O
association	O
with	O
SARS	O
patients	O
.	O

There	O
were	O
lung	O
infiltrates	O
1	O
to	O
6	O
days	O
after	O
fever	B-PROC
and	O
then	O
methylprednisolone	O
was	O
given	O
to	O
them	O
.	O

TITLE	O
:	O
[	O
Modeling	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-PROC
and	O
conformational	O
flexibility	O
of	O
the	O
active	O
site	O
].	O

Most	O
of	O
the	O
residents	O
believe	O
SARS	O
have	O
influenced	O
on	O
regular	O
life	O
,	O
stability	O
of	O
society	O
,	O
development	B-PROC
of	O
economy	O
and	O
international	O
communication	O
.	O

The	O
antiviral	O
activity	O
may	O
be	O
mediated	O
in	O
part	O
by	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
synthetase	O
,	O
RNA	O
-	O
dependent	O
protein	O
kinase	O
,	O
and	O
Mx	O
protein	O
,	O
which	O
inhibit	O
viral	B-PROC
replication	I-PROC
or	O
degrade	O
viral	O
components	O
,	O
because	O
limitin	O
induced	O
their	O
mRNA	B-PROC
expression	B-PROC
and	O
enzyme	O
activity	O
.	O

We	O
have	O
cloned	O
,	O
expressed	B-PROC
,	O
and	O
purified	O
this	O
protein	O
as	O
an	O
N	O
-	O
terminal	O
hexahistidine	O
fusion	O
in	O
Escherichia	O
coli	O
and	O
have	O
characterized	O
its	O
helicase	O
and	O
NTPase	O
activities	O
.	O

RESULTS	O
:	O
Among	O
32	O
patients	O
,	O
24	O
were	O
cured	O
,	O
2	O
died	B-PROC
of	O
respiratory	O
failure	O
,	O
6	O
died	B-PROC
of	O
their	O
primary	O
diseases	O
,	O
and	O
the	O
overall	O
mortality	O
was	O
25	O
.	O
00	O
percent	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
Fever	B-PROC
above	O
38	O
.	O
5	O
centigrade	O
,	O
dry	O
cough	O
,	O
short	O
of	O
breath	O
,	O
headache	O
,	O
myalgia	O
,	O
diarrhea	O
in	O
SARS	O
were	O
more	O
common	O
in	O
SARS	O
patients	O
than	O
those	O
in	O
CAP	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
time	O
of	O
bringing	O
down	O
the	O
fever	B-PROC
and	O
the	O
time	O
of	O
absorption	O
of	O
pathological	O
changes	O
in	O
SARS	O
patients	O
were	O
prolonged	O
than	O
those	O
of	O
the	O
pneumonia	O
patients	O
[	O
the	O
time	O
of	O
bringing	O
down	O
the	O
fever	B-PROC
(	O
13	O
.	O
92	O
+/-	O
8	O
.	O
35	O
)	O
days	O
vs	O
.	O
(	O
3	O
.	O
86	O
+/-	O
1	O
.	O
42	O
)	O
days	O
,	O
t	O
=	O
16	O
.	O
490	O
,	O
P	O
=	O
0	O
.	O
000	O
;	O
the	O
time	O
of	O
absorption	O
of	O
pathological	O
changes	O
:	O
(	O
11	O
.	O
97	O
+/-	O
4	O
.	O
41	O
)	O
days	O
vs	O
.	O
(	O
9	O
.	O
21	O
+/-	O
4	O
.	O
42	O
)	O
days	O
,	O
t	O
=	O
3	O
.	O
082	O
,	O
P	O
=	O
0	O
.	O
003	O
].	O

,	O
the	O
most	O
common	O
symptoms	O
are	O
fever	B-PROC
,	O
cough	O
,	O
headache	O
and	O
myalgia	O
,	O
other	O
common	O
findings	O
are	O
lymphopenia	O
,	O
the	O
CD	O
+	O
4	O
and	O
CD	O
+	O
8	O
in	O
T	O
cell	O
in	O
peripheral	O
blood	O
decrease	O
and	O
multi	O
-	O
infiltrate	O
through	O
out	O
the	O
lung	O
fields	O
.	O

ABSTRACT	O
:	O
Targeted	B-PROC
recombination	B-PROC
was	O
carried	O
out	O
to	O
select	O
mouse	O
hepatitis	O
viruses	O
(	O
MHVs	O
)	O
in	O
a	O
defined	O
genetic	O
background	O
,	O
containing	O
an	O
MHV	O
-	O
JHM	O
spike	O
gene	O
encoding	O
either	O
three	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
substitutions	O
(	O
Q1067H	O
,	O
Q1094H	O
,	O
and	O
L1114R	O
)	O
or	O
L1114R	O
alone	O
.	O

The	O
conservation	O
of	O
the	O
N	O
-	O
and	O
O	O
-	O
glycosylation	B-PROC
motifs	O
suggests	O
that	O
each	O
of	O
these	O
types	O
of	O
carbohydrate	O
modifications	O
is	O
beneficial	O
to	O
their	O
respective	O
virus	O
.	O

Since	O
glycosylation	B-PROC
of	O
the	O
M	O
protein	O
is	O
not	O
required	O
for	O
virus	B-PROC
assembly	I-PROC
,	O
the	O
oligosaccharides	O
are	O
likely	O
to	O
be	O
involved	O
in	O
the	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
.	O

This	O
apparent	O
correlation	O
might	O
be	O
explained	O
by	O
the	O
functioning	O
of	O
lectins	O
,	O
such	O
as	O
the	O
mannose	O
receptor	O
,	O
which	O
are	O
abundantly	O
expressed	B-PROC
in	O
the	O
liver	O
but	O
also	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
interferon	O
-	O
alpha	O
by	O
dendritic	O
cells	O
.	O

In	O
the	O
lungs	O
of	O
the	O
3	O
patients	O
,	O
localized	O
necrosis	B-PROC
occurred	O
where	O
infiltration	O
of	O
CD45RO	O
(+)	O
T	O
lymphocytes	O
was	O
observed	O
,	O
with	O
only	O
scarce	O
Ki67	O
(+)	O
T	O
lymphocytes	O
(	O
active	O
T	O
lymphocytes	O
)	O
and	O
B	O
lymphocytes	O
.	O

Evaluation	O
was	O
in	O
a	O
laboratory	O
intensive	O
care	O
unit	O
setting	O
for	O
48	O
h	O
.	O
The	O
sham	O
group	O
had	O
stable	O
cardiopulmonary	O
and	O
systemic	O
hemodynamics	B-PROC
.	O

The	O
initial	O
temperature	O
was	O
(	O
38	O
.	O
3	O
+/-	O
0	O
.	O
6	O
)	O
degrees	O
C	O
,	O
while	O
the	O
highest	O
was	O
(	O
39	O
.	O
2	O
+/-	O
0	O
.	O
6	O
)	O
degrees	O
C	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
with	O
a	O
mean	O
fever	B-PROC
duration	O
of	O
(	O
9	O
.	O
0	O
+/-	O
4	O
.	O
2	O
)	O
days	O
.	O

Fifteen	O
patients	O
died	B-PROC
,	O
the	O
mortality	O
rate	O
was	O
28	O
.	O
3	O
%.	O

There	O
has	O
been	O
no	O
evidence	O
of	O
further	O
transmission	O
within	O
the	O
hospital	O
after	O
the	O
elapse	O
of	O
2	O
full	O
incubation	O
periods	B-PROC
(	O
20	O
days	O
).	O

For	O
early	O
diagnosis	O
,	O
it	O
is	O
paramount	O
to	O
consider	O
malaria	O
in	O
every	O
febrile	B-PROC
patient	O
with	O
a	O
history	O
of	O
travel	O
in	O
an	O
area	O
endemic	O
for	O
malaria	O
.	O

The	O
first	O
SARS	O
case	O
was	O
identified	O
in	O
Foshan	O
municipality	O
on	O
November	O
16	O
,	O
2002	O
,	O
followed	O
by	O
1	O
511	O
clinically	O
confirmed	O
cases	O
(	O
including	O
58	O
deaths	B-PROC
)	O
up	O
to	O
May	O
15	O
,	O
2003	O
.	O

RESULTS	O
:	O
The	O
first	O
SARS	O
case	O
was	O
identified	O
in	O
Foshan	O
municipality	O
on	O
November	O
16	O
,	O
2002	O
,	O
followed	O
by	O
1	O
511	O
clinically	O
confirmed	O
cases	O
(	O
including	O
58	O
deaths	B-PROC
)	O
up	O
to	O
May	O
15	O
,	O
2003	O
.	O

Emphasis	O
has	O
been	O
given	O
in	O
this	O
review	O
to	O
swine	O
influenza	O
virus	O
,	O
paramyxovirus	O
(	O
Nipah	O
virus	O
,	O
Menagle	O
virus	O
,	O
LaPiedad	O
paramyxovirus	O
,	O
porcine	O
paramyxovirus	O
),	O
arterivirus	O
(	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
)	O
and	O
circovirus	O
as	O
either	O
they	O
represent	O
new	O
swine	O
viruses	O
or	O
present	O
the	O
greatest	O
risk	O
.	O

Vero	O
-	O
E6	O
cells	O
was	O
transfected	O
with	O
siRNA	O
before	O
SARS	O
virus	B-PROC
infection	I-PROC
,	O
and	O
the	O
effectiveness	O
of	O
siRNA	O
interference	O
was	O
evaluated	O
by	O
observing	O
the	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
on	O
Vero	O
-	O
E6	O
cells	O
.	O

TITLE	O
:	O
Increased	O
litter	O
survival	O
rates	O
,	O
reduced	O
clinical	O
illness	O
and	O
better	O
lactogenic	O
immunity	B-PROC
against	O
TGEV	O
in	O
gilts	O
that	O
were	O
primed	O
as	O
neonates	O
with	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
).	O

ABSTRACT	O
:	O
Establishing	O
immunological	B-PROC
memory	B-PROC
in	O
female	O
piglets	O
at	O
a	O
young	O
age	O
with	O
PRCV	O
was	O
effective	O
in	O
inducing	O
a	O
secondary	B-PROC
immune	B-PROC
response	I-PROC
to	O
a	O
limiting	O
dose	O
of	O
virulent	O
TGEV	O
given	O
orally	O
13	O
-	O
18	O
days	O
prior	O
to	O
farrowing	B-PROC
.	O

The	O
patient	O
was	O
placed	O
on	O
assisted	O
respiration	B-PROC
support	O
in	O
addition	O
to	O
anti	O
-	O
viral	O
medication	O
.	O

The	O
application	O
of	O
4	O
intermittent	O
MARS	O
treatments	O
(	O
8	O
h	O
each	O
,	O
mean	O
blood	B-PROC
flow	I-PROC
rate	O
180	O
ml	O
/	O
min	O
)	O
on	O
4	O
consecutive	O
days	O
resulted	O
in	O
an	O
immediate	O
improvement	O
of	O
clinical	O
conditions	O
within	O
the	O
treatment	O
days	O
.	O

However	O
,	O
the	O
development	B-PROC
and	O
aggravation	O
of	O
this	O
ARDS	O
-	O
like	O
severe	O
acute	O
respiratory	O
syndrome	O
is	O
pathologically	O
associated	O
with	O
the	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
)	O
which	O
may	O
then	O
mediate	O
or	O
cause	O
MODS	O
.	O

Infiltration	O
of	O
pancreatic	O
and	O
lung	O
tissue	O
with	O
neutrophils	O
(	O
measured	O
as	O
increase	O
in	O
myeloperoxidase	O
activity	O
)	O
was	O
associated	O
with	O
enhanced	O
lipid	B-PROC
peroxidation	I-PROC
(	O
increased	O
tissue	O
levels	O
of	O
malondialdehyde	O
).	O

Initial	O
use	O
of	O
pulse	B-PROC
methylprednisolone	O
therapy	O
appears	O
to	O
be	O
a	O
more	O
efficacious	O
and	O
an	O
equally	O
safe	O
steroid	O
regimen	O
when	O
compared	O
with	O
regimens	O
with	O
lower	O
dosage	O
and	O
should	O
be	O
considered	O
as	O
the	O
preferred	O
steroid	O
regimen	O
in	O
the	O
treatment	O
of	O
SARS	O
,	O
pending	O
data	O
from	O
future	O
randomized	O
controlled	O
trials	O
.	O

RESULTS	O
:	O
The	O
MARS	O
therapy	O
was	O
associated	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
INF	O
-	O
gamma	O
,	O
together	O
with	O
marked	O
reduction	O
of	O
other	O
non	O
-	O
water	O
-	O
soluble	O
albumin	O
bound	O
toxins	O
and	O
water	O
-	O
soluble	O
toxins	O
,	O
these	O
were	O
associated	O
with	O
a	O
improvement	O
of	O
the	O
patients	O
'	O
clinical	O
conditions	O
including	O
hepatic	O
encephalopathy	O
,	O
deranged	O
hemodynamic	B-PROC
situation	O
and	O
as	O
well	O
as	O
renal	O
and	O
respiratory	B-PROC
function	I-PROC
,	O
thus	O
resulted	O
into	O
marked	O
decrease	O
of	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
score	O
and	O
improved	O
outcome	O
:	O
nine	O
patients	O
were	O
able	O
to	O
be	O
discharged	O
from	O
the	O
hospital	O
or	O
bridged	O
to	O
successful	O
liver	O
transplantation	O
,	O
the	O
overall	O
survival	O
of	O
24	O
patients	O
was	O
37	O
.	O
5	O
%.	O

Aerosolisation	O
of	O
iloprost	O
(	O
in	O
total	O
0	O
.	O
7	O
microg	O
x	O
kg	O
(-	O
1	O
))	O
for	O
15	O
min	O
caused	O
a	O
more	O
sustained	O
decrease	O
in	O
Ppa	O
,	O
some	O
enhanced	O
reduction	O
of	O
oedema	O
formation	B-PROC
as	O
compared	O
with	O
PGI2	O
and	O
a	O
decrease	O
in	O
shunt	O
flow	O
to	O
approximately	O
32	O
%.	O

As	O
previously	O
shown	O
,	O
a	O
lower	O
pre	O
-	O
existing	O
anti	O
-	O
MHV	O
antibody	B-PROC
level	O
was	O
found	O
in	O
susceptible	O
HIII	O
mice	O
as	O
compared	O
to	O
resistant	O
LIII	O
mice	O
.	O

Mortality	O
rates	O
of	O
the	O
F1	O
(	O
H	O
x	O
L	O
)	O
hybrids	O
and	O
F2	O
and	O
backcross	O
segregants	O
reflected	O
co	O
-	O
dominance	O
of	O
both	O
characters	O
and	O
the	O
survivors	O
had	O
higher	O
preexisting	O
anti	O
-	O
MHV	O
antibody	B-PROC
titers	O
.	O

When	O
compared	O
to	O
uvMHV3	O
,	O
a	O
single	O
immunization	O
with	O
a	O
related	O
infectious	O
MHV	O
strain	O
induced	O
a	O
higher	O
antibody	B-PROC
synthesis	B-PROC
and	O
led	O
the	O
HIII	O
mice	O
to	O
resist	O
the	O
MHV3	O
challenge	O
.	O

The	O
resistance	B-PROC
and	O
the	O
survival	O
time	O
of	O
these	O
animals	O
increased	O
with	O
the	O
level	O
of	O
antibody	B-PROC
administered	O
.	O

HO	O
-	O
1	O
induction	O
was	O
mediated	O
in	O
part	O
through	O
a	O
rapid	O
increase	O
in	O
microsomal	O
free	O
heme	O
concentration	O
presumably	O
derived	O
from	O
hepatic	O
cytochrome	B-PROC
P450	I-PROC
.	O

We	O
explore	O
the	O
situation	O
where	O
these	O
epidemics	O
may	O
be	O
caused	O
either	O
by	O
a	O
virus	O
and	O
one	O
or	O
several	O
mutants	O
that	O
changed	O
its	O
tropism	B-PROC
,	O
or	O
by	O
two	O
unrelated	O
viruses	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
how	O
the	O
putative	O
MHV	O
RdRp	O
(	O
Pol	O
)	O
is	O
targeted	B-PROC
to	O
and	O
retained	O
on	O
cellular	O
membranes	O
.	O

To	O
determine	O
if	O
Pol	O
associated	O
with	O
cellular	O
membranes	O
in	O
the	O
absence	O
of	O
other	O
viral	O
factors	O
,	O
the	O
pol	O
domain	O
of	O
gene	O
1	O
was	O
cloned	O
and	O
expressed	B-PROC
in	O
cells	O
as	O
a	O
fusion	O
with	O
green	O
fluorescent	O
protein	O
,	O
termed	O
Gpol	O
.	O

Expression	B-PROC
of	O
Gpol	O
deletion	O
mutants	O
established	O
that	O
the	O
conserved	O
enzymatic	O
domains	O
of	O
Pol	O
were	O
dispensable	O
for	O
replication	O
complex	O
association	O
,	O
but	O
a	O
38	O
-	O
amino	O
-	O
acid	O
domain	O
in	O
the	O
RdRp	O
unique	O
region	O
of	O
Pol	O
was	O
required	O
.	O

TITLE	O
:	O
[	O
Relationship	O
between	O
acid	O
-	O
base	O
disturbance	O
in	O
blood	B-PROC
gas	I-PROC
analysis	O
and	O
prognosis	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

CONCLUSIONS	O
:	O
The	O
artery	O
blood	B-PROC
gas	I-PROC
analysis	O
is	O
useful	O
for	O
judging	O
the	O
conditions	O
and	O
prognosis	O
of	O
patients	O
with	O
SARS	O
,	O
and	O
is	O
beneficial	O
for	O
clinical	O
treatment	O
.	O

There	O
were	O
30	O
strains	O
of	O
bacteria	O
isolated	O
from	O
seven	O
cases	O
of	O
SARS	O
death	B-PROC
patients	O
with	O
secondary	O
bacterial	O
infection	O
.	O

None	O
was	O
dead	B-PROC
in	O
the	O
patients	O
with	O
non	O
-	O
invasive	O
ventilation	O
.	O

None	O
was	O
dead	B-PROC
in	O
the	O
patients	O
with	O
non	O
-	O
invasive	O
ventilation	O
.	O

In	O
addition	O
to	O
a	O
historical	O
session	O
looking	O
at	O
Scotland	O
'	O
s	O
own	O
contribution	O
to	O
the	O
control	O
of	O
infectious	O
diseases	O
,	O
the	O
meeting	O
involved	O
up	O
to	O
six	O
parallel	O
sessions	O
a	O
day	O
,	O
looking	O
at	O
all	O
the	O
major	O
aspects	O
of	O
infectious	O
diseases	O
,	O
treatment	O
,	O
surveillance	O
,	O
epidemiology	O
and	O
drug	O
pharmacodynamics	O
and	O
pharmacokinetics	B-PROC
.	O

Synthesis	B-PROC
and	O
evaluation	O
of	O
in	O
vitro	O
biological	O
activity	O
.	O

Factors	O
that	O
influence	O
whether	O
FCoV	O
establishes	O
lifelong	O
infection	O
in	O
some	O
cats	O
and	O
not	O
others	O
are	O
determined	O
mainly	O
by	O
the	O
host	B-PROC
response	I-PROC
to	O
infection	O
.	O

The	O
protein	O
responsible	O
for	O
viral	B-PROC
-	I-PROC
induced	I-PROC
membrane	I-PROC
fusion	I-PROC
of	O
HIV	O
-	O
1	O
(	O
gp41	O
)	O
differs	O
in	O
length	O
,	O
and	O
has	O
no	O
sequence	O
homology	O
with	O
S2	O
.	O

RESULTS	O
:	O
The	O
symptoms	O
mostly	O
often	O
revealed	O
in	O
patients	O
of	O
early	O
stage	O
were	O
fever	B-PROC
in	O
56	O
patients	O
,	O
cough	O
in	O
41	O
and	O
weakness	O
or	O
heaviness	O
of	O
limbs	O
in	O
40	O
,	O
which	O
in	O
patients	O
of	O
middle	O
or	O
crisis	O
stage	O
were	O
cough	O
in	O
53	O
and	O
weakness	O
or	O
heaviness	O
of	O
limbs	O
in	O
43	O
.	O

Cases	O
of	O
more	O
than	O
10	O
days	O
'	O
duration	O
exhibited	O
organizing	O
-	O
phase	O
DAD	O
,	O
type	O
II	O
pneumocyte	O
hyperplasia	O
,	O
squamous	O
metaplasia	B-PROC
,	O
multinucleated	O
giant	O
cells	O
,	O
and	O
acute	O
bronchopneumonia	O
.	O

Clinical	O
disease	O
is	O
characterized	O
by	O
fever	B-PROC
,	O
dry	O
cough	O
,	O
interstitial	O
infiltrates	O
,	O
and	O
variable	O
progression	O
to	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
To	O
elucidate	O
the	O
mechanism	O
of	O
strong	O
inflammatory	B-PROC
response	I-PROC
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

The	O
intestinal	O
tropism	B-PROC
of	O
the	O
SARS	O
-	O
CoV	O
has	O
major	O
implications	O
on	O
clinical	O
presentation	O
and	O
viral	B-PROC
transmission	I-PROC
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
collected	O
from	O
SARS	O
cases	O
infected	O
by	O
the	O
same	O
infectious	O
source	O
were	O
tested	O
for	O
both	O
negative	O
-	O
stranded	O
RNA	O
(	O
minus	O
-	O
RNA	O
,	O
""""	O
replicative	O
intermediates	O
""")"	O
and	O
positive	O
-	O
stranded	O
RNA	O
(	O
genomic	O
RNA	O
)	O
of	O
SARS	O
-	O
CoV	O
during	O
the	O
course	O
of	O
hospitalization	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
presence	O
of	O
fever	B-PROC
in	O
conjunction	O
with	O
a	O
SARS	O
exposure	O
history	O
should	O
prompt	O
one	O
to	O
consider	O
SARS	O
as	O
a	O
possible	O
diagnosis	O
in	O
children	O
irrespective	O
of	O
the	O
presence	O
or	O
absence	O
of	O
respiratory	O
symptoms	O
.	O

Nasopharyngeal	O
swab	O
specimens	O
were	O
negative	O
for	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
by	O
an	O
in	O
-	O
house	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
in	O
all	O
25	O
children	O
.	O

TITLE	O
:	O
Confirmed	O
persistent	O
mouse	O
hepatitis	O
virus	B-PROC
infection	I-PROC
and	O
transmission	O
by	O
mice	O
with	O
a	O
targeted	B-PROC
null	O
mutation	O
of	O
tumor	O
necrosis	B-PROC
factor	O
to	O
sentinel	O
mice	O
,	O
using	O
short	O
-	O
term	O
exposure	O
.	O

TITLE	O
:	O
De	O
novo	O
synthesis	B-PROC
of	O
PCR	O
templates	O
for	O
the	O
development	B-PROC
of	O
SARS	O
diagnostic	O
assay	O
.	O

TITLE	O
:	O
A	O
system	O
of	O
protein	B-PROC
target	I-PROC
sequences	O
for	O
anti	O
-	O
RNA	O
-	O
viral	O
chemotherapy	O
by	O
a	O
vitamin	O
B6	O
-	O
derived	O
zinc	O
-	O
chelating	B-PROC
trioxa	O
-	O
adamantane	O
-	O
triol	O
.	O

Caveolin	O
-	O
1	O
may	O
serve	O
as	O
a	O
possible	O
receptor	O
of	O
the	O
SARS	O
-	O
CoV	O
proteins	O
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
SARS	O
-	O
CoV	O
infection	O
,	O
replication	O
,	O
assembly	O
,	O
and	O
budding	B-PROC
.	O

The	O
clinical	O
symptoms	O
of	O
SARS	O
are	O
unspecific	O
and	O
its	O
evolution	B-PROC
may	O
be	O
misleading	O
.	O

CONCLUSIONS	O
:	O
The	O
clinical	O
symptoms	O
of	O
SARS	O
are	O
unspecific	O
and	O
its	O
evolution	B-PROC
may	O
be	O
misleading	O
.	O

Hemogram	O
and	O
blood	B-PROC
gas	I-PROC
analysis	O
showed	O
that	O
blood	O
sugar	O
and	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
);	O
lymphocyte	O
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
PaO	B-PROC
(	O
2	O
),	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
decreased	O
Progressively	O
(	O
P	O
<	O
0	O
.	O
005	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
late	O
stage	O
of	O
SARS	O
versus	O
just	O
entering	O
the	O
hospital	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
effects	O
of	O
noninvasive	O
positive	O
pressure	O
ventilation	O
(	O
NIPPV	O
)	O
on	O
oxygenation	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
,	O
and	O
to	O
discuss	O
the	O
timing	O
point	O
for	O
mechanical	O
ventilation	O
.	O

RESULTS	O
:	O
Although	O
NIPPV	O
administered	O
via	O
full	O
-	O
face	O
masks	O
might	O
be	O
an	O
effective	O
treatment	O
for	O
rapidly	O
improving	O
vital	O
signs	O
and	O
gas	O
exchange	O
and	O
sense	B-PROC
of	O
dyspnea	O
in	O
both	O
groups	O
during	O
the	O
initial	O
24	O
hours	O
of	O
ventilatory	O
support	O
,	O
the	O
patients	O
in	O
non	O
-	O
survivor	O
group	O
had	O
higher	O
APACHEII	O
score	O
,	O
respiratory	O
rates	O
and	O
lower	O
SpO	O
(	O
2	O
),	O
MRI	O
than	O
the	O
patients	O
in	O
survivor	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
at	O
the	O
same	O
intervals	O
after	O
initiation	O
of	O
support	O
.	O

The	O
results	O
are	O
consistent	O
with	O
coronavirus	O
transcription	B-PROC
models	O
in	O
which	O
the	O
transcription	B-PROC
from	O
upstream	O
TRSs	O
is	O
attenuated	O
by	O
downstream	O
TRSs	O
.	O

Altogether	O
,	O
our	O
observations	O
clearly	O
demonstrate	O
the	O
potential	O
of	O
coronaviruses	O
as	O
(	O
multivalent	O
)	O
expression	B-PROC
vectors	O
.	O

A	O
nonenteropathogenic	O
mutant	O
virus	O
that	O
lacked	O
a	O
sialic	O
acid	O
binding	B-PROC
activity	I-PROC
was	O
unable	O
to	O
bind	O
to	O
MGP	O
and	O
to	O
attach	O
to	O
goblet	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
has	O
been	O
proposed	O
to	O
be	O
a	O
key	O
target	O
for	O
structural	O
-	O
based	O
drug	O
design	O
against	O
SARS	O
.	O

Media	O
articles	O
were	O
sorted	B-PROC
and	O
classified	O
by	O
topic	O
,	O
and	O
themes	O
were	O
identified	O
.	O

TITLE	O
:	O
Establishment	O
of	O
persistent	O
avian	O
infectious	O
bronchitis	O
virus	B-PROC
infection	I-PROC
in	O
antibody	B-PROC
-	O
free	O
and	O
antibody	B-PROC
-	O
positive	O
chickens	O
.	O

Pass	O
70	O
of	O
the	O
GA98	O
/	O
0470	O
/	O
98	O
strain	O
of	O
IBV	O
when	O
given	O
at	O
1	O
day	O
of	O
age	O
by	O
coarse	O
spray	O
and	O
at	O
14	O
days	O
of	O
age	O
in	O
the	O
drinking	B-PROC
water	O
at	O
1	O
x	O
10	O
(	O
4	O
.	O
5	O
)	O
50	O
%	O
embryo	O
infectious	O
dose	O
/	O
bird	O
protected	O
against	O
the	O
homologous	O
GA98	O
challenge	O
as	O
well	O
as	O
provided	O
good	O
protection	O
against	O
the	O
DE072	O
-	O
type	O
virus	O
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RRT	O
-	O
PCR	O
)	O
diagnostic	O
test	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
with	O
the	O
use	O
of	O
fluorescence	O
resonance	O
energy	B-PROC
transfer	I-PROC
(	O
FRET	O
)	O
technology	O
.	O

For	O
the	O
respiratory	O
physician	O
,	O
detecting	O
SARS	O
in	O
its	O
earliest	O
stages	O
,	O
identifying	O
pathways	B-PROC
of	O
transmission	O
,	O
and	O
implementing	O
preventive	O
and	O
therapeutic	O
strategies	O
are	O
all	O
important	O
.	O

Recombinant	O
viruses	O
replicated	O
as	O
efficiently	O
as	O
WT	O
virus	O
and	O
both	O
were	O
inhibited	O
by	O
treatment	O
with	O
the	O
cysteine	O
proteinase	B-PROC
inhibitor	I-PROC
(	O
2S	O
,	O
3S	O
)-	O
transepoxysuccinyl	O
-	O
L	O
-	O
leucylamido	O
-	O
3	O
-	O
methylbutane	O
ethyl	O
ester	O
.	O

During	O
that	O
time	O
we	O
investigated	O
the	O
clinical	O
features	O
,	O
treatment	O
,	O
and	O
nursing	B-PROC
care	O
of	O
36	O
patients	O
and	O
reported	O
on	O
12	O
of	O
these	O
patients	O
'	O
perceptions	O
of	O
their	O
illness	O
experience	O
.	O

Less	O
common	O
symptoms	O
included	O
headache	O
(	O
38	O
.	O
9	O
%),	O
diarrhea	O
(	O
38	O
.	O
9	O
%),	O
dizziness	O
(	O
30	O
.	O
6	O
%),	O
myalgia	O
(	O
25	O
%),	O
chills	O
(	O
19	O
.	O
4	O
%),	O
nausea	O
and	O
vomiting	O
(	O
19	O
.	O
4	O
%)	O
and	O
rigor	O
(	O
the	O
occurrence	O
of	O
a	O
sensation	B-PROC
of	O
hot	O
-	O
and	O
-	O
cold	B-PROC
and	O
shivering	O
in	O
addition	O
to	O
teeth	O
chattering	O
and	O
bed	O
shaking	O
)	O
(	O
8	O
.	O
3	O
%).	O

In	O
treating	O
SARS	O
,	O
ICWM	O
was	O
superior	O
to	O
the	O
treatment	O
with	O
western	O
medicine	O
alone	O
in	O
aspects	O
of	O
improving	O
clinical	O
symptom	O
,	O
promoting	O
recovery	O
of	O
immune	B-PROC
function	I-PROC
and	O
absorption	O
of	O
lung	O
inflammation	O
,	O
decreasing	O
the	O
dosage	O
of	O
hormone	O
used	O
and	O
shortening	O
the	O
therapeutic	O
course	O
.	O

On	O
6	O
April	O
(	O
day	O
40	O
)	O
there	O
were	O
74	O
cases	O
and	O
7	O
deaths	B-PROC
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
the	O
anti	O
-	O
SARS	O
-	O
coronavirus	O
specific	O
antibody	B-PROC
levels	O
in	O
156	O
SARS	O
patients	O
].	O

Our	O
early	O
work	O
revealed	O
that	O
cerebral	O
compression	O
elicits	O
severe	O
hemorrhagic	O
pulmonary	O
edema	O
(	O
PE	O
),	O
leading	O
to	O
central	O
sympathetic	O
activation	O
that	O
results	O
in	O
systemic	O
vasoconstriction	B-PROC
.	O

Our	O
early	O
and	O
recent	O
studies	O
on	O
ARDS	O
and	O
PE	O
may	O
provide	O
information	O
for	O
clinical	O
practice	O
and	O
the	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

We	O
report	O
here	O
identification	O
of	O
9	O
single	O
nucleotide	O
polymorphisms	B-PROC
(	O
SNPs	O
)	O
in	O
ANPEP	O
,	O
encoding	O
human	O
aminopeptidase	O
N	O
,	O
in	O
Chinese	O
.	O

In	O
humans	O
it	O
is	O
readily	O
absorbed	O
by	O
ingestion	O
and	O
inhalation	B-PROC
but	O
is	O
less	O
well	O
absorbed	O
dermally	O
.	O

Tachycardia	O
,	O
tachypnoea	O
,	O
sweating	O
,	O
altered	O
consciousness	O
,	O
hyperthermia	B-PROC
,	O
convulsions	O
and	O
early	O
onset	O
of	O
marked	O
rigor	O
(	O
if	O
death	B-PROC
occurs	O
)	O
are	O
the	O
most	O
notable	O
features	O
.	O

BALB	O
/	O
b	O
mice	O
had	O
25	O
-	O
fold	O
more	O
MHV	O
-	O
specific	O
antibody	B-PROC
-	O
secreting	B-PROC
cells	O
in	O
the	O
central	O
nervous	O
system	O
,	O
the	O
site	O
of	O
infection	O
,	O
than	O
B6	O
mice	O
,	O
suggesting	O
that	O
local	O
production	O
of	O
anti	O
-	O
MHV	O
antibody	B-PROC
contributed	O
to	O
this	O
absence	O
of	O
CTL	O
escape	O
.	O

Our	O
results	O
,	O
thus	O
,	O
for	O
the	O
first	O
time	O
provide	O
unequivocal	O
evidence	O
that	O
infection	O
of	O
oligodendrocytes	O
with	O
MHV	O
directly	O
results	O
in	O
apoptosis	B-PROC
.	O

At	O
the	O
end	O
,	O
all	O
of	O
the	O
patients	O
died	B-PROC
from	O
sudden	O
cardiac	O
arrest	O
,	O
which	O
was	O
associated	O
with	O
acute	O
myocardial	O
infarction	O
in	O
2	O
cases	O
.	O

From	O
this	O
small	O
case	O
series	O
,	O
it	O
appeared	O
that	O
dialysis	O
patients	O
might	O
have	O
an	O
aggressive	B-PROC
clinical	O
course	O
and	O
poor	O
outcome	O
after	O
contracting	O
SARS	O
.	O

Post	O
-	O
neonatal	O
deaths	B-PROC
fell	O
by	O
79	O
%	O
(	O
95	O
%	O
CI	O
65	O
-	O
87	O
%)	O
while	O
neonatal	O
mortality	O
remained	O
unchanged	O
.	O

Before	O
its	O
recognition	O
approximately	O
7	O
%	O
of	O
all	O
infants	O
in	O
this	O
population	O
died	B-PROC
from	O
infantile	O
beri	O
-	O
beri	O
.	O

TITLE	O
:	O
Identifying	O
inhibitors	O
of	O
the	O
SARS	O
coronavirus	O
proteinase	B-PROC
.	O

Moreover	O
,	O
chloroquine	O
has	O
immunomodulatory	O
effects	O
,	O
suppressing	O
the	O
production	O
/	O
release	O
of	O
tumour	O
necrosis	B-PROC
factor	O
alpha	O
and	O
interleukin	O
6	O
,	O
which	O
mediate	O
the	O
inflammatory	O
complications	O
of	O
several	O
viral	B-PROC
diseases	I-PROC
.	O

Larger	O
maximal	O
radiographic	O
scores	O
,	O
lower	O
Sao2	B-PROC
at	O
maximal	O
radiographic	O
change	O
,	O
longer	O
time	O
from	O
treatment	O
to	O
maximal	O
radiographic	O
score	O
(	O
P	O
<.	O
01	O
),	O
and	O
diffuse	O
consolidation	O
at	O
maximal	O
radiographic	O
score	O
were	O
associated	O
with	O
oxygen	O
supplementation	O
.	O

But	O
we	O
could	O
not	O
maintain	O
stable	O
ventilation	O
until	O
her	O
spontaneous	O
breathing	B-PROC
appeared	O
.	O

This	O
finding	O
was	O
further	O
confirmed	O
by	O
quantitative	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
BNip3	O
-	O
promoter	O
-	O
luciferase	O
reporter	O
system	O
.	O

Interestingly	O
,	O
infection	O
with	O
live	O
and	O
ultraviolet	O
light	O
-	O
inactivated	O
viruses	O
equally	O
repressed	O
BNip3	O
expression	B-PROC
,	O
indicating	O
that	O
the	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
BNip3	O
expression	B-PROC
does	O
not	O
require	O
virus	B-PROC
replication	I-PROC
and	O
is	O
mediated	O
during	O
cell	O
entry	O
.	O

Continuing	O
public	O
education	O
about	O
preventive	O
measures	O
should	O
be	O
targeted	B-PROC
at	O
the	O
identified	O
groups	O
with	O
low	O
current	O
uptake	O
of	O
precautions	O
.	O

Older	O
persons	O
and	O
those	O
taking	O
corticosteroids	O
may	O
have	O
neither	O
fever	B-PROC
nor	O
respiratory	O
symptoms	O
.	O

TITLE	O
:	O
[	O
Analysis	O
on	O
diagnosis	O
,	O
treatment	O
and	O
influential	O
factors	O
in	O
fever	B-PROC
patients	O
during	O
epidemic	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

The	O
95	O
%	O
confidence	O
interval	O
of	O
total	O
average	O
for	O
the	O
complications	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
shock	O
and	O
kidney	O
failure	O
was	O
between	O
2	O
to	O
4	O
days	O
,	O
and	O
for	O
encephalopathy	O
,	O
hemorrhage	O
of	O
the	O
digestive	B-PROC
tract	O
,	O
bacterial	O
infection	O
,	O
fungous	O
infection	O
and	O
abscess	O
between	O
3	O
to	O
6	O
days	O
,	O
3	O
to	O
5	O
days	O
,	O
13	O
to	O
16	O
days	O
,	O
13	O
to	O
16	O
days	O
,	O
and	O
14	O
to	O
23	O
days	O
respectively	O
.	O

RESULTS	O
:	O
The	O
95	O
%	O
confidence	O
interval	O
of	O
total	O
average	O
for	O
the	O
complications	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
shock	O
and	O
kidney	O
failure	O
was	O
between	O
2	O
to	O
4	O
days	O
,	O
and	O
for	O
encephalopathy	O
,	O
hemorrhage	O
of	O
the	O
digestive	B-PROC
tract	O
,	O
bacterial	O
infection	O
,	O
fungous	O
infection	O
and	O
abscess	O
between	O
3	O
to	O
6	O
days	O
,	O
3	O
to	O
5	O
days	O
,	O
13	O
to	O
16	O
days	O
,	O
13	O
to	O
16	O
days	O
,	O
and	O
14	O
to	O
23	O
days	O
respectively	O
.	O

The	O
average	O
degree	O
of	O
degradation	O
during	O
overnight	O
digestion	B-PROC
was	O
found	O
to	O
be	O
approximately	O
51	O
and	O
approximately	O
34	O
%	O
for	O
Cys	O
and	O
Gln	O
,	O
respectively	O
;	O
more	O
detailed	O
information	O
on	O
the	O
time	O
course	O
of	O
the	O
reactions	O
was	O
obtained	O
for	O
the	O
peptides	O
CCTESLVNR	O
and	O
QYYTVFDR	O
.	O

Virus	B-PROC
neutralization	I-PROC
(	O
VN	B-PROC
)	O
antibodies	O
were	O
detected	O
by	O
tracheal	O
organ	O
cultures	O
,	O
and	O
the	O
results	O
showed	O
that	O
VN	B-PROC
titers	O
reached	O
respectively	O
1	O
:	O
160	O
to	O
1	O
:	O
320	O
and	O
1	O
:	O
320	O
to	O
1	O
:	O
2048	O
with	O
doses	O
of	O
0	O
.	O
5	O
g	O
and	O
1	O
g	O
.	O

Our	O
data	O
suggest	O
that	O
HSV	O
reactivation	O
or	O
infection	O
of	O
the	O
upper	O
respiratory	O
tract	O
is	O
frequent	O
among	O
patients	O
in	O
intensive	O
care	O
,	O
and	O
is	O
a	O
risk	O
factor	O
for	O
development	B-PROC
of	O
lower	O
respiratory	O
tract	O
infection	O
with	O
this	O
virus	O
,	O
possibly	O
by	O
means	O
of	O
aspiration	O
.	O

TITLE	O
:	O
Changes	O
in	O
some	O
acute	O
phase	O
protein	O
and	O
immunoglobulin	B-PROC
concentrations	O
in	O
cats	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
or	O
exposed	O
to	O
feline	O
coronavirus	O
infection	O
.	O

IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
12	O
,	O
IL	O
-	O
18	O
,	O
TNF	O
-	O
alpha	O
,	O
macrophage	O
inhibitory	O
protein	O
(	O
MIP	O
)-	O
1	O
alpha	O
,	O
and	O
RANTES	O
showed	O
no	O
upregulation	B-PROC
in	O
the	O
brains	O
of	O
control	O
cats	O
,	O
moderate	O
upregulation	B-PROC
in	O
neurological	O
FIP	O
cats	O
,	O
and	O
very	O
high	O
upregulation	B-PROC
in	O
generalized	O
FIP	O
cats	O
.	O

Thus	O
our	O
data	O
for	O
the	O
first	O
time	O
indicate	O
that	O
SARS	O
-	O
CoV	O
has	O
encoded	O
a	O
strategy	O
to	O
regulate	O
cellular	O
signaling	B-PROC
process	I-PROC
.	O

To	O
date	O
there	O
have	O
been	O
over	O
750	O
related	O
deaths	B-PROC
and	O
there	O
is	O
clearly	O
an	O
urgent	O
need	O
to	O
develop	O
specific	O
antiviral	O
drugs	O
to	O
combat	O
this	O
disease	O
.	O

During	O
an	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
March	O
2003	O
,	O
hybridization	B-PROC
to	O
this	O
microarray	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
uncharacterized	O
coronavirus	O
in	O
a	O
viral	O
isolate	O
cultivated	O
from	O
a	O
SARS	O
patient	O
.	O

In	O
general	O
,	O
fever	B-PROC
and	O
cough	O
were	O
the	O
most	O
common	O
clinical	O
presentations	O
amongst	O
younger	O
pediatric	O
SARS	O
cases	O
(	O
age	O
<	O
10	O
years	O
),	O
whereas	O
,	O
in	O
addition	O
to	O
these	O
symptoms	O
,	O
headache	O
,	O
myalgia	O
,	O
sore	O
throat	O
,	O
chills	O
,	O
and	O
/	O
or	O
rigor	O
were	O
common	O
in	O
older	O
patients	O
(	O
age	O
>/=	O
10	O
years	O
).	O

In	O
pediatric	O
cases	O
,	O
SARS	O
manifests	O
with	O
nonspecific	O
radiographic	O
features	O
making	O
radiological	O
differentiation	B-PROC
difficult	O
,	O
especially	O
from	O
other	O
commonly	O
encountered	O
childhood	O
respiratory	O
viral	O
illnesses	O
causing	O
airspace	O
disease	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
nucleotide	O
sequences	O
showed	O
the	O
clear	O
separation	O
of	O
sequences	O
analysed	O
on	O
the	O
basis	O
of	O
virulence	B-PROC
and	O
geographical	O
origin	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
presence	O
and	O
distribution	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
autopsy	O
tissues	O
obtained	O
from	O
patients	O
died	B-PROC
of	O
SARS	O
.	O

TITLE	O
:	O
Stress	O
,	O
coping	O
and	O
lessons	O
learned	B-PROC
from	O
the	O
SARS	O
outbreak	O
.	O

The	O
development	B-PROC
of	O
a	O
sensitive	O
and	O
rapid	O
test	O
for	O
early	O
diagnosis	O
is	O
underway	O
.	O

Descriptive	O
statistics	O
were	O
calculated	O
for	O
incidence	O
,	O
prevalence	O
,	O
and	O
the	O
number	O
of	O
deaths	B-PROC
due	O
to	O
SARS	O
in	O
Hong	O
Kong	O
from	O
March	O
14	O
to	O
May	O
31	O
,	O
2003	O
.	O

The	O
antibody	B-PROC
titer	O
in	O
medical	O
personnel	O
was	O
-	O
1	O
.	O
18	O
+/-	O

In	O
the	O
healthy	O
persons	O
,	O
the	O
antibody	B-PROC
titer	O
of	O
serum	O
samples	O
obtained	O
from	O
Beijing	O
in	O
May	O
,	O
2003	O
was	O
-	O
1	O
.	O
61	O
+/-	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
antibody	B-PROC
titer	O
between	O
patients	O
of	O
bacterial	O
pneumonia	O
and	O
patients	O
of	O
atypical	O
pneumonia	O
,	O
which	O
was	O
-	O
1	O
.	O
99	O
+/-	O

Close	O
contact	O
with	O
SARS	O
patients	O
can	O
cause	O
the	O
serum	O
anti	O
-	O
coronavirus	O
antibody	B-PROC
titer	O
to	O
increase	O
significantly	O
in	O
medical	O
personnel	O
,	O
a	O
phenomenon	O
deserves	O
further	O
study	O
.	O

Observing	O
the	O
dynamic	O
changes	O
in	O
blood	O
cytokine	O
levels	O
can	O
provide	O
us	O
with	O
a	O
scientific	O
basis	O
to	O
assess	O
pathogenesis	B-PROC
and	O
efficacy	O
of	O
clinical	O
treatment	O
of	O
SARS	O
.	O

The	O
monitoring	O
of	O
B	O
cells	O
,	O
B1	O
cells	O
and	O
the	O
expression	B-PROC
of	O
CD40	O
on	O
B	O
cells	O
is	O
useful	O
in	O
the	O
differential	O
diagnosis	O
of	O
SARS	O
.	O

N385	O
had	O
the	O
highest	O
affinity	O
for	O
forming	O
peptide	O
-	O
antibody	B-PROC
complexes	O
with	O
SARS	O
serum	O
.	O

We	O
used	O
experimental	O
infection	O
of	O
cats	O
with	O
a	O
highly	O
pathogenic	O
FIPV	O
isolate	O
,	O
UCD8	O
,	O
to	O
study	O
histologic	O
lesions	O
,	O
virus	B-PROC
replication	I-PROC
,	O
and	O
cytokine	O
expression	B-PROC
in	O
multiple	O
lymphoid	O
tissues	O
during	O
the	O
effusive	O
phase	O
of	O
disease	O
.	O

Although	O
no	O
differences	O
in	O
IFN	O
-	O
gamma	O
or	O
TNF	O
-	O
alpha	O
mRNA	O
were	O
measured	O
,	O
TNF	O
-	O
alpha	B-PROC
protein	B-PROC
expression	B-PROC
was	O
greater	O
in	O
affected	O
tissues	O
and	O
demonstrated	O
a	O
shift	O
in	O
the	O
source	O
of	O
TNF	O
-	O
alpha	O
from	O
macrophages	O
to	O
lymphocytes	O
.	O

A	O
possible	O
role	O
for	O
TNF	O
-	O
alpha	O
in	O
the	O
previously	O
described	O
FIPV	O
-	O
induced	O
lymphocyte	B-PROC
apoptosis	I-PROC
is	O
also	O
suggested	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
six	O
healthy	O
infants	O
were	O
included	O
in	O
this	O
prospective	O
birth	B-PROC
cohort	O
study	O
in	O
their	O
first	O
year	O
of	O
life	O
.	O

Moreover	O
,	O
work	O
on	O
viral	O
neuraminidase	O
has	O
led	O
to	O
the	O
licensing	O
of	O
potent	O
selective	O
antiviral	O
drugs	O
,	O
and	O
economic	O
decision	O
modelling	O
provides	O
further	O
justification	O
for	O
annual	O
vaccination	O
and	O
a	O
framework	O
for	O
the	O
use	O
of	O
neuraminidase	B-PROC
inhibitors	I-PROC
.	O

TITLE	O
:	O
[	O
Short	O
-	O
term	O
effects	O
of	O
prone	O
positioning	O
on	O
the	O
oxygenation	B-PROC
of	O
pediatric	O
patients	O
submitted	O
to	O
mechanical	O
ventilation	O
]	O
ABSTRACT	O
:	O
OBJECTIVE	O
:	O
To	O
analyze	O
the	O
short	O
-	O
term	O
effects	O
of	O
prone	O
positioning	O
on	O
the	O
oxygenation	B-PROC
of	O
mechanically	O
-	O
ventilated	O
children	O
suffering	O
from	O
severe	O
hypoxemia	O
.	O

Six	O
of	O
these	O
patients	O
presented	O
reduced	O
lung	B-PROC
compliance	I-PROC
(	O
four	O
of	O
them	O
had	O
acute	O
respiratory	O
distress	O
syndrome	O
);	O
and	O
twelve	O
patients	O
showed	O
increased	O
airway	B-PROC
resistance	I-PROC
(	O
six	O
of	O
them	O
presented	O
bronchiolitis	O
).	O

The	O
lesions	O
in	O
the	O
lung	O
from	O
SARS	O
patients	O
are	O
consisted	O
of	O
the	O
tissue	O
reaction	O
to	O
the	O
inflammatory	O
injury	O
,	O
including	O
extensive	O
exudation	B-PROC
,	O
capillary	O
proliferation	O
,	O
fibrosis	O
,	O
and	O
obvious	O
infiltration	O
of	O
macrophages	O
which	O
may	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
pulmonary	O
lesions	O
of	O
SARS	O
.	O

The	O
follow	O
-	O
up	O
study	O
included	O
interview	O
,	O
physical	O
examination	O
,	O
and	O
pulmonary	B-PROC
function	I-PROC
test	O
.	O

Totally	O
,	O
572	O
cases	O
notified	O
were	O
collected	O
during	O
this	O
period	O
in	O
Dongcheng	O
District	O
,	O
Beijing	O
,	O
and	O
99	O
of	O
them	O
were	O
excluded	O
from	O
SARS	O
,	O
because	O
of	O
diagnosis	O
of	O
common	O
cold	B-PROC
,	O
pneumonia	O
,	O
measles	O
,	O
or	O
rubella	O
,	O
etc	O
.	O

Eighteen	O
of	O
85	O
cases	O
of	O
SARS	O
occurred	O
in	O
health	O
care	O
workers	O
of	O
local	O
hospitals	O
,	O
accounting	O
for	O
4	O
.	O
5	O
%	O
of	O
the	O
total	O
number	O
of	O
health	O
care	O
workers	O
working	O
at	O
the	O
wards	O
caring	O
for	O
SARS	O
patients	O
or	O
at	O
fever	B-PROC
clinics	O
.	O

And	O
,	O
7	O
.	O
4	O
%	O
(	O
attack	O
rate	O
)	O
in	O
those	O
exposed	O
to	O
SARS	O
cases	O
suffered	O
the	O
illness	O
during	O
the	O
periods	B-PROC
of	O
quarantine	O
.	O

TITLE	O
:	O
[	O
Reliability	O
of	O
detecting	O
SARS	O
-	O
CoV	O
antibody	B-PROC
for	O
diagnosis	O
of	O
SARS	O
].	O

On	O
12	O
March	O
2003	O
,	O
the	O
World	O
Health	O
Organisation	B-PROC
(	O
WHO	O
)	O
issued	O
a	O
global	O
alert	O
about	O
SARS	O
so	O
it	O
became	O
a	O
global	O
challenge	O
.	O

TITLE	O
:	O
[	O
Origin	O
of	O
SARS	O
from	O
accelerated	O
evolution	B-PROC
of	O
a	O
virus	O
by	O
combined	O
pollution	O
].	O

ABSTRACT	O
:	O
The	O
SARS	O
virus	O
origin	O
which	O
obviously	O
differs	O
from	O
the	O
theory	O
of	O
out	O
-	O
space	O
origin	O
and	O
the	O
theory	O
of	O
wildlife	O
origin	O
was	O
theoretically	O
discussed	O
based	O
on	O
principles	O
of	O
pollution	O
-	O
evolution	B-PROC
ecology	O
,	O
pathogenesis	B-PROC
and	O
infectant	O
characteristics	O
of	O
SARS	O
,	O
and	O
some	O
relevant	O
experimental	O
evidence	O
.	O

It	O
emphasizes	O
on	O
the	O
fact	O
that	O
increasingly	O
combined	O
pollution	O
in	O
China	O
provides	O
a	O
substantial	O
basis	O
for	O
virus	O
evolution	B-PROC
.	O

Gene	O
recombination	B-PROC
and	O
fusion	O
of	O
more	O
than	O
one	O
virus	O
in	O
ecosystems	O
should	O
take	O
charge	O
with	O
the	O
origin	O
of	O
a	O
SARS	O
virus	O
.	O

The	O
positive	O
and	O
negative	O
predictive	O
values	O
of	O
presence	O
of	O
anti	O
-	O
coronavirus	O
antibodies	O
were	O
0	O
.	O
44	O
and	O
0	O
.	O
90	O
,	O
respectively	O
,	O
antibody	B-PROC
concentrations	O
(	O
1	O
:	O
1	O
,	O
600	O
)	O
were	O
0	O
.	O
94	O
and	O
0	O
.	O
88	O
.	O

In	O
addition	O
N	O
protein	O
binds	O
the	O
intracellular	O
form	O
of	O
the	O
genomic	O
RNA	O
,	O
all	O
of	O
the	O
MHV	O
subgenomic	O
mRNAs	O
,	O
and	O
expressed	B-PROC
non	O
-	O
MHV	O
RNA	O
transcripts	O
to	O
form	O
ribonucleoprotein	O
(	O
RNP	O
)	O
complexes	O
in	O
infected	O
cells	O
.	O

Tissue	O
sections	O
were	O
stained	O
with	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
),	O
and	O
in	O
situ	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
lung	O
sections	O
was	O
performed	O
using	O
SARS	O
coronavirus	O
-	O
specific	O
primers	O
.	O

Haemorrhagic	O
necrosis	B-PROC
and	O
reduced	O
numbers	O
of	O
lymphocytes	O
were	O
observed	O
in	O
lymph	O
nodes	O
and	O
spleen	O
.	O

TITLE	O
:	O
Emerging	O
viral	B-PROC
infections	I-PROC
in	O
a	O
rapidly	O
changing	O
world	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
ability	O
of	O
adenoviral	O
delivery	O
of	O
codon	O
-	O
optimised	O
SARS	O
-	O
CoV	O
strain	O
Urbani	O
structural	O
antigens	O
spike	O
protein	O
S1	O
fragment	O
,	O
membrane	O
protein	O
,	O
and	O
nucleocapsid	O
protein	O
to	O
induce	O
virus	O
-	O
specific	O
broad	O
immunity	B-PROC
in	O
rhesus	O
macaques	O
.	O

We	O
examined	O
three	O
types	O
of	O
soluble	O
form	O
MHVR	O
(	O
soMHVR	O
),	O
one	O
consisting	O
of	O
the	O
N	O
domain	O
alone	O
[	O
soR1	O
(	O
1	O
)],	O
one	O
with	O
the	O
N	O
and	O
second	O
domains	O
[	O
soR1	O
(	O
1	O
,	O
2	O
)],	O
and	O
one	O
[	O
soR1	O
(	O
1	O
,	O
4	O
)]	O
expressed	B-PROC
by	O
recombinant	O
baculoviruses	O
.	O

In	O
this	O
work	O
,	O
the	O
M	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
as	O
fusion	O
protein	O
with	O
maltose	O
binding	O
protein	O
at	O
N	O
-	O
terminus	O
and	O
MxeGyrA	O
intein	B-PROC
CBD	O
at	O
C	O
-	O
terminus	O
.	O

The	O
purified	O
protein	O
will	O
be	O
used	O
for	O
the	O
studies	O
on	O
M	O
protein	O
'	O
s	O
structure	O
and	O
the	O
development	B-PROC
of	O
diagnostic	O
method	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
The	O
membrane	O
-	O
associated	O
carboxypeptidase	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
an	O
essential	O
regulator	O
of	O
heart	B-PROC
function	I-PROC
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)--	O
paradigm	O
of	O
an	O
emerging	O
viral	B-PROC
infection	I-PROC
.	O

The	O
virus	O
can	O
persist	O
,	O
being	O
re	O
-	O
excreted	O
at	O
the	O
onset	O
of	O
egg	B-PROC
laying	I-PROC
(	O
4	O
to	O
5	O
months	O
of	O
age	O
),	O
believed	O
to	O
be	O
a	O
consequence	O
of	O
the	O
stress	O
of	O
coming	O
into	O
lay	O
.	O

In	O
experimental	O
situations	O
this	O
can	O
result	O
in	O
sterile	O
immunity	B-PROC
when	O
challenged	O
by	O
virulent	O
homologous	O
virus	O
.	O

The	O
large	O
spike	O
glycoprotein	O
(	O
S	O
)	O
comprises	O
a	O
carboxy	O
-	O
terminal	O
S2	O
subunit	O
(	O
approximately	O
625	O
amino	O
acid	O
residues	O
),	O
which	O
anchors	O
S	O
in	O
the	O
virus	O
envelope	O
,	O
and	O
an	O
amino	O
-	O
terminal	O
S1	O
subunit	O
(	O
approximately	O
520	O
residues	O
),	O
believed	O
to	O
largely	O
form	O
the	O
distal	O
bulbous	O
part	O
of	O
S	O
.	O
The	O
S1	O
subunit	O
(	O
purified	O
from	O
IBV	O
virus	O
,	O
expressed	B-PROC
using	O
baculovirus	O
or	O
expressed	B-PROC
in	O
birds	O
from	O
a	O
fowlpoxvirus	O
vector	O
)	O
induced	O
virus	O
neutralizing	O
antibody	B-PROC
.	O

The	O
basis	O
of	O
immunity	B-PROC
to	O
IBV	O
is	O
not	O
well	O
understood	O
.	O

However	O
,	O
the	O
cost	O
and	O
logistics	O
of	O
multiple	O
application	O
of	O
a	O
SARS	O
inactivated	O
vaccine	O
would	O
be	O
more	O
acceptable	O
for	O
the	O
protection	O
of	O
human	O
populations	O
,	O
especially	O
if	O
limited	O
to	O
targeted	B-PROC
groups	O
(	O
e	O
.	O
g	O
.	O
health	O
care	O
workers	O
and	O
high	O
-	O
risk	O
contacts	O
).	O

In	O
contrast	O
,	O
another	O
flight	B-PROC
carrying	O
four	O
symptomatic	O
persons	O
resulted	O
in	O
transmission	O
to	O
at	O
most	O
one	O
other	O
person	O
,	O
and	O
no	O
illness	O
was	O
documented	O
in	O
passengers	O
on	O
the	O
flight	B-PROC
that	O
carried	O
a	O
person	O
who	O
had	O
presymptomatic	O
SARS	O
.	O

Using	O
twelve	O
gene	O
prediction	O
methods	O
to	O
predict	O
coronavirus	O
known	O
genes	O
,	O
we	O
select	O
four	O
better	O
methods	O
including	O
Heuristic	O
models	O
,	O
Gene	O
Identification	O
,	O
ZCURVE_CoV	O
and	O
ORF	O
FINDER	O
to	O
predict	O
SARS	O
-	O
CoV	O
(	O
BJ01	O
),	O
and	O
use	O
ATGpr	O
for	O
analyzing	O
probability	O
of	O
initiation	O
codon	O
and	O
Kozak	O
rule	O
,	O
search	O
transcription	B-PROC
regulating	O
sequence	O
(	O
TRS	O
)	O
in	O
order	O
to	O
improve	O
the	O
accuracy	O
of	O
predicted	O
genes	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
experiences	O
and	O
lessons	O
learned	B-PROC
on	O
'	B-PROC
fever	I-PROC
clinics	O
'	O
during	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
epidemic	O
in	O
Beijing	O
and	O
to	O
propose	O
a	O
better	O
model	O
in	O
monitoring	O
SARS	O
to	O
fit	O
the	O
'	B-PROC
fever	I-PROC
clinics	O
'	O
into	O
current	O
situation	O
.	O

Significant	O
unbalance	O
in	O
daily	O
cost	O
and	O
effectiveness	O
in	O
most	O
of	O
the	O
'	B-PROC
fever	I-PROC
clinics	O
'	O
was	O
noticed	O
.	O

The	O
SARS	O
outbreak	O
has	O
illuminated	O
weaknesses	O
in	O
planning	O
for	O
sudden	O
outbreaks	O
of	O
disease	O
in	O
a	O
modern	O
society	O
and	O
in	O
particular	O
how	O
panic	O
can	O
grip	B-PROC
and	O
cause	O
intense	O
economic	O
disruption	O
.	O

The	O
neuraminidase	B-PROC
inhibitors	I-PROC
(	O
NAIs	O
)	O
are	O
a	O
new	O
class	O
of	O
antiviral	O
drug	O
targeting	B-PROC
a	O
viral	O
influenza	O
enzyme	O
,	O
the	O
neuraminidase	O
,	O
which	O
acts	O
both	O
to	O
facilitate	O
virus	B-PROC
infection	I-PROC
of	O
cells	O
by	O
clearing	O
a	O
passage	O
through	O
otherwise	O
protective	O
respiratory	O
fluids	O
and	O
also	O
by	O
helping	O
release	O
of	O
the	O
virus	O
by	O
cutting	O
the	O
chemical	O
umbilical	O
cord	O
which	O
links	O
up	O
the	O
virus	O
to	O
the	O
infected	O
cell	O
.	O

ABSTRACT	O
:	O
The	O
Dead	B-PROC
Sea	O
in	O
Israel	O
has	O
a	O
very	O
high	O
mineral	O
content	O
.	O

Among	O
almost	O
14	O
million	O
people	O
screened	O
for	O
fever	B-PROC
at	O
the	O
airport	O
,	O
train	O
stations	O
,	O
and	O
roadside	O
checkpoints	O
,	O
only	O
12	O
were	O
found	O
to	O
have	O
probable	O
SARS	O
.	O

Resolution	O
of	O
fever	B-PROC
and	O
lymphopenia	O
were	O
similar	O
between	O
the	O
2	O
treatment	O
groups	O
.	O

Of	O
the	O
9	O
patients	O
in	O
the	O
interferon	O
alfacon	O
-	O
1	O
treatment	O
group	O
,	O
3	O
(	O
33	O
.	O
3	O
%)	O
were	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
1	O
(	O
11	O
.	O
1	O
%)	O
required	O
intubation	O
and	O
mechanical	O
ventilation	O
,	O
and	O
none	O
died	B-PROC
.	O

TITLE	O
:	O
CXC	O
chemokine	O
ligand	B-PROC
10	O
controls	O
viral	B-PROC
infection	I-PROC
in	O
the	O
central	O
nervous	O
system	O
:	O
evidence	O
for	O
a	O
role	O
in	O
innate	B-PROC
immune	I-PROC
response	I-PROC
through	O
recruitment	O
and	O
activation	O
of	O
natural	O
killer	O
cells	O
.	O

However	O
,	O
chemokines	O
are	O
expressed	B-PROC
early	O
following	O
viral	B-PROC
infection	I-PROC
,	O
suggesting	O
an	O
important	O
role	O
in	O
coordinating	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

Herein	O
,	O
we	O
evaluated	O
the	O
contributions	O
of	O
CXC	O
chemokine	O
ligand	B-PROC
10	O
(	O
CXCL10	O
)	O
in	O
promoting	O
innate	O
defense	O
mechanisms	O
following	O
coronavirus	O
infection	O
of	O
the	O
CNS	O
.	O

These	O
results	O
indicate	O
that	O
CXCL10	O
expression	B-PROC
plays	O
a	O
pivotal	O
role	O
in	O
defense	O
following	O
coronavirus	O
infection	O
of	O
the	O
CNS	O
by	O
enhancing	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

The	O
canonical	O
CS	O
-	O
B	O
was	O
nonessential	O
for	O
the	O
generation	O
of	O
subgenomic	O
mRNAs	O
(	O
sgmRNAs	O
),	O
but	O
its	O
presence	O
led	O
to	O
transcription	B-PROC
levels	O
at	O
least	O
10	O
(	O
3	O
)-	O
fold	O
higher	O
than	O
those	O
in	O
its	O
absence	O
.	O

TITLE	O
:	O
Coronavirus	O
replication	O
complex	O
formation	B-PROC
utilizes	O
components	O
of	O
cellular	B-PROC
autophagy	I-PROC
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
autophagy	B-PROC
is	O
required	O
for	O
formation	B-PROC
of	O
double	O
membrane	O
-	O
bound	O
MHV	O
replication	O
complexes	O
and	O
that	O
DMV	O
formation	B-PROC
significantly	O
enhances	O
the	O
efficiency	O
of	O
replication	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
inflammatory	O
cytokine	O
profile	O
in	O
children	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
investigate	O
whether	O
monoclonal	O
antibody	B-PROC
to	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
could	O
be	O
considered	O
for	O
treatment	O
of	O
these	O
patients	O
.	O

Pediatric	O
SARS	O
patients	O
have	O
markedly	O
elevated	O
circulating	O
IL	O
-	O
1beta	O
levels	O
,	O
which	O
suggests	O
selective	O
activation	O
of	O
the	O
caspase	O
-	O
1	O
-	O
dependent	O
pathway	B-PROC
.	O

This	O
case	O
report	O
provides	O
additional	O
support	O
for	O
the	O
hypothesis	O
that	O
coronavirus	O
may	O
be	O
an	O
important	O
etiologic	O
factor	O
in	O
the	O
pathogenesis	B-PROC
of	O
demyelinating	O
disease	O
in	O
humans	O
.	O

After	O
the	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactoside	O
induction	O
,	O
S	O
protein	O
was	O
expressed	B-PROC
in	O
the	O
soluble	O
form	O
and	O
purified	O
by	O
nickel	O
-	O
affinity	O
chromatography	O
to	O
homogeneity	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
chronologically	O
document	O
the	O
time	O
sequence	O
of	O
symptom	O
development	B-PROC
in	O
probable	O
SARS	O
cases	O
and	O
compare	O
that	O
of	O
the	O
febrile	B-PROC
non	O
-	O
SARS	O
cases	O
,	O
thus	O
providing	O
valuable	O
information	O
for	O
early	O
recognition	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
In	O
a	O
pilot	O
study	O
conducted	O
during	O
March	O
14	O
to	O
April	O
2	O
,	O
2003	O
,	O
2	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
screening	O
scores	O
were	O
developed	O
for	O
predicting	O
SARS	O
among	O
febrile	B-PROC
patients	O
presenting	O
to	O
the	O
emergency	O
department	O
(	O
ED	O
).	O

After	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
the	O
California	O
isolate	O
exhibited	O
an	O
identical	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
(	O
RFLP	O
)	O
pattern	O
to	O
some	O
isolates	O
obtained	O
from	O
California	O
,	O
known	O
as	O
California	O
99	O
isolates	O
.	O

The	O
present	O
study	O
looked	O
at	O
only	O
those	O
patients	O
who	O
died	B-PROC
from	O
ARDS	O
and	O
did	O
not	O
evaluate	O
the	O
clinical	O
outcome	O
or	O
survival	O
pattern	O
of	O
ARDS	O
patients	O
.	O

TITLE	O
:	O
Fecal	O
immunoglobulin	B-PROC
A	O
antibodies	O
in	O
dogs	O
infected	O
or	O
vaccinated	O
with	O
canine	O
coronavirus	O
.	O

RESULTS	O
:	O
In	O
92	O
cases	O
of	O
induced	O
septic	O
abortions	O
,	O
comprising	O
6	O
%	O
of	O
total	O
abortions	O
;	O
nine	O
deaths	B-PROC
occurred	O
because	O
of	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
acute	O
renal	O
failure	O
and	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

Early	O
diagnosis	O
can	O
be	O
made	O
with	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
of	O
nasopharyngeal	O
aspirate	O
samples	O
.	O

None	O
of	O
these	O
healthcare	O
workers	O
had	O
antibody	B-PROC
to	O
SARS	O
CoV	O
,	O
indicating	O
that	O
subclinical	O
or	O
mild	O
infection	O
attributable	O
to	O
SARS	O
-	O
CoV	O
in	O
adults	O
is	O
rare	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
the	O
pathogenesis	B-PROC
of	O
pulmonary	O
diseases	O
:	O
implications	O
for	O
therapy	O
.	O

Our	O
data	O
suggested	O
that	O
lymphocytes	O
,	O
particularly	O
T	O
cells	O
,	O
were	O
probably	O
the	O
target	O
cells	O
of	O
SARS	O
CoV	O
.	O
The	O
viruses	O
may	O
actively	O
infected	O
the	O
immune	O
cells	O
during	O
SARS	O
CoV	O
acute	O
infection	O
phase	O
and	O
the	O
destruction	O
of	O
target	O
cells	O
may	O
be	O
one	O
of	O
the	O
important	O
reasons	O
for	O
the	O
death	B-PROC
of	O
the	O
circulating	O
leukocytes	O
in	O
SARS	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggested	O
that	O
lymphocytes	O
,	O
particularly	O
T	O
cells	O
,	O
were	O
probably	O
the	O
target	O
cells	O
of	O
SARS	O
CoV	O
.	O
The	O
viruses	O
may	O
actively	O
infected	O
the	O
immune	O
cells	O
during	O
SARS	O
CoV	O
acute	O
infection	O
phase	O
and	O
the	O
destruction	O
of	O
target	O
cells	O
may	O
be	O
one	O
of	O
the	O
important	O
reasons	O
for	O
the	O
death	B-PROC
of	O
the	O
circulating	O
leukocytes	O
in	O
SARS	O
.	O

TITLE	O
:	O
[	O
Effects	O
of	O
combined	O
surfactant	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
in	O
ventilated	O
rabbits	O
with	O
meconium	O
aspiration	O
-	O
induced	O
acute	O
lung	O
injury	O
].	O

In	O
both	O
Surf	O
and	O
NO	O
groups	O
modestly	O
improved	O
oxygenation	B-PROC
was	O
observed	O
.	O

TITLE	O
:	O
SARS	O
:	O
lessons	O
learned	B-PROC
from	O
other	O
coronaviruses	O
.	O

However	O
,	O
it	O
remains	O
unknown	O
whether	O
the	O
infectivity	O
and	O
the	O
virulence	B-PROC
of	O
the	O
pathogen	O
will	O
change	O
throughout	O
the	O
successive	O
transmission	O
.	O

The	O
gene	B-PROC
mutation	I-PROC
rates	O
of	O
replicase	O
1AB	O
,	O
S2	O
domain	O
of	O
spike	O
glycoprotein	O
and	O
nucleocapsid	O
protein	O
were	O
lower	O
(	O
0	O
.	O
079	O
%	O
-	O
0	O
.	O
103	O
%).	O

Amplicons	O
with	O
the	O
sizes	O
of	O
368	O
bp	O
and	O
348	O
bp	O
were	O
obtained	O
from	O
a	O
throat	O
swab	O
specimen	O
collected	O
from	O
a	O
17	O
years	O
old	O
girl	O
,	O
who	O
was	O
admitted	O
to	O
the	O
isolated	O
ward	O
because	O
of	O
high	O
fever	B-PROC
(	O
39	O
.	O
5	O
degrees	O
C	O
)	O
for	O
7	O
days	O
,	O
cough	O
for	O
2	O
days	O
,	O
low	O
WBC	O
count	O
,	O
and	O
pneumonia	O
shown	O
by	O
X	O
-	O
ray	O
when	O
she	O
visited	O
the	O
""""	O
Fever	B-PROC
and	O
Cough	O
""""	O
Clinic	O
,	O
and	O
without	O
known	O
history	O
of	O
contact	O
with	O
probable	O
SARS	O
patient	O
.	O

Death	B-PROC
occurred	O
at	O
a	O
mean	O
interval	O
of	O
18	O
.	O
2	O
days	O
(	O
range	O
,	O
9	O
-	O
36	O
days	O
)	O
from	O
the	O
initial	O
exposure	O
.	O

By	O
chromatography	O
on	O
nickel	O
-	O
agarose	O
column	O
,	O
the	O
expressed	B-PROC
N	O
protein	O
was	O
purified	O
to	O
near	O
homogeneity	O
as	O
judged	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
analysis	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
been	O
reported	O
in	O
30	O
countries	O
and	O
regions	O
,	O
with	O
a	O
cumulative	O
total	O
of	O
8	O
,	O
099	O
probable	O
cases	O
and	O
774	O
deaths	B-PROC
as	O
of	O
July	O
31	O
,	O
2003	O
,	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
.	O

ABSTRACT	O
:	O
Inflammatory	B-PROC
response	I-PROC
leading	O
to	O
organ	O
dysfunction	O
and	O
failure	O
continues	O
to	O
be	O
the	O
major	O
problem	O
after	O
injury	O
in	O
many	O
clinical	O
conditions	O
such	O
as	O
sepsis	O
,	O
severe	O
burns	O
,	O
acute	O
pancreatitis	O
,	O
haemorrhagic	O
shock	O
,	O
and	O
trauma	O
.	O

However	O
,	O
the	O
virus	O
isolated	O
from	O
the	O
fatal	O
case	O
displayed	O
14	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
,	O
some	O
of	O
which	O
may	O
be	O
associated	O
with	O
enhanced	O
disease	O
in	O
this	O
case	O
.	O

The	O
most	O
common	O
symptoms	O
in	O
this	O
cohort	O
were	O
fever	B-PROC
(	O
100	O
%)	O
and	O
cough	O
(	O
91	O
%).	O

The	O
presence	O
of	O
cysts	O
in	O
one	O
patient	O
who	O
received	O
short	O
-	O
term	O
and	O
one	O
patient	O
who	O
received	O
no	O
mechanical	O
ventilation	O
suggests	O
that	O
severe	O
SARS	O
-	O
induced	O
ARDS	O
may	O
independently	O
result	O
in	O
cyst	O
formation	B-PROC
.	O

ACE2	O
has	O
been	O
implicated	O
in	O
the	O
regulation	B-PROC
of	I-PROC
heart	B-PROC
function	I-PROC
and	O
also	O
as	O
a	O
functional	O
receptor	O
for	O
the	O
coronavirus	O
that	O
causes	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

There	O
are	O
two	O
main	O
moments	O
marking	O
the	O
reemergence	O
and	O
evolution	B-PROC
of	O
SARS	O
:	O
firstly	O
,	O
the	O
onset	O
of	O
the	O
epidemic	O
in	O
China	O
in	O
November	O
2002	O
followed	O
by	O
the	O
worldwide	O
spread	O
of	O
the	O
epidemiological	O
process	O
,	O
and	O
secondly	O
the	O
discovery	O
of	O
SARS	O
virus	O
as	O
a	O
mutant	O
of	O
coronaviruses	O
in	O
March	O
-	O
April	O
2003	O
in	O
USA	O
,	O
Canada	O
,	O
and	O
Hong	O
Kong	O
.	O

This	O
review	O
uses	O
historical	O
data	O
from	O
20th	O
century	O
outbreaks	O
to	O
assess	O
the	O
risks	O
to	O
current	O
populations	O
(	O
which	O
have	O
declining	O
immunity	B-PROC
)	O
from	O
a	O
deliberate	O
release	O
of	O
virus	O
.	O

ABSTRACT	O
:	O
Seven	O
cases	O
of	O
autopsy	O
from	O
SARS	O
patients	O
are	O
studied	O
to	O
investigate	O
the	O
pathogenesis	B-PROC
and	O
the	O
pathologic	O
changes	O
of	O
the	O
major	O
organs	O
.	O

It	O
is	O
postulated	O
that	O
viral	B-PROC
infection	I-PROC
induces	O
severe	O
damage	O
of	O
alveolar	O
epithelial	O
and	O
capillary	O
endothelial	O
cells	O
,	O
leads	O
to	O
pulmonary	O
edema	O
,	O
intra	O
-	O
alveolar	O
fibrin	O
deposit	O
,	O
and	O
hyaline	O
membrane	O
formation	B-PROC
.	O

Further	O
studies	O
showed	O
the	O
susceptibility	O
of	O
this	O
cell	O
was	O
due	O
to	O
the	O
expression	B-PROC
of	O
endogenous	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
which	O
was	O
activated	O
by	O
inserted	O
LTR	O
from	O
retroviral	O
vector	O
used	O
for	O
expression	B-PROC
cloning	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
viral	B-PROC
disease	I-PROC
that	O
may	O
be	O
contracted	O
by	O
exposure	O
to	O
a	O
newly	O
recognized	O
form	O
of	O
the	O
coronavirus	O
.	O

Marked	O
accumulation	O
of	O
cells	O
in	O
mitosis	B-PROC
was	O
observed	O
in	O
two	O
patients	O
and	O
apoptosis	B-PROC
was	O
observed	O
in	O
all	O
three	O
patients	O
.	O

TITLE	O
:	O
Molecular	O
cloning	O
,	O
expression	B-PROC
,	O
purification	O
,	O
and	O
mass	O
spectrometric	O
characterization	O
of	O
3C	O
-	O
like	O
protease	O
of	O
SARS	O
coronavirus	O
.	O

To	O
facilitate	O
the	O
studies	O
regarding	O
the	O
functions	O
and	O
structures	O
of	O
SARS_3CL	O
(	O
pro	O
),	O
in	O
this	O
report	O
the	O
synthetic	O
genes	O
encoding	O
3CL	O
(	O
pro	O
)	O
of	O
SARS_CoV	O
were	O
assembled	O
,	O
and	O
the	O
plasmid	O
was	O
constructed	O
using	O
pQE30	O
as	O
vector	O
and	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
M15	O
cells	O
.	O

Exposure	O
to	O
SARS	O
,	O
the	O
infection	O
rates	O
in	O
their	O
working	O
district	O
,	O
and	O
anxiety	O
levels	O
had	O
significant	O
impact	O
on	O
the	O
level	O
of	O
protection	O
or	O
prescribing	O
behaviour	B-PROC
.	O

The	O
recombinant	O
S1	O
protein	O
could	O
react	O
with	O
three	O
antibody	B-PROC
positive	O
samples	O
from	O
recovered	O
SARS	O
patients	O
,	O
which	O
showed	O
specific	O
bands	O
at	O
64	O
000	O
,	O
but	O
not	O
with	O
the	O
control	O
samples	O
according	O
to	O
results	O
of	O
western	O
blot	O
.	O

CONCLUSIONS	O
:	O
The	O
recombinant	O
N	O
-	O
terminal	O
protein	O
of	O
SARS	O
virus	O
S1	O
subunit	O
displays	O
specific	O
reaction	O
with	O
SARS	O
antibody	B-PROC
and	O
may	O
provide	O
a	O
good	O
tool	O
for	O
further	O
research	O
of	O
immune	B-PROC
response	I-PROC
to	O
SARS	O
virus	O
.	O

Here	O
,	O
the	O
ability	O
of	O
the	O
S	O
and	O
non	O
-	O
spike	O
genes	O
to	O
regulate	O
these	O
immune	B-PROC
responses	I-PROC
was	O
evaluated	O
using	O
chimeric	O
viruses	O
.	O

TITLE	O
:	O
Differential	O
regulation	B-PROC
of	O
innate	O
and	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
in	O
viral	O
encephalitis	O
.	O

The	O
ability	O
of	O
a	O
virus	O
to	O
modulate	O
the	O
immune	B-PROC
response	I-PROC
can	O
have	O
a	O
pivotal	O
effect	O
on	O
the	O
course	O
of	O
disease	O
and	O
the	O
fate	O
of	O
the	O
infected	O
host	O
.	O

A	O
joint	O
effort	B-PROC
by	O
the	O
Department	O
of	O
Otolaryngology	O
at	O
Queen	O
'	O
s	O
University	O
and	O
the	O
Infection	O
Control	O
Services	O
of	O
the	O
Hotel	O
Dieu	O
Hospital	O
,	O
Kingston	O
,	O
Ontario	O
,	O
was	O
carried	O
out	O
to	O
develop	O
specific	O
infection	O
control	O
guidelines	O
for	O
the	O
otolaryngologists	O
using	O
strategies	O
from	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
in	O
the	O
United	O
States	O
and	O
the	O
Laboratory	O
Center	O
for	O
Disease	O
Control	O
,	O
Health	O
Canada	O
.	O

Patients	O
of	O
SARS	O
are	O
mainly	O
youth	O
and	O
adults	O
in	O
the	O
prime	O
of	O
life	O
,	O
fever	B-PROC
always	O
appears	O
as	O
the	O
initiation	O
of	O
illness	O
and	O
some	O
accompanying	O
symptoms	O
would	O
appear	O
.	O

Avoiding	O
secondary	O
insults	O
is	O
the	O
cornerstone	O
of	O
supportive	O
care	O
,	O
and	O
this	O
is	O
based	O
primarily	O
on	O
aggressive	B-PROC
immune	B-PROC
surveillance	I-PROC
,	O
full	O
nutrition	B-PROC
,	O
and	O
unrelenting	O
oxygen	O
delivery	O
.	O

The	O
use	O
of	O
aggressive	B-PROC
immune	B-PROC
surveillance	I-PROC
,	O
nutritional	O
support	O
,	O
and	O
fluid	O
management	O
is	O
critical	O
to	O
support	O
ventilator	O
management	O
for	O
oxygenation	B-PROC
and	O
ventilation	O
.	O

We	O
also	O
show	O
that	O
prophylactic	O
treatment	O
of	O
SCV	O
-	O
infected	O
macaques	O
with	O
the	O
antiviral	O
agent	O
pegylated	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
significantly	O
reduces	O
viral	B-PROC
replication	I-PROC
and	O
excretion	B-PROC
,	O
viral	O
antigen	O
expression	B-PROC
by	O
type	O
1	O
pneumocytes	O
and	O
pulmonary	O
damage	O
,	O
compared	O
with	O
untreated	O
macaques	O
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
case	O
of	O
a	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
malaria	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
severe	O
hypoxemia	O
refractory	O
to	O
mechanical	O
ventilation	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
.	O

These	O
data	O
suggest	O
that	O
the	O
80R	O
human	O
monoclonal	O
antibody	B-PROC
may	O
be	O
a	O
useful	O
viral	O
entry	O
inhibitor	O
for	O
the	O
emergency	O
prophylaxis	O
and	O
treatment	O
of	O
SARS	O
,	O
and	O
that	O
the	O
ACE2	O
-	O
binding	O
site	O
of	O
S1	O
could	O
be	O
an	O
attractive	O
target	O
for	O
subunit	O
vaccine	O
and	O
drug	O
development	B-PROC
.	O

Another	O
interesting	O
finding	O
was	O
that	O
mouse	O
antibodies	O
elicited	O
separately	O
by	O
plasmids	O
encoding	O
S1	O
and	O
S2	O
subunits	O
cooperatively	O
neutralized	O
SARS	O
-	O
CoV	O
but	O
neither	O
the	O
S1	O
nor	O
S2	O
specific	O
antibodies	O
did	O
,	O
suggesting	O
the	O
possible	O
role	O
of	O
both	O
S1	O
and	O
S2	O
subunits	O
in	O
host	O
cell	O
docking	B-PROC
and	O
entry	O
.	O

RNA	B-PROC
interference	I-PROC
(	O
RNAi	B-PROC
)	O
is	O
a	O
process	O
by	O
which	O
the	O
introduced	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
could	O
cause	O
the	O
degradation	O
of	O
mRNA	O
with	O
identical	O
sequence	O
specificity	O
.	O

To	O
move	B-PROC
toward	O
a	O
mechanistic	O
understanding	O
of	O
these	O
phenomena	O
,	O
we	O
used	O
growth	B-PROC
media	O
enriched	O
with	O
methyl	O
-	O
beta	O
-	O
cyclodextrin	O
or	O
cholesterol	O
to	O
reduce	O
or	O
elevate	O
cellular	O
membrane	O
sterols	O
,	O
respectively	O
.	O

The	O
heterologous	O
genes	O
were	O
expressed	B-PROC
under	O
the	O
control	O
of	O
an	O
IBV	O
transcription	B-PROC
-	O
associated	O
sequence	O
(	O
TAS	O
)	O
derived	O
from	O
gene	O
5	O
of	O
IBV	O
Beaudette	O
.	O

Thus	O
,	O
the	O
enzymatic	B-PROC
activity	I-PROC
of	O
the	O
hemagglutinin	O
-	O
esterase	O
of	O
ISAV	O
is	O
comparable	O
to	O
that	O
of	O
the	O
sialate	O
-	O
4	O
-	O
O	O
-	O
esterases	O
of	O
murine	O
coronaviruses	O
and	O
related	O
group	O
2	O
coronaviruses	O
.	O

Improvement	O
in	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
,	O
complications	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
early	O
48	O
-	O
h	O
and	O
overall	O
mortality	O
,	O
compared	O
between	O
the	O
CPAP	O
and	O
standard	O
treatment	O
groups	O
.	O

Seventy	O
(	O
90	O
.	O
9	O
%)	O
patients	O
were	O
clinically	O
cured	O
and	O
seven	O
(	O
9	O
.	O
0	O
%)	O
died	B-PROC
.	O

Its	O
pathogenesis	B-PROC
is	O
unknown	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
two	O
heptad	O
repeat	O
regions	O
can	O
undergo	O
a	O
conformational	B-PROC
change	I-PROC
from	O
their	O
native	O
state	O
to	O
a	O
6	O
-	O
helix	O
bundle	O
(	O
trimer	O
of	O
dimers	O
),	O
which	O
mediates	O
fusion	O
of	O
viral	O
and	O
host	O
cell	O
membranes	O
.	O

ABSTRACT	O
:	O
We	O
verified	O
the	O
analytical	O
performance	O
characteristics	O
of	O
a	O
previously	O
described	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
targeting	B-PROC
the	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1b	O
region	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
with	O
RNA	O
transcripts	O
.	O

Staphylococcus	O
aureus	O
Cowan	O
1	O
(	O
SAC	B-PROC
)-	O
stimulated	O
IL	O
-	O
10	O
secreting	B-PROC
cells	O
were	O
increased	O
in	O
early	O
SARS	O
but	O
fell	O
during	O
treatment	O
.	O

About	O
90	O
%	O
of	O
the	O
probable	O
cases	O
were	O
positive	O
for	O
IgG	O
antibody	B-PROC
.	O

A	O
total	O
of	O
81	O
sera	O
,	O
including	O
67	O
from	O
convalescent	O
patients	O
and	O
seven	O
pairs	O
from	O
two	O
time	O
points	O
of	O
infection	O
,	O
were	O
analyzed	O
,	O
and	O
all	O
showed	O
immunoreactivity	B-PROC
towards	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
).	O

Peptides	O
with	O
high	O
affinity	O
for	O
HLA	O
-	O
A	O
*	O
0201	O
were	O
then	O
assessed	O
for	O
their	O
capacity	O
to	O
elicit	O
specific	O
immune	B-PROC
responses	I-PROC
mediated	O
by	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
both	O
in	O
vivo	O
,	O
in	O
HLA	O
-	O
A2	O
.	O
1	O
/	O
K	O
(	O
b	O
)	O
transgenic	O
mice	O
,	O
and	O
in	O
vitro	O
,	O
from	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
harvested	O
from	O
healthy	O
HLA	O
-	O
A2	O
.	O
1	O
(+)	O
donors	O
.	O

Subsequent	O
reviews	O
of	O
these	O
investigations	O
identified	O
shortcomings	O
in	O
the	O
conduct	B-PROC
of	O
the	O
studies	O
and	O
concluded	O
that	O
the	O
investigations	O
did	O
not	O
prove	O
an	O
association	O
between	O
APH	O
among	O
infants	O
and	O
exposure	O
to	O
molds	O
.	O

At	O
the	O
end	O
of	O
the	O
epidemic	O
,	O
the	O
global	O
cumulative	O
total	O
was	O
8098	O
with	O
774	O
deaths	B-PROC
.	O

Risk	O
factors	O
for	O
death	B-PROC
included	O
old	O
age	O
and	O
comorbid	O
illnesses	O
,	O
especially	O
diabetes	O
.	O

TITLE	O
:	O
Comparisons	O
of	O
envelope	O
through	O
5B	O
sequences	O
of	O
infectious	O
bronchitis	O
coronaviruses	O
indicates	O
recombination	B-PROC
occurs	O
in	O
the	O
envelope	O
and	O
membrane	O
genes	O
.	O

We	O
estimate	O
that	O
the	O
reproduction	B-PROC
number	O
varies	O
from	O
1	O
.	O
0698	O
to	O
3	O
.	O
2524	O
and	O
obtain	O
certain	O
important	O
epidemiological	O
parameters	O
.	O

The	O
prospect	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
older	O
adults	O
is	O
the	O
most	O
important	O
new	O
issue	O
to	O
emerge	O
,	O
as	O
older	O
adults	O
are	O
at	O
increased	O
risk	O
from	O
complications	O
and	O
death	B-PROC
.	O

Therapy	O
of	O
viral	B-PROC
infections	I-PROC
in	O
nonimmunocompromised	O
hosts	O
has	O
only	O
developed	O
slowly	O
during	O
recent	O
years	O
,	O
despite	O
the	O
enormous	O
socioeconomic	O
impact	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
DNA	O
vaccine	O
encoding	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
the	O
SARS	O
-	O
CoV	O
induces	O
T	O
cell	O
and	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
,	O
as	O
well	O
as	O
protective	O
immunity	B-PROC
,	O
in	O
a	O
mouse	O
model	O
.	O

RNA	O
viruses	O
commonly	O
have	O
a	O
high	O
rate	O
of	O
genetic	B-PROC
mutation	I-PROC
.	O

Together	O
,	O
the	O
elevation	O
of	O
Th1	O
cytokine	O
IFN	O
-	O
gamma	O
,	O
inflammatory	O
cytokines	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
12	O
and	O
chemokines	O
IL	O
-	O
8	O
,	O
MCP	O
-	O
1	O
and	O
IP	O
-	O
10	O
confirmed	O
the	O
activation	O
of	O
Th1	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immunity	I-PROC
and	O
hyperinnate	O
inflammatory	B-PROC
response	I-PROC
in	O
SARS	O
through	O
the	O
accumulation	O
of	O
monocytes	O
/	O
macrophages	O
and	O
neutrophils	O
.	O

Of	O
417	O
patients	O
with	O
clinical	O
SARS	O
from	O
whom	O
paired	O
serum	O
samples	O
were	O
available	O
,	O
92	O
%	O
had	O
an	O
antibody	B-PROC
response	I-PROC
.	O

ABSTRACT	O
:	O
A	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
rapidly	O
detect	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
rapid	O
emergence	O
of	O
SARS	O
and	O
the	O
substantial	O
illness	O
and	O
death	B-PROC
it	O
caused	O
have	O
made	O
it	O
a	O
critical	O
public	O
health	O
issue	O
.	O

Symptoms	O
on	O
admission	O
were	O
nonspecific	O
,	O
although	O
fever	B-PROC
,	O
malaise	O
,	O
and	O
lymphopenia	O
were	O
common	O
.	O

IgG	O
antibody	B-PROC
to	O
SARS	O
CoV	O
was	O
first	O
detected	O
between	O
day	O
5	O
and	O
day	O
47	O
after	O
onset	O
of	O
illness	O
(	O
mean	O
+/-	O

The	O
results	O
of	O
the	O
last	O
Critical	O
Assessment	O
of	O
Techniques	O
for	O
Protein	O
Structure	O
Prediction	O
(	O
CASP5	O
)	O
demonstrated	O
that	O
the	O
quality	O
of	O
homology	O
modeling	O
prediction	O
has	O
improved	O
;	O
reaching	B-PROC
a	O
level	O
of	O
reliability	O
that	O
biologists	O
can	O
now	O
confidently	O
use	O
homology	O
modeling	O
.	O

TITLE	O
:	O
Antibody	B-PROC
targeting	B-PROC
of	O
the	O
CC	O
chemokine	O
ligand	B-PROC
5	O
results	O
in	O
diminished	O
leukocyte	O
infiltration	O
into	O
the	O
central	O
nervous	O
system	O
and	O
reduced	O
neurologic	O
disease	O
in	O
a	O
viral	O
model	O
of	O
multiple	O
sclerosis	O
.	O

In	O
addition	O
,	O
administration	O
of	O
anti	O
-	O
CCL5	O
improved	O
neurological	B-PROC
function	I-PROC
and	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
005	O
)	O
reduced	O
the	O
severity	O
of	O
demyelination	O
and	O
macrophage	O
accumulation	O
within	O
the	O
CNS	O
.	O

More	O
recently	O
infectious	O
disease	O
rates	O
have	O
decreased	O
,	O
with	O
corresponding	O
and	O
extended	O
morbidity	O
and	O
mortality	O
associated	O
with	O
an	O
aging	B-PROC
population	O
in	O
a	O
rapidly	O
urbanising	O
society	O
.	O

ABSTRACT	O
:	O
Lung	O
injury	O
induced	O
by	O
ischemia	O
-	O
reperfusion	O
is	O
the	O
main	O
cause	O
of	O
early	O
graft	O
failure	O
after	O
lung	O
transplantation	O
,	O
which	O
may	O
result	O
from	O
oxygen	O
-	O
free	O
radicals	O
,	O
inflammatory	O
cytokine	B-PROC
production	I-PROC
,	O
and	O
polymorphonuclear	O
leukocyte	O
accumulation	O
into	O
the	O
interstitium	O
,	O
resulting	O
in	O
severe	O
lung	O
edema	O
.	O

The	O
mechanism	O
of	O
these	O
protective	O
effects	O
involves	O
inhibition	B-PROC
of	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
polymorphonuclear	O
leukocyte	O
accumulation	O
,	O
and	O
tissue	O
lipid	B-PROC
peroxidation	I-PROC
,	O
resulting	O
in	O
reduced	O
lung	O
edema	O
.	O

All	O
six	O
maternal	B-PROC
deaths	B-PROC
during	O
the	O
period	O
of	O
the	O
study	O
occurred	O
in	O
eclamptic	O
cases	O
(	O
mortality	O
rate	O
18	O
%),	O
four	O
relating	O
to	O
patients	O
who	O
had	O
not	O
received	O
prenatal	O
care	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	O
)	O
is	O
the	O
leading	O
cause	O
of	O
death	B-PROC
in	O
sickle	O
cell	O
disease	O
.	O

Age	O
was	O
found	O
to	O
be	O
an	O
independent	O
prognostic	O
indicator	O
for	O
death	B-PROC
with	O
an	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
of	O
0	O
.	O
96	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0	O
.	O
90	O
-	O
0	O
.	O
99	O
]	O
but	O
not	O
for	O
admission	O
to	O
ICU	O
[	O
AUC	O
=	O
0	O
.	O
61	O
(	O
CI	O
=	O
0	O
.	O
51	O
-	O
0	O
.	O
70	O
)].	O

RESULTS	O
:	O
Of	O
a	O
total	O
of	O
109	O
patients	O
,	O
41	O
were	O
admitted	O
to	O
ICU	O
and	O
42	O
died	B-PROC
.	O

Included	O
in	O
the	O
talks	O
were	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
presentations	O
about	O
infectious	O
clone	O
technology	O
and	O
recombinant	O
viruses	O
,	O
pathogen	O
and	O
receptor	B-PROC
interactions	I-PROC
at	O
the	O
cellular	O
and	O
molecular	O
level	O
,	O
genomic	O
responses	O
to	O
infection	O
,	O
and	O
new	O
information	O
on	O
antiviral	O
mechanisms	O
of	O
action	O
.	O

Finally	O
,	O
approaches	O
to	O
circumventing	O
and	O
directing	O
the	O
immune	B-PROC
response	I-PROC
using	O
genetic	O
engineering	O
will	O
be	O
reported	O
.	O

Ophthalmic	O
examinations	O
,	O
including	O
best	O
-	O
corrected	O
visual	O
acuity	O
,	O
intraocular	B-PROC
pressure	I-PROC
,	O
slit	O
-	O
lamp	O
,	O
and	O
indirect	O
ophthalmoscopy	O
examination	O
,	O
were	O
performed	O
at	O
baseline	O
and	O
at	O
2	O
-	O
month	O
and	O
3	O
-	O
month	O
follow	O
-	O
up	O
.	O

It	O
seemed	O
that	O
the	O
more	O
the	O
protective	O
measures	O
were	O
used	O
,	O
the	O
higher	O
the	O
protective	O
effect	O
was	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
could	O
reach	B-PROC
100	O
%	O
if	O
mask	O
,	O
gown	O
,	O
gloves	O
,	O
goggles	O
,	O
footwear	O
,	O
""""	O
hand	O
-	O
washing	O
and	O
disinfecting	O
""""	O
were	O
all	O
used	O
at	O
the	O
same	O
time	O
.	O

TITLE	O
:	O
Low	O
-	O
dose	O
inhaled	B-PROC
nitric	O
oxide	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

ABSTRACT	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
has	O
been	O
shown	O
to	O
improve	O
oxygenation	B-PROC
in	O
acute	O
lung	O
injury	O
.	O

An	O
intent	O
-	O
to	O
-	O
treat	O
analysis	O
revealed	O
that	O
inhaled	B-PROC
nitric	O
oxide	O
at	O
5	O
ppm	O
did	O
not	O
increase	O
the	O
number	O
of	O
days	O
patients	O
were	O
alive	O
and	O
off	O
assisted	O
breathing	B-PROC
(	O
mean	O
[	O
SD	O
],	O
10	O
.	O
6	O
[	O
9	O
.	O
8	O
]	O
days	O
in	O
the	O
placebo	O
group	O
and	O
10	O
.	O
7	O
[	O
9	O
.	O
7	O
]	O
days	O
in	O
the	O
inhaled	B-PROC
nitric	O
oxide	O
group	O
;	O
P	O
=.	O
97	O
;	O
difference	O
,	O
-	O
0	O
.	O
1	O
day	O
[	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
2	O
.	O
0	O
to	O
1	O
.	O
9	O
days	O
]).	O

However	O
,	O
the	O
target	O
cells	O
of	O
SARS	O
viral	B-PROC
infection	I-PROC
have	O
not	O
been	O
characterized	O
in	O
detail	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
similar	O
structure	O
patterns	O
exist	O
in	O
SARS	O
-	O
CoV	O
main	O
proteinase	B-PROC
with	O
Poliovirus	O
3c	O
Proteinase	B-PROC
,	O
Rhinovirus	O
3c	O
Protease	O
,	O
Nsp4	O
Proteinase	B-PROC
From	O
Equine	O
Arteritis	O
Virus	O
,	O
Hepatitis	O
C	O
Virus	O
Ns3	O
Protease	O
,	O
Hepatitis	O
A	O
Virus	O
3c	O
Protease	O
,	O
and	O
Dengue	O
Virus	O
Ns3	O
Protease	O
.	O

In	O
the	O
case	O
of	O
two	O
vaccine	O
injections	O
,	O
CTL	O
activity	O
was	O
also	O
high	O
(	O
56	O
.	O
6	O
+/-	O
12	O
.	O
7	O
%	O
(	O
E	O
:	O
T	O
=	O
25	O
:	O
1	O
),	O
57	O
.	O
4	O
+/-	O
11	O
.	O
7	O
%	O
(	O
E	O
:	O
T	O
=	O
50	O
:	O
1	O
)	O
and	O
63	O
.	O
0	O
+/-	O
6	O
.	O
3	O
%	O
(	O
E	O
:	O
T	O
=	O
100	O
:	O
1	O
))	O
However	O
,	O
antibody	B-PROC
titres	O
were	O
much	O
lower	O
(	O
1	O
:	O
200	O
-	O
1	O
:	O
3200	O
,	O
average	O
titre	O
is	O
1	O
:	O
980	O
).	O

The	O
intravenous	O
immunoglobulin	B-PROC
-	O
G	O
responsive	O
type	O
-	O
2	O
diabetes	O
polyneuropathy	O
usually	O
is	O
dysschwannian	O
,	O
sometimes	O
mainly	O
dysneuronal	O
intravenous	O
immunoglobulin	B-PROC
-	O
G	O
,	O
the	O
most	O
beneficial	O
and	O
safest	O
treatment	O
,	O
is	O
costly	O
,	O
but	O
if	O
intravenous	O
immunoglobulin	B-PROC
-	O
G	O
-	O
treatability	O
of	O
a	O
dysimmune	O
component	O
of	O
type	O
-	O
2	O
diabetes	O
neuropathy	O
is	O
overlooked	O
,	O
dismissed	O
or	O
rejected	O
,	O
as	O
commonly	O
happens	O
,	O
other	O
costs	O
are	O
high	O
regarding	O
the	O
patient	O
'	O
s	O
worsening	O
morbidity	O
and	O
disability	O
,	O
and	O
resultant	O
need	O
for	O
increased	O
medical	O
care	O
.	O

In	O
some	O
of	O
our	O
patients	O
,	O
especially	O
ones	O
having	O
a	O
strong	O
type	O
-	O
2	O
diabetes	O
genetic	O
background	O
,	O
the	O
intravenous	O
immunoglobulin	B-PROC
-	O
G	O
-	O
responsive	O
neuropathy	O
preceded	O
the	O
diagnosis	O
of	O
type	O
-	O
2	O
diabetes	O
by	O
5	O
-	O
10	O
years	O
.	O

Pediatric	O
considerations	O
included	O
a	O
more	O
likely	O
need	O
for	O
intubation	O
due	O
to	O
low	O
functional	B-PROC
residual	I-PROC
capacity	I-PROC
;	O
more	O
difficult	O
intravenous	O
access	O
;	O
fluid	O
resuscitation	O
based	O
on	O
weight	O
with	O
40	O
-	O
60	O
mL	O
/	O
kg	O
or	O
higher	O
needed	O
;	O
decreased	O
cardiac	O
output	O
and	O
increased	O
systemic	B-PROC
vascular	I-PROC
resistance	I-PROC
as	O
the	O
most	O
common	O
hemodynamic	B-PROC
profile	O
;	O
greater	O
use	O
of	O
physical	O
examination	O
therapeutic	O
end	O
points	O
;	O
unsettled	O
issue	O
of	O
high	O
-	O
dose	O
steroids	O
for	O
therapy	O
of	O
septic	O
shock	O
;	O
and	O
greater	O
risk	O
of	O
hypoglycemia	O
with	O
aggressive	B-PROC
glucose	O
control	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
time	O
-	O
course	O
of	O
viraemia	O
and	O
antibody	B-PROC
responses	I-PROC
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
RT	O
-	O
PCR	O
and	O
ELISA	O
were	O
used	O
to	O
assay	O
376	O
blood	O
samples	O
from	O
135	O
SARS	O
patients	O
at	O
various	O
stages	O
of	O
the	O
illness	O
,	O
including	O
samples	O
from	O
patients	O
who	O
were	O
in	O
their	O
early	O
convalescent	O
phase	O
.	O

Passive	O
transfer	O
of	O
serum	O
from	O
mice	O
immunized	O
with	O
MVA	O
/	O
S	O
to	O
naïve	O
mice	O
also	O
reduced	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
in	O
the	O
respiratory	O
tract	O
after	O
challenge	O
,	O
demonstrating	O
a	O
role	O
for	O
antibody	B-PROC
to	O
S	O
in	O
protection	O
.	O

The	O
attenuated	O
nature	O
of	O
MVA	O
and	O
the	O
ability	O
of	O
MVA	O
/	O
S	O
to	O
induce	O
neutralizing	O
antibody	B-PROC
that	O
protects	O
mice	O
support	O
further	O
development	B-PROC
of	O
this	O
candidate	O
vaccine	O
.	O

We	O
hypothesized	O
that	O
pediatric	O
PMs	O
would	O
have	O
an	O
enhanced	O
anti	B-PROC
-	I-PROC
inflammatory	I-PROC
response	I-PROC
compared	O
with	O
adult	O
PMs	O
.	O

Furthermore	O
,	O
pediatric	O
PMs	O
had	O
an	O
11	O
-	O
fold	O
increase	O
in	O
IL	O
-	O
1beta	O
-	O
induced	O
IL	B-PROC
-	I-PROC
10	I-PROC
production	I-PROC
,	O
while	O
adult	O
PMs	O
did	O
not	O
produce	O
IL	O
-	O
10	O
.	O

Therefore	O
,	O
IL	O
-	O
1beta	O
induces	O
both	O
a	O
pro	O
-	O
and	O
an	O
anti	B-PROC
-	I-PROC
inflammatory	I-PROC
response	I-PROC
in	O
pediatric	O
PMs	O
,	O
whereas	O
adult	O
PMs	O
produce	O
only	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
response	O
to	O
IL	O
-	O
1beta	O
.	O

Risk	O
factors	O
for	O
SARS	O
patients	O
who	O
had	O
been	O
healthy	O
prior	O
to	O
their	O
illness	O
included	O
old	O
age	O
,	O
high	O
peak	O
fever	B-PROC
grade	O
,	O
increased	O
neutrophil	O
count	O
,	O
increased	O
neutrophil	O
percentage	O
,	O
and	O
close	O
or	O
prolonged	O
contact	O
with	O
a	O
SARS	O
patient	O
.	O

TITLE	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
for	O
ARDS	O
due	O
to	O
sickle	O
cell	O
disease	O
.	O

Low	O
dose	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
during	O
pressure	O
controlled	O
mechanical	O
ventilation	O
(	O
pcMV	O
)	O
induced	O
a	O
clinically	O
relevant	O
increase	O
in	O
arterial	O
oxygenation	B-PROC
.	O

Dengue	O
-	O
fever	B-PROC
,	O
West	O
-	O
Nile	O
-	O
fever	B-PROC
,	O
SARS	O
,	O
avian	O
influenza	O
,	O
HIV	O
].	O

Expression	B-PROC
of	O
the	O
catalytic	O
region	O
alone	O
yields	O
a	O
protein	O
with	O
a	O
reduced	O
catalytic	O
efficiency	O
consistent	O
with	O
the	O
proposed	O
regulatory	O
role	O
of	O
the	O
alpha	O
-	O
helical	O
domain	O
.	O

The	O
critical	O
factor	O
in	O
containing	O
this	O
outbreak	O
was	O
early	O
detection	O
and	O
complete	O
assessment	O
of	O
movements	B-PROC
and	O
follow	O
-	O
up	O
of	O
patients	O
,	O
healthcare	O
workers	O
,	O
and	O
visitors	O
who	O
were	O
contacts	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
Taqman	O
RT	O
-	O
nested	O
PCR	O
system	O
for	O
clinical	O
SARS	O
-	O
CoV	O
detection	O
.	O

Many	O
people	O
already	O
look	O
to	O
the	O
Internet	O
for	O
information	O
during	O
a	O
public	O
health	O
crisis	O
,	O
and	O
information	O
found	O
online	O
can	O
positively	O
influence	O
behavioral	B-PROC
responses	O
to	O
such	O
crises	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
newly	O
emerged	O
,	O
highly	O
pathogenic	O
agent	O
that	O
caused	O
over	O
8	O
,	O
000	O
human	O
infections	O
with	O
nearly	O
800	O
deaths	B-PROC
between	O
November	O
2002	O
and	O
September	O
2003	O
.	O

However	O
,	O
the	O
analysis	O
was	O
complicated	O
by	O
apparent	O
breed	B-PROC
variation	O
in	O
FLA	O
-	O
DRB	O
and	O
the	O
small	O
number	O
of	O
individuals	O
in	O
this	O
study	O
.	O

At	O
necropsy	O
,	O
most	O
animals	O
tested	O
positive	O
for	O
viral	B-PROC
shedding	I-PROC
and	O
FCoV	O
RNA	O
was	O
found	O
in	O
spleen	O
,	O
mesenteric	O
lymph	O
nodes	O
and	O
bone	O
marrow	O
.	O

After	O
challenge	O
,	O
the	O
immunized	O
cats	O
demonstrated	O
one	O
of	O
four	O
clinical	O
outcomes	O
:	O
(	O
1	O
)	O
classical	O
effusive	O
FIP	O
;	O
(	O
2	O
)	O
accelerated	O
FIP	O
;	O
(	O
3	O
)	O
non	O
-	O
effusive	O
FIP	O
,	O
or	O
(	O
4	O
)	O
resistance	B-PROC
to	O
challenge	O
.	O

These	O
findings	O
did	O
not	O
depend	O
on	O
the	O
presence	O
of	O
FCoVs	O
or	O
of	O
myeloid	O
cells	O
,	O
suggesting	O
that	O
fAGPrP	O
is	O
not	O
directly	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
FIP	O
.	O

In	O
this	O
vector	O
,	O
the	O
M	O
gene	O
has	O
been	O
inserted	O
downstream	O
a	O
strong	O
early	O
/	O
late	O
promoter	O
,	O
whereas	O
the	O
two	O
previously	O
described	O
poxviruses	O
expressed	B-PROC
the	O
M	O
protein	O
during	O
their	O
early	O
stage	O
only	O
.	O

Our	O
results	O
suggest	O
a	O
crucial	O
role	O
for	O
the	O
type	O
of	O
poxviral	O
promoter	O
that	O
must	O
be	O
used	O
to	O
induce	O
an	O
effective	O
immune	B-PROC
response	I-PROC
against	O
FIPV	O
.	O

TITLE	O
:	O
Thrombolysis	O
for	O
central	O
venous	O
occlusion	B-PROC
causing	O
bilateral	O
chylothorax	O
in	O
a	O
patient	O
with	O
down	O
syndrome	O
.	O

The	O
amino	O
acid	O
pairs	O
whose	O
actual	O
frequencies	O
are	O
larger	O
than	O
their	O
predicted	O
frequencies	O
are	O
more	O
likely	O
to	O
be	O
targeted	B-PROC
by	O
mutations	O
,	O
whereas	O
the	O
amino	O
acid	O
pairs	O
whose	O
actual	O
frequencies	O
are	O
smaller	O
than	O
their	O
predicted	O
frequencies	O
are	O
more	O
likely	O
to	O
be	O
formed	O
after	O
mutations	O
.	O

There	O
were	O
no	O
differences	O
in	O
clinical	O
presentation	O
and	O
socio	O
-	O
demographic	O
variables	O
between	O
patients	O
who	O
had	O
viral	B-PROC
infections	I-PROC
and	O
those	O
in	O
whom	O
no	O
pathogen	O
could	O
be	O
identified	O
.	O

Some	O
patients	O
have	O
residual	O
symptoms	O
(	O
such	O
as	O
cough	O
,	O
fatigue	O
,	O
dyspnea	O
,	O
abnormality	O
of	O
liver	B-PROC
function	I-PROC
,	O
hyperglycemia	O
and	O
hyperglyceridemia	O
),	O
and	O
only	O
few	O
patients	O
have	O
lung	O
fibrosis	O
.	O

TITLE	O
:	O
[	O
Prognostic	O
analysis	O
of	O
lung	B-PROC
function	I-PROC
and	O
chest	O
X	O
-	O
ray	O
changes	O
of	O
258	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
rehabilitation	O
after	O
discharge	O
].	O

258	O
discharged	O
SARS	O
patients	O
received	O
regular	O
SARS	O
-	O
Co	O
virus	O
IgG	O
test	O
,	O
lung	B-PROC
function	I-PROC
test	O
and	O
chest	O
X	O
-	O
ray	O
and	O
/	O
or	O
high	O
resolution	O
computerized	O
tomography	O
(	O
HRCT	O
)	O
examination	O
at	O
General	O
Hospital	O
of	O
PLA	O
two	O
months	O
after	O
discharge	O
,	O
and	O
the	O
treatment	O
data	O
of	O
these	O
patients	O
were	O
retrospectively	O
analyzed	O
.	O

(	O
1	O
)	O
The	O
device	O
designed	O
is	O
capable	O
of	O
ensuring	O
control	O
of	O
inhalation	B-PROC
of	O
PFIB	O
;	O
(	O
2	O
)	O
Exposure	O
to	O
PFIB	O
for	O
30	O
mins	O
,	O
canines	O
all	O
met	O
the	O
criteria	O
for	O
diagnosing	O
ARDS	O
22	O
hours	O
after	O
inhalation	B-PROC
,	O
therefore	O
the	O
modeling	O
is	O
successful	O
;	O
(	O
3	O
)	O
PFIB	O
specifically	O
damages	O
the	O
lung	O
by	O
causing	O
excessive	O
inflammation	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
evaluation	O
of	O
a	O
novel	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
method	O
for	O
rapid	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

PCR	O
inhibitors	O
were	O
removed	O
by	O
ethanol	O
precipitation	B-PROC
,	O
and	O
a	O
PCR	O
for	O
the	O
pig	O
beta	O
-	O
actin	O
gene	O
was	O
used	O
as	O
a	O
positive	O
control	O
for	O
all	O
clinical	O
samples	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
evaluation	O
of	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)-	O
based	O
antibody	B-PROC
tests	O
for	O
serodiagnosis	O
of	O
SARS	O
-	O
CoV	O
pneumonia	O
and	O
compare	O
the	O
sensitivities	O
and	O
specificities	O
of	O
this	O
ELISA	O
for	O
detection	O
of	O
immunoglobulin	B-PROC
G	O
(	O
IgG	O
),	O
IgM	O
,	O
IgA	O
,	O
and	O
their	O
combinations	O
with	O
serum	O
samples	O
from	O
149	O
healthy	O
blood	O
donors	O
who	O
donated	O
blood	O
3	O
years	O
ago	O
as	O
controls	O
and	O
106	O
SARS	O
-	O
CoV	O
pneumonia	O
patients	O
in	O
Hong	O
Kong	O
.	O

According	O
the	O
clinical	O
diagnostic	O
standard	O
of	O
atypical	O
pneumonia	O
of	O
Ministry	O
of	O
Health	O
P	O
.	O
R	O
.	O
China	O
,	O
liver	B-PROC
function	I-PROC
was	O
assessed	O
in	O
110	O
SARS	O
patients	O
admitted	O
from	O
February	O
2003	O
to	O
June	O
2003	O
.	O

Respiratory	O
rate	O
decreased	O
from	O
29	O
-	O
49	O
breath	O
/	O
min	O
to	O
18	O
-	O
22	O
breath	O
/	O
min	O
,	O
heart	O
rate	O
decreased	O
from	O
89	O
-	O
145	O
beats	O
/	O
min	O
to	O
60	O
-	O
79	O
beats	O
/	O
min	O
,	O
two	O
faint	O
patients	O
regained	O
consciousness	O
,	O
hypoxemia	O
was	O
redressed	O
,	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
in	O
artery	O
increased	O
from	O
56	O
mm	O
Hg	O
(	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
)	O
to	O
87	O
mm	O
Hg	O
,	O
saturation	O
of	O
oxygen	O
increased	O
from	O
0	O
.	O
89	O
to	O
0	O
.	O
96	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
correlation	O
between	O
positive	O
rates	O
of	O
RNA	O
in	O
clinical	O
confirmed	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
and	O
its	O
appearance	O
in	O
relation	O
to	O
the	O
development	B-PROC
of	O
the	O
disease	O
in	O
order	O
to	O
provide	O
scientific	O
basis	O
for	O
early	O
diagnosis	O
,	O
effective	O
prevention	O
and	O
treatment	O
of	O
the	O
disease	O
.	O

Chi	O
-	O
square	O
for	O
trend	O
test	O
was	O
performed	O
to	O
study	O
the	O
correlation	O
between	O
positive	O
rates	O
of	O
RT	O
-	O
PCR	O
and	O
at	O
different	O
periods	B-PROC
after	O
the	O
onset	O
of	O
the	O
disease	O
.	O

Chi	O
-	O
square	O
for	O
trend	O
test	O
revealed	O
that	O
the	O
positive	O
rates	O
of	O
stools	O
and	O
sputa	O
of	O
SARS	O
patients	O
decreased	O
with	O
the	O
development	B-PROC
of	O
the	O
disease	O
(	O
chi	O
(	O
2	O
)	O
for	O
trend	O
=	O
12	O
.	O
55	O
and	O
16	O
.	O
408	O
,	O
P	O
=	O
0	O
.	O
0004	O
and	O
P	O
=	O
0	O
.	O
000	O
05	O
respectively	O
).	O

The	O
areas	O
for	O
coping	O
strategies	O
were	O
clear	O
directives	O
/	O
precautionary	O
measures	O
,	O
ability	O
to	O
give	O
feedback	O
to	O
/	O
obtain	O
support	O
from	O
management	O
,	O
support	O
from	O
supervisors	O
/	O
colleagues	O
,	O
support	O
from	O
the	O
family	O
,	O
ability	O
to	O
talk	B-PROC
to	O
someone	O
and	O
religious	O
convictions	O
.	O

Interferons	O
are	O
cytokines	O
which	O
induce	O
the	O
synthesis	B-PROC
of	O
several	O
antivirally	O
active	O
proteins	O
in	O
the	O
cell	O
.	O

We	O
studied	O
the	O
changes	O
in	O
AGP	O
glycosylation	B-PROC
in	O
the	O
course	O
of	O
FIP	O
.	O

Specifically	O
,	O
we	O
focussed	O
our	O
attention	O
on	O
the	O
degree	O
of	O
sialylation	O
,	O
fucosylation	B-PROC
and	O
branching	O
.	O

This	O
study	O
presents	O
a	O
purification	O
method	O
for	O
feline	O
AGP	O
(	O
fAGP	O
)	O
from	O
serum	O
,	O
using	O
an	O
ion	B-PROC
exchange	I-PROC
chromatography	O
strategy	O
.	O

The	O
glycosylation	B-PROC
pattern	O
was	O
analyzed	O
in	O
detail	O
by	O
means	O
of	O
interaction	O
of	O
purified	O
fAGP	O
with	O
specific	O
lectins	O
.	O

TITLE	O
:	O
Serosurvey	O
of	O
viral	B-PROC
infections	I-PROC
in	O
free	O
-	O
ranging	O
Namibian	O
cheetahs	O
(	O
Acinonyx	O
jubatus	O
).	O

MHV	O
infection	O
in	O
quiescent	O
17Cl	O
-	O
1	O
cells	O
that	O
had	O
been	O
synchronized	O
in	O
the	O
G	O
(	O
0	O
)	O
phase	O
by	O
serum	O
deprivation	O
prevented	O
infected	O
cells	O
from	O
entering	O
the	O
S	B-PROC
phase	I-PROC
after	O
serum	O
stimulation	O
.	O

Specific	O
antisense	O
activity	O
designed	O
to	O
block	O
translation	B-PROC
of	O
the	O
viral	O
replicase	O
polyprotein	O
was	O
first	O
confirmed	O
by	O
reduction	O
of	O
luciferase	O
expression	B-PROC
from	O
a	O
target	O
sequence	O
-	O
containing	O
reporter	O
construct	O
in	O
both	O
cell	O
-	O
free	O
and	O
transfected	O
cell	O
culture	O
assays	O
.	O

Inhibition	B-PROC
of	O
virus	O
infectivity	O
by	O
peptide	O
-	O
conjugated	O
morpholino	O
was	O
comparable	O
to	O
the	O
antiviral	O
activity	O
of	O
the	O
aminoglycoside	O
hygromycin	O
B	O
used	O
at	O
a	O
concentration	O
fivefold	O
higher	O
than	O
the	O
oligomer	O
.	O

Interestingly	O
,	O
the	O
IBV	O
S	O
protein	O
also	O
contains	O
a	O
tyrosine	O
-	O
based	O
endocytosis	B-PROC
signal	O
in	O
its	O
cytoplasmic	O
tail	O
,	O
suggesting	O
that	O
any	O
S	O
protein	O
that	O
escapes	O
the	O
ERGIC	O
will	O
be	O
rapidly	O
endocytosed	O
when	O
it	O
reaches	O
the	O
plasma	O
membrane	O
.	O

Mutations	O
predicted	O
to	O
allow	O
cleavage	B-PROC
at	O
CS1	O
yielded	O
viable	O
virus	O
that	O
grew	O
to	O
wild	O
-	O
type	O
MHV	O
titers	O
and	O
showed	O
normal	O
expression	B-PROC
and	O
processing	O
of	O
p28	O
and	O
p65	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
cleavage	B-PROC
between	O
p28	O
and	O
p65	O
at	O
CS1	O
is	O
not	O
required	O
for	O
MHV	O
replication	O
.	O

Since	O
identifying	O
the	O
possible	O
route	O
of	O
infection	O
has	O
major	O
implications	O
for	O
understanding	O
the	O
pathogenesis	B-PROC
and	O
future	O
treatment	O
strategies	O
for	O
SARS	O
,	O
the	O
present	O
study	O
investigated	O
the	O
localization	B-PROC
of	O
ACE2	O
protein	O
in	O
various	O
human	O
organs	O
(	O
oral	O
and	O
nasal	O
mucosa	O
,	O
nasopharynx	O
,	O
lung	O
,	O
stomach	O
,	O
small	O
intestine	O
,	O
colon	O
,	O
skin	O
,	O
lymph	O
nodes	O
,	O
thymus	O
,	O
bone	O
marrow	O
,	O
spleen	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
brain	O
).	O

In	O
conclusion	O
,	O
ACE2	O
is	O
abundantly	O
present	O
in	O
humans	O
in	O
the	O
epithelia	O
of	O
the	O
lung	O
and	O
small	O
intestine	O
,	O
which	O
might	O
provide	O
possible	O
routes	O
of	O
entry	O
for	O
the	O
SARS	O
-	O
CoV	O
.	O
This	O
epithelial	O
expression	B-PROC
,	O
together	O
with	O
the	O
presence	O
of	O
ACE2	O
in	O
vascular	O
endothelium	O
,	O
also	O
provides	O
a	O
first	O
step	O
in	O
understanding	O
the	O
pathogenesis	B-PROC
of	O
the	O
main	O
SARS	O
disease	O
manifestations	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
whether	O
the	O
complex	O
and	O
reactive	O
CNS	O
environment	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
model	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
could	O
support	O
transplant	O
-	O
mediated	O
remyelination	B-PROC
.	O

Experiments	O
with	O
various	O
timings	O
of	O
drug	O
addition	O
revealed	O
that	O
nelfinavir	O
exerted	B-PROC
its	O
effect	O
not	O
at	O
the	O
entry	O
step	O
,	O
but	O
at	O
the	O
post	O
-	O
entry	O
step	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
stability	O
of	O
this	O
complex	O
,	O
as	O
measured	O
by	O
its	O
resistance	B-PROC
to	O
heat	O
dissociation	O
,	O
appeared	O
to	O
be	O
much	O
lower	O
than	O
that	O
of	O
the	O
corresponding	O
MHV	O
complex	O
,	O
which	O
may	O
explain	O
the	O
different	O
inhibitory	O
potencies	O
of	O
the	O
HR2	O
peptides	O
.	O

To	O
examine	O
the	O
effect	O
of	O
storage	B-PROC
temperature	O
on	O
the	O
ability	O
to	O
detect	O
PEDV	O
and	O
TGEV	O
RNA	O
by	O
multiplex	O
RT	O
-	O
PCR	O
,	O
fecal	O
samples	O
were	O
stored	O
for	O
different	O
temperatures	O
(	O
4	O
,	O
21	O
,	O
36	O
,	O
and	O
45	O
C	O
)	O
before	O
extracting	O
viral	O
RNA	O
.	O

ABSTRACT	O
:	O
Pharmacophore	O
modeling	O
can	O
provide	O
valuable	O
insight	O
into	O
ligand	B-PROC
-	O
receptor	B-PROC
interactions	I-PROC
.	O

To	O
stimulate	O
the	O
structure	O
-	O
based	O
drug	O
design	O
against	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
),	O
a	O
pharmacophore	O
search	O
was	O
conducted	O
over	O
3	O
.	O
6	O
millions	O
of	O
compounds	O
based	O
on	O
the	O
atomic	O
coordinates	O
of	O
the	O
complex	O
obtained	O
by	O
docking	B-PROC
KZ7088	O
(	O
a	O
derivative	O
of	O
AG7088	O
)	O
to	O
SARS	O
CoV	O
M	O
(	O
pro	O
)	O
(	O
coronavirus	O
main	O
proteinase	B-PROC
),	O
as	O
reportedly	O
recently	O
(	O
Chou	O
,	O
K	O
.	O
C	O
.;	O
Wei	O
,	O
D	O
.	O
Q	O
.;	O
Zhong	O
,	O
W	O
.	O
Z	O
.	O
Biochem	O
.	O

Reverse	O
-	O
transcriptase	B-PROC
PCR	O
was	O
done	O
on	O
2134	O
specimens	O
of	O
different	O
types	O
.	O

The	O
main	O
goal	O
was	O
twofold	O
:	O
first	O
,	O
to	O
analyze	O
and	O
compare	O
nucleotide	O
sequences	O
and	O
to	O
identify	O
positions	O
of	O
single	O
nucleotide	O
polymorphism	B-PROC
(	O
SNP	O
),	O
insertions	O
and	O
deletions	O
,	O
and	O
second	O
,	O
to	O
group	O
them	O
according	O
to	O
sequence	O
similarity	O
,	O
eventually	O
pointing	O
to	O
phylogeny	O
of	O
SARS	O
-	O
CoV	O
isolates	O
.	O

Viral	O
excretion	B-PROC
peaked	O
at	O
4	O
dpi	O
and	O
decreased	O
to	O
zero	O
by	O
10	O
dpi	O
.	O

Viral	B-PROC
replication	I-PROC
was	O
restricted	O
to	O
the	O
respiratory	O
tract	O
and	O
associated	O
with	O
minimal	O
to	O
mild	O
,	O
multi	O
-	O
focal	O
erosive	O
and	O
inflammatory	O
changes	O
in	O
conducting	B-PROC
airways	O
,	O
and	O
increased	O
numbers	O
of	O
macrophages	O
in	O
alveoli	O
.	O

Of	O
the	O
182	O
patients	O
,	O
128	O
(	O
70	O
.	O
3	O
%)	O
had	O
abnormal	O
ALT	O
activity	O
,	O
57	O
(	O
31	O
.	O
3	O
%)	O
had	O
abnormal	O
AST	B-PROC
activity	I-PROC
and	O
87	O
(	O
47	O
.	O
8	O
%)	O
had	O
abnormal	O
LDH	O
activity	O
.	O

TITLE	O
:	O
S	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
mediates	O
entry	O
into	O
hepatoma	O
cell	O
lines	O
and	O
is	O
targeted	B-PROC
by	O
neutralizing	O
antibodies	O
in	O
infected	O
patients	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
SARS	O
-	O
CoV	O
infection	O
might	O
not	O
be	O
limited	O
to	O
lung	O
tissue	O
and	O
can	O
be	O
inhibited	O
by	O
the	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
in	O
infected	O
patients	O
.	O

Thus	O
such	O
a	O
molecular	O
complex	O
is	O
expected	O
to	O
serve	O
as	O
a	O
parameter	O
for	O
the	O
diagnosis	O
of	O
thrombus	O
formation	B-PROC
and	O
DIC	O
,	O
in	O
particular	O
its	O
early	O
stage	O
.	O

The	O
diagnosis	O
of	O
DIC	O
was	O
made	O
based	O
on	O
a	O
modified	O
version	O
of	O
the	O
criteria	O
established	O
by	O
the	O
Ministry	O
of	O
Health	O
,	O
Labor	B-PROC
and	O
Welfare	O
of	O
Japan	O
.	O

Soluble	O
fibrin	O
monomer	O
-	O
fibrinogen	O
complex	O
(	O
SF	O
)	O
is	O
formed	O
in	O
the	O
early	O
-	O
activated	O
state	O
of	O
blood	B-PROC
coagulation	I-PROC
.	O

Post	O
-	O
mortem	O
examination	O
,	O
carried	O
out	O
on	O
two	O
pups	O
which	O
died	B-PROC
without	O
neurological	O
signs	O
,	O
showed	O
pneumonia	O
and	O
enteritis	O
,	O
more	O
severe	O
in	O
one	O
of	O
the	O
two	O
examined	O
pups	O
.	O

Intraperitoneal	O
injection	O
of	O
cerulein	O
in	O
mice	O
resulted	O
in	O
severe	O
,	O
acute	O
pancreatitis	O
characterised	O
by	O
oedema	O
,	O
neutrophil	O
infiltration	O
,	O
tissue	O
haemorrhage	O
and	O
necrosis	B-PROC
and	O
elevated	O
serum	O
levels	O
of	O
amylase	O
and	O
lipase	O
.	O

Immunohistochemical	O
examination	O
demonstrated	O
a	O
marked	O
increase	O
in	O
immunoreactivity	B-PROC
for	O
nitrotyrosine	O
,	O
iNOS	O
and	O
PARS	O
in	O
the	O
pancreas	O
and	O
lung	O
of	O
cerulein	O
-	O
treated	O
mice	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
induces	O
apoptosis	B-PROC
in	O
Vero	O
E6	O
cells	O
.	O

A	O
specific	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
assay	O
for	O
SARS	O
-	O
CoV	O
yielded	O
positive	O
results	O
for	O
<	O
50	O
%	O
of	O
children	O
.	O

TITLE	O
:	O
Modulating	O
the	O
pulmonary	B-PROC
circulation	B-PROC
:	O
an	O
update	O
.	O

Therefore	O
,	O
inhaled	B-PROC
vasodilators	O
such	O
as	O
nitric	O
oxide	O
and	O
prostacyclin	O
have	O
been	O
suggested	O
for	O
the	O
treatment	O
of	O
pulmonary	O
hypertension	O
especially	O
when	O
concomitant	O
hypoxemia	O
is	O
present	O
due	O
to	O
a	O
ventilation	O
-	O
perfusion	O
mismatch	O
.	O

CONCLUSIONS	O
:	O
The	O
kit	O
""""	O
AmpliSens	O
SARS	O
""""	O
for	O
qualitative	O
detection	O
of	O
SARS	O
-	O
related	O
coronavirus	O
RNA	O
by	O
reverse	B-PROC
transcription	B-PROC
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
in	O
nasopharyngeal	O
wash	O
/	O
aspirates	O
,	O
naso	O
/	O
oropharyngeal	O
swabs	O
,	O
plasma	O
,	O
and	O
extract	O
from	O
feces	O
has	O
been	O
developed	O
in	O
the	O
Central	O
Research	O
Institute	O
for	O
Epidemiology	O
of	O
the	O
RF	O
Ministry	O
of	O
Health	O
.	O

The	O
epidemic	O
affected	O
>	O
8422	O
patients	O
and	O
caused	O
908	O
deaths	B-PROC
in	O
29	O
countries	O
on	O
5	O
continents	O
.	O

Moreover	O
,	O
food	O
allergy	B-PROC
can	O
elicit	O
airway	O
hyperreactivity	O
and	O
asthmatic	O
responses	O
.	O

Pathomorphological	O
changes	O
are	O
:	O
bronchial	O
epithelial	O
denudation	O
,	O
loss	O
of	O
cilia	O
,	O
squamous	O
metaplasia	B-PROC
,	O
a	O
giant	O
cells	O
infiltrate	O
of	O
macrophages	O
in	O
the	O
alveoli	O
,	O
haemophagocytosis	O
,	O
atrophy	O
white	O
pulp	O
of	O
the	O
spleen	O
.	O

Furthermore	O
,	O
the	O
method	O
might	O
assist	O
in	O
design	O
of	O
proteinase	B-PROC
inhibitors	O
for	O
treatment	O
of	O
SARS	O
and	O
possible	O
future	O
diseases	O
caused	O
by	O
coronaviruses	O
.	O

Cleavage	B-PROC
sites	O
were	O
predicted	O
in	O
proteins	O
such	O
as	O
the	O
cystic	B-PROC
fibrosis	I-PROC
transmembrane	I-PROC
conductance	I-PROC
regulator	I-PROC
(	O
CFTR	O
),	O
transcription	B-PROC
factors	O
CREB	O
-	O
RP	O
and	O
OCT	O
-	O
1	O
,	O
and	O
components	O
of	O
the	O
ubiquitin	B-PROC
pathway	B-PROC
.	O

Our	O
laboratory	O
has	O
focused	O
on	O
the	O
use	O
of	O
recombinant	O
nonhuman	O
primate	O
cytokines	O
as	O
adjunctive	O
therapies	O
for	O
inducing	O
antigen	O
-	O
specific	O
immune	B-PROC
responses	I-PROC
in	O
monkeys	O
because	O
most	O
recombinant	O
human	O
cytokines	O
appear	O
to	O
be	O
immunogenic	O
.	O

While	O
the	O
account	O
recovered	O
in	O
10	O
to	O
14	O
days	O
of	O
disease	O
course	O
in	O
the	O
38	O
patients	O
who	O
survived	O
,	O
there	O
was	O
no	O
recovery	O
in	O
7	O
patients	O
who	O
died	B-PROC
.	O

Among	O
six	O
fusion	O
peptides	O
,	O
S5	O
reacted	O
with	O
monoclonal	O
antibody	B-PROC
D3C5	O
and	O
S2	O
reacted	O
with	O
monoclonal	O
antibody	B-PROC
D3D1	O
against	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
epitopes	O
recognized	O
by	O
monoclonal	O
antibodies	O
D3C5	O
and	O
D3D1	O
are	O
linear	O
,	O
and	O
correspond	O
to	O
447	O
-	O
458	O
and	O
789	O
-	O
799	O
amino	O
acids	O
of	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
Trx	O
-	O
S2	O
fusion	O
protein	O
provides	O
a	O
basis	O
for	O
the	O
research	O
on	O
its	O
role	O
in	O
the	O
course	O
of	O
SARS	O
virus	B-PROC
infection	I-PROC
of	O
host	O
cells	O
and	O
preparation	O
of	O
recombinant	O
vaccine	O
against	O
SARS	O
virus	O
.	O

Deletion	O
of	O
a	O
major	O
portion	O
of	O
the	O
cytoplasmic	O
domain	O
of	O
ACE2	O
had	O
no	O
effect	O
on	O
S	O
-	O
driven	O
infection	O
,	O
indicating	O
that	O
this	O
domain	O
is	O
not	O
important	O
for	O
receptor	B-PROC
function	I-PROC
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
SARS	O
-	O
induced	O
cytopathic	O
effects	O
(	O
CPEs	O
)	O
is	O
a	O
rational	O
approach	O
for	O
the	O
prevention	O
of	O
SARS	O
,	O
and	O
an	O
understanding	O
of	O
the	O
cellular	O
stress	O
responses	O
induced	O
by	O
viral	B-PROC
infection	I-PROC
is	O
important	O
for	O
understanding	O
the	O
CPEs	O
.	O

Furthermore	O
,	O
detection	O
of	O
DNA	O
ladder	O
and	O
cleaved	O
caspase	O
-	O
3	O
in	O
the	O
virus	O
-	O
infected	O
cells	O
at	O
24h	O
.	O
p	O
.	O
i	O
.	O
indicated	O
that	O
SARS	O
-	O
CoV	O
infection	O
induced	O
apoptotic	B-PROC
cell	B-PROC
death	I-PROC
.	O

The	O
p38	O
MAPK	O
inhibitor	O
,	O
SB203580	O
,	O
inhibited	O
effectively	O
phosphorylation	B-PROC
of	O
HSP	O
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

TITLE	O
:	O
A	O
novel	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	O
,	O
U274	O
,	O
is	O
transported	O
to	O
the	O
cell	O
surface	O
and	O
undergoes	O
endocytosis	B-PROC
.	O

In	O
addition	O
,	O
U274	O
expressed	B-PROC
on	O
the	O
cell	O
surface	O
can	O
internalize	O
antibodies	O
from	O
the	O
culture	O
medium	O
into	O
the	O
cells	O
.	O

The	O
antibody	B-PROC
response	I-PROC
to	O
SCoV	O
S	O
protein	O
involves	O
antibodies	O
to	O
both	O
linear	O
and	O
conformational	O
epitopes	O
,	O
with	O
linear	O
epitopes	O
associated	O
with	O
the	O
carboxyl	O
domain	O
and	O
conformational	O
epitopes	O
associated	O
with	O
the	O
amino	O
terminal	O
domain	O
.	O

ABSTRACT	O
:	O
This	O
case	O
report	O
describes	O
rapid	O
and	O
persistent	O
improvement	O
after	O
one	O
single	O
dose	O
of	O
porcine	O
surfactant	O
(	O
Curosurf	O
)	O
0	O
.	O
5	O
ml	O
/	O
kg	O
(-	O
1	O
)	O
(	O
40	O
mg	O
/	O
kg	O
)	O
intratracheally	O
for	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
with	O
severe	O
oxygenation	B-PROC
failure	O
8	O
h	O
after	O
freshwater	O
near	O
-	O
drowning	O
in	O
a	O
12	O
-	O
year	O
-	O
old	O
girl	O
.	O

ABSTRACT	O
:	O
The	O
PiCCO	O
physiological	O
monitor	O
(	O
Pulsion	O
Medical	O
Systems	O
,	O
Munich	O
,	O
Germany	O
)	O
was	O
used	O
for	O
hemodynamic	B-PROC
diagnosis	O
and	O
monitoring	O
of	O
4	O
patients	O
:	O
a	O
polytraumatized	O
female	O
patient	O
with	O
septic	O
shock	O
and	O
ventilator	O
-	O
associated	O
pneumonia	O
;	O
a	O
man	O
with	O
congestive	O
heart	O
failure	O
and	O
cor	O
pulmonale	O
who	O
developed	O
acute	O
heart	O
failure	O
while	O
recovering	O
from	O
anterior	O
resection	O
of	O
the	O
rectum	O
;	O
a	O
man	O
with	O
severe	O
head	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
and	O
a	O
polytraumatized	O
male	O
patient	O
with	O
a	O
myocardial	O
contusion	O
.	O

One	O
example	O
,	O
the	O
PiCCO	O
monitor	O
,	O
combines	O
arterial	O
thermodilution	O
with	O
analysis	O
of	O
the	O
pulse	B-PROC
waveform	O
,	O
providing	O
a	O
series	O
of	O
hemodynamic	B-PROC
parameters	O
useful	O
for	O
managing	O
the	O
critically	O
ill	O
patient	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
injected	O
intratracheally	O
into	O
chickens	O
,	O
turkeys	O
,	O
geese	O
,	O
ducks	O
,	O
and	O
quail	O
,	O
or	O
into	O
the	O
allantoic	O
sac	B-PROC
of	O
their	O
embryonating	O
eggs	O
,	O
failed	O
to	O
cause	O
disease	O
or	O
replicate	O
.	O

TITLE	O
:	O
Coronavirus	O
replication	O
and	O
pathogenesis	B-PROC
:	O
Implications	O
for	O
the	O
recent	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
the	O
challenge	O
for	O
vaccine	O
development	B-PROC
.	O

Detection	O
of	O
ocular	B-PROC
infection	O
from	O
tears	O
using	O
the	O
PCR	O
technique	O
has	O
been	O
widely	O
used	O
by	O
ophthalmologists	O
to	O
diagnose	O
infections	O
for	O
other	O
viruses	O
.	O

CONCLUSIONS	O
:	O
The	O
pGEX	O
-	O
2T	O
/	O
N	O
has	O
been	O
constructed	O
and	O
expressed	B-PROC
in	O
the	O
form	O
of	O
fusion	O
protein	O
GST	O
-	O
N	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	O
.	O

TITLE	O
:	O
Amino	B-PROC
acid	I-PROC
substitutions	I-PROC
and	O
an	O
insertion	O
in	O
the	O
spike	O
glycoprotein	O
extend	O
the	O
host	O
range	O
of	O
the	O
murine	O
coronavirus	O
MHV	O
-	O
A59	O
.	O

TITLE	O
:	O
Avascular	O
necrosis	B-PROC
of	O
bone	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

TITLE	O
:	O
Nitric	O
oxide	O
synthase	O
-	O
2	O
down	O
-	O
regulates	O
surfactant	O
protein	O
-	O
B	O
expression	B-PROC
and	O
enhances	O
endotoxin	O
-	O
induced	O
lung	O
injury	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
This	O
study	O
describes	O
the	O
blood	B-PROC
gases	I-PROC
features	O
and	O
short	O
-	O
term	O
outcomes	O
with	O
noninvasive	O
positive	O
pressure	O
ventilation	O
(	O
NPPV	O
)	O
treatment	O
in	O
the	O
management	O
of	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
)	O
during	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
epidemic	O
.	O

SP	O
was	O
associated	O
with	O
increased	O
intubation	O
and	O
a	O
trend	O
towards	O
death	B-PROC
.	O

When	O
expressed	B-PROC
individually	O
in	O
murine	O
cells	O
,	O
the	O
S	O
-	O
GFP	O
chimeric	O
protein	O
induced	O
the	O
formation	B-PROC
of	O
fluorescent	O
syncytia	O
,	O
indicating	O
that	O
it	O
was	O
synthesized	O
and	O
folded	O
properly	O
,	O
trimerized	O
,	O
and	O
transported	O
to	O
the	O
plasma	O
membrane	O
,	O
where	O
it	O
exhibited	O
the	O
two	O
key	O
S	O
protein	O
functions	O
,	O
i	O
.	O
e	O
.,	O
interaction	O
with	O
virus	O
receptor	O
molecules	O
and	O
membrane	B-PROC
fusion	I-PROC
.	O

Receptor	B-PROC
down	I-PROC
regulation	B-PROC
was	O
independent	O
of	O
neutrophils	O
,	O
NK	O
cells	O
,	O
gamma	O
interferon	O
,	O
or	O
perforin	O
.	O

The	O
mean	O
duration	O
of	O
pECLA	O
therapy	O
was	O
6	O
.	O
5	O
days	O
,	O
15	O
patients	O
(	O
50	O
%)	O
died	B-PROC
due	O
to	O
ARDS	O
or	O
non	O
-	O
ARDS	O
related	O
reasons	O
.	O

Angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
has	O
recently	O
been	O
identified	O
as	O
the	O
functional	O
cellular	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
Studies	O
of	O
the	O
tissue	O
and	O
cellular	O
distribution	O
of	O
SARS	O
-	O
CoV	O
,	O
and	O
ACE2	O
protein	B-PROC
expression	B-PROC
,	O
reveal	O
new	O
insights	O
into	O
the	O
pathogenesis	B-PROC
of	O
this	O
deadly	O
disease	O
.	O

Remarkably	O
,	O
endothelial	O
cells	O
,	O
which	O
express	O
ACE2	O
to	O
a	O
high	O
level	O
,	O
have	O
not	O
been	O
shown	O
to	O
be	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
There	O
is	O
also	O
evidence	O
that	O
cell	O
types	O
without	O
detectable	O
ACE2	O
expression	B-PROC
may	O
also	O
be	O
infected	O
by	O
the	O
virus	O
.	O

It	O
is	O
clear	O
that	O
we	O
are	O
only	O
at	O
the	O
dawn	O
of	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

The	O
cDNA	O
derived	O
by	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
was	O
cloned	O
and	O
sequenced	O
.	O

Additional	O
studies	O
were	O
carried	O
out	O
to	O
further	O
understand	O
the	O
mode	O
of	O
action	O
of	O
some	O
active	O
compounds	O
,	O
including	O
ELISA	O
,	O
Western	O
blot	O
analysis	O
,	O
immunofluorescence	O
and	O
flow	O
cytometry	O
assays	O
,	O
and	O
inhibition	B-PROC
against	O
the	O
3CL	O
protease	O
and	O
viral	O
entry	O
.	O

An	O
assay	O
for	O
determining	O
neutralizing	O
antibody	B-PROC
titers	O
was	O
developed	O
.	O

Specifically	O
,	O
the	O
data	O
completion	O
rate	O
was	O
73	O
%	O
-	O
100	O
%	O
in	O
primary	O
medical	O
-	O
care	O
seeking	O
,	O
90	O
%	O
in	O
common	O
symptoms	O
and	O
signs	O
,	O
100	O
%	O
for	O
treatment	O
,	O
98	O
%	O
for	O
temperature	O
,	O
90	O
%	O
for	O
pulse	B-PROC
,	O
100	O
%	O
for	O
outcomes	O
and	O
98	O
%	O
for	O
costs	O
in	O
hospital	O
.	O

There	O
is	O
a	O
global	O
need	O
to	O
elucidate	O
protective	O
antigens	O
expressed	B-PROC
by	O
the	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
utility	O
of	O
these	O
mAbs	O
for	O
diagnostic	O
development	B-PROC
is	O
demonstrated	O
.	O

RESULTS	O
:	O
The	O
absorbance	O
(	O
A	O
)	O
value	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-PROC
ranged	O
from	O
0	O
.	O
81	O
to	O
2	O
.	O
06	O
in	O
patients	O
after	O
half	O
an	O
year	O
of	O
SARS	O
onset	O
,	O
and	O
form	O
0	O
.	O
79	O
to	O
2	O
.	O
01	O
in	O
patients	O
before	O
half	O
an	O
year	O
of	O
SARS	O
onset	O
.	O

In	O
addition	O
,	O
many	O
promising	O
vaccines	O
are	O
currently	O
in	O
development	B-PROC
.	O

By	O
studying	O
the	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
types	O
A	O
,	O
B	O
,	O
DR	O
,	O
and	O
DQ	O
alleles	O
in	O
90	O
Chinese	O
patients	O
with	O
serologically	O
confirmed	O
SARS	O
infections	O
,	O
we	O
identified	O
a	O
strong	O
association	O
between	O
HLA	O
-	O
B	O
*	O
0703	O
(	O
OR	O
,	O
4	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
03	O
-	O
8	O
.	O
18	O
;	O
P	O
=.	O
00072	O
[	O
Bonferroni	O
-	O
corrected	O
P	O
value	O
,	O
P	O
(	O
c	O
)	O
<.	O
0022	O
])	O
and	O
-	O
DRB1	O
*	O
0301	O
(	O
OR	O
,	O
0	O
.	O
06	O
;	O
95	O
%,	O
0	O
.	O
01	O
-	O
0	O
.	O
47	O
;	O
P	O
=.	O
00008	O
[	O
after	O
Bonferroni	O
correction	O
,	O
P	O
<.	O
0042	O
])	O
and	O
the	O
development	B-PROC
of	O
SARS	O
.	O

We	O
have	O
developed	O
an	O
improved	O
method	O
for	O
Epstein	O
-	O
Barr	O
virus	O
transformation	B-PROC
of	O
human	O
B	O
cells	O
.	O

The	O
study	O
included	O
HRCT	O
scores	O
(	O
0	O
to	O
100	O
),	O
dyspnea	O
scores	O
(	O
1	O
to	O
4	O
),	O
static	O
and	O
dynamic	O
lung	B-PROC
volumes	I-PROC
,	O
and	O
diffusing	O
capacity	O
of	O
the	O
lung	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
).	O

Older	O
subjects	O
may	O
present	O
without	O
the	O
typical	O
febrile	B-PROC
response	O
.	O

Pulse	B-PROC
dose	O
intravenous	O
corticosteroids	O
were	O
used	O
in	O
an	O
unsuccessful	O
attempt	O
to	O
treat	O
the	O
inflammatory	O
component	O
of	O
this	O
respiratory	O
illness	O
.	O

Furthermore	O
,	O
the	O
recent	O
development	B-PROC
of	O
influenza	O
-	O
like	O
clinical	O
syndromes	O
with	O
novel	O
aetiologies	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
SARS	O
)	O
has	O
increased	O
the	O
need	O
for	O
rapid	O
and	O
accurate	O
near	O
-	O
patient	O
diagnosis	O
.	O

There	O
were	O
three	O
deaths	B-PROC
in	O
the	O
pregnant	O
group	O
,	O
whereas	O
there	O
was	O
no	O
death	B-PROC
in	O
the	O
non	O
-	O
pregnant	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
006	O
).	O

We	O
describe	O
the	O
pulmonary	O
pathology	O
of	O
patients	O
who	O
died	B-PROC
in	O
the	O
2003	O
Toronto	O
outbreak	O
.	O

The	O
implications	O
of	O
the	O
subtraction	O
procedure	O
is	O
specially	O
analyzed	O
and	O
further	O
development	B-PROC
of	O
the	O
new	O
approach	O
is	O
indicated	O
.	O

Survival	O
and	O
mortality	O
groups	O
showed	O
no	O
significant	O
differences	O
with	O
respect	O
to	O
patient	O
sex	O
,	O
duration	O
of	O
SARS	O
-	O
related	O
lesions	O
,	O
development	B-PROC
of	O
lesion	O
shifting	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Nonetheless	O
,	O
these	O
procedures	O
do	O
not	O
ensure	O
a	O
complete	O
elimination	B-PROC
of	O
SARS	O
-	O
CoV	O
contamination	O
risk	O
since	O
a	O
major	O
risk	O
is	O
represented	O
by	O
blood	O
-	O
borne	O
infection	O
,	O
which	O
is	O
originated	O
by	O
the	O
mouth	O
of	O
patients	O
,	O
and	O
the	O
contamination	O
of	O
dental	O
units	O
water	O
lines	O
(	O
DUWLs	O
)	O
is	O
most	O
difficult	O
to	O
control	O
.	O

The	O
central	O
argument	O
in	O
this	O
case	O
is	O
that	O
crisis	O
managerial	O
behavior	O
is	O
the	O
result	O
of	O
how	O
managers	O
channel	O
and	O
distribute	O
the	O
attention	O
of	O
their	O
crisis	O
sense	B-PROC
.	O

Furthermore	O
,	O
activation	O
of	O
the	O
p38	O
MAPK	O
pathway	B-PROC
was	O
found	O
to	O
induce	O
actin	O
reorganization	O
in	O
cells	O
devoid	O
of	O
growth	B-PROC
factors	O
.	O

Alveolar	O
liquid	O
clearance	O
(	O
ALC	O
),	O
extravascular	O
lung	O
water	O
(	O
EVLW	O
)	O
content	O
and	O
arterial	O
blood	B-PROC
gases	I-PROC
were	O
measured	O
one	O
hour	O
thereafter	O
.	O

The	O
affinity	O
(	O
equilibrium	B-PROC
dissociation	O
constant	O
,	O
K	O
(	O
d	O
))	O
of	O
SARS	O
-	O
CoV	O
E	O
protein	O
was	O
5	O
.	O
7	O
x	O
10	O
(-	O
8	O
)	O
M	O
for	O
B10	O
and	O
8	O
.	O
9	O
x	O
10	O
(-	O
8	O
)	O
M	O
for	O
C20	O
.	O

Type	O
I	O
IFNs	O
protected	O
cells	O
from	O
cytopathic	O
effects	O
(	O
CPE	O
)	O
induced	O
by	O
SCoV	O
,	O
and	O
inhibited	O
viral	O
genomic	O
RNA	B-PROC
replication	I-PROC
in	O
FRhk	O
-	O
4	O
cells	O
(	O
measured	O
by	O
quantitative	O
RT	O
-	O
PCR	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
combination	O
of	O
severe	O
inflammation	O
and	O
secondary	O
changes	O
in	O
endocrine	O
profile	O
diminish	O
energy	O
production	O
,	O
metabolic	B-PROC
rate	I-PROC
,	O
and	O
normal	O
cellular	O
processes	O
,	O
leading	O
to	O
multiple	O
organ	O
dysfunction	O
.	O

Here	O
,	O
we	O
report	O
the	O
emergence	O
and	O
isolation	O
of	O
two	O
temperature	O
sensitive	O
(	O
ts	O
)	O
mutants	O
and	O
a	O
revertant	O
in	O
the	O
process	O
of	O
cold	B-PROC
-	O
adaptation	B-PROC
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
to	O
a	O
monkey	O
kidney	O
cell	O
line	O
.	O

Interestingly	O
,	O
unlike	O
wt	O
virus	O
,	O
the	O
revertant	O
grows	O
well	O
at	O
and	O
below	O
32	O
degrees	O
C	O
,	O
the	O
permissive	O
temperature	O
,	O
as	O
it	O
carries	O
other	O
mutations	O
in	O
multiple	O
genes	O
that	O
might	O
be	O
associated	O
with	O
the	O
cold	B-PROC
-	O
adaptation	B-PROC
phenotype	O
.	O

Only	O
two	O
patients	O
with	O
preexisting	O
illnesses	O
had	O
cough	O
on	O
the	O
same	O
day	O
the	O
fever	B-PROC
began	O
.	O

1	O
.	O
9	O
days	O
after	O
fever	B-PROC
onset	O
,	O
and	O
35	O
patients	O
(	O
66	O
%)	O
had	O
diarrhea	O
beginning	O
at	O
a	O
mean	O
time	O
of	O
6	O
.	O
0	O
+/-	O

Heart	O
rate	O
and	O
BP	O
were	O
recorded	O
at	O
regular	O
intervals	O
in	O
all	O
patients	O
,	O
and	O
hemodynamic	B-PROC
data	O
were	O
recorded	O
in	O
32	O
patients	O
who	O
had	O
pulmonary	O
artery	O
catheters	O
in	O
place	O
.	O

TITLE	O
:	O
A	O
novel	O
sorting	B-PROC
signal	O
for	O
intracellular	B-PROC
localization	I-PROC
is	O
present	O
in	O
the	O
S	O
protein	O
of	O
a	O
porcine	O
coronavirus	O
but	O
absent	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

Site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
indicated	O
that	O
a	O
tyrosine	O
-	O
dependent	O
signal	O
(	O
YXXI	O
)	O
in	O
the	O
cytoplasmic	O
tail	O
is	O
essential	O
for	O
intracellular	B-PROC
localization	I-PROC
of	O
the	O
S	O
protein	O
.	O

2	O
'-	O
O	O
-	O
ribose	O
-	O
methylated	O
RNA	O
substrates	O
proved	O
to	O
be	O
resistant	O
to	O
cleavage	B-PROC
by	O
NendoU	O
,	O
indicating	O
a	O
functional	O
link	O
with	O
the	O
2	O
'-	O
O	O
-	O
ribose	O
methyltransferase	O
located	O
adjacent	O
to	O
NendoU	O
in	O
the	O
coronavirus	O
replicative	O
polyprotein	O
.	O

Substitution	O
of	O
D6408	O
by	O
Ala	O
was	O
shown	O
to	O
abolish	O
viral	O
RNA	B-PROC
synthesis	I-PROC
,	O
demonstrating	O
that	O
NendoU	O
has	O
critical	O
functions	O
in	O
viral	B-PROC
replication	I-PROC
and	O
transcription	B-PROC
.	O

ABSTRACT	O
:	O
This	O
study	O
estimated	O
case	O
fatality	O
rates	O
in	O
Hong	O
Kong	O
,	O
Singapore	O
and	O
Beijing	O
using	O
the	O
number	O
of	O
new	O
admissions	O
,	O
deaths	B-PROC
and	O
discharges	O
by	O
cure	O
.	O

TITLE	O
:	O
Influenza	O
as	O
a	O
model	O
system	O
for	O
studying	O
the	O
cross	O
-	O
species	O
transfer	O
and	O
evolution	B-PROC
of	O
the	O
SARS	O
coronavirus	O
.	O

A	O
global	O
effort	B-PROC
coordinated	O
by	O
the	O
World	O
Health	O
Organization	O
successfully	O
defined	O
the	O
aetiology	O
,	O
epidemiology	O
and	O
clinical	O
characteristics	O
of	O
the	O
disease	O
,	O
and	O
the	O
implementation	O
of	O
case	O
identification	O
,	O
isolation	O
and	O
infection	O
control	O
measures	O
led	O
to	O
the	O
interruption	O
of	O
the	O
global	O
outbreak	O
by	O
July	O
2003	O
.	O

Rational	O
use	O
of	O
corticosteroid	O
,	O
non	O
-	O
invasive	O
ventilation	O
and	O
the	O
integration	B-PROC
of	O
traditional	O
Chinese	O
medicine	O
and	O
modern	O
medicine	O
may	O
partly	O
have	O
contributed	O
to	O
the	O
lowest	O
fatality	O
figure	O
.	O

Sixty	O
-	O
one	O
percent	O
of	O
the	O
respondents	O
expressed	B-PROC
some	O
concern	O
about	O
their	O
facility	O
'	O
s	O
preparation	O
and	O
capacity	O
for	O
managing	O
patients	O
with	O
SARS	O
.	O

All	O
of	O
the	O
recombinants	O
retained	O
21	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
and	O
a	O
7	O
-	O
amino	O
-	O
acid	O
insert	O
found	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
S	O
of	O
MHV	O
/	O
BHK	O
,	O
suggesting	O
that	O
these	O
residues	O
were	O
responsible	O
for	O
the	O
extended	O
host	O
range	O
of	O
MHV	O
/	O
BHK	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
mechanism	O
of	O
severe	O
hypoxemia	O
that	O
induced	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
by	O
way	O
of	O
observing	O
the	O
effective	O
local	O
blood	B-PROC
perfusion	I-PROC
in	O
different	O
lung	O
areas	O
of	O
ARDS	O
rabbits	O
.	O

According	O
to	O
patient	O
'	O
s	O
age	O
,	O
comorbid	O
conditions	O
,	O
one	O
can	O
effectively	O
predict	O
the	O
development	B-PROC
of	O
the	O
severe	O
SARS	O
by	O
closely	O
monitoring	O
temperature	O
,	O
pulse	B-PROC
rate	I-PROC
,	O
the	O
counts	O
of	O
lymphocytes	O
and	O
percent	O
of	O
neutrophils	O
.	O

No	O
differences	O
were	O
found	O
in	O
the	O
maximal	O
involved	O
pulmonary	O
fields	O
,	O
duration	O
from	O
initial	O
fever	B-PROC
to	O
appearance	O
of	O
pulmonary	O
lesions	O
and	O
course	O
from	O
the	O
initial	O
pulmonary	O
lesions	O
to	O
their	O
peak	O
among	O
the	O
above	O
three	O
generations	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

Mean	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
1	O
second	O
(	O
FEV	O
(	O
1	O
))	O
in	O
the	O
ECMO	O
group	O
at	O
1	O
year	O
was	O
59	O
+/-	O

TITLE	O
:	O
Analysis	O
of	O
IR	O
thermal	O
imager	O
for	O
mass	O
blind	O
fever	B-PROC
screening	O
.	O

As	O
a	O
result	O
,	O
they	O
may	O
create	O
a	O
false	O
sense	B-PROC
of	O
security	O
by	O
underestimating	O
the	O
number	O
of	O
febrile	B-PROC
(	O
and	O
possibly	O
infected	O
)	O
individuals	O
.	O

This	O
article	O
evaluates	O
the	O
effectiveness	O
of	O
thermal	O
scanner	O
when	O
it	O
is	O
being	O
used	O
for	O
mass	O
blind	O
screening	O
of	O
potential	O
fever	B-PROC
subjects	O
such	O
as	O
SARS	O
or	O
bird	O
flu	O
patients	O
.	O

Notably	O
,	O
the	O
SARS	O
-	O
CoV	O
virion	O
itself	O
was	O
able	O
to	O
induce	O
long	O
-	O
term	O
antibody	B-PROC
production	I-PROC
even	O
without	O
an	O
adjuvant	O
.	O

Furthermore	O
,	O
the	O
UV	O
-	O
inactivated	O
virion	O
induced	O
regional	O
lymph	O
node	O
T	B-PROC
-	I-PROC
cell	I-PROC
proliferation	I-PROC
and	O
significant	O
levels	O
of	O
cytokine	B-PROC
production	I-PROC
(	O
IL	O
-	O
2	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
,	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
)	O
upon	O
restimulation	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
virion	O
in	O
vitro	O
.	O

Regarding	O
the	O
current	O
literature	O
,	O
recruitment	O
maneuvers	O
may	O
be	O
considered	O
as	O
a	O
rescue	O
therapy	O
in	O
the	O
early	O
stage	O
of	O
severe	O
hypoxemic	O
lung	O
failure	O
,	O
if	O
a	O
lung	O
protective	O
ventilation	O
strategy	O
and	O
other	O
additive	O
adjuncts	O
like	O
prone	O
positioning	O
or	O
the	O
application	O
of	O
inhaled	B-PROC
vasodilators	O
failed	O
to	O
induce	O
adequate	O
gas	O
exchange	O
.	O

In	O
the	O
heat	O
-	O
induced	O
denaturation	B-PROC
in	O
phosphate	O
-	O
buffered	O
saline	O
buffer	O
,	O
N	O
-	O
protein	O
starts	O
to	O
unfold	O
at	O
35	O
degrees	O
C	O
and	O
is	O
completely	O
denatured	O
at	O
55	O
degrees	O
C	O
,	O
where	O
SARS	O
virus	O
was	O
also	O
reported	O
to	O
be	O
inactivated	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
psychiatric	O
morbidity	O
was	O
associated	O
with	O
post	O
-	O
traumatic	O
morbidity	O
(	O
p	O
=.	O
02	O
)	O
and	O
denial	O
(	O
p	O
=.	O
03	O
),	O
whereas	O
posttraumatic	O
morbidity	O
was	O
associated	O
with	O
younger	O
age	O
(	O
p	O
=.	O
007	O
),	O
being	O
married	O
(	O
p	O
=.	O
02	O
),	O
psychiatric	O
morbidity	O
(	O
p	O
=.	O
02	O
),	O
self	O
-	O
distraction	O
(	O
p	O
=.	O
02	O
),	O
behavioral	B-PROC
disengagement	O
(	O
p	O
=.	O
01	O
),	O
religion	O
(	O
p	O
=.	O
003	O
),	O
less	O
venting	O
(	O
p	O
=.	O
04	O
),	O
less	O
humor	O
(	O
p	O
=.	O
04	O
),	O
and	O
less	O
acceptance	O
(	O
p	O
=.	O
02	O
).	O

We	O
used	O
uncertainty	O
and	O
sensitivity	O
analysis	O
of	O
the	O
basic	O
reproductive	B-PROC
number	O
R0	O
to	O
assess	O
the	O
role	O
that	O
model	O
parameters	O
play	O
in	O
outbreak	O
control	O
.	O

This	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
implies	O
either	O
sequential	O
or	O
conformational	O
epitopes	O
from	O
both	O
the	O
viral	O
proteins	O
and	O
the	O
autoAg	O
and	O
may	O
differ	O
between	O
individuals	O
.	O

ABSTRACT	O
:	O
High	O
mobility	O
group	O
box	O
1	O
protein	O
(	O
HMGB1	O
)	O
is	O
released	O
by	O
necrotic	B-PROC
cells	O
or	O
activated	O
macrophages	O
/	O
monocytes	O
,	O
and	O
functions	O
as	O
a	O
late	O
mediator	O
of	O
lethal	O
systemic	O
and	O
local	O
pulmonary	O
inflammation	O
.	O

Additionally	O
,	O
the	O
example	O
of	O
SARS	O
demonstrates	O
not	O
only	O
how	O
quickly	O
emerging	O
viral	B-PROC
infections	I-PROC
can	O
spread	O
but	O
also	O
how	O
quickly	O
they	O
can	O
be	O
identified	O
and	O
contained	O
with	O
motivated	O
cooperation	O
.	O

These	O
results	O
confirm	O
the	O
predicted	O
protein	B-PROC
processing	I-PROC
pattern	O
for	O
mature	O
SARS	O
-	O
CoV	O
replicase	O
proteins	O
,	O
demonstrate	O
localization	B-PROC
of	O
replicase	O
proteins	O
to	O
cytoplasmic	O
complexes	O
containing	O
markers	O
for	O
autophagosome	O
membranes	O
,	O
and	O
suggest	O
conservation	O
of	O
protein	O
epitopes	O
in	O
the	O
replicase	O
and	O
nucleocapsid	O
of	O
SARS	O
-	O
CoV	O
and	O
the	O
group	O
II	O
coronavirus	O
,	O
MHV	O
.	O

In	O
order	O
to	O
probe	O
the	O
key	O
mechanisms	O
of	O
the	O
disease	O
'	O
s	O
occurrence	O
and	O
development	B-PROC
,	O
it	O
tries	O
to	O
develop	O
the	O
therapy	O
targeting	B-PROC
the	O
mechanism	O
.	O

Since	O
ARDS	O
/	O
ALI	O
carries	O
high	O
mortality	O
,	O
the	O
development	B-PROC
of	O
new	O
drugs	O
against	O
ARDS	O
/	O
ALI	O
is	O
required	O
.	O

ABSTRACT	O
:	O
To	O
find	O
out	O
the	O
timing	O
of	O
serologic	O
responses	O
after	O
illness	O
onset	O
and	O
distribution	O
of	O
IgG	O
antibody	B-PROC
to	O
SARS	O
-	O
CoV	O
in	O
SARS	O
cases	O
of	O
transmission	O
chain	O
or	O
non	O
-	O
transmission	O
chain	O
.	O

The	O
onset	O
symptoms	O
were	O
characterized	O
by	O
fever	B-PROC
(	O
100	O
%),	O
cough	O
(	O
49	O
.	O
1	O
%),	O
maylgia	O
(	O
24	O
.	O
5	O
%),	O
shortness	O
of	O
breath	O
(	O
20	O
.	O
8	O
%),	O
malaise	O
(	O
17	O
.	O
0	O
%),	O
and	O
diarrhea	O
(	O
5	O
.	O
7	O
%).	O

The	O
results	O
also	O
showed	O
that	O
interferon	O
alpha2b	O
could	O
inhibit	O
almost	O
the	O
whole	O
virus	O
gene	B-PROC
transcription	I-PROC
by	O
using	O
the	O
cDNA	O
chip	O
.	O

Meanwhile	O
,	O
the	O
immune	O
organs	O
,	O
including	O
lymph	O
nodes	O
and	O
spleens	O
from	O
2	O
autopsy	O
cases	O
of	O
SARS	O
whose	O
disease	O
courses	O
were	O
less	O
than	O
12	O
days	O
showed	O
extensive	O
hemorrhagic	O
necrosis	B-PROC
,	O
reactive	O
macrophage	O
/	O
histocyte	O
proliferation	O
,	O
with	O
relative	O
depression	O
of	O
mononuclear	O
and	O
granulocytic	O
clones	O
in	O
the	O
bone	O
marrows	O
.	O

SARS	O
coronaviruses	O
were	O
mainly	O
identified	O
in	O
type	O
I	O
and	O
II	O
alveolar	O
epithelia	O
,	O
macrophages	O
,	O
and	O
endothelia	O
;	O
meanwhile	O
,	O
some	O
renal	O
tubular	O
epithelial	O
cells	O
,	O
cardiomyocytes	O
,	O
mucosal	O
and	O
crypt	O
epithelial	O
cells	O
of	O
gastrointestinal	O
tracts	O
,	O
parenchymal	O
cells	O
in	O
adrenal	O
glands	O
,	O
lymphocytes	O
,	O
testicular	O
epithelial	O
cells	O
and	O
Leydig	O
'	O
s	O
cells	O
were	O
also	O
detected	O
by	O
electron	O
microscopy	O
combined	O
with	O
in	O
situ	O
hybridization	B-PROC
.	O

Standard	O
protections	O
and	O
procedures	O
for	O
infection	O
control	O
should	O
be	O
strictly	O
followed	O
during	O
transport	B-PROC
and	O
within	O
the	O
hospital	O
environment	O
.	O

Under	O
quarantine	O
,	O
SARS	O
-	O
like	O
symptoms	O
developed	O
in	O
68	O
paramedics	O
,	O
including	O
cough	O
(	O
53	O
[	O
78	O
%]),	O
myalgia	O
(	O
33	O
[	O
48	O
%]),	O
fatigue	O
(	O
30	O
[	O
44	O
%]),	O
headache	O
(	O
29	O
[	O
43	O
%]),	O
fever	B-PROC
(	O
11	O
[	O
16	O
%]),	O
and	O
shortness	O
of	O
breath	O
(	O
7	O
[	O
10	O
%]).	O

Our	O
recent	O
study	O
indicated	O
that	O
SARS	O
-	O
CoV	O
infection	O
induces	O
activation	O
of	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	B-PROC
pathway	I-PROC
and	O
the	O
p38	O
MAPK	O
inhibitor	O
partially	O
inhibited	O
its	O
cytopathic	O
effect	O
in	O
Vero	O
E6	O
cells	O
.	O

Lung	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
and	O
lung	O
vascular	B-PROC
permeability	I-PROC
were	O
also	O
measured	O
in	O
the	O
AQP1	O
knockout	O
mice	O
(	O
n	O
=	O
9	O
)	O
that	O
received	O
IT	O
LPS	O
(	O
5	O
mg	O
/	O
kg	O
)	O
at	O
2	O
days	O
.	O

The	O
potential	O
for	O
further	O
adaptation	B-PROC
to	O
people	O
could	O
set	O
the	O
stage	O
for	O
a	O
new	O
pandemic	O
.	O

The	O
pattern	O
of	O
endemic	O
pathogenic	O
organisms	O
,	O
the	O
rates	O
of	O
acquisition	O
of	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
),	O
and	O
the	O
rates	O
of	O
ventilator	O
-	O
associated	O
pneumonia	O
(	O
VAP	O
)	O
were	O
compared	O
with	O
those	O
of	O
the	O
pre	O
-	O
SARS	O
and	O
post	O
-	O
SARS	O
periods	B-PROC
.	O

Ampligen	O
,	O
currently	O
under	O
development	B-PROC
by	O
Hemispherx	O
Biopharma	O
in	O
the	O
US	O
,	O
acts	O
on	O
the	O
immunological	O
system	O
through	O
T	O
-	O
lymphocyte	B-PROC
stimulation	I-PROC
and	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
chronic	O
fatigue	O
syndrome	O
and	O
acquired	O
immunodeficiency	O
deficiency	O
syndrome	O
(	O
AIDS	O
),	O
as	O
part	O
of	O
the	O
combined	O
therapy	O
.	O

Empire	O
Health	O
Resources	O
,	O
a	O
healthcare	O
management	O
firm	O
,	O
will	O
be	O
responsible	O
for	O
accrual	O
and	O
retention	B-PROC
of	O
patients	O
for	O
HIV	O
trials	O
,	O
and	O
protocols	O
for	O
trials	O
in	O
patients	O
with	O
hepatitis	O
C	O
or	O
both	O
HIV	O
and	O
hepatitis	O
C	O
infections	O
.	O

PBMCs	O
from	O
normal	O
healthy	O
donors	O
were	O
inoculated	O
in	O
vitro	O
with	O
SARS	O
-	O
CoV	O
and	O
the	O
viral	B-PROC
replication	I-PROC
kinetics	O
was	O
studied	O
by	O
real	O
-	O
time	O
quantitative	O
assays	O
.	O

Array	O
data	O
showed	O
monocyte	O
-	O
macrophage	O
cell	B-PROC
activation	I-PROC
,	O
coagulation	B-PROC
pathway	B-PROC
upregulation	B-PROC
and	O
cytokine	B-PROC
production	I-PROC
together	O
with	O
lung	O
trafficking	B-PROC
chemokines	O
such	O
as	O
IL8	O
and	O
IL17	O
,	O
possibly	O
activated	O
through	O
the	O
TLR9	B-PROC
signaling	B-PROC
pathway	I-PROC
;	O
that	O
mimicked	O
clinical	O
features	O
of	O
the	O
disease	O
.	O

Mutational	O
analysis	O
of	O
the	O
3CLpro	O
demonstrated	O
the	O
importance	O
of	O
His41	O
,	O
Cys145	O
,	O
and	O
Glu166	O
in	O
the	O
substrate	O
-	O
binding	O
subsite	O
S1	O
for	O
keeping	O
the	O
proteolytic	B-PROC
activity	O
.	O

Many	O
patients	O
had	O
reduced	O
exercise	O
capacity	O
that	O
cannot	O
be	O
accounted	O
for	O
by	O
impairment	O
of	O
pulmonary	B-PROC
function	I-PROC
.	O

We	O
questioned	O
whether	O
CKLF1	O
could	O
be	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
inflammation	O
and	O
proliferation	O
in	O
the	O
lung	O
.	O

There	O
was	O
an	O
increase	O
in	O
reticulin	O
fiber	O
formation	B-PROC
.	O

There	O
was	O
also	O
evidence	O
of	O
organizing	O
pneumonia	O
,	O
with	O
an	O
increase	O
in	O
reticulin	O
fiber	O
formation	B-PROC
,	O
which	O
had	O
a	O
glomeruloid	O
appearance	O
on	O
special	O
stain	O
.	O

KBD	O
could	O
prevent	O
the	O
occurrence	O
of	O
SARS	O
,	O
it	O
is	O
possibly	O
realized	O
through	O
improving	O
symptoms	O
,	O
elevating	O
QOL	O
and	O
enhancing	O
immunity	B-PROC
of	O
organism	O
.	O

CONCLUSIONS	O
:	O
KBD	O
could	O
prevent	O
the	O
occurrence	O
of	O
SARS	O
,	O
it	O
is	O
possibly	O
realized	O
through	O
improving	O
symptoms	O
,	O
elevating	O
QOL	O
and	O
enhancing	O
immunity	B-PROC
of	O
organism	O
.	O

CONCLUSIONS	O
:	O
Phage	O
antibody	B-PROC
library	O
for	O
human	O
Fab	O
fragment	O
has	O
been	O
constructed	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
.	O

No	O
substantial	O
proteolytic	B-PROC
cleavage	B-PROC
of	O
S	O
was	O
observed	O
,	O
suggesting	O
that	O
S	O
is	O
not	O
processed	O
into	O
head	O
(	O
S1	O
)	O
and	O
stalk	O
(	O
S2	O
)	O
domains	O
as	O
observed	O
for	O
certain	O
other	O
coronaviruses	O
.	O

Expressed	B-PROC
p28	O
was	O
exclusively	O
localized	O
in	O
the	O
cytoplasm	O
.	O

Cell	B-PROC
cycle	I-PROC
analysis	O
by	O
flow	O
cytometry	O
demonstrated	O
that	O
p28	O
expression	B-PROC
induced	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
.	O

Expressed	B-PROC
cytoplasmic	O
p28	O
induces	O
the	O
stabilization	O
of	O
p53	O
,	O
and	O
accumulated	O
p53	O
causes	O
transcriptional	B-PROC
upregulation	B-PROC
of	O
p21	O
(	O
Cip1	O
).	O

Accumulation	O
of	O
hypophosphorylated	O
pRb	O
thus	O
prevents	O
cell	B-PROC
cycle	I-PROC
progression	I-PROC
from	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
to	O
S	B-PROC
phase	I-PROC
.	O

There	O
are	O
many	O
contributing	O
factors	O
to	O
this	O
increased	O
demand	O
,	O
including	O
the	O
ever	O
-	O
increasing	O
prevalence	O
of	O
chronic	O
viral	B-PROC
infections	I-PROC
such	O
as	O
HIV	O
and	O
hepatitis	O
B	O
and	O
C	O
,	O
and	O
the	O
emergence	O
of	O
new	O
viruses	O
such	O
as	O
the	O
SARS	O
coronavirus	O
.	O

The	O
potential	O
danger	O
of	O
haemorrhagic	O
fever	B-PROC
viruses	O
and	O
eradicated	O
viruses	O
such	O
as	O
variola	O
virus	O
being	O
used	O
as	O
bioterrorist	O
weapons	O
has	O
also	O
increased	O
the	O
profile	O
of	O
antiviral	O
drug	O
discovery	O
.	O

TITLE	O
:	O
Effects	O
of	O
expiratory	B-PROC
tracheal	O
gas	O
insufflation	O
in	O
patients	O
with	O
severe	O
head	O
trauma	O
and	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
This	O
study	O
analyzed	O
the	O
effect	O
of	O
phasic	O
tracheal	O
gas	O
insufflation	O
at	O
mid	O
-	O
to	O
end	B-PROC
-	I-PROC
expiration	I-PROC
in	O
patients	O
with	O
severe	O
head	O
trauma	O
and	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

No	O
changes	O
in	O
hemodynamic	B-PROC
or	O
cerebral	O
parameters	O
were	O
observed	O
during	O
the	O
study	O
.	O

A	O
recruitment	O
maneuver	O
followed	O
by	O
subsequent	O
reduction	O
in	O
airway	O
pressure	O
limits	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
atelectasis	O
,	O
overstretching	O
,	O
and	O
pressure	O
.	O

Angiotensin	O
II	O
,	O
the	O
main	O
product	O
of	O
ACE	O
,	O
is	O
a	O
pleiotropic	O
hormone	O
,	O
capable	O
of	O
serving	O
as	O
a	O
neurotransmitter	O
,	O
growth	B-PROC
factor	O
,	O
angiogenesis	B-PROC
factor	O
,	O
vasoconstrictor	O
,	O
pro	O
-	O
thrombotic	O
agent	O
,	O
and	O
cytokine	O
.	O

Extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
during	O
severe	O
ARDS	O
maintains	O
oxygen	O
and	O
carbon	O
dioxide	O
gas	O
exchange	O
while	O
providing	O
an	O
optimal	O
environment	O
for	O
recovery	O
of	O
pulmonary	B-PROC
function	I-PROC
.	O

The	O
influencing	O
factors	O
of	O
femoral	O
necrosis	B-PROC
included	O
the	O
degree	O
of	O
healing	B-PROC
activity	O
,	O
the	O
dosage	O
summation	B-PROC
of	O
corticosteroids	O
,	O
and	O
length	O
of	O
ictus	O
therapy	O
.	O

The	O
incidence	O
rates	O
of	O
avascular	O
necrosis	B-PROC
of	O
femoral	O
head	O
and	O
of	O
osteoporosis	O
were	O
higher	O
in	O
convalescent	O
SARS	O
patients	O
than	O
in	O
general	O
population	O
.	O

Rabbit	O
antisera	O
were	O
prepared	O
using	O
full	O
-	O
length	O
N	O
and	O
M	O
proteins	O
and	O
eight	O
expressed	B-PROC
fragments	O
covering	O
the	O
S	O
protein	O
.	O

When	O
S2	O
Ab	O
was	O
used	O
to	O
perform	O
immune	O
precipitation	B-PROC
with	O
lysate	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	O
,	O
a	O
cleaved	O
S2	O
fragment	O
was	O
detected	O
with	O
S2	O
-	O
specific	O
mAb	O
by	O
Western	O
blot	O
analysis	O
.	O

SARS	O
survivors	O
in	O
a	O
follow	O
up	O
clinic	O
in	O
a	O
regional	O
hospital	O
underwent	O
high	O
resolution	O
computed	O
tomography	O
(	O
HRCT	O
)	O
of	O
the	O
thorax	O
and	O
lung	B-PROC
function	I-PROC
tests	O
6	O
months	O
after	O
admission	O
to	O
hospital	O
.	O

Clinical	O
data	O
,	O
including	O
elements	O
of	O
cardiovascular	O
,	O
renal	O
,	O
hepatic	O
,	O
hematologic	O
,	O
neurologic	O
,	O
and	O
pulmonary	B-PROC
function	I-PROC
,	O
were	O
collected	O
daily	O
.	O

Potential	O
complications	O
related	O
to	O
severe	O
HS	O
are	O
acute	O
renal	O
failure	O
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
rhabdomyolysis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acid	O
-	O
base	O
disorders	O
,	O
and	O
electrolyte	O
disturbances	O
.	O

A	O
task	O
force	O
designed	O
to	O
ensure	O
representation	O
of	O
all	O
interested	O
parties	O
developed	O
a	O
multi	O
-	O
phase	O
approach	O
which	O
included	O
(	O
a	O
)	O
culling	O
of	O
nonessential	O
animals	O
,	O
(	O
b	O
)	O
cessation	O
of	O
breeding	B-PROC
,	O
(	O
c	O
)	O
testing	O
and	O
culling	O
of	O
individual	O
animals	O
,	O
and	O
(	O
d	O
)	O
cross	O
-	O
fostering	O
to	O
clean	O
dams	O
.	O

Although	O
a	O
multiplex	O
RT	O
-	O
PCR	O
could	O
detect	O
and	O
differentiate	O
NDV	O
and	O
IBV	O
genomes	O
present	O
in	O
the	O
same	O
sample	O
,	O
there	O
was	O
a	O
slight	O
inhibition	B-PROC
of	O
the	O
IBV	O
PCR	O
if	O
a	O
high	O
amount	O
of	O
NDV	O
genome	O
was	O
present	O
in	O
the	O
sample	O
.	O

TITLE	O
:	O
Antibody	B-PROC
World	O
Summit	O
2004	O
-	O
SRI	O
Conference	O
19	O
-	O
21	O
July	O
2004	O
,	O
Philadelphia	O
,	O
PA	O
,	O
USA	O
.	O

All	O
mutants	O
showed	O
undetectable	O
activity	O
in	O
trans	O
-	O
cleavage	B-PROC
assay	O
.	O

The	O
auto	O
-	O
cleavage	B-PROC
assay	O
also	O
provided	O
a	O
sensitive	O
and	O
reliable	O
compensation	B-PROC
to	O
the	O
traditional	O
trans	O
-	O
cleavage	B-PROC
assay	O
.	O

ABSTRACT	O
:	O
Upper	O
respiratory	O
tract	O
infections	O
(	O
ie	O
,	O
""""	O
the	O
common	O
cold	B-PROC
""")"	O
have	O
several	O
hundred	O
causes	O
,	O
the	O
most	O
common	O
of	O
which	O
include	O
rhino	O
-	O
virus	O
,	O
coronavirus	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
.	O

The	O
findings	O
of	O
the	O
present	O
study	O
suggest	O
that	O
steroid	O
toxicity	O
,	O
personal	O
vulnerability	O
,	O
and	O
,	O
probably	O
,	O
psychosocial	O
stressors	O
jointly	O
contributed	O
to	O
the	O
development	B-PROC
of	O
psychosis	O
in	O
patients	O
with	O
SARS	O
.	O

3CLpro	O
was	O
cloned	O
,	O
expressed	B-PROC
,	O
and	O
purified	O
from	O
the	O
Tor2	O
isolate	O
.	O

In	O
this	O
study	O
,	O
approximately	O
140	O
000	O
small	O
molecules	O
were	O
screened	O
by	O
in	O
silico	O
molecular	O
docking	B-PROC
.	O

Among	O
16	O
non	O
-	O
ICU	O
cases	O
,	O
SARS	O
-	O
CoV	O
RNA	O
was	O
detected	O
in	O
plasma	O
since	O
day	O
3	O
-	O
4	O
after	O
fever	B-PROC
onset	O
;	O
viral	O
concentration	O
peaked	O
in	O
the	O
first	O
week	O
,	O
which	O
then	O
rapidly	O
declined	O
in	O
the	O
second	O
week	O
of	O
illness	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
determine	O
highly	O
immunogenic	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
epitope	O
peptides	O
capable	O
of	O
inducing	O
long	O
-	O
lasting	O
immunity	B-PROC
,	O
we	O
first	O
screened	O
immunoglobulin	B-PROC
-	O
G	O
(	O
IgG	O
)	O
antibodies	O
reactive	O
to	O
197	O
different	O
overlapping	O
15	O
-	O
mers	O
from	O
the	O
SARS	O
-	O
CoV	O
proteins	O
in	O
the	O
sera	O
of	O
three	O
infected	O
patients	O
.	O

TITLE	O
:	O
Leukocyte	O
antibodies	O
and	O
biologically	O
active	O
mediators	O
in	O
the	O
pathogenesis	B-PROC
of	O
transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
.	O

The	O
second	O
event	O
causes	O
release	O
of	O
cellular	O
activators	O
with	O
subsequent	O
endothelial	O
damage	O
and	O
exudation	B-PROC
of	O
fluid	O
into	O
the	O
pulmonary	O
alveoli	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
blood	B-PROC
gas	I-PROC
features	O
and	O
short	O
-	O
term	O
outcomes	O
of	O
noninvasive	O
positive	O
pressure	O
ventilation	O
(	O
NPPV	O
)	O
treatment	O
for	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
)	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
this	O
retrospective	O
case	O
series	O
study	O
sought	O
.	O

Clinical	O
specimens	O
collected	O
from	O
these	O
patients	O
were	O
tested	O
by	O
provincial	O
and	O
national	O
laboratories	O
in	O
China	O
as	O
well	O
as	O
members	O
of	O
the	O
World	O
Health	O
Organization	O
SARS	O
Reference	O
and	O
Verification	O
Laboratory	O
Network	O
in	O
a	O
collaborative	O
effort	B-PROC
to	O
identify	O
and	O
confirm	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
SARS	O
coronavirus	O
excretion	B-PROC
from	O
patient	O
cohort	O
,	O
China	O
.	O

TITLE	O
:	O
Nidovirus	O
sialate	O
-	O
O	O
-	O
acetylesterases	O
:	O
evolution	B-PROC
and	O
substrate	O
specificity	O
of	O
coronaviral	O
and	O
toroviral	O
receptor	O
-	O
destroying	O
enzymes	O
.	O

SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-PROC
(	O
SARS	O
3CL	O
(	O
pro	O
))	O
plays	O
key	O
roles	O
in	O
viral	B-PROC
replication	I-PROC
and	O
transcription	B-PROC
and	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
discovery	O
.	O

This	O
conclusion	O
is	O
verified	O
by	O
the	O
surface	O
plasmon	O
resonance	O
biosensor	O
determination	O
,	O
indicating	O
that	O
the	O
model	O
substrate	O
cannot	O
bind	O
to	O
the	O
N	O
-	O
terminal	O
deleted	O
proteinase	B-PROC
.	O

To	O
facilitate	O
the	O
studies	O
on	O
the	O
function	O
and	O
structure	O
of	O
the	O
N	O
protein	O
,	O
this	O
report	O
describe	O
the	O
expression	B-PROC
and	O
purification	O
of	O
recombinant	O
SARS	O
-	O
CoV	O
N	O
protein	O
using	O
the	O
baculovirus	O
expression	B-PROC
system	O
.	O

This	O
protein	O
was	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
and	O
forms	O
a	O
typical	O
six	O
-	O
helix	O
coiled	O
coil	O
bundle	O
.	O

The	O
mean	O
and	O
variance	O
in	O
time	O
from	O
onset	O
to	O
admission	O
,	O
from	O
admission	O
to	O
discharge	O
,	O
or	O
from	O
admission	O
to	O
death	B-PROC
were	O
calculated	O
.	O

Mean	O
time	O
from	O
onset	O
to	O
death	B-PROC
was	O
23	O
.	O
7	O
days	O
(	O
CI	O
,	O
22	O
.	O
0	O
to	O
25	O
.	O
3	O
days	O
),	O
and	O
mean	O
time	O
from	O
onset	O
to	O
discharge	O
was	O
26	O
.	O
5	O
days	O
(	O
CI	O
,	O
25	O
.	O
8	O
to	O
27	O
.	O
2	O
days	O
).	O

TITLE	O
:	O
Expression	B-PROC
of	O
SARS	O
-	O
coronavirus	O
envelope	O
protein	O
in	O
Escherichia	O
coli	O
cells	O
alters	O
membrane	B-PROC
permeability	I-PROC
.	O

A	O
59	O
-	O
year	O
old	O
man	O
was	O
hospitalised	O
for	O
respiratory	O
problems	O
and	O
fever	B-PROC
3	O
days	O
after	O
his	O
return	O
from	O
China	O
during	O
the	O
epidemic	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Facilities	O
ranged	O
from	O
urban	O
hospitals	O
with	O
negative	O
-	O
pressure	O
isolation	O
rooms	O
and	O
high	O
-	O
efficiency	O
particulate	O
air	O
filtration	O
to	O
rural	O
hospitals	O
with	O
patient	O
rooms	O
open	O
to	O
outside	O
air	O
circulation	B-PROC
and	O
intermittent	O
running	O
water	O
.	O

TITLE	O
:	O
Differential	O
regulation	B-PROC
of	O
primary	O
and	O
secondary	O
CD8	O
+	O
T	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
.	O

These	O
data	O
suggest	O
that	O
an	O
instructional	O
program	O
intrinsic	O
to	O
T	B-PROC
cell	I-PROC
differentiation	I-PROC
,	O
rather	O
than	O
Ag	O
load	O
or	O
factors	O
in	O
the	O
inflamed	O
CNS	O
,	O
prominently	O
regulate	O
CD8	O
+	O
T	O
cell	B-PROC
function	I-PROC
.	O

No	O
recombination	B-PROC
was	O
found	O
between	O
H120	O
and	O
the	O
Taiwanese	O
strains	O
in	O
the	O
S1	O
gene	O
.	O

The	O
phylogenetic	O
trees	O
constructed	O
from	O
the	O
S1	O
and	O
N	O
genes	O
indicate	O
that	O
intergenic	O
recombination	B-PROC
has	O
occurred	O
.	O

However	O
,	O
limited	O
information	O
is	O
available	O
about	O
host	O
immune	B-PROC
responses	I-PROC
induced	O
by	O
the	O
inactivated	O
SARS	O
vaccine	O
.	O

Fever	B-PROC
,	O
malaise	O
,	O
cough	O
,	O
coryza	O
,	O
chills	O
or	O
rigor	O
,	O
sputum	B-PROC
production	I-PROC
,	O
headache	O
,	O
myalgia	O
,	O
leucopaenia	O
,	O
lymphopaenia	O
,	O
thrombocytopaenia	O
,	O
mildly	O
prolonged	O
activated	O
partial	O
thromboplastin	O
times	O
and	O
elevated	O
lactate	O
dehydrogenase	O
levels	O
are	O
common	O
presenting	O
features	O
.	O

The	O
final	O
optimal	O
concentration	O
of	O
methanol	O
was	O
20	O
mL	O
/	O
L	O
,	O
the	O
DO	O
had	O
a	O
significant	O
effect	O
on	O
rSCoVN	O
protein	B-PROC
expression	B-PROC
and	O
growth	B-PROC
of	O
recombinant	O
strains	O
.	O

The	O
causes	O
of	O
MODS	O
in	O
SARS	O
are	O
probably	O
injury	O
to	O
the	O
immune	O
system	O
and	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
.	O

SARS	O
cases	O
may	O
develop	O
leucocytosis	O
,	O
low	O
lymphocyte	O
count	O
,	O
low	O
platelet	O
count	O
,	O
low	O
hemoglobin	O
level	O
and	O
abnormal	O
liver	B-PROC
function	I-PROC
.	O

In	O
univariate	O
logistic	O
regression	O
analysis	O
,	O
fT3	O
was	O
the	O
only	O
factor	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-PROC
(	O
odds	O
ratio	O
,	O
64	O
.	O
23	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
78	O
-	O
2316	O
.	O
86	O
,	O
P	O
=	O
0	O
.	O
023	O
).	O

TITLE	O
:	O
Specific	O
immunoglobulin	B-PROC
g	O
antibody	B-PROC
detected	O
in	O
umbilical	O
blood	O
and	O
amniotic	O
fluid	O
from	O
a	O
pregnant	O
woman	O
infected	O
by	O
the	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

This	O
study	O
identified	O
an	O
additional	O
cellular	O
hnRNP	O
as	O
an	O
MHV	O
RNA	O
-	O
binding	O
protein	O
potentially	O
involved	O
in	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

Small	O
tidal	O
volume	O
ventilation	O
and	O
limitation	O
of	O
end	O
-	O
inspiratory	B-PROC
plateau	O
pressure	O
is	O
important	O
in	O
the	O
management	O
of	O
ARDS	O
and	O
may	O
be	O
facilitated	O
by	O
permissive	O
hypercapnia	O
.	O

CONCLUSIONS	O
:	O
A	O
minimum	O
amount	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
should	O
be	O
set	O
to	O
prevent	O
lung	O
collapse	O
at	O
end	O
expiration	B-PROC
in	O
ARDS	O
.	O

The	O
structural	O
proteins	O
E	O
,	O
M	O
and	O
N	O
of	O
SARS	O
-	O
CoV	O
play	O
important	O
roles	O
during	O
host	O
cell	O
entry	O
and	O
viral	O
morphogenesis	B-PROC
and	O
release	O
.	O

Among	O
a	O
total	O
of	O
26	O
antisense	O
PS	O
-	O
ODNs	O
targeting	B-PROC
E	O
,	O
M	O
and	O
N	O
genes	O
,	O
we	O
obtained	O
six	O
antisense	O
PS	O
-	O
ODNs	O
which	O
could	O
sequence	O
-	O
specifically	O
reduce	O
target	O
genes	O
expression	B-PROC
by	O
over	O
90	O
%	O
at	O
the	O
concentration	O
of	O
50	O
microM	O
in	O
the	O
cell	O
culture	O
medium	O
tested	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
antisense	O
effect	O
was	O
further	O
proved	O
by	O
down	O
-	O
regulating	O
the	O
expression	B-PROC
of	O
the	O
fusion	O
proteins	O
containing	O
the	O
structural	O
proteins	O
E	O
,	O
M	O
or	O
N	O
in	O
frame	O
with	O
the	O
reporter	O
protein	O
EGFP	O
.	O

ABSTRACT	O
:	O
Inhalation	B-PROC
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
improved	O
arterial	O
oxygenation	B-PROC
and	O
enabled	O
the	O
reduction	O
of	O
inspired	B-PROC
oxygen	O
therapy	O
and	O
airway	O
pressure	O
support	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

The	O
use	O
of	O
the	O
highly	O
sensitive	O
IHA	O
test	O
made	O
it	O
possible	O
to	O
determine	O
the	O
potential	O
for	O
both	O
serum	O
and	O
local	O
antibodies	B-PROC
production	I-PROC
in	O
the	O
patients	O
under	O
observation	O
.	O

Detailed	O
examination	O
of	O
the	O
dimer	O
-	O
monomer	O
equilibrium	B-PROC
at	O
different	O
pH	O
values	O
reveals	O
apparent	O
pK	O
(	O
a	O
)	O
values	O
of	O
8	O
.	O
0	O
+/-	O

However	O
,	O
it	O
was	O
increasing	O
with	O
the	O
recovery	O
of	O
the	O
disease	O
,	O
but	O
did	O
not	O
reach	B-PROC
to	O
normal	O
level	O
at	O
the	O
5th	O
week	O
after	O
onset	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
two	O
patients	O
(	O
24	O
.	O
1	O
%)	O
met	O
the	O
criteria	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
24	O
patients	O
(	O
18	O
.	O
0	O
%)	O
died	B-PROC
.	O

To	O
determine	O
the	O
role	O
of	O
LIX	O
in	O
the	O
induction	O
of	O
ALI	O
,	O
we	O
used	O
both	O
exogenous	O
LIX	O
and	O
a	O
LIX	O
blocking	O
antibody	B-PROC
.	O

ABSTRACT	O
:	O
On	O
March	O
11	O
,	O
2003	O
,	O
a	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
physician	O
was	O
admitted	O
to	O
Bamrasnaradura	O
Institute	O
,	O
after	O
alerting	O
the	O
world	O
to	O
the	O
dangers	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
Vietnam	O
and	O
developing	O
a	O
fever	B-PROC
himself	O
.	O

Serum	O
samples	O
from	O
35	O
close	O
contacts	O
obtained	O
after	O
day	O
28	O
had	O
a	O
negative	O
result	O
for	O
SARS	O
coronavirus	O
antibody	B-PROC
.	O

In	O
general	O
,	O
a	O
primary	O
dataset	O
measures	O
the	O
paired	O
expression	B-PROC
of	O
two	O
internally	O
controlled	O
reporter	O
genes	O
.	O

We	O
found	O
that	O
SARS	O
coronavirus	O
replicase	O
products	O
can	O
be	O
detected	O
by	O
4	O
h	O
postinfection	O
in	O
the	O
cytoplasm	O
of	O
infected	O
cells	O
and	O
that	O
nsps	O
1	O
to	O
3	O
colocalize	O
with	O
newly	O
synthesized	O
viral	O
RNA	O
in	O
punctate	O
,	O
perinuclear	O
sites	O
consistent	O
with	O
their	O
predicted	O
role	O
in	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

These	O
studies	O
revealed	O
that	O
PLpro	O
can	O
cleave	O
in	O
trans	O
at	O
the	O
three	O
predicted	O
cleavage	B-PROC
sites	O
and	O
that	O
it	O
requires	O
membrane	O
association	O
to	O
process	O
the	O
nsp3	O
/	O
4	O
cleavage	B-PROC
site	O
.	O

TITLE	O
:	O
Overexpression	B-PROC
of	O
7a	O
,	O
a	O
protein	O
specifically	O
encoded	O
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
induces	O
apoptosis	B-PROC
via	O
a	O
caspase	O
-	O
dependent	O
pathway	B-PROC
.	O

7a	O
induces	O
apoptosis	B-PROC
via	O
a	O
caspase	O
-	O
dependent	O
pathway	B-PROC
and	O
in	O
cell	O
lines	O
derived	O
from	O
different	O
organs	O
,	O
including	O
lung	O
,	O
kidney	O
,	O
and	O
liver	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-PROC
(	O
3CL	O
(	O
pro	O
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
is	O
a	O
key	O
target	O
for	O
structure	O
-	O
based	O
drug	O
design	O
against	O
this	O
viral	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Clinical	O
application	O
of	O
arteriovenous	O
(	O
AV	O
)	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
requires	O
assessment	O
of	O
cardiovascular	O
ability	O
to	O
respond	O
adequately	O
to	O
the	O
presence	O
of	O
an	O
AV	O
shunt	O
in	O
the	O
face	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

ABSTRACT	O
:	O
This	O
review	O
focuses	O
on	O
mechanical	O
ventilation	O
strategies	O
that	O
allow	O
unsupported	O
spontaneous	O
breathing	B-PROC
activity	O
in	O
any	O
phase	O
of	O
the	O
ventilatory	O
cycle	O
.	O

Based	O
on	O
currently	O
available	O
data	O
,	O
we	O
suggest	O
considering	O
the	O
use	O
of	O
techniques	O
of	O
mechanical	O
ventilatory	O
support	O
that	O
maintain	O
,	O
rather	O
than	O
suppress	O
,	O
spontaneous	O
ventilatory	O
effort	B-PROC
,	O
especially	O
in	O
patients	O
with	O
severe	O
pulmonary	O
dysfunction	O
.	O

Of	O
interest	O
,	O
SARS	O
-	O
CoV	O
proteins	O
were	O
detected	O
only	O
in	O
PM	O
that	O
did	O
not	O
produce	O
significant	O
amounts	O
of	O
interferon	O
(	O
IFN	O
)-	O
alpha	O
,	O
and	O
in	O
one	O
such	O
case	O
,	O
preliminary	O
electron	O
microscope	O
studies	O
demonstrated	O
that	O
SARS	O
-	O
CoV	O
-	O
like	O
particles	O
could	O
enter	O
the	O
cells	O
,	O
possibly	O
via	O
phagocytosis	B-PROC
.	O

CONCLUSIONS	O
:	O
The	O
modified	O
slide	O
surface	O
is	O
satisfactory	O
to	O
immobilize	O
unmodified	O
oligonucleotide	O
by	O
covalent	B-PROC
binding	O
,	O
which	O
enhances	O
not	O
only	O
the	O
sensitivity	O
of	O
the	O
prepared	O
oligonucleotide	O
microarray	O
but	O
also	O
the	O
binding	O
of	O
the	O
oligonucleotide	O
to	O
the	O
slide	O
surface	O
.	O

TITLE	O
:	O
[	O
Dynamic	O
changes	O
of	O
immunoglobulin	B-PROC
G	O
in	O
convalescents	O
who	O
have	O
suffered	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
].	O

However	O
,	O
the	O
antibody	B-PROC
level	O
gradually	O
decline	O
with	O
the	O
lapse	O
of	O
time	O
during	O
the	O
convalescence	O
.	O

There	O
are	O
several	O
proteins	O
that	O
have	O
never	O
been	O
identified	O
in	O
plasma	O
before	O
using	O
2D	O
gel	O
electrophoresis	O
,	O
among	O
which	O
peroxiredoxin	O
II	O
was	O
chosen	O
for	O
further	O
study	O
by	O
analyzing	O
additional	O
20	O
plasma	O
samples	O
from	O
patients	O
with	O
probable	O
and	O
suspected	O
SARS	O
and	O
patients	O
with	O
fever	B-PROC
,	O
respectively	O
.	O

Isolation	O
of	O
those	O
who	O
have	O
had	O
close	O
contact	O
with	O
confirmed	O
or	O
suspected	O
SARS	O
patients	O
and	O
/	O
or	O
who	O
have	O
persistent	O
fever	B-PROC
will	O
be	O
the	O
most	O
effective	O
and	O
practical	O
method	O
of	O
avoiding	O
contact	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
different	O
viruses	O
interact	O
with	O
the	O
cell	B-PROC
cycle	I-PROC
in	O
order	O
to	O
subvert	O
host	O
-	O
cell	B-PROC
function	I-PROC
and	O
increase	O
the	O
efficiency	O
of	O
virus	B-PROC
replication	I-PROC
;	O
examples	O
can	O
be	O
found	O
from	O
DNA	O
,	O
retro	O
,	O
and	O
RNA	O
viruses	O
.	O

The	O
ability	O
of	O
this	O
family	O
of	O
positive	O
strand	O
RNA	O
viruses	O
to	O
move	B-PROC
between	O
species	O
and	O
cause	O
severe	O
disease	O
in	O
humans	O
,	O
with	O
the	O
potential	O
for	O
pandemic	O
spread	O
,	O
has	O
been	O
confirmed	O
.	O

TITLE	O
:	O
Research	O
on	O
infectious	O
diseases	O
requires	O
better	O
coordination	B-PROC
.	O

Molecular	O
methods	O
have	O
had	O
a	O
major	O
impact	O
on	O
infectious	O
disease	O
through	O
the	O
rapid	O
identification	O
of	O
new	O
infectious	O
agents	O
,	O
SARS	O
,	O
and	O
the	O
characterization	O
of	O
drug	B-PROC
resistance	B-PROC
.	O

Gene	B-PROC
expression	I-PROC
microassay	O
profiles	O
of	O
various	O
lymphomas	O
have	O
modified	O
classification	O
systems	O
and	O
predict	O
prognosis	O
and	O
response	O
to	O
therapy	O
.	O

There	O
also	O
was	O
a	O
significant	O
improvement	O
in	O
lung	B-PROC
function	I-PROC
,	O
as	O
expressed	B-PROC
by	O
improvements	O
in	O
po2	B-PROC
,	O
pco2	O
,	O
and	O
pH	O
,	O
and	O
reduction	O
of	O
the	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
.	O

Furthermore	O
,	O
the	O
expression	B-PROC
of	O
cytokines	O
was	O
reduced	O
by	O
NP	O
treatment	O
.	O

L	O
-	O
arginine	O
and	O
L	O
-	O
NIL	O
also	O
had	O
a	O
beneficial	O
effect	O
on	O
lung	B-PROC
function	I-PROC
and	O
structure	O
.	O

More	O
importantly	O
,	O
the	O
immunized	O
mice	O
produced	O
strong	O
delayed	B-PROC
-	I-PROC
type	I-PROC
hypersensitivity	I-PROC
(	O
DTH	B-PROC
)	O
and	O
CD8	O
(+)	O
CTL	O
responses	O
to	O
N	O
protein	O
.	O

These	O
""""	O
exhaled	B-PROC
bioaerosols	O
""""	O
may	O
carry	O
airborne	O
pathogens	O
and	O
thereby	O
magnify	O
the	O
spread	O
of	O
certain	O
infectious	O
diseases	O
,	O
such	O
as	O
influenza	O
,	O
tuberculosis	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

However	O
,	O
the	O
different	O
composition	O
of	O
the	O
tested	O
samples	O
affected	O
the	O
heat	O
sensitivity	O
of	O
the	O
virus	O
strain	O
:	O
the	O
infectivity	O
of	O
the	O
virus	O
in	O
Antithrombin	O
III	O
preparation	O
still	O
remained	O
after	O
heating	O
for	O
30	O
min	O
at	O
60	O
degrees	O
C	O
.	O
If	O
by	O
rare	O
chance	O
SARS	O
-	O
CoV	O
contaminates	O
source	O
plasma	O
,	O
there	O
should	O
be	O
no	O
or	O
only	O
minor	O
risk	O
of	O
this	O
virus	B-PROC
infection	I-PROC
,	O
due	O
to	O
sufficient	O
inactivation	O
by	O
the	O
60	O
degrees	O
C	O
10	O
h	O
liquid	O
heating	O
step	O
,	O
although	O
we	O
must	O
pay	O
attention	O
to	O
the	O
composition	O
used	O
for	O
blood	O
product	O
preparation	O
.	O

ABSTRACT	O
:	O
The	O
inflammatory	B-PROC
response	I-PROC
and	O
the	O
intracellular	B-PROC
signaling	I-PROC
pathway	I-PROC
induced	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
(	O
CoV	O
)	O
were	O
studied	O
in	O
lung	O
epithelial	O
cells	O
and	O
fibroblasts	O
.	O

The	O
identification	O
of	O
the	O
functional	O
domain	O
for	O
IL	O
-	O
8	O
release	O
will	O
provide	O
for	O
the	O
drug	O
design	O
on	O
targeting	B-PROC
specific	O
sequence	O
domains	O
of	O
S	O
protein	O
responsible	O
for	O
initiating	O
the	O
inflammatory	B-PROC
response	I-PROC
.	O

Viral	B-PROC
replication	I-PROC
in	O
epithelial	O
cells	O
of	O
the	O
respiratory	O
tract	O
was	O
accompanied	O
by	O
cellular	B-PROC
necrosis	I-PROC
early	O
in	O
infection	O
,	O
followed	O
by	O
an	O
inflammatory	B-PROC
response	I-PROC
coincident	O
with	O
viral	O
clearance	O
,	O
focal	O
consolidation	O
in	O
pulmonary	O
tissue	O
,	O
and	O
eventual	O
pulmonary	O
tissue	B-PROC
repair	I-PROC
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
proteasome	B-PROC
inhibitors	I-PROC
blocked	O
mouse	O
hepatitis	O
virus	B-PROC
replication	I-PROC
at	O
an	O
early	O
step	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
.	O

In	O
some	O
patients	O
(	O
10	O
/	O
45	O
),	O
a	O
high	O
level	O
of	O
anti	O
-	O
nucleocapsid	O
antibody	B-PROC
appeared	O
very	O
early	O
in	O
the	O
course	O
of	O
the	O
illness	O
.	O

The	O
implication	O
of	O
differences	O
in	O
antibody	B-PROC
response	I-PROC
to	O
the	O
nucleocapsid	O
protein	O
deserves	O
further	O
investigation	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
induction	O
of	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immunity	I-PROC
to	O
SARS	O
-	O
CoV	O
and	O
thus	O
it	O
is	O
important	O
to	O
characterize	O
this	O
protein	O
.	O

In	O
this	O
paper	O
,	O
we	O
highlight	O
three	O
examples	O
of	O
emerging	O
pathogens	O
:	O
Nipah	O
and	O
Hendra	O
virus	O
,	O
which	O
emerged	O
in	O
Malaysia	O
and	O
Australia	O
in	O
the	O
1990s	O
respectively	O
,	O
with	O
recent	O
outbreaks	O
caused	O
by	O
similar	O
viruses	O
in	O
India	O
in	O
2000	O
and	O
Bangladesh	O
in	O
2004	O
;	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
which	O
emerged	O
in	O
the	O
New	O
World	O
in	O
1999	O
;	O
and	O
amphibian	O
chytridiomycosis	O
,	O
which	O
has	O
emerged	O
globally	O
as	O
a	O
threat	O
to	O
amphibian	O
populations	O
and	O
a	O
major	O
cause	O
of	O
amphibian	O
population	O
declines	O
.	O

Interestingly	O
,	O
the	O
expression	B-PROC
density	O
of	O
E	O
-	O
CR1	O
was	O
found	O
to	O
fall	O
significantly	O
during	O
the	O
initiation	O
and	O
progressive	O
phases	O
(	O
weeks	O
1	O
and	O
2	O
after	O
the	O
disease	O
onset	O
)	O
and	O
gradually	O
returned	O
close	O
to	O
normal	O
through	O
their	O
whole	O
convalescent	O
phase	O
(	O
beginning	O
from	O
weeks	O
2	O
or	O
3	O
to	O
weeks	O
7	O
or	O
8	O
)	O
in	O
SARS	O
patients	O
irrespective	O
CR1	O
genotype	O
.	O

The	O
kinetics	O
of	O
neutralisation	O
antibodies	O
obtained	O
with	O
100x	O
the	O
tissue	O
culture	O
infective	O
dose	O
(	O
TCID50	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
TW1	O
strain	O
in	O
five	O
patients	O
with	O
SARS	O
nearly	O
paralleled	O
those	O
for	O
IgG	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
kinetics	O
of	O
the	O
IgG	O
,	O
IgM	O
and	O
IgA	O
responses	O
between	O
patients	O
with	O
or	O
without	O
underlying	O
medical	O
disease	O
,	O
steroid	O
or	O
intravenous	O
immunoglobulin	B-PROC
therapy	O
,	O
or	O
mechanical	O
ventilation	O
.	O

The	O
old	O
model	O
explaining	O
subgenomic	O
mRNA	B-PROC
synthesis	I-PROC
,	O
which	O
was	O
called	O
leader	O
-	O
primed	O
transcription	B-PROC
,	O
was	O
based	O
on	O
erroneous	O
evidence	O
that	O
only	O
genome	O
-	O
length	O
negative	O
strands	O
were	O
present	O
in	O
replicative	O
intermediates	O
.	O

With	O
our	O
model	O
the	O
genome	O
is	O
copied	O
both	O
continuously	O
to	O
produce	O
minus	O
-	O
strand	O
templates	O
for	O
genome	O
RNA	B-PROC
synthesis	I-PROC
and	O
discontinuously	O
to	O
produce	O
minus	O
-	O
strand	O
templates	O
for	O
subgenomic	O
mRNA	B-PROC
synthesis	I-PROC
,	O
and	O
the	O
subgenomic	O
mRNAs	O
do	O
not	O
function	O
as	O
templates	O
for	O
minus	O
strand	O
synthesis	B-PROC
,	O
only	O
the	O
genome	O
does	O
.	O

ABSTRACT	O
:	O
Knowledge	O
of	O
coronavirus	O
replication	O
,	O
transcription	B-PROC
,	O
and	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
has	O
been	O
recently	O
improved	O
by	O
engineering	O
of	O
coronavirus	O
infectious	O
cDNAs	O
.	O

Vector	O
biosafety	O
is	O
being	O
increased	O
by	O
relocating	O
the	O
RNA	O
packaging	O
signal	O
to	O
the	O
position	O
previously	O
occupied	O
by	O
deleted	O
essential	O
genes	O
,	O
to	O
prevent	O
the	O
rescue	O
of	O
fully	O
competent	O
viruses	O
that	O
might	O
arise	O
from	O
recombination	B-PROC
events	O
with	O
wild	O
-	O
type	O
field	O
coronaviruses	O
.	O

These	O
proteins	O
include	O
rennin	O
,	O
amyloglucosidases	O
(	O
glucamylases	O
),	O
interferons	O
,	O
interleukins	O
,	O
insulin	O
,	O
monoclonal	O
antibodies	O
,	O
tissue	B-PROC
plasminogen	I-PROC
activators	I-PROC
(	O
t	O
-	O
PA	O
),	O
sexually	O
transmitted	O
disease	O
antigens	O
,	O
and	O
measles	O
,	O
mumps	O
and	O
rubella	O
antigens	O
,	O
growth	B-PROC
hormones	O
,	O
somatotropin	O
,	O
blood	B-PROC
clotting	I-PROC
factors	O
VIII	O
and	O
XIII	O
.	O

ROS	O
are	O
generated	O
inadvertently	O
by	O
single	O
metal	O
valency	O
couples	O
such	O
as	O
FeII	O
/	O
FeIII	O
and	O
by	O
FeIII	O
/	O
FeV	O
present	O
in	O
2700	O
(	O
including	O
57	O
human	O
)	O
isoforms	O
in	O
cytochromes	B-PROC
P450	O
mixed	O
-	O
function	O
oxidases	O
(	O
EC	O
1	O
.	O
14	O
.	O
14	O
.	O
1	O
;	O
O2	O
:	O
mono	O
-	O
oxygenase	B-PROC
NADPH	O
/	O
NADH	O
requiring	O
).	O

Furthermore	O
,	O
denaturation	B-PROC
-	O
renaturation	O
experiments	O
revealed	O
that	O
,	O
during	O
protein	B-PROC
refolding	I-PROC
,	O
Zn2	O
+	O
is	O
essential	O
for	O
the	O
rescue	O
of	O
the	O
enzymatic	O
activities	O
of	O
nidovirus	O
helicases	O
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
the	O
ZBD	O
is	O
critically	O
involved	O
in	O
nidovirus	O
replication	O
and	O
transcription	B-PROC
by	O
modulating	O
the	O
enzymatic	O
activities	O
of	O
the	O
helicase	O
domain	O
and	O
other	O
,	O
yet	O
unknown	O
,	O
mechanisms	O
.	O

Our	O
combined	O
observations	O
suggest	O
a	O
model	O
for	O
FIP	O
pathogenesis	B-PROC
in	O
which	O
virus	O
-	O
induced	O
T	O
-	O
cell	O
depletion	O
and	O
the	O
antiviral	O
T	O
-	O
cell	O
response	O
are	O
opposing	O
forces	O
and	O
in	O
which	O
the	O
efficacy	O
of	O
early	O
T	O
-	O
cell	O
responses	O
critically	O
determines	O
the	O
outcome	O
of	O
the	O
infection	O
.	O

Rising	O
amounts	O
of	O
viral	O
RNA	O
in	O
the	O
blood	O
,	O
consistently	O
seen	O
in	O
animals	O
with	O
end	O
-	O
stage	O
FIP	O
,	O
indicate	O
that	O
progression	O
to	O
fatal	O
disease	O
is	O
the	O
direct	O
consequence	O
of	O
a	O
loss	O
of	O
immune	O
control	O
,	O
resulting	O
in	O
unchecked	O
viral	B-PROC
replication	I-PROC
.	O

Correlation	O
between	O
PIT	O
(	O
50	O
)	O
and	O
clinical	O
parameters	O
(	O
duration	O
of	O
fever	B-PROC
,	O
cough	O
,	O
dyspnea	O
,	O
oxygen	O
supplementation	O
,	O
intubation	O
,	O
and	O
death	B-PROC
)	O
were	O
evaluated	O
using	O
Wilcoxon	O
'	O
s	O
rank	O
sum	O
testing	O
and	O
Spearman	O
'	O
s	O
correlation	O
.	O

ABSTRACT	O
:	O
This	O
review	O
reports	O
recent	O
findings	O
on	O
lipid	O
use	O
in	O
artificial	O
nutrition	B-PROC
in	O
patients	O
with	O
acute	O
respiratory	O
failure	O
or	O
severe	O
sepsis	O
or	O
undergoing	O
major	O
surgery	O
.	O

In	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
the	O
debate	O
concerning	O
the	O
use	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
as	O
opposed	O
to	O
physical	O
mixtures	O
of	O
medium	O
-	O
and	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
specifically	O
regarding	O
their	O
effects	O
on	O
gas	O
exchange	O
and	O
pulmonary	O
hemodynamics	B-PROC
,	O
still	O
remains	O
unresolved	O
.	O

Studies	O
suggest	O
that	O
lipid	O
use	O
in	O
critically	O
ill	O
patients	O
may	O
be	O
improved	O
by	O
increased	O
knowledge	O
of	O
genetic	O
determinants	O
of	O
severity	O
of	O
injury	O
and	O
response	O
to	O
therapeutic	O
agents	O
as	O
well	O
as	O
by	O
the	O
development	B-PROC
of	O
tools	O
that	O
allow	O
better	O
timing	O
of	O
immunonutritional	O
intervention	O
.	O

TITLE	O
:	O
Ventilator	O
strategies	O
for	O
posttraumatic	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
airway	O
pressure	O
release	O
ventilation	O
and	O
the	O
role	O
of	O
spontaneous	O
breathing	B-PROC
in	I-PROC
critically	O
ill	O
patients	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
39	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
post	O
-	O
streptococcal	O
acute	O
glomerulonephritis	O
(	O
PSAGN	O
)	O
super	O
-	O
imposed	O
on	O
long	O
-	O
term	O
immunoglobulin	B-PROC
A	O
nephropathy	O
(	O
IgA	O
-	O
N	O
).	O

In	O
South	O
-	O
East	O
Asia	O
severe	O
epidemics	O
of	O
dengue	O
hemorrhagic	O
fever	B-PROC
started	O
in	O
1954	O
and	O
flu	O
pandemics	O
have	O
originated	O
from	O
China	O
such	O
as	O
the	O
Asian	O
flu	O
(	O
H2N2	O
)	O
in	O
1957	O
,	O
the	O
Hong	O
-	O
Kong	O
flu	O
(	O
H3N2	O
)	O
in	O
1968	O
,	O
and	O
the	O
Russian	O
flu	O
(	O
H1N1	O
)	O
in	O
1977	O
.	O

ABSTRACT	O
:	O
Emergent	O
viral	B-PROC
infections	I-PROC
are	O
defined	O
as	O
those	O
the	O
incidence	O
of	O
which	O
has	O
increased	O
over	O
the	O
last	O
20	O
years	O
.	O

Understanding	O
epidemiology	O
and	O
disease	O
transmission	O
is	O
vital	O
to	O
nursing	B-PROC
care	O
.	O

A	O
good	O
example	O
is	O
SARS	O
-	O
CoV	O
,	O
which	O
was	O
a	O
cause	O
of	O
death	B-PROC
of	O
many	O
people	O
and	O
frightened	O
the	O
entire	O
world	O
with	O
its	O
fast	O
and	O
hard	O
to	O
prevent	O
propagation	O
.	O

TITLE	O
:	O
A	O
genome	O
sequence	O
of	O
novel	O
SARS	O
-	O
CoV	O
isolates	O
:	O
the	O
genotype	O
,	O
GD	O
-	O
Ins29	O
,	O
leads	O
to	O
a	O
hypothesis	O
of	O
viral	B-PROC
transmission	I-PROC
in	O
South	O
China	O
.	O

ABSTRACT	O
:	O
To	O
construct	O
human	O
phage	O
antibody	B-PROC
library	O
against	O
SARS	O
virus	O
.	O

CONCLUSIONS	O
:	O
Human	O
phage	O
antibody	B-PROC
library	O
against	O
SARS	O
virus	O
has	O
been	O
constructed	O
successfully	O
,	O
from	O
which	O
10	O
anti	O
-	O
SARS	O
virus	O
antibodies	O
were	O
obtained	O
.	O

TITLE	O
:	O
[	O
Preparation	O
of	O
specific	O
monoclonal	O
antibody	B-PROC
against	O
nucleocapsid	O
protein	O
of	O
SARS	O
coronavirus	O
].	O

After	O
being	O
confirmed	O
by	O
DNA	O
sequencing	O
,	O
the	O
gene	O
was	O
subcloned	O
into	O
prokaryotic	O
expression	B-PROC
vector	O
.	O

N	O
protein	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
was	O
recovered	O
from	O
SDS	O
-	O
PAGE	O
gel	O
and	O
served	O
as	O
immunogen	O
in	O
the	O
preparation	O
of	O
the	O
mAb	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
showed	O
that	O
the	O
M	O
(	O
r	O
)	O
of	O
the	O
expressed	B-PROC
protein	O
was	O
approximately	O
43	O
kd	O
.	O

T	O
lymphocyte	O
subsets	O
,	O
activated	O
states	O
of	O
T	O
and	O
B	O
lymphocytes	O
,	O
and	O
expressions	O
of	O
CD3	O
(+)	O
and	O
24	O
TCR	B-PROC
Vbeta	O
subfamilies	O
in	O
76	O
convalescent	O
SARS	O
patients	O
were	O
detected	O
by	O
flow	O
cytometry	O
.	O

All	O
SARS	O
cases	O
were	O
positive	O
except	O
one	O
by	O
immunity	B-PROC
adherence	O
test	O
.	O

Of	O
the	O
6	O
strains	O
,	O
1	O
was	O
identified	O
as	O
the	O
immunoglobulin	B-PROC
G3	O
(	O
IgG3	O
)	O
isotype	O
,	O
5	O
were	O
IgG1	O
.	O

The	O
ventilatory	O
pattern	O
should	O
be	O
directed	O
toward	O
minimizing	O
dynamic	O
hyperinflation	O
and	O
auto	O
-	O
PEEP	O
by	O
using	O
small	O
tidal	O
volume	O
and	O
preserving	O
expiratory	B-PROC
time	O
.	O

TITLE	O
:	O
Arginine	B-PROC
metabolism	I-PROC
during	O
macrophage	O
autocrine	B-PROC
activation	O
and	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
3	O
.	O

As	O
a	O
consequence	O
of	O
nitric	O
oxide	O
synthase	O
synthesis	B-PROC
and	O
arginine	O
consumption	O
in	O
IFNgamma	O
activated	O
BMMphi	O
,	O
we	O
observed	O
a	O
higher	O
synthesis	B-PROC
of	O
citrulline	O
.	O

Parameters	O
studied	O
included	O
serum	O
levels	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
IgG	O
antibody	B-PROC
,	O
tests	O
of	O
lung	B-PROC
function	I-PROC
,	O
and	O
imaging	O
data	O
to	O
evaluate	O
changes	O
in	O
lung	O
fibrosis	O
.	O

They	O
were	O
tested	O
regularly	O
for	O
serum	O
levels	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-PROC
and	O
lung	B-PROC
function	I-PROC
and	O
were	O
given	O
chest	O
X	O
-	O
rays	O
and	O
/	O
or	O
high	O
resolution	O
computerized	O
tomography	O
(	O
HRCT	O
)	O
examinations	O
at	O
the	O
Chinese	O
PLA	O
General	O
Hospital	O
during	O
the	O
12	O
months	O
that	O
followed	O
their	O
release	O
from	O
the	O
hospital	O
.	O

Other	O
challenges	O
encountered	O
during	O
SARS	O
include	O
the	O
following	O
:	O
closure	O
of	O
intensive	O
care	O
unit	O
beds	O
and	O
loss	O
of	O
staff	O
through	O
quarantine	O
and	O
illness	O
,	O
implementing	O
novel	O
infection	O
control	O
protocols	O
,	O
educating	O
staff	O
,	O
conducting	B-PROC
research	O
to	O
learn	B-PROC
about	O
SARS	O
,	O
system	O
planning	O
,	O
and	O
maintaining	O
staff	O
morale	O
during	O
this	O
very	O
difficult	O
period	O
.	O

TITLE	O
:	O
[	O
Development	B-PROC
and	O
preliminary	O
application	O
of	O
monoclonal	O
antibodies	O
against	O
N	O
protein	O
of	O
SARS	O
virus	O
].	O

The	O
monoclonal	O
antibody	B-PROC
has	O
good	O
specificity	O
and	O
may	O
be	O
used	O
to	O
detect	O
SARS	O
virus	O
antigen	O
.	O

S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
,	O
which	O
has	O
been	O
demonstrated	O
harboring	O
the	O
receptor	O
binding	O
domain	O
,	O
successfully	O
elicited	O
SARS	O
-	O
CoV	O
specific	O
IgG	O
antibody	B-PROC
in	O
mouse	O
after	O
combined	O
immunization	O
with	O
DNA	O
and	O
purified	O
S1	O
protein	O
;	O
the	O
antibody	B-PROC
elicited	O
solely	O
by	O
S1	O
could	O
potently	O
neutralize	O
SARS	O
-	O
CoV	O
(	O
HKU	O
-	O
39849	O
)	O
in	O
vitro	O
,	O
50	O
%	O
of	O
1	O
000	O
TCID50	O
SARS	O
-	O
CoV	O
challenged	O
cells	O
were	O
protected	O
from	O
viral	B-PROC
infection	I-PROC
by	O
a	O
1	O
:	O
1499	O
.	O
68	O
dilution	O
of	O
mice	O
sera	O
immunized	O
with	O
S1	O
protein	O
,	O
but	O
negative	O
control	O
sera	O
showed	O
no	O
protection	O
.	O

CONCLUSIONS	O
:	O
S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
receptor	O
binding	O
,	O
can	O
efficiently	O
and	O
sufficiently	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	B-PROC
in	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
pharmacophore	O
model	O
for	O
the	O
main	O
proteinase	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

This	O
means	O
that	O
our	O
pharmacophore	O
model	O
can	O
lead	O
to	O
the	O
discovery	O
of	O
potent	O
anti	O
-	O
SARS	O
-	O
CoV	O
inhibitors	O
or	O
promising	O
lead	O
compounds	O
for	O
further	O
SARS	O
-	O
CoV	O
main	O
proteinase	B-PROC
inhibitor	I-PROC
development	B-PROC
.	O

TITLE	O
:	O
Prokaryotic	O
expression	B-PROC
,	O
refolding	O
,	O
and	O
purification	O
of	O
fragment	O
450	O
-	O
650	O
of	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
829	O
serum	O
specimens	O
were	O
collected	O
from	O
643	O
patients	O
initially	O
reported	O
to	O
be	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
The	O
sera	O
were	O
tested	O
for	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
by	O
using	O
an	O
antigen	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
based	O
on	O
monoclonal	O
antibodies	O
against	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
and	O
compared	O
to	O
197	O
control	O
serum	O
samples	O
from	O
healthy	O
donors	O
and	O
non	O
-	O
SARS	O
febrile	B-PROC
patients	O
.	O

After	O
cell	B-PROC
fusion	I-PROC
and	O
three	O
rounds	O
of	O
cell	O
cloning	O
,	O
six	O
hybridoma	O
cell	O
lines	O
secreting	B-PROC
monoclonal	O
antibodies	O
specifically	O
against	O
SARS	O
-	O
CoV	O
nucleocapsid	O
were	O
obtained	O
.	O

TITLE	O
:	O
[	O
Sero	O
-	O
epidemiological	O
characteristics	O
of	O
antibody	B-PROC
to	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
Gansu	O
Province	O
].	O

CONCLUSIONS	O
:	O
The	O
positive	O
rate	O
of	O
SARS	O
coronavirus	O
IgG	O
antibody	B-PROC
of	O
patients	O
was	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
.	O

TITLE	O
:	O
Respiratory	O
syncytial	O
virus	B-PROC
infection	I-PROC
:	O
denominator	O
-	O
based	O
studies	O
in	O
Indonesia	O
,	O
Mozambique	O
,	O
Nigeria	O
and	O
South	O
Africa	O
.	O

We	O
performed	O
seven	O
SARS	O
autopsies	O
in	O
which	O
samples	O
of	O
alimentary	O
tract	O
and	O
digestive	B-PROC
glands	O
were	O
examined	O
with	O
routine	O
pathology	O
,	O
electron	O
microscopy	O
(	O
EM	O
),	O
in	O
situ	O
hybridization	B-PROC
(	O
ISH	O
),	O
immunohistochemistry	O
,	O
and	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O

From	O
a	O
positive	O
perspective	O
,	O
such	O
a	O
crisis	O
created	O
an	O
opportunity	O
to	O
learn	B-PROC
and	O
grow	O
in	O
terms	O
of	O
ethical	O
,	O
personal	O
and	O
aesthetic	O
arenas	O
.	O

Until	O
recently	O
,	O
traditional	O
approaches	O
to	O
mechanical	O
ventilatory	O
support	O
of	O
patients	O
with	O
acute	O
lung	O
injury	O
have	O
called	O
for	O
adaptation	B-PROC
of	O
the	O
patient	O
to	O
the	O
mechanical	O
ventilator	O
using	O
heavy	O
sedation	O
and	O
administration	O
of	O
neuromuscular	O
blocking	O
agents	O
.	O

Available	O
data	O
suggest	O
a	O
rapid	O
increase	O
in	O
S	O
.	O
pneumoniae	O
resistance	B-PROC
to	O
penicillin	O
and	O
macrolides	O
in	O
many	O
cases	O
of	O
community	O
acquired	O
pneumonia	O
,	O
which	O
has	O
resulted	O
in	O
shifts	O
in	O
outpatient	O
(	O
and	O
inpatient	O
)	O
antibiotic	O
treatment	O
regimens	O
.	O

Direct	O
sequencing	O
of	O
RT	O
-	O
PCR	O
products	O
derived	O
from	O
cells	O
infected	O
with	O
the	O
plaque	O
-	O
purified	O
virus	O
,	O
which	O
had	O
lost	O
expression	B-PROC
of	O
EGFP	O
,	O
confirmed	O
loss	O
of	O
the	O
EGFP	O
ORF	O
.	O

TITLE	O
:	O
Intragastric	O
administration	O
of	O
Lactobacillus	O
casei	O
expressing	O
transmissible	O
gastroentritis	O
coronavirus	O
spike	O
glycoprotein	O
induced	O
specific	O
antibody	B-PROC
production	I-PROC
.	O

Pigs	O
were	O
treated	O
with	O
antibiotics	O
and	O
fluids	O
,	O
placed	O
on	O
a	O
ventilator	O
before	O
sacrifice	O
to	O
obtain	O
hemodynamic	B-PROC
and	O
pulmonary	O
parameters	O
,	O
and	O
underwent	O
histologic	O
lung	O
assessment	O
.	O

A	O
second	O
group	O
of	O
Yorkshire	O
swine	O
[	O
group	O
2	O
,	O
superior	O
mesenteric	O
artery	O
(	O
SMA	O
)	O
+	O
FC	O
,	O
n	O
=	O
4	O
]	O
underwent	O
SMA	O
occlusion	B-PROC
for	O
30	O
min	O
(	O
I	O
/	O
R	O
)	O
followed	O
by	O
intraperitoneal	O
placement	O
of	O
a	O
FC	O
as	O
in	O
the	O
initial	O
group	O
.	O

Pigs	O
in	O
the	O
SMA	O
+	O
FC	O
group	O
were	O
sacrificed	O
at	O
48	O
h	O
after	O
clinical	O
deterioration	O
(	O
significant	O
decline	O
in	O
oxygenation	B-PROC
)	O
and	O
demonstrated	O
pathologic	O
evidence	O
of	O
lung	O
injury	O
indicated	O
by	O
increased	O
bronchoalveolar	O
lavage	O
fluid	O
protein	O
,	O
diffuse	O
and	O
thickened	O
alveolar	O
septae	O
,	O
hyaline	O
membrane	O
formation	B-PROC
,	O
and	O
pulmonary	O
edema	O
.	O

TITLE	O
:	O
Avian	O
infectious	O
bronchitis	O
virus	O
:	O
a	O
possible	O
cause	O
of	O
reduced	O
fertility	B-PROC
in	O
the	O
rooster	O
.	O

Seven	O
patients	O
with	O
histories	O
of	O
only	O
urban	O
exposure	O
to	O
leptospires	O
had	O
severe	O
pulmonary	O
manifestations	O
;	O
of	O
these	O
,	O
5	O
patients	O
died	B-PROC
;	O
4	O
of	O
the	O
deaths	B-PROC
were	O
caused	O
by	O
pulmonary	O
hemorrhage	O
,	O
and	O
1	O
was	O
caused	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multiorgan	O
failure	O
.	O

Data	O
suggest	O
that	O
the	O
proteins	O
of	O
SARS	O
-	O
CoV	O
with	O
toxic	O
motifs	O
might	O
play	O
crucial	O
roles	O
in	O
targeting	B-PROC
host	O
cells	O
and	O
interfering	O
with	O
the	O
immune	O
system	O
.	O

(	O
3	O
)	O
An	O
early	O
immunomodulatory	O
therapy	O
,	O
based	O
on	O
the	O
levels	O
of	O
proinflammatory	O
cytokines	O
and	O
clinical	O
parameters	O
to	O
evaluate	O
the	O
respiratory	B-PROC
function	I-PROC
such	O
as	O
arterial	B-PROC
oxygen	I-PROC
saturation	I-PROC
,	O
could	O
prevent	O
the	O
occurrence	O
of	O
distress	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
clinical	O
,	O
pathologic	O
,	O
and	O
laboratory	O
features	O
of	O
the	O
acute	O
renal	O
impairment	O
complicating	O
this	O
new	O
viral	B-PROC
infection	I-PROC
.	O

The	O
adjusted	O
relative	O
risk	O
of	O
mortality	O
associated	O
with	O
the	O
development	B-PROC
of	O
acute	O
renal	O
impairment	O
was	O
4	O
.	O
057	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

She	O
died	B-PROC
from	O
worsening	O
acute	O
respiratory	O
distress	O
syndrome	O
on	O
the	O
25th	O
day	O
.	O

TITLE	O
:	O
Pathogenesis	B-PROC
of	O
enterotropic	O
mouse	O
hepatitis	O
virus	O
in	O
immunocompetent	O
and	O
immunodeficient	O
mice	O
.	O

Thirty	O
-	O
six	O
hours	O
after	O
the	O
large	O
dose	O
of	O
corticosteroids	O
,	O
the	O
respiratory	B-PROC
mechanics	I-PROC
and	O
oxygenation	B-PROC
were	O
acceptable	O
for	O
extubation	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
Beta	O
interferon	O
induction	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
suggests	O
a	O
two	O
-	O
step	O
model	O
for	O
activation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
.	O

None	O
of	O
our	O
patients	O
had	O
a	O
platelet	O
count	O
<	O
80	O
x	O
10	O
(	O
9	O
)/	O
l	O
and	O
WCC	O
<	O
2	O
x	O
10	O
(	O
9	O
)/	O
l	O
in	O
the	O
first	O
5	O
days	O
of	O
symptoms	O
and	O
these	O
parameters	O
may	O
allow	O
early	O
stratification	O
of	O
febrile	B-PROC
patients	O
into	O
likely	O
and	O
unlikely	O
SARS	O
cases	O
to	O
allow	O
effective	O
utilization	O
of	O
isolation	O
facilities	O
.	O

TITLE	O
:	O
Function	O
of	O
HAb18G	O
/	O
CD147	O
in	O
invasion	B-PROC
of	I-PROC
host	I-PROC
cells	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Three	O
unique	O
detection	O
formats	O
were	O
developed	O
for	O
real	O
-	O
time	O
RNA	O
amplification	O
assays	O
:	O
a	O
post	O
amplification	O
detection	O
step	O
with	O
a	O
virus	O
-	O
specific	O
internal	O
capture	O
probe	O
based	O
on	O
Taqman	O
(	O
RT	O
-	O
PCR	O
TaqMan	O
assay	O
),	O
hybridization	B-PROC
probe	O
(	O
RT	O
-	O
PCR	O
hybridization	B-PROC
probe	O
assay	O
)	O
and	O
a	O
real	O
-	O
time	O
assay	O
with	O
virus	O
-	O
specific	O
molecular	O
beacon	O
probes	O
(	O
NASBA	O
-	O
Beacon	O
assay	O
).	O

The	O
limits	O
of	O
detection	O
were	O
at	O
least	O
10	O
copies	O
of	O
input	O
RNA	O
for	O
both	O
RT	O
-	O
PCR	O
formats	O
(	O
RT	O
-	O
PCR	O
TaqMan	O
and	O
RT	O
-	O
PCR	O
hybridization	B-PROC
probe	O
assays	O
),	O
while	O
the	O
NASBA	O
-	O
Beacon	O
assay	O
could	O
detect	O
as	O
little	O
as	O
1	O
copy	O
per	O
reaction	O
,	O
with	O
high	O
reproducibility	O
of	O
the	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
of	O
<	O
10	O
.	O

Here	O
,	O
I	O
report	O
the	O
ATVRLQ	O
(	O
p1	O
)	O
A	O
(	O
p1	O
')-	O
bound	O
CCP	O
3D	O
model	O
predicted	O
by	O
420	O
different	O
molecular	B-PROC
dynamics	I-PROC
simulations	O
(	O
2	O
.	O
0	O
ns	O
for	O
each	O
simulation	O
with	O
a	O
1	O
.	O
0	O
-	O
fs	O
time	O
step	O
).	O

TITLE	O
:	O
Molecular	O
modeling	O
and	O
chemical	O
modification	O
for	O
finding	O
peptide	O
inhibitor	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
main	O
proteinase	B-PROC
.	O

ABSTRACT	O
:	O
Two	O
natural	O
products	O
databases	O
,	O
the	O
marine	O
natural	O
products	O
database	O
(	O
MNPD	O
)	O
and	O
the	O
traditional	O
Chinese	O
medicines	O
database	O
(	O
TCMD	O
),	O
were	O
used	O
to	O
find	O
novel	O
structures	O
of	O
potent	O
SARS	O
-	O
CoV	O
protease	B-PROC
inhibitors	I-PROC
through	O
virtual	O
screening	O
.	O

The	O
number	O
of	O
catastrophic	O
outcomes	O
(	O
endotracheal	O
intubation	O
and	O
/	O
or	O
death	B-PROC
)	O
adjusted	O
for	O
older	O
age	O
and	O
sex	O
showed	O
that	O
hypouremic	O
patients	O
had	O
an	O
odds	O
ratio	O
of	O
10	O
.	O
57	O
(	O
confidence	O
interval	O
,	O
2	O
.	O
33	O
to	O
47	O
.	O
98	O
;	O
P	O
=	O
0	O
.	O
002	O
).	O

A	O
total	O
of	O
10	O
nursing	B-PROC
students	O
were	O
interviewed	O
.	O

TITLE	O
:	O
Differentiation	B-PROC
of	O
mouse	O
hepatitis	O
virus	O
genotypes	O
by	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
analysis	O
.	O

This	O
study	O
shows	O
that	O
RFLP	O
analyses	O
are	O
a	O
rapid	O
and	O
useful	O
method	O
for	O
differentiation	B-PROC
of	O
MHV	O
strains	O
.	O

Thus	O
,	O
our	O
system	O
represents	O
a	O
versatile	O
and	O
universal	O
tool	O
to	O
study	O
all	O
aspects	O
of	O
MHV	O
molecular	O
biology	O
and	O
pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
(	O
WNV	O
)	O
infection	O
is	O
an	O
ongoing	O
seasonal	O
epidemic	O
.	O

TITLE	O
:	O
Computed	O
tomography	O
--	O
a	O
possible	O
aid	O
in	O
the	O
diagnosis	O
of	O
smoke	O
inhalation	B-PROC
injury	O
?	O

We	O
need	O
to	O
find	O
ways	O
to	O
integrate	O
new	O
scientific	O
knowledge	O
into	O
our	O
environment	O
in	O
order	O
to	O
expedite	O
the	O
translation	B-PROC
of	O
research	O
to	O
practice	O
.	O

The	O
time	O
course	O
of	O
a	O
typical	O
fever	B-PROC
can	O
be	O
divided	O
into	O
three	O
stages	O
.	O

The	O
changes	O
of	O
the	O
PaO	B-PROC
(	O
2	O
)	O
were	O
similar	O
to	O
the	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
).	O

The	O
scalability	O
of	O
this	O
object	O
-	O
oriented	O
software	O
engineering	O
approach	O
indicates	O
that	O
we	O
can	O
apply	O
this	O
technology	O
for	O
the	O
integration	B-PROC
of	O
large	O
complex	O
biological	O
systems	O
.	O

Recently	O
,	O
we	O
showed	O
how	O
to	O
do	O
this	O
for	O
the	O
point	O
substitution	O
component	O
of	O
the	O
evolutionary	O
process	O
;	O
here	O
,	O
we	O
extend	O
these	O
results	O
to	O
the	O
indel	B-PROC
process	O
.	O

Software	O
implementing	O
the	O
algorithm	O
and	O
the	O
benchmark	O
is	O
available	O
under	O
GPL	O
from	O
http	O
://	O
www	O
.	O
biowiki	O
.	O
org	O
/	O
RESULTS	O
:	O
We	O
present	O
an	O
algorithm	O
for	O
maximum	O
-	O
likelihood	O
estimation	O
of	O
insertion	O
and	O
deletion	O
rates	O
from	O
multiple	O
sequence	O
alignments	O
,	O
using	O
EM	O
,	O
under	O
the	O
single	O
-	O
residue	O
indel	B-PROC
model	O
owing	O
to	O
Thorne	O
,	O
Kishino	O
and	O
Felsenstein	O
(	O
the	O
'	O
TKF91	O
'	O
model	O
).	O

Here	O
,	O
we	O
expressed	B-PROC
five	O
different	O
fragments	O
of	O
S	O
,	O
covering	O
the	O
entire	O
ectodomain	O
(	O
amino	O
acids	O
48	O
to	O
1192	O
),	O
as	O
glutathione	O
S	O
-	O
transferase	O
fusion	O
proteins	O
in	O
Escherichia	O
coli	O
and	O
used	O
the	O
purified	O
proteins	O
to	O
raise	O
antibodies	O
in	O
rabbits	O
.	O

These	O
S2	O
-	O
targeting	B-PROC
antibodies	O
were	O
shown	O
to	O
effectively	O
neutralize	O
the	O
coronavirus	O
,	O
indicating	O
that	O
they	O
provided	O
protective	O
immunity	B-PROC
to	O
help	O
the	O
patients	O
recover	B-PROC
from	O
the	O
viral	B-PROC
infection	I-PROC
.	O

None	O
of	O
the	O
children	O
died	B-PROC
of	O
transplantation	O
-	O
associated	O
complication	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
quantitative	O
assay	O
for	O
SARS	O
coronavirus	O
and	O
correlation	O
of	O
GAPDH	O
mRNA	O
with	O
SARS	O
coronavirus	O
in	O
clinical	O
specimens	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
quantitative	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
Q	O
-	O
RT	O
-	O
PCR	O
)	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
detection	O
and	O
explore	O
the	O
potential	O
of	O
using	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
mRNA	O
as	O
an	O
internal	O
control	O
to	O
exclude	O
false	O
negative	O
results	O
.	O

Considerable	O
genetic	O
and	O
antigenic	B-PROC
diversity	I-PROC
was	O
observed	O
for	O
human	O
metapneumovirus	O
,	O
but	O
the	O
implication	O
of	O
this	O
diversity	O
for	O
vaccine	O
development	B-PROC
and	O
virus	O
epidemiology	O
requires	O
further	O
study	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
early	O
diagnostic	O
reagents	O
,	O
effective	O
vaccines	O
,	O
and	O
even	O
drugs	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
human	O
single	O
fold	O
single	O
-	O
chain	O
antibody	B-PROC
fragments	O
,	O
(	O
scFv	O
)	O
libraries	O
I	O
+	O
J	O
(	O
Tomlinson	O
I	O
+	O
J	O
)	O
were	O
used	O
to	O
identify	O
novel	O
scFvs	O
,	O
which	O
can	O
specifically	O
bind	O
to	O
SARS	O
-	O
CoV	O
.	O
Interestingly	O
,	O
two	O
scFvs	O
(	O
B5	O
and	O
B9	O
)	O
exhibited	O
higher	O
binding	O
specificity	O
to	O
SARS	O
-	O
CoV	O
with	O
the	O
OD	O
(	O
450	O
)	O
value	O
0	O
.	O
608	O
and	O
0	O
.	O
545	O
,	O
respectively	O
,	O
and	O
their	O
coding	O
sequences	O
shared	O
the	O
identical	O
sequence	O
composed	O
of	O
V	O
(	O
H	O
)	O
gene	O
(	O
351bp	O
)	O
and	O
V	O
(	O
L	O
)	O
gene	O
(	O
327bp	O
),	O
so	O
the	O
two	O
scFvs	O
were	O
uniformly	O
named	O
as	O
SA59B	O
and	O
chosen	O
for	O
further	O
analysis	O
.	O

ABSTRACT	O
:	O
The	O
present	O
authors	O
hypothesised	O
that	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
pronation	B-PROC
may	O
reduce	O
ventilator	O
-	O
induced	O
overall	O
stress	O
(	O
i	O
.	O
e	O
.	O
transpulmonary	O
pressure	O
(	O
P	O
(	O
L	O
)))	O
and	O
strain	O
of	O
lung	O
parenchyma	O
(	O
i	O
.	O
e	O
.	O
tidal	O
volume	O
(	O
V	O
(	O
T	O
))/	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
lung	B-PROC
volume	I-PROC
(	O
EELV	O
)	O
ratio	O
),	O
which	O
constitute	O
major	O
ventilator	O
-	O
induced	O
lung	O
injury	O
determinants	O
.	O

All	O
patients	O
presented	O
with	O
fever	B-PROC
,	O
but	O
only	O
eight	O
had	O
accompanying	O
respiratory	O
symptoms	O
.	O

Early	O
isolation	O
of	O
febrile	B-PROC
patients	O
with	O
a	O
positive	O
contact	O
history	O
must	O
be	O
undertaken	O
,	O
even	O
in	O
the	O
face	O
of	O
another	O
identifiable	O
cause	O
.	O

Recombinant	O
soluble	O
protein	O
X4	O
was	O
purified	O
from	O
E	O
.	O
coli	O
using	O
ion	B-PROC
exchange	I-PROC
chromatography	O
,	O
and	O
the	O
preparation	O
was	O
injected	O
into	O
chicken	O
for	O
rising	O
specific	O
polyclonal	O
antibodies	O
.	O

Western	O
blot	O
was	O
employed	O
to	O
evaluate	O
the	O
expression	B-PROC
of	O
protein	O
X4	O
in	O
SARS	O
-	O
CoV	O
particles	O
.	O

We	O
expressed	B-PROC
and	O
purified	O
soluble	O
recombinant	O
protein	O
X4	O
from	O
E	O
.	O
coli	O
,	O
and	O
generated	O
specific	O
antibodies	O
against	O
protein	O
X4	O
.	O

Indirect	O
immunofluorescence	O
assays	O
revealed	O
that	O
the	O
expression	B-PROC
of	O
protein	O
X4	O
was	O
detected	O
at	O
8	O
hours	O
after	O
infection	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Because	O
of	O
its	O
public	O
health	O
impact	O
,	O
major	O
efforts	O
are	O
focused	O
on	O
development	B-PROC
of	O
SARS	O
vaccines	O
.	O

Occurrence	O
of	O
CoV	O
disease	O
at	O
mucosal	O
surfaces	O
necessitates	O
the	O
stimulation	O
of	O
local	O
immunity	B-PROC
,	O
having	O
an	O
impact	O
on	O
the	O
vaccine	O
type	O
,	O
delivery	O
and	O
adjuvant	O
needed	O
to	O
achieve	O
mucosal	B-PROC
immunity	I-PROC
.	O

We	O
further	O
demonstrated	O
that	O
2C5	O
,	O
but	O
not	O
1A5	O
,	O
was	O
able	O
to	O
block	O
binding	O
of	O
the	O
RBD	O
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
on	O
targeted	B-PROC
cells	O
.	O

However	O
,	O
viruses	O
with	O
Y162F	O
substitutions	O
had	O
wild	O
type	O
growth	B-PROC
,	O
suggesting	O
that	O
Y162	O
may	O
comprise	O
part	O
of	O
a	O
hydrophobic	O
domain	O
that	O
contacts	O
the	O
MHV	O
-	O
binding	O
site	O
of	O
mCEACAM1a	O
.	O

TITLE	O
:	O
Epitope	O
mapping	O
and	O
biological	B-PROC
function	I-PROC
analysis	O
of	O
antibodies	O
produced	O
by	O
immunization	O
of	O
mice	O
with	O
an	O
inactivated	O
Chinese	O
isolate	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
)	O
has	O
been	O
proposed	O
to	O
be	O
a	O
key	O
target	O
for	O
structural	O
based	O
drug	O
design	O
against	O
SARS	O
.	O

These	O
results	O
offer	O
helpful	O
information	O
for	O
the	O
research	O
on	O
the	O
mechanism	O
of	O
substrate	O
recognition	O
of	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-PROC
.	O

ABSTRACT	O
:	O
Granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
),	O
a	O
hematopoietic	O
growth	B-PROC
factor	O
,	O
is	O
widely	O
used	O
to	O
accelerate	O
recovery	O
from	O
neutropenia	O
after	O
severe	O
chemotherapy	O
,	O
both	O
decreasing	O
the	O
risk	O
of	O
infection	O
and	O
mobilizing	O
peripheral	O
blood	O
stem	O
cells	O
.	O

ABSTRACT	O
:	O
Antibody	B-PROC
detection	O
with	O
a	O
recombinant	O
COOH	O
portion	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
N13	O
(	O
amino	O
acids	O
221	O
to	O
422	O
),	O
was	O
demonstrated	O
to	O
be	O
more	O
specific	O
and	O
sensitive	O
than	O
that	O
with	O
the	O
full	O
-	O
length	O
N	O
protein	O
,	O
and	O
an	O
N13	O
-	O
based	O
antigen	O
-	O
capturing	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
providing	O
a	O
convenient	O
and	O
specific	O
test	O
for	O
serodiagnosis	O
and	O
epidemiological	O
study	O
of	O
SARS	O
was	O
developed	O
.	O

RESULTS	O
:	O
We	O
have	O
now	O
used	O
HFOV	O
in	O
36	O
severely	O
burned	O
patients	O
,	O
33	O
%	O
of	O
whom	O
had	O
an	O
associated	O
smoke	O
inhalation	B-PROC
injury	O
.	O

The	O
combination	O
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
and	O
recruitment	O
maneuvers	O
resulted	O
in	O
rapid	O
and	O
sustained	O
improvement	O
in	O
oxygenation	B-PROC
,	O
likely	O
through	O
lung	O
recruitment	O
.	O

In	O
a	O
standardised	O
sheep	O
model	O
,	O
this	O
study	O
aimed	O
to	O
quantify	O
the	O
development	B-PROC
of	O
acute	O
pulmonary	O
endothelial	O
changes	O
,	O
to	O
assess	O
the	O
activation	O
of	O
polymorphonuclear	O
leucocytes	O
(	O
PMNL	O
)	O
and	O
to	O
observe	O
the	O
effects	O
on	O
the	O
coagulation	B-PROC
system	O
associated	O
with	O
the	O
reamed	O
nailing	O
procedure	O
.	O

ABSTRACT	O
:	O
We	O
have	O
investigated	O
to	O
develop	O
novel	O
vaccines	O
against	O
SARS	O
CoV	O
using	O
cDNA	O
constructs	O
encoding	O
the	O
structural	O
antigen	O
;	O
spike	O
protein	O
(	O
S	O
),	O
membrane	O
protein	O
(	O
M	O
),	O
envelope	O
protein	O
(	O
E	O
),	O
or	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
derived	O
from	O
SARS	O
CoV	O
.	O
Mice	O
vaccinated	O
with	O
SARS	O
-	O
N	O
or	O
-	O
M	O
DNA	O
using	O
pcDNA	O
3	O
.	O
1	O
(+)	O
plasmid	O
vector	O
showed	O
T	O
cell	O
immune	B-PROC
responses	I-PROC
(	O
CTL	O
induction	O
and	O
proliferation	O
)	O
against	O
N	O
or	O
M	O
protein	O
,	O
respectively	O
.	O

CTL	O
responses	O
were	O
also	O
detected	O
to	O
SARS	O
DNA	O
-	O
transfected	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
(	O
T7	O
cell	O
clone	O
),	O
which	O
are	O
thought	O
to	O
be	O
initial	O
target	O
cells	O
for	O
SARS	O
virus	B-PROC
infection	I-PROC
in	O
human	O
.	O

To	O
determine	O
whether	O
these	O
DNA	O
vaccines	O
could	O
induce	O
T	O
cell	O
immune	B-PROC
responses	I-PROC
in	O
humans	O
as	O
well	O
as	O
in	O
mice	O
,	O
SCID	O
-	O
PBL	O
/	O
hu	O
mice	O
was	O
immunized	O
with	O
these	O
DNA	O
vaccines	O
.	O

These	O
two	O
N	O
proteins	O
degrade	O
rapidly	O
upon	O
storage	B-PROC
and	O
the	O
major	O
degraded	O
N	O
protein	O
is	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
amino	O
acid	O
(	O
aa	O
)	O
169	O
-	O
422	O
.	O

Further	O
refinement	O
of	O
these	O
antibodies	O
,	O
particularly	O
large	O
-	O
scale	O
production	O
of	O
monoclonal	O
antibodies	O
,	O
could	O
lead	O
to	O
the	O
development	B-PROC
of	O
useful	O
diagnostic	O
kits	O
for	O
diseases	O
associated	O
with	O
SARS	O
and	O
other	O
human	O
coronaviruses	O
.	O

TITLE	O
:	O
Subcellular	O
localization	B-PROC
and	O
membrane	O
association	O
of	O
SARS	O
-	O
CoV	O
3a	O
protein	O
.	O

With	O
the	O
assay	O
of	O
truncated	O
3a	O
protein	O
,	O
it	O
was	O
shown	O
that	O
3a	O
might	O
contain	O
three	O
transmembrane	O
regions	O
,	O
and	O
the	O
second	O
or	O
third	O
region	O
was	O
properly	O
responsible	O
for	O
Golgi	B-PROC
localization	I-PROC
.	O

Morphological	O
findings	O
showed	O
that	O
the	O
oleic	O
acid	O
group	O
demonstrated	O
a	O
marked	O
lung	O
injury	O
represented	O
by	O
prominent	O
atelectasis	O
,	O
intraalveolar	O
and	O
interstitial	O
patchy	O
hemorrhage	O
,	O
edema	O
,	O
thickened	O
alveolar	O
septum	O
,	O
formation	B-PROC
of	O
hyaline	O
membranes	O
and	O
the	O
existence	O
of	O
inflammatory	O
cells	O
in	O
alveolar	O
spaces	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
use	O
of	O
the	O
H	O
strain	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
from	O
the	O
Netherlands	O
as	O
a	O
vaccine	O
:	O
a	O
review	O
.	O

TITLE	O
:	O
Aerosol	O
-	O
induced	O
Mycoplasma	O
synoviae	O
arthritis	O
:	O
the	O
synergistic	O
effect	O
of	O
infectious	O
bronchitis	O
virus	B-PROC
infection	I-PROC
.	O

The	O
mortality	O
that	O
occurred	O
using	O
this	O
less	O
-	O
attenuated	O
vaccine	O
was	O
significantly	O
influenced	O
by	O
the	O
genetic	O
line	O
,	O
and	O
the	O
MHC	B-PROC
(	O
B	O
)	O
haplotype	O
in	O
chickens	O
of	O
three	O
B	O
congenic	O
lines	O
.	O

TITLE	O
:	O
Polymorphisms	B-PROC
of	O
interferon	O
-	O
inducible	O
genes	O
OAS	O
-	O
1	O
and	O
MxA	O
associated	O
with	O
SARS	O
in	O
the	O
Vietnamese	O
population	O
.	O

In	O
addition	O
,	O
global	O
research	O
efforts	O
have	O
focused	O
on	O
the	O
development	B-PROC
of	O
vaccines	O
against	O
SARS	O
.	O

In	O
addition	O
,	O
mRNA	B-PROC
expression	B-PROC
of	O
nonclassical	O
class	O
I	O
molecules	O
H2	O
-	O
T10	O
,	O
-	O
T17	O
,	O
-	O
M2	O
,	O
and	O
-	O
Q10	O
,	O
were	O
enhanced	O
three	O
-	O
to	O
fivefold	O
in	O
virus	O
-	O
infected	O
cells	O
compared	O
to	O
sham	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Critical	O
deep	O
venous	O
thrombosis	O
and	O
occlusion	B-PROC
constitutes	O
a	O
small	O
percentage	O
of	O
patients	O
with	O
venous	O
disease	O
,	O
who	O
exhibit	O
severe	O
symptomatology	O
.	O

Our	O
data	O
indicated	O
that	O
the	O
siRNA	O
targeting	B-PROC
the	O
Leader	O
sequence	O
inhibited	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
in	O
Vero	O
E6	O
cells	O
by	O
silencing	O
gene	B-PROC
expression	I-PROC
.	O

dsRNA	O
-	O
mediated	O
RNAi	B-PROC
can	O
be	O
used	O
in	O
a	O
wide	O
variety	O
of	O
eucaryotes	O
to	O
induce	O
the	O
sequence	O
-	O
specific	O
inhibition	B-PROC
of	O
gene	B-PROC
expression	I-PROC
.	O

Here	O
,	O
we	O
studied	O
the	O
effects	O
of	O
synthetic	O
siRNA	O
duplexes	O
targeted	B-PROC
to	O
SARS	O
coronavirus	O
structural	O
proteins	O
E	O
,	O
M	O
,	O
and	O
N	O
in	O
a	O
cell	O
culture	O
system	O
.	O

TITLE	O
:	O
Design	O
of	O
recombinant	O
protein	O
-	O
based	O
SARS	O
-	O
CoV	O
entry	O
inhibitors	O
targeting	B-PROC
the	O
heptad	O
-	O
repeat	O
regions	O
of	O
the	O
spike	O
protein	O
S2	O
domain	O
.	O

ABSTRACT	O
:	O
Entry	O
of	O
SARS	O
-	O
CoV	O
into	O
a	O
target	O
cell	O
is	O
initiated	O
by	O
binding	O
of	O
the	O
S1	O
domain	O
of	O
spike	O
protein	O
to	O
a	O
receptor	O
,	O
followed	O
by	O
conformational	O
changes	O
of	O
the	O
spike	O
protein	O
S2	O
domain	O
,	O
resulting	O
in	O
the	O
formation	B-PROC
of	O
a	O
six	O
-	O
helix	O
bundle	O
by	O
the	O
heptad	O
-	O
repeat	O
(	O
HR1	O
and	O
HR2	O
)	O
regions	O
.	O

SARS	O
-	O
CoV	O
seemed	O
to	O
elicit	O
effective	O
humoral	B-PROC
immunity	I-PROC
but	O
inhibited	O
cellular	B-PROC
immunity	I-PROC
,	O
especially	O
CD8	O
+	O
memory	B-PROC
T	O
lymphocytes	O
over	O
time	O
.	O

The	O
tagged	O
C145A	O
mutant	O
protein	O
served	O
as	O
a	O
substrate	O
for	O
the	O
wild	O
-	O
type	O
protease	O
,	O
and	O
the	O
N	O
terminus	O
was	O
first	O
digested	B-PROC
(	O
55	O
-	O
fold	O
faster	O
)	O
at	O
the	O
Gln	O
(-	O
1	O
)-	O
Ser1	O
site	O
followed	O
by	O
the	O
C	O
-	O
terminal	O
cleavage	B-PROC
at	O
the	O
Gln306	O
-	O
Gly307	O
site	O
.	O

Collectively	O
,	O
these	O
data	O
describe	O
molecular	O
interactions	O
important	O
to	O
the	O
adaptation	B-PROC
of	O
SARS	O
-	O
CoV	O
to	O
human	O
cells	O
,	O
and	O
provide	O
insight	O
into	O
the	O
severity	O
of	O
the	O
2002	O
-	O
2003	O
SARS	O
epidemic	O
.	O

TITLE	O
:	O
Immunohistochemical	O
,	O
in	O
situ	O
hybridization	B-PROC
,	O
and	O
ultrastructural	O
localization	B-PROC
of	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
lung	O
of	O
a	O
fatal	O
case	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
Taiwan	O
.	O

Immunohistochemical	O
and	O
in	O
situ	O
hybridization	B-PROC
assays	O
demonstrated	O
evidence	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
in	O
various	O
respiratory	O
epithelial	O
cells	O
,	O
predominantly	O
type	O
II	O
pneumocytes	O
,	O
and	O
in	O
alveolar	O
macrophages	O
in	O
the	O
lung	O
.	O

Therefore	O
,	O
analysis	O
of	O
host	O
CD8	O
+	O
T	O
-	O
cell	O
responses	O
to	O
unrelated	O
infections	O
demonstrates	O
that	O
bystander	O
memory	B-PROC
CD8	O
+	O
T	O
cells	O
can	O
comprise	O
a	O
significant	O
proportion	O
of	O
CNS	O
inflammatory	O
cells	O
during	O
virus	O
-	O
induced	O
encephalitis	O
.	O

However	O
,	O
transient	O
CNS	O
retention	B-PROC
and	O
the	O
absence	O
of	O
activation	O
suggest	O
that	O
memory	B-PROC
bystander	O
CD8	O
+	O
T	O
cells	O
may	O
not	O
overtly	O
contribute	O
to	O
pathology	O
in	O
the	O
absence	O
of	O
antigen	O
recognition	O
.	O

Bananin	O
,	O
iodobananin	O
,	O
vanillinbananin	O
,	O
and	O
eubananin	O
were	O
effective	O
inhibitors	O
of	O
the	O
ATPase	O
activity	O
of	O
the	O
SCV	O
helicase	O
with	O
IC50	O
values	O
in	O
the	O
range	O
0	O
.	O
5	O
-	O
3	O
microM	O
.	O
A	O
similar	O
trend	O
,	O
though	O
at	O
slightly	O
higher	O
inhibitor	O
concentrations	O
,	O
was	O
observed	O
for	O
inhibition	B-PROC
of	O
the	O
helicase	O
activities	O
,	O
using	O
a	O
FRET	O
-	O
based	O
fluorescent	O
assay	O
.	O

ABSTRACT	O
:	O
A	O
hybridisation	B-PROC
-	O
based	O
genosensor	O
was	O
designed	O
on	O
a	O
100	O
nm	O
sputtered	O
gold	O
film	O
.	O

TITLE	O
:	O
Mining	O
SARS	O
-	O
CoV	O
protease	O
cleavage	B-PROC
data	O
using	O
non	O
-	O
orthogonal	O
decision	O
trees	O
:	O
a	O
novel	O
method	O
for	O
decisive	O
template	O
selection	O
.	O

Among	O
these	O
sequences	O
,	O
252	O
cleavage	B-PROC
sites	O
were	O
experimentally	O
determined	O
.	O

Baseline	O
results	O
show	O
167	O
(	O
1	O
.	O
4	O
/	O
1000	O
staff	O
-	O
days	O
)	O
observed	O
in	O
staff	O
sick	O
leave	O
for	O
febrile	B-PROC
illnesses	O
,	O
and	O
1798	O
(	O
71	O
.	O
3	O
/	O
1000	O
bed	O
-	O
days	O
)	O
observed	O
for	O
inpatient	O
fever	B-PROC
.	O

An	O
average	O
of	O
4	O
.	O
6	O
wards	O
a	O
day	O
potentially	O
fulfilled	O
the	O
World	O
Health	O
Organisation	B-PROC
SARS	O
alert	O
criteria	O
.	O

Of	O
27	O
cases	O
with	O
fever	B-PROC
,	O
pneumonia	O
and	O
a	O
total	O
white	O
count	O
of	O
less	O
than	O
10	O
,	O
000	O
cells	O
per	O
cubic	O
mm	O
as	O
per	O
Ministry	O
of	O
Health	O
,	O
Singapore	O
criteria	O
for	O
the	O
diagnosis	O
of	O
atypical	O
pneumonia	O
,	O
only	O
five	O
were	O
identified	O
by	O
clinicians	O
.	O

Of	O
27	O
cases	O
with	O
fever	B-PROC
,	O
pneumonia	O
and	O
a	O
total	O
white	O
count	O
of	O
less	O
than	O
10	O
,	O
000	O
cells	O
per	O
cubic	O
mm	O
as	O
per	O
Ministry	O
of	O
Health	O
,	O
Singapore	O
criteria	O
for	O
the	O
diagnosis	O
of	O
atypical	O
pneumonia	O
,	O
only	O
five	O
were	O
identified	O
by	O
clinicians	O
.	O

RESULTS	O
:	O
Compared	O
to	O
the	O
pre	O
-	O
SARS	O
period	O
,	O
medical	O
centers	O
and	O
regional	O
hospitals	O
dropped	O
5	O
.	O
2	O
%	O
and	O
4	O
.	O
1	O
%	O
in	O
market	O
share	O
for	O
childbirth	B-PROC
services	O
during	O
the	O
peak	O
SARS	O
period	O
,	O
while	O
district	O
hospitals	O
and	O
clinics	O
increased	O
2	O
.	O
1	O
%	O
and	O
7	O
.	O
1	O
%,	O
respectively	O
.	O

Control	O
of	O
infectious	O
diseases	O
is	O
being	O
challenged	O
by	O
many	O
factors	O
,	O
like	O
standards	O
of	O
living	O
,	O
human	O
behaviour	B-PROC
,	O
mass	O
population	O
movements	B-PROC
,	O
emergence	O
of	O
infectious	O
like	O
HIV	O
/	O
AIDS	O
and	O
SARS	O
,	O
the	O
re	O
-	O
emergence	O
of	O
infections	O
such	O
as	O
tuberculosis	O
,	O
development	B-PROC
of	O
resistance	B-PROC
in	O
bacteria	O
,	O
viruses	O
and	O
parasites	O
,	O
modern	O
rate	O
of	O
global	O
travel	O
,	O
etc	O
.	O

In	O
65	O
.	O
1	O
%	O
of	O
symptomatic	O
cases	O
birth	B-PROC
occurred	O
prematurely	O
.	O

TITLE	O
:	O
Hepatic	O
failure	O
in	O
a	O
child	O
with	O
anti	O
-	O
epileptic	O
hypersensitivity	B-PROC
syndrome	O
.	O

ABSTRACT	O
:	O
A	O
Saccharomyces	O
cerevisiae	O
-	O
expressed	B-PROC
nucleocapsid	O
(	O
N	O
)	O
polypeptide	O
of	O
the	O
M41	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
was	O
used	O
as	O
antigen	O
in	O
a	O
recombinant	O
yeast	O
-	O
expressed	B-PROC
N	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
Y	O
-	O
N	O
-	O
ELISA	O
).	O

During	O
recent	O
years	O
,	O
most	O
of	O
these	O
programmes	O
have	O
been	O
developed	O
in	O
the	O
field	O
of	O
antimicrobial	O
resistance	B-PROC
and	O
nosocomial	O
infections	O
,	O
but	O
efforts	O
have	O
also	O
been	O
made	O
in	O
other	O
areas	O
.	O

TITLE	O
:	O
Species	O
-	O
independent	O
detection	O
of	O
RNA	O
virus	O
by	O
representational	O
difference	O
analysis	O
using	O
non	O
-	O
ribosomal	O
hexanucleotides	O
for	O
reverse	B-PROC
transcription	B-PROC
.	O

Occasional	O
intra	O
-	O
alveolar	O
macrophages	O
were	O
also	O
weakly	O
reactive	O
to	O
SARS	O
-	O
CoV	O
antibody	B-PROC
.	O

Moreover	O
,	O
there	O
is	O
also	O
no	O
evidence	O
that	O
ACE	O
I	O
/	O
D	O
polymorphism	B-PROC
is	O
associated	O
with	O
the	O
progression	O
to	O
ARDS	O
or	O
the	O
requirement	O
of	O
intensive	O
care	O
in	O
the	O
SARS	O
patients	O
.	O

The	O
ACE	O
I	O
/	O
D	O
polymorphism	B-PROC
is	O
not	O
directly	O
related	O
to	O
increased	O
susceptibility	O
to	O
SARS	O
-	O
coronavirus	O
infection	O
and	O
is	O
not	O
associated	O
with	O
poor	O
outcomes	O
after	O
SARS	O
-	O
coronavirus	O
infection	O
.	O

CONCLUSIONS	O
:	O
The	O
ACE	O
I	O
/	O
D	O
polymorphism	B-PROC
is	O
not	O
directly	O
related	O
to	O
increased	O
susceptibility	O
to	O
SARS	O
-	O
coronavirus	O
infection	O
and	O
is	O
not	O
associated	O
with	O
poor	O
outcomes	O
after	O
SARS	O
-	O
coronavirus	O
infection	O
.	O

Both	O
patients	O
died	B-PROC
later	O
on	O
in	O
spite	O
of	O
all	O
efforts	O
.	O

This	O
overview	O
highlights	O
selected	O
NIAID	O
-	O
sponsored	O
research	O
advances	O
over	O
the	O
past	O
decade	O
,	O
with	O
a	O
focus	O
on	O
progress	O
in	O
combating	O
HIV	O
/	O
AIDS	O
,	O
malaria	O
,	O
tuberculosis	O
,	O
influenza	O
,	O
SARS	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
and	O
potential	O
bioterror	O
agents	O
.	O

A	O
recombinant	O
named	O
pPROEX	O
HTc	O
-	O
hp	O
was	O
constructed	O
via	O
inserting	O
ORF7	O
gene	O
into	O
prokaryotic	O
expression	B-PROC
vector	O
pPROEX	O
HTc	O
.	O

In	O
this	O
study	O
,	O
the	O
subcellular	O
distribution	O
and	O
maturation	B-PROC
of	O
SARS	O
-	O
CoV	O
surface	O
proteins	O
S	O
,	O
M	O
and	O
E	O
were	O
analysed	O
by	O
using	O
C	O
-	O
terminally	O
tagged	O
proteins	O
.	O

The	O
ability	O
of	O
the	O
RV	O
-	O
SARS	O
-	O
CoV	O
S	O
vector	O
to	O
confer	O
immunity	B-PROC
after	O
a	O
single	O
inoculation	O
makes	O
this	O
live	O
vaccine	O
a	O
promising	O
candidate	O
for	O
eradication	O
of	O
SARS	O
-	O
CoV	O
in	O
animal	O
reservoirs	O
,	O
thereby	O
reducing	O
the	O
risk	O
of	O
transmitting	O
the	O
infection	O
to	O
humans	O
.	O

The	O
enhanced	O
cleavability	O
of	O
F1	O
-	O
R	O
F	O
was	O
previously	O
attributed	O
to	O
an	O
amino	O
acid	O
change	O
at	O
F115	O
that	O
is	O
adjacent	O
to	O
the	O
cleavage	B-PROC
site	O
at	O
amino	O
acid	O
116	O
.	O

To	O
clarify	O
which	O
mutation	O
(	O
s	O
)	O
are	O
necessary	O
for	O
plaque	O
formation	B-PROC
,	O
plaque	O
assays	O
were	O
done	O
using	O
other	O
recombinant	O
viruses	O
.	O

We	O
report	O
here	O
the	O
cloning	O
,	O
expression	B-PROC
,	O
and	O
purification	O
of	O
the	O
N	O
-	O
terminal	O
GST	O
-	O
fused	O
SARS	O
-	O
CoV	O
RdRp	O
and	O
its	O
polymerase	O
catalytic	O
domain	O
in	O
Escherichia	O
coli	O
.	O

hAPN	O
-	O
transgenic	O
mice	O
expressed	B-PROC
hAPN	O
mRNA	O
in	O
the	O
kidney	O
,	O
small	O
intestine	O
,	O
liver	O
,	O
and	O
lung	O
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
probable	O
patients	O
'	O
virus	O
RNA	O
in	O
Hangzhou	O
by	O
using	O
a	O
two	O
loci	O
and	O
a	O
modified	O
nested	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
].	O

RESULTS	O
:	O
Two	O
positives	O
were	O
found	O
in	O
the	O
3	O
SARS	O
probable	O
patients	O
,	O
and	O
none	O
positive	O
in	O
4	O
SARS	O
suspect	O
patients	O
and	O
other	O
27	O
patients	O
with	O
fever	B-PROC
,	O
using	O
the	O
nested	O
RT	O
-	O
PCR	O
.	O

All	O
of	O
17	O
patients	O
with	O
injury	O
of	O
retroperitoneal	O
rectum	O
underwent	O
diverting	O
colostomy	O
of	O
the	O
proximal	O
end	O
of	O
sigmoid	O
with	O
presacral	O
drainage	O
,	O
but	O
4	O
received	O
primary	O
repair	B-PROC
without	O
colostomy	O
.	O

In	O
22	O
patients	O
with	O
intraperitoneal	O
colorectal	O
injury	O
,	O
19	O
were	O
managed	O
with	O
primary	O
repair	B-PROC
or	O
anastomosis	O
while	O
3	O
received	O
a	O
colostomy	O
.	O

Development	B-PROC
of	O
an	O
effective	O
strategy	O
to	O
prepare	O
for	O
future	O
outbreaks	O
will	O
require	O
the	O
implementation	O
of	O
an	O
active	O
coordinated	O
clinical	O
reporting	O
system	O
,	O
international	O
collaboration	O
to	O
identify	O
cases	O
in	O
the	O
early	O
stage	O
,	O
development	B-PROC
of	O
laboratory	O
tools	O
for	O
early	O
diagnosis	O
,	O
a	O
robust	O
system	O
of	O
prepared	O
isolation	O
,	O
and	O
adequate	O
quarantine	O
facilities	O
.	O

Real	O
-	O
time	O
qRT	O
-	O
PCR	O
was	O
used	O
to	O
confirm	O
the	O
regulated	O
expression	B-PROC
of	O
genes	O
related	O
to	O
several	O
functional	O
classes	O
including	O
kinases	O
,	O
interferon	O
induced	O
genes	O
,	O
chemokines	O
and	O
adhesion	O
molecules	O
,	O
vesicular	O
trafficking	B-PROC
and	O
fusion	O
protein	O
genes	O
,	O
extracellular	O
matrix	O
protein	O
genes	O
,	O
cell	B-PROC
cycle	I-PROC
,	O
metabolism	B-PROC
,	O
cell	B-PROC
physiology	I-PROC
and	O
development	B-PROC
,	O
translation	B-PROC
,	O
RNA	O
binding	O
,	O
lysosomal	O
,	O
protein	B-PROC
degradation	I-PROC
and	O
ubiquitination	B-PROC
related	O
genes	O
.	O

IBV	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
at	O
all	O
sampling	O
times	O
,	O
except	O
for	O
1	O
and	O
6	O
h	O
of	O
storage	B-PROC
in	O
kidney	O
and	O
9	O
h	O
of	O
storage	B-PROC
in	O
kidney	O
and	O
rectum	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
protein	O
is	O
posttranslationally	O
modified	O
by	O
covalent	B-PROC
attachment	O
to	O
the	O
small	O
ubiquitin	B-PROC
-	O
like	O
modifier	O
.	O

This	O
is	O
the	O
first	O
report	O
showing	O
that	O
a	O
coronavirus	O
N	O
protein	O
undergoes	O
posttranslational	B-PROC
modification	I-PROC
by	O
sumoylation	B-PROC
,	O
and	O
the	O
functional	O
implication	O
of	O
this	O
modification	O
in	O
the	O
formation	B-PROC
of	O
coronavirus	O
ribouncleoprotein	O
complex	O
,	O
virion	B-PROC
assembly	I-PROC
and	O
virus	O
-	O
host	O
interactions	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
influence	O
of	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
on	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-PROC
expression	B-PROC
was	O
detected	O
in	O
cultured	O
cells	O
and	O
mouse	O
muscles	O
.	O

Four	O
siRNA	O
expression	B-PROC
cassettes	O
driven	O
by	O
mouse	O
U6	O
promoter	O
targeting	B-PROC
SARS	O
-	O
CoV	O
N	O
gene	O
were	O
prepared	O
,	O
and	O
their	O
inhibitory	O
effects	O
on	O
expression	B-PROC
of	O
N	O
and	O
enhanced	O
green	O
fluorescence	O
protein	O
(	O
EGFP	O
)	O
fusion	O
protein	O
were	O
observed	O
.	O

When	O
in	O
excess	O
,	O
the	O
truncated	O
construct	O
285	O
-	O
422	O
inhibits	O
the	O
homodimerization	B-PROC
of	O
full	O
-	O
length	O
N	O
protein	O
by	O
forming	O
a	O
heterodimer	O
with	O
the	O
full	O
-	O
length	O
N	O
protein	O
.	O

Of	O
the	O
four	O
patients	O
who	O
had	O
respiratory	O
failure	O
accompanied	O
by	O
hepatic	O
failure	O
,	O
one	O
patient	O
died	B-PROC
due	O
to	O
associated	O
septicemia	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	O
coronavirus	O
(	O
SARS_CoV	O
)	O
is	O
a	O
major	O
structural	O
component	O
of	O
virions	O
,	O
which	O
appears	O
to	O
be	O
a	O
multifunctional	O
protein	O
involved	O
in	O
viral	O
RNA	B-PROC
replication	I-PROC
and	O
translation	B-PROC
.	O

It	O
is	O
suggested	O
that	O
both	O
SARS_N	O
and	O
hnRNP	O
A1	O
proteins	O
are	O
possibly	O
within	O
the	O
SARS_CoV	O
replication	O
/	O
transcription	B-PROC
complex	O
and	O
SARS_N	O
/	O
human	O
hnRNP	O
A1	O
interaction	O
might	O
function	O
in	O
the	O
regulation	B-PROC
of	O
SARS_CoV	O
RNA	B-PROC
synthesis	I-PROC
.	O

Development	B-PROC
of	O
rapid	O
and	O
reliable	O
diagnostic	O
tools	O
is	O
urgently	O
needed	O
.	O

IL	O
-	O
12p70	O
,	O
IL	O
-	O
4	O
and	O
tumour	O
necrosis	B-PROC
factor	O
-	O
alpha	O
concentrations	O
were	O
consistently	O
highest	O
within	O
5	O
days	O
of	O
peak	O
viral	O
load	O
.	O

In	O
this	O
study	O
,	O
the	O
nsp13	O
gene	O
was	O
cloned	O
from	O
the	O
SARS	O
-	O
CoV	O
PUMC02	O
strain	O
viral	O
RNA	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
inserted	O
into	O
the	O
expression	B-PROC
plasmid	O
pET30a	O
(+).	O

In	O
this	O
study	O
,	O
a	O
dynamic	O
model	O
has	O
been	O
built	O
to	O
quantitatively	O
investigate	O
the	O
effect	O
of	O
the	O
relative	O
humidity	O
on	O
the	O
transport	B-PROC
of	O
liquid	O
-	O
droplets	O
in	O
air	O
using	O
coupled	O
mass	O
transfer	O
and	O
momentum	O
equations	O
.	O

Larger	O
droplets	O
fall	O
faster	O
,	O
which	O
could	O
reduce	O
the	O
probability	O
of	O
the	O
droplets	O
inhalation	B-PROC
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
plays	O
key	O
roles	O
in	O
viral	B-PROC
replication	I-PROC
and	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
discovery	O
.	O

Inspection	O
of	O
the	O
overlap	O
regions	O
between	O
ORF1a	O
and	O
ORF1b	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
revealed	O
that	O
,	O
similar	O
to	O
all	O
coronaviruses	O
,	O
a	O
programmed	O
-	O
1	O
ribosomal	B-PROC
frameshift	I-PROC
could	O
be	O
used	O
by	O
the	O
virus	O
to	O
produce	O
a	O
fusion	O
protein	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
construct	O
a	O
sensitive	O
and	O
specific	O
real	O
-	O
time	O
quantitative	O
fluorescent	O
(	O
QF	O
)	O
reverse	O
transcriptase	B-PROC
(	O
RT	O
)-	O
PCR	O
method	O
for	O
the	O
detection	O
of	O
SARS	O
-	O
CoV	O
RNA	O
.	O

All	O
assays	O
revealed	O
a	O
strong	O
inhibition	B-PROC
of	O
coronavirus	O
replication	O
at	O
nontoxic	O
drug	O
concentrations	O
.	O

The	O
data	O
obtained	O
thus	O
far	O
do	O
not	O
indicate	O
whether	O
macrophage	O
/	O
microglia	O
infiltration	O
,	O
in	O
the	O
absence	O
of	O
T	O
cells	O
or	O
antibody	B-PROC
,	O
is	O
sufficient	O
to	O
mediate	O
demyelination	O
.	O

This	O
animal	O
model	O
should	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
SARS	O
-	O
CoV	O
-	O
related	O
pulmonary	O
disease	O
and	O
greatly	O
facilitate	O
the	O
development	B-PROC
of	O
vaccines	O
and	O
therapeutics	O
against	O
SARS	O
.	O

HIV	O
-	O
1	O
(	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
)	O
lipopeptide	O
vaccine	O
candidate	O
elicits	O
immune	B-PROC
responses	I-PROC
,	O
and	O
sustains	O
HIV	O
control	O
after	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
).	O

TITLE	O
:	O
Production	O
of	O
a	O
monoclonal	O
antibody	B-PROC
against	O
SARS	O
-	O
CoV	O
spike	O
protein	O
with	O
single	O
intrasplenic	O
immunization	O
of	O
plasmid	O
DNA	O
.	O

TITLE	O
:	O
Expanding	O
the	O
frontiers	O
of	O
existing	O
antiviral	O
drugs	O
:	O
possible	O
effects	O
of	O
HIV	O
-	O
1	O
protease	B-PROC
inhibitors	I-PROC
against	O
SARS	O
and	O
avian	O
influenza	O
.	O

TITLE	O
:	O
Assays	O
for	O
the	O
assessment	O
of	O
neutralizing	O
antibody	B-PROC
activities	O
against	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
associated	O
coronavirus	O
(	O
SCV	O
).	O

This	O
synergism	B-PROC
was	O
significantly	O
attenuated	O
by	O
the	O
prior	O
administration	O
of	O
the	O
endotoxin	O
antagonist	B-PROC
E5564	O
(	O
eritoran	O
).	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
evaluation	O
of	O
isatin	O
derivatives	O
as	O
effective	O
SARS	O
coronavirus	O
3CL	O
protease	B-PROC
inhibitors	I-PROC
.	O

Here	O
,	O
cell	O
tropism	B-PROC
and	O
receptor	O
usage	O
of	O
HCoV	O
-	O
NL63	O
were	O
analyzed	O
.	O

The	O
nsp2	O
gene	O
was	O
amplified	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
cloned	O
into	O
eukaryotic	O
expression	B-PROC
vector	O
pCI	O
-	O
neo	O
(	O
pCI	O
-	O
neo	O
/	O
nsp2	O
).	O

The	O
expression	B-PROC
of	O
Green	O
Fluorescent	O
Protein	O
(	O
GFP	O
)	O
and	O
protein	O
N	O
were	O
detected	O
using	O
Western	O
blot	O
.	O

The	O
vector	O
,	O
pshRNA	O
-	O
N	O
expressing	O
shRNA	O
which	O
targeted	B-PROC
the	O
N	O
gene	O
of	O
SARS	O
-	O
CoV	O
,	O
was	O
successfully	O
constructed	O
.	O

The	O
introduction	O
of	O
RNAi	B-PROC
plasmid	O
efficiently	O
and	O
specifically	O
inhibited	O
the	O
synthesis	B-PROC
of	O
protein	O
N	O
.	O
RT	O
-	O
PCR	O
showed	O
that	O
RNAs	O
of	O
N	O
gene	O
were	O
clearly	O
reduced	O
when	O
the	O
pEGFP	O
-	O
C1	O
-	O
N	O
was	O
cotransfected	O
with	O
pshRNA	O
-	O
N	O
,	O
whereas	O
the	O
control	O
vector	O
did	O
not	O
exhibit	O
inhibitory	O
effect	O
on	O
N	O
gene	B-PROC
transcription	I-PROC
.	O

One	O
to	O
three	O
days	O
after	O
the	O
onset	O
of	O
SARS	O
,	O
the	O
major	O
clinical	O
symptoms	O
were	O
fever	B-PROC
(	O
in	O
88	O
.	O
14	O
%	O
of	O
patients	O
),	O
fatigue	O
,	O
headache	O
,	O
myalgia	O
,	O
arthralgia	O
(	O
25	O
-	O
36	O
%),	O
etc	O
.	O

RESULTS	O
:	O
One	O
to	O
three	O
days	O
after	O
the	O
onset	O
of	O
SARS	O
,	O
the	O
major	O
clinical	O
symptoms	O
were	O
fever	B-PROC
(	O
in	O
88	O
.	O
14	O
%	O
of	O
patients	O
),	O
fatigue	O
,	O
headache	O
,	O
myalgia	O
,	O
arthralgia	O
(	O
25	O
-	O
36	O
%),	O
etc	O
.	O

Tools	O
for	O
the	O
optimization	O
of	O
forensic	O
typing	O
using	O
Single	O
Nucleotide	O
Polymorphism	B-PROC
(	O
SNP	O
)	O
and	O
PCR	O
-	O
Restriction	O
Fragment	O
Length	O
Polymorphism	B-PROC
(	O
PCR	O
-	O
RFLP	O
)	O
analyses	O
across	O
multiple	O
isolate	O
sequences	O
of	O
a	O
species	O
are	O
described	O
.	O

Several	O
cases	O
of	O
extremely	O
low	O
birthweight	O
infants	O
with	O
circulatory	B-PROC
collapse	O
after	O
the	O
acute	O
period	O
have	O
been	O
described	O
recently	O
,	O
but	O
the	O
cause	O
has	O
been	O
unclear	O
.	O

They	O
reproduce	O
rapidly	O
,	O
mutate	B-PROC
frequently	O
,	O
breach	O
species	O
barriers	O
,	O
adapt	O
with	O
relative	O
ease	O
to	O
new	O
hosts	O
and	O
new	O
environments	O
,	O
and	O
develop	O
resistance	B-PROC
to	O
the	O
drugs	O
used	O
to	O
treat	O
them	O
.	O

The	O
ongoing	O
response	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
is	O
continued	O
effective	O
infection	O
control	O
education	O
,	O
development	B-PROC
of	O
local	O
and	O
global	O
policies	O
for	O
reacting	O
to	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
like	O
outbreak	O
in	O
the	O
future	O
,	O
and	O
continued	O
work	O
on	O
a	O
vaccine	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
In	O
previous	O
literature	O
,	O
the	O
stability	O
and	O
temporal	O
evolution	B-PROC
of	O
psychobehavioral	O
responses	O
to	O
an	O
outbreak	O
remained	O
undefined	O
,	O
because	O
of	O
the	O
exclusively	O
cross	O
-	O
sectional	O
nature	O
of	O
such	O
study	O
designs	O
.	O

Those	O
who	O
perceived	O
a	O
higher	O
likelihood	O
of	O
contracting	O
or	O
dying	B-PROC
of	O
SARS	O
had	O
significantly	O
higher	O
anxiety	O
scores	O
.	O

Our	O
findings	O
can	O
assist	O
in	O
modifying	O
public	O
service	O
announcements	O
in	O
the	O
future	O
,	O
which	O
should	O
be	O
tailored	O
to	O
psychobehavioral	O
surveillance	O
intelligence	O
to	O
achieve	O
the	O
desired	O
behavioral	B-PROC
outcomes	O
.	O

The	O
current	O
study	O
was	O
undertaken	O
to	O
clarify	O
whether	O
furosemide	O
attenuates	O
the	O
inflammatory	B-PROC
response	I-PROC
by	O
changing	O
the	O
epidermal	O
growth	B-PROC
factor	O
level	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

The	O
mean	O
arterial	B-PROC
pressure	I-PROC
and	O
heart	O
rate	O
was	O
greater	O
in	O
this	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
that	O
received	O
no	O
furosemide	O
)	O
on	O
day	O
7	O
(	O
P	O
=	O
.	O
027	O
).	O

TITLE	O
:	O
JNK	O
and	O
PI3k	O
/	O
Akt	O
signaling	B-PROC
pathways	B-PROC
are	O
required	O
for	O
establishing	O
persistent	O
SARS	O
-	O
CoV	O
infection	O
in	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
characteristics	O
,	O
cause	O
of	O
hospitalisation	O
and	O
symptoms	O
prior	O
to	O
death	B-PROC
in	O
patients	O
dying	B-PROC
in	O
hospital	O
without	O
resuscitation	O
being	O
started	O
and	O
the	O
extent	O
to	O
which	O
these	O
decisions	O
were	O
documented	O
.	O

Among	O
674	O
patients	O
,	O
71	O
%	O
suffered	O
respiratory	O
insufficiency	O
,	O
43	O
%	O
were	O
unconscious	O
and	O
32	O
%	O
had	O
congestive	O
heart	O
failure	O
during	O
the	O
24h	O
before	O
death	B-PROC
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
who	O
died	B-PROC
at	O
a	O
Swedish	O
University	O
Hospital	O
,	O
we	O
did	O
not	O
find	O
a	O
single	O
case	O
in	O
which	O
it	O
was	O
regarded	O
as	O
unethical	O
not	O
to	O
start	O
CPR	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
transgenic	O
mouse	O
model	O
susceptible	O
to	O
human	O
coronavirus	O
229E	O
.	O

So	O
far	O
,	O
no	O
animal	O
model	O
is	O
available	O
to	O
study	O
the	O
pathogenesis	B-PROC
of	O
infection	O
by	O
HCoV	O
-	O
229E	O
.	O

Double	O
transgenic	O
mice	O
allow	O
the	O
study	O
of	O
human	O
coronavirus	O
group	O
1	O
infections	O
in	O
an	O
animal	O
model	O
,	O
in	O
particular	O
,	O
viral	O
tropism	B-PROC
,	O
replication	O
,	O
recombination	B-PROC
,	O
and	O
spread	O
in	O
an	O
immunocompromised	O
situation	O
.	O

Virus	B-PROC
replication	I-PROC
was	O
monitored	O
by	O
measuring	O
the	O
levels	O
of	O
positive	O
-	O
and	O
negative	O
-	O
strand	O
RNA	O
,	O
by	O
immunofluorescence	O
detection	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleoprotein	O
,	O
and	O
by	O
titration	O
of	O
the	O
infectious	O
virus	O
.	O

The	O
gene	B-PROC
expression	I-PROC
profiles	O
of	O
macrophages	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
human	O
coronavirus	O
229E	O
,	O
and	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
were	O
compared	O
by	O
using	O
microarrays	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-PROC
PCR	O
.	O

Secreted	B-PROC
cytokines	O
were	O
measured	O
with	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

A	O
single	O
step	O
realtime	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
diagnostic	O
kit	O
was	O
performed	O
for	O
screening	O
SARS	O
-	O
CoV	O
like	O
virus	O
,	O
the	O
manual	O
nested	O
RT	O
-	O
PCR	O
and	O
DNA	O
sequencing	O
were	O
performed	O
for	O
confirmation	O
.	O

Evolution	B-PROC
of	O
new	O
viral	O
pathogens	O
,	O
such	O
as	O
avian	O
influenza	O
virus	O
and	O
the	O
SARS	O
-	O
CoV	O
,	O
are	O
discussed	O
.	O

ABSTRACT	O
:	O
Because	O
the	O
right	O
side	O
of	O
the	O
heart	O
supplies	O
blood	O
to	O
the	O
pulmonary	B-PROC
circulation	B-PROC
,	O
its	O
integrity	O
is	O
required	O
for	O
both	O
adequate	O
respiratory	O
and	O
circulatory	B-PROC
function	O
.	O

ABSTRACT	O
:	O
Acute	O
aortic	O
dissection	O
(	O
AAD	O
)	O
is	O
sometimes	O
complicated	O
by	O
respiratory	O
failure	O
due	O
to	O
severe	O
lung	O
oxygenation	B-PROC
impairment	O
.	O

Oxygenation	B-PROC
impairment	O
,	O
defined	O
as	O
the	O
lowest	O
PaO2	O
/	O
FIO2	O
ratio	O
<	O
or	O
=	O
200	O
mmHg	O
,	O
was	O
noted	O
in	O
31	O
patients	O
(	O
51	O
%).	O

Systemic	O
activation	O
of	O
the	O
inflammatory	O
system	O
after	O
aortic	O
injury	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	B-PROC
of	O
oxygenation	B-PROC
impairment	O
.	O

CONCLUSIONS	O
:	O
The	O
greater	O
serum	O
CRP	O
elevation	O
after	O
distal	O
type	O
AAD	O
was	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
oxygenation	B-PROC
impairment	O
and	O
poor	O
clinical	O
outcome	O
.	O

Our	O
study	O
suggests	O
that	O
the	O
SUMO	O
-	O
fusion	O
technology	O
will	O
be	O
useful	O
for	O
enhancing	O
expression	B-PROC
and	O
purification	O
of	O
the	O
viral	O
proteins	O
for	O
structural	O
and	O
functional	O
studies	O
as	O
well	O
as	O
for	O
therapeutic	O
uses	O
.	O

ABSTRACT	O
:	O
An	O
immune	O
antibody	B-PROC
phage	O
-	O
display	O
library	O
was	O
constructed	O
from	O
B	O
cells	O
of	O
SARS	O
convalescent	O
patients	O
.	O

This	O
study	O
not	O
only	O
first	O
made	O
a	O
human	O
neutralizing	O
antibody	B-PROC
,	O
which	O
recognized	O
an	O
epitope	O
on	O
S2	O
protein	O
like	O
natural	O
antibody	B-PROC
in	O
sera	O
,	O
but	O
also	O
may	O
help	O
us	O
to	O
better	O
understand	O
the	O
immunological	O
characteristics	O
of	O
SARS	O
protein	O
and	O
SARS	O
vaccine	O
design	O
.	O

(	O
2	O
)	O
Physician	O
'	O
s	O
alertness	O
/	O
sense	B-PROC
and	O
practice	O
of	O
self	O
-	O
protection	O
on	O
SARS	O
,	O
measures	O
on	O
quarantine	O
and	O
isolation	O
to	O
the	O
patients	O
,	O
ventilation	O
and	O
disinfection	O
process	O
in	O
the	O
wards	O
appeared	O
to	O
be	O
the	O
key	O
variables	O
for	O
the	O
control	O
of	O
epidemics	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
the	O
RNA	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
the	O
blood	O
and	O
excretion	B-PROC
of	O
convalescent	O
patient	O
with	O
SARS	O
for	O
prevention	O
and	O
treatment	O
of	O
the	O
disease	O
.	O

Using	O
paired	O
ELISA	O
assay	O
,	O
three	O
mAbs	O
N1E8	O
,	O
N8E1	O
and	O
N10E4	O
were	O
selected	O
as	O
capturing	O
antibody	B-PROC
and	O
rabbit	O
polyclonal	O
antibodies	O
as	O
detecting	O
antibody	B-PROC
then	O
triple	O
antibodies	O
-	O
based	O
sandwich	O
ELISA	O
was	O
established	O
following	O
horseradish	O
peroxidase	O
(	O
HRP	O
)-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
immunoglobulin	B-PROC
G	O
.	O
The	O
recombinant	O
N	O
protein	O
was	O
used	O
as	O
a	O
standard	O
to	O
establish	O
a	O
detection	O
sensitivity	O
of	O
approximated	O
50	O
pg	O
/	O
ml	O
with	O
this	O
assay	O
.	O

However	O
,	O
immunologic	O
alterations	O
of	O
circulating	O
and	O
resident	O
immune	O
cell	O
populations	O
contributing	O
to	O
the	O
posttraumatic	O
immunosuppression	B-PROC
are	O
poorly	O
understood	O
.	O

Moreover	O
,	O
this	O
immunosuppression	B-PROC
is	O
associated	O
with	O
an	O
increased	O
susceptibility	O
to	O
infectious	O
complications	O
,	O
which	O
results	O
in	O
a	O
decreased	O
survival	O
rate	O
if	O
blunt	O
chest	O
trauma	O
is	O
followed	O
by	O
a	O
septic	O
insult	O
.	O

Some	O
of	O
these	O
species	O
have	O
been	O
identified	O
elsewhere	O
as	O
causes	O
of	O
hypersensitivity	B-PROC
pneumonitis	O
and	O
other	O
respiratory	O
syndromes	O
.	O

ABSTRACT	O
:	O
To	O
follow	O
-	O
up	O
on	O
the	O
changes	O
in	O
lung	B-PROC
function	I-PROC
and	O
lung	O
radiographic	O
pictures	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
discharged	O
from	O
Xiaotangshan	O
Hospital	O
in	O
Beijing	O
(	O
by	O
regularly	O
receiving	O
examination	O
),	O
and	O
to	O
analyze	O
retrospectively	O
the	O
treatment	O
strategy	O
in	O
these	O
patients	O
.	O

RESULTS	O
:	O
Positive	O
SARS	O
-	O
Co	O
virus	O
IgG	O
antibody	B-PROC
results	O
were	O
seen	O
in	O
208	O
of	O
258	O
patients	O
,	O
with	O
21	O
.	O
3	O
%	O
(	O
55	O
of	O
258	O
patients	O
)	O
still	O
having	O
a	O
pulmonary	B-PROC
diffusion	I-PROC
abnormality	O
(	O
D	O
(	O
LCO	O
)	O
<	O
80	O
%	O
of	O
predicted	O
).	O

Nucleocapsid	O
gene	O
was	O
obtained	O
by	O
reverse	B-PROC
transcription	B-PROC
and	O
polymerase	O
chain	O
reaction	O
from	O
a	O
SARS	O
patient	O
and	O
inserted	O
into	O
the	O
vector	O
pFastBacHTa	O
expressing	O
baculovirus	O
.	O

Immunofluorescence	O
assay	O
(	O
IFA	O
)	O
technique	O
and	O
plaque	O
reduction	O
neutralization	O
test	O
(	O
PRNT	O
)	O
were	O
used	O
to	O
detect	O
7	O
samples	O
of	O
sera	O
of	O
4	O
newly	O
diagnosed	O
SARS	O
patients	O
collected	O
in	O
different	O
days	O
,	O
48	O
samples	O
of	O
convalescent	O
sera	O
of	O
SARS	O
patients	O
,	O
24	O
serum	O
samples	O
of	O
healthy	O
person	O
undergoing	O
physical	O
examination	O
,	O
and	O
40	O
serum	O
samples	O
from	O
non	O
-	O
SARS	O
patients	O
with	O
fever	B-PROC
by	O
double	O
blind	O
test	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
3	O
(	O
MHV3	O
)	O
infection	O
of	O
A	O
/	O
J	O
and	O
BALB	O
/	O
c	O
mice	O
has	O
been	O
used	O
as	O
a	O
model	O
of	O
resistance	B-PROC
/	O
susceptibility	O
.	O

The	O
development	B-PROC
of	O
rapid	O
screening	O
assays	O
is	O
essential	O
for	O
antiviral	O
drug	O
discovery	O
.	O

TITLE	O
:	O
Using	O
DNA	O
shuffling	O
to	O
create	O
novel	O
infectious	O
bronchitis	O
virus	O
S1	O
genes	O
:	O
implications	O
for	O
S1	O
gene	O
recombination	B-PROC
.	O

Firefly	O
luciferase	O
and	O
Renilla	O
luciferase	B-PROC
activity	I-PROC
were	O
measured	O
.	O

The	O
genes	O
were	O
over	O
-	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
either	O
as	O
inclusion	O
body	O
or	O
as	O
soluble	O
form	O
.	O

ABSTRACT	O
:	O
The	O
clinical	O
,	O
laboratory	O
,	O
and	O
radiological	O
features	O
at	O
presentation	O
of	O
16	O
children	O
(<	O
12	O
years	O
)	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
pneumonia	O
were	O
compared	O
with	O
32	O
age	O
matched	O
patients	O
with	O
community	O
acquired	O
pneumonia	O
for	O
determination	O
of	O
predictive	O
factors	O
that	O
could	O
allow	O
early	O
differentiation	B-PROC
of	O
the	O
two	O
conditions	O
.	O

Intriguingly	O
,	O
heat	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
elicited	O
recall	O
-	O
like	O
CTL	O
responses	O
to	O
SSp	O
-	O
1	O
but	O
not	O
to	O
S978	O
,	O
S1202	O
,	O
or	O
dominant	O
epitopes	O
from	O
several	O
other	O
human	O
viruses	O
in	O
5	O
of	O
36	O
(	O
13	O
.	O
8	O
%)	O
HLA	O
-	O
A	O
*	O
0201	O
(+)	O
healthy	O
donors	O
without	O
any	O
contact	O
history	O
with	O
SARS	O
-	O
CoV	O
.	O
SSp	O
-	O
1	O
-	O
specific	O
CTLs	O
expanded	O
from	O
memory	B-PROC
T	O
cells	O
of	O
both	O
recovered	O
SARS	O
patients	O
,	O
and	O
the	O
five	O
exceptional	O
healthy	O
donors	O
shared	O
a	O
differentiated	B-PROC
effector	O
CTL	O
phenotype	O
,	O
CD45RA	O
(+)	O
CCR7	O
(-)	O
CD62L	O
(-),	O
and	O
expressed	B-PROC
CCR5	O
and	O
CD44	O
.	O

ABSTRACT	O
:	O
A	O
diversified	O
library	O
of	O
peptide	O
anilides	O
was	O
prepared	O
,	O
and	O
their	O
inhibition	B-PROC
activities	O
against	O
the	O
SARS	O
-	O
CoV	O
3CL	O
protease	O
were	O
examined	O
by	O
a	O
fluorogenic	O
tetradecapeptide	O
substrate	O
.	O

This	O
anilide	O
is	O
a	O
competitive	O
inhibitor	O
of	O
the	O
SARS	O
-	O
CoV	O
3CL	O
protease	O
with	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
03	O
muM	O
.	O
The	O
molecular	O
docking	B-PROC
experiment	O
indicates	O
that	O
the	O
P1	O
residue	O
of	O
this	O
anilide	O
inhibitor	O
is	O
distant	O
from	O
the	O
nucleophilic	O
SH	O
of	O
Cys145	O
in	O
the	O
active	O
site	O
.	O

TITLE	O
:	O
Structural	O
analysis	O
of	O
inhibition	B-PROC
mechanisms	O
of	O
aurintricarboxylic	O
acid	O
on	O
SARS	O
-	O
CoV	O
polymerase	O
and	O
other	O
proteins	O
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
critical	O
amino	O
acid	O
residues	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
for	O
its	O
variation	O
in	O
zoonotic	O
tropism	B-PROC
transition	O
via	O
a	O
double	O
substitution	O
strategy	O
.	O

In	O
all	O
sheep	O
,	O
the	O
EVW	O
maintained	O
gas	O
exchange	O
during	O
and	O
after	O
bronchoconstriction	B-PROC
,	O
as	O
well	O
as	O
during	O
OA	O
injury	O
.	O

The	O
patients	O
in	O
each	O
group	O
were	O
equally	O
matched	O
in	O
terms	O
of	O
age	O
,	O
Pediatric	O
Risk	O
of	O
Mortality	O
,	O
and	O
number	O
with	O
dengue	O
hemorrhage	O
fever	B-PROC
grade	O
IV	O
,	O
although	O
the	O
platelet	O
counts	O
were	O
higher	O
in	O
the	O
W	O
group	O
compared	O
with	O
the	O
P	O
group	O
(	O
geometric	O
mean	O
42	O
.	O
2	O
,	O
confidence	O
interval	O
36	O
.	O
9	O
,	O
48	O
.	O
4	O
vs	O
.	O
geometric	O
mean	O
36	O
.	O
7	O
,	O
confidence	O
interval	O
33	O
.	O
3	O
,	O
40	O
.	O
5	O
,	O
p	O
<	O
.	O
05	O
).	O

Genetic	O
programs	O
regulating	O
the	O
synthesis	B-PROC
of	O
the	O
surfactant	O
proteins	O
and	O
lipids	O
required	O
for	O
the	O
production	O
and	O
function	O
of	O
pulmonary	O
surfactant	O
are	O
highly	O
conserved	O
across	O
vertebrates	O
,	O
and	O
include	O
proteins	O
that	O
regulate	O
the	O
synthesis	B-PROC
and	O
packaging	O
of	O
pulmonary	O
surfactant	O
proteins	O
and	O
lipids	O
.	O

Expression	B-PROC
of	O
SP	O
-	O
B	O
,	O
-	O
C	O
,	O
and	O
ABCA3	O
are	O
coregulated	O
during	O
late	O
gestation	B-PROC
by	O
transcriptional	B-PROC
programs	O
influenced	O
by	O
thyroid	O
transcription	B-PROC
factor	O
-	O
1	O
and	O
forkhead	O
box	O
a2	O
,	O
transcription	B-PROC
factors	O
that	O
regulate	O
both	O
differentiation	B-PROC
of	O
the	O
respiratory	O
epithelium	O
and	O
transcription	B-PROC
of	O
genes	O
required	O
for	O
perinatal	O
adaptation	B-PROC
to	O
air	O
breathing	B-PROC
.	O

However	O
,	O
it	O
is	O
difficult	O
to	O
predict	O
when	O
such	O
events	O
will	O
take	O
place	O
since	O
the	O
viral	O
adaptation	B-PROC
that	O
is	O
needed	O
to	O
accomplish	O
this	O
is	O
multifactorial	O
and	O
stochastic	O
.	O

ABSTRACT	O
:	O
To	O
construct	O
a	O
large	O
human	O
scFv	O
library	O
against	O
SARS	O
virus	O
by	O
using	O
in	O
vivo	O
recombination	B-PROC
.	O

S	O
-	O
peptide	O
showed	O
neutralizing	O
antibody	B-PROC
titers	O
of	O
>	O
or	O
=	O
1	O
:	O
1280	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
3CL	O
protease	O
by	O
peptidomimetic	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
esters	O
.	O

ABSTRACT	O
:	O
The	O
proteolytic	B-PROC
processing	I-PROC
of	O
polyproteins	O
by	O
the	O
3CL	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
is	O
essential	O
for	O
the	O
viral	O
propagation	O
.	O

Breed	B-PROC
,	O
sex	O
and	O
reproductive	B-PROC
status	O
of	O
affected	O
cats	O
were	O
compared	O
to	O
the	O
general	O
cat	O
population	O
and	O
to	O
mixed	O
breed	B-PROC
cats	O
evaluated	O
during	O
the	O
same	O
period	O
.	O

Abyssinians	O
,	O
Bengals	O
,	O
Birmans	O
,	O
Himalayans	O
,	O
Ragdolls	O
and	O
Rexes	O
had	O
a	O
significantly	O
higher	O
risk	O
,	O
whereas	O
Burmese	O
,	O
Exotic	O
Shorthairs	O
,	O
Manxes	O
,	O
Persians	O
,	O
Russian	O
Blues	O
and	O
Siamese	O
cats	O
were	O
not	O
at	O
increased	O
risk	O
for	O
development	B-PROC
of	O
FIP	O
.	O

The	O
remaining	O
patients	O
survived	O
showing	O
a	O
good	O
neurologic	B-PROC
function	I-PROC
.	O

This	O
signals	O
a	O
move	B-PROC
towards	O
a	O
closer	O
interplay	O
between	O
epidemiological	O
modelling	O
,	O
surveillance	O
and	O
disease	O
-	O
management	O
strategies	O
.	O

Blood	B-PROC
gases	I-PROC
were	O
measured	O
in	O
the	O
PP	O
and	O
supine	O
(	O
SP	O
)	O
positions	O
3	O
h	O
after	O
each	O
turn	O
,	O
for	O
36	O
h	O
,	O
yielding	O
six	O
measurement	O
sets	O
(	O
SP1	O
,	O
PP1	O
,	O
SP2	O
,	O
PP2	O
,	O
SP3	O
,	O
and	O
PP3	O
).	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
problems	O
and	O
solutions	O
of	O
setting	O
up	O
the	O
recombinant	O
SARS	O
-	O
CoV	O
S	O
-	O
based	O
ELISA	O
for	O
antibody	B-PROC
detection	O
.	O

Hypoxia	O
combined	O
with	O
anemia	O
increased	O
the	O
risk	O
for	O
death	B-PROC
in	O
SARS	O
patients	O
.	O

Mice	O
immunized	O
twice	O
with	O
the	O
whole	O
killed	O
virus	O
vaccine	O
elicited	O
higher	O
antibody	B-PROC
responses	I-PROC
than	O
mice	O
immunized	O
three	O
times	O
with	O
the	O
DNA	O
vaccine	O
or	O
once	O
with	O
the	O
whole	O
killed	O
virus	O
vaccine	O
.	O

SARS	O
-	O
CoV	O
infections	O
and	O
the	O
Spike	O
protein	O
of	O
the	O
SARS	O
-	O
CoV	O
reduce	O
ACE2	O
expression	B-PROC
.	O

Seven	O
of	O
nine	O
(	O
77	O
.	O
8	O
%)	O
patients	O
survived	O
;	O
two	O
died	B-PROC
because	O
of	O
severe	O
ARDS	O
,	O
MODS	O
,	O
and	O
respiratory	O
failure	O
.	O

Seven	O
of	O
nine	O
(	O
77	O
.	O
8	O
%)	O
patients	O
survived	O
;	O
two	O
died	B-PROC
because	O
of	O
severe	O
ARDS	O
,	O
MODS	O
,	O
and	O
respiratory	O
failure	O
.	O

These	O
pandemic	O
viral	B-PROC
diseases	I-PROC
originated	O
in	O
South	O
East	O
Asia	O
.	O

Postmortem	O
skeletal	O
muscles	O
from	O
8	O
consecutive	O
patients	O
who	O
died	B-PROC
of	O
SARS	O
in	O
March	O
2003	O
were	O
studied	O
under	O
light	O
and	O
electron	O
microscopy	O
as	O
well	O
as	O
immunohistochemistry	O
.	O

The	O
introduction	O
of	O
the	O
nucleic	O
acid	O
amplification	O
can	O
avoid	O
the	O
window	O
period	O
of	O
these	O
viral	B-PROC
infections	I-PROC
.	O

TITLE	O
:	O
[	O
Development	B-PROC
of	O
monoclonal	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
and	O
identification	O
of	O
antigenic	O
epitopes	O
].	O

Six	O
positive	O
hybridoma	O
cell	O
lines	O
stably	O
secreting	B-PROC
monoclonal	O
antibodies	O
were	O
selected	O
.	O

The	O
basic	O
reproduction	B-PROC
number	O
was	O
estimated	O
,	O
and	O
the	O
use	O
of	O
masks	O
alone	O
was	O
shown	O
to	O
be	O
insufficient	O
in	O
containing	O
an	O
epidemic	O
.	O

A	O
full	O
understanding	O
of	O
how	O
SARS	O
-	O
CoV	O
would	O
interact	O
with	O
lung	O
epithelial	O
cells	O
will	O
be	O
vital	O
for	O
advancing	O
our	O
knowledge	O
of	O
SARS	O
pathogenesis	B-PROC
.	O

With	O
available	O
information	O
from	O
federal	O
sources	O
and	O
calculating	O
the	O
additional	O
number	O
of	O
deaths	B-PROC
from	O
infection	O
by	O
using	O
data	O
on	O
prevalence	O
and	O
natural	O
history	O
,	O
we	O
estimate	O
the	O
annual	O
death	B-PROC
rate	O
for	O
healthcare	O
workers	O
from	O
occupational	O
events	O
,	O
including	O
infection	O
,	O
is	O
17	O
-	O
57	O
per	O
1	O
million	O
workers	O
.	O

Our	O
results	O
showed	O
that	O
all	O
of	O
the	O
immunized	O
animals	O
generated	O
humoral	B-PROC
immunity	I-PROC
against	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
and	O
the	O
sera	O
of	O
immunized	O
rats	O
showed	O
strong	O
capable	O
of	O
protecting	O
from	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

TITLE	O
:	O
Yeast	O
expression	B-PROC
and	O
characterization	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	O
.	O

The	O
N	O
protein	O
gene	O
has	O
been	O
cloned	O
into	O
a	O
yeast	O
expression	B-PROC
vector	O
pPIC9	O
,	O
transformed	O
into	O
Pichia	O
pastoris	O
strain	O
GS115	O
and	O
induced	O
for	O
expression	B-PROC
by	O
methanol	O
.	O

Molecular	O
scrutiny	O
of	O
viral	B-PROC
diseases	I-PROC
sometimes	O
permits	O
deeper	O
understanding	O
of	O
pathogenesis	B-PROC
and	O
epizootiology	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
contains	O
a	O
single	O
spike	O
(	O
S	O
)	O
protein	O
,	O
which	O
binds	O
to	O
its	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
induces	O
membrane	B-PROC
fusion	I-PROC
and	O
serves	O
as	O
a	O
neutralizing	O
antigen	O
.	O

However	O
,	O
caution	O
should	O
be	O
taken	O
with	O
the	O
safety	O
of	O
whole	O
virus	O
or	O
full	O
-	O
length	O
S	O
protein	O
-	O
based	O
immunogens	O
in	O
humans	O
because	O
they	O
may	O
induce	O
harmful	O
immune	O
or	O
inflammatory	B-PROC
responses	I-PROC
.	O

We	O
propose	O
to	O
use	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
(	O
residues	O
318	O
--	O
510	O
)	O
for	O
developing	O
a	O
safe	O
and	O
effective	O
subunit	O
SARS	O
vaccine	O
,	O
as	O
it	O
is	O
not	O
only	O
a	O
functional	O
domain	O
that	O
mediates	O
virus	O
-	O
receptor	O
binding	O
but	O
also	O
a	O
major	O
neutralization	O
determinant	O
of	O
SARSCoV	O
.	O
It	O
has	O
been	O
demonstrated	O
that	O
the	O
RBD	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
contains	O
multiple	O
conformational	O
epitopes	O
capable	O
of	O
inducing	O
highly	O
potent	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
and	O
protective	O
immunity	B-PROC
.	O

It	O
was	O
demonstrated	O
that	O
there	O
was	O
no	O
live	O
SARS	O
-	O
CoV	O
in	O
all	O
samples	O
collected	O
,	O
but	O
the	O
RNA	O
of	O
SARS	O
-	O
CoV	O
could	O
be	O
detected	O
in	O
seven	O
stool	O
samples	O
from	O
SARS	O
patients	O
with	O
any	O
one	O
of	O
the	O
symptoms	O
of	O
fever	B-PROC
,	O
malaise	O
,	O
cough	O
,	O
or	O
dyspnea	O
,	O
in	O
10	O
sewage	O
samples	O
before	O
disinfection	O
and	O
3	O
samples	O
after	O
disinfection	O
from	O
the	O
two	O
hospitals	O
.	O

RESULTS	O
:	O
It	O
was	O
demonstrated	O
that	O
there	O
was	O
no	O
live	O
SARS	O
-	O
CoV	O
in	O
all	O
samples	O
collected	O
,	O
but	O
the	O
RNA	O
of	O
SARS	O
-	O
CoV	O
could	O
be	O
detected	O
in	O
seven	O
stool	O
samples	O
from	O
SARS	O
patients	O
with	O
any	O
one	O
of	O
the	O
symptoms	O
of	O
fever	B-PROC
,	O
malaise	O
,	O
cough	O
,	O
or	O
dyspnea	O
,	O
in	O
10	O
sewage	O
samples	O
before	O
disinfection	O
and	O
3	O
samples	O
after	O
disinfection	O
from	O
the	O
two	O
hospitals	O
.	O

Our	O
study	O
provides	O
strong	O
evidence	O
that	O
the	O
NSP1	O
sequence	O
in	O
the	O
SARS	O
-	O
CoV	O
genome	O
is	O
a	O
valid	O
target	O
for	O
RNAi	B-PROC
and	O
the	O
effect	O
of	O
the	O
siRNAs	O
probably	O
mainly	O
resulted	O
from	O
effects	O
on	O
global	O
reduction	O
of	O
subgenome	O
synthesis	B-PROC
and	O
subsequent	O
protein	B-PROC
expression	B-PROC
of	O
SARS	O
-	O
CoV	O
.	O

Since	O
TNF	O
-	O
alpha	O
plays	O
a	O
role	O
in	O
immune	O
-	O
mediated	O
processes	O
we	O
evaluated	O
the	O
levels	O
of	O
TNF	O
-	O
alpha	O
/	O
TNF	O
-	O
alpha	O
receptors	O
and	O
the	O
downstream	O
signaling	B-PROC
molecule	O
nitric	O
oxide	O
(	O
NO	O
)	O
during	O
disease	O
in	O
both	O
retinal	O
degeneration	O
susceptible	O
BALB	O
/	O
c	O
and	O
degeneration	O
resistant	O
CD	O
-	O
1	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
structure	O
of	O
the	O
human	O
MHC	B-PROC
-	O
I	O
molecule	O
HLA	O
-	O
A	O
*	O
1101	O
in	O
complex	O
with	O
a	O
nonameric	O
peptide	O
(	O
KTFPPTEPK	O
)	O
has	O
been	O
determined	O
by	O
X	O
-	O
ray	O
crystallography	O
to	O
1	O
.	O
45	O
A	O
resolution	O
.	O

All	O
residues	O
except	O
Thr2p	O
and	O
Lys9p	O
are	O
accessible	O
for	O
T	O
-	O
cell	B-PROC
recognition	I-PROC
.	O

With	O
a	O
fluorogenic	O
inhibitor	O
-	O
screening	O
platform	O
,	O
we	O
show	O
that	O
zinc	O
ion	O
and	O
its	O
conjugates	O
potently	O
inhibit	O
the	O
enzymatic	B-PROC
activity	I-PROC
of	O
SARS	O
-	O
CoV	O
PLP2	O
.	O

TITLE	O
:	O
Multiple	O
organ	O
infection	O
and	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

A	O
total	O
of	O
305	O
febrile	B-PROC
patients	O
(	O
0	O
.	O
42	O
%)	O
was	O
detected	O
by	O
infrared	O
thermography	O
.	O

Therefore	O
,	O
it	O
should	O
be	O
considered	O
in	O
patients	O
who	O
present	O
with	O
stridor	O
and	O
fever	B-PROC
.	O

ABSTRACT	O
:	O
The	O
Harderian	O
gland	O
(	O
HG	O
),	O
a	O
sero	O
-	O
mucous	O
secreting	B-PROC
organ	O
in	O
the	O
eye	O
orbit	O
,	O
has	O
long	O
been	O
recognized	O
as	O
immunologically	O
important	O
in	O
chickens	O
.	O

TITLE	O
:	O
Early	O
open	O
thoracotomy	O
and	O
mediastinopleural	O
irrigation	B-PROC
for	O
severe	O
descending	O
necrotizing	O
mediastinitis	O
.	O

TITLE	O
:	O
Bcl	O
-	O
xL	O
inhibits	O
T	B-PROC
-	I-PROC
cell	I-PROC
apoptosis	I-PROC
induced	O
by	O
expression	B-PROC
of	O
SARS	O
coronavirus	O
E	O
protein	O
in	O
the	O
absence	O
of	O
growth	B-PROC
factors	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
a	O
cDNA	O
encoding	O
SARS	O
-	O
CoV	O
E	O
protein	O
was	O
created	O
using	O
whole	O
gene	O
synthesis	B-PROC
.	O

These	O
cases	O
of	O
severe	O
sepsis	O
and	O
immunosuppression	B-PROC
indicate	O
a	O
high	O
therapeutic	O
efficacy	O
of	O
drotrecogin	O
alfa	O
(	O
activated	O
).	O

Among	O
the	O
28	O
,	O
six	O
(	O
21	O
.	O
4	O
percent	O
)	O
did	O
not	O
complain	O
of	O
fever	B-PROC
and	O
22	O
(	O
78	O
.	O
6	O
percent	O
)	O
had	O
temperatures	O
less	O
than	O
38	O
.	O
0	O
degrees	O
Celsius	O
during	O
their	O
first	O
ED	O
visit	O
.	O

To	O
determine	O
whether	O
nsp1	O
is	O
required	O
for	O
MHV	O
replication	O
and	O
to	O
identify	O
residues	O
critical	O
for	O
protein	B-PROC
function	I-PROC
,	O
mutant	O
viruses	O
that	O
contained	O
deletions	O
or	O
point	B-PROC
mutations	I-PROC
within	O
the	O
nsp1	O
-	O
coding	O
region	O
were	O
generated	O
and	O
assayed	O
for	O
defects	O
in	O
viral	B-PROC
replication	I-PROC
,	O
viral	O
protein	B-PROC
expression	B-PROC
,	O
protein	B-PROC
localization	I-PROC
,	O
and	O
RNA	B-PROC
synthesis	I-PROC
.	O

The	O
results	O
demonstrated	O
that	O
the	O
carboxy	O
-	O
terminal	O
half	O
of	O
nsp1	O
(	O
residues	O
K	O
(	O
124	O
)	O
through	O
L	O
(	O
241	O
))	O
was	O
dispensable	O
for	O
virus	B-PROC
replication	I-PROC
in	O
culture	O
but	O
was	O
required	O
for	O
efficient	O
proteolytic	B-PROC
cleavage	B-PROC
of	O
nsp1	O
from	O
the	O
gene	O
1	O
polyprotein	O
and	O
for	O
optimal	O
viral	B-PROC
replication	I-PROC
.	O

This	O
study	O
identifies	O
nsp1	O
residues	O
important	O
for	O
protein	B-PROC
processing	I-PROC
,	O
viral	O
RNA	B-PROC
synthesis	I-PROC
,	O
and	O
viral	B-PROC
replication	I-PROC
.	O

Previous	O
studies	O
on	O
various	O
coronaviruses	O
indicate	O
that	O
protein	O
-	O
protein	O
interactions	O
amongst	O
various	O
coronavirus	O
proteins	O
are	O
critical	O
for	O
viral	B-PROC
assembly	I-PROC
and	O
morphogenesis	B-PROC
.	O

Transthoracic	O
and	O
transoesophageal	O
echocardiography	O
was	O
used	O
to	O
assess	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
(	O
LVEF	O
)	O
and	O
disturbances	O
of	O
segmental	O
contractility	O
.	O

PATIENT	O
AND	O
HISTORY	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
with	O
GIST	O
metastatic	O
to	O
the	O
right	O
lobe	O
of	O
the	O
liver	O
,	O
treated	O
with	O
tyrosine	B-PROC
kinase	B-PROC
inhibitors	I-PROC
,	O
underwent	O
a	O
right	O
hepatectomy	O
requiring	O
multiple	O
transfusions	O
.	O

As	O
the	O
complexity	O
of	O
this	O
crucial	O
pathway	B-PROC
is	O
unravelled	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
therapeutic	O
potential	O
of	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
ACE2	O
.	O

TITLE	O
:	O
Cutaneous	O
lesions	O
associated	O
with	O
coronavirus	O
-	O
induced	O
vasculitis	O
in	O
a	O
cat	O
with	O
feline	O
infectious	O
peritonitis	O
and	O
concurrent	O
feline	O
immunodeficiency	O
virus	B-PROC
infection	I-PROC
.	O

The	O
pathogenesis	B-PROC
of	O
FIP	O
involves	O
a	O
viral	O
associated	O
,	O
disseminated	O
phlebitis	O
and	O
periphlebitis	O
which	O
can	O
arise	O
at	O
many	O
sites	O
.	O

In	O
acute	O
lung	O
lesion	O
syndrome	O
(	O
ALLS	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
the	O
oxygenation	B-PROC
index	O
(	O
PaO2	O
/	O
FiO2	O
)	O
reflects	O
the	O
degree	O
of	O
alveolar	O
-	O
capillary	O
membrane	O
damage	O
.	O

Patients	O
non	O
-	O
responsive	O
to	O
immunoglobulin	B-PROC
therapy	O
are	O
labeled	O
as	O
having	O
""""	O
immunoglobulin	B-PROC
resistant	O
KD	O
"""."	O

Long	O
-	O
term	O
corticotherapy	O
,	O
chronic	O
immune	O
diseases	O
,	O
fever	B-PROC
of	O
38	O
degrees	O
C	O
or	O
higher	O
,	O
white	O
blood	O
cell	O
count	O
,	O
pulse	B-PROC
rate	I-PROC
,	O
FIM	O
,	O
SIRS	O
,	O
sepsis	O
,	O
CRP	O
of	O
3	O
mg	O
/	O
mL	O
or	O
higher	O
,	O
and	O
PCT	O
of	O
0	O
.	O
5	O
ng	O
/	O
mL	O
or	O
higher	O
were	O
associated	O
with	O
an	O
infection	O
at	O
admission	O
.	O

This	O
finding	O
may	O
also	O
be	O
related	O
to	O
aging	B-PROC
per	O
se	O
.	O

Here	O
,	O
we	O
have	O
applied	O
serine	O
-	O
scanning	O
mutagenesis	B-PROC
to	O
the	O
C	O
-	O
terminal	O
-	O
most	O
heptad	O
-	O
repeat	O
region	O
in	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
to	O
investigate	O
the	O
functional	O
role	O
of	O
this	O
region	O
in	O
membrane	B-PROC
fusion	I-PROC
.	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
infection	O
was	O
blocked	O
by	O
specific	O
inhibitors	O
of	O
the	O
pH	O
-	O
sensitive	O
endosomal	O
protease	O
cathepsin	O
L	O
.	O
A	O
cell	O
-	O
free	O
membrane	O
-	O
fusion	O
system	O
demonstrates	O
that	O
engagement	O
of	O
receptor	O
followed	O
by	O
proteolysis	B-PROC
is	O
required	O
for	O
SARS	O
-	O
CoV	O
membrane	B-PROC
fusion	I-PROC
and	O
indicates	O
that	O
cathepsin	O
L	O
is	O
sufficient	O
to	O
activate	O
membrane	B-PROC
fusion	I-PROC
by	O
SARS	O
-	O
CoV	O
S	O
.	O
These	O
results	O
suggest	O
that	O
SARS	O
-	O
CoV	O
infection	O
results	O
from	O
a	O
unique	O
,	O
three	O
-	O
step	O
process	O
:	O
receptor	O
binding	O
and	O
induced	O
conformational	O
changes	O
in	O
S	O
glycoprotein	O
followed	O
by	O
cathepsin	O
L	O
proteolysis	B-PROC
within	O
endosomes	O
.	O

There	O
is	O
improvement	O
over	O
the	O
first	O
6	O
months	O
,	O
with	O
lingering	O
mild	O
decreases	O
in	O
lung	B-PROC
volume	I-PROC
and	O
diffusing	O
capacity	O
in	O
most	O
patients	O
.	O

TITLE	O
:	O
Coordinate	O
induction	O
of	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
by	O
SARS	O
-	O
CoV	O
also	O
in	O
the	O
absence	O
of	O
virus	B-PROC
replication	I-PROC
.	O

The	O
selective	O
neutrophil	O
elastase	O
inhibitor	O
sivelestat	O
reduces	O
neutrophil	O
elastase	O
activity	O
and	O
attenuates	O
acute	O
changes	O
in	O
the	O
pulmonary	O
microcirculation	B-PROC
.	O

TITLE	O
:	O
Transfusions	O
result	O
in	O
pulmonary	O
morbidity	O
and	O
death	B-PROC
after	O
a	O
moderate	O
degree	O
of	O
injury	O
.	O

In	O
contrast	O
,	O
truncation	O
of	O
26	O
or	O
39	O
amino	O
acids	O
eliminating	O
either	O
one	O
or	O
both	O
of	O
the	O
two	O
endodomain	O
cysteine	O
-	O
rich	O
motifs	O
,	O
respectively	O
,	O
inhibited	O
cell	B-PROC
fusion	I-PROC
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
S	O
.	O
The	O
17	O
and	O
26	O
amino	O
-	O
acid	O
deletions	O
did	O
not	O
adversely	O
affect	O
S	O
cell	O
-	O
surface	O
expression	B-PROC
,	O
while	O
the	O
39	O
amino	O
-	O
acid	O
truncation	O
inhibited	O
S	O
cell	O
-	O
surface	O
expression	B-PROC
suggesting	O
that	O
the	O
membrane	O
proximal	O
cysteine	O
-	O
rich	O
motif	O
plays	O
an	O
essential	O
role	O
in	O
S	O
cell	O
-	O
surface	O
expression	B-PROC
.	O

Mutagenesis	B-PROC
of	O
the	O
acidic	O
amino	O
-	O
acid	O
cluster	O
in	O
the	O
carboxyl	O
terminus	O
of	O
the	O
S	O
glycoprotein	O
as	O
well	O
as	O
modification	O
of	O
a	O
predicted	O
phosphorylation	B-PROC
site	O
within	O
the	O
acidic	O
cluster	O
revealed	O
that	O
this	O
amino	O
-	O
acid	O
motif	O
may	O
play	O
a	O
functional	O
role	O
in	O
the	O
retention	B-PROC
of	O
S	O
at	O
cell	O
surfaces	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
method	O
for	O
concentrating	O
and	O
purifying	O
SARS	O
coronavirus	O
RNA	O
by	O
a	O
magnetic	O
bead	O
capture	O
system	O
.	O

Four	O
macaque	O
monkeys	O
demonstrated	O
diffuse	O
alveolar	O
damage	O
,	O
characterized	O
by	O
hemorrhagic	O
pneumonia	O
,	O
serosanguineous	O
exudates	O
,	O
formation	B-PROC
of	O
hyaline	O
membranes	O
,	O
and	O
type	O
II	O
pneumocyte	O
hyperplasia	O
,	O
which	O
were	O
similar	O
to	O
those	O
that	O
have	O
been	O
noted	O
in	O
SARS	O
patients	O
.	O

The	O
macaques	O
infected	O
with	O
the	O
newly	O
isolated	O
reovirus	O
developed	O
a	O
fever	B-PROC
,	O
diffuse	O
alveolar	O
damage	O
and	O
pulmonary	O
interstitial	O
inflammation	O
similar	O
to	O
that	O
noted	O
in	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Apoptosis	B-PROC
induced	O
by	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
Vero	O
cells	O
is	O
replication	O
-	O
dependent	O
and	O
involves	O
caspase	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-PROC
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
a	O
newly	O
emerging	O
life	O
-	O
threatening	O
disease	O
in	O
humans	O
,	O
remains	O
unknown	O
.	O

To	O
map	O
the	O
antigenic	O
epitope	O
of	O
this	O
linear	O
epitope	O
dominant	O
region	O
,	O
a	O
set	O
of	O
16	O
partially	O
overlapping	O
fragments	O
spanning	O
the	O
fragment	O
were	O
fused	O
with	O
GST	O
and	O
expressed	B-PROC
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
immune	B-PROC
responses	I-PROC
against	O
the	O
S2	O
subunit	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
which	O
were	O
vaccinated	O
either	O
with	O
plasmid	O
DNA	O
encoding	O
the	O
S2	O
domain	O
(	O
residues	O
681	O
-	O
1120	O
),	O
the	O
recombinant	O
S2	O
fragment	O
(	O
residues	O
681	O
-	O
980	O
)	O
in	O
incomplete	O
Freund	O
'	O
s	O
adjuvant	O
,	O
or	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
The	O
increased	O
number	O
of	O
specific	O
cytotoxic	O
cells	O
(	O
CTLs	O
)	O
and	O
the	O
high	O
titer	O
of	O
specific	O
antibody	B-PROC
showed	O
stimulation	O
of	O
both	O
arms	O
of	O
the	O
immune	O
system	O
in	O
these	O
groups	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
humoral	B-PROC
immunity	I-PROC
against	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
we	O
studied	O
the	O
profiles	O
of	O
IgG	O
antibodies	O
to	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
SARS	O
-	O
CoV	O
.	O
Serum	O
specimens	O
from	O
10	O
SARS	O
patients	O
were	O
analyzed	O
by	O
Western	O
blotting	O
and	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
purified	O
recombinant	O
N	O
and	O
truncated	O
S	O
(	O
S1	O
,	O
S2	O
,	O
and	O
S3	O
)	O
proteins	O
as	O
antigens	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
of	O
novel	O
test	O
compounds	O
for	O
antiviral	O
chemotherapy	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

The	O
selection	O
of	O
25	O
test	O
materials	O
includes	O
eleven	O
trioxa	O
-	O
adamantane	O
-	O
triols	O
(	O
TATs	O
)	O
[	O
BN	O
,	O
IBNCA	O
,	O
ABNCA	O
,	O
VANBA	O
,	O
ethylVANBA	O
,	O
euBN	O
,	O
euVANBA	O
,	O
ansaBN	O
,	O
Ehrlich	O
BN	O
,	O
[	O
6	O
]	O
prismaneBN	O
,	O
nitrodiBN	O
],	O
trivially	O
termed	O
bananins	O
,	O
one	O
trioxa	O
-	O
adamantan	O
-	O
ol	O
(	O
TAO	O
)	O
THYMOBA	O
,	O
one	O
bis	O
-	O
bananin	O
pi	O
-	O
bananin	O
(	O
piBN	O
),	O
one	O
triazaadamantane	O
delta	O
-	O
bananin	O
(	O
deltaBN	O
),	O
seven	O
potential	O
nucleic	O
acid	O
-	O
binding	O
drugs	O
(	O
XBQC	O
,	O
INDO	O
,	O
PivINDO	O
,	O
AZTRION	O
,	O
AZADO	O
,	O
AZOCYS	O
,	O
AZOGALL	O
),	O
one	O
potential	O
antiviral	O
interferon	O
-	O
inducer	O
and	O
distant	O
nucleoside	O
analog	O
diazon	O
,	O
one	O
potential	O
HIV	O
protein	O
Vif	O
antagonist	B-PROC
AZODIAZON	O
,	O
one	O
folic	O
acid	O
-	O
diazon	O
condensate	O
DIAZONOFOL	O
,	O
and	O
one	O
special	O
nucleoside	O
analog	O
(	O
fructoinosine	O
/	O
fructovir	O
).	O

TITLE	O
:	O
CXC	O
chemokine	O
expression	B-PROC
and	O
synthesis	B-PROC
in	O
skeletal	O
muscle	O
during	O
ischemia	O
/	O
reperfusion	O
.	O

Tissue	B-PROC
viability	I-PROC
decreased	O
52	O
%	O
after	O
4	O
hours	O
of	O
reperfusion	O
and	O
did	O
not	O
change	O
significantly	O
by	O
24	O
hours	O
.	O

The	O
data	O
suggest	O
that	O
reperfusion	O
is	O
when	O
chemokine	O
mRNA	O
and	O
protein	B-PROC
synthesis	I-PROC
increase	O
.	O

Coincidentally	O
,	O
the	O
N	O
protein	O
was	O
also	O
found	O
to	O
downregulate	O
the	O
expression	B-PROC
of	O
the	O
theta	O
isoform	O
of	O
14	O
-	O
3	O
-	O
3	O
(	O
14	O
-	O
3	O
-	O
3theta	O
),	O
leading	O
to	O
the	O
accumulation	O
of	O
phosphorylated	O
N	O
protein	O
in	O
the	O
nucleus	O
,	O
in	O
the	O
absence	O
of	O
growth	B-PROC
factors	O
.	O

Using	O
short	O
interfering	O
RNA	O
specific	O
to	O
14	O
-	O
3	O
-	O
3theta	O
we	O
have	O
inhibited	O
its	O
expression	B-PROC
to	O
show	O
accumulation	O
of	O
phosphorylated	O
N	O
protein	O
in	O
the	O
nucleus	O
.	O

Acinar	O
cell	O
injury	O
early	O
in	O
acute	O
pancreatitis	O
leads	O
to	O
a	O
local	O
inflammatory	O
reaction	O
;	O
if	O
marked	O
this	O
leads	O
to	O
a	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
).	O

This	O
review	O
intends	O
to	O
present	O
an	O
overview	O
of	O
the	O
inflammatory	B-PROC
response	I-PROC
that	O
takes	O
place	O
following	O
pancreatic	O
acinar	O
cell	O
injury	O
.	O

Anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-PROC
was	O
detected	O
using	O
indirect	O
immunofluorescence	O
technique	O
and	O
quantified	O
by	O
two	O
-	O
fold	O
serial	O
dilutions	O
.	O

In	O
addition	O
to	O
the	O
well	O
-	O
known	O
functions	O
of	O
chloroquine	O
such	O
as	O
elevations	O
of	O
endosomal	O
pH	O
,	O
the	O
drug	O
appears	O
to	O
interfere	O
with	O
terminal	B-PROC
glycosylation	I-PROC
of	O
the	O
cellular	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

This	O
may	O
negatively	O
influence	O
the	O
virus	O
-	O
receptor	O
binding	O
and	O
abrogate	O
the	O
infection	O
,	O
with	O
further	O
ramifications	O
by	O
the	O
elevation	O
of	O
vesicular	O
pH	O
,	O
resulting	O
in	O
the	O
inhibition	B-PROC
of	O
infection	O
and	O
spread	O
of	O
SARS	O
CoV	O
at	O
clinically	O
admissible	O
concentrations	O
.	O

In	O
this	O
study	O
,	O
Isatis	O
indigotica	O
root	O
extract	O
,	O
five	O
major	O
compounds	O
of	O
I	O
.	O
indigotica	O
root	O
,	O
and	O
seven	O
plant	O
-	O
derived	O
phenolic	O
compounds	O
were	O
tested	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
3CLpro	O
effects	O
using	O
cell	O
-	O
free	O
and	O
cell	O
-	O
based	O
cleavage	B-PROC
assays	O
.	O

The	O
siRNAs	O
used	O
provided	O
relief	O
from	O
SCV	O
infection	O
-	O
induced	O
fever	B-PROC
,	O
diminished	O
SCV	O
viral	O
levels	O
and	O
reduced	O
acute	O
diffuse	O
alveoli	O
damage	O
.	O

Then	O
the	O
fragment	O
was	O
amplified	O
and	O
subcloned	O
into	O
expression	B-PROC
vector	O
pET28a	O
(+)	O
and	O
pPIC9K	O
.	O

All	O
required	O
mechanical	O
ventilation	O
for	O
periods	B-PROC
of	O
3	O
-	O
26	O
days	O
and	O
received	O
oxygen	O
for	O
5	O
-	O
64	O
days	O
.	O

TITLE	O
:	O
Gene	B-PROC
expression	I-PROC
profiles	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
SARS	O
patients	O
.	O

Recent	O
endeavours	O
have	O
focussed	O
on	O
the	O
development	B-PROC
of	O
improved	O
antiviral	O
therapies	O
for	O
virus	O
infections	O
that	O
have	O
already	O
proved	O
amenable	O
to	O
antiviral	O
drug	O
treatment	O
,	O
as	O
well	O
as	O
for	O
virus	O
infections	O
for	O
which	O
,	O
at	O
present	O
,	O
no	O
antiviral	O
drugs	O
have	O
been	O
formally	O
approved	O
(	O
i	O
.	O
e	O
.	O
human	O
papilloma	O
viruses	O
,	O
adenoviruses	O
,	O
human	O
herpesvirus	O
type	O
6	O
,	O
poxviruses	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
hemorrhagic	O
fever	B-PROC
viruses	O
).	O

TITLE	O
:	O
Rational	O
monoclonal	O
antibody	B-PROC
development	B-PROC
to	O
emerging	O
pathogens	O
,	O
biothreat	O
agents	O
and	O
agents	O
of	O
foreign	O
animal	O
disease	O
:	O
The	O
antigen	O
scale	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
two	O
metal	O
catalysts	O
Ag	O
/	O
Al2O3	O
and	O
Cu	O
/	O
Al2O3	O
that	O
interdict	O
the	O
transmission	O
pathway	B-PROC
for	O
SARS	O
and	O
other	O
respiratory	O
infectious	O
diseases	O
.	O

Results	O
implicated	O
that	O
the	O
second	O
heptad	O
repeat	O
region	O
of	O
spike	O
protein	O
could	O
be	O
a	O
good	O
target	O
for	O
vaccine	O
development	B-PROC
against	O
SARS	O
-	O
CoV	O
.	O

Four	O
patients	O
underwent	O
abdominal	O
decompression	O
because	O
of	O
abdominal	O
compartment	O
syndrome	O
,	O
three	O
of	O
whom	O
died	B-PROC
in	O
the	O
early	O
postoperative	O
course	O
.	O

However	O
,	O
there	O
is	O
limited	O
experience	O
with	O
scoring	O
systems	O
in	O
the	O
ED	O
,	O
while	O
early	O
and	O
aggressive	B-PROC
intervention	O
in	O
critically	O
ill	O
patients	O
in	O
the	O
ED	O
is	O
becoming	O
increasingly	O
important	O
.	O

Development	B-PROC
and	O
implementation	O
of	O
physiologic	O
scoring	O
systems	O
specific	O
to	O
this	O
setting	O
is	O
potentially	O
useful	O
in	O
the	O
early	O
recognition	O
and	O
prognostication	O
of	O
illness	O
severity	O
.	O

This	O
may	O
explain	O
why	O
adaptation	B-PROC
is	O
a	O
rapid	O
process	O
and	O
the	O
dominant	O
strain	O
,	O
once	O
adapted	O
to	O
a	O
new	O
host	O
cell	O
,	O
becomes	O
relatively	O
stable	O
.	O

Within	O
the	O
pp1b	O
sequence	O
the	O
polymerase	O
and	O
helicase	O
domains	O
were	O
identified	O
,	O
as	O
well	O
as	O
sequences	O
predicted	O
to	O
be	O
involved	O
in	O
ribosomal	B-PROC
frameshifting	I-PROC
,	O
including	O
the	O
conserved	O
slippery	O
sequence	O
UUUAAAC	O
and	O
two	O
potential	O
pseudoknot	O
structures	O
.	O

This	O
suggests	O
that	O
NF	B-PROC
-	I-PROC
kappaB	I-PROC
activation	I-PROC
is	O
cell	O
-	O
specific	O
.	O

Although	O
the	O
exact	O
mechanism	O
linking	O
sleep	B-PROC
apnea	O
with	O
cardiovascular	O
disease	O
is	O
unknown	O
,	O
there	O
is	O
evidence	O
that	O
obstructive	O
apnea	O
is	O
associated	O
with	O
a	O
group	O
of	O
proinflammatory	O
and	O
prothrombic	O
factors	O
that	O
are	O
also	O
important	O
in	O
the	O
development	B-PROC
of	O
atherosclerosis	O
.	O

Apnea	O
,	O
hypoxia	O
,	O
CO2	O
retention	B-PROC
and	O
arousals	O
provoke	O
elevated	O
sympathetic	O
activity	O
,	O
increased	O
afterload	O
and	O
elevated	O
left	O
ventricular	O
transmural	O
pressure	O
,	O
and	O
promote	O
the	O
progression	O
of	O
heart	O
failure	O
.	O

These	O
latter	O
two	O
patients	O
died	B-PROC
of	O
infections	O
32	O
and	O
36	O
days	O
after	O
HSCT	O
,	O
with	O
grade	O
IV	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
and	O
multiorgan	O
dysfunction	O
.	O

One	O
patient	O
had	O
an	O
MDS	O
relapse	O
4	O
months	O
after	O
HSCT	O
and	O
died	B-PROC
10	O
months	O
later	O
.	O

ABSTRACT	O
:	O
Viral	B-PROC
infection	I-PROC
can	O
result	O
in	O
alterations	O
to	O
the	O
host	O
subcellular	O
membrane	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
defined	O
the	O
2	O
-	O
D	O
membrane	O
pattern	O
and	O
shape	O
associated	O
with	O
the	O
SARS	O
virus	B-PROC
infection	I-PROC
.	O

Survival	O
at	O
12	O
months	O
of	O
age	O
by	O
disease	O
and	O
functional	O
development	B-PROC
at	O
follow	O
up	O
.	O

TITLE	O
:	O
Propylene	O
glycol	O
-	O
induced	O
lactic	O
acidosis	O
in	O
a	O
patient	O
with	O
normal	O
renal	B-PROC
function	I-PROC
:	O
a	O
proposed	O
mechanism	O
and	O
monitoring	O
recommendations	O
.	O

ABSTRACT	O
:	O
The	O
210	O
-	O
nucleotide	O
(	O
nt	O
)	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
in	O
the	O
positive	O
-	O
strand	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
genome	O
is	O
predicted	O
to	O
contain	O
four	O
higher	O
-	O
order	O
structures	O
identified	O
as	O
stem	O
-	O
loops	O
I	O
to	O
IV	O
,	O
which	O
may	O
function	O
as	O
cis	O
-	O
acting	O
elements	O
in	O
genomic	O
RNA	B-PROC
replication	I-PROC
.	O

These	O
results	O
together	O
indicate	O
that	O
stem	O
-	O
loop	O
IV	O
in	O
the	O
BCoV	O
5	O
'	O
UTR	O
is	O
a	O
cis	O
-	O
acting	O
element	O
for	O
DI	O
RNA	B-PROC
replication	I-PROC
and	O
that	O
it	O
might	O
function	O
through	O
interactions	O
with	O
cellular	O
proteins	O
.	O

TITLE	O
:	O
1	O
-	O
year	O
pulmonary	B-PROC
function	I-PROC
and	O
health	O
status	O
in	O
survivors	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

No	O
pulmonary	B-PROC
function	I-PROC
abnormalities	O
were	O
detected	O
in	O
59	O
patients	O
(	O
63	O
%).	O

One	O
year	O
after	O
recovery	O
from	O
SARS	O
,	O
persistent	O
pulmonary	B-PROC
function	I-PROC
impairment	O
was	O
found	O
in	O
about	O
one	O
third	O
of	O
patients	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
a	O
29	O
-	O
bp	O
insertion	O
in	O
ORF	O
8	O
of	O
bat	O
-	O
SARS	O
-	O
CoV	O
genome	O
,	O
not	O
in	O
most	O
human	O
SARS	O
-	O
CoV	O
genomes	O
,	O
suggests	O
that	O
it	O
has	O
a	O
common	O
ancestor	O
with	O
civet	O
SARS	O
-	O
CoV	O
.	O
Antibody	B-PROC
against	O
recombinant	O
bat	O
-	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
was	O
detected	O
in	O
84	O
%	O
of	O
Chinese	O
horseshoe	O
bats	O
by	O
using	O
an	O
enzyme	O
immunoassay	O
.	O

A	O
total	O
of	O
123	O
(	O
36	O
.	O
0	O
%)	O
of	O
352	O
patients	O
with	O
SARS	O
and	O
100	O
(	O
25	O
.	O
5	O
%)	O
of	O
392	O
control	O
subjects	O
had	O
haplotype	O
pairs	O
associated	O
with	O
medium	O
or	O
low	O
expression	B-PROC
of	O
MBL	O
(	O
OR	O
,	O
1	O
.	O
67	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
21	O
-	O
2	O
.	O
29	O
];	O
P	O
=.	O
00187	O
).	O

qRT	O
-	O
PCR	O
assays	O
are	O
most	O
established	O
for	O
the	O
detection	O
of	O
viral	O
load	O
and	O
therapy	O
monitoring	O
,	O
and	O
the	O
development	B-PROC
of	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)-	O
associated	O
coronavirus	O
qRT	O
-	O
PCR	O
assays	O
provide	O
a	O
textbook	O
example	O
of	O
the	O
value	O
of	O
this	O
technology	O
for	O
clinical	O
diagnostics	O
.	O

TITLE	O
:	O
Generation	O
of	O
human	O
antibody	B-PROC
fragments	O
recognizing	O
distinct	O
epitopes	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
SARS	O
-	O
CoV	O
protein	O
using	O
a	O
phage	O
display	O
approach	O
.	O

TITLE	O
:	O
Properties	O
of	O
isonucleotide	O
-	O
incorporated	O
oligodeoxynucleotides	O
and	O
inhibition	B-PROC
of	O
the	O
expression	B-PROC
of	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Antisense	O
oligonucleotides	O
are	O
recognized	O
to	O
be	O
very	O
efficient	O
tools	O
for	O
the	O
inhibition	B-PROC
of	O
gene	B-PROC
expression	I-PROC
in	O
a	O
sequence	O
specific	O
way	O
.	O

The	O
DNA	O
/	O
RNA	O
hybrid	O
formed	O
by	O
a	O
modified	O
oligodeoxynucleotide	O
and	O
its	O
target	O
RNA	O
could	O
activate	O
RNase	O
H	O
.	O
The	O
3	O
'-	O
end	O
-	O
modified	O
antisense	O
oligodeoxynucelotides	O
inhibited	O
S	O
-	O
glycoprotein	O
expression	B-PROC
of	O
SARS	O
-	O
CoV	O
at	O
the	O
mRNA	O
levels	O
in	O
insect	O
Sf9	O
cells	O
.	O

Instead	O
of	O
employing	O
clustering	O
methods	O
,	O
we	O
ranked	O
the	O
severity	O
of	O
recovering	O
SARS	O
patients	O
by	O
generalized	O
associate	O
plots	O
(	O
GAP	O
)	O
according	O
to	O
the	O
expression	B-PROC
profiles	O
of	O
52	O
signature	O
genes	O
.	O

RESULTS	O
:	O
Based	O
on	O
changes	O
in	O
gene	B-PROC
expression	I-PROC
of	O
peripheral	O
blood	O
,	O
we	O
identified	O
52	O
signature	O
genes	O
that	O
accurately	O
discriminated	O
acute	O
SARS	O
patients	O
from	O
non	O
-	O
SARS	O
controls	O
.	O

The	O
results	O
showed	O
that	O
the	O
FBS	O
medium	O
was	O
optimal	O
for	O
recombinant	O
N	O
protein	B-PROC
expression	B-PROC
and	O
growth	B-PROC
of	O
the	O
recombinant	O
strain	O
.	O

The	O
optimal	O
final	O
concentration	O
of	O
methanol	O
is	O
1	O
%	O
(	O
V	O
/	O
V	O
),	O
and	O
the	O
DO	O
has	O
a	O
significant	O
effect	O
on	O
recombinant	O
N	O
protein	B-PROC
expression	B-PROC
and	O
growth	B-PROC
of	O
recombinant	O
strain	O
.	O

ABSTRACT	O
:	O
In	O
concert	O
with	O
increased	O
concerns	O
regarding	O
both	O
biologic	O
terrorism	O
and	O
new	O
natural	O
infectious	O
disease	O
threats	O
(	O
e	O
.	O
g	O
.,	O
severe	O
acute	O
respiratory	O
syndrome	O
[	O
SARS	O
]	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
),	O
as	O
a	O
result	O
of	O
advances	O
in	O
medical	O
informatics	O
,	O
various	O
data	O
sources	O
are	O
available	O
to	O
epidemiologists	O
for	O
routine	O
,	O
prospective	O
monitoring	O
of	O
public	O
health	O
.	O

Inhibition	B-PROC
of	I-PROC
cell	I-PROC
adhesion	I-PROC
and	O
caspase	O
-	O
3	O
activation	O
could	O
,	O
therefore	O
,	O
have	O
prevented	O
SARS	O
patients	O
from	O
developing	O
thrombocytopenia	O
and	O
lymphopenia	O
.	O

In	O
addition	O
,	O
the	O
expression	B-PROC
of	O
interferon	O
-	O
gamma	O
within	O
the	O
inflammatory	O
lesions	O
was	O
examined	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
biological	O
significance	O
of	O
the	O
novel	O
enzymatic	B-PROC
activity	I-PROC
in	O
vivo	O
remains	O
to	O
be	O
investigated	O
.	O

TITLE	O
:	O
Coronaviruses	O
as	O
vectors	O
:	O
stability	O
of	O
foreign	O
gene	B-PROC
expression	I-PROC
.	O

The	O
coronavirus	O
replicase	O
carries	O
out	O
regulatory	O
tasks	O
involved	O
in	O
the	O
maintenance	O
,	O
transcription	B-PROC
,	O
and	O
replication	O
of	O
the	O
coronavirus	O
genome	O
.	O

Novel	O
variant	O
strains	O
,	O
unrelated	O
by	O
S1	O
sequencing	O
and	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
analyses	O
to	O
reference	O
and	O
vaccine	O
strains	O
,	O
were	O
also	O
identified	O
.	O

The	O
injection	O
resulted	O
in	O
pulmonary	O
edema	O
and	O
acute	O
lung	O
injury	O
,	O
presumably	O
due	O
to	O
direct	O
toxicity	O
and	O
a	O
resultant	O
increase	O
in	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
.	O

Nevertheless	O
,	O
combination	O
of	O
the	O
intron	O
and	O
the	O
exon	O
splicing	B-PROC
enhancers	O
resulted	O
in	O
suppressing	O
the	O
intron	O
-	O
enhancing	O
e	O
STR2	O
protein	B-PROC
expression	B-PROC
in	O
in	O
CHO	O
/	O
dhFr	B-PROC
-	O
cells	O
.	O

Screening	O
for	O
viral	O
contamination	O
is	O
done	O
by	O
the	O
mouse	O
antibody	B-PROC
production	I-PROC
(	O
MAP	O
)	O
test	O
,	O
by	O
cell	O
culture	O
,	O
or	O
alternatively	O
by	O
direct	O
detection	O
of	O
the	O
viral	O
agents	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O

The	O
recombinant	O
expression	B-PROC
vector	O
produced	O
high	O
level	O
of	O
the	O
N	O
fusion	O
protein	O
after	O
induction	O
,	O
and	O
that	O
protein	O
was	O
purified	O
successfully	O
by	O
affinity	O
chromatography	O
and	O
displayed	O
higher	O
antigenicity	O
and	O
specificity	O
as	O
compared	O
with	O
whole	O
virus	O
lysates	O
.	O

Eligible	O
studies	O
included	O
patients	O
who	O
were	O
undergoing	O
surgery	O
,	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
),	O
admitted	O
with	O
advanced	O
heart	O
failure	O
,	O
or	O
diagnosed	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
/	O
or	O
sepsis	O
;	O
and	O
studies	O
that	O
reported	O
death	B-PROC
and	O
the	O
number	O
of	O
days	O
hospitalized	O
or	O
the	O
number	O
of	O
days	O
in	O
the	O
ICU	O
as	O
outcome	O
measures	O
.	O

A	O
random	O
-	O
effects	O
model	O
was	O
used	O
to	O
estimate	O
the	O
odds	O
ratios	O
(	O
ORs	O
)	O
for	O
death	B-PROC
,	O
number	O
of	O
days	O
hospitalized	O
,	O
and	O
use	O
of	O
inotropes	O
and	O
intravenous	O
vasodilators	O
.	O

The	O
present	O
study	O
attempted	O
to	O
fill	O
this	O
void	B-PROC
by	O
presenting	O
a	O
detailed	O
account	O
of	O
a	O
comprehensive	O
and	O
integrated	O
approach	O
to	O
developing	O
,	O
implementing	O
,	O
and	O
evaluating	O
a	O
tabletop	O
exercise	O
designed	O
to	O
enhance	O
emergency	O
preparedness	O
and	O
response	O
of	O
public	O
health	O
workers	O
.	O

The	O
flexibility	O
afforded	O
by	O
creating	O
a	O
standardized	O
competency	O
-	O
based	O
process	O
can	O
extend	O
to	O
other	O
state	O
and	O
local	O
health	O
departments	O
and	O
provides	O
evidence	O
of	O
the	O
reciprocal	O
relationship	O
between	O
research	O
and	O
practice	O
needed	O
to	O
advance	O
the	O
areas	O
of	O
emergency	O
preparedness	O
training	O
and	O
workforce	O
development	B-PROC
initiatives	O
in	O
public	O
health	O
.	O

The	O
antibody	B-PROC
development	B-PROC
in	O
seven	O
cats	O
experimentally	O
infected	O
with	O
FCoV	O
type	O
1	O
revealed	O
that	O
,	O
with	O
progressing	O
duration	O
of	O
infection	O
,	O
antibodies	O
to	O
FCoV	O
type	O
1	O
significantly	O
increased	O
over	O
those	O
to	O
FCoV	O
type	O
2	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
membrane	O
protein	O
and	O
5	O
-	O
lipoxygenase	O
-	O
activating	O
protein	O
(	O
FLAP	O
)	O
are	O
among	O
a	O
large	O
number	O
of	O
membrane	O
proteins	O
that	O
are	O
poorly	O
expressed	B-PROC
when	O
traditional	O
expression	B-PROC
systems	O
and	O
methods	O
are	O
employed	O
.	O

It	O
is	O
likely	O
that	O
the	O
immune	B-PROC
responses	I-PROC
induced	O
by	O
SARS	O
-	O
CoV	O
infection	O
could	O
also	O
cause	O
pathological	O
damage	O
to	O
the	O
host	O
,	O
especially	O
in	O
the	O
case	O
of	O
proinflammatory	O
cytokines	O
.	O

We	O
further	O
found	O
that	O
3a	O
misexpression	O
induces	O
apoptosis	B-PROC
,	O
which	O
could	O
be	O
modulated	O
by	O
cellular	O
cytochrome	B-PROC
c	I-PROC
levels	O
and	O
caspase	B-PROC
activity	I-PROC
.	O

The	O
peak	O
inflammatory	B-PROC
response	I-PROC
was	O
obtained	O
at	O
24	O
h	O
when	O
the	O
fluid	O
volume	O
,	O
protein	O
concentration	O
,	O
C	O
-	O
reactive	O
protein	O
and	O
cell	O
infiltration	O
were	O
maximums	O
.	O

Following	O
induction	O
of	O
acute	O
lung	O
injury	O
,	O
gut	O
epithelial	O
proliferation	O
and	O
apoptosis	B-PROC
were	O
assessed	O
in	O
a	O
)	O
C3H	O
/	O
HeN	O
wild	O
-	O
type	O
and	O
C3H	O
/	O
HeJ	O
mice	O
,	O
which	O
lack	O
functional	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
n	O
=	O
17	O
);	O
b	O
)	O
C57Bl	O
/	O
6	O
mice	O
that	O
received	O
monoclonal	O
anti	O
-	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
or	O
control	O
antibody	B-PROC
(	O
n	O
=	O
22	O
);	O
and	O
c	O
)	O
C57Bl	O
/	O
6	O
wild	O
-	O
type	O
and	O
transgenic	O
mice	O
that	O
overexpress	O
Bcl	O
-	O
2	O
in	O
their	O
gut	O
epithelium	O
(	O
n	O
=	O
21	O
).	O

Intestinal	O
epithelial	O
proliferation	O
and	O
death	B-PROC
were	O
also	O
examined	O
in	O
animals	O
with	O
differing	O
degrees	O
of	O
lung	O
inflammation	O
(	O
n	O
=	O
24	O
)	O
as	O
well	O
as	O
in	O
a	O
time	O
course	O
analysis	O
following	O
a	O
fixed	O
injury	O
(	O
n	O
=	O
18	O
).	O

C3H	O
/	O
HeJ	O
mice	O
had	O
higher	O
levels	O
of	O
proliferation	O
than	O
C3H	O
/	O
HeN	O
animals	O
without	O
additional	O
changes	O
in	O
apoptosis	B-PROC
.	O

Anti	O
-	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
antibody	B-PROC
had	O
no	O
effect	O
on	O
gut	O
epithelial	O
proliferation	O
or	O
death	B-PROC
.	O

Overexpression	B-PROC
of	O
Bcl	O
-	O
2	O
did	O
not	O
change	O
proliferation	O
despite	O
decreasing	O
gut	O
apoptosis	B-PROC
.	O

The	O
first	O
part	O
of	O
this	O
review	O
focuses	O
on	O
problems	O
not	O
yet	O
solved	O
,	O
such	O
as	O
1	O
)	O
surveillance	O
systems	O
,	O
which	O
should	O
be	O
active	O
and	O
extremely	O
flexible	O
;	O
2	O
)	O
infection	O
outbreaks	O
in	O
hospitals	O
and	O
strategies	O
to	O
avoid	O
them	O
;	O
3	O
)	O
hand	O
washing	O
and	O
alternatives	O
such	O
as	O
rapid	O
hand	O
antisepsis	O
;	O
4	O
)	O
water	O
and	O
food	O
in	O
the	O
hospital	O
as	O
potential	O
reservoirs	O
of	O
nosocomial	O
pathogens	O
;	O
5	O
)	O
upgrading	O
of	O
infection	O
control	O
programs	O
to	O
turn	O
them	O
into	O
systems	O
to	O
improve	O
the	O
quality	O
of	O
care	O
;	O
6	O
)	O
fatal	O
Gram	O
-	O
negative	O
bacteremias	O
in	O
hospitals	O
from	O
developing	O
countries	O
,	O
which	O
can	O
be	O
avoided	O
with	O
better	O
standards	O
of	O
care	O
;	O
7	O
)	O
the	O
elemental	O
role	O
of	O
the	O
microbiology	O
laboratory	O
in	O
the	O
prevention	O
and	O
control	O
of	O
infections	O
;	O
8	O
)	O
the	O
unprecedented	O
crisis	O
due	O
to	O
the	O
emergence	O
of	O
specific	O
multi	O
-	O
resistant	O
pathogens	O
;	O
9	O
)	O
the	O
risks	O
for	O
healthcare	O
workers	O
,	O
such	O
as	O
tuberculosis	O
,	O
hepatitis	O
,	O
HIV	O
,	O
SARS	O
,	O
and	O
hemorrhagic	O
fevers	B-PROC
;	O
and	O
10	O
)	O
the	O
need	O
for	O
the	O
consistent	O
application	O
of	O
guidelines	O
.	O

Consideration	O
is	O
given	O
to	O
the	O
asymmetric	O
development	B-PROC
of	O
infection	O
control	O
globally	O
.	O

The	O
crystal	O
structures	O
of	O
the	O
M	O
(	O
pro	O
):	O
APE	O
complex	O
in	O
the	O
space	O
groups	O
C2	O
and	O
P2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
revealed	O
the	O
formation	B-PROC
of	O
a	O
covalent	B-PROC
bond	O
between	O
the	O
catalytic	O
Cys145	O
S	O
(	O
gamma	O
)	O
atom	O
of	O
the	O
peptidase	O
and	O
the	O
epoxide	O
C3	O
atom	O
of	O
the	O
inhibitor	O
,	O
substantiating	O
the	O
mode	O
of	O
action	O
of	O
this	O
class	O
of	O
cysteine	O
-	O
peptidase	O
inhibitors	O
.	O

High	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
has	O
been	O
shown	O
to	O
prevent	O
both	O
acute	O
and	O
chronic	O
lung	O
injury	O
in	O
the	O
management	O
of	O
very	O
low	O
birth	B-PROC
weight	O
infants	O
with	O
RDS	O
,	O
with	O
gentle	O
ventilation	O
approach	O
.	O

The	O
addition	O
of	O
a	O
low	O
dose	O
of	O
PFC	O
with	O
HFO	O
was	O
effective	O
in	O
achieving	O
adequate	O
oxygenation	B-PROC
,	O
with	O
a	O
reduction	O
in	O
further	O
lung	O
injury	O
in	O
neonates	O
.	O

We	O
reconcile	O
discrepancies	O
between	O
published	O
estimates	O
of	O
the	O
basic	O
reproductive	B-PROC
number	O
R0	O
for	O
SARS	O
(	O
a	O
crucial	O
epidemiologic	O
parameter	O
),	O
discuss	O
insights	O
regarding	O
SARS	O
control	O
measures	O
that	O
have	O
emerged	O
uniquely	O
from	O
a	O
modeling	O
approach	O
,	O
and	O
argue	O
that	O
high	O
priorities	O
for	O
future	O
modeling	O
of	O
SARS	O
and	O
similar	O
respiratory	O
EIDs	O
should	O
include	O
informing	O
quarantine	O
policy	O
and	O
better	O
understanding	O
the	O
impact	O
of	O
population	O
heterogeneity	O
on	O
transmission	O
patterns	O
.	O

Various	O
types	O
of	O
cells	O
damaged	O
by	O
SARS	O
-	O
CoV	O
and	O
inflammatory	O
mediators	O
released	O
by	O
those	O
cells	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
lung	O
injury	O
in	O
SARS	O
.	O

Indirect	O
Immunofluorescence	O
assay	O
indicated	O
that	O
they	O
could	O
specifically	O
bind	O
to	O
protein	O
X4	O
expressed	B-PROC
in	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Cross	B-PROC
-	I-PROC
reaction	I-PROC
of	O
SARS	O
-	O
CoV	O
antigen	O
with	O
autoantibodies	O
in	O
autoimmune	O
diseases	O
.	O

Recently	O
,	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
protease	O
has	O
been	O
implied	O
to	O
be	O
possible	O
relevance	O
to	O
SARS	O
-	O
CoV	O
pathogenesis	B-PROC
.	O

In	O
addition	O
,	O
our	O
result	O
also	O
demonstrated	O
the	O
cleavage	B-PROC
of	O
the	O
V	O
-	O
ATPase	O
G1	O
fusion	O
protein	O
and	O
the	O
immunoprecipitation	O
of	O
cellular	O
V	O
-	O
ATPase	O
G1	O
by	O
the	O
3CL	O
(	O
pro	O
).	O

ABSTRACT	O
:	O
Coronavirus	O
spike	O
(	O
S	O
)	O
proteins	O
are	O
responsible	O
for	O
binding	O
and	O
fusion	O
with	O
target	O
cells	O
and	O
thus	O
play	O
an	O
essential	O
role	O
in	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
The	O
nsp2	O
replicase	O
proteins	O
of	O
murine	O
hepatitis	O
virus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
are	O
dispensable	O
for	O
viral	B-PROC
replication	I-PROC
.	O

The	O
Deltansp2	O
mutant	O
viruses	O
lacked	O
expression	B-PROC
of	O
both	O
nsp2	O
and	O
an	O
nsp2	O
-	O
nsp3	O
precursor	O
,	O
but	O
cleaved	O
the	O
engineered	O
chimeric	O
nsp1	O
-	O
nsp3	O
cleavage	B-PROC
site	O
as	O
efficiently	O
as	O
the	O
native	O
nsp1	O
-	O
nsp2	O
cleavage	B-PROC
site	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
fails	O
to	O
activate	O
cytokine	O
-	O
mediated	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
in	O
cultured	O
human	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
.	O

The	O
sensitivity	O
of	O
real	O
-	O
time	O
PCR	O
was	O
10	O
-	O
100	O
copies	O
/	O
ml	O
,	O
there	O
was	O
no	O
cross	B-PROC
reaction	I-PROC
to	O
other	O
respiratory	O
viruses	O
such	O
as	O
influenza	O
virus	O
etc	O
.	O

RESULTS	O
:	O
The	O
sensitivity	O
of	O
real	O
-	O
time	O
PCR	O
was	O
10	O
-	O
100	O
copies	O
/	O
ml	O
,	O
there	O
was	O
no	O
cross	B-PROC
reaction	I-PROC
to	O
other	O
respiratory	O
viruses	O
such	O
as	O
influenza	O
virus	O
etc	O
.	O

Prevention	O
and	O
management	O
of	O
ventilator	O
-	O
associated	O
pneumonia	O
,	O
pulmonary	O
infection	O
and	O
wound	O
infection	O
,	O
along	O
with	O
improvement	O
of	O
microcirculation	B-PROC
,	O
organ	O
function	O
protection	O
and	O
intensive	O
nutrition	B-PROC
support	O
,	O
are	O
effective	O
treatments	O
for	O
patients	O
with	O
blast	O
injury	O
of	O
the	O
lungs	O
and	O
extensive	O
burns	O
.	O

Other	O
forms	O
of	O
infectious	O
disease	O
that	O
district	O
nurses	O
encounter	O
--	O
such	O
as	O
hepatitis	O
B	O
and	O
C	O
and	O
the	O
HIV	O
virus	O
that	O
are	O
spread	O
through	O
contact	O
with	O
blood	O
or	O
sexual	B-PROC
intercourse	I-PROC
--	O
rely	O
far	O
more	O
on	O
the	O
infected	O
individual	O
to	O
act	O
responsibly	O
in	O
preventing	O
others	O
from	O
being	O
infected	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
pulmonary	B-PROC
function	I-PROC
,	O
exercise	O
capacity	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
among	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
survivors	O
.	O

SARS	O
viral	O
genomic	O
sequences	O
were	O
not	O
detected	O
in	O
the	O
testes	O
by	O
in	O
situ	O
hybridization	B-PROC
.	O

Scalable	O
transcriptional	B-PROC
analysis	O
routine	O
(	O
STAR	O
)	O
represents	O
a	O
novel	O
integration	B-PROC
of	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
and	O
capillary	O
electrophoresis	O
that	O
allows	O
detection	O
of	O
dozens	O
of	O
gene	O
transcripts	O
in	O
a	O
multiplexed	O
format	O
using	O
amplicon	O
size	O
as	O
an	O
identifier	O
for	O
each	O
target	O
.	O

Surprisingly	O
,	O
analysis	O
of	O
the	O
putative	O
cleavage	B-PROC
sites	O
of	O
the	O
3CL	O
(	O
pro	O
)	O
revealed	O
a	O
unique	O
putative	O
cleavage	B-PROC
site	O
.	O

The	O
complete	O
S1	O
expression	B-PROC
cassette	O
was	O
subcloned	O
into	O
the	O
shuttle	O
vector	O
pVAXE3	O
,	O
then	O
further	O
cloned	O
into	O
the	O
backbone	O
vector	O
pPoly2	O
-	O
CAV2	O
containing	O
complete	O
genome	O
of	O
CAV	O
-	O
2	O
.	O

We	O
describe	O
a	O
general	O
protocol	O
for	O
preparation	O
of	O
pure	O
,	O
monodisperse	O
third	O
-	O
generation	O
mannosylated	O
poly	O
-	O
L	O
-	O
lysine	O
dendrimer	O
-	O
peptide	O
conjugates	O
using	O
direct	O
,	O
machine	O
-	O
assisted	O
Fmoc	O
/	O
t	O
-	O
Bu	O
solid	O
phase	O
peptide	B-PROC
synthesis	I-PROC
.	O

Postural	O
reduction	O
in	O
lower	O
inflection	O
point	O
pressure	O
of	O
lung	O
PV	O
curve	O
was	O
the	O
sole	O
independent	O
predictor	O
of	O
pronation	B-PROC
-	O
induced	O
increases	O
in	O
PaO2	O
/	O
FIO2	O
(	O
R2	O
=	O
0	O
.	O
76	O
).	O

TITLE	O
:	O
Design	O
and	O
synthesis	B-PROC
of	O
peptidomimetic	O
severe	O
acute	O
respiratory	O
syndrome	O
chymotrypsin	O
-	O
like	O
protease	B-PROC
inhibitors	I-PROC
.	O

The	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
was	O
enhanced	O
most	O
effectively	O
through	O
the	O
use	O
of	O
inactivated	O
virus	O
with	O
adjuvants	O
,	O
either	O
MF59	O
or	O
alum	O
,	O
and	O
was	O
associated	O
with	O
stimulation	O
of	O
the	O
CD4	O
but	O
not	O
the	O
CD8	O
response	O
.	O

We	O
previously	O
reported	O
that	O
concanavalin	O
A	O
-	O
immobilized	O
polystyrene	O
nanospheres	O
(	O
Con	O
A	O
-	O
NS	O
)	O
could	O
efficiently	O
capture	O
HIV	O
-	O
1	O
particles	O
and	O
intranasal	O
immunization	O
with	O
inactivated	O
HIV	O
-	O
1	O
-	O
capturing	O
nanospheres	O
(	O
HIV	O
-	O
NS	O
)	O
induced	O
vaginal	O
anti	O
-	O
HIV	O
-	O
1	O
IgA	O
antibody	B-PROC
responses	I-PROC
in	O
mice	O
.	O

Commercially	O
available	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
tests	O
for	O
SARS	O
have	O
recently	O
appeared	O
;	O
however	O
,	O
meaningful	O
evaluations	O
of	O
these	O
assays	O
have	O
not	O
yet	O
been	O
performed	O
and	O
their	O
true	O
performance	O
has	O
not	O
been	O
determined	O
.	O

This	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
assay	O
could	O
be	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-PROC
.	O

It	O
is	O
also	O
something	O
I	O
have	O
learned	B-PROC
in	O
observing	O
others	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
induced	O
a	O
strong	O
anti	O
-	O
nucleocapsid	O
(	O
anti	O
-	O
N	O
)	O
antibody	B-PROC
response	I-PROC
.	O

The	O
2	O
patients	O
who	O
died	B-PROC
had	O
significantly	O
lower	O
hemoglobin	O
levels	O
,	O
monocyte	O
counts	O
,	O
albumin	O
levels	O
,	O
and	O
oxygen	O
saturation	O
levels	O
on	O
admission	O
and	O
had	O
more	O
-	O
extensive	O
involvement	O
visible	O
on	O
chest	O
radiographs	O
.	O

Our	O
results	O
suggest	O
that	O
pulmonary	O
vascular	O
occlusion	B-PROC
occurs	O
in	O
both	O
patients	O
with	O
uncomplicated	O
malaria	O
and	O
those	O
with	O
severe	O
malaria	O
,	O
likely	O
from	O
sequestration	O
of	O
both	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
and	O
white	O
blood	O
cells	O
.	O

Three	O
patients	O
developed	O
adult	O
respiratory	O
distress	O
syndrome	O
and	O
one	O
died	B-PROC
from	O
respiratory	O
failure	O
.	O

We	O
tested	O
the	O
hypotheses	O
that	O
oleic	O
acid	O
(	O
OA	O
)	O
infusion	O
causes	O
changes	O
in	O
intestinal	O
circulation	B-PROC
,	O
oxygenation	B-PROC
and	O
metabolism	B-PROC
,	O
and	O
that	O
OA	O
is	O
distributed	O
to	O
tissues	O
outside	O
the	O
lung	O
.	O

OA	O
infusion	O
induced	O
a	O
moderate	O
increase	O
in	O
mean	O
pulmonary	O
arterial	B-PROC
pressure	I-PROC
and	O
a	O
decrease	O
in	O
PaO2	O
/	O
Fraction	O
inspired	B-PROC
O2	O
(	O
P	O
/	O
F	O
)	O
ratio	O
,	O
giving	O
evidence	O
of	O
severe	O
lung	O
injury	O
.	O

TITLE	O
:	O
Structural	O
basis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphate	O
dephosphorylation	B-PROC
by	O
a	O
conserved	O
domain	O
of	O
nsP3	O
.	O

New	O
strategies	O
to	O
improve	O
upon	O
SCT	O
patient	O
outcome	O
include	O
use	O
of	O
a	O
scoring	O
system	O
to	O
predict	O
mortality	O
,	O
better	O
therapies	O
for	O
MOSF	O
and	O
integration	B-PROC
of	O
ICU	O
components	O
and	O
multispecialist	O
involvement	O
earlier	O
in	O
the	O
clinical	O
course	O
to	O
prevent	O
severe	O
complications	O
such	O
as	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
Cov	O
spike	O
protein	O
:	O
soluble	O
expression	B-PROC
in	O
E	O
.	O
coli	O
,	O
purification	O
and	O
functional	O
characterization	O
.	O

In	O
this	O
paper	O
,	O
we	O
get	O
sufficient	O
soluble	O
N	O
terminal	O
GST	O
tagged	O
RBD	O
protein	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
);	O
data	O
from	O
ELISA	O
and	O
flow	O
cytometry	O
assay	O
demonstrate	O
that	O
the	O
recombinant	O
protein	O
is	O
functional	O
and	O
binding	O
to	O
ACE2	O
positive	O
Vero	O
E6	O
cell	O
efficiently	O
.	O

TITLE	O
:	O
Seroprevalence	O
of	O
SARS	O
coronavirus	O
antibody	B-PROC
in	O
household	O
contacts	O
.	O

TITLE	O
:	O
Specific	O
targeting	B-PROC
highly	O
conserved	O
residues	O
in	O
the	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-PROC
primer	O
grip	B-PROC
region	O
.	O

TITLE	O
:	O
ACE2	O
receptor	B-PROC
expression	B-PROC
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
depend	O
on	O
differentiation	B-PROC
of	O
human	O
airway	O
epithelia	O
.	O

As	O
assessed	O
by	O
immunofluorescence	O
staining	O
and	O
membrane	O
biotinylation	O
,	O
ACE2	O
protein	O
was	O
more	O
abundantly	O
expressed	B-PROC
on	O
the	O
apical	O
than	O
the	O
basolateral	O
surface	O
of	O
polarized	O
airway	O
epithelia	O
.	O

The	O
results	O
indicate	O
that	O
infection	O
of	O
human	O
airway	O
epithelia	O
by	O
SARS	O
coronavirus	O
correlates	O
with	O
the	O
state	O
of	O
cell	B-PROC
differentiation	I-PROC
and	O
ACE2	O
expression	B-PROC
and	O
localization	B-PROC
.	O

It	O
is	O
believed	O
that	O
HR2	O
peptides	O
block	O
the	O
six	O
-	O
helix	O
bundle	O
formation	B-PROC
,	O
a	O
key	O
structure	O
in	O
the	O
viral	O
fusion	O
,	O
by	O
interacting	O
with	O
the	O
HR1	O
region	O
.	O

Recommended	O
isolation	O
practices	O
for	O
labor	B-PROC
and	O
delivery	O
and	O
proper	O
procedures	O
for	O
donning	O
,	O
using	O
,	O
and	O
doffing	O
personal	O
protective	O
equipment	O
are	O
provided	O
.	O

Potential	O
maternal	O
outcomes	O
include	O
spontaneous	O
miscarriage	O
during	O
the	O
first	O
trimester	O
,	O
preterm	O
birth	B-PROC
,	O
emergency	O
cesarean	O
section	O
,	O
renal	O
failure	O
,	O
secondary	O
bacterial	O
pneumonia	O
,	O
sepsis	O
,	O
adult	O
respiratory	O
distress	O
syndrome	O
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
surgical	O
site	O
infection	O
,	O
and	O
maternal	B-PROC
death	B-PROC
.	O

Hospitals	O
were	O
surveyed	O
for	O
fever	B-PROC
clusters	O
.	O

Lessons	O
learned	B-PROC
from	O
mounting	O
a	O
UK	O
response	O
to	O
SARS	O
included	O
:	O
the	O
importance	O
of	O
international	O
collaboration	O
;	O
formation	B-PROC
of	O
a	O
UK	O
-	O
wide	O
,	O
multidisciplinary	O
Task	O
Force	O
;	O
flexible	O
case	O
reporting	O
mechanisms	O
;	O
integration	B-PROC
of	O
surveillance	O
and	O
laboratory	O
data	O
;	O
generation	O
of	O
prompt	O
and	O
web	O
-	O
accessible	O
guidance	O
and	O
advice	O
;	O
availability	O
of	O
surge	O
capacity	O
;	O
and	O
contingency	O
planning	O
.	O

Lessons	O
learned	B-PROC
are	O
being	O
incorporated	O
into	O
the	O
HPA	O
'	O
s	O
preparedness	O
to	O
prevent	O
and	O
control	O
future	O
newly	O
emerging	O
infectious	O
disease	O
threats	O
.	O

TITLE	O
:	O
Transplantation	O
of	O
glial	O
-	O
committed	O
progenitor	O
cells	O
into	O
a	O
viral	O
model	O
of	O
multiple	O
sclerosis	O
induces	O
remyelination	B-PROC
in	O
the	O
absence	O
of	O
an	O
attenuated	O
inflammatory	B-PROC
response	I-PROC
.	O

TITLE	O
:	O
Anti	O
-	O
SARS	O
-	O
CoV	O
immunity	B-PROC
induced	O
by	O
a	O
novel	O
CpG	O
oligodeoxynucleotide	O
.	O

Although	O
we	O
confirmed	O
these	O
findings	O
,	O
we	O
observed	O
cytoplasmic	O
localization	B-PROC
of	O
IBV	O
3b	O
with	O
apparent	O
exclusion	O
from	O
the	O
nucleus	O
in	O
avian	O
cells	O
(	O
IBV	O
normally	O
infects	O
chickens	O
).	O

ABSTRACT	O
:	O
Rituximab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	B-PROC
approved	O
for	O
malignant	O
lymphoma	O
,	O
is	O
being	O
increasingly	O
,	O
effectively	O
,	O
and	O
safely	O
used	O
for	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
and	O
other	O
humoral	O
autoimmune	O
disorders	O
.	O

Four	O
patients	O
died	B-PROC
during	O
further	O
treatment	O
due	O
to	O
multiple	O
trauma	O
or	O
multiple	O
organ	O
failure	O
.	O

Recovered	O
patients	O
were	O
found	O
to	O
have	O
higher	O
and	O
sustainable	O
levels	O
of	O
both	O
N	O
protein	O
-	O
specific	O
and	O
S	O
glycoprotein	O
-	O
specific	O
Nab	O
responses	O
,	O
suggesting	O
that	O
antibody	B-PROC
responses	I-PROC
likely	O
play	O
an	O
important	O
role	O
in	O
determining	O
the	O
ultimate	O
disease	O
outcome	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
.	O

With	O
a	O
mean	O
follow	O
-	O
up	O
of	O
15	O
.	O
9	O
months	O
,	O
patient	O
survival	O
is	O
(	O
21	O
/	O
22	O
)	O
96	O
%	O
and	O
graft	B-PROC
survival	I-PROC
(	O
19	O
/	O
22	O
)	O
87	O
%.	O

TITLE	O
:	O
SARS	O
coronavirus	O
7a	O
protein	O
blocks	O
cell	B-PROC
cycle	I-PROC
progression	I-PROC
at	O
G0	O
/	O
G1	B-PROC
phase	I-PROC
via	O
the	O
cyclin	O
D3	O
/	O
pRb	O
pathway	B-PROC
.	O

These	O
results	O
suggest	O
that	O
the	O
insufficient	O
expression	B-PROC
of	O
cyclin	O
D3	O
may	O
cause	O
a	O
decreased	O
activity	O
of	O
cyclin	O
D	O
/	O
cdk4	O
/	O
6	O
,	O
resulting	O
in	O
the	O
inhibition	B-PROC
of	O
Rb	O
phosphorylation	B-PROC
.	O

Accumulation	O
of	O
hypo	O
-	O
or	O
non	O
-	O
phosphorylated	O
pRb	O
thus	O
prevents	O
cell	B-PROC
cycle	I-PROC
progression	I-PROC
at	O
G0	O
/	O
G1	B-PROC
phase	I-PROC
.	O

ABSTRACT	O
:	O
To	O
retrospectively	O
analyze	O
serial	O
chest	O
radiographs	O
in	O
all	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
Hong	O
Kong	O
for	O
temporal	O
changes	O
and	O
differences	O
between	O
patients	O
who	O
died	B-PROC
and	O
those	O
who	O
were	O
discharged	O
from	O
the	O
hospital	O
and	O
to	O
compare	O
radiographic	O
and	O
clinical	O
parameters	O
.	O

However	O
,	O
among	O
patients	O
who	O
died	B-PROC
,	O
older	O
patients	O
had	O
less	O
extensive	O
radiographic	O
opacification	O
at	O
the	O
worst	O
stage	O
of	O
disease	O
and	O
just	O
before	O
death	B-PROC
than	O
did	O
younger	O
patients	O
.	O

Increasingly	O
,	O
however	O
,	O
the	O
government	O
has	O
become	O
involved	O
in	O
more	O
targeted	B-PROC
countermeasure	O
development	B-PROC
efforts	O
.	O

Competition	O
experiments	O
with	O
mixed	O
infections	O
revealed	O
that	O
this	O
was	O
not	O
due	O
to	O
the	O
enzymatic	B-PROC
activity	I-PROC
:	O
MHVs	O
expressing	O
HE	O
+	O
or	O
HE0	O
propagated	O
with	O
equal	O
efficiencies	O
.	O

The	O
spike	O
glycoprotein	O
,	O
S	O
,	O
which	O
mediates	O
receptor	O
binding	O
and	O
membrane	B-PROC
fusion	I-PROC
,	O
plays	O
a	O
critical	O
role	O
in	O
MHV	O
pathogenesis	B-PROC
.	O

We	O
tested	O
this	O
hypothesis	O
by	O
measuring	O
the	O
deubiquitinating	B-PROC
activity	O
of	O
PLpro	O
by	O
two	O
independent	O
assays	O
.	O

SARS	O
CoV	O
-	O
PLpro	O
hydrolyzed	O
both	O
diubiquitin	O
and	O
ubiquitin	B-PROC
-	O
7	O
-	O
amino	O
-	O
4	O
-	O
methylcoumarin	O
(	O
AMC	O
)	O
substrates	O
,	O
and	O
hydrolysis	O
of	O
ubiquitin	B-PROC
-	O
AMC	O
is	O
approximately	O
180	O
-	O
fold	O
more	O
efficient	O
than	O
hydrolysis	O
of	O
a	O
peptide	O
substrate	O
that	O
mimics	O
the	O
PLpro	O
replicase	O
recognition	O
sequence	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
protease	O
(	O
SARS	O
-	O
CoV	O
PLpro	O
)	O
is	O
involved	O
in	O
the	O
processing	O
of	O
the	O
viral	O
polyprotein	O
and	O
,	O
thereby	O
,	O
contributes	O
to	O
the	O
biogenesis	B-PROC
of	O
the	O
virus	B-PROC
replication	I-PROC
complex	O
.	O

Structural	O
bioinformatics	O
has	O
revealed	O
a	O
relationship	O
for	O
the	O
SARS	O
-	O
CoV	O
PLpro	O
to	O
herpesvirus	O
-	O
associated	O
ubiquitin	B-PROC
-	O
specific	O
protease	O
(	O
HAUSP	O
),	O
a	O
ubiquitin	B-PROC
-	O
specific	O
protease	O
,	O
indicating	O
potential	O
deubiquitinating	B-PROC
activity	O
in	O
addition	O
to	O
its	O
function	O
in	O
polyprotein	O
processing	O
(	O
T	O
.	O
Sulea	O
,	O
H	O
.	O
A	O
.	O
Lindner	O
,	O
E	O
.	O
O	O
.	O
Purisima	O
,	O
and	O
R	O
.	O
Menard	O
,	O
J	O
.	O
Virol	O
.	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
PLpro	O
was	O
inhibited	O
by	O
the	O
specific	O
deubiquitinating	B-PROC
enzyme	I-PROC
inhibitor	O
ubiquitin	B-PROC
aldehyde	O
,	O
with	O
an	O
inhibition	B-PROC
constant	O
of	O
210	O
nM	O
.	O
The	O
purified	O
SARS	O
-	O
CoV	O
PLpro	O
disassembles	O
branched	O
polyubiquitin	B-PROC
chains	O
with	O
lengths	O
of	O
two	O
to	O
seven	O
(	O
Ub2	O
-	O
7	O
)	O
or	O
four	O
(	O
Ub4	O
)	O
units	O
,	O
which	O
involves	O
isopeptide	O
bond	O
cleavage	B-PROC
.	O

To	O
this	O
end	O
,	O
the	O
soR	O
domain	O
was	O
coupled	O
to	O
single	O
-	O
chain	O
monoclonal	O
antibody	B-PROC
425	O
,	O
which	O
is	O
directed	O
against	O
the	O
human	O
epidermal	O
growth	B-PROC
factor	O
receptor	O
(	O
EGFR	O
),	O
resulting	O
in	O
a	O
bispecific	O
adapter	O
protein	O
(	O
soR	O
-	O
425	O
).	O

This	O
approach	O
might	O
be	O
useful	O
in	O
the	O
development	B-PROC
of	O
tumor	O
-	O
targeted	B-PROC
coronaviruses	O
.	O

SV40	O
enclosed	O
in	O
caveolae	O
vesicles	O
move	B-PROC
to	O
the	O
caveosome	O
,	O
then	O
to	O
the	O
endoplasmic	O
reticulum	O
.	O

It	O
is	O
possible	O
that	O
we	O
may	O
have	O
a	O
vaccine	O
before	O
the	O
outbreak	O
;	O
this	O
development	B-PROC
is	O
even	O
faster	O
than	O
for	O
SARS	O
.	O

An	O
animal	O
model	O
of	O
human	O
coronavirus	O
infectious	O
disease	O
has	O
been	O
generated	O
by	O
gene	O
transfer	O
of	O
the	O
human	O
receptor	O
for	O
virus	B-PROC
-	I-PROC
cell	B-PROC
interaction	I-PROC
(	O
aminopeptidase	O
N	O
,	O
APN	O
,	O
CD13	O
)	O
into	O
mice	O
.	O

Adaptation	B-PROC
of	O
the	O
human	O
virus	O
to	O
murine	O
cells	O
led	O
to	O
successful	O
infection	O
of	O
the	O
humanized	O
transgenic	O
mice	O
.	O

Elevated	O
levels	O
of	O
lactate	O
in	O
brain	O
,	O
blood	O
,	O
and	O
cerebrospinal	O
fluid	O
,	O
abnormal	O
urine	O
organic	O
acids	O
,	O
and	O
changes	O
in	O
muscle	O
respiratory	B-PROC
chain	I-PROC
enzymes	O
are	O
present	O
but	O
inconsistent	O
,	O
without	O
identifiable	O
mitochondrial	O
DNA	O
mutations	O
or	O
deletions	O
.	O

Familial	O
occurrence	O
and	O
consanguinity	O
suggest	O
autosomal	O
recessive	B-PROC
inheritance	I-PROC
of	O
this	O
distinct	O
entity	O
.	O

The	O
historical	O
literature	O
on	O
nursing	B-PROC
in	O
yellow	O
fever	B-PROC
,	O
cholera	O
and	O
influenza	O
epidemics	O
has	O
been	O
employed	O
to	O
offer	O
insight	O
.	O

TITLE	O
:	O
Solution	O
structure	O
of	O
the	O
X4	O
protein	O
coded	O
by	O
the	O
SARS	O
related	O
coronavirus	O
reveals	O
an	O
immunoglobulin	B-PROC
like	O
fold	O
and	O
suggests	O
a	O
binding	B-PROC
activity	I-PROC
to	O
integrin	O
I	O
domains	O
.	O

Further	O
,	O
based	O
on	O
this	O
structure	O
based	O
prediction	O
,	O
potential	O
functions	O
of	O
X4	O
in	O
virus	B-PROC
replication	I-PROC
and	O
pathogenesis	B-PROC
are	O
discussed	O
.	O

Finally	O
,	O
an	O
inhibitor	O
of	O
endosomal	O
acidification	B-PROC
had	O
substantially	O
less	O
effect	O
on	O
infection	O
mediated	O
by	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	O
than	O
on	O
that	O
mediated	O
by	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

TITLE	O
:	O
Coronavirus	O
pathogenesis	B-PROC
and	O
the	O
emerging	O
pathogen	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

EtOH	O
stimulation	O
also	O
increased	O
eNOS	O
interaction	O
with	O
heat	B-PROC
shock	I-PROC
protein	O
(	O
hsp90	O
),	O
a	O
molecular	O
chaperone	O
known	O
to	O
enhance	O
eNOS	O
activity	O
.	O

TITLE	O
:	O
Functional	O
and	O
genetic	O
analysis	O
of	O
coronavirus	O
replicase	O
-	O
transcriptase	B-PROC
proteins	O
.	O

In	O
an	O
effort	B-PROC
to	O
develop	O
a	O
novel	O
microfluidic	O
based	O
drug	O
screening	O
platform	O
,	O
systematic	O
studies	O
on	O
the	O
interaction	O
between	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
and	O
sulfated	O
oligosaccharides	O
were	O
carried	O
out	O
at	O
both	O
molecular	O
and	O
cellular	O
levels	O
.	O

In	O
the	O
application	O
phase	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
diagnosis	O
based	O
on	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
microfluidic	O
chip	O
electrophoresis	O
(	O
MCE	O
)	O
with	O
18	O
cases	O
,	O
methylation	B-PROC
analysis	O
of	O
the	O
P16	O
gene	O
in	O
159	O
samples	O
of	O
patients	O
and	O
references	O
for	O
cancer	O
diagnosis	O
and	O
polymorphism	B-PROC
analysis	O
of	O
angiotenigen	O
gene	O
in	O
226	O
patients	O
and	O
references	O
with	O
essential	O
hypertension	O
are	O
described	O
.	O

These	O
results	O
thus	O
establish	O
the	O
involvement	O
of	O
the	O
mitochondrial	O
pathway	B-PROC
in	O
MHV	O
-	O
induced	O
oligodendrocyte	B-PROC
apoptosis	I-PROC
.	O

Concentrations	O
of	O
plasma	O
glucose	O
,	O
urea	O
N	O
,	O
and	O
insulin	B-PROC
-	I-PROC
like	I-PROC
growth	B-PROC
factor	I-PROC
-	O
I	O
were	O
increased	O
when	O
calves	O
were	O
fed	O
variable	O
amount	O
of	O
milk	O
replacer	O
.	O

Under	O
conditions	O
of	O
this	O
study	O
,	O
calves	O
fed	O
variable	O
amount	O
of	O
milk	O
replacer	O
and	O
exposed	O
to	O
immunological	O
challenge	O
before	O
weaning	B-PROC
had	O
greater	O
BW	O
gain	O
,	O
but	O
also	O
increased	O
incidence	O
of	O
diarrhea	O
that	O
required	O
added	O
veterinary	O
treatments	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
replicase	O
gene	O
encodes	O
one	O
or	O
two	O
papain	O
-	O
like	O
proteases	O
(	O
termed	O
PL1pro	O
and	O
PL2pro	O
)	O
implicated	O
in	O
the	O
N	O
-	O
terminal	O
processing	O
of	O
the	O
replicase	O
polyprotein	O
and	O
thus	O
contributing	O
to	O
the	O
formation	B-PROC
of	O
the	O
viral	O
replicase	O
complex	O
that	O
mediates	O
genome	O
replication	O
.	O

Subsequently	O
,	O
the	O
technique	O
was	O
employed	O
in	O
the	O
diagnosis	O
of	O
other	O
viral	B-PROC
infections	I-PROC
,	O
such	O
as	O
hepatitis	O
B	O
and	O
parvovirus	O
B19	O
.	O

The	O
first	O
sign	O
of	O
illness	O
in	O
most	O
cases	O
of	O
SARS	O
is	O
fever	B-PROC
,	O
headache	O
,	O
malaise	O
,	O
or	O
myalgia	O
,	O
and	O
then	O
majority	O
of	O
patients	O
present	O
severe	O
atypical	O
pneumonia	O
.	O

On	O
postoperative	O
day	O
9	O
she	O
was	O
found	O
to	O
have	O
an	O
anastamotic	O
breakdown	B-PROC
.	O

Since	O
the	O
driving	O
force	O
is	O
the	O
patient	O
'	O
s	O
blood	B-PROC
pressure	I-PROC
,	O
a	O
roller	O
pump	O
with	O
its	O
negative	O
side	O
effects	O
is	O
not	O
needed	O
.	O

ABSTRACT	O
:	O
It	O
was	O
recently	O
shown	O
that	O
the	O
7a	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
induces	O
biochemical	O
changes	O
associated	O
with	O
apoptosis	B-PROC
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
induction	B-PROC
of	I-PROC
apoptosis	I-PROC
by	O
the	O
7a	O
protein	O
may	O
be	O
related	O
to	O
its	O
ability	O
to	O
inhibit	O
cellular	O
translation	B-PROC
and	O
activate	O
p38	O
MAPK	O
.	O

Eighteen	O
hybridomas	O
secreting	B-PROC
the	O
S	O
protein	O
-	O
specific	O
MAbs	O
were	O
obtained	O
.	O

Viral	B-PROC
replication	I-PROC
appears	O
to	O
be	O
limited	O
to	O
the	O
first	O
two	O
weeks	O
after	O
symptom	O
onset	O
,	O
with	O
little	O
evidence	O
of	O
continued	O
widespread	O
replication	O
after	O
this	O
period	O
.	O

All	O
14	O
patients	O
had	O
fever	B-PROC
,	O
dry	O
cough	O
and	O
dyspnea	O
.	O

The	O
8	O
patients	O
who	O
died	B-PROC
tended	O
to	O
have	O
higher	O
peak	O
levels	O
of	O
serum	O
TNF	O
-	O
alpha	O
compared	O
to	O
those	O
who	O
survived	O
(	O
14	O
vs	O
9	O
.	O
1	O
pg	O
/	O
mL	O
;	O
p	O
=	O
0	O
.	O
06	O
).	O

The	O
antibody	B-PROC
of	O
SARS	O
-	O
IgG	O
,	O
T	O
cell	O
subsets	O
,	O
chest	O
CT	O
,	O
and	O
the	O
pulmonary	B-PROC
function	I-PROC
were	O
observed	O
in	O
patients	O
1	O
month	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
and	O
2	O
years	O
after	O
convalescence	O
from	O
SARS	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
spectrum	O
of	O
immune	B-PROC
responses	I-PROC
of	O
mice	O
to	O
three	O
different	O
forms	O
of	O
the	O
SARS	O
coronavirus	O
nucleocapsid	O
(	O
N	O
):	O
(	O
1	O
)	O
exogenous	O
recombinant	O
protein	O
(	O
N	O
-	O
GST	O
)	O
with	O
Freund	O
'	O
s	O
adjuvant	O
;	O
(	O
2	O
)	O
DNA	O
encoding	O
unmodified	O
N	O
as	O
an	O
endogenous	O
cytoplasmic	O
protein	O
(	O
pN	O
);	O
and	O
(	O
3	O
)	O
DNA	O
encoding	O
N	O
as	O
a	O
LAMP	O
-	O
1	O
chimera	O
targeted	B-PROC
to	O
the	O
lysosomal	O
MHC	B-PROC
II	O
compartment	O
(	O
p	O
-	O
LAMP	O
-	O
N	O
).	O

TITLE	O
:	O
Virus	O
safety	O
of	O
intravenous	O
immunoglobulin	B-PROC
:	O
future	O
challenges	O
.	O

Cytokines	O
and	O
chemokines	O
that	O
best	O
predicted	O
the	O
combination	O
of	O
acid	O
and	O
small	O
gastric	O
particles	O
were	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
1	O
(	O
6	O
h	O
)	O
and	O
MCP	O
-	O
1	O
(	O
24	O
h	O
)	O
in	O
rats	O
,	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
/	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
5	O
h	O
)	O
and	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
/	O
MCP	O
-	O
1	O
(	O
24	O
h	O
)	O
in	O
wild	O
-	O
type	O
mice	O
,	O
and	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
/	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
5	O
h	O
)	O
and	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
/	O
keratinocyte	O
-	O
derived	O
cytokine	O
(	O
24	O
h	O
)	O
in	O
MCP	O
-	O
1	O
(-/-)	O
mice	O
.	O

TITLE	O
:	O
The	O
impact	O
of	O
spontaneous	O
breathing	B-PROC
during	O
mechanical	O
ventilation	O
.	O

Although	O
introduced	O
as	O
weaning	B-PROC
techniques	O
,	O
partial	O
ventilator	O
support	O
modes	O
have	O
become	O
standard	O
techniques	O
for	O
primary	O
mechanical	O
ventilator	O
support	O
.	O

Conclusion	O
The	O
integrative	O
therapy	O
may	O
have	O
beneficial	O
effects	O
in	O
lowering	O
mortality	O
,	O
reducing	O
complications	O
,	O
shortening	O
the	O
duration	O
of	O
symptoms	O
and	O
fever	B-PROC
existence	O
and	O
lessening	O
pulmonary	O
inflammation	O
in	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Vascular	B-PROC
endothelial	I-PROC
growth	B-PROC
factor	I-PROC
in	O
the	O
lung	O
.	O

Furthermore	O
,	O
the	O
open	O
question	O
of	O
the	O
prevention	O
of	O
the	O
fungal	O
infection	O
of	O
necrosis	B-PROC
is	O
still	O
being	O
debated	O
.	O

ABSTRACT	O
:	O
The	O
reproduction	B-PROC
of	O
the	O
new	O
coronavirus	O
HCoV	O
/	O
SPb	O
/	O
01	O
/	O
03	O
in	O
the	O
cultured	O
human	O
embryo	O
lung	O
fibroblasts	O
(	O
HELFBs	O
)	O
was	O
electron	O
microscopically	O
studied	O
.	O

Although	O
the	O
rapidly	O
evolving	O
outbreak	O
did	O
not	O
allow	O
the	O
conducting	B-PROC
of	O
systematic	O
clinical	O
trails	O
to	O
evaluate	O
treatment	O
options	O
,	O
the	O
accumulated	O
experience	O
on	O
managing	O
SARS	O
patients	O
will	O
improve	O
the	O
clinical	O
outcome	O
should	O
SARS	O
return	O
.	O

This	O
is	O
achieved	O
by	O
cellular	O
palmitoyl	O
acyltransferases	O
(	O
PATs	O
),	O
which	O
can	O
modify	O
newly	O
synthesized	O
S	O
proteins	O
before	O
they	O
are	O
assembled	O
into	O
virion	O
envelopes	O
at	O
the	O
intermediate	O
compartment	O
of	O
the	O
exocytic	O
pathway	B-PROC
.	O

2	O
-	O
BP	O
effected	O
only	O
two	O
-	O
to	O
fivefold	O
reductions	O
in	O
S	O
palmitoylation	B-PROC
,	O
yet	O
this	O
correlated	O
with	O
reduced	O
S	O
complexing	O
with	O
virion	O
membrane	O
(	O
M	O
)	O
proteins	O
and	O
consequent	O
exclusion	O
of	O
S	O
from	O
virions	O
.	O

S	O
(	O
VSV	O
-	O
TMDCyt	O
),	O
a	O
chimera	O
with	O
the	O
cytoplasmic	O
and	O
transmembrane	O
domains	O
of	O
VSV	O
-	O
G	O
,	O
was	O
impaired	O
in	O
the	O
SARSpp	O
and	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
assays	O
,	O
showing	O
3	O
to	O
25	O
%	O
activity	O
compared	O
to	O
the	O
wild	O
type	O
,	O
depending	O
on	O
the	O
assay	O
and	O
the	O
cells	O
used	O
.	O

The	O
recombinant	O
proteins	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
were	O
efficiently	O
expressed	B-PROC
in	O
an	O
insoluble	O
form	O
in	O
E	O
.	O
coli	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
the	O
redox	B-PROC
state	I-PROC
of	O
the	O
20	O
cysteine	O
residues	O
of	O
the	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
)	O
Spike	O
glycoprotein	O
S1	O
subdomain	O
and	O
its	O
functional	O
properties	O
.	O

(	O
i	O
)	O
about	O
50	O
%	O
of	O
respiratory	O
tract	O
infections	O
of	O
lung	O
transplant	O
recipients	O
were	O
associated	O
with	O
one	O
or	O
more	O
respiratory	O
viruses	O
;	O
(	O
ii	O
)	O
hMPV	O
largely	O
predominates	O
in	O
bronchoalveolar	O
lavage	O
of	O
symptomatic	O
lung	O
transplant	O
recipients	O
,	O
thus	O
suggesting	O
a	O
causative	O
role	O
in	O
lower	O
respiratory	O
tract	O
infections	O
;	O
(	O
iii	O
)	O
RT	O
-	O
PCR	O
appears	O
to	O
be	O
the	O
method	O
of	O
choice	O
for	O
detection	O
of	O
respiratory	O
viruses	O
in	O
lung	O
transplant	O
recipients	O
,	O
(	O
iv	O
)	O
a	O
high	O
HCMV	O
load	O
in	O
bronchoalveolar	O
lavage	O
is	O
a	O
risk	O
factor	O
for	O
viral	O
pneumonia	O
,	O
suggesting	O
some	O
measure	O
of	O
intervention	O
for	O
the	O
control	O
of	O
viral	B-PROC
infection	I-PROC
.	O

For	O
example	O
,	O
the	O
extraordinary	O
resistance	B-PROC
of	O
SJL	O
mice	O
to	O
experimental	O
infections	O
with	O
hepatitis	O
virus	O
strain	O
A59	O
is	O
the	O
consequence	O
of	O
a	O
structural	O
alteration	O
of	O
a	O
cell	B-PROC
adhesion	I-PROC
molecule	O
which	O
normally	O
binds	O
to	O
the	O
spikes	O
of	O
the	O
virus	O
,	O
allowing	O
its	O
entry	O
into	O
the	O
cells	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
fostering	O
on	O
the	O
genetic	O
expression	B-PROC
of	O
locomotor	O
sensitivity	O
to	O
alcohol	O
.	O

TITLE	O
:	O
The	O
expression	B-PROC
of	O
membrane	O
protein	O
augments	O
the	O
specific	O
responses	O
induced	O
by	O
SARS	O
-	O
CoV	O
nucleocapsid	O
DNA	O
immunization	O
.	O

Immunoglobulin	B-PROC
kappa	O
light	O
chain	O
(	O
m	O
/	O
z	O
24	O
505	O
)	O
positively	O
correlated	O
with	O
viral	O
load	O
.	O

NPS	O
examination	O
for	O
the	O
presence	O
of	O
SARS	O
-	O
CoV	O
by	O
two	O
nested	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
.	O

Only	O
those	O
with	O
significant	O
clinical	O
symptoms	O
or	O
disease	O
would	O
have	O
active	B-PROC
immunity	I-PROC
.	O

ABSTRACT	O
:	O
This	O
study	O
presented	O
preliminary	O
results	O
on	O
the	O
efficacy	O
of	O
a	O
novel	O
group	O
debriefing	O
model	O
called	O
Strength	O
-	O
Focused	O
and	O
Meaning	O
-	O
Oriented	O
Approach	O
for	O
Resilience	O
and	O
Transformation	B-PROC
(	O
SMART	O
).	O

Delivery	O
of	O
a	O
vaccine	O
to	O
a	O
mucosal	O
surface	O
optimizes	O
the	O
induction	O
of	O
mucosal	B-PROC
immunity	I-PROC
.	O

The	O
N	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
bears	O
signature	O
motifs	O
for	O
binding	O
to	O
cyclin	O
and	O
phosphorylation	B-PROC
by	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
and	O
has	O
recently	O
been	O
reported	O
by	O
us	O
to	O
get	O
phosphorylated	O
by	O
the	O
cyclin	O
-	O
CDK	O
complex	O
(	O
Surjit	O
,	O
M	O
.,	O
Kumar	O
,	O
R	O
.,	O
Mishra	O
,	O
R	O
.	O
N	O
.,	O
Reddy	O
,	O
M	O
.	O
K	O
.,	O
Chow	O
,	O
V	O
.	O
T	O
.,	O
and	O
Lal	O
,	O
S	O
.	O
K	O
.	O
(	O
2005	O
)	O
J	O
.	O
Virol	O
.	O
79	O
,	O
11476	O
-	O
11486	O
).	O

RNA	B-PROC
interference	I-PROC
induced	O
by	O
small	O
interfering	O
RNA	O
can	O
inhibit	O
the	O
expression	B-PROC
of	O
viral	O
antigens	O
and	O
so	O
provides	O
a	O
new	O
approach	O
to	O
the	O
therapy	O
of	O
pathogenic	O
viruses	O
.	O

It	O
was	O
found	O
that	O
the	O
prescription	O
I	O
possessed	O
obvious	O
inhibitory	O
effects	O
on	O
the	O
UV	O
induction	O
of	O
lambda	O
-	O
lysogen	O
,	O
the	O
inhibitory	O
rate	O
reaching	B-PROC
83	O
.	O
87	O
%.	O

Five	O
patients	O
with	O
probable	O
SARS	O
(	O
11	O
.	O
6	O
%)	O
died	B-PROC
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
an	O
aggressive	B-PROC
systemic	O
protocol	O
including	O
strategies	O
improving	O
body	O
'	O
s	O
immune	B-PROC
function	I-PROC
.	O

Rapid	O
screening	O
tests	O
for	O
other	O
newly	O
described	O
pathogens	O
such	O
as	O
WNV	O
require	O
time	O
for	O
development	B-PROC
and	O
may	O
be	O
<	O
100	O
%	O
reliable	O
.	O

ABSTRACT	O
:	O
Typing	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strains	O
is	O
useful	O
for	O
implementation	O
of	O
control	O
measures	O
and	O
for	O
understanding	O
the	O
epidemiology	O
and	O
evolution	B-PROC
of	O
IBV	O
.	O

A	O
procedure	O
was	O
developed	O
for	O
differentiation	B-PROC
of	O
IBV	O
strains	O
by	O
restriction	O
endonuclease	O
fragment	O
length	O
polymorphism	B-PROC
(	O
RFLP	O
)	O
analysis	O
of	O
a	O
7	O
.	O
5	O
kb	O
DNA	O
fragment	O
amplified	O
from	O
their	O
genome	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
compounds	O
were	O
tested	O
against	O
SARS	O
-	O
CoV	O
-	O
induced	O
cell	B-PROC
death	I-PROC
in	O
Vero	O
or	O
CaCo2	O
cells	O
as	O
a	O
measurement	O
of	O
the	O
inhibiting	O
effects	O
of	O
the	O
compounds	O
on	O
the	O
replication	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
Changes	O
in	O
respiratory	B-PROC
mechanics	I-PROC
and	O
gas	O
exchange	O
during	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

(	O
1	O
)	O
UIP	O
decreased	O
from	O
early	O
to	O
established	O
(	O
intermediate	O
and	O
late	O
)	O
ARDS	O
[	O
30	O
(	O
28	O
-	O
30	O
)	O
cmH2O	O
,	O
27	O
(	O
25	O
-	O
30	O
)	O
cmH2O	O
and	O
25	O
(	O
23	O
-	O
28	O
)	O
cmH2O	O
(	O
P	O
=	O
0	O
.	O
014	O
)];	O
(	O
2	O
)	O
oxygenation	B-PROC
improved	O
in	O
survivors	O
and	O
in	O
patients	O
with	O
non	O
-	O
pulmonary	O
etiology	O
in	O
late	O
ARDS	O
,	O
whereas	O
all	O
patients	O
developed	O
hypercapnia	O
from	O
early	O
to	O
established	O
ARDS	O
;	O
and	O
(	O
3	O
)	O
dead	B-PROC
-	O
space	O
ventilation	O
and	O
pulmonary	O
shunt	O
were	O
larger	O
in	O
patients	O
with	O
pulmonary	O
etiology	O
during	O
late	O
ARDS	O
.	O

The	O
improvements	O
in	O
lung	B-PROC
function	I-PROC
were	O
sustained	O
,	O
with	O
no	O
differences	O
between	O
groups	O
.	O

The	O
demonstration	O
of	O
successful	O
postexposure	O
MAb	O
201	O
therapy	O
in	O
an	O
animal	O
model	O
that	O
demonstrates	O
viral	B-PROC
replication	I-PROC
and	O
associated	O
pulmonary	O
pathological	O
findings	O
suggests	O
that	O
MAb	O
201	O
may	O
be	O
useful	O
in	O
the	O
arsenal	O
of	O
tools	O
to	O
combat	O
SARS	O
.	O

Transfusion	O
-	O
Related	O
Acute	O
Lung	O
Injury	O
or	O
TRALI	O
is	O
one	O
of	O
the	O
most	O
frequent	O
severe	O
transfusion	O
reactions	O
(	O
one	O
third	O
of	O
Non	O
Hemolytic	O
Febrile	B-PROC
Transfusion	O
Reactions	O
).	O

TRALI	O
prevention	O
rests	O
on	O
donor	B-PROC
selection	I-PROC
for	O
plasma	O
donation	O
,	O
hemovigilance	O
system	O
effectiveness	O
and	O
restrictive	O
transfusion	O
strategy	O
.	O

TITLE	O
:	O
Regulation	B-PROC
of	O
p90RSK	O
phosphorylation	B-PROC
by	O
SARS	O
-	O
CoV	O
infection	O
in	O
Vero	O
E6	O
cells	O
.	O

Thus	O
,	O
in	O
virus	O
-	O
infected	O
cells	O
,	O
phosphorylation	B-PROC
of	O
Thr573	O
was	O
not	O
necessary	O
to	O
induce	O
phosphorylation	B-PROC
of	O
Ser380	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
psychiatric	O
morbidity	O
and	O
psychological	O
adaptation	B-PROC
of	O
the	O
nurses	O
in	O
a	O
structured	O
SARS	O
caring	O
unit	O
during	O
outbreak	O
:	O
a	O
prospective	O
and	O
periodic	O
assessment	O
study	O
in	O
Taiwan	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
rapidly	O
changing	O
psychological	O
status	O
of	O
nurses	O
during	O
the	O
acute	O
phase	O
of	O
the	O
2003	O
SARS	O
outbreak	O
,	O
we	O
conducted	O
a	O
prospective	O
and	O
periodic	O
evaluation	O
of	O
psychiatric	O
morbidity	O
and	O
psychological	O
adaptation	B-PROC
among	O
nurses	O
in	O
SARS	O
units	O
and	O
non	O
-	O
SARS	O
units	O
.	O

An	O
example	O
of	O
cancer	O
diagnostics	O
by	O
detection	O
of	O
altered	O
gene	B-PROC
expression	I-PROC
patterns	O
will	O
also	O
be	O
shown	O
.	O

Comparing	O
with	O
pGL3	O
-	O
a	O
-	O
5	O
'	O
UTR	O
,	O
pGL3	O
-	O
5	O
'	O
UTR	O
expressed	B-PROC
luciferase	O
obviously	O
.	O

A	O
whole	O
killed	O
(	O
inactivated	O
by	O
beta	O
-	O
propiolactone	O
)	O
SARS	O
-	O
CoV	O
vaccine	O
and	O
a	O
combination	O
of	O
two	O
adenovirus	O
-	O
based	O
vectors	O
,	O
one	O
expressing	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
the	O
other	O
expressing	O
the	O
spike	O
(	O
S	O
)	O
protein	O
(	O
collectively	O
designated	O
Ad	O
S	O
/	O
N	O
),	O
were	O
evaluated	O
for	O
the	O
induction	O
of	O
serum	O
neutralizing	O
antibodies	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
and	O
their	O
ability	O
to	O
protect	O
against	O
pulmonary	O
SARS	O
-	O
CoV	O
replication	O
.	O

TITLE	O
:	O
Differential	O
roles	O
for	O
CXCR3	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cell	O
trafficking	B-PROC
following	O
viral	B-PROC
infection	I-PROC
of	O
the	O
CNS	O
.	O

However	O
,	O
treatment	O
with	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
small	O
interfering	O
RNA	O
indicated	O
that	O
the	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
signaling	B-PROC
pathway	I-PROC
was	O
not	O
related	O
to	O
inhibition	B-PROC
of	I-PROC
cell	I-PROC
proliferation	I-PROC
.	O

These	O
results	O
suggested	O
that	O
inhibition	B-PROC
of	I-PROC
cell	I-PROC
proliferation	I-PROC
is	O
regulated	O
by	O
both	O
the	O
phosphatidylinositol	O
3	O
'-	O
kinase	O
/	O
Akt	B-PROC
signaling	B-PROC
pathway	I-PROC
and	O
by	O
apoptosis	B-PROC
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
analyze	O
SARS	O
-	O
CoV	O
-	O
induced	O
cell	B-PROC
growth	B-PROC
inhibition	B-PROC
.	O

ABSTRACT	O
:	O
To	O
identify	O
key	O
nursing	B-PROC
issues	O
for	O
paediatric	O
patients	O
suspected	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
relation	O
to	O
the	O
family	O
-	O
centred	O
model	O
of	O
nursing	B-PROC
care	O
and	O
to	O
develop	O
a	O
data	O
-	O
based	O
model	O
of	O
paediatric	O
nursing	B-PROC
care	O
to	O
be	O
better	O
applied	O
in	O
situations	O
of	O
suspected	O
SARS	O
or	O
where	O
outbreaks	O
of	O
other	O
infectious	O
diseases	O
occur	O
.	O

This	O
is	O
a	O
retrospective	O
descriptive	O
case	O
series	O
,	O
which	O
analysed	O
the	O
medical	O
and	O
nursing	B-PROC
records	O
of	O
all	O
highly	O
-	O
suspected	O
/	O
suspected	O
SARS	O
patients	O
admitted	O
to	O
a	O
major	O
acute	O
hospital	O
in	O
Hong	O
Kong	O
.	O

These	O
results	O
suggested	O
that	O
TCoV	O
probably	O
shared	O
the	O
same	O
origin	O
with	O
that	O
of	O
IBV	O
and	O
acquired	O
sequences	O
of	O
S	O
gene	O
for	O
turkey	O
intestine	O
tropism	B-PROC
during	O
the	O
process	O
of	O
evolution	B-PROC
in	O
a	O
separate	O
environment	O
.	O

By	O
July	O
2003	O
,	O
Vancouver	O
had	O
identified	O
5	O
cases	O
(	O
4	O
imported	O
);	O
Toronto	O
reported	O
247	O
cases	O
(	O
3	O
imported	O
)	O
and	O
43	O
deaths	B-PROC
.	O

To	O
identify	O
functional	O
CTL	O
epitopes	O
of	O
the	O
N	O
protein	O
,	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
peptides	O
containing	O
the	O
H	O
-	O
2K	O
(	O
d	O
)	O
CTL	O
motif	O
emulsified	O
in	O
adjuvant	O
ISA	O
-	O
51	O
/	O
CpG	O
.	O
Using	O
an	O
IFN	B-PROC
-	I-PROC
gamma	I-PROC
secretion	I-PROC
cell	O
assay	O
and	O
analysis	O
by	O
flow	O
cytometry	O
,	O
peptides	O
containing	O
residues	O
81	O
-	O
95	O
were	O
found	O
to	O
be	O
capable	O
of	O
stimulating	O
both	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
cell	B-PROC
proliferation	I-PROC
in	O
vitro	O
.	O

Livers	O
recovered	O
from	O
untreated	O
infected	O
mice	O
showed	O
greater	O
than	O
90	O
%	O
necrosis	B-PROC
.	O

Neutralizing	O
antibody	B-PROC
titers	O
correlated	O
closely	O
with	O
standard	O
ELISA	O
reactivity	O
against	O
the	O
S	O
glycoprotein	O
.	O

TITLE	O
:	O
The	O
rationale	O
of	O
fever	B-PROC
surveillance	O
to	O
identify	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
Taiwan	O
.	O

Results	O
from	O
637	O
Coronase	O
and	O
191	O
7B	O
FIP	O
antibody	B-PROC
tests	O
were	O
recorded	O
.	O

Despite	O
the	O
availability	O
of	O
antimicrobial	O
agents	O
,	O
pneumonia	O
constitutes	O
the	O
sixth	O
most	O
common	O
cause	O
of	O
death	B-PROC
and	O
the	O
number	O
one	O
cause	O
of	O
death	B-PROC
from	O
infection	O
.	O

Pneumonia	O
can	O
be	O
particularly	O
life	O
-	O
threatening	O
in	O
the	O
elderly	O
,	O
in	O
individuals	O
who	O
have	O
pre	O
-	O
existing	O
heart	O
and	O
lung	O
conditions	O
,	O
in	O
patients	O
who	O
have	O
suppressed	O
or	O
weakened	O
immunity	B-PROC
,	O
and	O
in	O
pregnant	O
women	O
.	O

Because	O
there	O
often	O
is	O
considerable	O
overlap	O
,	O
infections	O
are	O
categorized	O
by	O
the	O
host	O
immune	B-PROC
status	I-PROC
that	O
is	O
most	O
likely	O
to	O
be	O
associated	O
with	O
a	O
particular	O
pathogen	O
.	O

The	O
extent	O
of	O
acute	O
lung	O
injury	O
was	O
evaluated	O
by	O
lung	O
weight	O
/	O
body	O
weight	O
ratio	O
,	O
lung	O
weight	O
gain	O
,	O
protein	O
concentration	O
in	O
bronchoalveolar	O
lavage	O
,	O
and	O
exhaled	B-PROC
nitric	O
oxide	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
expression	B-PROC
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
in	O
mammalian	O
cells	O
alters	O
the	O
membrane	B-PROC
permeability	I-PROC
of	O
these	O
cells	O
.	O

Systematic	O
mutagenesis	B-PROC
studies	O
confirm	O
that	O
the	O
membrane	O
permeabilizing	O
activity	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
is	O
associated	O
with	O
its	O
transmembrane	O
domain	O
.	O

However	O
,	O
the	O
CNS	O
inflammatory	O
cell	O
composition	O
and	O
CD8	O
(+)	O
T	O
-	O
cell	O
effector	O
functions	O
were	O
similar	O
between	O
transgenic	O
and	O
wild	O
-	O
type	O
mice	O
,	O
supporting	O
unimpaired	O
peripheral	O
and	O
CNS	O
immune	B-PROC
responses	I-PROC
in	O
transgenic	O
mice	O
.	O

Surprisingly	O
,	O
increased	O
viral	O
load	O
in	O
oligodendroglia	O
did	O
not	O
affect	O
the	O
extent	O
of	O
myelin	O
loss	O
,	O
the	O
frequency	O
of	O
oligodendroglial	O
apoptosis	B-PROC
,	O
or	O
CNS	O
recruitment	O
of	O
macrophages	O
.	O

These	O
data	O
demonstrate	O
that	O
IFN	O
-	O
gamma	O
receptor	B-PROC
signaling	B-PROC
is	O
critical	O
for	O
the	O
control	O
of	O
JHMV	O
replication	O
in	O
oligodendroglia	O
.	O

To	O
reveal	O
a	O
role	O
for	O
innate	O
effectors	O
in	O
anti	O
-	O
viral	O
immunity	B-PROC
and	O
neurological	O
disease	O
,	O
JHMV	O
pathogenesis	B-PROC
was	O
studied	O
in	O
mice	O
deficient	O
in	O
interleukin	O
-	O
15	O
(	O
IL	O
-	O
15	O
-/-)	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

TITLE	O
:	O
Anti	O
-	O
infective	O
monoclonal	O
antibodies	O
:	O
perils	O
and	O
promise	O
of	O
development	B-PROC
.	O

Here	O
,	O
we	O
analyse	O
trends	O
in	O
the	O
development	B-PROC
and	O
approval	O
of	O
anti	O
-	O
infective	O
monoclonal	O
antibodies	O
,	O
and	O
discuss	O
factors	O
that	O
influence	O
their	O
success	O
.	O

This	O
study	O
should	O
aid	O
in	O
the	O
manufacture	O
of	O
neutralizing	O
antibody	B-PROC
,	O
provide	O
a	O
better	O
understanding	O
the	O
immunological	O
characteristics	O
of	O
SARS	O
protein	O
and	O
facilitate	O
the	O
design	O
of	O
a	O
SARS	O
vaccine	O
.	O

To	O
determine	O
whether	O
proteolytic	B-PROC
cleavage	B-PROC
of	O
the	O
S	O
glycoprotein	O
might	O
be	O
important	O
for	O
the	O
newly	O
emerged	O
SARS	O
-	O
CoV	O
,	O
we	O
introduced	O
a	O
furin	O
recognition	O
site	O
at	O
single	O
basic	O
residues	O
within	O
the	O
putative	O
S1	O
-	O
S2	O
junctional	O
region	O
.	O

Six	O
patients	O
(	O
7	O
.	O
9	O
%)	O
died	B-PROC
acutely	O
within	O
21	O
days	O
from	O
the	O
onset	O
of	O
the	O
disease	O
.	O

A	O
computer	O
algorithm	O
that	O
uses	O
multiple	O
classifiers	O
to	O
predict	O
samples	O
from	O
SARS	O
patients	O
was	O
developed	O
and	O
used	O
to	O
predict	O
206	O
sera	O
from	O
Chinese	O
fever	B-PROC
patients	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
roles	O
of	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
and	O
HR2	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
virus	O
-	O
cell	B-PROC
interactions	I-PROC
,	O
the	O
conserved	O
Leu	O
or	O
Ile	O
residues	O
located	O
at	O
positions	O
913	O
,	O
927	O
,	O
941	O
,	O
and	O
955	O
in	O
HR1	O
and	O
1151	O
,	O
1165	O
,	O
and	O
1179	O
in	O
HR2	O
were	O
individually	O
replaced	O
with	O
an	O
alpha	O
-	O
helix	O
-	O
breaker	O
Pro	O
residue	O
.	O

The	O
913P	O
mutant	O
was	O
expressed	B-PROC
mainly	O
as	O
a	O
faster	O
-	O
migrating	O
,	O
lower	O
-	O
molecular	O
-	O
weight	O
S	O
(	O
L	O
)	O
form	O
,	O
while	O
the	O
wild	O
type	O
and	O
all	O
other	O
mutants	O
produced	O
similar	O
levels	O
of	O
both	O
the	O
S	O
(	O
L	O
)	O
form	O
and	O
the	O
slower	O
-	O
migrating	O
,	O
higher	O
-	O
molecular	O
-	O
weight	O
S	O
(	O
H	O
)	O
form	O
.	O

The	O
mutation	O
at	O
Ile	O
-	O
1151	O
did	O
not	O
affect	O
membrane	B-PROC
fusion	I-PROC
or	O
viral	O
entry	O
.	O

Our	O
study	O
demonstrates	O
the	O
functional	O
importance	O
of	O
HR1	O
and	O
HR2	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
in	O
membrane	B-PROC
fusion	I-PROC
and	O
viral	O
entry	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
failure	O
due	O
to	O
sweet	B-PROC
syndrome	O
.	O

ABSTRACT	O
:	O
A	O
67	O
-	O
year	O
-	O
old	O
patient	O
with	O
newly	O
diagnosed	O
acute	O
myeloid	O
leukemia	O
developed	O
acute	O
respiratory	O
failure	O
with	O
high	O
-	O
grade	O
fever	B-PROC
and	O
bilateral	O
pulmonary	O
infiltrates	O
.	O

Sweet	B-PROC
syndrome	O
with	O
pulmonary	O
involvement	O
was	O
suspected	O
and	O
a	O
treatment	O
with	O
corticosteroids	O
was	O
started	O
.	O

ABSTRACT	O
:	O
The	O
virally	O
encoded	O
integrase	O
protein	O
is	O
an	O
essential	O
enzyme	O
in	O
the	O
life	O
cycle	O
of	O
the	O
HIV	O
-	O
1	O
virus	O
and	O
represents	O
an	O
attractive	O
and	O
validated	O
target	O
in	O
the	O
development	B-PROC
of	O
therapeutics	O
against	O
HIV	O
infection	O
.	O

Drugs	O
that	O
selectively	O
inhibit	O
this	O
enzyme	O
,	O
when	O
used	O
in	O
combination	O
with	O
inhibitors	O
of	O
reverse	O
transcriptase	B-PROC
and	O
protease	O
,	O
are	O
believed	O
to	O
be	O
highly	O
effective	O
in	O
suppressing	O
the	O
viral	B-PROC
replication	I-PROC
.	O

It	O
suggests	O
that	O
amino	O
acid	O
changes	O
that	O
result	O
in	O
overall	O
shift	O
of	O
residue	O
charge	O
and	O
polarity	O
should	O
be	O
paid	O
special	O
attention	O
to	O
during	O
the	O
development	B-PROC
of	O
vaccines	O
.	O

Transpulmonary	O
ICG	O
concentration	O
curves	O
were	O
analyzed	O
automatically	O
using	O
a	O
computer	O
system	O
(	O
COLD	B-PROC
-	O
Z021	O
,	O
Pulsion	O
Medical	O
Systems	O
,	O
Munich	O
,	O
Germany	O
).	O

The	O
selected	O
Fab	O
antibodies	O
expressed	B-PROC
in	O
the	O
periplasma	O
of	O
E	O
.	O
coli	O
were	O
soluble	O
and	O
further	O
purified	O
and	O
tested	O
for	O
their	O
binding	O
properties	O
and	O
antiviral	O
function	O
to	O
SARS	O
virus	O
.	O

In	O
addition	O
,	O
the	O
SARS	O
N	O
protein	O
-	O
targeted	B-PROC
human	O
Fab	O
antibody	B-PROC
reacted	O
with	O
the	O
denatured	O
N	O
proteins	O
,	O
whereas	O
none	O
of	O
the	O
S	O
and	O
M	O
protein	O
specific	O
neutralizing	O
antibodies	O
did	O
.	O

TITLE	O
:	O
Changes	O
in	O
coagulation	B-PROC
and	O
fibrinolysis	B-PROC
of	O
post	O
-	O
SARS	O
osteonecrosis	O
in	O
a	O
Chinese	O
population	O
.	O

The	O
high	O
-	O
level	O
expression	B-PROC
of	O
S	O
-	O
protein	O
in	O
HEK293	O
cells	O
mediated	O
by	O
adenovirus	O
can	O
be	O
achieved	O
under	O
the	O
optimized	O
expression	B-PROC
conditions	O
.	O

CONCLUSIONS	O
:	O
The	O
high	O
-	O
level	O
expression	B-PROC
of	O
S	O
-	O
protein	O
in	O
HEK293	O
cells	O
mediated	O
by	O
adenovirus	O
can	O
be	O
achieved	O
under	O
the	O
optimized	O
expression	B-PROC
conditions	O
.	O

RESULTS	O
:	O
All	O
three	O
components	O
of	O
occupational	O
and	O
organizational	O
commitments	O
were	O
negatively	O
associated	O
with	O
nurses	O
'	O
intentions	O
to	O
leave	O
the	O
nursing	B-PROC
profession	O
and	O
the	O
organization	O
.	O

Moreover	O
,	O
in	O
vivo	O
signalling	B-PROC
pathway	B-PROC
assay	O
indicated	O
that	O
3CLpro	O
increased	O
the	O
activation	O
of	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
-	O
dependent	O
reporter	O
,	O
but	O
inhibited	O
activator	O
protein	O
-	O
1	O
-	O
dependent	O
transcription	B-PROC
.	O

The	O
relationship	O
between	O
serological	O
score	O
and	O
six	O
major	O
factors	O
(	O
breed	B-PROC
,	O
age	O
,	O
gender	O
,	O
number	O
of	O
cats	O
per	O
household	O
,	O
living	O
environment	O
and	O
health	O
status	O
)	O
in	O
the	O
owned	O
cat	O
sample	O
population	O
was	O
analysed	O
and	O
compared	O
to	O
cats	O
with	O
FIR	O
RESULTS	O
:	O
The	O
seroprevalence	O
of	O
FCoV	O
infection	O
in	O
the	O
sample	O
population	O
of	O
owned	O
and	O
feral	O
cats	O
was	O
34	O
%	O
and	O
0	O
%,	O
respectively	O
.	O

Sleep	B-PROC
disturbances	O
are	O
extremely	O
common	O
in	O
patients	O
with	O
end	O
-	O
stage	O
renal	O
disease	O
,	O
with	O
sleep	B-PROC
apnea	O
occurring	O
in	O
60	O
%	O
or	O
more	O
of	O
such	O
patients	O
.	O

These	O
processes	O
affect	O
the	O
management	O
of	O
mechanical	O
ventilation	O
in	O
such	O
patients	O
and	O
may	O
interfere	O
with	O
weaning	B-PROC
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
the	O
first	O
potentially	O
lethal	O
complication	O
in	O
rabies	O
virus	B-PROC
infection	I-PROC
,	O
although	O
its	O
occurrence	O
is	O
rare	O
.	O

We	O
report	O
on	O
a	O
fatal	O
case	O
of	O
rabies	O
virus	B-PROC
infection	I-PROC
in	O
a	O
45	O
-	O
year	O
-	O
old	O
woman	O
from	O
Hu	O
-	O
Nan	O
Province	O
,	O
China	O
.	O

TITLE	O
:	O
Biodistribution	O
of	O
DNA	O
plasmid	O
vaccines	O
against	O
HIV	O
-	O
1	O
,	O
Ebola	O
,	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
,	O
or	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
is	O
similar	O
,	O
without	O
integration	B-PROC
,	O
despite	O
differing	O
plasmid	O
backbones	O
or	O
gene	O
inserts	O
.	O

The	O
inhibitor	O
was	O
identified	O
through	O
high	O
-	O
throughput	O
screening	O
of	O
a	O
compound	O
library	O
using	O
a	O
luciferase	O
-	O
expressing	O
West	O
Nile	O
(	O
WN	O
)	O
virus	B-PROC
infection	I-PROC
assay	O
.	O

Indeed	O
,	O
studies	O
with	O
a	O
neurotropic	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
have	O
provided	O
important	O
insight	O
into	O
the	O
functional	O
roles	O
of	O
chemokines	O
and	O
chemokine	O
receptors	O
in	O
participating	O
in	O
various	O
aspects	O
of	O
host	B-PROC
defense	I-PROC
as	O
well	O
as	O
disease	O
development	B-PROC
within	O
the	O
CNS	O
.	O

In	O
particular	O
,	O
SARS	O
-	O
CoV	O
did	O
not	O
activate	O
significant	O
transcription	B-PROC
of	O
the	O
interferons	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
lambda1	O
,	O
IFN	O
-	O
lambda2	O
/	O
3	O
,	O
as	O
well	O
as	O
of	O
the	O
interferon	O
-	O
induced	O
antiviral	O
genes	O
ISG56	O
and	O
MxA	O
,	O
the	O
chemokine	O
RANTES	O
and	O
the	O
interleukine	O
IL	O
-	O
6	O
.	O

However	O
,	O
synthesis	B-PROC
of	O
IP	O
-	O
10	O
and	O
IL	O
-	O
8	O
,	O
which	O
are	O
established	O
markers	O
for	O
acute	O
-	O
stage	O
SARS	O
,	O
escapes	O
the	O
virus	O
-	O
induced	O
silencing	O
at	O
least	O
in	O
some	O
cell	O
types	O
.	O

Recombinant	O
fusion	O
proteins	O
comprised	O
of	O
PgsA	O
and	O
the	O
Spike	O
(	O
S	O
)	O
protein	O
segments	O
SA	O
(	O
residues	O
2	O
to	O
114	O
)	O
and	O
SB	O
(	O
residues	O
264	O
to	O
596	O
)	O
were	O
stably	O
expressed	B-PROC
in	O
Lactobacillus	O
casei	O
.	O

Surface	O
localization	B-PROC
of	O
the	O
fusion	O
protein	O
was	O
verified	O
by	O
cellular	O
fractionation	O
analyses	O
,	O
immunofluorescence	O
microscopy	O
,	O
and	O
flow	O
cytometry	O
.	O

Samples	O
were	O
first	O
screened	O
for	O
FCoV	O
via	O
a	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
procedure	O
involving	O
primers	O
that	O
encompassed	O
the	O
3	O
'-	O
untranslated	O
region	O
.	O

In	O
most	O
isolates	O
,	O
substantial	O
deletional	O
mutations	O
in	O
the	O
7a	O
gene	O
were	O
detected	O
that	O
would	O
result	O
in	O
aberrant	O
or	O
no	O
expression	B-PROC
of	O
the	O
7a	O
product	O
because	O
of	O
altered	O
reading	O
frames	O
.	O

RESULTS	O
:	O
In	O
most	O
isolates	O
,	O
substantial	O
deletional	O
mutations	O
in	O
the	O
7a	O
gene	O
were	O
detected	O
that	O
would	O
result	O
in	O
aberrant	O
or	O
no	O
expression	B-PROC
of	O
the	O
7a	O
product	O
because	O
of	O
altered	O
reading	O
frames	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
plays	O
a	O
central	O
role	O
in	O
generating	O
angiotensin	O
II	O
from	O
angiotensin	O
I	O
,	O
and	O
capillary	O
blood	O
vessels	O
in	O
the	O
lung	O
are	O
one	O
of	O
the	O
major	O
sites	O
of	O
ACE	O
expression	B-PROC
and	O
angiotensin	O
II	O
production	O
in	O
the	O
human	O
body	O
.	O

The	O
RAS	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	B-PROC
of	O
pulmonary	O
hypertension	O
and	O
pulmonary	O
fibrosis	O
,	O
both	O
commonly	O
seen	O
in	O
chronic	O
lung	O
diseases	O
such	O
as	O
chronic	O
obstructive	O
lung	O
disease	O
.	O

Macro	O
domains	O
are	O
also	O
present	O
in	O
a	O
number	O
of	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
,	O
but	O
their	O
precise	O
function	O
in	O
viral	B-PROC
replication	I-PROC
is	O
still	O
unknown	O
.	O

This	O
enzyme	O
plays	O
an	O
essential	O
role	O
in	O
viral	B-PROC
replication	I-PROC
and	O
transcription	B-PROC
since	O
a	O
mutation	O
in	O
the	O
related	O
H229E	O
human	O
coronavirus	O
nsp15	O
gene	O
can	O
abolish	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

The	O
ensuing	O
targeted	B-PROC
destruction	O
of	O
viral	O
RNA	O
should	O
interfere	O
with	O
viral	B-PROC
replication	I-PROC
without	O
entailing	O
negative	O
effects	O
on	O
ongoing	O
cellular	O
processes	O
.	O

The	O
strains	O
were	O
selected	O
for	O
cross	O
-	O
challenge	O
in	O
specific	O
pathogen	O
free	O
chickens	O
and	O
virus	B-PROC
neutralization	I-PROC
in	O
chick	O
embryos	O
on	O
the	O
basis	O
of	O
partial	O
S1	O
sequence	O
amino	O
acid	O
identity	O
values	O
.	O

Each	O
batch	O
of	O
mixed	O
peptide	O
substrates	O
with	O
defined	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
at	O
the	O
target	O
amino	O
acid	O
position	O
was	O
synthesized	O
via	O
the	O
""""	O
cartridge	O
replacement	O
""""	O
approach	O
and	O
was	O
subjected	O
to	O
enzymatic	O
cleavage	B-PROC
by	O
recombinant	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

The	O
hydrophobic	O
pocket	O
in	O
the	O
P2	O
position	O
at	O
the	O
protease	O
cleavage	B-PROC
site	O
is	O
crucial	O
to	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)-	O
specific	O
binding	O
,	O
which	O
is	O
limited	O
to	O
substitution	O
by	O
hydrophobic	O
residue	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
susceptibility	O
to	O
infection	O
by	O
IBV	O
was	O
connected	O
to	O
the	O
expression	B-PROC
of	O
alpha2	O
,	O
3	O
-	O
linked	O
sialic	O
acid	O
as	O
indicated	O
by	O
the	O
reactivity	O
with	O
the	O
lectin	O
Maackia	O
amurensis	O
agglutinin	O
.	O

In	O
contrast	O
,	O
the	O
relative	O
conservation	O
of	O
the	O
M	O
and	O
E	O
proteins	O
of	O
BCoV	O
including	O
Korean	O
WD	O
strains	O
and	O
the	O
other	O
coronaviruses	O
suggested	O
that	O
structural	O
constraints	O
on	O
these	O
proteins	O
are	O
rigid	O
,	O
resulting	O
in	O
more	O
limited	O
evolution	B-PROC
of	O
these	O
proteins	O
.	O

In	O
addition	O
,	O
BCoV	O
and	O
human	O
coronavirus	O
HCV	O
-	O
OC43	O
contained	O
four	O
potential	O
O	O
-	O
glycosylation	B-PROC
sites	O
in	O
the	O
M	O
gene	O
.	O

However	O
,	O
the	O
M	O
gene	O
sequence	O
of	O
both	O
BCoV	O
and	O
HCV	O
-	O
OC43	O
might	O
not	O
contain	O
a	O
signal	O
peptide	O
,	O
suggesting	O
the	O
M	O
protein	O
might	O
be	O
unlikely	O
to	O
be	O
exposed	O
to	O
the	O
O	O
-	O
glycosylation	B-PROC
machinery	O
in	O
vivo	O
.	O

Adequate	O
animal	O
models	O
are	O
required	O
to	O
study	O
the	O
underlying	O
pathogenesis	B-PROC
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
and	O
to	O
develop	O
effective	O
vaccines	O
and	O
therapeutics	O
.	O

The	O
results	O
indicate	O
that	O
the	O
ILA	O
use	O
may	O
not	O
be	O
justified	O
if	O
the	O
improvement	O
of	O
oxygenation	B-PROC
is	O
the	O
primary	O
therapy	O
goal	O
.	O

CONCLUSIONS	O
:	O
Oxygenation	B-PROC
is	O
increased	O
by	O
ILA	O
in	O
severe	O
lung	O
injury	O
.	O

Five	O
patients	O
in	O
the	O
ARF	O
group	O
and	O
1	O
female	O
patient	O
with	O
end	O
-	O
stage	O
renal	O
failure	O
underwent	O
renal	O
replacement	O
therapy	O
during	O
hospitalization	O
;	O
however	O
,	O
both	O
eventually	O
died	B-PROC
.	O

TITLE	O
:	O
Characterization	O
and	O
inhibition	B-PROC
of	O
SARS	O
-	O
coronavirus	O
main	O
protease	O
.	O

The	O
objective	O
here	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
PP	O
on	O
oxygenation	B-PROC
.	O

One	O
accidental	O
extubation	O
and	O
four	O
cases	O
of	O
deterioration	O
through	O
oxygenation	B-PROC
were	O
detected	O
.	O

For	O
a	O
significant	O
number	O
of	O
ARDS	O
patients	O
,	O
PP	O
may	O
rapidly	O
enhance	O
arterial	O
oxygenation	B-PROC
and	O
its	O
inclusion	O
for	O
management	O
of	O
severe	O
ARDS	O
is	O
justified	O
.	O

TITLE	O
:	O
A	O
single	O
amino	O
acid	O
substitution	O
(	O
R441A	O
)	O
in	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
coronavirus	O
spike	O
protein	O
disrupts	O
the	O
antigenic	O
structure	O
and	O
binding	B-PROC
activity	I-PROC
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
two	O
major	O
functions	O
:	O
interacting	O
with	O
the	O
receptor	O
to	O
mediate	O
virus	O
entry	O
and	O
inducing	O
protective	O
immunity	B-PROC
.	O

With	O
a	O
panel	O
of	O
anti	O
-	O
RBD	O
mAbs	O
as	O
probes	O
,	O
we	O
observed	O
that	O
R441A	O
substitution	O
was	O
able	O
to	O
disrupt	O
the	O
majority	O
of	O
neutralizing	O
epitopes	O
in	O
the	O
RBD	O
,	O
suggesting	O
that	O
this	O
residue	O
is	O
critical	O
for	O
the	O
antigenic	O
structure	O
responsible	O
for	O
inducing	O
protective	O
immune	B-PROC
responses	I-PROC
.	O

We	O
also	O
demonstrated	O
that	O
the	O
RBD	O
-	O
Fc	O
bearing	O
R441A	O
mutation	O
could	O
not	O
bind	O
to	O
soluble	O
and	O
cell	O
-	O
associated	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
and	O
failed	O
to	O
block	O
S	O
protein	O
-	O
mediated	O
pseudovirus	O
entry	O
,	O
indicating	O
that	O
this	O
point	B-PROC
mutation	I-PROC
also	O
disrupted	O
the	O
receptor	O
-	O
binding	O
motif	O
(	O
RBM	O
)	O
in	O
the	O
RBD	O
.	O

Peptides	O
analogous	O
to	O
regions	O
of	O
the	O
N	O
-	O
terminus	O
or	O
the	O
pre	O
-	O
transmembrane	O
domain	O
of	O
the	O
S2	O
subunit	O
inhibited	O
SARS	O
-	O
CoV	O
plaque	O
formation	B-PROC
by	O
40	O
-	O
70	O
%	O
at	O
concentrations	O
of	O
15	O
-	O
30	O
microM	O
.	O
Interestingly	O
,	O
peptides	O
analogous	O
to	O
the	O
SARS	O
-	O
CoV	O
or	O
MHV	O
loop	O
region	O
inhibited	O
viral	O
plaque	O
formation	B-PROC
by	O
>	O
80	O
%	O
at	O
similar	O
concentrations	O
.	O

Other	O
IMP	O
dehydrogenase	O
inhibitors	O
administered	O
near	O
maximum	O
tolerated	O
doses	O
using	O
the	O
same	O
dosing	O
regimen	O
as	O
for	O
ribavirin	O
were	O
found	O
to	O
slightly	O
enhance	O
virus	B-PROC
replication	I-PROC
in	O
the	O
lungs	O
.	O

METHODS	O
:	O
S2	O
gene	O
fragment	O
was	O
amplified	O
from	O
SARS	O
-	O
CoV	O
GD322	O
genome	O
with	O
RT	O
-	O
PCR	O
and	O
ligated	O
to	O
pGEM	O
-	O
T	O
vector	O
for	O
sequence	O
analysis	O
after	O
transformation	B-PROC
of	O
the	O
plasmid	O
into	O
E	O
.	O
coli	O
DH5a	O
.	O

Partial	O
ventilatory	O
support	O
can	O
effectively	O
unload	O
the	O
respiratory	O
workload	O
and	O
improve	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
with	O
less	O
hemodynamic	B-PROC
compromise	O
.	O

This	O
study	O
compares	O
the	O
effects	O
of	O
assisted	O
ventilatory	O
techniques	O
on	O
breathing	B-PROC
pattern	O
,	O
gas	O
exchange	O
,	O
hemodynamic	B-PROC
function	O
,	O
and	O
respiratory	O
effort	B-PROC
with	O
those	O
of	O
controlled	O
mechanical	O
ventilation	O
in	O
similarly	O
sedated	O
subjects	O
.	O

Gas	O
exchange	O
,	O
respiratory	O
effort	B-PROC
,	O
and	O
hemodynamic	B-PROC
function	O
were	O
measured	O
,	O
and	O
ventilation	O
-	O
perfusion	O
distributions	O
were	O
calculated	O
by	O
multiple	O
inert	O
-	O
gas	O
-	O
elimination	B-PROC
techniques	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
plays	O
an	O
essential	O
role	O
in	O
SARS	O
-	O
CoV	O
genome	O
packaging	O
and	O
virion	B-PROC
assembly	I-PROC
.	O

These	O
interactions	O
include	O
the	O
accidental	O
and	O
deliberate	O
sharing	O
of	O
microbial	O
agents	O
and	O
antimicrobial	O
resistance	B-PROC
and	O
allow	O
the	O
emergence	O
of	O
new	O
and	O
unrecognized	O
microbial	O
disease	O
agents	O
.	O

The	O
main	O
research	O
question	O
is	O
:	O
what	O
can	O
we	O
learn	B-PROC
from	O
the	O
SARS	O
experience	O
about	O
effective	O
prevention	O
of	O
HIV	O
/	O
AIDS	O
?	O

Moreover	O
,	O
this	O
new	O
class	O
of	O
bioorganometallic	O
compounds	O
exert	B-PROC
antiviral	O
effects	O
with	O
some	O
selectivity	O
toward	O
SARS	O
-	O
CoV	O
infection	O
.	O

Unusual	O
hemodynamics	B-PROC
secondary	O
to	O
severe	O
tricuspid	O
stenosis	O
were	O
demonstrated	O
by	O
CW	O
Doppler	O
with	O
intermittent	O
""""	O
signal	O
fusion	O
""""	O
resulting	O
from	O
blunted	O
respiratory	O
variation	O
in	O
the	O
markedly	O
elevated	O
right	O
atrial	O
pressure	O
relative	O
to	O
right	O
ventricular	O
pressure	O
.	O

Early	O
avian	O
influenza	O
in	O
children	O
resembled	O
the	O
more	O
common	O
dengue	O
fever	B-PROC
,	O
but	O
presence	O
of	O
cough	O
and	O
absence	O
of	O
hemoconcentration	O
distinguished	O
avian	O
influenza	O
,	O
which	O
often	O
progressed	O
rapidly	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
requiring	O
intensive	O
care	O
.	O

The	O
gene	O
for	O
the	O
enzyme	O
was	O
cloned	O
in	O
the	O
absence	O
of	O
purification	O
tags	O
,	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
and	O
the	O
enzyme	O
purified	O
.	O

Bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
)	O
infections	O
occurred	O
only	O
every	O
second	O
year	O
and	O
were	O
associated	O
with	O
a	O
treatment	O
peak	O
and	O
one	O
death	B-PROC
on	O
one	O
occasion	O
(	O
December	O
).	O

One	O
HCW	O
died	B-PROC
,	O
and	O
the	O
remaining	O
16	O
recovered	O
.	O

We	O
tested	O
the	O
polymorphisms	B-PROC
of	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
10	O
for	O
their	O
associations	O
with	O
SARS	O
.	O

TITLE	O
:	O
[	O
Hematological	O
changes	O
and	O
related	O
gene	B-PROC
mutation	I-PROC
of	O
post	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
with	O
osteonecrosis	O
].	O

Some	O
experts	O
feel	O
we	O
are	O
overdue	O
for	O
a	O
flu	O
pandemic	O
and	O
the	O
SARS	O
pandemic	O
of	O
2003	O
could	O
have	O
been	O
the	O
wake	B-PROC
up	O
call	O
to	O
begin	O
preparations	O
.	O

While	O
some	O
believe	O
that	O
the	O
AI	O
(	O
H5N1	O
)	O
causing	O
illness	O
and	O
deaths	B-PROC
in	O
Asia	O
and	O
Turkey	O
will	O
be	O
the	O
pandemic	O
flu	O
strain	O
,	O
there	O
is	O
no	O
guarantee	O
that	O
will	O
occur	O
.	O

TITLE	O
:	O
An	O
evaluation	O
of	O
nursing	B-PROC
practice	O
models	O
in	O
the	O
context	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
epidemic	O
in	O
Hong	O
Kong	O
:	O
a	O
preliminary	O
study	O
.	O

Providing	O
a	O
preliminary	O
understanding	O
,	O
this	O
paper	O
compares	O
the	O
conventional	O
with	O
different	O
nursing	B-PROC
delivery	O
models	O
in	O
a	O
simulated	O
SARS	O
ward	O
and	O
focuses	O
on	O
nurses	O
'	O
efficiency	O
,	O
infection	O
control	O
practices	O
and	O
views	O
of	O
the	O
two	O
models	O
.	O

The	O
latter	O
depicted	O
a	O
modified	O
primary	O
nursing	B-PROC
approach	O
in	O
a	O
team	O
,	O
with	O
delegation	O
of	O
care	O
.	O

Cl2	O
causes	O
severe	O
,	O
dose	O
-	O
related	O
lung	O
injury	O
,	O
with	O
features	O
seen	O
in	O
both	O
smoke	O
inhalation	B-PROC
and	O
in	O
ARDS	O
secondary	O
to	O
systemic	O
disease	O
.	O

ABSTRACT	O
:	O
A	O
method	O
for	O
the	O
parallel	O
solid	O
-	O
phase	O
synthesis	B-PROC
of	O
peptide	O
aldehydes	O
has	O
been	O
developed	O
.	O

A	O
set	O
of	O
25	O
peptide	O
aldehydes	O
was	O
prepared	O
by	O
this	O
method	O
and	O
investigated	O
in	O
inhibition	B-PROC
assays	O
against	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
).	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
a	O
structural	O
component	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
can	O
induce	O
antibody	B-PROC
responses	I-PROC
in	O
SARS	O
patients	O
during	O
infection	O
.	O

ARDS	O
develops	O
in	O
response	O
to	O
inflammatory	O
stresses	O
including	O
sepsis	O
,	O
trauma	O
,	O
and	O
severe	O
pneumonia	O
,	O
and	O
despite	O
aggressive	B-PROC
critical	O
care	O
management	O
,	O
it	O
still	O
has	O
a	O
mortality	O
of	O
30	O
-	O
50	O
%.	O

The	O
phages	O
specifically	O
inhibited	O
IBV	O
infectivity	O
in	O
HeLa	O
cells	O
and	O
blocked	O
IBV	O
haemagglutination	B-PROC
.	O

TITLE	O
:	O
[	O
The	O
research	O
and	O
development	B-PROC
of	O
new	O
diagnostic	O
gene	O
chips	O
for	O
SARS	O
coronavirus	O
].	O

TITLE	O
:	O
Phase	O
I	O
trial	O
of	O
the	O
trifunctional	O
anti	O
-	O
HER2	O
x	O
anti	O
-	O
CD3	O
antibody	B-PROC
ertumaxomab	O
in	O
metastatic	O
breast	O
cancer	O
.	O

One	O
patient	O
(	O
200	O
mug	O
dose	O
)	O
developed	O
severe	O
hypotension	O
and	O
respiratory	O
distress	O
syndrome	O
,	O
another	O
patient	O
(	O
150	O
mug	O
dose	O
)	O
developed	O
a	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
and	O
acute	O
renal	O
failure	O
.	O

Similar	O
changes	O
have	O
been	O
documented	O
in	O
diabetes	O
,	O
sepsis	O
,	O
children	O
with	O
vasculitis	O
,	O
allograft	O
rejection	O
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
patients	O
with	O
recurrent	O
pregnancy	O
losses	O
,	O
hereditary	O
angioedema	O
,	O
adult	O
respiratory	O
distress	O
syndrome	O
and	O
coronary	O
artery	O
disease	O
.	O

In	O
summary	O
,	O
these	O
results	O
indicate	O
that	O
the	O
plasma	O
KKS	O
plays	O
a	O
central	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
chronic	O
intestinal	O
inflammation	O
,	O
arthritis	O
and	O
angiogenesis	B-PROC
.	O

ABSTRACT	O
:	O
Infection	O
by	O
different	O
coronaviruses	O
(	O
CoVs	O
)	O
causes	O
alterations	O
in	O
the	O
transcriptional	B-PROC
and	O
translational	B-PROC
patterns	O
,	O
cell	B-PROC
cycle	I-PROC
,	O
cytoskeleton	O
,	O
and	O
apoptosis	B-PROC
pathways	B-PROC
of	O
the	O
host	O
cells	O
.	O

Here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
rationally	O
designed	O
fusion	O
core	O
of	O
HCoV	O
-	O
229E	O
(	O
HR1	O
-	O
SGGRGG	O
-	O
HR2	O
),	O
which	O
was	O
in	O
vitro	O
produced	O
in	O
GST	O
prokaryotic	O
expression	B-PROC
system	O
.	O

The	O
clinical	O
data	O
for	O
these	O
patients	O
were	O
correlated	O
to	O
identify	O
risk	O
factors	O
that	O
might	O
increase	O
the	O
likelihood	O
of	O
the	O
development	B-PROC
of	O
CT	O
abnormalities	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
that	O
32	O
%	O
of	O
the	O
children	O
(	O
15	O
/	O
47	O
)	O
affected	O
with	O
SARS	O
showed	O
thin	O
-	O
section	O
CT	O
abnormalities	O
up	O
to	O
12	O
months	O
after	O
diagnosis	O
despite	O
clinical	O
remission	O
and	O
unremarkable	O
pulmonary	B-PROC
function	I-PROC
assessment	O
.	O

ABSTRACT	O
:	O
Starting	O
from	O
a	O
collection	O
of	O
1386	O
druggable	O
compounds	O
obtained	O
from	O
the	O
3D	O
pharmacophore	O
search	O
,	O
we	O
performed	O
a	O
similarity	O
search	O
to	O
narrow	O
down	O
the	O
scope	O
of	O
docking	B-PROC
studies	O
.	O

Group	O
D	O
mAb	O
(	O
S25	O
)	O
was	O
directed	O
against	O
a	O
unique	O
epitope	O
by	O
its	O
competitive	B-PROC
binding	I-PROC
.	O

TITLE	O
:	O
Endosomal	O
proteolysis	B-PROC
by	O
cathepsins	O
is	O
necessary	O
for	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
type	O
2	O
spike	O
-	O
mediated	O
entry	O
.	O

ABSTRACT	O
:	O
Most	O
strains	O
of	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
express	O
a	O
cleavable	O
spike	O
glycoprotein	O
that	O
mediates	O
viral	O
entry	O
and	O
pH	O
-	O
independent	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
.	O

The	O
MHV	O
type	O
2	O
(	O
MHV	O
-	O
2	O
)	O
strain	O
of	O
murine	O
coronavirus	O
differs	O
from	O
other	O
strains	O
in	O
that	O
it	O
expresses	O
an	O
uncleaved	O
spike	O
and	O
cannot	O
induce	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
at	O
neutral	O
pH	O
values	O
.	O

In	O
contrast	O
,	O
trypsin	O
treatment	O
can	O
both	O
overcome	O
ammonium	O
chloride	O
inhibition	B-PROC
and	O
promote	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
.	O

Electron	O
microscopy	O
revealed	O
the	O
early	O
formation	B-PROC
and	O
accumulation	O
of	O
typical	O
double	O
-	O
membrane	O
vesicles	O
,	O
which	O
probably	O
carry	O
the	O
viral	B-PROC
replication	I-PROC
complex	O
.	O

Molecular	O
modelling	O
,	O
using	O
the	O
solution	O
structure	O
of	O
severe	O
acute	O
respiratory	O
(	O
SARS	O
)	O
coronavirus	O
N	O
-	O
protein	O
,	O
revealed	O
that	O
this	O
motif	O
is	O
available	O
for	O
interaction	O
with	O
cellular	O
factors	O
which	O
may	O
mediate	O
nucleolar	O
localization	B-PROC
.	O

In	O
the	O
paper	O
,	O
according	O
to	O
the	O
intensity	O
properties	O
of	O
the	O
chest	O
radiograph	O
,	O
the	O
chest	O
radiographic	O
image	O
is	O
divided	O
into	O
three	O
subregions	O
,	O
and	O
a	O
piecewise	O
linear	O
transformation	B-PROC
model	O
is	O
established	O
.	O

ABSTRACT	O
:	O
A	O
22	O
-	O
year	O
-	O
old	O
woman	O
is	O
presented	O
with	O
acute	O
gastric	O
dilation	O
after	O
an	O
eating	B-PROC
binge	O
,	O
who	O
died	B-PROC
of	O
complications	O
of	O
acute	O
reperfusion	O
syndrome	O
.	O

Her	O
initial	O
complaints	O
--	O
diarrhea	O
,	O
vomiting	O
and	O
abdominal	O
pain	O
--	O
began	O
after	O
an	O
enormous	O
food	B-PROC
intake	I-PROC
.	O

Both	O
pregnancies	B-PROC
had	O
intrauterine	O
growth	B-PROC
retardation	O
,	O
oligohydramnios	O
and	O
newborns	O
small	O
for	O
gestation	B-PROC
.	O

Both	O
bone	B-PROC
resorption	B-PROC
and	O
formation	B-PROC
markers	O
were	O
unable	O
to	O
predict	O
the	O
subsequent	O
development	B-PROC
of	O
osteonecrosis	O
.	O

In	O
WLH	O
hens	O
,	O
significantly	O
higher	O
haemolytic	O
complement	B-PROC
activity	I-PROC
post	O
vaccination	O
was	O
found	O
as	O
compared	O
to	O
RIR	O
hens	O
.	O

Possible	O
consequences	O
of	O
the	O
observed	O
differences	O
in	O
immune	O
responsiveness	O
of	O
the	O
two	O
breeds	B-PROC
to	O
viral	O
vaccines	O
are	O
discussed	O
.	O

Despite	O
a	O
shorter	O
duration	O
of	O
fever	B-PROC
(	O
mean	O
,	O
1	O
.	O
7	O
days	O
)	O
and	O
no	O
difference	O
in	O
maximum	O
temperature	O
in	O
children	O
with	O
CoV	O
-	O
HKU1	O
infections	O
compared	O
to	O
patients	O
with	O
most	O
other	O
respiratory	O
virus	O
infections	O
,	O
a	O
high	O
incidence	O
of	O
febrile	B-PROC
seizures	O
(	O
50	O
%)	O
was	O
noted	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
those	O
for	O
HCoV	O
-	O
OC43	O
(	O
14	O
%),	O
adenovirus	O
(	O
9	O
%),	O
human	O
parainfluenza	O
virus	O
1	O
(	O
0	O
%),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
8	O
%)	O
infections	O
.	O

The	O
RDRP	O
and	O
envelope	O
E	O
genes	O
,	O
based	O
on	O
published	O
sequences	O
,	O
have	O
been	O
synthesized	O
and	O
cloned	O
into	O
mammalian	O
expression	B-PROC
vectors	O
.	O

The	O
siRNA	O
or	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
expression	B-PROC
cassettes	O
were	O
co	O
-	O
transfected	O
with	O
the	O
SARS	O
viral	O
RDRP	O
or	O
envelope	O
E	O
expression	B-PROC
vectors	O
into	O
NIH	O
3T3	O
cells	O
.	O

These	O
siRNA	O
molecules	O
could	O
be	O
used	O
to	O
examine	O
the	O
function	O
of	O
these	O
genes	O
in	O
SARS	O
virus	B-PROC
replication	I-PROC
and	O
assembly	O
.	O

Additionally	O
,	O
SARS	O
-	O
CoV	O
infection	O
induced	O
a	O
delayed	O
activation	O
of	O
IFN	O
-	O
alpha	O
expression	B-PROC
.	O

Blood	O
samples	O
were	O
tested	O
for	O
total	O
antibodies	O
to	O
SARS	O
-	O
CoV	O
by	O
immunofluorescence	O
antibody	B-PROC
test	O
.	O

ABSTRACT	O
:	O
Describe	O
initial	O
development	B-PROC
and	O
validation	O
of	O
a	O
test	O
battery	O
composed	O
of	O
established	O
instruments	O
designed	O
to	O
detect	O
,	O
via	O
telephone	O
interview	O
,	O
cognitive	O
abnormalities	O
in	O
survivors	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Novel	O
mfgl2	O
antisense	O
plasmid	O
inhibits	O
murine	O
fgl2	O
expression	B-PROC
and	O
ameliorates	O
murine	O
hepatitis	O
virus	O
type	O
3	O
-	O
induced	O
fulminant	O
hepatitis	O
in	O
BALB	O
/	O
cJ	O
mice	O
.	O

On	O
hydrodynamic	O
delivery	O
,	O
mfgl2	O
antisense	O
plasmid	O
significantly	O
reduced	O
mfgl2	O
expression	B-PROC
in	O
vivo	O
;	O
markedly	O
ameliorated	O
inflammatory	O
cell	O
infiltration	O
,	O
fibrin	O
deposition	O
,	O
and	O
hepatocyte	O
necrosis	B-PROC
;	O
prolonged	O
the	O
survival	O
time	O
period	O
;	O
and	O
elevated	O
the	O
survival	O
rate	O
among	O
BALB	O
/	O
cJ	O
mice	O
with	O
murine	O
hepatitis	O
virus	O
type	O
3	O
-	O
induced	O
fulminant	O
hepatitis	O
.	O

TITLE	O
:	O
Ageing	B-PROC
and	O
psychological	O
response	O
during	O
the	O
post	O
-	O
SARS	O
period	O
.	O

Interestingly	O
,	O
only	O
the	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-PROC
can	O
inhibit	O
SARS	O
-	O
CoV	O
propagation	O
in	O
Vero	O
E6	O
culture	O
although	O
the	O
binding	O
affinity	O
of	O
the	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-PROC
was	O
lower	O
than	O
the	O
anti	O
-	O
3a	O
C	O
-	O
terminal	O
antibody	B-PROC
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immunity	I-PROC
in	O
human	O
SARS	O
-	O
CoV	O
infection	O
is	O
still	O
not	O
well	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
memory	B-PROC
T	O
-	O
cell	O
responses	O
against	O
the	O
spike	O
(	O
S	O
)	O
protein	O
were	O
persistent	O
for	O
more	O
than	O
1	O
year	O
after	O
SARS	O
-	O
CoV	O
infection	O
by	O
detecting	O
the	O
production	O
of	O
IFN	O
-	O
gamma	O
using	O
ELISA	O
and	O
ELISpot	O
assays	O
.	O

B	O
group	O
:	O
large	O
V	O
(	O
T	O
)	O
(	O
20	O
ml	O
/	O
kg	O
)	O
with	O
respiratory	O
rate	O
30	O
/	O
minutes	O
,	O
high	O
inspiratory	B-PROC
flow	O
20	O
ml	O
.	O
kg	O
(-	O
1	O
).	O
s	O
(-	O
1	O
).	O

Reduction	O
of	O
inspiratory	B-PROC
flow	O
and	O
respiratory	O
rate	O
with	O
large	O
tidal	O
volume	O
ventilation	O
may	O
provide	O
pulmonary	O
protection	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
multiplex	O
RT	O
-	O
PCR	O
)	O
that	O
can	O
detect	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
and	O
porcine	O
group	O
A	O
rotavirus	O
(	O
GAR	O
)	O
was	O
developed	O
.	O

3	O
.	O
8	O
micromol	O
/	O
L	O
;	O
selectivity	O
index	O
(	O
SI	O
)	O
=	O
26	O
.	O
6	O
)	O
and	O
B2	O
(	O
CC50	B-PROC
=	O
383	O
.	O
3	O
+/-	O

The	O
results	O
demonstrated	O
that	O
(	O
1	O
)	O
a	O
single	O
dose	O
of	O
RBD	O
-	O
rAAV	O
vaccination	O
could	O
induce	O
sufficient	O
neutralizing	O
antibody	B-PROC
against	O
SARS	O
-	O
CoV	O
infection	O
;	O
(	O
2	O
)	O
two	O
more	O
repeated	O
doses	O
of	O
the	O
vaccination	O
boosted	O
the	O
neutralizing	O
antibody	B-PROC
to	O
about	O
5	O
times	O
of	O
the	O
level	O
achieved	O
by	O
a	O
single	O
dose	O
of	O
the	O
immunization	O
and	O
(	O
3	O
)	O
the	O
level	O
of	O
the	O
antibody	B-PROC
continued	O
to	O
increase	O
for	O
the	O
entire	O
duration	O
of	O
the	O
experiment	O
of	O
5	O
.	O
5	O
months	O
.	O

Conversely	O
,	O
the	O
M	O
protein	O
expressed	B-PROC
in	O
mammalian	O
cells	O
did	O
not	O
induce	O
apoptosis	B-PROC
.	O

ABSTRACT	O
:	O
Fifty	O
-	O
seven	O
cleft	O
palate	O
patients	O
underwent	O
primary	O
repair	B-PROC
with	O
Furlow	O
palatoplasty	O
by	O
the	O
same	O
surgeon	O
from	O
January	O
2001	O
to	O
January	O
2005	O
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
reported	O
the	O
establishment	O
of	O
cells	O
with	O
persistent	O
SARS	O
-	O
CoV	O
infection	O
after	O
apoptotic	O
events	O
and	O
showed	O
that	O
both	O
JNK	O
and	O
PI3K	O
/	O
Akt	O
signaling	B-PROC
pathways	B-PROC
are	O
important	O
for	O
persistence	O
by	O
treatment	O
with	O
inhibitors	O
at	O
the	O
early	O
stages	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Protease	O
cleavage	B-PROC
of	O
the	O
trimer	O
occurs	O
at	O
the	O
S1	O
-	O
S2	O
boundary	O
;	O
an	O
ensuing	O
S1	O
dissociation	O
leads	O
to	O
a	O
major	O
rearrangement	B-PROC
of	O
the	O
trimeric	O
S2	O
and	O
to	O
formation	B-PROC
of	O
rosettes	O
likely	O
to	O
represent	O
clusters	O
of	O
elongated	O
,	O
postfusion	O
trimers	O
of	O
S2	O
associated	O
through	O
their	O
fusion	O
peptides	O
.	O

Using	O
another	O
set	O
of	O
isogenic	O
recombinant	O
viruses	O
with	O
JHM	O
background	O
genes	O
expressing	O
either	O
the	O
JHM	O
or	O
A59	O
spike	O
,	O
we	O
have	O
further	O
investigated	O
the	O
roles	O
of	O
viral	O
genes	O
in	O
pathogenesis	B-PROC
.	O

While	O
expression	B-PROC
of	O
the	O
JHM	O
spike	O
is	O
sufficient	O
to	O
confer	O
a	O
neurovirulent	O
phenotype	O
,	O
as	O
well	O
as	O
increased	O
macrophage	O
infiltration	O
,	O
background	O
genes	O
contribute	O
to	O
virulence	B-PROC
as	O
well	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
dictating	O
the	O
extent	O
of	O
the	O
T	O
-	O
cell	O
immune	B-PROC
response	I-PROC
.	O

TITLE	O
:	O
Enhanced	O
induction	O
of	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
-	O
specific	B-PROC
immune	B-PROC
response	I-PROC
using	O
DNA	O
vaccination	O
followed	O
by	O
adenovirus	O
boosting	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

Three	O
serum	O
specimens	O
were	O
positive	O
for	O
the	O
antibody	B-PROC
to	O
SARS	O
-	O
CoV	O
.	O
The	O
IgG	O
antibody	B-PROC
to	O
poliovirus	O
were	O
detected	O
in	O
4	O
SARS	O
patients	O
and	O
23	O
healthy	O
persons	O
.	O

The	O
positive	O
rate	O
of	O
the	O
poliovirus	O
antibody	B-PROC
in	O
the	O
serum	O
of	O
SARS	O
patients	O
2	O
years	O
after	O
recovery	O
was	O
significantly	O
different	O
from	O
that	O
of	O
the	O
normal	O
controls	O
,	O
and	O
the	O
positive	O
rate	O
of	O
poliovirus	O
in	O
the	O
fecal	O
specimens	O
was	O
still	O
very	O
high	O
,	O
and	O
more	O
importantly	O
back	O
mutations	O
have	O
occurred	O
in	O
the	O
attenuating	O
mutation	O
sites	O
at	O
nucleotide	O
position	O
which	O
plays	O
an	O
important	O
role	O
in	O
the	O
poliomyelitis	O
.	O

While	O
many	O
different	O
viruses	O
target	O
proteins	O
to	O
the	O
nucleolus	O
and	O
recruit	O
nucleolar	O
proteins	O
to	O
facilitate	O
virus	B-PROC
replication	I-PROC
,	O
the	O
effect	O
of	O
infection	O
on	O
the	O
nucleolus	O
in	O
terms	O
of	O
morphology	O
and	O
protein	O
content	O
is	O
unknown	O
.	O

The	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
association	O
between	O
the	O
genetic	B-PROC
polymorphisms	I-PROC
of	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
synthetase	O
1	O
(	O
OAS1	O
)	O
gene	O
as	O
well	O
as	O
myxovirus	O
resistance	B-PROC
1	O
(	O
MxA	O
)	O
gene	O
and	O
susceptibility	O
to	O
SARS	O
in	O
Chinese	O
Han	O
population	O
.	O

The	O
expression	B-PROC
of	O
pulmonary	O
surfactant	O
associated	O
protein	O
A	O
in	O
AT	O
group	O
was	O
significantly	O
higher	O
in	O
the	O
AT	O
group	O
(	O
18	O
.	O
97	O
%	O
+/-	O

ABSTRACT	O
:	O
Specimens	O
obtained	O
from	O
96	O
dogs	O
with	O
respiratory	O
and	O
enteric	O
clinical	O
signs	O
in	O
Japan	O
were	O
retrospectively	O
examined	O
for	O
group	O
2	O
coronavirus	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
.	O

Under	O
the	O
circumstance	O
where	O
several	O
fatal	O
communicable	O
diseases	O
are	O
predictable	O
,	O
conflicts	O
between	O
professional	O
responsibility	O
and	O
their	O
personal	O
risks	O
should	O
be	O
taken	O
into	O
considerations	O
by	O
nurses	O
themselves	O
and	O
by	O
nursing	B-PROC
administrators	O
in	O
order	O
to	O
improve	O
quality	O
of	O
care	O
.	O

During	O
the	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
epidemic	O
in	O
Toronto	O
,	O
nursing	B-PROC
resources	O
were	O
stretched	O
to	O
their	O
limits	O
.	O

Adverse	O
events	O
were	O
defined	O
as	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
or	O
death	B-PROC
.	O

TITLE	O
:	O
Photochemical	O
treatment	O
of	O
plasma	O
with	O
amotosalen	O
and	O
long	O
-	O
wavelength	O
ultraviolet	O
light	O
inactivates	O
pathogens	O
while	O
retaining	O
coagulation	B-PROC
function	O
.	O

Retention	B-PROC
was	O
72	O
to	O
73	O
percent	O
of	O
baseline	O
fibrinogen	O
and	O
Factor	O
(	O
F	O
)	O
VIII	O
activity	O
and	O
78	O
to	O
98	O
percent	O
for	O
FII	O
,	O
FV	O
,	O
FVII	O
,	O
F	O
IX	O
,	O
FX	O
,	O
FXI	O
,	O
FXIII	O
,	O
protein	O
C	O
,	O
protein	O
S	O
,	O
antithrombin	O
,	O
and	O
alpha2	O
-	O
antiplasmin	O
.	O

Although	O
the	O
virus	O
spreading	O
has	O
been	O
contained	O
,	O
due	O
preparedness	O
and	O
planning	O
,	O
including	O
the	O
successful	O
development	B-PROC
of	O
antiviral	O
drugs	O
against	O
SARS	O
-	O
CoV	O
,	O
is	O
necessary	O
for	O
possible	O
reappearance	O
of	O
SARS	O
.	O

This	O
indicates	O
that	O
formyl	O
peptide	O
receptor	O
may	O
be	O
important	O
in	O
viral	B-PROC
infections	I-PROC
and	O
that	O
variations	O
in	O
its	O
sequence	O
among	O
individuals	O
may	O
affect	O
their	O
likelihood	O
of	O
viral	O
and	O
bacterial	O
infections	O
.	O

The	O
samples	O
represented	O
virus	O
-	O
producing	O
cell	O
cultures	O
(	O
such	O
as	O
SARS	O
-	O
coronavirus	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
Orthopox	O
virus	O
),	O
bacteria	O
suspensions	O
(	O
cultures	O
of	O
Escherichia	O
coli	O
and	O
genetically	O
knockout	O
apathogenic	O
Bacillus	O
anthracis	O
),	O
suspensions	O
of	O
parasites	O
(	O
malaria	O
Plasmodium	O
falciparum	O
,	O
Leishmania	O
major	O
,	O
Microsporidia	O
cuniculi	O
,	O
Caenorhabditis	O
elegans	O
),	O
and	O
whole	O
Drosophila	O
melanogaster	O
flies	O
infected	O
with	O
microsporidia	O
.	O

TITLE	O
:	O
Human	O
memory	B-PROC
T	O
cell	O
responses	O
to	O
SARS	O
-	O
CoV	O
E	O
protein	O
.	O

Thus	O
,	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
is	O
considered	O
a	O
potential	O
target	O
for	O
the	O
development	B-PROC
of	O
antiviral	O
drugs	O
.	O

No	O
deaths	B-PROC
were	O
observed	O
.	O

Patients	O
were	O
randomized	O
to	O
be	O
continuously	O
tube	O
-	O
fed	O
with	O
either	O
a	O
diet	O
enriched	O
with	O
EPA	O
,	O
GLA	O
,	O
and	O
elevated	O
antioxidants	O
or	O
an	O
isonitrogenous	O
and	O
isocaloric	O
control	O
diet	O
,	O
delivered	O
at	O
a	O
constant	O
rate	O
to	O
achieve	O
a	O
minimum	O
of	O
75	O
%	O
of	O
basal	O
energy	B-PROC
expenditure	I-PROC
x	O
1	O
.	O
3	O
during	O
a	O
minimum	O
of	O
4	O
days	O
.	O

ABSTRACT	O
:	O
The	O
early	O
release	O
of	O
cytokines	O
by	O
cells	O
involved	O
in	O
innate	B-PROC
immunity	B-PROC
is	O
an	O
important	O
host	B-PROC
response	I-PROC
to	O
intracellular	O
pathogens	O
.	O

To	O
better	O
understand	O
innate	O
and	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
after	O
infection	O
with	O
Porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
we	O
investigated	O
serum	O
IFN	O
-	O
gamma	O
concentrations	O
and	O
the	O
duration	O
of	O
viremia	O
.	O

The	O
eligibility	O
criteria	O
were	O
:	O
(	O
1	O
)	O
aged	O
55	O
or	O
above	O
;	O
(	O
2	O
)	O
able	O
to	O
speak	O
Cantonese	O
;	O
(	O
3	O
)	O
no	O
hearing	B-PROC
impairment	O
,	O
and	O
(	O
4	O
)	O
reachable	O
by	O
telephone	O
.	O

Unexpectedly	O
,	O
the	O
Sgamma	O
of	O
Cys172	O
forms	O
two	O
covalent	B-PROC
bonds	O
with	O
each	O
inhibitor	O
,	O
yielding	O
an	O
unusual	O
episulfide	O
cation	O
(	O
thiiranium	O
ring	O
)	O
stabilized	O
by	O
a	O
nearby	O
oxyanion	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
IL	O
-	O
4	O
and	O
IFN	O
-	O
gamma	O
downregulated	O
cell	O
surface	O
expression	B-PROC
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
SARS	O
-	O
CoV	O
receptor	O
.	O

Besides	O
diminished	O
ACE2	O
cell	O
surface	O
expression	B-PROC
,	O
ACE2	O
mRNA	O
levels	O
were	O
also	O
decreased	O
after	O
treatment	O
with	O
these	O
cytokines	O
.	O

By	O
in	O
situ	O
hybridization	B-PROC
,	O
the	O
IBV	O
Nc	O
gene	O
was	O
more	O
consistently	O
detected	O
in	O
the	O
trachea	O
at	O
early	O
stages	O
of	O
infection	O
(	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
and	O
in	O
the	O
cecal	O
tonsils	O
at	O
late	O
stages	O
of	O
infection	O
(	O
21	O
,	O
28	O
,	O
and	O
35	O
days	O
).	O

Themes	O
and	O
subthemes	O
from	O
the	O
data	O
were	O
organized	O
into	O
2	O
categories	O
:	O
The	O
Experience	O
(	O
operational	O
,	O
organizational	O
,	O
and	O
personal	O
narratives	O
),	O
and	O
Learning	B-PROC
from	O
the	O
Experience	O
(	O
opportunities	O
for	O
personal	O
learning	B-PROC
,	O
professional	O
and	O
policy	O
development	B-PROC
,	O
and	O
insight	O
into	O
policy	O
and	O
administrative	O
implications	O
).	O

Based	O
on	O
the	O
structure	O
,	O
we	O
propose	O
that	O
nsp10	O
is	O
a	O
transcription	B-PROC
factor	O
for	O
coronavirus	O
replication	O
/	O
transcription	B-PROC
.	O

Our	O
results	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
assembly	O
pathway	B-PROC
used	O
by	O
coronaviruses	O
and	O
other	O
pleomorphic	O
viruses	O
and	O
provide	O
the	O
first	O
detailed	O
view	O
of	O
coronavirus	O
ultrastructure	O
.	O

There	O
were	O
no	O
additional	O
deaths	B-PROC
,	O
coronary	O
events	O
nor	O
haemorrhage	O
at	O
the	O
end	O
of	O
an	O
average	O
follow	O
-	O
up	O
of	O
15	O
+/-	O

Bovine	O
coronavirus	O
infection	O
was	O
significantly	O
associated	O
with	O
respiratory	O
tract	O
disease	O
and	O
decreased	O
growth	B-PROC
performance	O
in	O
AR	O
calves	O
.	O

The	O
complex	O
includes	O
an	O
RNA	O
endonuclease	O
,	O
NendoU	O
,	O
that	O
is	O
conserved	O
among	O
nidoviruses	O
but	O
no	O
other	O
RNA	O
virus	O
,	O
making	O
it	O
a	O
genetic	B-PROC
marker	I-PROC
of	O
this	O
virus	O
order	O
.	O

The	O
mortality	O
in	O
patients	O
with	O
ARDS	O
is	O
more	O
commonly	O
associated	O
with	O
the	O
sequels	O
of	O
sepsis	O
and	O
multiple	O
organ	O
dysfunction	O
than	O
with	O
respiratory	O
failure	O
although	O
the	O
latest	O
papers	O
on	O
protective	O
ventilation	O
suggest	O
that	O
death	B-PROC
in	O
these	O
patients	O
directly	O
results	O
from	O
lung	O
lesion	O
in	O
a	O
number	O
of	O
cases	O
.	O

Mechanistically	O
,	O
mixed	O
regulatory	O
circuits	O
promoted	O
inefficient	O
subgenomic	O
transcription	B-PROC
from	O
inappropriate	O
start	O
sites	O
,	O
resulting	O
in	O
truncated	O
ORFs	O
and	O
effectively	O
minimize	O
viral	O
structural	O
protein	B-PROC
expression	B-PROC
.	O

In	O
this	O
model	O
,	O
AIDS	O
is	O
seen	O
to	O
be	O
the	O
result	O
of	O
the	O
development	B-PROC
of	O
resistance	B-PROC
of	O
the	O
virus	O
(	O
PTRV	O
)	O
to	O
continuous	O
exposure	O
to	O
pro	O
-	O
apoptotic	O
(	O
schizonticidal	O
)	O
aminoquinoline	O
drugs	O
used	O
to	O
prevent	O
malaria	O
.	O

We	O
have	O
synthesised	O
and	O
characterised	O
the	O
first	O
generation	O
of	O
a	O
red	O
-	O
shifted	O
internally	O
quenched	O
fluorogenic	O
substrate	O
(	O
RS	O
-	O
IQFS	O
)	O
for	O
3CLpro	O
based	O
on	O
resonance	O
energy	B-PROC
transfer	I-PROC
between	O
the	O
donor	O
and	O
acceptor	O
pair	O
CAL	O
Fluor	O
Red	O
610	O
and	O
Black	O
Hole	O
Quencher	O
-	O
1	O
(	O
Km	O
and	O
kcat	O
values	O
of	O
14	O
microM	O
and	O
0	O
.	O
65	O
min	O
-	O
1	O
).	O

TITLE	O
:	O
The	O
structure	O
of	O
the	O
endoribonuclease	O
XendoU	O
:	O
From	O
small	O
nucleolar	O
RNA	B-PROC
processing	I-PROC
to	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
.	O

XendoU	O
is	O
broadly	O
conserved	O
among	O
eukaryotes	O
,	O
and	O
it	O
is	O
a	O
genetic	B-PROC
marker	I-PROC
of	O
nidoviruses	O
,	O
including	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
where	O
it	O
is	O
essential	O
for	O
replication	O
and	O
transcription	B-PROC
.	O

All	O
patients	O
had	O
fever	B-PROC
(	O
mean	O
body	O
temperature	O
39	O
+/-	O
1	O
degrees	O
C	O
)	O
and	O
altered	O
mental	O
status	O
(	O
mean	O
Glasgow	O
Coma	O
Score	O
11	O
+/-	O
2	O
).	O

Mean	O
SOFA	O
score	O
was	O
9	O
+/-	O
2	O
;	O
eight	O
patients	O
had	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
,	O
five	O
septic	O
shock	O
,	O
and	O
six	O
acute	O
respiratory	O
failure	O
(	O
usually	O
from	O
central	O
origin	O
)	O
requiring	O
mechanical	O
ventilation	O
.	O

Only	O
4	O
.	O
9	O
%	O
of	O
individuals	O
displayed	O
aggressive	B-PROC
behaviour	I-PROC
leading	O
to	O
injury	O
of	O
the	O
victim	O
.	O

RESULTS	O
:	O
The	O
12	O
-	O
month	O
prevalence	O
of	O
aggressive	B-PROC
behaviour	I-PROC
was	O
51	O
.	O
8	O
%:	O
24	O
%	O
property	O
damage	O
,	O
37	O
.	O
6	O
%	O
verbal	O
,	O
24	O
.	O
4	O
%	O
self	O
-	O
oriented	O
and	O
24	O
.	O
4	O
%	O
physical	O
aggression	B-PROC
,	O
and	O
9	O
.	O
8	O
%	O
sexually	O
aggressive	B-PROC
behaviour	I-PROC
,	O
most	O
of	O
which	O
being	O
mild	O
in	O
severity	O
.	O

The	O
full	O
length	O
NP	O
could	O
be	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
at	O
very	O
high	O
level	O
within	O
inclusion	O
bodies	O
.	O

Serologic	O
evidence	O
of	O
SARS	O
-	O
CoV	O
infection	O
was	O
detected	O
in	O
4	O
individuals	O
,	O
including	O
2	O
non	O
-	O
clinical	O
workers	O
,	O
who	O
had	O
not	O
previously	O
been	O
identified	O
as	O
SARS	O
cases	O
;	O
none	O
reported	O
having	O
had	O
fever	B-PROC
or	O
cough	O
.	O

Entering	O
the	O
index	O
patient	O
'	O
s	O
room	O
and	O
having	O
seen	O
(	O
viewed	O
)	O
the	O
patient	O
were	O
the	O
behaviors	B-PROC
associated	O
with	O
highest	O
risk	O
for	O
infection	O
by	O
univariate	O
analysis	O
(	O
odds	O
ratios	O
20	O
.	O
0	O
,	O
14	O
.	O
0	O
;	O
95	O
%	O
confidence	O
intervals	O
4	O
.	O
1	O
-	O
97	O
.	O
1	O
,	O
3	O
.	O
6	O
-	O
55	O
.	O
3	O
,	O
respectively	O
).	O

Using	O
various	O
inhibitors	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
,	O
we	O
identified	O
that	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
1	O
/	O
2	O
were	O
involved	O
in	O
the	O
activation	O
of	O
Egr	O
-	O
1	O
transcription	B-PROC
by	O
MHV	O
infection	O
.	O

Within	O
90	O
minutes	O
after	O
receiving	O
a	O
single	O
intravenous	O
dose	O
of	O
the	O
drug	O
,	O
all	O
six	O
volunteers	O
had	O
a	O
systemic	O
inflammatory	B-PROC
response	I-PROC
characterized	O
by	O
a	O
rapid	O
induction	O
of	O
proinflammatory	O
cytokines	O
and	O
accompanied	O
by	O
headache	O
,	O
myalgias	O
,	O
nausea	O
,	O
diarrhea	O
,	O
erythema	O
,	O
vasodilatation	B-PROC
,	O
and	O
hypotension	O
.	O

All	O
six	O
patients	O
were	O
transferred	O
to	O
the	O
care	O
of	O
the	O
authors	O
at	O
an	O
intensive	O
care	O
unit	O
at	O
a	O
public	O
hospital	O
,	O
where	O
they	O
received	O
intensive	O
cardiopulmonary	O
support	O
(	O
including	O
dialysis	O
),	O
high	O
-	O
dose	O
methylprednisolone	O
,	O
and	O
an	O
anti	O
-	O
interleukin	O
-	O
2	O
receptor	O
antagonist	B-PROC
antibody	B-PROC
.	O

Although	O
it	O
is	O
difficult	O
to	O
synthesize	O
all	O
of	O
these	O
abnormalities	O
into	O
a	O
single	O
,	O
unified	O
,	O
pathogenetic	O
pathway	B-PROC
,	O
a	O
theme	O
that	O
emerges	O
repeatedly	O
is	O
that	O
of	O
imbalance	O
,	O
be	O
it	O
between	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
oxidants	O
and	O
antioxidants	O
,	O
procoagulants	O
and	O
anticoagulants	O
,	O
neutrophil	B-PROC
recruitment	I-PROC
and	O
activation	O
and	O
mechanisms	O
of	O
neutrophil	B-PROC
clearance	I-PROC
,	O
or	O
proteases	O
and	O
protease	B-PROC
inhibitors	I-PROC
.	O

TITLE	O
:	O
The	O
role	O
of	O
the	O
coagulation	B-PROC
cascade	O
in	O
the	O
continuum	O
of	O
sepsis	O
and	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
cell	O
-	O
to	O
-	O
cell	B-PROC
fusion	I-PROC
efficiency	O
was	O
simply	O
determined	O
for	O
quantitative	O
analysis	O
based	O
on	O
the	O
number	O
of	O
syncytium	O
detected	O
by	O
flow	O
cytometry	O
.	O

Our	O
data	O
showed	O
that	O
H5N1	O
viral	B-PROC
infection	I-PROC
in	O
mice	O
resulted	O
in	O
typical	O
ARDS	O
,	O
which	O
was	O
characterized	O
by	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
about	O
80	O
%	O
of	O
mice	O
(	O
13	O
of	O
16	O
)	O
dead	B-PROC
on	O
Days	O
6	O
to	O
8	O
postinoculation	O
;	O
(	O
2	O
)	O
highly	O
edematous	O
lungs	O
and	O
dramatically	O
increased	O
lung	O
wet	O
:	O
dry	O
weight	O
ratios	O
and	O
lung	O
wet	O
weight	O
:	O
body	O
weight	O
ratios	O
;	O
(	O
3	O
)	O
inflammatory	O
cellular	B-PROC
infiltration	I-PROC
,	O
alveolar	O
and	O
interstitial	O
edema	O
,	O
and	O
hemorrhage	O
in	O
lungs	O
;	O
(	O
4	O
)	O
progressive	O
and	O
severe	O
hypoxemia	O
;	O
and	O
(	O
5	O
)	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
,	O
and	O
interleukin	O
-	O
6	O
in	O
BALF	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggested	O
that	O
we	O
successfully	O
established	O
a	O
mouse	O
model	O
of	O
ARDS	O
with	O
H5N1	O
viral	B-PROC
infection	I-PROC
,	O
which	O
may	O
benefit	O
further	O
investigation	O
into	O
the	O
pathogenesis	B-PROC
of	O
human	O
ARDS	O
induced	O
by	O
H5N1	O
virus	O
.	O

Mice	O
immunized	O
with	O
the	O
adjuvanted	O
antigen	O
elicited	O
strong	O
antibody	B-PROC
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
;	O
furthermore	O
,	O
adding	O
the	O
CpG	O
ODN	O
to	O
the	O
alum	O
resulted	O
in	O
increased	O
IgG2a	O
antibody	B-PROC
titers	O
and	O
a	O
higher	O
number	O
of	O
INF	O
-	O
gamma	O
-	O
secreting	B-PROC
murine	O
splenocytes	O
.	O

In	O
pulmonary	B-PROC
function	I-PROC
tests	O
,	O
the	O
diffusing	O
capacity	O
of	O
the	O
lungs	O
showed	O
a	O
moderate	O
decrease	O
.	O

TITLE	O
:	O
Construction	O
of	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infectious	O
cDNA	O
clone	O
and	O
a	O
replicon	O
to	O
study	O
coronavirus	O
RNA	B-PROC
synthesis	I-PROC
.	O

ABSTRACT	O
:	O
This	O
paper	O
explores	O
the	O
balance	B-PROC
between	O
common	O
good	O
and	O
individual	O
liberty	O
in	O
the	O
context	O
of	O
public	O
health	O
regulation	B-PROC
.	O

Available	O
data	O
suggest	O
that	O
vaccines	O
should	O
be	O
based	O
on	O
the	O
the	O
180kDa	O
viral	O
spike	O
protein	O
,	O
S	O
,	O
the	O
only	O
significant	O
neutralization	O
antigen	O
capable	O
of	O
inducing	O
protective	O
immune	B-PROC
responses	I-PROC
in	O
animals	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
evaluation	O
of	O
a	O
real	O
-	O
time	O
Taqman	O
RT	O
-	O
PCR	O
assay	O
for	O
the	O
detection	O
of	O
infectious	O
bronchitis	O
virus	O
from	O
infected	O
chickens	O
.	O

The	O
expression	B-PROC
of	O
S	O
protein	O
exerts	B-PROC
different	O
effects	O
on	O
the	O
three	O
major	O
signaling	B-PROC
pathways	B-PROC
of	O
the	O
UPR	O
.	O

TITLE	O
:	O
Preparation	O
and	O
characterization	O
of	O
a	O
novel	O
monoclonal	O
antibody	B-PROC
specific	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	O
protein	O
.	O

Laboratory	O
diagnosis	O
of	O
these	O
viral	B-PROC
infections	I-PROC
based	O
on	O
viral	O
isolation	O
or	O
detection	O
by	O
immune	O
electron	O
microscopy	O
,	O
immunoassay	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
has	O
dramatically	O
improved	O
in	O
the	O
recent	O
years	O
,	O
and	O
SARS	O
represents	O
a	O
good	O
example	O
of	O
a	O
diagnostic	O
approach	O
to	O
emerging	O
viral	B-PROC
infections	I-PROC
.	O

Organic	O
material	O
and	O
ammonia	O
nitrogen	O
was	O
found	O
to	O
be	O
significant	O
on	O
inactivation	O
and	O
DBPs	O
formation	B-PROC
.	O

TITLE	O
:	O
Accumulation	O
of	O
recombinant	O
SARS	O
-	O
CoV	O
spike	O
protein	O
in	O
plant	O
cytosol	O
and	O
chloroplasts	O
indicate	O
potential	O
for	O
development	B-PROC
of	O
plant	O
-	O
derived	O
oral	O
vaccines	O
.	O

TITLE	O
:	O
Structural	O
basis	O
of	O
neutralization	O
by	O
a	O
human	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
spike	O
protein	O
antibody	B-PROC
,	O
80R	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
spike	O
(	O
S	O
)	O
and	O
hemagglutinin	O
/	O
esterase	O
(	O
HE	O
)	O
proteins	O
revealed	O
that	O
all	O
the	O
Korean	O
BCoVs	O
clustered	O
together	O
regardless	O
of	O
season	O
and	O
were	O
distinct	O
from	O
the	O
other	O
known	O
BCoVs	O
,	O
suggesting	O
a	O
distinct	O
evolutionary	O
pathway	B-PROC
for	O
the	O
Korean	O
BCoVs	O
.	O

Both	O
ARDS	O
and	O
death	B-PROC
were	O
prevented	O
by	O
administration	O
of	O
a	O
plasminogen	O
activator	O
,	O
and	O
ARDS	O
in	O
human	O
septic	O
or	O
traumatic	O
shock	O
were	O
safely	O
and	O
effectively	O
treated	O
by	O
administration	O
of	O
a	O
plasminogen	O
activator	O
.	O

ABSTRACT	O
:	O
Persistent	O
impaired	O
pulmonary	B-PROC
function	I-PROC
and	O
functional	O
capacity	O
are	O
common	O
among	O
survivors	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

No	O
significant	O
correlation	O
between	O
exercise	O
capacity	O
and	O
pulmonary	B-PROC
function	I-PROC
was	O
found	O
.	O

We	O
studied	O
exhaled	B-PROC
air	O
and	O
particle	O
dispersion	O
through	O
an	O
oronasal	O
mask	O
attached	O
to	O
a	O
human	O
-	O
patient	O
simulator	O
(	O
HPS	O
)	O
during	O
noninvasive	O
positive	O
-	O
pressure	O
ventilation	O
(	O
NPPV	O
).	O

To	O
assess	O
this	O
risk	O
,	O
a	O
human	O
lung	O
model	O
(	O
respiration	B-PROC
rate	O
,	O
12	O
breaths	O
/	O
min	O
)	O
was	O
designed	O
to	O
test	O
the	O
potential	O
for	O
a	O
simple	O
oxygen	O
mask	O
at	O
a	O
common	O
setting	O
(	O
4	O
L	O
/	O
min	O
)	O
to	O
disperse	O
potentially	O
infectious	O
exhaled	B-PROC
air	O
into	O
the	O
surrounding	O
area	O
.	O

A	O
laser	O
sheet	O
was	O
used	O
to	O
illuminate	O
the	O
exhaled	B-PROC
air	O
from	O
the	O
mask	O
,	O
which	O
contained	O
fine	O
tracer	O
smoke	O
particles	O
.	O

An	O
analysis	O
of	O
captured	O
digital	O
images	O
showed	O
that	O
the	O
exhaled	B-PROC
air	O
at	O
the	O
peak	O
of	O
simulated	O
exhalation	B-PROC
reached	O
a	O
distance	O
of	O
approximately	O
0	O
.	O
40	O
m	O
.	O

Most	O
research	O
ferrets	O
are	O
males	O
,	O
due	O
to	O
estrus	B-PROC
-	O
related	O
health	O
problems	O
in	O
females	O
.	O

Successful	O
housing	O
requires	O
knowledge	O
of	O
ferret	O
behaviors	B-PROC
including	O
social	O
behavior	B-PROC
,	I-PROC
eating	B-PROC
habits	O
,	O
a	O
general	O
inquisitive	O
nature	O
,	O
and	O
a	O
species	O
-	O
typical	O
need	O
to	O
burrow	O
and	O
hide	O
.	O

To	O
determine	O
the	O
role	O
in	O
replication	O
of	O
processing	O
between	O
nsp2	O
and	O
nsp3	O
at	O
cleavage	B-PROC
site	O
2	O
(	O
CS2	O
)	O
and	O
PLP1	O
proteinase	B-PROC
activity	I-PROC
,	O
mutations	O
were	O
engineered	O
into	O
the	O
MHV	O
genome	O
at	O
CS2	O
,	O
at	O
CS1	O
and	O
CS2	O
,	O
and	O
at	O
the	O
PLP1	O
catalytic	O
site	O
,	O
alone	O
and	O
in	O
combination	O
.	O

Mutant	O
viruses	O
with	O
abolished	O
cleavage	B-PROC
at	O
CS2	O
were	O
delayed	O
in	O
growth	B-PROC
and	O
RNA	B-PROC
synthesis	I-PROC
but	O
grew	O
to	O
wild	O
-	O
type	O
titers	O
of	O
>	O
10	O
(	O
7	O
)	O
PFU	O
/	O
ml	O
.	O

With	O
HFOV	O
and	O
CLPV	O
,	O
mean	O
arterial	B-PROC
pressure	I-PROC
,	O
cardiac	O
output	O
,	O
and	O
stroke	O
volume	O
decreased	O
significantly	O
;	O
pulmonary	O
arterial	O
elastance	O
increased	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
potential	O
B	O
-	O
cell	O
antigenic	O
epitopes	O
within	O
the	O
N	O
-	O
terminus	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
)	O
M	O
protein	O
and	O
characterize	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
)	O
against	O
the	O
protein	O
as	O
well	O
as	O
its	O
recognizing	O
region	O
,	O
we	O
expressed	B-PROC
and	O
purified	O
a	O
portion	O
of	O
SARS	O
-	O
CoV	O
M	O
protein	O
(	O
amino	O
acid	O
1	O
-	O
43	O
)	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
).	O

Furthermore	O
,	O
we	O
characterized	O
one	O
representative	O
IgG2	O
MAb	O
,	O
3H9	O
,	O
which	O
exhibited	O
a	O
strong	O
immunoreaction	B-PROC
to	O
both	O
recombinant	O
M	O
protein	O
and	O
native	O
viral	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
We	O
found	O
a	O
B	O
-	O
cell	O
antigenic	O
epitope	O
located	O
between	O
amino	O
acid	O
1	O
-	O
15	O
and	O
defined	O
the	O
MAb	O
recognizing	O
region	O
within	O
amino	O
acid	O
16	O
-	O
28	O
of	O
M	O
.	O
These	O
findings	O
not	O
only	O
suggest	O
that	O
both	O
recombinant	O
M	O
protein	O
and	O
its	O
specific	O
MAbs	O
may	O
be	O
used	O
as	O
the	O
diagnostic	O
reagents	O
for	O
SARS	O
,	O
but	O
also	O
provide	O
a	O
potential	O
target	O
site	O
for	O
the	O
design	O
of	O
an	O
epitope	O
-	O
based	O
vaccine	O
against	O
SARS	O
.	O

TITLE	O
:	O
Coronavirus	O
nucleocapsid	O
protein	O
is	O
an	O
RNA	B-PROC
chaperone	I-PROC
.	O

Therefore	O
,	O
it	O
was	O
concluded	O
that	O
TGEV	O
N	O
protein	O
is	O
an	O
RNA	B-PROC
chaperone	I-PROC
.	O

Substitution	B-PROC
mutation	I-PROC
of	O
the	O
Arg132	O
residue	O
to	O
a	O
positively	O
charged	O
amino	O
acid	O
Lys	O
affected	O
neither	O
the	O
infectivity	O
of	O
the	O
in	O
vitro	O
-	O
synthesized	O
transcripts	O
nor	O
the	O
growth	B-PROC
properties	O
of	O
the	O
rescued	O
virus	O
.	O

On	O
the	O
contrary	O
,	O
a	O
G	O
-	O
C	O
and	O
a	O
G	O
-	O
A	O
point	B-PROC
mutations	I-PROC
at	O
nucleotide	O
positions	O
4330	O
and	O
9230	O
,	O
respectively	O
,	O
causing	O
Glu	O
-	O
Gln	O
and	O
Gly	O
-	O
Glu	O
mutations	O
in	O
or	O
near	O
the	O
catalytic	O
centers	O
of	O
the	O
papain	O
-	O
like	O
(	O
Nsp3	O
)	O
and	O
3C	O
-	O
like	O
(	O
Nsp5	O
)	O
proteinases	O
,	O
did	O
not	O
show	O
detectable	O
detrimental	O
effect	O
on	O
the	O
rescue	O
of	O
infectious	O
viruses	O
and	O
the	O
infectivity	O
of	O
the	O
rescued	O
viruses	O
.	O

After	O
recombination	B-PROC
with	O
an	O
immunostimulatory	O
sequence	O
(	O
ISS	O
),	O
the	O
gene	O
was	O
cloned	O
into	O
the	O
plasmid	O
pIRES	O
to	O
produce	O
pIRES	O
-	O
ISS	O
-	O
S1	O
.	O

On	O
confirmation	O
of	O
the	O
expression	B-PROC
of	O
S1	O
protein	O
by	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
after	O
the	O
transfection	B-PROC
of	O
pIRES	O
-	O
ISS	O
-	O
S1	O
into	O
BHK	O
-	O
21	O
cells	O
,	O
the	O
DNA	O
vaccine	O
was	O
repeatedly	O
administrated	O
to	O
BALB	O
/	O
c	O
mice	O
.	O

In	O
our	O
study	O
,	O
the	O
highest	O
creatinine	O
levels	O
were	O
found	O
in	O
patients	O
with	O
the	O
lowest	O
ex	O
vivo	O
TNF	B-PROC
-	I-PROC
alpha	I-PROC
production	I-PROC
.	O

Here	O
we	O
review	O
the	O
role	O
of	O
ACE2	O
in	O
disease	O
pathogenesis	B-PROC
,	O
including	O
lung	O
diseases	O
and	O
cardiovascular	O
diseases	O
.	O

TITLE	O
:	O
Modification	O
of	O
SARS	O
-	O
CoV	O
S1	O
gene	O
render	O
expression	B-PROC
in	O
Pichia	O
pastoris	O
.	O

The	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUPT	O
nick	O
end	O
-	O
labeling	O
assay	O
demonstrated	O
many	O
cells	O
undergoing	O
apoptosis	B-PROC
.	O

In	O
this	O
article	O
,	O
we	O
introduce	O
its	O
ventilation	O
design	O
and	O
evaluate	O
the	O
airflow	B-PROC
performance	O
in	O
relation	O
to	O
different	O
combinations	O
of	O
medical	O
lamp	O
configurations	O
and	O
modes	O
of	O
launching	O
infectious	O
particles	O
into	O
the	O
room	O
air	O
.	O

Although	O
there	O
is	O
a	O
host	O
of	O
technologies	O
available	O
,	O
either	O
commercially	O
or	O
in	O
the	O
scientific	O
literature	O
,	O
the	O
development	B-PROC
of	O
biosensors	O
for	O
the	O
detection	O
of	O
emerging	O
infectious	O
diseases	O
(	O
EIDs	O
)	O
is	O
still	O
in	O
its	O
infancy	O
.	O

Analysis	O
of	O
crude	O
plant	O
extracts	O
revealed	O
that	O
both	O
the	O
plant	O
-	O
expressed	B-PROC
alphaSIP	O
and	O
IgA	O
molecules	O
could	O
bind	O
to	O
and	O
neutralize	O
TGEV	O
in	O
tissue	O
culture	O
,	O
indicating	O
that	O
active	O
molecules	O
were	O
produced	O
.	O

These	O
include	O
the	O
integration	B-PROC
of	O
the	O
emergency	O
medical	O
services	O
and	O
health	O
-	O
facility	O
medical	O
systems	O
with	O
other	O
response	O
systems	O
;	O
the	O
use	O
of	O
the	O
hospital	O
emergency	O
incident	O
command	O
system	O
;	O
crisis	O
risk	O
-	O
communications	O
approaches	O
;	O
and	O
the	O
use	O
of	O
practical	O
,	O
hands	O
-	O
on	O
training	O
programs	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
pregnancy	O
.	O

Neurological	O
findings	O
,	O
vital	B-PROC
capacity	I-PROC
,	O
and	O
signs	O
of	O
respiratory	O
distress	O
were	O
recorded	O
at	O
admission	O
and	O
at	O
intubation	O
.	O

Positive	O
selection	O
was	O
detected	O
in	O
the	O
first	O
two	O
groups	O
,	O
which	O
represent	O
the	O
course	O
of	O
SARS	O
-	O
CoV	O
interspecies	O
transmission	O
and	O
of	O
viral	O
adaptation	B-PROC
to	O
human	O
host	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
three	O
specific	O
replacements	O
(	O
F360S	O
,	O
T487S	O
and	O
L665S	O
)	O
were	O
only	O
found	O
between	O
03	O
-	O
human	O
SARS	O
-	O
CoVs	O
and	O
strains	O
from	O
02	O
-	O
04	O
interspecies	O
epidemic	O
group	O
,	O
which	O
reveals	O
that	O
selective	O
sweep	O
may	O
also	O
force	O
the	O
evolution	B-PROC
of	O
S	O
genes	O
before	O
the	O
jump	O
of	O
SARS	O
-	O
CoVs	O
into	O
human	O
hosts	O
.	O

The	O
variation	O
of	O
positive	O
selective	O
pressures	O
and	O
positively	O
selected	O
sites	O
are	O
likely	O
to	O
contribute	O
to	O
the	O
adaptive	O
evolution	B-PROC
of	O
S	O
protein	O
from	O
animals	O
to	O
humans	O
.	O

Both	O
controls	O
were	O
purified	O
by	O
Co2	O
+	O
affinity	O
chromatography	O
and	O
were	O
included	O
in	O
a	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
assay	O
for	O
SARS	O
-	O
CoV	O
.	O
The	O
noncompetitive	O
internal	O
positive	O
control	O
can	O
be	O
added	O
to	O
clinical	O
samples	O
before	O
RNA	O
extraction	O
and	O
enables	O
the	O
identification	O
of	O
potential	O
inhibitive	O
effects	O
without	O
interfering	O
with	O
target	O
amplification	O
.	O

This	O
protein	O
strongly	O
prefers	O
the	O
internal	O
5	O
'-(	O
G	O
/	O
U	O
)	O
CC	O
-	O
3	O
'	O
trinucleotides	O
on	O
RNA	O
templates	O
to	O
initiate	O
the	O
synthesis	B-PROC
of	O
complementary	O
oligonucleotides	O
of	O
<	O
6	O
residues	O
in	O
a	O
reaction	O
whose	O
fidelity	O
is	O
relatively	O
low	O
.	O

We	O
found	O
that	O
genes	O
encoded	O
by	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
were	O
obviously	O
upregulated	O
,	O
while	O
mitochondria	O
were	O
now	O
found	O
to	O
be	O
closely	O
connected	O
with	O
antiviral	O
immunity	B-PROC
.	O

A	O
total	O
of	O
16	O
surgical	O
ARDS	O
patients	O
with	O
severe	O
oxygenation	B-PROC
failure	O
received	O
HFOV	O
,	O
despite	O
aggressive	B-PROC
conventional	O
mechanical	O
ventilatory	O
support	O
.	O

Other	O
outcome	O
measures	O
included	O
duration	O
of	O
HFOV	O
,	O
successful	O
weaning	B-PROC
rate	O
,	O
cause	O
of	O
failure	O
,	O
complications	O
,	O
survival	O
rate	O
,	O
and	O
cause	O
of	O
death	B-PROC
.	O

Mortality	O
of	O
ARF	O
combined	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
even	O
higher	O
and	O
may	O
reach	B-PROC
80	O
%.	O

This	O
defect	O
was	O
associated	O
with	O
altered	O
surface	O
expression	B-PROC
of	O
L	O
-	O
selectin	B-PROC
;	O
sialyl	O
Lewis	O
(	O
x	O
),	O
an	O
L	O
-	O
selectin	B-PROC
counterreceptor	O
,	O
previously	O
was	O
proved	O
to	O
be	O
critical	O
in	O
aseptic	O
ALI	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
epitope	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
specific	O
neutralizing	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
)	O
2C5	O
.	O

However	O
,	O
whatever	O
functions	O
nsp14	O
serves	O
appear	O
to	O
be	O
retained	O
by	O
noncleaved	O
or	O
partially	O
processed	O
nsp14	O
,	O
since	O
abolition	O
of	O
either	O
the	O
amino	O
-	O
terminal	O
or	O
carboxy	O
-	O
terminal	O
cleavage	B-PROC
site	O
allowed	O
recovery	O
of	O
viable	O
virus	O
.	O

While	O
this	O
may	O
be	O
the	O
case	O
,	O
it	O
should	O
be	O
noted	O
that	O
nsp2	O
,	O
in	O
some	O
form	O
,	O
exists	O
in	O
all	O
coronaviruses	O
studied	O
to	O
date	O
and	O
likely	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
.	O

Vaccine	O
development	B-PROC
is	O
a	O
key	O
component	O
in	O
the	O
prevention	O
of	O
widespread	O
viral	B-PROC
infection	I-PROC
and	O
in	O
the	O
reduction	O
of	O
morbidity	O
and	O
mortality	O
associated	O
with	O
many	O
viral	B-PROC
infections	I-PROC
.	O

Oxygenation	B-PROC
and	O
lung	O
mechanics	O
did	O
not	O
improve	O
with	O
low	O
tidal	O
volume	O
ventilation	O
using	O
high	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressures	O
(	O
PEEPs	O
).	O

RESULTS	O
:	O
Oxygenation	B-PROC
and	O
lung	B-PROC
compliance	I-PROC
improved	O
rapidly	O
and	O
aeration	O
of	O
the	O
entire	O
lung	O
was	O
confirmed	O
by	O
computed	O
tomography	O
27	O
h	O
after	O
the	O
recruitment	O
manoeuvre	O
.	O

TITLE	O
:	O
Association	O
between	O
nitric	B-PROC
oxide	I-PROC
synthesis	I-PROC
and	O
vaccination	O
-	O
acquired	O
resistance	B-PROC
to	O
murine	O
hepatitis	O
virus	O
by	O
spf	O
mice	O
.	O

Since	O
entering	O
regular	O
service	O
,	O
routine	O
measurements	O
and	O
observations	O
have	O
indicated	O
that	O
the	O
airflow	B-PROC
performance	O
has	O
been	O
satisfactory	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
one	O
of	O
the	O
most	O
promising	O
targets	O
for	O
discovery	O
of	O
drugs	O
against	O
SARS	O
,	O
because	O
of	O
its	O
critical	O
role	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
.	O

In	O
this	O
study	O
,	O
a	O
natural	O
compound	O
called	O
quercetin	O
-	O
3	O
-	O
beta	O
-	O
galactoside	O
was	O
identified	O
as	O
an	O
inhibitor	O
of	O
the	O
protease	O
by	O
molecular	O
docking	B-PROC
,	O
SPR	O
/	O
FRET	O
-	O
based	O
bioassays	O
,	O
and	O
mutagenesis	B-PROC
studies	O
.	O

The	O
SARS	O
3c	O
like	O
protease	O
,	O
namely	O
the	O
SARS	O
3CL	O
(	O
pro	O
)	O
is	O
the	O
key	O
function	O
protease	O
for	O
virus	B-PROC
replication	I-PROC
as	O
well	O
as	O
transcription	B-PROC
and	O
thus	O
can	O
be	O
taken	O
as	O
one	O
of	O
the	O
key	O
targets	O
for	O
anti	O
-	O
SARS	O
drug	O
design	O
.	O

We	O
investigated	O
whether	O
a	O
recombinant	O
native	O
full	O
-	O
length	O
S	O
-	O
protein	O
trimer	O
(	O
triSpike	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
able	O
to	O
elicit	O
a	O
neutralizing	O
and	O
protective	O
immune	B-PROC
response	I-PROC
in	O
animals	O
and	O
analyzed	O
the	O
capacity	O
of	O
anti	O
-	O
S	O
antibodies	O
to	O
mediate	O
antibody	B-PROC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
virus	O
entry	O
in	O
vitro	O
and	O
enhancement	O
of	O
replication	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
binds	O
viral	O
RNA	O
to	O
form	O
the	O
ribonucleocapsid	O
and	O
regulate	O
RNA	B-PROC
synthesis	I-PROC
.	O

In	O
the	O
ZEEP	O
group	O
on	O
day	O
1	O
static	O
elastance	O
and	O
minimal	O
resistance	B-PROC
were	O
above	O
normal	O
limits	O
(	O
18	O
.	O
9	O
+/-	O

Effectively	O
addressing	O
the	O
threat	O
of	O
SARS	O
will	O
require	O
enhanced	O
global	O
infectious	O
disease	O
surveillance	O
,	O
the	O
development	B-PROC
of	O
rapid	O
diagnostics	O
,	O
new	O
therapies	O
,	O
and	O
vaccines	O
,	O
implementation	O
of	O
aggressive	B-PROC
evidence	O
-	O
based	O
infection	O
control	O
strategies	O
,	O
and	O
effective	O
communication	O
.	O

The	O
PaO	B-PROC
(	O
2	O
),	O
SaO	O
(	O
2	O
)	O
and	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
of	O
all	O
18	O
patients	O
were	O
improved	O
greatly	O
.	O

All	O
18	O
patients	O
were	O
weaned	B-PROC
and	O
extubated	O
successfully	O
with	O
the	O
survival	O
rate	O
of	O
100	O
%.	O

RESULTS	O
:	O
The	O
PaO	B-PROC
(	O
2	O
),	O
SaO	O
(	O
2	O
)	O
and	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
of	O
all	O
18	O
patients	O
were	O
improved	O
greatly	O
.	O

These	O
alterations	O
in	O
N	O
-	O
linked	O
glycosylation	B-PROC
sites	O
reflected	O
3	O
nucleotide	O
changes	O
,	O
which	O
were	O
related	O
to	O
the	O
above	O
-	O
mentioned	O
nucleotide	O
changes	O
and	O
are	O
suggested	O
to	O
influence	O
the	O
pathogenicity	O
of	O
attenuated	O
PEDV	O
DR13	O
.	O

Infection	O
results	O
in	O
macrophage	O
and	O
lymphocyte	O
infiltration	O
in	O
the	O
lungs	O
and	O
upregulation	B-PROC
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
in	O
both	O
the	O
lung	O
and	O
the	O
brain	O
.	O

The	O
median	O
(	O
interquartile	O
range	O
)	O
duration	O
of	O
mechanical	O
ventilation	O
(	O
10	O
[	O
6	O
-	O
17	O
]	O
vs	O
.	O
7	O
[	O
2	O
-	O
12	O
]	O
days	O
,	O
p	O
=	O
.	O
017	O
)	O
and	O
duration	O
of	O
weaning	B-PROC
from	O
mechanical	O
ventilation	O
(	O
41	O
[	O
16	O
-	O
97	O
]	O
vs	O
.	O
21	O
[	O
7	O
-	O
33	O
.	O
5	O
]	O
hrs	O
,	O
p	O
=	O
.	O
018	O
)	O
were	O
longer	O
in	O
AKI	O
patients	O
compared	O
with	O
control	O
patients	O
.	O

The	O
data	O
were	O
expressed	B-PROC
corrected	O
and	O
uncorrected	O
for	O
urine	O
creatinine	O
(	O
Cr	O
).	O

Expected	O
worldwide	O
human	O
mortality	O
from	O
a	O
moderate	O
pandemic	O
scenario	O
is	O
45	O
million	O
people	O
or	O
more	O
than	O
75	O
%	O
of	O
the	O
current	O
annual	O
global	O
death	B-PROC
burden	O
.	O

Air	O
transport	B-PROC
border	O
control	O
measures	O
purporting	O
to	O
delay	O
importation	O
and	O
spread	O
of	O
human	O
avian	O
influenza	O
are	O
scientifically	O
controversial	O
.	O

Nine	O
children	O
weighted	O
3	O
.	O
1	O
kg	O
-	O
14	O
.	O
0	O
kg	O
with	O
septic	O
shock	O
were	O
treated	O
with	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
(	O
CVVH	O
)	O
which	O
is	O
also	O
referred	O
to	O
as	O
CBP	O
with	O
blood	O
access	O
of	O
double	O
-	O
lumen	O
hemodialysis	O
catheter	O
of	O
6	O
.	O
5	O
to	O
8Fr	O
inserted	O
via	O
central	O
vein	O
,	O
hemofilters	O
of	O
Minifilter	O
plus	O
(	O
for	O
children	O
with	O
body	O
weight	O
<	O
5	O
kg	O
)	O
or	O
AV400s	O
(	O
for	O
children	O
with	O
body	O
weight	O
>	O
or	O
=	O
5	O
kg	O
),	O
child	O
'	O
s	O
type	O
extracorporeal	O
circuit	O
vessel	O
and	O
heparin	O
anticoagulation	B-PROC
.	O

Six	O
deaths	B-PROC
of	O
refractory	O
shock	O
included	O
4	O
who	O
had	O
ARDS	O
and	O
DIC	O
and	O
2	O
who	O
had	O
shock	O
with	O
DIC	O
3	O
patients	O
had	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	O
)	O
has	O
not	O
been	O
previously	O
described	O
in	O
children	O
with	O
DSS	O
and	O
may	O
lead	O
to	O
fluid	O
refractory	O
shock	O
if	O
not	O
corrected	O
.	O

Severe	O
refractory	O
shock	O
,	O
DIC	O
,	O
ARDS	O
,	O
hepatic	O
failure	O
and	O
neurological	O
manifestations	O
singly	O
or	O
in	O
combination	O
were	O
the	O
commonest	O
causes	O
of	O
death	B-PROC
in	O
the	O
present	O
study	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
induces	O
long	O
-	O
term	O
protective	O
immunity	B-PROC
in	O
an	O
animal	O
model	O
.	O

HCoV	O
-	O
229E	O
infection	O
was	O
blocked	O
by	O
an	O
N	O
-	O
glycosylation	B-PROC
sequon	O
present	O
between	O
aa	O
288	O
to	O
290	O
in	O
murine	O
APN	O
.	O

Surprisingly	O
,	O
this	O
region	O
tolerated	O
numerous	O
deletions	O
,	O
rearrangements	O
,	O
and	O
point	B-PROC
mutations	I-PROC
.	O

Balancing	B-PROC
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
requires	O
both	O
arterial	O
PO2	B-PROC
and	O
PCO2	O
values	O
to	O
determine	O
at	O
what	O
level	O
hyperinflated	O
regions	O
become	O
seriously	O
underperfused	O
(	O
develop	O
very	O
high	O
ventilation	B-PROC
-	I-PROC
perfusion	I-PROC
ratios	I-PROC
),	O
adding	O
to	O
the	O
hypercarbia	O
from	O
increased	O
deadspace	O
.	O

Further	O
investigation	O
is	O
needed	O
to	O
clarify	O
the	O
pathogenesis	B-PROC
of	O
this	O
disease	O
.	O

We	O
describe	O
modifications	O
of	O
the	O
aryl	O
,	O
ester	O
,	O
and	O
amino	O
acid	O
regions	O
of	O
the	O
ProTide	O
and	O
how	O
these	O
changes	O
affect	O
antiviral	O
activity	O
and	O
metabolic	B-PROC
stability	O
.	O

After	O
1	O
-	O
year	O
treatment	O
,	O
no	O
significant	O
differences	O
were	O
found	O
in	O
morning	O
and	O
evening	O
peak	O
expiratory	B-PROC
flow	O
of	O
predicted	O
value	O
(	O
PEF	O
%),	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
one	O
second	O
of	O
predicted	O
value	O
(	O
FEV	O
(	O
1	O
)/	O
FVC	B-PROC
),	O
forced	B-PROC
vital	I-PROC
capacity	I-PROC
of	O
predicted	O
value	O
(	O
FVC	B-PROC
%),	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
one	O
second	O
to	O
forced	B-PROC
vital	I-PROC
capacity	I-PROC
ratio	O
(	O
FEV	O
(	O
1	O
)/	O
FVC	B-PROC
),	O
provoking	O
dose	O
decreasing	O
FEV	O
(	O
1	O
)	O
by	O
20	O
%	O
(	O
PD	O
(	O
20	O
)-	O
FEV	O
(	O
1	O
))	O
between	O
the	O
active	O
group	O
[(	O
97	O
+/-	O
17	O
)%,	O
(	O
98	O
+/-	O
18	O
)%,	O
(	O
91	O
+/-	O

Specimens	O
collected	O
over	O
a	O
1	O
-	O
year	O
period	O
from	O
pediatric	O
patients	O
presenting	O
with	O
acute	O
respiratory	O
illness	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
4	O
coronavirus	O
subtypes	O
using	O
consensus	O
and	O
subtype	O
-	O
specific	O
real	O
-	O
time	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
assays	O
.	O

TITLE	O
:	O
Palmitoylation	B-PROC
of	O
the	O
cysteine	O
-	O
rich	O
endodomain	O
of	O
the	O
SARS	O
-	O
coronavirus	O
spike	O
glycoprotein	O
is	O
important	O
for	O
spike	O
-	O
mediated	O
cell	B-PROC
fusion	I-PROC
.	O

Individual	O
cysteine	O
clusters	O
were	O
altered	O
via	O
cysteine	O
-	O
to	O
-	O
alanine	O
amino	O
acid	O
replacement	O
and	O
the	O
modified	O
S	O
glycoproteins	O
were	O
tested	O
for	O
their	O
transport	B-PROC
to	O
cell	O
-	O
surfaces	O
and	O
ability	O
to	O
cause	O
cell	B-PROC
fusion	I-PROC
in	O
transient	O
transfection	B-PROC
assays	O
.	O

Pigs	O
infected	O
by	O
a	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
showed	O
virus	O
-	O
specific	O
IgG	O
Ab	O
-	O
secreting	B-PROC
cells	O
in	O
the	O
bronchial	O
lymph	O
nodes	O
,	O
whereas	O
the	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
induced	O
more	O
IgA	O
Ab	O
-	O
secreting	B-PROC
cells	O
in	O
gut	O
tissues	O
,	O
which	O
illustrates	O
the	O
importance	O
of	O
the	O
route	O
of	O
antigen	O
administration	O
for	O
inducing	O
local	O
immune	O
effector	O
mechanisms	O
.	O

We	O
constructed	O
recombinant	O
adenoviral	O
vectors	O
that	O
can	O
express	O
shRNAs	O
,	O
which	O
inhibited	O
the	O
expression	B-PROC
of	O
SARS	O
-	O
CoV	O
genes	O
effectively	O
in	O
mammalian	O
cells	O
.	O

The	O
effects	O
of	O
adenovirus	O
-	O
delivered	O
small	O
hairpin	O
RNA	O
on	O
SARS	O
-	O
CoV	O
gene	B-PROC
expression	I-PROC
were	O
determined	O
by	O
RT	O
-	O
PCR	O
,	O
Western	O
blot	O
,	O
and	O
luciferase	B-PROC
activity	I-PROC
assays	O
.	O

Since	O
many	O
cell	O
types	O
can	O
be	O
efficiently	O
infected	O
by	O
adenovirus	O
,	O
recombinant	O
adenoviruses	O
could	O
serve	O
as	O
an	O
alternative	O
powerful	O
tool	O
for	O
shRNA	O
delivery	O
and	O
for	O
gene	O
suppression	B-PROC
,	O
especially	O
when	O
the	O
targeted	B-PROC
cells	O
are	O
resistant	O
to	O
transfection	B-PROC
by	O
DNA	O
or	O
RNA	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
viral	O
mRNAs	O
and	O
viral	O
proteins	O
of	O
the	O
targets	O
were	O
significantly	O
decreased	O
or	O
completely	O
inhibited	O
in	O
cell	O
lines	O
after	O
being	O
infected	O
with	O
the	O
recombinant	O
adenoviruses	O
that	O
expressed	B-PROC
specific	O
shRNA	O
molecules	O
.	O

is	O
one	O
of	O
eight	O
Bioinformatics	O
Resource	O
Centers	O
(	O
BRCs	O
)	O
funded	O
by	O
the	O
National	O
Institute	O
of	O
Allergy	B-PROC
and	O
Infection	O
Diseases	O
(	O
NIAID	O
)	O
to	O
create	O
a	O
data	O
and	O
analysis	O
resource	O
for	O
selected	O
NIAID	O
priority	O
pathogens	O
,	O
specifically	O
proteobacteria	O
of	O
the	O
genera	O
Brucella	O
,	O
Rickettsia	O
and	O
Coxiella	O
,	O
and	O
corona	O
-,	O
calici	O
-	O
and	O
lyssaviruses	O
and	O
viruses	O
associated	O
with	O
hepatitis	O
A	O
and	O
E	O
.	O
The	O
goal	O
of	O
the	O
project	O
is	O
to	O
provide	O
a	O
comprehensive	O
bioinformatics	O
resource	O
for	O
these	O
pathogens	O
,	O
including	O
consistently	O
annotated	O
genome	O
,	O
proteome	O
and	O
metabolic	B-PROC
pathway	B-PROC
data	O
to	O
facilitate	O
research	O
into	O
counter	O
-	O
measures	O
,	O
including	O
drugs	O
,	O
vaccines	O
and	O
diagnostics	O
.	O

Blocking	O
CXCL10	O
signaling	B-PROC
results	O
in	O
increased	O
mortality	O
accompanied	O
by	O
reduced	O
T	O
cell	O
infiltration	O
and	O
increased	O
viral	O
titers	O
within	O
the	O
brain	O
suggesting	O
that	O
CXCL10	O
functions	O
in	O
host	B-PROC
defense	I-PROC
by	O
attracting	O
T	O
cells	O
into	O
the	O
CNS	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
extend	O
our	O
understanding	O
of	O
the	O
functional	O
role	O
of	O
CXCL10	O
in	O
response	O
to	O
MHV	O
infection	O
given	O
that	O
CXCL10	O
signaling	B-PROC
has	O
been	O
implicated	O
in	O
coordinating	O
both	O
effector	O
T	O
cell	O
generation	O
and	O
trafficking	B-PROC
.	O

Analysis	O
of	O
chemokine	O
receptor	B-PROC
expression	B-PROC
on	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
obtained	O
from	O
MHV	O
-	O
immunized	O
CXCL10	O
(+/+)	O
and	O
CXCL10	O
(-/-)	O
mice	O
revealed	O
comparable	O
levels	O
of	O
CXCR3	O
and	O
CCR5	O
,	O
which	O
are	O
capable	O
of	O
responding	O
to	O
ligands	O
CXCL10	O
and	O
CCL5	O
,	O
respectively	O
.	O

Respiratory	O
infections	O
may	O
have	O
a	O
human	O
source	O
such	O
as	O
tuberculosis	O
or	O
viral	B-PROC
diseases	I-PROC
or	O
may	O
originate	O
in	O
ventilation	O
systems	O
such	O
as	O
Legionnaire	O
'	O
s	O
disease	O
(	O
Legionella	O
pneumophila	O
pneumonia	O
).	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
main	O
proteinase	B-PROC
(	O
SARS	O
CoV	O
main	O
proteinase	B-PROC
)	O
is	O
required	O
for	O
the	O
replication	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
),	O
the	O
virus	O
that	O
causes	O
SARS	O
.	O

Pathogens	O
with	O
modified	O
antibiotic	O
susceptibility	O
patterns	O
have	O
emerged	O
,	O
which	O
display	O
an	O
increased	O
antibiotic	O
resistance	B-PROC
,	O
such	O
as	O
S	O
.	O
pneumoniae	O
,	O
S	O
.	O
aureus	O
,	O
H	O
.	O
influenzae	O
.	O

This	O
progressive	O
-	O
docking	B-PROC
procedure	O
,	O
therefore	O
,	O
substantially	O
accelerates	O
high	O
throughput	O
screening	O
,	O
especially	O
when	O
using	O
high	O
accuracy	O
(	O
slower	O
)	O
docking	B-PROC
approaches	O
and	O
large	O
-	O
sized	O
datasets	O
,	O
and	O
has	O
allowed	O
us	O
to	O
identify	O
several	O
novel	O
potent	O
nonsteroidal	O
SHBG	O
ligands	O
.	O

Publicity	O
on	O
health	O
knowledge	O
and	O
coping	O
system	O
on	O
emergency	O
should	O
play	O
key	O
roles	O
in	O
the	O
development	B-PROC
of	O
an	O
effective	O
public	O
health	O
system	O
while	O
the	O
government	O
should	O
lead	O
the	O
battle	O
.	O

Despite	O
the	O
increasing	O
operating	O
cost	O
,	O
declining	O
patient	O
attendance	O
and	O
high	O
price	O
of	O
the	O
PPE	O
,	O
they	O
persist	O
in	O
using	O
PPE	O
and	O
change	O
their	O
behaviour	B-PROC
in	O
order	O
to	O
reduce	O
the	O
perceived	O
threat	O
to	O
their	O
lives	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
showed	O
that	O
infection	O
of	O
rat	O
oligodendrocytes	O
by	O
ultraviolet	O
light	O
-	O
inactivated	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
apoptosis	B-PROC
,	O
suggesting	O
that	O
the	O
apoptosis	B-PROC
is	O
triggered	O
during	O
cell	O
entry	O
.	O

Heart	O
rate	O
,	O
systemic	O
blood	B-PROC
pressure	I-PROC
and	O
oxygen	O
saturation	O
were	O
monitored	O
continuously	O
.	O

TITLE	O
:	O
Essential	O
role	O
for	O
collectrin	O
in	O
renal	O
amino	B-PROC
acid	I-PROC
transport	B-PROC
.	O

TITLE	O
:	O
An	O
overall	O
picture	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
-	O
encoded	O
major	O
proteins	O
:	O
structures	O
,	O
functions	O
and	O
drug	O
development	B-PROC
.	O

Due	O
to	O
the	O
lack	O
of	O
potential	O
drugs	O
for	O
the	O
treatment	O
of	O
SARS	O
,	O
the	O
discovery	O
of	O
inhibitors	O
against	O
SARS	O
3C	O
-	O
like	O
proteinase	B-PROC
,	O
which	O
can	O
potentially	O
be	O
optimized	O
as	O
drugs	O
appears	O
to	O
be	O
highly	O
desirable	O
.	O

TITLE	O
:	O
Drug	O
design	O
targeting	B-PROC
the	O
main	O
protease	O
,	O
the	O
Achilles	O
'	O
heel	O
of	O
coronaviruses	O
.	O

The	O
present	O
mini	O
review	O
is	O
focused	O
on	O
the	O
area	O
of	O
computer	O
-	O
aided	O
drug	O
discovery	O
,	O
i	O
.	O
e	O
.,	O
the	O
advances	O
achieved	O
mainly	O
from	O
the	O
approaches	O
of	O
structural	O
bioinformatics	O
,	O
pharmacophore	O
modeling	O
,	O
molecular	O
docking	B-PROC
,	O
peptide	O
-	O
cleavage	B-PROC
site	O
prediction	O
,	O
and	O
other	O
computational	O
means	O
.	O

It	O
has	O
therefore	O
been	O
demonstrated	O
that	O
it	O
is	O
possible	O
to	O
confer	O
passive	O
immunization	O
to	O
newborn	O
pigs	O
by	O
feeding	O
them	O
with	O
recombinant	O
SIPs	B-PROC
.	O

Our	O
results	O
provide	O
an	O
initial	O
basis	O
for	O
understanding	O
an	O
intriguing	O
interplay	O
between	O
the	O
presence	O
or	O
absence	O
of	O
proteolytic	B-PROC
maturation	B-PROC
among	O
the	O
coronavirus	O
groups	O
and	O
the	O
membrane	B-PROC
fusion	I-PROC
activity	I-PROC
of	O
their	O
S	O
glycoproteins	O
.	O

To	O
investigate	O
the	O
role	O
of	O
E	O
protein	O
in	O
the	O
whole	O
virus	O
,	O
we	O
previously	O
generated	O
E	O
gene	O
mutants	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
that	O
were	O
defective	O
in	O
viral	O
growth	B-PROC
and	O
produced	O
aberrantly	O
assembled	O
virions	O
.	O

We	O
developed	O
an	O
extension	O
of	O
a	O
standard	O
outbreak	O
model	O
,	O
the	O
simple	O
stochastic	O
epidemic	O
,	O
which	O
accounts	O
for	O
societal	O
learning	B-PROC
.	O

As	O
an	O
example	O
,	O
we	O
estimated	O
the	O
learning	B-PROC
rate	O
for	O
the	O
2003	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
Singapore	O
.	O

By	O
contrast	O
,	O
the	O
expected	O
outbreak	O
size	O
for	O
societal	O
learning	B-PROC
twice	O
as	O
effective	O
was	O
116	O
cases	O
.	O

These	O
results	O
show	O
that	O
the	O
rate	O
of	O
societal	O
learning	B-PROC
can	O
greatly	O
affect	O
the	O
final	O
size	O
of	O
disease	O
outbreaks	O
,	O
justifying	O
investment	O
in	O
early	O
warning	O
systems	O
and	O
attentiveness	O
to	O
disease	O
outbreak	O
by	O
both	O
government	O
authorities	O
and	O
the	O
public	O
.	O

High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
is	O
an	O
unconventional	O
form	O
of	O
ventilation	O
that	O
may	O
improve	O
oxygenation	B-PROC
in	O
patients	O
with	O
ARDS	O
,	O
while	O
limiting	O
further	O
lung	O
injury	O
associated	O
with	O
high	O
ventilatory	O
pressures	O
and	O
volumes	O
delivered	O
during	O
conventional	O
ventilation	O
.	O

After	O
cultivation	O
of	O
the	O
isolated	O
infected	O
cells	O
,	O
52	O
+/-	O
10	O
%	O
of	O
the	O
infected	O
cells	O
re	O
-	O
expressed	B-PROC
viral	O
antigens	O
on	O
the	O
plasma	O
membrane	O
.	O

In	O
conclusion	O
,	O
it	O
can	O
be	O
stated	O
that	O
in	O
FIP	O
cats	O
,	O
FIPV	O
replicates	O
in	O
cells	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
without	O
carrying	O
viral	O
antigens	O
in	O
their	O
plasma	O
membrane	O
,	O
which	O
could	O
allow	O
them	O
to	O
escape	O
from	O
antibody	B-PROC
-	O
dependent	O
cell	O
lysis	B-PROC
.	O

TITLE	O
:	O
Production	O
of	O
authentic	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
with	O
enhanced	O
activity	O
:	O
application	O
as	O
a	O
novel	O
tag	O
-	O
cleavage	B-PROC
endopeptidase	O
for	O
protein	O
overproduction	O
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
found	O
four	O
risk	O
factors	O
for	O
SARS	O
-	O
related	O
deaths	B-PROC
.	O

CONCLUSIONS	O
:	O
Old	O
age	O
(	O
over	O
60	O
years	O
)	O
is	O
the	O
major	O
risk	O
factor	O
for	O
SARS	O
-	O
related	O
deaths	B-PROC
.	O

TITLE	O
:	O
The	O
synergistic	O
interaction	O
of	O
interferon	O
types	O
I	O
and	O
II	O
leads	O
to	O
marked	O
reduction	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
replication	O
and	O
increase	O
in	O
the	O
expression	B-PROC
of	O
mRNAs	O
for	O
interferon	O
-	O
induced	O
proteins	O
.	O

This	O
inhibition	B-PROC
was	O
prevented	O
by	O
addition	O
of	O
cholesterol	O
to	O
the	O
culture	O
medium	O
,	O
indicating	O
that	O
the	O
reduction	O
of	O
virus	O
particle	O
release	O
was	O
caused	O
by	O
the	O
loss	O
of	O
cholesterol	O
in	O
the	O
cell	O
membrane	O
.	O

Five	O
patients	O
died	B-PROC
.	O

TITLE	O
:	O
Transcriptome	O
of	O
local	O
innate	O
and	O
adaptive	O
immunity	B-PROC
during	O
early	O
phase	O
of	O
infectious	O
bronchitis	O
viral	B-PROC
infection	I-PROC
.	O

Results	O
suggested	O
that	O
the	O
transcription	B-PROC
levels	O
of	O
365	O
genes	O
were	O
either	O
upregulated	O
or	O
downregulated	O
(	O
2	O
-	O
fold	O
and	O
higher	O
)	O
after	O
IBV	O
infection	O
.	O

These	O
upregulated	O
immune	B-PROC
response	I-PROC
genes	O
included	O
TLR2	O
,	O
TLR3	O
,	O
interferon	O
-	O
induced	O
antiviral	O
genes	O
(	O
Mx	O
),	O
and	O
genes	O
responsible	O
for	O
cytotoxic	O
T	O
cell	B-PROC
killing	I-PROC
such	O
as	O
Fas	O
antigen	O
and	O
granzyme	O
-	O
A	O
.	O
Overall	O
,	O
a	O
diversity	O
of	O
innate	B-PROC
immunity	B-PROC
and	O
helper	O
T	O
cell	O
type	O
1	O
(	O
Th1	O
)-	O
biased	O
adaptive	O
immunity	B-PROC
are	O
activated	O
in	O
the	O
host	O
'	O
s	O
early	O
defense	O
against	O
IBV	O
invasion	O
,	O
and	O
they	O
are	O
responsible	O
for	O
the	O
rapid	O
clearance	O
of	O
virus	O
from	O
the	O
local	O
infection	O
.	O

In	O
this	O
study	O
,	O
a	O
leucine	O
-	O
rich	O
nuclear	B-PROC
export	I-PROC
signal	O
(	O
NES	O
)	O
(	O
291	O
-	O
LQLDGLHL	O
-	O
298	O
)	O
present	O
in	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
IBV	O
N	O
protein	O
was	O
analyzed	O
by	O
using	O
alanine	O
substitution	O
and	O
deletion	O
mutagenesis	B-PROC
to	O
investigate	O
the	O
relative	O
contributions	O
that	O
leucine	O
residues	O
make	O
to	O
nuclear	B-PROC
export	I-PROC
and	O
where	O
these	O
residues	O
are	O
located	O
on	O
the	O
structure	O
of	O
the	O
IBV	O
N	O
protein	O
.	O

Oxygen	B-PROC
metabolism	I-PROC
abnormality	O
was	O
found	O
after	O
trauma	O
,	O
and	O
it	O
was	O
correlated	O
with	O
ISS	O
,	O
RTS	O
,	O
injured	O
organ	O
or	O
region	O
and	O
number	O
of	O
injured	O
organs	O
,	O
shock	O
,	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
)	O
and	O
respiratory	O
complications	O
.	O

There	O
was	O
marked	O
difference	O
in	O
the	O
ratio	O
of	O
change	O
in	O
oxygen	B-PROC
metabolism	I-PROC
between	O
MODS	O
and	O
NMODS	O
groups	O
.	O

More	O
marked	O
changes	O
in	O
metabolic	B-PROC
variables	O
indicated	O
severer	O
organ	O
dysfunction	O
,	O
reaching	B-PROC
their	O
peak	O
values	O
before	O
death	B-PROC
.	O

This	O
must	O
be	O
avoided	O
or	O
given	O
with	O
caution	O
under	O
expert	O
supervision	O
in	O
patients	O
with	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
deficiency	O
(	O
G6PD	O
),	O
in	O
whom	O
it	O
may	O
cause	O
severe	O
haemolysis	B-PROC
.	O

Lethality	O
is	O
preceded	O
by	O
rapid	O
and	O
high	O
titer	O
viral	B-PROC
replication	I-PROC
in	O
lungs	O
,	O
viremia	O
,	O
and	O
dissemination	O
of	O
virus	O
to	O
extrapulmonary	O
sites	O
accompanied	O
by	O
lymphopenia	O
,	O
neutrophilia	O
,	O
and	O
pathological	O
changes	O
in	O
the	O
lungs	O
.	O

Thirty	O
-	O
six	O
underwent	O
pulmonary	B-PROC
function	I-PROC
testing	O
and	O
a	O
6	O
-	O
minute	O
walk	O
test	O
,	O
and	O
35	O
underwent	O
HRQoL	O
evaluation	O
by	O
Short	O
Form	O
-	O
36	O
questionnaire	O
at	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
illness	O
onset	O
.	O

These	O
approaches	O
were	O
able	O
to	O
achieve	O
or	O
induce	O
antibody	B-PROC
titers	O
sufficient	O
to	O
reduce	O
viral	O
load	O
,	O
protect	O
from	O
weight	O
loss	O
and	O
reduce	O
or	O
eliminate	O
histopathologic	O
changes	O
in	O
the	O
lungs	O
of	O
aged	O
mice	O
.	O

TITLE	O
:	O
Ribonucleocapsid	O
formation	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
through	O
molecular	O
action	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
N	O
protein	O
.	O

Molecules	O
resulting	O
from	O
these	O
switches	O
were	O
not	O
templates	O
for	O
subgenomic	O
mRNA	B-PROC
synthesis	I-PROC
but	O
,	O
rather	O
,	O
ambisense	O
chimeras	O
potentially	O
exceeding	O
the	O
viral	O
genome	O
in	O
length	O
.	O

ABSTRACT	O
:	O
A	O
nonfluorescent	O
low	O
-	O
cost	O
,	O
low	O
-	O
density	O
oligonucleotide	O
array	O
was	O
designed	O
for	O
detecting	O
the	O
whole	O
coronavirus	O
genus	O
after	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
.	O

This	O
result	O
suggests	O
that	O
not	O
only	O
E	O
.	O
R	O
.-	O
association	O
but	O
also	O
specific	O
protein	O
sequence	O
is	O
important	O
for	O
the	O
HCV	O
core	O
protein	O
signal	O
peptide	O
cleavage	B-PROC
by	O
SPP	O
.	O

Innate	B-PROC
immunity	B-PROC
is	O
important	O
for	O
viral	O
clearance	O
in	O
the	O
mouse	O
model	O
.	O

ABSTRACT	O
:	O
Expression	B-PROC
of	O
the	O
exceptionally	O
large	O
RNA	O
genomes	O
of	O
CoVs	O
involves	O
multiple	O
regulatory	O
mechanisms	O
,	O
including	O
extensive	O
proteolytic	B-PROC
processing	I-PROC
of	O
the	O
large	O
replicase	O
polyproteins	O
,	O
pp1a	O
and	O
pp1ab	O
,	O
by	O
two	O
types	O
of	O
cysteine	O
proteases	O
:	O
the	O
chymotrypsin	O
-	O
like	O
main	O
protease	O
and	O
papain	O
-	O
like	O
accessory	O
proteases	O
(	O
PLpros	O
).	O

The	O
PL1pro	O
-	O
negative	O
mutant	O
genotype	O
could	O
be	O
stably	O
maintained	O
in	O
cell	O
culture	O
when	O
the	O
nsp1	O
-	O
nsp2	O
site	O
was	O
replaced	O
by	O
a	O
short	O
autoproteolytic	O
sequence	O
,	O
suggesting	O
that	O
the	O
major	O
driving	O
force	O
for	O
the	O
observed	O
reversion	O
of	O
the	O
PL1pro	O
mutation	O
was	O
the	O
requirement	O
for	O
efficient	O
nsp1	O
-	O
nsp2	O
cleavage	B-PROC
.	O

Human	O
metapneumovirus	O
was	O
identified	O
in	O
nasopharyngeal	O
aspirate	O
amplification	O
of	O
the	O
viral	O
fusion	O
and	O
nucleocapsid	O
genes	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
sequencing	O
and	O
phylogenetic	O
analysis	O
.	O

The	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
was	O
induced	O
more	O
effectively	O
by	O
the	O
DNA	O
priming	O
and	O
recombinant	O
adenovirus	O
boosting	O
regimen	O
.	O

Comparison	O
of	O
detection	O
results	O
with	O
different	O
SARS	O
antibody	B-PROC
assays	O
indicated	O
that	O
our	O
panel	O
should	O
differentiate	O
the	O
specificity	O
and	O
sensitivity	O
of	O
different	O
assays	O
.	O

Most	O
commercial	O
mAbs	O
studied	O
as	O
antiviral	O
agents	O
in	O
the	O
clinic	O
have	O
either	O
directly	O
or	O
indirectly	O
targeted	B-PROC
human	O
immunodeficiency	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
or	O
hepatitis	O
C	O
virus	O
infections	O
.	O

However	O
,	O
the	O
ability	O
of	O
mAbs	O
to	O
bind	O
to	O
specific	O
targets	O
and	O
utilize	O
various	O
anti	O
-	O
infective	O
modes	O
of	O
action	O
would	O
seem	O
to	O
make	O
them	O
well	O
suited	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
a	O
wider	O
variety	O
of	O
viral	B-PROC
diseases	I-PROC
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
the	O
nucleocapsid	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
activated	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
expression	B-PROC
.	O

Further	O
surveillance	O
of	O
bat	O
and	O
other	O
animal	O
populations	O
is	O
needed	O
to	O
fully	O
describe	O
the	O
ecology	O
and	O
evolution	B-PROC
of	O
this	O
virus	O
family	O
.	O

In	O
this	O
study	O
,	O
we	O
focused	O
on	O
the	O
development	B-PROC
of	O
a	O
HIV	O
-	O
1	O
vaccine	O
using	O
polymeric	O
nanoparticles	O
.	O

Using	O
the	O
N	O
protein	O
gene	O
as	O
target	O
,	O
IBVs	O
were	O
analyzed	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
/	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
(	O
RT	O
-	O
PCR	O
/	O
RFLP	O
)	O
with	O
the	O
restriction	O
enzymes	O
AvaII	O
,	O
HphI	O
,	O
Sau96I	O
,	O
and	O
Tsp509I	O
and	O
cDNA	O
sequencing	O
.	O

Apoptosis	B-PROC
was	O
induced	O
easily	O
in	O
M	O
.	O
fermentans	O
-	O
infected	O
cells	O
,	O
indicating	O
that	O
they	O
were	O
primed	O
for	O
apoptosis	B-PROC
.	O

Caspase	O
-	O
1	O
activation	O
,	O
and	O
overproduction	O
of	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
18	O
play	O
an	O
important	O
role	O
in	O
the	O
course	O
of	O
ALI	O
,	O
and	O
Caspase	O
-	O
1	O
inhibition	B-PROC
is	O
effective	O
for	O
the	O
treatment	O
of	O
ALI	O
in	O
experimental	O
SAP	O
.	O

The	O
cell	O
signalling	B-PROC
pathways	B-PROC
responsible	O
for	O
this	O
differential	O
effect	O
remain	O
to	O
be	O
explored	O
.	O

To	O
study	O
the	O
underlying	O
mechanisms	O
,	O
we	O
have	O
developed	O
a	O
ferret	O
model	O
of	O
canine	O
distemper	O
virus	B-PROC
infection	I-PROC
.	O

The	O
highest	O
values	O
of	O
sICAM	O
-	O
1	O
were	O
observed	O
in	O
patients	O
with	O
TBI	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
those	O
of	O
sE	O
-	O
Selectin	B-PROC
in	O
patients	O
with	O
sepsis	O
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

Patients	O
in	O
the	O
control	O
group	O
did	O
not	O
show	O
an	O
elevation	O
of	O
sE	O
-	O
Selectin	B-PROC
and	O
sICAM	O
-	O
1	O
levels	O
longitudinally	O
.	O

Increased	O
levels	O
of	O
measured	O
molecules	O
(	O
TGF	O
-	O
beta1	O
,	O
p	O
<	O
0	O
.	O
02	O
,	O
sE	O
-	O
Selectin	B-PROC
,	O
p	O
<	O
0	O
.	O
02	O
,	O
sL	O
-	O
Selectin	B-PROC
,	O
p	O
=	O
0	O
.	O
06	O
,	O
sICAM	O
-	O
1	O
,	O
p	O
<	O
0	O
.	O
03	O
)	O
were	O
demonstrated	O
among	O
survivors	O
in	O
the	O
sepsis	O
and	O
ARDS	O
groups	O
of	O
patients	O
and	O
were	O
positively	O
correlated	O
with	O
length	O
of	O
stay	O
(	O
p	O
<	O
0	O
.	O
04	O
)	O
and	O
mechanical	O
ventilation	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
the	O
coronavirus	O
of	O
the	O
chicken	O
(	O
Gallus	O
gallus	O
),	O
is	O
one	O
of	O
the	O
foremost	O
causes	O
of	O
economic	O
loss	O
within	O
the	O
poultry	O
industry	O
,	O
affecting	O
the	O
performance	O
of	O
both	O
meat	O
-	O
type	O
and	O
egg	B-PROC
-	I-PROC
laying	I-PROC
birds	O
.	O

Severely	O
obese	O
patients	O
were	O
more	O
likely	O
to	O
be	O
discharged	O
to	O
a	O
rehabilitation	O
or	O
skilled	O
nursing	B-PROC
facility	O
than	O
to	O
home	O
.	O

TITLE	O
:	O
The	O
potential	O
of	O
targeted	B-PROC
antibody	B-PROC
prophylaxis	O
in	O
SARS	O
outbreak	O
control	O
:	O
a	O
mathematic	O
analysis	O
.	O

Antibody	B-PROC
prophylaxis	O
may	O
also	O
be	O
employed	O
to	O
reduce	O
R	O
below	O
one	O
and	O
thereby	O
restrict	O
outbreak	O
size	O
and	O
duration	O
.	O

Comparing	O
the	O
refined	O
public	O
health	O
estimate	O
with	O
recent	O
data	O
from	O
the	O
Organization	O
for	O
Economic	O
Cooperation	O
and	O
Development	B-PROC
still	O
positions	O
Canada	O
with	O
the	O
highest	O
share	O
of	O
total	O
health	O
expenditure	O
devoted	O
to	O
public	O
health	O
than	O
any	O
other	O
country	O
reporting	O
.	O

ABSTRACT	O
:	O
General	B-PROC
anesthesia	I-PROC
in	O
patients	O
with	O
mediastinal	O
masses	O
can	O
lead	O
to	O
life	O
-	O
threatening	O
cardiorespiratory	O
complications	O
.	O

We	O
report	O
the	O
cases	O
of	O
2	O
pediatric	O
patients	O
with	O
mediastinal	O
masses	O
who	O
developed	O
serious	O
complications	O
during	O
general	B-PROC
anesthesia	I-PROC
.	O

This	O
effect	O
is	O
independent	O
of	O
cyclooxygenase	O
inhibition	B-PROC
.	O

We	O
found	O
that	O
the	O
SARS	O
-	O
CoV	O
M	O
protein	O
induced	O
apoptosis	B-PROC
in	O
both	O
HEK293T	O
cells	O
and	O
transgenic	O
Drosophila	O
.	O

ABSTRACT	O
:	O
To	O
summarize	O
lessons	O
learned	B-PROC
from	O
an	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
China	O
during	O
the	O
spring	O
of	O
2004	O
.	O

Inhibition	B-PROC
of	O
iNOS	O
is	O
effective	O
in	O
mitigating	O
the	O
endotoxaemic	O
changes	O
and	O
lung	O
pathology	O
.	O

Toronto	O
workers	O
were	O
more	O
likely	O
to	O
have	O
reduced	O
patient	O
contact	O
and	O
work	O
hours	O
and	O
to	O
report	O
behavioral	B-PROC
consequences	O
of	O
stress	O
.	O

This	O
review	O
will	O
provide	O
first	O
-	O
hand	O
information	O
,	O
particularly	O
from	O
Guangdong	O
,	O
China	O
,	O
about	O
the	O
initial	O
epidemiology	O
,	O
the	O
identification	O
of	O
the	O
aetiological	O
agent	O
of	O
the	O
disease	O
,	O
the	O
molecular	O
evolution	B-PROC
study	O
of	O
the	O
virus	O
,	O
the	O
finding	O
of	O
SARS	O
-	O
like	O
CoV	O
in	O
horseshoe	O
bats	O
and	O
the	O
mechanistic	O
analysis	O
for	O
the	O
cross	O
-	O
host	O
tropism	B-PROC
transition	O
.	O

ABSTRACT	O
:	O
Myelin	O
transcription	B-PROC
factor	O
1	O
(	O
Myt1	O
)	O
is	O
a	O
zinc	O
-	O
finger	O
DNA	O
binding	O
protein	O
that	O
influences	O
developing	O
oligodendrocyte	O
progenitor	O
(	O
OP	O
)	O
cell	B-PROC
proliferation	I-PROC
,	O
differentiation	B-PROC
,	O
and	O
myelin	O
gene	B-PROC
transcription	I-PROC
in	O
vitro	O
.	O

TITLE	O
:	O
Heterologous	O
viral	O
RNA	O
export	O
elements	O
improve	O
expression	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
spike	O
protein	O
and	O
protective	O
efficacy	O
of	O
DNA	O
vaccines	O
against	O
SARS	O
.	O

Immunocytochemistry	O
indicated	O
that	O
all	O
the	O
mAbs	O
to	O
the	O
(	O
poly100	O
)	O
S1	O
proteins	O
can	O
react	O
with	O
the	O
homologous	O
S1	O
glycoprotein	O
expressed	B-PROC
in	O
Vero	O
cells	O
.	O

More	O
detailed	O
microbiological	O
investigations	O
of	O
affected	O
children	O
even	O
without	O
apparent	O
signs	O
of	O
a	O
respiratory	O
tract	O
infection	O
may	O
help	O
to	O
clarify	O
the	O
etiology	O
in	O
some	O
patients	O
and	O
extend	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
sepsis	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
a	O
controversial	O
means	O
of	O
life	O
support	O
,	O
particularly	O
in	O
adults	O
.	O

Examples	O
of	O
CBAs	O
include	O
the	O
procaryotic	O
cyanovirin	O
-	O
N	O
(	O
CV	O
-	O
N	O
),	O
plant	O
lectins	O
such	O
as	O
HHA	O
,	O
GNA	O
,	O
NPA	O
,	O
CA	O
and	O
UDA	O
,	O
the	O
monoclonal	O
antibody	B-PROC
2G12	O
directed	O
against	O
a	O
glycan	O
-	O
containing	O
epitope	O
on	O
HIV	O
envelope	O
gp120	O
,	O
and	O
the	O
mannose	O
-	O
specific	O
non	O
-	O
peptidic	O
antibiotic	O
Pradimicin	O
A	O
,	O
which	O
inhibits	O
the	O
entry	O
of	O
HIV	O
-	O
1	O
into	O
its	O
target	O
cells	O
.	O

Multiple	O
mutations	O
at	O
N	O
-	O
glycosylation	B-PROC
sites	O
are	O
required	O
before	O
pronounced	O
phenotypic	O
drug	B-PROC
resistance	B-PROC
development	B-PROC
becomes	O
evident	O
.	O

The	O
development	B-PROC
of	O
consolidation	O
during	O
the	O
course	O
of	O
the	O
disease	O
correlated	O
with	O
the	O
occurrence	O
of	O
respiratory	O
failure	O
(	O
P	O
=	O
0	O
.	O
068	O
)	O
but	O
not	O
with	O
mortality	O
(	O
P	O
=	O
0	O
.	O
193	O
).	O

On	O
logistic	O
regression	O
analysis	O
,	O
the	O
development	B-PROC
of	O
respiratory	O
failure	O
and	O
other	O
organ	O
dysfunctions	O
were	O
independent	O
risk	O
factors	O
for	O
mortality	O
.	O

Confocal	O
microscopy	O
revealed	O
that	O
cyclin	O
D1	O
decreased	O
in	O
IBV	O
-	O
infected	O
cells	O
as	O
infection	O
progressed	O
and	O
inhibition	B-PROC
studies	O
indicated	O
that	O
a	O
population	O
of	O
cyclin	O
D1	O
could	O
be	O
targeted	B-PROC
for	O
degradation	O
by	O
a	O
virus	O
mediated	O
pathway	B-PROC
.	O

ABSTRACT	O
:	O
Over	O
the	O
last	O
century	O
,	O
changes	O
in	O
land	O
-	O
use	O
,	O
modification	O
of	O
agriculture	O
-	O
livestock	O
production	O
systems	O
,	O
disruption	O
of	O
wildlife	O
habitats	O
,	O
increase	O
of	O
human	O
activities	O
,	O
higher	O
frequency	O
of	O
international	O
and	O
intercontinental	O
travels	O
,	O
wider	O
circulation	B-PROC
of	O
animals	O
and	O
animal	O
products	O
have	O
contributed	O
to	O
alter	O
the	O
distribution	O
,	O
presence	O
and	O
density	O
of	O
hosts	O
and	O
vectors	O
.	O

Moreover	O
,	O
Bcl	O
-	O
2	O
has	O
a	O
role	O
in	O
halting	O
the	O
cell	B-PROC
cycle	I-PROC
(	O
though	O
p27	O
),	O
which	O
may	O
slow	O
down	O
tumor	O
growth	B-PROC
;	O
and	O
Bcl	O
-	O
2	O
even	O
has	O
pro	O
-	O
apoptotic	O
roles	O
in	O
the	O
execution	O
of	O
apoptosis	B-PROC
initiated	O
by	O
external	O
death	B-PROC
signals	O
(	O
via	O
Fas	O
/	O
CD95	O
and	O
caspase	O
3	O
).	O

In	O
order	O
to	O
further	O
characterize	O
the	O
molecular	O
mechanisms	O
governing	O
T	B-PROC
cell	I-PROC
activation	I-PROC
and	O
accumulation	O
within	O
the	O
CNS	O
in	O
response	O
to	O
viral	B-PROC
infection	I-PROC
,	O
MHV	O
was	O
instilled	O
into	O
the	O
CNS	O
of	O
Drak2	O
-	O
/	O
-	O
mice	O
.	O

These	O
results	O
demonstrate	O
that	O
DRAK2	O
signaling	B-PROC
is	O
dispensable	O
for	O
T	O
cell	O
recruitment	O
into	O
the	O
CNS	O
following	O
viral	B-PROC
infection	I-PROC
,	O
suggesting	O
that	O
the	O
resistance	B-PROC
of	O
Drak2	O
-	O
/	O
-	O
mice	O
to	O
EAE	O
is	O
not	O
due	O
to	O
overt	O
T	O
cell	O
trafficking	B-PROC
defects	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
),	O
spanning	O
residues	O
248	O
-	O
365	O
(	O
NP248	O
-	O
365	O
),	O
had	O
stronger	O
nucleic	O
acid	O
-	O
binding	B-PROC
activity	I-PROC
than	O
the	O
NTD	O
.	O

Both	O
episodes	O
were	O
successfully	O
treated	O
with	O
steroid	O
pulse	B-PROC
therapy	O
.	O

Understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
local	O
inflammation	O
in	O
the	O
pancreas	O
leads	O
to	O
end	O
-	O
organ	O
injury	O
is	O
crucial	O
for	O
the	O
development	B-PROC
of	O
new	O
therapeutic	O
strategies	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
expression	B-PROC
level	O
of	O
the	O
FIPV	O
virus	O
receptor	O
,	O
feline	O
aminopeptidase	O
N	O
(	O
fAPN	O
),	O
was	O
increased	O
in	O
macrophages	O
of	O
FIP	O
cats	O
.	O

Reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
to	O
detect	O
and	O
quantify	O
SARS	O
-	O
CoV	O
in	O
934	O
sera	O
and	O
self	O
-	O
collected	O
throat	O
washes	O
and	O
fecal	O
samples	O
from	O
271	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	O
managed	O
at	O
a	O
single	O
institution	O
.	O

Increasingly	O
,	O
however	O
,	O
it	O
is	O
becoming	O
apparent	O
that	O
certain	O
pyruvate	O
esters	O
,	O
including	O
EP	O
,	O
have	O
pharmacological	O
effects	O
,	O
such	O
as	O
suppression	B-PROC
of	O
inflammation	O
,	O
that	O
are	O
quite	O
distinct	O
from	O
those	O
exerted	B-PROC
by	O
pyruvate	O
anion	O
.	O

TITLE	O
:	O
Pathology	O
and	O
pathogenesis	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Extensive	O
studies	O
have	O
provided	O
a	O
basic	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
this	O
disease	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
replication	O
requires	O
proteolytic	B-PROC
processing	I-PROC
of	O
the	O
large	O
polyprotein	O
encoded	O
by	O
ORF1a	O
/	O
ab	O
into	O
putative	O
functional	O
intermediates	O
and	O
eventually	O
approximately	O
15	O
mature	O
proteins	O
.	O

All	O
viable	O
mutants	O
showed	O
reductions	O
in	O
growth	B-PROC
kinetics	O
and	O
overall	O
viral	O
RNA	B-PROC
synthesis	I-PROC
,	O
implicating	O
nsp10	O
as	O
being	O
a	O
cofactor	O
in	O
positive	O
-	O
or	O
negative	O
-	O
strand	O
synthesis	B-PROC
.	O

We	O
found	O
that	O
PLP1	O
processes	O
cleavage	B-PROC
site	O
1	O
to	O
release	O
nsp1	O
,	O
whereas	O
PLP2	O
is	O
responsible	O
for	O
processing	O
both	O
cleavage	B-PROC
sites	O
2	O
and	O
3	O
to	O
release	O
nsp2	O
and	O
nsp3	O
.	O

These	O
data	O
provide	O
useful	O
insights	O
regarding	O
immunity	B-PROC
against	O
SARS	O
-	O
CoV	O
and	O
have	O
the	O
potential	O
to	O
help	O
guide	O
the	O
design	O
of	O
peptide	O
-	O
based	O
vaccines	O
.	O

In	O
the	O
mid	O
1960s	O
,	O
two	O
human	O
coronaviruses	O
were	O
identified	O
that	O
cause	O
the	O
common	O
cold	B-PROC
:	O
human	O
coronaviruses	O
(	O
HCoV	O
)-	O
229E	O
and	O
HCoV	O
-	O
OC43	O
.	O

Stigmatization	O
of	O
and	O
discrimination	O
against	O
the	O
chronically	O
ill	O
and	O
the	O
sense	B-PROC
of	O
searching	O
coping	O
strategy	O
during	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
outbreak	O
further	O
motivated	O
their	O
practice	O
.	O

When	O
DT	O
was	O
administrated	O
to	O
the	O
mice	O
they	O
suffered	O
from	O
acute	O
lung	O
injury	O
and	O
died	B-PROC
within	O
4	O
days	O
.	O

In	O
addition	O
,	O
confocal	O
image	O
analysis	O
has	O
shown	O
release	O
of	O
mitochondrial	O
apoptogenic	O
apoptosis	B-PROC
-	O
inducing	O
factor	O
and	O
cytochrome	B-PROC
c	I-PROC
into	O
the	O
cytosol	O
.	O

Structure	O
studies	O
of	O
the	O
full	O
-	O
length	O
form	O
of	O
the	O
obligate	O
hexameric	O
enzyme	O
from	O
two	O
CoVs	O
,	O
SARS	O
-	O
CoV	O
and	O
murine	O
hepatitis	O
virus	O
,	O
and	O
its	O
monomeric	O
homologue	O
,	O
XendoU	O
from	O
Xenopus	O
laevis	O
,	O
combined	O
with	O
mutagenesis	B-PROC
studies	O
have	O
implicated	O
several	O
residues	O
in	O
enzymatic	B-PROC
activity	I-PROC
and	O
the	O
N	O
-	O
terminal	O
domain	O
as	O
the	O
major	O
determinant	O
of	O
hexamerization	O
.	O

Here	O
we	O
expressed	B-PROC
the	O
SARS	O
-	O
CoV	O
S	O
-	O
protein	O
to	O
investigate	O
its	O
interactions	O
with	O
innate	O
immune	O
mechanisms	O
in	O
the	O
lung	O
.	O

TITLE	O
:	O
G1	B-PROC
phase	I-PROC
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
induced	O
by	O
SARS	O
-	O
CoV	O
3a	O
protein	O
via	O
the	O
cyclin	O
D3	O
/	O
pRb	O
pathway	B-PROC
.	O

Mutation	O
analysis	O
of	O
3a	O
revealed	O
that	O
C	O
-	O
terminal	O
region	O
(	O
176	O
aa	O
approximately	O
274	O
aa	O
),	O
including	O
a	O
potential	O
calcium	O
ATPase	O
motif	O
,	O
was	O
essential	O
for	O
induction	O
of	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
.	O

Reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
performed	O
on	O
nasopharyngeal	O
aspirate	O
is	O
the	O
most	O
reliable	O
method	O
for	O
the	O
laboratory	O
diagnosis	O
of	O
AI	O
H5N1	O
.	O

S100A12	O
was	O
also	O
analyzed	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
eight	O
healthy	O
subjects	O
after	O
challenge	O
with	O
lipopolysaccharide	O
and	O
compared	O
with	O
eight	O
controls	O
who	O
received	O
placebo	O
inhalation	B-PROC
.	O

ABSTRACT	O
:	O
An	O
important	O
effort	B-PROC
has	O
been	O
performed	O
after	O
the	O
emergence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
epidemic	O
in	O
2003	O
to	O
diagnose	O
and	O
prevent	O
virus	O
spreading	O
.	O

Being	O
able	O
to	O
modify	O
a	O
'	O
core	O
'	O
vaccine	O
strain	O
to	O
make	O
it	O
applicable	O
to	O
a	O
prevailing	O
serotype	O
requires	O
a	O
procedure	O
for	O
doing	O
so	O
,	O
and	O
the	O
demonstration	O
that	O
'	O
spike	O
-	O
swapping	O
'	O
is	O
sufficient	O
to	O
induce	O
good	O
immunity	B-PROC
.	O

Uniquely	O
,	O
our	O
molecular	O
clone	O
of	O
Beaudette	O
is	O
benign	O
when	O
administered	O
to	O
18	O
-	O
day	O
-	O
old	O
embryos	O
,	O
even	O
at	O
high	O
doses	O
,	O
and	O
induces	O
immunity	B-PROC
after	O
this	O
route	O
of	O
vaccination	O
.	O

TITLE	O
:	O
Influenza	O
viral	B-PROC
infection	I-PROC
in	O
2005	O
-	O
2006	O
in	O
Samitivej	O
Hospital	O
.	O

After	O
cure	O
,	O
post	O
-	O
transplant	O
blastomycosis	O
may	O
not	O
require	O
lifelong	O
antifungal	O
suppression	B-PROC
.	O

Two	O
motif	O
cleavage	B-PROC
sites	O
(	O
R	O
-	O
R	O
-	O
X	O
-	O
R	O
-	O
R	O
/	O
S	O
,	O
H	O
-	O
R	O
-	O
R	O
-	O
R	O
-	O
R	O
/	O
S	O
)	O
were	O
observed	O
in	O
the	O
five	O
sequenced	O
strains	O
.	O

These	O
results	O
indicated	O
that	O
recombinant	O
SL7207	O
(	O
pVAX1	O
-	O
S1	O
)	O
induced	O
both	O
systemic	O
and	O
local	O
mucosal	B-PROC
immunity	I-PROC
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
patient	O
with	O
Down	O
'	O
s	O
syndrome	O
(	O
DS	O
)	O
who	O
died	B-PROC
of	O
a	O
fulminant	O
NMO	O
.	O

In	O
early	O
onset	O
,	O
primary	O
,	O
severe	O
ARDS	O
,	O
short	O
-	O
term	O
HFO	O
-	O
TGI	O
improves	O
oxygenation	B-PROC
relative	O
to	O
standard	O
HFO	O
and	O
ARDS	O
Network	O
CMV	O
.	O

Consequently	O
,	O
TNF	B-PROC
production	I-PROC
is	O
enhanced	O
,	O
leading	O
to	O
the	O
development	B-PROC
of	O
multi	O
-	O
organ	O
failure	O
in	O
sepsis	O
.	O

The	O
case	O
described	O
herein	O
involves	O
a	O
patient	O
with	O
multidrug	O
-	O
resistant	O
smear	O
-	O
positive	O
penile	O
TB	O
that	O
was	O
undiagnosed	O
initially	O
due	O
to	O
the	O
lack	O
of	O
clinical	O
suspicion	O
of	O
TB	O
,	O
and	O
once	O
diagnosed	O
failed	O
to	O
respond	O
to	O
first	O
line	O
antitubercular	O
drugs	O
because	O
of	O
multiple	O
drug	B-PROC
resistance	B-PROC
.	O

Septic	O
shock	O
(	O
36	O
.	O
2	O
%)	O
and	O
heart	O
failure	O
(	O
20	O
.	O
6	O
%)	O
were	O
major	O
lethal	O
causes	O
,	O
while	O
only	O
14	O
.	O
6	O
%	O
died	B-PROC
of	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Intracellular	B-PROC
localization	I-PROC
of	O
the	O
SARS	O
coronavirus	O
protein	O
9b	O
:	O
evidence	O
of	O
active	O
export	O
from	O
the	O
nucleus	O
.	O

We	O
previously	O
reported	O
the	O
isolation	O
of	O
HCoV	O
-	O
229E	O
/	O
myelin	O
basic	O
protein	O
(	O
MBP	O
)	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
T	O
-	O
cell	O
lines	O
(	O
TCL	O
)	O
in	O
MS	O
patients	O
.	O

RACE	O
RT	O
-	O
PCR	O
amplification	O
of	O
the	O
Vbeta	O
chains	O
of	O
five	O
of	O
ten	O
the	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
TCC	O
confirmed	O
clonality	O
and	O
sequencing	O
identified	O
the	O
CDR3	O
region	O
associated	O
with	O
cross	O
-	O
reactivity	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
and	O
innate	B-PROC
immunity	B-PROC
.	O

Using	O
SARS	O
-	O
CoV	O
as	O
a	O
model	O
,	O
we	O
will	O
review	O
the	O
current	O
knowledge	O
of	O
the	O
interplay	O
between	O
coronavirus	O
infection	O
and	O
the	O
host	O
innate	O
immune	O
system	O
in	O
vivo	O
,	O
and	O
then	O
discuss	O
the	O
mechanisms	O
by	O
which	O
specific	O
gene	O
products	O
antagonize	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
in	O
cell	O
culture	O
models	O
.	O

Our	O
data	O
suggests	O
that	O
the	O
SARS	O
-	O
CoV	O
uses	O
specific	O
strategies	O
to	O
evade	O
and	O
antagonize	O
the	O
sensing	O
and	O
signaling	B-PROC
arms	O
of	O
the	O
interferon	O
pathway	B-PROC
.	O

Efficient	O
SARS	O
-	O
CoV	O
infection	O
of	O
ciliated	O
cell	O
-	O
types	O
in	O
HAE	O
provides	O
a	O
useful	O
in	O
vitro	O
model	O
of	O
human	O
lung	O
origin	O
to	O
study	O
characteristics	O
of	O
SARS	O
-	O
CoV	O
replication	O
and	O
pathogenesis	B-PROC
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
induced	O
apoptosis	B-PROC
of	O
COS	O
-	O
1	O
mediated	O
by	O
the	O
mitochondrial	O
pathway	B-PROC
.	O

His	O
course	O
was	O
further	O
complicated	O
by	O
anuric	O
renal	O
failure	O
,	O
rhabdomyolysis	O
,	O
severe	O
hepatitis	O
,	O
pancytopenia	O
,	O
elevation	O
of	O
cardiac	O
enzymes	O
,	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
over	O
the	O
following	O
days	O
.	O

Newer	O
diagnostic	O
tests	O
such	O
as	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
have	O
greatly	O
expanded	O
our	O
understanding	O
of	O
the	O
importance	O
of	O
these	O
respiratory	O
viruses	O
.	O

Although	O
there	O
are	O
no	O
currently	O
approved	O
antiviral	O
agents	O
for	O
clinical	O
use	O
,	O
our	O
increased	O
understanding	O
of	O
the	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
should	O
lead	O
to	O
new	O
intervention	O
strategies	O
.	O

To	O
ascertain	O
the	O
requirements	O
of	O
cell	O
-	O
surface	O
HS	O
for	O
Beaudette	O
infectivity	O
,	O
we	O
assayed	O
for	O
infectivity	O
in	O
the	O
presence	O
of	O
soluble	O
heparin	O
as	O
a	O
competitor	O
and	O
determined	O
infectivity	O
in	O
mutant	O
cell	O
lines	O
with	O
no	O
HS	O
or	O
glycosaminoglycan	O
expression	B-PROC
.	O

Our	O
results	O
indicate	O
that	O
HS	O
plays	O
a	O
role	O
as	O
an	O
attachment	O
factor	O
for	O
IBV	O
,	O
working	O
in	O
concert	O
with	O
other	O
factors	O
like	O
sialic	O
acid	O
to	O
mediate	O
virus	O
binding	O
to	O
cells	O
,	O
and	O
may	O
explain	O
in	O
part	O
the	O
extended	O
tropism	B-PROC
of	O
IBV	O
Beaudette	O
.	O

TITLE	O
:	O
In	O
silico	O
prediction	O
of	O
SARS	O
protease	B-PROC
inhibitors	I-PROC
by	O
virtual	O
high	O
throughput	O
screening	O
.	O

Selected	O
molecules	O
having	O
close	O
structural	O
relationship	O
to	O
a	O
2	O
-	O
methyl	O
-	O
2	O
,	O
4	O
-	O
pentanediol	O
may	O
provide	O
candidate	O
lead	O
compounds	O
toward	O
the	O
development	B-PROC
of	O
novel	O
allosteric	O
severe	O
acute	O
respiratory	O
syndrome	O
protease	B-PROC
inhibitors	I-PROC
.	O

Agents	O
being	O
developed	O
to	O
target	O
these	O
signaling	B-PROC
cascades	O
may	O
be	O
important	O
for	O
the	O
design	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
drugs	O
.	O

The	O
cleavage	B-PROC
could	O
be	O
blocked	O
by	O
a	O
PC	O
-	O
inhibitor	O
,	O
alpha1	O
-	O
PDX	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Several	O
strong	O
to	O
weak	O
NMR	O
ROESY	O
correlations	O
were	O
detected	O
,	O
and	O
a	O
3D	O
structure	O
of	O
the	O
spike	O
IQF	O
peptide	O
that	O
contains	O
the	O
crucial	O
cleavage	B-PROC
site	O
R	O
(	O
761	O
)	O
E	O
has	O
been	O
proposed	O
.	O

Host	O
cell	O
protein	B-PROC
synthesis	I-PROC
still	O
took	O
place	O
in	O
LiCl	O
-	O
treated	O
cells	O
and	O
the	O
level	O
of	O
a	O
standard	O
cellular	O
housekeeping	O
protein	O
remained	O
unchanged	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
LiCl	O
was	O
specifically	O
against	O
IBV	O
.	O

Our	O
approach	O
was	O
to	O
produce	O
retroviral	O
pseudotypes	O
that	O
bear	O
the	O
type	O
I	O
or	O
type	O
II	O
feline	O
coronavirus	O
surface	O
glycoprotein	O
and	O
to	O
screen	O
a	O
range	O
of	O
feline	O
cell	O
lines	O
for	O
the	O
expression	B-PROC
of	O
a	O
functional	O
receptor	O
for	O
attachment	O
and	O
entry	O
.	O

When	O
present	O
,	O
cerebral	O
edema	O
and	O
altered	O
cerebral	B-PROC
blood	I-PROC
flow	I-PROC
are	O
the	O
main	O
concerns	O
.	O

Further	O
,	O
we	O
have	O
mapped	O
the	O
interaction	O
domain	O
of	O
the	O
3a	O
protein	O
responsible	O
for	O
this	O
RNA	B-PROC
-	I-PROC
protein	I-PROC
interaction	I-PROC
using	O
a	O
series	O
of	O
deletion	O
mutants	O
and	O
defined	O
it	O
to	O
the	O
central	O
75	O
amino	O
acid	O
region	O
.	O

Concomitantly	O
,	O
phosphorylation	B-PROC
of	O
the	O
eukaryotic	O
translation	B-PROC
initiation	I-PROC
factor	O
2alpha	O
was	O
increased	O
in	O
MHV	O
-	O
infected	O
cells	O
.	O

Promoter	O
analyses	O
suggested	O
that	O
NF	O
-	O
kappaB	O
binding	O
element	O
was	O
required	O
for	O
IL	O
-	O
6	O
expression	B-PROC
regulated	O
by	O
N	O
protein	O
.	O

TITLE	O
:	O
Cell	B-PROC
cycle	I-PROC
arrest	I-PROC
and	O
apoptosis	B-PROC
induced	O
by	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
in	O
the	O
absence	O
of	O
p53	O
.	O

This	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
was	O
catalyzed	O
by	O
the	O
modulation	O
of	O
various	O
cell	B-PROC
cycle	I-PROC
regulatory	O
genes	O
and	O
the	O
accumulation	O
of	O
hypophosphorylated	O
RB	O
,	O
but	O
was	O
independent	O
of	O
p53	O
.	O

Our	O
data	O
also	O
showed	O
that	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
at	O
both	O
S	O
-	O
and	O
G	O
(	O
2	O
)/	O
M	O
-	O
phases	O
was	O
manipulated	O
by	O
IBV	O
for	O
the	O
enhancement	O
of	O
viral	B-PROC
replication	I-PROC
.	O

The	O
results	O
showed	O
that	O
specific	O
humoral	O
and	O
cellular	B-PROC
immunities	I-PROC
could	O
be	O
induced	O
in	O
mice	O
by	O
inoculating	O
them	O
with	O
SARS	O
-	O
CoV	O
spike	O
DNA	O
vaccine	O
alone	O
or	O
by	O
coinoculation	O
with	O
IL	O
-	O
2	O
-	O
expressing	O
plasmids	O
.	O

The	O
comparison	O
between	O
the	O
three	O
vaccination	O
routes	O
indicated	O
that	O
oral	O
vaccination	O
evoked	O
a	O
vigorous	O
T	O
-	O
cell	O
response	O
and	O
a	O
weak	O
response	O
predominantly	O
with	O
subclass	O
immunoglobulin	B-PROC
G2a	O
(	O
IgG2a	O
)	O
antibody	B-PROC
.	O

A	O
coronavirus	O
was	O
detected	O
by	O
electron	O
microscopy	O
and	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
in	O
the	O
faeces	O
and	O
in	O
the	O
intestinal	O
content	O
of	O
the	O
dead	B-PROC
quails	O
.	O

TITLE	O
:	O
Antigenic	O
characterization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	O
protein	O
expressed	B-PROC
in	O
insect	O
cells	O
:	O
The	O
effect	O
of	O
phosphorylation	B-PROC
on	O
immunoreactivity	B-PROC
and	O
specificity	O
.	O

ABSTRACT	O
:	O
We	O
summarize	O
findings	O
of	O
SARS	O
-	O
CoV	O
infections	O
in	O
several	O
animal	O
models	O
each	O
of	O
which	O
support	O
viral	B-PROC
replication	I-PROC
in	O
lungs	O
accompanied	O
by	O
histopathological	O
changes	O
and	O
/	O
or	O
clinical	O
signs	O
of	O
illness	O
to	O
varying	O
degrees	O
.	O

More	O
high	O
-	O
risk	O
health	O
care	O
workers	O
reported	O
fatigue	O
,	O
poor	O
sleep	B-PROC
,	O
worry	O
about	O
health	O
,	O
and	O
fear	O
of	O
social	O
contact	O
,	O
despite	O
their	O
confidence	O
in	O
infection	O
-	O
control	O
measures	O
.	O

Using	O
the	O
same	O
expression	B-PROC
system	O
,	O
two	O
structural	O
proteins	O
,	O
membrane	O
(	O
M	O
)	O
and	O
envelope	O
(	O
E	O
),	O
were	O
co	O
-	O
expressed	B-PROC
to	O
form	O
SARS	O
-	O
CoV	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
within	O
an	O
insect	O
cell	O
.	O

To	O
study	O
the	O
maturation	B-PROC
pathway	B-PROC
of	O
the	O
S	O
glycoprotein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
(	O
CoV	O
)	O
within	O
the	O
host	O
cell	O
,	O
a	O
T7	O
/	O
vaccinia	O
virus	O
-	O
based	O
expression	B-PROC
system	O
coupled	O
to	O
immunoprecipitation	O
with	O
anti	O
-	O
S	O
antibodies	O
was	O
used	O
to	O
test	O
and	O
analyze	O
different	O
forms	O
of	O
the	O
S	O
glycoprotein	O
.	O

With	O
this	O
system	O
,	O
many	O
different	O
constructs	O
of	O
the	O
S	O
glycoprotein	O
can	O
be	O
analyzed	O
in	O
parallel	O
thus	O
providing	O
another	O
method	O
by	O
which	O
to	O
study	O
the	O
functional	O
domains	O
of	O
S	O
involved	O
in	O
membrane	B-PROC
fusion	I-PROC
event	O
that	O
occurs	O
during	O
viral	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
The	O
implication	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
in	O
the	O
regulation	B-PROC
of	O
the	O
cardiovascular	O
system	O
has	O
been	O
well	O
known	O
for	O
many	O
years	O
.	O

However	O
,	O
with	O
almost	O
30	O
%	O
of	O
the	O
medicated	O
hypertensive	O
patients	O
harboring	O
an	O
uncontrolled	O
blood	B-PROC
pressure	I-PROC
,	O
a	O
need	O
for	O
new	O
drugs	O
and	O
new	O
targets	O
appears	O
necessary	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
compare	O
the	O
structures	O
,	O
distributions	O
and	O
properties	O
of	O
ACE	O
and	O
its	O
new	O
homologue	O
in	O
the	O
context	O
of	O
cardiovascular	B-PROC
function	I-PROC
,	O
focusing	O
on	O
the	O
autocrine	B-PROC
/	O
paracrine	B-PROC
cardiac	O
and	O
brain	O
renin	O
-	O
angiotensin	O
systems	O
and	O
we	O
will	O
present	O
recent	O
data	O
from	O
the	O
literature	O
and	O
our	O
laboratory	O
offering	O
a	O
new	O
perspective	O
on	O
this	O
potential	O
target	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
diseases	O
.	O

All	O
viruses	O
replicated	O
efficiently	O
,	O
but	O
none	O
produced	O
clinical	O
disease	O
or	O
death	B-PROC
in	O
young	O
animals	O
.	O

In	O
contrast	O
,	O
severe	O
clinical	O
disease	O
,	O
diffuse	O
alveolar	O
damage	O
,	O
hyaline	O
membrane	O
formation	B-PROC
,	O
alveolitis	O
,	O
and	O
death	B-PROC
were	O
noted	O
in	O
12	O
-	O
month	O
-	O
old	O
mice	O
inoculated	O
with	O
the	O
palm	O
civet	O
HC	O
/	O
SZ	O
/	O
61	O
/	O
03	O
strain	O
or	O
early	O
-	O
human	O
-	O
phase	O
GZ02	O
variants	O
but	O
not	O
with	O
related	O
middle	O
-	O
and	O
late	O
-	O
phase	O
epidemic	O
or	O
raccoon	O
dog	O
strains	O
.	O

Analysis	O
of	O
the	O
immunogenicity	O
of	O
the	O
UV	O
-	O
F	O
-	O
V	O
+	O
alum	O
vaccine	O
in	O
mice	O
revealed	O
that	O
it	O
generated	O
comparable	O
neutralizing	O
serum	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-PROC
levels	O
as	O
the	O
UV	O
-	O
V	O
+	O
alum	O
vaccine	O
.	O

The	O
iLA	O
was	O
removed	O
after	O
15	O
and	O
8	O
days	O
of	O
continuous	O
operation	O
,	O
respectively	O
,	O
and	O
both	O
soldiers	O
were	O
successfully	O
weaned	B-PROC
from	O
mechanical	O
ventilation	O
.	O

It	O
was	O
shown	O
by	O
others	O
that	O
nsp8	O
is	O
essential	O
for	O
viral	B-PROC
replication	I-PROC
in	O
vitro	O
,	O
whereas	O
nsp2	O
is	O
not	O
.	O

We	O
hypothesized	O
that	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
and	O
associated	O
downstream	O
signaling	B-PROC
pathways	B-PROC
play	O
a	O
role	O
in	O
the	O
PLY	O
-	O
induced	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
interaction	O
between	O
a	O
SARS	O
-	O
CoV	O
accessory	O
protein	O
and	O
nsp8	O
and	O
our	O
findings	O
suggest	O
that	O
ORF6	O
protein	O
may	O
play	O
a	O
role	O
in	O
virus	B-PROC
replication	I-PROC
.	O

TITLE	O
:	O
Immune	B-PROC
response	I-PROC
induced	O
by	O
spike	O
protein	O
from	O
transmissible	O
gastroenteritis	O
coronavirus	O
expressed	B-PROC
in	O
mouse	O
mammary	O
cells	O
.	O

The	O
antibody	B-PROC
titer	O
in	O
BALB	O
/	O
c	O
mice	O
following	O
immunization	O
with	O
recombinant	O
S	O
protein	O
was	O
detectable	O
after	O
the	O
first	O
immunization	O
.	O

Maximum	O
titers	O
of	O
antibody	B-PROC
(	O
8	O
.	O
86	O
+/-	O
0	O
.	O
19	O
ng	O
/	O
ml	O
of	O
serum	O
)	O
were	O
attained	O
after	O
the	O
second	O
immunization	O
.	O

Further	O
experiments	O
showed	O
that	O
IL	O
-	O
6	O
and	O
TNF	B-PROC
-	I-PROC
alpha	I-PROC
production	I-PROC
were	O
dependent	O
on	O
NF	O
-	O
kappaB	O
,	O
which	O
was	O
activated	O
through	O
I	O
-	O
kappaBalpha	O
degradation	O
.	O

There	O
was	O
no	O
significant	O
change	O
in	O
mortality	O
in	O
the	O
Greater	O
Toronto	O
Area	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
period	O
of	O
the	O
SARS	O
outbreak	O
in	O
2003	O
compared	O
to	O
the	O
corresponding	O
time	O
periods	B-PROC
in	O
2002	O
and	O
2001	O
.	O

NDV	O
has	O
the	O
potential	O
for	O
further	O
development	B-PROC
as	O
a	O
pretested	O
,	O
highly	O
attenuated	O
,	O
intranasal	O
vector	O
to	O
be	O
available	O
for	O
expedited	O
vaccine	O
development	B-PROC
for	O
humans	O
,	O
who	O
generally	O
lack	O
preexisting	O
immunity	B-PROC
against	O
NDV	O
.	O

There	O
was	O
mild	O
inflammation	O
of	O
the	O
hindgut	O
but	O
no	O
evidence	O
of	O
intestinal	O
pathogens	O
or	O
marked	O
inflammation	O
or	O
necrosis	B-PROC
of	O
pancreas	O
,	O
either	O
alone	O
or	O
as	O
part	O
of	O
a	O
multisystemic	O
inflammatory	O
condition	O
.	O

A	O
wider	O
implication	O
is	O
that	O
runting	O
coupled	O
with	O
steatorrhea	O
are	O
phenotypic	O
criteria	O
to	O
suspect	O
pancreatic	O
disease	O
that	O
could	O
be	O
used	O
in	O
the	O
context	O
of	O
a	O
mouse	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
-	O
mutagenesis	B-PROC
program	O
to	O
identify	O
potential	O
mutants	O
with	O
defects	O
in	O
pancreas	B-PROC
development	B-PROC
.	O

TITLE	O
:	O
Argatroban	O
in	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
All	O
plus	O
-	O
strand	O
RNA	O
viruses	O
encode	O
an	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
that	O
functions	O
as	O
the	O
catalytic	O
subunit	O
of	O
the	O
viral	B-PROC
replication	I-PROC
/	O
transcription	B-PROC
complex	O
,	O
directing	O
viral	O
RNA	B-PROC
synthesis	I-PROC
in	O
concert	O
with	O
other	O
viral	O
proteins	O
and	O
,	O
sometimes	O
,	O
host	O
proteins	O
.	O

In	O
this	O
study	O
,	O
using	O
the	O
family	O
prototype	O
equine	O
arteritis	O
virus	O
(	O
EAV	O
),	O
we	O
address	O
the	O
mechanism	O
of	O
initiation	O
of	O
RNA	B-PROC
synthesis	I-PROC
in	O
arteriviruses	O
.	O

The	O
EAV	O
nsp9	O
/	O
RdRp	O
initiates	O
RNA	B-PROC
synthesis	I-PROC
by	O
a	O
de	O
novo	O
mechanism	O
on	O
homopolymeric	O
templates	O
in	O
a	O
template	O
-	O
specific	O
manner	O
.	O

TITLE	O
:	O
The	O
association	O
of	O
RANTES	O
polymorphism	B-PROC
with	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
Hong	O
Kong	O
and	O
Beijing	O
Chinese	O
.	O

However	O
,	O
-	O
28	O
CG	O
(	O
OR	O
=	O
4	O
.	O
27	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
64	O
-	O
11	O
.	O
1	O
)	O
and	O
GG	O
(	O
OR	O
=	O
3	O
.	O
34	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
37	O
-	O
30	O
.	O
7	O
)	O
were	O
associated	O
with	O
admission	O
to	O
intensive	O
care	O
units	O
or	O
death	B-PROC
due	O
to	O
SARS	O
(	O
P	O
=	O
0	O
.	O
011	O
).	O

Data	O
from	O
experimental	O
models	O
of	O
sepsis	O
,	O
ALI	O
,	O
and	O
ARDS	O
indicate	O
that	O
some	O
of	O
these	O
agents	O
improve	O
lung	B-PROC
function	I-PROC
and	O
oxygenation	B-PROC
.	O

Ninety	O
-	O
nine	O
diarrheic	O
and	O
114	O
normal	O
fecal	O
samples	O
from	O
calves	O
in	O
Hokkaido	O
Prefecture	O
and	O
38	O
diarrheic	O
fecal	O
samples	O
from	O
calves	O
in	O
10	O
other	O
prefectures	O
were	O
examined	O
by	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
with	O
primers	O
designed	O
in	O
the	O
spike	O
(	O
S	O
)	O
gene	O
for	O
the	O
presence	O
of	O
BoTV	O
.	O

CONCLUSIONS	O
:	O
The	O
development	B-PROC
of	O
coagulopathy	O
is	O
a	O
frequent	O
complication	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
traumatic	O
brain	O
injury	O
.	O

The	O
E	O
.	O
coli	O
-	O
mycobacterium	O
expression	B-PROC
shuttle	O
plasmid	O
pR	O
-	O
alpha	O
-	O
S1	O
was	O
constructed	O
by	O
inserting	O
the	O
S1	O
gene	O
to	O
the	O
pRR3	O
with	O
human	O
mycobacterium	O
tuberculosis	O
HSP70	O
promoter	O
and	O
a	O
signal	O
peptide	O
.	O

The	O
result	O
indicated	O
that	O
the	O
expressed	B-PROC
product	O
maintain	O
the	O
antigenicity	O
of	O
TGEV	O
as	O
expected	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
simple	O
,	O
sensitive	O
,	O
and	O
quantitative	O
assay	O
to	O
study	O
the	O
membrane	B-PROC
fusion	I-PROC
process	O
by	O
measuring	O
the	O
extracellular	O
activity	O
of	O
SEAP	O
.	O

Severe	O
adverse	O
effects	O
of	O
treatment	O
were	O
observed	O
and	O
varicella	O
zoster	O
virus	B-PROC
infection	I-PROC
was	O
frequent	O
.	O

This	O
beneficial	O
effect	O
of	O
AM	O
on	O
acute	O
lung	O
injury	O
may	O
be	O
mediated	O
by	O
inhibition	B-PROC
of	O
inflammation	O
,	O
hyperpermeability	O
,	O
and	O
alveolar	O
wall	O
cell	O
apoptosis	B-PROC
.	O

Angiotensin	O
II	O
is	O
one	O
key	O
effector	O
peptide	O
of	O
the	O
RAS	O
,	O
inducing	O
vasoconstriction	B-PROC
and	O
exerting	B-PROC
multiple	O
biological	O
functions	O
.	O

Before	O
death	B-PROC
,	O
severe	O
hypotension	O
and	O
bradycardia	O
occurred	O
.	O

The	O
pathogenesis	B-PROC
of	O
lung	O
and	O
organ	O
injury	O
may	O
involve	O
iNOS	O
and	O
NO	O
production	O
.	O

These	O
data	O
indicate	O
that	O
a	O
heterologous	O
adenovirus	O
-	O
based	O
prime	O
-	O
boost	O
vaccine	O
strategy	O
could	O
safely	O
stimulate	O
strong	O
immunity	B-PROC
that	O
may	O
be	O
needed	O
for	O
complete	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
presence	O
of	O
carbohydrate	O
-	O
binding	O
agents	O
strongly	O
inhibited	O
coronaviruses	O
(	O
transmissible	O
gastroenteritis	O
virus	O
,	O
infectious	O
bronchitis	O
virus	O
,	O
feline	O
coronaviruses	O
serotypes	O
I	O
and	O
II	O
,	O
mouse	O
hepatitis	O
virus	O
),	O
arteriviruses	O
(	O
equine	O
arteritis	O
virus	O
and	O
porcine	O
respiratory	O
and	O
reproductive	B-PROC
syndrome	O
virus	O
)	O
and	O
torovirus	O
(	O
equine	O
Berne	O
virus	O
).	O

If	O
this	O
fails	O
,	O
intermittent	O
oral	O
leukotriene	B-PROC
receptor	I-PROC
antagonists	I-PROC
or	O
short	O
courses	O
of	O
very	O
high	O
dose	O
inhaled	B-PROC
corticosteroids	O
could	O
be	O
considered	O
.	O

CONCLUSIONS	O
:	O
Intra	O
-	O
abdominal	O
hypertension	O
induced	O
acute	O
lung	O
injury	O
and	O
MODS	O
with	O
IL	O
-	O
8	O
elevation	O
,	O
even	O
though	O
AD	O
improved	O
hemodynamic	B-PROC
parameters	O
in	O
extensively	O
burned	O
patients	O
.	O

ABSTRACT	O
:	O
Polysomnography	O
findings	O
between	O
matched	O
groups	O
with	O
obstructive	O
sleep	B-PROC
apnea	O
(	O
OSA	O
)	O
and	O
OSA	O
plus	O
obesity	O
-	O
hypoventilation	O
syndrome	O
(	O
OHS	O
)	O
before	O
and	O
after	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
),	O
particularly	O
in	O
the	O
extremely	O
severe	O
obese	O
(	O
body	O
mass	O
index	O
[	O
BMI	O
]	O
>	O
or	O
=	O
50	O
kg	O
/	O
m2	O
),	O
are	O
unclear	O
.	O

The	O
expression	B-PROC
of	O
CD209L	O
was	O
relatively	O
higher	O
in	O
the	O
human	O
lymphatic	O
endothelial	O
cells	O
.	O

The	O
in	O
vitro	O
reconstruction	O
of	O
a	O
step	O
in	O
mitotic	O
regulation	B-PROC
shows	O
how	O
this	O
expression	B-PROC
system	O
can	O
be	O
successfully	O
applied	O
to	O
the	O
detailed	O
analysis	O
of	O
complex	O
metabolic	B-PROC
pathways	B-PROC
.	O

TITLE	O
:	O
Cell	O
entry	O
by	O
enveloped	O
viruses	O
:	O
redox	B-PROC
considerations	O
for	O
HIV	O
and	O
SARS	O
-	O
coronavirus	O
.	O

In	O
addition	O
,	O
to	O
compare	O
and	O
contrast	O
the	O
situation	O
outlined	O
for	O
HIV	O
with	O
an	O
enveloped	O
virus	O
that	O
can	O
fuse	O
with	O
the	O
cell	O
plasma	O
membrane	O
independent	O
of	O
the	O
redox	B-PROC
status	O
of	O
its	O
envelope	O
protein	O
,	O
we	O
review	O
parallel	O
data	O
obtained	O
on	O
SARS	O
coronavirus	O
entry	O
.	O

We	O
investigated	O
the	O
role	O
of	O
extracranial	O
predisposing	O
factors	O
,	O
including	O
hemodynamic	B-PROC
and	O
ventilatory	O
management	O
,	O
as	O
independent	O
predictors	O
of	O
acute	O
lung	O
injury	O
in	O
brain	O
-	O
injured	O
patients	O
.	O

We	O
estimate	O
the	O
effective	O
reproductive	B-PROC
number	O
Rt	O
for	O
the	O
Beijing	O
SARS	O
epidemic	O
,	O
which	O
represents	O
the	O
average	O
number	O
of	O
secondary	O
cases	O
per	O
primary	O
case	O
on	O
each	O
day	O
of	O
the	O
epidemic	O
and	O
is	O
therefore	O
a	O
measure	O
of	O
the	O
underlying	O
transmission	O
dynamics	O
.	O

ICAM3	O
,	O
an	O
intercellular	O
adhesion	O
molecule	O
important	O
for	O
T	B-PROC
cell	I-PROC
activation	I-PROC
,	O
and	O
FCER2	O
(	O
CD23	O
),	O
an	O
immune	B-PROC
response	I-PROC
gene	O
,	O
both	O
located	O
on	O
chromosome	O
19p13	O
.	O
3	O
,	O
were	O
investigated	O
for	O
host	O
genetic	O
susceptibility	O
and	O
association	O
with	O
clinical	O
outcome	O
.	O

Affinity	O
ligand	B-PROC
is	O
the	O
most	O
important	O
factor	O
in	O
affinity	O
chromatography	O
,	O
therefore	O
,	O
the	O
selection	O
and	O
the	O
screening	O
of	O
affinity	O
ligand	B-PROC
become	O
the	O
first	O
issue	O
to	O
be	O
considered	O
when	O
a	O
novel	O
type	O
of	O
affinity	O
packing	O
or	O
a	O
novel	O
system	O
of	O
affinity	O
chromatography	O
needs	O
to	O
be	O
developed	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
SARS	O
-	O
CoV	O
.	O
In	O
previous	O
studies	O
,	O
we	O
showed	O
that	O
a	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
-	O
based	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	O
-	O
S	O
)	O
vaccine	O
could	O
induce	O
strong	O
neutralizing	O
antibody	B-PROC
(	O
Nab	O
)	O
response	O
which	O
might	O
have	O
played	O
a	O
critical	O
role	O
in	O
protecting	O
Chinese	O
rhesus	O
monkeys	O
from	O
the	O
pathogenic	O
viral	O
challenge	O
.	O

Thus	O
,	O
our	O
data	O
provides	O
a	O
promising	O
optimal	O
regimen	O
for	O
vaccine	O
development	B-PROC
in	O
humans	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
generated	O
anti	O
-	O
KC	O
(	O
KC	O
=	O
chemokine	O
(	O
CXC	O
motif	O
)	O
ligand	B-PROC
1	O
(	O
CXCL1	O
))	O
autoantibody	O
:	O
KC	O
immune	O
complexes	O
(	O
KC	O
-	O
functional	O
IL	O
-	O
8	O
)	O
in	O
lungs	O
of	O
mice	O
to	O
develop	O
a	O
mouse	O
model	O
of	O
autoimmune	O
complex	O
-	O
induced	O
lung	O
inflammation	O
.	O

Virus	B-PROC
replication	I-PROC
was	O
monitored	O
by	O
cytopathic	O
effect	O
observation	O
,	O
electron	O
microscopy	O
,	O
indirect	O
immunofluorescence	O
,	O
and	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Contact	O
exposure	O
outside	O
health	O
-	O
care	O
institutions	O
also	O
appeared	O
to	O
carry	O
higher	O
risk	O
of	O
death	B-PROC
.	O

Contact	O
exposure	O
outside	O
health	O
-	O
care	O
institutions	O
also	O
appeared	O
to	O
carry	O
higher	O
risk	O
of	O
death	B-PROC
.	O

These	O
findings	O
demonstrated	O
that	O
the	O
three	O
M	O
-	O
specific	O
siRNAs	O
were	O
able	O
to	O
specifically	O
and	O
effectively	O
inhibit	O
M	O
glycoprotein	O
expression	B-PROC
in	O
cultured	O
cells	O
by	O
blocking	O
the	O
accumulation	O
of	O
mRNA	O
,	O
which	O
provides	O
an	O
approach	O
for	O
studies	O
on	O
the	O
functions	O
of	O
M	O
protein	O
and	O
for	O
the	O
development	B-PROC
of	O
novel	O
prophylactic	O
or	O
therapeutic	O
agents	O
for	O
SCoV	O
infection	O
.	O

ABSTRACT	O
:	O
An	O
incident	O
involving	O
the	O
release	O
of	O
chlorine	O
gas	O
from	O
the	O
pump	O
room	O
at	O
a	O
local	O
swimming	B-PROC
pool	O
resulted	O
in	O
54	O
patients	O
seeking	O
treatment	O
in	O
the	O
emergency	O
departments	O
(	O
EDs	O
)	O
of	O
two	O
local	O
,	O
tertiary	O
-	O
level	O
hospitals	O
in	O
Singapore	O
.	O

Nuclear	B-PROC
import	I-PROC
factors	O
function	O
as	O
key	O
gatekeepers	O
that	O
regulate	O
the	O
transport	B-PROC
of	O
innate	O
immune	O
regulatory	O
cargo	O
to	O
the	O
nucleus	O
of	O
cells	O
to	O
activate	O
the	O
antiviral	B-PROC
response	I-PROC
.	O

Maximal	O
MHC	B-PROC
expression	B-PROC
in	O
both	O
glial	O
cell	O
types	O
correlated	O
with	O
IFN	O
-	O
gamma	O
levels	O
and	O
lymphocyte	O
accumulation	O
.	O

CXCL10	O
-	O
mediated	O
protection	O
within	O
the	O
liver	O
was	O
not	O
dependent	O
on	O
CXC	O
-	O
chemokine	O
receptor	O
2	O
(	O
CXCR2	O
)	O
signaling	B-PROC
as	O
anti	O
-	O
CXCR2	O
treatment	O
of	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
mice	O
did	O
not	O
modulate	O
viral	O
clearance	O
or	O
liver	O
pathology	O
.	O

Identification	O
of	O
type	O
I	O
and	O
type	O
II	O
coronavirus	O
in	O
this	O
subject	O
had	O
been	O
previously	O
confirmed	O
by	O
genotype	O
-	O
specific	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
of	O
the	O
intestinal	O
contents	O
,	O
while	O
only	O
Coronavirus	O
type	O
II	O
was	O
detected	O
in	O
visceral	O
organs	O
.	O

Transplanted	O
EPC	O
may	O
play	O
an	O
important	O
role	O
in	O
reestablishing	O
the	O
endothelial	O
integrity	O
in	O
vessels	O
after	O
severe	O
injury	O
or	O
at	O
inflammatory	O
sites	O
and	O
might	O
further	O
contribute	O
to	O
vascular	O
repair	B-PROC
or	O
wound	B-PROC
healing	I-PROC
processes	O
in	O
severely	O
damaged	O
tissue	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
adaptation	B-PROC
of	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
in	O
a	O
human	O
cell	O
line	O
may	O
be	O
beneficial	O
to	O
understanding	O
the	O
potential	O
mechanisms	O
of	O
coronavirus	O
interspecies	O
infection	O
.	O

These	O
results	O
indicated	O
that	O
the	O
virus	O
adaptation	B-PROC
would	O
probably	O
be	O
determined	O
by	O
host	O
cell	O
modification	O
such	O
as	O
receptor	O
glycosylation	B-PROC
and	O
different	O
receptor	O
utilization	O
instead	O
of	O
viral	O
gene	B-PROC
mutation	I-PROC
.	O

TITLE	O
:	O
Medical	O
referral	O
of	O
patients	O
with	O
acute	O
respiratory	O
failure	O
:	O
lessons	O
learned	B-PROC
from	O
a	O
large	O
outbreak	O
of	O
botulism	O
in	O
northern	O
Thailand	O
.	O

TITLE	O
:	O
Role	O
of	O
endocytosis	B-PROC
and	O
low	O
pH	O
in	O
murine	O
hepatitis	O
virus	O
strain	O
A59	O
cell	O
entry	O
.	O

Here	O
,	O
the	O
entry	O
pathway	B-PROC
of	O
MHV	O
-	O
A59	O
into	O
murine	O
fibroblast	O
cells	O
was	O
studied	O
by	O
independent	O
approaches	O
.	O

Infection	O
of	O
cells	O
assessed	O
by	O
plaque	O
reduction	O
assay	O
was	O
strongly	O
inhibited	O
by	O
lysosomotropic	O
compounds	O
and	O
substances	O
that	O
interfere	O
with	O
clathrin	B-PROC
-	I-PROC
dependent	I-PROC
endocytosis	I-PROC
,	O
suggesting	O
that	O
MHV	O
-	O
A59	O
is	O
taken	O
up	O
via	O
endocytosis	B-PROC
and	O
delivered	O
to	O
acidic	O
endosomal	O
compartments	O
.	O

Fluorescence	O
confocal	O
microscopy	O
of	O
labeled	O
MHV	O
-	O
A59	O
confirmed	O
that	O
virus	O
is	O
taken	O
up	O
via	O
endocytosis	B-PROC
.	O

The	O
highly	O
conserved	O
region	O
at	O
the	O
carboxy	O
terminus	O
of	O
ORF1a	O
is	O
processed	O
by	O
the	O
nsp5	O
proteinase	B-PROC
(	O
Mpro	O
)	O
into	O
mature	O
products	O
,	O
including	O
nsp7	O
,	O
nsp8	O
,	O
nsp9	O
,	O
and	O
nsp10	O
,	O
proteins	O
with	O
predicted	O
or	O
identified	O
activities	O
involved	O
in	O
RNA	B-PROC
synthesis	I-PROC
.	O

Although	O
continuous	O
translation	B-PROC
and	O
proteolytic	B-PROC
processing	I-PROC
of	O
ORF1ab	O
by	O
Mpro	O
is	O
required	O
for	O
replication	O
,	O
it	O
is	O
unknown	O
whether	O
specific	O
cleavage	B-PROC
events	O
within	O
the	O
polyprotein	O
are	O
dispensable	O
.	O

Disruption	O
of	O
the	O
cleavage	B-PROC
sites	O
was	O
lethal	O
with	O
the	O
exception	O
of	O
that	O
of	O
the	O
nsp9	O
-	O
nsp10	O
site	O
,	O
which	O
resulted	O
in	O
a	O
mutant	O
virus	O
with	O
attenuated	O
replication	O
.	O

Similarly	O
,	O
normal	O
levels	O
of	O
dystrophin	O
expression	B-PROC
were	O
restored	O
in	O
the	O
diaphragms	O
of	O
mdx	O
mice	O
,	O
with	O
treatment	O
starting	O
at	O
the	O
neonatal	O
stage	O
,	O
and	O
protein	O
was	O
still	O
detecTable	O
22	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
an	O
(	O
R	O
-	O
Ahx	O
-	O
R	O
)(	O
4	O
)	O
AhxB	O
-	O
PMO	O
conjugate	O
.	O

While	O
leptospirosis	O
is	O
rare	O
in	O
pregnancy	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
acute	O
infection	O
without	O
fever	B-PROC
mimicking	O
the	O
clinical	O
pattern	O
of	O
HELLP	O
syndrome	O
or	O
AFLP	O

High	O
titer	O
antibody	B-PROC
was	O
detected	O
in	O
the	O
serum	O
of	O
immunized	O
Balb	O
/	O
c	O
mice	O
,	O
and	O
mice	O
immunized	O
with	O
S1	O
protein	O
produced	O
high	O
titer	O
IgG1	O
,	O
IgG2a	O
,	O
IgG2b	O
and	O
IgG3	O
,	O
while	O
those	O
immunized	O
with	O
S2	O
protein	O
produced	O
high	O
titer	O
IgG1	O
,	O
IgG2a	O
,	O
but	O
lower	O
titer	O
IgG2b	O
and	O
IgG3	O
.	O

Other	O
recorded	O
variables	O
included	O
age	O
,	O
sex	O
,	O
biochemical	O
indicators	O
,	O
blood	B-PROC
gas	I-PROC
analysis	O
,	O
length	O
of	O
stay	O
in	O
ICU	O
,	O
length	O
of	O
ventilation	O
,	O
presence	O
or	O
absence	O
of	O
tracheostomy	O
,	O
ventilation	O
variables	O
,	O
elective	O
operation	O
or	O
emergency	O
operation	O
.	O

The	O
main	O
cause	O
of	O
death	B-PROC
was	O
multiple	O
organ	O
failure	O
.	O

ABSTRACT	O
:	O
To	O
clarify	O
the	O
molecular	O
basis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
adaptation	B-PROC
to	O
different	O
host	O
species	O
,	O
we	O
serially	O
passaged	O
SARS	O
-	O
CoV	O
in	O
rat	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
Epitopes	O
often	O
require	O
co	O
-	O
delivery	O
with	O
adjuvant	O
and	O
targeting	B-PROC
proteins	O
to	O
enable	O
recognition	O
by	O
the	O
immune	O
system	O
,	O
and	O
this	O
approach	O
may	O
also	O
increase	O
the	O
efficacy	O
of	O
the	O
antigen	O
.	O

The	O
derivation	O
depends	O
on	O
an	O
explicit	O
formula	O
for	O
the	O
basic	O
reproduction	B-PROC
number	O
of	O
a	O
general	O
class	O
of	O
disease	O
transmission	O
models	O
,	O
which	O
is	O
extended	O
to	O
calculate	O
the	O
basic	O
reproduction	B-PROC
number	O
in	O
models	O
with	O
vertical	O
transmission	O
.	O

Human	O
interleukin	O
8	O
and	O
its	O
mouse	O
functional	O
counterpart	O
,	O
CXCL2	O
,	O
are	O
early	O
-	O
expressed	B-PROC
chemokines	O
.	O

Here	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
and	O
MHV	O
induce	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
Cxcl2	O
mRNA	B-PROC
transcription	B-PROC
during	O
infection	O
in	O
vitro	O
.	O

Our	O
results	O
demonstrate	O
that	O
expression	B-PROC
of	O
CoV	O
spike	O
proteins	O
induces	O
ER	O
stress	O
,	O
which	O
could	O
subsequently	O
trigger	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

TITLE	O
:	O
Impaired	O
heart	B-PROC
contractility	I-PROC
in	O
Apelin	O
gene	O
-	O
deficient	O
mice	O
associated	O
with	O
aging	B-PROC
and	O
pressure	O
overload	O
.	O

TITLE	O
:	O
Immune	B-PROC
responses	I-PROC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
induced	O
by	O
virus	O
-	O
like	O
particles	O
in	O
mice	O
.	O

Electron	O
microscope	O
analysis	O
demonstrated	O
the	O
formation	B-PROC
of	O
VLPs	O
in	O
vAcME	O
and	O
vAcS	O
coinfected	O
insect	O
cells	O
.	O

Mice	O
immunized	O
four	O
times	O
with	O
VLPs	O
developed	O
high	O
antibody	B-PROC
titres	O
against	O
SARS	O
CoV	O
.	O
In	O
addition	O
,	O
VLPs	O
elicited	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immunity	I-PROC
as	O
demonstrated	O
by	O
enhanced	O
interferon	O
-	O
gamma	O
and	O
interleukin	B-PROC
-	I-PROC
4	I-PROC
production	I-PROC
.	O

These	O
cytokines	O
induce	O
fever	B-PROC
,	O
leucocytosis	O
and	O
release	O
of	O
serum	O
acute	O
phase	O
proteins	O
(	O
APPs	O
).	O

AGP	O
plays	O
an	O
important	O
role	O
in	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
may	O
also	O
be	O
useful	O
also	O
in	O
studies	O
of	O
FIP	O
pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
The	O
proteins	O
encoded	O
by	O
gene	O
7	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
have	O
been	O
demonstrated	O
to	O
have	O
proapoptotic	O
activity	O
when	O
expressed	B-PROC
from	O
cDNA	O
but	O
appear	O
to	O
be	O
dispensable	O
for	O
virus	B-PROC
replication	I-PROC
.	O

Recombinant	O
SARS	O
-	O
CoVs	O
bearing	O
deletions	O
in	O
gene	O
7	O
were	O
used	O
to	O
assess	O
the	O
contribution	O
of	O
gene	O
7	O
to	O
virus	B-PROC
replication	I-PROC
and	O
apoptosis	B-PROC
in	O
several	O
transformed	O
cell	O
lines	O
,	O
as	O
well	O
as	O
to	O
replication	O
and	O
pathogenesis	B-PROC
in	O
golden	O
Syrian	O
hamsters	O
.	O

However	O
,	O
viruses	O
with	O
gene	O
7	O
disruptions	O
were	O
not	O
as	O
efficient	O
as	O
wild	O
-	O
type	O
virus	O
in	O
inducing	O
DNA	B-PROC
fragmentation	I-PROC
,	O
as	O
judged	O
by	O
terminal	O
deoxynucleotidyltransferase	O
-	O
mediated	O
dUTP	O
-	O
biotin	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
staining	O
,	O
indicating	O
that	O
the	O
gene	O
7	O
products	O
do	O
contribute	O
to	O
virus	O
-	O
induced	O
apoptosis	B-PROC
.	O

As	O
opposed	O
to	O
many	O
in	O
vitro	O
experiments	O
,	O
SARS	O
-	O
CoV	O
induced	O
a	O
wide	O
range	O
of	O
type	O
I	O
interferons	O
(	O
IFNs	O
)	O
and	O
nuclear	B-PROC
translocation	B-PROC
of	O
phosphorylated	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-PROC
1	O
in	O
the	O
lungs	O
of	O
macaques	O
.	O

The	O
tumors	O
were	O
treated	O
with	O
pancreaticoduodenectomy	O
,	O
but	O
the	O
patient	O
died	B-PROC
2	O
weeks	O
after	O
the	O
operation	O
as	O
a	O
result	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
molecular	O
mechanism	O
of	O
SARS	O
pathogenesis	B-PROC
remains	O
elusive	O
.	O

Expression	B-PROC
of	O
M	O
suppressed	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
induced	O
NF	B-PROC
-	I-PROC
kappaB	I-PROC
activation	I-PROC
using	O
a	O
luciferase	O
reporter	O
assay	O
.	O

Further	O
investigation	O
showed	O
M	O
protein	O
suppressed	O
Cox	O
-	O
2	O
expression	B-PROC
using	O
a	O
luciferase	O
reporter	O
gene	O
assay	O
,	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
.	O

The	O
LPV	O
/	O
RTV	O
treatment	O
also	O
inhibited	O
the	O
formation	B-PROC
of	O
SN38	O
glucuronide	O
(	O
SN38G	O
),	O
as	O
shown	O
by	O
the	O
36	O
%	O
decrease	O
in	O
the	O
SN38G	O
/	O
SN38	O
AUCs	O
ratio	O
(	O
5	O
.	O
9	O
+/-	O
1	O
.	O
6	O
vs	O
9	O
.	O
2	O
+/-	O
2	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
consistent	O
with	O
UGT1A1	O
inhibition	B-PROC
by	O
LPV	O
/	O
RTV	O
.	O

However	O
,	O
mutant	O
virus	B-PROC
replication	I-PROC
was	O
strongly	O
attenuated	O
in	O
cells	O
with	O
an	O
intact	O
IFN	O
response	O
.	O

As	O
expected	O
,	O
glycans	O
on	O
spike	O
(	O
S	O
)	O
glycoprotein	O
are	O
important	O
for	O
DC	O
/	O
L	O
-	O
SIGN	O
-	O
mediated	O
virus	B-PROC
infection	I-PROC
.	O

Amino	O
acid	O
sequence	O
analyses	O
of	O
S	O
proteins	O
encoded	O
by	O
viruses	O
isolated	O
from	O
animals	O
and	O
humans	O
suggest	O
that	O
glycosylation	B-PROC
sites	O
N227	O
and	O
N699	O
have	O
facilitated	O
zoonotic	O
transmission	O
.	O

Many	O
prior	O
studies	O
have	O
suggested	O
that	O
the	O
majority	O
of	O
deaths	B-PROC
in	O
severe	O
acute	O
pancreatitis	O
occur	O
in	O
the	O
late	O
phase	O
of	O
the	O
disease	O
as	O
a	O
result	O
of	O
pancreatic	O
sepsis	O
.	O

While	O
gallstones	O
represent	O
the	O
main	O
etiologic	O
factor	O
in	O
most	O
larger	O
clinical	O
series	O
,	O
biliary	O
etiology	O
seems	O
to	O
play	O
only	O
a	O
minor	O
role	O
in	O
outpatient	O
deaths	B-PROC
undergoing	O
medicolegal	O
autopsies	O
.	O

The	O
initial	O
examination	O
noted	O
neurological	O
disorders	O
in	O
52	O
%	O
of	O
cases	O
and	O
hemodynamic	B-PROC
disorders	O
in	O
8	O
%	O
of	O
cases	O
.	O

There	O
were	O
2	O
deaths	B-PROC
.	O

We	O
propose	O
that	O
the	O
severe	O
diarrhea	O
exhibited	O
in	O
PEDV	O
and	O
PGAR	O
co	O
-	O
infected	O
piglets	O
may	O
be	O
more	O
associated	O
with	O
the	O
immunity	B-PROC
level	O
of	O
the	O
host	O
rather	O
than	O
to	O
any	O
synergistic	O
effect	O
of	O
PGAR	O
on	O
PEDV	O
enteritis	O
.	O

ABSTRACT	O
:	O
A	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
based	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
(	O
RFLP	O
)	O
analysis	O
based	O
on	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
was	O
developed	O
to	O
differentiate	O
between	O
field	O
isolates	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
and	O
a	O
vaccine	O
strain	O
,	O
J	O
-	O
vac	O
.	O

nsp3a	O
exhibits	O
a	O
ubiquitin	B-PROC
-	O
like	O
globular	O
fold	O
of	O
residues	O
1	O
to	O
112	O
and	O
a	O
flexibly	O
extended	O
glutamic	O
acid	O
-	O
rich	O
domain	O
of	O
residues	O
113	O
to	O
183	O
.	O

We	O
included	O
systematic	O
reviews	O
/	O
meta	O
-	O
analyses	O
,	O
randomized	O
and	O
non	O
-	O
randomized	O
comparative	O
trials	O
,	O
prospective	O
cohort	O
,	O
and	O
case	O
-	O
control	O
studies	O
on	O
the	O
effects	O
of	O
breastfeeding	B-PROC
and	O
relevant	O
outcomes	O
published	O
in	O
the	O
English	O
language	O
.	O

Included	O
studies	O
must	O
have	O
a	O
comparative	O
arm	O
of	O
formula	O
feeding	O
or	O
different	O
durations	O
of	O
breastfeeding	B-PROC
.	O

Early	O
cessation	O
of	O
breastfeeding	B-PROC
or	O
not	O
breastfeeding	B-PROC
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
maternal	O
postpartum	O
depression	O
.	O

In	O
a	O
multivariate	O
model	O
,	O
inbreeding	B-PROC
coefficient	O
strongly	O
predicted	O
mortality	O
,	O
with	O
closely	O
inbred	O
mole	O
-	O
rats	O
(	O
F	O
>	O
or	O
=	O
0	O
.	O
25	O
)	O
over	O
300	O
%	O
more	O
likely	O
to	O
die	O
than	O
their	O
outbred	O
counterparts	O
.	O

TITLE	O
:	O
[	O
Changes	O
in	O
pulmonary	B-PROC
function	I-PROC
in	O
SARS	O
patients	O
during	O
the	O
three	O
-	O
year	O
convalescent	O
period	O
].	O

RESULTS	O
:	O
Compared	O
with	O
the	O
healthy	O
controls	O
,	O
there	O
were	O
significant	O
decrease	O
in	O
forced	B-PROC
vital	I-PROC
capacity	I-PROC
(	O
FVC	B-PROC
),	O
vital	B-PROC
capacity	I-PROC
(	O
VC	O
),	O
one	O
second	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
(	O
FEV1	O
),	O
25	O
%-	O
75	O
%	O
forced	O
expiratory	B-PROC
flow	O
(	O
25	O
%-	O
75	O
%	O
FEF	O
)	O
of	O
SARS	O
patients	O
within	O
three	O
years	O
after	O
their	O
discharge	O
from	O
hospital	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Anergy	B-PROC
to	O
these	O
stimuli	O
was	O
observed	O
on	O
four	O
occasions	O
,	O
in	O
particular	O
during	O
acute	O
disease	O
.	O

Primary	O
cultures	O
of	O
alveolar	O
epithelial	O
cells	O
are	O
an	O
important	O
model	O
for	O
the	O
early	O
events	O
in	O
viral	B-PROC
infection	I-PROC
that	O
lead	O
to	O
pulmonary	O
inflammation	O
.	O

Replacement	O
of	O
conserved	O
MHV	O
ExoN	O
active	O
-	O
site	O
residues	O
with	O
alanines	O
resulted	O
in	O
viable	O
mutant	O
viruses	O
with	O
growth	B-PROC
and	O
RNA	B-PROC
synthesis	I-PROC
defects	O
that	O
during	O
passage	O
accumulated	O
15	O
-	O
fold	O
more	O
mutations	O
than	O
wild	O
-	O
type	O
virus	O
without	O
changes	O
in	O
growth	B-PROC
fitness	O
.	O

On	O
the	O
35th	O
month	O
after	O
the	O
onset	O
,	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
were	O
still	O
having	O
the	O
neutralizing	O
antibody	B-PROC
level	O
of	O
above	O
1	O
:	O
36	O
,	O
but	O
the	O
neutralizing	O
antibody	B-PROC
level	O
in	O
another	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
had	O
decreased	O
to	O
as	O
low	O
as	O
1	O
:	O
10	O
,	O
when	O
the	O
cut	O
-	O
off	O
level	O
was	O
set	O
as	O
1	O
:	O
8	O
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
the	O
study	O
indicated	O
that	O
the	O
neutralizing	O
antibody	B-PROC
of	O
SARS	O
cases	O
could	O
last	O
for	O
at	O
least	O
three	O
years	O
,	O
but	O
the	O
sera	O
specific	O
antibody	B-PROC
in	O
SARS	O
cases	O
decreased	O
gradually	O
when	O
time	O
went	O
by	O
.	O

A	O
subtotal	O
colectomy	O
with	O
Hartmann	O
'	O
s	O
procedure	O
was	O
performed	O
,	O
but	O
the	O
patient	O
died	B-PROC
13	O
days	O
later	O
of	O
a	O
multiple	O
organ	O
failure	O
.	O

TITLE	O
:	O
Structure	O
-	O
based	O
design	O
,	O
synthesis	B-PROC
,	O
and	O
biological	O
evaluation	O
of	O
peptidomimetic	O
SARS	O
-	O
CoV	O
3CLpro	O
inhibitors	O
.	O

ABSTRACT	O
:	O
Structure	O
-	O
based	O
design	O
,	O
synthesis	B-PROC
,	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
peptidomimetic	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
chymotrypsin	O
-	O
like	O
protease	B-PROC
inhibitors	I-PROC
are	O
described	O
.	O

Incorporation	O
of	O
Boc	O
-	O
Ser	O
as	O
the	O
P	O
(	O
4	O
)-	O
ligand	B-PROC
resulted	O
in	O
enhanced	O
SARS	O
-	O
CoV	O
3CLpro	O
inhibitory	O
activity	O
.	O

TITLE	O
:	O
Genetic	O
analysis	O
of	O
Murine	O
hepatitis	O
virus	O
nsp4	O
in	O
virus	B-PROC
replication	I-PROC
.	O

nsp4	O
contains	O
four	O
predicted	O
transmembrane	O
-	O
spanning	O
regions	O
(	O
TM1	O
,	O
-	O
2	O
,	O
-	O
3	O
,	O
and	O
-	O
4	O
),	O
demonstrates	O
characteristics	O
of	O
an	O
integral	O
membrane	O
protein	O
,	O
and	O
is	O
thought	O
to	O
be	O
essential	O
for	O
the	O
formation	B-PROC
and	O
function	O
of	O
viral	B-PROC
replication	I-PROC
complexes	O
on	O
cellular	O
membranes	O
.	O

ABSTRACT	O
:	O
To	O
retrospectively	O
evaluate	O
the	O
efficacy	O
of	O
total	O
lymphoid	O
irradiation	O
(	O
TLI	O
)-	O
based	O
reconditioning	O
regimens	O
in	O
patients	O
with	O
graft	O
failure	O
or	O
graft	B-PROC
rejection	I-PROC
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

Differences	O
in	O
viral	O
structure	O
and	O
clinical	O
outcome	O
prompted	O
us	O
to	O
postulate	O
that	O
innate	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
would	O
be	O
markedly	O
different	O
following	O
rotavirus	O
and	O
coronavirus	O
infections	O
.	O

Both	O
viruses	O
also	O
downregulated	O
IFN	O
-	O
and	O
pro	O
-	O
inflammatory	O
cytokine	O
-	O
associated	O
pathways	B-PROC
.	O

All	O
of	O
these	O
results	O
together	O
suggested	O
either	O
that	O
very	O
early	O
events	O
of	O
host	O
responses	O
at	O
18	O
h	O
post	O
-	O
infection	O
were	O
being	O
observed	O
,	O
or	O
that	O
both	O
viruses	O
have	O
unique	O
effective	O
strategies	O
to	O
evade	O
host	O
immune	B-PROC
responses	I-PROC
.	O

The	O
airway	O
epithelium	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
many	O
lung	O
diseases	O
,	O
but	O
its	O
role	O
in	O
ricin	O
intoxication	O
has	O
not	O
been	O
elucidated	O
.	O

Among	O
the	O
genes	O
upregulated	O
by	O
ricin	O
and	O
identified	O
by	O
microarray	O
analysis	O
were	O
those	O
associated	O
with	O
transcription	B-PROC
,	O
nucleosome	B-PROC
assembly	I-PROC
,	O
inflammation	O
,	O
and	O
response	B-PROC
to	I-PROC
stress	I-PROC
.	O

Sequence	O
analysis	O
of	O
the	O
promoters	O
of	O
these	O
genes	O
identified	O
NF	O
-	O
kappaB	O
as	O
one	O
of	O
the	O
transcription	B-PROC
factors	O
whose	O
binding	O
sites	O
were	O
overrepresented	O
.	O

To	O
date	O
,	O
RNAi	B-PROC
has	O
been	O
extensively	O
used	O
as	O
a	O
novel	O
and	O
effective	O
tool	O
for	O
functional	O
genomic	O
studies	O
,	O
and	O
has	O
displayed	O
great	O
potential	O
in	O
treating	O
human	O
diseases	O
,	O
including	O
human	O
genetic	O
and	O
acquired	O
disorders	O
such	O
as	O
cancer	O
and	O
viral	B-PROC
infections	I-PROC
.	O

TITLE	O
:	O
High	O
-	O
cell	O
-	O
passage	O
canine	O
coronavirus	O
vaccine	O
providing	O
sterilising	O
immunity	B-PROC
.	O

Findings	O
of	O
this	O
study	O
suggest	O
that	O
older	O
adults	O
may	O
be	O
better	O
at	O
emotional	O
regulation	B-PROC
than	O
are	O
their	O
younger	O
counterparts	O
,	O
they	O
react	O
to	O
a	O
crisis	O
with	O
less	O
anger	O
and	O
are	O
better	O
able	O
to	O
adapt	O
their	O
coping	O
strategies	O
to	O
the	O
changing	O
environment	O
.	O

Here	O
we	O
describe	O
a	O
rapid	O
and	O
sensitive	O
genotyping	O
assay	O
and	O
microarray	O
for	O
URI	O
identification	O
using	O
standard	O
amplification	O
and	O
hybridization	B-PROC
techniques	O
,	O
with	O
electrochemical	O
detection	O
(	O
ECD	O
)	O
on	O
a	O
semiconductor	O
-	O
based	O
oligonucleotide	O
microarray	O
.	O

Cells	O
infected	O
with	O
mNsp15	O
mutant	O
viruses	O
accumulated	O
lesser	O
amounts	O
of	O
plus	O
-	O
and	O
minus	O
-	O
sense	B-PROC
subgenomic	O
RNAs	O
and	O
spike	O
protein	O
than	O
WT	O
virus	O
.	O

The	O
causative	O
antibody	B-PROC
is	O
of	O
the	O
IgG	O
immunoglobulin	B-PROC
class	O
and	O
is	O
a	O
biphasic	O
hemolysin	O
that	O
is	O
demonstrated	O
by	O
incubation	O
in	O
the	O
cold	B-PROC
followed	O
by	O
incubation	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
complement	O
.	O

The	O
secretion	B-PROC
level	O
of	O
IFN	O
-	O
gamma	O
was	O
much	O
higher	O
than	O
that	O
of	O
IL	O
-	O
4	O
in	O
vAc	O
-	O
N	O
or	O
vAc	O
-	O
S	O
immunized	O
groups	O
,	O
suggesting	O
a	O
strong	O
Th1	O
bias	O
towards	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
.	O

Swaddling	O
immediately	O
after	O
birth	B-PROC
can	O
cause	O
delayed	O
postnatal	O
weight	O
gain	O
under	O
certain	O
conditions	O
,	O
but	O
does	O
not	O
seem	O
to	O
influence	O
breastfeeding	B-PROC
parameters	O
.	O

These	O
data	O
directly	O
demonstrate	O
a	O
critical	O
role	O
for	O
antiviral	O
antibody	B-PROC
in	O
protecting	O
from	O
the	O
selective	O
outgrowth	O
of	O
CTL	O
escape	O
variant	O
viruses	O
.	O

The	O
prevalence	O
of	O
the	O
CD14	O
-	O
159CC	O
polymorphism	B-PROC
was	O
significantly	O
higher	O
in	O
the	O
patients	O
with	O
severe	O
SARS	O
than	O
in	O
the	O
those	O
with	O
mild	O
SARS	O
or	O
controls	O
(	O
31	O
%	O
versus	O
15	O
%	O
[	O
mild	O
SARS	O
]	O
or	O
20	O
%	O
[	O
controls	O
];	O
mild	O
SARS	O
:	O
P	O
=	O
0	O
.	O
029	O
;	O
odds	O
ratio	O
,	O
2	O
.	O
74	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
15	O
to	O
6	O
.	O
57	O
;	O
controls	O
,	O
P	O
=	O
0	O
.	O
04	O
;	O
odds	O
ratio	O
,	O
2	O
.	O
41	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
05	O
to	O
5	O
.	O
54	O
),	O
and	O
both	O
CD14	O
-	O
159CC	O
and	O
FcgammaRIIA	O
-	O
RR131	O
are	O
risk	O
genotypes	O
for	O
severe	O
SARS	O
-	O
CoV	O
infection	O
.	O

Virus	O
isolation	O
,	O
hemagglutination	B-PROC
and	O
receptor	O
-	O
destroying	O
enzyme	O
activity	O
showed	O
that	O
the	O
buffalo	O
coronavirus	O
(	O
BuCoV	O
)	O
is	O
closely	O
related	O
to	O
BCoV	O
but	O
possesses	O
some	O
different	O
biological	O
properties	O
.	O

Through	O
targeted	B-PROC
recombination	B-PROC
and	O
reverse	O
genetic	O
manipulation	O
,	O
studies	O
of	O
infection	O
with	O
MHV	O
-	O
JHM	O
variants	O
have	O
identified	O
phenotypic	O
differences	O
and	O
examined	O
the	O
effects	O
of	O
these	O
differences	O
on	O
viral	O
pathogenesis	B-PROC
and	O
anti	O
-	O
viral	O
host	O
immune	B-PROC
responses	I-PROC
.	O

The	O
univariate	O
analysis	O
and	O
multivariate	O
analysis	O
demonstrated	O
that	O
the	O
clinical	O
conditions	O
such	O
as	O
elder	O
age	O
,	O
shock	O
,	O
dyspnea	O
,	O
abnormal	O
arterial	O
blood	B-PROC
gas	I-PROC
,	O
hemopneumothorax	O
,	O
pulmonary	O
contusion	O
,	O
flail	O
chest	O
,	O
coexisting	O
pulmonary	O
diseases	O
,	O
multiple	O
abdominal	O
injury	O
and	O
high	O
ISS	O
score	O
were	O
the	O
independent	O
high	O
risk	O
factors	O
related	O
to	O
ARDS	O
.	O

We	O
have	O
cloned	O
and	O
expressed	B-PROC
the	O
nsp14	O
protein	O
in	O
Escherichia	O
coli	O
,	O
and	O
characterized	O
the	O
nature	O
and	O
the	O
role	O
(	O
s	O
)	O
of	O
the	O
metal	O
ions	O
in	O
the	O
reaction	O
chemistry	O
.	O

We	O
propose	O
that	O
the	O
conformational	B-PROC
change	I-PROC
induced	O
by	O
metal	O
ions	O
may	O
be	O
a	O
prerequisite	O
for	O
catalytic	O
activity	O
by	O
correctly	O
positioning	O
the	O
side	O
chains	O
of	O
the	O
residues	O
located	O
in	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

Most	O
importantly	O
,	O
our	O
results	O
provide	O
the	O
structural	O
basis	O
for	O
rational	O
design	O
of	O
wide	O
-	O
spectrum	O
antiviral	O
drugs	O
targeting	B-PROC
the	O
chymotrypsin	O
-	O
like	O
cysteine	O
proteinases	O
from	O
coronaviruses	O
and	O
picornaviruses	O
.	O

The	O
virtue	O
ethics	O
movement	B-PROC
stresses	O
the	O
need	O
to	O
consider	O
not	O
only	O
rules	O
and	O
outcomes	O
but	O
also	O
the	O
character	O
of	O
the	O
individual	O
(	O
s	O
)	O
involved	O
.	O

TITLE	O
:	O
[	O
Influenza	O
type	O
A	O
(	O
H5N1	O
)	O
virus	B-PROC
infection	I-PROC
].	O

There	O
is	O
no	O
evidence	O
that	O
people	O
have	O
been	O
infected	O
with	O
bird	O
flu	O
by	O
eating	B-PROC
safely	O
handled	O
and	O
properly	O
cooked	O
poultry	O
.	O

After	O
a	O
mean	O
incubation	O
period	O
of	O
2	O
-	O
5	O
days	O
,	O
infection	O
onsets	O
with	O
high	O
fever	B-PROC
,	O
lower	O
respiratory	O
tract	O
symptoms	O
and	O
diarrhea	O
.	O

TITLE	O
:	O
Maturation	B-PROC
and	O
localization	B-PROC
of	O
macrophages	O
and	O
microglia	O
during	O
infection	O
with	O
a	O
neurotropic	O
murine	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Several	O
studies	O
have	O
implicated	O
the	O
CXCL2	O
chemokine	O
as	O
a	O
mediator	O
in	O
the	O
development	B-PROC
of	O
sepsis	O
.	O

These	O
results	O
are	O
discussed	O
with	O
respect	O
to	O
the	O
possible	O
roles	O
of	O
the	O
3a	O
protein	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
.	O

Acrosome	O
damage	O
was	O
increased	O
in	O
vaccinated	O
cockerels	O
in	O
week	O
22	O
,	O
and	O
decreased	O
in	O
weeks	O
25	O
and	O
27	O
when	O
compared	O
to	O
controls	O
,	O
which	O
correlate	O
to	O
the	O
period	O
of	O
epididymal	O
stone	O
development	B-PROC
.	O

Furthermore	O
,	O
our	O
results	O
show	O
that	O
receptor	O
binding	O
and	O
subsequent	O
membrane	B-PROC
fusion	I-PROC
are	O
distinct	O
steps	O
,	O
and	O
that	O
each	O
spike	O
can	O
bind	O
up	O
to	O
three	O
ACE2	O
molecules	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	O
provides	O
an	O
ideal	O
model	O
system	O
to	O
study	O
receptor	O
binding	O
and	O
membrane	B-PROC
fusion	I-PROC
in	O
the	O
native	O
state	O
,	O
employing	O
cryo	O
-	O
electron	O
microscopy	O
and	O
single	O
-	O
particle	O
image	O
analysis	O
.	O

ABSTRACT	O
:	O
Virus	B-PROC
infection	I-PROC
in	O
vitro	O
can	O
either	O
result	O
in	O
a	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
or	O
proceed	O
without	O
visible	O
changes	O
in	O
infected	O
cells	O
(	O
noncytopathic	O
infection	O
).	O

In	O
contrast	O
,	O
using	O
quantitative	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
and	O
metabolic	B-PROC
labeling	O
of	O
RNA	O
,	O
we	O
found	O
that	O
the	O
rate	O
of	O
viral	O
RNA	O
amplification	O
in	O
NIH	O
3T3	O
cells	O
was	O
lower	O
than	O
the	O
rate	O
in	O
cells	O
in	O
which	O
MHV	O
induces	O
a	O
CPE	O
.	O

The	O
rate	O
of	O
cellular	O
RNA	B-PROC
synthesis	I-PROC
in	O
contact	O
-	O
inhibited	O
confluent	O
NIH	O
3T3	O
cells	O
was	O
also	O
lower	O
than	O
in	O
cells	O
permissive	O
to	O
cytopathic	O
MHV	O
infection	O
.	O

Transfer	O
of	O
Drak2	O
(-/-)	O
memory	B-PROC
T	O
cells	O
into	O
Rag1	O
(-/-)	O
mice	O
infected	O
intracerebrally	O
with	O
MHV	O
resulted	O
in	O
accelerated	O
clearance	O
of	O
virus	O
from	O
the	O
brain	O
.	O

Thus	O
,	O
DRAK2	O
may	O
be	O
a	O
novel	O
target	O
for	O
stimulating	O
protective	O
immunity	B-PROC
to	O
viral	O
pathogens	O
.	O

Our	O
results	O
demonstrated	O
that	O
this	O
DNAzyme	O
could	O
efficiently	O
cleave	O
the	O
SARS	O
-	O
CoV	O
RNA	O
substrate	O
in	O
vitro	O
and	O
inhibit	O
the	O
expression	B-PROC
of	O
the	O
SARS	O
-	O
CoV	O
5	O
'	O
UTR	O
-	O
eGFP	O
fusion	O
RNA	O
in	O
mammalian	O
cells	O
.	O

This	O
work	O
presents	O
a	O
model	O
system	O
to	O
rapidly	O
screen	O
effective	O
DNAzymes	O
targeting	B-PROC
SARS	O
and	O
provides	O
a	O
basis	O
for	O
potential	O
therapeutic	O
use	O
of	O
DNA	O
enzymes	O
to	O
combat	O
the	O
SARS	O
infection	O
.	O

Group	O
1	O
showed	O
significantly	O
higher	O
oxygenation	B-PROC
than	O
Group	O
2	O
,	O
and	O
the	O
same	O
oxygenation	B-PROC
with	O
significantly	O
higher	O
mean	O
blood	B-PROC
pressure	I-PROC
compared	O
to	O
Group	O
3	O
.	O

Adequate	O
CNEP	O
combined	O
with	O
HFO	O
improves	O
oxygenation	B-PROC
with	O
less	O
impact	O
on	O
blood	B-PROC
pressure	I-PROC
than	O
high	O
-	O
frequency	O
oscillation	O
alone	O
in	O
an	O
animal	O
model	O
of	O
respiratory	O
failure	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
decrease	O
of	O
Na	O
,	O
K	O
-	O
ATPase	O
function	O
seen	O
during	O
lung	O
injury	O
is	O
due	O
to	O
its	O
endocytosis	B-PROC
from	O
the	O
cell	O
plasma	O
membrane	O
into	O
intracellular	O
pools	O
.	O

These	O
mice	O
will	O
be	O
valuable	O
for	O
testing	O
potential	O
vaccine	O
and	O
antiviral	O
drug	O
therapies	O
and	O
for	O
furthering	O
our	O
understanding	O
of	O
SARS	O
pathogenesis	B-PROC
.	O

In	O
an	O
effort	B-PROC
to	O
characterize	O
molecular	O
components	O
of	O
the	O
virus	O
that	O
are	O
absent	O
in	O
other	O
coronaviruses	O
,	O
all	O
of	O
which	O
are	O
considerably	O
less	O
pathogenic	O
for	O
humans	O
,	O
we	O
recombinantly	O
produced	O
the	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
within	O
non	O
-	O
structural	O
protein	O
3	O
(	O
Nsp3	O
)	O
of	O
SARS	O
-	O
CoV	O
and	O
characterized	O
its	O
nucleic	O
-	O
acid	O
binding	O
properties	O
.	O

Finally	O
,	O
two	O
patients	O
deceased	B-PROC
from	O
an	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
due	O
to	O
inadequate	O
radiation	O
therapy	O
planning	O
.	O

The	O
complex	O
structures	O
reveal	O
two	O
major	O
inhibition	B-PROC
modes	O
:	O
Hg	O
(	O
2	O
+)-	O
PMA	O
is	O
coordinated	O
to	O
C	O
(	O
44	O
),	O
M	O
(	O
49	O
)	O
and	O
Y	O
(	O
54	O
)	O
with	O
a	O
square	O
planar	O
geometry	O
at	O
the	O
S3	O
pocket	O
,	O
whereas	O
each	O
Zn	O
(	O
2	O
+)	O
of	O
the	O
four	O
zinc	O
-	O
inhibitors	O
is	O
tetrahedrally	O
coordinated	O
to	O
the	O
H	O
(	O
41	O
)-	O
C	O
(	O
145	O
)	O
catalytic	O
dyad	O
.	O

TITLE	O
:	O
Molecular	O
mechanisms	O
of	O
primary	O
and	O
secondary	O
mucosal	B-PROC
immunity	I-PROC
using	O
avian	O
infectious	O
bronchitis	O
virus	O
as	O
a	O
model	O
system	O
.	O

Probably	O
because	O
of	O
their	O
particular	O
immune	O
system	O
,	O
bats	O
can	O
be	O
considered	O
an	O
important	O
reservoir	O
for	O
new	O
emerging	O
viral	B-PROC
diseases	I-PROC
like	O
SARS	O
-	O
Coronavirus	O
,	O
Marburg	O
fever	B-PROC
,	O
Ebola	O
fever	B-PROC
and	O
Nipah	O
virus	O
encephalitis	O
.	O

Z	O
gene	O
was	O
successfully	O
designed	O
and	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
).	O

Group	O
B	O
infants	O
(	O
n	O
=	O
33	O
)	O
did	O
not	O
receive	O
iNO	O
therapy	O
,	O
receive	O
inhaled	B-PROC
oxygen	O
placebo	O
only	O
,	O
was	O
served	O
as	O
control	O
group	O
.	O

The	O
levels	O
of	O
IBV	O
-	O
specific	O
IgA	O
in	O
tears	O
of	O
vaccinated	O
and	O
challenged	O
chickens	O
did	O
not	O
differ	O
significantly	O
between	O
MHC	B-PROC
genotypes	O
.	O

IBV	O
genomes	O
were	O
present	O
in	O
the	O
tears	O
of	O
vaccinated	O
and	O
challenged	O
birds	O
,	O
and	O
the	O
incidence	O
of	O
detectable	O
IBV	O
genomes	O
did	O
not	O
vary	O
significantly	O
with	O
MHC	B-PROC
B	O
genotype	O
.	O

The	O
S1	O
glycoprotein	O
genes	O
of	O
these	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RTPCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
(	O
RFLP	O
)	O
analysis	O
.	O

Genetic	B-PROC
polymorphisms	I-PROC
and	O
haplotypes	O
in	O
the	O
urokinase	O
gene	O
were	O
determined	O
.	O

Six	O
polymorphisms	B-PROC
,	O
rs1916341	O
,	O
rs2227562	O
,	O
rs2227564	O
,	O
rs2227566	O
,	O
rs2227571	O
,	O
and	O
rs4065	O
,	O
defining	O
98	O
%	O
of	O
all	O
urokinase	O
haplotypes	O
,	O
were	O
analyzed	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
safety	O
,	O
immunogenicity	O
and	O
pharmacokinetics	B-PROC
of	O
equine	O
anti	O
-	O
SARS	O
-	O
CoV	O
F	O
(	O
ab	O
')(	O
2	O
)	O
in	O
macaque	O
.	O

TITLE	O
:	O
Dying	B-PROC
and	O
caring	O
on	O
the	O
edge	O
:	O
Taiwan	O
'	O
s	O
surviving	O
nurses	O
'	O
reflections	O
on	O
taking	O
care	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
This	O
study	O
has	O
two	O
objectives	O
:	O
to	O
study	O
the	O
clinical	O
symptoms	O
associated	O
with	O
the	O
detection	O
of	O
the	O
four	O
human	O
coronaviruses	O
(	O
HCoVs	O
),	O
229E	O
,	O
OC43	O
,	O
NL63	O
and	O
HKU1	O
types	O
,	O
in	O
the	O
respiratory	O
specimens	O
sampled	O
from	O
hospitalised	O
children	O
in	O
France	O
between	O
September	O
2004	O
and	O
May	O
2005	O
;	O
and	O
to	O
develop	O
a	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
allowing	O
for	O
the	O
simultaneous	O
detection	O
of	O
the	O
four	O
HCoVs	O
.	O

TITLE	O
:	O
Cloning	O
,	O
expression	B-PROC
and	O
characterization	O
of	O
ferret	O
CXCL10	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
endogenous	O
ferret	O
CXCL10	O
exhibits	O
similar	O
mRNA	B-PROC
expression	B-PROC
patterns	O
in	O
the	O
lungs	O
of	O
deceased	B-PROC
SARS	O
patients	O
and	O
ferrets	O
experimentally	O
infected	O
with	O
SARS	O
coronavirus	O
.	O

This	O
study	O
therefore	O
represents	O
an	O
important	O
step	O
towards	O
development	B-PROC
of	O
the	O
ferret	O
as	O
a	O
model	O
for	O
the	O
role	O
of	O
CXCL9	O
,	O
CXCL10	O
and	O
CXCL11	O
:	O
CXCR3	O
axis	O
in	O
severe	O
viral	B-PROC
infections	I-PROC
.	O

Their	O
mechanical	O
properties	O
are	O
directly	O
relevant	O
to	O
their	O
unfolding	O
by	O
ribosomes	O
during	O
translation	B-PROC
.	O

In	O
order	O
to	O
investigate	O
the	O
potential	O
role	O
of	O
proinflammatory	O
cytokines	O
in	O
disease	O
severity	O
after	O
coinfection	O
,	O
a	O
second	O
experiment	O
was	O
performed	O
to	O
examine	O
cytokine	O
transcription	B-PROC
in	O
alveolar	O
macrophages	O
from	O
single	O
and	O
dually	O
infected	O
pigs	O
.	O

We	O
isolated	O
human	O
alveolar	O
type	O
II	O
cells	O
and	O
maintained	O
them	O
in	O
a	O
highly	O
differentiated	B-PROC
state	O
.	O

Aggressive	B-PROC
management	O
was	O
practiced	O
with	O
continuous	O
transfusion	O
of	O
blood	O
products	O
and	O
administration	O
of	O
vasocopressors	O
.	O

The	O
presented	O
computational	O
approach	O
shows	O
that	O
the	O
integration	B-PROC
of	O
long	O
-	O
range	O
mobility	O
and	O
demographic	O
data	O
provides	O
epidemic	O
models	O
with	O
a	O
predictive	O
power	O
that	O
can	O
be	O
consistently	O
tested	O
and	O
theoretically	O
motivated	O
.	O

All	O
pups	O
seroconverted	O
for	O
CCoV	O
,	O
as	O
shown	O
by	O
the	O
high	O
optical	O
density	O
values	O
and	O
antibody	B-PROC
titres	O
detected	O
by	O
ELISA	O
and	O
virusneutralisation	O
tests	O
,	O
respectively	O
.	O

Seven	O
substitutions	O
were	O
located	O
in	O
the	O
amino	O
-	O
terminal	O
S1	O
cleavage	B-PROC
subunit	O
,	O
and	O
six	O
were	O
located	O
in	O
the	O
carboxy	O
-	O
terminal	O
S2	O
cleavage	B-PROC
subunit	O
.	O

TITLE	O
:	O
Are	O
nidoviruses	O
hijacking	O
the	O
autophagy	B-PROC
machinery	O
?	O

ABSTRACT	O
:	O
Autophagy	B-PROC
is	O
an	O
intracellular	O
catabolic	B-PROC
transport	B-PROC
route	O
conserved	O
among	O
all	O
eukaryotic	O
cells	O
.	O

The	O
present	O
study	O
investigated	O
the	O
sensitivity	O
of	O
CCoV	O
to	O
disinfectants	O
currently	O
used	O
for	O
prophylaxis	O
in	O
kennel	O
and	O
dog	O
breeding	B-PROC
locations	O
.	O

Coronavirus	O
specific	O
inhibition	B-PROC
was	O
also	O
demonstrated	O
using	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

A	O
high	O
number	O
of	O
these	O
traumatic	O
memories	O
from	O
the	O
ICU	O
has	O
been	O
shown	O
to	O
be	O
a	O
significant	O
risk	O
factor	O
for	O
the	O
later	O
development	B-PROC
of	O
PTSD	O
in	O
long	O
-	O
term	O
survivors	O
.	O

The	O
hyperthermia	B-PROC
in	O
this	O
patient	O
was	O
refractory	O
to	O
antipyretic	O
therapy	O
and	O
was	O
not	O
due	O
to	O
other	O
drug	O
-	O
induced	O
hyperthermic	B-PROC
syndromes	O
.	O

In	O
this	O
review	O
,	O
we	O
have	O
compiled	O
the	O
current	O
knowledge	O
about	O
SARS	O
-	O
CoV	O
accessory	O
proteins	O
,	O
obtained	O
from	O
studies	O
in	O
cell	O
culture	O
systems	O
,	O
reverse	O
genetics	O
and	O
animal	O
models	O
,	O
to	O
shed	O
some	O
light	O
into	O
the	O
possible	O
role	O
of	O
these	O
proteins	O
in	O
the	O
propagation	O
and	O
virulence	B-PROC
of	O
SARS	O
-	O
CoV	O
in	O
its	O
natural	O
host	O
.	O

ABSTRACT	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
Philippine	O
woman	O
had	O
had	O
fever	B-PROC
and	O
general	O
fatigue	O
from	O
September	O
,	O
2006	O
(	O
11th	O
week	O
of	O
pregnancy	O
).	O

N	O
protein	O
associates	O
with	O
Smad3	O
and	O
promotes	O
Smad3	O
-	O
p300	O
complex	O
formation	B-PROC
while	O
it	O
interferes	O
with	O
the	O
complex	O
formation	B-PROC
between	O
Smad3	O
and	O
Smad4	O
.	O

TITLE	O
:	O
Differential	B-PROC
gene	B-PROC
expression	I-PROC
profiles	O
in	O
acute	O
hepatic	O
failure	O
model	O
in	O
mice	O
infected	O
with	O
MHV	O
-	O
3	O
virus	O
intervened	O
by	O
anti	O
-	O
hepatic	O
failure	O
compound	O
.	O

Before	O
and	O
after	O
the	O
experiment	O
,	O
the	O
cytokines	O
in	O
peripheral	O
blood	O
of	O
the	O
survival	O
mice	O
were	O
determined	O
,	O
and	O
RNA	O
was	O
extracted	O
from	O
survival	O
mouse	O
liver	O
tissue	O
for	O
the	O
analysis	O
of	O
the	O
differential	B-PROC
gene	B-PROC
expression	I-PROC
by	O
a	O
36	O
kb	O
mouse	O
oligonucleotide	O
DNA	O
array	O
.	O

Through	O
clustering	O
analysis	O
,	O
the	O
differential	O
expression	B-PROC
of	O
immune	O
related	O
genes	O
,	O
including	O
TNF	O
receptor	O
superfamily	O
,	O
Kctd9	O
,	O
Bcl	O
-	O
2	O
,	O
Fgl2	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
6	O
,	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
etc	O
.	O

It	O
was	O
suggested	O
that	O
AHFC	O
can	O
balance	B-PROC
the	O
immune	O
state	O
of	O
mouse	O
model	O
of	O
acute	O
hepatic	O
failure	O
infected	O
with	O
MHV	O
-	O
3	O
virus	O
mainly	O
through	O
regulating	O
the	O
expression	B-PROC
of	O
immune	O
related	O
genes	O
,	O
decrease	O
the	O
immune	O
damage	O
and	O
inhibit	O
liver	O
cell	O
apoptosis	B-PROC
of	O
mouse	O
acute	O
hepatic	O
failure	O
model	O
obviously	O
so	O
as	O
to	O
increase	O
the	O
survival	O
rate	O
of	O
mouse	O
models	O
of	O
acute	O
hepatic	O
failure	O
.	O

ABSTRACT	O
:	O
The	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
of	O
a	O
289	O
base	O
pair	O
Alu	O
repeat	O
sequence	O
polymorphism	B-PROC
in	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
gene	O
(	O
ACE	O
)	O
has	O
been	O
shown	O
to	O
predict	O
susceptibility	O
and	O
outcome	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
hypothesized	O
that	O
the	O
I	O
/	O
D	O
polymorphism	B-PROC
also	O
confers	O
susceptibility	O
to	O
sepsis	O
and	O
is	O
a	O
predisposing	O
factor	O
for	O
morbidity	O
and	O
mortality	O
of	O
patients	O
with	O
severe	O
sepsis	O
.	O

TITLE	O
:	O
Conventional	O
surgical	O
repair	B-PROC
and	O
endovascular	O
treatment	O
of	O
acute	O
traumatic	O
aortic	O
rupture	O
.	O

TITLE	O
:	O
A	O
touch	B-PROC
of	O
TRALI	O
.	O

FCV3	O
-	O
70	O
monoclonal	O
antibody	B-PROC
produced	O
immunolabelling	O
of	O
group	O
1	O
coronavirus	O
antigen	O
in	O
tissue	O
samples	O
from	O
eight	O
animals	O
,	O
the	O
antigen	O
being	O
present	O
in	O
the	O
cytoplasm	O
of	O
macrophages	O
in	O
the	O
different	O
types	O
of	O
granulomatous	O
lesions	O
.	O

The	O
majority	O
of	O
reported	O
cases	O
of	O
gasoline	O
intoxication	O
involve	O
oral	O
ingestion	O
or	O
inhalation	B-PROC
.	O

The	O
virus	B-PROC
replication	I-PROC
kinetics	O
,	O
histopathological	O
changes	O
and	O
mRNA	B-PROC
expression	B-PROC
levels	O
of	O
proinflammatory	O
cytokines	O
in	O
the	O
brain	O
did	O
not	O
differ	O
between	O
TNFalpha	O
-	O
deficient	O
and	O
control	O
C57BL	O
/	O
6	O
mice	O
.	O

This	O
pathophysiology	O
included	O
decreased	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
and	O
lung	B-PROC
compliance	I-PROC
,	O
increased	O
pulmonary	O
edema	O
,	O
and	O
extensive	O
airway	O
obstruction	O
.	O

The	O
aerosolization	O
of	O
rhAT	O
or	O
heparin	O
alone	O
did	O
not	O
significantly	O
improve	O
deteriorated	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
.	O

We	O
have	O
analyzed	O
the	O
evolution	B-PROC
of	O
the	O
mouse	O
hepatitis	O
coronavirus	O
during	O
multiple	O
passaging	O
in	O
the	O
presence	O
of	O
an	O
HR2	O
-	O
based	O
fusion	O
inhibitor	O
.	O

Elimination	B-PROC
procedures	O
minimize	O
the	O
low	O
residual	O
risk	O
of	O
transmitting	O
pathogens	O
,	O
including	O
unknown	O
or	O
previously	O
undetected	O
ones	O
.	O

This	O
has	O
resulted	O
in	O
the	O
development	B-PROC
of	O
plans	O
to	O
build	O
""""	O
high	O
containment	O
""""	O
facilities	O
around	O
the	O
world	O
and	O
an	O
array	O
of	O
new	O
regulations	O
at	O
both	O
national	O
and	O
international	O
levels	O
regarding	O
the	O
management	O
of	O
pathogens	O
,	O
the	O
operation	O
of	O
high	O
containment	O
facilities	O
,	O
the	O
use	O
of	O
genetically	O
modified	O
material	O
,	O
and	O
the	O
transportation	O
of	O
such	O
agents	O
and	O
personnel	O
security	O
issues	O
.	O

CONCLUSIONS	O
:	O
Chronic	O
alcoholism	O
and	O
alcoholic	O
liver	O
disease	O
are	O
both	O
associated	O
with	O
an	O
important	O
degree	O
of	O
immunosuppression	B-PROC
.	O

TITLE	O
:	O
[	O
Development	B-PROC
and	O
application	O
of	O
a	O
safe	O
SARS	O
-	O
CoV	O
neutralization	O
assay	O
based	O
on	O
lentiviral	O
vectors	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
spike	O
protein	O
].	O

In	O
this	O
study	O
,	O
we	O
examined	O
one	O
of	O
the	O
most	O
likely	O
virus	O
-	O
spread	O
mechanisms	O
,	O
which	O
is	O
related	O
to	O
the	O
inter	O
-	O
flat	O
or	O
inter	O
-	O
zonal	O
airflow	B-PROC
through	O
open	O
-	O
windows	O
caused	O
by	O
buoyancy	O
effects	O
.	O

Surface	O
expression	B-PROC
was	O
analyzed	O
by	O
immunofluorescence	O
microscopy	O
,	O
by	O
surface	O
biotinylation	O
,	O
and	O
by	O
syncytium	B-PROC
formation	I-PROC
by	O
S	O
-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
SCID	O
mice	O
with	O
a	O
recombinant	O
murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
[	O
MHV	O
])	O
expressing	O
the	O
T	O
-	O
cell	O
chemoattractant	O
CXC	O
chemokine	O
ligand	B-PROC
10	O
(	O
CXCL10	O
)	O
resulted	O
in	O
increased	O
survival	O
and	O
reduced	O
viral	O
burden	O
within	O
the	O
brain	O
and	O
liver	O
compared	O
to	O
those	O
of	O
mice	O
infected	O
with	O
an	O
isogenic	O
control	O
virus	O
(	O
MHV	O
),	O
supporting	O
an	O
important	O
role	O
for	O
CXCL10	O
in	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
following	O
viral	B-PROC
infection	I-PROC
.	O

The	O
administration	O
of	O
an	O
NKG2D	O
-	O
blocking	O
antibody	B-PROC
to	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
mice	O
did	O
not	O
reduce	O
survival	O
,	O
dampen	O
IFN	O
-	O
gamma	O
production	O
in	O
the	O
brain	O
,	O
or	O
affect	O
liver	O
pathology	O
.	O

Both	O
wild	O
-	O
type	O
donor	O
CD90	O
.	O
1	O
and	O
recipient	O
CD90	O
.	O
2	O
CD4	O
(+)	O
T	O
cells	O
trafficked	B-PROC
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
parenchyma	O
and	O
localized	O
to	O
infected	O
white	O
matter	O
,	O
correlating	O
with	O
decreased	O
numbers	O
of	O
virus	O
-	O
infected	O
oligodendrocytes	O
in	O
the	O
CNS	O
.	O

The	O
in	O
vitro	O
evolution	B-PROC
of	O
icSZ16	O
-	O
S	O
K479N	O
on	O
human	O
airway	O
epithelial	O
(	O
HAE	O
)	O
cells	O
produced	O
two	O
viruses	O
(	O
icSZ16	O
-	O
S	O
K479N	O
D8	O
and	O
D22	O
)	O
with	O
enhanced	O
growth	B-PROC
on	O
HAE	O
cells	O
and	O
on	O
delayed	O
brain	O
tumor	O
cells	O
expressing	O
the	O
SARS	O
-	O
CoV	O
receptor	O
,	O
human	O
angiotensin	O
I	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
).	O

Surprisingly	O
,	O
we	O
found	O
that	O
PGE2	O
produced	O
by	O
IL	O
-	O
1beta	O
-	O
stimulated	O
fibroblasts	O
enhances	O
fibroblast	B-PROC
proliferation	I-PROC
.	O

As	O
it	O
was	O
thought	O
that	O
surviving	O
neutrophils	O
would	O
also	O
be	O
damaged	O
from	O
antibodies	O
binding	O
with	O
the	O
neutrophil	O
membrane	O
,	O
we	O
studied	O
the	O
functional	O
influence	O
of	O
neutrophil	O
antibodies	O
on	O
natural	O
phagocytosis	B-PROC
and	O
immune	B-PROC
phagocytosis	B-PROC
by	O
using	O
neutrophil	O
-	O
specific	O
monoclonal	O
antibodies	O
(	O
MoAbs	O
),	O
TAG1	O
:	O
HNA	O
-	O
la	O
on	O
FgammaRIIIb	O
,	O
TAG2	O
:	O
HNA	O
-	O
1b	O
on	O
FgammaRIIIa	O
/	O
b	O
,	O
TAG3	O
:	O
FgammaRIIIa	O
/	O
b	O
and	O
TAG4	O
:	O
HNA	O
-	O
2a	O
.	O

2	O
beats	O
/	O
min	O
;	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
,	O
0	O
.	O
5	O
+/-	O
0	O
.	O
1	O
),	O
early	O
(<	O
24	O
hours	O
)	O
significant	O
improvement	O
of	O
respiratory	B-PROC
function	I-PROC
,	O
and	O
reduction	O
of	O
plasmatic	O
interleukin	O
-	O
6	O
levels	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
Murray	O
score	O
(	O
1	O
.	O
25	O
+/-	O
0	O
.	O
1	O
;	O
p	O
<	O
0	O
.	O
003	O
).	O

The	O
integration	B-PROC
of	O
this	O
device	O
to	O
near	O
static	O
mechanical	O
ventilation	O
of	O
the	O
residual	O
native	O
lung	O
(	O
s	O
)	O
is	O
feasible	O
and	O
highly	O
effective	O
in	O
patients	O
with	O
severe	O
and	O
unresponsive	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
pulmonary	O
resection	O
.	O

We	O
used	O
the	O
Grades	O
of	O
Recommendation	O
,	O
Assessment	O
,	O
Development	B-PROC
and	O
Evaluation	O
(	O
GRADE	O
)	O
system	O
to	O
guide	O
assessment	O
of	O
quality	O
of	O
evidence	O
from	O
high	O
(	O
A	O
)	O
to	O
very	O
low	O
(	O
D	O
)	O
and	O
to	O
determine	O
the	O
strength	O
of	O
recommendations	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
CC	O
chemokine	O
receptor	O
1	O
(	O
CCR1	O
)	O
in	O
host	B-PROC
defense	I-PROC
and	O
disease	O
development	B-PROC
was	O
determined	O
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
neurologic	O
disease	O
.	O

TITLE	O
:	O
Innovation	O
and	O
challenges	O
in	O
funding	O
rapid	O
research	O
responses	O
to	O
emerging	O
infectious	O
diseases	O
:	O
Lessons	O
learned	B-PROC
from	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

SARS	O
-	O
CoV	O
N	O
and	O
N199	O
(	O
a	O
truncated	O
nucleocapsid	O
gene	O
)	O
genes	O
were	O
cloned	O
,	O
expressed	B-PROC
,	O
identified	O
by	O
Western	O
blotting	O
,	O
and	O
applied	O
in	O
screening	O
of	O
human	O
and	O
swine	O
samples	O
.	O

Monitoring	O
of	O
haemodynamic	O
parameters	O
(	O
invasive	O
blood	B-PROC
pressure	I-PROC
,	O
electrocardiography	O
)	O
and	O
ventilatory	O
parameters	O
(	O
ETCO2	O
,	O
SpO2	O
,	O
airway	O
pressure	O
monitoring	O
)	O
are	O
important	O
in	O
the	O
recognition	O
of	O
this	O
possible	O
event	O
.	O

TITLE	O
:	O
Severe	O
febrile	B-PROC
respiratory	O
illnesses	O
as	O
a	O
cause	O
of	O
mass	O
critical	O
care	O
.	O

However	O
,	O
a	O
small	O
number	O
of	O
rare	O
and	O
highly	O
contagious	O
agents	O
can	O
initially	O
present	O
as	O
febrile	B-PROC
respiratory	O
illnesses	O
,	O
which	O
can	O
lead	O
to	O
an	O
epidemic	O
that	O
can	O
greatly	O
impact	O
the	O
health	O
care	O
system	O
.	O

Viral	B-PROC
shedding	I-PROC
at	O
3	O
weeks	O
occurred	O
in	O
20	O
%	O
of	O
cases	O
.	O

Such	O
a	O
conclusion	O
could	O
be	O
further	O
verified	O
by	O
the	O
results	O
that	O
the	O
proteolytic	B-PROC
activities	O
of	O
these	O
mutants	O
also	O
decrease	O
to	O
varying	O
degrees	O
.	O

This	O
process	O
depends	O
on	O
interactions	O
with	O
membranes	O
that	O
may	O
involve	O
palmitoylation	B-PROC
,	O
a	O
common	O
posttranslational	O
lipidation	O
of	O
cysteine	O
residues	O
.	O

Thus	O
,	O
variations	O
in	O
the	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
are	O
unlikely	O
to	O
have	O
contributed	O
significantly	O
to	O
either	O
the	O
susceptibility	O
or	O
the	O
severity	O
of	O
SARS	O
in	O
the	O
population	O
of	O
Guangdong	O
.	O

A	O
proper	O
ventilation	O
strategy	O
,	O
early	O
pharmacologic	O
therapy	O
including	O
glucocorticoids	O
,	O
and	O
complication	O
prevention	O
may	O
contribute	O
to	O
good	O
treatment	O
outcomes	O
after	O
white	O
smoke	O
inhalation	B-PROC
.	O

Both	O
genosensors	O
rely	O
on	O
the	O
hybridization	B-PROC
of	O
the	O
oligonucleotide	O
target	O
with	O
its	O
complementary	O
probe	O
,	O
which	O
is	O
immobilized	O
on	O
positively	O
charged	O
polylysine	O
modified	O
screen	O
-	O
printed	O
carbon	O
electrodes	O
(	O
SPCEs	O
),	O
through	O
electrostatic	O
interactions	O
.	O

In	O
the	O
other	O
design	O
,	O
the	O
target	O
is	O
labeled	O
using	O
an	O
Au	O
(	O
I	O
)	O
complex	O
,	O
sodium	O
aurothiomalate	O
,	O
and	O
the	O
duplex	O
formation	B-PROC
is	O
detected	O
by	O
measuring	O
,	O
for	O
first	O
time	O
,	O
the	O
current	O
generated	O
by	O
the	O
hydrogen	O
evolution	B-PROC
catalyzed	O
by	O
the	O
gold	O
label	O
.	O

The	O
glycosylation	B-PROC
sequence	O
Asn	O
-	O
Phe	O
-	O
Thr	O
was	O
highly	O
conserved	O
in	O
the	O
M	O
proteins	O
of	O
six	O
PEDV	O
isolates	O
.	O

More	O
than	O
twelve	O
peaks	O
were	O
differentially	O
expressed	B-PROC
in	O
SARS	O
patients	O
with	O
one	O
at	O
m	O
/	O
z	O
of	O
11	O
,	O
695	O
(	O
later	O
identified	O
to	O
be	O
serum	O
amyloid	O
A	O
protein	O
),	O
which	O
had	O
increase	O
in	O
peak	O
intensity	O
correlating	O
with	O
the	O
extent	O
of	O
SARS	O
-	O
coronavirus	O
induced	O
pneumonia	O
as	O
defined	O
by	O
a	O
serial	O
chest	O
X	O
-	O
ray	O
opacity	O
score	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
through	O
a	O
novel	O
clathrin	O
-	O
and	O
caveolae	O
-	O
independent	O
endocytic	O
pathway	B-PROC
.	O

Further	O
analyses	O
using	O
specific	O
endocytic	O
pathway	B-PROC
inhibitors	O
and	O
dominant	O
-	O
negative	O
Eps15	O
as	O
well	O
as	O
caveolin	O
-	O
1	O
colocalization	O
study	O
suggested	O
that	O
virus	O
entry	O
was	O
mediated	O
by	O
a	O
clathrin	O
-	O
and	O
caveolae	O
-	O
independent	O
mechanism	O
.	O

Except	O
for	O
3	O
in	O
47	O
cases	O
whose	O
parents	O
refused	O
treatment	O
,	O
dyspnea	O
in	O
other	O
44	O
cases	O
were	O
relieved	O
with	O
inhaling	B-PROC
oxygen	O
and	O
drug	O
treatment	O
,	O
37	O
case	O
received	O
tracheal	O
intubation	O
and	O
sputum	O
suction	O
,	O
19	O
cases	O
received	O
direct	O
laryngoscope	O
or	O
self	O
-	O
retaining	O
laryngoscope	O
operation	O
.	O

Positive	O
antibody	B-PROC
titers	O
were	O
found	O
only	O
against	O
CDV	O
,	O
CPV	O
,	O
and	O
T	O
.	O
gondii	O
.	O

Positive	O
antibody	B-PROC
titers	O
against	O
T	O
.	O
gondii	O
were	O
found	O
in	O
seven	O
of	O
the	O
19	O
giant	O
pandas	O
.	O

These	O
interactions	O
led	O
to	O
the	O
inhibition	B-PROC
of	O
translation	B-PROC
of	O
a	O
reporter	O
gene	O
in	O
both	O
in	O
vitro	O
expression	B-PROC
system	O
and	O
intact	O
cells	O
.	O

At	O
29	O
d	O
.	O
p	O
.	O
i	O
.,	O
one	O
group	O
was	O
challenged	O
with	O
10	O
(	O
3	O
)	O
TCID50	O
SARS	O
-	O
CoV	O
,	O
and	O
an	O
anamnestic	B-PROC
response	I-PROC
in	O
neutralizing	O
antibodies	O
was	O
evident	O
with	O
no	O
detectable	O
virus	O
.	O

Caesarean	O
section	O
before	O
the	O
onset	O
of	O
labour	B-PROC
seems	O
to	O
be	O
a	O
triggering	O
factor	O
.	O

One	O
infant	O
died	B-PROC
.	O

The	O
development	B-PROC
of	O
clinically	O
significant	O
pulmonary	O
oedema	O
and	O
severe	O
myocardial	O
dysfunction	O
in	O
the	O
setting	O
of	O
acute	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
exacerbation	O
is	O
very	O
rare	O
and	O
poorly	O
understood	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
inhibits	O
B23	O
phosphorylation	B-PROC
.	O

In	O
vitro	O
phosphorylation	B-PROC
assay	O
showed	O
that	O
the	O
N	O
protein	O
inhibited	O
the	O
B23	O
phosphorylation	B-PROC
at	O
Thr199	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
although	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
provides	O
an	O
excellent	O
method	O
for	O
detecting	O
the	O
presence	O
of	O
viral	B-PROC
shedding	I-PROC
,	O
quantification	O
of	O
FCoV	O
RNA	O
in	O
faecal	O
material	O
has	O
to	O
take	O
into	O
account	O
the	O
possible	O
effects	O
of	O
RT	O
-	O
PCR	O
inhibitors	O
.	O

Neutropenia	O
was	O
not	O
a	O
predictor	O
of	O
respiratory	O
syncytial	O
virus	O
lower	O
respiratory	O
tract	O
infection	O
or	O
death	B-PROC
.	O

TITLE	O
:	O
Orchitis	O
in	O
roosters	O
with	O
reduced	O
fertility	B-PROC
associated	O
with	O
avian	O
infectious	O
bronchitis	O
virus	O
and	O
avian	O
metapneumovirus	O
infections	O
.	O

These	O
results	O
indicate	O
that	O
IBV	O
and	O
perhaps	O
aMPV	O
are	O
likely	O
to	O
have	O
played	O
a	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
the	O
testicular	O
disease	O
described	O
and	O
should	O
be	O
regarded	O
as	O
factors	O
that	O
can	O
influence	O
male	O
fertility	B-PROC
disease	O
in	O
chickens	O
.	O

Combination	O
vaccinations	O
using	O
B1	O
and	O
VG	O
/	O
GA	O
did	O
not	O
interfere	O
with	O
IBV	O
immunity	B-PROC
based	O
on	O
challenge	O
or	O
serum	O
antibody	B-PROC
production	I-PROC
.	O

Moreover	O
,	O
NDV	O
immunity	B-PROC
was	O
not	O
compromised	O
in	O
two	O
of	O
three	O
trials	O
using	O
single	O
entity	O
vaccines	O
of	O
NDV	O
and	O
Ark	O
IBV	O
vaccines	O
manufactured	O
separately	O
but	O
administered	O
simultaneously	O
.	O

The	O
interaction	O
map	O
thus	O
provides	O
a	O
sum	O
of	O
the	O
interactions	O
that	O
may	O
occur	O
at	O
some	O
point	O
during	O
coronavirus	O
RNA	B-PROC
synthesis	I-PROC
and	O
provides	O
a	O
framework	O
for	O
future	O
research	O
.	O

We	O
assessed	O
the	O
role	O
of	O
lymphocytic	O
bronchiolitis	O
as	O
a	O
risk	O
factor	O
for	O
bronchiolitis	O
obliterans	O
syndrome	O
(	O
BOS	O
)	O
and	O
death	B-PROC
after	O
lung	O
transplantation	O
.	O

Laboratory	O
data	O
showed	O
carbohydrate	O
intolerance	B-PROC
,	O
severe	O
hypokalemia	O
,	O
and	O
hypophosphatemia	O
.	O

This	O
review	O
explores	O
recent	O
advances	O
in	O
the	O
field	O
of	O
fibroproliferative	O
ARDS	O
/	O
ALI	O
,	O
with	O
a	O
special	O
emphasis	O
on	O
(	O
a	O
)	O
the	O
primary	O
contributing	O
factors	O
with	O
a	O
focus	O
on	O
cellular	O
and	O
soluble	O
factors	O
,	O
and	O
(	O
b	O
)	O
mechanisms	O
involved	O
in	O
repair	B-PROC
and	O
remodelling	O
as	O
they	O
pertain	O
to	O
the	O
importance	O
of	O
cell	B-PROC
death	I-PROC
,	O
re	O
-	O
population	O
,	O
and	O
matrix	O
deposition	O
.	O

At	O
the	O
local	O
level	O
,	O
China	O
'	O
s	O
crisis	O
-	O
management	O
ability	O
and	O
multisectoral	O
coordination	B-PROC
are	O
weak	O
.	O

TITLE	O
:	O
[	O
Potent	O
immune	B-PROC
responses	I-PROC
elicited	O
by	O
a	O
bicistronic	O
IBV	O
DNA	O
vaccine	O
expressing	O
S1	O
and	O
IL	O
-	O
2	O
gene	O
].	O

In	O
fact	O
,	O
in	O
transmissible	O
gastroenteritis	O
CoV	O
,	O
a	O
good	O
correlation	O
has	O
been	O
observed	O
between	O
subgenomic	O
mRNA	O
(	O
sg	O
mRNA	O
)	O
levels	O
and	O
the	O
free	O
energy	O
(	O
DeltaG	O
)	O
of	O
TRS	O
-	O
L	O
and	O
cTRS	O
-	O
B	O
duplex	O
formation	B-PROC
.	O

The	O
strategy	O
may	O
be	O
more	O
effective	O
if	O
the	O
priority	O
is	O
given	O
to	O
development	B-PROC
of	O
means	O
to	O
prevent	O
URI	O
associated	O
with	O
adenovirus	O
and	O
respiratory	O
syncytial	O
virus	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
mortality	O
,	O
instant	O
death	B-PROC
incidence	O
between	O
steroid	O
treatment	O
and	O
non	O
-	O
steroid	O
treatment	O
group	O
of	O
SARS	O
patients	O
diagnosed	O
with	O
the	O
diagnostic	O
criteria	O
issued	O
by	O
Ministry	O
of	O
Health	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
no	O
significant	O
difference	O
in	O
mortality	O
,	O
instant	O
death	B-PROC
incidence	O
between	O
steroid	O
treatment	O
and	O
non	O
-	O
steroid	O
treatment	O
group	O
of	O
SARS	O
patients	O
diagnosed	O
with	O
the	O
diagnostic	O
criteria	O
issued	O
by	O
Ministry	O
of	O
Health	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
assessed	O
the	O
immune	B-PROC
responses	I-PROC
and	O
protective	O
effect	O
of	O
the	O
immunization	O
with	O
RBD	O
-	O
rAAV	O
prime	O
/	O
RBD	O
-	O
specific	O
T	O
cell	O
peptide	O
boost	O
.	O

No	O
significant	O
immune	B-PROC
responses	I-PROC
and	O
protective	O
effects	O
were	O
detected	O
in	O
mice	O
vaccinated	O
with	O
RBD	O
-	O
Pep	O
or	O
blank	O
AAV	O
alone	O
.	O

We	O
found	O
that	O
nsp4	O
-	O
N237A	O
is	O
lethal	O
and	O
nsp4	O
-	O
N258T	O
generated	O
a	O
virus	O
(	O
designated	O
Alb	O
ts6	O
icv	O
)	O
that	O
is	O
temperature	O
sensitive	O
for	O
viral	B-PROC
replication	I-PROC
.	O

Occurrence	O
of	O
a	O
mutation	O
at	O
the	O
corresponding	O
position	O
of	O
the	O
CK	O
/	O
CH	O
/	O
LLN	O
/	O
98I	O
start	O
codon	O
in	O
the	O
3a	O
gene	O
led	O
to	O
the	O
absence	O
of	O
ORF	O
3a	O
in	O
this	O
virus	O
,	O
resulting	O
in	O
a	O
novel	O
genomic	O
organization	O
at	O
the	O
3	O
'-	O
encoding	O
regions	O
:	O
S	O
-	O
3b	O
,	O
3c	O
-	O
M	O
-	O
5a	O
,	O
5b	O
-	O
N	O
.	O
Comparison	O
with	O
other	O
viruses	O
carrying	O
the	O
normal	O
3a	O
gene	O
revealed	O
that	O
CK	O
/	O
CH	O
/	O
LLN	O
/	O
98I	O
had	O
replication	O
and	O
pathogenicity	O
abilities	O
in	O
vivo	O
similar	O
to	O
those	O
of	O
other	O
IBVs	O
;	O
however	O
,	O
its	O
growth	B-PROC
ability	O
in	O
embryos	O
was	O
lower	O
,	O
although	O
the	O
relationship	O
between	O
the	O
lower	O
growth	B-PROC
ability	O
and	O
the	O
ORF	O
3a	O
defect	O
requires	O
further	O
confirmation	O
.	O

TITLE	O
:	O
Aryl	O
methylene	O
ketones	O
and	O
fluorinated	O
methylene	O
ketones	O
as	O
reversible	O
inhibitors	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
3C	O
-	O
like	O
proteinase	B-PROC
.	O

Structure	O
-	O
activity	O
relationships	O
and	O
modeling	O
studies	O
indicate	O
that	O
three	O
aromatic	O
rings	O
,	O
including	O
a	O
5	O
-	O
bromopyridin	O
-	O
3	O
-	O
yl	O
moiety	O
,	O
are	O
key	O
features	O
for	O
good	O
inhibition	B-PROC
of	O
SARS	O
3CL	O
(	O
pro	O
).	O

Therefore	O
,	O
the	O
development	B-PROC
of	O
effective	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
continues	O
to	O
be	O
the	O
current	O
focus	O
of	O
SARS	O
research	O
.	O

TITLE	O
:	O
Viral	B-PROC
infections	I-PROC
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Translation	B-PROC
initiation	I-PROC
factor	O
eIF2alpha	O
is	O
highly	O
phosphorylated	O
during	O
MHV	O
infection	O
,	O
and	O
translation	B-PROC
of	O
cellular	O
mRNAs	O
is	O
attenuated	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
critical	O
homeostasis	B-PROC
regulator	O
GADD34	O
,	O
which	O
recruits	O
protein	O
phosphatase	O
1	O
to	O
dephosphorylate	O
eIF2alpha	O
during	O
the	O
recovery	O
phase	O
of	O
the	O
UPR	O
,	O
is	O
not	O
expressed	B-PROC
during	O
MHV	O
infection	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nsp1	O
suppresses	O
host	O
gene	B-PROC
expression	I-PROC
,	O
including	O
that	O
of	O
type	O
I	O
interferon	O
,	O
in	O
infected	O
cells	O
.	O

We	O
generated	O
an	O
nsp1	O
mutant	O
(	O
nsp1	O
-	O
mt	O
)	O
that	O
neither	O
promoted	O
host	O
mRNA	B-PROC
degradation	I-PROC
nor	O
suppressed	O
host	O
protein	B-PROC
synthesis	I-PROC
in	O
expressing	O
cells	O
.	O

These	O
data	O
revealed	O
that	O
nsp1	O
indeed	O
promoted	O
host	O
mRNA	B-PROC
degradation	I-PROC
and	O
contributed	O
to	O
host	O
protein	B-PROC
translation	B-PROC
inhibition	B-PROC
in	O
infected	O
cells	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
-	O
863	O
AC	O
genotype	O
was	O
manifested	O
as	O
another	O
risk	O
effect	O
associated	O
with	O
femoral	O
head	O
necrosis	B-PROC
with	O
OR	O
(	O
95	O
%	O
CI	O
)	O
of	O
6	O
.	O
42	O
(	O
1	O
.	O
53	O
-	O
26	O
.	O
88	O
)	O
and	O
the	O
adjusted	O
OR	O
was	O
8	O
.	O
40	O
(	O
95	O
%	O
CI	O
1	O
.	O
76	O
-	O
40	O
.	O
02	O
)	O
in	O
cured	O
SARS	O
patients	O
compared	O
to	O
CC	O
genotype	O
.	O

In	O
addition	O
,	O
the	O
plasma	O
from	O
active	O
SARS	O
patients	O
had	O
an	O
inhibitory	O
effect	O
on	O
CFU	O
-	O
MK	O
formation	B-PROC
,	O
which	O
could	O
be	O
neutralized	O
by	O
anti	O
-	O
TGF	O
-	O
beta	O
antibodies	O
.	O

We	O
conclude	O
that	O
amiodarone	O
alters	O
late	O
compartments	O
of	O
the	O
endocytic	O
pathway	B-PROC
and	O
inhibits	O
SARS	O
coronavirus	O
infection	O
by	O
acting	O
after	O
the	O
transit	O
of	O
the	O
virus	O
through	O
endosomes	O
.	O

Additionally	O
,	O
H2S	O
administration	O
attenuated	O
protein	B-PROC
oxidation	B-PROC
following	O
injury	O
and	O
improved	O
the	O
histological	O
condition	O
of	O
the	O
lung	O
.	O

Another	O
peptide	O
D10	O
(	O
residues	O
490	O
-	O
502	O
)	O
stimulated	O
A549	O
to	O
proliferate	O
and	O
secrete	B-PROC
IL	O
-	O
8	O
.	O

The	O
more	O
severe	O
the	O
disease	O
,	O
the	O
more	O
intense	O
is	O
endotoxemia	O
but	O
the	O
lower	O
is	O
the	O
capacity	O
of	O
mononuclear	O
cells	O
to	O
release	O
cytokines	O
(	O
tolerance	B-PROC
).	O

ABSTRACT	O
:	O
The	O
sudden	O
emergence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
boosted	O
research	O
on	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
coronaviruses	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	B-PROC
,	O
and	O
evaluation	O
of	O
trifluoromethyl	O
ketones	O
as	O
inhibitors	O
of	O
SARS	O
-	O
CoV	O
3CL	O
protease	O
.	O

Recent	O
animal	O
studies	O
have	O
demonstrated	O
that	O
administration	O
of	O
heparins	O
,	O
activated	O
protein	O
C	O
(	O
APC	O
),	O
Antithrombin	O
(	O
AT	O
),	O
Tissue	O
factor	O
-	O
Factor	O
VIIa	O
(	O
TF	O
-	O
FVIIa	O
)	O
pathway	B-PROC
inhibitors	O
,	O
plasminogen	B-PROC
activators	I-PROC
(	O
PA	O
)	O
and	O
thrombomodulin	O
(	O
TM	O
)	O
can	O
attenuate	O
pulmonary	O
coagulopathy	O
and	O
reduce	O
lung	O
injury	O
and	O
/	O
or	O
improve	O
oxygenation	B-PROC
.	O

Chronic	O
alcohol	O
abuse	O
increases	O
alveolar	O
epithelial	O
permeability	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
part	O
due	O
to	O
altered	O
tight	B-PROC
junction	I-PROC
formation	I-PROC
.	O

Chronic	O
alcohol	O
ingestion	O
significantly	O
increased	O
gene	O
and	O
protein	B-PROC
expression	B-PROC
of	O
each	O
Na	O
,	O
K	O
-	O
ATPase	O
subunit	O
in	O
rat	O
lungs	O
.	O

Immunohistochemical	O
analyses	O
of	O
the	O
alcoholic	O
lung	O
also	O
revealed	O
that	O
protein	B-PROC
expression	B-PROC
of	O
the	O
Na	O
,	O
K	O
-	O
ATPase	O
alpha1	O
subunit	O
was	O
increased	O
throughout	O
the	O
alveolar	O
epithelium	O
.	O

These	O
findings	O
indicate	O
that	O
chronic	O
alcohol	O
ingestion	O
,	O
which	O
is	O
known	O
to	O
increase	O
alveolar	O
epithelial	O
paracellular	O
permeability	O
,	O
actually	O
increases	O
the	O
expression	B-PROC
of	O
Na	O
,	O
K	O
-	O
ATPase	O
in	O
the	O
lung	O
as	O
a	O
compensatory	O
mechanism	O
.	O

Experiments	O
using	O
lysosomotropic	O
agents	O
clarified	O
that	O
acidification	B-PROC
of	O
the	O
endosome	O
is	O
necessary	O
for	O
cellular	O
invasion	O
by	O
FIPV	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
antibodies	O
.	O

Clinical	O
investigation	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
HIV	O
-	O
infected	O
patients	O
should	O
not	O
be	O
restricted	O
to	O
prototype	O
viruses	O
and	O
also	O
need	O
to	O
target	O
all	O
the	O
different	O
family	O
of	O
viruses	O
as	O
it	O
seems	O
likely	O
that	O
these	O
viruses	O
contribute	O
to	O
pulmonary	O
complications	O
and	O
morbidity	O
in	O
this	O
population	O
.	O

We	O
measured	O
plasma	O
markers	O
of	O
inflammation	O
,	O
coagulation	B-PROC
and	O
fibrinolysis	B-PROC
simultaneously	O
to	O
assess	O
whether	O
these	O
markers	O
remain	O
predictive	O
in	O
the	O
era	O
of	O
lung	O
-	O
protective	O
ventilation	O
.	O

CONCLUSIONS	O
:	O
Despite	O
lung	O
-	O
protective	O
ventilation	O
,	O
abnormalities	O
in	O
plasma	O
levels	O
of	O
markers	O
of	O
inflammation	O
,	O
coagulation	B-PROC
and	O
fibrinolysis	B-PROC
predict	O
mortality	O
in	O
ALI	O
patients	O
,	O
indicating	O
more	O
severe	O
activation	O
of	O
these	O
biologic	O
pathways	B-PROC
in	O
nonsurvivors	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
phagocytic	O
cells	O
in	O
enhanced	O
susceptibility	O
of	O
broilers	O
to	O
colibacillosis	O
after	O
Infectious	O
Bronchitis	O
Virus	B-PROC
infection	I-PROC
.	O

Bactericidal	B-PROC
activity	I-PROC
of	O
PBMC	O
in	O
IBV	O
-	O
inoculated	O
animals	O
at	O
7dpi	O
was	O
lower	O
than	O
in	O
PBS	O
-	O
and	O
E	O
.	O
coli	O
-	O
inoculated	O
birds	O
,	O
but	O
phagocytic	O
capacity	O
and	O
recruitment	O
were	O
not	O
severely	O
impaired	O
.	O

In	O
spleen	O
samples	O
of	O
IBV	O
-	O
infected	O
animals	O
reduced	O
expression	B-PROC
of	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
18	O
and	O
IFN	O
-	O
gamma	O
mRNA	O
was	O
found	O
1dpi	O
.	O

ABSTRACT	O
:	O
Twin	O
reversed	O
-	O
arterial	O
-	O
perfusion	O
syndrome	O
(	O
TRAPS	O
)	O
is	O
a	O
rare	O
complication	O
of	O
monochorionic	O
twin	O
pregnancies	B-PROC
.	O

TRAPS	O
is	O
characterized	O
by	O
the	O
hemodynamic	B-PROC
dependence	O
of	O
a	O
""""	O
recipient	O
""""	O
twin	O
from	O
a	O
""""	O
pump	O
""""	O
twin	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
infection	O
and	O
growth	B-PROC
are	O
dependent	O
on	O
initiating	O
signaling	B-PROC
and	O
enzyme	O
actions	O
upon	O
viral	O
entry	O
into	O
the	O
host	O
cell	O
.	O

We	O
used	O
published	O
interaction	O
data	O
to	O
identify	O
hubs	O
of	O
connectivity	O
with	O
potential	O
significance	O
for	O
virion	O
formation	B-PROC
.	O

Immortalized	O
cultures	O
of	O
differentiated	B-PROC
proximal	O
tubular	O
epithelial	O
cells	O
(	O
PTEC	O
),	O
glomerular	O
mesangial	O
cells	O
(	O
MC	O
),	O
and	O
glomerular	O
epithelial	O
cells	O
(	O
podocytes	O
)	O
were	O
found	O
to	O
express	O
the	O
SARS	O
-	O
CoV	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
on	O
their	O
surface	O
.	O

The	O
E11A	O
point	B-PROC
mutation	I-PROC
was	O
sufficient	O
for	O
enhanced	O
SARS	O
-	O
CoV	O
replication	O
and	O
persistence	O
in	O
PTEC	O
when	O
introduced	O
in	O
a	O
SARS	O
-	O
CoV	O
recombinant	O
infectious	O
clone	O
.	O

Quantitative	O
prediction	O
of	O
the	O
efficiency	O
of	O
-	O
1	O
frameshifting	O
is	O
crucial	O
for	O
understanding	O
the	O
viral	O
gene	B-PROC
expression	I-PROC
.	O

ABSTRACT	O
:	O
Containment	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SCV	O
)	O
outbreak	O
was	O
accompanied	O
by	O
the	O
rapid	O
characterization	O
of	O
this	O
new	O
pathogen	O
'	O
s	O
genome	O
sequence	O
in	O
2003	O
,	O
encouraging	O
the	O
development	B-PROC
of	O
anti	O
-	O
SCV	O
therapeutics	O
using	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
inhibitors	O
.	O

TITLE	O
:	O
Analysis	O
of	O
cell	O
-	O
to	O
-	O
cell	O
and	O
long	O
-	O
distance	O
movement	B-PROC
of	O
apple	O
latent	O
spherical	O
virus	O
in	O
infected	O
plants	O
using	O
green	O
,	O
cyan	O
,	O
and	O
yellow	O
fluorescent	O
proteins	O
.	O

We	O
recently	O
showed	O
that	O
elastase	O
enhances	O
SARS	O
-	O
CoV	O
infection	O
in	O
cultured	O
cells	O
,	O
which	O
suggests	O
that	O
SARS	O
development	B-PROC
may	O
be	O
due	O
to	O
elastase	O
-	O
mediated	O
,	O
enhanced	O
SARS	O
-	O
CoV	O
infection	O
in	O
the	O
lungs	O
.	O

Criteria	O
for	O
administration	O
,	O
weaning	B-PROC
and	O
discontinuation	O
of	O
these	O
supportive	O
interventions	O
have	O
never	O
been	O
described	O
in	O
detail	O
.	O

After	O
five	O
cycles	O
of	O
screening	O
,	O
a	O
dodecapeptide	O
KKKKYRNIRRPG	O
(	O
DP	O
)	O
was	O
identified	O
to	O
possess	O
the	O
highest	O
binding	O
affinity	O
to	O
the	O
immobilized	O
sense	B-PROC
peptide	O
.	O

TITLE	O
:	O
A	O
novel	O
mutation	O
in	O
murine	O
hepatitis	O
virus	O
nsp5	O
,	O
the	O
viral	O
3C	O
-	O
like	O
proteinase	B-PROC
,	O
causes	O
temperature	O
-	O
sensitive	O
defects	O
in	O
viral	O
growth	B-PROC
and	O
protein	B-PROC
processing	I-PROC
.	O

The	O
introduction	O
of	O
the	O
T10651C	O
mutation	O
into	O
the	O
infectious	O
MHV	O
clone	O
resulted	O
in	O
the	O
recovery	O
of	O
a	O
mutant	O
virus	O
,	O
the	O
nsp5	O
/	O
V148A	O
virus	O
,	O
that	O
demonstrated	O
reduced	O
growth	B-PROC
and	O
nsp5	O
proteinase	B-PROC
activity	I-PROC
identical	O
to	O
that	O
of	O
Alb	O
/	O
ts	O
/	O
nsp5	O
/	O
V148A	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

The	O
introduction	O
of	O
the	O
Ser133Asn	O
or	O
His134Tyr	O
substitution	O
into	O
the	O
cloned	O
nsp5	O
/	O
V148A	O
mutant	O
virus	O
background	O
resulted	O
in	O
the	O
recovery	O
of	O
viruses	O
with	O
increased	O
growth	B-PROC
fitness	O
and	O
the	O
partial	O
restoration	O
of	O
nsp5	O
activity	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

However	O
,	O
due	O
to	O
potential	O
inhibition	B-PROC
of	O
the	O
RT	O
-	O
PCR	O
or	O
inefficient	O
extraction	O
,	O
this	O
sample	O
type	O
can	O
present	O
significant	O
challenges	O
to	O
accurate	O
patient	O
testing	O
.	O

Here	O
we	O
analyze	O
the	O
importance	O
of	O
the	O
sialic	O
acid	O
binding	B-PROC
activity	I-PROC
for	O
the	O
infection	O
of	O
tracheal	O
organ	O
cultures	O
(	O
TOCs	O
)	O
by	O
different	O
IBV	O
strains	O
.	O

ARDS	O
has	O
a	O
high	O
risk	O
of	O
death	B-PROC
,	O
and	O
the	O
infiltration	O
shadows	O
in	O
2	O
-	O
3	O
quadrants	O
,	O
PCIS	O
,	O
and	O
PaCO2	O
are	O
independently	O
associated	O
with	O
mortality	O
.	O

EVLI	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
)	O
II	O
score	O
,	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
chest	O
X	O
-	O
ray	O
score	O
,	O
lung	O
injury	O
score	O
,	O
body	O
mass	O
index	O
,	O
prior	O
24h	O
fluid	B-PROC
balance	I-PROC
,	O
albumin	O
,	O
and	O
white	O
blood	O
cell	O
counts	O
were	O
shown	O
to	O
be	O
predictors	O
of	O
in	O
-	O
hospital	O
survival	O
by	O
a	O
bivariate	O
analysis	O
.	O

The	O
investigation	O
included	O
death	B-PROC
record	O
reviews	O
,	O
chart	O
reviews	O
,	O
case	O
finding	O
and	O
contact	O
tracing	O
.	O

Staff	O
members	O
who	O
worked	O
the	O
evening	O
shift	O
or	O
the	O
morning	O
shift	O
and	O
therefore	O
likely	O
attended	O
a	O
nursing	B-PROC
appreciation	O
breakfast	O
were	O
five	O
times	O
more	O
likely	O
to	O
acquire	O
SARS	O
than	O
those	O
who	O
did	O
not	O
attend	O
.	O

The	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE	O
-	O
2	O
)	O
has	O
been	O
identified	O
as	O
a	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
ACE	O
-	O
2	O
has	O
been	O
shown	O
to	O
be	O
expressed	B-PROC
at	O
the	O
apical	O
domain	O
of	O
polarized	O
Calu	O
-	O
3	O
cells	O
.	O

TITLE	O
:	O
Lost	O
in	O
translation	B-PROC
?	O

TITLE	O
:	O
Characterization	O
of	O
ubiquitin	B-PROC
and	O
ubiquitin	B-PROC
-	O
like	O
-	O
protein	O
isopeptidase	O
activities	O
.	O

Isopeptidase	O
activity	O
releases	O
PLA	O
(	O
2	O
),	O
which	O
cleaves	O
its	O
substrate	O
,	O
generating	O
a	O
signal	O
that	O
is	O
linear	O
with	O
deubiquitylase	B-PROC
(	O
DUB	B-PROC
)	O
concentration	O
and	O
is	O
able	O
to	O
discriminate	O
DUB	B-PROC
,	O
deSUMOylase	O
,	O
deNEDDylase	O
,	O
and	O
deISGylase	O
activities	O
.	O

In	O
8	O
of	O
the	O
trials	O
(	O
n	O
=	O
633	O
),	O
the	O
ratio	O
of	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
to	O
inspired	B-PROC
fraction	O
of	O
oxygen	O
on	O
day	O
1	O
was	O
34	O
%	O
higher	O
among	O
patients	O
in	O
the	O
prone	O
position	O
than	O
among	O
those	O
who	O
remained	O
supine	O
(	O
p	O
<	O
0	O
.	O
001	O
);	O
these	O
results	O
were	O
similar	O
in	O
4	O
trials	O
on	O
day	O
2	O
and	O
in	O
5	O
trials	O
on	O
day	O
3	O
.	O

Mechanical	O
ventilation	O
in	O
the	O
prone	O
position	O
does	O
not	O
reduce	O
mortality	O
or	O
duration	O
of	O
ventilation	O
despite	O
improved	O
oxygenation	B-PROC
and	O
a	O
decreased	O
risk	O
of	O
pneumonia	O
.	O

The	O
most	O
promising	O
compounds	O
include	O
carbohydrate	O
-	O
binding	O
agents	O
,	O
neutralizing	O
antibodies	O
and	O
drugs	O
targeting	B-PROC
a	O
coronaviral	O
envelope	O
protein	O
.	O

Microscopic	O
examination	O
revealed	O
diffuse	O
alveolar	O
damage	O
with	O
hyaline	O
membrane	O
formation	B-PROC
and	O
interstitial	O
pneumonitis	O
with	O
infiltration	O
of	O
inflammatory	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
HEPIS	O
may	O
function	O
as	O
a	O
potential	O
transcriptional	B-PROC
repressor	O
.	O

We	O
report	O
two	O
cases	O
of	O
patients	O
suffering	O
from	O
severe	O
ARDS	O
who	O
beneficiated	O
from	O
extracorporeal	O
oxygenation	B-PROC
,	O
pointing	O
out	O
the	O
interest	O
of	O
this	O
technique	O
during	O
severe	O
ARDS	O
as	O
well	O
as	O
the	O
accessibility	O
and	O
the	O
feasibility	O
of	O
the	O
technique	O
even	O
apart	O
from	O
a	O
specialized	O
center	O
.	O

One	O
patient	O
died	B-PROC
of	O
progressive	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
pulmonary	O
hemorrhage	O
.	O

We	O
conclude	O
that	O
scrub	O
typhus	O
should	O
be	O
taken	O
into	O
consideration	O
among	O
patients	O
of	O
acute	O
systemic	O
febrile	B-PROC
illness	O
,	O
especially	O
those	O
with	O
suspected	O
exposure	O
history	O
and	O
typical	O
skin	O
lesion	O
.	O

The	O
oxygenation	B-PROC
parameters	O
,	O
protein	O
and	O
histological	O
data	O
were	O
similar	O
,	O
except	O
for	O
the	O
fact	O
that	O
significantly	O
more	O
normal	O
alveoli	O
were	O
observed	O
upon	O
protective	O
ventilation	O
.	O

Determination	O
of	O
the	O
lower	O
inflection	O
point	O
of	O
the	O
pressure	O
-	O
volume	O
curve	O
is	O
important	O
for	O
setting	O
the	O
minimum	O
end	O
expiratory	B-PROC
pressure	O
needed	O
to	O
keep	O
the	O
airways	O
opened	O
.	O

The	O
analysis	O
can	O
predict	O
the	O
temporal	O
trend	O
of	O
the	O
epidemic	O
given	O
its	O
spatial	O
pattern	O
,	O
to	O
estimate	O
spatial	O
exposure	O
given	O
temporal	O
evolution	B-PROC
,	O
and	O
to	O
infer	O
the	O
driving	O
forces	O
of	O
SARS	O
transmission	O
given	O
the	O
spatial	O
exposure	O
distribution	O
.	O

These	O
findings	O
demonstrate	O
the	O
significant	O
protection	O
of	O
CoPPIX	O
against	O
LPS	O
-	O
induced	O
ALI	O
,	O
and	O
the	O
effect	O
mechanism	O
of	O
CoPPIX	O
was	O
associated	O
with	O
decreasing	O
the	O
expression	B-PROC
of	O
TNF	O
-	O
a	O
and	O
Hmgb1	O
.	O

ABSTRACT	O
:	O
In	O
Bangladesh	O
,	O
4	O
outbreaks	O
of	O
Nipah	O
virus	B-PROC
infection	I-PROC
were	O
identified	O
during	O
the	O
period	O
2001	O
-	O
2004	O
.	O

These	O
results	O
enhance	O
our	O
understanding	O
of	O
host	O
adaptations	B-PROC
and	O
cross	O
-	O
species	O
infections	O
of	O
SARS	O
-	O
CoV	O
and	O
other	O
emerging	O
animal	O
viruses	O
.	O

By	O
expressing	O
a	O
U6	O
promoter	O
-	O
driven	O
small	O
interfering	O
RNA	O
containing	O
sequences	O
homologous	O
to	O
part	O
of	O
ACE2	O
mRNA	O
,	O
we	O
successfully	O
silenced	O
ACE2	O
expression	B-PROC
in	O
Vero	O
E6	O
cells	O
.	O

By	O
detecting	O
negative	O
strand	O
SARS	O
-	O
CoV	O
RNA	O
and	O
measuring	O
RNA	O
copy	O
numbers	O
of	O
SARS	O
-	O
CoV	O
by	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
we	O
demonstrated	O
that	O
SARS	O
-	O
CoV	O
infection	O
was	O
reduced	O
in	O
the	O
ACE2	O
-	O
silenced	O
cell	O
lines	O
.	O

Our	O
data	O
establish	O
a	O
vital	O
functional	O
dependence	O
of	O
SARS	O
-	O
CoV	O
RNA	B-PROC
synthesis	I-PROC
on	O
virus	O
-	O
induced	O
membrane	O
structures	O
.	O

Thirty	O
-	O
four	O
cases	O
(	O
24	O
.	O
1	O
%)	O
among	O
the	O
141	O
patients	O
died	B-PROC
.	O

The	O
evolution	B-PROC
of	O
these	O
viruses	O
occurs	O
through	O
some	O
features	O
:	O
the	O
generation	O
of	O
multiple	O
mutants	O
during	O
the	O
replication	O
resulting	O
on	O
a	O
quasispecies	O
structure	O
of	O
the	O
viral	O
population	O
,	O
the	O
demonstrated	O
ability	O
of	O
coronaviruses	O
to	O
establish	O
persistent	O
infections	O
,	O
the	O
flexibility	O
of	O
the	O
genome	O
due	O
to	O
a	O
high	O
frequency	O
of	O
homologue	O
or	O
heterologue	O
recombinations	B-PROC
,	O
the	O
ability	O
to	O
jump	O
barrier	O
species	O
and	O
to	O
adapt	O
to	O
the	O
new	O
environment	O
.	O

Clinical	O
diagnoses	O
included	O
9	O
pneumonia	O
,	O
6	O
bronchiolitis	O
,	O
2	O
cold	B-PROC
,	O
1	O
asthma	O
exacerbation	O
for	O
rhinovirus	O
;	O
10	O
pneumonia	O
,	O
4	O
bronchiolitis	O
,	O
and	O
1	O
clinical	O
sepsis	O
for	O
hPMV	O
;	O
and	O
1	O
pneumonia	O
,	O
2	O
croup	O
,	O
and	O
1	O
cold	B-PROC
for	O
coronavirus	O
.	O

Serologic	O
cross	O
-	O
reactivity	O
with	O
human	O
coronaviruses	O
causing	O
the	O
common	O
cold	B-PROC
may	O
be	O
a	O
problem	O
with	O
some	O
serologic	O
assays	O
.	O

We	O
investigated	O
serum	O
LD	O
isoenzymes	O
and	O
blood	O
lymphocyte	O
subsets	O
of	O
SARS	O
patients	O
,	O
and	O
found	O
LD1	O
activity	O
as	O
the	O
best	O
biochemical	O
prognostic	O
indicator	O
for	O
death	B-PROC
,	O
while	O
CD3	O
+,	O
CD4	O
+,	O
CD8	O
+	O
and	O
natural	O
killer	O
cell	O
counts	O
were	O
promising	O
predictors	O
for	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
.	O

Plasma	O
cytokine	O
and	O
chemokine	O
profiles	O
showed	O
markedly	O
elevated	O
Th1	O
cytokine	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
,	O
inflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
12	O
,	O
neutrophil	O
chemokine	O
IL	O
-	O
8	O
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
),	O
and	O
Th1	O
chemokine	O
IFN	O
-	O
gamma	O
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
)	O
for	O
at	O
least	O
two	O
weeks	O
after	O
disease	O
onset	O
,	O
but	O
there	O
was	O
no	O
significant	O
elevation	O
of	O
inflammatory	O
cytokine	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)-	O
alpha	O
and	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	O
-	O
10	O
.	O

These	O
patients	O
often	O
have	O
longer	O
courses	O
of	O
viral	B-PROC
shedding	I-PROC
and	O
undergo	O
higher	O
-	O
risk	O
procedures	O
that	O
may	O
potentially	O
generate	O
aerosols	O
,	O
such	O
as	O
intubation	O
,	O
bronchoscopy	O
,	O
bag	O
-	O
valve	O
mask	O
ventilation	O
,	O
noninvasive	O
positive	O
pressure	O
ventilation	O
,	O
and	O
medication	O
nebulization	O
,	O
further	O
illustrating	O
the	O
importance	O
of	O
early	O
detection	O
and	O
isolation	O
.	O

Effect	O
of	O
temperature	O
on	O
the	O
RNA	O
-	O
DNA	O
hybridization	B-PROC
was	O
also	O
examined	O
.	O

Further	O
investigations	O
of	O
target	O
antigen	O
included	O
reviews	O
of	O
phage	O
display	O
technique	O
,	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
RACE	O
)	O
technique	O
,	O
protein	B-PROC
expression	B-PROC
and	O
purification	O
,	O
Western	O
blotting	O
validation	O
,	O
serological	O
and	O
immunohistochemical	O
staining	O
in	O
postmortem	O
tissue	O
.	O

Moribund	O
adult	O
mice	O
showed	O
severe	O
pulmonary	O
edema	O
and	O
diffuse	O
alveolar	O
damage	O
accompanied	O
by	O
virus	B-PROC
replication	I-PROC
.	O

Finally	O
,	O
we	O
detected	O
the	O
amplified	O
target	O
cDNA	O
by	O
employing	O
the	O
functionalized	O
silica	O
coated	O
fluorescent	O
nanoparticles	O
as	O
signaling	B-PROC
probes	O
with	O
a	O
sandwich	O
hybridization	B-PROC
format	O
.	O

For	O
any	O
of	O
the	O
other	O
three	O
polymorphisms	B-PROC
,	O
however	O
,	O
no	O
significant	O
difference	O
can	O
be	O
detected	O
in	O
allele	O
or	O
genotype	O
frequencies	O
between	O
patients	O
and	O
controls	O
.	O

ABSTRACT	O
:	O
Viral	B-PROC
diseases	I-PROC
are	O
a	O
moving	B-PROC
world	O
with	O
epidemic	O
upsurges	O
,	O
the	O
disappearance	O
of	O
some	O
infections	O
and	O
the	O
temporary	O
or	O
definitive	O
appearance	O
of	O
others	O
.	O

Severity	O
of	O
malaria	O
-	O
induced	O
ALI	O
varied	O
in	O
a	O
panel	O
of	O
inbred	O
mouse	O
strains	O
,	O
and	O
development	B-PROC
of	O
ALI	O
correlated	O
with	O
peripheral	O
parasite	O
burden	O
but	O
not	O
CM	O
susceptibility	O
.	O

TITLE	O
:	O
Respiratory	O
dysfunction	O
in	O
sleep	B-PROC
apnea	O
associated	O
with	O
quetiapine	O
.	O

Respiratory	B-PROC
function	I-PROC
should	O
be	O
monitored	O
when	O
using	O
quetiapine	O
in	O
patients	O
with	O
possible	O
sleep	B-PROC
apnea	O
,	O
particularly	O
in	O
obese	O
patients	O
and	O
when	O
given	O
in	O
combination	O
with	O
benzodiazepines	O
.	O

In	O
the	O
current	O
study	O
,	O
12	O
BVDV	O
-	O
seronegative	O
heifers	O
were	O
inoculated	O
intranasally	O
with	O
a	O
2	O
-	O
ml	O
4	O
.	O
4	O
log	O
(	O
10	O
)	O
TCID	O
(	O
50	O
)/	O
ml	O
dose	O
of	O
noncytopathic	O
type	O
2	O
BVDV	O
at	O
75	O
and	O
175	O
days	O
of	O
gestation	B-PROC
to	O
create	O
persistently	O
and	O
transiently	O
infected	O
fetuses	O
,	O
respectively	O
.	O

Hospital	O
emergency	O
planning	O
could	O
be	O
more	O
robust	O
by	O
including	O
additional	O
organizational	O
supports	O
such	O
as	O
emotional	O
/	O
psychological	O
support	O
services	O
,	O
delineating	O
management	O
responsibilities	O
,	O
human	O
resources	O
,	O
vaccine	O
/	O
anti	O
-	O
viral	O
planning	O
,	O
recognition	O
/	O
compensation	B-PROC
,	O
media	O
strategies	O
,	O
and	O
professional	O
development	B-PROC
.	O

These	O
findings	O
may	O
lead	O
to	O
the	O
development	B-PROC
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
agents	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
causes	O
neuronal	O
death	B-PROC
in	O
the	O
absence	O
of	O
encephalitis	O
in	O
mice	O
transgenic	O
for	O
human	O
ACE2	O
.	O

Brain	O
infection	O
may	O
result	O
in	O
long	O
-	O
term	O
neurological	O
sequelae	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
-	O
CoV	O
in	O
this	O
organ	O
.	O

Death	B-PROC
of	O
the	O
animal	O
likely	O
results	O
from	O
dysfunction	O
and	O
/	O
or	O
death	B-PROC
of	O
infected	O
neurons	O
,	O
especially	O
those	O
located	O
in	O
cardiorespiratory	O
centers	O
in	O
the	O
medulla	O
.	O

Critical	O
illness	O
-	O
related	O
corticosteroid	O
insufficiency	O
is	O
caused	O
by	O
adrenal	O
insufficiency	O
together	O
with	O
tissue	O
corticosteroid	O
resistance	B-PROC
and	O
is	O
characterized	O
by	O
an	O
exaggerated	O
and	O
protracted	O
proinflammatory	O
response	O
.	O

At	O
this	O
time	O
,	O
the	O
diagnosis	O
of	O
tissue	O
corticosteroid	O
resistance	B-PROC
remains	O
problematic	O
.	O

Based	O
on	O
the	O
Coroners	O
'	O
suicide	O
death	B-PROC
records	O
,	O
overall	O
severity	O
of	O
illness	O
,	O
level	O
of	O
dependency	O
and	O
worrying	O
of	O
having	O
sickness	O
among	O
the	O
older	O
adult	O
suicides	O
were	O
found	O
to	O
be	O
significantly	O
different	O
in	O
the	O
pre	O
-	O
SARS	O
,	O
peri	O
-	O
SARS	O
and	O
post	O
-	O
SARS	O
periods	B-PROC
.	O

Attention	O
and	O
effort	B-PROC
should	O
also	O
be	O
made	O
to	O
enhance	O
the	O
community	O
'	O
s	O
ability	O
to	O
manage	O
fear	O
and	O
anxiety	O
,	O
especially	O
in	O
vulnerable	O
groups	O
over	O
the	O
period	O
of	O
epidemic	O
to	O
prevent	O
tragic	O
and	O
unnecessary	O
suicide	O
deaths	B-PROC
.	O

In	O
the	O
H5N1	O
/	O
PR8	O
-	O
5B19	O
virus	O
,	O
the	O
HA	O
cleavage	B-PROC
site	O
was	O
modified	O
to	O
resemble	O
that	O
of	O
low	O
-	O
pathogenic	O
avian	O
strains	O
and	O
a	O
portion	O
of	O
the	O
NA	O
stalk	O
region	O
was	O
replaced	O
by	O
the	O
immunodominant	O
5B19	O
epitope	O
of	O
the	O
S2	O
glycoprotein	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

The	O
finding	O
of	O
many	O
divergent	O
and	O
previously	O
unrecognized	O
HRV	O
strains	O
has	O
drawn	O
attention	O
and	O
resources	O
back	O
to	O
the	O
most	O
widespread	O
and	O
frequent	O
infectious	O
agent	O
of	O
humans	O
;	O
providing	O
us	O
the	O
chance	O
to	O
seize	O
the	O
advantage	O
in	O
a	O
decades	O
-	O
long	O
cold	B-PROC
war	O
.	O

I	O
also	O
provide	O
new	O
insight	O
on	O
how	O
the	O
SARS	O
-	O
associated	O
stigma	O
could	O
create	O
problems	O
for	O
public	O
health	O
development	B-PROC
in	O
Hong	O
Kong	O
.	O

RESULTS	O
:	O
Microscopic	O
examination	O
and	O
blood	B-PROC
gas	I-PROC
analysis	O
indicated	O
severe	O
injury	O
of	O
the	O
lung	O
tissues	O
in	O
ALI	O
group	O
.	O

The	O
second	O
antibody	B-PROC
in	O
the	O
kit	O
was	O
replaced	O
with	O
horseradish	O
peroxidase	O
-	O
conjugated	O
protein	O
-	O
A	O
(	O
HRP	O
-	O
SPA	O
)	O
based	O
on	O
the	O
characteristics	O
of	O
binding	O
between	O
Staphylococcus	O
aureus	O
protein	O
A	O
(	O
SPA	O
)	O
and	O
mammal	O
IgG	O
Fc	O
fragment	O
.	O

Rotavirus	O
also	O
has	O
marked	O
environmental	O
resistance	B-PROC
,	O
but	O
periodic	O
reintroduction	O
into	O
facilities	O
,	O
possibly	O
on	O
bags	O
of	O
feed	O
,	O
bedding	O
,	O
or	O
other	O
supplies	O
or	O
equipment	O
,	O
also	O
seems	O
likely	O
.	O

ABSTRACT	O
:	O
Viral	B-PROC
infection	I-PROC
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
results	O
in	O
varied	O
outcomes	O
ranging	O
from	O
encephalitis	O
,	O
paralytic	O
poliomyelitis	O
or	O
other	O
serious	O
consequences	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
programmed	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
in	O
coronavirus	O
propagation	O
.	O

Therefore	O
,	O
the	O
usage	O
of	O
this	O
drug	O
is	O
not	O
recommended	O
during	O
pregnancy	O
and	O
lactation	B-PROC
.	O

His	O
situation	O
further	O
declined	O
with	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Because	O
its	O
complications	O
are	O
life	O
threatening	O
,	O
when	O
we	O
see	O
a	O
patient	O
with	O
fever	B-PROC
and	O
eruptions	O
,	O
it	O
is	O
necessary	O
to	O
keep	O
in	O
mind	O
the	O
possibility	O
of	O
Tsutsugamushi	O
disease	O
.	O

TITLE	O
:	O
A	O
chimeric	O
multi	O
-	O
epitope	O
DNA	O
vaccine	O
elicited	O
specific	O
antibody	B-PROC
response	I-PROC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
which	O
attenuated	O
the	O
virulence	B-PROC
of	O
SARS	O
-	O
CoV	O
in	O
vitro	O
.	O

TITLE	O
:	O
[	O
Genetic	O
variation	O
of	O
S1	O
gene	O
hypervariable	O
region	O
I	O
of	O
infectious	O
bronchitis	O
viruses	O
isolated	O
in	O
different	O
periods	B-PROC
in	O
Guangxi	O
].	O

TITLE	O
:	O
Pathogenesis	B-PROC
of	O
feline	O
enteric	O
coronavirus	O
infection	O
.	O

Pregnancy	O
,	O
parturition	B-PROC
and	O
lactation	B-PROC
had	O
no	O
influence	O
on	O
fecal	O
shedding	O
by	O
queens	O
.	O

Evidence	O
is	O
presented	O
for	O
an	O
equilibrium	B-PROC
between	O
a	O
structured	O
trimer	O
thought	O
to	O
represent	O
a	O
prefusion	O
state	O
and	O
an	O
ensemble	O
of	O
unstructured	O
monomers	O
thought	O
to	O
represent	O
a	O
novel	O
transition	O
state	O
.	O

After	O
the	O
animals	O
were	O
euthanized	O
at	O
4	O
hours	O
treatment	O
time	O
point	O
,	O
the	O
right	O
middle	O
lobe	O
of	O
rabbit	O
lung	O
was	O
harvested	O
for	O
the	O
examination	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
contents	O
and	O
relative	O
values	O
,	O
as	O
well	O
as	O
mRNA	B-PROC
expression	B-PROC
of	O
caspase	O
-	O
3	O
and	O
p73	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
induce	O
in	O
infected	O
cells	O
the	O
formation	B-PROC
of	O
double	O
membrane	O
vesicles	O
,	O
which	O
are	O
the	O
sites	O
of	O
RNA	B-PROC
replication	I-PROC
.	O

Upon	O
loading	O
the	O
cell	O
samples	O
and	O
lysis	B-PROC
solution	O
into	O
the	O
mixing	O
chamber	O
,	O
the	O
integrated	O
microfluidic	O
device	O
allows	O
efficient	O
cell	O
disruption	O
by	O
rotation	O
of	O
a	O
micromagnetic	O
disk	O
and	O
control	O
of	O
mixing	O
time	O
using	O
the	O
Teflon	O
-	O
coated	O
hydrophobic	O
film	O
as	O
a	O
microvalve	O
.	O

It	O
was	O
used	O
for	O
the	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
an	O
infectious	O
viral	B-PROC
disease	I-PROC
,	O
as	O
an	O
example	O
case	O
.	O

Our	O
discoveries	O
may	O
have	O
some	O
implications	O
for	O
the	O
development	B-PROC
of	O
the	O
SARS	O
vaccine	O
.	O

Elevated	O
intracranial	B-PROC
pressure	I-PROC
causes	O
encephalopathy	O
and	O
the	O
risk	O
of	O
neuronal	O
damage	O
due	O
to	O
the	O
sharp	O
decrease	O
in	O
cerebral	O
perfusion	O
pressure	O
.	O

TITLE	O
:	O
A	O
structural	O
view	O
of	O
the	O
inactivation	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-PROC
by	O
benzotriazole	O
esters	O
.	O

TITLE	O
:	O
Peptides	O
from	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
as	O
tags	O
for	O
protein	B-PROC
expression	B-PROC
and	O
purification	O
.	O

The	O
data	O
show	O
recognition	O
of	O
prokaryotically	O
expressed	B-PROC
HIV	O
-	O
1	O
Gag	O
/	O
p24	O
fusion	O
protein	O
by	O
Western	O
blot	O
and	O
efficient	O
affinity	O
purification	O
using	O
monoclonal	O
antibodies	O
against	O
the	O
tags	O
.	O

The	O
SARS	O
peptide	O
antibody	B-PROC
system	O
described	O
presents	O
an	O
alternative	O
tagging	O
opportunity	O
in	O
the	O
growing	O
field	O
of	O
protein	O
science	O
.	O

The	O
disease	O
is	O
characterized	O
by	O
uncontrolled	O
replication	O
of	O
the	O
virus	O
and	O
a	O
prominent	O
pro	O
-	O
inflammatory	B-PROC
response	I-PROC
.	O

These	O
results	O
can	O
be	O
useful	O
for	O
the	O
development	B-PROC
of	O
new	O
compounds	O
against	O
SARS	O
.	O

Her	O
vocal	O
cord	O
movements	B-PROC
were	O
restored	O
to	O
near	O
normal	O
with	O
time	O
and	O
she	O
was	O
discharged	O
on	O
the	O
20th	O
day	O
after	O
admission	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
protective	O
T	O
-	O
cell	O
response	O
following	O
coronavirus	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
is	O
not	O
dependent	O
on	O
IL	O
-	O
12	O
/	O
23	O
signaling	B-PROC
.	O

All	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
by	O
conventional	O
RT	O
-	O
PCR	O
and	O
indirect	O
fluorescent	O
antibody	B-PROC
assay	O
(	O
IFA	O
)	O
for	O
all	O
tested	O
samples	O
.	O

With	O
IFA	O
as	O
a	O
reference	O
assay	O
,	O
sensitivity	O
and	O
specificity	O
of	O
D	O
-	O
IHC	O
were	O
98	O
and	O
58	O
%,	O
whereas	O
sensitivity	O
and	O
specificity	O
of	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
were	O
96	O
and	O
66	O
%,	O
calculated	O
from	O
the	O
total	O
of	O
tested	O
samples	O
from	O
experimental	O
infection	O
.	O

The	O
most	O
common	O
cause	O
(	O
27	O
%)	O
of	O
96	O
perinatal	O
deaths	B-PROC
was	O
asphyxia	O
alone	O
(	O
21	O
)	O
or	O
with	O
neonatal	O
sepsis	O
(	O
5	O
),	O
while	O
18	O
/	O
49	O
(	O
37	O
%)	O
early	O
and	O
9	O
/	O
19	O
(	O
47	O
%)	O
late	O
neonatal	O
deaths	B-PROC
were	O
from	O
respiratory	O
distress	O
syndrome	O
(	O
12	O
)	O
or	O
sepsis	O
(	O
9	O
)	O
alone	O
or	O
together	O
(	O
6	O
).	O

(	O
Correction	O
added	O
after	O
online	O
publication	O
5	O
June	O
2008	O
:	O
The	O
denominators	O
112	O
pregnancies	B-PROC
,	O
labours	O
,	O
and	O
labour	B-PROC
/	O
deliveries	O
,	O
and	O
16	O
and	O
68	O
neonates	O
were	O
included	O
;	O
and	O
9	O
%	O
of	O
labours	O
was	O
corrected	O
to	O
10	O
%.)	O

We	O
demonstrate	O
that	O
the	O
compounds	O
inhibited	O
SARS	O
-	O
CoV	O
replication	O
-	O
dependent	O
GFP	O
expression	B-PROC
in	O
the	O
replicon	O
cells	O
and	O
reduced	O
SARS	O
-	O
CoV	O
viral	O
protein	O
accumulation	O
and	O
viral	O
RNA	O
copy	O
number	O
in	O
the	O
replicon	O
cells	O
.	O

SARS	O
-	O
CoV	O
antigen	O
expression	B-PROC
occurred	O
mainly	O
in	O
type	O
I	O
and	O
II	O
pneumocytes	O
and	O
serous	O
cells	O
of	O
tracheo	O
-	O
bronchial	O
submucosal	O
glands	O
of	O
cats	O
and	O
in	O
type	O
II	O
pneumocytes	O
of	O
ferrets	O
.	O

In	O
most	O
cases	O
the	O
results	O
show	O
flexibility	O
in	O
the	O
P4	O
position	O
,	O
very	O
high	O
specificity	O
for	O
arginine	O
in	O
the	O
P3	O
position	O
and	O
glycine	O
in	O
the	O
P2	O
position	O
,	O
in	O
accord	O
with	O
the	O
sequence	O
of	O
the	O
natural	O
substrate	O
,	O
ubiquitin	B-PROC
.	O

Surprisingly	O
,	O
screening	O
of	O
the	O
P2	O
position	O
revealed	O
that	O
UCH	O
-	O
L3	O
,	O
in	O
contrast	O
with	O
all	O
the	O
other	O
tested	O
DUBs	O
,	O
demonstrates	O
substantial	O
tolerance	B-PROC
of	O
alanine	O
and	O
valine	O
at	O
P2	O
,	O
and	O
a	O
parallel	O
analysis	O
using	O
the	O
appropriate	O
mutation	O
of	O
the	O
full	O
-	O
length	O
ubiquitin	B-PROC
confirms	O
this	O
.	O

In	O
contrast	O
,	O
host	O
cell	O
entry	O
by	O
the	O
FIPV	O
strains	O
WSU	O
79	O
-	O
1146	O
(	O
FIPV	O
-	O
1146	O
)	O
and	O
FIPV	O
-	O
DF2	O
proceeds	O
independently	O
of	O
cathepsin	B-PROC
L	I-PROC
activity	I-PROC
and	O
low	O
pH	O
,	O
but	O
is	O
still	O
highly	O
dependent	O
on	O
cathepsin	B-PROC
B	I-PROC
activity	I-PROC
.	O

A	O
safer	O
in	O
vitro	O
system	O
is	O
desirable	O
for	O
conducting	B-PROC
research	O
on	O
SARS	O
-	O
CoV	O
and	O
to	O
screen	O
for	O
antiviral	O
drugs	O
against	O
the	O
virus	O
.	O

Successful	O
replication	O
was	O
achieved	O
as	O
evident	O
from	O
continuous	O
expression	B-PROC
of	O
eGFP	O
detected	O
by	O
both	O
fluorescence	O
and	O
Western	O
blot	O
.	O

As	O
part	O
of	O
such	O
efforts	O
,	O
a	O
simple	O
,	O
easy	O
to	O
use	O
immunoswab	O
method	O
was	O
developed	O
by	O
generating	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
(	O
MAbs	O
),	O
Bispecific	O
MAbs	O
and	O
chicken	O
polyclonal	O
IgY	O
antibody	B-PROC
against	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
(	O
NP	O
).	O

Tubular	O
function	O
alterations	O
precede	O
a	O
decrease	O
in	O
the	O
glomerular	B-PROC
filtration	I-PROC
rate	O
,	O
which	O
could	O
explain	O
the	O
high	O
frequency	O
of	O
hypokalemia	O
.	O

In	O
agreement	O
,	O
SL	O
-	O
CoV	O
S	O
DNA	O
vaccine	O
evoked	O
a	O
more	O
vigorous	O
antibody	B-PROC
response	I-PROC
and	O
a	O
stronger	O
T	O
cell	O
response	O
than	O
SARS	O
-	O
CoV	O
S	O
DNA	O
in	O
mice	O
.	O

Finding	O
in	O
this	O
study	O
may	O
provide	O
important	O
information	O
for	O
vaccine	O
development	B-PROC
as	O
well	O
as	O
for	O
understanding	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
-	O
like	O
CoV	O
.	O

Characteristic	O
changes	O
in	O
RNS	O
,	O
preceding	O
the	O
development	B-PROC
of	O
IMS	O
,	O
help	O
to	O
identify	O
a	O
subgroup	O
of	O
patients	O
at	O
high	O
risk	O
of	O
developing	O
respiratory	O
failure	O
.	O

Moreover	O
,	O
phosphorylation	B-PROC
of	O
the	O
RS	O
motif	O
could	O
modulate	O
the	O
translation	B-PROC
inhibitory	O
activity	O
of	O
the	O
nucleocapsid	O
protein	O
.	O

When	O
expressed	B-PROC
independently	O
or	O
during	O
virus	B-PROC
infection	I-PROC
,	O
ORF7b	O
accumulates	O
in	O
the	O
Golgi	O
compartment	O
,	O
colocalizing	O
with	O
both	O
cis	O
-	O
and	O
trans	O
-	O
Golgi	O
markers	O
.	O

ABSTRACT	O
:	O
The	O
relationship	O
between	O
immunosenescence	O
and	O
the	O
host	O
response	B-PROC
to	I-PROC
virus	I-PROC
infection	O
is	O
poorly	O
understood	O
at	O
the	O
molecular	O
level	O
.	O

Interestingly	O
,	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
aged	O
mice	O
,	O
a	O
subset	O
of	O
genes	O
,	O
including	O
Tnfa	O
,	O
Il6	O
,	O
Ccl2	O
,	O
Ccl3	O
,	O
Cxcl10	O
,	O
and	O
Ifng	O
,	O
was	O
induced	O
in	O
a	O
biphasic	O
pattern	O
that	O
correlated	O
with	O
peak	O
viral	B-PROC
replication	I-PROC
and	O
a	O
subsequent	O
influx	O
of	O
lymphocytes	O
and	O
severe	O
histopathologic	O
changes	O
in	O
the	O
lungs	O
.	O

In	O
the	O
intrinsic	O
pathway	B-PROC
,	O
there	O
was	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
cytochrome	B-PROC
c	I-PROC
release	O
from	O
the	O
mitochondria	O
.	O

The	O
genetic	O
evolution	B-PROC
of	O
dog	O
CoVs	O
is	O
paradigmatic	O
of	O
how	O
CoVs	O
evolve	O
through	O
accumulation	O
of	O
point	B-PROC
mutations	I-PROC
,	O
insertions	O
or	O
deletions	O
in	O
the	O
viral	O
genome	O
,	O
that	O
led	O
to	O
the	O
emergence	O
of	O
new	O
genotypes	O
(	O
CCoV	O
type	O
I	O
),	O
biotypes	O
(	O
pantropic	O
CCoV	O
)	O
and	O
host	O
variants	O
(	O
canine	O
respiratory	O
coronavirus	O
).	O

ABSTRACT	O
:	O
Pumpless	O
extracorporeal	O
lung	O
assist	O
(	O
PECLA	O
)	O
was	O
developed	O
to	O
support	O
pulmonary	B-PROC
function	I-PROC
in	O
patients	O
with	O
severe	O
respiratory	O
insufficiency	O
.	O

TITLE	O
:	O
Relationship	O
between	O
treatment	O
resistance	B-PROC
to	O
hemoperfusion	O
using	O
a	O
polymyxin	O
B	O
-	O
immobilized	O
fiber	O
column	O
and	O
oxidative	O
stress	O
.	O

Heterozygous	O
PBEF	O
(+/-)	O
mice	O
were	O
significantly	O
protected	O
(	O
reduced	O
BAL	O
protein	O
,	O
BAL	O
IL	O
-	O
6	O
levels	O
,	O
peak	O
inspiratory	B-PROC
pressures	O
)	O
when	O
exposed	O
to	O
a	O
model	O
of	O
severe	O
VILI	O
(	O
4	O
h	O
,	O
40	O
ml	O
/	O
kg	O
tidal	O
volume	O
)	O
and	O
exhibited	O
significantly	O
reduced	O
expression	B-PROC
of	O
VILI	O
-	O
associated	O
gene	B-PROC
expression	I-PROC
modules	O
.	O

Finally	O
,	O
strategies	O
to	O
reduce	O
PBEF	O
availability	O
(	O
neutralizing	O
antibody	B-PROC
)	O
resulted	O
in	O
significant	O
protection	O
from	O
VILI	O
.	O

406	O
pregnant	O
women	O
with	O
acute	O
respiratory	O
viral	B-PROC
infection	I-PROC
(	O
ARVI	O
)	O
during	O
pregnancy	O
were	O
delivered	O
to	O
Tashkent	O
perinatal	O
center	O
in	O
2002	O
-	O
2004	O
ages	O
.	O

When	O
infected	O
with	O
MHV	O
,	O
mice	O
deficient	O
in	O
IFN	O
-	O
associated	O
receptor	B-PROC
expression	B-PROC
(	O
IFNAR	O
(-/-))	O
became	O
moribund	O
by	O
48	O
h	O
postinfection	O
.	O

Thus	O
,	O
MHV	O
induces	O
type	O
I	O
IFN	O
in	O
macrophages	O
and	O
microglia	O
in	O
the	O
brains	O
of	O
infected	O
animals	O
and	O
is	O
recognized	O
by	O
an	O
MDA5	O
-	O
dependent	O
pathway	B-PROC
in	O
macrophages	O
.	O

Detailed	O
study	O
of	O
RAGE	O
in	O
the	O
pulmonary	O
tissues	O
will	O
facilitate	O
the	O
understanding	O
of	O
the	O
importance	O
of	O
RAGE	O
signaling	B-PROC
in	O
the	O
pulmonary	O
health	O
and	O
pathophysiology	O
.	O

Typical	O
avascular	O
necrosis	B-PROC
at	O
different	O
stages	O
and	O
severities	O
was	O
found	O
on	O
bone	O
scintigraphy	O
at	O
31	O
femoral	O
heads	O
of	O
16	O
SARS	O
patients	O
,	O
97	O
%	O
of	O
which	O
were	O
MRI	O
positive	O
.	O

Viral	B-PROC
infections	I-PROC
are	O
common	O
in	O
adults	O
with	O
pneumonia	O
.	O

In	O
the	O
subgroup	O
of	O
patients	O
with	O
severe	O
ARDS	O
due	O
to	O
pneumonia	O
or	O
aspiration	O
,	O
surfactant	O
treatment	O
was	O
associated	O
with	O
markedly	O
improved	O
oxygenation	B-PROC
(	O
p	O
=	O
0	O
.	O
0008	O
)	O
and	O
improved	O
survival	O
(	O
p	O
=	O
0	O
.	O
018	O
).	O

In	O
the	O
subgroup	O
of	O
patients	O
with	O
severe	O
ARDS	O
due	O
to	O
pneumonia	O
or	O
aspiration	O
,	O
surfactant	O
treatment	O
was	O
associated	O
with	O
markedly	O
improved	O
oxygenation	B-PROC
(	O
p	O
=	O
0	O
.	O
0008	O
)	O
and	O
improved	O
survival	O
(	O
p	O
=	O
0	O
.	O
018	O
).	O

We	O
propose	O
that	O
both	O
forms	O
of	O
the	O
Nsp9	O
dimer	O
are	O
biologically	O
relevant	O
;	O
the	O
occurrence	O
of	O
the	O
disulfide	O
-	O
bonded	O
form	O
may	O
be	O
correlated	O
with	O
oxidative	O
stress	O
induced	O
in	O
the	O
host	O
cell	O
by	O
the	O
viral	B-PROC
infection	I-PROC
.	O

A	O
variable	O
number	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
polymorphism	B-PROC
in	O
its	O
neck	O
region	O
was	O
recently	O
associated	O
with	O
susceptibility	O
to	O
SARS	O
infection	O
.	O

Because	O
cystatins	O
added	O
to	O
cell	O
cultures	O
can	O
inhibit	O
polio	O
,	O
herpes	O
simplex	O
and	O
coronavirus	O
replication	O
,	O
which	O
are	O
intracellular	O
processes	O
,	O
the	O
internalization	O
and	O
intracellular	O
regulation	B-PROC
of	O
cysteine	O
proteases	O
by	O
cystatin	O
C	O
should	O
be	O
considered	O
.	O

Sepsis	O
is	O
still	O
a	O
vital	O
risk	O
factor	O
referring	O
to	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
,	O
infection	O
,	O
and	O
secondary	O
multiple	O
organs	O
dysfunction	O
.	O

Furthermore	O
,	O
it	O
was	O
identified	O
that	O
budded	O
virus	O
(	O
BV	O
)	O
can	O
induce	O
antiviral	O
effects	O
in	O
HD	O
11	O
cells	O
contrary	O
to	O
occlusion	B-PROC
-	O
derived	O
virus	O
(	O
ODV	O
).	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
spread	O
from	O
China	O
to	O
more	O
than	O
30	O
countries	O
,	O
causing	O
severe	O
outbreaks	O
of	O
atypical	O
pneumonia	O
and	O
over	O
800	O
deaths	B-PROC
worldwide	O
.	O

All	O
these	O
data	O
suggest	O
that	O
ORF	O
-	O
6	O
induces	O
apoptosis	B-PROC
via	O
Caspase	O
-	O
3	O
mediated	O
,	O
ER	O
stress	O
and	O
JNK	O
-	O
dependent	O
pathways	B-PROC
.	O

The	O
cellular	B-PROC
localisation	I-PROC
and	O
function	O
of	O
the	O
SARS	O
-	O
CoV	O
accessory	O
proteins	O
was	O
determined	O
.	O

RBD	O
-	O
rAAV	O
vaccination	O
provoked	O
a	O
prolonged	O
antibody	B-PROC
response	I-PROC
with	O
continually	O
increasing	O
levels	O
of	O
neutralising	O
activity	O
.	O

Deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
S1	O
glycoprotein	O
indicated	O
differences	O
between	O
strains	O
that	O
were	O
,	O
in	O
general	O
,	O
consistent	O
with	O
virus	B-PROC
neutralization	I-PROC
patterns	O
.	O

ABSTRACT	O
:	O
Myocarditis	O
is	O
caused	O
frequently	O
by	O
viral	B-PROC
infections	I-PROC
of	O
the	O
myocardium	O
.	O

ABSTRACT	O
:	O
Antigenic	O
group	O
2	O
coronavirus	O
was	O
detected	O
in	O
a	O
fecal	O
sample	O
of	O
an	O
adult	O
alpaca	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Haemophagocytic	O
lymphohistiocytosis	O
secondary	O
to	O
viral	B-PROC
infection	I-PROC
is	O
an	O
unusual	O
but	O
well	O
recognised	O
cause	O
of	O
bone	O
marrow	O
dysfunction	O
and	O
multiple	O
organ	O
failure	O
in	O
young	O
patients	O
.	O

Serological	O
tests	O
and	O
bone	O
marrow	O
examination	O
with	O
in	O
-	O
situ	O
hybridisation	B-PROC
revealed	O
severe	O
acquired	O
haemophagocytic	O
lymphohistiocytosis	O
secondary	O
to	O
acute	O
Epstein	O
-	O
Barr	O
virus	B-PROC
infection	I-PROC
.	O

Both	O
patients	O
died	B-PROC
despite	O
full	O
supportive	O
therapy	O
;	O
the	O
first	O
due	O
to	O
pulmonary	O
haemorrhage	O
,	O
the	O
second	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
refractory	O
to	O
high	O
frequency	O
oscillatory	O
ventilation	O
.	O

However	O
,	O
despite	O
high	O
neutralizing	O
antibody	B-PROC
titres	O
,	O
protection	O
was	O
incomplete	O
for	O
all	O
vaccine	O
preparations	O
and	O
administration	O
routes	O
.	O

Syrian	O
golden	O
hamsters	O
are	O
among	O
the	O
best	O
small	O
animal	O
models	O
,	O
though	O
little	O
clinical	O
illness	O
and	O
no	O
mortality	O
are	O
observed	O
after	O
virus	B-PROC
infection	I-PROC
.	O

The	O
resultant	O
recombinant	O
protein	O
was	O
produced	O
and	O
used	O
in	O
antibody	B-PROC
detection	O
assays	O
via	O
western	O
blot	O
analysis	O
of	O
serum	O
samples	O
.	O

Hospital	O
admissions	O
were	O
more	O
frequent	O
during	O
months	O
of	O
higher	O
respiratory	B-PROC
circulation	B-PROC
.	O

TITLE	O
:	O
The	O
studies	O
on	O
the	O
aetiology	O
of	O
diarrhoea	O
in	O
neonatal	O
calves	O
and	O
determination	O
of	O
virulence	B-PROC
gene	O
markers	O
of	O
Escherichia	O
coli	O
strains	O
by	O
multiplex	O
PCR	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
known	O
to	O
take	O
an	O
endosomal	O
pathway	B-PROC
for	O
cell	O
entry	O
;	O
however	O
,	O
it	O
is	O
thought	O
to	O
enter	O
directly	O
from	O
the	O
cell	O
surface	O
when	O
a	O
receptor	O
-	O
bound	O
virion	O
spike	O
(	O
S	O
)	O
protein	O
is	O
affected	O
by	O
trypsin	O
,	O
which	O
induces	O
cleavage	B-PROC
of	O
the	O
S	O
protein	O
and	O
activates	O
its	O
fusion	O
potential	O
.	O

ABSTRACT	O
:	O
The	O
extracellular	O
superoxide	O
dismutase	O
3	O
(	O
SOD3	O
)	O
is	O
highly	O
expressed	B-PROC
in	O
both	O
blood	O
vessels	O
and	O
lungs	O
.	O

Symptoms	O
of	O
PTS	O
and	O
of	O
depression	O
,	O
and	O
having	O
used	O
drinking	B-PROC
as	O
a	O
coping	O
method	O
,	O
were	O
also	O
significantly	O
associated	O
with	O
increased	O
alcohol	O
abuse	O
/	O
dependence	O
symptoms	O
.	O

However	O
,	O
SARS	O
-	O
CoV	O
M	O
protein	O
is	O
co	O
-	O
localized	O
almost	O
entirely	O
with	O
S	O
,	O
E	O
,	O
or	O
NC	O
protein	O
when	O
co	O
-	O
expressed	B-PROC
in	O
the	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
M	O
protein	O
,	O
similar	O
to	O
the	O
M	O
proteins	O
of	O
other	O
coronaviruses	O
,	O
plays	O
a	O
pivotal	O
role	O
in	O
virus	B-PROC
assembly	I-PROC
.	O

The	O
training	O
model	O
included	O
nosocomial	O
infection	O
control	O
guidelines	O
,	O
a	O
training	O
CD	O
,	O
training	O
program	O
,	O
evaluation	O
form	O
,	O
and	O
descriptive	O
procedures	O
for	O
conducting	B-PROC
training	O
and	O
evaluation	O
.	O

ABSTRACT	O
:	O
Design	O
,	O
synthesis	B-PROC
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
5	O
-	O
chloropyridine	O
ester	O
-	O
derived	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
chymotrypsin	O
-	O
like	O
protease	B-PROC
inhibitors	I-PROC
is	O
described	O
.	O

Generally	O
,	O
their	O
ultrastructure	O
,	O
morphogenesis	B-PROC
,	O
and	O
exact	O
role	O
in	O
viral	B-PROC
replication	I-PROC
remain	O
to	O
be	O
defined	O
.	O

Our	O
data	O
document	O
the	O
extensive	O
virus	O
-	O
induced	O
reorganization	O
of	O
host	O
cell	O
membranes	O
into	O
a	O
network	O
that	O
is	O
used	O
to	O
organize	O
viral	B-PROC
replication	I-PROC
and	O
possibly	O
hide	O
replicating	O
RNA	O
from	O
antiviral	O
defense	O
mechanisms	O
.	O

Our	O
cases	O
show	O
that	O
DL	O
may	O
help	O
patients	O
with	O
SAP	O
to	O
recover	B-PROC
from	O
severe	O
respiratory	O
failure	O
.	O

These	O
discoveries	O
establish	O
coronaviruses	O
as	O
important	O
human	O
pathogens	O
and	O
underscore	O
the	O
need	O
for	O
continued	O
research	O
toward	O
the	O
development	B-PROC
of	O
platforms	O
that	O
will	O
enable	O
genetic	O
manipulation	O
of	O
the	O
viral	O
genome	O
,	O
allowing	O
for	O
rapid	O
and	O
rational	O
development	B-PROC
and	O
testing	O
of	O
candidate	O
vaccines	O
,	O
vaccine	O
vectors	O
,	O
and	O
therapeutics	O
.	O

In	O
order	O
to	O
more	O
fully	O
appreciate	O
the	O
potential	O
effect	O
of	O
the	O
ABO	O
polymorphism	B-PROC
on	O
the	O
epidemiology	O
of	O
SARS	O
,	O
we	O
built	O
a	O
mathematical	O
model	O
of	O
the	O
virus	O
transmission	O
dynamics	O
that	O
takes	O
into	O
account	O
the	O
protective	O
effect	O
of	O
ABO	O
natural	O
antibodies	O
.	O

Outcomes	O
were	O
development	B-PROC
of	O
ALI	O
(	O
ICD	O
-	O
9	O
-	O
CM	O
:	O
570	O
.	O
0	O
,	O
572	O
.	O
2	O
,	O
573	O
.	O
3	O
),	O
in	O
-	O
hospital	O
mortality	O
,	O
severe	O
liver	O
failure	O
,	O
and	O
resource	O
utilization	O
.	O

The	O
expression	B-PROC
of	O
CD69	O
on	O
liver	O
NK	O
cells	O
was	O
highly	O
up	O
-	O
regulated	O
after	O
the	O
infection	O
and	O
the	O
cytotoxic	O
activity	O
of	O
hepatic	O
NK	O
cells	O
at	O
48	O
h	O
was	O
also	O
significantly	O
enhanced	O
.	O

TITLE	O
:	O
A	O
SARS	O
DNA	O
vaccine	O
induces	O
neutralizing	O
antibody	B-PROC
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
in	O
healthy	O
adults	O
in	O
a	O
Phase	O
I	O
clinical	O
trial	O
.	O

Over	O
8000	O
cases	O
and	O
900	O
deaths	B-PROC
occurred	O
during	O
the	O
epidemic	O
.	O

TITLE	O
:	O
Design	O
and	O
synthesis	B-PROC
of	O
cinanserin	O
analogs	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3CL	O
protease	B-PROC
inhibitors	I-PROC
.	O

Single	O
nucleotide	O
polymorphisms	B-PROC
were	O
individually	O
assessed	O
at	O
the	O
genotype	O
level	O
,	O
and	O
multiple	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
adjust	O
for	O
baseline	O
variables	O
.	O

Haplotype	O
analyses	O
of	O
sliding	O
windows	O
including	O
2	O
-	O
5	O
single	O
nucleotide	O
polymorphisms	B-PROC
were	O
conducted	O
.	O

Experience	O
with	O
human	O
immunodeficiency	O
virus	O
/	O
acquired	O
immunodeficiency	O
syndrome	O
,	O
the	O
return	O
of	O
cholera	O
to	O
the	O
Americas	O
in	O
1991	O
,	O
the	O
plague	O
outbreak	O
in	O
India	O
in	O
1994	O
,	O
and	O
the	O
emergence	O
of	O
Ebola	O
in	O
Zaire	O
in	O
1995	O
created	O
awareness	O
of	O
a	O
new	O
vulnerability	O
to	O
epidemics	O
due	O
to	O
population	O
growth	B-PROC
,	O
unplanned	O
urbanization	O
,	O
antimicrobial	O
resistance	B-PROC
,	O
poverty	O
,	O
societal	O
change	O
,	O
and	O
rapid	O
mass	O
movement	B-PROC
of	O
people	O
.	O

In	O
addition	O
,	O
the	O
absence	O
of	O
the	O
A1	O
allele	O
also	O
appeared	O
to	O
be	O
associated	O
with	O
the	O
development	B-PROC
of	O
community	O
-	O
acquired	O
pneumonia	O
-	O
induced	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
odds	O
ratio	O
=	O
3	O
.	O
1	O
,	O
confidence	O
interval	O
,	O
0	O
.	O
99	O
-	O
9	O
.	O
67	O
).	O

The	O
novel	O
immunogenic	O
chimeric	O
multi	O
-	O
epitope	O
DNA	O
vaccine	O
revealed	O
in	O
this	O
study	O
provided	O
a	O
new	O
candidate	O
target	O
for	O
IBV	O
vaccine	O
development	B-PROC
.	O

Among	O
the	O
farms	O
,	O
Farm	O
A	O
showed	O
a	O
high	O
antibody	B-PROC
incidence	O
.	O

How	O
these	O
structures	O
are	O
assembled	O
is	O
still	O
largely	O
unknown	O
,	O
but	O
it	O
is	O
likely	O
that	O
the	O
membrane	O
-	O
spanning	O
members	O
of	O
these	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
are	O
responsible	O
for	O
the	O
induction	O
of	O
the	O
double	O
-	O
membrane	O
vesicles	O
and	O
for	O
anchoring	B-PROC
the	O
replication	O
complexes	O
to	O
these	O
membranes	O
.	O

To	O
look	O
into	O
this	O
incongruity	O
,	O
we	O
studied	O
the	O
membrane	O
disposition	O
of	O
nsp3	O
and	O
nsp6	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
murine	O
hepatitis	O
virus	O
by	O
analyzing	O
tagged	O
forms	O
of	O
the	O
proteins	O
expressed	B-PROC
in	O
cultured	O
cells	O
.	O

Comparative	O
genetic	O
analysis	O
of	O
CoVs	O
of	O
captive	O
wild	O
ruminants	O
with	O
BCoV	O
strains	O
suggests	O
that	O
no	O
specific	O
genomic	O
markers	O
are	O
present	O
that	O
allow	O
discrimination	O
between	O
the	O
bovine	O
strains	O
and	O
bovine	O
-	O
like	O
CoVs	O
from	O
captive	O
wild	O
ruminants	O
;	O
furthermore	O
,	O
no	O
specific	O
genetic	B-PROC
markers	I-PROC
were	O
identified	O
that	O
defined	O
cell	O
cultured	O
or	O
calf	O
-	O
passaged	O
strains	O
or	O
the	O
host	O
origin	O
of	O
strains	O
.	O

ABSTRACT	O
:	O
Apolipoprotein	B-PROC
D	O
(	O
apoD	O
)	O
is	O
a	O
lipocalin	O
upregulated	O
in	O
the	O
nervous	O
system	O
after	O
injury	O
or	O
pathologies	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
,	O
Parkinson	O
'	O
s	O
disease	O
,	O
and	O
multiple	O
sclerosis	O
.	O

Further	O
investigation	O
into	O
similarities	O
and	O
pathways	B-PROC
common	O
in	O
AEs	O
of	O
various	O
fibrotic	O
lung	O
diseases	O
may	O
yield	O
additional	O
insight	O
into	O
this	O
recently	O
recognized	O
syndrome	O
.	O

Secondary	O
deterioration	O
of	O
respiratory	B-PROC
function	I-PROC
is	O
not	O
part	O
of	O
the	O
natural	O
history	O
of	O
ARDS	O
and	O
should	O
suggest	O
other	O
diagnoses	O
.	O

The	O
data	O
suggest	O
that	O
the	O
native	O
form	O
of	O
HCoV	O
-	O
HKU1	O
spike	O
expressed	B-PROC
in	O
our	O
system	O
can	O
be	O
used	O
in	O
developing	O
serological	O
diagnostic	O
assay	O
and	O
in	O
understanding	O
the	O
role	O
of	O
S	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
.	O

In	O
immunocompetent	O
hosts	O
,	O
antiviral	O
therapy	O
can	O
be	O
stopped	O
early	O
because	O
adaptive	B-PROC
immune	I-PROC
response	I-PROC
can	O
usually	O
be	O
mounted	O
within	O
5	O
-	O
14	O
days	O
.	O

TITLE	O
:	O
Acute	O
death	B-PROC
in	O
heartworm	O
-	O
infected	O
cats	O
:	O
unraveling	O
the	O
puzzle	O
.	O

In	O
women	O
with	O
cervical	O
changes	O
,	O
by	O
application	O
of	O
hybridization	B-PROC
technique	O
in	O
situ	O
,	O
the	O
most	O
frequently	O
identified	O
virus	O
genotypes	O
are	O
human	O
papilloma	O
viruses	O
16	O
and	O
18	O
(	O
in	O
21	O
.	O
67	O
%),	O
genotypes	O
6	O
and	O
11	O
in	O
8	O
.	O
33	O
%	O
and	O
genotypes	O
31	O
,	O
33	O
and	O
35	O
in	O
3	O
.	O
33	O
%	O
examined	O
women	O
.	O

Viruses	O
are	O
important	O
agents	O
involved	O
in	O
various	O
disorders	O
of	O
the	O
immunological	O
homeostasis	B-PROC
of	O
the	O
organism	O
.	O

Hemodynamics	B-PROC
,	O
respiratory	B-PROC
mechanics	I-PROC
and	O
gas	O
exchange	O
were	O
measured	O
15	O
minutes	O
after	O
each	O
PEEP	O
level	O
was	O
applied	O
,	O
and	O
lung	O
specimens	O
for	O
pathological	O
examination	O
were	O
harvested	O
after	O
sacrifice	O
of	O
the	O
animals	O
.	O

Compared	O
to	O
supine	O
position	O
,	O
prone	O
position	O
improved	O
oxygenation	B-PROC
index	O
(	O
PaO2	O
/	O
FiO2	O
)	O
at	O
ZEEP	O
and	O
PEEP10	O
[	O
ZEEP	O
:	O
(	O
234	O
.	O
00	O
+/-	O
72	O
.	O
55	O
)	O
mm	O
Hg	O
vs	O
.	O
(	O
106	O
.	O
58	O
+/-	O
34	O
.	O
93	O
)	O
mm	O
Hg	O
,	O
PEEP10	O
:	O
(	O
342	O
.	O
97	O
+/-	O
60	O
.	O
15	O
)	O
mm	O
Hg	O
vs	O
.	O
(	O
246	O
.	O
80	O
+/-	O
83	O
.	O
69	O
)	O
mm	O
Hg	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
,	O
both	O
P	O
<	O
0	O
.	O
05	O
],	O
but	O
not	O
at	O
PEEP20	O
.	O

This	O
study	O
reveals	O
what	O
is	O
probably	O
a	O
new	O
internalization	O
pathway	B-PROC
into	O
primary	O
monocytes	O
,	O
confirming	O
once	O
more	O
the	O
complexity	O
of	O
endocytic	O
processes	O
.	O

Based	O
on	O
sequence	O
similarity	O
,	O
human	O
PP11	O
was	O
included	O
in	O
a	O
protein	O
family	O
whose	O
characterized	O
members	O
are	O
XendoU	O
,	O
a	O
Xenopus	O
laevis	O
endoribonuclease	O
involved	O
in	O
small	O
nucleolar	O
RNA	B-PROC
processing	I-PROC
,	O
and	O
Nsp15	O
,	O
an	O
endoribonuclease	O
essential	O
for	O
coronavirus	O
replication	O
.	O

Here	O
we	O
show	O
that	O
the	O
bacterially	O
expressed	B-PROC
human	O
PP11	O
displays	O
RNA	O
binding	O
capability	O
and	O
cleaves	O
single	O
stranded	O
RNA	O
in	O
a	O
Mn	O
(	O
2	O
+)-	O
dependent	O
manner	O
at	O
uridylates	O
,	O
to	O
produce	O
molecules	O
with	O
2	O
',	O
3	O
'-	O
cyclic	O
phosphate	O
ends	O
.	O

Lung	B-PROC
function	I-PROC
,	O
mechanics	O
,	O
pathology	O
,	O
leukocyte	O
infiltration	O
,	O
and	O
local	O
cytokine	O
levels	O
were	O
measured	O
after	O
6	O
hrs	O
.	O

A	O
number	O
of	O
different	O
types	O
of	O
vaccines	O
,	O
such	O
as	O
inactivated	O
virus	O
vaccine	O
,	O
subunit	O
vaccine	O
,	O
DNA	O
vaccine	O
and	O
vaccine	O
using	O
viral	O
expression	B-PROC
vector	O
as	O
well	O
as	O
attenuated	O
live	O
vaccine	O
so	O
far	O
reported	O
indicate	O
that	O
neutralizing	O
antibodies	O
play	O
an	O
important	O
role	O
for	O
protection	O
.	O

Nasal	O
discharge	O
was	O
recorded	O
,	O
and	O
antibody	B-PROC
response	I-PROC
and	O
virus	O
shedding	O
were	O
measured	O
.	O

These	O
findings	O
increase	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

Significant	O
associations	O
of	O
coronavirus	O
seropositivity	O
and	O
antibody	B-PROC
levels	O
with	O
age	O
,	O
gender	O
,	O
race	O
,	O
socioeconomic	O
status	O
,	O
smoking	O
status	O
,	O
and	O
season	O
of	O
the	O
blood	O
draw	O
were	O
tested	O
with	O
chi	O
-	O
square	O
and	O
regression	O
analyses	O
.	O

Mycobacteria	O
were	O
identified	O
after	O
patient	O
'	O
s	O
death	B-PROC
on	O
the	O
smear	O
from	O
BAL	O
,	O
from	O
blood	O
cultures	O
,	O
and	O
in	O
a	O
postmortem	O
liver	O
biopsy	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
association	O
of	O
a	O
previous	O
history	O
of	O
varicella	O
virus	B-PROC
infection	I-PROC
with	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
and	O
its	O
subtypes	O
.	O

ABSTRACT	O
:	O
The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
N	O
-	O
aryl	O
-	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)	O
thiocarbamates	O
(	O
C	O
-	O
TCs	O
)	O
and	O
their	O
imide	O
ring	O
-	O
opened	O
congeners	O
(	O
O	O
-	O
TCs	O
)	O
as	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-PROC
transcriptase	I-PROC
inhibitors	I-PROC
were	O
further	O
investigated	O
.	O

The	O
SAR	O
strategy	O
involved	O
modifications	O
of	O
the	O
N	O
-	O
phenyl	O
ring	O
followed	O
by	O
the	O
hybridization	B-PROC
of	O
the	O
most	O
promising	O
N	O
-	O
aryl	O
and	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)	O
substructures	O
.	O

Seventy	O
-	O
six	O
analogues	O
were	O
prepared	O
by	O
parallel	O
solution	O
-	O
phase	O
synthesis	B-PROC
.	O

These	O
results	O
suggest	O
that	O
the	O
middle	O
or	O
C	O
-	O
terminal	O
region	O
of	O
the	O
SARS	O
N	O
protein	O
is	O
important	O
for	O
eliciting	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
during	O
the	O
immune	B-PROC
response	I-PROC
,	O
and	O
ELISA	O
reactions	O
using	O
N1	O
or	O
N3	O
may	O
be	O
a	O
valuable	O
tool	O
for	O
SARS	O
diagnosis	O
.	O

ABSTRACT	O
:	O
Mechanical	O
circulatory	B-PROC
support	O
has	O
evolved	O
markedly	O
over	O
recent	O
years	O
.	O

By	O
using	O
infectious	O
viruses	O
and	O
pseudotyped	O
viruses	O
bearing	O
the	O
229E	O
S	O
protein	O
,	O
we	O
found	O
that	O
its	O
infection	O
was	O
profoundly	O
blocked	O
by	O
lysosomotropic	O
agents	O
as	O
well	O
as	O
by	O
protease	B-PROC
inhibitors	I-PROC
that	O
also	O
prevented	O
infection	O
with	O
SARS	O
-	O
CoV	O
but	O
not	O
that	O
caused	O
by	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
strain	O
JHMV	O
,	O
which	O
enters	O
cells	O
directly	O
from	O
the	O
cell	O
surface	O
.	O

We	O
found	O
that	O
cathepsin	O
L	O
(	O
CPL	O
)	O
inhibitors	O
blocked	O
229E	O
infection	O
the	O
most	O
remarkably	O
among	O
a	O
variety	O
of	O
protease	B-PROC
inhibitors	I-PROC
tested	O
.	O

Although	O
previous	O
studies	O
have	O
reported	O
that	O
the	O
training	O
of	O
individual	O
leaders	O
is	O
an	O
important	O
approach	O
,	O
the	O
systemic	O
and	O
scientific	O
training	O
model	O
need	O
further	O
improvement	O
and	O
development	B-PROC
.	O

Sections	O
of	O
trachea	O
,	O
lung	O
and	O
airsacs	O
were	O
stained	O
for	O
CD4	O
,	O
CD8	O
,	O
gammadelta	O
-	O
TCR	B-PROC
,	O
alphabeta1	O
-	O
TCR	B-PROC
,	O
and	O
for	O
macrophages	O
(	O
KUL	O
-	O
01	O
)	O
and	O
both	O
pathogens	O
.	O

RESULTS	O
:	O
Twelve	O
infants	O
were	O
studied	O
;	O
median	O
gestation	B-PROC
39	O
weeks	O
(	O
36	O
-	O
41	O
),	O
birth	B-PROC
weight	O
3150	O
g	O
(	O
1930	O
-	O
4010	O
).	O

The	O
differential	O
activity	O
profiles	O
of	O
the	O
human	O
proteins	O
implicate	O
them	O
in	O
different	O
cellular	O
pathways	B-PROC
,	O
some	O
of	O
which	O
may	O
involve	O
RNA	O
rather	O
than	O
ADP	O
-	O
ribose	O
derivatives	O
.	O

TITLE	O
:	O
Identification	O
of	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
I	O
C	O
molecule	O
as	O
an	O
attachment	O
factor	O
that	O
facilitates	O
coronavirus	O
HKU1	O
spike	O
-	O
mediated	O
infection	O
.	O

To	O
search	O
for	O
the	O
functional	O
receptor	O
for	O
HCoV	O
-	O
HKU1	O
,	O
an	O
A549	O
cDNA	O
expression	B-PROC
library	O
was	O
constructed	O
and	O
transduced	O
into	O
the	O
nonpermissive	O
,	O
baby	O
hamster	O
kidney	O
cells	O
line	O
BHK	O
-	O
21	O
.	O

In	O
the	O
coronavirus	O
,	O
nsp3	O
resides	O
a	O
domain	O
with	O
the	O
macroH2A	O
-	O
like	O
fold	O
and	O
ADP	O
-	O
ribose	O
-	O
1	O
"""-"	O
monophosphatase	O
(	O
ADRP	O
)	O
activity	O
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
the	O
replication	B-PROC
process	I-PROC
.	O

Together	O
with	O
data	O
from	O
a	O
previous	O
analysis	O
of	O
the	O
ADRP	O
domain	O
from	O
the	O
group	O
II	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
from	O
other	O
related	O
functional	O
studies	O
of	O
ADRP	O
domains	O
,	O
a	O
systematic	O
structural	O
analysis	O
of	O
the	O
coronavirus	O
ADRP	O
domains	O
was	O
realized	O
for	O
the	O
first	O
time	O
to	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
function	O
of	O
this	O
domain	O
in	O
the	O
coronavirus	O
replication	B-PROC
process	I-PROC
.	O

Several	O
fluorescent	O
and	O
non	O
-	O
fluorescent	O
peptides	O
from	O
these	O
domains	O
were	O
synthesized	O
to	O
examine	O
their	O
interactions	O
by	O
circular	O
dichroism	O
,	O
thermal	O
denaturation	B-PROC
,	O
native	O
-	O
page	O
,	O
mass	O
spectrometry	O
and	O
fluorescence	O
spectroscopy	O
studies	O
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
insights	O
into	O
the	O
molecular	O
and	O
cellular	O
bases	O
of	O
the	O
host	O
antiviral	O
innate	B-PROC
immunity	B-PROC
within	O
the	O
lungs	O
that	O
eventually	O
lead	O
to	O
an	O
exacerbated	O
inflammatory	O
cascades	O
and	O
severe	O
tissue	O
damage	O
in	O
SARS	O
patients	O
.	O

Well	O
-	O
trained	O
technologists	O
and	O
microbiologists	O
,	O
and	O
the	O
introduction	O
of	O
new	O
technologies	O
,	O
will	O
facilitate	O
the	O
development	B-PROC
of	O
a	O
wide	O
variety	O
of	O
molecular	O
tests	O
for	O
other	O
infectious	O
diseases	O
at	O
public	O
health	O
laboratories	O
geographically	O
distant	O
from	O
Toronto	O
,	O
thus	O
enhancing	O
overall	O
laboratory	O
testing	O
capacity	O
in	O
the	O
province	O
of	O
Ontario	O
.	O

Within	O
two	O
hours	O
of	O
iLA	O
treatment	O
,	O
arterial	O
oxygen	B-PROC
partial	I-PROC
pressure	I-PROC
/	O
inspired	B-PROC
oxygen	O
fraction	O
ratio	O
increased	O
significantly	O
and	O
a	O
fast	O
improvement	O
in	O
arterial	O
carbon	O
dioxide	O
partial	O
pressure	O
and	O
pH	O
was	O
observed	O
.	O

There	O
may	O
well	O
be	O
a	O
delicate	O
balance	B-PROC
between	O
the	O
induction	O
of	O
protective	O
immunity	B-PROC
on	O
the	O
one	O
hand	O
and	O
the	O
induction	O
of	O
enhanced	O
susceptibility	O
on	O
the	O
other	O
.	O

These	O
cleavage	B-PROC
products	O
are	O
believed	O
to	O
play	O
essential	O
roles	O
in	O
replication	O
of	O
the	O
giant	O
RNA	O
genome	O
of	O
approximately	O
30	O
kb	O
and	O
transcription	B-PROC
of	O
a	O
nested	O
set	O
of	O
5	O
to	O
9	O
subgenomic	O
RNA	O
species	O
by	O
a	O
unique	O
discontinuous	O
transcription	B-PROC
mechanism	O
.	O

Meanwhile	O
,	O
mutations	O
of	O
some	O
positively	O
charged	O
residues	O
in	O
the	O
beta	O
-	O
barrel	O
regions	O
of	O
the	O
IBV	O
nsp9	O
protein	O
significantly	O
reduced	O
its	O
RNA	O
-	O
binding	B-PROC
activity	I-PROC
,	O
but	O
with	O
no	O
obvious	O
effect	O
on	O
dimerization	O
of	O
the	O
protein	O
.	O

Introduction	O
of	O
these	O
mutations	O
into	O
the	O
viral	O
genome	O
showed	O
only	O
mild	O
to	O
moderate	O
effects	O
on	O
the	O
growth	B-PROC
and	O
infectivity	O
of	O
the	O
rescued	O
mutant	O
viruses	O
.	O

The	O
active	O
form	O
of	O
the	O
TCoV	O
nsp15	O
was	O
a	O
homohexamer	O
and	O
disulfide	O
bond	O
was	O
essential	O
for	O
the	O
enzymatic	B-PROC
activity	I-PROC
.	O

ABSTRACT	O
:	O
Propagation	O
of	O
new	O
human	O
respiratory	O
virus	O
pathogens	O
in	O
established	O
cell	O
lines	O
is	O
hampered	O
by	O
a	O
lack	O
of	O
predictability	O
regarding	O
cell	O
line	O
permissivity	O
and	O
by	O
availability	O
of	O
suitable	O
antibody	B-PROC
reagents	O
to	O
detect	O
infection	O
in	O
cell	O
lines	O
that	O
do	O
not	O
exhibit	O
significant	O
cytopathic	O
effect	O
.	O

TITLE	O
:	O
[	O
The	O
proteomics	O
research	O
on	O
relational	O
expressed	B-PROC
serum	O
proteins	O
among	O
the	O
recovered	O
SARS	O
patients	O
complicating	O
avascular	O
necrosis	B-PROC
of	O
femoral	O
head	O
].	O

42	O
respectively	O
,	O
and	O
the	O
matching	O
rate	O
of	O
protein	O
points	O
was	O
ranged	O
from	O
85	O
%	O
to	O
95	O
%;	O
eighteen	O
differentially	O
expressed	B-PROC
proteins	O
were	O
discovered	O
including	O
transthyretin	O
,	O
serpin	O
peptidase	O
inhibitor	O
,	O
alpha	O
-	O
1	O
-	O
antitrypsin	O
precursor	O
,	O
serum	O
amyloid	O
P	O
components	O
,	O
etc	O
.	O

Fluorescent	O
quantitative	O
RT	O
-	O
PCR	O
showed	O
that	O
BALB	O
/	O
c	O
mice	O
challenged	O
intranasally	O
with	O
SARSCoV	O
at	O
day	O
33	O
post	O
injection	O
were	O
completely	O
protected	O
from	O
virus	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
A	O
new	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)-	O
based	O
immunoglobulin	B-PROC
G	O
(	O
IgG	O
)-	O
plus	O
-	O
IgM	O
antibody	B-PROC
detection	O
test	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
been	O
developed	O
by	O
using	O
a	O
cocktail	O
of	O
four	O
recombinant	O
polypeptides	O
as	O
the	O
antigen	O
.	O

Immunization	O
with	O
a	O
cocktail	O
of	O
these	O
four	O
polypeptides	O
yielded	O
a	O
specific	O
polyclonal	O
antibody	B-PROC
that	O
is	O
able	O
to	O
recognize	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
by	O
an	O
immunofluorescence	O
assay	O
.	O

This	O
polypeptide	O
cocktail	O
was	O
also	O
used	O
to	O
set	O
up	O
an	O
ELISA	O
-	O
based	O
IgG	O
-	O
plus	O
-	O
IgM	O
antibody	B-PROC
detection	O
test	O
,	O
which	O
showed	O
99	O
%	O
specificity	O
and	O
90	O
%	O
sensitivity	O
upon	O
evaluation	O
using	O
sera	O
from	O
100	O
healthy	O
negative	O
controls	O
and	O
20	O
SARS	O
patients	O
.	O

Separate	O
immunoreactivity	B-PROC
assays	O
with	O
each	O
recombinant	O
polypeptide	O
demonstrated	O
that	O
a	O
combination	O
of	O
N	O
and	O
S	O
protein	O
fragments	O
was	O
more	O
suitable	O
than	O
the	O
individual	O
peptides	O
for	O
developing	O
a	O
serological	O
assay	O
for	O
SARS	O
-	O
CoV	O
.	O

These	O
data	O
suggest	O
that	O
virus	O
-	O
infected	O
macrophages	O
overproduce	O
B	B-PROC
-	I-PROC
cell	I-PROC
differentiation	I-PROC
/	O
survival	O
factors	O
,	O
and	O
these	O
factors	O
act	O
on	O
B	O
-	O
cells	O
and	O
promote	O
B	B-PROC
-	I-PROC
cell	I-PROC
differentiation	I-PROC
into	O
plasma	O
cells	O
in	O
FIPV	O
-	O
infected	O
cats	O
.	O

ABSTRACT	O
:	O
An	O
83	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
fever	B-PROC
and	O
difficulty	O
in	O
walking	O
with	O
marked	O
hypoxemia	O
and	O
diffuse	O
ground	O
glass	O
opacities	O
in	O
bilateral	O
lung	O
fields	O
by	O
chest	O
radiography	O
and	O
CT	O
scanning	O
.	O

Treatment	O
with	O
antibiotics	O
and	O
corticosteroids	O
resulted	O
in	O
improvement	O
of	O
the	O
clinical	O
findings	O
and	O
successful	O
weaning	B-PROC
from	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Viral	O
protease	B-PROC
inhibitors	I-PROC
.	O

Since	O
many	O
different	O
viruses	O
encode	O
essential	O
proteases	O
,	O
it	O
is	O
possible	O
to	O
envision	O
the	O
development	B-PROC
of	O
a	O
potent	O
protease	O
inhibitor	O
for	O
other	O
viruses	O
if	O
the	O
processing	O
site	O
sequence	O
and	O
the	O
catalytic	O
mechanism	O
are	O
known	O
.	O

The	O
current	O
results	O
underscore	O
the	O
important	O
roles	O
of	O
multisite	O
nucleic	O
acid	O
binding	O
and	O
intrinsic	O
disorder	O
in	O
N	O
protein	B-PROC
function	I-PROC
and	O
RNP	O
packaging	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
function	O
of	O
NS1	O
can	O
be	O
modulated	O
by	O
chemical	O
inhibitors	O
and	O
that	O
such	O
inhibitors	O
will	O
be	O
useful	O
as	O
probes	O
of	O
biological	B-PROC
function	I-PROC
and	O
as	O
starting	O
points	O
for	O
clinical	O
drug	O
development	B-PROC
.	O

These	O
viruses	O
have	O
broad	O
or	O
specific	O
host	O
ranges	O
,	O
suggesting	O
the	O
possibility	O
of	O
novel	O
strategies	O
for	O
targeting	B-PROC
and	O
regulating	O
host	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
following	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Detection	O
of	O
SARS	O
coronavirus	O
in	O
humans	O
and	O
animals	O
by	O
conventional	O
and	O
quantitative	O
(	O
real	O
time	O
)	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reactions	O
.	O

Virus	O
isolation	O
and	O
detection	O
of	O
antibody	B-PROC
,	O
antigen	O
,	O
and	O
nucleic	O
acid	O
.	O

Neutralization	O
assay	O
with	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-PROC
revealed	O
that	O
VSV	O
-	O
SARS	O
-	O
St19	O
/	O
GFP	O
pseudotype	O
infection	O
is	O
mediated	O
by	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

Thus	O
,	O
VSV	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
S	O
protein	O
is	O
useful	O
for	O
developing	O
a	O
rapid	O
detection	O
system	O
for	O
neutralizing	O
antibody	B-PROC
specific	O
for	O
SARS	O
-	O
CoV	O
infection	O
as	O
well	O
as	O
studying	O
the	O
S	O
-	O
mediated	O
cell	O
entry	O
of	O
SARS	O
-	O
CoV	O
.	O

In	O
this	O
virus	O
the	O
ectodomain	O
of	O
the	O
spike	O
glycoprotein	O
is	O
replaced	O
by	O
that	O
of	O
a	O
coronavirus	O
with	O
a	O
different	O
species	O
tropism	B-PROC
.	O

We	O
have	O
learned	B-PROC
many	O
lessons	O
from	O
the	O
recent	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Docking	B-PROC
simulations	O
were	O
carried	O
out	O
to	O
rationalize	O
the	O
most	O
relevant	O
SARs	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
critical	O
syndrome	O
associated	O
with	O
respiratory	O
dysfunction	O
,	O
and	O
neutrophils	O
are	O
considered	O
to	O
be	O
central	O
to	O
the	O
pathogenesis	B-PROC
of	O
ALI	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
,	O
and	O
complications	O
associated	O
with	O
High	O
Frequency	O
Oscillatory	O
Ventilation	O
(	O
HFOV	O
)	O
in	O
burn	O
patients	O
with	O
the	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
)	O
who	O
have	O
had	O
a	O
smoke	O
inhalation	B-PROC
injury	O
,	O
and	O
to	O
compare	O
with	O
those	O
without	O
an	O
inhalation	B-PROC
injury	O
.	O

There	O
was	O
also	O
a	O
trend	O
towards	O
higher	O
rates	O
of	O
early	O
HFOV	O
failure	O
and	O
severe	O
hypercapnia	O
while	O
on	O
HFOV	O
among	O
the	O
patients	O
with	O
inhalation	B-PROC
injury	O
.	O

Severe	O
hypercapnia	O
tended	O
to	O
be	O
more	O
frequent	O
during	O
HFOV	O
among	O
patients	O
with	O
smoke	O
inhalation	B-PROC
.	O

These	O
findings	O
,	O
combined	O
with	O
the	O
difficulties	O
in	O
delivery	O
of	O
nebulized	O
medications	O
during	O
HFOV	O
suggest	O
that	O
HFOV	O
may	O
not	O
be	O
the	O
optimal	O
""""	O
rescue	O
""""	O
ventilation	O
modality	O
in	O
cases	O
of	O
ARDS	O
if	O
there	O
has	O
been	O
an	O
inhalation	B-PROC
injury	O
.	O

Z	O
scores	O
<	O
-	O
3	O
were	O
insensitive	O
for	O
malnutrition	O
-	O
attributable	O
deaths	B-PROC
and	O
admissions	O
,	O
and	O
no	O
single	O
threshold	O
was	O
both	O
specific	O
and	O
sensitive	O
.	O

In	O
conclusion	O
,	O
the	O
penile	O
shaft	O
seemed	O
to	O
be	O
the	O
preferred	O
site	O
for	O
HPV	O
-	O
16	O
viral	B-PROC
replication	I-PROC
.	O

Further	O
,	O
assuming	O
that	O
the	O
general	O
principles	O
underlying	O
MIRR	O
-	O
mediated	O
transmembrane	O
signaling	B-PROC
mechanisms	O
are	O
similar	O
,	O
the	O
SCHOOL	O
model	O
can	O
be	O
applied	O
to	O
any	O
particular	O
receptor	O
of	O
the	O
MIRR	O
family	O
.	O

It	O
also	O
demonstrates	O
how	O
the	O
lessons	O
learned	B-PROC
from	O
viral	O
pathogenesis	B-PROC
can	O
be	O
used	O
practically	O
for	O
rational	O
drug	O
design	O
.	O

Instead	O
of	O
comparing	O
the	O
frequencies	O
of	O
all	O
fixed	O
-	O
length	O
words	O
in	O
two	O
sequences	O
,	O
we	O
consider	O
(	O
1	O
)	O
the	O
probability	O
of	O
'	O
generating	O
'	O
one	O
sequence	O
under	O
the	O
Poisson	O
model	O
estimated	O
from	O
the	O
other	O
;	O
(	O
2	O
)	O
their	O
different	O
expression	B-PROC
levels	O
of	O
words	O
.	O

CONCLUSIONS	O
:	O
This	O
cross	O
-	O
sectional	O
study	O
provides	O
preliminary	O
evidence	O
that	O
knowledge	O
sharing	O
is	O
significantly	O
correlated	O
with	O
impact	O
of	O
SARS	O
and	O
professional	O
commitment	O
of	O
nursing	B-PROC
personnel	O
.	O

ABSTRACT	O
:	O
Fulminant	O
viral	O
hepatitis	O
(	O
FH	O
)	O
remains	O
an	O
important	O
clinical	O
problem	O
in	O
which	O
the	O
underlying	O
pathogenesis	B-PROC
is	O
not	O
well	O
understood	O
.	O

The	O
breakdown	B-PROC
of	O
suspected	O
causative	O
pathogens	O
was	O
as	O
follows	O
:	O
24	O
.	O
4	O
%	O
were	O
Streptococcus	O
pneumoniae	O
,	O
14	O
.	O
8	O
%	O
were	O
Mycoplasma	O
pneumoniae	O
,	O
11	O
.	O
3	O
%	O
were	O
Haemophilus	O
influenzae	O
,	O
and	O
1	O
.	O
4	O
%	O
were	O
Chlamydophila	O
pneumoniae	O
.	O

She	O
died	B-PROC
two	O
weeks	O
after	O
hospital	O
admission	O
due	O
to	O
acute	O
respiratory	O
failure	O
.	O

Hence	O
,	O
we	O
speculate	O
that	O
the	O
Ark	O
DPI	O
strain	O
originated	O
from	O
the	O
Conn	O
strain	O
,	O
but	O
diverged	O
and	O
evolved	O
independently	O
by	O
point	B-PROC
mutations	I-PROC
and	O
recombination	B-PROC
between	O
field	O
strains	O
.	O

However	O
,	O
virus	B-PROC
replication	I-PROC
was	O
not	O
impaired	O
by	O
these	O
events	O
,	O
suggesting	O
that	O
SARS	O
-	O
CoV	O
possesses	O
a	O
mechanism	O
to	O
overcome	O
the	O
inhibitory	O
effects	O
of	O
phosphorylated	O
eIF2alpha	O
on	O
viral	O
mRNA	B-PROC
translation	B-PROC
.	O

CONCLUSIONS	O
:	O
LSECtin	O
is	O
expressed	B-PROC
by	O
liver	O
myeloid	O
cells	O
,	O
and	O
its	O
expression	B-PROC
is	O
dependent	O
on	O
the	O
PU	O
.	O
1	O
transcription	B-PROC
factor	O
.	O

ABSTRACT	O
:	O
Pertussis	O
is	O
a	O
leading	O
cause	O
of	O
death	B-PROC
from	O
community	O
infections	O
in	O
infant	O
.	O

RESULTS	O
:	O
Neutralizing	O
antibody	B-PROC
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
was	O
demonstrated	O
in	O
8	O
of	O
25	O
children	O
admitted	O
with	O
suspect	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
infection	O
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
assembly	O
,	O
we	O
cloned	O
the	O
genes	O
encoding	O
these	O
four	O
proteins	O
into	O
the	O
eukaryotic	O
expression	B-PROC
vector	O
pCAGGS	O
and	O
transfected	O
them	O
into	O
293T	O
cells	O
.	O

TITLE	O
:	O
Mass	O
screening	O
of	O
suspected	O
febrile	B-PROC
patients	O
with	O
remote	O
-	O
sensing	O
infrared	O
thermography	O
:	O
alarm	O
temperature	O
and	O
optimal	O
distance	O
.	O

ABSTRACT	O
:	O
Detection	O
of	O
fever	B-PROC
has	O
become	O
an	O
essential	O
step	O
in	O
identifying	O
patients	O
who	O
may	O
have	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
or	O
avian	O
influenza	O
.	O

Transfer	O
experiments	O
indicated	O
that	O
the	O
protective	O
role	O
of	O
IFN	O
-	O
gamma	O
is	O
mediated	O
through	O
a	O
direct	O
effect	O
on	O
cells	O
targeted	B-PROC
by	O
the	O
virus	O
rather	O
than	O
through	O
indirect	O
activation	O
of	O
T	O
lymphocytes	O
.	O

Resilience	O
is	O
supported	O
at	O
an	O
organizational	O
level	O
by	O
effective	O
training	O
and	O
support	O
,	O
development	B-PROC
of	O
material	O
and	O
relational	O
reserves	O
,	O
effective	O
leadership	O
,	O
the	O
effects	O
of	O
the	O
characteristics	O
of	O
""""	O
magnet	O
hospitals	O
","""	O
and	O
a	O
culture	O
of	O
organizational	O
justice	O
.	O

Therefore	O
,	O
the	O
development	B-PROC
of	O
a	O
vaccine	O
against	O
SARS	O
is	O
in	O
grave	O
need	O
.	O

Consequently	O
,	O
the	O
antisera	O
exhibited	O
neutralization	O
activity	O
in	O
an	O
in	O
vitro	O
infection	O
inhibition	B-PROC
assay	O
.	O

Nsp9	O
forms	O
a	O
dimer	O
through	O
the	O
interaction	O
of	O
parallel	O
alpha	O
-	O
helices	O
containing	O
the	O
protein	B-PROC
-	I-PROC
protein	I-PROC
interaction	I-PROC
motif	O
GXXXG	O
.	O

In	O
order	O
to	O
study	O
the	O
role	O
of	O
the	O
nsp9	O
dimer	O
in	O
viral	B-PROC
reproduction	I-PROC
,	O
residues	O
G100	O
and	O
G104	O
at	O
the	O
helix	O
interface	O
were	O
targeted	B-PROC
for	O
mutation	O
.	O

For	O
rhinovirus	O
,	O
new	O
OM	O
occurred	O
in	O
50	O
%	O
of	O
children	O
with	O
and	O
32	O
%	O
without	O
a	O
concurrent	O
CLI	O
(	O
P	O
=	O
.	O
15	O
),	O
and	O
OM	O
risk	O
was	O
predicted	O
by	O
OM	O
and	O
breastfeeding	B-PROC
histories	O
and	O
by	O
daily	O
environment	O
outside	O
the	O
home	O
.	O

International	O
concerns	O
about	O
good	O
governance	O
and	O
its	O
aspiration	O
to	O
become	O
a	O
'	O
responsible	O
'	O
state	O
have	O
exerted	B-PROC
a	O
normative	O
effect	O
on	O
China	O
to	O
change	O
tack	O
.	O

Its	O
interactions	O
with	O
United	O
Nations	O
agencies	O
have	O
triggered	O
a	O
learning	B-PROC
process	O
for	O
China	O
to	O
securitize	O
the	O
spread	O
of	O
infectious	O
diseases	O
as	O
a	O
security	O
threat	O
.	O

ABSTRACT	O
:	O
Mucosal	O
vaccination	O
offers	O
great	O
advantage	O
for	O
inducing	O
protective	O
immune	B-PROC
response	I-PROC
to	O
prevent	O
viral	B-PROC
transmission	I-PROC
and	O
dissemination	O
.	O

The	O
government	O
can	O
promote	O
vaccination	O
by	O
educating	O
the	O
public	O
about	O
the	O
advantages	O
,	O
by	O
publicizing	O
locations	O
where	O
vaccinations	O
are	O
available	O
,	O
and	O
having	O
nursing	B-PROC
,	O
other	O
medical	O
staff	O
,	O
family	O
and	O
friends	O
encourage	O
elderly	O
people	O
to	O
be	O
vaccinated	O
.	O

Using	O
computer	O
modeling	O
,	O
the	O
structural	O
features	O
of	O
these	O
compounds	O
as	O
individual	O
and	O
common	O
protease	B-PROC
inhibitors	I-PROC
were	O
elucidated	O
to	O
enhance	O
our	O
knowledge	O
for	O
developing	O
anti	O
-	O
viral	O
agents	O
against	O
PV	O
and	O
CoV	O
.	O

Lung	O
contusion	O
is	O
also	O
a	O
risk	O
factor	O
for	O
the	O
development	B-PROC
of	O
pneumonia	O
,	O
severe	O
clinical	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

In	O
addition	O
,	O
expression	B-PROC
of	O
heme	O
oxygenase	B-PROC
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
mRNA	O
increased	O
at	O
2	O
days	O
after	O
exposure	O
.	O

TITLE	O
:	O
Organ	O
-	O
specific	O
attenuation	O
of	O
murine	O
hepatitis	O
virus	O
strain	O
A59	O
by	O
replacement	O
of	O
catalytic	O
residues	O
in	O
the	O
putative	O
viral	O
cyclic	O
phosphodiesterase	B-PROC
ns2	O
.	O

ABSTRACT	O
:	O
The	O
Murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
ns2	O
protein	O
is	O
a	O
30	O
-	O
kDa	O
nonstructural	O
protein	O
that	O
is	O
expressed	B-PROC
from	O
a	O
subgenomic	O
mRNA	O
in	O
the	O
cytoplasm	O
of	O
virus	O
-	O
infected	O
cells	O
.	O

These	O
results	O
show	O
that	O
the	O
ns2	O
protein	O
of	O
MHV	O
-	O
A59	O
has	O
an	O
important	O
role	O
in	O
virus	O
pathogenicity	O
and	O
that	O
a	O
substitution	O
of	O
the	O
histidine	O
residues	O
of	O
the	O
MHV	O
-	O
A59	O
ns2	O
His	O
-	O
x	O
-	O
Thr	O
/	O
Ser	O
motifs	O
is	O
critical	O
for	O
virus	O
virulence	B-PROC
in	O
the	O
liver	O
but	O
not	O
in	O
the	O
brain	O
.	O

TITLE	O
:	O
Demonstration	O
of	O
passive	O
protection	O
in	O
neonatal	O
calves	O
against	O
colibacillosis	O
following	O
immunization	O
of	O
pregnant	O
heifers	O
at	O
3	O
months	O
of	O
gestation	B-PROC
.	O

Although	O
not	O
yet	O
formally	O
published	O
,	O
the	O
results	O
of	O
this	O
study	O
,	O
if	O
confirmed	O
,	O
represent	O
the	O
first	O
positive	O
randomized	O
clinical	O
trial	O
on	O
adult	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
application	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
.	O

TITLE	O
:	O
Hypercapnia	O
in	O
late	O
-	O
phase	O
ALI	O
/	O
ARDS	O
:	O
providing	O
spontaneous	O
breathing	B-PROC
using	O
pumpless	O
extracorporeal	O
lung	O
assist	O
.	O

CONCLUSIONS	O
:	O
In	O
case	O
of	O
new	O
outbreaks	O
of	O
SARS	O
/	O
avian	O
flu	O
in	O
China	O
,	O
local	O
authorities	O
in	O
the	O
UK	O
and	O
The	O
Netherlands	O
can	O
best	O
reach	B-PROC
Chinese	O
people	O
through	O
informal	O
networks	O
and	O
British	O
/	O
Dutch	O
TV	O
,	O
while	O
trying	O
to	O
improve	O
confidence	O
in	O
information	O
from	O
the	O
government	O
.	O

ABSTRACT	O
:	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)-	O
based	O
approaches	O
to	O
the	O
detection	O
,	O
differentiation	B-PROC
and	O
characterization	O
of	O
avian	O
pathogens	O
continue	O
to	O
be	O
developed	O
and	O
refined	O
.	O

An	O
NF	B-PROC
-	I-PROC
kappaB	I-PROC
inhibitor	I-PROC
,	O
TPCK	O
(	O
N	O
-	O
Tosyl	O
-	O
L	O
-	O
Phenylalanine	O
Chloromethyl	O
Ketone	O
)	O
could	O
suppress	O
IL	B-PROC
-	I-PROC
8	I-PROC
production	I-PROC
and	O
secretion	B-PROC
in	O
response	O
to	O
S	O
protein	O
in	O
PBMC	O
and	O
THP	O
-	O
1	O
cells	O
and	O
in	O
HCoV	O
-	O
229E	O
virus	O
-	O
infected	O
PBMC	O
.	O

In	O
contrast	O
,	O
the	O
orally	O
DNA	O
vaccine	O
evoked	O
vigorous	O
T	O
cell	O
response	O
and	O
a	O
weak	O
antibody	B-PROC
production	I-PROC
.	O

However	O
,	O
APC	O
failed	O
to	O
prevent	O
the	O
decrease	O
in	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
.	O

Two	O
hundred	O
and	O
ninety	O
-	O
seven	O
nasopharyngeal	O
secretions	O
were	O
collected	O
and	O
multiplex	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reactions	O
(	O
RT	O
-	O
PCR	O
)/	O
polymerase	O
chain	O
reactions	O
(	O
PCR	O
)	O
were	O
performed	O
to	O
detect	O
respiratory	O
viruses	O
.	O

To	O
differentiate	O
the	O
genotypes	O
without	O
sequencing	O
,	O
a	O
simple	O
technique	O
-	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
/	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
analysis	O
(	O
RT	O
-	O
PCR	O
/	O
RFLP	O
)-	O
was	O
developed	O
.	O

These	O
results	O
were	O
consistent	O
with	O
virus	O
isolation	O
and	O
denote	O
the	O
wide	O
tissue	B-PROC
tropism	B-PROC
of	O
IBV	O
M41	O
in	O
the	O
chicken	O
embryo	O
.	O

ABSTRACT	O
:	O
The	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
severe	O
illness	O
that	O
is	O
often	O
the	O
cause	O
of	O
death	B-PROC
in	O
ICU	O
patients	O
.	O

The	O
three	O
major	O
diagnostic	O
methods	O
available	O
for	O
SARS	O
includes	O
viral	O
RNA	O
detection	O
by	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
virus	O
induced	O
antibodies	O
by	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
or	O
by	O
enzyme	O
linked	O
immunosorbant	O
assay	O
(	O
ELISA	O
)	O
of	O
nucleocapsid	O
protein	O
(	O
NP	O
).	O

TITLE	O
:	O
Predictive	O
factors	O
of	O
psychological	O
disorder	O
development	B-PROC
during	O
recovery	O
following	O
SARS	O
outbreak	O
.	O

Similarly	O
,	O
the	O
majority	O
of	O
studies	O
investigating	O
risk	O
perceptions	O
and	O
protective	O
behaviors	B-PROC
were	O
not	O
model	O
-	O
based	O
.	O

TITLE	O
:	O
International	O
travels	O
and	O
fever	B-PROC
screening	O
during	O
epidemics	O
:	O
a	O
literature	O
review	O
on	O
the	O
effectiveness	O
and	O
potential	O
use	O
of	O
non	O
-	O
contact	O
infrared	O
thermometers	O
.	O

ABSTRACT	O
:	O
Several	O
countries	O
plan	O
to	O
introduce	O
non	O
-	O
contact	O
infrared	O
thermometers	O
(	O
NCIT	O
)	O
at	O
international	O
airports	O
in	O
order	O
to	O
detect	O
febrile	B-PROC
passengers	O
,	O
thus	O
to	O
delay	O
the	O
introduction	O
of	O
a	O
novel	O
influenza	O
strain	O
.	O

Nevertheless	O
,	O
progress	O
has	O
been	O
made	O
in	O
the	O
identification	O
of	O
genetic	O
variants	O
in	O
select	O
candidate	O
genes	O
,	O
which	O
has	O
enhanced	O
our	O
understanding	O
of	O
the	O
specific	O
pathways	B-PROC
involved	O
in	O
disease	O
manifestation	O
.	O

We	O
propose	O
that	O
INO	O
may	O
decrease	O
the	O
inflammatory	B-PROC
response	I-PROC
in	O
patients	O
with	O
increased	O
intracranial	B-PROC
pressure	I-PROC
caused	O
by	O
traumatic	O
brain	O
injury	O
accompanied	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
thereby	O
contributing	O
to	O
improved	O
outcomes	O
.	O

The	O
majority	O
of	O
patients	O
had	O
residual	O
lung	O
parenchymal	O
changes	O
on	O
HRCT	O
suggestive	O
of	O
fibrosis	O
,	O
but	O
the	O
extension	O
of	O
morphologic	O
abnormalities	O
was	O
limited	O
and	O
without	O
the	O
typical	O
anterior	O
localization	B-PROC
presumed	O
to	O
indicate	O
ventilator	O
-	O
associated	O
lung	O
injury	O
.	O

Viruses	O
were	O
identified	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
studied	O
ARTI	O
,	O
providing	O
useful	O
information	O
on	O
clinical	O
features	O
and	O
epidemiology	O
of	O
specific	O
agents	O
affecting	O
children	O
in	O
cold	B-PROC
months	O
.	O

TITLE	O
:	O
[	O
Expression	B-PROC
,	O
purification	O
and	O
antibody	B-PROC
preparation	O
of	O
recombinat	O
SARS	O
-	O
CoV	O
X5	O
protein	O
].	O

There	O
are	O
no	O
treatment	O
guidelines	O
for	O
hip	O
necrosis	B-PROC
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

Nucleotide	O
sequence	O
alignments	O
revealed	O
many	O
point	B-PROC
mutations	I-PROC
,	O
short	O
deletions	O
,	O
and	O
insertions	O
in	O
S1	O
region	O
of	O
both	O
IBV	O
isolates	O
.	O

Treatment	O
of	O
animals	O
with	O
a	O
PPS	O
aerosol	O
significantly	O
increased	O
the	O
phospholipid	O
content	O
in	O
the	O
BALF	O
,	O
improved	O
lung	B-PROC
function	I-PROC
,	O
reduced	O
pulmonary	O
oedema	O
,	O
decreased	O
total	O
protein	O
and	O
TNF	O
-	O
alpha	O
concentrations	O
in	O
BALF	O
,	O
ameliorated	O
lung	O
injury	O
and	O
improved	O
animal	O
survival	O
.	O

TITLE	O
:	O
Roles	O
of	O
spike	O
protein	O
in	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
coronavirus	O
.	O

These	O
have	O
important	O
implications	O
in	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
,	O
providing	O
opportunities	O
for	O
developing	O
vaccines	O
and	O
antivirals	O
against	O
SARS	O
-	O
CoV	O
.	O
4	O
.	O

The	O
receptor	O
-	O
binding	O
domain	O
of	O
S	O
protein	O
delivered	O
via	O
adeno	O
-	O
associated	O
virus	O
can	O
efficiently	O
induce	O
mucosal	B-PROC
immunity	I-PROC
and	O
provide	O
long	O
-	O
term	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

When	O
different	O
forms	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
-	O
based	O
vaccines	O
for	O
generation	O
of	O
a	O
neutralising	O
antibody	B-PROC
response	I-PROC
to	O
SARS	O
-	O
CoV	O
were	O
injected	O
into	O
a	O
mouse	O
model	O
,	O
all	O
the	O
mice	O
immunised	O
with	O
intramuscular	O
tPA	O
-	O
optimised	O
800	O
DNA	O
vaccine	O
boosted	O
with	O
intraperitoneal	O
recombinant	O
spike	O
polypeptide	O
generated	O
by	O
Escherichia	O
coli	O
and	O
intramuscular	O
CTLA4Hinge	O
SARS800	O
DNA	O
vaccine	O
boosted	O
with	O
intraperitoneal	O
S	O
-	O
peptide	O
had	O
neutralising	O
antibody	B-PROC
titres	O
of	O
>	O
1	O
:	O
1280	O
.	O
2	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
the	O
phase	O
of	O
sepsis	O
is	O
related	O
to	O
the	O
effects	O
of	O
PMX	O
-	O
DHP	O
treatment	O
on	O
oxygenation	B-PROC
in	O
patients	O
with	O
ALI	O
and	O
ARDS	O
.	O

It	O
was	O
suggested	O
that	O
early	O
introduction	O
of	O
PMX	O
-	O
DHP	O
for	O
severe	O
sepsis	O
may	O
improve	O
oxygenation	B-PROC
.	O

We	O
employed	O
several	O
methods	O
to	O
investigate	O
selective	O
pressure	O
among	O
different	O
SARS	O
-	O
CoV	O
groups	O
representing	O
different	O
epidemic	O
periods	B-PROC
and	O
hosts	O
.	O

RESULTS	O
:	O
We	O
employed	O
several	O
methods	O
to	O
investigate	O
selective	O
pressure	O
among	O
different	O
SARS	O
-	O
CoV	O
groups	O
representing	O
different	O
epidemic	O
periods	B-PROC
and	O
hosts	O
.	O

The	O
cell	O
tropism	B-PROC
of	O
the	O
respective	O
pseudotypes	O
corresponded	O
to	O
the	O
tropism	B-PROC
of	O
the	O
viruses	O
from	O
which	O
the	O
S	O
protein	O
was	O
derived	O
.	O

Electromyography	O
and	O
nerve	B-PROC
conduction	B-PROC
studies	O
showed	O
absence	O
of	O
compound	O
muscle	O
action	B-PROC
potentials	I-PROC
and	O
sural	O
nerve	O
sensory	O
action	B-PROC
potential	I-PROC
,	O
which	O
was	O
suggestive	O
of	O
a	O
severe	O
Guillain	O
-	O
Barré	O
syndrome	O
.	O

ABSTRACT	O
:	O
Wide	O
variation	O
between	O
hospitals	O
in	O
the	O
quality	O
of	O
critical	O
care	O
lead	O
to	O
many	O
potentially	O
avoidable	O
deaths	B-PROC
.	O

This	O
commentary	O
introduces	O
the	O
technique	O
of	O
network	O
analysis	O
as	O
a	O
framework	O
for	O
the	O
following	O
:	O
(	O
1	O
)	O
understanding	O
how	O
critically	O
ill	O
patients	O
move	B-PROC
between	O
hospitals	O
,	O
(	O
2	O
)	O
defining	O
the	O
roles	O
hospitals	O
play	O
in	O
regional	O
care	O
delivery	O
,	O
and	O
(	O
3	O
)	O
suggesting	O
systematic	O
improvements	O
that	O
may	O
benefit	O
population	O
health	O
.	O

The	O
patients	O
showed	O
a	O
statistically	O
significant	O
improvement	O
in	O
Pao	B-PROC
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
(	O
92	O
+/-	O
12	O
vs	O
227	O
+/-	O

The	O
URI	O
symptoms	O
that	O
precede	O
BACM	O
are	O
consistent	O
with	O
an	O
uncomplicated	O
viral	O
influenza	O
infection	O
and	O
include	O
fever	B-PROC
,	O
malaise	O
,	O
cough	O
,	O
sore	O
throat	O
,	O
headache	O
,	O
and	O
rhinitis	O
.	O

Currently	O
the	O
blood	B-PROC
supply	I-PROC
is	O
much	O
safer	O
because	O
of	O
very	O
sensitive	O
testing	O
for	O
HIV	O
as	O
well	O
as	O
hepatitis	O
C	O
.	O
However	O
,	O
new	O
infectious	O
agents	O
emerge	O
constantly	O
and	O
pose	O
a	O
threat	O
to	O
our	O
blood	B-PROC
supply	I-PROC
.	O

Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
poses	O
a	O
threat	O
to	O
the	O
blood	B-PROC
supply	I-PROC
but	O
has	O
never	O
been	O
transmitted	O
in	O
a	O
transfusion	O
.	O

Moreover	O
,	O
a	O
high	O
level	O
of	O
IL	O
-	O
6	O
and	O
MCP	B-PROC
-	I-PROC
1	I-PROC
production	I-PROC
,	O
but	O
not	O
other	O
18	O
cytokines	O
tested	O
,	O
on	O
days	O
2	O
and	O
3	O
after	O
SARS	O
-	O
CoV	O
infection	O
was	O
closely	O
linked	O
to	O
the	O
virus	B-PROC
replication	I-PROC
and	O
disease	O
severity	O
,	O
suggesting	O
the	O
importance	O
of	O
these	O
cytokines	O
in	O
the	O
lung	O
pathogenicity	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Today	O
,	O
the	O
multidisciplinary	O
treatment	O
of	O
severe	O
sepsis	O
includes	O
haemodynamic	O
,	O
respiratory	O
,	O
endocrine	O
,	O
immune	O
,	O
and	O
coagulation	B-PROC
aspects	O
besides	O
the	O
control	O
of	O
the	O
underlying	O
infection	O
.	O

Aside	O
from	O
targeted	B-PROC
regions	O
,	O
other	O
brain	O
structures	O
also	O
showed	O
GFP	O
signal	O
(	O
internal	O
and	O
external	O
globus	O
pallidus	O
,	O
subthalamic	O
nucleus	O
),	O
supporting	O
the	O
idea	O
that	O
AAV1	O
is	O
actively	O
trafficked	B-PROC
to	O
regions	O
distal	O
from	O
the	O
infusion	O
site	O
.	O

We	O
observed	O
a	O
strong	O
humoral	O
and	O
cell	O
-	O
mediated	O
response	O
against	O
AAV1	O
-	O
hrGFP	O
in	O
transduced	O
monkeys	O
irrespective	O
of	O
the	O
anatomic	O
location	O
of	O
the	O
infusion	O
,	O
as	O
evidenced	O
by	O
induction	O
of	O
circulating	O
anti	O
-	O
AAV1	O
and	O
anti	O
-	O
hrGFP	O
antibodies	O
,	O
as	O
well	O
as	O
infiltration	O
of	O
CD4	O
(+)	O
lymphocytes	O
and	O
upregulation	B-PROC
of	O
MHC	B-PROC
-	O
II	O
in	O
regions	O
infused	O
with	O
vector	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
patient	O
who	O
presented	O
a	O
severe	O
Panton	O
-	O
Valentine	O
-	O
secreting	B-PROC
methicillin	O
-	O
susceptible	O
Staphylococcus	O
aureus	O
pneumonia	O
with	O
threatening	O
multi	O
-	O
organ	O
failure	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
cardiac	O
failure	O
,	O
renal	O
failure	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
.	O

Consistently	O
,	O
recombinant	O
full	O
-	O
length	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
or	O
its	O
receptor	O
-	O
binding	O
domain	O
in	O
the	O
presence	O
of	O
rOv	O
-	O
ASP	O
-	O
1	O
could	O
effectively	O
induce	O
a	O
mixed	O
but	O
Th1	O
-	O
skewed	O
immune	B-PROC
response	I-PROC
in	O
immunized	O
mice	O
.	O

A	O
30	O
-	O
year	O
-	O
old	O
,	O
previously	O
healthy	O
man	O
presented	O
with	O
sore	O
throat	O
,	O
fever	B-PROC
,	O
rigor	O
,	O
and	O
dyspnea	O
.	O

Cough	O
was	O
present	O
in	O
all	O
(	O
100	O
%),	O
fever	B-PROC
in	O
90	O
%,	O
and	O
X	O
-	O
ray	O
evidence	O
of	O
pneumonia	O
in	O
7	O
patients	O
.	O

In	O
addition	O
,	O
decreasing	O
responsiveness	O
of	O
active	O
FcgammaRII	O
on	O
PMNs	O
was	O
found	O
in	O
patients	O
who	O
developed	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
)	O
or	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
ARDS	O
.	O

ABSTRACT	O
:	O
The	O
relative	O
contributions	O
of	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
and	O
IL	O
-	O
23	O
to	O
viral	O
pathogenesis	B-PROC
have	O
not	O
been	O
extensively	O
studied	O
.	O

However	O
,	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
levels	O
and	O
virus	O
-	O
specific	O
IFN	O
-	O
gamma	O
-	O
secreting	B-PROC
CD4	O
and	O
CD8	O
T	O
cells	O
were	O
all	O
reduced	O
in	O
the	O
central	O
nervous	O
systems	O
(	O
CNS	O
)	O
of	O
infected	O
p35	O
(-/-)	O
mice	O
.	O

Furthermore	O
,	O
although	O
transforming	O
growth	B-PROC
factor	O
beta	O
mRNA	O
was	O
not	O
affected	O
,	O
IL	O
-	O
10	O
was	O
increased	O
in	O
the	O
CNS	O
in	O
the	O
absence	O
of	O
IL	O
-	O
12	O
.	O

Total	O
MABC	O
scores	O
,	O
socio	O
-	O
economic	O
status	O
,	O
growth	B-PROC
and	O
CBCL	O
scores	O
were	O
not	O
related	O
to	O
each	O
other	O
,	O
but	O
negative	O
motor	O
outcome	O
was	O
related	O
to	O
lower	O
intelligence	O
quotient	O
(	O
IQ	O
)	O
scores	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

RESULTS	O
:	O
Twenty	O
-	O
two	O
percent	O
of	O
the	O
children	O
died	B-PROC
before	O
the	O
age	O
of	O
five	O
,	O
86	O
%	O
(	O
n	O
=	O
149	O
)	O
of	O
the	O
survivors	O
were	O
assessed	O
.	O

An	O
ELISA	O
-	O
based	O
IgG	O
antibody	B-PROC
detection	O
assay	O
using	O
recombinant	O
HCoV	O
-	O
HKU1	O
nucleocapsid	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
(	O
genotype	O
A	O
)	O
were	O
developed	O
for	O
the	O
diagnosis	O
of	O
CoV	O
-	O
HKU1	O
infections	O
,	O
Additionally	O
,	O
a	O
neutralization	O
antibody	B-PROC
assay	O
using	O
the	O
HCoV	O
-	O
HKU1	O
pseudotyped	O
virus	O
was	O
developed	O
to	O
detect	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
in	O
serum	O
with	O
antibody	B-PROC
positivity	O
in	O
an	O
S	O
protein	O
-	O
based	O
ELISA	O
.	O

Irrespective	O
of	O
the	O
specific	O
features	O
of	O
the	O
course	O
of	O
an	O
early	O
neonatal	O
period	O
,	O
neonatal	O
infants	O
need	O
Doppler	O
echocardiographic	O
monitoring	O
for	O
the	O
evaluation	O
of	O
intracardiac	O
hemodynamics	B-PROC
.	O

The	O
pooled	O
relative	O
risk	O
obtained	O
from	O
these	O
three	O
trials	O
showed	O
a	O
trend	O
towards	O
improved	O
mortality	O
with	O
high	O
PEEP	O
,	O
even	O
though	O
the	O
difference	O
did	O
not	O
reach	B-PROC
statistical	O
significance	O
:	O
Pooled	O
cumulative	O
risk	O
of	O
0	O
.	O
90	O
(	O
95	O
%	O
CI	O
0	O
.	O
72	O
-	O
1	O
.	O
02	O
,	O
P	O
=	O
0	O
.	O
077	O
).	O

The	O
reduction	O
in	O
absolute	O
risk	O
of	O
death	B-PROC
was	O
approximately	O
4	O
%.	O

ABSTRACT	O
:	O
The	O
divergence	O
and	O
antigenic	O
shifts	O
in	O
influenza	O
viruses	O
represent	O
significant	O
challenges	O
for	O
the	O
development	B-PROC
of	O
effective	O
vaccines	O
and	O
antiviral	O
drugs	O
against	O
influenza	O
viruses	O
.	O

In	O
order	O
to	O
assess	O
the	O
role	O
of	O
activated	O
neutrophils	O
,	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
adhesion	O
molecules	O
at	O
the	O
onset	O
and	O
development	B-PROC
of	O
respiratory	O
complications	O
and	O
respiratory	O
failure	O
,	O
we	O
measured	O
the	O
serum	O
levels	O
of	O
pro	O
-	O
inflammatory	O
(	O
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
18	O
,	O
TNF	O
-	O
alpha	O
)	O
and	O
anti	O
-	O
inflammatory	O
(	O
IL	O
-	O
1	O
ra	O
,	O
IL	O
-	O
10	O
)	O
cytokines	O
in	O
51	O
AP	O
patients	O
who	O
had	O
been	O
diagnosed	O
with	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
with	O
and	O
without	O
the	O
development	B-PROC
of	O
organ	O
dysfunction	O
.	O

These	O
results	O
together	O
indicate	O
that	O
nsp1	O
is	O
an	O
RNA	O
-	O
binding	O
protein	O
that	O
may	O
function	O
to	O
regulate	O
viral	O
genome	O
translation	B-PROC
or	O
replication	O
but	O
not	O
by	O
binding	O
SLV	O
-	O
VI	O
within	O
its	O
own	O
coding	O
region	O
.	O

Among	O
them	O
,	O
CEACAM1	O
(	O
a	O
)-	O
4C1	O
was	O
the	O
major	O
secreted	B-PROC
isoform	O
in	O
vivo	O
due	O
to	O
the	O
soluble	O
/	O
secreted	B-PROC
CEACAM1	O
(	O
a	O
)	O
with	O
a	O
frameshift	O
sequence	O
in	O
the	O
C	O
-	O
terminus	O
,	O
specific	O
for	O
CEACAM1	O
(	O
a	O
)-	O
2C1	O
and	O
-	O
4C1	O
.	O

ABSTRACT	O
:	O
Critical	O
Care	O
Air	O
Transport	B-PROC
Teams	O
(	O
CCATTs	O
)	O
are	O
an	O
integral	O
component	O
of	O
modern	O
casualty	O
care	O
,	O
allowing	O
early	O
transport	B-PROC
of	O
critically	O
ill	O
and	O
injured	O
patients	O
.	O

TITLE	O
:	O
[	O
Scleroedema	O
adultorum	O
Buschke	O
in	O
a	O
diabetic	O
subject	O
:	O
intravenous	O
immunoglobulin	B-PROC
therapy	O
].	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
plays	O
important	O
roles	O
in	O
both	O
viral	B-PROC
replication	I-PROC
and	O
modulation	O
of	O
host	O
cell	O
processes	O
.	O

PLP	O
blocks	O
these	O
pathways	B-PROC
by	O
affecting	O
activation	O
of	O
the	O
important	O
signaling	B-PROC
proteins	O
in	O
each	O
pathway	B-PROC
,	O
IRF3	O
and	O
NF	O
-	O
kappaB	O
.	O
We	O
also	O
show	O
that	O
the	O
ubiquitin	B-PROC
-	O
like	O
domain	O
of	O
PLP	O
is	O
necessary	O
for	O
pathway	B-PROC
antagonism	O
but	O
not	O
sufficient	O
by	O
itself	O
to	O
block	O
these	O
pathways	B-PROC
regardless	O
of	O
the	O
enzymatic	B-PROC
activity	I-PROC
of	O
the	O
protease	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
SR	O
-	O
rich	O
motif	O
is	O
critical	O
for	O
effective	O
virus	B-PROC
replication	I-PROC
.	O

The	O
initial	O
symptom	O
was	O
unremitting	O
high	O
fever	B-PROC
,	O
and	O
then	O
the	O
clinical	O
situation	O
deteriorated	O
progressively	O
with	O
occurrence	O
of	O
dyspnea	O
.	O

CONCLUSIONS	O
:	O
Early	O
detection	O
,	O
early	O
diagnosis	O
,	O
and	O
finely	O
effective	O
intervention	O
are	O
to	O
improve	O
oxygenation	B-PROC
by	O
mechanical	O
ventilation	O
with	O
low	O
tidal	O
volume	O
and	O
adequate	O
PEEP	O
are	O
critical	O
to	O
reducing	O
the	O
mortality	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
M	O
protein	O
inhibits	O
type	B-PROC
I	I-PROC
interferon	B-PROC
production	I-PROC
by	O
impeding	O
the	O
formation	B-PROC
of	O
TRAF3	O
.	O
TANK	O
.	O
TBK1	O
/	O
IKKepsilon	O
complex	O
.	O

TITLE	O
:	O
Target	O
-	O
dependent	O
B7	O
-	O
H1	O
regulation	B-PROC
contributes	O
to	O
clearance	O
of	O
central	O
nervous	O
system	O
infection	O
and	O
dampens	O
morbidity	O
.	O

Oligodendroglia	O
and	O
microglia	O
up	O
-	O
regulated	O
B7	O
-	O
H1	O
following	O
infection	O
;	O
however	O
,	O
although	O
B7	O
-	O
H1	O
expression	B-PROC
on	O
oligodendroglia	O
was	O
prominent	O
and	O
sustained	O
,	O
it	O
was	O
significantly	O
reduced	O
and	O
transient	O
on	O
microglia	O
.	O

The	O
immunogenicity	O
of	O
the	O
vaccine	O
was	O
assessed	O
by	O
intramuscular	O
injection	O
of	O
one	O
vaccine	O
dose	O
to	O
30	O
BCoV	O
-	O
antibody	B-PROC
negative	O
2	O
-	O
3	O
-	O
month	O
-	O
old	O
calves	O
.	O

In	O
the	O
case	O
of	O
severe	O
clinical	O
symptoms	O
and	O
large	O
mediastinal	O
tumours	O
,	O
we	O
consider	O
it	O
absolutely	O
essential	O
to	O
cannulate	O
the	O
femoral	O
vessels	O
preoperatively	O
under	O
local	O
anaesthesia	O
and	O
to	O
provide	O
for	O
the	O
availability	O
of	O
cardiopulmonary	O
bypass	O
in	O
the	O
operating	O
theatre	O
,	O
should	O
extracorporeal	O
circulation	B-PROC
become	O
necessary	O
.	O

The	O
plant	O
virus	O
,	O
cowpea	O
mosaic	O
virus	O
(	O
CPMV	O
),	O
has	O
recently	O
been	O
explored	O
as	O
a	O
nanoparticle	O
delivery	O
system	O
for	O
therapeutics	O
targeting	B-PROC
a	O
number	O
of	O
diseases	O
including	O
cancer	O
and	O
neurodegeneration	O
.	O

3a	O
expression	B-PROC
is	O
detected	O
in	O
both	O
SARS	O
-	O
CoV	O
infected	O
cultured	O
cells	O
and	O
patients	O
.	O

We	O
previously	O
showed	O
that	O
caspase	O
pathways	B-PROC
are	O
involved	O
in	O
3a	O
-	O
induced	O
apoptosis	B-PROC
.	O

Although	O
there	O
are	O
no	O
commercial	O
products	O
on	O
the	O
market	O
yet	O
,	O
the	O
development	B-PROC
and	O
testing	O
of	O
oral	O
,	O
plant	O
-	O
based	O
vaccines	O
is	O
now	O
beyond	O
the	O
proof	O
-	O
of	O
-	O
principle	O
stage	O
.	O

TITLE	O
:	O
Molecular	O
determinants	O
for	O
subcellular	O
localization	B-PROC
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
open	O
reading	O
frame	O
3b	O
protein	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
characterized	O
the	O
molecular	O
components	O
that	O
regulate	O
intracellular	B-PROC
localization	I-PROC
of	O
the	O
ORF	O
3b	O
protein	O
.	O

This	O
study	O
describes	O
a	O
novel	O
role	O
for	O
MAVS	O
in	O
controlling	O
viral	B-PROC
infections	I-PROC
through	O
the	O
induction	B-PROC
of	I-PROC
apoptosis	I-PROC
,	O
and	O
identifies	O
viral	O
proteins	O
which	O
inhibit	O
this	O
host	B-PROC
response	I-PROC
.	O

Thirty	O
individuals	O
with	O
SARS	O
were	O
chosen	O
for	O
analysis	O
of	O
MASP2	O
polymorphisms	B-PROC
by	O
means	O
of	O
PCR	O
direct	O
sequencing	O
.	O

It	O
provides	O
a	O
broadly	O
targeted	B-PROC
and	O
rational	O
single	O
tube	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
PCR	O
"("""	O
NQPCR	O
""")"	O
for	O
the	O
generic	O
detection	O
and	O
discovery	O
of	O
CoV	O
.	O
Degenerate	O
primers	O
,	O
previously	O
published	O
,	O
and	O
the	O
new	O
probes	O
,	O
were	O
from	O
a	O
conserved	O
stretch	O
of	O
open	O
reading	O
frame	O
1b	O
,	O
encoding	O
the	O
replicase	O
.	O

TITLE	O
:	O
Expression	B-PROC
,	O
crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
human	O
coronavirus	O
HKU1	O
nonstructural	O
protein	O
9	O
.	O

In	O
those	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
there	O
was	O
a	O
significant	O
increase	O
from	O
baseline	O
in	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO2	O
)	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
FiO2	O
)	O
ratio	O
at	O
24	O
hours	O
in	O
the	O
CVVH	O
group	O
(	O
n	O
=	O
16	O
,	O
174	O
+/-	O

This	O
represents	O
a	O
promising	O
system	O
for	O
development	B-PROC
of	O
coronavirus	O
-	O
based	O
gene	B-PROC
delivery	I-PROC
vectors	O
and	O
vaccines	O
against	O
coronavirus	O
and	O
other	O
viral	B-PROC
infections	I-PROC
in	O
chicken	O
.	O

In	O
the	O
case	O
of	O
the	O
S2	O
domain	O
of	O
protein	O
S	O
,	O
it	O
has	O
been	O
found	O
a	O
highly	O
hydrophobic	O
and	O
interfacial	O
domain	O
flanked	O
by	O
the	O
heptad	O
repeat	O
1	O
and	O
2	O
regions	O
;	O
significantly	O
,	O
different	O
peptides	O
pertaining	O
to	O
this	O
domain	O
have	O
shown	O
a	O
significant	O
leakage	O
effect	O
and	O
an	O
important	O
plaque	O
formation	B-PROC
inhibition	B-PROC
,	O
which	O
,	O
similarly	O
to	O
HIV	O
-	O
1	O
gp41	O
,	O
support	O
the	O
role	O
of	O
this	O
region	O
in	O
the	O
fusion	O
process	O
.	O

Although	O
the	O
molecular	O
mechanisms	O
governing	O
ARDS	O
pathophysiology	O
remain	O
unknown	O
in	O
aged	O
animals	O
,	O
these	O
studies	O
reveal	O
a	O
strategy	O
for	O
dissecting	O
the	O
genetic	O
pathways	B-PROC
by	O
which	O
SARS	O
-	O
CoV	O
infection	O
induces	O
changes	O
in	O
the	O
host	B-PROC
response	I-PROC
,	O
leading	O
to	O
death	B-PROC
.	O

TITLE	O
:	O
Analysis	O
of	O
the	O
properties	O
of	O
neutralizing	O
monoclonal	O
antibodies	O
against	O
the	O
hemagglutinating	O
encephalomyelitis	O
virus	O
and	O
inhibition	B-PROC
of	O
HEV	O
infection	O
by	O
specific	O
MAb	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
chimeric	O
DNA	O
-	O
RNA	O
hammerhead	O
ribozyme	O
targeting	B-PROC
SARS	O
virus	O
.	O

Effects	O
of	O
the	O
chimeric	O
ribozyme	O
on	O
expression	B-PROC
of	O
SARS	O
-	O
CoV	O
were	O
evaluated	O
in	O
cultured	O
3T3	O
cells	O
.	O

The	O
chimeric	O
DNA	O
-	O
RNA	O
hammerhead	O
ribozyme	O
targeting	B-PROC
SARS	O
-	O
CoV	O
significantly	O
inhibited	O
multiplication	O
of	O
MHV	O
in	O
DBT	O
cells	O
by	O
about	O
60	O
%.	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
contains	O
multiple	O
conformation	O
-	O
dependent	O
epitopes	O
that	O
induce	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
.	O

N	O
protein	O
is	O
thought	O
to	O
dysregulate	O
cell	O
signalling	B-PROC
and	O
the	O
transcription	B-PROC
of	O
cellular	O
genes	O
,	O
including	O
FGL2	O
,	O
which	O
encodes	O
a	O
prothrombinase	O
implicated	O
in	O
vascular	O
thrombosis	O
,	O
fibrin	O
deposition	O
and	O
pneumocyte	O
necrosis	B-PROC
.	O

Here	O
,	O
we	O
present	O
an	O
overview	O
of	O
recently	O
identified	O
substances	O
that	O
inhibit	O
and	O
/	O
or	O
reverse	O
endothelial	O
barrier	O
disruption	O
and	O
permeability	O
or	O
alveolar	O
epithelial	O
dysfunction	O
:	O
(	O
1	O
)	O
zinc	O
chelators	O
,	O
which	O
were	O
shown	O
to	O
attenuate	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
the	O
pulmonary	O
endothelium	O
;	O
(	O
2	O
)	O
peroxisome	O
proliferator	O
activated	O
receptor	O
(	O
PPAR	O
)	O
ligands	O
,	O
which	O
have	O
been	O
shown	O
to	O
exert	B-PROC
anti	O
-	O
inflammatory	O
effects	O
,	O
by	O
decreasing	O
the	O
expression	B-PROC
of	O
pro	O
-	O
inflammatory	O
genes	O
;	O
(	O
3	O
)	O
extracellular	O
ATP	O
,	O
produced	O
during	O
inflammation	O
,	O
which	O
induces	O
a	O
rapid	O
and	O
dose	O
-	O
dependent	O
increase	O
in	O
transendothelial	O
electrical	O
resistance	B-PROC
(	O
TER	O
)	O
across	O
pulmonary	O
endothelial	O
cells	O
;	O
(	O
4	O
)	O
the	O
lectin	O
-	O
like	O
domain	O
of	O
TNF	O
,	O
which	O
is	O
spatially	O
distinct	O
from	O
the	O
receptor	O
binding	O
sites	O
and	O
which	O
protects	O
from	O
hydrostatic	O
and	O
permeability	O
edema	O
and	O
(	O
5	O
)	O
Hsp90	O
inhibitors	O
,	O
which	O
prevent	O
and	O
repair	B-PROC
toxin	O
-	O
induced	O
hyperpermeability	O
.	O

Taken	O
together	O
,	O
CC	O
/	O
Fr	O
.	O
2	O
contains	O
unknown	O
substances	O
,	O
that	O
could	O
inhibit	O
the	O
infection	O
,	O
probably	O
by	O
interfering	O
with	O
endocytosis	B-PROC
,	O
and	O
it	O
also	O
contains	O
procyanidins	O
that	O
did	O
not	O
inhibit	O
the	O
internalization	O
but	O
inhibited	O
the	O
infection	O
.	O

Here	O
,	O
we	O
describe	O
the	O
heterologous	O
expression	B-PROC
of	O
pAPN	O
without	O
signal	O
peptide	O
in	O
BL21	O
(	O
DE3	O
)	O
pLysS	O
host	O
cells	O
.	O

By	O
inoculating	O
a	O
rabbit	O
with	O
the	O
purified	O
pAPN	O
,	O
a	O
high	O
tittered	O
specific	O
antibody	B-PROC
was	O
achieved	O
.	O

This	O
Review	O
focuses	O
on	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
mechanisms	O
of	O
coronavirus	O
replication	O
,	O
interactions	O
with	O
the	O
host	O
immune	B-PROC
response	I-PROC
and	O
disease	O
pathogenesis	B-PROC
.	O

The	O
significant	O
correlation	O
between	O
plasma	O
SP	O
-	O
D	O
and	O
anti	O
-	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibodies	O
support	O
the	O
role	O
for	O
SP	O
-	O
D	O
in	O
interlinking	O
innate	O
and	O
adaptive	O
immune	O
pathways	B-PROC
.	O

ABSTRACT	O
:	O
Many	O
viral	O
fusion	O
proteins	O
are	O
primed	O
by	O
proteolytic	B-PROC
cleavage	B-PROC
near	O
their	O
fusion	O
peptides	O
.	O

While	O
the	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
is	O
known	O
to	O
be	O
cleaved	O
at	O
the	O
S1	O
/	O
S2	O
boundary	O
,	O
this	O
cleavage	B-PROC
site	O
is	O
not	O
closely	O
linked	O
to	O
a	O
fusion	O
peptide	O
.	O

We	O
propose	O
that	O
proteolytic	B-PROC
cleavage	B-PROC
within	O
S2	O
exposes	O
a	O
novel	O
internal	O
fusion	O
peptide	O
for	O
SARS	O
-	O
CoV	O
S	O
,	O
which	O
may	O
be	O
conserved	O
across	O
the	O
Coronaviridae	O
.	O

We	O
applied	O
a	O
population	O
-	O
based	O
interrupted	O
time	O
series	O
study	O
design	O
and	O
used	O
the	O
time	O
series	O
auto	O
-	O
regressive	O
integrated	O
moving	B-PROC
-	O
average	O
model	O
to	O
compare	O
the	O
actual	O
and	O
predicted	O
admission	O
rates	O
of	O
seven	O
selected	O
chronic	O
ACSCs	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
emerged	O
fleetingly	O
in	O
the	O
winter	O
of	O
2002	O
and	O
again	O
in	O
the	O
winter	O
of	O
2003	O
,	O
resulting	O
in	O
the	O
infection	O
of	O
~	O
8	O
,	O
000	O
people	O
and	O
the	O
death	B-PROC
of	O
~	O
800	O
.	O

Of	O
the	O
viral	O
-	O
entry	O
inhibitors	O
,	O
monoclonal	O
antibodies	O
have	O
demonstrated	O
efficacy	O
,	O
clinical	O
application	O
in	O
other	O
viral	B-PROC
infections	I-PROC
,	O
and	O
the	O
potential	O
to	O
impact	O
a	O
future	O
epidemic	O
.	O

Patients	O
with	O
SARS	O
also	O
suffered	O
from	O
cardiac	O
disease	O
including	O
arrhythmias	O
,	O
sudden	O
cardiac	O
death	B-PROC
,	O
and	O
systolic	O
and	O
diastolic	O
dysfunction	O
.	O

Autopsy	O
heart	O
samples	O
from	O
patients	O
who	O
succumbed	O
to	O
the	O
SARS	O
crisis	O
in	O
Toronto	O
(	O
Canada	O
)	O
were	O
used	O
to	O
investigate	O
the	O
impact	O
of	O
SARS	O
on	O
myocardial	O
structure	O
,	O
inflammation	O
and	O
ACE2	O
protein	B-PROC
expression	B-PROC
.	O

ABSTRACT	O
:	O
Development	B-PROC
of	O
cancer	O
after	O
transplantation	O
has	O
rapidly	O
became	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	B-PROC
in	O
kidney	O
transplant	O
recipients	O
with	O
functioning	O
grafts	O
.	O

Failing	O
to	O
account	O
for	O
dynamic	O
molecular	O
evolution	B-PROC
can	O
affect	O
greatly	O
estimating	O
index	O
case	O
dates	O
,	O
resulting	O
in	O
an	O
overestimated	O
age	O
for	O
the	O
SARS	O
-	O
CoV	O
-	O
human	O
infection	O
,	O
for	O
instance	O
.	O

ABSTRACT	O
:	O
In	O
this	O
review	O
,	O
recent	O
developments	O
in	O
the	O
field	O
of	O
viral	B-PROC
diseases	I-PROC
of	O
the	O
dog	O
and	O
the	O
cat	O
are	O
discussed	O
.	O

Th2	O
cell	B-PROC
polarization	I-PROC
,	O
Smad4	O
and	O
Smad7	O
should	O
be	O
the	O
crucial	O
molecular	O
mechanism	O
of	O
ALI	O
-	O
induced	O
rapid	O
fibrosis	O
.	O

Nevertheless	O
,	O
patient	O
became	O
comatose	O
with	O
severe	O
muscle	O
stiffness	O
,	O
persistent	O
shock	O
,	O
coagulation	B-PROC
problems	O
,	O
metabolic	B-PROC
acidosis	O
,	O
hyperkalemia	O
and	O
died	B-PROC
less	O
than	O
24	O
hours	O
later	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
conduct	B-PROC
fast	O
screening	O
of	O
passengers	O
with	O
infections	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
or	O
pandemic	O
influenza	O
at	O
a	O
quarantine	O
depot	O
,	O
we	O
developed	O
a	O
non	O
-	O
contact	O
screening	O
system	O
with	O
self	O
-	O
produced	O
program	O
to	O
conduct	B-PROC
a	O
human	O
screening	O
within	O
five	O
seconds	O
,	O
via	O
a	O
linear	O
discriminant	O
function	O
from	O
non	O
-	O
contact	O
derived	O
variables	O
,	O
i	O
.	O
e	O
.	O
palmer	O
pulse	B-PROC
derived	O
from	O
a	O
laser	O
Doppler	O
blood	O
-	O
flow	O
meter	O
,	O
respiration	B-PROC
rate	O
determined	O
by	O
a	O
10	O
-	O
GHz	O
microwave	O
radar	O
,	O
and	O
facial	O
temperature	O
measured	O
by	O
thermography	O
.	O

ABSTRACT	O
:	O
Events	O
in	O
the	O
last	O
decade	O
have	O
taught	O
us	O
that	O
we	O
are	O
now	O
,	O
more	O
than	O
ever	O
,	O
vulnerable	O
to	O
fatal	O
zoonotic	O
diseases	O
such	O
as	O
those	O
caused	O
by	O
haemorrhagic	O
fever	B-PROC
viruses	O
,	O
influenza	O
,	O
rabies	O
and	O
BSE	O
/	O
vCJD	O
.	O

Isolates	O
of	O
Streptococcus	O
pyogenes	O
were	O
collected	O
from	O
scarlet	O
fever	B-PROC
patients	O
in	O
central	O
Taiwan	O
and	O
were	O
characterized	O
by	O
emm	O
sequencing	O
and	O
a	O
standardized	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
method	O
.	O

The	O
occurrences	O
of	O
scarlet	O
fever	B-PROC
in	O
central	O
Taiwan	O
in	O
2000	O
-	O
2006	O
were	O
primarily	O
caused	O
by	O
five	O
emm	O
types	O
,	O
which	O
accounted	O
for	O
96	O
.	O
8	O
%	O
of	O
the	O
isolates	O
collected	O
.	O

The	O
fluctuation	O
in	O
the	O
number	O
of	O
scarlet	O
fever	B-PROC
cases	O
during	O
the	O
seven	O
years	O
can	O
be	O
primarily	O
attributed	O
to	O
the	O
shuffling	O
of	O
six	O
prevalent	O
emm	O
clones	O
and	O
to	O
the	O
SARS	O
outbreak	O
in	O
2003	O
.	O

In	O
2003	O
,	O
the	O
dramatic	O
drop	O
in	O
scarlet	O
fever	B-PROC
cases	O
in	O
central	O
Taiwan	O
and	O
throughout	O
the	O
whole	O
country	O
was	O
associated	O
with	O
the	O
occurrence	O
of	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
that	O
occurred	O
between	O
late	O
-	O
February	O
and	O
mid	O
-	O
June	O
in	O
Taiwan	O
.	O

ABSTRACT	O
:	O
Systemic	O
administration	O
of	O
corticosteroid	O
,	O
plasmapheresis	O
and	O
high	O
-	O
dose	O
immunoglobulin	B-PROC
therapy	O
(	O
IVIG	O
)	O
are	O
the	O
main	O
treatment	O
of	O
Stevens	O
-	O
Johnson	O
syndrome	O
(	O
SJS	O
)	O
and	O
toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
).	O

TITLE	O
:	O
Sivelestat	O
(	O
selective	O
neutrophil	O
elastase	O
inhibitor	O
)	O
improves	O
the	O
mortality	O
rate	O
of	O
sepsis	O
associated	O
with	O
both	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
patients	O
.	O

Our	O
results	O
demonstrates	O
that	O
SARS	O
-	O
CoV	O
did	O
not	O
modulate	O
TLR	O
-	O
1	O
to	O
TLR	O
-	O
10	O
gene	B-PROC
expression	I-PROC
but	O
significantly	O
induced	O
the	O
expression	B-PROC
of	O
CCR	O
-	O
1	O
,	O
CCR	O
-	O
3	O
,	O
and	O
CCR	O
-	O
5	O
.	O

TITLE	O
:	O
The	O
impact	O
on	O
neonatal	O
mortality	O
of	O
shifting	O
childbirth	B-PROC
services	O
among	O
levels	O
of	O
hospitals	O
:	O
Taiwan	O
'	O
s	O
experience	O
.	O

ABSTRACT	O
:	O
There	O
is	O
considerable	O
discussion	O
surrounding	O
whether	O
advanced	O
hospitals	O
provide	O
better	O
childbirth	B-PROC
care	O
than	O
local	O
community	O
hospitals	O
.	O

The	O
database	O
included	O
all	O
probable	O
5327	O
SARS	O
cases	O
,	O
of	O
whom	O
343	O
died	B-PROC
.	O

The	O
average	O
duration	O
of	O
onset	O
of	O
symptoms	O
to	O
hospital	O
admission	O
was	O
3	O
.	O
8	O
days	O
,	O
of	O
admission	O
to	O
discharge	O
for	O
those	O
who	O
survived	O
was	O
29	O
.	O
7	O
days	O
,	O
while	O
admission	O
to	O
death	B-PROC
for	O
casualties	O
was	O
17	O
.	O
4	O
days	O
.	O

The	O
duration	O
of	O
hospital	O
admission	O
to	O
death	B-PROC
in	O
mainland	O
China	O
,	O
however	O
,	O
appeared	O
to	O
be	O
shorter	O
than	O
in	O
other	O
areas	O
,	O
which	O
is	O
in	O
striking	O
contrast	O
to	O
the	O
much	O
lower	O
case	O
fatality	O
in	O
mainland	O
China	O
.	O

Because	O
of	O
their	O
deteriorated	O
health	O
status	O
and	O
apparent	O
complications	O
,	O
SARS	O
patients	O
aged	O
>	O
60	O
years	O
had	O
a	O
much	O
higher	O
risk	O
of	O
dying	B-PROC
than	O
younger	O
patients	O
.	O

SARS	O
-	O
CoV	O
protein	O
eukaryotic	O
expression	B-PROC
plasmids	O
were	O
transfected	O
respectively	O
into	O
CHO	O
cells	O
.	O

Immunohistochemistry	O
was	O
employed	O
to	O
detect	O
the	O
expression	B-PROC
of	O
the	O
structural	O
proteins	O
of	O
SARS	O
-	O
CoV	O
in	O
transfected	O
cells	O
.	O

TITLE	O
:	O
Altered	O
pathogenicity	O
,	O
immunogenicity	O
,	O
tissue	B-PROC
tropism	B-PROC
and	O
3	O
'-	O
7kb	O
region	O
sequence	O
of	O
an	O
avian	O
infectious	O
bronchitis	O
coronavirus	O
strain	O
after	O
serial	O
passage	O
in	O
embryos	O
.	O

The	O
changes	O
described	O
in	O
the	O
3	O
'-	O
7kb	O
region	O
of	O
the	O
virus	O
are	O
possibly	O
responsible	O
for	O
virus	O
attenuation	O
,	O
immunogenicity	O
decrease	O
and	O
tissue	B-PROC
tropism	B-PROC
changes	O
;	O
however	O
,	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
other	O
parts	O
of	O
the	O
genome	O
may	O
also	O
be	O
involved	O
in	O
those	O
changes	O
.	O

During	O
vaccination	O
of	O
rN	O
protein	O
,	O
the	O
expression	B-PROC
of	O
IFN	O
-	O
gamma	O
and	O
IL	O
-	O
10	O
was	O
evidently	O
up	O
-	O
regulated	O
in	O
splenocytes	O
at	O
different	O
time	O
points	O
,	O
while	O
the	O
expression	B-PROC
of	O
IL	O
-	O
2	O
and	O
IL	O
-	O
4	O
was	O
not	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
CoV	O
infection	O
of	O
human	O
results	O
in	O
antigen	O
-	O
specific	O
cellular	O
and	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
.	O

Our	O
results	O
demonstrated	O
that	O
low	O
levels	O
of	O
specific	O
memory	B-PROC
T	O
cell	O
responses	O
to	O
SARS	O
-	O
CoV	O
S	O
,	O
M	O
,	O
E	O
and	O
N	O
peptides	O
were	O
detected	O
in	O
a	O
proportion	O
of	O
SARS	O
-	O
recovered	O
patients	O
,	O
and	O
IFN	O
-	O
gamma	O
was	O
the	O
predominant	O
cytokine	O
produced	O
by	O
T	O
cells	O
after	O
stimulation	O
with	O
peptides	O
.	O

DATA	O
SYNTHESIS	B-PROC
AND	O
RECOMMENDATIONS	O
:	O
Lower	O
mortality	O
combined	O
with	O
a	O
relatively	O
lower	O
frequency	O
of	O
ALI	O
/	O
ARDS	O
in	O
children	O
makes	O
performance	O
of	O
clinical	O
trials	O
challenging	O
.	O

The	O
5	O
-	O
Acetyl	O
-	O
2	O
-(	O
4	O
'-	O
nitrobiphenyl	O
-	O
4	O
-	O
yl	O
)-	O
1H	O
-	O
benzimidazole	O
(	O
24	O
)	O
emerged	O
as	O
potent	O
active	O
lead	O
compound	O
against	O
Yellow	O
Fever	B-PROC
Virus	O
(	O
a	O
Flavivirus	O
)	O
(	O
EC	O
(	O
50	O
)	O
=	O
0	O
.	O
5	O
microM	O
)	O
and	O
CVB	O
-	O
2	O
at	O
1	O
microM	O
and	O
was	O
not	O
cytotoxic	O
,	O
whereas	O
the	O
other	O
title	O
benzimidazoles	O
showed	O
no	O
antiviral	O
activity	O
at	O
concentrations	O
not	O
cytotoxic	O
for	O
the	O
resting	O
cell	O
monolayers	O
.	O

TITLE	O
:	O
Analysis	O
of	O
putative	O
recombination	B-PROC
hot	O
sites	O
in	O
the	O
S	O
gene	O
of	O
canine	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
In	O
this	O
review	O
,	O
the	O
current	O
state	O
of	O
vaccine	O
development	B-PROC
against	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
,	O
focusing	O
on	O
recently	O
published	O
data	O
is	O
assessed	O
.	O

Pneumonia	O
improved	O
in	O
59	O
(	O
54	O
.	O
1	O
%)	O
out	O
of	O
109	O
patients	O
;	O
49	O
(	O
44	O
.	O
5	O
%)	O
out	O
of	O
110	O
patients	O
died	B-PROC
.	O

TITLE	O
:	O
[	O
Effect	O
on	O
mRNA	O
and	O
secretion	B-PROC
levels	O
of	O
proinflammatory	O
cytokines	O
in	O
DC	O
infected	O
by	O
SARS	O
-	O
CoV	O
N	O
gene	O
recombinant	O
adenovirus	O
].	O

It	O
is	O
suggested	O
that	O
N	O
protein	O
may	O
be	O
related	O
to	O
the	O
excessive	O
secretion	B-PROC
of	O
proinflammatory	O
cytokines	O
during	O
SARS	O
-	O
CoV	O
infection	O
at	O
the	O
acute	O
phase	O
.	O

TITLE	O
:	O
[	O
Synthesis	B-PROC
in	O
Escherichia	O
coli	O
cells	O
and	O
characterization	O
of	O
the	O
active	O
exoribonuclease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
].	O

Complications	O
included	O
pseudocysts	O
(	O
n	O
=	O
34	O
),	O
abscess	O
(	O
n	O
=	O
2	O
),	O
necrosis	B-PROC
(	O
n	O
=	O
6	O
),	O
ascites	O
(	O
n	O
=	O
13	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
n	O
=	O
13	O
),	O
acute	O
renal	O
failure	O
(	O
n	O
=	O
14	O
),	O
shock	O
(	O
n	O
=	O
14	O
),	O
coagulopathy	O
(	O
n	O
=	O
1	O
)	O
and	O
pleural	O
effusion	O
(	O
n	O
=	O
26	O
).	O

The	O
administration	O
of	O
phenobarbital	O
in	O
this	O
patient	O
allowed	O
improved	O
symptom	O
control	O
,	O
minimized	O
the	O
potential	O
for	O
propylene	O
glycol	O
toxicity	O
,	O
was	O
not	O
associated	O
with	O
respiratory	O
depression	O
,	O
and	O
facilitated	O
successful	O
weaning	B-PROC
of	O
benzodiazepines	O
.	O

Barbiturates	O
offer	O
a	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
that	O
is	O
different	O
from	O
that	O
of	O
benzodiazepines	O
.	O

Forty	O
-	O
two	O
nurses	O
(	O
84	O
%)	O
thought	O
that	O
nebulizer	O
was	O
more	O
effective	O
for	O
treating	O
acute	O
airflow	B-PROC
obstruction	O
in	O
the	O
hospital	O
.	O

All	O
patients	O
had	O
fever	B-PROC
,	O
cough	O
,	O
dyspnea	O
or	O
respiratory	O
distress	O
,	O
increased	O
serum	O
lactate	O
dehydrogenase	O
levels	O
,	O
and	O
bilateral	O
patchy	O
pneumonia	O
.	O

S	O
-	O
OIV	O
infection	O
can	O
cause	O
severe	O
illness	O
,	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
death	B-PROC
in	O
previously	O
healthy	O
persons	O
who	O
are	O
young	O
to	O
middle	O
-	O
aged	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
for	O
59	O
days	O
without	O
changing	O
the	O
ECMO	O
circuit	O
:	O
a	O
case	O
of	O
Legionella	O
pneumonia	O
.	O

Blood	O
DNA	O
samples	O
were	O
evaluated	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
proviral	O
DNA	O
,	O
whereas	O
reverse	O
transcriptase	B-PROC
-	O
PCR	O
was	O
run	O
on	O
fecal	O
samples	O
for	O
detection	O
of	O
coronavirus	O
RNA	O
.	O

Results	O
showed	O
that	O
Penn	O
-	O
98	O
-	O
1	O
behaved	O
like	O
MHV	O
-	O
2	O
,	O
thus	O
establishing	O
a	O
role	O
for	O
the	O
spike	O
protein	O
in	O
viral	O
growth	B-PROC
.	O

Little	O
is	O
known	O
about	O
the	O
host	O
immune	B-PROC
response	I-PROC
to	O
MHV	O
-	O
1	O
and	O
how	O
it	O
might	O
contribute	O
to	O
some	O
of	O
the	O
pathological	O
changes	O
detected	O
in	O
infected	O
mice	O
.	O

A	O
2	O
.	O
2kb	O
DNA	O
fragment	O
,	O
encoding	O
for	O
N	O
-	O
terminal	O
domain	O
glycoprotein	O
S	O
of	O
TGEV	O
,	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
and	O
cloned	O
into	O
eukaryotic	O
expression	B-PROC
vector	O
pVAX1	O
.	O

Cellular	O
and	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
were	O
assessed	O
by	O
indirect	O
ELISA	O
,	O
lymphocyte	B-PROC
proliferation	I-PROC
assays	O
,	O
ELISPOT	O
and	O
FACS	O
.	O

The	O
nucleocapsid	O
DNA	O
vaccine	O
had	O
good	O
immunogenicity	O
and	O
can	O
induce	O
specific	O
humoral	O
and	O
cellular	B-PROC
immunity	I-PROC
in	O
BALB	O
/	O
c	O
mice	O
,	O
while	O
IL	O
-	O
2	O
plays	O
an	O
immunoadjuvant	O
role	O
and	O
enhances	O
specific	O
immune	B-PROC
responses	I-PROC
.	O

In	O
the	O
severely	O
obese	O
patients	O
undergoing	O
DCL	O
,	O
significantly	O
elevated	O
prevalence	O
ratios	O
(	O
PR	O
)	O
for	O
development	B-PROC
of	O
postoperative	O
infectious	O
complications	O
,	O
acute	O
renal	O
insufficiency	O
,	O
and	O
failure	O
of	O
primary	O
abdominal	O
wall	O
fascial	O
closure	O
were	O
1	O
.	O
75	O
,	O
3	O
.	O
07	O
,	O
and	O
2	O
.	O
62	O
,	O
respectively	O
.	O

Absence	O
,	O
or	O
inactivation	O
,	O
of	O
E	O
protein	O
results	O
in	O
attenuated	O
viruses	O
,	O
due	O
to	O
alterations	O
in	O
either	O
virion	O
morphology	O
or	O
tropism	B-PROC
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
malnutrition	O
affects	O
13	O
million	O
children	O
worldwide	O
and	O
causes	O
1	O
-	O
2	O
million	O
deaths	B-PROC
every	O
year	O
.	O

These	O
recommendations	O
provide	O
a	O
pragmatic	O
approach	O
to	O
the	O
initial	O
diagnosis	O
and	O
management	O
of	O
fever	B-PROC
in	O
returned	O
travellers	O
,	O
based	O
on	O
evidence	O
where	O
it	O
is	O
available	O
and	O
on	O
consensus	O
of	O
expert	O
opinion	O
where	O
it	O
is	O
not	O
.	O

Infections	O
and	O
crush	O
syndrome	O
caused	O
sepsis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
renal	O
failure	O
,	O
heart	O
failure	O
,	O
liver	O
dysfunction	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
in	O
a	O
short	O
time	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
known	O
to	O
efficiently	O
suppress	O
the	O
induction	O
of	O
antiviral	O
type	O
I	O
interferons	O
(	O
IFN	O
-	O
alpha	O
/	O
beta	O
)	O
in	O
non	O
-	O
lymphatic	O
cells	O
through	O
inhibition	B-PROC
of	O
the	O
transcription	B-PROC
factor	O
IRF	O
-	O
3	O
.	O

Expression	B-PROC
and	O
localization	B-PROC
of	O
the	O
transcribed	O
SN	O
protein	O
from	O
the	O
recombinant	O
LNZ9000	O
-	O
rTGEV	O
-	O
SN	O
were	O
detected	O
via	O
SDS	O
-	O
PAGE	O
,	O
Western	O
blot	O
,	O
and	O
immunofluorescence	O
.	O

These	O
data	O
indicated	O
that	O
the	O
recombinant	O
L	O
.	O
lactis	O
could	O
be	O
a	O
valuable	O
tool	O
in	O
the	O
development	B-PROC
of	O
future	O
vaccines	O
against	O
TGEV	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
coverage	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccine	O
field	O
boost	O
in	O
commercial	O
broilers	O
,	O
estimate	O
the	O
relative	O
amount	O
of	O
vaccine	O
virus	O
in	O
the	O
trachea	O
,	O
and	O
follow	O
the	O
clearance	O
of	O
the	O
vaccine	O
,	O
we	O
collected	O
approximately	O
100	O
tracheal	O
swabs	O
at	O
various	O
times	O
postvaccination	O
from	O
10	O
different	O
flocks	O
and	O
used	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
detect	O
the	O
virus	O
.	O

Alveolar	O
epithelial	O
cells	O
are	O
an	O
important	O
target	O
for	O
coronavirus	O
infection	O
in	O
the	O
lung	O
,	O
and	O
infected	O
cells	O
can	O
initiate	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
viral	B-PROC
infection	I-PROC
.	O

Primary	O
cultures	O
of	O
differentiated	B-PROC
alveolar	O
epithelial	O
cells	O
will	O
be	O
useful	O
for	O
identifying	O
the	O
interactions	O
between	O
coronaviruses	O
and	O
alveolar	O
epithelial	O
cells	O
that	O
influence	O
the	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
infection	O
in	O
the	O
lung	O
.	O

However	O
,	O
PH	O
may	O
worsen	O
during	O
exercise	O
,	O
sleep	B-PROC
,	O
and	O
exacerbations	O
of	O
the	O
disease	O
.	O

After	O
induction	O
of	O
ARDS	O
in	O
eight	O
female	O
pigs	O
(	O
56	O
.	O
1	O
+/-	O
3	O
.	O
2	O
kg	O
),	O
lung	O
recruitment	O
was	O
performed	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
was	O
set	O
3	O
cmH2O	O
above	O
the	O
lower	O
inflection	O
point	O
of	O
the	O
pressure	O
-	O
volume	O
curve	O
.	O

After	O
lung	O
recruitment	O
,	O
oxygenation	B-PROC
remained	O
significantly	O
improved	O
although	O
VTs	O
were	O
minimized	O
to	O
0	O
ml	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

We	O
have	O
carried	O
out	O
computational	O
docking	B-PROC
studies	O
and	O
generated	O
a	O
predictive	O
3D	O
-	O
QSAR	O
model	O
for	O
SARS	O
-	O
CoV	O
PLpro	O
inhibitors	O
.	O

The	O
pathology	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
involves	O
diffuse	O
alveolar	O
damage	O
,	O
which	O
comprises	O
severe	O
alveolar	O
epithelial	O
cell	O
damage	O
,	O
hyaline	O
membrane	O
formation	B-PROC
,	O
and	O
festinate	O
myofibroblast	O
proliferation	O
and	O
fibrosis	O
in	O
the	O
intra	O
-	O
alveolar	O
spaces	O
.	O

Gene	B-PROC
expression	I-PROC
profiling	O
of	O
these	O
mice	O
identified	O
type	O
I	O
IFN	O
-	O
independent	O
responses	O
to	O
infection	O
,	O
with	O
IFN	O
-	O
gamma	O
as	O
the	O
central	O
player	O
.	O

CONCLUSIONS	O
:	O
Transcriptional	B-PROC
profiling	O
of	O
mice	O
infected	O
with	O
MHV	O
demonstrated	O
the	O
induction	O
of	O
a	O
robust	O
IFN	O
response	O
,	O
which	O
correlated	O
with	O
the	O
viral	O
load	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
reference	O
ranges	O
of	O
normal	O
oral	O
temperatures	O
of	O
students	O
in	O
Singapore	O
and	O
recommend	O
the	O
cut	O
-	O
off	O
values	O
for	O
febrile	B-PROC
patients	O
.	O

This	O
study	O
demonstrated	O
that	O
an	O
ongoing	O
respiratory	O
virus	B-PROC
infection	I-PROC
compromises	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
and	O
affects	O
the	O
pathogenesis	B-PROC
of	O
a	O
respiratory	O
CoV	O
co	O
-	O
infection	O
.	O

Collectively	O
,	O
these	O
observations	O
suggest	O
interactive	O
effects	O
between	O
PRCV	O
and	O
PRRSV	O
via	O
early	O
innate	O
(	O
IFN	O
-	O
alpha	O
)	O
and	O
later	O
adaptive	O
Th1	O
(	O
IFN	O
-	O
gamma	O
)	O
and	O
Th2	O
(	O
IL	O
-	O
4	O
)	O
immune	B-PROC
responses	I-PROC
.	O

The	O
best	O
descriptors	O
describing	O
the	O
inhibition	B-PROC
mechanism	O
were	O
solvation	O
connectivity	O
index	O
,	O
length	O
to	O
breadth	O
ratio	O
,	O
relative	O
negative	O
charge	O
,	O
harmonic	O
oscillator	O
of	O
aromatic	O
index	O
,	O
average	O
molecular	O
weight	O
and	O
total	O
path	O
count	O
.	O

The	O
accuracy	O
and	O
robustness	O
of	O
shuffling	O
MARS	O
-	O
ANFIS	O
model	O
in	O
predicting	O
inhibition	B-PROC
behavior	O
of	O
pyridine	O
N	O
-	O
oxide	O
derivatives	O
(	O
pIC50	O
)	O
was	O
illustrated	O
using	O
leave	O
-	O
one	O
-	O
out	O
and	O
leave	O
-	O
multiple	O
-	O
out	O
cross	O
-	O
validation	O
techniques	O
and	O
also	O
by	O
Y	O
-	O
randomization	O
.	O

Understanding	O
the	O
roles	O
of	O
the	O
Arf1	O
GEFs	O
in	O
membrane	O
dynamics	O
is	O
crucial	O
to	O
a	O
full	O
understanding	O
of	O
trafficking	B-PROC
in	O
the	O
secretory	B-PROC
and	O
endosomal	O
pathways	B-PROC
,	O
which	O
in	O
turn	O
will	O
provide	O
essential	O
insights	O
into	O
human	O
diseases	O
that	O
arise	O
from	O
misregulation	O
of	O
these	O
pathways	B-PROC
.	O

The	O
only	O
contraindication	O
was	O
correlated	O
with	O
known	O
hypersensitivity	B-PROC
to	O
any	O
of	O
the	O
product	O
components	O
.	O

The	O
potential	O
recurrence	O
of	O
the	O
disease	O
from	O
animal	O
reservoirs	O
highlights	O
the	O
significance	O
of	O
development	B-PROC
of	O
safe	O
and	O
efficient	O
vaccines	O
to	O
prevent	O
a	O
future	O
SARS	O
epidemic	O
.	O

In	O
this	O
study	O
,	O
we	O
expressed	B-PROC
the	O
recombinant	O
receptor	O
-	O
binding	O
domain	O
(	O
rRBD	O
)	O
in	O
mammalian	O
(	O
293T	O
)	O
cells	O
,	O
insect	O
(	O
Sf9	O
)	O
cells	O
,	O
and	O
E	O
.	O
coli	O
,	O
respectively	O
,	O
and	O
compared	O
their	O
immunogenicity	O
and	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
in	O
an	O
established	O
mouse	O
model	O
.	O

These	O
results	O
suggest	O
that	O
all	O
three	O
rRBDs	O
are	O
effective	O
in	O
eliciting	O
immune	B-PROC
responses	I-PROC
and	O
protection	O
against	O
SARS	O
-	O
CoV	O
and	O
any	O
of	O
the	O
above	O
expression	B-PROC
systems	O
can	O
be	O
used	O
for	O
production	O
of	O
rRBD	O
-	O
based	O
SARS	O
subunit	O
vaccines	O
.	O

Using	O
a	O
SELEX	O
(	O
systematic	O
evolution	B-PROC
of	O
ligand	B-PROC
by	O
exponential	O
enrichment	O
)	O
procedure	O
and	O
recombinant	O
N	O
protein	O
,	O
we	O
selected	O
a	O
high	O
-	O
affinity	O
RNA	O
aptamer	O
capable	O
of	O
binding	O
to	O
N	O
protein	O
with	O
a	O
dissociation	O
constant	O
of	O
1	O
.	O
65	O
nM	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
RNA	O
competition	O
experiments	O
showed	O
that	O
the	O
selected	O
aptamer	O
recognized	O
selectively	O
the	O
C	O
-	O
terminal	O
region	O
of	O
N	O
protein	O
with	O
high	O
specificity	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
human	O
monocytes	O
,	O
potential	O
precursors	O
of	O
osteoclasts	O
,	O
partly	O
express	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
cellular	O
receptor	O
of	O
SARS	O
-	O
CoV	O
,	O
and	O
that	O
expression	B-PROC
of	O
an	O
accessory	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
3a	O
/	O
X1	O
,	O
in	O
murine	O
macrophage	O
cell	O
line	O
RAW264	O
.	O
7	O
cells	O
,	O
enhanced	O
NF	O
-	O
kappaB	O
activity	O
and	O
differentiation	B-PROC
into	O
osteoclast	O
-	O
like	O
cells	O
in	O
the	O
presence	O
of	O
receptor	O
activator	O
of	O
NF	O
-	O
kappaB	O
ligand	B-PROC
(	O
RANKL	O
).	O

3a	O
/	O
X1	O
also	O
enhanced	O
RANKL	O
expression	B-PROC
in	O
mouse	O
stromal	O
ST2	O
cells	O
.	O

The	O
clinical	O
disease	O
profile	O
suggested	O
that	O
the	O
pandas	O
may	O
have	O
suffered	O
a	O
viral	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
an	O
inflammatory	O
disorder	O
associated	O
with	O
reduced	O
alveolar	O
-	O
capillary	O
barrier	O
function	O
,	O
increased	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
,	O
and	O
infiltration	O
of	O
leukocytes	O
into	O
the	O
alveolar	O
space	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
is	O
one	O
of	O
the	O
causes	O
of	O
the	O
""""	O
common	O
cold	B-PROC
""""	O
in	O
human	O
during	O
seasons	O
of	O
cold	B-PROC
weather	O
.	O

SPR	O
experiments	O
demonstrated	O
that	O
the	O
C	O
-	O
terminal	O
region	O
(	O
residues	O
301	O
-	O
448	O
)	O
of	O
HCoV	O
-	O
OC43	O
N	O
protein	O
lacks	O
RNA	O
-	O
binding	B-PROC
activity	I-PROC
,	O
while	O
crosslinking	O
and	O
gel	O
filtration	O
analyses	O
revealed	O
that	O
the	O
C	O
-	O
terminal	O
region	O
is	O
mainly	O
involved	O
in	O
the	O
oligomerization	O
of	O
the	O
HCoV	O
-	O
OC43	O
N	O
protein	O
.	O

Aggressive	B-PROC
ventilation	O
patterns	O
,	O
intermittent	O
prone	O
positioning	O
,	O
and	O
high	O
-	O
dose	O
catecholamine	O
therapy	O
were	O
performed	O
.	O

He	O
died	B-PROC
after	O
12	O
days	O
of	O
septic	O
multiple	O
organ	O
failure	O
.	O

Legal	O
medicine	O
autopsy	O
identified	O
aggressive	B-PROC
Candida	O
famata	O
mycosis	O
.	O

The	O
effective	O
contact	O
rates	O
,	O
which	O
were	O
estimated	O
on	O
a	O
daily	O
basis	O
,	O
decreased	O
with	O
time	O
,	O
reaching	B-PROC
zero	O
inside	O
hospitals	O
.	O

ARDS	O
was	O
treated	O
successfully	O
with	O
a	O
complex	O
respiratory	O
therapy	O
plus	O
intravenous	O
immunoglobulin	B-PROC
substitution	O
.	O

Thirty	O
-	O
two	O
months	O
after	O
presentation	O
of	O
the	O
initial	O
symptoms	O
,	O
the	O
patient	O
died	B-PROC
due	O
to	O
complications	O
related	O
to	O
leukaemia	O
recurrence	O
(	O
haemorrhage	O
,	O
sepsis	O
and	O
respiratory	O
distress	O
syndrome	O
).	O

TITLE	O
:	O
Rhesus	O
theta	O
-	O
defensin	O
prevents	O
death	B-PROC
in	O
a	O
mouse	O
model	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
pulmonary	O
disease	O
.	O

This	O
heterogeneity	O
has	O
been	O
measured	O
for	O
gene	B-PROC
transcription	I-PROC
,	O
phosphorylation	B-PROC
,	O
cell	O
morphology	O
and	O
drug	O
perturbations	O
,	O
and	O
used	O
to	O
explain	O
various	O
aspects	O
of	O
cellular	B-PROC
physiology	I-PROC
.	O

In	O
addition	O
to	O
a	O
well	O
-	O
recognized	O
cleavage	B-PROC
site	O
at	O
the	O
S1	O
-	O
S2	O
boundary	O
,	O
a	O
second	O
proteolytic	B-PROC
cleavage	B-PROC
site	O
has	O
been	O
identified	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
S2	O
domain	O
(	O
R797	O
).	O

Although	O
one	O
has	O
to	O
keep	O
in	O
mind	O
that	O
the	O
cCFR	O
for	O
an	O
entire	O
population	O
is	O
vulnerable	O
to	O
its	O
variations	O
among	O
sub	O
-	O
populations	O
and	O
underdiagnosis	O
,	O
our	O
method	O
is	O
useful	O
for	O
assessing	O
virulence	B-PROC
at	O
the	O
early	O
stage	O
of	O
an	O
epidemic	O
and	O
for	O
informing	O
policy	O
makers	O
and	O
the	O
public	O
.	O

TITLE	O
:	O
Absence	O
of	O
antibody	B-PROC
-	O
dependent	O
,	O
complement	O
-	O
mediated	O
lysis	B-PROC
of	O
feline	O
infectious	O
peritonitis	O
virus	O
-	O
infected	O
cells	O
.	O

One	O
of	O
the	O
mechanisms	O
that	O
can	O
help	O
resolving	O
infection	O
is	O
antibody	B-PROC
-	O
dependent	O
,	O
complement	O
-	O
mediated	O
lysis	B-PROC
(	O
ADCML	O
)	O
of	O
infected	O
cells	O
.	O

They	O
do	O
so	O
by	O
acting	O
both	O
as	O
lectins	O
and	O
as	O
receptor	O
-	O
destroying	O
enzymes	O
,	O
functions	O
exerted	B-PROC
by	O
separate	O
protein	O
domains	O
.	O

Apparently	O
,	O
esterase	O
and	O
lectin	O
pockets	O
coevolved	O
;	O
also	O
the	O
porcine	O
torovirus	O
HE	O
receptor	O
-	O
binding	O
site	O
seems	O
to	O
have	O
been	O
designed	O
to	O
use	O
9	O
-	O
mono	O
-	O
and	O
exclude	O
di	O
-	O
O	O
-	O
acetylated	O
Sias	O
,	O
possibly	O
as	O
an	O
adaptation	B-PROC
to	O
replication	O
in	O
swine	O
.	O

During	O
the	O
SARS	O
epidemic	O
,	O
the	O
use	O
of	O
web	O
-	O
based	O
learning	B-PROC
,	O
role	O
play	O
,	O
video	O
vignettes	O
and	O
both	O
live	O
and	O
mannequin	O
-	O
based	O
simulated	O
patients	O
minimised	O
disruptions	O
to	O
medical	O
education	O
.	O

The	O
induction	O
of	O
IL	O
-	O
6	O
and	O
TNF	B-PROC
-	I-PROC
alpha	I-PROC
production	I-PROC
was	O
related	O
rather	O
to	O
the	O
fixation	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
MHV3	O
on	O
Toll	O
-	O
like	O
receptor	O
2	O
(	O
TLR2	O
)	O
in	O
regions	O
enriched	O
in	O
heparan	O
sulphate	O
and	O
did	O
not	O
rely	O
on	O
viral	B-PROC
replication	I-PROC
,	O
as	O
demonstrated	O
with	O
denatured	O
S	O
protein	O
and	O
UV	O
-	O
inactivated	O
virus	O
.	O

The	O
synergistic	O
IFN	O
-	O
gamma	O
production	O
involves	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
rather	O
than	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
-	O
1	O
/	O
2	O
MAPK	B-PROC
signalling	B-PROC
pathway	B-PROC
.	O

The	O
preparation	O
of	O
a	O
knowledgeable	O
,	O
cared	O
-	O
for	O
nursing	B-PROC
workforce	O
promises	O
optimal	O
outcomes	O
with	O
the	O
emergence	O
of	O
the	O
next	O
global	O
infection	O
.	O

RESULTS	O
:	O
Chinese	O
nurses	O
faced	O
personal	O
challenge	O
,	O
focused	O
on	O
the	O
essence	O
of	O
care	O
and	O
experienced	O
self	O
-	O
growth	B-PROC
while	O
caring	O
for	O
SARS	O
patients	O
.	O

HCoV	O
-	O
NL63	O
-	O
infected	O
patients	O
were	O
younger	O
and	O
more	O
likely	O
to	O
have	O
croup	O
,	O
febrile	B-PROC
convulsions	O
,	O
and	O
acute	O
gastroenteritis	O
.	O

TITLE	O
:	O
The	O
making	O
of	O
a	O
Chinese	O
head	O
of	O
the	O
WHO	O
:	O
a	O
study	O
of	O
the	O
media	O
discourse	O
on	O
Margaret	O
Chan	O
'	O
s	O
contest	O
for	O
the	O
WHO	O
director	O
-	O
generalship	O
and	O
its	O
implications	O
for	O
the	O
collective	O
memory	B-PROC
of	O
SARS	O
.	O

ABSTRACT	O
:	O
Destruction	O
of	O
the	O
architectural	O
and	O
subsequently	O
the	O
functional	O
integrity	O
of	O
the	O
lung	O
following	O
pulmonary	O
viral	B-PROC
infections	I-PROC
is	O
attributable	O
to	O
both	O
the	O
extent	O
of	O
pathogen	O
replication	O
and	O
to	O
the	O
host	O
-	O
generated	O
inflammation	O
associated	O
with	O
the	O
recruitment	O
of	O
immune	B-PROC
responses	I-PROC
.	O

The	O
presence	O
of	O
antigenically	O
disparate	O
pulmonary	O
viruses	O
and	O
the	O
emergence	O
of	O
novel	O
viruses	O
assures	O
the	O
recurrence	O
of	O
lung	O
damage	O
with	O
infection	O
and	O
resolution	O
of	O
each	O
primary	O
viral	B-PROC
infection	I-PROC
.	O

Thus	O
,	O
there	O
is	O
a	O
need	O
to	O
develop	O
safe	O
broad	O
spectrum	O
immunoprophylactic	O
strategies	O
capable	O
of	O
enhancing	O
protective	O
immune	B-PROC
responses	I-PROC
in	O
the	O
lung	O
but	O
which	O
limits	O
immune	O
-	O
mediated	O
lung	O
damage	O
.	O

The	O
enhanced	O
protection	O
appears	O
to	O
be	O
dependent	O
upon	O
the	O
prior	O
development	B-PROC
of	O
inducible	O
bronchus	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
iBALT	O
)	O
in	O
the	O
lung	O
in	O
response	O
to	O
the	O
PCN	O
treatment	O
and	O
to	O
be	O
mediated	O
through	O
CD4	O
+	O
T	O
cell	O
and	O
B	O
cell	O
dependent	O
mechanisms	O
.	O

The	O
synthesis	B-PROC
of	O
the	O
second	O
strand	O
was	O
carried	O
out	O
with	O
a	O
random	O
primer	O
sequence	O
(	O
5	O
'-	O
GTTTCCCAGTAGGTCTCNNNNNNNN	O
-	O
3	O
').	O

This	O
microarray	O
-	O
based	O
method	O
used	O
the	O
highly	O
conserved	O
consensus	O
primers	O
to	O
synthesize	O
specifically	O
the	O
virus	O
cDNA	O
and	O
could	O
identify	O
effectively	O
Chikungunya	O
virus	O
,	O
Japanese	O
encephalitis	O
virus	O
,	O
Yellow	O
fever	B-PROC
virus	O
,	O
Dengue	O
virus	O
,	O
Tick	O
borne	O
encephalitis	O
virus	O
,	O
and	O
H5N1	O
avian	O
influenza	O
virus	O
.	O

TITLE	O
:	O
Regulation	B-PROC
of	O
proinflammatory	O
cytokine	O
expression	B-PROC
in	O
primary	O
mouse	O
astrocytes	O
by	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
shown	O
that	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
),	O
are	O
differentially	O
induced	O
in	O
primary	O
mouse	O
astrocytes	O
by	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
and	O
MHV	O
-	O
2	O
.	O

Taken	O
together	O
,	O
these	O
results	O
confirm	O
that	O
IBV	O
has	O
developed	O
a	O
combination	O
of	O
two	O
mechanisms	O
,	O
i	O
.	O
e	O
.,	O
blocking	O
PKR	O
activation	O
and	O
inducing	O
GADD34	O
expression	B-PROC
,	O
to	O
maintain	O
de	O
novo	O
protein	B-PROC
synthesis	I-PROC
in	O
IBV	O
-	O
infected	O
cells	O
and	O
,	O
meanwhile	O
,	O
to	O
enhance	O
viral	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
immune	B-PROC
responses	I-PROC
of	O
recombinant	O
Lactobacillus	O
casei	O
393	O
expressing	O
Porcine	O
Epidemic	O
Diarrhea	O
Viral	O
(	O
PEDV	O
)	O
N	O
protein	O
as	O
oral	O
vaccine	O
,	O
n	O
gene	O
of	O
PEDV	O
was	O
subcloned	O
into	O
the	O
expression	B-PROC
vector	O
pPG	O
-	O
1	O
,	O
and	O
then	O
transformed	O
into	O
L	O
.	O
casei	O
393	O
by	O
electroporation	O
,	O
resulting	O
in	O
recombinant	O
strain	O
pPG	O
-	O
1	O
-	O
n	O
/	O
L	O
,	O
casei	O
393	O
.	O

ABSTRACT	O
:	O
A	O
previous	O
study	O
demonstrated	O
that	O
infection	O
of	O
a	O
canine	O
fibrosarcoma	O
cell	O
line	O
(	O
A	O
-	O
72	O
cells	O
)	O
by	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
resulted	O
in	O
apoptosis	B-PROC
(	O
Ruggieri	O
et	O
al	O
.,	O
2007	O
).	O

Furthermore	O
,	O
CCoV	O
-	O
II	O
infection	O
resulted	O
in	O
truncated	O
bid	O
(	O
tbid	O
)	O
translocation	B-PROC
from	O
the	O
cytosolic	O
to	O
the	O
mitochondrial	O
fraction	O
,	O
the	O
cytochrome	B-PROC
c	I-PROC
release	O
from	O
mitochondria	O
,	O
and	O
alterations	O
in	O
the	O
pro	O
-	O
and	O
anti	O
-	O
apoptotic	O
proteins	O
of	O
bcl	O
-	O
2	O
family	O
.	O

Although	O
the	O
antibody	B-PROC
levels	O
in	O
the	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
-	O
vaccinated	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
attenuated	O
live	O
IB	O
vaccine	O
H120	O
group	O
and	O
the	O
rFPV	O
-	O
IBVS1	O
group	O
,	O
the	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
provided	O
the	O
strongest	O
protection	O
against	O
an	O
IBV	O
LX4	O
virus	O
challenge	O
(	O
15	O
out	O
of	O
16	O
chickens	O
immunized	O
with	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
were	O
protected	O
),	O
followed	O
by	O
the	O
attenuated	O
live	O
IB	O
vaccine	O
(	O
13	O
/	O
16	O
protected	O
)	O
and	O
the	O
rFPV	O
-	O
IBVS1	O
(	O
12	O
/	O
16	O
protected	O
).	O

Thirty	O
-	O
five	O
patients	O
with	O
a	O
CTSI	O
>	O
8	O
.	O
0	O
were	O
randomly	O
selected	O
for	O
surgery	O
or	O
PCD	B-PROC
treatment	O
.	O

After	O
randomization	O
,	O
six	O
patients	O
(	O
four	O
patients	O
in	O
the	O
surgery	O
group	O
and	O
two	O
patients	O
in	O
the	O
PCD	B-PROC
group	O
)	O
were	O
dropped	O
from	O
the	O
study	O
.	O

Patients	O
with	O
SAP	O
and	O
a	O
CTSI	O
<	O
or	O
=	O
8	O
.	O
0	O
could	O
be	O
treated	O
with	O
conservative	O
therapy	O
,	O
while	O
patients	O
with	O
a	O
CTSI	O
>	O
8	O
.	O
0	O
should	O
be	O
treated	O
with	O
surgery	O
or	O
PCD	B-PROC
therapy	O
if	O
the	O
life	O
-	O
threatening	O
complications	O
of	O
extensive	O
fluid	O
collection	O
or	O
necrosis	B-PROC
are	O
a	O
factor	O
.	O

ABSTRACT	O
:	O
IFN	O
-	O
alpha	O
/	O
beta	O
plays	O
a	O
critical	O
role	O
in	O
limiting	O
viral	O
spread	O
,	O
restricting	O
viral	O
tropism	B-PROC
and	O
protecting	O
mice	O
from	O
neurotropic	O
coronavirus	O
infection	O
.	O

Oxygenation	B-PROC
and	O
serum	O
enzyme	O
levels	O
returned	O
to	O
normal	O
gradually	O
,	O
and	O
most	O
of	O
the	O
lung	O
infiltrates	O
disappeared	O
.	O

A	O
44	O
-	O
year	O
-	O
old	O
woman	O
with	O
pneuminian	O
was	O
diagnosed	O
as	O
A	O
/	O
H5N1	O
infection	O
by	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
laboratory	O
from	O
the	O
sample	O
of	O
secretion	B-PROC
of	O
respiratory	O
tracts	O
.	O

Occlusion	B-PROC
operation	O
by	O
biogel	O
and	O
OB	O
gel	O
through	O
bronchoscopy	O
might	O
be	O
an	O
alternative	O
choice	O
for	O
fixing	O
the	O
bronchopleural	O
fistula	O
.	O

RESULTS	O
:	O
A	O
44	O
-	O
year	O
-	O
old	O
woman	O
with	O
pneuminian	O
was	O
diagnosed	O
as	O
A	O
/	O
H5N1	O
infection	O
by	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
laboratory	O
from	O
the	O
sample	O
of	O
secretion	B-PROC
of	O
respiratory	O
tracts	O
.	O

Fever	B-PROC
,	O
headache	O
and	O
myalgia	O
after	O
exposure	O
to	O
a	O
rodent	O
-	O
contaminated	O
environment	O
raised	O
clinical	O
suspicion	O
.	O

The	O
nature	O
of	O
work	O
-	O
family	O
and	O
family	O
-	O
work	O
conflict	O
perceived	O
and	O
experienced	O
by	O
nurses	O
during	O
infectious	O
disease	O
outbreaks	O
,	O
as	O
well	O
as	O
the	O
supports	O
needed	O
to	O
enable	O
them	O
to	O
balance	B-PROC
their	O
social	O
roles	O
during	O
this	O
type	O
of	O
heightened	O
stress	O
,	O
are	O
explored	O
.	O

They	O
learned	B-PROC
the	O
techniques	O
of	O
airway	O
management	O
,	O
passed	O
the	O
performance	O
checklist	O
of	O
technical	O
workshop	O
,	O
and	O
received	O
higher	O
scores	O
during	O
re	O
-	O
simulation	O
regardless	O
of	O
scoring	O
methods	O
.	O

This	O
was	O
measurable	O
by	O
de	O
novo	O
intracellular	O
nucleoprotein	O
production	O
and	O
virus	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
To	O
describe	O
clinical	O
characteristics	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
in	O
a	O
hospital	O
in	O
Tianjin	O
,	O
China	O
,	O
thereby	O
comparing	O
probable	O
and	O
suspected	O
cases	O
;	O
to	O
study	O
risk	O
factors	O
associated	O
with	O
the	O
death	B-PROC
of	O
cases	O
;	O
to	O
describe	O
the	O
implementation	O
of	O
preventive	O
interventions	O
during	O
the	O
hospital	O
outbreak	O
.	O

These	O
cases	O
resulted	O
in	O
33	O
deaths	B-PROC
,	O
five	O
of	O
which	O
occurred	O
in	O
hospital	O
staff	O
.	O

Rectal	O
swabs	O
or	O
faecal	O
samples	O
were	O
collected	O
from	O
a	O
total	O
of	O
44	O
clinically	O
healthy	O
Persian	O
purebred	O
and	O
mix	O
-	O
breed	B-PROC
cats	O
.	O

The	O
predicted	O
spike	O
protein	O
of	O
CRCoV	O
contained	O
20	O
or	O
21	O
N	O
-	O
glycosylation	B-PROC
sites	O
,	O
whereas	O
that	O
of	O
BCoV	O
contained	O
19	O
sites	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
used	O
for	O
most	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
cases	O
in	O
specialized	O
centers	O
.	O

Plasmatic	O
coagulation	B-PROC
was	O
slightly	O
activated	O
in	O
all	O
groups	O
demonstrated	O
by	O
increased	O
thrombin	O
-	O
anti	O
-	O
thrombin	O
III	O
-	O
complex	O
.	O

Main	O
outcome	O
measurements	O
were	O
age	O
,	O
breastfeeding	B-PROC
history	O
,	O
family	O
smoking	O
habits	O
,	O
family	O
history	O
for	O
asthma	O
and	O
atopy	O
,	O
blood	O
eosinophil	O
count	O
,	O
chest	O
radiological	O
findings	O
,	O
clinical	O
severity	O
score	O
and	O
number	O
of	O
days	O
of	O
hospitalisation	O
.	O

Time	O
from	O
hospital	O
to	O
ICU	O
admission	O
was	O
short	O
(	O
median	O
,	O
1	O
day	O
[	O
interquartile	O
range	O
{	O
IQR	O
},	O
0	O
-	O
3	O
days	O
]),	O
and	O
all	O
patients	O
but	O
2	O
received	O
mechanical	O
ventilation	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
refractory	O
hypoxemia	O
(	O
median	O
day	O
1	O
ratio	O
of	O
Pao	B-PROC
(	O
2	O
)	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
,	O
83	O
[	O
IQR	O
,	O
59	O
-	O
145	O
]	O
mm	O
Hg	O
).	O

Neuraminidase	B-PROC
inhibitors	I-PROC
were	O
administered	O
to	O
152	O
patients	O
(	O
90	O
.	O
5	O
%).	O

All	O
patients	O
were	O
severely	O
hypoxemic	O
(	O
mean	O
[	O
SD	O
]	O
ratio	O
of	O
Pao	B-PROC
(	O
2	O
)	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
[	O
Fio	O
(	O
2	O
)]	O
of	O
147	O
[	O
128	O
]	O
mm	O
Hg	O
)	O
at	O
ICU	O
admission	O
.	O

Before	O
ECMO	O
,	O
patients	O
had	O
severe	O
respiratory	O
failure	O
despite	O
advanced	O
mechanical	O
ventilatory	O
support	O
with	O
a	O
median	O
(	O
IQR	O
)	O
Pao	B-PROC
(	O
2	O
)/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
Fio	O
(	O
2	O
))	O
ratio	O
of	O
56	O
(	O
48	O
-	O
63	O
),	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
of	O
18	O
(	O
15	O
-	O
20	O
)	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
and	O
an	O
acute	O
lung	O
injury	O
score	O
of	O
3	O
.	O
8	O
(	O
3	O
.	O
5	O
-	O
4	O
.	O
0	O
).	O

Fourteen	O
patients	O
(	O
21	O
%;	O
95	O
%	O
CI	O
,	O
11	O
%-	O
30	O
%)	O
had	O
died	B-PROC
and	O
6	O
remained	O
in	O
the	O
ICU	O
,	O
2	O
of	O
whom	O
were	O
still	O
receiving	O
ECMO	O
.	O

Fourteen	O
patients	O
(	O
21	O
%;	O
95	O
%	O
CI	O
,	O
11	O
%-	O
30	O
%)	O
had	O
died	B-PROC
and	O
6	O
remained	O
in	O
the	O
ICU	O
,	O
2	O
of	O
whom	O
were	O
still	O
receiving	O
ECMO	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
presentation	O
,	O
the	O
patient	O
developed	O
respiratory	O
failure	O
and	O
hemodynamic	B-PROC
instability	O
refractory	O
to	O
conventional	O
therapy	O
,	O
and	O
ECLS	O
was	O
initiated	O
on	O
hospital	O
day	O
2	O
.	O

A	O
history	O
of	O
breastfeeding	B-PROC
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
risk	O
of	O
acute	O
otitis	O
media	O
,	O
nonspecific	O
gastroenteritis	O
,	O
severe	O
lower	O
respiratory	O
tract	O
infections	O
,	O
atopic	O
dermatitis	O
,	O
asthma	O
(	O
young	O
children	O
),	O
obesity	O
,	O
type	O
1	O
and	O
2	O
diabetes	O
,	O
childhood	O
leukemia	O
,	O
and	O
sudden	O
infant	O
death	B-PROC
syndrome	O
.	O

In	O
our	O
case	O
the	O
only	O
residual	O
impairment	O
for	O
the	O
patient	O
is	O
dysarthria	O
with	O
corresponding	O
symmetric	O
cerebellar	O
pyramidal	O
cell	O
destruction	O
demonstrated	O
by	O
increased	O
signal	O
intensity	O
in	O
T2	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
,	O
most	O
likely	O
caused	O
by	O
the	O
excessive	O
hyperthermia	B-PROC
.	O

TITLE	O
:	O
A	O
case	O
of	O
benign	O
acute	O
childhood	O
myositis	O
associated	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
One	O
in	O
every	O
7	O
pregnancies	B-PROC
ends	O
with	O
meconium	O
-	O
stained	O
amniotic	O
fluid	O
and	O
approximately	O
5	O
%	O
of	O
these	O
infants	O
develop	O
the	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	O
).	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nsp1	O
protein	O
suppresses	O
host	O
gene	B-PROC
expression	I-PROC
,	O
including	O
type	B-PROC
I	I-PROC
interferon	B-PROC
production	I-PROC
,	O
by	O
promoting	O
host	O
mRNA	B-PROC
degradation	I-PROC
and	O
inhibiting	O
host	O
translation	B-PROC
,	O
in	O
infected	O
cells	O
.	O

TITLE	O
:	O
Morphogenesis	B-PROC
of	O
Coronavirus	O
HCoV	O
-	O
NL63	O
in	O
Cell	O
Culture	O
:	O
A	O
Transmission	O
Electron	O
Microscopic	O
Study	O
.	O

The	O
virus	O
was	O
released	O
via	O
exocytosis	B-PROC
and	O
cell	O
lysis	B-PROC
.	O

Multiple	O
inert	O
gas	O
elimination	B-PROC
technique	O
revealed	O
a	O
more	O
homogeneous	O
pulmonary	O
blood	B-PROC
flow	I-PROC
after	O
treatment	O
with	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

A	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
)	O
(	O
designated	O
as	O
15E2	O
)	O
against	O
the	O
IBV	O
M	O
protein	O
was	O
prepared	O
and	O
a	O
series	O
of	O
14	O
partially	O
-	O
overlapping	O
fragments	O
of	O
the	O
IBV	O
M	O
gene	O
were	O
expressed	B-PROC
with	O
a	O
GST	O
tag	O
.	O

Ribavirin	O
,	O
UDA	O
,	O
and	O
Ampligen	O
decreased	O
IL	O
-	O
6	O
expression	B-PROC
.	O

ALI	O
/	O
ARDS	O
is	O
the	O
response	O
of	O
the	O
lung	O
to	O
a	O
local	O
or	O
systemic	O
aggression	B-PROC
,	O
resulting	O
in	O
local	O
inflammation	O
and	O
coagulation	B-PROC
disorders	O
,	O
which	O
lead	O
to	O
increased	O
inflammatory	O
pulmonary	O
edema	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
a	O
virus	O
escapes	O
from	O
antibody	B-PROC
-	I-PROC
mediated	I-PROC
neutralization	I-PROC
,	O
we	O
have	O
investigated	O
the	O
interactions	O
of	O
non	O
-	O
neutralizing	O
and	O
neutralizing	O
antibodies	O
at	O
an	O
epitope	O
cluster	O
on	O
the	O
spike	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Transient	O
virulence	B-PROC
of	O
emerging	O
pathogens	O
.	O

We	O
discuss	O
the	O
need	O
for	O
better	O
data	O
on	O
tradeoff	O
curves	O
and	O
genetic	O
variance	O
in	O
order	O
to	O
evaluate	O
the	O
plausibility	O
of	O
various	O
scenarios	O
of	O
virulence	B-PROC
evolution	B-PROC
.	O

ABSTRACT	O
:	O
Disruption	O
of	O
fibrinolytic	O
homeostasis	B-PROC
participates	O
in	O
the	O
pathogenesis	B-PROC
of	O
severe	O
lung	O
diseases	O
like	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
idiopathic	O
pulmonary	O
fibrosis	O
(	O
IPF	O
)	O
and	O
plastic	O
bronchitis	O
.	O

In	O
Australia	O
,	O
84	O
%	O
of	O
AOM	O
is	O
treated	O
with	O
antibiotic	O
therapy	O
,	O
which	O
contributes	O
to	O
development	B-PROC
of	O
antibiotic	O
resistance	B-PROC
.	O

The	O
present	O
study	O
demonstrates	O
that	O
strain	O
CB	O
/	O
05	O
is	O
able	O
to	O
induce	O
infection	O
and	O
disease	O
in	O
dogs	O
seropositive	O
to	O
enteric	O
CCoV	O
,	O
thus	O
highlighting	O
the	O
need	O
for	O
extensive	O
epidemiological	O
investigation	O
and	O
for	O
the	O
possible	O
development	B-PROC
of	O
novel	O
antigenically	O
relevant	O
vaccines	O
.	O

TITLE	O
:	O
The	O
open	O
reading	O
frame	O
3a	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
promotes	O
membrane	O
rearrangement	B-PROC
and	O
cell	B-PROC
death	I-PROC
.	O

These	O
results	O
establish	O
an	O
important	O
role	O
for	O
ORF	O
3a	O
in	O
SARS	O
-	O
CoV	O
-	O
induced	O
cell	B-PROC
death	I-PROC
,	O
Golgi	O
fragmentation	O
,	O
and	O
the	O
accumulation	O
of	O
intracellular	O
vesicles	O
.	O

Confocal	O
microscopy	O
studies	O
showed	O
that	O
early	O
secretory	B-PROC
pathway	I-PROC
components	O
are	O
not	O
associated	O
with	O
SARS	O
-	O
CoV	O
-	O
induced	O
replication	O
sites	O
,	O
although	O
our	O
studies	O
revealed	O
that	O
infection	O
induces	O
a	O
remarkable	O
redistribution	O
of	O
the	O
translocon	O
subunit	O
Sec61alpha	O
.	O

The	O
BFA	O
-	O
induced	O
disruption	O
of	O
ER	O
integrity	O
and	O
functionality	O
probably	O
affects	O
the	O
overall	O
quality	O
of	O
the	O
membrane	O
scaffold	O
that	O
is	O
needed	O
to	O
support	O
the	O
viral	O
RTC	O
and	O
/	O
or	O
the	O
availability	O
of	O
specific	O
host	O
factors	O
,	O
which	O
in	O
turn	O
compromises	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

We	O
analysed	O
the	O
3c	O
gene	O
--	O
a	O
proposed	O
virulence	B-PROC
marker	O
--	O
in	O
27	O
FECV	O
-	O
and	O
28	O
FIPV	O
-	O
infected	O
cats	O
.	O

ABSTRACT	O
:	O
Siegrist	O
'	O
s	O
(	O
1996	O
)	O
Effort	B-PROC
-	O
Reward	O
Imbalance	O
(	O
ERI	O
)	O
Model	O
provided	O
the	O
theoretical	O
basis	O
for	O
this	O
secondary	O
data	O
analysis	O
that	O
examines	O
the	O
relationship	O
between	O
nurses	O
'	O
ERI	O
and	O
their	O
self	O
-	O
reported	O
compliance	O
with	O
infection	O
control	O
,	O
between	O
ERI	O
and	O
burnout	O
and	O
nurses	O
'	O
compliance	O
,	O
and	O
between	O
nurses	O
'	O
experience	O
in	O
caring	O
for	O
SARS	O
patients	O
and	O
their	O
compliance	O
with	O
infection	O
control	O
.	O

While	O
ERI	O
was	O
shown	O
to	O
be	O
associated	O
with	O
burnout	O
(	O
beta	O
=	O
.	O
60	O
,	O
p	O
<	O
.	O
001	O
),	O
the	O
combined	O
effect	O
of	O
these	O
two	O
variables	O
did	O
not	O
significantly	O
improve	O
the	O
prediction	O
of	O
compliance	O
behaviour	B-PROC
(	O
beta	O
=	O
-.	O
03	O
,	O
p	O
=	O
.	O
63	O
).	O

ABSTRACT	O
:	O
The	O
functional	O
role	O
of	O
ELR	O
-	O
positive	O
CXC	O
chemokines	O
in	O
host	B-PROC
defense	I-PROC
during	O
acute	O
viral	O
-	O
induced	O
encephalomyelitis	O
was	O
determined	O
.	O

Blocking	O
CXCR2	O
signaling	B-PROC
did	O
not	O
impair	O
the	O
generation	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
,	O
indicating	O
that	O
CXCR2	O
is	O
not	O
required	O
to	O
tailor	O
anti	O
-	O
JHMV	O
T	O
cell	O
responses	O
.	O

Treatment	O
of	O
JHMV	O
-	O
infected	O
CXCR2	O
-/-	O
mice	O
with	O
anti	O
-	O
CXCR2	O
antibody	B-PROC
did	O
not	O
modulate	O
PMN	B-PROC
migration	B-PROC
nor	O
alter	O
viral	O
clearance	O
or	O
mortality	O
,	O
indicating	O
the	O
existence	O
of	O
compensatory	O
mechanisms	O
that	O
facilitate	O
sufficient	O
migration	B-PROC
of	O
PMNs	O
into	O
the	O
CNS	O
in	O
the	O
absence	O
of	O
CXCR2	O
.	O

Anti	O
-	O
CD134	O
binding	O
caused	O
displacement	O
of	O
SU	O
from	O
the	O
surface	O
of	O
the	O
cell	O
and	O
inhibition	B-PROC
of	O
infection	O
.	O

We	O
also	O
observed	O
that	O
recombinant	O
FCoVs	O
display	O
a	O
large	O
-	O
plaque	O
phenotype	O
and	O
,	O
unexpectedly	O
,	O
accelerated	O
growth	B-PROC
kinetics	O
indistinguishable	O
from	O
that	O
of	O
type	O
II	O
FCoV	O
strain	O
79	O
-	O
1146	O
.	O

Thus	O
,	O
the	O
main	O
phenotypic	O
differences	O
for	O
type	O
I	O
and	O
type	O
II	O
FCoVs	O
in	O
cell	O
culture	O
,	O
namely	O
,	O
the	O
growth	B-PROC
kinetics	O
and	O
the	O
efficient	O
usage	O
of	O
fAPN	O
as	O
a	O
cellular	O
receptor	O
,	O
can	O
be	O
attributed	O
solely	O
to	O
the	O
FCoV	O
S	O
protein	O
.	O

The	O
dry	O
lung	O
-	O
to	O
-	O
body	O
weight	O
ratio	O
was	O
significantly	O
increased	O
in	O
infected	O
group	O
,	O
which	O
might	O
be	O
associated	O
with	O
the	O
formation	B-PROC
of	O
PF	O
in	O
H5N1	O
-	O
infected	O
mice	O
.	O

TITLE	O
:	O
Humanized	O
monoclonal	O
antibody	B-PROC
against	O
the	O
chemokine	O
CXCL	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
effectively	O
prevents	O
acute	O
lung	O
injury	O
.	O

The	O
results	O
of	O
this	O
study	O
emphasize	O
the	O
need	O
for	O
research	O
on	O
infectious	O
diseases	O
of	O
giant	O
pandas	O
and	O
development	B-PROC
of	O
suitable	O
vaccines	O
for	O
the	O
species	O
.	O

Eighty	O
-	O
four	O
intestine	O
segments	O
assayed	O
by	O
the	O
developed	O
RRT	O
-	O
PCR	O
and	O
immunofluorescence	O
antibody	B-PROC
assay	O
(	O
IFA	O
)	O
revealed	O
that	O
there	O
were	O
6	O
segments	O
negative	O
for	O
TCoV	O
by	O
both	O
assays	O
,	O
45	O
positive	O
for	O
TCoV	O
by	O
IFA	O
,	O
and	O
77	O
positive	O
for	O
TCoV	O
by	O
RRT	O
-	O
PCR	O
.	O

Twelve	O
patients	O
(	O
92	O
%)	O
improved	O
lung	B-PROC
function	I-PROC
,	O
were	O
extubated	O
,	O
and	O
discharged	O
alive	O
from	O
the	O
ICU	O
.	O

His	O
body	O
temperature	O
was	O
38	O
.	O
4	O
C	O
,	O
with	O
a	O
heart	O
rate	O
of	O
124	O
/	O
min	O
,	O
a	O
blood	B-PROC
pressure	I-PROC
of	O
120	O
/	O
70	O
mmHg	O
and	O
a	O
positive	O
shock	O
index	O
.	O

Ten	O
days	O
after	O
transfer	O
,	O
the	O
patient	O
regained	O
spontaneous	O
respiration	B-PROC
,	O
and	O
he	O
most	O
likely	O
survives	O
the	O
infection	O
.	O

The	O
antigenic	O
relatedness	O
(	O
R	O
value	O
),	O
based	O
on	O
a	O
calculated	O
virus	B-PROC
neutralization	I-PROC
index	O
,	O
of	O
the	O
K	O
-	O
IIb	O
type	O
field	O
strain	O
and	O
K	O
-	O
IIa	O
type	O
strain	O
KM91	O
(	O
isolated	O
in	O
1991	O
)	O
was	O
30	O
%,	O
which	O
indicated	O
that	O
the	O
recent	O
strain	O
,	O
Kr	O
/	O
Q43	O
/	O
06	O
,	O
is	O
a	O
new	O
variant	O
that	O
is	O
antigenically	O
distinct	O
from	O
strain	O
KM91	O
.	O

ABSTRACT	O
:	O
Acute	O
kidney	O
injury	O
contributes	O
to	O
the	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
and	O
vice	O
-	O
versa	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
kidney	O
and	O
lung	O
interact	O
(	O
crosstalk	B-PROC
)	O
during	O
severe	O
insults	O
,	O
such	O
as	O
shock	O
,	O
trauma	O
,	O
and	O
sepsis	O
,	O
due	O
to	O
a	O
loss	O
of	O
the	O
normal	O
balance	B-PROC
of	O
immune	O
,	O
inflammatory	O
and	O
soluble	O
mediators	O
.	O

The	O
Chinese	O
isolate	O
of	O
QX	O
-	O
like	O
virus	O
caused	O
the	O
most	O
severe	O
lesions	O
and	O
induced	O
the	O
highest	O
antibody	B-PROC
titres	O
.	O

Potential	O
factors	O
that	O
may	O
hamper	O
the	O
implementation	O
of	O
new	O
therapies	O
and	O
strategies	O
include	O
translational	B-PROC
problems	O
,	O
potentially	O
biased	O
expert	O
opinions	O
,	O
concerns	O
about	O
side	O
-	O
effects	O
and	O
costs	O
and	O
problems	O
with	O
the	O
recognition	O
of	O
critically	O
-	O
ill	O
patients	O
who	O
might	O
actually	O
benefit	O
from	O
a	O
new	O
therapy	O
or	O
strategy	O
.	O

Most	O
ARDS	O
patients	O
survive	O
the	O
acute	O
initial	O
phase	O
of	O
lung	O
injury	O
and	O
progress	O
to	O
either	O
reparation	O
of	O
the	O
lesion	O
or	O
evolution	B-PROC
of	O
the	O
syndrome	O
.	O

In	O
this	O
line	O
,	O
mechanical	O
ventilation	O
may	O
affect	O
the	O
macromolecules	O
that	O
constitute	O
the	O
extracellular	O
matrix	O
(	O
collagen	O
,	O
elastin	B-PROC
,	O
fibronectin	O
,	O
laminin	O
,	O
proteoglycan	O
and	O
glycosaminoglycans	O
),	O
suffer	O
changes	O
and	O
impact	O
the	O
biomechanical	O
behavior	O
of	O
lung	O
parenchyma	O
.	O

Clinically	O
it	O
is	O
characterized	O
by	O
spiking	O
fever	B-PROC
,	O
arthritis	O
,	O
rash	O
,	O
and	O
impairment	O
of	O
multiple	O
organs	O
.	O

TITLE	O
:	O
Protein	O
transfer	O
enhances	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
to	O
DNA	O
vaccination	O
against	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
current	O
DNA	O
vaccine	O
formulations	O
are	O
not	O
optimal	O
for	O
stimulation	O
of	O
CD8	O
(+)	O
T	O
cells	O
,	O
which	O
are	O
required	O
for	O
clearing	O
virally	O
-	O
infected	O
cells	O
.	O

Several	O
novel	O
diagnostic	O
and	O
therapeutic	O
tools	O
,	O
such	O
as	O
electrical	B-PROC
impedance	I-PROC
tomography	O
,	O
high	O
frequency	O
oscillatory	O
ventilation	O
,	O
minimally	O
invasive	O
extracorporeal	O
CO2	O
removal	O
devices	O
and	O
neurally	O
adjusted	O
ventilatory	O
assist	O
,	O
have	O
recently	O
been	O
studied	O
to	O
minimize	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Up	O
to	O
104	O
cDNA	O
clones	O
of	O
eight	O
viruses	O
were	O
obtained	O
by	O
reverse	B-PROC
transcription	B-PROC
PCR	O
with	O
different	O
pairs	O
of	O
primers	O
designed	O
for	O
each	O
virus	O
and	O
a	O
pair	O
of	O
universal	O
primers	O
designed	O
for	O
the	O
RNA	O
polymerase	O
gene	O
of	O
coronavirus	O
.	O

All	O
labeled	O
cDNAs	O
and	O
prepared	O
gene	O
chips	O
were	O
subjected	O
to	O
specific	O
hybridization	B-PROC
.	O

The	O
hybridization	B-PROC
results	O
showed	O
that	O
this	O
gene	O
chip	O
could	O
specifically	O
identify	O
and	O
distinguish	O
the	O
eight	O
coronaviruses	O
and	O
the	O
sensitivity	O
of	O
the	O
chip	O
may	O
be	O
1	O
,	O
000x	O
more	O
sensitive	O
than	O
PCR	O
,	O
indicating	O
that	O
it	O
can	O
be	O
used	O
for	O
the	O
diagnosis	O
of	O
eight	O
coronavirus	O
infections	O
at	O
the	O
same	O
time	O
.	O

The	O
7	O
-	O
day	O
and	O
28	O
-	O
day	O
mortality	O
,	O
the	O
days	O
in	O
ICU	O
and	O
the	O
length	O
of	O
stay	O
,	O
the	O
changes	O
of	O
oxygenation	B-PROC
index	O
,	O
the	O
days	O
of	O
mechanical	O
ventilation	O
and	O
the	O
rates	O
of	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
),	O
acute	O
renal	O
failure	O
(	O
ARF	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
were	O
observed	O
.	O

RESULTS	O
:	O
The	O
majority	O
of	O
physicians	O
agreed	O
that	O
home	O
quarantine	O
of	O
contacts	O
of	O
patients	O
with	O
probable	O
SARS	O
was	O
warranted	O
(	O
95	O
%),	O
government	O
'	O
s	O
public	O
education	O
effort	B-PROC
was	O
effective	O
(	O
83	O
%),	O
and	O
the	O
overall	O
Singapore	O
'	O
s	O
response	O
was	O
commendable	O
(	O
82	O
%).	O

High	O
case	O
-	O
fatality	O
rates	O
,	O
virulence	B-PROC
,	O
and	O
high	O
proportion	O
of	O
atypical	O
manifestations	O
impacted	O
cost	O
-	O
effectiveness	O
the	O
most	O
.	O

The	O
input	O
to	O
the	O
network	O
is	O
the	O
measured	O
expression	B-PROC
levels	O
of	O
biomarkers	O
,	O
and	O
the	O
output	O
is	O
the	O
summation	B-PROC
of	O
regulatory	O
strengths	O
from	O
other	O
biomarkers	O
.	O

The	O
discovered	O
regulation	B-PROC
relationships	O
can	O
potentially	O
provide	O
insights	O
to	O
revealing	O
the	O
molecular	O
signaling	B-PROC
pathways	B-PROC
.	O

Since	O
the	O
downregulation	B-PROC
of	O
ACE2	O
by	O
SARS	O
-	O
S	O
protein	O
was	O
proposed	O
as	O
an	O
etiological	O
event	O
in	O
the	O
severe	O
clinical	O
manifestations	O
,	O
our	O
data	O
suggest	O
that	O
TACE	O
antagonists	O
block	O
SARS	O
-	O
CoV	O
infection	O
and	O
also	O
attenuate	O
its	O
severe	O
clinical	O
outcome	O
.	O

Careful	O
planning	O
is	O
therefore	O
important	O
to	O
ensure	O
expensive	O
policies	O
to	O
mitigate	O
the	O
pandemic	O
are	O
effective	O
in	O
minimising	O
illness	O
and	O
deaths	B-PROC
.	O

A	O
rapid	O
increase	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
PaO2	O
/	O
FiO2	O
)	O
from	O
64	O
(	O
48	O
to	O
86	O
)	O
mmHg	O
to	O
120	O
(	O
84	O
to	O
171	O
)	O
mmHg	O
and	O
a	O
decrease	O
of	O
PaCO2	O
from	O
63	O
(	O
50	O
to	O
80	O
)	O
mmHg	O
to	O
33	O
(	O
29	O
to	O
39	O
)	O
mmHg	O
were	O
observed	O
after	O
start	O
of	O
the	O
extracorporeal	O
support	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
with	O
a	O
new	O
miniaturized	O
device	O
supports	O
gas	O
transfer	O
effectively	O
,	O
allows	O
for	O
highly	O
protective	O
ventilation	O
and	O
is	O
very	O
reliable	O
.	O

Since	O
ER	O
stress	O
can	O
cause	O
differential	O
modulation	O
of	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
),	O
which	O
includes	O
the	O
inositol	O
-	O
requiring	O
enzyme	O
1	O
(	O
IRE	O
-	O
1	O
),	O
activating	O
transcription	B-PROC
factor	O
6	O
(	O
ATF6	O
)	O
and	O
PKR	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	O
)	O
pathways	B-PROC
,	O
these	O
were	O
individually	O
tested	O
in	O
3a	O
-	O
expressing	O
cells	O
.	O

The	O
3a	O
protein	O
was	O
found	O
to	O
induce	O
serine	O
phosphorylation	B-PROC
within	O
the	O
IFN	O
alpha	O
-	O
receptor	O
subunit	O
1	O
(	O
IFNAR1	O
)	O
degradation	O
motif	O
and	O
to	O
increase	O
IFNAR1	O
ubiquitination	B-PROC
.	O

Confocal	O
microscopic	O
analysis	O
showed	O
increased	O
translocation	B-PROC
of	O
IFNAR1	O
into	O
the	O
lysosomal	O
compartment	O
and	O
flow	O
cytometry	O
showed	O
reduced	O
levels	O
of	O
IFNAR1	O
in	O
3a	O
-	O
expressing	O
cells	O
.	O

This	O
is	O
the	O
first	O
evidence	O
that	O
recombination	B-PROC
can	O
directly	O
lead	O
to	O
the	O
emergence	O
of	O
new	O
coronaviruses	O
and	O
new	O
coronaviral	O
diseases	O
,	O
emphasizing	O
the	O
importance	O
of	O
limiting	O
exposure	O
to	O
reservoirs	O
of	O
coronaviruses	O
that	O
can	O
serve	O
as	O
a	O
source	O
of	O
genetic	O
material	O
for	O
emerging	O
viruses	O
.	O

Although	O
the	O
epidemiological	O
aspects	O
of	O
the	O
three	O
20th	O
century	O
influenza	O
pandemics	O
have	O
been	O
widely	O
investigated	O
,	O
little	O
is	O
known	O
about	O
population	O
behaviour	B-PROC
in	O
a	O
pandemic	O
situation	O
.	O

On	O
multivariate	O
analysis	O
,	O
enteral	O
feeding	O
>	O
2000	O
Kcal	O
before	O
day	O
5	O
[	O
odds	O
ratio	O
(	O
OR	O
):	O
0	O
.	O
33	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
0	O
.	O
21	O
-	O
0	O
.	O
85	O
]	O
and	O
initial	O
neurosurgical	O
procedure	O
(	O
OR	O
:	O
0	O
.	O
36	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
15	O
-	O
0	O
.	O
89	O
)	O
remained	O
protective	O
factors	O
for	O
EOVAP	O
,	O
whereas	O
immunosuppression	B-PROC
(	O
OR	O
:	O
7	O
.	O
15	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
66	O
-	O
30	O
.	O
73	O
)	O
and	O
barbiturate	O
use	O
(	O
OR	O
:	O
2	O
.	O
68	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
06	O
-	O
6	O
.	O
80	O
)	O
remained	O
risk	O
factors	O
for	O
EOVAP	O
.	O

ABSTRACT	O
:	O
To	O
estimate	O
the	O
rate	O
of	O
pregnancy	O
hospitalizations	O
for	O
women	O
with	O
two	O
groups	O
of	O
myocardial	O
disorders	O
,	O
cardiomyopathy	O
and	O
other	O
myocardial	O
disorders	O
,	O
and	O
report	O
the	O
rate	O
of	O
severe	O
obstetric	O
complications	O
among	O
these	O
hospitalizations	O
in	O
delivery	O
and	O
postpartum	O
periods	B-PROC
.	O

During	O
a	O
17	O
hour	O
flight	B-PROC
,	O
a	O
greater	O
number	O
of	O
infections	O
would	O
occur	O
in	O
First	O
Class	O
than	O
in	O
Economy	O
if	O
the	O
First	O
Class	O
Cabin	O
is	O
fully	O
occupied	O
,	O
but	O
Economy	O
class	O
is	O
less	O
than	O
30	O
%	O
full	O
.	O

TITLE	O
:	O
Tempol	O
ameliorates	O
murine	O
viral	O
encephalomyelitis	O
by	O
preserving	O
the	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
,	O
reducing	O
viral	O
load	O
,	O
and	O
lessening	O
inflammation	O
.	O

Treatment	O
with	O
tempol	O
(	O
24	O
mg	O
/	O
kg	O
,	O
ip	O
,	O
two	O
doses	O
on	O
the	O
first	O
day	O
and	O
daily	O
doses	O
for	O
7	O
days	O
plus	O
2	O
mM	O
tempol	O
in	O
the	O
drinking	B-PROC
water	O
ad	O
libitum	O
)	O
profoundly	O
altered	O
the	O
disease	O
outcome	O
:	O
neurological	O
symptoms	O
were	O
attenuated	O
,	O
mouse	O
survival	O
increased	O
up	O
to	O
70	O
%,	O
and	O
half	O
of	O
the	O
survivors	O
behaved	O
as	O
normal	O
mice	O
.	O

Furthermore	O
,	O
treatment	O
with	O
tempol	O
decreased	O
CNS	O
viral	O
titers	O
,	O
macrophage	O
and	O
T	O
lymphocyte	O
infiltration	O
,	O
and	O
levels	O
of	O
markers	O
of	O
inflammation	O
,	O
such	O
as	O
expression	B-PROC
of	O
inducible	O
nitric	O
oxide	O
synthase	O
,	O
transcription	B-PROC
of	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
and	O
interferon	O
-	O
gamma	O
,	O
and	O
protein	O
nitration	O
.	O

Importantly	O
,	O
the	O
initial	O
specimen	O
evaluated	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
was	O
negative	O
for	O
novel	O
2009	O
H1N1	O
influenza	O
virus	O
.	O

The	O
infection	O
of	O
cells	O
with	O
srr7	O
(	O
soluble	O
-	O
receptor	O
-	O
resistant	O
mutant	O
7	O
)	O
is	O
dependent	O
on	O
a	O
known	O
MHV	O
receptor	O
(	O
MHVR	O
),	O
carcinoembryonic	O
cell	B-PROC
adhesion	I-PROC
molecule	O
1a	O
,	O
whereas	O
cl	O
-	O
2	O
shows	O
MHVR	O
-	O
independent	O
infection	O
.	O

Furthermore	O
,	O
the	O
observation	O
indicates	O
that	O
viral	B-PROC
infection	I-PROC
has	O
cytopathic	O
effects	O
on	O
the	O
monocyte	O
lineage	O
,	O
which	O
plays	O
a	O
critical	O
role	O
in	O
innate	B-PROC
immunity	B-PROC
,	O
leading	O
to	O
the	O
rapid	O
spread	O
of	O
viruses	O
during	O
the	O
early	O
stage	O
of	O
infection	O
.	O

The	O
sequence	O
comparison	O
revealed	O
that	O
the	O
field	O
isolates	O
had	O
96	O
%	O
homology	O
with	O
a	O
few	O
point	B-PROC
mutations	I-PROC
.	O

TITLE	O
:	O
Circulation	B-PROC
of	O
group	O
2	O
coronaviruses	O
in	O
a	O
bat	O
species	O
common	O
to	O
urban	O
areas	O
in	O
Western	O
Europe	O
.	O

Complete	O
genome	O
sequencing	O
of	O
10	O
SARSr	O
-	O
Rh	O
-	O
BatCoV	O
strains	O
showed	O
frequent	O
recombination	B-PROC
between	O
different	O
strains	O
.	O

The	O
present	O
data	O
suggest	O
that	O
SARSr	O
-	O
Rh	O
-	O
BatCoV	O
causes	O
acute	O
,	O
self	O
-	O
limiting	O
infection	O
in	O
horseshoe	O
bats	O
,	O
which	O
serve	O
as	O
a	O
reservoir	O
for	O
recombination	B-PROC
between	O
strains	O
from	O
different	O
geographical	O
locations	O
within	O
reachable	O
foraging	O
range	O
.	O

TITLE	O
:	O
Contribution	O
of	O
the	O
porcine	O
aminopeptidase	O
N	O
(	O
CD13	O
)	O
receptor	B-PROC
density	I-PROC
to	O
porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
.	O

Moreover	O
,	O
the	O
only	O
APN	O
inhibitor	O
blocking	O
the	O
protease	B-PROC
activity	I-PROC
site	O
had	O
no	O
obvious	O
negative	O
effect	O
on	O
viral	B-PROC
infection	I-PROC
,	O
indicating	O
that	O
the	O
enzymatic	O
role	O
of	O
APN	O
is	O
dispensable	O
for	O
the	O
process	O
of	O
virus	B-PROC
replication	I-PROC
.	O

Therefore	O
,	O
this	O
implicit	O
membrane	O
environment	O
,	O
though	O
in	O
lattice	O
space	O
,	O
can	O
make	O
an	O
elaborate	O
balance	B-PROC
between	O
different	O
driving	O
forces	O
for	O
the	O
membrane	O
protein	O
'	O
s	O
folding	O
,	O
thus	O
offering	O
a	O
potential	O
means	O
for	O
the	O
simulation	O
of	O
transmembrane	O
protein	O
oligomers	O
in	O
feasible	O
time	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
(	O
TGE	O
),	O
characterized	O
by	O
high	O
mortality	O
and	O
severely	O
retarded	O
growth	B-PROC
in	O
piglets	O
that	O
dramatically	O
affects	O
the	O
porcine	O
industry	O
.	O

The	O
specificity	O
of	O
these	O
pandemic	O
strains	O
to	O
infect	O
lower	O
respiratory	O
tract	O
is	O
of	O
immunological	O
origin	O
:	O
only	O
patients	O
with	O
little	O
or	O
no	O
immunity	B-PROC
to	O
the	O
virus	O
can	O
develop	O
viral	O
pneumonia	O
and	O
ARDS	O
.	O

We	O
explored	O
the	O
anti	O
-	O
SARS	O
quarantine	O
experience	O
of	O
patients	O
in	O
a	O
hospital	O
-	O
based	O
fever	B-PROC
screening	O
station	O
.	O

Nevertheless	O
,	O
currently	O
,	O
the	O
pandemic	O
A	O
/	O
H1N1	O
2009	O
seems	O
to	O
be	O
a	O
mild	O
disease	O
clinically	O
,	O
although	O
causing	O
death	B-PROC
,	O
but	O
it	O
has	O
not	O
yet	O
eased	O
,	O
and	O
there	O
are	O
still	O
major	O
question	O
marks	O
concerning	O
its	O
future	O
.	O

We	O
also	O
showed	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
IFN	O
-	O
beta	O
and	O
IFN	O
-	O
lambdas	O
were	O
capable	O
of	O
exerting	B-PROC
previously	O
unrecognized	O
,	O
non	O
-	O
redundant	O
,	O
and	O
complementary	O
abilities	O
to	O
limit	O
SARS	O
-	O
CoV	O
replication	O
,	O
even	O
though	O
their	O
expression	B-PROC
could	O
not	O
be	O
detected	O
in	O
infected	O
2B4	O
bronchial	O
epithelial	O
cells	O
until	O
48	O
hrs	O
p	O
.	O
i	O
.	O

TITLE	O
:	O
Classification	O
of	O
IBV	O
S1	O
genotypes	O
by	O
direct	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
relationship	O
between	O
serotypes	O
and	O
genotypes	O
of	O
strains	O
isolated	O
between	O
1998	O
and	O
2008	O
in	O
Japan	O
.	O

Twelve	O
patients	O
(	O
66	O
.	O
7	O
%)	O
could	O
be	O
weaned	B-PROC
,	O
with	O
a	O
30	O
-	O
day	O
mortality	O
of	O
55	O
.	O
6	O
%.	O

TITLE	O
:	O
Are	O
inhaled	B-PROC
vasodilators	O
useful	O
in	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
?	O

Inhaled	B-PROC
prostacyclins	O
are	O
as	O
effective	O
physiologically	O
as	O
INO	O
and	O
cost	O
less	O
.	O

These	O
findings	O
could	O
potentially	O
inform	O
the	O
development	B-PROC
of	O
practical	O
community	O
mental	O
health	O
programs	O
for	O
future	O
infectious	O
disease	O
outbreaks	O
.	O

Psychiatric	O
morbidity	O
was	O
further	O
associated	O
with	O
being	O
seen	O
at	O
fever	B-PROC
stations	O
(	O
adjusted	O
OR	O
1	O
.	O
90	O
,	O
95	O
%	O
CI	O
1	O
.	O
08	O
-	O
3	O
.	O
34	O
,	O
P	O
=.	O
026	O
),	O
younger	O
age	O
(	O
adjusted	O
OR	O
0	O
.	O
97	O
,	O
95	O
%	O
CI	O
0	O
.	O
94	O
-	O
0	O
.	O
98	O
,	O
P	O
=.	O
021	O
),	O
increased	O
self	O
blame	O
(	O
adjusted	O
OR	O
1	O
.	O
67	O
,	O
95	O
%	O
CI	O
1	O
.	O
22	O
-	O
2	O
.	O
28	O
,	O
P	O
=.	O
001	O
),	O
less	O
substance	O
use	O
(	O
adjusted	O
OR	O
0	O
.	O
74	O
,	O
95	O
%	O
CI	O
0	O
.	O
56	O
-	O
0	O
.	O
98	O
,	O
P	O
=.	O
034	O
)	O
and	O
posttraumatic	O
morbidity	O
was	O
associated	O
with	O
increased	O
use	O
of	O
denial	O
(	O
adjusted	O
OR	O
1	O
.	O
31	O
,	O
95	O
%	O
CI	O
1	O
.	O
04	O
-	O
1	O
.	O
67	O
,	O
P	O
=.	O
024	O
),	O
and	O
planning	O
(	O
adjusted	O
OR	O
1	O
.	O
51	O
,	O
95	O
%	O
CI	O
1	O
.	O
16	O
-	O
1	O
.	O
95	O
,	O
P	O
=.	O
002	O
)	O
as	O
coping	O
measures	O
.	O

The	O
primary	O
objectives	O
of	O
this	O
review	O
are	O
to	O
identify	O
the	O
key	O
demographic	O
and	O
attitudinal	O
determinants	O
of	O
three	O
types	O
of	O
protective	O
behaviour	B-PROC
during	O
a	O
pandemic	O
:	O
preventive	O
,	O
avoidant	O
,	O
and	O
management	O
of	O
illness	O
behaviours	O
,	O
in	O
order	O
to	O
describe	O
conceptual	O
frameworks	O
in	O
which	O
to	O
better	O
understand	O
these	O
behaviours	O
and	O
to	O
inform	O
future	O
communications	O
and	O
interventions	O
in	O
the	O
current	O
outbreak	O
of	O
swine	O
flu	O
and	O
subsequent	O
influenza	O
pandemics	O
.	O

We	O
also	O
show	O
that	O
rSARS	O
-	O
CoV	O
-	O
DeltaE	O
and	O
rSARS	O
-	O
CoV	O
-	O
Delta	O
[	O
E	O
,	O
6	O
-	O
9b	O
]	O
induced	O
anti	O
-	O
virus	O
T	O
cell	O
and	O
antibody	B-PROC
responses	I-PROC
.	O

However	O
,	O
he	O
suffered	O
from	O
sudden	O
-	O
onset	O
severe	O
respiratory	O
distress	O
,	O
and	O
blood	B-PROC
gas	I-PROC
analysis	O
showed	O
profound	O
hypoxemia	O
with	O
a	O
marked	O
arterial	O
-	O
alveolar	O
oxygen	O
difference	O
.	O

Treatment	O
with	O
the	O
glucosidase	O
inhibitor	O
N	O
-	O
butyl	O
-	O
deoxynojirimycin	O
(	O
NB	O
-	O
DNJ	O
)	O
inhibited	O
N	B-PROC
-	I-PROC
glycan	I-PROC
processing	I-PROC
as	O
evidenced	O
by	O
the	O
appearance	O
of	O
glycans	O
of	O
composition	O
Glc	O
(	O
3	O
)	O
Man	O
(	O
7	O
-	O
9	O
)	O
GlcNAc	O
(	O
2	O
).	O

The	O
ARDS	O
-	O
death	B-PROC
group	O
had	O
a	O
slower	O
decline	O
in	O
nasopharyngeal	O
viral	O
loads	O
,	O
had	O
higher	O
plasma	O
levels	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
and	O
were	O
more	O
likely	O
to	O
have	O
bacterial	O
coinfections	O
(	O
30	O
.	O
4	O
%),	O
myocarditis	O
(	O
21	O
.	O
7	O
%),	O
or	O
viremia	O
(	O
13	O
.	O
0	O
%)	O
than	O
patients	O
in	O
the	O
survived	O
-	O
without	O
-	O
ARDS	O
or	O
the	O
mild	O
-	O
disease	O
groups	O
.	O

The	O
molecular	O
pathways	B-PROC
,	O
however	O
,	O
that	O
cause	O
virus	O
-	O
induced	O
ALI	O
/	O
ARDS	O
in	O
aged	O
individuals	O
are	O
ill	O
-	O
defined	O
.	O

ABSTRACT	O
:	O
In	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
negative	O
Hodgkin	O
'	O
s	O
cell	O
lines	O
and	O
classical	O
EBV	O
-	O
negative	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
HL	O
),	O
Reed	O
-	O
Sternberg	O
cells	O
(	O
RS	O
cells	O
)	O
represent	O
end	O
-	O
stage	O
tumor	O
cells	O
,	O
in	O
which	O
further	O
nuclear	B-PROC
division	I-PROC
becomes	O
impossible	O
because	O
of	O
sustained	O
telomere	O
loss	O
,	O
shortening	O
and	O
aggregation	O
.	O

Rotenone	O
or	O
1	O
-	O
methyl	O
-	O
4	O
-	O
phenyl	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
6	O
-	O
tetrahydropyridine	O
(	O
MPTP	O
)	O
inhibit	O
the	O
mitochondrial	O
complex	O
I	O
and	O
they	O
cause	O
the	O
death	B-PROC
of	O
substantia	O
nigra	O
dopaminergic	O
neurons	O
,	O
thereby	O
providing	O
acute	O
murine	O
models	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
has	O
been	O
identified	O
as	O
a	O
major	O
target	O
of	O
protective	O
immunity	B-PROC
and	O
contains	O
3	O
regions	O
that	O
are	O
targeted	B-PROC
by	O
neutralizing	O
antibodies	O
in	O
the	O
S1	O
and	O
S2	O
domains	O
.	O

These	O
data	O
provide	O
a	O
mechanism	O
for	O
overcoming	O
neutralization	O
escape	O
by	O
use	O
of	O
broadly	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
cocktails	O
of	O
cross	O
-	O
neutralizing	O
MAbs	O
that	O
recognize	O
residues	O
within	O
the	O
receptor	O
-	O
binding	O
domain	O
that	O
are	O
critical	O
for	O
virus	B-PROC
replication	I-PROC
and	O
virulence	B-PROC
.	O

There	O
was	O
also	O
an	O
inverse	O
correlation	O
between	O
lowest	O
measured	O
fT	O
(	O
4	O
)	O
and	O
highest	O
mean	O
airway	O
pressure	O
,	O
oxygenation	B-PROC
index	O
,	O
and	O
A	O
-	O
a	O
gradient	O
.	O

High	O
-	O
growth	B-PROC
properties	O
and	O
narrow	O
tissue	O
tropisms	B-PROC
(	O
limited	O
replication	O
in	O
respiratory	O
tracts	O
)	O
were	O
achieved	O
by	O
the	O
adaptation	B-PROC
process	O
.	O

In	O
conclusion	O
,	O
K2p170	O
exhibits	O
a	O
fine	O
balance	B-PROC
between	O
attenuation	O
and	O
immunogenicity	O
,	O
possesses	O
cross	O
-	O
protective	O
efficacy	O
,	O
and	O
merits	O
further	O
investigation	O
as	O
a	O
potential	O
live	O
vaccine	O
as	O
an	O
alternative	O
means	O
of	O
protection	O
against	O
the	O
recently	O
emergent	O
nephropathogenic	O
IBV	O
infection	O
in	O
many	O
Eurasian	O
countries	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
membrane	O
(	O
M	O
)	O
protein	O
can	O
form	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
when	O
coexpressed	O
with	O
nucleocapsid	O
(	O
N	O
)	O
or	O
envelope	O
(	O
E	O
)	O
proteins	O
,	O
suggesting	O
a	O
pivotal	O
role	O
for	O
M	O
in	O
virion	B-PROC
assembly	I-PROC
.	O

In	O
the	O
present	O
paper	O
we	O
provide	O
evidence	O
that	O
MLK3	O
undergoes	O
proteolysis	B-PROC
to	O
generate	O
a	O
stable	O
CTF	O
in	O
response	O
to	O
different	O
stimuli	O
,	O
including	O
PMA	O
and	O
TNFalpha	O
(	O
tumour	O
necrosis	B-PROC
factor	O
alpha	O
).	O

TITLE	O
:	O
Recent	O
advances	O
in	O
targeting	B-PROC
viral	O
proteases	O
for	O
the	O
discovery	O
of	O
novel	O
antivirals	O
.	O

In	O
addition	O
,	O
viral	O
proteases	O
can	O
be	O
involved	O
in	O
further	O
processes	O
relevant	O
for	O
viral	B-PROC
replication	I-PROC
.	O

Recent	O
observational	O
studies	O
suggest	O
,	O
that	O
preterm	O
infants	O
<	O
34	O
weeks	O
of	O
gestation	B-PROC
with	O
acute	O
hypoxic	O
lung	O
failure	O
could	O
benefit	O
from	O
inhaled	B-PROC
NO	O
(	O
iNO	O
)	O
by	O
improved	O
oxygenation	B-PROC
.	O

One	O
such	O
multifunctional	O
domain	O
is	O
the	O
coronavirus	O
papain	O
-	O
like	O
protease	O
(	O
PLP	O
),	O
which	O
processes	O
the	O
viral	O
replicase	O
polyprotein	O
,	O
has	O
deubiquitinating	B-PROC
(	O
DUB	O
)	O
activity	O
,	O
and	O
antagonizes	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
).	O

The	O
selection	O
pressures	O
that	O
may	O
contribute	O
to	O
the	O
evolution	B-PROC
of	O
Taiwan	O
IBV	O
during	O
recent	O
decades	O
were	O
assessed	O
.	O

Allantoic	O
fluid	O
was	O
collected	O
for	O
hemagglutination	B-PROC
titer	O
assay	O
.	O

A	O
trial	O
of	O
nebulized	O
prostacyclin	O
was	O
initiated	O
during	O
HFPV	O
leading	O
to	O
a	O
significant	O
improvement	O
in	O
arterial	O
oxygen	B-PROC
tension	I-PROC
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
to	O
147	O
mm	O
Hg	O
.	O

TITLE	O
:	O
Inhaled	B-PROC
aerosolized	O
insulin	O
:	O
a	O
""""	O
topical	O
""""	O
anti	O
-	O
inflammatory	O
treatment	O
for	O
acute	O
lung	O
injury	O
and	O
respiratory	O
distress	O
syndrome	O
?	O

Excessive	O
inflammatory	B-PROC
response	I-PROC
to	O
necrotic	B-PROC
debris	O
might	O
contribute	O
to	O
the	O
development	B-PROC
of	O
ARDS	O
.	O

All	O
were	O
managed	O
with	O
a	O
lung	O
protective	O
ventilator	O
strategy	O
(	O
average	O
number	O
of	O
days	O
on	O
the	O
ventilator	O
:	O
16	O
),	O
and	O
4	O
patients	O
also	O
required	O
additional	O
rescue	O
therapies	O
for	O
refractory	O
hypoxemia	O
,	O
including	O
very	O
high	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
,	O
inhaled	B-PROC
epoprostenol	O
,	O
recruitment	O
maneuvers	O
,	O
and	O
prone	O
positioning	O
.	O

Despite	O
these	O
measures	O
,	O
3	O
patients	O
(	O
43	O
%)	O
ultimately	O
died	B-PROC
.	O

Despite	O
these	O
measures	O
,	O
3	O
patients	O
(	O
43	O
%)	O
ultimately	O
died	B-PROC
.	O

We	O
examine	O
how	O
pleiotropic	O
mutations	O
that	O
have	O
antagonistic	O
effects	O
(	O
i	O
.	O
e	O
.,	O
antibody	B-PROC
evasion	O
vs	O
.	O
receptor	O
binding	O
)	O
on	O
viral	B-PROC
replication	I-PROC
within	O
hosts	O
can	O
impact	O
viral	O
immune	O
escape	O
in	O
the	O
host	O
population	O
.	O

To	O
investigate	O
the	O
causal	O
relation	O
between	O
a	O
mutation	O
in	O
a	O
viral	O
genome	O
and	O
adaptive	O
evolution	B-PROC
of	O
a	O
viral	O
population	O
,	O
we	O
developed	O
a	O
mathematical	O
model	O
that	O
describes	O
the	O
population	O
dynamics	O
of	O
viruses	O
,	O
antibodies	O
,	O
and	O
normal	O
/	O
infected	O
cells	O
within	O
a	O
host	O
.	O

ABSTRACT	O
:	O
Ventilating	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
the	O
prone	O
position	O
has	O
been	O
shown	O
to	O
improve	O
arterial	O
oxygenation	B-PROC
,	O
but	O
prolonged	O
prone	O
positioning	O
frequently	O
requires	O
continuous	O
deep	O
sedation	O
,	O
which	O
may	O
be	O
harmful	O
to	O
patients	O
.	O

The	O
main	O
presenting	O
symptoms	O
were	O
itchy	O
skin	O
rash	O
,	O
fever	B-PROC
,	O
cough	O
,	O
sputum	O
,	O
breathlessness	O
,	O
throat	O
pain	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
,	O
confusion	O
and	O
headache	O
.	O

Stem	O
loops	O
(	O
SL	O
)	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
5	O
were	O
predicted	O
in	O
all	O
CoVs	O
,	O
while	O
the	O
core	O
leader	O
transcription	B-PROC
-	O
regulating	O
sequence	O
(	O
L	O
-	O
TRS	O
)	O
forms	O
SL3	O
in	O
only	O
some	O
CoVs	O
.	O

SL5	O
in	O
group	O
I	O
and	O
II	O
CoVs	O
,	O
with	O
the	O
exception	O
of	O
group	O
IIa	O
CoVs	O
,	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
large	O
sequence	B-PROC
insertion	I-PROC
capable	O
of	O
forming	O
hairpins	O
with	O
the	O
conserved	O
5	O
'-	O
UUYCGU	O
-	O
3	O
'	O
loop	O
sequence	O
.	O

Most	O
of	O
these	O
deaths	B-PROC
are	O
caused	O
by	O
preventable	O
or	O
curable	O
infections	O
.	O

ABSTRACT	O
:	O
The	O
2002	O
-	O
2003	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
outbreak	O
infected	O
8	O
,	O
422	O
individuals	O
leading	O
to	O
916	O
deaths	B-PROC
around	O
the	O
world	O
.	O

It	O
is	O
shown	O
,	O
using	O
Lyapunov	O
function	O
theory	O
and	O
the	O
theory	O
of	O
compound	O
matrices	O
,	O
that	O
the	O
dynamics	O
of	O
the	O
model	O
are	O
determined	O
by	O
a	O
certain	O
threshold	O
quantity	O
known	O
as	O
the	O
control	O
reproduction	B-PROC
number	O
(	O
R	O
(	O
v	O
)).	O

The	O
response	O
(	O
or	O
output	O
)	O
of	O
interest	O
is	O
the	O
control	O
reproduction	B-PROC
number	O
,	O
which	O
is	O
an	O
epidemiological	O
threshold	O
governing	O
the	O
persistence	O
or	O
elimination	B-PROC
of	O
SARS	O
in	O
a	O
given	O
population	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
qingyi	O
decoction	O
in	O
treating	O
severe	O
acute	O
pancreatitis	O
and	O
its	O
impacts	O
on	O
blood	O
level	O
of	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
,	O
interleukin	O
-	O
6	O
and	O
inteleukin	O
-	O
8	O
].	O

Seven	O
of	O
the	O
eight	O
TGEV	O
antibody	B-PROC
-	O
positive	O
farms	O
were	O
also	O
positive	O
for	O
PRCV	O
antibody	B-PROC
.	O

Five	O
months	O
after	O
the	O
antibody	B-PROC
examination	O
,	O
a	O
TGE	O
outbreak	O
occurred	O
at	O
one	O
of	O
these	O
seven	O
farms	O
.	O

The	O
entry	O
pathway	B-PROC
of	O
SARS	O
-	O
CoV	O
could	O
influence	O
the	O
severity	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
Our	O
studies	O
and	O
those	O
of	O
many	O
others	O
have	O
implicated	O
hepatocyte	O
necrosis	B-PROC
and	O
apoptosis	B-PROC
mediated	O
by	O
fibrinogen	O
-	O
like	O
protein	O
-	O
2	O
(	O
fgl2	O
)	O
prothrombinase	O
and	O
tumor	O
necrosis	B-PROC
factor	O
receptor	O
(	O
TNFR	O
)	O
in	O
the	O
development	B-PROC
of	O
fulminant	O
viral	O
hepatitis	O
,	O
a	O
disease	O
with	O
a	O
mortality	O
rate	O
greater	O
than	O
80	O
%	O
in	O
cases	O
lacking	O
immediate	O
organ	O
transplantation	O
.	O

Cotransfection	O
of	O
individual	O
shRNA	O
plasmids	O
and	O
pcDNA3	O
.	O
0	O
-	O
mfgl2	O
and	O
pcDNA3	O
.	O
0	O
-	O
mTNFR1	O
expression	B-PROC
constructs	O
into	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
significantly	O
inhibited	O
mfgl2	O
and	O
mTNFR1	O
gene	B-PROC
expression	I-PROC
,	O
as	O
evidenced	O
by	O
fluorescence	O
microscopy	O
,	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
Western	O
blotting	O
.	O

In	O
vivo	O
hydrodynamic	O
delivery	O
of	O
dual	O
-	O
interference	O
shRNA	O
plasmids	O
for	O
mfgl2	O
and	O
mTNFR1	O
significantly	O
decreased	O
mfgl2	O
and	O
mTNFR1	O
expression	B-PROC
;	O
markedly	O
ameliorated	O
fibrin	O
deposition	O
,	O
hepatocyte	O
necrosis	B-PROC
,	O
and	O
apoptosis	B-PROC
;	O
and	O
prolonged	O
survival	O
against	O
fulminant	O
viral	O
hepatitis	O
induced	O
by	O
MHV	O
-	O
3	O
in	O
BALB	O
/	O
cJ	O
mice	O
compared	O
with	O
mfgl2	O
or	O
TNFR1	O
single	O
-	O
gene	O
interference	O
.	O

Our	O
data	O
indicate	O
that	O
RNA	O
recombination	B-PROC
in	O
the	O
recombinant	O
5	O
'	O
end	O
of	O
the	O
N	O
gene	O
may	O
have	O
caused	O
the	O
emergence	O
of	O
the	O
current	O
IBV	O
population	O
in	O
Taiwan	O
.	O

Kidney	O
failure	O
was	O
associated	O
with	O
increased	O
death	B-PROC
(	O
OR	O
,	O
11	O
.	O
29	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
29	O
-	O
98	O
.	O
9	O
),	O
whereas	O
the	O
need	O
for	O
dialysis	O
was	O
associated	O
with	O
an	O
increase	O
in	O
length	O
of	O
stay	O
(	O
RR	O
,	O
2	O
.	O
38	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
13	O
-	O
25	O
.	O
75	O
).	O

TITLE	O
:	O
What	O
have	O
we	O
learned	B-PROC
from	O
the	O
novel	O
influenza	O
A	O
(	O
H1N1	O
)	O
pandemic	O
in	O
2009	O
for	O
strengthening	O
pandemic	O
influenza	O
preparedness	O
?	O

Modifications	O
in	O
a	O
patient	O
'	O
s	O
respiratory	O
assistance	O
were	O
made	O
depending	O
on	O
the	O
clinical	O
,	O
blood	B-PROC
gas	I-PROC
,	O
and	O
radiologic	O
evolution	B-PROC
of	O
the	O
patient	O
.	O

RESULTS	O
:	O
Two	O
early	O
postoperative	O
death	B-PROC
occurred	O
in	O
this	O
group	O
due	O
to	O
severe	O
low	O
cardiac	O
output	O
syndrome	O
,	O
with	O
the	O
mortality	O
rate	O
of	O
1	O
.	O
57	O
%.	O

Interestingly	O
,	O
we	O
found	O
that	O
SARS	O
coronavirus	O
was	O
present	O
in	O
feces	O
from	O
infected	O
mice	O
lacking	O
receptors	O
for	O
both	O
type	O
I	O
and	O
type	O
III	O
IFN	O
but	O
not	O
in	O
those	O
from	O
mice	O
lacking	O
single	O
receptors	O
,	O
supporting	O
the	O
view	O
that	O
IFN	O
-	O
lambda	O
contributes	O
to	O
the	O
control	O
of	O
viral	B-PROC
infections	I-PROC
in	O
epithelial	O
cells	O
of	O
both	O
respiratory	O
and	O
gastrointestinal	O
tracts	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
determined	O
the	O
tissue	B-PROC
tropism	B-PROC
and	O
safety	O
of	O
MVTT	O
-	O
S	O
after	O
the	O
vaccine	O
was	O
administrated	O
through	O
various	O
routes	O
including	O
:	O
intramuscular	O
(	O
i	O
.	O
m	O
.),	O
intranasal	O
(	O
i	O
.	O
n	O
.),	O
and	O
intravaginal	O
(	O
i	O
.	O
vag	O
.)	O
inoculations	O
,	O
respectively	O
.	O

Using	O
real	O
-	O
time	O
PCR	O
,	O
nested	O
PCR	O
,	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	B-PROC
assays	O
,	O
we	O
found	O
that	O
MVTT	O
-	O
S	O
was	O
able	O
to	O
produce	O
a	O
transient	O
infection	O
in	O
all	O
cases	O
within	O
48	O
hr	O
post	O
-	O
inoculation	O
,	O
yet	O
the	O
major	O
site	O
of	O
viral	B-PROC
replication	I-PROC
in	O
various	O
tissues	O
or	O
organs	O
was	O
dependent	O
on	O
the	O
route	O
of	O
viral	O
administration	O
.	O

Serum	O
samples	O
were	O
collected	O
from	O
super	O
transmitters	O
and	O
tested	O
for	O
SARS	O
-	O
CoV	O
antibody	B-PROC
by	O
neutralization	O
test	O
and	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

ABSTRACT	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
improves	O
gas	O
exchange	O
in	O
about	O
60	O
%	O
of	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Preservation	O
of	O
SB	O
was	O
provided	O
by	O
4	O
different	O
modes	O
:	O
Unassisted	O
SB	O
was	O
enabled	O
by	O
biphasic	O
positive	O
airway	O
pressure	O
(	O
BIPAP	O
),	O
moderate	O
inspiratory	B-PROC
assist	O
was	O
provided	O
by	O
pressure	O
support	O
(	O
PS	O
)	O
and	O
volume	O
-	O
assured	O
pressure	O
support	O
(	O
VAPS	O
),	O
maximum	O
assist	O
was	O
ensured	O
by	O
assist	O
control	O
(	O
A	O
/	O
C	O
).	O

This	O
study	O
aimed	O
to	O
quantify	O
the	O
variation	O
in	O
individual	O
test	O
-	O
day	O
milk	O
yield	O
and	O
somatic	O
cell	O
count	O
,	O
risk	O
of	O
reproductive	B-PROC
failure	O
after	O
first	O
service	O
of	O
dairy	O
cows	O
,	O
and	O
risk	O
of	O
death	B-PROC
of	O
calves	O
and	O
heifers	O
according	O
to	O
the	O
BCV	O
and	O
BRSV	O
status	O
of	O
the	O
herd	O
.	O

RESULTS	O
:	O
In	O
85	O
BAL	O
samples	O
from	O
82	O
patients	O
,	O
median	O
viral	O
loads	O
were	O
as	O
follows	O
:	O
for	O
RSV	O
(	O
n	O
=	O
35	O
),	O
2	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
copies	O
/	O
mL	O
;	O
for	O
parainfluenza	O
virus	O
(	O
n	O
=	O
35	O
),	O
4	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
mL	O
;	O
for	O
influenza	O
virus	O
(	O
n	O
=	O
9	O
),	O
6	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
copies	O
/	O
mL	O
;	O
for	O
MPV	O
(	O
n	O
=	O
7	O
),	O
3	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
mL	O
;	O
and	O
for	O
CoV	O
(	O
n	O
=	O
4	O
),	O
1	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
copies	O
/	O
mL	O
.	O
Quantitative	O
viral	O
load	O
was	O
not	O
associated	O
with	O
mechanical	O
ventilation	O
or	O
death	B-PROC
.	O

ABSTRACT	O
:	O
To	O
verify	O
if	O
secretory	B-PROC
phospholipase	O
A2	O
(	O
sPLA2	O
)	O
is	O
increased	O
in	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
triggered	O
or	O
not	O
by	O
respiratory	O
syncytial	O
virus	B-PROC
infection	I-PROC
and	O
to	O
clarify	O
how	O
the	O
enzyme	O
may	O
influence	O
the	O
disease	O
severity	O
and	O
the	O
degree	O
of	O
ventilatory	O
support	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
an	O
invasively	O
monitored	O
porcine	O
model	O
of	O
acetaminophen	O
-	O
induced	O
acute	O
liver	O
failure	O
.	O

Liver	O
histology	O
revealed	O
evidence	O
of	O
severe	O
centrilobular	O
necrosis	B-PROC
with	O
coagulative	O
necrosis	B-PROC
.	O

Curiously	O
,	O
we	O
observed	O
no	O
block	O
in	O
the	O
well	O
-	O
defined	O
IFN	O
-	O
beta	O
signaling	B-PROC
pathway	I-PROC
that	O
leads	O
to	O
STAT1	O
-	O
STAT2	O
phosphorylation	B-PROC
and	O
translocation	B-PROC
to	O
the	O
nucleus	O
in	O
cultures	O
infected	O
with	O
MHV	O
.	O

Transcription	B-PROC
from	O
an	O
IRF	O
-	O
3	O
-	O
responsive	O
promoter	O
was	O
partially	O
inhibited	O
by	O
MHV	O
;	O
however	O
,	O
IRF	O
-	O
3	O
was	O
transported	O
to	O
the	O
nucleus	O
and	O
bound	O
DNA	O
in	O
MHV	O
-	O
infected	O
cells	O
superinfected	O
with	O
SeV	O
.	O

Sympathetic	O
vasoconstriction	B-PROC
of	O
the	O
systemic	O
and	O
pulmonary	O
resistance	B-PROC
and	O
capacitance	O
vessels	O
caused	O
shift	O
of	O
blood	O
volume	O
from	O
the	O
splanchnic	O
vascular	O
beds	O
to	O
the	O
lung	O
.	O

The	O
hemodynamic	B-PROC
changes	O
led	O
to	O
systemic	O
and	O
pulmonary	O
hypertension	O
.	O

These	O
changes	O
finally	O
produced	O
severe	O
alveolar	O
flooding	O
and	O
sudden	O
death	B-PROC
.	O

The	O
28	O
-	O
day	O
mortality	O
was	O
33	O
.	O
3	O
%	O
(	O
6	O
/	O
18	O
)	O
with	O
1	O
additional	O
late	O
death	B-PROC
.	O

All	O
patients	O
were	O
mechanically	O
ventilated	O
,	O
1	O
patient	O
underwent	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

Failure	O
to	O
obtain	O
satisfactory	O
oxygenation	B-PROC
with	O
high	O
-	O
level	O
ventilation	O
settings	O
within	O
the	O
first	O
7	O
-	O
days	O
,	O
onset	O
of	O
acute	O
kidney	O
injury	O
and	O
barotrauma	O
,	O
and	O
continuous	O
need	O
for	O
vasopressors	O
portend	O
a	O
poor	O
prognosis	O
.	O

Fifty	O
-	O
three	O
patients	O
were	O
complicated	O
with	O
pneumonia	O
(	O
70	O
.	O
67	O
%)	O
and	O
41	O
patients	O
with	O
pre	O
-	O
existing	O
medical	O
conditions	O
(	O
54	O
.	O
67	O
%),	O
65	O
patients	O
with	O
fever	B-PROC
(	O
86	O
.	O
67	O
%),	O
63	O
patients	O
with	O
cough	O
and	O
sputum	O
(	O
84	O
.	O
00	O
%),	O
61	O
patients	O
with	O
dyspnea	O
(	O
81	O
.	O
33	O
%),	O
1	O
patients	O
with	O
meningitis	O
as	O
the	O
main	O
manifestation	O
,	O
2	O
patients	O
with	O
acute	O
pulmonary	O
edema	O
and	O
left	O
heart	O
failure	O
,	O
28	O
patients	O
with	O
leucopenia	O
(	O
37	O
.	O
33	O
%),	O
28	O
patients	O
with	O
myocardial	O
enzyme	O
abnormalities	O
(	O
37	O
.	O
33	O
%),	O
23	O
patients	O
with	O
blood	O
glucose	O
abnormalities	O
(	O
30	O
.	O
67	O
%),	O
8	O
patients	O
with	O
coagulopathy	O
(	O
10	O
.	O
67	O
%),	O
4	O
patients	O
with	O
lipid	O
abnormalities	O
(	O
5	O
.	O
33	O
%),	O
51	O
patients	O
with	O
increased	O
C	O
-	O
reactive	O
protein	O
(	O
68	O
.	O
00	O
%).	O

Except	O
1	O
patient	O
out	O
of	O
75	O
patients	O
died	B-PROC
,	O
and	O
the	O
rest	O
were	O
cured	O
.	O

TITLE	O
:	O
Pathogenesis	B-PROC
of	O
murine	O
coronavirus	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
child	O
was	O
discharged	O
after	O
72	O
days	O
with	O
moderate	O
renal	B-PROC
function	I-PROC
impairment	O
(	O
blood	O
urea	O
-	O
53	O
mg	O
%,	O
creatinine	O
-	O
1	O
,	O
2	O
mg	O
%),	O
mild	O
hypertension	O
and	O
proteinuria	O
.	O

The	O
present	O
review	O
highlights	O
the	O
drug	O
design	O
approaches	O
utilized	O
to	O
understand	O
the	O
mechanism	O
of	O
inhibition	B-PROC
and	O
discovery	O
of	O
inhibitors	O
against	O
protozoal	O
cysteine	O
protease	O
,	O
falcipain	O
(	O
a	O
cysteine	O
protease	O
of	O
P	O
.	O
falciparum	O
which	O
causes	O
malaria	O
),	O
and	O
viral	O
cysteine	O
protease	O
,	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
(	O
a	O
cysteine	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
corona	O
virus	O
).	O

The	O
article	O
describes	O
rational	O
approaches	O
for	O
the	O
design	O
of	O
inhibitors	O
and	O
focuses	O
on	O
a	O
variety	O
of	O
structure	O
as	O
well	O
as	O
ligand	B-PROC
-	O
based	O
modeling	O
strategies	O
adopted	O
for	O
the	O
discovery	O
of	O
the	O
inhibitors	O
.	O

The	O
current	O
review	O
would	O
be	O
of	O
interest	O
to	O
scientists	O
engaged	O
in	O
the	O
development	B-PROC
of	O
drug	O
design	O
strategies	O
to	O
target	O
the	O
cysteine	O
proteases	O
present	O
in	O
mammals	O
and	O
other	O
lower	O
order	O
organisms	O
.	O

TITLE	O
:	O
A	O
219	O
-	O
mer	O
CHO	O
-	O
expressing	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
induces	O
potent	O
immune	B-PROC
responses	I-PROC
and	O
protective	O
immunity	B-PROC
.	O

ABSTRACT	O
:	O
Death	B-PROC
to	O
trauma	O
is	O
caused	O
by	O
disastrous	O
injuries	O
on	O
scene	O
,	O
bleeding	O
shock	O
or	O
acute	O
respiratory	O
failure	O
(	O
ARDS	O
)	O
induced	O
by	O
trauma	O
and	O
massive	O
blood	O
transfusion	O
.	O

We	O
report	O
our	O
first	O
experiences	O
in	O
application	O
of	O
initially	O
heparin	O
-	O
free	O
ECMO	O
in	O
severe	O
trauma	O
patients	O
with	O
resistant	O
cardiopulmonary	O
failure	O
and	O
coexisting	O
bleeding	O
shock	O
retrospectively	O
and	O
describe	O
blood	B-PROC
coagulation	I-PROC
management	O
on	O
ECMO	O
.	O

RESULTS	O
:	O
Prior	O
to	O
ECMO	O
median	O
oxygenation	B-PROC
ratio	O
(	O
OR	O
)	O
was	O
47	O
(	O
36	O
-	O
90	O
)	O
mmHg	O
,	O
median	O
paCO	O
(	O
2	O
)	O
was	O
67	O
(	O
36	O
-	O
89	O
)	O
mmHg	O
and	O
median	O
norepinephrine	O
demand	O
was	O
3	O
.	O
0	O
(	O
1	O
.	O
0	O
-	O
13	O
.	O
5	O
)	O
mg	O
/	O
h	O
.	O

In	O
contrast	O
to	O
most	O
models	O
of	O
viral	O
pathogenesis	B-PROC
,	O
infection	O
of	O
type	O
I	O
,	O
type	O
II	O
or	O
type	O
III	O
interferon	O
knockout	O
mice	O
(	O
129	O
background	O
)	O
with	O
either	O
Urbani	O
or	O
MA15	O
viruses	O
resulted	O
in	O
clinical	O
disease	O
outcomes	O
,	O
including	O
transient	O
weight	O
loss	O
,	O
denuding	O
bronchiolitis	O
and	O
alveolar	O
inflammation	O
and	O
recovery	O
,	O
identical	O
to	O
that	O
seen	O
in	O
infection	O
of	O
wildtype	O
mice	O
.	O

We	O
diagnosed	O
pulmonary	O
tuberculosis	O
complicated	O
with	O
septic	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
based	O
on	O
his	O
clinical	O
course	O
and	O
laboratory	O
data	O
.	O

The	O
5	O
-	O
fluoro	O
derivative	O
inhibited	O
the	O
HCV	O
RNA	B-PROC
synthesis	I-PROC
at	O
6	O
mug	O
/	O
ml	O
,	O
without	O
toxicity	O
at	O
a	O
concentration	O
up	O
to	O
42	O
mug	O
/	O
ml	O
in	O
Huh	O
5	O
-	O
2	O
cells	O
.	O

Similar	O
to	O
SPF	O
egg	O
layers	O
,	O
the	O
mean	O
daily	O
egg	O
production	O
per	O
hen	O
was	O
significantly	O
reduced	O
by	O
the	O
M	O
.	O
synoviae	O
EAA	O
strain	O
and	O
there	O
was	O
a	O
general	O
negative	O
effect	O
on	O
eggshell	O
strength	O
by	O
this	O
strain	O
,	O
suggesting	O
it	O
could	O
also	O
have	O
a	O
detrimental	O
effect	O
on	O
hatching	B-PROC
egg	O
quality	O
.	O

In	O
contrast	O
,	O
the	O
Ser	O
(	O
32	O
)	O
amino	O
acid	O
substitution	O
totally	O
abolished	O
enzymatic	B-PROC
activity	I-PROC
while	O
receptor	O
binding	O
increased	O
,	O
as	O
observed	O
by	O
agglutination	B-PROC
of	O
Atlantic	O
salmon	O
red	O
blood	O
cells	O
.	O

TITLE	O
:	O
A	O
multiplex	O
reverse	O
transcriptase	B-PROC
-	O
PCR	O
assay	O
for	O
the	O
genotyping	O
of	O
avian	O
infectious	O
bronchitis	O
viruses	O
.	O

TITLE	O
:	O
Role	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
receptor	O
murine	O
CEACAM1	O
in	O
the	O
resistance	B-PROC
of	O
mice	O
to	O
MHV	O
infection	O
:	O
studies	O
of	O
mice	O
with	O
chimeric	O
mCEACAM1a	O
and	O
mCEACAM1b	O
.	O

Unexpectedly	O
,	O
cB61ba	O
mice	O
were	O
more	O
resistant	O
to	O
MHV	O
-	O
A59	O
infection	O
than	O
SJL	O
mice	O
as	O
measured	O
by	O
virus	B-PROC
replication	I-PROC
in	O
target	O
organs	O
,	O
including	O
liver	O
and	O
brain	O
.	O

TITLE	O
:	O
Activating	O
transcription	B-PROC
factor	O
3	O
confers	O
protection	O
against	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

ATF3	O
protein	B-PROC
expression	B-PROC
and	O
nuclear	B-PROC
translocation	B-PROC
is	O
increased	O
in	O
the	O
lung	O
after	O
mechanical	O
ventilation	O
in	O
wild	O
-	O
type	O
mice	O
.	O

TITLE	O
:	O
Rapid	O
differentiation	B-PROC
of	O
vaccine	O
strain	O
and	O
Chinese	O
field	O
strains	O
of	O
transmissible	O
gastroenteritis	O
virus	O
by	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
of	O
the	O
N	O
gene	O
.	O

The	O
suitability	O
of	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
(	O
RFLP	O
)	O
analysis	O
for	O
differentiation	B-PROC
of	O
the	O
vaccine	O
strain	O
from	O
the	O
other	O
TGEVs	O
was	O
investigated	O
.	O

The	O
RFLP	O
analysis	O
identified	O
a	O
change	O
in	O
the	O
cleavage	B-PROC
sites	O
of	O
AclI	O
at	O
passages	O
155	O
and	O
165	O
.	O

Articles	O
for	O
review	O
were	O
selected	O
based	O
on	O
the	O
following	O
criteria	O
:	O
(	O
i	O
)	O
prospective	O
or	O
cross	O
-	O
sectional	O
study	O
,	O
(	O
ii	O
)	O
original	O
research	O
,	O
(	O
iii	O
)	O
viral	O
detection	O
used	O
the	O
highly	O
sensitive	O
techniques	O
of	O
PCR	O
and	O
/	O
or	O
Reverse	O
Transcriptase	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
(	O
iv	O
)	O
viral	O
prevalence	O
in	O
AECOPD	O
defined	O
,	O
and	O
(	O
v	O
)	O
full	O
paper	O
available	O
in	O
English	O
.	O

TITLE	O
:	O
Mutation	O
of	O
Asn28	O
disrupts	O
the	O
dimerization	O
and	O
enzymatic	B-PROC
activity	I-PROC
of	O
SARS	O
3CL	O
(	O
pro	O
)	O
.	O

However	O
,	O
knockdown	O
of	O
RIG	O
-	O
I	O
only	O
partially	O
blocked	O
NF	O
-	O
kappaB	O
activity	O
induced	O
by	O
MHV	O
infection	O
and	O
inhibition	B-PROC
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
a	O
decoy	O
peptide	O
inhibitor	O
had	O
little	O
effect	O
on	O
IFN	O
-	O
alpha	O
/	O
beta	O
production	O
.	O

In	O
a	O
case	O
of	O
severe	O
AKI	O
and	O
multi	O
-	O
organ	O
failure	O
from	O
whom	O
histological	O
material	O
was	O
obtained	O
,	O
the	O
renal	O
histopathological	O
findings	O
were	O
typical	O
of	O
acute	O
tubular	O
necrosis	B-PROC
.	O

Examples	O
of	O
these	O
emerging	O
zoonotic	O
diseases	O
are	O
highly	O
pathogenic	O
avian	O
influenza	O
,	O
bovine	O
spongiform	O
encephalopathy	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Patients	O
with	O
influenza	O
A	O
pH1N1	O
respiratory	O
virus	B-PROC
infection	I-PROC
presented	O
with	O
more	O
severe	O
illness	O
.	O

Reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
14	O
respiratory	O
viruses	O
was	O
performed	O
on	O
nasopharyngeal	O
swabs	O
collected	O
at	O
admission	O
and	O
after	O
recovery	O
in	O
stable	O
condition	O
.	O

TITLE	O
:	O
Rationale	O
and	O
use	O
of	O
n	O
-	O
3	O
fatty	O
acids	O
in	O
artificial	O
nutrition	B-PROC
.	O

These	O
fatty	O
acids	O
influence	O
inflammatory	O
and	O
immune	B-PROC
responses	I-PROC
and	O
so	O
may	O
be	O
useful	O
in	O
particular	O
situations	O
where	O
those	O
responses	O
are	O
not	O
optimal	O
.	O

TITLE	O
:	O
Use	O
of	O
therapeutic	O
plasma	O
exchange	O
as	O
a	O
rescue	O
therapy	O
in	O
2009	O
pH1N1	O
influenza	O
A	O
--	O
an	O
associated	O
respiratory	O
failure	O
and	O
hemodynamic	B-PROC
shock	O
.	O

Nine	O
patients	O
presented	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
one	O
patient	O
died	B-PROC
.	O

ABSTRACT	O
:	O
Myxovirus	O
resistance	B-PROC
A	O
(	O
MxA	O
)	O
is	O
an	O
antiviral	O
protein	O
induced	O
by	O
interferon	O
alpha	O
and	O
beta	O
(	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
beta	O
)	O
that	O
can	O
inhibit	O
viral	B-PROC
replication	I-PROC
.	O

The	O
minor	O
alleles	O
of	O
the	O
-	O
88G	O
>	O
T	O
and	O
-	O
123C	O
>	O
A	O
MxA	O
promoter	O
single	O
-	O
nucleotide	O
polymorphisms	B-PROC
(	O
SNPs	O
)	O
are	O
associated	O
with	O
increased	O
promoter	O
activity	O
and	O
altered	O
response	O
to	O
IFN	O
-	O
alpha	O
and	O
IFN	O
-	O
beta	O
treatment	O
.	O

ABSTRACT	O
:	O
Tumour	O
necrosis	B-PROC
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
many	O
inflammatory	O
conditions	O
.	O

Initially	O
,	O
the	O
availability	O
in	O
the	O
lungs	O
and	O
circulation	B-PROC
,	O
and	O
possible	O
clinical	O
and	O
inflammatory	O
effects	O
of	O
etanercept	O
alone	O
were	O
assessed	O
in	O
4	O
pigs	O
after	O
intratracheal	O
and	O
intraperitoneal	O
administration	O
of	O
0	O
.	O
5mg	O
/	O
per	O
route	O
/	O
per	O
pig	O
.	O

A	O
transient	O
kinetic	O
analysis	O
using	O
a	O
single	O
-	O
step	O
competitive	B-PROC
inhibition	I-PROC
model	O
provided	O
rate	O
constants	O
of	O
k	O
(	O
on	O
)	O
=	O
153	O
,	O
000	O
M	O
(-	O
1	O
)	O
s	O
(-	O
1	O
)	O
and	O
k	O
(	O
off	O
)	O
=	O
4	O
.	O
40	O
x	O
10	O
(-	O
5	O
)	O
s	O
(-	O
1	O
)	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
29	O
nM	O
).	O

A	O
34	O
-	O
year	O
old	O
woman	O
consulted	O
our	O
hospital	O
complaining	O
of	O
vomiting	O
,	O
diarrhea	O
and	O
fever	B-PROC
that	O
developed	O
early	O
in	O
the	O
morning	O
.	O

Thus	O
,	O
the	O
TSL	O
-	O
1	O
-	O
induced	O
apoptosis	B-PROC
was	O
further	O
confirmed	O
by	O
cell	O
morphology	O
,	O
subG1	O
peak	O
accumulation	O
,	O
poly	O
(	O
adenosine	O
diphosphate	O
[	O
ADP	O
]-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
cleavage	B-PROC
,	O
propidium	O
iodide	O
(	O
PI	O
)-	O
Annexin	O
-	O
V	O
double	O
staining	O
,	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
-	O
labeling	O
(	O
TUNEL	O
)	O
assay	O
.	O

ABSTRACT	O
:	O
Alveolar	O
hypoxia	O
and	O
hypoxic	O
vasoconstriction	B-PROC
lead	O
to	O
trapping	O
of	O
sickle	O
cells	O
within	O
the	O
pulmonary	O
vasculature	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
major	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
It	O
is	O
not	O
clear	O
whether	O
ACE2	O
conveys	O
signals	O
from	O
the	O
cell	O
surface	O
to	O
the	O
nucleus	O
and	O
regulates	O
expression	B-PROC
of	O
cellular	O
genes	O
upon	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
upregulation	B-PROC
of	O
CCL2	O
by	O
SARS	O
-	O
CoV	O
spike	O
protein	O
was	O
mainly	O
mediated	O
by	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
and	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
and	O
AP	O
-	O
1	O
but	O
not	O
the	O
IkappaBalpha	O
-	O
NF	O
-	O
kappaB	O
signaling	B-PROC
pathway	I-PROC
.	O

Rather	O
,	O
inhibition	B-PROC
of	O
the	O
proteasome	B-PROC
caused	O
enhanced	O
infection	O
with	O
lethal	O
outcome	O
,	O
calling	O
for	O
caution	O
when	O
using	O
this	O
type	O
of	O
drug	O
during	O
infection	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
dose	O
-	O
response	O
model	O
for	O
SARS	O
coronavirus	O
.	O

Among	O
multiple	O
acute	O
symptoms	O
we	O
observed	O
high	B-PROC
temperature	I-PROC
,	O
cough	O
,	O
myalgia	O
and	O
neurological	O
manifestations	O
,	O
very	O
frequent	O
.	O

One	O
patient	O
died	B-PROC
due	O
to	O
ARDS	O
and	O
encephalitis	O
.	O

ABSTRACT	O
:	O
Proteolytic	B-PROC
priming	O
is	O
a	O
common	O
method	O
of	O
controlling	O
the	O
activation	O
of	O
membrane	B-PROC
fusion	I-PROC
mediated	O
by	O
viral	O
glycoproteins	O
.	O

TITLE	O
:	O
Patients	O
with	O
acute	O
pancreatitis	O
complicated	O
by	O
organ	O
failure	O
show	O
highly	O
aberrant	O
monocyte	O
signaling	B-PROC
profiles	O
assessed	O
by	O
phospho	O
-	O
specific	O
flow	O
cytometry	O
.	O

IBV	O
encodes	O
15	O
nonstructural	O
proteins	O
(	O
nsp2	O
-	O
nsp16	O
)	O
which	O
play	O
crucial	O
roles	O
in	O
RNA	O
transcription	B-PROC
and	O
genome	O
replication	O
.	O

Conversely	O
,	O
insertion	O
of	O
gene	O
5a	O
,	O
or	O
its	O
homologs	O
from	O
related	O
group	O
2	O
coronaviruses	O
,	O
at	O
an	O
upstream	O
genomic	O
position	O
in	O
an	O
MHV	O
-	O
A59	O
/	O
S	O
chimera	O
restored	O
IFN	O
resistance	B-PROC
.	O

RESULTS	O
:	O
Apart	O
from	O
the	O
virus	O
-	O
encoded	O
structural	O
proteins	O
,	O
we	O
detected	O
60	O
host	O
proteins	O
in	O
the	O
purified	O
virions	O
which	O
can	O
be	O
grouped	O
into	O
several	O
functional	O
categories	O
including	O
intracellular	O
trafficking	B-PROC
proteins	O
(	O
20	O
%),	O
molecular	O
chaperone	O
(	O
18	O
%),	O
macromolcular	O
biosynthesis	B-PROC
proteins	O
(	O
17	O
%),	O
cytoskeletal	O
proteins	O
(	O
15	O
%),	O
signal	O
transport	B-PROC
proteins	O
(	O
15	O
%),	O
protein	B-PROC
degradation	I-PROC
(	O
8	O
%),	O
chromosome	O
associated	O
proteins	O
(	O
2	O
%),	O
ribosomal	O
proteins	O
(	O
2	O
%),	O
and	O
other	O
function	O
proteins	O
(	O
3	O
%).	O

TITLE	O
:	O
Amiodarone	O
:	O
review	O
of	O
pulmonary	B-PROC
effects	I-PROC
and	O
toxicity	O
.	O

Multiple	O
organ	O
failure	O
and	O
sepsis	O
developed	O
in	O
eight	O
patients	O
,	O
but	O
no	O
patients	O
died	B-PROC
.	O

ABSTRACT	O
:	O
CD200	O
,	O
a	O
type	O
I	O
membrane	O
glycoprotein	O
,	O
plays	O
an	O
important	O
role	O
in	O
prevention	O
of	O
inflammatory	O
disorders	O
,	O
graft	B-PROC
rejection	I-PROC
,	O
autoimmune	O
diseases	O
and	O
spontaneous	O
fetal	O
loss	O
.	O

Future	O
trials	O
targeting	B-PROC
pulmonary	O
vascular	O
dysfunction	O
may	O
be	O
indicated	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
is	O
a	O
report	O
of	O
the	O
effectiveness	O
of	O
a	O
purpose	O
-	O
designed	O
education	O
program	O
in	O
improving	O
undergraduate	O
nursing	B-PROC
students	O
'	O
understanding	O
and	O
practice	O
of	O
infection	O
control	O
precautions	O
.	O

A	O
total	O
of	O
175	O
preservice	O
nursing	B-PROC
students	O
participated	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
175	O
preservice	O
nursing	B-PROC
students	O
participated	O
in	O
the	O
study	O
.	O

It	O
was	O
concluded	O
that	O
novel	O
IBVs	O
,	O
which	O
have	O
not	O
been	O
detected	O
since	O
1993	O
,	O
and	O
which	O
are	O
phylogenically	O
more	O
distant	O
from	O
classical	O
IBVs	O
than	O
turkey	O
coronaviruses	O
,	O
might	O
still	O
be	O
circulating	O
and	O
contributing	O
to	O
the	O
evolution	B-PROC
of	O
IBV	O
in	O
Australia	O
.	O

In	O
all	O
domestic	O
cats	O
of	O
different	O
breeds	B-PROC
:	O
female	O
Abyssinian	O
,	O
female	O
American	O
shorthair	O
,	O
male	O
Cornish	O
Rex	O
,	O
female	O
European	O
Burmese	O
,	O
female	O
Persian	O
,	O
female	O
Siamese	O
,	O
a	O
male	O
Ragdoll	O
and	O
a	O
female	O
African	O
wildcat	O
were	O
sequenced	O
lightly	O
.	O

Surprisingly	O
,	O
however	O
,	O
palmitoylation	B-PROC
of	O
S	O
was	O
not	O
required	O
for	O
interaction	O
with	O
SARS	O
-	O
CoV	O
M	O
protein	O
.	O

To	O
determine	O
role	O
of	O
the	O
combination	O
of	O
Systemic	O
Inflammatory	B-PROC
Response	I-PROC
Syndrome	O
(	O
SIRS	O
)	O
score	O
and	O
serum	O
Interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
level	O
on	O
admission	O
as	O
predictor	O
of	O
illness	O
severity	O
and	O
outcome	O
of	O
Severe	O
Acute	O
Pancreatitis	O
(	O
SAP	O
).	O

A	O
total	O
of	O
77	O
(	O
33	O
%)	O
patients	O
died	B-PROC
.	O

However	O
,	O
the	O
production	O
of	O
tumour	O
necrosis	B-PROC
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
12	O
was	O
increased	O
significantly	O
in	O
MHV	O
-	O
3	O
-	O
induced	O
macrophages	O
treated	O
with	O
telbivudine	O
.	O

If	O
the	O
political	O
will	O
for	O
data	O
sharing	O
remains	O
strong	O
,	O
the	O
frontier	O
for	O
progress	O
in	O
emerging	O
infectious	O
diseases	O
will	O
be	O
in	O
analysis	O
of	O
sequence	O
data	O
and	O
translation	B-PROC
of	O
results	O
into	O
better	O
public	O
health	O
science	O
and	O
policy	O
.	O

The	O
severity	O
of	O
acute	O
lung	O
injury	O
was	O
determined	O
by	O
histology	O
,	O
morphometric	O
analysis	O
and	O
invasive	O
pulmonary	B-PROC
function	I-PROC
testing	O
.	O

Special	O
attention	O
has	O
been	O
provided	O
to	O
the	O
use	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
as	O
vector	O
for	O
the	O
expression	B-PROC
of	O
PRRSV	O
antigens	O
.	O

None	O
of	O
the	O
women	O
had	O
the	O
birth	B-PROC
experience	O
they	O
had	O
hoped	O
for	O
because	O
of	O
changes	O
in	O
hospital	O
practices	O
.	O

These	O
results	O
indicate	O
for	O
the	O
first	O
time	O
that	O
IBV	O
undergoes	O
intraspatial	O
variation	O
during	O
host	B-PROC
invasion	I-PROC
,	O
i	O
.	O
e	O
.,	O
the	O
dominant	O
genotype	O
/	O
phenotype	O
further	O
changes	O
during	O
host	B-PROC
invasion	I-PROC
as	O
the	O
microenvironment	O
of	O
distinct	O
tissues	O
exerts	B-PROC
selective	O
pressure	O
on	O
the	O
replicating	O
virus	O
population	O
.	O

ABSTRACT	O
:	O
The	O
nsp1	O
protein	O
of	O
the	O
highly	O
pathogenic	O
SARS	O
coronavirus	O
suppresses	O
host	O
protein	B-PROC
synthesis	I-PROC
,	O
including	O
genes	O
involved	O
in	O
the	O
innate	O
immune	O
system	O
.	O

However	O
,	O
synthesis	B-PROC
of	O
host	O
immune	O
and	O
non	O
-	O
immune	O
proteins	O
was	O
inhibited	O
by	O
nsp1	O
proteins	O
at	O
both	O
transcriptional	B-PROC
and	O
translational	B-PROC
levels	O
,	O
similar	O
to	O
SARS	O
coronavirus	O
nsp1	O
.	O

ABSTRACT	O
:	O
A	O
dysregulated	O
innate	B-PROC
immune	I-PROC
response	I-PROC
and	O
exuberant	O
cytokine	O
/	O
chemokine	O
expression	B-PROC
are	O
believed	O
to	O
be	O
critical	O
factors	O
in	O
the	O
pathogenesis	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
caused	O
by	O
a	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Here	O
,	O
we	O
extend	O
these	O
results	O
to	O
show	O
that	O
virus	O
-	O
specific	O
T	O
cells	O
,	O
in	O
the	O
absence	O
of	O
activation	O
of	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
,	O
were	O
sufficient	O
to	O
significantly	O
enhance	O
survival	O
and	O
diminish	O
clinical	O
disease	O
.	O

No	O
consistent	O
antigenic	O
or	O
genetic	B-PROC
markers	I-PROC
have	O
been	O
identified	O
to	O
discriminate	O
BCoVs	O
from	O
the	O
different	O
clinical	O
syndromes	O
.	O

The	O
way	O
in	O
which	O
these	O
agents	O
could	O
be	O
used	O
favours	O
the	O
development	B-PROC
of	O
generic	O
countermeasures	O
.	O

To	O
this	O
end	O
,	O
keratinocyte	O
growth	B-PROC
factor	O
(	O
KGF	O
),	O
epithelial	O
growth	B-PROC
factor	O
(	O
EGF	O
)	O
and	O
basic	O
fibroblast	O
growth	B-PROC
factor	O
(	O
bFGF	O
)	O
are	O
emerging	O
as	O
the	O
most	O
important	O
candidates	O
.	O

ABSTRACT	O
:	O
Young	O
adults	O
,	O
especially	O
pregnant	O
woman	O
and	O
patients	O
with	O
pre	O
-	O
existing	O
medical	O
conditions	O
,	O
appear	O
to	O
be	O
at	O
risk	O
for	O
the	O
development	B-PROC
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
from	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
,	O
leading	O
to	O
critical	O
hypoxemia	O
.	O

These	O
strains	O
also	O
exhibited	O
resistance	B-PROC
to	O
most	O
of	O
the	O
antibiotics	O
analyzed	O
.	O

The	O
inhibition	B-PROC
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
and	O
enteric	O
bacterial	O
pathogens	O
as	O
well	O
as	O
the	O
bile	O
tolerance	B-PROC
,	O
high	O
survival	O
in	O
gastric	O
juice	O
,	O
and	O
the	O
antibiotic	O
resistance	B-PROC
indicate	O
that	O
the	O
two	O
isolated	O
bacterial	O
strains	O
are	O
ideal	O
probiotic	O
candidates	O
for	O
animal	O
application	O
after	O
proper	O
in	O
vivo	O
experiments	O
.	O

Therefore	O
,	O
the	O
MHV	O
model	O
of	O
demyelination	O
is	O
a	O
relevant	O
model	O
for	O
studying	O
disease	O
and	O
evaluating	O
therapeutic	O
approaches	O
to	O
protect	O
cells	O
of	O
the	O
oligodendrocyte	O
lineage	O
and	O
promote	O
remyelination	B-PROC
.	O

The	O
prevalence	O
,	O
clinical	O
predictors	O
and	O
inflammatory	O
mediator	O
profile	O
of	O
respiratory	O
viral	B-PROC
infection	I-PROC
in	O
serious	O
acute	O
respiratory	O
illness	O
were	O
investigated	O
.	O

IP	O
-	O
10	O
may	O
be	O
a	O
useful	O
biomarker	O
for	O
respiratory	O
viral	B-PROC
infection	I-PROC
.	O

The	O
viral	O
7a	O
accessory	O
protein	O
suppressed	O
both	O
transgene	O
and	O
virus	B-PROC
-	I-PROC
induced	I-PROC
gene	I-PROC
silencing	I-PROC
by	O
reducing	O
the	O
levels	O
of	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
).	O

In	O
19	O
of	O
the	O
37	O
patients	O
,	O
weaning	B-PROC
and	O
extubation	O
became	O
possible	O
within	O
the	O
first	O
24	O
hours	O
.	O

We	O
found	O
that	O
strain	O
ZJ971	O
is	O
probably	O
a	O
virulence	B-PROC
revertant	O
of	O
H120	O
.	O

37	O
.	O
3	O
mmHg	O
,	O
with	O
a	O
mean	O
positive	O
end	O
expiratory	B-PROC
pressure	O
at	O
16	O
.	O
1	O
+/-	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
plays	O
an	O
essential	O
role	O
in	O
virion	B-PROC
assembly	I-PROC
via	O
interactions	O
with	O
the	O
large	O
,	O
positive	O
-	O
strand	O
RNA	O
viral	O
genome	O
and	O
the	O
carboxy	O
-	O
terminal	O
endodomain	O
of	O
the	O
membrane	O
protein	O
(	O
M	O
).	O

Our	O
results	O
suggest	O
a	O
role	O
for	O
this	O
previously	O
unknown	O
N	O
-	O
nsp3	O
interaction	O
in	O
the	O
localization	B-PROC
of	O
genomic	O
RNA	O
to	O
the	O
replicase	O
complex	O
at	O
an	O
early	O
stage	O
of	O
infection	O
.	O

TITLE	O
:	O
Perceptions	O
and	O
behaviors	B-PROC
related	O
to	O
hand	O
hygiene	O
for	O
the	O
prevention	O
of	O
H1N1	O
influenza	O
transmission	O
among	O
Korean	O
university	O
students	O
during	O
the	O
peak	O
pandemic	O
period	O
.	O

It	O
also	O
looks	O
at	O
animal	O
susceptibility	O
after	O
experimental	O
infection	O
,	O
animal	O
models	O
of	O
SARS	O
,	O
and	O
the	O
pathogenesis	B-PROC
of	O
this	O
disease	O
.	O

These	O
results	O
identify	O
a	O
new	O
cistron	O
in	O
the	O
MHV	O
replicase	O
gene	O
locus	O
and	O
show	O
that	O
nsp3	O
has	O
an	O
essential	O
role	O
in	O
the	O
assembly	O
of	O
a	O
functional	O
MHV	O
replication	O
-	O
transcription	B-PROC
complex	O
.	O

Like	O
its	O
PL2	O
(	O
pro	O
)	O
paralogs	O
from	O
several	O
coronaviruses	O
,	O
TGEV	O
PL1	O
(	O
pro	O
)	O
was	O
also	O
found	O
to	O
have	O
deubiquitinating	B-PROC
activity	O
in	O
an	O
in	O
vitro	O
cleavage	B-PROC
assay	O
,	O
implicating	O
it	O
in	O
counteracting	O
ubiquitin	B-PROC
-	O
regulated	O
host	O
cell	O
pathways	B-PROC
,	O
likely	O
including	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

TITLE	O
:	O
Quantification	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
in	O
the	O
serum	O
of	O
patients	O
with	O
obstructive	O
sleep	B-PROC
apnea	O
-	O
hypopnea	O
syndrome	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
serum	O
DNA	O
concentrations	O
were	O
elevated	O
in	O
patients	O
with	O
obstructive	O
sleep	B-PROC
apnea	O
-	O
hypopnea	O
syndrome	O
(	O
OSAHS	O
).	O

In	O
addition	O
,	O
enhanced	O
DNA	B-PROC
unwinding	I-PROC
was	O
observed	O
for	O
gapped	O
DNA	O
substrates	O
that	O
had	O
a	O
5	O
'-	O
overhang	O
,	O
indicating	O
that	O
the	O
translocated	O
nsP13	O
molecules	O
pile	O
up	O
and	O
the	O
preceding	O
helicase	O
facilitate	O
DNA	B-PROC
unwinding	I-PROC
.	O

This	O
article	O
addresses	O
the	O
clinical	O
signs	O
,	O
pathology	O
,	O
pathogenesis	B-PROC
,	O
diagnosis	O
,	O
treatment	O
,	O
and	O
prevention	O
of	O
this	O
ferret	O
FIP	O
-	O
like	O
disease	O
.	O

TITLE	O
:	O
Loop	O
-	O
mediated	O
isothermal	O
amplification	O
for	O
rapid	O
detection	O
and	O
differentiation	B-PROC
of	O
wild	O
-	O
type	O
pseudorabies	O
and	O
gene	O
-	O
deleted	O
virus	O
vaccines	O
.	O

RESULTS	O
:	O
A	O
2	O
(	O
1	O
/	O
2	O
)-	O
year	O
-	O
old	O
girl	O
cold	B-PROC
-	O
water	O
drowning	O
victim	O
with	O
severe	O
,	O
intractable	O
hypoxemia	O
after	O
submersion	O
time	O
of	O
approximately	O
15	O
minutes	O
and	O
arrest	O
time	O
of	O
approximately	O
45	O
minutes	O
was	O
given	O
80	O
mL	O
/	O
m	O
of	O
calfactant	O
endotracheally	O
with	O
reversal	O
of	O
her	O
hypoxemia	O
and	O
eventual	O
neurologically	O
intact	O
survival	O
.	O

This	O
report	O
describes	O
a	O
severe	O
case	O
of	O
atypical	O
pneumonia	O
due	O
to	O
M	O
.	O
pneumoniae	O
in	O
a	O
formerly	O
healthy	O
young	O
woman	O
who	O
developed	O
high	O
grade	O
fever	B-PROC
and	O
cough	O
leading	O
to	O
severe	O
disseminated	O
lung	O
disease	O
and	O
finally	O
to	O
fatal	O
ARDS	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
H1N1	O
2009	O
influenza	O
A	O
,	O
in	O
a	O
previously	O
fit	O
woman	O
at	O
24	O
weeks	O
of	O
gestation	B-PROC
,	O
who	O
presented	O
atypically	O
with	O
abdominal	O
pain	O
.	O

Northern	O
and	O
western	O
blot	O
analyses	O
were	O
conducted	O
to	O
evaluate	O
antiviral	O
activity	O
on	O
viral	O
entry	O
,	O
viral	O
RNA	O
and	O
protein	B-PROC
expression	B-PROC
,	O
and	O
release	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
.	O

Sanguisorbae	O
radix	O
reduced	O
coronavirus	O
production	O
,	O
partly	O
as	O
a	O
result	O
of	O
decreased	B-PROC
protein	B-PROC
synthesis	I-PROC
,	O
but	O
without	O
a	O
significant	O
reduction	O
in	O
intracellular	O
viral	O
RNA	O
levels	O
.	O

TITLE	O
:	O
Panton	O
-	O
Valentine	O
leukocidin	O
expressing	O
Staphylococcus	O
aureus	O
pneumonia	O
managed	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
:	O
experience	O
and	O
outcome	O
.	O

Little	O
information	O
is	O
available	O
on	O
the	O
management	O
of	O
patients	O
with	O
Panton	O
-	O
Valentine	O
leukocidin	O
expressing	O
S	O
.	O
aureus	O
pneumonia	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
.	O

As	O
a	O
large	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
center	O
,	O
we	O
reviewed	O
our	O
experience	O
and	O
outcomes	O
with	O
Panton	O
-	O
Valentine	O
Leukocidin	O
expressing	O
S	O
.	O
aureus	O
pneumonia	O
.	O

Locally	O
held	O
register	O
of	O
all	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
patients	O
at	O
Glenfield	O
Hospital	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
104	O
children	O
suffering	O
from	O
HCMV	O
infection	O
,	O
in	O
an	O
effort	B-PROC
to	O
find	O
any	O
association	O
between	O
MBL	O
and	O
HCMV	O
infection	O
of	O
children	O
in	O
China	O
.	O

Significantly	O
better	O
oxygenation	B-PROC
with	O
higher	O
PaO	B-PROC
(	O
2	O
)	O
and	O
alveolar	O
-	O
arterial	O
oxygen	O
difference	O
was	O
noted	O
in	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
.	O

RESULTS	O
:	O
Significantly	O
better	O
oxygenation	B-PROC
with	O
higher	O
PaO	B-PROC
(	O
2	O
)	O
and	O
alveolar	O
-	O
arterial	O
oxygen	O
difference	O
was	O
noted	O
in	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
.	O

After	O
surgical	O
decompression	O
,	O
renal	O
or	O
respiratory	B-PROC
function	I-PROC
was	O
improved	O
in	O
14	O
patients	O
(	O
54	O
%).	O

However	O
,	O
it	O
is	O
critical	O
to	O
develop	O
suitable	O
in	O
vitro	O
platforms	O
to	O
isolate	O
and	O
characterize	O
the	O
replication	O
kinetics	O
and	O
pathogenesis	B-PROC
of	O
recently	O
identified	O
human	O
pathogens	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
characteristics	O
,	O
clinical	O
evolution	B-PROC
and	O
outcome	O
in	O
adult	O
patients	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
treated	O
with	O
or	O
without	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

TITLE	O
:	O
Synthesis	B-PROC
,	O
antiviral	O
activity	O
and	O
cytotoxicity	O
evaluation	O
of	O
Schiff	O
bases	O
of	O
some	O
2	O
-	O
phenyl	O
quinazoline	O
-	O
4	O
(	O
3	O
)	O
H	O
-	O
ones	O
.	O

ABSTRACT	O
:	O
A	O
new	O
series	O
of	O
3	O
-(	O
benzylideneamino	O
)-	O
2	O
-	O
phenylquinazoline	O
-	O
4	O
(	O
3H	O
)-	O
ones	O
were	O
prepared	O
through	O
Schiff	O
base	O
formation	B-PROC
of	O
3	O
-	O
amino	O
-	O
2	O
-	O
phenyl	O
quinazoline	O
-	O
4	O
(	O
3	O
)	O
H	O
-	O
one	O
with	O
various	O
substituted	O
carbonyl	O
compounds	O
.	O

TITLE	O
:	O
Impact	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
at	O
different	O
periods	B-PROC
of	O
pregnancy	O
on	O
subsequent	O
reproductive	B-PROC
performance	O
in	O
gilts	O
and	O
sows	O
.	O

ABSTRACT	O
:	O
The	O
discovery	O
and	O
development	B-PROC
of	O
new	O
,	O
highly	O
potent	O
anti	O
-	O
coronavirus	O
agents	O
and	O
effective	O
approaches	O
for	O
controlling	O
the	O
potential	O
emergence	O
of	O
epidemic	O
coronaviruses	O
still	O
remains	O
an	O
important	O
mission	O
.	O

Furthermore	O
,	O
the	O
potent	O
tylophorine	O
compounds	O
exerted	B-PROC
profound	O
anti	O
-	O
TGEV	O
replication	O
activity	O
and	O
thereby	O
blocked	O
the	O
TGEV	O
-	O
induced	O
apoptosis	B-PROC
and	O
subsequent	O
cytopathic	O
effect	O
in	O
ST	O
cells	O
.	O

ANP	O
treatment	O
stimulated	O
Rac	O
-	O
dependent	O
PAK1	O
phosphorylation	B-PROC
,	O
attenuated	O
endothelial	O
permeability	O
caused	O
by	O
LPS	O
,	O
TNF	O
-	O
α	O
,	O
and	O
IL	O
-	O
6	O
,	O
decreased	O
LPS	O
-	O
induced	O
cell	O
and	O
protein	O
accumulation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
and	O
suppressed	O
Evans	O
blue	O
extravasation	O
in	O
the	O
murine	O
model	O
of	O
acute	O
lung	O
injury	O
.	O

Molecular	O
inhibition	B-PROC
of	O
PAK1	O
suppressed	O
the	O
protective	O
effects	O
of	O
ANP	O
treatment	O
against	O
LPS	O
-	O
induced	O
lung	O
injury	O
and	O
endothelial	O
barrier	O
dysfunction	O
.	O

Quantification	O
of	O
mRNA	O
for	O
the	O
ceacam1a	O
-	O
related	O
genes	O
ceacam2	O
and	O
psg16	O
(	O
bCEA	O
),	O
which	O
encode	O
proposed	O
alternative	O
MHV	O
receptors	O
,	O
revealed	O
low	O
ceacam2	O
expression	B-PROC
in	O
microglia	O
and	O
oligodendrocytes	O
and	O
psg16	O
expression	B-PROC
exclusively	O
in	O
neurons	O
;	O
however	O
,	O
only	O
CEACAM2	O
mediated	O
infection	O
in	O
human	O
293T	O
cells	O
.	O

TITLE	O
:	O
SARS	O
-	O
coronavirus	O
protein	O
6	O
conformations	O
required	O
to	O
impede	O
protein	B-PROC
import	I-PROC
into	O
the	O
nucleus	O
.	O

Respiratory	O
symptoms	O
(	O
98	O
.	O
0	O
%),	O
including	O
cough	O
(	O
90	O
.	O
1	O
%),	O
were	O
the	O
most	O
frequently	O
reported	O
symptoms	O
,	O
followed	O
by	O
muscle	O
aches	O
(	O
66	O
.	O
2	O
%),	O
fever	B-PROC
(	O
62	O
.	O
5	O
%),	O
headache	O
(	O
57	O
.	O
9	O
%),	O
diarrhea	O
(	O
16	O
.	O
5	O
%),	O
and	O
vomiting	O
(	O
9	O
.	O
8	O
%).	O

Growth	B-PROC
hormone	O
releasing	O
peptide	O
-	O
2	O
(	O
GHRP	O
-	O
2	O
),	O
a	O
ghrelin	O
agonist	O
,	O
has	O
been	O
shown	O
to	O
exert	B-PROC
beneficial	O
effects	O
on	O
various	O
inflammatory	O
diseases	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
∼	O
115	O
kDa	O
glycoform	O
of	O
S	O
(	O
TR2	O
)	O
protein	O
was	O
capable	O
of	O
increasing	O
after	O
gene	B-PROC
amplification	I-PROC
.	O

Respondents	O
examined	O
the	O
impact	O
of	O
national	O
laws	O
on	O
the	O
movements	B-PROC
of	O
information	O
,	O
goods	O
,	O
services	O
and	O
people	O
across	O
borders	O
in	O
a	O
time	O
of	O
pandemic	O
,	O
the	O
capacity	O
for	O
surveillance	O
,	O
case	O
detection	O
,	O
case	O
management	O
and	O
community	O
control	O
,	O
the	O
deployment	O
of	O
strategies	O
of	O
prevention	O
,	O
containment	O
,	O
mitigation	O
and	O
recovery	O
and	O
the	O
identification	O
of	O
commonalities	O
and	O
disconnects	O
across	O
states	O
.	O

States	O
differ	O
in	O
the	O
range	O
and	O
the	O
nature	O
of	O
intervention	O
measures	O
authorized	O
by	O
law	O
,	O
the	O
extent	O
to	O
which	O
borders	O
could	O
be	O
closed	O
to	O
movement	B-PROC
of	O
persons	O
and	O
goods	O
during	O
a	O
pandemic	O
,	O
and	O
access	O
to	O
healthcare	O
of	O
non	O
-	O
resident	O
persons	O
.	O

This	O
suggests	O
that	O
the	O
deaths	B-PROC
of	O
fellow	O
healthcare	O
workers	O
from	O
an	O
occupational	O
acquired	O
infection	O
had	O
an	O
overwhelming	O
effect	O
on	O
their	O
compliance	O
with	O
infection	O
control	O
measures	O
.	O

TITLE	O
:	O
The	O
many	O
paths	O
to	O
frameshifting	O
:	O
kinetic	O
modelling	O
and	O
analysis	O
of	O
the	O
effects	O
of	O
different	O
elongation	O
steps	O
on	O
programmed	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
.	O

ABSTRACT	O
:	O
We	O
aimed	O
to	O
review	O
the	O
impact	O
of	O
introducing	O
binasal	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
for	O
acute	O
respiratory	O
distress	O
in	O
newborns	O
≥	O
32	O
weeks	O
gestation	B-PROC
during	O
retrieval	O
in	O
Western	O
Australia	O
.	O

Retrospective	O
review	O
of	O
newborns	O
≥	O
32	O
weeks	O
gestation	B-PROC
with	O
acute	O
respiratory	O
distress	O
,	O
transported	O
by	O
the	O
Western	O
Australian	O
Neonatal	O
Transport	B-PROC
Service	O
between	O
February	O
2002	O
and	O
December	O
2004	O
.	O

One	O
of	O
these	O
(	O
an	O
H	O
-	O
to	O
-	O
R	O
substitution	O
at	O
residue	O
1	O
,	O
381	O
)	O
was	O
first	O
detected	O
in	O
PEDV	O
isolated	O
after	O
eight	O
passages	O
,	O
and	O
both	O
this	O
virus	O
(	O
MK	O
-	O
p8	O
)	O
and	O
MK	O
-	O
p10	O
showed	O
enhanced	O
syncytium	B-PROC
formation	I-PROC
relative	O
to	O
the	O
original	O
MK	O
strain	O
and	O
viruses	O
isolated	O
after	O
two	O
,	O
four	O
,	O
and	O
six	O
passages	O
,	O
suggesting	O
the	O
possibility	O
that	O
the	O
H	O
-	O
to	O
-	O
R	O
mutation	O
was	O
responsible	O
for	O
this	O
activity	O
.	O

The	O
large	O
ARDS	O
Network	O
clinical	O
trial	O
on	O
the	O
magnitude	O
of	O
tidal	O
volume	O
impressively	O
demonstrated	O
the	O
feasibility	O
of	O
targeted	B-PROC
clinical	O
trials	O
in	O
patients	O
with	O
ARDS	O
that	O
provide	O
robust	O
evidence	O
in	O
this	O
field	O
.	O

RESULTS	O
:	O
A	O
nonameric	O
epitope	O
Mn2	O
and	O
a	O
decameric	O
epitope	O
Md3	O
derived	O
from	O
the	O
M	O
protein	O
were	O
identified	O
and	O
used	O
for	O
the	O
evaluation	O
of	O
M	O
protein	O
-	O
specific	B-PROC
immunity	I-PROC
.	O

TITLE	O
:	O
The	O
influence	O
of	O
race	O
on	O
the	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
in	O
trauma	O
patients	O
.	O

Specifically	O
,	O
cell	O
-	O
mediated	O
responses	O
were	O
diminished	O
in	O
T3	O
-	O
injured	O
mice	O
,	O
as	O
seen	O
by	O
reduction	O
in	O
virus	O
-	O
specific	O
CD4	O
(+)	O
T	B-PROC
lymphocyte	I-PROC
proliferation	I-PROC
and	O
IFN	O
-	O
γ	O
production	O
and	O
decreased	O
numbers	O
of	O
activated	O
antigen	O
presenting	O
cells	O
compared	O
to	O
infected	O
un	O
-	O
injured	O
mice	O
.	O

However	O
,	O
there	O
is	O
still	O
significant	O
mortality	O
associated	O
with	O
antineutrophil	O
cytoplasmic	O
antibody	B-PROC
-	O
associated	O
vasculitis	O
.	O

We	O
checked	O
and	O
analyzed	O
the	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-PROC
(	O
Ab	O
)	O
for	O
five	O
consecutive	O
years	O
using	O
the	O
commercial	O
ELISA	O
test	O
kit	O
.	O

ABSTRACT	O
:	O
Inhalation	B-PROC
injury	O
contributes	O
to	O
the	O
morbidity	O
and	O
mortality	O
of	O
burn	O
victims	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
undergoing	O
mechanical	O
ventilation	O
for	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
neuromuscular	O
blocking	O
agents	O
may	O
improve	O
oxygenation	B-PROC
and	O
decrease	O
ventilator	O
-	O
induced	O
lung	O
injury	O
but	O
may	O
also	O
cause	O
muscle	O
weakness	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
proportion	O
of	O
patients	O
who	O
died	B-PROC
either	O
before	O
hospital	O
discharge	O
or	O
within	O
90	O
days	O
after	O
study	O
enrollment	O
(	O
i	O
.	O
e	O
.,	O
the	O
90	O
-	O
day	O
in	O
-	O
hospital	O
mortality	O
rate	O
),	O
adjusted	O
for	O
predefined	O
covariates	O
and	O
baseline	O
differences	O
between	O
groups	O
with	O
the	O
use	O
of	O
a	O
Cox	O
model	O
.	O

TITLE	O
:	O
[	O
Expression	B-PROC
of	O
secretory	B-PROC
type	O
II	O
phospholipase	B-PROC
A₂	O
in	O
acute	O
lung	O
injury	O
following	O
acute	O
pancreatitis	O
and	O
interventional	O
effect	O
of	O
Qingyi	O
decoction	O
on	O
it	O
].	O

ABSTRACT	O
:	O
Ubiquitination	B-PROC
is	O
a	O
critical	O
regulator	O
of	O
the	O
host	O
immune	B-PROC
response	I-PROC
to	O
viral	B-PROC
infection	I-PROC
,	O
and	O
many	O
viruses	O
,	O
including	O
coronaviruses	O
,	O
encode	O
proteins	O
that	O
target	O
the	O
ubiquitination	B-PROC
system	O
.	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
E	O
protein	O
interacts	O
with	O
PALS1	O
and	O
alters	O
tight	B-PROC
junction	I-PROC
formation	I-PROC
and	O
epithelial	O
morphogenesis	B-PROC
.	O

Enteric	O
fever	B-PROC
was	O
associated	O
with	O
loose	O
stools	O
,	O
normal	O
to	O
low	O
leukocyte	O
counts	O
and	O
normal	O
platelet	O
counts	O
.	O

Molecular	O
pharmacologic	O
studies	O
focused	O
on	O
the	O
molecular	O
and	O
the	O
biochemical	B-PROC
mechanisms	I-PROC
underlying	O
the	O
protective	O
effects	O
of	O
caffeine	O
are	O
also	O
being	O
done	O
to	O
optimize	O
treatment	O
regimes	O
and	O
to	O
target	O
potential	O
molecular	O
pathways	B-PROC
leading	O
to	O
further	O
decreases	O
in	O
acute	O
and	O
long	O
term	O
neonatal	O
morbidities	O
.	O

TITLE	O
:	O
Enhanced	O
antiviral	O
T	O
cell	B-PROC
function	I-PROC
in	O
the	O
absence	O
of	O
B7	O
-	O
H1	O
is	O
insufficient	O
to	O
prevent	O
persistence	O
but	O
exacerbates	O
axonal	O
bystander	O
damage	O
during	O
viral	O
encephalomyelitis	O
.	O

We	O
enrolled	O
21	O
ALI	O
/	O
ARDS	O
patients	O
admitted	O
to	O
our	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
assayed	O
plasma	O
sRAGE	O
on	O
the	O
first	O
2	O
days	O
after	O
diagnosis	O
,	O
every	O
three	O
days	O
for	O
the	O
first	O
month	O
and	O
then	O
once	O
a	O
week	O
,	O
until	O
ICU	O
discharge	O
or	O
death	B-PROC
.	O

Other	O
viruses	O
,	O
porcine	O
transmissible	O
gastroenteritis	O
coronavirus	O
,	O
avian	O
infectious	O
bronchitis	O
coronavirus	O
,	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
,	O
classic	O
swine	O
fever	B-PROC
virus	O
and	O
porcine	O
pseudorabies	O
virus	O
,	O
were	O
unreactive	O
.	O

A	O
single	O
dose	O
of	O
vaccine	O
with	O
or	O
without	O
adjuvant	O
was	O
poorly	O
immunogenic	O
in	O
mice	O
;	O
a	O
second	O
dose	O
resulted	O
in	O
a	O
significant	O
boost	O
in	O
antibody	B-PROC
levels	O
,	O
even	O
in	O
the	O
absence	O
of	O
adjuvant	O
.	O

Although	O
antibody	B-PROC
titers	O
had	O
declined	O
in	O
all	O
groups	O
of	O
vaccinated	O
hamsters	O
18	O
wk	O
after	O
the	O
second	O
dose	O
,	O
the	O
vaccinated	O
hamsters	O
were	O
still	O
partially	O
protected	O
from	O
wild	O
-	O
type	O
virus	O
challenge	O
.	O

RESULTS	O
:	O
We	O
identified	O
53	O
laboratory	O
-	O
confirmed	O
secondary	O
case	O
patients	O
with	O
pH1N1	O
virus	B-PROC
infection	I-PROC
,	O
for	O
an	O
SAR	O
of	O
45	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
35	O
.	O
6	O
%-	O
53	O
.	O
5	O
%).	O

Further	O
,	O
this	O
study	O
showed	O
that	O
hypertonic	O
saline	O
resuscitation	O
and	O
suppression	B-PROC
of	O
iNOS	O
might	O
improve	O
immunosuppressive	O
reaction	O
after	O
hemorrhagic	O
shock	O
.	O

To	O
investigate	O
E	O
protein	B-PROC
function	I-PROC
,	O
we	O
previously	O
generated	O
E	O
gene	O
point	O
mutants	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
that	O
were	O
defective	O
in	O
growth	B-PROC
and	O
assembled	O
virions	O
with	O
anomalous	O
morphologies	O
.	O

Thus	O
,	O
TMPRSS2	O
affects	O
the	O
entry	O
of	O
virus	O
but	O
not	O
other	O
phases	O
of	O
virus	B-PROC
replication	I-PROC
.	O

Results	O
indicate	O
that	O
TMPRSS2	O
needs	O
to	O
be	O
expressed	B-PROC
in	O
the	O
opposing	O
(	O
target	O
)	O
cell	O
membrane	O
to	O
activate	O
S	O
protein	O
rather	O
than	O
in	O
the	O
producer	O
cell	O
,	O
as	O
found	O
for	O
influenza	O
A	O
virus	O
and	O
metapneumoviruses	O
.	O

In	O
all	O
cases	O
,	O
ARDS	O
was	O
diagnosed	O
by	O
the	O
presence	O
of	O
hypoxia	O
with	O
PaO	B-PROC
(	O
2	O
)	O
/	O
FiO	O
(	O
2	O
)	O
ratio	O
<	O
200	O
and	O
bilateral	O
pulmonary	O
infiltration	O
,	O
and	O
by	O
excluding	O
cardiac	O
disease	O
by	O
echocardiography	O
.	O

The	O
currently	O
available	O
extracorporeal	O
lung	O
assist	O
systems	O
are	O
described	O
in	O
this	O
article	O
,	O
including	O
high	O
flow	O
systems	O
such	O
as	O
traditional	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
CO₂	O
removal	O
systems	O
(	O
interventional	O
lung	O
assist	O
or	O
iLA	O
,	O
with	O
or	O
without	O
associated	O
centrifugal	O
pumps	O
),	O
and	O
the	O
new	O
low	O
flow	O
and	O
less	O
invasive	O
systems	O
under	O
development	B-PROC
.	O

TITLE	O
:	O
Identifying	O
genetic	B-PROC
markers	I-PROC
of	O
adaptation	B-PROC
for	O
surveillance	O
of	O
viral	O
host	O
jumps	O
.	O

ABSTRACT	O
:	O
Adaptation	B-PROC
is	O
often	O
thought	O
to	O
affect	O
the	O
likelihood	O
that	O
a	O
virus	O
will	O
be	O
able	O
to	O
successfully	O
emerge	O
in	O
a	O
new	O
host	O
species	O
.	O

We	O
argue	O
that	O
using	O
a	O
multidisciplinary	O
approach	O
for	O
surveillance	O
will	O
provide	O
a	O
better	O
understanding	O
of	O
when	O
adaptations	B-PROC
are	O
required	O
for	O
host	O
jumps	O
and	O
thus	O
when	O
predictive	O
genetic	B-PROC
markers	I-PROC
may	O
be	O
present	O
.	O

Correlations	O
were	O
highest	O
for	O
serum	O
antibody	B-PROC
titers	O
between	O
group	O
I	O
strains	O
(	O
HCoV	O
-	O
229E	O
and	O
-	O
NL63	O
[	O
r	O
=	O
0	O
.	O
443	O
;	O
P	O
<	O
0	O
.	O
0001	O
])	O
and	O
between	O
group	O
II	O
strains	O
(	O
HCoV	O
-	O
OC43	O
and	O
-	O
HKU1	O
[	O
r	O
=	O
0	O
.	O
603	O
;	O
P	O
<	O
0	O
.	O
0001	O
])	O
and	O
not	O
statistically	O
significant	O
between	O
HCoV	O
-	O
NL63	O
and	O
-	O
OC43	O
and	O
between	O
HCoV	O
-	O
NL63	O
and	O
-	O
HKU1	O
.	O

Both	O
si	O
-	O
M1	O
and	O
si	O
-	O
M2	O
significantly	O
downregulated	O
M	O
gene	O
mediated	O
upregulation	B-PROC
of	O
interferon	O
b	O
expression	B-PROC
.	O

Fifteen	O
days	O
later	O
,	O
X	O
-	O
ray	O
and	O
CT	O
showed	O
complete	O
or	O
significant	O
absorption	O
in	O
19	O
cases	O
(	O
85	O
.	O
5	O
%);	O
delayed	O
recovery	O
was	O
identified	O
in	O
8	O
cases	O
(	O
27	O
.	O
6	O
%),	O
pulmonary	O
fibrosis	O
was	O
found	O
in	O
3	O
cases	O
(	O
10	O
.	O
3	O
%),	O
and	O
3	O
patients	O
(	O
10	O
.	O
3	O
%)	O
died	B-PROC
.	O

These	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
N	O
protein	O
targets	O
the	O
initial	O
step	O
,	O
probably	O
the	O
cellular	O
PRRs	O
(	O
pattern	O
recognition	O
receptors	O
)-	O
RNAs	O
-	O
recognition	O
step	O
in	O
the	O
innate	O
immune	O
pathways	B-PROC
,	O
to	O
suppress	O
IFN	O
expression	B-PROC
responses	O
.	O

As	O
expected	O
,	O
BMM	O
but	O
not	O
BMDC	O
expressed	B-PROC
type	O
I	O
IFN	O
.	O

Exogenous	O
IFN	O
enhanced	O
IFN	O
-	O
dependent	O
gene	B-PROC
expression	I-PROC
in	O
BMM	O
at	O
early	O
times	O
after	O
infection	O
and	O
in	O
BMDC	O
at	O
all	O
times	O
after	O
infection	O
but	O
did	O
not	O
stimulate	O
expression	B-PROC
of	O
molecules	O
that	O
signal	O
through	O
myeloid	O
differentiation	B-PROC
factor	O
88	O
(	O
MyD88	O
),	O
such	O
as	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
).	O

Collectively	O
,	O
our	O
results	O
show	O
that	O
IFN	O
is	O
produced	O
at	O
early	O
times	O
postinfection	O
(	O
p	O
.	O
i	O
.)	O
in	O
MHV	O
-	O
infected	O
BMM	O
,	O
but	O
not	O
in	O
BMDC	O
,	O
and	O
primes	O
expression	B-PROC
of	O
IFN	O
and	O
IFN	O
-	O
responsive	O
genes	O
.	O

We	O
observed	O
differential	O
expression	B-PROC
of	O
approximately	O
500	O
annotated	O
,	O
long	O
ncRNAs	O
and	O
1	O
,	O
000	O
nonannotated	O
genomic	O
regions	O
during	O
infection	O
.	O

Exploration	O
into	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
successful	O
vaccination	O
in	O
the	O
immunosenescent	O
should	O
aid	O
in	O
the	O
development	B-PROC
of	O
successful	O
vaccine	O
strategies	O
for	O
other	O
viral	B-PROC
diseases	I-PROC
disproportionately	O
affecting	O
the	O
elderly	O
,	O
like	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
influenza	O
virus	O
,	O
norovirus	O
,	O
or	O
other	O
emerging	O
viruses	O
of	O
the	O
future	O
.	O

High	O
gestational	O
age	O
,	O
high	O
SNAP	O
-	O
II	O
score	O
and	O
oxygenation	B-PROC
index	O
(	O
OI	O
),	O
and	O
Apgar	O
score	O
at	O
5	O
minutes	O
<	O
5	O
were	O
independent	O
risks	O
for	O
death	B-PROC
.	O

The	O
main	O
cause	O
of	O
death	B-PROC
is	O
severe	O
infection	O
complicating	O
of	O
MOSF	O
and	O
most	O
patients	O
require	O
prolonged	O
mechanical	O
ventilation	O
.	O

This	O
work	O
allowed	O
dissection	O
of	O
several	O
molecular	O
signatures	O
present	O
during	O
SARS	O
-	O
CoV	O
which	O
are	O
part	O
of	O
a	O
robust	O
IFN	O
antiviral	B-PROC
response	I-PROC
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
8b	O
protein	O
,	O
which	O
is	O
not	O
expressed	B-PROC
by	O
other	O
known	O
coronaviruses	O
,	O
can	O
down	O
-	O
regulate	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
via	O
a	O
proteasome	B-PROC
-	O
dependent	O
pathway	B-PROC
.	O

By	O
using	O
Vero	O
E6	O
cells	O
stably	O
expressing	O
green	O
fluorescence	O
protein	O
-	O
tagged	O
8b	O
,	O
ectopic	B-PROC
expression	B-PROC
of	O
8b	O
was	O
shown	O
to	O
significantly	O
reduce	O
the	O
production	O
of	O
progeny	O
virus	O
and	O
down	O
-	O
regulate	O
E	O
expression	B-PROC
.	O

IHC	O
and	O
RT	O
-	O
PCR	O
were	O
performed	O
for	O
WNv	O
antigen	O
on	O
41	O
dead	B-PROC
birds	O
(	O
belonging	O
to	O
five	O
orders	O
)	O
collected	O
from	O
the	O
northwest	O
region	O
of	O
the	O
Riverside	O
County	O
of	O
California	O
.	O

ABSTRACT	O
:	O
The	O
nsp1	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
an	O
alphacoronavirus	O
,	O
efficiently	O
suppressed	O
protein	B-PROC
synthesis	I-PROC
in	O
mammalian	O
cells	O
.	O

Furthermore	O
,	O
we	O
observed	O
that	O
overexpression	B-PROC
of	O
IBV	O
E	O
,	O
but	O
not	O
EG3	O
,	O
induced	O
the	O
disassembly	O
of	O
the	O
Golgi	O
complex	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
hydrophobic	O
domain	O
of	O
IBV	O
E	O
alters	O
the	O
host	O
secretory	B-PROC
pathway	I-PROC
to	O
the	O
apparent	O
advantage	O
of	O
the	O
virus	O
.	O

Australian	O
subgroup	O
2	O
IBVs	O
contain	O
sequence	B-PROC
insertions	I-PROC
and	O
multiple	O
gene	B-PROC
deletions	I-PROC
that	O
have	O
resulted	O
in	O
a	O
substantial	O
genomic	O
divergence	O
from	O
international	O
IBVs	O
.	O

The	O
body	O
temperature	O
was	O
higher	O
than	O
39	O
°	O
C	O
accompanied	O
by	O
chill	O
and	O
low	O
blood	B-PROC
pressure	I-PROC
at	O
the	O
onset	O
of	O
the	O
illness	O
.	O

During	O
H1N1	O
prevalent	O
season	O
when	O
high	O
fever	B-PROC
occurred	O
,	O
H1N1	O
infection	O
should	O
be	O
considered	O
.	O

A	O
positive	O
correlation	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
IL	O
-	O
15	O
levels	O
with	O
C	O
-	O
reactive	O
protein	O
and	O
with	O
>	O
5	O
-	O
day	O
interval	O
between	O
symptom	O
onset	O
and	O
admission	O
,	O
and	O
a	O
negative	O
correlation	O
with	O
the	O
PaO	B-PROC
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
,	O
were	O
found	O
in	O
nvA	O
(	O
H1N1	O
)	O
groups	O
.	O

In	O
our	O
critically	O
ill	O
patients	O
with	O
novel	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	B-PROC
infection	I-PROC
,	O
the	O
hallmarks	O
of	O
the	O
severity	O
of	O
disease	O
were	O
IL	O
-	O
6	O
,	O
IL	O
-	O
15	O
,	O
IL	O
-	O
8	O
and	O
TNFα	O
.	O

For	O
a	O
10	O
-	O
year	O
period	O
between	O
1998	O
and	O
2007	O
we	O
studied	O
the	O
trend	O
,	O
epidemiological	O
characteristics	O
,	O
proportion	O
of	O
imported	O
versus	O
local	O
transmission	O
of	O
malaria	O
,	O
viral	O
hepatitis	O
(	O
hepatitis	O
A	O
and	O
E	O
),	O
enteric	O
fevers	B-PROC
(	O
typhoid	O
and	O
paratyphoid	O
),	O
cholera	O
,	O
chikungunya	O
and	O
SARS	O
.	O

Additionally	O
,	O
the	O
validated	O
multi	O
-	O
zone	O
model	O
combining	O
the	O
two	O
-	O
way	O
airflow	B-PROC
effect	O
could	O
simulate	O
the	O
pollutant	O
transport	B-PROC
with	O
reasonable	O
accuracy	O
but	O
much	O
less	O
computational	O
time	O
.	O

JHM	O
.	O
SD	O
induces	O
a	O
generally	O
protective	O
innate	B-PROC
immune	I-PROC
response	I-PROC
;	O
however	O
,	O
the	O
strong	O
neutrophil	O
response	O
may	O
be	O
more	O
pathogenic	O
than	O
protective	O
.	O

These	O
resistance	B-PROC
assays	O
together	O
with	O
new	O
viral	O
load	O
tests	O
will	O
enable	O
clinical	O
laboratories	O
to	O
provide	O
physicians	O
with	O
important	O
information	O
for	O
optimal	O
treatment	O
of	O
patients	O
.	O

The	O
RNA	B-PROC
synthesis	I-PROC
of	O
these	O
two	O
distantly	O
related	O
nidoviruses	O
is	O
catalyzed	O
by	O
an	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
which	O
is	O
the	O
core	O
enzyme	O
of	O
their	O
multiprotein	O
replication	O
and	O
transcription	B-PROC
complex	O
(	O
RTC	O
).	O

These	O
expressed	B-PROC
proteins	O
were	O
the	O
pre	O
-	O
coil	O
region	O
which	O
is	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
putative	O
fusion	O
protein	O
(	O
FP	O
),	O
the	O
region	O
from	O
FP	O
to	O
the	O
heptad	O
repeat	O
(	O
HR	O
)	O
2	O
(	O
FP	O
-	O
HR2	O
)	O
region	O
,	O
and	O
the	O
inter	O
-	O
helical	O
region	O
which	O
is	O
sandwiched	O
between	O
HR1	O
and	O
HR2	O
.	O

Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
gripped	O
the	O
world	O
in	O
2003	O
,	O
spreading	O
via	O
air	O
-	O
links	O
and	O
throwing	B-PROC
the	O
global	O
economy	O
into	O
disarray	O
.	O

Severe	O
,	O
asymmetrical	O
ventricular	O
dilation	O
associated	O
with	O
hydrocephalus	O
,	O
cerebellar	O
and	O
brainstem	O
hypoplasia	O
,	O
and	O
punctuate	O
calcifications	B-PROC
of	O
the	O
thalamus	O
,	O
third	O
and	O
fourth	O
ventricles	O
,	O
around	O
the	O
aqueduct	O
,	O
were	O
observed	O
on	O
computed	O
tomography	O
(	O
CT	O
).	O

MHV	O
-	O
A59	O
virus	O
is	O
the	O
main	O
cause	O
of	O
elevated	O
NF	O
-	O
κB	O
expression	B-PROC
and	O
CD4	O
(+)/	O
CD8	O
(+)/	O
ratio	O
,	O
while	O
damp	O
-	O
heat	O
syndrome	O
is	O
responsible	O
for	O
increased	O
AQP4	O
expression	B-PROC
,	O
and	O
their	O
synergistic	O
effect	O
results	O
in	O
increased	O
IFN	O
-	O
γ	O
/	O
IL	O
-	O
4	O
ratio	O
.	O

TITLE	O
:	O
Positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
,	O
prone	O
positioning	O
,	O
and	O
activated	O
protein	O
C	O
:	O
a	O
critical	O
review	O
of	O
meta	O
-	O
analyses	O
.	O

ABSTRACT	O
:	O
The	O
results	O
of	O
meta	O
-	O
analyses	O
on	O
the	O
effectiveness	O
of	O
high	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
and	O
prone	O
positioning	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
not	O
consistent	O
.	O

The	O
detection	O
rate	O
of	O
suckling	O
pigs	O
,	O
weaning	B-PROC
pigs	O
,	O
growers	O
and	O
finishers	O
were	O
14	O
.	O
3	O
%	O
(	O
12	O
/	O
84	O
),	O
6	O
.	O
5	O
%	O
(	O
7	O
/	O
107	O
),	O
7	O
%	O
(	O
3	O
/	O
43	O
),	O
and	O
0	O
%	O
(	O
0	O
/	O
5	O
),	O
respectively	O
.	O

RESULTS	O
:	O
Multivariate	O
logistic	O
regression	O
analysis	O
showed	O
that	O
female	O
gender	O
as	O
well	O
as	O
the	O
presence	O
of	O
chronic	O
medical	O
illnesses	O
diagnosed	O
before	O
the	O
onset	O
of	O
SARS	O
and	O
avascular	O
necrosis	B-PROC
were	O
independent	O
predictors	O
of	O
PTSD	O
at	O
30	O
months	O
post	O
-	O
SARS	O
.	O

All	O
other	O
patients	O
left	O
the	O
hospital	O
alive	O
,	O
but	O
two	O
(	O
non	O
-	O
traumatic	O
)	O
patients	O
died	B-PROC
from	O
sepsis	O
,	O
and	O
one	O
(	O
traumatic	O
)	O
patient	O
died	B-PROC
in	O
a	O
hemorrhagic	O
shock	O
,	O
thereafter	O
.	O

Sepsis	O
was	O
the	O
main	O
cause	O
of	O
death	B-PROC
after	O
LT	O
.	O

We	O
also	O
studied	O
the	O
distribution	O
and	O
measured	O
the	O
amounts	O
of	O
NEP	O
protein	O
,	O
using	O
immuno	O
-	O
histochemical	O
and	O
immunoblot	O
analyses	O
,	O
and	O
measured	O
the	O
levels	O
of	O
NEP	O
mRNA	O
,	O
using	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
,	O
in	O
the	O
lungs	O
of	O
mice	O
with	O
ALI	O
.	O

TITLE	O
:	O
Simultaneous	O
detection	O
and	O
differentiation	B-PROC
of	O
respiratory	O
syncytial	O
virus	O
and	O
other	O
respiratory	O
viral	O
pathogens	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
the	O
degree	O
of	O
pulmonary	O
hypoplasia	O
could	O
be	O
measured	O
using	O
bedside	O
pulmonary	O
graphics	O
and	O
whether	O
survival	O
could	O
be	O
predicted	O
in	O
potential	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
candidates	O
.	O

Subanalysis	O
of	O
the	O
prone	O
cases	O
showed	O
no	O
significant	O
changes	O
in	O
the	O
PaO₂	O
/	O
FiO₂	O
ratio	O
or	O
oxygenation	B-PROC
index	O
but	O
again	O
showed	O
a	O
significant	O
but	O
temporary	O
increase	O
in	O
intraoperative	O
PaCO₂	O
.	O
HFOV	O
was	O
aborted	O
for	O
conventional	O
mechanical	O
ventilation	O
in	O
three	O
cases	O
due	O
to	O
respiratory	O
deterioration	O
(	O
2	O
cases	O
)	O
and	O
hemodynamic	B-PROC
instability	O
(	O
1	O
case	O
).	O

Thrombolysis	O
during	O
spontaneous	O
circulation	B-PROC
only	O
for	O
myocardial	O
infarction	O
or	O
massive	O
pulmonary	O
embolism	O
;	O
during	O
on	O
-	O
going	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	O
)	O
only	O
when	O
indications	O
of	O
massive	O
pulmonary	O
embolism	O
.	O

Prediction	O
of	O
CPR	O
outcome	O
is	O
not	O
possible	O
at	O
the	O
scene	O
,	O
determine	O
neurological	O
outcome	O
<	O
72	O
h	O
after	O
cardiac	O
arrest	O
with	O
somatosensory	B-PROC
evoked	I-PROC
potentials	I-PROC
,	O
biochemical	O
tests	O
and	O
neurological	O
examination	O
.	O

An	O
18	O
-	O
residue	O
fragment	O
comprising	O
the	O
N	O
-	O
terminal	O
helix	O
of	O
SP	O
-	O
B	O
was	O
investigated	O
in	O
oxidized	O
and	O
unmodified	O
forms	O
by	O
solution	O
and	O
solid	O
-	O
state	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
),	O
circular	O
dichroism	O
(	O
CD	O
),	O
and	O
molecular	B-PROC
dynamics	I-PROC
(	I-PROC
MD	I-PROC
)	I-PROC
simulation	I-PROC
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
tryptophan	O
oxidation	B-PROC
causes	O
substantial	O
disruptions	O
in	O
helical	O
structure	O
and	O
lipid	O
interactions	O
.	O

Tryptophan	O
oxidation	B-PROC
causes	O
significant	O
modifications	O
to	O
the	O
peptide	O
-	O
lipid	O
interactions	O
,	O
and	O
the	O
peptide	O
likely	O
shifts	O
to	O
a	O
more	O
in	O
-	O
plane	O
orientation	O
within	O
the	O
lipids	O
.	O

Reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
targeting	B-PROC
the	O
3	O
'	O
untranslated	O
region	O
was	O
used	O
to	O
detect	O
CoV	O
RNA	O
,	O
and	O
positive	O
samples	O
were	O
submitted	O
for	O
sequence	O
analysis	O
.	O

This	O
plant	O
expression	B-PROC
vector	O
was	O
transformed	O
into	O
lettuce	O
(	O
Lactuca	O
sativa	O
L	O
.)	O
using	O
the	O
Agrobacterium	O
-	O
mediated	O
transformation	B-PROC
method	O
.	O

The	O
results	O
of	O
western	O
blot	O
analysis	O
with	O
anti	O
-	O
cholera	O
toxin	O
and	O
anti	O
-	O
COE	O
antibody	B-PROC
showed	O
the	O
synthesis	B-PROC
and	O
assembly	O
of	O
CTB	O
-	O
COE	O
fusion	O
protein	O
into	O
oligomeric	O
structures	O
with	O
pentameric	O
sizing	O
.	O

In	O
the	O
Champagne	O
-	O
Ardenne	O
area	O
(	O
north	O
eastern	O
)	O
this	O
new	O
epidemic	O
strain	O
was	O
detected	O
in	O
the	O
respiratory	O
samples	O
of	O
14	O
severe	O
S	O
-	O
OIV	O
infection	O
cases	O
resulting	O
in	O
5	O
deaths	B-PROC
.	O

1	O
case	O
also	O
expressed	B-PROC
in	O
the	O
intestinal	O
tissue	O
slurry	O
columnar	O
epithelium	O
and	O
interstitial	O
cells	O
.	O

In	O
particular	O
,	O
several	O
studies	O
have	O
explored	O
the	O
feasibility	O
and	O
efficacy	O
of	O
extracorporeal	O
oxygenation	B-PROC
and	O
carbon	O
dioxide	O
removal	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
cytotoxic	O
T	O
-	O
lymphocyte	O
-	O
based	O
,	O
broadly	O
protective	O
influenza	O
vaccine	O
.	O

On	O
the	O
other	O
hand	O
,	O
it	O
is	O
known	O
that	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
CTL	O
)	O
populations	O
directed	O
against	O
internal	O
antigens	O
of	O
influenza	O
A	O
virus	O
are	O
broadly	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
to	O
influenza	O
virus	O
subtypes	O
.	O

Small	O
molecules	O
,	O
especially	O
peptides	O
are	O
an	O
expanding	O
area	O
for	O
therapy	O
or	O
diagnostic	O
assays	O
for	O
viral	B-PROC
diseases	I-PROC
.	O

Three	O
chemically	O
synthesized	O
peptides	O
recognizing	O
the	O
pAPN	O
showed	O
effective	O
inhibition	B-PROC
ability	O
to	O
TGEV	O
infection	O
in	O
vitro	O
.	O

Four	O
patients	O
required	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

The	O
ASC	O
survival	O
factors	O
B	O
cell	O
-	O
activating	O
factor	O
of	O
the	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)	O
family	O
(	O
BAFF	O
)	O
and	O
a	O
proliferating	O
-	O
inducing	O
ligand	B-PROC
(	O
APRIL	O
)	O
were	O
also	O
significantly	O
elevated	O
in	O
the	O
infected	O
CNS	O
,	O
albeit	O
delayed	O
relative	O
to	O
the	O
chemokines	O
.	O

Here	O
,	O
we	O
examine	O
the	O
role	O
of	O
Th17	O
response	O
in	O
the	O
development	B-PROC
of	O
the	O
acute	O
hepatitis	O
following	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

TITLE	O
:	O
Partial	O
deletion	O
in	O
the	O
spike	O
endodomain	O
of	O
mouse	O
hepatitis	O
virus	O
decreases	O
the	O
cytopathic	O
effect	O
but	O
maintains	O
foreign	O
protein	B-PROC
expression	B-PROC
in	O
infected	O
cells	O
.	O

The	O
replication	O
and	O
foreign	O
protein	B-PROC
expression	B-PROC
of	O
the	O
S	O
-	O
mutated	O
recombinants	O
were	O
found	O
to	O
be	O
more	O
efficient	O
in	O
L2	O
cells	O
than	O
in	O
Neuro	O
-	O
2a	O
and	O
NIH	O
/	O
3T3	O
cells	O
.	O

The	O
similarity	O
between	O
the	O
structures	O
of	O
these	O
two	O
domains	O
from	O
SARS	O
-	O
CoV	O
,	O
IBV	O
and	O
MHV	O
corroborates	O
a	O
conserved	O
mechanism	O
of	O
nucleocapsid	O
formation	B-PROC
for	O
coronaviruses	O
.	O

As	O
all	O
eight	O
active	O
sites	O
are	O
bound	O
with	O
inhibitors	O
,	O
the	O
polyvalent	O
nature	O
of	O
the	O
interaction	O
between	O
AO	O
-	O
M	O
(	O
pro	O
)	O
and	O
its	O
polyprotein	O
substrates	O
with	O
multiple	O
cleavage	B-PROC
sites	O
,	O
would	O
make	O
AO	O
-	O
M	O
(	O
pro	O
)	O
functionally	O
much	O
more	O
superior	O
than	O
the	O
M	O
(	O
pro	O
)	O
active	O
dimer	O
for	O
polyprotein	O
processing	O
.	O

China	O
'	O
s	O
surveillance	O
system	O
for	O
endemic	O
infectious	O
diseases	O
has	O
improved	O
greatly	O
since	O
2003	O
,	O
but	O
the	O
country	O
'	O
s	O
ability	O
to	O
conduct	B-PROC
surveillance	O
for	O
laboratory	O
-	O
confirmed	O
infections	O
remains	O
underdeveloped	O
.	O

An	O
enhanced	O
disease	O
-	O
detection	O
system	O
in	O
China	O
will	O
help	O
prevent	O
and	O
contain	O
outbreaks	O
before	O
they	O
cause	O
substantial	O
illness	O
and	O
death	B-PROC
in	O
China	O
and	O
other	O
countries	O
.	O

This	O
study	O
demonstrated	O
that	O
sRAGE	O
was	O
independently	O
associated	O
with	O
death	B-PROC
in	O
ARDS	O
patients	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
prepared	O
neutralizing	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
)-	O
resistant	O
(	O
mar	O
)	O
mutant	O
viruses	O
using	O
a	O
laboratory	O
strain	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
79	O
-	O
1146	O
(	O
Kida	O
et	O
al	O
.,	O
1999	O
).	O

We	O
clarified	O
that	O
MAb	O
used	O
to	O
prepare	O
mar	O
mutant	O
viruses	O
also	O
lost	O
its	O
activity	O
to	O
enhance	O
homologous	O
mar	O
mutant	O
viruses	O
,	O
strongly	O
suggesting	O
that	O
neutralizing	O
and	O
antibody	B-PROC
-	O
dependent	O
enhancing	O
epitopes	O
are	O
present	O
in	O
the	O
same	O
region	O
in	O
the	O
strain	O
FIPV	O
79	O
-	O
1146	O
.	O

During	O
persistent	O
infection	O
,	O
the	O
individual	O
qualitative	O
immune	B-PROC
response	I-PROC
might	O
address	O
the	O
accumulations	O
of	O
mutations	O
in	O
the	O
N	O
gene	O
and	O
the	O
development	B-PROC
of	O
FIP	O
.	O

The	O
Th1	O
and	O
linear	O
immunodominant	O
antibody	B-PROC
-	O
binding	O
epitopes	O
were	O
located	O
at	O
different	O
positions	O
in	O
both	O
the	O
S2	O
domain	O
and	O
N	O
protein	O
.	O

However	O
,	O
increasing	O
evidence	O
suggests	O
that	O
this	O
dichotomy	O
is	O
no	O
longer	O
fruitful	O
when	O
recognising	O
human	O
hantavirus	O
disease	O
and	O
understanding	O
the	O
pathogenesis	B-PROC
.	O

In	O
conclusion	O
,	O
sudden	O
death	B-PROC
by	O
myocarditis	O
may	O
be	O
a	O
rare	O
complication	O
of	O
novel	O
influenza	O
A	O
/	O
H1N1	O
infection	O
in	O
otherwise	O
healthy	O
individuals	O
,	O
even	O
in	O
the	O
absence	O
of	O
significant	O
respiratory	O
tract	O
infection	O
.	O

TITLE	O
:	O
Cough	O
hypersensitivity	B-PROC
syndrome	O
:	O
a	O
distinct	O
clinical	O
entity	O
.	O

TITLE	O
:	O
LTB4	O
increases	O
nasal	O
neutrophil	O
activity	O
and	O
conditions	O
neutrophils	O
to	O
exert	B-PROC
antiviral	O
effects	O
.	O

IL	O
-	O
8	O
,	O
eosinophil	O
cationic	O
protein	O
(	O
ECP	O
)	O
and	O
α	O
(	O
2	O
)-	O
macroglobulin	O
were	O
measured	O
as	O
indices	O
of	O
pro	O
-	O
inflammatory	O
cytokine	B-PROC
production	I-PROC
,	O
eosinophil	O
activity	O
,	O
and	O
plasma	O
exudation	B-PROC
.	O

LTB4	O
can	O
condition	O
neutrophils	O
to	O
exert	B-PROC
virucidal	O
effects	O
in	O
vitro	O
and	O
may	O
reduce	O
virus	B-PROC
replication	I-PROC
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Due	O
to	O
their	O
different	O
virulence	B-PROC
and	O
infectivity	O
,	O
both	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
H1N1	O
09	O
revealed	O
different	O
strengths	O
and	O
weaknesses	O
in	O
our	O
ability	O
to	O
contain	O
new	O
viral	O
threats	O
over	O
the	O
past	O
decade	O
.	O

Here	O
we	O
tested	O
the	O
hypothesis	O
that	O
simultaneous	O
blockade	O
of	O
inducible	O
and	O
neuronal	O
NO	O
synthase	O
effectively	O
prevents	O
the	O
pulmonary	O
lesions	O
in	O
an	O
ovine	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
combined	O
burn	O
and	O
smoke	O
inhalation	B-PROC
injury	O
.	O

A	O
proteomics	O
approach	O
demonstrated	O
downregulation	B-PROC
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
1	O
and	O
upregulation	B-PROC
of	O
ubiquitin	B-PROC
-	O
conjugating	O
enzyme	O
(	O
UBC	O
)	O
E2	O
-	O
25k	O
as	O
inhibitory	O
mechanism	O
of	O
PLpro	O
on	O
IFN	O
-	O
α	O
-	O
induced	O
responses	O
.	O

IFN	O
-	O
α	O
treatment	O
significantly	O
induced	O
mRNA	B-PROC
expression	B-PROC
of	O
UBC	O
E2	O
-	O
25k	O
,	O
but	O
not	O
ERK1	O
,	O
causing	O
time	O
-	O
dependent	O
decrease	O
of	O
ERK1	O
,	O
but	O
not	O
ERK2	O
,	O
in	O
PLpro	O
-	O
expressing	O
cells	O
.	O

The	O
level	O
of	O
the	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
must	O
be	O
chosen	O
in	O
relation	O
to	O
oxygen	O
requirement	O
.	O

On	O
comparing	O
the	O
isolated	O
virus	O
(	O
isolate	O
Tokachi09	O
)	O
with	O
the	O
equine	O
coronavirus	O
NC99	O
strain	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
several	O
biological	O
properties	O
such	O
as	O
hemagglutinating	O
activity	O
,	O
antigenicity	O
(	O
in	O
indirect	O
immunofluorescence	O
and	O
neutralization	O
tests	O
),	O
and	O
one	O
-	O
step	O
growth	B-PROC
(	O
in	O
cell	O
culture	O
).	O

TITLE	O
:	O
The	O
multicenter	O
Italian	O
birth	B-PROC
cohort	O
study	O
on	O
incidence	O
and	O
determinants	O
of	O
lower	O
respiratory	O
tract	O
infection	O
hospitalization	O
in	O
infants	O
at	O
33	O
weeks	O
GA	O
or	O
more	O
:	O
preliminary	O
results	O
.	O

HCoV	O
-	O
HKU1	O
S	O
protein	O
was	O
constructed	O
in	O
the	O
eukaryotic	O
expression	B-PROC
plasmids	O
,	O
and	O
confirmed	O
by	O
Western	O
Blotting	O
,	O
S	O
antibody	B-PROC
assay	O
was	O
established	O
using	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
).	O

Expression	B-PROC
of	O
S	O
and	O
N	O
protein	O
were	O
confirmed	O
;	O
100	O
normal	O
adult	O
serum	O
were	O
analyzed	O
using	O
the	O
established	O
serological	O
detection	O
assay	O
,	O
in	O
which	O
HCoV	O
-	O
HKU1	O
S	O
antibody	B-PROC
positive	O
rate	O
was	O
47	O
%,	O
N	O
antibody	B-PROC
positive	O
rate	O
was	O
48	O
%,	O
Both	O
S	O
and	O
N	O
antibodies	O
positive	O
were	O
21	O
%,	O
Both	O
S	O
and	O
N	O
antibodies	O
negative	O
were	O
22	O
%.	O

Multivariable	O
analysis	O
indicated	O
that	O
both	O
of	O
these	O
single	O
nucleotide	O
polymorphisms	B-PROC
are	O
independently	O
associated	O
with	O
need	O
for	O
mechanical	O
ventilation	O
(	O
p	O
=	O
.	O
040	O
and	O
p	O
=	O
.	O
012	O
,	O
respectively	O
)	O
as	O
was	O
rs7316	O
when	O
its	O
interaction	O
with	O
age	O
was	O
considered	O
(	O
p	O
=	O
.	O
015	O
).	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
is	O
the	O
configuration	O
mode	O
an	O
important	O
predictor	O
for	O
the	O
outcome	O
?	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
increasingly	O
applied	O
as	O
rescue	O
-	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Chest	O
CT	O
(	O
16	O
-/	O
64	O
-	O
row	O
multidetector	O
CT	O
)	O
of	O
23	O
patients	O
(	O
of	O
whom	O
9	O
patients	O
died	B-PROC
)	O
were	O
retrospectively	O
reviewed	O
by	O
three	O
independent	O
blinded	O
observers	O
.	O

Sequence	O
alignment	O
and	O
structural	O
bioinformatics	O
analyses	O
revealed	O
that	O
the	O
catalytic	O
residues	O
(	O
Cys51	O
and	O
His148	O
)	O
are	O
highly	O
conserved	O
in	O
FMDV	O
Lb	O
(	O
pro	O
)	O
of	O
all	O
seven	O
serotypes	O
and	O
that	O
the	O
topology	O
of	O
FMDV	O
Lb	O
(	O
pro	O
)	O
is	O
remarkably	O
similar	O
to	O
that	O
of	O
ubiquitin	B-PROC
-	O
specific	O
protease	O
14	O
(	O
USP14	O
),	O
a	O
cellular	O
deubiquitylation	O
enzyme	O
(	O
DUB	O
),	O
and	O
to	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
coronaviral	O
DUB	O
.	O

Four	O
variables	O
affected	O
time	O
to	O
recovery	O
of	O
consciousness	O
:	O
age	O
(	O
hazard	O
ratio	O
,	O
0	O
.	O
98	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
97	O
-	O
0	O
.	O
99	O
;	O
p	O
=	O
0	O
.	O
009	O
),	O
bilateral	O
absence	O
of	O
light	O
reflexes	B-PROC
(	O
hazard	O
ratio	O
,	O
0	O
.	O
51	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
27	O
-	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
041	O
),	O
multiplicity	O
of	O
CCL	O
(	O
hazard	O
ratio	O
,	O
0	O
.	O
40	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
25	O
-	O
0	O
.	O
66	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
total	O
GCS	O
on	O
admission	O
(	O
hazard	O
ratio	O
,	O
1	O
.	O
45	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
23	O
-	O
1	O
.	O
71	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

Extracorporeal	O
blood	B-PROC
flow	I-PROC
was	O
maintained	O
at	O
32	O
%	O
±	O
6	O
%	O
of	O
cardiac	O
output	O
.	O

Thirty	O
third	O
-	O
year	O
and	O
fourth	O
-	O
year	O
nursing	B-PROC
students	O
were	O
first	O
taught	O
the	O
procedure	O
and	O
then	O
given	O
both	O
an	O
anxious	O
-	O
mood	O
and	O
a	O
calm	O
-	O
mood	O
induction	O
in	O
a	O
randomly	O
assigned	O
counterbalanced	O
order	O
.	O

Anxiety	O
was	O
induced	O
by	O
showing	O
a	O
video	O
of	O
interviews	O
with	O
frontline	O
nurses	O
and	O
doctors	O
during	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
epidemic	O
in	O
Hong	O
Kong	O
,	O
China	O
;	O
calmness	O
was	O
induced	O
by	O
a	O
video	O
of	O
a	O
nursing	B-PROC
student	O
'	O
s	O
pleasant	O
orientation	O
to	O
a	O
clinical	O
placement	O
site	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
caused	O
by	O
influenza	O
A	O
virus	O
H5N1	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
supposedly	O
depend	O
on	O
activation	O
of	O
the	O
oxidative	O
-	O
stress	O
machinery	O
that	O
is	O
coupled	O
with	O
innate	B-PROC
immunity	B-PROC
,	O
resulting	O
in	O
a	O
strong	O
proinflammatory	O
host	B-PROC
response	I-PROC
.	O

To	O
obtain	O
further	O
insight	O
into	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
-	O
CoV	O
-	O
associated	O
ALI	O
,	O
we	O
compared	O
SARS	O
-	O
CoV	O
infections	O
in	O
two	O
different	O
nonhuman	O
primate	O
species	O
,	O
cynomolgus	O
macaques	O
and	O
African	O
green	O
monkeys	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
SARS	O
S	O
was	O
cleaved	O
into	O
several	O
fragments	O
upon	O
coexpression	O
of	O
TMPRSS2	O
(	O
cis	O
-	O
cleavage	B-PROC
)	O
and	O
upon	O
contact	O
between	O
SARS	O
S	O
-	O
expressing	O
cells	O
and	O
TMPRSS2	O
-	O
positive	O
cells	O
(	O
trans	O
-	O
cleavage	B-PROC
).	O

It	O
was	O
shown	O
that	O
HCoV	O
-	O
NL63	O
infection	O
resulted	O
in	O
an	O
increased	O
adherence	O
of	O
Streptococcus	O
pneumoniae	O
to	O
virus	O
-	O
infected	O
cell	O
lines	O
and	O
fully	O
differentiated	B-PROC
primary	O
human	O
airway	O
epithelium	O
cultures	O
.	O

Yet	O
in	O
critical	O
illness	O
other	O
factors	O
also	O
affect	O
respiratory	O
muscle	B-PROC
function	I-PROC
,	O
including	O
prolonged	O
use	O
of	O
neuromuscular	O
blocking	O
agents	O
,	O
administration	O
of	O
corticosteroids	O
,	O
and	O
sepsis	O
.	O

However	O
,	O
promotion	O
of	O
unassisted	O
spontaneous	O
breathing	B-PROC
in	I-PROC
the	O
acute	O
phase	O
of	O
critical	O
illness	O
also	O
may	O
carry	O
a	O
substantial	O
risk	O
of	O
respiratory	O
muscle	O
injury	O
and	O
weakness	O
.	O

ABSTRACT	O
:	O
Airway	O
pressure	O
release	O
ventilation	O
(	O
APRV	O
)	O
and	O
bi	O
-	O
level	O
positive	O
airway	O
pressure	O
(	O
BIPAP	O
)	O
are	O
proposed	O
to	O
reduce	O
patient	O
work	B-PROC
of	I-PROC
breathing	B-PROC
(	O
WOB	O
)	O
sufficiently	O
and	O
to	O
obviate	O
issues	O
related	O
to	O
patient	O
-	O
ventilator	O
synchrony	O
,	O
so	O
that	O
spontaneous	O
breathing	B-PROC
can	O
be	O
maintained	O
throughout	O
the	O
course	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

To	O
date	O
,	O
low	O
-	O
level	O
evidence	O
suggests	O
that	O
promoting	O
spontaneous	O
breathing	B-PROC
with	O
APRV	O
/	O
BIPAP	O
may	O
not	O
be	O
appropriate	O
in	O
patients	O
with	O
relatively	O
severe	O
ALI	O
/	O
ARDS	O
.	O

Nevertheless	O
,	O
the	O
patient	O
died	B-PROC
of	O
diffuse	O
alveolar	O
hemorrhage	O
and	O
respiratory	O
failure	O
and	O
shock	O
.	O

UDA	O
inhibited	O
virus	B-PROC
replication	I-PROC
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
reduced	O
virus	O
yields	O
of	O
the	O
Urbani	O
strain	O
by	O
90	O
%	O
at	O
1	O
.	O
1	O
±	O
0	O
.	O
4	O
μg	O
/	O
ml	O
in	O
Vero	O
76	O
cells	O
.	O

In	O
addition	O
,	O
the	O
coexpression	O
of	O
nsp4	O
with	O
nsp3	O
affected	O
the	O
subcellular	O
localization	B-PROC
of	O
the	O
two	O
proteins	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
in	O
acute	O
hypercapnic	O
respiratory	O
failure	O
,	O
cardiogenic	O
pulmonary	O
oedema	O
,	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
community	O
-	O
acquired	O
pneumonia	O
and	O
weaning	B-PROC
/	O
post	O
-	O
extubation	O
failure	O
is	O
considered	O
common	O
in	O
clinical	O
practice	O
.	O

All	O
7	O
patients	O
were	O
treated	O
with	O
oral	O
oseltamivir	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
prior	O
to	O
ECMO	O
.	O

Mean	O
oxygenation	B-PROC
index	O
was	O
50	O
(	O
range	O
26	O
-	O
73	O
)	O
at	O
ECMO	O
cannulation	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
immunogenicity	O
of	O
recombinant	O
GapA	O
(+)	O
Mycoplasma	O
gallisepticum	O
vaccine	O
strain	O
ts	O
-	O
11	O
expressing	O
infectious	O
bronchitis	O
virus	O
-	O
S1	O
glycoprotein	O
and	O
chicken	O
interleukin	O
-	O
6	O
.	O

With	O
some	O
improvements	O
in	O
the	O
expression	B-PROC
system	O
,	O
it	O
could	O
be	O
used	O
to	O
induce	O
a	O
targeted	B-PROC
immune	B-PROC
response	I-PROC
against	O
specific	O
mucosal	O
pathogens	O
,	O
and	O
co	O
-	O
expression	B-PROC
of	O
several	O
antigens	O
would	O
allow	O
development	B-PROC
of	O
a	O
novel	O
multivalent	O
vaccine	O
.	O

TITLE	O
:	O
Cutting	O
edge	O
:	O
attrition	O
of	O
Plasmodium	O
-	O
specific	O
memory	B-PROC
CD8	O
T	O
cells	O
results	O
in	O
decreased	O
protection	O
that	O
is	O
rescued	O
by	O
booster	O
immunization	O
.	O

However	O
,	O
infections	O
with	O
unrelated	O
pathogens	O
,	O
as	O
may	O
occur	O
in	O
areas	O
endemic	O
to	O
malaria	O
,	O
can	O
dramatically	O
decrease	O
pre	O
-	O
existing	O
memory	B-PROC
CD8	O
T	O
cells	O
.	O

PubMed	O
was	O
searched	O
using	O
the	O
terms	O
toxic	O
epidermal	O
necrolysis	O
,	O
Stevens	O
-	O
Johnson	O
syndrome	O
,	O
drug	O
toxicity	O
,	O
drug	B-PROC
interaction	I-PROC
,	O
and	O
skin	O
diseases	O
.	O

The	O
mechanism	O
of	O
disease	O
is	O
not	O
completely	O
understood	O
,	O
but	O
immunologic	O
mechanisms	O
,	O
cytotoxic	O
reactions	O
,	O
and	O
delayed	B-PROC
hypersensitivity	I-PROC
seem	O
to	O
be	O
involved	O
.	O

ABSTRACT	O
:	O
A	O
retrieval	O
program	O
was	O
developed	O
in	O
New	O
South	O
Wales	O
(	O
NSW	O
),	O
Australia	O
to	O
provide	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
(	O
ECMO	O
)	O
for	O
the	O
safe	O
transport	B-PROC
of	O
adults	O
with	O
severe	O
,	O
acute	O
respiratory	O
or	O
cardiac	O
failure	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
baseline	O
characteristics	O
,	O
development	B-PROC
of	O
VAHS	O
,	O
related	O
treatments	O
and	O
associated	O
mortality	O
rate	O
of	O
consecutive	O
critically	O
ill	O
patients	O
with	O
confirmed	O
2009	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
and	O
respiratory	O
failure	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
development	B-PROC
of	O
VAHS	O
and	O
related	O
mortality	O
.	O

An	O
additional	O
17	O
patients	O
(	O
68	O
%)	O
required	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
a	O
median	O
of	O
10	O
days	O
(	O
IQR	O
,	O
6	O
to	O
19	O
days	O
).	O

RESULTS	O
:	O
VAHS	O
developed	O
in	O
9	O
(	O
36	O
%)	O
of	O
25	O
critically	O
ill	O
patients	O
with	O
confirmed	O
2009	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
,	O
and	O
8	O
(	O
89	O
%)	O
of	O
them	O
died	B-PROC
.	O

ABSTRACT	O
:	O
Interferon	O
gamma	O
(	O
IFN	O
-	O
γ	O
)	O
plays	O
an	O
important	O
role	O
in	O
cell	O
mediated	O
responses	O
against	O
mutated	O
feline	O
coronavirus	O
strains	O
(	O
FCoV	O
)	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

In	O
the	O
context	O
of	O
CoV	O
RNA	B-PROC
synthesis	I-PROC
,	O
these	O
cellular	O
ribonucleoproteins	O
might	O
also	O
participate	O
in	O
RNA	O
-	O
protein	O
complexes	O
to	O
bring	O
into	O
physical	O
proximity	O
TRS	O
-	O
L	O
and	O
distant	O
TRS	O
-	O
B	O
,	O
as	O
proposed	O
for	O
CoV	O
discontinuous	O
transcription	B-PROC
.	O

In	O
a	O
small	O
percentage	O
of	O
infants	O
(	O
aged	O
6	O
months	O
to	O
3	O
years	O
),	O
HFMD	O
was	O
accompanied	O
by	O
acute	O
neurological	O
complications	O
,	O
such	O
as	O
serous	O
meningitis	O
,	O
poliomyelitis	O
-	O
like	O
syndrome	O
(	O
extremity	O
pareses	O
and	O
muscle	O
paralyses	O
);	O
brain	O
stem	O
encephalitis	O
(	O
myoclonic	O
jerks	O
,	O
tremor	O
,	O
lethargy	O
,	O
swallowing	B-PROC
and	O
speech	B-PROC
disorders	O
,	O
cardiopulmonary	O
failure	O
,	O
pulmonary	O
edema	O
,	O
shock	O
,	O
coma	O
,	O
death	B-PROC
).	O

ABSTRACT	O
:	O
Conditions	O
characterized	O
by	O
immunosuppression	B-PROC
have	O
been	O
recently	O
reported	O
as	O
risk	O
factors	O
for	O
severe	O
novel	O
swine	O
-	O
origin	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
(	O
S	O
-	O
OIV	O
)	O
infection	O
during	O
the	O
current	O
2009	O
pandemic	O
.	O

The	O
viral	O
genome	O
was	O
amplified	O
by	O
real	O
time	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
a	O
nasopharyngeal	O
swab	O
specimen	O
.	O

The	O
lesions	O
were	O
most	O
consistent	O
with	O
a	O
viral	B-PROC
infection	I-PROC
.	O

Using	O
immunohistochemistry	O
,	O
virus	B-PROC
neutralization	I-PROC
,	O
fluorescent	O
antibody	B-PROC
test	O
,	O
and	O
nested	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
,	O
Porcine	O
teschovirus	O
was	O
identified	O
in	O
tissues	O
from	O
affected	O
individuals	O
.	O

HRV	O
may	O
be	O
the	O
commonest	O
viral	B-PROC
infection	I-PROC
in	O
young	O
South	O
African	O
children	O
with	O
acute	O
wheezing	O
.	O

Its	O
frequency	O
is	O
estimated	O
at	O
6	O
%	O
in	O
adult	O
patients	O
and	O
is	O
more	O
often	O
described	O
in	O
patients	O
with	O
venous	O
ulcers	O
and	O
higher	O
levels	O
of	O
chronic	O
hemolysis	B-PROC
.	O

Prognosis	O
is	O
poor	O
with	O
12	O
.	O
5	O
%	O
of	O
patients	O
dying	B-PROC
in	O
the	O
first	O
two	O
years	O
following	O
diagnosis	O
irrespective	O
of	O
the	O
actual	O
pulmonary	O
artery	O
pressure	O
level	O
.	O

Providing	O
a	O
core	O
component	O
of	O
the	O
front	O
line	O
response	O
to	O
disasters	O
,	O
paramedics	O
potentially	O
expose	O
themselves	O
to	O
a	O
variety	O
of	O
health	O
and	O
safety	O
risks	O
,	O
including	O
physical	O
injury	O
,	O
death	B-PROC
,	O
communicable	O
disease	O
,	O
and	O
psychological	O
effects	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
(	O
CoV	O
)	O
discontinuous	O
transcription	B-PROC
mechanism	O
is	O
driven	O
by	O
long	O
-	O
distance	O
RNA	O
-	O
RNA	O
interactions	O
between	O
transcription	B-PROC
-	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
located	O
at	O
the	O
5	O
'	O
terminal	O
leader	O
(	O
TRS	O
-	O
L	O
)	O
and	O
also	O
preceding	O
each	O
mRNA	O
-	O
coding	O
sequence	O
(	O
TRS	O
-	O
B	O
).	O

Silencing	O
the	O
expression	B-PROC
of	O
PTB	O
with	O
small	O
interfering	O
RNA	O
in	O
two	O
cell	O
lines	O
(	O
Huh7	O
and	O
HEK	O
293T	O
)	O
led	O
to	O
a	O
significant	O
increase	O
of	O
up	O
to	O
4	O
-	O
fold	O
in	O
mRNA	O
levels	O
and	O
virus	O
titer	O
,	O
indicating	O
a	O
negative	O
effect	O
of	O
PTB	O
on	O
CoV	O
RNA	O
accumulation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
structural	O
features	O
of	O
the	O
hot	O
spot	O
on	O
hACE2	O
were	O
among	O
the	O
driving	O
forces	O
for	O
the	O
convergent	O
evolution	B-PROC
of	O
NL63	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
severe	O
traumatic	O
brain	O
injury	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
may	O
be	O
lifesaving	O
in	O
multiple	O
injured	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
chest	O
trauma	O
.	O

When	O
treating	O
rapidly	O
progressive	O
glomerulonephritis	O
,	O
immunosuppressive	O
status	O
should	O
be	O
carefully	O
monitored	O
regarding	O
not	O
only	O
the	O
dosage	O
of	O
therapeutic	O
regimen	O
but	O
also	O
the	O
mental	O
health	O
status	O
and	O
nutrition	B-PROC
of	O
the	O
patient	O
.	O

Using	O
cycloheximide	O
and	O
puromycin	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
translation	B-PROC
inhibition	B-PROC
on	O
the	O
RNA	B-PROC
synthesis	I-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
mouse	O
hepatitis	O
virus	O
.	O

The	O
reduction	O
of	O
a	O
given	O
social	O
network	O
was	O
described	O
like	O
an	O
involution	B-PROC
of	O
the	O
algebraic	O
complexity	O
of	O
the	O
associated	O
Tutte	O
polynomial	O
.	O

TITLE	O
:	O
A	O
modified	O
technique	O
for	O
insertion	O
of	O
dual	O
lumen	O
bicaval	O
cannulae	O
for	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

The	O
post	O
-	O
SARS	O
group	O
also	O
reported	O
less	O
pre	O
-	O
sleep	B-PROC
and	O
post	O
-	O
sleep	B-PROC
musculoskeletal	O
pain	O
symptoms	O
.	O

The	O
clinical	O
and	O
sleep	B-PROC
features	O
of	O
chronic	O
post	O
-	O
SARS	O
form	O
a	O
syndrome	O
of	O
chronic	O
fatigue	O
,	O
pain	O
,	O
weakness	O
,	O
depression	O
and	O
sleep	B-PROC
disturbance	O
,	O
which	O
overlaps	O
with	O
the	O
clinical	O
and	O
sleep	B-PROC
features	O
of	O
FMS	O
and	O
chronic	O
fatigue	O
syndrome	O
.	O

However	O
,	O
the	O
cleavage	B-PROC
sites	O
in	O
SARS	O
-	O
S	O
and	O
the	O
protease	O
(	O
s	O
)	O
activating	O
SARS	O
-	O
S	O
are	O
incompletely	O
defined	O
.	O

Thus	O
,	O
different	O
host	O
cell	O
proteases	O
activate	O
SARS	O
-	O
S	O
for	O
virus	O
-	O
cell	O
and	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
and	O
SARS	O
-	O
S	O
cleavage	B-PROC
at	O
R667	O
and	O
758	O
-	O
RXXR	O
-	O
762	O
can	O
be	O
dispensable	O
for	O
SARS	O
-	O
S	O
activation	O
.	O

ABSTRACT	O
:	O
Adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
secondary	O
to	O
H1N1	O
viral	B-PROC
infection	I-PROC
has	O
been	O
a	O
worldwide	O
medical	O
and	O
organizational	O
challenge	O
.	O

We	O
conclude	O
that	O
not	O
all	O
viral	B-PROC
infections	I-PROC
in	O
children	O
with	O
asthma	O
lead	O
to	O
an	O
asthma	O
exacerbation	O
and	O
the	O
attributing	O
effect	O
of	O
different	O
triggers	O
of	O
asthma	O
exacerbations	O
in	O
children	O
vary	O
across	O
different	O
time	O
periods	B-PROC
and	O
across	O
different	O
localities	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
Golgi	O
complex	O
-	O
targeting	B-PROC
signal	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	O
.	O

TITLE	O
:	O
Pandemic	O
2009	O
H1N1	O
virus	B-PROC
infection	I-PROC
associated	O
with	O
purpuric	O
skin	O
lesions	O
:	O
a	O
case	O
report	O
.	O

There	O
have	O
been	O
cases	O
of	O
vasculitis	O
following	O
influenza	O
vaccination	O
,	O
and	O
rash	O
and	O
acute	O
purpura	O
may	O
occur	O
in	O
certain	O
viral	B-PROC
infections	I-PROC
.	O

Our	O
case	O
suggests	O
that	O
steroid	O
therapy	O
associated	O
with	O
antivirals	O
can	O
prevent	O
the	O
risk	O
of	O
further	O
complications	O
such	O
as	O
hemorrhage	O
and	O
multi	O
-	O
organ	O
failure	O
during	O
severe	O
vasculitis	O
,	O
without	O
enhancing	O
the	O
virulence	B-PROC
of	O
the	O
influenza	O
virus	O
.	O

TITLE	O
:	O
[	O
Expression	B-PROC
of	O
green	O
fluorescent	O
protein	O
using	O
an	O
infectious	O
cDNA	O
clone	O
of	O
infectious	O
bronchitis	O
virus	O
].	O

This	O
study	O
showed	O
that	O
the	O
5a	O
ORF	O
is	O
a	O
good	O
candidate	O
for	O
an	O
insertion	O
site	O
of	O
recombinant	O
genes	O
for	O
the	O
development	B-PROC
of	O
IBV	O
infectious	O
cDNA	O
clone	O
as	O
a	O
gene	O
transfer	O
vector	O
.	O

The	O
development	B-PROC
of	O
a	O
safe	O
and	O
effective	O
mucosal	O
adjuvant	O
and	O
vaccine	O
for	O
prevention	O
of	O
emergent	O
infectious	O
diseases	O
such	O
as	O
SARS	O
will	O
be	O
an	O
important	O
advancement	O
.	O

Increasing	O
quartiles	O
of	O
plasma	O
cotinine	O
were	O
associated	O
with	O
the	O
development	B-PROC
of	O
ALI	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
for	O
developing	O
ALI	O
in	O
highest	O
cotinine	O
quartile	O
,	O
3	O
.	O
25	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
22	O
-	O
8	O
.	O
68	O
;	O
P	O
=	O
0	O
.	O
017	O
for	O
trend	O
across	O
quartiles	O
).	O

Both	O
moderate	O
to	O
heavy	O
passive	O
smoking	O
and	O
active	O
smoking	O
are	O
independently	O
associated	O
with	O
the	O
development	B-PROC
of	O
ALI	O
after	O
severe	O
blunt	O
trauma	O
.	O

This	O
finding	O
has	O
important	O
implications	O
both	O
for	O
public	O
health	O
and	O
for	O
understanding	O
the	O
pathogenesis	B-PROC
of	O
ALI	O
.	O

TITLE	O
:	O
Viral	B-PROC
infection	I-PROC
in	O
acute	O
exacerbation	O
of	O
idiopathic	O
pulmonary	O
fibrosis	O
.	O

We	O
investigated	O
vascular	B-PROC
endothelial	I-PROC
growth	B-PROC
factor	I-PROC
(	O
VEGF	B-PROC
)	O
to	O
examine	O
the	O
relationship	O
between	O
VEGF	B-PROC
levels	O
and	O
the	O
amounts	O
of	O
effusion	O
in	O
cats	O
with	O
FIP	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
validation	O
of	O
RT	O
-	O
PCR	O
tests	O
for	O
the	O
detection	O
and	O
S1	O
genotyping	O
of	O
infectious	O
bronchitis	O
virus	O
and	O
other	O
closely	O
related	O
gammacoronaviruses	O
within	O
clinical	O
samples	O
.	O

Recently	O
,	O
CCoV	O
type	O
II	O
strains	O
of	O
potential	O
recombinant	O
origin	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
were	O
detected	O
and	O
characterized	O
as	O
a	O
new	O
subtype	O
(	O
CCoV	O
-	O
IIb	O
)	O
of	O
canine	O
coronavirus	O
,	O
in	O
order	O
to	O
be	O
differentiated	B-PROC
from	O
the	O
""""	O
classical	O
""""	O
CCoV	O
type	O
II	O
strains	O
(	O
CCoV	O
-	O
IIa	O
).	O

ABSTRACT	O
:	O
Novel	O
gene	O
-	O
based	O
therapies	O
for	O
disease	O
will	O
depend	O
in	O
many	O
cases	O
on	O
long	O
-	O
term	O
persistent	O
transgene	O
expression	B-PROC
.	O

ABSTRACT	O
:	O
Neuralgic	O
amyotrophy	B-PROC
(	O
brachial	O
plexus	O
neuropathy	O
,	O
brachial	O
plexus	O
neuritis	O
,	O
or	O
Parsonage	O
-	O
Turner	O
syndrome	O
)	O
is	O
an	O
uncommon	O
inflammatory	O
condition	O
typically	O
characterized	O
by	O
acute	O
and	O
severe	O
shoulder	O
pain	O
followed	O
by	O
paresis	O
with	O
muscle	O
weakness	O
and	O
atrophy	O
of	O
the	O
upper	O
limb	O
or	O
shoulder	O
girdle	O
.	O

Faecal	O
samples	O
from	O
84	O
Australian	O
dairy	O
and	O
dairy	O
beef	O
properties	O
(	O
597	O
samples	O
)	O
were	O
screened	O
for	O
rotavirus	O
and	O
coronavirus	O
using	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
,	O
for	O
Salmonella	O
spp	O
.	O

Patients	O
with	O
clinically	O
stable	O
asthma	O
and	O
healthy	O
controls	O
have	O
similar	O
detection	O
rates	O
of	O
respiratory	O
viruses	O
in	O
samples	O
from	O
nasopharynx	O
,	O
sputum	O
and	O
exhaled	B-PROC
air	O
.	O

Bacterial	O
isolates	O
from	O
specimens	O
recovered	O
from	O
our	O
patient	O
before	O
and	O
after	O
his	O
death	B-PROC
were	O
analyzed	O
using	O
microarray	O
DNA	O
analysis	O
and	O
spa	O
typing	O
,	O
and	O
the	O
results	O
revealed	O
that	O
the	O
S	O
.	O
aureus	O
isolates	O
belonged	O
to	O
clonal	O
complex	O
8	O
,	O
were	O
methicillin	O
-	O
susceptible	O
and	O
positive	O
for	O
Panton	O
-	O
Valentine	O
leukocidin	O
.	O

Herein	O
we	O
describe	O
a	O
molecule	O
from	O
this	O
screen	O
that	O
prevents	O
the	O
interaction	O
between	O
eIF4E	O
(	O
the	O
cap	O
-	O
binding	O
protein	O
)	O
and	O
eIF4G	O
(	O
a	O
large	O
scaffolding	O
protein	O
),	O
inhibiting	O
cap	O
-	O
dependent	O
translation	B-PROC
.	O

TITLE	O
:	O
CXCR3	O
-	O
dependent	O
plasma	O
blast	O
migration	B-PROC
to	O
the	O
central	O
nervous	O
system	O
during	O
viral	O
encephalomyelitis	O
.	O

ABSTRACT	O
:	O
In	O
the	O
Southern	O
hemisphere	O
,	O
Réunion	O
Island	O
acts	O
as	O
a	O
sentinel	O
for	O
infections	O
preferentially	O
occurring	O
during	O
the	O
austral	O
winter	O
that	O
are	O
likely	O
to	O
reach	B-PROC
the	O
Northern	O
hemisphere	O
a	O
few	O
months	O
later	O
.	O

Twenty	O
-	O
two	O
out	O
of	O
25	O
patients	O
needed	O
mechanical	O
ventilation	O
,	O
some	O
required	O
rescue	O
therapies	O
such	O
as	O
extracorporeal	O
membranous	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
or	O
hi	O
-	O
frequency	O
oscillation	O
ventilation	O
(	O
HFOV	O
),	O
both	O
only	O
available	O
in	O
few	O
French	O
hospitals	O
.	O

By	O
the	O
virus	O
recovery	O
trials	O
,	O
70	O
/	O
80	O
of	O
the	O
strains	O
resulted	O
in	O
the	O
deaths	B-PROC
or	O
distresses	O
of	O
birds	O
from	O
nephritis	O
.	O

His	O
-	O
tagged	O
RdRp	O
was	O
expressed	B-PROC
in	O
baculovirus	O
,	O
purified	O
and	O
used	O
as	O
immunogen	O
to	O
produce	O
mAbs	O
.	O

Based	O
on	O
available	O
observations	O
,	O
we	O
could	O
not	O
observe	O
an	O
association	O
between	O
respiratory	O
viral	B-PROC
infection	I-PROC
and	O
acute	O
rejection	O
(	O
OR	O
=	O
1	O
.	O
35	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
41	O
-	O
4	O
.	O
43	O
).	O

In	O
addition	O
,	O
measurement	O
of	O
plasma	O
membrane	O
voltage	B-PROC
gated	I-PROC
ion	I-PROC
channel	I-PROC
activity	O
by	O
whole	O
-	O
cell	O
patch	O
clamp	O
suggested	O
that	O
E	O
protein	O
was	O
not	O
present	O
in	O
the	O
plasma	O
membrane	O
.	O

TITLE	O
:	O
The	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
monophosphatase	O
domains	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
human	O
coronavirus	O
229E	O
mediate	O
resistance	B-PROC
to	O
antiviral	O
interferon	O
responses	O
.	O

Infection	O
of	O
transgenic	O
IL	O
-	O
10	O
/	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
reporter	O
mice	O
revealed	O
that	O
CNS	O
-	O
infiltrating	O
T	O
cells	O
were	O
the	O
major	O
source	O
of	O
IL	O
-	O
10	O
,	O
with	O
minimal	O
IL	B-PROC
-	I-PROC
10	I-PROC
production	I-PROC
by	O
macrophages	O
and	O
resident	O
microglia	O
.	O

Disease	O
-	O
specific	O
guidance	O
documents	O
on	O
tuberculosis	O
,	O
SARS	O
,	O
meningococcal	O
infections	O
,	O
measles	O
,	O
rubella	O
,	O
Ebola	O
and	O
Marburg	O
haemorrhagic	O
fevers	B-PROC
,	O
Lassa	O
fever	B-PROC
,	O
smallpox	O
and	O
anthrax	O
were	O
the	O
result	O
of	O
consultations	O
of	O
disease	O
-	O
specific	O
expert	O
panels	O
.	O

TITLE	O
:	O
Differentiation	B-PROC
of	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
N	O
protein	O
using	O
a	O
virus	O
-	O
based	O
ELISA	O
.	O

ABSTRACT	O
:	O
The	O
bacterially	O
expressed	B-PROC
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
porcine	O
respiratory	O
and	O
reproductive	B-PROC
syndrome	O
virus	O
(	O
PRRSV	O
)	O
was	O
used	O
as	O
immunogen	O
to	O
generate	O
a	O
rabbit	O
-	O
derived	O
polyclonal	O
antibody	B-PROC
.	O

Viral	B-PROC
replication	I-PROC
was	O
higher	O
in	O
animals	O
infected	O
with	O
a	O
late	O
human	O
phase	O
isolate	O
compared	O
to	O
a	O
zoonotic	O
isolate	O
.	O

Protocols	O
for	O
propagating	O
MHV	O
in	O
DBT	O
and	O
17CL	O
-	O
1	O
cells	O
;	O
the	O
storage	B-PROC
and	O
titration	O
of	O
viral	O
stocks	O
;	O
purification	O
of	O
MHV	O
on	O
sucrose	O
gradients	O
;	O
and	O
the	O
generation	O
of	O
recombinant	O
viruses	O
by	O
a	O
cDNA	O
assembly	O
method	O
and	O
by	O
targeted	B-PROC
recombination	B-PROC
will	O
be	O
presented	O
.	O

TITLE	O
:	O
Interference	O
of	O
ribosomal	B-PROC
frameshifting	I-PROC
by	O
antisense	O
peptide	O
nucleic	O
acids	O
suppresses	O
SARS	O
coronavirus	O
replication	O
.	O

Our	O
findings	O
elucidate	O
augmentation	O
of	O
AP	O
-	O
1	O
-	O
dependent	O
gene	B-PROC
expression	I-PROC
in	O
3b	O
-	O
transfected	O
Huh7	O
cells	O
.	O

Analysis	O
of	O
CD	O
spectra	O
showed	O
a	O
minimal	O
difference	O
in	O
the	O
secondary	O
structure	O
of	O
the	O
peptide	O
analogues	O
in	O
the	O
buffer	O
system	O
used	O
for	O
the	O
ADAM17	O
cleavage	B-PROC
assay	O
.	O

A	O
demyelinating	O
MHV	O
strain	O
induces	O
optic	O
neuritis	O
,	O
but	O
whether	O
this	O
is	O
due	O
to	O
the	O
retrograde	B-PROC
axonal	I-PROC
transport	I-PROC
of	O
viral	O
particles	O
to	O
the	O
retina	O
or	O
due	O
to	O
traumatic	O
disruption	O
of	O
retinal	O
ganglion	O
cell	O
axons	O
during	O
intracranial	O
inoculation	O
is	O
not	O
known	O
.	O

These	O
data	O
indicate	O
that	O
MHV	O
spreads	O
by	O
retrograde	B-PROC
axonal	I-PROC
transport	I-PROC
to	O
the	O
eye	O
and	O
that	O
targeting	B-PROC
spike	O
protein	O
interactions	O
with	O
axonal	B-PROC
transport	I-PROC
machinery	O
is	O
a	O
potential	O
therapeutic	O
strategy	O
for	O
central	O
nervous	O
system	O
viral	B-PROC
infections	I-PROC
and	O
associated	O
diseases	O
.	O

A	O
case	O
control	O
study	O
was	O
conducted	O
among	O
a	O
cohort	O
of	O
patients	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
with	O
risk	O
factors	O
for	O
the	O
development	B-PROC
of	O
ARDS	O
.	O

Moreover	O
,	O
immunofluorescence	O
(	O
IF	O
)	O
and	O
flow	O
cytometry	O
analyses	O
based	O
on	O
staining	O
of	O
Annexin	O
V	O
and	O
propidium	O
iodide	O
staining	O
of	O
nuclei	O
indicated	O
that	O
early	O
and	O
late	O
cell	O
apoptosis	B-PROC
induced	O
by	O
TGEV	O
was	O
inhibited	O
efficiently	O
.	O

The	O
ability	O
of	O
LiCl	O
to	O
inhibit	O
apoptosis	B-PROC
was	O
investigated	O
by	O
IF	O
analysis	O
of	O
caspase	O
-	O
3	O
expression	B-PROC
.	O

TITLE	O
:	O
Lack	O
of	O
peripheral	O
memory	B-PROC
B	O
cell	O
responses	O
in	O
recovered	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
:	O
a	O
six	O
-	O
year	O
follow	O
-	O
up	O
study	O
.	O

Memory	B-PROC
T	O
cell	O
responses	O
to	O
a	O
pool	O
of	O
SARS	O
-	O
CoV	O
S	O
peptides	O
were	O
identified	O
in	O
14	O
of	O
23	O
(	O
60	O
.	O
9	O
%)	O
recovered	O
SARS	O
patients	O
,	O
whereas	O
there	O
was	O
no	O
such	O
specific	O
response	O
in	O
either	O
close	O
contacts	O
or	O
healthy	O
controls	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
their	O
safety	O
profile	O
and	O
ability	O
to	O
induce	O
potent	O
immune	B-PROC
responses	I-PROC
against	O
infections	O
,	O
subunit	O
vaccines	O
have	O
been	O
used	O
as	O
candidates	O
for	O
a	O
wide	O
variety	O
of	O
pathogens	O
.	O

Since	O
the	O
mammalian	O
cell	O
system	O
is	O
capable	O
of	O
post	B-PROC
-	I-PROC
translational	B-PROC
modification	I-PROC
,	O
thus	O
forming	O
properly	O
folded	O
and	O
glycosylated	O
proteins	O
,	O
recombinant	O
proteins	O
expressed	B-PROC
in	O
mammalian	O
cells	O
have	O
shown	O
the	O
greatest	O
potential	O
to	O
maintain	O
high	O
antigenicity	O
and	O
immunogenicity	O
.	O

Mortality	O
in	O
intubated	O
patients	O
receiving	O
a	O
combination	O
of	O
proning	O
and	O
APRV	O
was	O
27	O
.	O
3	O
%	O
(	O
3	O
/	O
11	O
)	O
with	O
2	O
of	O
these	O
dying	B-PROC
during	O
the	O
first	O
wave	O
of	O
the	O
H1N1	O
influenza	O
pandemic	O
.	O

The	O
protective	O
effects	O
of	O
increased	O
IL	O
-	O
10	O
levels	O
were	O
associated	O
with	O
reductions	O
in	O
microglial	O
activation	O
,	O
inflammatory	O
cell	O
infiltration	O
into	O
the	O
brain	O
,	O
and	O
proinflammatory	O
cytokine	O
and	O
chemokine	B-PROC
production	I-PROC
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
survive	O
and	O
propagate	O
,	O
RNA	O
viruses	O
must	O
achieve	O
a	O
balance	B-PROC
between	O
the	O
capacity	O
for	O
adaptation	B-PROC
to	O
new	O
environmental	O
conditions	O
or	O
host	O
cells	O
with	O
the	O
need	O
to	O
maintain	O
an	O
intact	O
and	O
replication	O
competent	O
genome	O
.	O

Elucidation	O
of	O
the	O
mechanisms	O
of	O
nsp14	O
-	O
mediated	O
proofreading	O
will	O
have	O
major	O
implications	O
for	O
our	O
understanding	O
of	O
the	O
evolution	B-PROC
of	O
RNA	O
viruses	O
,	O
and	O
also	O
will	O
provide	O
a	O
robust	O
model	O
to	O
investigate	O
the	O
balance	B-PROC
between	O
fidelity	O
,	O
diversity	O
and	O
pathogenesis	B-PROC
.	O

Polyclonal	O
antibodies	O
raised	O
against	O
expressed	B-PROC
S1	O
(	O
amino	O
acid	O
position	O
1	O
to	O
573	O
from	O
start	O
codon	O
of	O
S	O
protein	O
),	O
4F	O
/	O
4R	O
(	O
482	O
-	O
678	O
),	O
6F	O
/	O
6R	O
(	O
830	O
-	O
1071	O
),	O
or	O
Mod4F	O
/	O
Epi4R	O
(	O
476	O
-	O
520	O
)	O
S	O
fragment	O
recognized	O
native	O
S1	O
protein	O
and	O
TCoV	O
in	O
the	O
intestines	O
of	O
TCoV	O
-	O
infected	O
turkey	O
embryos	O
.	O

A	O
combined	O
ligand	B-PROC
and	O
structure	O
-	O
based	O
virtual	O
screening	O
was	O
carried	O
out	O
against	O
the	O
Asinex	O
Platinum	O
collection	O
.	O

Twelve	O
patients	O
(	O
50	O
%)	O
died	B-PROC
in	O
the	O
first	O
3	O
days	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
investigate	O
whether	O
soluble	O
endothelial	O
selectin	B-PROC
(	O
sES	O
)	O
could	O
be	O
a	O
biomarker	O
for	O
ALI	O
.	O

Cell	O
-	O
to	O
-	O
cell	B-PROC
fusion	I-PROC
of	O
PEDV	O
-	O
infected	O
cells	O
and	O
cleavage	B-PROC
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
were	O
observed	O
in	O
cells	O
with	O
protease	O
.	O

Evolution	B-PROC
to	O
ARDS	O
was	O
found	O
in	O
eight	O
cases	O
that	O
necessitated	O
ICU	O
care	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
B	O
virus	O
core	O
antibody	B-PROC
(	O
HBcAb	O
)-	O
positive	O
organ	O
donors	O
have	O
the	O
potential	O
to	O
transmit	O
infection	O
to	O
transplant	O
recipients	O
.	O

We	O
previously	O
identified	O
mucroporin	O
,	O
a	O
cationic	O
host	B-PROC
defense	I-PROC
peptide	O
from	O
scorpion	O
venom	O
,	O
which	O
can	O
effectively	O
inhibit	O
standard	O
bacteria	O
.	O

The	O
PEEP	O
was	O
then	O
progressively	O
reduced	O
until	O
the	O
PaO	B-PROC
(	O
2	O
)	O
decreased	O
by	O
more	O
than	O
10	O
%	O
of	O
the	O
maximum	O
PaO	B-PROC
(	O
2	O
);	O
the	O
PEEP	O
was	O
subsequently	O
set	O
to	O
2	O
cmH	O
(	O
2	O
)	O
O	O
above	O
this	O
level	O
.	O

RESULTS	O
:	O
Two	O
hours	O
after	O
the	O
RM	O
,	O
the	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
higher	O
than	O
at	O
baseline	O
(	O
187	O
±	O
102	O
versus	O
339	O
±	O
136	O
mmHg	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
have	O
also	O
revealed	O
that	O
this	O
NES	O
activity	O
influences	O
the	O
half	O
-	O
life	O
of	O
9b	O
and	O
affects	O
host	O
cell	B-PROC
death	I-PROC
.	O

Here	O
,	O
we	O
showed	O
that	O
nuclear	O
shuttling	O
of	O
9b	O
and	O
its	O
interaction	O
with	O
Crm1	O
are	O
essential	O
for	O
the	O
proper	O
degradation	O
of	O
9b	O
and	O
blocking	O
the	O
nuclear	B-PROC
export	I-PROC
of	O
this	O
protein	O
induces	O
apoptosis	B-PROC
.	O

Optimal	O
treatment	O
involves	O
judicious	O
fluid	O
management	O
,	O
protective	O
lung	O
ventilation	O
with	O
low	O
tidal	O
volumes	O
and	O
moderate	O
positive	O
end	O
expiratory	B-PROC
pressure	O
,	O
multi	O
-	O
organ	O
support	O
,	O
and	O
treatment	O
where	O
possible	O
of	O
the	O
underlying	O
cause	O
.	O

There	O
was	O
dramatic	O
improvement	O
in	O
the	O
hemodynamic	B-PROC
and	O
respiratory	B-PROC
function	I-PROC
directly	O
after	O
laparotomy	O
.	O

We	O
hypothesize	O
that	O
the	O
slowing	O
effects	O
of	O
hibernation	B-PROC
on	O
metabolic	B-PROC
and	O
viral	O
activity	O
maintains	O
infected	O
individuals	O
and	O
their	O
pathogens	O
until	O
susceptibles	O
from	O
the	O
annual	O
birth	B-PROC
pulse	B-PROC
become	O
infected	O
and	O
continue	O
the	O
cycle	O
.	O

ABSTRACT	O
:	O
Ulcerative	O
dermatitis	O
caused	O
by	O
feline	O
herpes	O
virus	O
1	O
(	O
FHV	O
-	O
1	O
)	O
is	O
an	O
uncommon	O
disease	O
characterized	O
by	O
cutaneous	O
ulcers	O
secondary	O
to	O
epidermal	O
,	O
adnexal	O
and	O
dermal	O
necrosis	B-PROC
.	O

The	O
nine	O
patients	O
(	O
28	O
·	O
1	O
%)	O
who	O
died	B-PROC
had	O
greater	O
initial	O
severity	O
of	O
illness	O
(	O
SAPS	O
II	O
and	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
scores	O
)	O
but	O
also	O
a	O
higher	O
SOFA	O
score	O
and	O
increasing	O
severity	O
of	O
organ	O
dysfunction	O
during	O
their	O
ICU	O
evolution	B-PROC
.	O

This	O
review	O
encompasses	O
the	O
initial	O
management	O
which	O
is	O
subdivided	O
into	O
analgesia	B-PROC
,	O
investigations	O
and	O
supportive	O
care	O
.	O

Diuresis	B-PROC
,	O
respiratory	O
support	O
,	O
vasodilator	O
therapy	O
,	O
and	O
gradual	O
attenuation	O
of	O
the	O
activation	O
of	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
(	O
RAAS	O
)	O
and	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
are	O
the	O
keystones	O
of	O
AHFS	O
management	O
.	O

These	O
results	O
suggested	O
that	O
the	O
removal	O
of	O
gene	O
7	O
promoted	O
an	O
intensified	O
dsRNA	O
-	O
activated	O
host	O
antiviral	B-PROC
response	I-PROC
.	O

Moreover	O
,	O
the	O
interaction	O
between	O
protein	O
7	O
and	O
PP1	O
was	O
required	O
,	O
during	O
the	O
infection	O
,	O
for	O
eIF2α	O
dephosphorylation	B-PROC
and	O
inhibition	B-PROC
of	O
cell	O
RNA	B-PROC
degradation	I-PROC
.	O

As	O
a	O
result	O
,	O
all	O
infected	O
mice	O
died	B-PROC
within	O
9	O
days	O
postinfection	O
.	O

RESULTS	O
:	O
Adverse	O
event	O
reports	O
identified	O
three	O
health	O
care	O
workers	O
who	O
developed	O
nevirapine	O
-	O
associated	O
Stevens	O
-	O
Johnson	O
syndrome	O
following	O
occupational	O
exposure	O
to	O
HIV	O
-	O
infected	O
blood	O
or	O
blood	O
products	O
;	O
four	O
persons	O
with	O
localized	O
hypersensitivity	B-PROC
and	O
fatal	O
cardiac	O
events	O
associated	O
with	O
rapamycin	O
-	O
or	O
paclitaxel	O
-	O
coated	O
coronary	O
artery	O
stent	O
placements	O
;	O
and	O
six	O
persons	O
with	O
breast	O
cancer	O
who	O
developed	O
severe	O
or	O
fatal	O
anaphylaxis	O
after	O
receiving	O
adjuvant	O
chemotherapy	O
with	O
Cremophor	O
-	O
EL	O
containing	O
paclitaxel	O
.	O

TITLE	O
:	O
Bacterial	O
expression	B-PROC
of	O
antigenic	O
sites	O
A	O
and	O
D	O
in	O
the	O
spike	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
and	O
evaluation	O
of	O
their	O
inhibitory	O
effects	O
on	O
viral	B-PROC
infection	I-PROC
.	O

In	O
these	O
patients	O
,	O
rescue	O
therapies	O
such	O
as	O
high	O
-	O
frequency	O
ventilation	O
,	O
prone	O
ventilation	O
,	O
nitric	O
oxide	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
are	O
considered	O
.	O

In	O
this	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
severe	O
smoke	O
inhalation	B-PROC
in	O
swine	O
,	O
airway	O
pressure	O
release	O
ventilation	O
-	O
treated	O
animals	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
faster	O
than	O
conventional	O
mechanical	O
ventilation	O
-	O
treated	O
animals	O
,	O
showing	O
a	O
lower	O
PaO2	O
/	O
Fio2	O
ratio	O
at	O
12	O
,	O
18	O
,	O
and	O
24	O
hrs	O
after	O
injury	O
.	O

Based	O
on	O
these	O
facts	O
,	O
the	O
field	O
IBV	O
in	O
Thailand	O
has	O
undergone	O
genetic	B-PROC
recombination	I-PROC
.	O

Specifically	O
,	O
we	O
review	O
the	O
effects	O
of	O
hypercapnia	O
and	O
acidosis	O
on	O
the	O
attenuation	O
of	O
pulmonary	O
inflammation	O
,	O
reduction	O
of	O
apoptosis	B-PROC
in	O
alveolar	O
epithelial	O
cells	O
,	O
improvement	O
in	O
sepsis	O
-	O
induced	O
ALI	O
and	O
the	O
therapeutic	O
effects	O
on	O
other	O
organ	O
systems	O
,	O
as	O
well	O
as	O
the	O
potentially	O
harmful	O
effects	O
of	O
these	O
strategies	O
.	O

Rainfall	O
simulations	O
on	O
stream	O
banks	O
resulted	O
in	O
greater	O
(	O
<	O
0	O
.	O
10	O
)	O
proportions	O
of	O
applied	O
precipitation	B-PROC
and	O
amounts	O
of	O
sediment	O
and	O
P	O
transported	O
in	O
runoff	O
from	O
bare	O
sites	O
than	O
from	O
vegetated	O
sites	O
across	O
grazing	O
treatments	O
.	O

RESULTS	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
was	O
tolerated	O
well	O
;	O
no	O
adverse	O
effects	O
or	O
severe	O
hyperinflation	O
and	O
hemodynamic	B-PROC
compromise	O
were	O
observed	O
.	O

Relocation	O
of	O
the	O
active	O
domain	O
upstream	O
of	O
the	O
N	O
gene	O
TRS	O
core	O
sequence	O
in	O
the	O
absence	O
of	O
the	O
proximal	O
and	O
distal	O
elements	O
also	O
enhanced	O
sgmRNA	O
N	O
transcription	B-PROC
.	O

SL1	O
and	O
SL2	O
are	O
required	O
for	O
subgenomic	O
RNA	B-PROC
synthesis	I-PROC
.	O

These	O
results	O
suggest	O
that	O
the	O
proposed	O
SL4	O
in	O
the	O
MHV	O
5	O
'	O
UTR	O
functions	O
in	O
part	O
as	O
a	O
spacer	O
element	O
that	O
orients	O
SL1	O
,	O
SL2	O
,	O
and	O
the	O
transcriptional	B-PROC
regulatory	O
sequence	O
(	O
TRS	O
),	O
and	O
this	O
spacer	O
function	O
may	O
play	O
an	O
important	O
role	O
in	O
directing	O
subgenomic	O
RNA	B-PROC
synthesis	I-PROC
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
5	O
patients	O
with	O
bronchial	O
fistula	O
with	O
severe	O
acute	O
lung	O
injury	O
.	O

This	O
strategy	O
allowed	O
fistula	O
healing	B-PROC
in	O
3	O
patients	O
.	O

However	O
,	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
which	O
was	O
previously	O
absent	O
from	O
HiP	O
,	O
appears	O
to	O
have	O
been	O
introduced	O
into	O
the	O
lion	O
population	O
through	O
translocation	B-PROC
.	O

A	O
2	O
-	O
dimensional	O
Doppler	O
echocardiogram	O
showed	O
a	O
dilated	O
and	O
poorly	O
contractile	B-PROC
left	O
ventricle	O
,	O
severe	O
aortic	O
regurgitation	O
,	O
and	O
a	O
large	O
aneurysm	O
of	O
the	O
sinus	O
of	O
Valsalva	O
.	O

In	O
this	O
review	O
,	O
those	O
variables	O
are	O
defined	O
as	O
PaO	B-PROC
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
≤	O
100	O
mm	O
Hg	O
and	O
≥	O
15	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
respectively	O
.	O

These	O
AER	O
/	O
AED	O
mice	O
developed	O
life	O
-	O
threatening	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
displayed	O
by	O
diffuse	O
alveolar	O
damage	O
(	O
DAD	O
)	O
resulting	O
from	O
i	O
)	O
dramatic	O
interstitial	O
alveolar	O
septa	O
-	O
thickening	O
with	O
mononuclear	O
cells	O
,	O
ii	O
)	O
some	O
hyperplasia	O
of	O
alveolar	O
type	O
-	O
II	O
pneumocytes	O
,	O
iii	O
)	O
copious	O
intra	O
-	O
alveolar	O
protein	B-PROC
secretion	I-PROC
,	O
iv	O
)	O
some	O
hyaline	O
membrane	O
-	O
covered	O
alveolar	O
walls	O
,	O
and	O
v	O
)	O
DENV	O
-	O
2	O
antigen	O
-	O
positive	O
alveolar	O
macrophages	O
.	O

Their	O
spleens	O
contained	O
infiltrated	O
megakaryocytes	O
with	O
DENV	O
-	O
2	O
antigen	O
-	O
positive	O
red	O
-	O
pulp	O
macrophages	O
,	O
while	O
their	O
livers	O
displayed	O
extensive	O
necrosis	B-PROC
,	O
apoptosis	B-PROC
and	O
macro	O
-	O
and	O
micro	O
-	O
steatosis	O
,	O
with	O
DENV	O
-	O
2	O
antigen	O
-	O
positive	O
Kuppfer	O
cells	O
and	O
hepatocytes	O
.	O

Similarly	O
,	O
nuclear	O
trafficking	B-PROC
of	O
the	O
RSV	O
Gag	O
protein	O
is	O
required	O
for	O
efficient	O
encapsidation	O
of	O
the	O
viral	O
genomic	O
RNA	O
(	O
gRNA	O
)	O
into	O
assembling	O
virus	O
particles	O
.	O
19	O
Recently	O
,	O
we	O
reported	O
that	O
the	O
viral	O
RNA	O
itself	O
appears	O
to	O
be	O
a	O
key	O
factor	O
in	O
controlling	O
the	O
nucleus	O
/	O
cytosol	O
distribution	O
of	O
RSV	O
Gag	O
.	O
22	O
Our	O
data	O
demonstrate	O
that	O
binding	O
of	O
RSV	O
RNA	O
to	O
the	O
Gag	O
protein	O
promotes	O
Gag	O
-	O
CRM1	O
-	O
RanGTP	O
binding	O
,	O
resulting	O
in	O
export	O
of	O
the	O
retroviral	O
RNP	O
from	O
the	O
nucleus	O
.	O

It	O
is	O
a	O
condensed	B-PROC
version	O
of	O
a	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
Working	O
Paper	O
prepared	O
for	O
the	O
WHO	O
Working	O
Group	O
on	O
Ethics	O
and	O
Tuberculosis	O
.	O

ABSTRACT	O
:	O
Multiple	O
respiratory	B-PROC
chain	I-PROC
deficiencies	O
represent	O
a	O
common	O
cause	O
of	O
mitochondrial	O
diseases	O
and	O
often	O
result	O
in	O
hepatic	O
failure	O
.	O

The	O
description	O
of	O
a	O
third	O
syndrome	O
associated	O
with	O
a	O
same	O
TSFM	O
mutation	O
gives	O
support	O
to	O
the	O
broad	O
clinical	O
and	O
genetic	O
heterogeneity	O
of	O
mitochondrial	B-PROC
translation	B-PROC
deficiencies	O
in	O
human	O
.	O

It	O
suggests	O
that	O
mitochondrial	B-PROC
translation	B-PROC
deficiency	O
represents	O
a	O
growing	O
cause	O
of	O
hepatic	O
failure	O
of	O
mitochondrial	O
origin	O
in	O
infants	O
.	O

Despite	O
all	O
endeavors	O
,	O
the	O
respiratory	O
situation	O
could	O
not	O
be	O
improved	O
significantly	O
;	O
the	O
patient	O
additionally	O
developed	O
multiorgan	O
failure	O
during	O
the	O
time	O
course	O
and	O
died	B-PROC
on	O
the	O
28th	O
day	O
of	O
treatment	O
.	O

ABSTRACT	O
:	O
The	O
inhibitory	O
receptor	O
programmed	O
death	B-PROC
-	O
1	O
(	O
PD	O
-	O
1	O
)	O
has	O
the	O
capacity	O
to	O
maintain	O
peripheral	O
tolerance	B-PROC
and	O
limit	O
immunopathological	O
damage	O
;	O
however	O
,	O
its	O
precise	O
role	O
in	O
fulminant	O
viral	O
hepatitis	O
(	O
FH	O
)	O
has	O
yet	O
to	O
be	O
described	O
.	O

TITLE	O
:	O
Cell	O
-	O
type	O
-	O
specific	O
type	O
I	O
interferon	O
antagonism	O
influences	O
organ	O
tropism	B-PROC
of	O
murine	O
coronavirus	O
.	O

Upon	O
high	O
-	O
multiplicity	O
infection	O
,	O
CsA	O
treatment	O
rendered	O
SARS	O
-	O
CoV	O
RNA	O
and	O
protein	B-PROC
synthesis	I-PROC
almost	O
undetectable	O
,	O
suggesting	O
an	O
early	O
block	O
in	O
replication	O
.	O

The	O
enzyme	O
responsible	O
for	O
its	O
synthesis	B-PROC
,	O
Angiotensin	O
-	O
converting	O
-	O
enzyme	O
(	O
ACE	O
),	O
is	O
present	O
in	O
high	O
concentrations	O
in	O
lung	O
tissue	O
.	O

Twenty	O
-	O
two	O
(	O
39	O
%)	O
had	O
severe	O
malaria	O
;	O
of	O
these	O
,	O
6	O
(	O
27	O
%)	O
died	B-PROC
.	O

Pathophysiological	O
mechanisms	O
implicated	O
in	O
the	O
development	B-PROC
of	O
AEP	O
in	O
our	O
patient	O
seems	O
to	O
be	O
associated	O
with	O
eotaxin	O
and	O
serotonin	O
eosinophilic	O
-	O
specific	O
chemoattracting	O
action	O
.	O

These	O
findings	O
illuminate	O
the	O
origin	O
and	O
the	O
evolutionary	O
history	O
of	O
the	O
SARS	O
-	O
CoV	O
group	O
found	O
in	O
bats	O
by	O
pushing	B-PROC
forward	O
the	O
hypothesis	O
of	O
a	O
Betacoronavirus	O
spill	O
-	O
over	O
from	O
Hipposideridae	O
to	O
Rhinolophidae	O
and	O
then	O
from	O
Rhinolophidae	O
to	O
civets	O
and	O
Human	O
.	O

A	O
minority	O
had	O
lower	O
PaO₂	O
/	O
FiO₂	O
(	O
32	O
.	O
5	O
%)	O
or	O
a	O
hemodynamic	B-PROC
(	O
27	O
.	O
5	O
%)	O
or	O
ventilatory	O
(	O
30	O
.	O
5	O
%)	O
complication	O
.	O

But	O
lung	O
-	O
protective	O
ventilation	O
with	O
adjusted	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
remains	O
the	O
most	O
effective	O
therapeutic	O
tool	O
despite	O
advances	O
in	O
prone	O
positioning	O
,	O
inhalation	B-PROC
of	O
nitric	O
oxide	O
and	O
the	O
use	O
of	O
steroids	O
.	O

TITLE	O
:	O
[	O
Expression	B-PROC
and	O
purification	O
of	O
different	O
segments	O
from	O
HCoV	O
-	O
NL63	O
nucleocapsid	O
protein	O
and	O
their	O
application	O
in	O
detection	O
of	O
antibodies	O
].	O

Their	O
expression	B-PROC
location	O
in	O
cell	O
and	O
level	O
were	O
characterized	O
using	O
indirect	O
immune	O
fluorescence	O
assay	O
(	O
IFA	O
)	O
and	O
Western	O
-	O
Blot	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
It	O
is	O
anticipated	O
that	O
the	O
next	O
generation	O
of	O
computational	O
epidemic	O
models	O
will	O
simulate	O
both	O
infectious	O
disease	O
transmission	O
and	O
dynamic	O
human	O
behaviour	B-PROC
change	O
.	O

RESULTS	O
:	O
All	O
participants	O
who	O
were	O
still	O
working	O
in	O
the	O
isolation	O
wards	O
during	O
the	O
novel	O
H1N1	O
pandemic	O
showed	O
professional	O
senses	B-PROC
that	O
were	O
strongly	O
related	O
to	O
the	O
willingness	O
to	O
work	O
.	O

More	O
scientists	O
are	O
focusing	O
on	O
therapies	O
involving	O
stem	O
cells	O
,	O
which	O
have	O
self	O
-	O
renewing	O
capabilities	O
and	O
differentiate	O
into	O
multiple	O
cell	O
lineages	O
,	O
and	O
,	O
genomics	O
therapy	O
which	O
has	O
the	O
potential	O
to	O
upregulate	O
expression	B-PROC
of	O
anti	O
-	O
inflammatory	O
mediators	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
,	O
antiviral	O
and	O
cytotoxic	O
investigation	O
of	O
2	O
-	O
phenyl	O
-	O
3	O
-	O
substituted	O
quinazolin	O
-	O
4	O
(	O
3H	O
)-	O
ones	O
.	O

Compound	O
3d	O
was	O
found	O
inhibit	O
viral	B-PROC
replication	I-PROC
of	O
para	O
influenza	O
-	O
3virus	O
,	O
reovirus	O
-	O
1	O
,	O
Sindbis	O
virus	O
,	O
Coxsackie	O
virus	O
B4	O
,	O
Punta	O
Toro	O
virus	O
in	O
Vero	O
cell	O
cultures	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
mediates	O
both	O
cell	B-PROC
attachment	I-PROC
by	O
binding	O
to	O
its	O
receptor	O
hACE2	O
and	O
membrane	B-PROC
fusion	I-PROC
during	O
virus	O
entry	O
.	O

Base	O
-	O
pairing	O
to	O
create	O
the	O
pseudoknot	O
-	O
forming	O
stem	O
(	O
P1	O
(	O
pk	O
))	O
is	O
mutually	O
exclusive	O
with	O
formation	B-PROC
of	O
stem	O
P0a	O
at	O
the	O
base	O
of	O
the	O
bulged	O
stem	O
-	O
loop	O
;	O
as	O
a	O
result	O
,	O
the	O
two	O
structures	O
cannot	O
be	O
present	O
simultaneously	O
.	O

TITLE	O
:	O
[	O
Co	O
-	O
localization	B-PROC
analysis	O
between	O
porcine	O
epidemic	O
diarrhea	O
virus	O
nucleocapsid	O
protein	O
and	O
nucleolar	O
phosphoprotein	O
B23	O
.	O
1	O
].	O

ABSTRACT	O
:	O
To	O
elucidate	O
the	O
co	O
-	O
localization	B-PROC
characteristic	O
between	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
N	O
protein	O
and	O
B23	O
.	O
1	O
phosphoprotein	O
.	O

The	O
PEDV	O
N	O
gene	O
and	O
B23	O
.	O
1	O
gene	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
from	O
PEDV	O
strain	O
CV777	O
and	O
Vero	O
E6	O
cells	O
,	O
respectively	O
;	O
then	O
cloned	O
into	O
eukaryotic	O
expression	B-PROC
vector	O
pAcGFP1	O
-	O
C1	O
and	O
pDsRed2	O
-	O
N1	O
,	O
to	O
generate	O
the	O
recombinant	O
plasmids	O
pAcGFP1	O
-	O
C1	O
/	O
N	O
and	O
pDsRed2	O
-	O
N1	O
/	O
B23	O
.	O
1	O
,	O
respectively	O
.	O

Despite	O
their	O
similarities	O
,	O
these	O
proteins	O
are	O
involved	O
in	O
distinct	O
RNA	O
-	O
processing	O
pathways	B-PROC
in	O
different	O
organisms	O
.	O

The	O
identified	O
compounds	O
,	O
while	O
allowing	O
deep	O
investigation	O
of	O
the	O
molecular	O
functions	O
of	O
this	O
enzyme	O
family	O
,	O
may	O
also	O
represent	O
leads	O
for	O
the	O
development	B-PROC
of	O
new	O
therapeutic	O
tools	O
.	O

A	O
subset	O
of	O
79	O
participants	O
completed	O
pulmonary	B-PROC
function	I-PROC
testing	O
.	O

In	O
contrast	O
,	O
adults	O
who	O
reported	O
recurrent	O
,	O
severe	O
episodes	O
of	O
wheezing	O
(	O
N	O
=	O
34	O
),	O
regardless	O
of	O
asthma	O
,	O
had	O
twice	O
the	O
rates	O
of	O
pain	O
and	O
ACS	O
,	O
decreased	O
lung	B-PROC
function	I-PROC
and	O
increased	O
risk	O
of	O
death	B-PROC
compared	O
with	O
adults	O
without	O
recurrent	O
,	O
severe	O
wheezing	O
.	O

In	O
this	O
study	O
,	O
we	O
first	O
investigated	O
at	O
6	O
years	O
postinfection	O
whether	O
SARS	O
-	O
specific	O
memory	B-PROC
T	O
cells	O
persist	O
in	O
SARS	O
-	O
recovered	O
individuals	O
,	O
demonstrating	O
that	O
these	O
subjects	O
still	O
possess	O
polyfunctional	O
SARS	O
-	O
specific	O
memory	B-PROC
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
.	O

These	O
engineered	O
CD8	O
+	O
T	O
cells	O
displayed	O
avidity	O
and	O
functionality	O
similar	O
to	O
that	O
of	O
natural	O
SARS	O
-	O
specific	O
memory	B-PROC
CD8	O
+	O
T	O
cells	O
.	O

Searches	O
of	O
MEDLINE	O
(	O
1975	O
-	O
May	O
2011	O
),	O
EMBASE	O
(	O
1980	O
-	O
May	O
2011	O
),	O
and	O
Cumulative	O
Index	O
to	O
Nursing	B-PROC
and	O
Allied	O
Health	O
Literature	O
(	O
1981	O
-	O
May	O
2011	O
)	O
were	O
conducted	O
to	O
identify	O
observational	O
and	O
interventional	O
studies	O
evaluating	O
the	O
efficacy	O
or	O
safety	O
of	O
NMBAs	O
for	O
management	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
status	O
asthmaticus	O
,	O
elevated	O
intracranial	B-PROC
pressure	I-PROC
(	O
ICP	O
),	O
and	O
therapeutic	O
hypothermia	O
.	O

In	O
this	O
work	O
we	O
used	O
circular	O
dichroism	O
to	O
show	O
that	O
HR2	O
helix	O
formation	B-PROC
is	O
induced	O
at	O
pH	O
5	O
,	O
the	O
pH	O
of	O
the	O
endosome	O
.	O

ARDS	O
is	O
caused	O
by	O
an	O
excessive	O
innate	B-PROC
immune	I-PROC
response	I-PROC
with	O
a	O
clear	O
role	O
for	O
neutrophils	O
.	O

At	O
3	O
,	O
9	O
and	O
24	O
h	O
after	O
injury	O
,	O
the	O
expression	B-PROC
of	O
circulating	O
activating	O
molecules	O
on	O
neutrophils	O
and	O
levels	O
of	O
circulating	O
interleukine	O
(	O
IL	O
)-	O
6	O
were	O
determined	O
.	O

Expression	B-PROC
of	O
l	O
-	O
selectin	B-PROC
,	O
CXCR2	O
and	O
C5aR	O
was	O
partially	O
restored	O
at	O
24	O
h	O
after	O
injury	O
.	O

In	O
addition	O
,	O
the	O
mean	O
expression	B-PROC
of	O
FcγRIII	O
(	O
CD16	O
)	O
dropped	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
indicating	O
the	O
recruitment	O
of	O
young	O
neutrophils	O
into	O
the	O
circulation	B-PROC
.	O

With	O
the	O
former	O
,	O
an	O
emphasis	O
on	O
individualized	O
self	O
-	O
protection	O
,	O
in	O
the	O
health	O
sense	B-PROC
,	O
justified	O
the	O
generalized	O
avoidance	O
of	O
those	O
stigmatized	O
.	O

TITLE	O
:	O
Massive	O
systemic	O
air	O
embolism	O
during	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
of	O
a	O
neonate	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
cardiac	O
surgery	O
.	O

They	O
were	O
44	O
±	O
15	O
years	O
of	O
age	O
,	O
with	O
Acute	O
Physiology	O
And	O
Chronic	O
Health	O
Evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
scores	O
of	O
18	O
±	O
7	O
,	O
and	O
most	O
frequent	O
comorbidities	O
were	O
obesity	O
(	O
26	O
%),	O
previous	O
respiratory	O
disease	O
(	O
24	O
%)	O
and	O
immunosuppression	B-PROC
(	O
16	O
%).	O

Death	B-PROC
and	O
evolution	B-PROC
to	O
prolonged	O
mechanical	O
ventilation	O
were	O
common	O
outcomes	O
.	O

ABSTRACT	O
:	O
Although	O
human	O
coronavirus	O
OC43	O
-	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
is	O
the	O
coronavirus	O
most	O
commonly	O
associated	O
with	O
human	O
infections	O
,	O
little	O
is	O
known	O
about	O
its	O
molecular	O
epidemiology	O
and	O
evolution	B-PROC
.	O

ABSTRACT	O
:	O
The	O
effect	O
of	O
sialodacryoadenitis	O
virus	O
(	O
SDAV	O
)	O
infection	O
on	O
axonal	O
regeneration	B-PROC
and	O
functional	O
recovery	O
was	O
investigated	O
in	O
male	O
Lewis	O
rats	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
receptor	O
-	O
interacting	O
protein	O
kinases	O
(	O
RIPKs	O
)	O
RIPK1	O
and	O
RIPK3	O
together	O
facilitate	O
TNF	O
-	O
induced	O
necroptosis	B-PROC
,	O
but	O
the	O
precise	O
role	O
of	O
RIPKs	O
in	O
the	O
demise	O
of	O
T	O
cells	O
lacking	O
FADD	O
or	O
casp8	O
activity	O
is	O
unknown	O
.	O

TITLE	O
:	O
Thioacetamide	O
-	O
induced	O
fulminant	O
hepatic	O
failure	O
induces	O
cerebral	O
mitochondrial	O
dysfunction	O
by	O
altering	O
the	O
electron	B-PROC
transport	I-PROC
chain	I-PROC
complexes	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
role	O
of	O
cerebral	O
electron	B-PROC
transport	I-PROC
chain	I-PROC
complexes	O
,	O
including	O
complex	O
I	O
,	O
II	O
,	O
III	O
IV	O
,	O
and	O
pyruvate	O
dehydrogenase	O
in	O
the	O
non	O
-	O
synaptic	O
mitochondria	O
isolated	O
from	O
the	O
cortex	O
of	O
the	O
thioacetamide	O
-	O
induced	O
FHF	O
rats	O
.	O

Our	O
results	O
also	O
suggest	O
mitochondrial	B-PROC
swelling	I-PROC
in	O
FHF	O
induced	O
rats	O
.	O

LF	O
may	O
play	O
a	O
protective	O
role	O
in	O
host	B-PROC
defense	I-PROC
against	O
SARS	O
-	O
CoV	O
infection	O
through	O
binding	O
to	O
HSPGs	O
and	O
blocking	O
the	O
preliminary	O
interaction	O
between	O
SARS	O
-	O
CoV	O
and	O
host	O
cells	O
.	O

ABSTRACT	O
:	O
MTU1	O
(	O
TRMU	O
)	O
is	O
a	O
mitochondrial	O
enzyme	O
responsible	O
for	O
the	O
2	O
-	O
thiolation	O
of	O
the	O
wobble	O
U	O
in	O
tRNA	O
(	O
Lys	O
),	O
tRNA	O
(	O
Glu	O
)	O
and	O
tRNA	O
(	O
Gln	O
),	O
a	O
post	O
-	O
transcriptional	B-PROC
modification	O
believed	O
to	O
be	O
important	O
for	O
accurate	O
and	O
efficient	O
synthesis	B-PROC
of	O
the	O
13	O
respiratory	B-PROC
chain	I-PROC
subunits	O
encoded	O
by	O
mtDNA	O
.	O

The	O
only	O
respiratory	B-PROC
chain	I-PROC
abnormality	O
that	O
we	O
could	O
observe	O
in	O
these	O
cells	O
was	O
an	O
accumulation	O
of	O
a	O
Complex	B-PROC
II	I-PROC
assembly	O
intermediate	O
,	O
which	O
,	O
however	O
,	O
did	O
not	O
affect	O
the	O
level	O
of	O
the	O
fully	O
assembled	O
enzyme	O
.	O

Quantitation	O
by	O
qPCR	O
of	O
the	O
transcript	O
levels	O
of	O
ChPLA2	O
-	O
IB	O
,	O
-	O
IIA	O
,	O
-	O
IIE	O
,	O
-	O
V	O
and	O
-	O
X	O
in	O
several	O
tissues	O
from	O
healthy	O
chicken	O
indicated	O
that	O
the	O
expression	B-PROC
patterns	O
and	O
mRNA	O
levels	O
diverged	O
among	O
the	O
phospholipases	O
tested	O
.	O

In	O
addition	O
,	O
a	O
meta	O
-	O
analysis	O
was	O
conducted	O
on	O
the	O
association	O
between	O
sudden	O
infant	O
death	B-PROC
syndrome	O
(	O
SIDS	O
)	O
and	O
maternal	O
smoking	O
during	O
pregnancy	O
as	O
well	O
as	O
postnatal	O
exposure	O
to	O
environmental	O
tobacco	O
smoke	O
(	O
ETS	O
).	O

ABSTRACT	O
:	O
Perturbation	O
of	O
cell	B-PROC
cycle	I-PROC
regulation	I-PROC
is	O
a	O
characteristic	O
feature	O
of	O
infection	O
by	O
many	O
DNA	O
and	O
RNA	O
viruses	O
,	O
including	O
Coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

IBV	O
infection	O
was	O
shown	O
to	O
induce	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
at	O
both	O
S	O
and	O
G	O
(	O
2	O
)/	O
M	B-PROC
phases	I-PROC
for	O
the	O
enhancement	O
of	O
viral	B-PROC
replication	I-PROC
and	O
progeny	O
production	O
.	O

Fever	B-PROC
and	O
cough	O
were	O
the	O
most	O
frequent	O
symptoms	O
reported	O
in	O
all	O
age	O
groups	O
.	O

There	O
is	O
concern	O
about	O
adverse	O
effects	O
,	O
especially	O
growth	B-PROC
and	O
adrenal	O
suppression	B-PROC
,	O
induced	O
by	O
systemic	O
CS	O
in	O
children	O
.	O

A	O
bronchoscopic	O
grading	O
for	O
inhalation	B-PROC
injury	O
has	O
been	O
proposed	O
but	O
has	O
not	O
yet	O
been	O
validated	O
in	O
burn	O
patients	O
.	O

They	O
also	O
compared	O
changes	O
in	O
oxygenation	B-PROC
,	O
airway	O
pressures	O
,	O
chest	O
radiograph	O
findings	O
,	O
fluid	O
administration	O
,	O
and	O
early	O
development	B-PROC
of	O
pneumonia	O
and	O
organ	O
failure	O
,	O
by	O
severity	O
of	O
inhalation	B-PROC
injury	O
according	O
to	O
the	O
AIS	O
.	O

Oxygenation	B-PROC
indices	O
were	O
worse	O
as	O
grade	O
worsened	O
by	O
24	O
,	O
48	O
,	O
and	O
72	O
hours	O
.	O

A	O
specific	O
therapy	O
by	O
intravenous	O
polyvalent	O
immunoglobulin	B-PROC
was	O
prescribed	O
for	O
14	O
patients	O
.	O

Tumor	O
necrosis	B-PROC
factor	O
α	O
was	O
significantly	O
elevated	O
in	O
all	O
types	O
of	O
organ	O
failures	O
,	O
except	O
for	O
intestinal	O
failure	O
.	O

TITLE	O
:	O
Regulation	B-PROC
of	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
and	O
dual	O
-	O
specificity	O
phosphatase	O
1	O
feedback	O
loop	O
modulates	O
the	O
induction	O
of	O
interleukin	O
6	O
and	O
8	O
in	O
cells	O
infected	O
with	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

Along	O
with	O
other	O
innate	B-PROC
immunity	B-PROC
,	O
this	O
nonspecific	O
response	O
would	O
either	O
clear	O
the	O
invading	O
viruses	O
or	O
allow	O
the	O
adaptive	O
immune	O
system	O
to	O
establish	O
an	O
effective	O
antiviral	B-PROC
response	I-PROC
at	O
late	O
stages	O
of	O
the	O
infection	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
characterize	O
cellular	O
mechanisms	O
exploited	O
by	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
to	O
regulate	O
the	O
induction	O
of	O
two	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	O
-	O
8	O
,	O
at	O
the	O
transcriptional	B-PROC
level	O
.	O

TITLE	O
:	O
IL	B-PROC
-	I-PROC
17	I-PROC
boosts	O
proinflammatory	O
outcome	O
of	O
antiviral	B-PROC
response	I-PROC
in	O
human	O
cells	O
.	O

Knockdown	O
of	O
expression	B-PROC
of	O
known	O
mediators	O
of	O
the	O
antiviral	O
signaling	B-PROC
pathway	I-PROC
revealed	O
that	O
the	O
IL	B-PROC
-	I-PROC
17	I-PROC
-	O
poly	O
(	O
I	O
:	O
C	O
)	O
synergy	O
depends	O
on	O
the	O
presence	O
of	O
the	O
transcriptional	B-PROC
factors	O
RelA	O
and	O
IFN	O
regulatory	O
factor	O
3	O
and	O
IκB	O
kinases	O
.	O

Production	O
of	O
DNA	O
fragment	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
induced	O
by	O
PEDV	O
infection	O
were	O
studied	O
using	O
DNA	B-PROC
fragmentation	I-PROC
assay	O
and	O
flow	O
cytometry	O
.	O

Also	O
,	O
Q7R	O
did	O
not	O
induce	O
DNA	B-PROC
fragmentation	I-PROC
.	O

Such	O
a	O
mechanism	O
allows	O
for	O
tight	O
temporal	O
control	O
over	O
fusion	O
by	O
protecting	O
the	O
activating	O
cleavage	B-PROC
site	O
from	O
premature	O
proteolysis	B-PROC
yet	O
allowing	O
efficient	O
cleavage	B-PROC
upon	O
binding	O
to	O
the	O
receptor	O
on	O
target	O
cells	O
.	O

Flame	O
burn	O
was	O
responsible	O
for	O
92	O
.	O
9	O
%	O
of	O
the	O
deaths	B-PROC
,	O
followed	O
by	O
5	O
.	O
3	O
%	O
of	O
deaths	B-PROC
due	O
to	O
chemical	O
burns	O
and	O
1	O
.	O
8	O
%	O
to	O
scalding	O
.	O

Ocular	B-PROC
sequelae	O
may	O
appear	O
after	O
the	O
acute	O
period	O
and	O
they	O
can	O
be	O
extremely	O
disabling	O
,	O
even	O
causing	O
almost	O
complete	O
loss	O
of	O
vision	B-PROC
.	O

Three	O
genotypes	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
of	O
HCoV	O
-	O
HKU1	O
and	O
homologous	B-PROC
recombination	B-PROC
among	O
their	O
genomes	O
,	O
are	O
observed	O
.	O

ABSTRACT	O
:	O
Recombination	B-PROC
in	O
the	O
family	O
Coronaviridae	O
has	O
been	O
well	O
documented	O
and	O
is	O
thought	O
to	O
be	O
a	O
contributing	O
factor	O
in	O
the	O
emergence	O
and	O
evolution	B-PROC
of	O
different	O
coronaviral	O
genotypes	O
as	O
well	O
as	O
different	O
species	O
of	O
coronavirus	O
.	O

Areas	O
that	O
have	O
the	O
highest	O
occurrence	O
of	O
recombination	B-PROC
are	O
located	O
in	O
regions	O
of	O
the	O
genome	O
that	O
code	O
for	O
nonstructural	O
proteins	O
2	O
,	O
3	O
and	O
16	O
,	O
and	O
the	O
structural	O
spike	O
glycoprotein	O
.	O

Incidences	O
of	O
critical	O
care	O
syndromes	O
were	O
respiratory	O
failure	O
,	O
430	O
(	O
390	O
-	O
470	O
);	O
acute	O
kidney	O
injury	O
,	O
290	O
(	O
257	O
-	O
323	O
);	O
severe	O
sepsis	O
,	O
286	O
(	O
253	O
-	O
319	O
);	O
all	O
-	O
cause	O
shock	O
,	O
194	O
(	O
167	O
-	O
221	O
);	O
acute	O
lung	O
injury	O
,	O
86	O
(	O
68	O
-	O
105	O
);	O
all	O
-	O
cause	O
coma	O
,	O
43	O
(	O
30	O
-	O
55	O
);	O
and	O
overt	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
18	O
(	O
10	O
-	O
26	O
).	O

The	O
remaining	O
four	O
patients	O
who	O
had	O
reduced	O
oxygen	O
requirements	O
received	O
surfactant	O
earlier	O
following	O
their	O
injury	O
(	O
4	O
.	O
8	O
±	O
0	O
.	O
9	O
days	O
postinjury	O
vs	O
17	O
.	O
7	O
±	O
8	O
days	O
postinjury	O
)	O
and	O
had	O
less	O
derangement	O
in	O
oxygenation	B-PROC
before	O
surfactant	O
dosing	O
(	O
PaO	B-PROC
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
:	O
105	O
.	O
2	O
±	O
26	O
.	O
4	O
vs	O
64	O
.	O
5	O
±	O
5	O
.	O
2	O
).	O

TITLE	O
:	O
Modification	O
of	O
a	O
high	O
frequency	O
oscillator	O
circuit	O
with	O
a	O
heated	O
expiratory	B-PROC
filter	O
to	O
prevent	O
infectious	O
pathogen	O
transmission	O
:	O
a	O
bench	O
study	O
.	O

We	O
modified	O
the	O
circuit	O
to	O
include	O
a	O
heated	O
expiratory	B-PROC
filter	O
,	O
eliminating	O
the	O
need	O
for	O
daily	O
filter	O
changes	O
due	O
to	O
buildup	O
of	O
condensate	O
.	O

ABSTRACT	O
:	O
The	O
D	O
allele	O
of	O
the	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	B-PROC
of	O
a	O
287	O
-	O
bp	O
sequence	O
in	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
gene	O
has	O
been	O
associated	O
with	O
an	O
increased	O
activity	O
of	O
this	O
enzyme	O
.	O

ACE	O
I	O
/	O
D	O
polymorphism	B-PROC
modified	O
angiotensin	O
-	O
II	O
levels	O
in	O
pediatric	O
ARDS	O
,	O
but	O
its	O
pathogenic	O
role	O
is	O
not	O
well	O
understood	O
and	O
needs	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

After	O
confirming	O
reactivity	O
of	O
the	O
recombinant	O
protein	O
pAPN	O
-	O
C	O
to	O
antibody	B-PROC
against	O
native	O
pAPN	O
,	O
polyclonal	O
antibody	B-PROC
against	O
the	O
recombinant	O
protein	O
pAPN	O
-	O
C	O
was	O
prepared	O
in	O
rabbit	O
using	O
purified	O
protein	O
as	O
immunogen	O
.	O

Viral	B-PROC
infections	I-PROC
are	O
especially	O
difficult	O
to	O
treat	O
and	O
the	O
CESAR	O
study	O
indicated	O
that	O
the	O
use	O
of	O
ECMO	O
or	O
extracorporeal	O
CO2	O
removal	O
devices	O
may	O
result	O
in	O
a	O
lower	O
mortality	O
when	O
compared	O
with	O
standard	O
therapy	O
.	O

Moreover	O
,	O
LA	O
-	O
N	O
-	O
5	O
neuronal	O
cells	O
treated	O
with	O
cyclosporine	O
(	O
CsA	O
),	O
an	O
inhibitor	O
of	O
the	O
mitochondrial	O
permeabilization	O
transition	O
pore	O
(	O
mPTP	O
),	O
or	O
knocked	O
down	O
for	O
cyclophilin	B-PROC
D	O
(	O
CypD	O
)	O
were	O
completely	O
protected	O
from	O
rOC	O
/	O
ATCC	O
-	O
induced	O
neuronal	O
PCD	B-PROC
,	O
underlining	O
the	O
involvement	O
of	O
CypD	O
in	O
the	O
process	O
.	O

These	O
mishandling	O
treatments	O
simulated	O
different	O
conditions	O
that	O
might	O
occur	O
during	O
routine	O
blood	O
collection	O
,	O
transport	B-PROC
or	O
storage	B-PROC
in	O
a	O
clinical	O
practice	O
setting	O
.	O

Moderate	O
levels	O
of	O
haemolysis	B-PROC
had	O
a	O
similar	O
,	O
but	O
less	O
consistent	O
,	O
effect	O
to	O
that	O
of	O
severe	O
haemolysis	B-PROC
,	O
producing	O
results	O
that	O
were	O
significantly	O
different	O
from	O
the	O
reference	O
standard	O
only	O
for	O
the	O
IBV	O
(	O
less	O
positive	O
)	O
and	O
AEV	O
(	O
more	O
positive	O
)	O
ELISAs	O
.	O

By	O
combining	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
transient	O
transfection	B-PROC
system	O
,	O
a	O
simple	O
and	O
safe	O
method	O
is	O
established	O
to	O
measure	O
ORF6	O
'	O
s	O
ability	O
to	O
suppress	O
the	O
expression	B-PROC
of	O
co	O
-	O
transfected	O
myc	O
-	O
nsp8	O
.	O

Their	O
PaO	B-PROC
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
ratio	O
was	O
<	O
150	O
at	O
a	O
tidal	O
volume	O
of	O
6	O
-	O
8	O
mL	O
·	O
kg	O
(-	O
1	O
)	O
ideal	O
body	O
weight	O
and	O
a	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
≥	O
5	O
cm	O
H	O
(	O
2	O
)	O
O	O
for	O
<	O
48	O
hr	O
.	O

One	O
other	O
patient	O
died	B-PROC
due	O
to	O
a	O
subarachnoidal	O
bleeding	O
under	O
the	O
anticoagulatory	O
regime	O
during	O
ECMO	O
therapy	O
.	O

TITLE	O
:	O
Effects	O
of	O
immune	O
stress	O
on	O
growth	B-PROC
performance	O
,	O
immunity	B-PROC
,	O
and	O
cecal	O
microflora	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
Immune	O
stress	O
is	O
the	O
loss	O
of	O
immune	O
homeostasis	B-PROC
by	O
external	O
forces	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
different	O
types	O
of	O
immune	O
stress	O
on	O
growth	B-PROC
performance	O
,	O
immunity	B-PROC
,	O
and	O
the	O
distribution	O
of	O
cecal	O
microflora	O
in	O
broiler	O
chickens	O
.	O

By	O
western	O
blotting	O
and	O
ELISA	O
test	O
,	O
all	O
recombinant	O
proteins	O
were	O
recognized	O
by	O
the	O
antibody	B-PROC
against	O
native	O
porcine	O
aminopeptidase	O
N	O
.	O
Recombinant	O
proteins	O
,	O
rpAPN	O
-	O
C2	O
(	O
aa	O
623	O
-	O
722	O
)	O
and	O
rpAPN	O
-	O
C3	O
(	O
aa	O
673	O
-	O
772	O
),	O
had	O
the	O
highest	O
binding	B-PROC
activity	I-PROC
with	O
swine	O
transmissible	O
gastroenteritis	O
virus	O
among	O
the	O
truncated	O
pAPN	O
-	O
C	O
recombinant	O
proteins	O
.	O

A	O
majority	O
of	O
identified	O
microRNAs	O
(	O
miRNAs	O
)	O
showed	O
divergent	O
changes	O
in	O
expression	B-PROC
across	O
mouse	O
strains	O
with	O
respect	O
to	O
SARS	O
-	O
CoV	O
and	O
influenza	O
virus	O
infections	O
and	O
responded	O
differently	O
to	O
a	O
highly	O
pathogenic	O
reconstructed	O
1918	O
virus	O
compared	O
to	O
a	O
minimally	O
pathogenic	O
seasonal	O
influenza	O
virus	O
isolate	O
.	O

With	O
the	O
advent	O
of	O
deep	O
-	O
sequencing	O
technologies	O
,	O
systematic	O
transcriptome	O
analysis	O
of	O
the	O
host	B-PROC
response	I-PROC
,	O
including	O
analysis	O
of	O
ncRNAs	O
of	O
different	O
sizes	O
,	O
is	O
now	O
possible	O
.	O

The	O
innate	B-PROC
immune	I-PROC
response	I-PROC
of	O
AMs	O
to	O
HCoV	O
-	O
229E	O
infection	O
was	O
evaluated	O
for	O
cytokine	B-PROC
production	I-PROC
and	O
interferon	O
(	O
IFN	O
)	O
gene	B-PROC
expression	I-PROC
.	O

There	O
was	O
neither	O
a	O
difference	O
in	O
quality	O
of	O
life	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
892	O
),	O
in	O
the	O
amount	O
of	O
effusion	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
710	O
),	O
the	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
α	O
)	O
concentration	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
355	O
),	O
nor	O
in	O
any	O
other	O
variable	O
investigated	O
in	O
this	O
study	O
,	O
including	O
a	O
complete	O
blood	O
count	O
,	O
and	O
a	O
small	O
animal	O
biochemistry	O
profile	O
.	O

This	O
review	O
focuses	O
primarily	O
on	O
the	O
pathogenesis	B-PROC
of	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
severe	O
acute	O
respiratory	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

CMV	O
pneumonia	O
can	O
also	O
occur	O
in	O
mechanically	O
ventilated	O
patients	O
,	O
but	O
is	O
difficult	O
to	O
diagnose	O
because	O
virus	O
recovery	O
does	O
not	O
necessarily	O
mean	O
viral	B-PROC
disease	I-PROC
.	O

Although	O
management	O
of	O
the	O
ECMO	O
circuit	O
,	O
including	O
anticoagulation	B-PROC
(	O
activated	O
clotting	B-PROC
time	O
:	O
150	O
-	O
250	O
),	O
was	O
conducted	O
following	O
the	O
institutional	O
practice	O
guidelines	O
,	O
it	O
was	O
difficult	O
to	O
control	O
the	O
bleeding	O
.	O

Here	O
,	O
we	O
show	O
that	O
increases	O
in	O
prostaglandin	O
D	O
(	O
2	O
)	O
(	O
PGD	O
(	O
2	O
))	O
expression	B-PROC
in	O
mouse	O
lungs	O
upon	O
aging	B-PROC
correlate	O
with	O
a	O
progressive	O
impairment	O
in	O
rDC	O
migration	B-PROC
to	O
DLNs	O
.	O

Decreased	O
rDC	O
migration	B-PROC
resulted	O
in	O
diminished	O
T	O
cell	O
responses	O
and	O
more	O
severe	O
clinical	O
disease	O
in	O
older	O
mice	O
infected	O
with	O
respiratory	O
viruses	O
.	O

ABSTRACT	O
:	O
Decline	O
in	O
immune	B-PROC
function	I-PROC
with	O
age	O
has	O
been	O
attributed	O
to	O
defects	O
or	O
alterations	O
in	O
both	O
the	O
innate	O
and	O
the	O
adaptive	O
immune	O
system	O
.	O

In	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Zhao	O
and	O
coworkers	O
provide	O
evidence	O
for	O
a	O
novel	O
mechanism	O
of	O
immune	O
dysfunction	O
in	O
aging	B-PROC
mice	O
.	O

TITLE	O
:	O
Differentiation	B-PROC
syndrome	O
in	O
promyelocytic	O
leukemia	O
:	O
clinical	O
presentation	O
,	O
pathogenesis	B-PROC
and	O
treatment	O
.	O

The	O
presence	O
of	O
stress	O
factors	O
in	O
the	O
history	O
of	O
CFS	O
patients	O
is	O
associated	O
with	O
severe	O
oxidative	O
stress	O
and	O
the	O
suppression	B-PROC
of	O
protective	O
HSP27	O
and	O
HSP70	O
responses	O
to	O
exercise	O
.	O

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
stress	O
factors	O
in	O
the	O
history	O
of	O
CFS	O
patients	O
is	O
associated	O
with	O
severe	O
oxidative	O
stress	O
and	O
the	O
suppression	B-PROC
of	O
protective	O
HSP27	O
and	O
HSP70	O
responses	O
to	O
exercise	O
.	O

On	O
49th	O
day	O
after	O
the	O
last	O
immunization	O
,	O
splenocytes	O
were	O
prepared	O
from	O
mice	O
immunized	O
with	O
surface	O
-	O
displayed	O
mixture	O
,	O
secretory	B-PROC
mixture	O
and	O
negative	O
control	O
to	O
be	O
stimulated	O
by	O
purified	O
N	O
and	O
S	O
protein	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
and	O
its	O
more	O
severe	O
form	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
are	O
characterized	O
by	O
an	O
acute	B-PROC
inflammatory	I-PROC
response	I-PROC
in	O
the	O
airspaces	O
and	O
lung	O
parenchyma	O
.	O

Furthermore	O
,	O
lung	O
regeneration	B-PROC
was	O
much	O
slower	O
in	O
FXR	O
-/-	O
mice	O
.	O

In	O
addition	O
,	O
expression	B-PROC
of	O
a	O
constitutively	O
active	O
FXR	O
repressed	O
the	O
expression	B-PROC
of	O
proinflammatory	O
genes	O
and	O
improved	O
lung	O
permeability	O
and	O
lung	O
regeneration	B-PROC
in	O
FXR	O
-/-	O
mice	O
.	O

ABSTRACT	O
:	O
Pneumonia	O
is	O
a	O
leading	O
cause	O
of	O
death	B-PROC
in	O
adults	O
in	O
the	O
industrialised	O
countries	O
and	O
in	O
the	O
rest	O
of	O
the	O
world	O
in	O
infants	O
.	O

In	O
contrast	O
,	O
protein	O
intakes	O
between	O
1	O
.	O
2	O
and	O
1	O
.	O
5	O
g	O
/	O
kg	O
body	O
weight	O
/	O
day	O
with	O
neutral	O
energy	B-PROC
balance	I-PROC
minimize	O
total	O
body	O
protein	O
mass	O
loss	O
.	O

VIRsiRNAdb	O
would	O
prove	O
useful	O
for	O
researchers	O
in	O
picking	O
up	O
the	O
best	O
viral	O
siRNA	O
for	O
antiviral	O
therapeutics	O
development	B-PROC
and	O
also	O
for	O
developing	O
better	O
viral	O
siRNA	O
design	O
tools	O
.	O

Advances	O
in	O
cannula	O
technology	O
allow	O
greater	O
ease	O
of	O
patient	O
positioning	O
,	O
in	O
some	O
cases	O
facilitating	O
extubation	O
and	O
ambulation	B-PROC
on	O
ECMO	O
.	O

Several	O
observational	O
and	O
randomized	O
trials	O
support	O
the	O
safety	O
of	O
HFOV	O
and	O
improvements	O
in	O
oxygenation	B-PROC
in	O
adult	O
patients	O
with	O
severe	O
ARDS	O
,	O
who	O
remain	O
hypoxemic	O
during	O
conventional	O
mechanical	O
ventilation	O
.	O

This	O
maneuver	O
consistently	O
improves	O
systemic	O
oxygenation	B-PROC
in	O
70	O
%	O
to	O
80	O
%	O
of	O
patients	O
with	O
ARDS	O
.	O

The	O
use	O
of	O
surfactant	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
has	O
led	O
to	O
the	O
decreased	O
mortality	O
and	O
the	O
need	O
for	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
use	O
.	O

Five	O
chemical	O
suppressors	O
of	O
the	O
slow	O
-	O
growth	B-PROC
phenotype	O
were	O
identified	O
from	O
the	O
2000	O
member	O
NIH	O
Diversity	O
Set	O
library	O
.	O

The	O
effect	O
of	O
NSC158362	O
on	O
PLP	O
protease	O
,	O
deubiquitinase	B-PROC
and	O
anti	O
-	O
interferon	O
activities	O
was	O
investigated	O
but	O
the	O
compound	O
did	O
not	O
alter	O
these	O
activities	O
.	O

Sequence	O
analysis	O
of	O
this	O
isolate	O
and	O
Aichi	O
/	O
2004	O
indicated	O
that	O
both	O
strains	O
have	O
truncated	O
HE	O
genes	O
with	O
deletions	O
in	O
the	O
3	O
'	O
region	O
that	O
occurred	O
through	O
cell	O
culture	O
-	O
adaptation	B-PROC
.	O

TITLE	O
:	O
New	O
insights	O
on	O
infectious	O
bronchitis	O
virus	O
pathogenesis	B-PROC
:	O
characterization	O
of	O
Italy	O
02	O
serotype	O
in	O
chicks	O
and	O
adult	O
hens	O
.	O

Furthermore	O
,	O
new	O
data	O
about	O
IBV	O
pathogenesis	B-PROC
essential	O
in	O
field	O
control	O
is	O
afforded	O
.	O

Experiments	O
using	O
dicistronic	O
mRNAs	O
carrying	O
different	O
IRESes	O
showed	O
that	O
nsp1	O
induced	O
endonucleolytic	O
RNA	O
cleavage	B-PROC
within	O
the	O
ribosome	O
loading	O
region	O
of	O
type	O
I	O
and	O
type	O
II	O
picornavirus	O
IRES	O
elements	O
,	O
but	O
not	O
that	O
of	O
classical	O
swine	O
fever	B-PROC
virus	O
IRES	O
,	O
which	O
is	O
characterized	O
as	O
a	O
hepatitis	O
C	O
virus	O
-	O
like	O
IRES	O
.	O

Remarkably	O
,	O
SCoV	O
mRNAs	O
,	O
which	O
have	O
a	O
5	O
'	O
cap	O
structure	O
and	O
3	O
'	O
poly	O
A	O
tail	O
like	O
those	O
of	O
typical	O
host	O
mRNAs	O
,	O
were	O
not	O
susceptible	O
to	O
nsp1	O
-	O
mediated	O
RNA	O
cleavage	B-PROC
and	O
importantly	O
,	O
the	O
presence	O
of	O
the	O
5	O
'-	O
end	O
leader	O
sequence	O
protected	O
the	O
SCoV	O
mRNAs	O
from	O
nsp1	O
-	O
induced	O
endonucleolytic	O
RNA	O
cleavage	B-PROC
.	O

This	O
Review	O
presents	O
the	O
recent	O
progress	O
that	O
has	O
been	O
made	O
in	O
understanding	O
the	O
role	O
of	O
co	O
-	O
opted	O
host	O
proteins	O
and	O
membranes	O
during	O
(+)	O
RNA	O
virus	B-PROC
replication	I-PROC
,	O
and	O
discusses	O
common	O
themes	O
employed	O
by	O
different	O
viruses	O
.	O

In	O
this	O
study	O
we	O
sought	O
to	O
uncover	O
the	O
host	O
transcriptional	B-PROC
responses	O
underlying	O
differences	O
between	O
high	O
-	O
and	O
low	O
-	O
pathogenic	O
infections	O
.	O

From	O
a	O
compendium	O
of	O
12	O
studies	O
that	O
included	O
responses	O
to	O
influenza	O
A	O
subtype	O
H5N1	O
,	O
reconstructed	O
1918	O
influenza	O
A	O
virus	O
,	O
and	O
SARS	O
coronavirus	O
,	O
we	O
used	O
meta	O
-	O
analysis	O
to	O
derive	O
multiple	O
gene	B-PROC
expression	I-PROC
signatures	O
.	O

TITLE	O
:	O
Ultrastructural	O
characterization	O
of	O
arterivirus	O
replication	O
structures	O
:	O
reshaping	O
the	O
endoplasmic	O
reticulum	O
to	O
accommodate	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

ABSTRACT	O
:	O
Virus	O
-	O
induced	O
membrane	O
structures	O
support	O
the	O
assembly	O
and	O
function	O
of	O
positive	O
-	O
strand	O
RNA	O
virus	B-PROC
replication	I-PROC
complexes	O
.	O

Virus	B-PROC
neutralization	I-PROC
(	O
VN	B-PROC
)	O
tests	O
were	O
performed	O
in	O
tracheal	O
organ	O
cultures	O
(	O
TOCs	O
)	O
using	O
these	O
10	O
strains	O
with	O
the	O
antisera	O
,	O
and	O
a	O
one	O
-	O
way	O
VN	B-PROC
test	O
was	O
then	O
used	O
to	O
compare	O
the	O
relationship	O
of	O
10	O
monovalent	O
antisera	O
to	O
the	O
other	O
19	O
field	O
isolates	O
.	O

We	O
found	O
that	O
different	O
serotypes	O
were	O
prevalent	O
during	O
different	O
time	O
periods	B-PROC
,	O
that	O
more	O
new	O
serotypes	O
have	O
been	O
prevalent	O
in	O
more	O
recent	O
years	O
,	O
and	O
the	O
prevalence	O
of	O
the	O
original	O
dominant	O
serotype	O
has	O
been	O
in	O
constant	O
decline	O
since	O
2004	O
.	O

ABSTRACT	O
:	O
This	O
review	O
highlights	O
the	O
advantages	O
and	O
current	O
status	O
of	O
plant	O
-	O
derived	O
vaccine	O
development	B-PROC
with	O
special	O
reference	O
to	O
the	O
dengue	O
virus	O
.	O

Droplet	O
diffusion	O
is	O
found	O
to	O
be	O
an	O
inefficient	O
mode	O
of	O
droplet	O
transport	B-PROC
leading	O
to	O
minimal	O
spatial	O
spread	O
of	O
infection	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
common	O
variable	O
immunodeficiency	O
in	O
IgA	O
-	O
and	O
IgG2	O
-	O
deficient	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

There	O
have	O
been	O
few	O
reports	O
on	O
children	O
who	O
developed	O
common	O
variable	O
immunodeficiency	O
(	O
CVID	O
)	O
in	O
association	O
with	O
immunoglobulin	B-PROC
A	O
(	O
IgA	O
)	O
and	O
IgG2	O
deficiencies	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
).	O

The	O
administration	O
of	O
intravenous	O
immunoglobulin	B-PROC
(	O
IVIG	O
)	O
was	O
required	O
to	O
prevent	O
subsequent	O
infections	O
,	O
and	O
no	O
relapse	O
of	O
SLE	O
was	O
observed	O
.	O

To	O
prevent	O
the	O
development	B-PROC
of	O
CVID	O
in	O
IgA	O
-	O
and	O
IgG2	O
-	O
deficient	O
patients	O
with	O
SLE	O
,	O
it	O
is	O
important	O
to	O
prevent	O
immune	O
dysregulation	O
by	O
the	O
avoidance	O
of	O
infections	O
through	O
the	O
use	O
of	O
IVIG	O
therapy	O
.	O

She	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
within	O
a	O
short	O
time	O
after	O
the	O
symptoms	O
commenced	O
and	O
she	O
died	B-PROC
within	O
4	O
days	O
.	O

TITLE	O
:	O
Single	O
site	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
as	O
an	O
alternative	O
to	O
invasive	O
ventilation	O
in	O
post	O
-	O
pneumonectomy	O
fistula	O
with	O
acute	O
respiratory	O
failure	O
.	O

The	O
differentiation	B-PROC
of	O
leukemic	O
blasts	O
and	O
promyelocytes	O
induced	O
by	O
ATRA	O
and	O
/	O
or	O
ATO	O
may	O
lead	O
to	O
cellular	B-PROC
migration	B-PROC
,	O
endothelial	O
activation	O
,	O
and	O
release	O
of	O
interleukins	O
and	O
vascular	O
factors	O
responsible	O
of	O
tissue	O
damage	O
.	O

Although	O
the	O
development	B-PROC
of	O
the	O
DS	O
,	O
particularly	O
of	O
the	O
severe	O
form	O
,	O
is	O
still	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
morbidity	O
and	O
mortality	O
during	O
induction	O
,	O
the	O
early	O
administration	O
of	O
high	O
-	O
dose	O
dexamethasone	O
at	O
the	O
onset	O
of	O
the	O
first	O
symptoms	O
seems	O
likely	O
to	O
have	O
dramatically	O
reduced	O
the	O
mortality	O
rate	O
of	O
this	O
complication	O
.	O

TITLE	O
:	O
Characterization	O
of	O
germline	O
antibody	B-PROC
libraries	O
from	O
human	O
umbilical	O
cord	O
blood	O
and	O
selection	O
of	O
monoclonal	O
antibodies	O
to	O
viral	O
envelope	O
glycoproteins	O
:	O
Implications	O
for	O
mechanisms	O
of	O
immune	B-PROC
evasion	I-PROC
and	O
design	O
of	O
vaccine	O
immunogens	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
induced	O
by	O
pandemic	O
2009	O
H1N1	O
influenza	O
virus	O
has	O
been	O
widely	O
reported	O
and	O
was	O
considered	O
the	O
main	O
cause	O
of	O
death	B-PROC
in	O
critically	O
ill	O
patients	O
with	O
2009	O
H1N1	O
infection	O
.	O

We	O
reviewed	O
all	O
patients	O
with	O
osteolysis	O
of	O
lymphatic	O
origin	O
and	O
treated	O
in	O
our	O
department	O
who	O
had	O
died	B-PROC
in	O
the	O
last	O
15	O
years	O
,	O
and	O
we	O
reviewed	O
all	O
published	O
cases	O
of	O
death	B-PROC
with	O
this	O
disease	O
since	O
the	O
1950	O
'	O
s	O
.	O

A	O
diagnostic	O
test	O
should	O
be	O
performed	O
in	O
all	O
patients	O
with	O
fever	B-PROC
and	O
flu	O
symptoms	O
that	O
require	O
hospitalization	O
.	O

The	O
treatment	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
patients	O
with	O
influenza	O
A	O
/	O
H1N1	O
must	O
be	O
based	O
on	O
the	O
use	O
of	O
a	O
protective	O
ventilatory	O
strategy	O
(	O
tidal	O
volume	O
<	O
10	O
ml	O
/	O
kg	O
and	O
plateau	O
pressure	O
<	O
35	O
mmHg	O
)	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
set	O
to	O
high	O
patient	O
lung	O
mechanics	O
,	O
combined	O
with	O
the	O
use	O
of	O
prone	O
ventilation	O
,	O
muscle	B-PROC
relaxation	I-PROC
and	O
recruitment	O
maneuvers	O
.	O

The	O
scientific	O
evidence	O
is	O
weak	O
,	O
however	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
not	O
the	O
technique	O
of	O
choice	O
.	O

The	O
centralization	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
referral	O
hospitals	O
is	O
recommended	O
.	O

These	O
changes	O
were	O
associated	O
with	O
increased	O
expression	B-PROC
of	O
the	O
profibrotic	O
genes	O
α	O
-	O
smooth	O
muscle	O
actin	O
(	O
α	O
-	O
SMA	O
)	O
and	O
Transforming	O
Growth	B-PROC
Factor	O
ß1	O
.	O

Treatment	O
with	O
intraperitoneal	O
recombinant	O
human	O
(	O
rh	O
)	O
ACE2	O
(	O
2	O
mg	O
/	O
kg	O
)	O
for	O
21	O
days	O
improved	O
survival	O
,	O
exercise	O
capacity	O
,	O
and	O
lung	B-PROC
function	I-PROC
and	O
decreased	O
lung	O
inflammation	O
and	O
fibrosis	O
in	O
male	O
BLM	O
-	O
WT	O
mice	O
.	O

ABSTRACT	O
:	O
We	O
determined	O
prevalence	O
of	O
antibody	B-PROC
to	O
selected	O
viral	O
pathogens	O
important	O
for	O
domestic	O
pigs	O
and	O
livestock	O
in	O
556	O
wild	O
boar	O
(	O
Sus	O
scrofa	O
)	O
sera	O
collected	O
during	O
2005	O
-	O
06	O
and	O
2009	O
-	O
10	O
in	O
four	O
counties	O
in	O
Croatia	O
.	O

We	O
recommend	O
continued	O
monitoring	O
of	O
wild	O
tigers	O
throughout	O
Asia	O
,	O
development	B-PROC
of	O
standardized	O
sampling	O
and	O
postmortem	O
examination	O
procedures	O
,	O
and	O
additional	O
research	O
to	O
better	O
understand	O
potential	O
domestic	O
and	O
wild	O
animal	O
sources	O
for	O
these	O
pathogens	O
.	O

These	O
observations	O
give	O
some	O
insights	O
into	O
the	O
pathogenesis	B-PROC
of	O
coronavirus	O
infection	O
and	O
are	O
thought	O
to	O
help	O
understand	O
the	O
interactions	O
between	O
sensory	O
neurons	O
and	O
their	O
satellite	O
cells	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
3b	O
accessory	O
protein	O
modulates	O
transcriptional	B-PROC
activity	O
of	O
RUNX1b	O
.	O

In	O
this	O
study	O
,	O
using	O
yeast	O
two	O
-	O
hybrid	O
and	O
co	O
-	O
immunoprecipitation	O
techniques	O
,	O
we	O
have	O
identified	O
a	O
host	O
transcription	B-PROC
factor	O
RUNX1b	O
(	O
Runt	O
related	O
transcription	B-PROC
factor	O
,	O
isoform	O
b	O
)	O
as	O
a	O
novel	O
interacting	O
partner	O
for	O
SARS	O
-	O
CoV	O
3b	O
protein	O
.	O

ABSTRACT	O
:	O
Obstructive	O
Sleep	B-PROC
Apnea	O
Syndrome	O
(	O
OSAS	O
)	O
is	O
defined	O
as	O
a	O
sleep	B-PROC
related	O
breathing	B-PROC
disorder	O
that	O
causes	O
the	O
body	O
to	O
stop	O
breathing	B-PROC
for	O
about	O
10	O
seconds	O
and	O
mostly	O
ends	O
with	O
a	O
loud	O
sound	O
due	O
to	O
the	O
opening	O
of	O
the	O
airway	O
.	O

OSAS	O
is	O
traditionally	O
diagnosed	O
using	O
polysomnography	O
,	O
which	O
requires	O
a	O
whole	O
night	O
stay	O
at	O
the	O
sleep	B-PROC
laboratory	O
of	O
a	O
hospital	O
,	O
with	O
multiple	O
electrodes	O
attached	O
to	O
the	O
patient	O
'	O
s	O
body	O
.	O

Snoring	O
is	O
a	O
symptom	O
which	O
may	O
indicate	O
the	O
presence	O
of	O
OSAS	O
;	O
thus	O
investigation	O
of	O
snoring	O
sounds	O
,	O
which	O
can	O
be	O
recorded	O
in	O
the	O
patient	O
'	O
s	O
own	O
sleeping	B-PROC
environment	O
,	O
has	O
become	O
popular	O
in	O
recent	O
years	O
to	O
diagnose	O
OSAS	O
.	O

It	O
significantly	O
lowered	O
plasma	O
concentrations	O
of	O
interleukin	O
1β	O
(	O
IL	O
-	O
1β	O
),	O
tumor	O
necrosis	B-PROC
factor	O
α	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IL	O
-	O
10	O
.	O

It	O
is	O
concluded	O
that	O
network	O
measures	O
for	O
the	O
relevant	O
time	O
period	O
based	O
on	O
updated	O
databases	O
of	O
animal	O
movements	B-PROC
can	O
provide	O
a	O
simple	O
and	O
straight	O
forward	O
tool	O
for	O
risk	O
-	O
based	O
sampling	O
.	O

Moreover	O
,	O
they	O
all	O
have	O
the	O
same	O
putative	O
transcription	B-PROC
regulatory	O
sequence	O
of	O
ACACCA	O
.	O

From	O
our	O
studies	O
,	O
it	O
appears	O
that	O
bats	O
and	O
birds	O
,	O
the	O
warm	O
blooded	O
flying	O
vertebrates	O
,	O
are	O
ideal	O
hosts	O
for	O
the	O
coronavirus	O
gene	O
source	O
,	O
bats	O
for	O
Alphacoronavirus	O
and	O
Betacoronavirus	O
and	O
birds	O
for	O
Gammacoronavirus	O
and	O
Deltacoronavirus	O
,	O
to	O
fuel	O
coronavirus	O
evolution	B-PROC
and	O
dissemination	O
.	O

However	O
,	O
only	O
few	O
studies	O
have	O
linked	O
these	O
pathways	B-PROC
to	O
hypoxemia	O
,	O
the	O
most	O
important	O
clinical	O
aspect	O
of	O
ALI	O
/	O
ARDS	O
.	O

RESULTS	O
:	O
At	O
baseline	O
:	O
APACHE	O
II	O
score	O
of	O
22	O
±	O
6	O
,	O
7	O
,	O
PaO2	O
/	O
FiO2	O
ratio	O
was	O
176	O
.	O
6	O
±	O
48	O
.	O
6	O
and	O
the	O
oxygenation	B-PROC
index	O
was	O
9	O
.	O
74	O
±	O
3	O
.	O
78	O
.	O

Viral	B-PROC
infections	I-PROC
in	O
established	O
asthmatics	O
are	O
associated	O
with	O
acute	O
exacerbations	O
.	O

TITLE	O
:	O
The	O
murine	O
coronavirus	O
hemagglutinin	O
-	O
esterase	O
receptor	O
-	O
binding	O
site	O
:	O
a	O
major	O
shift	O
in	O
ligand	B-PROC
specificity	O
through	O
modest	O
changes	O
in	O
architecture	O
.	O

Mutations	O
in	O
the	O
pRb	O
-	O
binding	O
motif	O
rendered	O
sNsp15	O
to	O
be	O
differentially	O
modified	O
by	O
ubiquitin	B-PROC
in	O
cells	O
,	O
and	O
cytotoxicity	O
was	O
observed	O
upon	O
its	O
expression	B-PROC
.	O

Hypothermia	O
and	O
other	O
metabolic	B-PROC
abnormalities	O
are	O
now	O
better	O
explained	O
thanks	O
to	O
actual	O
knowledge	O
about	O
endogenous	O
H2S	O
function	O
.	O

Lessons	O
learned	B-PROC
from	O
paediatric	O
accidents	O
should	O
result	O
in	O
better	O
information	O
about	O
this	O
threat	O
for	O
farmers	O
and	O
families	O
living	O
in	O
houses	O
with	O
septic	O
tanks	O
,	O
reducing	O
the	O
risk	O
to	O
their	O
own	O
and	O
their	O
children	O
'	O
s	O
safety	O
.	O

TITLE	O
:	O
SARS	O
CoV	O
subunit	O
vaccine	O
:	O
antibody	B-PROC
-	O
mediated	O
neutralisation	O
and	O
enhancement	O
.	O

Antibody	B-PROC
-	O
mediated	O
infection	O
of	O
SARS	O
-	O
CoV	O
triggers	O
entry	O
into	O
human	O
haematopoietic	O
cells	O
via	O
an	O
FcγR	O
-	O
dependent	O
and	O
ACE2	O
-,	O
pH	O
-,	O
cysteine	O
-	O
protease	O
-	O
independent	O
pathways	B-PROC
.	O

These	O
data	O
suggest	O
that	O
CXC	O
chemokines	O
produced	O
by	O
RCoV	O
-	O
infected	O
AT1	O
-	O
like	O
cells	O
inhibit	O
PMN	B-PROC
apoptosis	B-PROC
during	O
infection	O
.	O

These	O
studies	O
provide	O
new	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
whereby	O
alveolar	O
epithelial	O
cells	O
direct	O
the	O
functions	O
of	O
PMNs	O
during	O
viral	B-PROC
infection	I-PROC
of	O
the	O
lung	O
.	O

TITLE	O
:	O
The	O
paradox	O
of	O
feline	O
coronavirus	O
pathogenesis	B-PROC
:	O
a	O
review	O
.	O

Although	O
the	O
precise	O
cause	O
of	O
FIP	O
pathogenesis	B-PROC
remains	O
unclear	O
,	O
some	O
hypotheses	O
have	O
been	O
suggested	O
.	O

It	O
may	O
also	O
explain	O
why	O
some	O
Asian	O
countries	O
in	O
tropical	O
area	O
(	O
such	O
as	O
Malaysia	O
,	O
Indonesia	O
or	O
Thailand	O
)	O
with	O
high	B-PROC
temperature	I-PROC
and	O
high	O
relative	O
humidity	O
environment	O
did	O
not	O
have	O
major	O
community	O
outbreaks	O
of	O
SARS	O
.	O

The	O
approach	O
considered	O
the	O
characteristics	O
of	O
the	O
exhalation	B-PROC
of	O
the	O
droplets	O
carrying	O
infectious	O
agents	O
from	O
the	O
index	O
passenger	O
,	O
the	O
dispersion	O
of	O
these	O
droplets	O
,	O
and	O
the	O
inhalation	B-PROC
of	O
the	O
droplets	O
by	O
susceptible	O
passengers	O
.	O

RESULTS	O
:	O
In	O
6	O
cases	O
,	O
pulse	B-PROC
blood	B-PROC
oxygen	I-PROC
saturation	I-PROC
[	O
SpO	O
(	O
2	O
)]	O
was	O
elevated	O
(	O
0	O
.	O
45	O
-	O
0	O
.	O
92	O
up	O
to	O
0	O
.	O
94	O
-	O
1	O
.	O
00	O
),	O
PEEP	O
level	O
[	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
1	O
cm	O
H	O
(	O
2	O
)	O
O	O
=	O
0	O
.	O
098	O
kPa	O
]	O
and	O
[	O
FiO	O
(	O
2	O
)]	O
were	O
lowered	O
[	O
PEEP	O
:	O
10	O
.	O
0	O
-	O
22	O
.	O
0	O
down	O
to	O
4	O
.	O
0	O
-	O
15	O
.	O
0	O
;	O
FiO	O
(	O
2	O
):	O
1	O
.	O
00	O
down	O
to	O
0	O
.	O
30	O
-	O
0	O
.	O
60	O
]	O
after	O
treatment	O
with	O
ECMO	O
.	O

ABSTRACT	O
:	O
To	O
summarize	O
the	O
clinical	O
experiences	O
and	O
indications	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
severe	O
ARDS	O
caused	O
by	O
novel	O
2009	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
.	O

TITLE	O
:	O
Diagnostics	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
antigen	O
using	O
chicken	O
immunoglobulin	B-PROC
Y	O
.	O
ABSTRACT	O
:	O

One	O
of	O
the	O
most	O
important	O
findings	O
was	O
the	O
use	O
of	O
inexpensive	O
polyclonal	O
IgY	O
antibody	B-PROC
to	O
increase	O
the	O
sensitivity	O
of	O
the	O
detection	O
system	O
for	O
SARS	O
-	O
CoV	O
at	O
the	O
picogram	O
level	O
.	O

Hemodynamic	B-PROC
and	O
pulmonary	B-PROC
function	I-PROC
data	O
were	O
measured	O
.	O

The	O
angle	O
of	O
the	O
exhaled	B-PROC
air	O
from	O
coughing	O
was	O
around	O
38	O
°	O
for	O
the	O
males	O
and	O
32	O
°	O
for	O
the	O
females	O
,	O
while	O
that	O
of	O
the	O
exhaled	B-PROC
air	O
from	O
speaking	O
was	O
around	O
49	O
°	O
and	O
78	O
°	O
respectively	O
.	O

Both	O
D2	O
-	O
tsS133A	O
and	O
D3	O
-	O
tsF219L	O
were	O
impaired	O
for	O
viral	B-PROC
replication	I-PROC
and	O
nsp5	O
-	O
mediated	O
polyprotein	O
processing	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

ABSTRACT	O
:	O
Our	O
knowledge	O
regarding	O
immune	O
-	O
protective	O
and	O
immunopathogenic	O
events	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
is	O
limited	O
,	O
and	O
little	O
is	O
known	O
about	O
the	O
dynamics	O
of	O
the	O
immune	B-PROC
response	I-PROC
at	O
the	O
primary	O
site	O
of	O
disease	O
.	O

This	O
study	O
represents	O
one	O
of	O
the	O
first	O
comprehensive	O
analyses	O
of	O
lung	O
immunity	B-PROC
,	O
including	O
changes	O
in	O
leukocyte	O
populations	O
,	O
lung	O
-	O
specific	O
cytokines	O
,	O
and	O
antibody	B-PROC
responses	I-PROC
following	O
SARS	O
-	O
CoV	O
rechallenge	O
in	O
AGMs	O
.	O

The	O
new	O
peptides	O
acted	O
at	O
an	O
early	O
phase	O
of	O
viral	B-PROC
infection	I-PROC
,	O
and	O
,	O
when	O
combined	O
with	O
pulmonary	O
surfactant	O
protein	O
D	O
,	O
their	O
antiviral	O
effects	O
were	O
additive	O
.	O

ABSTRACT	O
:	O
In	O
2011	O
,	O
outbreaks	O
of	O
viral	O
diarrhea	O
were	O
observed	O
on	O
most	O
swine	O
-	O
breeding	B-PROC
farms	O
in	O
most	O
of	O
the	O
provinces	O
of	O
China	O
.	O

The	O
core	O
-	O
streptavidin	O
arm	O
of	O
fusion	O
protein	O
binds	O
with	O
biotinylated	O
nanoparticles	O
,	O
while	O
anti	O
-	O
DEC	O
-	O
205	O
scFv	O
imparts	O
targeting	B-PROC
specificity	O
to	O
DC	O
DEC	O
-	O
205	O
receptor	O
.	O

Sexually	O
transmitted	O
infections	O
are	O
in	O
a	O
rapid	O
,	O
exponential	O
growth	B-PROC
phase	O
,	O
spreading	O
from	O
core	O
groups	O
to	O
the	O
general	O
population	O
.	O

Using	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
against	O
MADP1	O
,	O
defective	O
viral	O
RNA	B-PROC
synthesis	I-PROC
was	O
observed	O
in	O
the	O
knockdown	O
cells	O
,	O
therefore	O
indicating	O
the	O
importance	O
of	O
the	O
protein	O
in	O
coronaviral	O
RNA	B-PROC
synthesis	I-PROC
.	O

The	O
assay	O
displayed	O
high	O
specificity	O
detecting	O
only	O
BCoV	O
-	O
1	O
with	O
no	O
cross	B-PROC
reaction	I-PROC
with	O
other	O
viruses	O
.	O

The	O
new	O
viruses	O
cause	O
respiratory	O
illnesses	O
such	O
as	O
common	O
cold	B-PROC
,	O
bronchitis	O
,	O
bronchiolitis	O
,	O
exacerbations	O
of	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
pneumonia	O
.	O

Four	O
patients	O
were	O
identified	O
with	O
capillary	O
leak	O
syndrome	O
associated	O
with	O
a	O
primary	O
diagnosis	O
:	O
cardiac	O
transplant	B-PROC
rejection	I-PROC
in	O
one	O
,	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
two	O
,	O
and	O
neonatal	O
hydrops	O
fetalis	O
in	O
one	O
patient	O
.	O

Supportive	O
measures	O
in	O
the	O
management	O
of	O
ARDS	O
include	O
attention	O
to	O
fluid	B-PROC
balance	I-PROC
,	O
restrictive	O
transfusion	O
strategies	O
,	O
and	O
minimization	O
of	O
sedatives	O
and	O
neuromuscular	O
blocking	O
agents	O
.	O

However	O
,	O
one	O
patient	O
died	B-PROC
of	O
adenovirus	O
(	O
AdV	O
)	O
pneumonia	O
with	O
pulmonary	O
hemorrhage	O
;	O
the	O
mortality	O
rate	O
of	O
RV	O
infection	O
within	O
28	O
d	O
after	O
HSCT	O
was	O
0	O
.	O
57	O
%.	O

TITLE	O
:	O
Portable	O
miniaturized	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
systems	O
for	O
H1N1	O
-	O
related	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
case	O
series	O
.	O

RESULTS	O
:	O
Ten	O
adult	O
patients	O
with	O
severe	O
ARDS	O
secondary	O
to	O
H1N1	O
infection	O
(	O
Pao	B-PROC
(	O
2	O
)/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
,	O
69	O
mm	O
Hg	O
[	O
56	O
-	O
84	O
];	O
Murray	O
score	O
,	O
3	O
.	O
5	O
[	O
3	O
.	O
5	O
-	O
3	O
.	O
8	O
])	O
were	O
included	O
,	O
and	O
60	O
%	O
survived	O
to	O
hospital	O
discharge	O
.	O

Antibody	B-PROC
against	O
RbCoV	O
was	O
detected	O
in	O
20	O
(	O
67	O
%)	O
of	O
30	O
rabbit	O
sera	O
tested	O
by	O
an	O
N	O
-	O
protein	O
-	O
based	O
Western	O
blot	O
assay	O
,	O
whereas	O
neutralizing	O
antibody	B-PROC
was	O
detected	O
in	O
1	O
of	O
these	O
20	O
rabbits	O
.	O

A	O
preliminary	O
structure	O
-	O
activity	O
relationship	O
study	O
(	O
SARs	O
)	O
revealed	O
the	O
necessity	O
of	O
the	O
biflavonoid	O
skeleton	O
,	O
the	O
influence	O
of	O
number	O
and	O
position	O
of	O
methoxylations	O
,	O
and	O
the	O
importance	O
of	O
a	O
free	O
rotation	O
of	O
the	O
linkage	B-PROC
between	O
the	O
two	O
apigenin	O
monomers	O
of	O
the	O
biflavonoids	O
.	O

Levels	O
of	O
MMP	O
-	O
2	O
and	O
MMP	B-PROC
-	I-PROC
9	I-PROC
activity	I-PROC
,	O
T1	O
-	O
α	O
and	O
thrombomodulin	O
were	O
also	O
diminished	O
in	O
the	O
DOX	O
-	O
treated	O
group	O
.	O

These	O
results	O
suggest	O
that	O
multiple	O
cysteine	O
as	O
well	O
as	O
charged	O
residues	O
concurrently	O
improves	O
the	O
membrane	O
-	O
associated	O
functions	O
of	O
S	O
protein	O
in	O
viral	B-PROC
replication	I-PROC
and	O
cytopathogenesis	O
.	O

Of	O
the	O
top	O
five	O
pathways	B-PROC
,	O
we	O
found	O
53	O
differentially	O
expressed	B-PROC
genes	O
affected	O
by	O
at	O
least	O
five	O
of	O
the	O
seven	O
viruses	O
.	O

We	O
suggest	O
five	O
new	O
therapeutic	O
indications	O
for	O
existing	O
small	O
molecules	O
or	O
biological	O
agents	O
targeting	B-PROC
proteins	O
encoded	O
by	O
the	O
genes	O
F3	O
,	O
IL1B	O
,	O
TNF	O
,	O
CASP1	O
and	O
MMP9	O
.	O

Pathway	B-PROC
enrichment	O
analysis	O
also	O
identified	O
a	O
potential	O
novel	O
host	B-PROC
response	I-PROC
,	O
the	O
Parkin	O
-	O
Ubiquitin	B-PROC
Proteasomal	O
System	O
(	O
Parkin	O
-	O
UPS	O
)	O
pathway	B-PROC
,	O
which	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
progression	O
of	O
neurodegenerative	O
Parkinson	O
'	O
s	O
disease	O
.	O

TITLE	O
:	O
[	O
KCTD9	O
,	O
a	O
novel	O
potassium	O
channel	O
related	O
gene	O
,	O
was	O
highly	O
expressed	B-PROC
in	O
hepatic	O
NK	O
cells	O
and	O
T	O
cells	O
of	O
fulminant	O
hepatitis	O
mice	O
induced	O
by	O
MHV	O
-	O
3	O
].	O

Basal	O
expression	B-PROC
was	O
also	O
investigated	O
and	O
showed	O
constitutive	O
expression	B-PROC
of	O
KCTD9	O
in	O
brain	O
,	O
thymus	O
and	O
other	O
organs	O
in	O
BALB	O
/	O
cJ	O
mice	O
.	O

A	O
novel	O
potassium	O
channel	O
gene	O
KCTD9	O
was	O
highly	O
expressed	B-PROC
in	O
hepatic	O
NK	O
cells	O
and	O
T	O
cells	O
of	O
fulminant	O
hepatitis	O
mice	O
induced	O
by	O
MHV	O
-	O
3	O
.	O

Hospitalized	O
patients	O
with	O
pH1N1	O
and	O
pneumonia	O
were	O
at	O
risk	O
for	O
severe	O
outcomes	O
including	O
ARDS	O
,	O
sepsis	O
,	O
and	O
death	B-PROC
;	O
antiviral	O
treatment	O
was	O
often	O
delayed	O
.	O

Double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
),	O
the	O
presumed	O
intermediate	O
in	O
RNA	B-PROC
synthesis	I-PROC
,	O
is	O
localized	O
to	O
the	O
DMV	O
interior	O
.	O

ABSTRACT	O
:	O
Various	O
approaches	O
such	O
as	O
ventilator	O
management	O
involving	O
lung	O
-	O
protective	O
ventilation	O
,	O
corticosteroids	O
,	O
prone	O
positioning	O
,	O
and	O
nitric	O
oxide	O
have	O
failed	O
to	O
maintain	O
sufficient	O
lung	O
oxygenation	B-PROC
or	O
appropriate	O
ventilation	O
competence	O
in	O
very	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Outcomes	O
such	O
as	O
need	O
for	O
ventilation	O
and	O
development	B-PROC
of	O
intermediate	O
syndrome	O
(	O
IMS	O
)	O
were	O
noted	O
.	O

The	O
proteomic	O
alterations	O
described	O
here	O
may	O
suggest	O
that	O
these	O
changes	O
to	O
protein	B-PROC
expression	B-PROC
correlate	O
with	O
IBV	O
virus	O
'	O
virulence	B-PROC
in	O
chicken	O
,	O
hence	O
provides	O
valuable	O
insights	O
into	O
the	O
interactions	O
of	O
IBV	O
with	O
its	O
host	O
and	O
may	O
also	O
assist	O
with	O
investigations	O
of	O
the	O
pathogenesis	B-PROC
of	O
IBV	O
and	O
other	O
coronavirus	O
infections	O
.	O

We	O
therefore	O
tested	O
the	O
hypothesis	O
that	O
these	O
factors	O
share	O
common	O
signaling	B-PROC
pathways	B-PROC
and	O
may	O
be	O
mutually	O
regulated	O
.	O

Then	O
,	O
we	O
further	O
determined	O
the	O
mechanisms	O
how	O
STAT3	O
regulates	O
HO	O
-	O
1	O
and	O
CXCL10	O
as	O
well	O
as	O
mutual	O
regulation	B-PROC
among	O
them	O
in	O
CRL	O
-	O
2581	O
,	O
a	O
murine	O
endothelial	O
cell	O
line	O
.	O

TITLE	O
:	O
Effect	O
of	O
pulmonary	O
support	O
using	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
adult	O
liver	O
transplant	O
recipients	O
with	O
respiratory	O
failure	O
.	O

Twelve	O
patients	O
had	O
undergone	O
living	O
donor	O
and	O
six	O
deceased	B-PROC
donor	O
OLT	O
.	O

The	O
precise	O
mechanisms	O
underlying	O
this	O
synergism	B-PROC
,	O
however	O
,	O
are	O
not	O
known	O
.	O

In	O
the	O
absence	O
of	O
TMPRSS2	O
,	O
SARS	O
-	O
CoV	O
achieves	O
cell	O
entry	O
via	O
an	O
endosomal	O
pathway	B-PROC
in	O
which	O
cathepsin	O
L	O
may	O
play	O
an	O
important	O
role	O
,	O
i	O
.	O
e	O
.,	O
the	O
activation	O
of	O
spike	O
protein	O
fusogenicity	O
.	O

ABSTRACT	O
:	O
HELLP	O
syndrome	O
(	O
hemolysis	B-PROC
,	O
elevated	O
liver	O
enzymes	O
,	O
low	O
platelets	O
)	O
is	O
a	O
severe	O
microcirculatory	O
disturbance	O
during	O
pregnancy	O
,	O
associated	O
with	O
pre	O
-	O
eclampsia	O
,	O
but	O
it	O
may	O
occur	O
also	O
without	O
it	O
.	O

By	O
engaging	O
with	O
issues	O
of	O
global	O
biosecurity	O
,	O
migration	B-PROC
and	O
citizenship	O
,	O
and	O
intersubjectivity	O
in	O
medicine	O
,	O
I	O
argue	O
that	O
in	O
their	O
attempts	O
to	O
prevent	O
another	O
SARS	O
and	O
protect	O
their	O
own	O
subject	O
positions	O
as	O
modern	O
,	O
urban	O
citizens	O
,	O
Shenzhen	O
'	O
s	O
public	O
health	O
professionals	O
worked	O
to	O
maintain	O
precarious	O
boundaries	O
between	O
themselves	O
and	O
their	O
city	O
'	O
s	O
majority	O
migrant	O
population	O
.	O

Among	O
25	O
cases	O
in	O
India	O
during	O
2010	O
-	O
2011	O
,	O
associated	O
conditions	O
were	O
renal	O
failure	O
,	O
thrombocytopenia	O
,	O
jaundice	O
,	O
severe	O
anemia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
shock	O
,	O
cerebral	O
malaria	O
,	O
hypoglycemia	O
,	O
and	O
death	B-PROC
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
in	O
farmed	O
European	O
wild	O
boars	O
the	O
prevalence	O
of	O
and	O
risk	O
factors	O
associated	O
with	O
a	O
range	O
of	O
common	O
porcine	O
viral	O
and	O
bacterial	O
infections	O
,	O
namely	O
,	O
porcine	O
parvovirus	O
(	O
PPV	O
),	O
porcine	O
circovirus	O
type	O
2	O
(	O
PCV2	O
),	O
swine	O
influenza	O
virus	O
(	O
SIV	O
),	O
Aujeszky	O
'	O
s	O
disease	O
virus	O
(	O
ADV	O
),	O
classical	O
swine	O
fever	B-PROC
virus	O
(	O
CSFV	O
),	O
swine	O
vesicular	O
disease	O
virus	O
(	O
SVDV	O
),	O
coronavirus	O
causing	O
transmissible	O
gastroenteritis	O
(	O
TGEV	O
),	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
Mycoplasma	O
hyopneumoniae	O
,	O
Lawsonia	O
intracellularis	O
,	O
Brucella	O
spp	O
.,	O
and	O
Leptospira	O
spp	O
.	O

ABSTRACT	O
:	O
In	O
puppies	O
weaning	B-PROC
is	O
a	O
high	O
risk	O
period	O
.	O

Fecal	O
changes	O
are	O
frequent	O
and	O
can	O
be	O
signs	O
of	O
infection	O
by	O
digestive	B-PROC
pathogens	O
(	O
bacteria	O
,	O
viruses	O
,	O
parasites	O
)	O
and	O
indicators	O
of	O
nutritional	O
and	O
environmental	O
stress	O
.	O

The	O
scoring	O
was	O
performed	O
immediately	O
after	O
a	O
spontaneous	O
defecation	B-PROC
based	O
on	O
a	O
13	O
-	O
point	O
scale	O
(	O
from	O
1	O
;	O
liquid	O
to	O
13	O
;	O
dry	O
and	O
hard	O
feces	O
).	O

It	O
also	O
emphasizes	O
the	O
importance	O
to	O
be	O
given	O
to	O
age	O
and	O
breed	B-PROC
size	O
in	O
that	O
evaluation	O
.	O

The	O
findings	O
allow	O
adaption	B-PROC
of	O
treatment	O
to	O
milder	O
forms	O
of	O
acute	O
lung	O
injury	O
and	O
severe	O
forms	O
.	O

We	O
conducted	O
a	O
prospective	O
observational	O
cohort	O
study	O
of	O
618	O
inpatients	O
with	O
2009	O
H1N1	O
virus	B-PROC
infection	I-PROC
admitted	O
to	O
36	O
Spanish	O
hospitals	O
between	O
July	O
2009	O
and	O
February	O
2010	O
.	O

Specifically	O
,	O
sigma	O
(	O
σ	O
)	O
C	O
protein	O
of	O
avian	O
reovirus	O
(	O
ARV	O
),	O
a	O
functional	O
homolog	O
of	O
mammalian	O
reovirus	O
σ1	O
protein	O
and	O
responsible	O
for	O
M	O
-	O
cell	O
targeting	B-PROC
,	O
was	O
administered	O
together	O
with	O
a	O
subfragment	O
of	O
the	O
spike	O
protein	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

In	O
the	O
absence	O
of	O
an	O
effective	O
vaccine	O
for	O
HIV	O
,	O
development	B-PROC
of	O
new	O
anti	O
-	O
HIV	O
agents	O
is	O
urgently	O
needed	O
.	O

TITLE	O
:	O
Targeting	B-PROC
matrix	O
metalloproteinases	O
in	O
acute	O
inflammatory	O
shock	O
syndromes	O
.	O

Over	O
the	O
next	O
6	O
days	O
,	O
the	O
patient	O
'	O
s	O
cardiac	O
and	O
respiratory	B-PROC
function	I-PROC
improved	O
,	O
and	O
a	O
repeat	O
echocardiogram	O
demonstrated	O
complete	O
normalization	O
of	O
RV	O
function	O
.	O

Analysing	O
viral	O
proteins	O
is	O
not	O
only	O
important	O
to	O
characterise	O
the	O
cellular	O
pathogens	O
but	O
also	O
instrumental	O
to	O
decipher	O
the	O
palmitoylation	B-PROC
machinery	O
of	O
cells	O
.	O

TITLE	O
:	O
A	O
human	O
coronavirus	O
responsible	O
for	O
the	O
common	O
cold	B-PROC
massively	O
kills	O
dendritic	O
cells	O
but	O
not	O
monocytes	O
.	O

Cell	B-PROC
death	I-PROC
induced	O
by	O
HCoV	O
-	O
229E	O
is	O
independent	O
of	O
TRAIL	O
,	O
FasL	O
,	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
,	O
and	O
caspase	B-PROC
activity	I-PROC
,	O
indicating	O
that	O
viral	B-PROC
replication	I-PROC
is	O
directly	O
responsible	O
for	O
the	O
observed	O
cytopathic	O
effects	O
.	O

The	O
consequence	O
of	O
DC	O
death	B-PROC
at	O
the	O
early	O
stage	O
of	O
HCoV	O
-	O
229E	O
infection	O
may	O
have	O
an	O
impact	O
on	O
the	O
early	O
control	O
of	O
viral	O
dissemination	O
and	O
on	O
the	O
establishment	O
of	O
long	O
-	O
lasting	O
immune	O
memory	B-PROC
,	O
since	O
people	O
can	O
be	O
reinfected	O
multiple	O
times	O
by	O
HCoV	O
-	O
229E	O
.	O

TITLE	O
:	O
Learning	B-PROC
from	O
SARS	O
:	O
Preparing	O
for	O
the	O
Next	O
Disease	O
Outbreak	O
:	O
Workshop	O
Summary	O
ABSTRACT	O
:	O
The	O
emergence	O
of	O
a	O
novel	O
human	O
coronavirus	O
in	O
late	O
2002	O
alarmed	O
populations	O
across	O
the	O
globe	O
,	O
elicited	O
a	O
massive	O
public	O
health	O
response	O
,	O
gave	O
rise	O
to	O
a	O
multinational	O
research	O
network	O
,	O
gripped	O
the	O
news	O
media	O
,	O
wreaked	O
political	O
havoc	O
in	O
China	O
,	O
and	O
struck	O
a	O
blow	O
to	O
the	O
tourism	O
and	O
travel	O
industries	O
of	O
several	O
countries	O
.	O

We	O
describe	O
a	O
case	O
of	O
sigmoid	O
volvulus	O
in	O
a	O
patient	O
with	O
33	O
weeks	O
of	O
gestation	B-PROC
that	O
developed	O
complete	O
necrosis	B-PROC
of	O
the	O
left	O
colon	O
.	O

With	O
a	O
diagnosis	O
of	O
complicate	O
sigmoid	O
volvulus	O
she	O
was	O
underwent	O
to	O
the	O
laparotomy	O
where	O
we	O
found	O
necrosis	B-PROC
of	O
all	O
descending	O
colon	O
due	O
to	O
double	O
twist	B-PROC
volvulus	O
of	O
the	O
sigmoid	O
.	O

TITLE	O
:	O
Emergency	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
to	O
treat	O
massive	O
aspiration	O
during	O
anaesthesia	O
induction	O
.	O

In	O
conclusion	O
,	O
in	O
conditions	O
where	O
a	O
viability	O
staining	O
is	O
inadequate	O
to	O
quantitate	O
virus	O
-	O
induced	O
CPE	O
,	O
a	O
novel	O
simple	O
and	O
convenient	O
method	O
that	O
detects	O
cell	O
-	O
death	B-PROC
and	O
that	O
is	O
suitable	O
for	O
high	O
-	O
throughput	O
screening	O
purposes	O
can	O
be	O
employed	O
.	O

The	O
cellular	O
and	O
molecular	O
mechanisms	O
leading	O
to	O
the	O
development	B-PROC
of	O
ALI	O
/	O
ARDS	O
are	O
not	O
completely	O
understood	O
,	O
but	O
there	O
is	O
evidence	O
that	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generated	O
by	O
inflammatory	O
cells	O
as	O
well	O
as	O
epithelial	O
and	O
endothelial	O
cells	O
are	O
responsible	O
for	O
inflammatory	B-PROC
response	I-PROC
,	O
lung	O
damage	O
,	O
and	O
abnormal	O
repair	B-PROC
.	O

Among	O
all	O
ROS	O
-	O
producing	O
enzymes	O
,	O
the	O
members	O
of	O
NADPH	O
oxidases	O
(	O
NOXs	O
),	O
which	O
are	O
widely	O
expressed	B-PROC
in	O
different	O
lung	O
cell	O
types	O
,	O
have	O
been	O
shown	O
to	O
participate	O
in	O
cellular	O
processes	O
involved	O
in	O
the	O
maintenance	O
of	O
lung	O
integrity	O
.	O

However	O
,	O
phase	O
1	O
students	O
expressed	B-PROC
significantly	O
greater	O
degree	O
of	O
anxiety	O
compared	O
to	O
Phase	O
II	O
in	O
relation	O
to	O
attendance	O
and	O
personal	O
protection	O
in	O
hospital	O
,	O
and	O
in	O
meeting	O
people	O
coughing	O
in	O
public	O
places	O
.	O

Recent	O
studies	O
have	O
indicated	O
that	O
the	O
E	O
protein	O
has	O
functions	O
during	O
infection	O
beyond	O
assembly	O
,	O
including	O
in	O
virus	O
egress	O
and	O
in	O
the	O
host	O
stress	B-PROC
response	I-PROC
.	O

Most	O
patients	O
(	O
86	O
%)	O
presented	O
with	O
fever	B-PROC
or	O
a	O
sepsis	O
-	O
like	O
syndrome	O
.	O

Our	O
identification	O
of	O
severe	O
respiratory	O
illness	O
due	O
to	O
adenovirus	O
,	O
especially	O
type	O
11	O
may	O
highlight	O
the	O
need	O
for	O
rapid	O
diagnosis	O
and	O
improved	O
surveillance	O
,	O
which	O
may	O
assist	O
with	O
targeted	B-PROC
development	B-PROC
of	O
antiviral	O
agents	O
or	O
type	O
-	O
specific	O
vaccines	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
in	O
a	O
situation	O
of	O
diagnostic	O
dilemma	O
.	O

Rapid	O
evolution	B-PROC
in	O
IBV	O
is	O
facilitated	O
by	O
strong	O
selection	O
,	O
large	O
population	O
sizes	O
and	O
high	O
genetic	O
diversity	O
within	O
hosts	O
,	O
and	O
transmission	O
bottlenecks	O
between	O
hosts	O
.	O

These	O
data	O
suggest	O
that	O
CCoV	O
-	O
A76	O
represents	O
a	O
recombinant	O
coronavirus	O
form	O
,	O
with	O
distinct	O
host	O
cell	O
tropism	B-PROC
.	O

The	O
reason	O
for	O
death	B-PROC
in	O
all	O
these	O
patients	O
was	O
low	O
cardiac	O
output	O
syndrome	O
with	O
subsequent	O
multi	O
-	O
organ	O
failure	O
.	O

We	O
therefore	O
hypothesize	O
that	O
CD200R	O
ligation	O
suppresses	O
TLR7	O
responses	O
and	O
that	O
release	O
of	O
this	O
inhibition	B-PROC
enlarges	O
sex	O
differences	O
in	O
TLR7	O
signaling	B-PROC
.	O

Therefore	O
,	O
it	O
was	O
important	O
to	O
verify	O
that	O
the	O
host	O
responses	O
to	O
self	O
will	O
not	O
affect	O
the	O
adjuvanticity	B-PROC
of	O
rOv	O
-	O
ASP	O
-	O
1	O
when	O
it	O
is	O
used	O
in	O
subsequent	O
vaccinations	O
with	O
the	O
same	O
or	O
different	O
vaccine	O
antigens	O
.	O

When	O
expressed	B-PROC
as	O
N	O
-	O
terminal	O
enhanced	O
green	O
fluorescence	O
protein	O
(	O
EGFP	O
)	O
fusion	O
,	O
it	O
predominantly	O
formed	O
speckles	O
in	O
the	O
cytoplasm	O
.	O

However	O
,	O
addition	O
of	O
surrounding	O
sequences	O
in	O
Domain	O
III	O
abolished	O
the	O
speckle	O
formation	B-PROC
for	O
TGEV	O
nsp15	O
but	O
not	O
for	O
MHV	O
and	O
SARS	O
-	O
CoV	O
nsp15s	O
.	O

Moreover	O
,	O
the	O
biological	O
functions	O
of	O
the	O
expressed	B-PROC
nsp15s	O
were	O
assessed	O
in	O
MHV	O
-	O
infected	O
cells	O
.	O

Hence	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
a	O
broader	O
range	O
of	O
antigenic	O
regions	O
that	O
have	O
strong	O
antibody	B-PROC
eliciting	O
ability	O
;	O
these	O
could	O
then	O
be	O
applied	O
for	O
development	B-PROC
of	O
an	O
IBV	O
-	O
diagnostic	O
tool	O
.	O

This	O
phylogenetic	O
cluster	O
was	O
also	O
the	O
only	O
group	O
of	O
sequences	O
in	O
which	O
no	O
recombination	B-PROC
events	O
were	O
detected	O
.	O

In	O
addition	O
to	O
the	O
activation	O
of	O
nsp16	O
-	O
mediated	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
,	O
nsp10	O
also	O
activates	O
nsp14	O
in	O
an	O
RNA	B-PROC
processing	I-PROC
function	O
potentially	O
connected	O
to	O
a	O
replicative	O
mismatch	B-PROC
repair	I-PROC
mechanism	O
.	O

The	O
B	O
and	O
T	O
lymphocyte	O
attenuator	O
(	O
BTLA	O
)	O
is	O
an	O
immunoglobulin	B-PROC
-	O
domain	O
-	O
containing	O
protein	O
that	O
has	O
the	O
capacity	O
to	O
maintain	O
peripheral	O
tolerance	B-PROC
and	O
limit	O
immunopathological	O
damage	O
during	O
immune	B-PROC
responses	I-PROC
.	O

At	O
48	O
hours	O
after	O
admission	O
,	O
the	O
growth	B-PROC
of	O
Gram	O
negative	O
bacilli	O
in	O
the	O
blood	O
culture	O
was	O
reported	O
,	O
which	O
was	O
subsequently	O
identified	O
as	O
Salmonella	O
enteritidis	O
.	O

While	O
prolonged	O
corticosteroid	O
use	O
is	O
a	O
known	O
risk	O
factor	O
for	O
development	B-PROC
of	O
invasive	O
fungal	O
disease	O
,	O
the	O
authors	O
postulate	O
that	O
by	O
causing	O
immunologic	O
defects	O
and	O
FLAARDS	O
,	O
the	O
2009	O
-	O
pandemic	O
H1N1	O
virus	O
may	O
represent	O
an	O
additional	O
independent	O
risk	O
for	O
the	O
development	B-PROC
of	O
C	O
neoformans	O
meningitis	O
in	O
a	O
previously	O
healthy	O
individual	O
.	O

Precisely	O
identifying	O
the	O
mat_peptide	O
cleavage	B-PROC
for	O
some	O
viruses	O
is	O
a	O
built	O
-	O
in	O
feature	O
of	O
VIGOR	O
.	O

ABSTRACT	O
:	O
The	O
influenza	O
A	O
(	O
H1N1pdm09	O
)	O
[	O
pH1N1	O
]	O
virus	O
resulted	O
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admissions	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
death	B-PROC
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
is	O
a	O
causative	O
agent	O
of	O
the	O
common	O
cold	B-PROC
.	O

Our	O
data	O
suggest	O
that	O
neither	O
of	O
the	O
two	O
CEACAM1	O
isoforms	O
defines	O
MHV	O
organ	O
tropism	B-PROC
.	O

Here	O
the	O
authors	O
report	O
a	O
case	O
of	O
dengue	O
haemorrhagic	O
fever	B-PROC
that	O
develops	O
acute	O
pancreatitis	O
and	O
presented	O
with	O
acute	O
onset	O
of	O
breathlessness	O
,	O
which	O
then	O
progressed	O
to	O
full	O
-	O
blown	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Prone	O
positioning	O
(	O
PP	O
)	O
improves	O
oxygenation	B-PROC
and	O
may	O
provide	O
a	O
benefit	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Increased	O
antibody	B-PROC
affinity	O
confers	O
broad	O
in	O
vitro	O
protection	O
against	O
escape	O
mutants	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Importantly	O
,	O
higher	O
affinity	O
also	O
led	O
to	O
the	O
suppression	B-PROC
of	O
viral	O
escape	O
mutants	O
in	O
vitro	O
.	O

This	O
study	O
has	O
systematically	O
examined	O
the	O
assembly	O
and	O
dissemination	O
of	O
HEV	O
67N	O
in	O
the	O
primary	O
motor	O
cortex	O
of	O
infected	O
rats	O
and	O
provides	O
additional	O
evidence	O
indicating	O
that	O
membranous	O
-	O
coating	O
-	O
mediated	O
endo	O
-/	O
exocytosis	B-PROC
can	O
be	O
used	O
by	O
HEV	O
for	O
its	O
transsynaptic	O
transfer	O
.	O

Human	O
θ	O
-	O
defensin	O
genes	O
contain	O
a	O
premature	O
stop	O
codon	O
that	O
prevents	O
effective	O
translation	B-PROC
of	O
the	O
needed	O
precursors	O
;	O
consequently	O
,	O
these	O
peptides	O
are	O
not	O
present	O
in	O
human	O
leukocytes	O
.	O

Febrile	B-PROC
convulsion	O
was	O
noted	O
at	O
a	O
higher	O
rate	O
in	O
medical	O
past	O
-	O
history	O
in	O
cases	O
without	O
sequelae	O
(	O
40	O
of	O
the	O
149	O
cases	O
;	O
27	O
%)	O
than	O
in	O
serious	O
cases	O
.	O

Culturing	O
the	O
virus	O
at	O
the	O
suboptimal	O
temperature	O
of	O
37	O
°	O
C	O
resulted	O
in	O
low	O
replication	O
of	O
the	O
virus	O
and	O
the	O
effect	O
on	O
ACE2	O
expression	B-PROC
was	O
lost	O
.	O

However	O
,	O
two	O
of	O
four	O
cats	O
inoculated	O
with	O
C3663	O
died	B-PROC
of	O
FIP	O
,	O
and	O
a	O
third	O
C3663	O
-	O
inoculated	O
cat	O
showed	O
FIP	O
lesions	O
at	O
91	O
days	O
after	O
challenge	O
.	O

We	O
present	O
achievements	O
in	O
synthesis	B-PROC
of	O
DBCs	O
and	O
their	O
amplification	O
based	O
on	O
molecular	O
biology	O
techniques	O
.	O

Resistant	O
cells	O
encode	O
distinct	O
mutations	O
in	O
the	O
NPC1	O
gene	O
,	O
resulting	O
in	O
loss	O
of	O
protein	B-PROC
expression	B-PROC
.	O

These	O
detrimental	O
changes	O
are	O
orchestrated	O
by	O
cross	O
talk	B-PROC
between	O
a	O
complex	O
network	O
of	O
cells	O
,	O
mediators	O
,	O
and	O
signaling	B-PROC
pathways	B-PROC
.	O

This	O
review	O
summarizes	O
current	O
knowledge	O
on	O
the	O
formation	B-PROC
and	O
potential	O
functional	O
role	O
of	O
different	O
MPs	O
in	O
inflammatory	O
diseases	O
with	O
a	O
specific	O
focus	O
on	O
ALI	O
/	O
ARDS	O
.	O

ABSTRACT	O
:	O
Scrub	O
typhus	O
is	O
a	O
rickettsial	O
disease	O
,	O
caused	O
by	O
Orientia	O
tsutsugamushi	O
,	O
which	O
is	O
transmitted	O
via	O
the	O
bite	B-PROC
of	O
a	O
chigger	O
.	O

His	O
rapid	O
course	O
was	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
status	O
epilepticus	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
).	O

Our	O
results	O
suggest	O
that	O
PF4	O
and	O
beta	O
-	O
TG	O
may	O
also	O
play	O
similar	O
roles	O
in	O
the	O
development	B-PROC
of	O
ARDS	O
in	O
SARS	O
patients	O
.	O

At	O
the	O
end	O
of	O
1	O
-	O
year	O
follow	O
-	O
up	O
,	O
five	O
patients	O
(	O
55	O
.	O
7	O
%)	O
were	O
weaned	B-PROC
from	O
ECMO	O
.	O

Four	O
patients	O
(	O
44	O
.	O
4	O
%)	O
died	B-PROC
while	O
undergoing	O
ECMO	O
.	O

TITLE	O
:	O
Liver	O
TCRγδ	O
(+)	O
CD3	O
(+)	O
CD4	O
(-)	O
CD8	O
(-)	O
T	O
cells	O
contribute	O
to	O
murine	O
hepatitis	O
virus	O
strain	O
3	O
-	O
induced	O
hepatic	O
injury	O
through	O
a	O
TNF	O
-	O
α	O
-	O
dependent	O
pathway	B-PROC
.	O

Coronaviruses	O
(	O
CoVs	O
)	O
are	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	B-PROC
RNA	O
viruses	O
that	O
cause	O
acute	O
and	O
chronic	O
infections	O
and	O
can	O
productively	O
infect	O
macrophages	O
.	O

We	O
demonstrate	O
that	O
activation	O
of	O
TLR3	O
with	O
the	O
synthetic	O
ligand	B-PROC
poly	O
I	O
:	O
C	O
mediates	O
antiviral	O
immunity	B-PROC
that	O
diminishes	O
(	O
MHV	O
-	O
A59	O
)	O
or	O
suppresses	O
(	O
MHV	O
-	O
JHM	O
,	O
MHV	O
-	O
3	O
)	O
virus	O
production	O
in	O
macrophages	O
.	O

The	O
objective	O
was	O
to	O
assess	O
the	O
effectiveness	O
of	O
HFNC	O
oxygen	O
therapy	O
in	O
adult	O
patients	O
with	O
SARI	O
by	O
confirmed	O
2009	O
influenza	O
A	O
/	O
H1N1v	O
infection	O
(	O
by	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
testing	O
).	O

Cases	O
of	O
murine	O
typhus	O
were	O
often	O
found	O
during	O
the	O
summer	O
and	O
had	O
acute	O
febrile	B-PROC
hepatitis	O
.	O

TITLE	O
:	O
[	O
Progress	O
on	O
development	B-PROC
and	O
research	O
of	O
coronavirus	O
based	O
vector	O
].	O

Over	O
half	O
(	O
29	O
;	O
51	O
%)	O
died	B-PROC
.	O

The	O
primary	O
complication	O
in	O
patients	O
in	O
which	O
malaria	O
contributed	O
to	O
death	B-PROC
was	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
pulmonary	O
edema	O
associated	O
with	O
the	O
accumulation	O
of	O
neutrophils	O
in	O
the	O
interalveolar	O
space	O
(	O
6	O
cases	O
).	O

RESULTS	O
:	O
Of	O
17	O
autopsies	O
,	O
13	O
revealed	O
that	O
death	B-PROC
could	O
be	O
attributed	O
to	O
P	O
.	O
vivax	O
infection	O
;	O
in	O
the	O
remaining	O
4	O
,	O
acute	O
diseases	O
other	O
than	O
malaria	O
were	O
found	O
to	O
be	O
the	O
cause	O
of	O
death	B-PROC
.	O

ABSTRACT	O
:	O
Ovarian	O
hyperstimulation	O
syndrome	O
(	O
OHSS	O
)	O
is	O
an	O
iatrogenic	O
complication	O
that	O
occurs	O
in	O
the	O
luteal	B-PROC
phase	I-PROC
of	O
an	O
induced	O
hormonal	O
cycle	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
the	O
clinical	O
presentation	O
,	O
treatment	O
,	O
and	O
outcome	O
of	O
pleural	O
effusion	O
associated	O
with	O
OHSS	O
in	O
three	O
patients	O
undergoing	O
in	O
vitro	O
fertilization	B-PROC
.	O

In	O
fact	O
,	O
m	O
-	O
calpain	O
inhibition	B-PROC
with	O
MDL28170	O
resulted	O
in	O
an	O
even	O
more	O
pronounced	O
inhibition	B-PROC
of	O
SARS	O
-	O
CoV	O
replication	O
(>	O
7	O
orders	O
of	O
magnitude	O
)	O
than	O
did	O
MG132	O
.	O

A	O
rat	O
model	O
of	O
bleomycin	O
(	O
BLM	O
)-	O
induced	O
lung	O
fibrosis	O
and	O
a	O
fibrotic	O
cell	O
model	O
with	O
transforming	O
growth	B-PROC
factor	O
beta	O
-	O
1	O
induction	O
were	O
employed	O
in	O
the	O
studies	O
.	O

This	O
epithelial	B-PROC
-	I-PROC
mesenchymal	I-PROC
transition	I-PROC
could	O
be	O
partially	O
reverted	O
by	O
cordycepin	O
,	O
a	O
major	O
component	O
of	O
Cordyceps	O
.	O

The	O
clinical	O
outcome	O
measures	O
included	O
the	O
mortality	O
rate	O
at	O
28th	O
day	O
,	O
respiratory	O
index	O
(	O
FiO2	O
/	O
PO2	B-PROC
),	O
dynamic	O
lung	B-PROC
compliance	I-PROC
(	O
Cdyn	O
),	O
arterial	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
(	O
PaO2	O
),	O
arterial	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO2	O
),	O
mechanical	O
ventilation	O
parameters	O
,	O
vasoactive	O
drug	O
dose	O
and	O
lung	O
X	O
-	O
ray	O
changes	O
.	O

This	O
study	O
focused	O
on	O
exploring	O
the	O
clinical	O
efficacy	O
of	O
exogenous	O
pulmonary	O
surfactant	O
in	O
treating	O
infant	O
patients	O
with	O
acute	O
lung	O
injury	O
after	O
cardiac	O
surgery	O
with	O
the	O
use	O
of	O
extracorporeal	O
circulation	B-PROC
.	O

One	O
patient	O
(	O
0	O
.	O
01	O
%)	O
with	O
underlying	O
severe	O
co	O
-	O
morbidity	O
died	B-PROC
.	O

The	O
main	O
indications	O
for	O
pleural	O
procedures	O
were	O
possible	O
infection	O
(	O
49	O
%)	O
and	O
respiratory	O
symptoms	O
(	O
48	O
%),	O
and	O
concomitant	O
clinical	O
symptoms	O
included	O
fever	B-PROC
(	O
34	O
%),	O
dyspnea	O
(	O
74	O
%),	O
chest	O
pain	O
(	O
24	O
%)	O
and	O
cough	O
(	O
37	O
%).	O

Epidemics	O
with	O
k	O
<	O
1	O
can	O
be	O
simulated	O
by	O
postulating	O
coexisting	O
high	O
virulence	B-PROC
virus	O
(	O
HVV	O
)	O
and	O
low	O
virulence	B-PROC
virus	O
(	O
LVV	O
),	O
with	O
the	O
former	O
being	O
propagated	O
at	O
slower	O
speed	O
and	O
with	O
a	O
higher	O
mortality	O
rate	O
than	O
the	O
latter	O
.	O

Patients	O
who	O
died	B-PROC
had	O
a	O
higher	O
prevalence	O
of	O
comorbidities	O
(	O
86	O
·	O
4	O
%)	O
than	O
those	O
who	O
survived	O
(	O
57	O
%),	O
suggesting	O
that	O
the	O
presence	O
of	O
chronic	O
illness	O
may	O
increase	O
the	O
likelihood	O
of	O
death	B-PROC
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
SCoV	O
viral	O
proteins	O
are	O
efficiently	O
produced	O
in	O
infected	O
cells	O
in	O
which	O
host	O
protein	B-PROC
synthesis	I-PROC
is	O
impaired	O
by	O
nsp1	O
is	O
unknown	O
.	O

TITLE	O
:	O
Implications	O
of	O
altered	O
replication	O
fidelity	O
on	O
the	O
evolution	B-PROC
and	O
pathogenesis	B-PROC
of	O
coronaviruses	O
.	O

mAbs	O
against	O
N	O
protein	O
of	O
MHV	O
with	O
high	O
activity	O
and	O
specificity	O
were	O
prepared	O
successfully	O
,	O
which	O
provides	O
a	O
potential	O
basis	O
for	O
further	O
researches	O
on	O
N	O
protein	B-PROC
function	I-PROC
and	O
diagnostic	O
methods	O
.	O

APN	O
is	O
also	O
considered	O
a	O
target	O
for	O
cancer	O
therapy	O
and	O
its	O
structure	O
,	O
reported	O
here	O
,	O
could	O
facilitate	O
the	O
development	B-PROC
of	O
anti	O
-	O
cancer	O
drugs	O
.	O

Further	O
computational	O
analysis	O
will	O
provide	O
framework	O
for	O
understanding	O
the	O
underlying	O
genetic	O
and	O
molecular	O
determinants	O
related	O
to	O
maturation	B-PROC
pathways	B-PROC
of	O
antiviral	O
bnAbs	O
that	O
could	O
be	O
useful	O
for	O
applying	O
novel	O
approaches	O
to	O
the	O
design	O
of	O
effective	O
vaccine	O
immunogens	O
and	O
antibody	B-PROC
-	O
based	O
therapeutics	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
characterized	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
pulmonary	O
fibrosis	O
,	O
and	O
monocytes	O
/	O
macrophages	O
are	O
the	O
key	O
players	O
in	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

Systemic	O
antibiotic	O
is	O
considered	O
as	O
the	O
major	O
risk	O
factor	O
for	O
the	O
development	B-PROC
of	O
C	O
difficile	O
colitis	O
.	O

Influenza	O
virus	B-PROC
infection	I-PROC
is	O
treated	O
worldwide	O
mainly	O
by	O
neuraminidase	B-PROC
inhibitors	I-PROC
(	O
NAIs	O
).	O

Histopathological	O
examination	O
,	O
a	O
hydrostatic	O
lung	O
test	O
and	O
blood	B-PROC
gas	I-PROC
analysis	O
showed	O
positive	O
results	O
in	O
the	O
combination	O
therapy	O
group	O
.	O

Combination	O
therapy	O
of	O
laninamivir	O
octanoate	O
with	O
artificial	O
surfactant	O
reduces	O
lethality	O
in	O
mice	O
infected	O
with	O
influenza	O
virus	O
,	O
and	O
eventually	O
suppresses	O
DAD	O
formation	B-PROC
and	O
preserves	O
lung	B-PROC
function	I-PROC
.	O

This	O
combination	O
could	O
be	O
effective	O
for	O
prevention	O
of	O
severe	O
pneumonia	O
secondary	O
to	O
influenza	O
virus	B-PROC
infection	I-PROC
in	O
humans	O
,	O
which	O
is	O
not	O
improved	O
by	O
NAI	O
monotherapy	O
.	O

Additionally	O
,	O
the	O
inhibition	B-PROC
is	O
selective	O
because	O
these	O
compounds	O
do	O
not	O
exert	B-PROC
significant	O
inhibitory	O
effects	O
against	O
other	O
proteases	O
including	O
chymotrysin	O
,	O
papain	O
,	O
and	O
HIV	O
protease	O
.	O

Our	O
results	O
showed	O
that	O
the	O
IL	B-PROC
-	I-PROC
17	I-PROC
expression	B-PROC
was	O
significantly	O
elevated	O
in	O
the	O
liver	O
and	O
serum	O
of	O
BALB	O
/	O
cJ	O
mice	O
infected	O
with	O
MHV	O
-	O
3	O
.	O

This	O
one	O
-	O
to	O
-	O
one	O
relation	O
provides	O
us	O
an	O
explicit	O
formula	O
in	O
calculating	O
the	O
basic	O
reproduction	B-PROC
number	O
.	O

The	O
IBV	O
-	O
Ark	O
vaccine	O
was	O
applied	O
ocularly	O
and	O
tears	O
were	O
collected	O
from	O
infected	O
chickens	O
for	O
subsequent	O
ocular	B-PROC
inoculation	O
in	O
later	O
passages	O
.	O

Their	O
pathogenicity	O
for	O
pigs	O
has	O
been	O
tested	O
by	O
oral	O
infection	O
of	O
colostrum	O
-	O
deprived	O
newborn	O
,	O
and	O
of	O
severely	O
immunosuppressed	O
weaned	B-PROC
pigs	O
,	O
but	O
colonisation	O
of	O
conventional	O
weaned	B-PROC
pigs	O
by	O
porcine	O
EPEC	O
has	O
not	O
been	O
experimentally	O
studied	O
.	O

Thus	O
,	O
the	O
ability	O
of	O
this	O
porcine	O
EPEC	O
strain	O
to	O
colonise	O
conventional	O
weaned	B-PROC
pigs	O
under	O
farming	O
conditions	O
became	O
a	O
question	O
of	O
relevance	O
to	O
human	O
health	O
.	O

In	O
three	O
experiments	O
moderate	O
predispositions	O
were	O
applied	O
:	O
coinfections	O
with	O
enterotoxigenic	O
E	O
.	O
coli	O
(	O
ETEC	O
)	O
or	O
with	O
low	O
-	O
virulence	B-PROC
TGE	O
coronavirus	O
,	O
application	O
of	O
fumonisin	O
B1	O
with	O
a	O
normal	O
therapeutic	O
dose	O
of	O
dexamethasone	O
,	O
and	O
the	O
increase	O
of	O
soybean	O
protein	O
concentration	O
in	O
the	O
feed	O
.	O

The	O
results	O
indicate	O
that	O
under	O
normal	O
farm	O
conditions	O
porcine	O
EPEC	O
may	O
colonise	O
conventional	O
weaned	B-PROC
pigs	O
by	O
inducing	O
ileal	O
attaching	O
effacing	O
(	O
AE	O
)	O
lesions	O
with	O
reasonable	O
frequency	O
,	O
without	O
clinical	O
signs	O
.	O

TITLE	O
:	O
Avian	O
coronavirus	O
spike	O
glycoprotein	O
ectodomain	O
shows	O
a	O
low	O
codon	O
adaptation	B-PROC
to	O
Gallus	O
gallus	O
with	O
virus	O
-	O
exclusive	O
codons	O
in	O
strategic	O
amino	O
acids	O
positions	O
.	O

Initially	O
the	O
application	O
of	O
ECMO	O
was	O
associated	O
with	O
severe	O
complications	O
,	O
but	O
significant	O
technical	O
progress	O
in	O
recent	O
years	O
has	O
led	O
to	O
the	O
development	B-PROC
of	O
safer	O
systems	O
and	O
promotes	O
a	O
wider	O
distribution	O
of	O
the	O
technique	O
.	O

Age	O
<	O
30	O
years	O
,	O
symptoms	O
of	O
fever	B-PROC
,	O
cough	O
and	O
dyspnea	O
,	O
and	O
death	B-PROC
were	O
independently	O
associated	O
with	O
influenza	O
A	O
infection	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Phylogenetic	O
analysis	O
has	O
demonstrated	O
that	O
some	O
positive	O
-	O
sense	B-PROC
RNA	O
viruses	O
can	O
be	O
classified	O
into	O
the	O
picornavirus	O
-	O
like	O
supercluster	O
,	O
which	O
includes	O
picornaviruses	O
,	O
caliciviruses	O
,	O
and	O
coronaviruses	O
.	O

We	O
conclude	O
that	O
these	O
compounds	O
have	O
the	O
potential	O
to	O
be	O
developed	O
as	O
antiviral	O
therapeutics	O
aimed	O
at	O
a	O
single	O
virus	O
or	O
multiple	O
viruses	O
in	O
the	O
picornavirus	O
-	O
like	O
supercluster	O
by	O
targeting	B-PROC
3Cpro	O
or	O
3CLpro	O
.	O

Pseudotyped	O
virus	O
carrying	O
S	O
protein	O
(	O
S	O
-	O
pseudovirus	O
)	O
produced	O
by	O
human	O
cells	O
that	O
were	O
treated	O
with	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
for	O
calnexin	O
expression	B-PROC
(	O
calnexin	O
siRNA	O
-	O
treated	O
cells	O
)	O
showed	O
significantly	O
lower	O
infectivity	O
than	O
S	O
-	O
pseudoviruses	O
produced	O
by	O
untreated	O
and	O
control	O
siRNA	O
-	O
treated	O
cells	O
.	O

Poly	O
(	O
I	O
·	O
C	O
)	O
pretreatment	O
upregulated	O
beta	O
interferon	O
(	O
IFN	O
-	O
β	O
),	O
IFN	O
-	O
γ	O
,	O
IL	O
-	O
1β	O
,	O
and	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)	O
gene	B-PROC
expression	I-PROC
in	O
the	O
lungs	O
.	O

TITLE	O
:	O
[	O
Antigenicity	O
characterization	O
of	O
six	O
different	O
fragments	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
].	O

Molecular	O
detection	O
for	O
18	O
viral	O
pathogens	O
using	O
multiplex	O
polymerase	O
chain	O
reaction	O
/	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reactions	O
was	O
performed	O
.	O

A	O
minimum	O
level	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
and	O
mutually	O
exclusive	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
thresholds	O
were	O
chosen	O
for	O
the	O
different	O
levels	O
of	O
ARDS	O
severity	O
(	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
to	O
better	O
categorize	O
patients	O
with	O
different	O
outcomes	O
and	O
potential	O
responses	O
to	O
therapy	O
.	O

RNA	B-PROC
interference	I-PROC
has	O
been	O
confirmed	O
as	O
a	O
new	O
approach	O
for	O
controlling	O
viral	B-PROC
infections	I-PROC
.	O

In	O
-	O
ICU	O
mortality	O
was	O
52	O
.	O
9	O
%	O
overall	O
,	O
reaching	B-PROC
80	O
.	O
9	O
%	O
and	O
86	O
.	O
8	O
%,	O
respectively	O
,	O
for	O
patients	O
who	O
required	O
ETI	O
and	O
for	O
patients	O
with	O
ARDS	O
.	O

SARS	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
,	O
and	O
one	O
of	O
its	O
components	O
,	O
a	O
viral	O
helicase	O
,	O
is	O
emerging	O
as	O
a	O
promising	O
target	O
for	O
the	O
development	B-PROC
of	O
chemical	O
SARS	O
inhibitors	O
.	O

PLpro	O
significantly	O
increased	O
TGF	O
-	O
β1	O
mRNA	B-PROC
expression	B-PROC
(	O
greater	O
than	O
fourfold	O
)	O
and	O
protein	O
production	O
(	O
greater	O
than	O
threefold	O
).	O

PLpro	O
upregulated	O
HSP27	O
,	O
linking	O
with	O
activation	O
of	O
p38	O
MAPK	O
and	O
ERK1	O
/	O
2	O
signaling	B-PROC
.	O

The	O
emergence	O
or	O
re	O
-	O
emergence	O
of	O
bacterial	O
(	O
Mycobacterium	O
bovis	O
and	O
Brucella	O
spp	O
)	O
or	O
viral	O
(	O
hepatitis	O
E	O
virus	O
)	O
infections	O
shows	O
that	O
zoonoses	O
should	O
be	O
considered	O
as	O
emerging	O
risks	O
in	O
agricultural	O
and	O
animal	O
breeding	B-PROC
and	O
should	O
be	O
addressed	O
by	O
specific	O
preventive	O
interventions	O
.	O

Analysis	O
of	O
the	O
functional	O
importance	O
of	O
side	O
-	O
chains	O
by	O
mutational	O
study	O
may	O
exaggerate	O
the	O
effect	O
by	O
imposing	O
a	O
structural	O
disturbance	O
or	O
an	O
unusual	O
steric	O
,	O
electrostatic	O
or	O
hydrophobic	B-PROC
interaction	I-PROC
.	O

CONCLUSIONS	O
:	O
In	O
cases	O
such	O
as	O
this	O
,	O
in	O
which	O
patients	O
with	O
severe	O
acute	O
respiratory	O
failure	O
requiring	O
full	O
-	O
time	O
noninvasive	O
positive	O
pressure	O
ventilation	O
therapy	O
also	O
show	O
sleep	B-PROC
-	O
disordered	O
breathing	B-PROC
,	O
different	O
ventilator	O
settings	O
must	O
be	O
used	O
for	O
waking	B-PROC
and	O
sleeping	B-PROC
.	O

TITLE	O
:	O
[	O
Comparative	O
study	O
on	O
the	O
effect	O
of	O
restrictive	O
fluid	O
management	O
strategy	O
on	O
the	O
early	O
pulmonary	B-PROC
function	I-PROC
of	O
patients	O
with	O
severe	O
burn	O
].	O

RFMS	O
is	O
a	O
useful	O
strategy	O
in	O
improving	O
early	O
pulmonary	O
oxygenation	B-PROC
of	O
patients	O
with	O
extremely	O
severe	O
and	O
extensive	O
burn	O
by	O
promoting	O
the	O
process	O
of	O
fluid	O
reabsorption	O
and	O
rebalance	O
.	O

Of	O
the	O
isolated	O
diarylheptanoids	O
,	O
hirsutenone	O
(	O
2	O
)	O
showed	O
the	O
most	O
potent	O
PL	O
(	O
pro	O
)	O
inhibitory	O
activity	O
,	O
with	O
an	O
inhibitory	O
concentration	O
(	O
IC	O
(	O
50	O
))	O
value	O
of	O
4	O
.	O
1	O
µM	O
.	O
Structure	O
-	O
activity	O
analysis	O
showed	O
that	O
catechol	O
and	O
α	O
,	O
β	O
-	O
unsaturated	O
carbonyl	O
moiety	O
in	O
the	O
molecule	O
were	O
the	O
key	O
requirement	O
for	O
SARS	O
-	O
CoV	O
cysteine	O
protease	O
inhibition	B-PROC
.	O

RESULTS	O
:	O
Animals	O
treated	O
with	O
air	O
-	O
PS	O
for	O
20	O
minutes	O
had	O
significantly	O
improved	O
lung	B-PROC
function	I-PROC
,	O
reduced	O
pulmonary	O
edema	O
,	O
decreased	O
concentration	O
of	O
total	O
protein	O
and	O
proinflammatory	O
cytokines	O
in	O
BALF	O
,	O
ameliorated	O
lung	O
injury	O
,	O
and	O
improved	O
animal	O
survival	O
.	O

With	O
the	O
number	O
of	O
emerging	O
viral	B-PROC
diseases	I-PROC
increasing	O
the	O
last	O
decades	O
,	O
there	O
is	O
a	O
growing	O
need	O
for	O
appropriate	O
animal	O
models	O
for	O
virus	O
studies	O
.	O

The	O
6x	O
His	O
-	O
tagged	O
N	O
protein	O
was	O
expressed	B-PROC
by	O
inducing	O
the	O
bacterial	O
cells	O
with	O
isopropyl	O
-	O
1	O
-	O
thio	O
-	O
D	O
-	O
galactopyranoside	O
(	O
IPTG	O
)	O
and	O
purified	O
by	O
Ni	O
-	O
NTA	O
affinity	O
resin	O
.	O

TITLE	O
:	O
Programmed	O
-	O
1	O
frameshifting	O
efficiency	O
correlates	O
with	O
RNA	O
pseudoknot	O
conformational	O
plasticity	O
,	O
not	O
resistance	B-PROC
to	O
mechanical	O
unfolding	O
.	O

The	O
spike	O
glycoprotein	O
of	O
IBV	O
is	O
essential	O
for	O
host	O
cell	B-PROC
attachment	I-PROC
,	O
neutralization	O
,	O
and	O
is	O
involved	O
in	O
the	O
induction	O
of	O
protective	O
immunity	B-PROC
.	O

An	O
additional	O
palmitoylation	B-PROC
site	O
was	O
observed	O
in	O
CK	O
/	O
SWE	O
/	O
082066	O
/	O
2010	O
a	O
QX	O
-	O
like	O
strain	O
.	O

ABSTRACT	O
:	O
The	O
authors	O
report	O
the	O
results	O
of	O
clinical	O
examination	O
of	O
the	O
respiratory	O
,	O
organs	O
of	O
97	O
patients	O
with	O
hemorrhagic	O
fever	B-PROC
and	O
renal	O
syndrome	O
(	O
HFRS	O
)	O
with	O
confirmed	O
Puumala	O
serotype	O
.	O

immunization	O
with	O
rADV	O
did	O
not	O
redirect	O
the	O
rADV	O
vector	O
to	O
the	O
olfactory	B-PROC
bulb	O
.	O

The	O
same	O
detection	O
limit	O
was	O
found	O
with	O
P136	O
.	O
8D12	O
as	O
a	O
coating	O
antibody	B-PROC
and	O
biotinylated	O
F26G18	O
as	O
a	O
detection	O
antibody	B-PROC
.	O

In	O
conclusion	O
,	O
the	O
method	O
described	O
in	O
this	O
study	O
allows	O
sensitive	O
detection	O
of	O
a	O
recombinant	O
SARS	O
spike	O
protein	O
by	O
sandwich	O
ELISA	O
with	O
bi	O
-	O
specific	O
monoclonal	O
antibody	B-PROC
and	O
could	O
be	O
used	O
for	O
the	O
diagnosis	O
of	O
patients	O
suspected	O
with	O
SARS	O
.	O

In	O
addition	O
,	O
both	O
R	O
-	O
H120	O
and	O
H120	O
induced	O
a	O
comparable	O
titer	O
of	O
HA	O
inhibition	B-PROC
(	O
HI	O
)	O
antibody	B-PROC
in	O
immunized	O
chickens	O
and	O
also	O
provided	O
up	O
to	O
85	O
%	O
of	O
immune	O
protection	O
to	O
the	O
chickens	O
that	O
were	O
challenged	O
with	O
Mass41	O
IBV	O
strain	O
.	O

There	O
is	O
a	O
need	O
for	O
effective	O
infection	O
prevention	O
and	O
control	O
measures	O
and	O
strict	O
use	O
of	O
antibiotics	O
in	O
China	O
to	O
control	O
the	O
rise	O
and	O
spread	O
of	O
antibiotic	O
resistance	B-PROC
in	O
the	O
country	O
.	O

At	O
the	O
time	O
of	O
presentation	O
,	O
his	O
serum	O
TG	O
(	O
triglyceride	O
)	O
level	O
was	O
10	O
,	O
278	O
mg	O
/	O
dL	O
.	O
He	O
underwent	O
one	O
of	O
the	O
three	O
planned	O
sessions	O
of	O
plasma	O
exchange	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
TG	O
level	O
from	O
4728	O
mg	O
/	O
dL	O
to	O
1708	O
mg	O
/	O
dL	O
.	O
The	O
hospital	O
course	O
was	O
complicated	O
with	O
shock	O
,	O
hemorrhagic	O
transformation	B-PROC
of	O
the	O
pancreatitis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
have	O
shown	O
that	O
STAT1	O
plays	O
an	O
important	O
role	O
in	O
the	O
severity	O
of	O
SARS	O
-	O
CoV	O
pathogenesis	B-PROC
and	O
that	O
it	O
is	O
independent	O
of	O
the	O
role	O
of	O
STAT1	O
in	O
interferon	O
signaling	B-PROC
.	O

However	O
,	O
severe	O
complications	O
induced	O
by	O
malposition	O
of	O
nasogastric	O
tube	O
caused	O
great	O
danger	O
and	O
even	O
death	B-PROC
to	O
the	O
patients	O
.	O

Repeated	O
lung	O
lavage	O
combined	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
was	O
performed	O
after	O
transferring	O
to	O
the	O
ICU	O
of	O
our	O
hospital	O
.	O

We	O
evaluated	O
the	O
benefits	O
of	O
inhaled	B-PROC
epoprostenol	O
as	O
a	O
less	O
expensive	O
alternative	O
to	O
nitric	O
oxide	O
in	O
ventilated	O
surgical	O
intensive	O
care	O
patients	O
with	O
severe	O
hypoxemia	O
.	O

CONCLUSIONS	O
:	O
Treatment	O
with	O
inhaled	B-PROC
epoprostenol	O
improved	O
gas	O
exchange	O
in	O
severely	O
hypoxemic	O
surgical	O
patients	O
.	O

RESULTS	O
:	O
In	O
penehyclidine	O
hydrochloride	O
sequential	O
to	O
atropine	O
group	O
,	O
except	O
for	O
1	O
case	O
of	O
cancer	O
of	O
gastric	O
cardia	O
with	O
poisoning	O
after	O
operation	O
showing	O
intermediate	O
syndrome	O
of	O
poisoning	O
,	O
the	O
remaining	O
patients	O
did	O
not	O
have	O
any	O
complication	O
,	O
and	O
the	O
incidence	O
of	O
complications	O
was	O
1	O
.	O
67	O
％.	O
No	O
death	B-PROC
occurred	O
in	O
all	O
the	O
patients	O
,	O
and	O
the	O
cure	O
rate	O
was	O
100	O
.	O
00	O
％.	O
Time	O
of	O
recovery	O
from	O
ChE	O
activity	O
to	O
70	O
％	O
was	O
(	O
4	O
.	O
0	O
±	O
1	O
.	O
1	O
)	O
days	O
;	O
hospital	O
stay	O
was	O
(	O
7	O
.	O
0	O
+	O
2	O
.	O
2	O
)	O
days	O
;	O
hospital	O
expenses	O
were	O
(	O
6268	O
±	O
238	O
)	O
yuan	O
.	O

Results	O
showed	O
that	O
the	O
intratracheal	O
route	O
of	O
MG	O
infection	O
caused	O
increased	O
air	O
sac	B-PROC
and	O
tracheal	O
lesion	O
scores	O
and	O
tracheal	O
mucosal	O
thickness	O
at	O
one	O
week	O
post	O
infection	O
,	O
whereas	O
the	O
eye	O
drop	O
route	O
produced	O
no	O
noticeable	O
pathology	O
.	O

ABSTRACT	O
:	O
In	O
terms	O
of	O
its	O
highly	O
pathogenic	O
nature	O
,	O
there	O
remains	O
a	O
significant	O
need	O
to	O
further	O
define	O
the	O
immune	O
pathology	O
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
,	O
as	O
well	O
as	O
identify	O
correlates	O
of	O
immunity	B-PROC
to	O
help	O
develop	O
vaccines	O
for	O
severe	O
coronaviral	O
infections	O
.	O

Acute	O
SARS	O
-	O
CoV	O
infection	O
prompted	O
coordinated	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
that	O
were	O
dominated	O
by	O
antiviral	O
IFN	O
response	O
gene	O
(	O
IRG	O
)	O
expression	B-PROC
.	O

Lack	O
of	O
IFN	O
-	O
mediated	O
immune	O
enhancement	O
in	O
infected	O
ferrets	O
that	O
were	O
previously	O
inoculated	O
with	O
,	O
or	O
vaccinated	O
against	O
,	O
SARS	O
-	O
CoV	O
revealed	O
9	O
IRG	O
correlates	O
of	O
protective	O
immunity	B-PROC
.	O

We	O
used	O
an	O
nsp1	O
mutant	O
,	O
nsp1	O
-	O
CD	O
,	O
lacking	O
the	O
RNA	O
cleavage	B-PROC
function	O
,	O
to	O
delineate	O
the	O
mechanism	O
of	O
nsp1	O
-	O
mediated	O
translation	B-PROC
inhibition	B-PROC
and	O
identify	O
the	O
translation	B-PROC
step	O
(	O
s	O
)	O
targeted	B-PROC
by	O
nsp1	O
.	O

nsp1	O
inhibited	O
the	O
translation	B-PROC
initiation	I-PROC
step	O
by	O
targeting	B-PROC
at	O
least	O
two	O
separate	O
stages	O
:	O
48S	O
initiation	O
complex	O
formation	B-PROC
and	O
the	O
steps	O
involved	O
in	O
the	O
formation	B-PROC
of	O
the	O
80S	O
initiation	O
complex	O
from	O
the	O
48S	O
complex	O
.	O

IBV	O
evolution	B-PROC
has	O
often	O
been	O
explained	O
as	O
variation	O
in	O
gene	O
frequencies	O
as	O
if	O
evolution	B-PROC
were	O
driven	O
by	O
genetic	B-PROC
drift	I-PROC
alone	O
.	O

IBV	O
'	O
s	O
generation	O
of	O
genetic	O
diversity	O
has	O
been	O
extensively	O
investigated	O
and	O
ultimately	O
involves	O
mutations	O
and	O
recombination	B-PROC
events	O
occurring	O
during	O
viral	B-PROC
replication	I-PROC
.	O

Accumulating	O
evidence	O
suggests	O
that	O
multiple	O
environmental	O
forces	O
within	O
the	O
host	O
,	O
including	O
immune	B-PROC
responses	I-PROC
(	O
or	O
lack	O
thereof	O
)	O
and	O
affinity	O
for	O
cell	O
receptors	O
,	O
as	O
well	O
as	O
physical	O
and	O
biochemical	O
conditions	O
,	O
are	O
responsible	O
for	O
the	O
selection	O
process	O
.	O

The	O
evolutionary	O
process	O
involves	O
generation	O
of	O
genetic	O
diversity	O
by	O
mutations	O
and	O
recombination	B-PROC
followed	O
by	O
replication	O
of	O
those	O
phenotypes	O
favored	O
by	O
selection	O
.	O

The	O
first	O
patient	O
,	O
a	O
man	O
aged	O
60	O
years	O
from	O
Saudi	O
Arabia	O
,	O
was	O
hospitalized	O
in	O
June	O
2012	O
and	O
died	B-PROC
;	O
the	O
second	O
patient	O
,	O
a	O
man	O
aged	O
49	O
years	O
from	O
Qatar	O
with	O
onset	O
of	O
symptoms	O
in	O
September	O
2012	O
was	O
transported	O
to	O
the	O
United	O
Kingdom	O
for	O
intensive	O
care	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
transcription	B-PROC
requires	O
a	O
high	O
-	O
frequency	O
recombination	B-PROC
process	O
that	O
links	O
newly	O
synthesized	O
minus	O
-	O
strand	O
subgenomic	O
RNA	O
copies	O
to	O
the	O
leader	O
region	O
,	O
which	O
is	O
present	O
only	O
once	O
,	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
.	O

Tissue	O
expression	B-PROC
of	O
the	O
protein	O
was	O
compared	O
in	O
three	O
different	O
groups	O
of	O
patients	O
:	O
COPD	O
smokers	O
,	O
COPD	O
nonsmokers	O
,	O
and	O
in	O
patients	O
with	O
age	O
-	O
related	O
emphysema	O
.	O

These	O
techniques	O
do	O
not	O
treat	O
the	O
underlying	O
lung	O
condition	O
;	O
rather	O
,	O
they	O
improve	O
gas	O
exchange	O
while	O
enabling	O
the	O
implantation	B-PROC
of	O
a	O
protective	O
ventilation	O
strategy	O
to	O
prevent	O
further	O
damage	O
to	O
the	O
lung	O
tissues	O
imposed	O
by	O
the	O
ventilator	O
.	O

As	O
such	O
,	O
extracorporeal	O
lung	O
support	O
technologies	O
have	O
been	O
used	O
in	O
three	O
major	O
lung	O
failure	O
case	O
types	O
:	O
As	O
a	O
bridge	O
to	O
recovery	O
in	O
acute	O
lung	O
failure	O
-	O
for	O
patients	O
with	O
injured	O
or	O
diseased	O
lungs	O
to	O
give	O
their	O
lungs	O
time	O
to	O
heal	B-PROC
and	O
regain	O
normal	O
physiologic	O
function	O
.	O

Engineering	O
methods	O
that	O
are	O
usually	O
carried	O
out	O
by	O
the	O
building	O
'	O
s	O
heating	O
,	O
ventilation	O
,	O
and	O
air	O
conditioning	O
(	O
HVAC	O
)	O
system	O
function	O
to	O
prevent	O
the	O
spread	O
of	O
airborne	O
infectious	O
pathogens	O
by	O
diluting	O
(	O
dilution	O
ventilation	O
)	O
and	O
removing	O
(	O
exhaust	O
ventilation	O
)	O
contaminated	O
air	O
from	O
a	O
room	O
,	O
controlling	O
the	O
direction	O
of	O
airflow	B-PROC
and	O
the	O
air	O
flow	O
patterns	O
in	O
a	O
building	O
.	O

During	O
2009	O
-	O
2010	O
and	O
2010	O
-	O
2011	O
influenza	O
pandemics	O
total	O
number	O
of	O
the	O
laboratory	O
-	O
confirmed	O
influenza	O
cases	O
were	O
1286	O
with	O
33	O
deaths	B-PROC
(	O
all	O
of	O
them	O
influenza	O
type	O
A	O
)	O
and	O
1203	O
(	O
51	O
.	O
4	O
%	O
type	O
A	O
)	O
with	O
44	O
deaths	B-PROC
,	O
respectively	O
.	O

Maternal	O
clinical	O
characteristics	O
,	O
hemodynamic	B-PROC
profiles	O
,	O
laboratory	O
findings	O
,	O
and	O
perinatal	O
outcomes	O
were	O
evaluated	O
.	O

ABSTRACT	O
:	O
Pneumonia	O
remains	O
a	O
leading	O
cause	O
of	O
child	O
death	B-PROC
in	O
developing	O
countries	O
.	O

DAMPs	O
originate	O
from	O
multiple	O
sources	O
,	O
including	O
injured	O
and	O
dying	B-PROC
cells	O
,	O
the	O
extracellular	O
matrix	O
,	O
or	O
exist	O
as	O
immunomodulatory	O
proteins	O
within	O
the	O
airspace	O
and	O
interstitium	O
.	O

TITLE	O
:	O
Institute	O
for	O
Quality	O
and	O
Efficiency	O
in	O
Health	O
Care	O
:	O
Executive	O
Summaries	O
ABSTRACT	O
:	O
Gestational	O
diabetes	O
(	O
GDM	O
:	O
gestational	O
diabetes	O
mellitus	O
)	O
is	O
generally	O
understood	O
to	O
mean	O
any	O
impaired	O
glucose	B-PROC
tolerance	I-PROC
(	O
IGT	O
)	O
first	O
occurring	O
or	O
diagnosed	O
during	O
pregnancy	O
.	O

IFN	O
-	O
γ	O
secretion	B-PROC
from	O
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
isolated	O
from	O
infected	O
EBI3	O
-/-	O
mice	O
was	O
augmented	O
while	O
IL	O
-	O
10	O
expression	B-PROC
muted	O
in	O
comparison	O
to	O
infected	O
WT	O
mice	O
.	O

Our	O
results	O
--	O
demonstrating	O
striking	O
changes	O
in	O
the	O
immune	O
regulation	B-PROC
by	O
co	O
-	O
infection	O
with	O
Plasmodium	O
and	O
Mycobacterium	O
--	O
are	O
highly	O
relevant	O
for	O
the	O
medical	O
management	O
of	O
both	O
infections	O
in	O
humans	O
.	O

ABSTRACT	O
:	O
Historically	O
,	O
economic	O
changes	O
have	O
negatively	O
affected	O
the	O
nursing	B-PROC
workforce	O
in	O
Ontario	O
.	O

Pathological	O
studies	O
in	O
autopsy	O
specimens	O
indicated	O
that	O
the	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
mainly	O
targeted	B-PROC
the	O
lower	O
respiratory	O
tract	O
,	O
resulting	O
in	O
diffuse	O
alveolar	O
damage	O
(	O
edema	O
,	O
hyaline	O
membranes	O
,	O
inflammation	O
,	O
and	O
fibrosis	O
),	O
manifested	O
clinically	O
by	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
refractory	O
hypoxemia	O
.	O

TITLE	O
:	O
Relevance	O
of	O
feline	O
interferon	O
omega	O
for	O
clinical	O
improvement	O
and	O
reduction	O
of	O
concurrent	O
viral	O
excretion	B-PROC
in	O
retrovirus	O
infected	O
cats	O
from	O
a	O
rescue	O
shelter	O
.	O

In	O
conclusion	O
,	O
rFeIFNω	O
improves	O
clinical	O
signs	O
and	O
reduces	O
concurrent	O
viral	O
excretion	B-PROC
in	O
naturally	O
infected	O
retroviral	O
cats	O
.	O

Four	O
horses	O
from	O
3	O
different	O
outbreaks	O
were	O
euthanized	O
or	O
died	B-PROC
due	O
to	O
rapid	O
progression	O
of	O
clinical	O
signs	O
.	O

Bortezomib	O
is	O
a	O
proteasome	B-PROC
inhibitor	O
indicated	O
for	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
patients	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
engineered	O
inactivation	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
ExoN	O
activity	O
results	O
in	O
a	O
stable	O
mutator	O
phenotype	O
with	O
profoundly	O
decreased	O
fidelity	O
in	O
vivo	O
and	O
attenuation	O
of	O
pathogenesis	B-PROC
in	O
young	O
,	O
aged	O
and	O
immunocompromised	O
mice	O
.	O

We	O
induced	O
nonviral	O
ARDS	O
by	O
acid	O
aspiration	O
and	O
viral	O
ARDS	O
by	O
intratracheal	O
influenza	O
virus	B-PROC
infection	I-PROC
in	O
wild	O
-	O
type	O
mice	O
and	O
mice	O
deficient	O
in	O
CXCL10	O
,	O
CXCR3	O
,	O
IFNAR1	O
(	O
IFN	O
-	O
α	O
/	O
β	O
receptor	O
1	O
),	O
or	O
TIR	O
domain	O
-	O
containing	O
adaptor	O
inducing	O
IFN	O
-	O
β	O
(	O
TRIF	O
).	O

CXCL10	O
-	O
CXCR3	O
acts	O
in	O
an	O
autocrine	B-PROC
fashion	O
on	O
the	O
oxidative	B-PROC
burst	I-PROC
and	O
chemotaxis	B-PROC
in	O
the	O
inflamed	O
neutrophils	O
,	O
leading	O
to	O
fulminant	O
pulmonary	O
inflammation	O
.	O

CXCL10	O
-	O
CXCR3	O
signaling	B-PROC
appears	O
to	O
be	O
a	O
critical	O
factor	O
for	O
the	O
exacerbation	O
of	O
the	O
pathology	O
of	O
ARDS	O
.	O

In	O
this	O
study	O
,	O
the	O
COE	O
and	O
LTB	O
-	O
COE	O
genes	O
were	O
engineered	O
into	O
the	O
Lactobacillus	O
-	O
Escherichia	O
coli	O
shuttle	O
vectors	O
pSAPG1	O
(	O
surface	O
-	O
displaying	O
)	O
and	O
pSAPG2	O
(	O
secreting	B-PROC
)	O
followed	O
by	O
electrotransformation	O
into	O
Lactobacillus	O
casei	O
(	O
Lc	O
)	O
to	O
yield	O
the	O
following	O
recombinant	O
strains	O
:	O
Lc	O
:	O
PG1	O
-	O
LTB	O
-	O
COE	O
,	O
Lc	O
:	O
PG2	O
-	O
LTB	O
-	O
COE	O
,	O
Lc	O
:	O
PG1	O
-	O
COE	O
,	O
and	O
Lc	O
:	O
PG2	O
-	O
COE	O
.	O

RESULTS	O
:	O
The	O
duration	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
hepatitis	O
,	O
acute	O
renal	O
failure	O
,	O
gastrointestinal	O
failure	O
and	O
blood	B-PROC
coagulation	I-PROC
dysfunction	O
were	O
shorter	O
in	O
the	O
treatment	O
group	O
than	O
in	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

A	O
/	O
H1N1	O
/	O
09	O
infection	O
rate	O
did	O
not	O
differ	O
in	O
patients	O
with	O
and	O
without	O
cirrhosis	O
(	O
4	O
/	O
21	O
,	O
19	O
%;	O
4	O
/	O
27	O
,	O
15	O
%),	O
but	O
three	O
patients	O
with	O
cirrhosis	O
died	B-PROC
of	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
with	O
fungal	O
or	O
bacterial	O
superinfection	O
in	O
two	O
cases	O
,	O
despite	O
antiviral	O
treatment	O
.	O

This	O
work	O
aimed	O
to	O
study	O
the	O
relationship	O
between	O
deep	O
pectoral	O
myopathy	O
and	O
IBV	O
by	O
describing	O
tracheal	O
and	O
muscle	O
lesions	O
and	O
comparing	O
the	O
frequency	O
of	O
IBV	O
detection	O
via	O
reverse	O
-	O
transcription	B-PROC
(	O
RT	O
)	O
PCR	O
in	O
muscle	O
,	O
tracheal	O
,	O
and	O
cecal	O
tonsil	O
samples	O
from	O
broilers	O
with	O
and	O
without	O
myopathy	O
.	O

Upon	O
microscopic	O
examination	O
,	O
the	O
muscle	O
samples	O
from	O
the	O
case	O
group	O
presented	O
extensive	O
necrosis	B-PROC
,	O
intense	O
mononuclear	O
inflammatory	O
infiltration	O
,	O
muscle	O
fiber	O
fragmentation	O
,	O
and	O
fibrotic	O
tissue	O
,	O
confirming	O
myopathy	O
,	O
whereas	O
muscles	O
from	O
the	O
control	O
group	O
showed	O
no	O
alterations	O
.	O

ABSTRACT	O
:	O
Many	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
receive	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
as	O
a	O
rescue	O
therapy	O
.	O

We	O
presented	O
a	O
male	O
patient	O
,	O
aged	O
50	O
,	O
hospitalized	O
in	O
the	O
Emergency	O
Center	O
Kragujevac	O
due	O
to	O
altered	O
mental	O
status	O
(	O
Glasgow	O
Coma	O
Score	O
11	O
),	O
partial	O
respiratory	O
insufficiency	O
(	O
pO2	B-PROC
7	O
.	O
5	O
kPa	O
,	O
pCO2	O
4	O
.	O
3	O
kPa	O
,	O
SpO2	O
89	O
%),	O
weakness	O
of	O
lower	O
extremities	O
and	O
atypical	O
electrocardiographic	O
changes	O
.	O

Intraoperative	O
and	O
post	O
-	O
operative	O
hemodynamics	B-PROC
was	O
stable	O
.	O

ABSTRACT	O
:	O
The	O
history	O
of	O
clinical	O
application	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
has	O
been	O
more	O
than	O
30	O
years	O
.	O

The	O
underlying	O
causes	O
of	O
cardiorespiratory	O
failure	O
were	O
as	O
follows	O
:	O
two	O
cases	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
leading	O
to	O
respiratory	O
failure	O
,	O
4	O
with	O
failure	O
of	O
weaning	B-PROC
from	O
cardiopulmonary	O
bypass	O
,	O
3	O
with	O
fulminant	O
myocarditis	O
,	O
1	O
with	O
right	O
ventricular	O
cardiomyopathy	O
leading	O
to	O
repeated	O
cardiac	O
arrest	O
,	O
1	O
with	O
preoperative	O
severe	O
hypoxemia	O
,	O
and	O
1	O
with	O
anaphylactic	O
shock	O
complicated	O
with	O
massive	O
pulmonary	O
hemorrhage	O
and	O
severe	O
hypoxemia	O
.	O

The	O
mean	O
ECMO	O
support	O
time	O
was	O
151	O
.	O
75	O
(	O
15	O
-	O
572	O
)	O
h	O
.	O
Seven	O
patients	O
(	O
58	O
.	O
33	O
%)	O
were	O
weaned	B-PROC
from	O
ECMO	O
,	O
6	O
patients	O
(	O
50	O
.	O
00	O
%)	O
were	O
successfully	O
discharged	O
.	O

RESULTS	O
:	O
Of	O
the	O
5	O
patients	O
,	O
the	O
female	O
newborn	O
affected	O
by	O
the	O
Currarino	O
syndrome	O
,	O
associated	O
with	O
persistence	O
of	O
the	O
common	O
cloacal	O
canal	O
and	O
anal	O
imperforation	O
,	O
died	B-PROC
two	O
days	O
after	O
surgery	O
,	O
of	O
cardiovascular	O
and	O
respiratory	O
complications	O
.	O

ABSTRACT	O
:	O
The	O
applicability	O
of	O
pulse	B-PROC
pressure	I-PROC
variation	O
(	O
ΔPP	O
)	O
to	O
predict	O
fluid	O
responsiveness	O
using	O
lung	O
-	O
protective	O
ventilation	O
strategies	O
is	O
uncertain	O
in	O
clinical	O
practice	O
.	O

Both	O
genotypes	O
A	O
and	O
B	O
were	O
detected	O
but	O
no	O
recombination	B-PROC
between	O
them	O
was	O
found	O
.	O

While	O
influenza	O
virus	O
,	O
enterovirus	O
,	O
RSV	O
,	O
and	O
HMPV	O
had	O
a	O
defined	O
period	O
of	O
circulation	B-PROC
,	O
the	O
other	O
viruses	O
were	O
detected	O
throughout	O
the	O
year	O
.	O

Generalized	O
estimated	O
equations	O
were	O
used	O
to	O
evaluate	O
associations	O
between	O
viral	B-PROC
infection	I-PROC
and	O
marker	O
elevation	O
,	O
and	O
between	O
marker	O
elevation	O
and	O
symptom	O
score	O
.	O

While	O
many	O
aspirates	O
were	O
dilute	O
and	O
showed	O
no	O
mRNA	O
signal	O
,	O
viral	B-PROC
infection	I-PROC
significantly	O
increased	O
the	O
number	O
of	O
samples	O
that	O
were	O
positive	O
for	O
IFN	O
-	O
λ1	O
,	O
IFN	O
-	O
λ2	O
/	O
3	O
,	O
TLR3	O
,	O
RIG	O
-	O
I	O
,	O
and	O
IRF7	O
mRNA	O
.	O

EAV	O
replication	O
could	O
be	O
fully	O
restored	O
in	O
these	O
cells	O
by	O
expression	B-PROC
of	O
a	O
nonlipidated	O
form	O
of	O
LC3	O
.	O

Targeting	B-PROC
ezrin	O
function	O
by	O
small	O
interfering	O
RNA	O
increased	O
S	O
-	O
mediated	O
entry	O
of	O
pseudotyped	O
particles	O
in	O
epithelial	O
cells	O
.	O

We	O
randomly	O
tested	O
(	O
30	O
min	O
)	O
while	O
recording	O
EAdi	O
:	O
(	O
1	O
)	O
PSV30	O
(	O
PSV	O
with	O
an	O
expiratory	B-PROC
trigger	O
at	O
30	O
%	O
of	O
flow	O
peak	O
value	O
);	O
(	O
2	O
)	O
PSV1	O
(	O
PSV	O
with	O
expiratory	B-PROC
trigger	O
at	O
1	O
%);	O
(	O
3	O
)	O
NAVA	O
.	O

Patients	O
had	O
direct	O
contact	O
with	O
dead	B-PROC
/	O
sick	O
poultry	O
infected	O
with	O
H5N1	O
virus	O
or	O
lived	O
in	O
areas	O
where	O
H5N1	O
poultry	O
outbreaks	O
had	O
been	O
reported	O
at	O
the	O
same	O
time	O
as	O
their	O
illness	O
.	O

hMPV	O
was	O
significantly	O
more	O
likely	O
to	O
be	O
identified	O
in	O
mono	O
infection	O
as	O
compared	O
with	O
ADV	O
,	O
CRV	O
,	O
PIV	O
,	O
and	O
RSV	O
with	O
the	O
exception	O
of	O
ERV	B-PROC
[	O
p	O
<	O
0	O
.	O
05	O
].	O

TITLE	O
:	O
Human	O
coronaviruses	O
:	O
insights	O
into	O
environmental	O
resistance	B-PROC
and	O
its	O
influence	O
on	O
the	O
development	B-PROC
of	O
new	O
antiseptic	O
strategies	O
.	O

They	O
have	O
also	O
been	O
involved	O
in	O
nosocomial	O
viral	B-PROC
infections	I-PROC
.	O

This	O
provides	O
the	O
virus	O
with	O
a	O
platform	O
for	O
the	O
assembly	O
of	O
viral	B-PROC
replication	I-PROC
complexes	O
,	O
improving	O
efficiency	O
of	O
RNA	B-PROC
synthesis	I-PROC
.	O

In	O
addition	O
,	O
coronavirus	O
infection	O
has	O
been	O
demonstrated	O
to	O
induce	O
autophagy	B-PROC
.	O

Our	O
data	O
show	O
that	O
field	O
IBVs	O
in	O
Korea	O
are	O
continuing	O
to	O
evolve	O
and	O
that	O
vaccine	O
strains	O
might	O
actually	O
play	O
a	O
critical	O
role	O
in	O
the	O
appearance	O
of	O
new	O
IBV	O
strains	O
via	O
recombination	B-PROC
in	O
the	O
field	O
.	O

ABSTRACT	O
:	O
Bronchiolitis	O
obliterans	O
syndrome	O
(	O
BOS	O
)	O
after	O
allogeneic	O
hematopoietic	O
SCT	O
(	O
HSCT	O
)	O
is	O
recognized	O
as	O
a	O
new	O
-	O
onset	O
obstructive	O
lung	O
defect	O
(	O
OLD	O
)	O
in	O
pulmonary	B-PROC
function	I-PROC
testing	O
and	O
is	O
related	O
to	O
pulmonary	O
chronic	O
GVHD	O
.	O

Control	O
of	O
viral	B-PROC
replication	I-PROC
during	O
acute	O
disease	O
is	O
mediated	O
by	O
infiltrating	O
virus	O
-	O
specific	O
T	O
cells	O
via	O
cytokine	B-PROC
secretion	I-PROC
and	O
cytolytic	O
activity	O
,	O
however	O
sterile	O
immunity	B-PROC
is	O
not	O
achieved	O
and	O
virus	O
persists	O
resulting	O
in	O
chronic	O
neuroinflammation	O
associated	O
with	O
demyelination	O
.	O

In	O
in	O
vitro	O
systems	O
,	O
histones	O
damaged	O
endothelial	O
cells	O
,	O
stimulated	O
cytokine	O
release	O
,	O
and	O
induced	O
neutrophil	O
extracellular	O
trap	O
formation	B-PROC
and	O
myeloperoxidase	O
release	O
.	O

Successful	O
ECMO	O
weaning	B-PROC
was	O
possible	O
in	O
44	O
%	O
(	O
n	O
=	O
8	O
)	O
of	O
patients	O
and	O
overall	O
mortality	O
was	O
61	O
%	O
(	O
n	O
=	O
11	O
).	O

Platypnea	O
-	O
orthodeoxia	O
syndrome	O
referring	O
to	O
abnormal	O
oxygenation	B-PROC
in	O
the	O
upright	O
position	O
has	O
been	O
correlated	O
with	O
reopening	O
of	O
foramen	O
ovale	O
and	O
acute	O
right	O
-	O
to	O
-	O
left	O
intracardiac	O
shunt	O
.	O

It	O
is	O
associated	O
with	O
precordial	O
pain	O
,	O
ST	O
segment	O
elevation	O
,	O
absence	O
of	O
coronary	O
occlusion	B-PROC
and	O
reversible	O
deformation	O
of	O
the	O
left	O
ventricle	O
due	O
to	O
anteroapical	O
dyskinesia	O
that	O
is	O
reminiscent	O
of	O
a	O
Japanese	O
art	O
of	O
fishing	O
octopuses	O
(	O
tako	O
-	O
tsubo	O
).	O

In	O
case	O
of	O
the	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
a	O
member	O
of	O
the	O
family	O
Flaviviridae	O
,	O
infected	O
cells	O
contain	O
accumulations	O
of	O
vesicles	O
forming	O
a	O
membranous	O
web	O
(	O
MW	O
)	O
that	O
is	O
thought	O
to	O
be	O
the	O
site	O
of	O
viral	O
RNA	B-PROC
replication	I-PROC
.	O

Flow	O
cytometry	O
and	O
gene	B-PROC
expression	I-PROC
analysis	O
of	O
purified	O
T	O
-	O
cell	O
populations	O
from	O
lymph	O
nodes	O
and	O
the	O
CNS	O
was	O
used	O
to	O
directly	O
monitor	O
ex	O
vivo	O
T	O
-	O
cell	O
effector	O
function	O
.	O

CD4	O
depletion	O
in	O
B7	O
-	O
H1	O
-/-	O
mice	O
also	O
decreased	O
inducible	O
nitric	O
oxide	O
synthase	O
expression	B-PROC
by	O
microglia	O
and	O
macrophages	O
,	O
consistent	O
with	O
decreased	O
microglia	O
/	O
macrophage	B-PROC
activation	I-PROC
and	O
reduced	O
interferon	O
(	O
IFN	O
)-	O
γ	O
.	O

The	O
local	O
requirement	O
of	O
CD4	O
T	O
-	O
cell	O
help	O
for	O
CD8	O
T	O
-	O
cell	B-PROC
function	I-PROC
is	O
not	O
overcome	O
if	O
B7	O
-	O
H1	O
inhibitory	O
signals	O
are	O
lost	O
.	O

Moreover	O
,	O
the	O
increased	O
effector	O
activity	O
by	O
CD8	O
T	O
cells	O
in	O
the	O
CNS	O
of	O
B7	O
-	O
H1	O
-/-	O
mice	O
is	O
attributable	O
not	O
only	O
to	O
the	O
absence	O
of	O
B7	O
-	O
H1	O
upregulation	B-PROC
on	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
I	O
-	O
presenting	O
resident	O
target	O
cells	O
,	O
but	O
also	O
to	O
enhanced	O
local	O
CD4	O
T	O
-	O
cell	B-PROC
function	I-PROC
.	O

ABSTRACT	O
:	O
There	O
is	O
a	O
high	O
incidence	O
of	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
pediatric	O
patients	O
with	O
major	O
burns	O
,	O
and	O
this	O
development	B-PROC
leads	O
to	O
higher	O
mortality	O
.	O

The	O
study	O
was	O
performed	O
in	O
13	O
mechanically	O
ventilated	O
patients	O
with	O
severe	O
pulmonary	O
conditions	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
n	O
=	O
5	O
;	O
status	O
post	O
lung	O
transplantation	O
,	O
n	O
=	O
5	O
;	O
other	O
,	O
n	O
=	O
3	O
)	O
and	O
declining	O
respiratory	B-PROC
function	I-PROC
.	O

ABSTRACT	O
:	O
We	O
describe	O
here	O
the	O
design	O
,	O
synthesis	B-PROC
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
molecules	O
toward	O
the	O
development	B-PROC
of	O
novel	O
peptidomimetic	O
inhibitors	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

The	O
peptidomimetic	O
compounds	O
identified	O
through	O
this	O
process	O
are	O
attractive	O
leads	O
for	O
the	O
development	B-PROC
of	O
potential	O
therapeutic	O
agents	O
against	O
SARS	O
.	O

A	O
roadmap	O
for	O
the	O
product	O
development	B-PROC
of	O
the	O
RBD	O
-	O
S	O
SARS	O
vaccine	O
is	O
outlined	O
with	O
a	O
goal	O
to	O
manufacture	O
the	O
vaccine	O
for	O
clinical	O
testing	O
within	O
the	O
next	O
5	O
years	O
.	O

TITLE	O
:	O
Respiratory	O
and	O
hemodynamic	B-PROC
effects	O
of	O
a	O
stepwise	O
lung	O
recruitment	O
maneuver	O
in	O
pediatric	O
ARDS	O
:	O
a	O
feasibility	O
study	O
.	O

We	O
discovered	O
an	O
unexpected	O
concentration	O
of	O
positively	O
selected	O
genes	O
in	O
the	O
DNA	B-PROC
damage	I-PROC
checkpoint	I-PROC
and	O
nuclear	O
factor	O
κB	O
pathways	B-PROC
that	O
may	O
be	O
related	O
to	O
the	O
origin	O
of	O
flight	B-PROC
,	O
as	O
well	O
as	O
expansion	O
and	O
contraction	O
of	O
important	O
gene	O
families	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
causes	O
diarrhea	O
of	O
pigs	O
age	O
-	O
independently	O
and	O
death	B-PROC
of	O
young	O
piglets	O
,	O
resulting	O
in	O
economic	O
loss	O
of	O
porcine	O
industry	O
.	O

First	O
line	O
hypoxaemic	O
rescue	O
therapies	O
include	O
inhaled	B-PROC
nitric	O
oxide	O
,	O
prone	O
positioning	O
,	O
alveolar	O
recruitment	O
manoeuvres	O
and	O
high	O
frequency	O
oscillatory	O
ventilation	O
,	O
which	O
have	O
all	O
been	O
shown	O
to	O
be	O
effective	O
in	O
improving	O
oxygenation	B-PROC
.	O

Inadequate	O
tissue	B-PROC
oxygenation	B-PROC
and	O
excessive	O
oxygen	O
administration	O
can	O
be	O
detrimental	O
to	O
outcome	O
but	O
safety	O
thresholds	O
lack	O
definition	O
in	O
critically	O
ill	O
patients	O
.	O

Implementation	O
of	O
precise	O
control	O
of	O
arterial	O
oxygenation	B-PROC
may	O
avoid	O
the	O
harms	O
associated	O
with	O
excessive	O
and	O
inadequate	O
oxygenation	B-PROC
.	O

Here	O
we	O
demonstrate	O
the	O
removal	O
and	O
inactivation	O
capabilities	O
of	O
soft	O
-	O
X	O
-	O
ray	O
-	O
enhanced	O
electrostatic	O
precipitation	B-PROC
technology	O
targeting	B-PROC
infectious	O
agents	O
(	O
Bacillus	O
anthracis	O
,	O
Mycobacterium	O
bovis	O
BCG	O
,	O
and	O
poxviruses	O
),	O
allergens	O
,	O
and	O
ultrafine	O
particles	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
mice	O
in	O
high	O
-	O
fat	O
diet	O
group	O
and	O
the	O
two	O
virus	B-PROC
infection	I-PROC
groups	O
had	O
significantly	O
increased	O
AST	O
and	O
ALT	O
levels	O
with	O
also	O
elevated	O
TC	O
and	O
LDL	O
-	O
C	O
levels	O
.	O

The	O
two	O
virus	B-PROC
infection	I-PROC
groups	O
both	O
exhibited	O
obvious	O
pathologies	O
in	O
the	O
liver	O
characteristic	O
of	O
chronic	O
viral	O
hepatitis	O
with	O
increased	O
lipid	O
accumulation	O
in	O
the	O
hepatocytes	O
.	O

Therefore	O
,	O
PEDV	O
exhibits	O
rapid	O
variation	O
and	O
genetic	O
evolution	B-PROC
,	O
and	O
the	O
currently	O
prevailing	O
PEDV	O
strains	O
in	O
central	O
China	O
are	O
a	O
new	O
genotype	O
.	O

ABSTRACT	O
:	O
Chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-PROC
2	O
(	O
CCL2	O
),	O
a	O
chemoattractant	O
for	O
macrophages	O
,	O
T	O
cells	O
,	O
and	O
cells	O
expressing	O
CCR2	O
,	O
is	O
upregulated	O
during	O
acute	O
and	O
chronic	O
inflammation	O
.	O

TITLE	O
:	O
Structure	O
of	O
alphacoronavirus	O
transmissible	O
gastroenteritis	O
virus	O
nsp1	O
has	O
implications	O
for	O
coronavirus	O
nsp1	O
function	O
and	O
evolution	B-PROC
.	O

High	O
concentrations	O
of	O
inspired	B-PROC
oxygen	O
may	O
play	O
a	O
role	O
in	O
such	O
injury	O
,	O
but	O
aggressive	B-PROC
measures	O
to	O
reduce	O
them	O
in	O
order	O
to	O
avoid	O
oxygen	O
toxicity	O
-	O
which	O
dominated	O
ventilator	O
management	O
in	O
previous	O
decades	O
-	O
have	O
been	O
tempered	O
in	O
the	O
present	O
era	O
of	O
lung	O
-	O
protective	O
ventilation	O
.	O

TITLE	O
:	O
Conditional	O
ligands	O
for	O
Asian	O
HLA	O
variants	O
facilitate	O
the	O
definition	O
of	O
CD8	O
+	O
T	O
-	O
cell	O
responses	O
in	O
acute	O
and	O
chronic	O
viral	B-PROC
diseases	I-PROC
.	O

Peptide	O
exchange	O
was	O
accomplished	O
for	O
all	O
variants	O
as	O
demonstrated	O
by	O
an	O
ELISA	O
-	O
based	O
MHC	B-PROC
stability	O
assay	O
.	O

The	O
primary	O
outcome	O
was	O
death	B-PROC
or	O
severe	O
disability	O
within	O
3	O
months	O
.	O

The	O
mean	O
PaO2	O
/	O
fraction	O
of	O
inspired	B-PROC
oxygenation	B-PROC
(	O
FiO2	O
)	O
ratio	O
was	O
(	O
54	O
±	O
18	O
)	O
mm	O
Hg	O
(	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
),	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
was	O
(	O
11	O
±	O
6	O
)	O
cm	O
H2O	O
(	O
1	O
cm	O
H2O	O
=	O
0	O
.	O
098	O
kPa	O
),	O
Murray	O
lung	O
injury	O
score	O
was	O
3	O
.	O
6	O
±	O
0	O
.	O
5	O
,	O
serum	O
lactate	O
was	O
(	O
2	O
.	O
5	O
±	O
2	O
.	O
0	O
)	O
mmol	O
/	O
L	O
,	O
serum	O
white	O
blood	O
cell	O
count	O
was	O
(	O
16	O
±	O
6	O
)×	O
10	O
(	O
9	O
)/	O
L	O
,	O
and	O
APACHEII	O
score	O
was	O
17	O
±	O
8	O
.	O

RESULTS	O
:	O
After	O
hemofiltration	O
,	O
the	O
clinical	O
symptoms	O
such	O
as	O
abdominal	O
pain	O
,	O
fever	B-PROC
,	O
tachycardia	O
and	O
respiratory	O
distress	O
in	O
hemofiltration	O
group	O
were	O
significantly	O
remitted	O
compared	O
to	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

There	O
were	O
6	O
deaths	B-PROC
whose	O
3	O
were	O
forensic	O
cases	O
.	O

In	O
fatalities	O
,	O
the	O
common	O
symptoms	O
were	O
cardiovascular	O
shock	O
,	O
cardiorespiratory	O
arrest	O
,	O
haemodynamic	O
disturbance	O
,	O
intravascular	O
disseminated	O
coagulation	B-PROC
and	O
multiple	O
organ	O
failure	O
.	O

Blood	B-PROC
gases	I-PROC
and	O
hemodynamic	B-PROC
parameters	O
were	O
evaluated	O
after	O
changing	O
one	O
of	O
three	O
ECMO	O
settings	O
,	O
namely	O
,	O
circuit	O
blood	B-PROC
flow	I-PROC
,	O
FiO	O
(	O
2ECMO	O
)	O
(	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
in	O
circuit	O
),	O
or	O
sweep	O
gas	O
flow	O
ventilating	O
the	O
membrane	O
,	O
while	O
leaving	O
the	O
other	O
two	O
parameters	O
at	O
their	O
maximum	O
setting	O
.	O

The	O
purpose	O
of	O
this	O
prospective	O
case	O
-	O
control	O
study	O
was	O
to	O
survey	O
the	O
detection	O
rate	O
of	O
respiratory	O
viruses	O
in	O
children	O
with	O
Kawasaki	O
disease	O
(	O
KD	O
)	O
by	O
using	O
multiplex	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
to	O
investigate	O
the	O
clinical	O
implications	O
of	O
the	O
prevalence	O
of	O
respiratory	O
viruses	O
during	O
the	O
acute	O
phase	O
of	O
KD	O
.	O

However	O
,	O
neither	O
CXCL9	O
nor	O
CXCL10	O
deficiency	O
diminished	O
neutralizing	O
serum	O
Ab	O
,	O
supporting	O
a	O
direct	O
role	O
for	O
CXCL10	O
in	O
ASC	O
migration	B-PROC
.	O

NMR	O
chemical	O
shift	O
perturbation	O
analysis	O
reveals	O
that	O
the	O
N	O
-	O
terminal	O
region	O
of	O
an	O
MHV	O
N	O
SR	O
-	O
rich	O
linker	O
peptide	O
(	O
residues	O
198	O
to	O
230	O
)	O
binds	O
to	O
the	O
acidic	O
face	O
of	O
MHV	O
nsp3a	O
containing	O
the	O
acidic	O
α2	O
helix	O
with	O
an	O
affinity	O
(	O
expressed	B-PROC
as	O
K	O
(	O
a	O
))	O
of	O
8	O
.	O
1	O
×	O
10	O
(	O
3	O
)	O
M	O
(-	O
1	O
).	O

TITLE	O
:	O
Morbidity	O
and	O
outcome	O
of	O
severe	O
respiratory	O
syncytial	O
virus	B-PROC
infection	I-PROC
.	O

Out	O
of	O
240	O
enrolled	O
patients	O
,	O
24	O
patients	O
(	O
10	O
%)	O
were	O
admitted	O
to	O
the	O
ICU	O
,	O
57	O
patients	O
(	O
24	O
.	O
3	O
%)	O
had	O
a	O
PLOS	O
of	O
>	O
9	O
days	O
and	O
12	O
patients	O
(	O
5	O
%)	O
died	B-PROC
.	O

HBP	O
is	O
a	O
potential	O
biomarker	O
candidate	O
for	O
early	O
detection	O
of	O
ARDS	O
development	B-PROC
after	O
trauma	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
heat	B-PROC
shock	I-PROC
,	O
both	O
IRAK1	O
and	O
TAK1	O
are	O
again	O
detergent	O
soluble	O
,	O
which	O
correlates	O
with	O
the	O
IL	O
-	O
1β	O
-	O
dependent	O
p38	O
activation	O
.	O

Ten	O
(	O
22	O
%)	O
patients	O
died	B-PROC
,	O
all	O
with	O
underlying	O
major	O
systemic	O
diseases	O
and	O
7	O
(	O
70	O
%)	O
infected	O
with	O
serotype	O
7	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
citrulline	O
supplementation	O
could	O
prevent	O
the	O
development	B-PROC
of	O
ARDS	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
to	O
determine	O
its	O
role	O
in	O
NOS	O
coupling	O
and	O
function	O
.	O

We	O
have	O
used	O
them	O
to	O
study	O
autophagy	B-PROC
during	O
replication	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

However	O
,	O
expression	B-PROC
of	O
IBV	O
nonstructural	O
protein	O
6	O
alone	O
did	O
induce	O
autophagic	O
signaling	B-PROC
in	O
avian	O
cells	O
,	O
as	O
seen	O
previously	O
in	O
mammalian	O
cells	O
.	O

However	O
,	O
the	O
subcellular	O
localization	B-PROC
and	O
other	O
functions	O
of	O
PEDV	O
E	O
protein	O
still	O
require	O
more	O
research	O
.	O

Chief	O
symptoms	O
of	O
HCoV	O
-	O
OC43	O
infection	O
were	O
fever	B-PROC
(	O
in	O
78	O
%	O
of	O
cases	O
),	O
cough	O
(	O
67	O
%)	O
and	O
upper	O
respiratory	O
tract	O
infection	O
symptoms	O
(	O
57	O
%).	O

RESULTS	O
:	O
During	O
the	O
study	O
period	O
,	O
68	O
patients	O
were	O
identified	O
as	O
infected	O
with	O
HCoV	O
-	O
OC43	O
(	O
1	O
.	O
8	O
%	O
of	O
specimens	O
tested	O
,	O
4	O
.	O
2	O
%	O
of	O
all	O
respiratory	O
viruses	O
identified	O
by	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
).	O

The	O
ND	O
,	O
IB	O
and	O
AI	O
antibody	B-PROC
titers	O
and	O
the	O
lymphocyte	B-PROC
proliferation	I-PROC
were	O
enhanced	O
at	O
30	O
mg	O
/	O
mL	O
SPP	O
.	O

TITLE	O
:	O
Chronic	O
-	O
alcohol	O
-	O
abuse	O
-	O
induced	O
oxidative	O
stress	O
in	O
the	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Macrophages	O
from	O
ADORA2A	O
(-/-)	O
mice	O
exposed	O
to	O
LPS	O
plus	O
oxygen	O
expressed	B-PROC
higher	O
concentrations	O
of	O
proinflammatory	O
cytokines	O
and	O
cosignaling	O
molecules	O
.	O

Severe	O
respiratory	O
acidosis	O
may	O
be	O
effectively	O
prevented	O
by	O
decreasing	O
instrumental	O
dead	B-PROC
space	O
and	O
by	O
increasing	O
respiratory	O
rate	O
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
therapy	O
with	O
face	O
mask	O
oxygen	O
,	O
high	O
flow	O
nasal	O
cannula	O
oxygen	O
,	O
or	O
nasopharyngeal	O
continuous	O
PEEP	O
in	O
the	O
presence	O
of	O
respiratory	O
distress	O
and	O
hypoxemia	O
(	O
2C	O
),	O
use	O
of	O
physical	O
examination	O
therapeutic	O
endpoints	O
such	O
as	O
capillary	B-PROC
refill	I-PROC
(	O
2C	O
);	O
for	O
septic	O
shock	O
associated	O
with	O
hypovolemia	O
,	O
the	O
use	O
of	O
crystalloids	O
or	O
albumin	O
to	O
deliver	O
a	O
bolus	O
of	O
20	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
or	O
albumin	O
equivalent	O
)	O
over	O
5	O
to	O
10	O
mins	O
(	O
2C	O
);	O
more	O
common	O
use	O
of	O
inotropes	O
and	O
vasodilators	O
for	O
low	O
cardiac	O
output	O
septic	O
shock	O
associated	O
with	O
elevated	O
systemic	B-PROC
vascular	I-PROC
resistance	I-PROC
(	O
2C	O
);	O
and	O
use	O
of	O
hydrocortisone	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
""""	O
absolute	O
"""'"	O
adrenal	O
insufficiency	O
(	O
2C	O
).	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
therapy	O
with	O
face	O
mask	O
oxygen	O
,	O
high	O
flow	O
nasal	O
cannula	O
oxygen	O
,	O
or	O
nasopharyngeal	O
continuous	O
PEEP	O
in	O
the	O
presence	O
of	O
respiratory	O
distress	O
and	O
hypoxemia	O
(	O
2C	O
),	O
use	O
of	O
physical	O
examination	O
therapeutic	O
endpoints	O
such	O
as	O
capillary	B-PROC
refill	I-PROC
(	O
2C	O
);	O
for	O
septic	O
shock	O
associated	O
with	O
hypovolemia	O
,	O
the	O
use	O
of	O
crystalloids	O
or	O
albumin	O
to	O
deliver	O
a	O
bolus	O
of	O
20	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
or	O
albumin	O
equivalent	O
)	O
over	O
5	O
-	O
10	O
min	O
(	O
2C	O
);	O
more	O
common	O
use	O
of	O
inotropes	O
and	O
vasodilators	O
for	O
low	O
cardiac	O
output	O
septic	O
shock	O
associated	O
with	O
elevated	O
systemic	B-PROC
vascular	I-PROC
resistance	I-PROC
(	O
2C	O
);	O
and	O
use	O
of	O
hydrocortisone	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
""""	O
absolute	O
"""'"	O
adrenal	O
insufficiency	O
(	O
2C	O
).	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
therapy	O
with	O
face	O
mask	O
oxygen	O
,	O
high	O
flow	O
nasal	O
cannula	O
oxygen	O
,	O
or	O
nasopharyngeal	O
continuous	O
PEEP	O
in	O
the	O
presence	O
of	O
respiratory	O
distress	O
and	O
hypoxemia	O
(	O
2C	O
),	O
use	O
of	O
physical	O
examination	O
therapeutic	O
endpoints	O
such	O
as	O
capillary	B-PROC
refill	I-PROC
(	O
2C	O
);	O
for	O
septic	O
shock	O
associated	O
with	O
hypovolemia	O
,	O
the	O
use	O
of	O
crystalloids	O
or	O
albumin	O
to	O
deliver	O
a	O
bolus	O
of	O
20	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
or	O
albumin	O
equivalent	O
)	O
over	O
5	O
-	O
10	O
min	O
(	O
2C	O
);	O
more	O
common	O
use	O
of	O
inotropes	O
and	O
vasodilators	O
for	O
low	O
cardiac	O
output	O
septic	O
shock	O
associated	O
with	O
elevated	O
systemic	B-PROC
vascular	I-PROC
resistance	I-PROC
(	O
2C	O
);	O
and	O
use	O
of	O
hydrocortisone	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
""""	O
absolute	O
"""'"	O
adrenal	O
insufficiency	O
(	O
2C	O
).	O

The	O
recent	O
implication	O
of	O
a	O
novel	O
beta	O
(	O
β	O
)-	O
CoV	O
as	O
the	O
cause	O
of	O
fatal	O
respiratory	O
disease	O
in	O
the	O
Middle	O
East	O
emphasizes	O
the	O
importance	O
of	O
surveillance	O
for	O
CoVs	O
that	O
have	O
potential	O
to	O
move	B-PROC
from	O
bats	O
into	O
the	O
human	O
population	O
.	O

Analyses	O
of	O
these	O
viruses	O
in	O
the	O
context	O
of	O
their	O
hosts	O
and	O
ecological	O
habitat	O
indicated	O
that	O
host	O
species	O
is	O
a	O
strong	O
selective	O
driver	O
in	O
CoV	O
evolution	B-PROC
,	O
even	O
in	O
allopatric	O
populations	O
separated	O
by	O
significant	O
geographical	O
distance	O
;	O
and	O
that	O
a	O
single	O
species	O
/	O
genus	O
of	O
bat	O
can	O
contain	O
multiple	O
CoVs	O
.	O

Our	O
data	O
demonstrated	O
that	O
ORF6	O
protein	B-PROC
expression	B-PROC
attenuates	O
the	O
activity	O
of	O
numerous	O
karyopherin	O
-	O
dependent	O
host	O
transcription	B-PROC
factors	O
(	O
VDR	O
,	O
CREB1	O
,	O
SMAD4	O
,	O
p53	O
,	O
EpasI	O
,	O
and	O
Oct3	O
/	O
4	O
)	O
that	O
are	O
critical	O
for	O
establishing	O
antiviral	O
responses	O
and	O
regulating	O
key	O
host	O
responses	O
during	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Asthma	O
in	O
patients	O
hospitalized	O
with	O
pandemic	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	B-PROC
infection	I-PROC
-	O
United	O
States	O
,	O
2009	O
.	O

Among	O
patients	O
with	O
asthma	O
,	O
those	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
or	O
who	O
died	B-PROC
(	O
n	O
=	O
38	O
)	O
compared	O
with	O
survivors	O
not	O
admitted	O
to	O
an	O
ICU	O
(	O
n	O
=	O
99	O
)	O
were	O
more	O
likely	O
to	O
have	O
pneumonia	O
on	O
admission	O
(	O
60	O
%	O
vs	O
.	O
27	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
24	O
%	O
vs	O
.	O
0	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
less	O
likely	O
to	O
receive	O
influenza	O
antiviral	O
agents	O
≤	O
2	O
days	O
of	O
admission	O
(	O
73	O
%	O
vs	O
.	O
92	O
%,	O
p	O
=	O
0	O
.	O
02	O
).	O

Although	O
not	O
a	O
systematic	O
review	O
,	O
this	O
report	O
provides	O
an	O
update	O
for	O
dental	O
professionals	O
,	O
including	O
an	O
overview	O
of	O
general	O
and	O
oral	O
health	O
-	O
related	O
benefits	O
associated	O
with	O
breastfeeding	B-PROC
.	O

The	O
American	O
Academy	O
of	O
Pediatric	O
Dentistry	O
,	O
Chicago	O
,	O
suggests	O
that	O
parents	O
gently	O
clean	O
infants	O
'	O
gums	O
and	O
teeth	O
after	O
breastfeeding	B-PROC
.	O

Respiratory	O
symptoms	O
also	O
may	O
be	O
due	O
to	O
hemorrhagic	O
fever	B-PROC
viruses	O
,	O
especially	O
hantaviruses	O
,	O
that	O
not	O
occur	O
in	O
Poland	O
.	O

The	O
clinical	O
course	O
of	O
viral	B-PROC
infections	I-PROC
varies	O
from	O
asymptomatic	O
to	O
rapidly	O
-	O
progressing	O
,	O
high	O
-	O
mortality	O
disease	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
relationship	O
between	O
angiogenic	B-PROC
factors	O
,	O
their	O
soluble	O
receptors	O
and	O
ALI	O
/	O
ARDS	O
associated	O
with	O
critically	O
ill	O
patients	O
,	O
including	O
sepsis	O
,	O
severe	O
trauma	O
,	O
and	O
post	O
-	O
cardiac	O
arrest	O
syndrome	O
(	O
PCAS	O
).	O

These	O
results	O
suggest	O
that	O
kallistatin	O
may	O
serve	O
as	O
a	O
novel	O
marker	O
for	O
severe	O
CAP	O
prognosis	O
and	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
CAP	O
through	O
antiinflammatory	O
and	O
anticoagulation	B-PROC
effects	O
.	O

In	O
addition	O
,	O
new	O
types	O
of	O
the	O
virus	O
continue	O
to	O
arise	O
due	O
to	O
mutations	O
and	O
recombination	B-PROC
events	O
in	O
the	O
viral	O
genome	O
,	O
making	O
this	O
virus	O
difficult	O
to	O
identify	O
and	O
extremely	O
difficult	O
to	O
control	O
.	O

Fourteen	O
preterm	O
lambs	O
(	O
85	O
%	O
gestation	B-PROC
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
SF	O
-	O
aero	O
or	O
SF	O
-	O
bolus	O
.	O

There	O
is	O
an	O
accumulating	O
evidence	O
in	O
human	O
and	O
animal	O
studies	O
that	O
changes	O
of	O
perfusion	O
,	O
particularly	O
to	O
the	O
microvasculature	B-PROC
,	O
are	O
crucial	O
events	O
in	O
the	O
progression	O
of	O
acute	O
pancreatitis	O
(	O
AP	O
).	O

Our	O
objective	O
is	O
to	O
describe	O
prediction	O
models	O
for	O
surgical	O
patients	O
who	O
have	O
suspected	O
obstructive	O
sleep	B-PROC
apnea	O
(	O
OSA	O
)	O
at	O
risk	O
for	O
postoperative	O
respiratory	O
complications	O
and	O
for	O
surgical	O
patients	O
at	O
risk	O
for	O
postoperative	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

These	O
results	O
help	O
in	O
elucidating	O
the	O
tendency	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
.	O

ABSTRACT	O
:	O
In	O
continuation	O
of	O
our	O
efforts	O
toward	O
identification	O
and	O
optimization	O
of	O
novel	O
non	B-PROC
-	I-PROC
nucleoside	I-PROC
reverse	I-PROC
transcriptase	I-PROC
inhibitors	I-PROC
(	O
NNRTIs	O
),	O
we	O
have	O
employed	O
a	O
structure	O
-	O
based	O
bioisosterism	O
strategy	O
,	O
with	O
which	O
a	O
new	O
series	O
of	O
diarylpyridazine	O
(	O
DAPD	O
)	O
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
-	O
1	O
(	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
)	O
activity	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
explore	O
the	O
perceptions	O
of	O
the	O
highly	O
specialized	O
nurses	O
who	O
provided	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
therapy	O
for	O
the	O
mostly	O
young	O
and	O
critically	O
ill	O
patients	O
during	O
the	O
2009	O
H1N1	O
pandemic	O
.	O

TITLE	O
:	O
Hemagglutination	B-PROC
mediated	O
by	O
the	O
spike	O
protein	O
of	O
cell	O
-	O
adapted	O
bovine	O
torovirus	O
.	O

AKI	O
was	O
associated	O
with	O
oliguria	O
/	O
anuria	O
(	O
48	O
%),	O
anaemia	O
(	O
70	O
%),	O
thrombocytopenia	O
(	O
84	O
%),	O
hepatic	O
dysfunction	O
(	O
48	O
%),	O
gastrointestinal	O
manifestations	O
(	O
33	O
%),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
(	O
14	O
%),	O
cerebral	O
malaria	O
(	O
6	O
%),	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
8	O
%)	O
and	O
shock	O
(	O
11	O
%).	O

Poor	O
prognostic	O
factors	O
were	O
delayed	O
diagnosis	O
,	O
anaemia	O
,	O
severe	O
AKI	O
,	O
shock	O
,	O
ARDS	O
,	O
need	O
for	O
ventilatory	O
support	O
,	O
raised	O
serum	O
transaminases	O
and	O
metabolic	B-PROC
acidosis	O
.	O

Acute	O
rejection	O
,	O
lymphocytic	O
bronchiolitis	O
,	O
colonization	O
with	O
pseudomonas	O
,	O
infection	O
,	O
and	O
BAL	O
eosinophilia	O
and	O
neutrophilia	O
are	O
risk	O
factors	O
for	O
the	O
later	O
development	B-PROC
not	O
only	O
of	O
RAS	O
but	O
also	O
of	O
BOS	O
.	O

One	O
such	O
model	O
is	O
differentiated	B-PROC
normal	O
human	O
bronchial	O
epithelial	O
cells	O
(	O
NHBE	O
).	O

TITLE	O
:	O
Isolation	O
and	O
characterization	O
of	O
current	O
human	O
coronavirus	O
strains	O
in	O
primary	O
human	O
epithelial	O
cell	O
cultures	O
reveal	O
differences	O
in	O
target	O
cell	O
tropism	B-PROC
.	O

Surprisingly	O
,	O
by	O
visualizing	O
HCoV	O
infection	O
by	O
confocal	O
microscopy	O
,	O
we	O
observed	O
that	O
HCoV	O
-	O
229E	O
employs	O
a	O
target	O
cell	O
tropism	B-PROC
for	O
nonciliated	O
cells	O
,	O
whereas	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
HKU1	O
,	O
and	O
HCoV	O
-	O
NL63	O
all	O
infect	O
ciliated	O
cells	O
.	O

TCoV	O
viral	O
RNA	O
loads	O
measured	O
by	O
quantitative	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
were	O
lower	O
in	O
vaccinated	O
turkeys	O
than	O
those	O
in	O
challenge	O
control	O
turkeys	O
.	O

The	O
turkeys	O
in	O
G3	O
-	O
750DDP	O
produced	O
the	O
highest	O
level	O
of	O
TCoV	O
S	O
protein	O
-	O
specific	O
antibody	B-PROC
and	O
virus	B-PROC
neutralization	I-PROC
(	O
VN	O
)	O
titer	O
.	O

TITLE	O
:	O
Immunohistochemical	O
evaluation	O
of	O
the	O
effects	O
of	O
paraffin	O
section	O
storage	B-PROC
on	O
biomarker	O
stability	O
.	O

ABSTRACT	O
:	O
Environmental	O
stresses	O
can	O
alter	O
immunoreactivity	B-PROC
of	O
biomarkers	O
in	O
stored	O
tissue	O
sections	O
.	O

Immunoreactivity	B-PROC
was	O
compared	O
with	O
that	O
in	O
the	O
corresponding	O
1	O
-	O
day	O
-	O
old	O
section	O
and	O
scored	O
as	O
4	O
(<	O
10	O
%	O
reduction	O
),	O
3	O
(	O
10	O
%-	O
25	O
%	O
reduction	O
),	O
2	O
(	O
26	O
%-	O
60	O
%	O
reduction	O
),	O
1	O
(>	O
60	O
%	O
reduction	O
),	O
or	O
0	O
(	O
no	O
reactivity	O
).	O

Any	O
loss	O
of	O
immunoreactivity	B-PROC
was	O
proportional	O
to	O
the	O
tissue	O
section	O
age	O
and	O
was	O
least	O
in	O
sections	O
stored	O
in	O
the	O
dark	O
.	O

Eight	O
markers	O
(	O
Bartonella	O
spp	O
,	O
CD11d	O
,	O
high	O
molecular	O
weight	O
cytokeratins	O
,	O
feline	O
coronavirus	O
,	O
GATA	O
-	O
4	O
,	O
insulin	O
,	O
p63	O
,	O
progesterone	O
receptor	O
)	O
had	O
minimal	O
decrease	O
in	O
immunoreactivity	B-PROC
,	O
regardless	O
of	O
treatment	O
.	O

The	O
MHV	O
PS	O
is	O
an	O
RNA	O
structure	O
that	O
maps	O
to	O
the	O
region	O
of	O
the	O
replicase	O
gene	O
encoding	O
the	O
nonstructural	O
protein	O
15	O
subunit	O
of	O
the	O
viral	O
replicase	O
-	O
transcriptase	B-PROC
complex	O
.	O

The	O
stimulation	O
occurs	O
in	O
two	O
steps	O
,	O
with	O
approximately	O
eightfold	O
stimulation	O
by	O
N	O
-	O
terminal	O
cleavage	B-PROC
,	O
approximately	O
fourfold	O
stimulation	O
by	O
C	O
-	O
terminal	O
cleavage	B-PROC
,	O
and	O
23	O
-	O
fold	O
stimulation	O
by	O
the	O
cleavage	B-PROC
of	O
both	O
termini	O
,	O
compared	O
to	O
the	O
pro	O
-	O
form	O
with	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
pro	O
-	O
sequences	O
.	O

Such	O
cleavage	B-PROC
mainly	O
occurs	O
in	O
a	O
trans	O
manner	O
;	O
i	O
.	O
e	O
.	O
the	O
pro	O
-	O
form	O
dimer	O
cleaves	O
the	O
monomeric	O
form	O
.	O

A	O
numerical	O
simulation	O
of	O
the	O
maturation	B-PROC
pathway	B-PROC
is	O
presented	O
.	O

Endocan	O
,	O
specifically	O
secreted	B-PROC
by	O
activated	O
-	O
pulmonary	O
vascular	O
endothelial	O
cells	O
,	O
is	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
control	O
of	O
the	O
lung	O
inflammatory	O
reaction	O
.	O

Taken	O
together	O
,	O
the	O
p14	O
endocan	O
fragment	O
represents	O
a	O
novel	O
interesting	O
biomarker	O
which	O
could	O
participate	O
to	O
the	O
pathogenesis	B-PROC
of	O
sepsis	O
.	O

ABSTRACT	O
:	O
Granuloma	B-PROC
formation	I-PROC
occurs	O
in	O
the	O
human	O
body	O
if	O
there	O
is	O
a	O
particle	O
which	O
persists	O
in	O
phagocytes	O
and	O
which	O
the	O
immune	O
system	O
cannot	O
eliminate	O
.	O

TITLE	O
:	O
The	O
spike	O
protein	O
of	O
the	O
emerging	O
betacoronavirus	O
EMC	O
uses	O
a	O
novel	O
coronavirus	O
receptor	O
for	O
entry	O
,	O
can	O
be	O
activated	O
by	O
TMPRSS2	O
,	O
and	O
is	O
targeted	B-PROC
by	O
neutralizing	O
antibodies	O
.	O

Here	O
we	O
investigated	O
the	O
viral	O
and	O
cellular	O
determinants	O
governing	O
hCoV	O
-	O
EMC	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
.	O

TITLE	O
:	O
Ocular	B-PROC
tropism	B-PROC
of	O
respiratory	O
viruses	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
the	O
findings	O
of	O
a	O
recent	O
study	O
suggesting	O
a	O
decreased	O
cold	B-PROC
-	O
induced	O
ascites	O
incidence	O
in	O
broiler	O
progeny	O
from	O
hyperthyroid	O
(	O
HYPER	O
)	O
breeder	O
hens	O
,	O
and	O
a	O
controversy	O
on	O
the	O
effects	O
of	O
hyperthyroidism	O
on	O
immunocompetence	B-PROC
,	O
the	O
present	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
probable	O
adverse	O
effect	O
of	O
induced	O
maternal	O
hyperthyroidism	O
on	O
immune	B-PROC
function	I-PROC
in	O
progeny	O
chicks	O
.	O

The	O
risk	O
of	O
widespread	O
epidemics	O
in	O
humans	O
can	O
be	O
assessed	O
by	O
monitoring	O
the	O
reproduction	B-PROC
number	O
R	O
(	O
average	O
number	O
of	O
persons	O
infected	O
by	O
a	O
human	O
case	O
).	O

Data	O
including	O
comorbidities	O
,	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
score	O
,	O
Acute	O
Physiological	O
Assessment	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
PaO2	O
,	O
FiO2	O
,	O
PaO2	O
/	O
FiO2	O
,	O
PEEP	O
,	O
mean	O
airway	O
pressure	O
(	O
mPaw	O
),	O
and	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
on	O
the	O
1st	O
and	O
the	O
3rd	O
day	O
of	O
mechanical	O
ventilation	O
,	O
and	O
change	O
in	O
OI	O
within	O
3	O
days	O
were	O
recorded	O
.	O

Primary	O
outcome	O
was	O
hospital	O
mortality	O
;	O
secondary	O
outcome	O
measure	O
was	O
ventilator	O
weaning	B-PROC
failure	O
.	O

Preexisting	O
cerebrovascular	O
accident	O
(	O
CVA	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
was	O
the	O
predictor	O
of	O
weaning	B-PROC
failure	O
.	O

Primary	O
outcome	O
was	O
hospital	O
mortality	O
;	O
secondary	O
outcome	O
measure	O
was	O
ventilator	O
weaning	B-PROC
failure	O
.	O

As	O
of	O
March	O
7	O
,	O
2013	O
,	O
a	O
total	O
of	O
14	O
confirmed	O
cases	O
of	O
novel	O
coronavirus	O
infection	O
have	O
been	O
reported	O
to	O
WHO	O
,	O
with	O
eight	O
deaths	B-PROC
.	O

Accurate	O
diagnosis	O
and	O
differentiation	B-PROC
from	O
other	O
treatable	O
conditions	O
is	O
crucial	O
.	O

HFOV	O
is	O
effective	O
in	O
improving	O
oxygenation	B-PROC
in	O
adults	O
with	O
ARDS	O
,	O
particularly	O
when	O
instituted	O
early	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
which	O
is	O
a	O
major	O
structural	O
protein	O
of	O
CoVs	O
,	O
binds	O
to	O
the	O
viral	O
RNA	O
genome	O
to	O
form	O
the	O
virion	O
core	O
and	O
results	O
in	O
the	O
formation	B-PROC
of	O
the	O
ribonucleoprotein	O
(	O
RNP	O
)	O
complex	O
.	O

To	O
assess	O
the	O
role	O
of	O
R106	O
in	O
RNA	O
binding	O
,	O
we	O
undertook	O
a	O
series	O
of	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
experiments	O
and	O
docking	B-PROC
simulations	O
to	O
characterize	O
the	O
interaction	O
between	O
R106	O
and	O
RNA	O
.	O

This	O
finding	O
suggests	O
that	O
R106	O
,	O
by	O
enhancing	O
binding	O
of	O
the	O
N	O
protein	O
to	O
viral	O
RNA	O
plays	O
a	O
critical	O
role	O
in	O
the	O
viral	B-PROC
replication	I-PROC
.	O

We	O
tested	O
acute	O
and	O
convalescent	O
sera	O
for	O
antigen	O
and	O
antibody	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
avian	O
influenza	O
,	O
and	O
plague	O
.	O

Successful	O
ECMO	O
weaning	B-PROC
with	O
uneventful	O
discharge	O
from	O
hospital	O
was	O
noted	O
in	O
14	O
(	O
63	O
.	O
6	O
%)	O
patients	O
,	O
whereas	O
in	O
-	O
hospital	O
mortality	O
despite	O
successful	O
ECMO	O
weaning	B-PROC
occurred	O
in	O
5	O
patients	O
(	O
22	O
.	O
7	O
%).	O

Failure	O
in	O
ECMO	O
weaning	B-PROC
and	O
in	O
-	O
hospital	O
death	B-PROC
was	O
noted	O
in	O
3	O
patients	O
(	O
13	O
.	O
6	O
%).	O

TITLE	O
:	O
Identification	O
of	O
the	O
first	O
synthetic	O
inhibitors	O
of	O
the	O
type	O
II	O
transmembrane	O
serine	O
protease	O
TMPRSS2	O
suitable	O
for	O
inhibition	B-PROC
of	O
influenza	O
virus	B-PROC
activation	I-PROC
.	O

Finally	O
,	O
immunohistochemistry	O
revealed	O
that	O
TMPRSS2	O
is	O
coexpressed	O
with	O
CD13	O
,	O
the	O
HCoV	O
-	O
229E	O
receptor	O
,	O
in	O
human	O
airway	O
epithelial	O
(	O
HAE	O
)	O
cells	O
,	O
and	O
that	O
CD13	O
(+)	O
TMPRSS2	O
(+)	O
cells	O
are	O
preferentially	O
targeted	B-PROC
by	O
HCoV	O
-	O
229E	O
,	O
suggesting	O
that	O
TMPRSS2	O
can	O
activate	O
HCoV	O
-	O
229E	O
in	O
infected	O
humans	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
validated	O
scores	O
on	O
the	O
Alcohol	O
Use	O
Disorders	O
Identification	O
Test	O
that	O
correspond	O
to	O
past	O
-	O
year	O
abstinence	O
(	O
zone	O
1	O
),	O
low	O
-	O
risk	O
drinking	B-PROC
(	O
zone	O
2	O
),	O
mild	O
to	O
moderate	O
alcohol	O
misuse	O
(	O
zone	O
3	O
),	O
and	O
severe	O
alcohol	O
misuse	O
(	O
zone	O
4	O
)	O
are	O
associated	O
with	O
poor	O
outcomes	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
a	O
large	O
family	O
of	O
viruses	O
which	O
include	O
viruses	O
that	O
cause	O
the	O
common	O
cold	B-PROC
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
humans	O
and	O
other	O
diseases	O
in	O
animals	O
.	O

ABSTRACT	O
:	O
Progress	O
in	O
intensive	O
care	O
(	O
ICU	O
)	O
treatment	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
over	O
the	O
last	O
20	O
years	O
includes	O
the	O
introduction	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
CO2	O
removal	O
and	O
the	O
widespread	O
use	O
of	O
evidence	O
-	O
based	O
lung	O
-	O
protective	O
ventilatory	O
strategies	O
.	O

The	O
results	O
show	O
that	O
the	O
PEDV	O
N	O
protein	O
localizes	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
),	O
inhibits	O
the	O
IEC	O
growth	B-PROC
and	O
prolongs	O
S	B-PROC
-	I-PROC
phase	I-PROC
cell	B-PROC
cycle	I-PROC
.	O

The	O
S	B-PROC
-	I-PROC
phase	I-PROC
is	O
prolonged	O
which	O
is	O
associated	O
with	O
a	O
decrease	O
of	O
cyclin	O
A	O
transcription	B-PROC
level	O
and	O
an	O
increase	O
of	O
cyclin	O
A	O
degradation	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
that	O
PEDV	O
N	O
protein	O
can	O
induce	O
cell	B-PROC
cycle	I-PROC
prolongation	O
at	O
the	O
S	B-PROC
-	I-PROC
phase	I-PROC
,	O
ER	O
stress	O
and	O
up	B-PROC
-	I-PROC
regulation	B-PROC
interleukin	O
-	O
8	O
expression	B-PROC
.	O

These	O
findings	O
provide	O
novel	O
information	O
on	O
the	O
function	O
of	O
the	O
PEDV	O
N	O
protein	O
and	O
are	O
likely	O
to	O
be	O
very	O
useful	O
in	O
understanding	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
PEDV	O
pathogenesis	B-PROC
.	O

The	O
main	O
underlying	O
causes	O
of	O
ARDS	O
are	O
trauma	O
,	O
pancreatitis	O
,	O
and	O
pulmonary	O
manifestation	O
of	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
/	O
sepsis	O
.	O

An	O
outbreak	O
of	O
heartworm	O
exposure	O
occurred	O
from	O
1995	O
to	O
2003	O
and	O
higher	O
than	O
expected	O
levels	O
of	O
FCoV	O
-	O
antibody	B-PROC
-	O
positive	O
mountain	O
lions	O
were	O
observed	O
from	O
2005	O
to	O
2008	O
,	O
with	O
foci	O
in	O
southern	O
Mendocino	O
and	O
eastern	O
Lake	O
counties	O
.	O

Data	O
analysis	O
was	O
performed	O
by	O
a	O
multidisciplinary	O
team	O
using	O
a	O
grounded	O
theory	O
approach	O
to	O
generate	O
themes	O
inductively	O
from	O
respondents	O
'	O
expressed	B-PROC
perspectives	O
.	O

Five	O
common	O
themes	O
characterized	O
respondents	O
'	O
experiences	O
with	O
pandemic	O
planning	O
and	O
response	O
:	O
1	O
)	O
national	O
pandemic	O
influenza	O
preparedness	O
guidance	O
has	O
not	O
fully	O
penetrated	O
to	O
the	O
level	O
of	O
pediatric	O
emergency	O
physician	O
(	O
EP	O
)	O
leaders	O
,	O
leading	O
to	O
variable	O
states	O
of	O
preparedness	O
;	O
2	O
)	O
pediatric	O
EDs	O
that	O
maintained	O
strong	O
relationships	O
with	O
local	O
public	O
health	O
and	O
other	O
health	O
care	O
entities	O
found	O
those	O
relationships	O
to	O
be	O
beneficial	O
to	O
pandemic	O
response	O
;	O
3	O
)	O
pediatric	O
EP	O
leaders	O
reported	O
difficulty	O
reconciling	O
public	O
health	O
guidance	O
with	O
the	O
reality	O
of	O
ED	O
practice	O
;	O
4	O
)	O
although	O
many	O
anticipated	O
obstacles	O
did	O
not	O
materialize	O
,	O
in	O
some	O
cases	O
pediatric	O
EP	O
leaders	O
experienced	O
unexpected	O
institutional	O
challenges	O
;	O
and	O
5	O
)	O
pediatric	O
EP	O
leaders	O
described	O
varied	O
experiences	O
with	O
organizational	O
learning	B-PROC
following	O
the	O
H1N1	O
pandemic	O
experience	O
.	O

Nerve	B-PROC
conduction	B-PROC
studies	O
confirmed	O
the	O
diagnosis	O
of	O
GBS	O
.	O

An	O
oxygenator	O
used	O
in	O
conjunction	O
with	O
a	O
VAD	O
may	O
be	O
a	O
life	O
-	O
saving	O
therapy	O
,	O
allowing	O
adequate	O
oxygenation	B-PROC
and	O
ventilation	O
in	O
severe	O
respiratory	O
and	O
cardiac	O
failure	O
.	O

Respiratory	O
specimens	O
were	O
tested	O
for	O
influenza	O
and	O
other	O
respiratory	O
viruses	O
by	O
means	O
of	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-PROC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
assays	O
,	O
viral	O
culturing	O
,	O
and	O
sequence	O
analyses	O
.	O

All	O
three	O
patients	O
presented	O
with	O
fever	B-PROC
,	O
cough	O
,	O
and	O
dyspnea	O
.	O

Anti	O
-	O
HCoV	O
-	O
EMC	O
and	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibodies	O
were	O
detected	O
using	O
screening	O
indirect	O
immunofluorescence	O
(	O
IF	O
)	O
and	O
confirmatory	O
neutralizing	O
antibody	B-PROC
tests	O
.	O

RESULTS	O
:	O
Two	O
(	O
2	O
.	O
1	O
%)	O
animal	O
handlers	O
had	O
IF	O
antibody	B-PROC
titer	O
of	O
≥	O
1	O
:	O
20	O
against	O
both	O
HCoV	O
-	O
EMC	O
and	O
SARS	O
-	O
CoV	O
with	O
neutralizing	O
antibody	B-PROC
titer	O
of	O
<	O
1	O
:	O
10	O
.	O

Bronchoscopy	O
showed	O
a	O
normal	O
macroscopic	O
appearance	O
in	O
all	O
cases	O
,	O
the	O
broncho	O
-	O
alveolar	O
lavage	O
was	O
predominated	O
by	O
neutrophilic	B-PROC
formula	O
in	O
four	O
cases	O
.	O

Moreover	O
,	O
we	O
think	O
that	O
ECMO	O
,	O
in	O
addition	O
to	O
providing	O
oxygenation	B-PROC
,	O
reduced	O
bleeding	O
by	O
creating	O
a	O
negative	O
pressure	O
along	O
the	O
injured	O
IVC	O
.	O

TITLE	O
:	O
H7N9	O
Incident	O
,	O
immune	B-PROC
status	I-PROC
,	O
the	O
elderly	O
and	O
a	O
warning	O
of	O
an	O
influenza	O
pandemic	O
.	O

To	O
further	O
analyze	O
the	O
mechanism	O
of	O
the	O
attenuation	O
of	O
the	O
mutant	O
virus	O
,	O
changes	O
in	O
reporter	O
gene	B-PROC
expression	I-PROC
were	O
measured	O
in	O
nsp1	O
-	O
or	O
nsp1	O
-	O
27D	O
-	O
expressing	O
cells	O
;	O
the	O
results	O
showed	O
that	O
nsp1	O
inhibited	O
reporter	O
gene	B-PROC
expression	I-PROC
controlled	O
by	O
different	O
promoters	O
,	O
but	O
that	O
this	O
inhibition	B-PROC
was	O
reduced	O
for	O
nsp1	O
-	O
27D	O
.	O

When	O
the	O
single	O
-	O
channel	O
ME	O
method	O
was	O
applied	O
to	O
a	O
multi	O
-	O
channel	O
ME	O
for	O
high	O
-	O
throughput	O
screening	O
,	O
the	O
precision	O
of	O
migration	B-PROC
time	O
and	O
peak	O
area	O
showed	O
standard	O
deviations	O
of	O
less	O
than	O
1	O
.	O
0	O
%	O
without	O
any	O
loss	O
of	O
resolving	O
power	O
.	O

Our	O
results	O
provide	O
two	O
plausible	O
models	O
that	O
recapitulate	O
two	O
fundamental	O
hypotheses	O
about	O
volume	O
change	O
at	O
the	O
alveolar	O
level	O
:	O
(	O
1	O
)	O
increase	O
in	O
alveolar	O
size	O
through	O
isotropic	O
volume	O
change	O
,	O
or	O
(	O
2	O
)	O
minimal	O
change	O
in	O
AS	O
radius	O
with	O
primary	O
expansion	O
of	O
the	O
mouth	O
of	O
the	O
AS	O
,	O
with	O
the	O
implication	O
that	O
the	O
majority	O
of	O
change	O
in	O
lung	B-PROC
volume	I-PROC
during	O
the	O
respiratory	O
cycle	O
occurs	O
in	O
the	O
alveolar	O
ducts	O
.	O

In	O
this	O
study	O
,	O
a	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
)	O
designated	O
7G7	O
,	O
against	O
the	O
TGEV	O
M	O
protein	O
was	O
generated	O
by	O
inoculating	O
BALB	O
/	O
c	O
mice	O
with	O
TGEV	O
followed	O
by	O
hybridoma	O
technique	O
.	O

TITLE	O
:	O
Expression	B-PROC
and	O
Purification	O
of	O
the	O
scFv	O
from	O
hybridoma	O
cells	O
secreting	B-PROC
a	O
monoclonal	O
antibody	B-PROC
against	O
S	O
PROTEIN	O
of	O
PEDV	O
.	O

In	O
addition	O
to	O
its	O
anti	O
-	O
coagulant	O
activity	O
,	O
recombinant	O
thrombomodulin	O
(	O
rTM	O
)	O
possesses	O
an	O
ability	O
to	O
suppress	O
the	O
inflammatory	B-PROC
response	I-PROC
through	O
neutralizing	O
HMGB1	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
a	O
therapy	O
that	O
has	O
been	O
used	O
in	O
severe	O
cases	O
of	O
ARDS	O
when	O
patients	O
fail	O
to	O
improve	O
with	O
traditional	O
management	O
.	O

Carriers	O
are	O
indeed	O
reported	O
to	O
have	O
various	O
advantageous	O
phenotypes	O
related	O
to	O
haemostasis	B-PROC
,	O
inflammation	O
and	O
fertility	B-PROC
:	O
less	O
acute	O
blood	O
loss	O
;	O
less	O
menstrual	B-PROC
blood	O
loss	O
;	O
decreased	O
risk	O
of	O
intracranial	O
haemorrhage	O
;	O
milder	O
phenotypes	O
of	O
haemophilia	O
;	O
higher	O
survival	O
in	O
and	O
lower	O
susceptibility	O
to	O
severe	O
sepsis	O
;	O
higher	O
survival	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
less	O
severe	O
diabetic	O
nephropathy	O
and	O
higher	O
fecundity	B-PROC
in	O
both	O
men	O
and	O
women	O
.	O

The	O
procoagulant	O
phenotype	O
and	O
perhaps	O
also	O
certain	O
pregnancy	O
complications	O
follow	O
from	O
activated	O
protein	O
C	O
(	O
APC	O
)	O
resistance	B-PROC
.	O

Five	O
candidate	O
genes	O
ELMO1	O
,	O
RRAGA	O
,	O
TNFSF10	O
,	O
ERAP1	O
and	O
ERAP2	O
,	O
all	O
relevant	O
to	O
what	O
is	O
known	O
about	O
FIP	O
virus	O
pathogenesis	B-PROC
,	O
were	O
identified	O
but	O
no	O
single	O
association	O
was	O
fully	O
concordant	O
with	O
the	O
disease	O
phenotype	O
.	O

MERS	O
-	O
CoV	O
infection	O
did	O
not	O
prevent	O
the	O
IFN	O
-	O
induced	O
nuclear	B-PROC
translocation	B-PROC
of	O
phosphorylated	O
STAT1	O
,	O
in	O
contrast	O
to	O
infection	O
with	O
SARS	O
-	O
CoV	O
where	O
this	O
block	O
inhibits	O
the	O
expression	B-PROC
of	O
antiviral	O
genes	O
.	O

Although	O
T	O
cell	O
zone	O
reticular	O
cells	O
had	O
lost	O
podoplanin	O
expression	B-PROC
,	O
they	O
still	O
formed	O
a	O
functional	O
conduit	O
system	O
and	O
showed	O
enhanced	O
expression	B-PROC
of	O
myofibroblastic	O
markers	O
.	O

Thus	O
,	O
myofibroblasic	O
FRC	B-PROC
precursors	O
are	O
able	O
to	O
generate	O
the	O
basic	O
T	O
cell	O
zone	O
infrastructure	O
,	O
whereas	O
LTβR	O
-	O
dependent	O
maturation	B-PROC
of	O
FRCs	B-PROC
guarantees	O
full	O
immunocompetence	B-PROC
and	O
hence	O
optimal	O
LN	O
function	O
during	O
infection	O
.	O

Samples	O
were	O
screened	O
for	O
NL63	O
using	O
a	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
sequencing	O
.	O

This	O
could	O
have	O
an	O
important	O
impact	O
on	O
the	O
ability	O
of	O
the	O
host	O
to	O
mount	O
an	O
adaptive	O
host	B-PROC
response	I-PROC
.	O

A	O
unique	O
set	O
of	O
207	O
genes	O
was	O
dysregulated	O
early	O
and	O
permanently	O
throughout	O
infection	O
with	O
HCoV	O
-	O
EMC	O
,	O
and	O
was	O
used	O
in	O
a	O
computational	O
screen	O
to	O
predict	O
potential	O
antiviral	O
compounds	O
,	O
including	O
kinase	B-PROC
inhibitors	I-PROC
and	O
glucocorticoids	O
.	O

Identification	O
of	O
a	O
novel	O
coronavirus	O
causing	O
fatal	O
respiratory	O
infection	O
in	O
humans	O
raises	O
concerns	O
about	O
a	O
possible	O
widespread	O
outbreak	O
of	O
severe	O
respiratory	O
infection	O
similar	O
to	O
the	O
one	O
caused	O
by	O
SARS	O
-	O
CoV	O
.	O
Using	O
a	O
human	O
lung	O
epithelial	O
cell	O
line	O
and	O
global	O
transcriptomic	O
profiling	O
,	O
we	O
identified	O
differences	O
in	O
the	O
host	B-PROC
response	I-PROC
between	O
HCoV	O
-	O
EMC	O
and	O
SARS	O
-	O
CoV	O
.	O
This	O
enables	O
rapid	O
assessment	O
of	O
viral	O
properties	O
and	O
the	O
ability	O
to	O
anticipate	O
possible	O
differences	O
in	O
human	O
clinical	O
responses	O
to	O
HCoV	O
-	O
EMC	O
and	O
SARS	O
-	O
CoV	O
.	O
We	O
used	O
this	O
information	O
to	O
predict	O
potential	O
effective	O
drugs	O
against	O
HCoV	O
-	O
EMC	O
,	O
a	O
method	O
that	O
could	O
be	O
more	O
generally	O
used	O
to	O
identify	O
candidate	O
therapeutics	O
in	O
future	O
disease	O
outbreaks	O
.	O

An	O
example	O
is	O
the	O
stimulation	O
of	O
-	O
1	O
programmed	O
ribosomal	B-PROC
frameshifting	I-PROC
,	O
leading	O
to	O
3	O
'	O
direction	O
slippage	O
of	O
the	O
reading	O
-	O
frame	O
during	O
elongation	O
,	O
by	O
specific	O
pseudoknot	O
stimulators	O
downstream	O
of	O
the	O
frameshifting	O
site	O
.	O

There	O
are	O
multiple	O
murine	O
models	O
of	O
severe	O
respiratory	O
viral	B-PROC
infections	I-PROC
that	O
have	O
been	O
used	O
to	O
identify	O
viral	O
and	O
host	O
factors	O
that	O
contribute	O
to	O
disease	O
severity	O
.	O

In	O
contrast	O
,	O
ATII	O
cells	O
that	O
were	O
cultured	O
to	O
trans	O
-	O
differentiate	O
into	O
an	O
ATI	O
-	O
like	O
cell	O
phenotype	O
were	O
susceptible	O
to	O
MHV	O
-	O
1	O
and	O
PR8	O
,	O
but	O
not	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
.	O
Epithelial	O
cells	O
produce	O
cytokines	O
in	O
response	O
to	O
viral	B-PROC
infections	I-PROC
,	O
thereby	O
activating	O
immune	B-PROC
responses	I-PROC
.	O

Thus	O
,	O
virus	O
-	O
induced	O
cytokine	O
expression	B-PROC
was	O
quantified	O
in	O
ATI	O
and	O
ATII	O
cells	O
.	O

All	O
three	O
patients	O
had	O
severe	O
pneumonia	O
,	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
died	B-PROC
from	O
their	O
illness	O
.	O

Clinicians	O
should	O
consider	O
the	O
diagnosis	O
of	O
avian	O
influenza	O
A	O
(	O
H7N9	O
)	O
virus	B-PROC
infection	I-PROC
in	O
persons	O
with	O
acute	O
respiratory	O
illness	O
and	O
relevant	O
exposure	O
history	O
and	O
should	O
contact	O
their	O
state	O
health	O
departments	O
regarding	O
specimen	O
collection	O
and	O
facilitation	B-PROC
of	O
confirmatory	O
testing	O
.	O

TITLE	O
:	O
Review	O
of	O
Dengue	O
hemorrhagic	O
fever	B-PROC
fatal	O
cases	O
seen	O
among	O
adults	O
:	O
a	O
retrospective	O
study	O
.	O

TITLE	O
:	O
A	O
combination	O
of	O
epitope	O
prediction	O
and	O
molecular	O
docking	B-PROC
allows	O
for	O
good	O
identification	O
of	O
MHC	B-PROC
class	O
I	O
restricted	O
T	O
-	O
cell	O
epitopes	O
.	O

We	O
suggest	O
the	O
use	O
of	O
epitope	O
prediction	O
methods	O
in	O
combination	O
with	O
3D	O
structural	O
modelling	O
of	O
peptide	O
-	O
MHC	B-PROC
-	O
TCR	B-PROC
complex	O
to	O
identify	O
MHC	B-PROC
class	O
I	O
restricted	O
T	O
-	O
cell	O
epitopes	O
for	O
use	O
in	O
epitope	O
based	O
vaccines	O
like	O
HIV	O
and	O
human	O
cancers	O
,	O
which	O
should	O
provide	O
a	O
valuable	O
step	O
forward	O
for	O
the	O
design	O
of	O
better	O
vaccines	O
and	O
may	O
provide	O
in	O
depth	O
understanding	O
about	O
activation	O
of	O
T	O
-	O
cell	O
epitopes	O
by	O
MHC	B-PROC
binding	O
peptides	O
.	O

ABSTRACT	O
:	O
Puumala	O
virus	O
(	O
PUUV	O
)	O
is	O
considered	O
a	O
classic	O
Old	O
World	O
etiologic	O
agent	O
of	O
nephropathia	O
epidemica	O
(	O
NE	O
),	O
or	O
hemorrhagic	O
fever	B-PROC
with	O
renal	O
syndrome	O
(	O
HFRS	O
).	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	B-PROC
of	O
p53	O
and	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPK	O
)	O
signalling	B-PROC
pathways	B-PROC
in	O
the	O
interaction	O
of	O
TGEV	O
with	O
host	O
cells	O
.	O

Blocking	O
of	O
p53	O
activation	O
significantly	O
inhibited	O
the	O
occurrence	O
of	O
apoptosis	B-PROC
through	O
suppressing	O
the	O
TGEV	O
-	O
induced	O
FasL	O
expression	B-PROC
,	O
Bcl	O
-	O
2	O
reduction	O
,	O
Bax	O
and	O
cytochrome	B-PROC
c	I-PROC
redistribution	O
,	O
while	O
inhibition	B-PROC
of	O
p38	O
activity	O
moderately	O
blocked	O
apoptosis	B-PROC
induction	I-PROC
and	O
partly	O
attenuated	O
the	O
accumulation	O
and	O
activation	O
of	O
p53	O
.	O

Analysis	O
of	O
the	O
pathways	B-PROC
downstream	O
of	O
GADD153	O
revealed	O
much	O
more	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	O
)	O
pathway	B-PROC
in	O
GADD153	O
-	O
knockdown	O
cells	O
during	O
IBV	O
infection	O
,	O
indicating	O
that	O
GADD153	O
may	O
modulate	O
apoptosis	B-PROC
through	O
suppression	B-PROC
of	O
the	O
pathway	B-PROC
.	O

Patients	O
died	B-PROC
rather	O
late	O
when	O
severe	O
cholinergic	O
crisis	O
had	O
mostly	O
been	O
overcome	O
and	O
death	B-PROC
was	O
therefore	O
related	O
to	O
non	O
-	O
poison	O
specific	O
complications	O
.	O

ABSTRACT	O
:	O
CblD	O
disorder	O
is	O
an	O
autosomal	O
recessive	O
,	O
rare	O
,	O
heterogeneous	O
disease	O
with	O
variable	O
clinical	O
presentations	O
,	O
depending	O
on	O
the	O
nature	O
and	O
location	O
of	O
the	O
MMADHC	O
gene	B-PROC
mutations	I-PROC
.	O

TITLE	O
:	O
Anti	O
-	O
inflammatory	O
mechanisms	O
of	O
apolipoprotein	B-PROC
A	O
-	O
I	O
mimetic	O
peptide	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
sepsis	O
.	O

Absolute	O
contraindications	O
are	O
uncontrolled	O
coagulopathy	O
and	O
severe	O
intracranial	O
bleeding	O
,	O
which	O
precludes	O
the	O
use	O
of	O
anticoagulation	B-PROC
therapy	O
.	O

During	O
the	O
evaluation	O
period	O
,	O
the	O
novel	O
H7N9	O
virus	O
caused	O
severe	O
illness	O
,	O
including	O
pneumonia	O
and	O
ARDS	O
,	O
with	O
high	O
rates	O
of	O
ICU	O
admission	O
and	O
death	B-PROC
.	O

However	O
,	O
rRNA	B-PROC
degradation	I-PROC
was	O
induced	O
by	O
treatment	O
of	O
astrocytes	O
or	O
oligodendrocytes	O
with	O
poly	O
(	O
I	O
·	O
C	O
).	O

It	O
has	O
been	O
reported	O
that	O
a	O
cyclophilin	B-PROC
inhibitor	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
),	O
could	O
inhibit	O
the	O
replication	O
of	O
coronaviruses	O
.	O

Moreover	O
,	O
the	O
accumulation	O
of	O
m7GTP	O
or	O
presence	O
of	O
protein	O
nsp14	O
could	O
interfere	O
with	O
protein	B-PROC
translation	B-PROC
of	O
cellular	O
mRNAs	O
.	O

The	O
positivity	O
was	O
significantly	O
higher	O
in	O
males	O
(	O
51	O
.	O
5	O
%)	O
than	O
in	O
females	O
(	O
35	O
.	O
7	O
%)	O
(	O
P	O
<	O
0	O
.	O
0001	O
),	O
whereas	O
no	O
gender	O
difference	O
has	O
generally	O
been	O
noted	O
in	O
FCoV	O
antibody	B-PROC
prevalence	O
,	O
indicating	O
that	O
FIP	O
more	O
frequently	O
develops	O
in	O
males	O
among	O
FCoV	O
-	O
infected	O
cats	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
bats	O
in	O
its	O
origin	O
,	O
we	O
examined	O
the	O
molecular	O
epidemiology	O
and	O
evolution	B-PROC
of	O
lineage	O
C	O
betacoronaviruses	O
among	O
bats	O
.	O

Compared	O
with	O
saline	O
solution	O
and	O
with	O
non	O
-	O
pathological	O
fAGP	O
,	O
pathological	O
fAGP	O
significantly	O
decreased	B-PROC
phagocytosis	B-PROC
in	O
neutrophils	O
and	O
monocytes	O
.	O

ABSTRACT	O
:	O
The	O
design	O
,	O
synthesis	B-PROC
,	O
and	O
in	O
vitro	O
evaluation	O
of	O
the	O
first	O
macrocyclic	O
inhibitor	O
of	O
3C	O
and	O
3C	O
-	O
like	O
proteases	O
of	O
picornavirus	O
,	O
norovirus	O
,	O
and	O
coronavirus	O
are	O
reported	O
.	O

Patient	O
1	O
died	B-PROC
on	O
May	O
28	O
,	O
due	O
to	O
refractory	O
multiple	O
organ	O
failure	O
.	O

Several	O
factors	O
contribute	O
to	O
the	O
inflammatory	O
process	O
,	O
including	O
hypoxia	O
(	O
inadequate	O
oxygen	O
),	O
hyperoxia	O
(	O
higher	O
than	O
normal	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
),	O
inflammatory	O
mediators	O
(	O
such	O
as	O
cytokines	O
),	O
infections	O
(	O
viral	O
and	O
bacterial	O
),	O
and	O
environmental	O
conditions	O
(	O
such	O
as	O
cigarette	O
smoke	O
or	O
noxious	O
gases	O
).	O

Interestingly	O
,	O
recent	O
studies	O
also	O
suggest	O
that	O
spatially	O
and	O
temporally	O
regulated	O
production	O
of	O
oxidants	O
plays	O
an	O
important	O
role	O
antimicrobial	O
defense	O
and	O
immunomodulatory	O
function	O
(	O
such	O
as	O
transcription	B-PROC
factor	O
activation	O
).	O

PIXE	O
technique	O
was	O
employed	O
with	O
a	O
1	O
.	O
7	O
MV	O
5SDH	O
Tandem	O
Pelletron	O
accelerator	O
available	O
at	O
Centre	O
for	O
Energy	O
Research	O
and	O
Development	B-PROC
O	O
.	O
A	O
.	O
U	O
Ile	O
-	O
Ife	O
,	O
Nigeria	O
.	O

In	O
patients	O
as	O
well	O
as	O
in	O
mice	O
,	O
severe	O
edema	O
and	O
impaired	O
gas	O
exchange	O
are	O
associated	O
with	O
abundant	O
inflammatory	O
infiltrates	O
consisting	O
of	O
mainly	O
mononuclear	O
cells	O
and	O
parasite	O
sequestration	O
,	O
and	O
the	O
pathogenesis	B-PROC
appears	O
different	O
from	O
cerebral	O
malaria	O
(	O
CM	O
).	O

Infrequent	O
manifestations	O
of	O
the	O
disease	O
are	O
gastroesophageal	O
reflux	O
,	O
malabsorption	O
,	O
gastrointestinal	O
mucosal	O
ulceration	O
,	O
soft	O
tissue	O
calcification	B-PROC
,	O
Raynaud	O
'	O
s	O
syndrome	O
,	O
arthralgia	O
/	O
arthritis	O
and	O
some	O
other	O
less	O
common	O
clinical	O
manifestations	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
In	O
vitro	O
antiviral	O
activity	O
of	O
phlorotannins	O
isolated	O
from	O
Ecklonia	O
cava	O
against	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
infection	O
and	O
hemagglutination	B-PROC
.	O

Compounds	O
1	O
-	O
5	O
were	O
completely	O
blocked	O
binding	O
of	O
viral	O
spike	O
protein	O
to	O
sialic	O
acids	O
at	O
less	O
than	O
36	O
.	O
6	O
μM	O
concentrations	O
by	O
hemagglutination	B-PROC
inhibition	B-PROC
.	O

Moreover	O
,	O
compounds	O
4	O
and	O
5	O
of	O
five	O
phlorotannins	O
inhibited	O
viral	B-PROC
replication	I-PROC
with	O
IC₅₀	O
values	O
of	O
12	O
.	O
2	O
±	O
2	O
.	O
8	O
and	O
14	O
.	O
6	O
±	O
1	O
.	O
3	O
μM	O
in	O
the	O
post	O
-	O
treatment	O
assay	O
,	O
respectively	O
.	O

Interestingly	O
,	O
compounds	O
4	O
and	O
5	O
inhibited	O
both	O
viral	O
entry	O
by	O
hemagglutination	B-PROC
inhibition	B-PROC
and	O
viral	B-PROC
replication	I-PROC
by	O
inhibition	B-PROC
of	O
viral	O
RNA	O
and	O
viral	B-PROC
protein	I-PROC
synthesis	I-PROC
,	O
but	O
not	O
viral	O
protease	O
.	O

Management	O
challenges	O
included	O
sedation	O
,	O
weaning	B-PROC
from	O
sedation	O
,	O
and	O
liberation	O
from	O
mechanical	O
ventilation	O
.	O

These	O
results	O
imply	O
that	O
a	O
rapid	O
variation	O
and	O
evolution	B-PROC
of	O
central	O
China	O
PEDV	O
strains	O
has	O
occurred	O
in	O
recent	O
years	O
,	O
and	O
a	O
more	O
efficient	O
vaccine	O
strain	O
should	O
be	O
selected	O
to	O
prevent	O
and	O
control	O
outbreaks	O
of	O
PEDV	O
in	O
China	O
.	O

The	O
febrile	B-PROC
respiratory	O
illness	O
screening	O
tool	O
missed	O
26	O
%	O
of	O
active	O
influenza	O
cases	O
,	O
while	O
67	O
%	O
of	O
noninfluenza	O
patients	O
were	O
unnecessarily	O
placed	O
under	O
respiratory	O
isolation	O
.	O

However	O
,	O
the	O
pathogenesis	B-PROC
of	O
PHEV	O
and	O
the	O
relationship	O
between	O
PHEV	O
and	O
the	O
host	O
cells	O
are	O
not	O
fully	O
understood	O
.	O

This	O
conclusion	O
was	O
supported	O
by	O
the	O
ultrastructure	O
images	O
of	O
the	O
early	O
stage	O
of	O
DEV	O
infection	O
,	O
which	O
showed	O
that	O
the	O
replication	O
of	O
virus	O
nucleic	O
acid	O
and	O
the	O
formation	B-PROC
of	O
the	O
capsid	O
in	O
the	O
cell	O
nucleus	O
were	O
suppressed	O
.	O

In	O
the	O
indirect	O
immunofluorescence	O
assay	O
,	O
proteins	O
expression	B-PROC
in	O
DEV	O
infected	O
duck	O
embryo	O
fibroblasts	O
(	O
DEFs	O
)	O
within	O
24	O
h	O
post	O
-	O
infection	O
(	O
p	O
.	O
i	O
.)	O
was	O
also	O
effectively	O
suppressed	O
by	O
resveratrol	O
.	O

In	O
summary	O
,	O
the	O
resveratrol	O
has	O
a	O
good	O
activity	O
against	O
DEV	O
infection	O
in	O
vitro	O
,	O
which	O
could	O
be	O
attributed	O
to	O
that	O
fact	O
that	O
several	O
essential	O
immediate	O
early	O
viral	O
proteins	O
for	O
virus	B-PROC
replication	I-PROC
were	O
impacted	O
by	O
resveratrol	O
.	O

The	O
complications	O
seen	O
in	O
vivax	O
malaria	O
were	O
:	O
thrombocytopenia	O
(	O
68	O
%),	O
leukopenia	O
(	O
19	O
%),	O
ARDS	O
(	O
3	O
%),	O
high	O
bilirubin	O
(	O
5	O
%),	O
acute	O
renal	O
failure	O
(	O
3	O
.	O
5	O
%),	O
anemia	O
(	O
3	O
%),	O
mucosal	O
bleeding	O
(	O
8	O
%),	O
cerebral	O
malaria	O
(	O
3	O
.	O
5	O
%),	O
hypotension	O
(	O
5	O
%),	O
metabolic	B-PROC
acidosis	O
(	O
4	O
%)	O
and	O
death	B-PROC
(	O
1	O
.	O
77	O
%).	O

The	O
volume	O
of	O
crystalloids	O
on	O
KM	O
survival	O
curve	O
in	O
HRR	B-PROC
MTP	O
patients	O
was	O
not	O
significant	O
for	O
mortality	O
(	O
p	O
=	O
0	O
.	O
52	O
).	O

This	O
is	O
the	O
first	O
MIA	O
to	O
demonstrate	O
increased	O
morbidity	O
from	O
crystalloid	O
use	O
in	O
HRR	B-PROC
.	O

Caution	O
in	O
overzealous	O
use	O
of	O
crystalloid	O
during	O
HRR	B-PROC
is	O
warranted	O
.	O

The	O
patient	O
died	B-PROC
on	O
day	O
18	O
,	O
due	O
to	O
septic	O
shock	O
.	O

Overall	O
detection	O
in	O
356	O
enrolled	O
adults	O
were	O
92	O
(	O
26	O
%)	O
cases	O
of	O
a	O
single	O
bacterial	O
pathogen	O
,	O
80	O
(	O
22	O
%)	O
cases	O
of	O
a	O
single	O
viral	O
pathogen	O
,	O
60	O
(	O
17	O
%)	O
cases	O
with	O
mixed	O
bacterial	O
and	O
viral	B-PROC
infection	I-PROC
and	O
124	O
(	O
35	O
%)	O
cases	O
with	O
no	O
identified	O
pathogen	O
.	O

ABSTRACT	O
:	O
The	O
most	O
frequent	O
complication	O
of	O
A	O
(	O
H1N1	O
)	O
influenza	O
and	O
the	O
leading	O
cause	O
of	O
death	B-PROC
was	O
pneumonia	O
with	O
a	O
primary	O
viral	O
or	O
mixed	O
viral	O
and	O
bacterial	O
etiology	O
.	O

182	O
patients	O
had	O
died	B-PROC
because	O
of	O
a	O
pandemic	O
influenza	O
in	O
Poland	O
by	O
31st	O
July	O
2010	O
.	O

Although	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
strains	O
are	O
frequently	O
circulating	O
in	O
cattle	O
farms	O
worldwide	O
,	O
causing	O
both	O
enteric	O
and	O
respiratory	O
disease	O
,	O
little	O
is	O
known	O
about	O
their	O
genomic	O
evolution	B-PROC
.	O

Of	O
98	O
consecutive	O
ICU	O
patients	O
who	O
died	B-PROC
and	O
underwent	O
autopsy	O
,	O
51	O
met	O
the	O
inclusion	O
criteria	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
biological	O
activity	O
evaluation	O
of	O
5	O
-	O
pyrazoline	O
substituted	O
4	O
-	O
thiazolidinones	O
.	O

A	O
combination	O
therapy	O
with	O
ribavirin	O
,	O
intravenous	O
immunoglobulin	B-PROC
(	O
IVIG	O
)	O
and	O
steroid	O
under	O
ECMO	O
support	O
was	O
started	O
with	O
considerable	O
improvement	O
.	O

No	O
death	B-PROC
was	O
observed	O
in	O
this	O
series	O
.	O

While	O
all	O
RT	O
inhibitors	O
approved	O
for	O
therapy	O
target	O
the	O
DNA	O
polymerase	O
activity	O
,	O
there	O
is	O
the	O
pressing	O
need	O
for	O
new	O
RT	O
inhibitors	O
possibly	O
targeting	B-PROC
the	O
RNase	O
H	O
function	O
.	O

Inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
and	O
neuromuscular	O
blockers	O
(	O
NMBs	O
)	O
are	O
used	O
in	O
patients	O
with	O
severe	O
hypoxemia	O
.	O

A	O
total	O
of	O
132	O
confirmed	O
cases	O
and	O
39	O
deaths	B-PROC
have	O
been	O
reported	O
.	O

TITLE	O
:	O
Alphacoronavirus	O
protein	O
7	O
modulates	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

Viruses	O
have	O
developed	O
diverse	O
strategies	O
to	O
subvert	O
host	B-PROC
defense	I-PROC
mechanisms	O
and	O
increase	O
their	O
survival	O
.	O

Genes	O
involved	O
in	O
the	O
immune	B-PROC
response	I-PROC
,	O
the	O
interferon	O
response	O
,	O
and	O
inflammation	O
were	O
upregulated	O
during	O
TGEV	O
infection	O
in	O
the	O
absence	O
of	O
gene	O
7	O
.	O

Here	O
we	O
showed	O
that	O
residues	O
377	O
to	O
662	O
in	O
the	O
S	O
protein	O
of	O
MERS	O
-	O
CoV	O
specifically	O
bound	O
to	O
DPP4	O
-	O
expressing	O
cells	O
and	O
soluble	O
DPP4	O
protein	O
and	O
induced	O
significant	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
,	O
suggesting	O
that	O
this	O
region	O
contains	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
which	O
has	O
a	O
potential	O
to	O
be	O
developed	O
as	O
a	O
MERS	O
-	O
CoV	O
vaccine	O
.	O

At	O
day	O
30	O
,	O
one	O
death	B-PROC
had	O
occurred	O
in	O
each	O
group	O
.	O

Sequence	O
alignment	O
indicates	O
,	O
among	O
betacoronaviruses	O
,	O
a	O
possible	O
structural	O
conservation	O
for	O
the	O
region	O
homologous	O
to	O
the	O
MERS	O
-	O
CoV	O
RBD	O
core	O
,	O
but	O
a	O
high	O
variation	O
in	O
the	O
external	O
receptor	O
binding	O
motif	O
region	O
for	O
virus	O
-	O
specific	O
pathogenesis	B-PROC
such	O
as	O
receptor	O
recognition	O
.	O

To	O
deliver	O
viral	O
antigens	O
to	O
the	O
mucosal	O
immune	O
system	O
of	O
chickens	O
safely	O
and	O
effectively	O
,	O
we	O
constructed	O
a	O
Lactococcus	O
lactis	O
strain	O
carrying	O
IBV	O
multi	O
-	O
epitope	O
gene	O
EpiC	O
fused	O
with	O
the	O
gene	O
of	O
the	O
cell	O
-	O
wall	O
anchoring	B-PROC
domain	O
of	O
Staphylococcus	O
aureus	O
protein	O
A	O
.	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blot	O
results	O
indicated	O
that	O
the	O
fused	O
peptide	O
was	O
located	O
partially	O
on	O
the	O
cell	O
surface	O
.	O

MSCs	O
could	O
reduce	O
the	O
over	O
-	O
production	O
of	O
inflammatory	O
mediators	O
,	O
leucocyte	O
infiltration	O
,	O
tissue	O
injury	O
and	O
pulmonary	O
failure	O
,	O
and	O
produce	O
a	O
number	O
of	O
benefit	O
factors	O
through	O
interaction	O
with	O
other	O
cells	O
in	O
the	O
process	O
of	O
lung	O
tissue	B-PROC
repair	I-PROC
.	O

Reporter	O
gene	B-PROC
expression	I-PROC
was	O
confirmed	O
by	O
fluorescence	O
microscopy	O
,	O
or	O
luciferase	B-PROC
activity	I-PROC
assays	O
,	O
for	O
all	O
successfully	O
rescued	O
rIBVs	O
following	O
infection	O
of	O
primary	O
chick	O
kidney	O
(	O
CK	O
)	O
cells	O
.	O

Repeated	O
passaging	O
of	O
rIBVs	O
expressing	O
hRluc	O
at	O
an	O
MOI	O
of	O
0	O
.	O
01	O
demonstrated	O
an	O
increase	O
in	O
stability	O
,	O
with	O
hRluc	O
expression	B-PROC
stable	O
up	O
to	O
at	O
least	O
P12	O
following	O
the	O
replacement	O
of	O
Gene	O
5	O
.	O

The	O
relationship	O
between	O
these	O
categories	O
and	O
pulmonary	O
microvascular	B-PROC
permeability	I-PROC
as	O
well	O
as	O
extravascular	O
lung	O
water	O
content	O
,	O
which	O
is	O
the	O
hallmark	O
of	O
lung	O
pathophysiology	O
,	O
remains	O
to	O
be	O
elucidated	O
.	O

Severity	O
categories	O
of	O
ARDS	O
described	O
by	O
the	O
Berlin	O
definition	O
have	O
good	O
predictive	O
validity	O
and	O
may	O
be	O
associated	O
with	O
increased	O
extravascular	O
lung	O
water	O
and	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
.	O

Patients	O
received	O
consecutive	O
,	O
daily	O
,	O
12	O
-	O
hour	O
rescue	O
sessions	O
of	O
HFO	O
-	O
TGI	O
interspersed	O
with	O
12	O
-	O
hour	O
periods	B-PROC
of	O
CMV	O
.	O

After	O
acid	O
aspiration	O
,	O
computed	O
tomography	O
scans	O
revealed	O
that	O
lung	O
density	O
had	O
increased	O
in	O
the	O
injured	O
regions	O
and	O
that	O
these	O
regions	O
colocalized	O
with	O
areas	O
of	O
increased	O
blood	B-PROC
flow	I-PROC
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
ATR	O
-	O
dependent	O
phosphorylation	B-PROC
sites	O
on	O
coronavirus	O
nucleocapsid	O
protein	O
with	O
nonessential	O
functions	O
in	O
viral	B-PROC
replication	I-PROC
and	O
infectivity	O
in	O
cultured	O
cells	O
.	O

Previous	O
studies	O
have	O
identified	O
Ser190	O
,	O
Ser192	O
,	O
Thr378	O
and	O
Ser379	O
as	O
the	O
phosphorylation	B-PROC
sites	O
for	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
N	O
protein	O
.	O

A	O
mutant	O
virus	O
(	O
rIBV	O
-	O
Nm4	O
)	O
carrying	O
the	O
four	O
Ala	O
substitutions	O
grew	O
at	O
a	O
similar	O
,	O
if	O
not	O
better	O
,	O
growth	B-PROC
rate	O
as	O
wild	O
type	O
virus	O
.	O

RESULTS	O
:	O
Among	O
the	O
58	O
patients	O
enrolled	O
,	O
10	O
had	O
at	O
least	O
one	O
systemic	O
involvement	O
:	O
hepatic	B-PROC
function	I-PROC
test	O
results	O
were	O
abnormal	O
for	O
seven	O
;	O
six	O
had	O
renal	O
insufficiency	O
;	O
two	O
developed	O
acute	O
respiratory	O
distress	O
,	O
with	O
one	O
patient	O
'	O
s	O
bronchoalveolar	O
lavage	O
fluid	O
containing	O
many	O
neutrophils	O
but	O
no	O
microorganisms	O
;	O
one	O
was	O
agranulocytotic	O
.	O

RESULTS	O
:	O
33	O
differentially	O
expressed	B-PROC
protein	O
spots	O
,	O
of	O
which	O
23	O
were	O
up	O
-	O
regulated	O
and	O
10	O
were	O
down	O
-	O
regulated	O
were	O
identified	O
.	O

Microglia	O
remain	O
quiescent	O
,	O
unable	O
to	O
perform	O
effector	O
and	O
antigen	B-PROC
presentation	I-PROC
(	O
APC	O
)	O
functions	O
until	O
activated	O
by	O
injury	O
or	O
infection	O
,	O
and	O
have	O
been	O
suggested	O
to	O
represent	O
the	O
first	O
line	O
of	O
defence	O
for	O
the	O
CNS	O
.	O

Moreover	O
,	O
birds	O
of	O
vaccinated	O
groups	O
,	O
especially	O
with	O
full	O
dose	O
,	O
developed	O
higher	O
levels	O
of	O
lachrymal	O
IBV	O
-	O
specific	O
IgG	O
and	O
IgA	O
and	O
increased	O
the	O
expression	B-PROC
of	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immunity	I-PROC
(	O
CMI	O
)	O
genes	O
,	O
such	O
as	O
gamma	O
interferon	O
(	O
IFNγ	O
),	O
CD8	O
+	O
T	O
cell	O
marker	O
,	O
and	O
granzyme	O
homolog	O
A	O
more	O
rapidly	O
.	O

In	O
addition	O
,	O
these	O
humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
evaluated	O
at	O
mucosal	O
sites	O
correlated	O
significantly	O
with	O
tracheal	O
protection	O
against	O
homologous	O
IBV	O
challenge	O
in	O
a	O
vaccine	O
dose	O
-	O
dependent	O
manner	O
.	O

Animals	O
were	O
mechanically	O
ventilated	O
for	O
24	O
-	O
48	O
hours	O
,	O
and	O
then	O
animals	O
were	O
weaned	B-PROC
from	O
ventilation	O
and	O
cared	O
for	O
until	O
day	O
7	O
.	O

The	O
isolation	O
protocol	O
consisted	O
of	O
affinity	O
chromatography	O
,	O
ion	B-PROC
exchange	I-PROC
chromatography	O
,	O
and	O
gel	O
filtration	O
.	O

In	O
the	O
serum	O
the	O
acute	O
phase	O
proteins	O
(	O
haptoglobin	O
and	O
serum	O
amyloid	O
A	O
),	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
interferon	O
-	O
γ	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
),	O
and	O
serum	O
sialic	O
acid	O
(	O
total	O
,	O
TSA	O
;	O
lipid	O
-	O
bound	O
,	O
LBSA	O
;	O
and	O
protein	O
-	O
bound	O
,	O
PBSA	O
)	O
concentrations	O
were	O
measured	O
using	O
validated	O
standard	O
procedures	O
.	O

RESULTS	O
:	O
At	O
admission	O
45	O
%	O
had	O
severe	O
deficits	O
,	O
percentage	O
which	O
improves	O
throughout	O
the	O
evolution	B-PROC
of	O
the	O
illness	O
,	O
with	O
full	O
recovery	O
or	O
minor	O
deficits	O
in	O
the	O
87	O
%	O
of	O
patients	O
at	O
the	O
first	O
year	O
review	O
.	O

To	O
understand	O
the	O
effect	O
of	O
transport	B-PROC
-	O
related	O
infection	O
on	O
disease	O
spread	O
,	O
an	O
SEIRS	O
(	O
Susceptible	O
,	O
Exposed	O
,	O
Infectious	O
,	O
Recovered	O
)	O
epidemic	O
model	O
for	O
two	O
cities	O
is	O
formulated	O
and	O
analyzed	O
.	O

The	O
results	O
show	O
that	O
transportation	O
among	O
regions	O
will	O
change	O
the	O
disease	O
dynamics	O
and	O
break	O
infection	O
out	O
even	O
if	O
infectious	O
diseases	O
will	O
go	O
to	O
extinction	O
in	O
each	O
isolated	O
region	O
without	O
transport	B-PROC
-	O
related	O
infection	O
.	O

ABSTRACT	O
:	O
Efficient	O
and	O
productive	O
virus	B-PROC
infection	I-PROC
often	O
requires	O
viral	O
countermeasures	O
that	O
block	O
innate	B-PROC
immunity	B-PROC
.	O

ABSTRACT	O
:	O
Ovarian	O
hyperstimulation	O
syndrome	O
(	O
OHSS	O
)	O
is	O
an	O
iatrogenic	O
complication	O
of	O
controlled	O
ovarian	O
hyperstimulation	O
(	O
COH	O
)	O
protocols	O
performed	O
in	O
women	O
undergoing	O
assisted	O
reproductive	B-PROC
technologies	O
.	O

TITLE	O
:	O
Recent	O
developments	O
on	O
coronavirus	O
main	O
protease	O
/	O
3C	O
like	O
protease	B-PROC
inhibitors	I-PROC
.	O

In	O
the	O
years	O
since	O
the	O
initial	O
SARS	O
outbreak	O
,	O
the	O
arsenal	O
to	O
fight	O
this	O
virus	O
family	O
has	O
been	O
significantly	O
increased	O
by	O
the	O
rapid	O
growth	B-PROC
of	O
coronavirus	O
research	O
.	O

The	O
following	O
adverse	O
events	O
were	O
considered	O
:	O
hypoxia	O
(	O
arterial	O
PO2	B-PROC
<	O
80	O
mm	O
Hg	O
),	O
pneumothorax	O
(	O
any	O
air	O
leak	O
into	O
the	O
pleural	O
space	O
requiring	O
therapeutic	O
intervention	O
),	O
hypotension	O
(	O
systolic	O
blood	B-PROC
pressure	I-PROC
<	O
90	O
mm	O
Hg	O
sustained	O
for	O
longer	O
than	O
two	O
minutes	O
or	O
requiring	O
treatment	O
with	O
fluids	O
or	O
vasoactive	O
drugs	O
),	O
bradycardia	O
(	O
heart	O
rate	O
<	O
50	O
beats	O
per	O
minute	O
sustained	O
for	O
longer	O
than	O
one	O
minute	O
or	O
requiring	O
therapeutic	O
intervention	O
)	O
and	O
cardiac	O
arrest	O
(	O
absence	O
of	O
effective	O
cardiac	O
output	O
).	O

Clinical	O
and	O
laboratory	O
research	O
data	O
generated	O
in	O
the	O
past	O
few	O
months	O
have	O
provided	O
new	O
insights	O
into	O
the	O
possible	O
animal	O
reservoirs	O
,	O
transmissibility	O
,	O
and	O
virulence	B-PROC
of	O
MERS	O
-	O
CoV	O
,	O
and	O
the	O
optimal	O
laboratory	O
diagnostic	O
options	O
and	O
potential	O
antiviral	O
targets	O
for	O
MERS	O
-	O
CoV	O
-	O
associated	O
infection	O
.	O

Moreover	O
,	O
the	O
platform	O
offers	O
versatile	O
,	O
precise	O
control	O
over	O
the	O
sequence	O
of	O
triggers	O
for	O
fusion	O
;	O
these	O
triggers	O
may	O
define	O
the	O
fusion	O
pathway	B-PROC
,	O
tissue	B-PROC
tropism	B-PROC
,	O
and	O
pathogenicity	O
of	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Viruses	O
account	O
for	O
the	O
majority	O
of	O
the	O
acute	O
respiratory	O
tract	O
infections	O
(	O
ARIs	O
)	O
globally	O
with	O
a	O
mortality	O
exceeding	O
4	O
million	O
deaths	B-PROC
per	O
year	O
.	O

General	O
infection	O
control	O
measures	O
effective	O
for	O
all	O
respiratory	O
viral	B-PROC
infections	I-PROC
are	O
reviewed	O
and	O
followed	O
by	O
discussion	O
on	O
some	O
of	O
the	O
common	O
viruses	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
and	O
the	O
recently	O
discovered	O
novel	O
coronavirus	O
.	O

To	O
assess	O
pulmonary	O
co	O
-	O
morbidities	O
,	O
we	O
used	O
infant	O
pulmonary	B-PROC
function	I-PROC
testing	O
through	O
the	O
raised	O
volume	O
rapid	O
thoracoabdominal	O
compression	O
technique	O
as	O
both	O
an	O
established	O
study	O
of	O
early	O
cystic	O
fibrosis	O
and	O
also	O
as	O
a	O
newer	O
study	O
of	O
mechanism	O
for	O
early	O
sickle	O
cell	O
lung	O
disease	O
.	O

Infant	O
pulmonary	B-PROC
function	I-PROC
testing	O
data	O
demonstrated	O
moderate	O
-	O
to	O
-	O
severe	O
lower	O
airways	O
obstruction	O
,	O
moderate	O
air	O
trapping	O
,	O
and	O
no	O
evidence	O
of	O
restrictive	O
lung	O
disease	O
.	O

However	O
,	O
rebreathing	O
and	O
work	B-PROC
of	I-PROC
breathing	B-PROC
were	O
relatively	O
high	O
if	O
a	O
high	O
respiratory	O
rate	O
was	O
simulated	O
.	O

This	O
study	O
also	O
presents	O
a	O
structural	O
comparison	O
of	O
MERS	O
-	O
CoV	O
RBD	O
with	O
other	O
coronavirus	O
RBDs	O
,	O
successfully	O
positioning	O
MERS	O
-	O
CoV	O
on	O
the	O
landscape	O
of	O
coronavirus	O
evolution	B-PROC
and	O
providing	O
insights	O
into	O
receptor	O
binding	O
by	O
MERS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
MERS	O
-	O
CoV	O
RBD	O
functions	O
as	O
an	O
effective	O
entry	O
inhibitor	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
identified	O
MERS	O
-	O
CoV	O
RBD	O
may	O
also	O
serve	O
as	O
a	O
potential	O
candidate	O
for	O
MERS	O
-	O
CoV	O
subunit	O
vaccines	O
.	O

Independent	O
risk	O
factors	O
associated	O
with	O
increased	O
risk	O
of	O
ARDS	O
development	B-PROC
included	O
intermediate	O
(	O
2	O
-	O
3	O
.	O
9	O
mmol	O
/	O
L	O
)	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
and	O
high	O
(≥	O
4	O
)	O
serum	O
lactate	O
levels	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
Lung	O
Injury	O
Prediction	O
score	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
microbiologically	O
proven	O
infection	O
(	O
P	O
=	O
0	O
.	O
01	O
).	O

In	O
this	O
study	O
,	O
a	O
mouse	O
model	O
of	O
fulminant	O
liver	O
failure	O
(	O
FHF	O
)	O
induced	O
by	O
murine	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
)	O
was	O
used	O
to	O
study	O
the	O
role	O
of	O
hepatic	O
CD69	O
+	O
NK	O
cells	O
in	O
the	O
development	B-PROC
of	O
FHF	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
designed	O
to	O
identify	O
factors	O
associated	O
with	O
death	B-PROC
by	O
6	O
months	O
post	O
-	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
discharge	O
and	O
to	O
develop	O
a	O
practical	O
mortality	O
risk	O
score	O
for	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)-	O
treated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
.	O

These	O
cell	O
lines	O
are	O
valuable	O
tools	O
to	O
perform	O
in	O
vitro	O
studies	O
in	O
a	O
mouse	O
cell	O
system	O
that	O
reflects	O
the	O
species	O
used	O
for	O
in	O
vivo	O
studies	O
of	O
SARS	O
-	O
CoV	O
-	O
MA15	O
pathogenesis	B-PROC
.	O

Using	O
computed	O
tomography	O
,	O
single	O
,	O
basal	O
slices	O
of	O
the	O
lung	O
were	O
obtained	O
during	O
inspiratory	B-PROC
and	O
expiratory	B-PROC
pauses	O
at	O
a	O
tidal	O
volume	O
of	O
6	O
ml	O
/	O
kg	O
and	O
a	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
of	O
5	O
,	O
10	O
,	O
15	O
and	O
20	O
cmH2O	O
.	O

In	O
addition	O
,	O
increasing	O
levels	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
systematically	O
increased	O
strain	O
along	O
the	O
sternovertebral	O
axis	O
.	O

After	O
12	O
h	O
va	O
-	O
ECMO	O
was	O
converted	O
to	O
veno	O
-	O
venoarterial	O
ECMO	O
(	O
vva	O
-	O
ECMO	O
)	O
for	O
improvement	O
of	O
pulmonary	O
and	O
systemic	O
oxygenation	B-PROC
.	O

Both	O
decedents	O
'	O
deaths	B-PROC
were	O
attributed	O
to	O
relevant	O
natural	O
causes	O
in	O
a	O
setting	O
of	O
MDPV	O
abuse	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
unbiased	O
modeling	O
approach	O
to	O
identify	O
new	O
pathways	B-PROC
and	O
network	O
connections	O
mediating	O
acute	O
lung	O
injury	O
,	O
using	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
as	O
a	O
model	O
pathogen	O
.	O

We	O
identified	O
sets	O
of	O
differentially	O
expressed	B-PROC
genes	O
that	O
contribute	O
to	O
ALI	O
and	O
ARDS	O
using	O
lethal	O
and	O
sublethal	O
SARS	O
-	O
CoV	O
infection	O
models	O
.	O

Functional	O
analyses	O
of	O
poly	O
(	O
A	O
)	O
tail	O
length	O
on	O
specific	O
viral	O
RNA	O
species	O
,	O
furthermore	O
,	O
revealed	O
that	O
translation	B-PROC
,	O
in	O
vivo	O
,	O
of	O
RNAs	O
with	O
the	O
longer	O
poly	O
(	O
A	O
)	O
tail	O
was	O
enhanced	O
over	O
those	O
with	O
the	O
shorter	O
poly	O
(	O
A	O
).	O

The	O
regulation	B-PROC
of	O
coronavirus	O
translation	B-PROC
by	O
poly	O
(	O
A	O
)	O
tail	O
length	O
resembles	O
that	O
during	O
embryonal	B-PROC
development	B-PROC
suggesting	O
there	O
may	O
be	O
mechanistic	O
parallels	O
.	O

Employing	O
a	O
validated	O
stability	O
-	O
indicating	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
method	O
,	O
the	O
ribavirin	O
content	O
of	O
the	O
extemporaneous	O
preparation	O
has	O
been	O
demonstrated	O
to	O
exhibit	O
negligible	O
changes	O
throughout	O
the	O
storage	B-PROC
period	O
.	O

Mutations	O
at	O
the	O
hemagglutinin	O
(	O
HA	O
)	O
receptor	O
binding	O
site	O
(	O
RBS	O
)	O
have	O
been	O
associated	O
with	O
increased	O
virulence	B-PROC
and	O
disease	O
severity	O
,	O
representing	O
a	O
potential	O
marker	O
of	O
critical	O
illness	O
.	O

To	O
assess	O
the	O
contribution	O
of	O
HA	O
-	O
RBS	O
variability	O
in	O
critically	O
ill	O
patients	O
,	O
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
from	O
adult	O
patients	O
with	O
severe	O
infection	O
admitted	O
to	O
ICU	O
for	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
(	O
ECMO	O
)	O
during	O
influenza	O
season	O
2009	O
-	O
2011	O
in	O
Piemonte	O
(	O
4	O
·	O
2	O
million	O
inhabitants	O
),	O
northwestern	O
Italy	O
,	O
was	O
studied	O
.	O

ABSTRACT	O
:	O
Mice	O
that	O
are	O
transgenic	O
(	O
Tg	O
)	O
for	O
T	O
cell	O
receptor	O
(	O
TCR	B-PROC
)	O
expression	B-PROC
are	O
used	O
extensively	O
to	O
analyze	O
longitudinal	O
T	O
cell	O
responses	O
during	O
effector	O
and	O
memory	B-PROC
phases	O
of	O
the	O
T	O
cell	O
response	O
.	O

Generation	O
of	O
TCR	B-PROC
Tg	O
mice	O
generally	O
requires	O
T	O
cell	O
stimulation	O
and	O
cloning	O
in	O
vitro	O
prior	O
to	O
amplification	O
,	O
processes	O
which	O
introduce	O
biases	O
into	O
selection	O
of	O
the	O
TCR	B-PROC
that	O
is	O
ultimately	O
chosen	O
for	O
TCR	B-PROC
Tg	O
mouse	O
generation	O
.	O

MERS	O
-	O
CoV	O
neutralising	O
antibody	B-PROC
titres	O
varied	O
between	O
1	O
/	O
320	O
and	O
1	O
/	O
2560	O
for	O
the	O
Omani	O
camel	O
sera	O
and	O
between	O
1	O
/	O
20	O
and	O
1	O
/	O
320	O
for	O
the	O
Spanish	O
camel	O
sera	O
.	O

In	O
particular	O
,	O
inhaled	B-PROC
epoprostenol	O
(	O
Flolan	O
)	O
is	O
becoming	O
an	O
increasingly	O
common	O
alternative	O
to	O
nitric	O
oxide	O
in	O
the	O
treatment	O
of	O
severe	O
,	O
refractory	O
hypoxemia	O
.	O

Research	O
comparing	O
the	O
2	O
inhaled	B-PROC
vasodilators	O
suggests	O
that	O
epoprostenol	O
is	O
equally	O
efficacious	O
,	O
easier	O
to	O
administer	O
,	O
less	O
costly	O
,	O
and	O
has	O
fewer	O
adverse	O
effects	O
.	O

There	O
are	O
pathogen	O
-	O
specific	O
pathways	B-PROC
underlying	O
virally	O
mediated	O
ALI	O
that	O
converge	O
onto	O
a	O
common	O
end	O
pathway	B-PROC
resulting	O
in	O
diffuse	O
alveolar	O
damage	O
.	O

In	O
addition	O
,	O
we	O
inserted	O
heterologous	O
genes	O
(	O
i	O
.	O
e	O
.	O
the	O
GFP	O
and	O
Renilla	O
luciferase	O
genes	O
)	O
at	O
two	O
positions	O
in	O
the	O
viral	O
genome	O
,	O
either	O
as	O
an	O
extra	O
expression	B-PROC
cassette	O
or	O
as	O
a	O
replacement	O
for	O
the	O
ORF3	O
gene	O
.	O

Systems	O
biology	O
provides	O
an	O
opportunity	O
to	O
explore	O
and	O
understand	O
these	O
multifaceted	O
interactions	O
based	O
on	O
integration	B-PROC
and	O
modeling	O
of	O
multiple	O
biological	O
parameters	O
.	O

Increased	O
interferon	O
gamma	O
(	O
IFN	O
-	O
γ	O
)	O
expression	B-PROC
was	O
observed	O
in	O
the	O
mucosal	O
immune	O
compartment	O
,	O
i	O
.	O
e	O
.,	O
HALT	O
,	O
after	O
primary	O
vaccination	O
,	O
but	O
shifted	O
to	O
the	O
systemic	O
immune	O
compartment	O
after	O
boosting	O
.	O

TITLE	O
:	O
Emerging	O
indications	O
for	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
adults	O
with	O
respiratory	O
failure	O
.	O

To	O
increase	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
the	O
disease	O
caused	O
by	O
this	O
virus	O
,	O
we	O
investigated	O
the	O
response	O
of	O
chickens	O
to	O
2	O
IBV	O
with	O
different	O
genotypes	O
,	O
KIIa	O
and	O
ChVI	O
.	O

In	O
addition	O
,	O
ACE2	O
has	O
functions	O
independent	O
of	O
the	O
RAS	O
:	O
ACE2	O
is	O
the	O
receptor	O
for	O
the	O
SARS	O
coronavirus	O
and	O
ACE2	O
is	O
essential	O
for	O
expression	B-PROC
of	O
neutral	O
amino	O
acid	O
transporters	O
in	O
the	O
gut	O
.	O

In	O
contrast	O
to	O
FIPV	O
strains	O
,	O
FECVs	O
showed	O
a	O
clear	O
tropism	B-PROC
for	O
intestinal	O
epithelial	O
cells	O
,	O
giving	O
an	O
explanation	O
for	O
the	O
observation	O
that	O
FECV	O
is	O
the	O
main	O
pathotype	O
circulating	O
among	O
cats	O
.	O

Toxin	O
-	O
induced	O
endothelial	O
hyperpermeability	O
can	O
involve	O
myosin	O
light	O
chain	O
phosphorylation	B-PROC
and	O
/	O
or	O
microtubule	O
rearrangement	B-PROC
.	O

Despite	O
intensive	O
treatment	O
the	O
patient	O
died	B-PROC
from	O
acute	O
respiratory	O
failure	O
.	O

It	O
seems	O
likely	O
that	O
development	B-PROC
of	O
acute	O
myeloid	O
leukemia	O
in	O
patient	O
with	O
VHL	O
disease	O
can	O
be	O
related	O
to	O
epigenetic	O
alterations	O
of	O
the	O
VHL	O
gene	O
,	O
but	O
further	O
studies	O
are	O
needed	O
.	O

The	O
antibody	B-PROC
activity	I-PROC
was	O
measured	O
by	O
ELISA	O
.	O

Addition	O
of	O
a	O
viral	O
-	O
bacterial	O
filter	O
during	O
manual	O
ventilation	O
by	O
bagging	O
may	O
reduce	O
the	O
exhaled	B-PROC
air	O
leakage	O
forward	O
and	O
yet	O
increase	O
the	O
sideway	O
leakage	O
.	O

Emerging	O
evidence	O
for	O
the	O
pathogenic	O
role	O
of	O
microglia	O
and	O
the	O
activation	O
of	O
inflammatory	O
pathways	B-PROC
in	O
these	O
cells	O
in	O
MHV	O
infection	O
supports	O
the	O
concept	O
that	O
microglia	O
induced	O
neuroinflammation	O
is	O
an	O
amplifier	O
of	O
virus	O
-	O
induced	O
neuropathology	O
.	O

Balancing	B-PROC
the	O
end	O
-	O
point	O
between	O
lungs	O
and	O
brain	O
becomes	O
a	O
challenging	O
issue	O
,	O
and	O
non	O
-	O
conventional	O
modes	O
of	O
mechanical	O
ventilation	O
might	O
play	O
a	O
role	O
in	O
the	O
more	O
difficult	O
clinical	O
cases	O
.	O

TITLE	O
:	O
[	O
Respiratory	O
support	O
and	O
treatment	O
of	O
severe	O
inhalation	B-PROC
injury	O
].	O

This	O
article	O
reviews	O
the	O
recent	O
progress	O
in	O
research	O
and	O
treatment	O
of	O
inhalation	B-PROC
injury	O
,	O
acute	O
lung	O
injury	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
at	O
home	O
and	O
abroad	O
,	O
focusing	O
on	O
the	O
effect	O
of	O
mechanical	O
ventilation	O
models	O
,	O
including	O
the	O
non	O
-	O
invasive	O
ventilation	O
,	O
lung	O
protective	O
ventilation	O
,	O
liquid	O
ventilation	O
,	O
high	O
frequency	O
ventilation	O
,	O
on	O
respiratory	O
support	O
in	O
early	O
stage	O
of	O
inhalation	B-PROC
injury	O
.	O

The	O
initial	O
PaO2	O
/	O
FiO2	O
index	O
was	O
64	O
(	O
51	O
-	O
67	O
)	O
mmHg	O
and	O
the	O
arterial	O
carbon	B-PROC
dioxide	I-PROC
tension	I-PROC
was	O
60	O
(	O
50	O
-	O
71	O
)	O
mmHg	O
.	O

Pathophysiological	O
mechanisms	O
implicated	O
in	O
the	O
development	B-PROC
of	O
AEP	O
in	O
our	O
patient	O
seem	O
to	O
be	O
associated	O
with	O
eotaxin	O
and	O
serotonin	O
eosinophilic	O
-	O
specific	O
chemoattracting	O
action	O
,	O
through	O
the	O
serotoninergic	O
action	O
of	O
risperidone	O
.	O

Moreover	O
,	O
puppies	O
from	O
large	O
breeding	B-PROC
kennels	O
,	O
excreting	O
a	O
high	O
level	O
of	O
G	O
.	O
intestinalis	O
and	O
/	O
or	O
excreting	O
a	O
high	O
level	O
of	O
C	O
.	O
canis	O
oocysts	O
showed	O
a	O
higher	O
probability	O
of	O
being	O
positive	O
for	O
P	O
.	O
hominis	O
infection	O
.	O

TITLE	O
:	O
Clinical	O
management	O
and	O
infection	O
control	O
of	O
SARS	O
:	O
lessons	O
learned	B-PROC
.	O

TITLE	O
:	O
Development	B-PROC
of	O
potent	O
dipeptide	O
-	O
type	O
SARS	O
-	O
CoV	O
3CL	O
protease	B-PROC
inhibitors	I-PROC
with	O
novel	O
P3	O
scaffolds	O
:	O
design	O
,	O
synthesis	B-PROC
,	O
biological	O
evaluation	O
,	O
and	O
docking	B-PROC
studies	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
design	O
and	O
synthesis	B-PROC
of	O
a	O
series	O
of	O
dipeptide	O
-	O
type	O
inhibitors	O
with	O
novel	O
P3	O
scaffolds	O
that	O
display	O
potent	O
inhibitory	O
activity	O
against	O
SARS	O
-	O
CoV	O
3CLpro	O
.	O

A	O
docking	B-PROC
study	O
involving	O
binding	O
between	O
the	O
dipeptidic	O
lead	O
compound	O
4	O
and	O
3CLpro	O
suggested	O
the	O
modification	O
of	O
a	O
structurally	O
flexible	O
P3	O
N	O
-(	O
3	O
-	O
methoxyphenyl	O
)	O
glycine	O
with	O
various	O
rigid	O
P3	O
moieties	O
in	O
4	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
γ	O
-	O
PGA	O
induces	O
type	O
I	O
IFN	O
signaling	B-PROC
pathway	I-PROC
via	O
the	O
TLR4	B-PROC
signaling	B-PROC
pathway	I-PROC
.	O

As	O
their	O
conditions	O
became	O
better	O
,	O
patients	O
'	O
EVLWI	O
decreased	O
to	O
5	O
.	O
5	O
±	O
2	O
.	O
7	O
ml	O
/	O
kg	O
and	O
7	O
.	O
0	O
±	O
3	O
.	O
0	O
ml	O
/	O
kg	O
,	O
respectively	O
at	O
weaning	B-PROC
.	O

The	O
resistance	B-PROC
to	O
infection	O
was	O
overcome	O
if	O
cells	O
were	O
transfected	O
to	O
express	O
the	O
respective	O
cellular	O
receptor	O
,	O
porcine	O
aminopeptidase	O
N	O
for	O
TGEV	O
or	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
for	O
SARS	O
-	O
CoV	O
.	O
VSV	O
pseudotypes	O
containing	O
the	O
S	O
proteins	O
of	O
two	O
bat	O
SARS	O
-	O
related	O
CoV	O
(	O
Bg08	O
and	O
Rp3	O
)	O
were	O
unable	O
to	O
infect	O
any	O
of	O
the	O
six	O
tested	O
bat	O
cell	O
lines	O
.	O

ABSTRACT	O
:	O
The	O
incidence	O
and	O
outcomes	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
lung	O
transplant	O
recipients	O
(	O
LTR	O
)	O
are	O
not	O
well	O
defined	O
.	O

All	O
specimens	O
underwent	O
testing	O
with	O
a	O
wide	O
panel	O
of	O
molecular	O
assays	O
targeting	B-PROC
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
accessory	O
protein	O
4a	O
is	O
a	O
type	O
I	O
interferon	O
antagonist	B-PROC
.	O

A	O
conserved	O
step	O
of	O
CoV	O
replication	O
is	O
the	O
translation	B-PROC
and	O
processing	O
of	O
replicase	O
polyproteins	O
containing	O
16	O
nonstructural	O
protein	O
domains	O
(	O
nsp	O
'	O
s	O
1	O
to	O
16	O
).	O

Inhalation	B-PROC
of	O
vaporized	O
PFC	O
results	O
in	O
sustained	O
improvement	O
of	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
and	O
lung	O
mechanics	O
in	O
a	O
detergent	O
-	O
induced	O
animal	O
model	O
of	O
lung	O
injury	O
.	O

RESULTS	O
:	O
Vaporized	O
PFC	O
treatment	O
significantly	O
increased	O
oxygenation	B-PROC
index	O
(	O
P	O
/	O
F	O
ratio	O
)	O
and	O
static	O
lung	B-PROC
compliance	I-PROC
(	O
Cst	O
)	O
2	O
h	O
after	O
therapy	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Gene	B-PROC
expression	I-PROC
profiling	O
was	O
performed	O
via	O
DNA	O
microarrays	O
in	O
leukocytes	O
from	O
critically	O
ill	O
trauma	O
patients	O
nonseptic	O
upon	O
admission	O
to	O
the	O
ICU	O
,	O
who	O
subsequently	O
developed	O
either	O
sepsis	O
(	O
n	O
=	O
2	O
)	O
or	O
severe	O
sepsis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
n	O
=	O
3	O
).	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
rescue	O
therapy	O
in	O
a	O
case	O
of	O
portopulmonary	O
hypertension	O
during	O
liver	O
transplantation	O
:	O
a	O
case	O
report	O
.	O

Our	O
data	O
show	O
that	O
knockdown	O
of	O
LIMK1	O
destabilizes	O
whereas	O
knockdown	O
of	O
SSH	O
-	O
1L	O
stabilizes	O
the	O
actin	O
filaments	O
through	O
modulation	O
of	O
cofilin	O
phosphorylation	B-PROC
;	O
however	O
,	O
in	O
either	O
case	O
thrombin	O
-	O
induced	O
NF	O
-	O
κB	O
activity	O
and	O
expression	B-PROC
of	O
its	O
target	O
genes	O
(	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
)	O
is	O
inhibited	O
.	O

TITLE	O
:	O
Detection	O
and	O
differentiation	B-PROC
of	O
Newcastle	O
disease	O
virus	O
and	O
influenza	O
virus	O
by	O
using	O
duplex	O
real	O
-	O
time	O
PCR	O
.	O

LOH	B-PROC
is	O
frequently	O
associated	O
with	O
chronic	O
conditions	O
including	O
cardiovascular	O
diseases	O
(	O
CVD	O
),	O
obesity	O
,	O
osteoporosis	O
,	O
HIV	O
infection	O
,	O
renal	O
failure	O
,	O
and	O
obstructive	O
pulmonary	O
diseases	O
.	O

Available	O
evidence	O
also	O
suggests	O
that	O
TRT	O
might	O
ameliorate	O
central	O
obesity	O
and	O
glycometabolic	O
control	O
in	O
patients	O
with	O
metabolic	B-PROC
syndrome	O
and	O
type	O
2	O
diabetes	O
.	O

These	O
results	O
suggest	O
that	O
hepatocyte	O
-	O
specific	O
IL	O
-	O
33	O
expression	B-PROC
in	O
poly	O
(	O
I	O
:	O
C	O
)	O
induced	O
liver	O
injury	O
was	O
partially	O
dependent	O
of	O
NK	O
cells	O
and	O
with	O
limited	O
role	O
of	O
NKT	O
cells	O
.	O

The	O
LSEC	O
and	O
VEC	O
expressed	B-PROC
inducible	O
expression	B-PROC
of	O
IL	O
-	O
33	O
following	O
L2	O
-	O
MHV3	O
infection	O
but	O
the	O
hepatocyte	O
-	O
specific	O
IL	O
-	O
33	O
expression	B-PROC
was	O
only	O
evident	O
between	O
24	O
to	O
32h	O
of	O
post	O
infection	O
.	O

The	O
availability	O
of	O
an	O
animal	O
disease	O
model	O
is	O
essential	O
for	O
understanding	O
pathogenesis	B-PROC
and	O
developing	O
effective	O
countermeasures	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
effects	O
of	O
low	O
dietary	O
vitamin	O
A	O
content	O
on	O
antibody	B-PROC
responses	I-PROC
in	O
feedlot	O
calves	O
inoculated	O
with	O
an	O
inactivated	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
vaccine	O
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
),	O
multiplex	O
PCR	O
techniques	O
,	O
traditional	O
Sanger	O
Sequencing	O
and	O
classical	O
viral	O
culture	O
methods	O
were	O
used	O
.	O

ABSTRACT	O
:	O
The	O
high	O
mortality	O
associated	O
with	O
the	O
novel	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
raised	O
questions	O
about	O
the	O
possible	O
role	O
of	O
a	O
cytokine	O
storm	O
in	O
its	O
pathogenesis	B-PROC
.	O

Their	O
heterogeneity	O
was	O
investigated	O
by	O
analysis	O
of	O
the	O
ORF3	O
gene	O
because	O
of	O
its	O
potential	O
function	O
as	O
a	O
representation	O
of	O
virulence	B-PROC
.	O

ABSTRACT	O
:	O
Following	O
the	O
recognition	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
as	O
the	O
""""	O
endothelium	O
-	O
derived	O
relaxing	O
factor	O
","""	O
an	O
explosion	O
of	O
laboratory	O
and	O
clinical	O
research	O
led	O
to	O
the	O
development	B-PROC
of	O
inhaled	B-PROC
NO	O
as	O
a	O
potential	O
therapy	O
for	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	O
).	O

MAb	O
2	O
-	O
4	O
exhibited	O
high	O
neutralizing	O
activity	O
against	O
natural	O
TNF	O
-	O
alpha	O
derived	O
from	O
FIPV	O
-	O
infected	O
macrophages	O
,	O
and	O
was	O
confirmed	O
to	O
inhibit	O
the	O
following	O
feline	O
TNF	O
-	O
alpha	O
-	O
induced	O
conditions	O
in	O
vitro	O
:	O
(	O
i	O
)	O
an	O
increase	O
in	O
the	O
survival	O
rate	O
of	O
neutrophils	O
from	O
cats	O
with	O
FIP	O
,	O
(	O
ii	O
)	O
aminopeptidase	O
N	O
(	O
APN	O
)	O
mRNA	B-PROC
expression	B-PROC
in	O
macrophages	O
,	O
and	O
(	O
iii	O
)	O
apoptosis	B-PROC
of	O
a	O
feline	O
T	O
-	O
lymphocyte	O
cell	O
line	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
TGEV	O
infection	O
on	O
the	O
cell	B-PROC
cycle	I-PROC
of	O
host	O
cells	O
and	O
the	O
roles	O
of	O
p53	O
activation	O
in	O
this	O
process	O
.	O

He	O
had	O
neither	O
coagulation	B-PROC
abnormality	O
nor	O
autoimmune	O
disease	O
.	O

These	O
experiments	O
show	O
that	O
if	O
S	O
protein	O
on	O
MERS	O
pseudovirions	O
is	O
uncleaved	O
,	O
then	O
viruses	O
enter	O
by	O
endocytosis	B-PROC
in	O
a	O
cathepsin	O
L	O
-	O
dependent	O
manner	O
,	O
but	O
if	O
MERS	O
-	O
CoV	O
S	O
is	O
cleaved	O
,	O
either	O
during	O
virus	B-PROC
maturation	B-PROC
by	O
serine	O
proteases	O
or	O
on	O
pseudovirions	O
by	O
trypsin	O
in	O
extracellular	O
fluids	O
,	O
then	O
viruses	O
enter	O
at	O
the	O
plasma	O
membrane	O
at	O
neutral	O
pH	O
and	O
cause	O
massive	O
syncytia	O
formation	B-PROC
even	O
in	O
cells	O
that	O
express	O
little	O
or	O
no	O
MERS	O
-	O
CoV	O
receptor	O
.	O

We	O
further	O
showed	O
that	O
the	O
generated	O
IBV	O
VLPs	O
could	O
induce	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
in	O
a	O
level	O
comparable	O
to	O
that	O
of	O
inactivated	O
IBV	O
vaccine	O
,	O
and	O
more	O
importantly	O
the	O
IBV	O
VLPs	O
could	O
elicit	O
significantly	O
higher	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
than	O
the	O
inactivated	O
IBV	O
vaccine	O
.	O

Although	O
AEP	O
was	O
self	O
-	O
limiting	O
,	O
consecutively	O
experienced	O
recurrent	O
respiratory	O
infections	O
,	O
severe	O
atopic	O
dermatitis	O
,	O
and	O
vulnerability	O
to	O
viral	B-PROC
infections	I-PROC
,	O
prompted	O
us	O
to	O
evaluate	O
the	O
possibility	O
of	O
DOCK8	O
deficiency	O
.	O

TITLE	O
:	O
Adaptive	O
evolution	B-PROC
of	O
bat	O
dipeptidyl	O
peptidase	O
4	O
(	O
dpp4	O
):	O
implications	O
for	O
the	O
origin	O
and	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

While	O
a	O
multitude	O
of	O
studies	O
have	O
examined	O
nucleocapsid	O
function	O
,	O
none	O
have	O
described	O
the	O
effects	O
of	O
OC43	O
nucleocapsid	O
on	O
the	O
transcription	B-PROC
factor	O
NF	O
-	O
κB	O
.	O
We	O
report	O
that	O
the	O
nucleocapsid	O
protein	O
of	O
OC43	O
causes	O
potentiation	O
of	O
NF	O
-	O
κB	O
activation	O
.	O

ABSTRACT	O
:	O
After	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
,	O
many	O
international	O
airport	O
quarantine	O
stations	O
conducted	O
fever	B-PROC
-	O
based	O
screening	O
to	O
identify	O
infected	O
passengers	O
using	O
infrared	O
thermography	O
for	O
preventing	O
global	O
pandemics	O
.	O

Then	O
,	O
female	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
the	O
purified	O
recombinant	O
S1	O
protein	O
(	O
rS1	O
),	O
and	O
a	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
designated	O
as	O
5E12	O
)	O
against	O
the	O
rS1	O
protein	O
was	O
achieved	O
by	O
hybridoma	O
technique	O
.	O

Patients	O
under	O
invasive	O
or	O
noninvasive	O
mechanical	O
ventilation	O
,	O
with	O
PaO2	O
/	O
FiO2	O
<	O
300	O
mmHg	O
regardless	O
of	O
the	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
level	O
,	O
and	O
acute	O
onset	O
of	O
new	O
or	O
increased	O
bilateral	O
infiltrates	O
or	O
opacities	O
on	O
chest	O
X	O
-	O
ray	O
were	O
screened	O
from	O
ICU	O
admission	O
up	O
to	O
discharge	O
.	O

In	O
contrast	O
,	O
the	O
most	O
important	O
behaviors	B-PROC
they	O
should	O
avoid	O
are	O
concealing	O
the	O
truth	O
and	O
misreporting	O
the	O
truth	O
.	O

Moreover	O
,	O
the	O
ORF3	O
genes	O
recovered	O
from	O
the	O
feline	O
strains	O
exhibited	O
shared	O
deletions	O
,	O
never	O
described	O
before	O
,	O
suggesting	O
that	O
these	O
deletions	O
could	O
be	O
critical	O
in	O
the	O
adaptation	B-PROC
of	O
these	O
strains	O
to	O
the	O
feline	O
host	O
.	O

The	O
Rivalta	O
'	O
s	O
test	O
was	O
repeated	O
up	O
to	O
21	O
days	O
after	O
storage	B-PROC
at	O
room	O
temperature	O
,	O
in	O
the	O
refrigerator	O
,	O
or	O
freezer	O
.	O

In	O
the	O
present	O
report	O
,	O
a	O
series	O
of	O
three	O
cases	O
of	O
imported	O
malaria	O
complicated	O
by	O
refractory	O
severe	O
ARDS	O
supported	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
presented	O
.	O

Despite	O
lung	O
protective	O
ventilation	O
,	O
a	O
conservative	O
strategy	O
of	O
fluid	O
management	O
,	O
corticosteroids	O
(	O
two	O
patients	O
),	O
prone	O
position	O
(	O
two	O
patients	O
)	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
one	O
patient	O
),	O
refractory	O
severe	O
ARDS	O
supervened	O
(	O
PaO2	O
to	O
FiO2	O
ratio	O
68	O
)	O
and	O
venovenous	O
ECMO	O
was	O
then	O
initiated	O
.	O

Considering	O
the	O
enhanced	O
inflammation	O
in	O
females	O
,	O
cytokine	B-PROC
production	I-PROC
may	O
be	O
assumed	O
to	O
be	O
higher	O
in	O
females	O
than	O
males	O
.	O

Here	O
we	O
report	O
the	O
emergence	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
in	O
the	O
United	O
States	O
and	O
determination	O
of	O
its	O
origin	O
,	O
evolution	B-PROC
,	O
and	O
genotypes	O
based	O
on	O
temporal	O
and	O
geographical	O
evidence	O
.	O

Here	O
we	O
report	O
the	O
detailed	O
genetic	O
characterization	O
,	O
origin	O
,	O
and	O
evolution	B-PROC
of	O
emergent	O
PEDV	O
strains	O
in	O
the	O
United	O
States	O
.	O

ABSTRACT	O
:	O
Treatment	O
with	O
inhaled	B-PROC
nitric	O
oxide	O
improves	O
oxygenation	B-PROC
but	O
not	O
survival	O
in	O
mechanically	O
ventilated	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
but	O
the	O
effect	O
may	O
depend	O
on	O
the	O
severity	O
of	O
hypoxemia	O
.	O

As	O
the	O
distribution	O
of	O
perfusion	O
remains	O
nearly	O
constant	O
in	O
both	O
postures	O
,	O
proning	O
usually	O
improves	O
oxygenation	B-PROC
.	O

Despite	O
normal	O
gasp	O
latency	O
,	O
breathing	B-PROC
frequency	O
and	O
a	O
larger	O
tidal	O
volume	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
5	O
-	O
HT	O
-	O
deficient	O
pups	O
survived	O
one	O
-	O
half	O
the	O
number	O
of	O
episodes	O
as	O
controls	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Calcium	B-PROC
signaling	I-PROC
-	O
related	O
proteins	O
are	O
associated	O
with	O
broncho	O
-	O
pulmonary	O
dysplasia	O
progression	O
.	O

The	O
majority	O
of	O
patients	O
presented	O
with	O
fever	B-PROC
98	O
%,	O
fever	B-PROC
with	O
cough	O
83	O
%,	O
and	O
shortness	O
of	O
breath	O
72	O
%.	O

79	O
.	O
66	O
%	O
(	O
141	O
of	O
177	O
)	O
pig	O
farms	O
in	O
29	O
provinces	O
(	O
excluding	O
Tibet	O
and	O
Hainan	O
,	O
China	O
)	O
and	O
72	O
.	O
27	O
%	O
(	O
417	O
of	O
577	O
)	O
samples	O
were	O
positive	O
for	O
PEDV	O
confirmed	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

In	O
response	O
,	O
we	O
developed	O
two	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
assays	O
targeting	B-PROC
the	O
MERS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
and	O
evaluated	O
these	O
assays	O
as	O
a	O
panel	O
with	O
a	O
previously	O
published	O
assay	O
targeting	B-PROC
the	O
region	O
upstream	O
of	O
the	O
MERS	O
-	O
CoV	O
envelope	O
gene	O
(	O
upE	O
)	O
for	O
the	O
detection	O
and	O
confirmation	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
the	O
CNS	O
(	O
central	O
nervous	O
system	O
)	O
with	O
a	O
sublethal	O
neurotropic	O
coronavirus	O
(	O
JHMV	O
)	O
induces	O
a	O
vigorous	O
inflammatory	B-PROC
response	I-PROC
.	O

An	O
enigma	O
in	O
understanding	O
the	O
contribution	O
of	O
T	O
cell	O
subsets	O
in	O
pathogenesis	B-PROC
resides	O
in	O
their	O
distinct	O
migration	B-PROC
pattern	O
across	O
the	O
BBB	O
(	O
blood	O
brain	O
barrier	O
).	O

A	O
panel	O
that	O
included	O
11	O
biomarkers	O
of	O
inflammation	O
,	O
fibroblast	B-PROC
activation	I-PROC
,	O
proteolytic	B-PROC
injury	O
,	O
endothelial	O
injury	O
,	O
and	O
lung	O
epithelial	O
injury	O
was	O
measured	O
in	O
plasma	O
from	O
the	O
morning	O
of	O
ICU	O
day	O
two	O
.	O

RESULTS	O
:	O
Using	O
the	O
five	O
best	O
-	O
performing	O
biomarkers	O
(	O
surfactant	O
protein	O
-	O
D	O
(	O
SP	O
-	O
D	O
),	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
RAGE	O
),	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
),	O
club	O
cell	O
secretory	B-PROC
protein	O
(	O
CC	O
-	O
16	O
),	O
and	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
))	O
the	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
75	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
to	O
0	O
.	O
84	O
)	O
for	O
the	O
diagnosis	O
of	O
ARDS	O
.	O

Compared	O
to	O
controls	O
,	O
the	O
main	O
echocardiographic	O
findings	O
in	O
patients	O
during	O
the	O
acute	O
phase	O
were	O
significantly	O
higher	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
,	O
higher	O
systolic	O
pulmonary	O
artery	O
pressure	O
,	O
lower	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
and	O
impaired	O
left	O
atrial	O
myocardial	O
motion	O
.	O

In	O
the	O
most	O
severe	O
cases	O
,	O
it	O
can	O
cause	O
pneumonia	O
,	O
respiratory	O
failure	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
pulmonary	O
hypertension	O
,	O
and	O
death	B-PROC
.	O

IBV	O
infection	O
contributed	O
to	O
differential	O
expression	B-PROC
of	O
1777	O
genes	O
,	O
of	O
which	O
876	O
were	O
up	O
-	O
regulated	O
and	O
901	O
down	O
-	O
regulated	O
in	O
the	O
kidney	O
compared	O
to	O
those	O
of	O
control	O
chickens	O
and	O
103	O
associated	O
with	O
immune	O
and	O
inflammatory	B-PROC
responses	I-PROC
may	O
play	O
important	O
roles	O
in	O
the	O
host	B-PROC
defense	B-PROC
response	I-PROC
during	O
IBV	O
infection	O
.	O

Age	O
,	O
SOFA	O
score	O
,	O
and	O
a	O
diagnosis	O
of	O
influenza	O
may	O
be	O
used	O
to	O
accurately	O
evaluate	O
the	O
risk	O
of	O
death	B-PROC
in	O
ARDS	O
patients	O
considered	O
for	O
retrieval	O
under	O
ECMO	O
from	O
distant	O
hospitals	O
.	O

This	O
compartmentalization	O
allows	O
coordination	B-PROC
of	O
the	O
different	O
steps	O
of	O
the	O
viral	B-PROC
replication	I-PROC
cycle	I-PROC
,	O
highly	O
efficient	O
genome	O
replication	O
and	O
protection	O
of	O
the	O
viral	O
RNA	O
from	O
cellular	O
defense	O
mechanisms	O
.	O

This	O
review	O
discusses	O
common	O
themes	O
and	O
distinct	O
differences	O
in	O
the	O
architecture	O
of	O
plus	O
-	O
strand	O
RNA	O
virus	O
-	O
induced	O
membrane	O
alterations	O
and	O
summarizes	O
recent	O
progress	O
that	O
has	O
been	O
made	O
in	O
understanding	O
the	O
complex	O
interplay	O
between	O
viral	O
and	O
co	O
-	O
opted	O
cellular	O
factors	O
in	O
biogenesis	B-PROC
and	O
maintenance	O
of	O
plus	O
-	O
strand	O
RNA	O
virus	B-PROC
replication	I-PROC
factories	O
.	O

Children	O
below	O
14	O
years	O
of	O
age	O
contribute	O
to	O
approximately	O
42	O
%	O
of	O
all	O
the	O
deaths	B-PROC
.	O

There	O
have	O
been	O
case	O
reports	O
of	O
complications	O
like	O
thrombocytopaenia	O
,	O
cerebral	O
malaria	O
,	O
a	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
hepatic	O
dysfunction	O
and	O
renal	O
involvement	O
.	O

Although	O
parasites	O
were	O
cleared	O
off	O
the	O
circulation	B-PROC
,	O
the	O
patient	O
'	O
s	O
condition	O
worsened	O
.	O

In	O
around	O
80	O
%	O
of	O
cases	O
,	O
NMO	O
is	O
caused	O
by	O
autoantibodies	O
to	O
astrocytic	O
aquaporin	B-PROC
-	O
4	O
(	O
AQP4	O
),	O
the	O
most	O
abundant	O
water	O
channel	O
in	O
the	O
CNS	O
.	O

An	O
increase	O
in	O
AQP4	O
membrane	O
expression	B-PROC
during	O
acute	O
NMO	O
attacks	O
could	O
potentially	O
enhance	O
the	O
complement	O
-	O
mediated	O
humoral	B-PROC
immune	I-PROC
reaction	I-PROC
against	O
AQP4	O
-	O
expressing	O
astrocytes	O
characteristic	O
for	O
NMO	O
and	O
,	O
thus	O
,	O
result	O
in	O
more	O
severe	O
astrocytic	O
damage	O
.	O

Finally	O
,	O
increased	O
AQP4	O
expression	B-PROC
could	O
be	O
an	O
independent	O
risk	O
factor	O
in	O
NMO	O
and	O
other	O
forms	O
of	O
CNS	O
inflammation	O
,	O
as	O
indicated	O
by	O
the	O
finding	O
of	O
grossly	O
attenuated	O
experimental	O
autoimmune	O
encephalomyelitis	O
in	O
AQP4	O
-	O
null	O
mice	O
.	O

Several	O
coronavirus	O
accessory	O
genes	O
play	O
a	O
central	O
role	O
in	O
these	O
pathways	B-PROC
,	O
but	O
for	O
feline	O
coronaviruses	O
this	O
has	O
never	O
to	O
our	O
knowledge	O
been	O
studied	O
.	O

TITLE	O
:	O
Bedside	O
selection	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
aimed	O
to	O
determine	O
which	O
bedside	O
method	O
would	O
provide	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
better	O
related	O
to	O
lung	O
recruitability	O
.	O

Virus	O
production	O
in	O
cell	O
culture	O
was	O
confirmed	O
by	O
PEDV	O
-	O
specific	O
real	O
-	O
time	O
reverse	O
-	O
transcription	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
immunofluorescence	O
assays	O
,	O
and	O
electron	O
microscopy	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
NF	O
-	O
κB	O
-	O
mediated	O
inflammation	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
-	O
infected	O
mice	O
increases	O
survival	O
.	O

We	O
recommend	O
that	O
primary	O
care	O
physicians	O
refer	O
patients	O
promptly	O
to	O
an	O
asthma	O
specialist	O
for	O
consultation	O
to	O
reduce	O
the	O
frequency	O
of	O
acute	O
exacerbations	O
and	O
prevent	O
the	O
development	B-PROC
of	O
CAS	O
.	O

Patients	O
with	O
ARDS	O
receiving	O
mechanical	O
ventilation	O
should	O
receive	O
lung	O
-	O
protective	O
ventilation	O
,	O
whereby	O
tidal	O
volume	O
is	O
decreased	O
to	O
6	O
ml	O
/	O
kg	O
of	O
their	O
predicted	O
weight	O
and	O
distending	O
pressures	O
are	O
maintained	O
≤	O
30	O
cm	O
H2	O
O	O
,	O
as	O
well	O
as	O
increased	O
inspired	B-PROC
oxygen	O
concentrations	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
to	O
prevent	O
atelectasis	O
and	O
support	O
oxygenation	B-PROC
.	O

While	O
much	O
attention	O
is	O
devoted	O
to	O
these	O
strategies	O
,	O
clinicians	O
must	O
not	O
lose	O
sight	B-PROC
of	O
simple	O
interventions	O
that	O
affect	O
patient	O
outcomes	O
including	O
head	O
of	O
bed	O
elevation	O
,	O
prophylaxis	O
against	O
venous	O
thromboembolism	O
and	O
gastrointestinal	O
bleeding	O
,	O
judicious	O
use	O
of	O
fluids	O
in	O
the	O
post	O
-	O
resuscitative	O
phase	O
,	O
and	O
a	O
protocol	O
-	O
based	O
approach	O
to	O
sedation	O
and	O
spontaneous	O
breathing	B-PROC
trials	O
.	O

ABSTRACT	O
:	O
The	O
value	O
of	O
adjunctive	O
immunomodulatory	O
therapies	O
in	O
treating	O
severe	O
influenza	O
and	O
other	O
respiratory	O
viral	B-PROC
infections	I-PROC
remains	O
uncertain	O
.	O

Although	O
often	O
used	O
,	O
systemic	O
corticosteroids	O
may	O
increase	O
the	O
risk	O
of	O
mortality	O
and	O
morbidity	O
(	O
e	O
.	O
g	O
.	O
secondary	O
infections	O
)	O
in	O
severe	O
influenza	O
and	O
other	O
viral	B-PROC
infections	I-PROC
,	O
especially	O
if	O
there	O
is	O
delay	O
or	O
lack	O
of	O
effective	O
antiviral	O
therapy	O
.	O

Animal	O
models	O
for	O
MERS	O
-	O
CoV	O
infection	O
of	O
humans	O
are	O
needed	O
to	O
elucidate	O
MERS	O
pathogenesis	B-PROC
and	O
to	O
develop	O
vaccines	O
and	O
antivirals	O
.	O

The	O
infected	O
monkeys	O
showed	O
clinical	O
signs	O
of	O
disease	O
,	O
virus	B-PROC
replication	I-PROC
,	O
histological	O
lesions	O
,	O
and	O
neutralizing	O
antibody	B-PROC
production	I-PROC
,	O
indicating	O
that	O
this	O
monkey	O
model	O
is	O
suitable	O
for	O
studies	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
roles	O
and	O
regulation	B-PROC
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
TGEV	O
-	O
activated	O
apoptotic	O
signaling	B-PROC
.	O

Furthermore	O
,	O
the	O
two	O
scavengers	O
significantly	O
inhibited	O
the	O
activation	O
of	O
p38	O
MAPK	O
and	O
p53	O
and	O
further	O
blocked	O
apoptosis	B-PROC
occurrence	O
through	O
suppressing	O
the	O
TGEV	O
-	O
induced	O
Bcl	O
-	O
2	O
reduction	O
,	O
Bax	O
redistribution	O
,	O
cytochrome	B-PROC
c	I-PROC
release	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

Here	O
,	O
we	O
show	O
that	O
arginine	O
and	O
lysine	O
residues	O
within	O
ACE2	O
amino	O
acids	O
697	O
to	O
716	O
are	O
essential	O
for	O
cleavage	B-PROC
by	O
TMPRSS2	O
and	O
HAT	O
and	O
that	O
ACE2	O
processing	O
is	O
required	O
for	O
augmentation	O
of	O
SARS	O
-	O
S	O
-	O
driven	O
entry	O
by	O
these	O
proteases	O
.	O

Expression	B-PROC
of	O
TMPRSS2	O
increased	O
cellular	O
uptake	O
of	O
soluble	O
SARS	O
-	O
S	O
,	O
suggesting	O
that	O
protease	O
-	O
dependent	O
augmentation	O
of	O
viral	O
entry	O
might	O
be	O
due	O
to	O
increased	O
uptake	O
of	O
virions	O
into	O
target	O
cells	O
.	O

This	O
novel	O
action	O
of	O
memantine	O
on	O
viral	B-PROC
replication	I-PROC
strongly	O
suggests	O
that	O
it	O
could	O
be	O
used	O
as	O
an	O
antiviral	O
agent	O
to	O
directly	O
limit	O
viral	B-PROC
replication	I-PROC
while	O
improving	O
neurological	O
symptoms	O
in	O
various	O
neurological	O
diseases	O
with	O
a	O
viral	O
involvement	O
.	O

We	O
herein	O
report	O
a	O
case	O
of	O
LAS	O
,	O
which	O
developed	O
after	O
a	O
transient	O
hypoxic	O
event	O
without	O
an	O
overt	O
cardiac	O
arrest	O
due	O
to	O
hematoma	O
formation	B-PROC
in	O
the	O
neck	O
after	O
partial	O
glossectomy	O
.	O

Hemorheological	O
disorder	O
in	O
the	O
form	O
of	O
hyperviscosity	O
syndrome	O
has	O
been	O
detected	O
in	O
all	O
patients	O
with	O
severe	O
forms	O
of	O
acute	O
respiratory	O
viral	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
poly	O
(	O
adenosine	O
diphosphate	O
-	O
ribose	O
)	O
polymerase	O
attenuates	O
lung	O
-	O
kidney	O
crosstalk	B-PROC
induced	O
by	O
intratracheal	O
lipopolysaccharide	O
instillation	O
in	O
rats	O
.	O

All	O
of	O
these	O
effects	O
were	O
associated	O
with	O
strong	O
expression	B-PROC
of	O
PARP	O
and	O
NF	O
-	O
κB	O
.	O
Treatment	O
with	O
3	O
-	O
AB	O
prevented	O
the	O
LPS	O
-	O
induced	O
metabolic	B-PROC
acidosis	O
and	O
hypotension	O
,	O
reduced	O
the	O
plasma	O
levels	O
of	O
lactate	O
,	O
creatinine	O
and	O
potassium	O
,	O
reduced	O
the	O
cytokine	O
mRNA	O
expressions	O
,	O
reduced	O
the	O
expression	B-PROC
of	O
PARP	O
and	O
NF	O
-	O
κB	O
,	O
improved	O
pulmonary	O
edema	O
and	O
oxygenation	B-PROC
and	O
preserved	O
renal	B-PROC
function	I-PROC
.	O

RESULTS	O
:	O
LPS	O
induced	O
metabolic	B-PROC
acidosis	O
,	O
hypotension	O
,	O
hypoxemia	O
,	O
increased	O
the	O
lung	O
wet	O
/	O
dry	O
ratio	O
,	O
increased	O
the	O
plasma	O
levels	O
of	O
creatinine	O
and	O
potassium	O
,	O
and	O
increased	O
the	O
cytokine	O
mRNA	O
expressions	O
in	O
the	O
lung	O
and	O
kidney	O
.	O

Etiology	O
,	O
clinical	O
disease	O
,	O
pathogenesis	B-PROC
,	O
and	O
epidemiology	O
are	O
described	O
for	O
each	O
pathogen	O
,	O
with	O
an	O
emphasis	O
on	O
recent	O
discoveries	O
or	O
novel	O
findings	O
.	O

A	O
recruitment	O
maneuver	O
and	O
CPAP	O
valve	O
may	O
be	O
used	O
in	O
severe	O
ARDS	O
for	O
safe	O
apnea	O
testing	O
in	O
brain	O
death	B-PROC
determination	O
.	O

RESULTS	O
:	O
During	O
brain	O
death	B-PROC
examination	O
,	O
despite	O
meeting	O
criteria	O
for	O
severe	O
ARDS	O
,	O
apnea	O
testing	O
was	O
successfully	O
completed	O
with	O
the	O
use	O
of	O
a	O
pretest	O
recruitment	O
maneuver	O
and	O
20	O
cm	O
H	O
(	O
2	O
)	O
O	O
CPAP	O
valve	O
.	O

ABSTRACT	O
:	O
The	O
biosynthesis	B-PROC
of	O
fusion	O
-	O
competent	O
envelope	O
glycoproteins	O
(	O
GPs	O
)	O
is	O
a	O
crucial	O
step	O
in	O
productive	O
viral	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
VV	O
-	O
ECMO	O
)	O
is	O
an	O
effective	O
rescue	O
therapy	O
for	O
improving	O
oxygenation	B-PROC
in	O
selected	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

CONCLUSIONS	O
:	O
PP	O
may	O
be	O
considered	O
in	O
selected	O
patients	O
difficult	O
to	O
wean	B-PROC
or	O
remaining	O
very	O
hypoxemic	O
despite	O
VV	O
-	O
ECMO	O
support	O
.	O

Adenosine	O
deaminase	O
(	O
ADA	O
),	O
a	O
DPP4	O
binding	O
protein	O
,	O
competed	O
for	O
virus	O
binding	O
,	O
acting	O
as	O
a	O
natural	O
antagonist	B-PROC
for	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
significant	O
and	O
strong	O
relationship	O
between	O
actual	O
results	O
and	O
forecast	O
is	O
encouraging	O
for	O
the	O
potential	O
development	B-PROC
of	O
an	O
early	O
warning	O
system	O
for	O
detecting	O
this	O
type	O
of	O
disease	O
outbreaks	O
.	O

The	O
following	O
article	O
reviews	O
the	O
current	O
knowledge	O
on	O
the	O
effects	O
of	O
SCD	O
on	O
lung	B-PROC
growth	B-PROC
and	O
function	O
.	O

Public	O
health	O
research	O
and	O
prevention	O
in	O
India	O
should	O
consider	O
targeting	B-PROC
RSV	O
and	O
influenza	O
in	O
young	O
children	O
.	O

RESULTS	O
:	O
Of	O
245	O
hospitalized	O
children	O
,	O
respiratory	O
viruses	O
were	O
detected	O
among	O
98	O
(	O
40	O
%),	O
of	O
whom	O
92	O
(	O
94	O
%)	O
had	O
fever	B-PROC
or	O
respiratory	O
symptoms	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
to	O
document	O
the	O
long	O
-	O
term	O
effects	O
of	O
severe	O
H1N1	O
infection	O
requiring	O
high	O
frequency	O
oscillation	O
on	O
respiratory	B-PROC
function	I-PROC
.	O

Our	O
results	O
show	O
that	O
TCoV	O
infection	O
can	O
affect	O
the	O
reproductive	B-PROC
performance	O
in	O
turkey	O
hens	O
,	O
causing	O
a	O
transient	O
drop	O
in	O
egg	O
production	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
strategies	O
aimed	O
at	O
either	O
enhancing	O
ATP	B-PROC
catabolism	B-PROC
(	O
ip	O
ecto	O
-	O
5	O
'-	O
nucleotidase	O
administration	O
)	O
or	O
inhibiting	O
glycolytic	O
ATP	O
production	O
(	O
ip	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
glucose	O
treatment	O
)	O
reduce	O
extracellular	O
ATP	O
accumulation	O
,	O
limit	O
vascular	O
leakage	O
,	O
and	O
effectively	O
block	O
the	O
late	O
,	O
but	O
not	O
the	O
early	O
,	O
stages	O
of	O
neutrophil	B-PROC
recruitment	I-PROC
to	O
the	O
lung	O
after	O
LPS	O
instillation	O
.	O

TITLE	O
:	O
AVPdb	O
:	O
a	O
database	O
of	O
experimentally	O
validated	O
antiviral	O
peptides	O
targeting	B-PROC
medically	O
important	O
viruses	O
.	O

Therefore	O
,	O
we	O
have	O
developed	O
AVPdb	O
,	O
available	O
online	O
at	O
http	O
://	O
crdd	O
.	O
osdd	O
.	O
net	O
/	O
servers	O
/	O
avpdb	O
,	O
to	O
provide	O
a	O
dedicated	O
resource	O
of	O
experimentally	O
verified	O
AVPs	O
targeting	B-PROC
over	O
60	O
medically	O
important	O
viruses	O
including	O
Influenza	O
,	O
HCV	O
,	O
HSV	O
,	O
RSV	O
,	O
HBV	O
,	O
DENV	O
,	O
SARS	O
,	O
etc	O
.	O

Additionally	O
,	O
aptamers	O
can	O
potentially	O
bind	O
any	O
targets	O
and	O
any	O
pathogen	O
that	O
is	O
theoretically	O
amenable	O
to	O
rapid	O
targeting	B-PROC
,	O
making	O
aptamers	O
invaluable	O
tools	O
for	O
treating	O
a	O
wide	O
range	O
of	O
diseases	O
.	O

ABSTRACT	O
:	O
A	O
previous	O
randomized	O
study	O
showed	O
that	O
clarithromycin	O
decreases	O
the	O
risk	O
of	O
death	B-PROC
due	O
to	O
ventilator	O
-	O
associated	O
pneumonia	O
and	O
shortens	O
the	O
time	O
until	O
infection	O
resolution	O
.	O

ABSTRACT	O
:	O
The	O
identification	O
of	O
pathogens	O
of	O
viral	O
(	O
Rotavirus	O
,	O
Coronavirus	O
),	O
parasitic	O
(	O
Toxocara	O
spp	O
.)	O
and	O
bacterial	O
(	O
Escherichia	O
coli	O
,	O
Salmonella	O
spp	O
.,	O
Rhodococcus	O
equi	O
)	O
origin	O
shed	O
in	O
feces	O
,	O
and	O
the	O
virulence	B-PROC
profile	O
of	O
R	O
.	O
equi	O
and	O
E	O
.	O
coli	O
isolates	O
were	O
investigated	O
in	O
200	O
samples	O
of	O
sand	O
obtained	O
from	O
40	O
parks	O
,	O
located	O
in	O
central	O
region	O
of	O
state	O
of	O
Sao	O
Paulo	O
,	O
Brazil	O
,	O
using	O
different	O
diagnostic	O
methods	O
.	O

The	O
following	O
genes	O
encoding	O
virulence	B-PROC
factors	O
were	O
identified	O
in	O
E	O
.	O
coli	O
:	O
eae	O
,	O
bfp	O
,	O
saa	O
,	O
iucD	O
,	O
papGI	O
,	O
sfa	O
and	O
hly	O
.	O

Scoring	O
systems	O
have	O
been	O
developed	O
in	O
an	O
effort	B-PROC
to	O
quantify	O
the	O
severity	O
of	O
lung	O
injury	O
,	O
with	O
the	O
most	O
recent	O
being	O
the	O
Berlin	O
Definition	O
.	O

Our	O
results	O
show	O
that	O
field	O
IBVs	O
in	O
China	O
are	O
continuing	O
to	O
evolve	O
and	O
vaccine	O
strains	O
may	O
have	O
an	O
important	O
role	O
in	O
the	O
appearance	O
of	O
new	O
IBV	O
strains	O
via	O
recombination	B-PROC
.	O

CQCQD	O
could	O
decrease	O
the	O
serum	O
MMP	O
-	O
9	O
to	O
relieve	O
the	O
severity	O
of	O
clinical	O
symptoms	O
and	O
prevent	O
the	O
development	B-PROC
of	O
multiple	O
organ	O
dysfunction	O
syndrome	O
in	O
patients	O
with	O
SAP	O
.	O

All	O
patients	O
died	B-PROC
on	O
day	O
7	O
to	O
day	O
86	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

All	O
patients	O
died	B-PROC
on	O
day	O
7	O
to	O
day	O
86	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

TITLE	O
:	O
Dendritic	O
cell	O
-	O
specific	O
delivery	O
of	O
Flt3L	O
by	O
coronavirus	O
vectors	O
secures	O
induction	O
of	O
therapeutic	O
antitumor	O
immunity	B-PROC
.	O

The	O
results	O
demonstrated	O
that	O
peptide	O
(	O
FP5	O
)	O
at	O
concentrations	O
below	O
20	O
μM	O
inhibited	O
viral	B-PROC
replication	I-PROC
by	O
up	O
to	O
97	O
%.	O

By	O
analyzing	O
the	O
ability	O
of	O
recombinantly	O
expressed	B-PROC
chimeric	O
and	O
truncated	O
spike	O
proteins	O
to	O
bind	O
to	O
chicken	O
tissues	O
,	O
we	O
demonstrate	O
that	O
the	O
N	O
-	O
terminal	O
253	O
amino	O
acids	O
of	O
the	O
spike	O
are	O
both	O
required	O
and	O
sufficient	O
for	O
binding	O
to	O
chicken	O
respiratory	O
tract	O
in	O
an	O
α	O
-	O
2	O
,	O
3	O
-	O
sialic	O
acid	O
-	O
dependent	O
manner	O
.	O

3CL	O
(	O
pro	O
)	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
viral	B-PROC
replication	I-PROC
cycle	I-PROC
and	O
is	O
a	O
potential	O
target	O
for	O
SARS	O
inhibitor	O
development	B-PROC
.	O

In	O
contrast	O
,	O
MPA	O
showed	O
strong	O
inhibition	B-PROC
,	O
with	O
an	O
IC₅₀	O
of	O
2	O
.	O
87	O
µM	O
.	O
This	O
drug	O
has	O
not	O
been	O
previously	O
tested	O
against	O
MERS	O
-	O
CoV	O
and	O
may	O
provide	O
an	O
alternative	O
to	O
ribavirin	O
for	O
treatment	O
of	O
MERS	O
-	O
CoV	O
.	O
In	O
conclusion	O
,	O
IFN	O
-	O
β	O
,	O
MPA	O
or	O
a	O
combination	O
of	O
the	O
two	O
may	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
MERS	O
-	O
CoV	O
or	O
as	O
a	O
post	O
-	O
exposure	O
intervention	O
in	O
high	O
-	O
risk	O
patients	O
with	O
known	O
exposures	O
to	O
MERS	O
-	O
CoV	O
.	O

Development	B-PROC
of	O
effective	O
therapeutics	O
and	O
vaccines	O
is	O
crucial	O
to	O
save	O
lives	O
and	O
halt	O
the	O
spread	O
of	O
MERS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
show	O
that	O
a	O
recombinant	O
protein	O
containing	O
a	O
212	O
-	O
amino	O
acid	O
fragment	O
(	O
residues	O
377	O
-	O
588	O
)	O
in	O
the	O
truncated	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
:	O
residues	O
367	O
-	O
606	O
)	O
of	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
fused	O
with	O
human	O
IgG	O
Fc	O
fragment	O
(	O
S377	O
-	O
588	O
-	O
Fc	O
)	O
is	O
highly	O
expressed	B-PROC
in	O
the	O
culture	O
supernatant	O
of	O
transfected	O
293T	O
cells	O
.	O

An	O
emerging	O
theme	O
is	O
that	O
polymorphisms	B-PROC
in	O
the	O
genes	O
encoding	O
these	O
factors	O
can	O
influence	O
the	O
host	B-PROC
response	I-PROC
to	O
infection	O
and	O
the	O
course	O
of	O
disease	O
.	O

TITLE	O
:	O
VIRsiRNApred	O
:	O
a	O
web	O
server	O
for	O
predicting	O
inhibition	B-PROC
efficacy	O
of	O
siRNAs	O
targeting	B-PROC
human	O
viruses	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
employed	O
a	O
new	O
dataset	O
of	O
1725	O
viral	O
siRNAs	O
with	O
experimentally	O
verified	O
quantitative	O
efficacies	O
tested	O
under	O
heterogeneous	O
experimental	O
conditions	O
and	O
targeting	B-PROC
as	O
many	O
as	O
37	O
important	O
human	O
viruses	O
including	O
HIV	O
,	O
Influenza	O
,	O
HCV	O
,	O
HBV	O
,	O
SARS	O
etc	O
.	O

Important	O
siRNA	O
sequence	O
features	O
including	O
mono	O
to	O
penta	O
nucleotide	O
frequencies	O
,	O
binary	O
pattern	O
,	O
thermodynamic	O
properties	O
and	O
secondary	O
structure	O
were	O
employed	O
for	O
model	O
development	B-PROC
.	O

VIRsiRNApred	O
is	O
the	O
first	O
algorithm	O
for	O
predicting	O
inhibition	B-PROC
efficacy	O
of	O
viral	O
siRNAs	O
which	O
is	O
developed	O
using	O
experimentally	O
verified	O
viral	O
siRNAs	O
.	O

CONCLUSIONS	O
:	O
VIRsiRNApred	O
is	O
the	O
first	O
algorithm	O
for	O
predicting	O
inhibition	B-PROC
efficacy	O
of	O
viral	O
siRNAs	O
which	O
is	O
developed	O
using	O
experimentally	O
verified	O
viral	O
siRNAs	O
.	O

TITLE	O
:	O
A	O
genome	O
-	O
wide	O
association	O
study	O
identifies	O
major	O
loci	O
affecting	O
the	O
immune	B-PROC
response	I-PROC
against	O
infectious	O
bronchitis	O
virus	O
in	O
chicken	O
.	O

ABSTRACT	O
:	O
Severe	O
sepsis	O
is	O
a	O
leading	O
cause	O
of	O
death	B-PROC
in	O
the	O
United	O
States	O
and	O
the	O
most	O
common	O
cause	O
of	O
death	B-PROC
among	O
critically	O
ill	O
patients	O
in	O
non	O
-	O
coronary	O
intensive	O
care	O
units	O
(	O
ICU	O
).	O

New	O
modes	O
of	O
assisted	O
mechanical	O
ventilation	O
with	O
improved	O
patient	O
ventilator	O
interaction	O
and	O
enhanced	O
variability	O
of	O
the	O
respiratory	O
pattern	O
offer	O
additional	O
benefit	O
on	O
lung	B-PROC
function	I-PROC
and	O
damage	O
.	O

FiO	O
(	O
2	O
)	O
level	O
independently	O
predicted	O
outcome	O
in	O
infants	O
with	O
RSV	O
-	O
induced	O
ARDS	O
,	O
whereas	O
both	O
PEEP	O
and	O
the	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
did	O
not	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
found	O
that	O
an	O
intraleader	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
in	O
genomic	O
and	O
subgenomic	O
mRNA	O
(	O
sgmRNA	O
)	O
molecules	O
is	O
selected	O
during	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
persistence	O
which	O
leads	O
to	O
translation	B-PROC
attenuation	O
of	O
the	O
downstream	O
ORF	O
.	O

We	O
tested	O
swabs	O
with	O
RT	O
-	O
PCR	O
,	O
with	O
amplification	O
targeting	B-PROC
the	O
E	O
gene	O
(	O
upE	O
),	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
,	O
and	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1a	O
.	O

More	O
importantly	O
,	O
RBD219	O
-	O
N1	O
induced	O
significantly	O
stronger	O
RBD	O
-	O
specific	O
antibody	B-PROC
responses	I-PROC
and	O
a	O
higher	O
level	O
of	O
neutralizing	O
antibodies	O
in	O
immunized	O
mice	O
than	O
RBD193	O
-	O
WT	O
,	O
RBD193	O
-	O
N1	O
,	O
RBD193	O
-	O
N3	O
,	O
or	O
RBD219	O
-	O
WT	O
.	O

Histopathological	O
observations	O
confirmed	O
the	O
nephritis	O
and	O
described	O
an	O
unusual	O
erosive	O
/	O
necrotic	B-PROC
proventriculitis	O
with	O
infiltration	O
of	O
lymphocytes	O
,	O
plasma	O
cells	O
and	O
heterophils	O
,	O
as	O
well	O
as	O
fibroplasia	O
in	O
the	O
lamina	O
propria	O
.	O

Despite	O
these	O
findings	O
and	O
the	O
isolation	O
of	O
the	O
Q1	O
IB	O
virus	O
directly	O
from	O
proventricular	O
tissue	O
,	O
further	O
studies	O
are	O
necessary	O
to	O
confirm	O
the	O
role	O
of	O
this	O
IBV	O
strain	O
in	O
the	O
development	B-PROC
of	O
proventricular	O
lesions	O
.	O

The	O
balance	B-PROC
between	O
inflammatory	O
mediators	O
is	O
key	O
for	O
the	O
outcome	O
of	O
the	O
pulmonary	O
infection	O
;	O
elimination	B-PROC
of	O
invading	O
pathogen	O
was	O
marked	O
by	O
the	O
release	O
of	O
cytokines	O
and	O
other	O
inflammatory	O
mediators	O
from	O
alveolar	O
macrophages	O
and	O
glucocorticoid	O
steroids	O
(	O
GCs	O
)	O
acting	O
on	O
the	O
inflammatory	O
component	O
.	O

Compared	O
with	O
patients	O
with	O
the	O
rs12252	O
-	O
T	O
/	O
T	O
or	O
rs12252	O
-	O
T	O
/	O
C	O
genotype	O
of	O
IFITM3	O
,	O
patients	O
with	O
the	O
C	O
/	O
C	O
genotype	O
had	O
a	O
shorter	O
time	O
from	O
disease	O
onset	O
to	O
the	O
time	O
point	O
when	O
they	O
sought	O
medical	O
aid	O
(	O
hospital	O
admission	O
or	O
antiviral	O
therapy	O
)	O
and	O
a	O
shorter	O
interval	O
to	O
development	B-PROC
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
stage	O
(	O
reflected	O
by	O
shorter	O
intervals	O
between	O
clinical	O
onset	O
and	O
methylprednisolone	O
treatments	O
and	O
higher	O
rates	O
of	O
mechanical	O
ventilator	O
use	O
),	O
as	O
well	O
as	O
experiencing	O
elevated	O
/	O
prolonged	O
lung	O
virus	O
titers	O
and	O
cytokine	B-PROC
production	I-PROC
and	O
higher	O
mortality	O
.	O

TITLE	O
:	O
Acute	O
effects	O
of	O
autoadjusting	O
and	O
fixed	O
continuous	O
positive	O
airway	O
pressure	O
treatments	O
on	O
cardiorespiratory	O
coupling	O
in	O
obese	O
patients	O
with	O
obstructive	O
sleep	B-PROC
apnea	O
.	O

RESULTS	O
:	O
In	O
CPAP	O
and	O
CON	O
,	O
LFnu	O
and	O
LF	O
/	O
HF	O
,	O
markers	O
of	O
sympathetic	O
modulation	O
,	O
decreased	O
from	O
N2	O
to	O
N3	O
and	O
increased	O
during	O
REM	B-PROC
sleep	B-PROC
(	O
p	O
<	O
0	O
.	O
001	O
),	O
while	O
in	O
APAP	O
group	O
,	O
sympathetic	O
modulation	O
was	O
significantly	O
higher	O
compared	O
with	O
those	O
of	O
CPAP	O
and	O
CON	O
during	O
all	O
sleep	B-PROC
stages	I-PROC
.	O

The	O
results	O
of	O
nuclear	O
magnetic	O
resonance	O
and	O
HNE	O
inhibition	B-PROC
kinetic	O
analysis	O
showed	O
that	O
the	O
pentacyclic	O
triterpenes	O
competitively	O
and	O
reversibly	O
inhibited	O
HNE	O
.	O

Our	O
results	O
provide	O
insights	O
into	O
the	O
effects	O
of	O
pentacyclic	O
triterpenes	O
on	O
lung	O
inflammatory	O
actions	O
through	O
reversible	O
inhibition	B-PROC
of	O
HNE	O
activity	O
.	O

FJU	O
-	O
C4	O
prolongs	O
mouse	O
survival	O
and	O
prevents	O
mouse	O
death	B-PROC
from	O
LPS	O
-	O
induced	O
systemic	O
inflammation	O
when	O
the	O
dose	O
of	O
FJU	O
-	O
C4	O
is	O
over	O
5	O
mg	O
/	O
kg	O
.	O

Coagulation	B-PROC
studies	O
revealed	O
lupus	O
anticoagulant	O
.	O

Further	O
non	O
-	O
invasive	O
ventilation	O
can	O
successfully	O
support	O
the	O
weaning	B-PROC
after	O
a	O
long	O
-	O
lasting	O
ventilation	O
therapy	O
and	O
improve	O
the	O
prognosis	O
of	O
COPD	O
patients	O
.	O

Primary	O
outcomes	O
were	O
change	O
in	O
,	O
and	O
prevalence	O
of	O
,	O
metabolic	B-PROC
syndrome	O
score	O
at	O
follow	O
-	O
up	O
(	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]).	O

We	O
observed	O
a	O
significant	O
decrease	O
in	O
metabolic	B-PROC
syndrome	O
scores	O
(	O
P	O
for	O
trend	O
=	O
0	O
.	O
003	O
)	O
for	O
AER	O
(-	O
0	O
.	O
59	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
-	O
0	O
.	O
21	O
)	O
and	O
AER	O
+	O
RES	O
(-	O
0	O
.	O
79	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
40	O
to	O
-	O
0	O
.	O
35	O
),	O
both	O
being	O
significant	O
(	O
P	O
≤	O
0	O
.	O
02	O
)	O
versus	O
control	O
(	O
0	O
.	O
26	O
,	O
95	O
%	O
CI	O
=	O
-	O
0	O
.	O
58	O
to	O
0	O
.	O
40	O
)	O
and	O
RES	O
(-	O
0	O
.	O
13	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
0	O
.	O
24	O
).	O

Genotypes	O
HKU1	O
A	O
and	O
B	O
were	O
both	O
isolated	O
from	O
clinical	O
specimens	O
and	O
propagated	O
on	O
primary	O
human	O
tracheal	O
-	O
bronchial	O
epithelial	O
cells	O
cultured	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
and	O
were	O
neutralized	O
in	O
vitro	O
by	O
human	O
intravenous	O
immunoglobulin	B-PROC
and	O
by	O
polyclonal	O
rabbit	O
antibodies	O
to	O
the	O
spike	O
glycoprotein	O
of	O
HKU1	O
.	O

TITLE	O
:	O
Cytokine	O
levels	O
(	O
IL	O
-	O
4	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
TGFβ	O
)	O
as	O
potential	O
biomarkers	O
of	O
systemic	O
inflammatory	B-PROC
response	I-PROC
in	O
trauma	O
patients	O
.	O

High	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
1β	O
,-	O
6	O
,-	O
8	O
,-	O
12	O
,	O
tumour	O
necrosis	B-PROC
factor	O
alpha	O
and	O
interferon	O
gamma	O
were	O
found	O
in	O
all	O
injured	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

RESULTS	O
:	O
High	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
1β	O
,-	O
6	O
,-	O
8	O
,-	O
12	O
,	O
tumour	O
necrosis	B-PROC
factor	O
alpha	O
and	O
interferon	O
gamma	O
were	O
found	O
in	O
all	O
injured	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

Kounis	O
Hypersensitivity	B-PROC
-	O
Associated	O
Syndrome	O
Seems	O
to	O
be	O
the	O
Primary	O
Cause	O
.	O

Combined	O
tissue	O
suppression	B-PROC
from	O
arterial	O
involvement	O
and	O
peripheral	O
vasodilatation	B-PROC
,	O
perhaps	O
,	O
occur	O
simultaneously	O
.	O

ABSTRACT	O
:	O
A	O
higher	O
prevalence	O
of	O
periodontal	O
disease	O
has	O
been	O
reported	O
in	O
patients	O
with	O
obstructive	O
sleep	B-PROC
apnea	O
syndrome	O
(	O
OSAS	O
),	O
and	O
these	O
two	O
chronic	O
conditions	O
may	O
be	O
linked	O
via	O
inflammatory	O
pathways	B-PROC
.	O

Transmembrane	O
serine	O
protease	O
TMPRSS2	O
catalyzed	O
the	O
cleavage	B-PROC
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
,	O
but	O
not	O
the	O
counterpart	O
in	O
HCoV	O
-	O
HKU1	O
.	O

SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
HKU1	O
S	O
proteins	O
use	O
distinct	O
UPR	O
-	O
activating	O
domains	O
to	O
exert	B-PROC
the	O
same	O
modulatory	O
effects	O
on	O
UPR	O
signaling	B-PROC
.	O

To	O
evaluate	O
the	O
effect	O
of	O
extracts	O
of	O
Ah	O
,	O
Ns	O
and	O
Cs	O
on	O
the	O
replication	O
of	O
coronavirus	O
(	O
CoV	O
)	O
and	O
on	O
the	O
expression	B-PROC
of	O
TRP	O
genes	O
during	O
coronavirus	O
infection	O
,	O
HeLa	O
-	O
CEACAM1a	O
(	O
HeLa	O
-	O
epithelial	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecule	O
1a	O
)	O
cells	O
were	O
inoculated	O
with	O
MHV	O
-	O
A59	O
(	O
mouse	O
hepatitis	O
virus	O
-	O
A59	O
)	O
at	O
moi	O
of	O
30	O
.	O

TITLE	O
:	O
T	O
cell	O
mediated	O
suppression	B-PROC
of	O
neurotropic	O
coronavirus	O
replication	O
in	O
neural	O
precursor	O
cells	O
.	O

ABSTRACT	O
:	O
Neural	O
precursor	O
cells	O
(	O
NPCs	O
)	O
are	O
the	O
subject	O
of	O
intense	O
investigation	O
for	O
their	O
potential	O
to	O
treat	O
neurodegenerative	O
disorders	O
,	O
yet	O
the	O
consequences	O
of	O
neuroinvasive	O
virus	B-PROC
infection	I-PROC
of	O
NPCs	O
remain	O
unclear	O
.	O

Importantly	O
,	O
cytokines	O
secreted	B-PROC
by	O
CD4	O
+	O
T	O
cells	O
inhibit	O
JHMV	O
replication	O
in	O
NPCs	O
,	O
and	O
CD8	O
+	O
T	O
cells	O
specifically	O
target	O
viral	O
peptide	O
-	O
pulsed	O
NPCs	O
for	O
lysis	B-PROC
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
T	O
cells	O
play	O
a	O
critical	O
role	O
in	O
controlling	O
replication	O
of	O
a	O
neurotropic	O
virus	O
in	O
NPCs	O
,	O
a	O
finding	O
which	O
has	O
important	O
implications	O
when	O
considering	O
immune	B-PROC
modulation	I-PROC
for	O
NPC	O
-	O
based	O
therapies	O
for	O
treatment	O
of	O
human	O
neurologic	O
diseases	O
.	O

Our	O
results	O
suggest	O
that	O
BST2	O
exerts	B-PROC
a	O
broad	O
blocking	O
effect	O
against	O
enveloped	O
virus	O
release	O
,	O
regardless	O
of	O
whether	O
budding	B-PROC
occurs	O
at	O
the	O
plasma	O
membrane	O
or	O
intracellular	O
compartments	O
.	O

Using	O
this	O
data	O
set	O
,	O
independent	O
co	O
-	O
expression	B-PROC
networks	O
were	O
built	O
.	O

ABSTRACT	O
:	O
Aluminium	O
phosphide	O
(	O
AlP	O
)	O
is	O
a	O
highly	O
toxic	O
pesticide	O
that	O
inhibits	O
cytochrome	B-PROC
oxidase	O
c	O
and	O
causes	O
oxidative	O
stress	O
.	O

ABSTRACT	O
:	O
Programmed	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
(-	O
1	O
PRF	O
)	O
stimulated	O
by	O
mRNA	O
pseudoknots	O
regulates	O
gene	B-PROC
expression	I-PROC
in	O
many	O
viruses	O
,	O
making	O
pseudoknots	O
potential	O
targets	O
for	O
anti	O
-	O
viral	O
drugs	O
.	O

Complications	O
included	O
pneumonia	O
in	O
21	O
%,	O
adult	O
respiratory	O
distress	O
syndrome	O
in	O
14	O
%,	O
sepsis	O
in	O
7	O
%,	O
and	O
death	B-PROC
in	O
16	O
%.	O

More	O
than	O
99	O
%	O
of	O
these	O
patients	O
were	O
treated	O
nonoperatively	O
,	O
and	O
only	O
a	O
small	O
proportion	O
(	O
8	O
%)	O
received	O
aggressive	B-PROC
pain	O
management	O
with	O
epidural	O
catheters	O
.	O

The	O
most	O
effective	O
one	O
was	O
the	O
glycoside	O
juglanin	O
(	O
carrying	O
an	O
arabinose	O
residue	O
)	O
with	O
an	O
IC50	O
value	O
of	O
2	O
.	O
3	O
µM	O
for	O
inhibition	B-PROC
of	O
the	O
3a	O
-	O
mediated	O
current	O
.	O

TITLE	O
:	O
Benign	O
prostatic	O
hyperplasia	O
:	O
a	O
new	O
metabolic	B-PROC
disease	O
?	O

In	O
addition	O
,	O
the	O
role	O
of	O
other	O
determinants	O
,	O
such	O
as	O
metabolic	B-PROC
syndrome	O
or	O
prostate	O
inflammation	O
,	O
is	O
emerging	O
.	O

We	O
reviewed	O
the	O
evidence	O
regarding	O
the	O
pathogenesis	B-PROC
of	O
BPH	O
/	O
LUTS	O
with	O
particular	O
attention	O
to	O
metabolic	B-PROC
influence	O
.	O

TITLE	O
:	O
Ocular	B-PROC
manifestations	O
of	O
feline	O
viral	B-PROC
diseases	I-PROC
.	O

Ocular	B-PROC
disease	O
associated	O
with	O
viral	O
pathogens	O
is	O
not	O
unusual	O
,	O
particularly	O
with	O
viruses	O
causing	O
upper	O
respiratory	O
tract	O
disease	O
in	O
cats	O
,	O
such	O
as	O
feline	O
herpesvirus	O
type	O
1	O
and	O
feline	O
calicivirus	O
.	O

Sleep	B-PROC
disturbance	O
correlates	O
poorly	O
with	O
other	O
symptoms	O
of	O
AMS	O
(	O
Mean	O
Spearman	O
correlation	O
0	O
.	O
25	O
).	O

Herein	O
,	O
we	O
experimentally	O
infected	O
SPF	O
pigs	O
using	O
two	O
strains	O
of	O
PRRSV	O
with	O
different	O
pathogenicity	O
and	O
observed	O
the	O
lung	O
pathological	O
changes	O
looking	O
for	O
new	O
sights	O
on	O
the	O
possible	O
pathogenesis	B-PROC
associated	O
with	O
the	O
virulence	B-PROC
of	O
HP	O
-	O
PRRSV	O
.	O

This	O
case	O
series	O
report	O
showed	O
that	O
lung	O
injury	O
and	O
respiratory	O
failure	O
can	O
occur	O
as	O
a	O
result	O
of	O
inhaling	B-PROC
humidifier	O
disinfectants	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
decade	O
,	O
Vietnam	O
has	O
successfully	O
responded	O
to	O
global	O
health	O
security	O
(	O
GHS	O
)	O
challenges	O
,	O
including	O
domestic	O
elimination	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
rapid	O
public	O
health	O
responses	O
to	O
human	O
infections	O
with	O
influenza	O
A	O
(	O
H5N1	O
)	O
virus	O
.	O

For	O
SARS	O
-	O
CoV	O
,	O
the	O
absence	O
of	O
this	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
results	O
in	O
significant	O
attenuation	O
characterized	O
by	O
decreased	O
viral	B-PROC
replication	I-PROC
,	O
reduced	O
weight	O
loss	O
,	O
and	O
limited	O
breathing	B-PROC
dysfunction	O
in	O
mice	O
.	O

Understanding	O
this	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
provided	O
an	O
opportunity	O
to	O
design	O
a	O
successful	O
live	O
-	O
attenuated	O
vaccine	O
for	O
SARS	O
-	O
CoV	O
and	O
opens	O
avenues	O
for	O
treatment	O
and	O
prevention	O
of	O
emerging	O
CoVs	O
and	O
other	O
RNA	O
virus	O
infections	O
.	O

Five	O
patients	O
presented	O
acute	O
respiratory	O
distress	O
at	O
birth	B-PROC
requiring	O
intubation	O
and	O
ventilatory	O
support	O
.	O

Moreover	O
,	O
we	O
showed	O
that	O
the	O
expression	B-PROC
of	O
pulmonary	O
myeloperoxidase	O
(	O
MPO	O
),	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
of	O
endothelial	O
cells	O
and	O
CD11b	O
of	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	B-PROC
)	O
induced	O
by	O
LPS	O
were	O
significantly	O
decreased	O
by	O
PFC	O
treatment	O
in	O
vivo	O
.	O

We	O
developed	O
a	O
novel	O
high	O
-	O
throughput	O
screening	O
assay	O
to	O
identify	O
small	O
molecules	O
that	O
can	O
prevent	O
cathepsin	O
L	O
cleavage	B-PROC
of	O
viral	O
glycoproteins	O
derived	O
from	O
SARS	O
-	O
CoV	O
and	O
Ebola	O
,	O
Hendra	O
,	O
and	O
Nipah	O
viruses	O
that	O
are	O
required	O
for	O
their	O
entry	O
into	O
the	O
host	O
cell	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
has	O
deISGylating	O
and	O
deubiquitinating	B-PROC
activities	O
.	O

Overall	O
these	O
results	O
indicate	O
that	O
the	O
PLpro	O
domains	O
of	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
have	O
the	O
potential	O
to	O
modify	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
to	O
viral	B-PROC
infection	I-PROC
and	O
contribute	O
to	O
viral	O
pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
replicates	O
in	O
the	O
epithelial	O
cells	O
of	O
trachea	O
and	O
lungs	O
of	O
chicken	O
,	O
however	O
the	O
mechanism	O
of	O
generation	O
of	O
innate	B-PROC
immune	I-PROC
response	I-PROC
against	O
IBV	O
infection	O
in	O
these	O
tissues	O
has	O
not	O
been	O
fully	O
characterized	O
.	O

Initiation	O
of	O
the	O
transcription	B-PROC
of	O
selected	O
innate	O
immune	O
genes	O
such	O
as	O
TLR3	O
,	O
TLR7	O
,	O
MyD88	O
,	O
IL	O
-	O
1β	O
and	O
IFN	O
-	O
β	O
,	O
as	O
well	O
as	O
recruitment	O
of	O
macrophages	O
,	O
were	O
evident	O
following	O
an	O
initial	O
down	B-PROC
regulation	B-PROC
of	O
some	O
of	O
the	O
observed	O
genes	O
(	O
TLR3	O
,	O
IL	O
-	O
1β	O
,	O
and	O
IFN	O
-	O
γ	O
)	O
in	O
trachea	O
and	O
lung	O
.	O

Potential	O
induction	O
of	O
innate	B-PROC
immunity	B-PROC
before	O
infection	O
occurs	O
may	O
be	O
necessary	O
to	O
reduce	O
the	O
consequences	O
since	O
vaccine	O
induced	O
immunity	B-PROC
is	O
slow	O
to	O
develop	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
is	O
an	O
artificial	O
means	O
of	O
maintaining	O
adequate	O
oxygenation	B-PROC
and	O
carbon	O
dioxide	O
elimination	B-PROC
to	O
enable	O
injured	O
lungs	O
to	O
recover	B-PROC
from	O
underlying	O
disease	O
.	O

Despite	O
significantly	O
prolonged	O
weaning	B-PROC
off	O
extracorporeal	O
lung	O
support	O
and	O
intensive	O
care	O
unit	O
stay	O
in	O
H1N1	O
patients	O
,	O
the	O
proportion	O
of	O
survivors	O
did	O
not	O
differ	O
significantly	O
.	O

TITLE	O
:	O
Suppression	B-PROC
of	O
innate	O
antiviral	B-PROC
response	I-PROC
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
M	O
protein	O
is	O
mediated	O
through	O
the	O
first	O
transmembrane	O
domain	O
.	O

We	O
have	O
previously	O
shown	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
M	O
protein	O
suppresses	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
production	O
by	O
impeding	O
the	O
formation	B-PROC
of	O
functional	O
TRAF3	O
-	O
containing	O
complex	O
.	O

Direct	O
florescent	O
antibody	B-PROC
technique	O
(	O
dFAT	O
)	O
and	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
used	O
to	O
confirm	O
the	O
isolated	O
virus	O
strains	O
at	O
antigenic	O
and	O
genomic	O
levels	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
review	O
studies	O
describing	O
the	O
PLPs	O
'	O
enzymatic	B-PROC
activity	I-PROC
and	O
their	O
role	O
in	O
virus	O
pathogenesis	B-PROC
.	O

All	O
three	O
ICA	O
kits	O
were	O
capable	O
of	O
detecting	O
anti	O
-	O
FCoV	O
antibodies	O
;	O
however	O
,	O
non	O
-	O
specific	O
positive	O
reactions	O
of	O
anti	O
-	O
FCoV	O
antibody	B-PROC
-	O
negative	O
plasma	O
samples	O
with	O
the	O
test	O
line	O
were	O
observed	O
in	O
2	O
ICA	O
kits	O
(	O
CJIgG	O
/	O
TNP	O
and	O
CJNP	O
/	O
TNP	O
),	O
in	O
which	O
rNP	O
was	O
used	O
as	O
the	O
test	O
line	O
.	O

Upon	O
binding	O
of	O
antibodies	O
,	O
these	O
proteins	O
are	O
quickly	O
internalised	O
through	O
a	O
new	O
clathrin	O
-	O
and	O
caveolae	O
-	O
independent	O
internalisation	O
pathway	B-PROC
.	O

Since	O
inhibiting	O
MLCK	O
with	O
ML	O
-	O
7	O
was	O
so	O
efficient	O
in	O
blocking	O
the	O
internalisation	O
pathway	B-PROC
,	O
this	O
target	O
can	O
be	O
used	O
for	O
the	O
development	B-PROC
of	O
a	O
new	O
treatment	O
for	O
FIPV	O
.	O

ABSTRACT	O
:	O
The	O
cause	O
of	O
death	B-PROC
in	O
215	O
cattle	O
on	O
20	O
long	O
-	O
haul	O
live	O
export	O
voyages	O
from	O
Australia	O
to	O
the	O
Middle	O
East	O
,	O
Russia	O
,	O
and	O
China	O
was	O
investigated	O
between	O
2010	O
and	O
2012	O
using	O
gross	O
,	O
histologic	O
,	O
and	O
/	O
or	O
molecular	O
pathology	O
techniques	O
.	O

A	O
comprehensive	O
SARS	O
-	O
CoV	O
S2	O
analysis	O
showed	O
that	O
specific	O
hydrophobic	O
positions	O
at	O
the	O
C	O
-	O
terminal	O
end	O
of	O
the	O
HR2	O
,	O
rather	O
than	O
electrostatics	O
are	O
critical	O
for	O
fusion	O
protein	B-PROC
stabilization	I-PROC
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
MERS	O
-	O
CoV	O
4a	O
protein	O
as	O
a	O
novel	O
immunosuppressive	O
factor	O
that	O
antagonizes	O
type	B-PROC
I	I-PROC
interferon	B-PROC
production	I-PROC
.	O

This	O
work	O
not	O
only	O
provides	O
a	O
new	O
understanding	O
of	O
the	O
abilities	O
of	O
MERS	O
-	O
CoV	O
and	O
closely	O
related	O
bat	O
viruses	O
to	O
subvert	O
virus	O
sensing	O
but	O
also	O
might	O
prove	O
useful	O
in	O
revealing	O
new	O
strategies	O
for	O
the	O
development	B-PROC
of	O
vaccines	O
and	O
antivirals	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
synthetic	O
peptides	O
including	O
Th1	O
and	O
a	O
linear	O
immunodominant	O
antibody	B-PROC
-	O
binding	O
epitope	O
in	O
the	O
S1	O
domain	O
and	O
M	O
protein	O
of	O
FIPV	O
.	O

ABSTRACT	O
:	O
The	O
5	O
'-	O
cap	O
structure	O
is	O
a	O
distinct	O
feature	O
of	O
eukaryotic	O
mRNAs	O
and	O
is	O
important	O
for	O
RNA	O
stability	O
and	O
protein	B-PROC
translation	B-PROC
by	O
providing	O
a	O
molecular	O
signature	O
for	O
the	O
distinction	O
of	O
self	O
or	O
non	O
-	O
self	O
mRNA	O
.	O

ABSTRACT	O
:	O
Papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
one	O
of	O
two	O
cysteine	O
proteases	O
involved	O
in	O
the	O
proteolytic	B-PROC
processing	I-PROC
of	O
the	O
polyproteins	O
of	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
working	O
mechanism	O
of	O
IVIg	O
in	O
autoimmune	O
diseases	O
has	O
not	O
been	O
elucidated	O
,	O
but	O
previous	O
studies	O
indicate	O
that	O
some	O
anti	O
-	O
inflammatory	O
effects	O
may	O
be	O
mediated	O
by	O
the	O
N	O
-	O
glycosylation	B-PROC
of	O
the	O
Fc	O
-	O
portion	O
of	O
IgG	O
.	O
GBS	O
is	O
a	O
model	O
disease	O
to	O
investigate	O
these	O
effects	O
because	O
GBS	O
is	O
an	O
acute	O
and	O
monophasic	O
disorder	O
usually	O
affecting	O
healthy	O
persons	O
,	O
which	O
is	O
treated	O
with	O
a	O
standard	O
course	O
of	O
IVIg	O
,	O
although	O
the	O
clinical	O
response	O
is	O
highly	O
variable	O
.	O

Kaplan	O
-	O
Meier	O
analysis	O
showed	O
that	O
these	O
patients	O
also	O
needed	O
more	O
time	O
to	O
be	O
able	O
to	O
walk	O
again	O
compared	O
with	O
patients	O
with	O
a	O
normalized	O
IgG	O
Fc	O
glycosylation	B-PROC
profile	O
.	O

TITLE	O
:	O
Distinct	O
immune	B-PROC
response	I-PROC
in	O
two	O
MERS	O
-	O
CoV	O
-	O
infected	O
patients	O
:	O
can	O
we	O
go	O
from	O
bench	O
to	O
bedside	O
?	O

Moderate	O
and	O
severe	O
ARDS	O
increased	O
the	O
odds	O
of	O
death	B-PROC
by	O
more	O
than	O
fourfold	O
and	O
ninefold	O
,	O
respectively	O
.	O

Proteolytic	B-PROC
processing	I-PROC
of	O
coronavirus	O
spike	O
(	O
S	O
)	O
fusion	O
proteins	O
during	O
virus	O
entry	O
has	O
been	O
suggested	O
but	O
not	O
yet	O
formally	O
demonstrated	O
,	O
while	O
the	O
nature	O
and	O
functionality	O
of	O
the	O
resulting	O
subunit	O
is	O
still	O
unclear	O
.	O

However	O
,	O
even	O
the	O
low	O
-	O
affinity	O
receptors	O
could	O
hypersensitize	O
cells	O
to	O
infection	O
when	O
an	O
S	O
-	O
cleaving	O
protease	O
(	O
s	O
)	O
was	O
present	O
,	O
indicating	O
that	O
affinity	O
thresholds	O
for	O
virus	O
entry	O
must	O
be	O
considered	O
in	O
the	O
context	O
of	O
host	O
-	O
cell	O
proteolytic	B-PROC
environments	O
.	O

immunization	O
pathways	B-PROC
.	O

TITLE	O
:	O
The	O
discovery	O
of	O
asunaprevir	O
(	O
BMS	O
-	O
650032	O
),	O
an	O
orally	O
efficacious	O
NS3	O
protease	O
inhibitor	O
for	O
the	O
treatment	O
of	O
hepatitis	O
C	O
virus	B-PROC
infection	I-PROC
.	O

Twelve	O
(	O
63	O
.	O
15	O
%)	O
patients	O
could	O
not	O
be	O
weaned	B-PROC
off	O
and	O
died	B-PROC
while	O
still	O
on	O
extracorporeal	O
membrane	O
oxygenator	O
support	O
.	O

TITLE	O
:	O
Detection	O
of	O
common	O
respiratory	O
viruses	O
in	O
tonsillar	O
tissue	O
of	O
children	O
with	O
obstructive	O
sleep	B-PROC
apnea	O
.	O

Respiratory	O
viruses	O
are	O
detected	O
in	O
OSA	O
hypertrophic	O
tonsils	O
,	O
suggestive	O
of	O
their	O
role	O
in	O
the	O
evolution	B-PROC
of	O
tonsillar	O
inflammation	O
and	O
hypertrophy	O
.	O

Less	O
improved	O
oxygenation	B-PROC
,	O
longer	O
ventilator	O
dependency	O
and	O
worse	O
survival	O
were	O
observed	O
in	O
pneumonia	O
-	O
related	O
ARDS	O
.	O

The	O
patient	O
required	O
salvage	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Secondly	O
,	O
the	O
pathology	O
and	O
pathogenesis	B-PROC
of	O
SARS	O
and	O
influenza	O
in	O
man	O
and	O
experimental	O
animals	O
are	O
compared	O
.	O

The	O
emergence	O
of	O
a	O
second	O
highly	O
pathogenic	O
coronavirus	O
within	O
a	O
decade	O
highlights	O
the	O
importance	O
of	O
a	O
coordinated	O
global	O
response	O
incorporating	O
reservoir	O
surveillance	O
,	O
high	O
-	O
containment	O
capacity	O
with	O
fundamental	O
and	O
applied	O
research	O
programs	O
,	O
and	O
dependable	O
communication	O
pathways	B-PROC
to	O
ensure	O
outbreak	O
containment	O
.	O

PBFIPV	O
-	O
DF	O
-	O
2	O
infection	O
induced	O
significantly	O
lower	O
virus	B-PROC
neutralization	I-PROC
titers	O
than	O
its	O
parent	O
virus	O
,	O
and	O
lacked	O
the	O
second	O
phase	O
of	O
viremia	O
and	O
development	B-PROC
of	O
fatal	O
course	O
of	O
the	O
disease	O
.	O

The	O
analytical	O
sensitivity	O
of	O
the	O
RT	O
-	O
LAMP	O
method	O
was	O
estimated	O
to	O
be	O
as	O
low	O
as	O
5	O
viral	O
copies	O
and	O
was	O
1000	O
-	O
fold	O
more	O
sensitive	O
than	O
the	O
conventional	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
.	O

Here	O
,	O
we	O
show	O
that	O
mice	O
were	O
sensitized	O
to	O
MERS	O
-	O
CoV	O
infection	O
by	O
prior	O
transduction	B-PROC
with	O
adenoviral	O
vectors	O
expressing	O
the	O
human	O
host	O
-	O
cell	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
.	O

Clinical	O
disease	O
and	O
histopathological	O
changes	O
were	O
more	O
severe	O
in	O
the	O
absence	O
of	O
type	O
-	O
I	O
IFN	O
signaling	B-PROC
whereas	O
the	O
T	O
-	O
cell	O
response	O
was	O
required	O
for	O
virus	O
clearance	O
.	O

Adult	O
respiratory	O
distress	O
syndrome	O
,	O
bleeding	O
diathesis	O
,	O
hypotension	O
,	O
hepatic	O
failure	O
and	O
acute	O
renal	O
failure	O
were	O
the	O
common	O
causes	O
of	O
death	B-PROC
despite	O
early	O
hospitalization	O
,	O
intravenous	O
fluid	O
,	O
and	O
blood	O
-	O
product	O
support	O
.	O

Dengue	O
is	O
associated	O
with	O
severe	O
disease	O
,	O
and	O
deaths	B-PROC
do	O
occur	O
despite	O
current	O
supportive	O
management	O
.	O

Both	O
of	O
these	O
conditions	O
can	O
present	O
with	O
hyperthermia	B-PROC
,	O
marked	O
muscle	O
rigidity	O
,	O
altered	O
consciousness	O
,	O
autonomic	O
dysfunction	O
,	O
and	O
elevated	O
serum	O
creatine	O
-	O
kinase	O
(	O
CK	O
)	O
levels	O
.	O

Lacking	O
understanding	O
of	O
FH	O
pathogenesis	B-PROC
has	O
in	O
essence	O
hindered	O
efficient	O
clinical	O
treatment	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
mouse	O
susceptibility	O
to	O
MHV	O
-	O
3	O
-	O
induced	O
FH	O
may	O
rely	O
on	O
C5a	O
/	O
C5aR	O
interactions	O
,	O
for	O
which	O
ERK1	O
/	O
2	O
and	O
p38	O
pathways	B-PROC
participate	O
in	O
up	O
-	O
regulating	O
Fgl2	O
expression	B-PROC
.	O

Our	O
recent	O
assessment	O
of	O
mitochondrial	O
function	O
in	O
MeCP2	O
(	O
methyl	O
-	O
CpG	O
-	O
binding	O
protein	O
2	O
)-	O
deficient	O
mouse	O
(	O
Mecp2	O
(-)	O
(/	O
y	O
))	O
hippocampus	O
confirmed	O
early	O
metabolic	B-PROC
alterations	O
,	O
an	O
increased	O
oxidative	O
burden	O
,	O
and	O
a	O
more	O
vulnerable	O
cellular	O
redox	B-PROC
balance	B-PROC
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
viral	B-PROC
infections	I-PROC
(	O
ARVI	O
)	O
and	O
influenza	O
take	O
a	O
leading	O
place	O
in	O
the	O
structure	O
of	O
the	O
general	O
morbidity	O
of	O
the	O
population	O
in	O
most	O
countries	O
of	O
the	O
world	O
.	O

Transduction	B-PROC
of	O
mammalian	O
and	O
avian	O
cells	O
with	O
BacMam	O
viruses	O
revealed	O
that	O
dual	O
expression	B-PROC
cassettes	O
yielded	O
high	O
levels	O
of	O
protein	O
from	O
both	O
transcription	B-PROC
units	O
.	O

To	O
this	O
aim	O
,	O
we	O
generated	O
live	O
attenuated	O
recombinant	O
measles	O
vaccine	O
(	O
MV	O
)	O
candidates	O
expressing	O
either	O
the	O
membrane	O
-	O
anchored	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
or	O
its	O
secreted	B-PROC
soluble	O
ectodomain	O
(	O
Ssol	O
).	O

We	O
hypothesized	O
that	O
distinct	O
immune	B-PROC
responses	I-PROC
in	O
the	O
lung	O
and	O
gut	O
during	O
the	O
primary	O
and	O
chronic	O
stages	O
of	O
viral	B-PROC
infection	I-PROC
contribute	O
to	O
these	O
differences	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
STAT	O
/	O
NF	O
-	O
κB	O
inhibitor	O
and	O
free	O
radical	O
scavenger	O
,	O
was	O
administered	O
systemically	O
to	O
a	O
subset	O
of	O
mice	O
to	O
determine	O
whether	O
this	O
altered	O
the	O
muscle	B-PROC
contraction	I-PROC
response	O
.	O

Gene	B-PROC
expression	I-PROC
of	O
collagen	O
type	O
I	O
,	O
but	O
not	O
collagen	O
type	O
V	O
,	O
in	O
the	O
isthmus	O
and	O
CaBP	O
-	O
D28K	O
in	O
the	O
uterus	O
was	O
decreased	O
in	O
the	O
aIBV	O
group	O
compared	O
with	O
that	O
in	O
the	O
control	O
.	O

Recombination	B-PROC
events	O
coupled	O
with	O
the	O
accumulation	O
of	O
mutations	O
in	O
the	O
ck	O
/	O
CH	O
/	O
LJL	O
/	O
111054	O
genome	O
may	O
account	O
for	O
its	O
increased	O
virulence	B-PROC
in	O
specific	O
-	O
pathogen	O
free	O
chickens	O
.	O

ABSTRACT	O
:	O
Organophosphate	O
(	O
OP	O
)	O
poisoning	O
is	O
the	O
most	O
common	O
cause	O
(	O
27	O
.	O
64	O
%)	O
and	O
has	O
the	O
highest	O
death	B-PROC
rate	O
(	O
13	O
.	O
88	O
%)	O
of	O
poisoning	O
in	O
Bangladesh	O
.	O

Investigations	O
revealed	O
neutrophilic	B-PROC
leucocytosis	O
(	O
30	O
,	O
000	O
/	O
cubic	O
millimeter	O
;	O
86	O
%)	O
with	O
high	O
serum	O
lipase	O
(	O
770	O
Unit	O
/	O
Liter	O
)	O
and	O
alanine	O
transaminase	O
(	O
379	O
Unit	O
/	O
Liter	O
)	O
and	O
low	O
serum	O
potassium	O
(	O
3	O
.	O
0	O
millimol	O
/	O
Liter	O
).	O

We	O
found	O
that	O
expression	B-PROC
of	O
the	O
membrane	O
-	O
anchored	O
PLpro	O
domain	O
(	O
PLpro	O
-	O
TM	O
)	O
from	O
SARS	O
-	O
CoV	O
inhibits	O
STING	O
/	O
TBK1	O
/	O
IKKε	O
-	O
mediated	O
activation	O
of	O
type	O
I	O
IFNs	O
and	O
disrupts	O
the	O
phosphorylation	B-PROC
and	O
dimerization	O
of	O
IRF3	O
,	O
which	O
are	O
activated	O
by	O
STING	O
and	O
TBK1	O
.	O

These	O
viruses	O
allow	O
early	O
quantitation	O
of	O
virus	B-PROC
replication	I-PROC
as	O
well	O
as	O
real	O
-	O
time	O
measurement	O
of	O
replication	O
complexes	O
.	O

Fueling	O
the	O
explosive	O
growth	B-PROC
is	O
a	O
combination	O
of	O
technological	O
improvements	O
and	O
accumulating	O
,	O
although	O
controversial	O
,	O
evidence	O
.	O

Immature	O
immune	O
system	O
and	O
lack	O
of	O
fully	O
established	O
microbiota	O
at	O
birth	B-PROC
predispose	O
neonatal	O
piglets	O
to	O
infection	O
with	O
enteric	O
pathogens	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	B-PROC
with	O
oligonucleotide	O
probes	O
was	O
applied	O
on	O
the	O
fixed	O
intestinal	O
tissue	O
samples	O
from	O
51	O
diarrheic	O
and	O
50	O
non	O
-	O
diarrheic	O
piglets	O
collected	O
from	O
four	O
Danish	O
farms	O
during	O
outbreaks	O
of	O
neonatal	O
diarrhea	O
not	O
caused	O
by	O
well	O
-	O
known	O
enteric	O
pathogens	O
.	O

The	O
results	O
of	O
this	O
study	O
showed	O
that	O
simultaneous	O
colonization	O
of	O
the	O
intestinal	O
mucosa	O
by	O
adherent	O
non	O
-	O
ETEC	O
E	O
.	O
coli	O
and	O
Enterococcus	O
spp	O
.	O
can	O
be	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
neonatal	O
porcine	O
diarrhea	O
.	O

Nasopharyngeal	O
aspirate	O
and	O
sputum	O
samples	O
should	O
be	O
collected	O
for	O
diagnosis	O
,	O
preferably	O
using	O
reverse	O
transcriptase	B-PROC
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
express	O
a	O
deubiquitinating	B-PROC
protein	O
,	O
the	O
papain	O
-	O
like	O
protease	O
-	O
2	O
(	O
PLP2	O
),	O
that	O
removes	O
both	O
ubiquitin	B-PROC
and	O
the	O
ubiquitin	B-PROC
-	O
like	O
interferon	O
(	O
IFN	O
)-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
protein	O
from	O
target	O
proteins	O
.	O

Overall	O
,	O
these	O
results	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
ISGylation	O
in	O
an	O
in	O
vivo	O
model	O
of	O
coronavirus	O
-	O
induced	O
mouse	O
hepatitis	O
and	O
illustrate	O
that	O
PLP2	O
manipulates	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
through	O
the	O
ISG15	O
/	O
USP18	O
pathway	B-PROC
.	O

Recombinant	O
spike	O
protein	O
-	O
specific	O
immunofluorescence	O
and	O
virus	B-PROC
neutralization	I-PROC
tests	O
enabled	O
clear	O
discrimination	O
between	O
MERS	O
-	O
CoV	O
and	O
bovine	O
CoV	O
infections	O
.	O

We	O
present	O
a	O
case	O
of	O
traumatic	O
rupture	O
of	O
the	O
aortic	O
valve	O
complicated	O
by	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
interhospital	O
transport	B-PROC
using	O
ECMO	O
and	O
subsequent	O
aortic	O
valve	O
replacement	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
apoptosis	B-PROC
induced	O
by	O
BYD1	O
,	O
its	O
outer	O
capsid	O
protein	O
μ1	O
,	O
and	O
its	O
cell	O
-	O
attachment	O
protein	O
σ1	O
to	O
understand	O
the	O
pathogenesis	B-PROC
of	O
BYD1	O
.	O

Notably	O
,	O
ectopically	O
expressed	B-PROC
μ1	O
and	O
σ1	O
induced	O
similar	O
pathological	O
apoptosis	B-PROC
,	O
independent	O
of	O
BYD1	O
infection	O
,	O
in	O
host	O
cells	O
in	O
which	O
they	O
were	O
expressed	B-PROC
,	O
which	O
suggests	O
that	O
μ1	O
and	O
σ1	O
are	O
both	O
apoptotic	O
virulence	B-PROC
factors	O
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
BYD1	O
μ1	O
-	O
and	O
σ1	O
-	O
induced	O
apoptosis	B-PROC
is	O
involved	O
in	O
the	O
multi	O
-	O
organ	O
lesions	O
in	O
a	O
suckling	O
mouse	O
BYD1	O
infection	O
model	O
.	O

However	O
,	O
patients	O
with	O
sepsis	O
-	O
related	O
acute	O
respiratory	O
distress	O
syndrome	O
could	O
demonstrate	O
compromised	O
arterial	O
oxygenation	B-PROC
with	O
OCT	O
impairment	O
decoupled	O
to	O
circulatory	B-PROC
failure	O
.	O

Passage	O
of	O
BtCoV	O
HKU5	O
-	O
SE	O
in	O
young	O
mice	O
resulted	O
in	O
enhanced	O
virulence	B-PROC
,	O
causing	O
20	O
%	O
weight	O
loss	O
,	O
diffuse	O
alveolar	O
damage	O
,	O
and	O
hyaline	O
membrane	O
formation	B-PROC
in	O
aged	O
mice	O
.	O

Because	O
no	O
small	O
animal	O
model	O
exists	O
to	O
evaluate	O
MERS	O
-	O
CoV	O
pathogenesis	B-PROC
or	O
to	O
test	O
vaccines	O
,	O
we	O
constructed	O
a	O
recombinant	O
BtCoV	O
HKU5	O
that	O
expressed	B-PROC
a	O
region	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
thereby	O
allowing	O
the	O
recombinant	O
virus	O
to	O
grow	O
in	O
cell	O
culture	O
and	O
in	O
mice	O
.	O

Treatment	O
modalities	O
were	O
grouped	O
in	O
five	O
categories	O
:	O
mechanical	O
ventilation	O
strategies	O
and	O
respiratory	O
care	O
,	O
enteral	O
or	O
parenteral	O
therapies	O
,	O
inhaled	B-PROC
/	O
intratracheal	O
medications	O
,	O
nutritional	O
support	O
,	O
and	O
hemodynamic	B-PROC
monitoring	O
.	O

After	O
administration	O
of	O
endotoxin	O
,	O
there	O
was	O
a	O
rapid	O
decline	O
in	O
oxygenation	B-PROC
to	O
hypoxemic	O
values	O
,	O
indicative	O
of	O
severe	O
-	O
to	O
-	O
moderate	O
ARDS	O
.	O

These	O
results	O
suggest	O
that	O
high	O
dietary	O
Zn	O
could	O
provide	O
enhanced	O
protection	O
in	O
the	O
intestinal	O
tract	O
and	O
stimulate	O
the	O
systemic	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
against	O
TGEV	O
infection	O
.	O

However	O
,	O
the	O
cognitive	O
-	O
behavioral	B-PROC
associations	O
were	O
weaker	O
and	O
inconsistent	O
across	O
the	O
ten	O
surveys	O
.	O

RESULTS	O
:	O
Excepting	O
state	O
anxiety	O
,	O
other	O
affective	O
measures	O
including	O
""""	O
anticipated	O
worry	O
""","	O
""""	O
experienced	O
worry	O
""""	O
and	O
""""	O
current	O
worry	O
""""	O
specific	O
to	O
A	O
/	O
H1N1	O
risk	O
were	O
consistently	O
and	O
strongly	O
associated	O
with	O
adoption	O
of	O
protective	O
behaviors	B-PROC
across	O
different	O
survey	O
periods	B-PROC
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
anti	O
-	O
HIV	O
activity	O
of	O
4	O
-(	O
naphthalen	O
-	O
1	O
-	O
yl	O
)-	O
1	O
,	O
2	O
,	O
5	O
-	O
thiadiazol	O
-	O
3	O
-	O
hydroxyl	O
derivatives	O
.	O

Antibody	B-PROC
titer	O
against	O
Newcastle	O
disease	O
(	O
ND	O
),	O
infectious	O
bursal	O
disease	O
(	O
IBD	O
),	O
and	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
T2	O
and	O
T3	O
groups	O
.	O

In	O
the	O
present	O
studies	O
,	O
we	O
first	O
evaluated	O
if	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
activated	O
the	O
UPR	O
pathways	B-PROC
.	O

All	O
these	O
results	O
support	O
the	O
therapeutic	O
potential	O
of	O
using	O
2	O
-	O
DG	O
or	O
glucose	O
/	O
mannose	O
analogs	O
to	O
induce	O
the	O
UPR	O
to	O
block	O
virus	B-PROC
replication	I-PROC
.	O

A	O
negative	O
correlation	O
between	O
antiviral	O
cytokines	O
and	O
IL	O
-	O
10	O
,	O
IL	B-PROC
-	I-PROC
17	I-PROC
,	O
IL	O
-	O
37	O
,	O
FOXP3	O
,	O
and	O
RORC2	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
viruses	O
,	O
and	O
interestingly	O
,	O
IL	O
-	O
13	O
strongly	O
correlated	O
with	O
antiviral	O
cytokines	O
.	O

The	O
importance	O
of	O
respiratory	O
and	O
non	O
-	O
respiratory	O
viral	O
agents	O
for	O
the	O
pathogenesis	B-PROC
,	O
especially	O
for	O
the	O
exacerbation	O
of	O
bacterial	O
lower	O
respiratory	O
tract	O
infections	O
and	O
course	O
of	O
CF	O
,	O
is	O
stressed	O
,	O
especially	O
emphasizing	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
virus	O
,	O
rhinovirus	O
,	O
and	O
human	O
herpes	O
viruses	O
.	O

Blast	O
crisis	O
with	O
transformation	B-PROC
into	O
acute	O
myeloid	O
leukemia	O
occurs	O
in	O
one	O
third	O
of	O
patients	O
.	O

A	O
salient	O
feature	O
of	O
JMML	O
is	O
their	O
frequent	O
association	O
with	O
predisposition	O
syndromes	O
such	O
as	O
Noonan	O
syndrome	O
,	O
neurofibromatosis	O
and	O
CBL	O
syndrome	O
,	O
which	O
are	O
developmental	O
diseases	O
associated	O
with	O
a	O
constitutional	O
RAS	O
pathway	B-PROC
deregulation	O
,	O
now	O
grouped	O
under	O
the	O
name	O
RASopathies	O
.	O

Some	O
rare	O
patients	O
have	O
an	O
indolent	O
evolution	B-PROC
or	O
even	O
spontaneous	O
remission	O
.	O

For	O
the	O
first	O
time	O
,	O
this	O
directly	O
demonstrates	O
that	O
replication	O
and	O
organelle	O
formation	B-PROC
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
studied	O
separately	O
during	O
infection	O
with	O
positive	O
-	O
stranded	O
RNA	O
virus	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
viral	B-PROC
infections	I-PROC
in	O
cats	O
in	O
southwestern	O
Poland	O
in	O
the	O
years	O
2006	O
to	O
2010	O
.	O

Two	O
liquid	O
chip	O
panels	O
were	O
developed	O
which	O
used	O
a	O
target	O
-	O
enriched	O
multiplexed	O
RT	O
-	O
PCR	O
amplification	O
followed	O
by	O
Luminex	O
liquid	O
chip	O
hybridization	B-PROC
based	O
on	O
xMAP	O
technology	O
.	O

He	O
was	O
placed	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
to	O
stabilise	O
his	O
condition	O
.	O

A	O
slide	O
tracheoplasty	O
and	O
complete	O
repair	B-PROC
of	O
the	O
partial	O
atrioventricular	O
septal	O
defect	O
was	O
successfully	O
undertaken	O
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
slide	O
tracheoplasty	O
and	O
partial	O
atrioventricular	O
septal	O
defect	O
repair	B-PROC
in	O
a	O
child	O
following	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
.	O

Despite	O
causing	O
severe	O
,	O
and	O
often	O
refractory	O
,	O
hypoxaemia	O
,	O
the	O
high	O
mortality	O
and	O
long	O
-	O
term	O
morbidity	O
of	O
ARDS	O
results	O
mainly	O
from	O
extra	O
-	O
pulmonary	O
organ	O
failure	O
;	O
however	O
the	O
mechanism	O
for	O
this	O
organ	O
crosstalk	B-PROC
has	O
not	O
been	O
determined	O
.	O

Furthermore	O
,	O
the	O
binding	O
of	O
the	O
circular	O
TFO	O
RNA	O
with	O
the	O
targeted	B-PROC
viral	O
genome	O
segment	O
was	O
also	O
confirmed	O
using	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Among	O
these	O
extracts	O
,	O
CBM	O
and	O
DBM	O
also	O
showed	O
significant	O
inhibition	B-PROC
of	O
SARS	O
-	O
CoV	O
3CL	O
protease	B-PROC
activity	I-PROC
with	O
IC50	O
values	O
of	O
39	O
μg	O
/	O
ml	O
and	O
44	O
μg	O
/	O
ml	O
,	O
respectively	O
.	O

TITLE	O
:	O
ARDS	O
associated	O
with	O
pneumonia	O
caused	O
by	O
avian	O
influenza	O
A	O
H7N9	O
virus	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

These	O
results	O
indicate	O
that	O
the	O
cooperation	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibodies	O
and	O
phagocytic	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
elimination	B-PROC
of	O
SARS	O
-	O
CoV	O
.	O

Second	O
,	O
MERS	O
-	O
CoV	O
induced	O
significantly	O
higher	O
levels	O
of	O
IFN	O
-	O
γ	O
,	O
IP	O
-	O
10	O
,	O
IL	O
-	O
12	O
,	O
and	O
RANTES	O
expression	B-PROC
than	O
SARS	O
-	O
CoV	O
.	O
Third	O
,	O
MERS	O
-	O
CoV	O
-	O
infection	O
induced	O
higher	O
surface	O
expression	B-PROC
of	O
MHC	B-PROC
class	O
II	O
(	O
HLA	O
-	O
DR	O
)	O
and	O
the	O
co	O
-	O
stimulatory	O
molecule	O
CD86	O
than	O
SARS	O
-	O
CoV	O
-	O
infection	O
.	O

Overall	O
,	O
our	O
data	O
suggests	O
that	O
the	O
dendritic	O
cell	O
can	O
serve	O
as	O
an	O
important	O
target	O
of	O
viral	B-PROC
replication	I-PROC
and	O
a	O
vehicle	O
for	O
dissemination	O
.	O

MERS	O
-	O
CoV	O
-	O
infection	O
in	O
DCs	O
results	O
in	O
the	O
production	O
of	O
a	O
rich	O
combination	O
of	O
cytokines	O
and	O
chemokines	O
,	O
and	O
modulates	O
innate	B-PROC
immune	I-PROC
response	I-PROC
differently	O
from	O
that	O
of	O
SARS	O
-	O
CoV	O
-	O
infection	O
.	O

Interestingly	O
,	O
compound	O
4e	O
could	O
inhibit	O
not	O
only	O
HBsAg	O
and	O
HBeAg	O
secretions	O
but	O
also	O
HBV	O
DNA	B-PROC
replication	I-PROC
with	O
SI	O
values	O
of	O
20	O
.	O
3	O
,	O
125	O
.	O
0	O
and	O
104	O
.	O
9	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
need	O
for	O
development	B-PROC
of	O
a	O
rapid	O
method	O
of	O
vaccine	O
development	B-PROC
that	O
can	O
respond	O
to	O
emerging	O
pathogens	O
in	O
a	O
short	O
time	O
frame	O
.	O

Dendritic	O
cells	O
(	O
DCs	O
),	O
through	O
uptake	O
and	O
presentation	O
of	O
antigens	O
to	O
T	O
cells	O
,	O
initiate	O
distinct	O
immune	B-PROC
responses	I-PROC
to	O
different	O
infections	O
.	O

On	O
an	O
evolutionary	O
scale	O
,	O
this	O
host	O
-	O
virus	O
interaction	O
might	O
have	O
resulted	O
in	O
the	O
large	O
diversity	O
of	O
zoonotic	O
viruses	O
in	O
bats	O
,	O
possibly	O
through	O
bat	O
viruses	O
adapting	O
to	O
be	O
more	O
tolerant	O
of	O
the	O
fever	B-PROC
response	O
and	O
less	O
virulent	O
to	O
their	O
natural	O
hosts	O
.	O

PEDV	O
was	O
found	O
in	O
5	O
.	O
2	O
%	O
of	O
trailers	O
not	O
contaminated	O
at	O
arrival	O
,	O
,	O
suggesting	O
that	O
the	O
transport	B-PROC
process	I-PROC
is	O
a	O
source	O
of	O
transmission	O
if	O
adequate	O
hygiene	O
measures	O
are	O
not	O
implemented	O
.	O

Porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
)	O
was	O
detected	O
in	O
suckling	O
and	O
weaning	B-PROC
pigs	O
by	O
RT	O
-	O
PCR	O
assays	O
.	O

The	O
serological	O
test	O
supported	O
no	O
involvement	O
of	O
HCoV	O
-	O
NL63	O
but	O
suggested	O
the	O
possible	O
involvement	O
of	O
HCoV	O
-	O
229E	O
in	O
the	O
development	B-PROC
of	O
Kawasaki	O
disease	O
.	O

TITLE	O
:	O
Membrane	O
ectopeptidases	O
targeted	B-PROC
by	O
human	O
coronaviruses	O
.	O

One	O
symptomatic	O
patient	O
died	B-PROC
and	O
the	O
other	O
symptomatic	O
patient	O
recovered	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
envelope	O
protein	B-PROC
palmitoylation	B-PROC
or	O
nucleocapid	O
association	O
is	O
not	O
required	O
for	O
promoting	O
virus	O
-	O
like	O
particle	O
production	O
.	O

Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
M	O
co	O
-	O
expression	B-PROC
with	O
either	O
N	O
or	O
E	O
is	O
sufficient	O
for	O
producing	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
),	O
although	O
at	O
a	O
lower	O
level	O
compared	O
to	O
M	O
,	O
N	O
and	O
E	O
co	O
-	O
expression	B-PROC
.	O

Electronic	O
nose	O
(	O
eNose	O
)	O
technology	O
can	O
rapidly	O
and	O
non	O
-	O
invasively	O
provide	O
breath	O
prints	O
,	O
which	O
are	O
profiles	O
of	O
volatile	O
metabolites	O
in	O
the	O
exhaled	B-PROC
breath	O
.	O

Tissue	O
and	O
faecal	O
samples	O
collected	O
post	O
mortem	O
from	O
cats	O
diagnosed	O
with	O
or	O
without	O
FIP	O
were	O
subjected	O
to	O
RNA	O
extraction	O
and	O
quantitative	O
reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
to	O
detect	O
FCoV	O
RNA	O
.	O

In	O
patients	O
with	O
severe	O
ARDS	O
in	O
prone	O
position	O
,	O
gravitational	O
pressure	O
transmits	O
through	O
abdominal	O
support	O
,	O
resulting	O
in	O
better	O
chest	O
wall	O
expansion	O
and	O
leading	O
to	O
more	O
oxygenation	B-PROC
and	O
opening	O
of	O
the	O
alveoli	O
in	O
ventral	O
lung	O
along	O
with	O
the	O
dorsal	O
lung	O
portion	O
that	O
is	O
usually	O
better	O
ventilated	O
in	O
prone	O
position	O
.	O

ABSTRACT	O
:	O
Three	O
strains	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
were	O
isolated	O
from	O
dead	B-PROC
or	O
diseased	O
pigs	O
at	O
different	O
swine	O
farms	O
in	O
Guangdong	O
during	O
2011	O
-	O
2013	O
,	O
and	O
their	O
S	O
genes	O
were	O
sequenced	O
.	O

We	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
two	O
potent	O
human	O
RBD	O
-	O
specific	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
MERS	O
-	O
4	O
and	O
MERS	O
-	O
27	O
)	O
derived	O
from	O
single	O
-	O
chain	O
variable	O
region	O
fragments	O
of	O
a	O
nonimmune	O
human	O
antibody	B-PROC
library	O
.	O

E	O
gene	O
encodes	O
a	O
small	O
multifunctional	O
protein	O
that	O
possesses	O
ion	O
channel	O
(	O
IC	O
)	O
activity	O
,	O
an	O
important	O
function	O
in	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
.	O

Reduced	O
edema	O
correlated	O
with	O
lung	O
epithelia	O
integrity	O
and	O
proper	O
localization	B-PROC
of	O
Na	O
+/	O
K	O
+	O
ATPase	O
,	O
which	O
participates	O
in	O
edema	O
resolution	O
.	O

In	O
this	O
study	O
,	O
using	O
mice	O
infected	O
with	O
a	O
murine	O
coronavirus	O
that	O
encodes	O
epitopes	O
that	O
elicit	O
high	O
(	O
S510	O
,	O
CSLWNGPHL	O
)-	O
and	O
low	O
(	O
S598	O
,	O
RCQIFANI	O
)-	O
functional	O
avidity	O
responses	O
,	O
we	O
show	O
that	O
increased	O
expression	B-PROC
of	O
peptide	O
S598	O
but	O
not	O
S510	O
generated	O
T	O
cells	O
with	O
enhanced	O
functional	O
avidity	O
.	O

Thus	O
,	O
immune	B-PROC
responses	I-PROC
can	O
be	O
augmented	O
toward	O
T	O
cell	O
epitopes	O
with	O
low	O
functional	O
avidity	O
by	O
increasing	O
Ag	O
density	O
.	O

We	O
also	O
identified	O
a	O
heteroclitic	O
epitope	O
(	O
RCVIFANI	O
)	O
that	O
elicited	O
a	O
T	O
cell	O
response	O
with	O
nearly	O
complete	O
cross	O
-	O
reactivity	O
with	O
native	O
epitope	O
and	O
demonstrated	O
increased	O
MHC	B-PROC
/	O
peptide	O
abundance	O
compared	O
with	O
native	O
S598	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
detection	O
rates	O
of	O
respiratory	O
viruses	O
from	O
nasopharyngeal	O
swabs	O
and	O
sputum	O
using	O
a	O
multiplex	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

However	O
,	O
the	O
range	O
of	O
reagents	O
available	O
to	O
measure	O
the	O
ferret	O
immune	B-PROC
response	I-PROC
is	O
very	O
limited	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
foamy	O
virus	O
reverse	O
transcriptase	B-PROC
by	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
RNase	O
H	O
inhibitors	O
.	O

Therefore	O
,	O
it	O
is	O
a	O
promising	O
target	O
for	O
drug	O
development	B-PROC
.	O

Based	O
on	O
these	O
results	O
and	O
previous	O
data	O
,	O
in	O
silico	O
docking	B-PROC
analysis	O
showed	O
a	O
putative	O
RDS1643	O
binding	O
region	O
that	O
reaches	O
into	O
the	O
PFV	O
RNase	O
H	O
active	O
site	O
.	O

TITLE	O
:	O
Proteolytic	B-PROC
activation	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
spike	O
fusion	O
protein	O
by	O
trypsin	O
in	O
cell	O
culture	O
.	O

Our	O
study	O
focused	O
on	O
the	O
role	O
of	O
protease	B-PROC
activity	I-PROC
on	O
infection	O
by	O
investigating	O
the	O
spike	O
protein	O
of	O
a	O
PEDV	O
isolate	O
(	O
wtPEDV	O
)	O
using	O
a	O
reverse	O
genetics	O
system	O
based	O
on	O
the	O
trypsin	O
-	O
independent	O
cell	O
culture	O
-	O
adapted	O
strain	O
DR13	O
(	O
caPEDV	O
).	O

Whereas	O
coronaviruses	O
are	O
typically	O
processed	O
by	O
endogenous	O
proteases	O
of	O
the	O
producer	O
or	O
target	O
cell	O
,	O
PEDV	O
S	O
protein	B-PROC
activation	I-PROC
strictly	O
required	O
supplementation	O
of	O
a	O
protease	O
,	O
enabling	O
us	O
to	O
study	O
mechanistic	O
details	O
of	O
proteolytic	B-PROC
processing	I-PROC
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
influence	O
of	O
different	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
levels	O
on	O
cerebral	B-PROC
blood	I-PROC
flow	I-PROC
(	O
CBF	O
)	O
and	O
cerebrovascular	O
autoregulation	B-PROC
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Patients	O
were	O
divided	O
into	O
the	O
survival	O
group	O
(	O
n	O
=	O
24	O
)	O
and	O
the	O
death	B-PROC
group	O
(	O
n	O
=	O
19	O
)	O
.	O

The	O
value	O
of	O
0	O
h	O
blood	O
lactate	O
,	O
6	O
h	O
lactate	O
clearance	O
rate	O
and	O
APACHE	O
II	O
score	O
for	O
predicting	O
death	B-PROC
was	O
evaluated	O
by	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
.	O

We	O
aimed	O
to	O
elucidate	O
the	O
correlation	O
between	O
QTc	O
prolongation	O
and	O
in	O
-	O
hospital	O
death	B-PROC
,	O
respiratory	O
arrest	O
,	O
and	O
endotracheal	O
intubation	O
in	O
acute	O
methadone	O
-	O
intoxicated	O
patients	O
presenting	O
to	O
the	O
emergency	O
department	O
and	O
to	O
assess	O
the	O
value	O
of	O
QTc	O
in	O
predicting	O
these	O
outcomes	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
currently	O
has	O
limited	O
effective	O
treatments	O
;	O
however	O
,	O
recent	O
evidence	O
suggests	O
that	O
modulation	O
of	O
alveolar	O
macrophage	O
responses	O
may	O
be	O
an	O
effective	O
method	O
for	O
protection	O
or	O
repair	B-PROC
of	O
lung	O
injury	O
.	O

Conversely	O
,	O
in	O
α7	O
(-/-)	O
mice	O
,	O
virus	B-PROC
replication	I-PROC
was	O
restricted	O
mostly	O
to	O
the	O
bronchial	O
epithelium	O
with	O
marginal	O
alveolar	O
infection	O
,	O
resulting	O
in	O
significantly	O
reduced	O
lung	O
damage	O
and	O
enhanced	O
animal	O
survival	O
.	O

Here	O
,	O
we	O
report	O
the	O
requirement	O
of	O
a	O
cellular	O
factor	O
,	O
importin	O
-	O
α7	O
,	O
for	O
efficient	O
virus	B-PROC
replication	I-PROC
in	O
the	O
alveolar	O
epithelium	O
of	O
mice	O
.	O

Taken	O
together	O
,	O
our	O
results	O
show	O
that	O
importin	O
-	O
α7	O
is	O
particularly	O
required	O
for	O
virus	B-PROC
replication	I-PROC
in	O
the	O
alveolar	O
epithelium	O
in	O
association	O
with	O
severe	O
pneumonia	O
and	O
death	B-PROC
in	O
mice	O
.	O

ABSTRACT	O
:	O
Analysis	O
of	O
clinical	O
samples	O
from	O
patients	O
with	O
new	O
viral	B-PROC
infections	I-PROC
is	O
critical	O
to	O
confirm	O
the	O
diagnosis	O
,	O
to	O
specify	O
the	O
viral	O
load	O
,	O
and	O
to	O
sequence	O
data	O
necessary	O
for	O
characterizing	O
the	O
viral	O
kinetics	O
,	O
transmission	O
,	O
and	O
evolution	B-PROC
.	O

What	O
are	O
the	O
interactions	O
between	O
host	O
and	O
virus	O
that	O
determine	O
both	O
disease	O
form	O
(	O
wet	O
or	O
dry	O
)	O
and	O
outcome	O
(	O
death	B-PROC
or	O
resistance	B-PROC
)?	O

Although	O
poorly	O
understood	O
,	O
it	O
has	O
long	O
been	O
recognized	O
that	O
host	O
regulation	B-PROC
of	O
virus	O
-	O
associated	O
disease	O
severity	O
is	O
multigenic	O
.	O

TITLE	O
:	O
Two	O
-	O
photon	O
imaging	O
of	O
remyelination	B-PROC
of	O
spinal	O
cord	O
axons	O
by	O
engrafted	O
neural	O
precursor	O
cells	O
in	O
a	O
viral	O
model	O
of	O
multiple	O
sclerosis	O
.	O

NPCs	O
engrafted	O
into	O
spinal	O
cords	O
of	O
JHMV	O
-	O
infected	O
mice	O
exhibited	O
diminished	O
migration	B-PROC
velocities	O
and	O
increased	O
proliferation	O
compared	O
with	O
transplanted	O
cells	O
in	O
noninfected	O
mice	O
.	O

In	O
moderate	O
and	O
severe	O
ARDS	O
tracheal	O
intubation	O
associated	O
with	O
heavy	O
sedation	O
/	O
muscle	B-PROC
relaxation	I-PROC
allows	O
to	O
fully	O
characterize	O
the	O
patient	O
.	O

The	O
patient	O
developed	O
posttraumatic	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
,	O
which	O
began	O
to	O
resolve	O
after	O
72	O
hours	O
,	O
and	O
he	O
started	O
breathing	B-PROC
spontaneously	O
.	O

After	O
7	O
days	O
,	O
he	O
was	O
weaned	B-PROC
from	O
vv	O
-	O
ECMO	O
and	O
recovered	O
in	O
a	O
rehabilitation	O
facility	O
.	O

In	O
this	O
study	O
,	O
the	O
ability	O
of	O
adjuvant	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	O
to	O
reduce	O
the	O
side	O
effects	O
of	O
UV	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
vaccination	O
in	O
a	O
BALB	O
/	O
c	O
mouse	O
model	O
was	O
tested	O
,	O
using	O
the	O
mouse	O
-	O
passaged	O
Frankfurt	O
1	O
isolate	O
of	O
SARS	O
-	O
CoV	O
.	O
We	O
found	O
that	O
TLR	O
stimulation	O
reduced	O
the	O
high	O
level	O
of	O
eosinophilic	O
infiltration	O
that	O
occurred	O
in	O
the	O
lungs	O
of	O
mice	O
immunized	O
with	O
UV	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
Microarray	O
analysis	O
revealed	O
that	O
genes	O
associated	O
with	O
chemotaxis	B-PROC
,	O
eosinophil	B-PROC
migration	B-PROC
,	O
eosinophilia	O
,	O
and	O
cell	B-PROC
movement	I-PROC
and	O
the	O
polarization	O
of	O
Th2	O
cells	O
were	O
upregulated	O
in	O
UV	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
-	O
immunized	O
mice	O
.	O

This	O
study	O
may	O
be	O
helpful	O
for	O
elucidating	O
the	O
pathogenesis	B-PROC
underlying	O
eosinophilic	O
infiltration	O
resulting	O
from	O
immunization	O
with	O
inactivated	O
vaccine	O
.	O

Multiplex	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
MRT	O
-	O
PCR	O
)	O
assays	O
for	O
detection	O
of	O
multiple	O
viruses	O
are	O
being	O
used	O
increasingly	O
in	O
clinical	O
settings	O
.	O

Immunization	O
using	O
vaccines	O
is	O
routine	O
practice	O
;	O
however	O
,	O
to	O
combat	O
infectious	O
diseases	O
,	O
conventional	O
vaccines	O
as	O
well	O
as	O
new	O
-	O
generation	O
recombinant	O
vaccines	O
alone	O
,	O
due	O
to	O
relatively	O
weak	O
immunogenicity	O
,	O
may	O
not	O
be	O
effective	O
enough	O
to	O
provide	O
optimum	O
immunity	B-PROC
.	O

The	O
phase	O
of	O
T	O
cell	O
-	O
dependent	O
,	O
antibody	B-PROC
-	O
independent	O
control	O
of	O
infectious	O
virus	O
was	O
associated	O
with	O
a	O
similar	O
recruitment	O
of	O
naive	O
/	O
early	O
-	O
activated	O
IgD	O
(+)	O
IgM	O
(+)	O
B	O
cells	O
into	O
both	O
the	O
brain	O
and	O
spinal	O
cord	O
.	O

This	O
population	O
was	O
progressively	O
replaced	O
by	O
CD138	O
(-)	O
IgD	O
(-)	O
IgM	O
(+)	O
B	O
cells	O
,	O
isotype	O
-	O
switched	O
CD138	O
(-)	O
IgD	O
(-)	O
IgM	O
(-)	O
memory	B-PROC
B	O
cells	O
(	O
B	O
(	O
mem	O
)),	O
and	O
CD138	O
(+)	O
antibody	B-PROC
-	O
secreting	B-PROC
cells	O
(	O
ASC	O
).	O

The	O
results	O
demonstrate	O
that	O
naive	O
/	O
early	O
-	O
activated	O
B	O
cells	O
are	O
recruited	O
early	O
during	O
coronavirus	O
CNS	O
infection	O
but	O
are	O
subsequently	O
replaced	O
by	O
more	O
differentiated	B-PROC
B	O
cells	O
.	O

Moreover	O
,	O
CNS	O
viral	O
persistence	O
is	O
a	O
driving	O
force	O
promoting	O
differentiated	B-PROC
B	O
cells	O
with	O
protective	O
potential	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
nucleocapsid	O
protein	O
antagonizes	O
beta	O
interferon	B-PROC
production	I-PROC
by	O
sequestering	B-PROC
the	O
interaction	O
between	O
IRF3	O
and	O
TBK1	O
.	O

Here	O
we	O
screened	O
a	O
collection	O
of	O
16671	O
diverse	O
compounds	O
for	O
anti	O
-	O
human	O
coronavirus	O
229E	O
activity	O
and	O
identified	O
an	O
inhibitor	O
,	O
designated	O
K22	O
,	O
that	O
specifically	O
targets	O
membrane	O
-	O
bound	O
coronaviral	O
RNA	B-PROC
synthesis	I-PROC
.	O

K22	O
-	O
resistant	O
viruses	O
contained	O
substitutions	O
in	O
non	O
-	O
structural	O
protein	O
6	O
(	O
nsp6	O
),	O
a	O
membrane	O
-	O
spanning	O
integral	O
component	O
of	O
the	O
viral	B-PROC
replication	I-PROC
complex	O
implicated	O
in	O
DMV	O
formation	B-PROC
,	O
corroborating	O
that	O
K22	O
targets	O
membrane	O
bound	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

We	O
expect	O
this	O
mode	O
of	O
action	O
to	O
serve	O
as	O
a	O
paradigm	O
for	O
the	O
development	B-PROC
of	O
potent	O
antiviral	O
drugs	O
to	O
combat	O
many	O
animal	O
and	O
human	O
virus	O
infections	O
.	O

ABSTRACT	O
:	O
Activin	B-PROC
A	O
and	O
its	O
binding	O
protein	O
follistatin	O
(	O
FS	O
)	O
are	O
increased	O
in	O
inflammatory	O
disorders	O
and	O
sepsis	O
.	O

Furthermore	O
,	O
only	O
FcγRII	O
with	O
intact	O
cytoplasmic	O
signaling	B-PROC
domains	O
were	O
competent	O
to	O
sustain	O
ADE	O
of	O
SARS	O
-	O
CoVpp	O
infection	O
,	O
thus	O
providing	O
additional	O
information	O
on	O
the	O
role	O
of	O
downstream	O
signaling	B-PROC
by	O
FcγRII	O
.	O

Furthermore	O
,	O
only	O
FcγRII	O
with	O
intact	O
cytoplasmic	O
signaling	B-PROC
domains	O
were	O
competent	O
to	O
sustain	O
ADE	O
of	O
SARS	O
-	O
CoVpp	O
infection	O
,	O
thus	O
providing	O
additional	O
information	O
on	O
the	O
role	O
of	O
downstream	O
signaling	B-PROC
by	O
FcγRII	O
.	O

Since	O
cellular	B-PROC
immunity	I-PROC
is	O
thought	O
to	O
be	O
critical	O
in	O
preventing	O
FIP	O
and	O
because	O
diseased	O
cats	O
often	O
show	O
a	O
significant	O
decrease	O
in	O
interferon	O
-	O
γ	O
(	O
IFN	O
-	O
γ	O
)	O
production	O
,	O
we	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	B-PROC
(	O
SNP	O
)	O
in	O
the	O
feline	O
IFN	O
-	O
γ	O
gene	O
(	O
fIFNG	O
)	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
infection	O
.	O

The	O
contemporaneous	O
treatment	O
of	O
acute	O
uncomplicated	O
P	O
.	O
vivax	O
and	O
the	O
onset	O
of	O
ARDS	O
on	O
day	O
3	O
in	O
this	O
patient	O
implies	O
a	O
possible	O
but	O
unconfirmed	O
association	O
with	O
death	B-PROC
in	O
this	O
patient	O
.	O

Assuming	O
this	O
death	B-PROC
was	O
caused	O
by	O
P	O
.	O
vivax	O
,	O
the	O
risk	O
of	O
ARDS	O
-	O
related	O
maternal	O
mortality	O
in	O
this	O
setting	O
did	O
not	O
differ	O
significantly	O
between	O
Plasmodium	O
falciparum	O
and	O
P	O
.	O
vivax	O
(	O
0	O
.	O
24	O
per	O
1	O
,	O
000	O
(	O
1	O
/	O
4	O
,	O
158	O
)	O
versus	O
0	O
.	O
23	O
per	O
1	O
,	O
000	O
(	O
1	O
/	O
4	O
,	O
298	O
),	O
contrary	O
to	O
the	O
increased	O
risk	O
of	O
maternal	O
mortality	O
from	O
P	O
.	O
falciparum	O
compared	O
to	O
P	O
.	O
vivax	O
,	O
2	O
.	O
89	O
per	O
1	O
,	O
000	O
(	O
12	O
/	O
4	O
,	O
158	O
)	O
versus	O
0	O
.	O
23	O
per	O
1	O
,	O
000	O
(	O
1	O
/	O
4	O
,	O
298	O
),	O
P	O
=	O
0	O
.	O
003	O
.	O

The	O
primary	O
outcome	O
will	O
be	O
death	B-PROC
.	O

Although	O
there	O
were	O
no	O
clear	O
differences	O
in	O
the	O
levels	O
of	O
cytokines	O
examined	O
in	O
the	O
brains	O
between	O
Fut9	O
(-/-)	O
and	O
wild	O
-	O
type	O
mice	O
except	O
for	O
interferon	O
-	O
β	O
expression	B-PROC
,	O
some	O
of	O
those	O
in	O
the	O
spleens	O
,	O
including	O
interferon	O
-	O
γ	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
1	O
,	O
showed	O
higher	O
levels	O
in	O
Fut9	O
(-/-)	O
than	O
in	O
wild	O
-	O
type	O
mice	O
.	O

Understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
TRALI	O
has	O
resulted	O
in	O
the	O
development	B-PROC
of	O
preventive	O
measures	O
that	O
have	O
contributed	O
to	O
reducing	O
its	O
incidence	O
.	O

reverse	O
-	O
transcription	B-PROC
was	O
more	O
frequently	O
detected	O
in	O
the	O
digestive	B-PROC
system	O
of	O
breeders	O
(	O
40	O
%),	O
and	O
in	O
the	O
digestive	B-PROC
(	O
43	O
.	O
5	O
%)	O
and	O
respiratory	O
(	O
37	O
.	O
7	O
%)	O
systems	O
of	O
broilers	O
.	O

Viral	B-PROC
infection	I-PROC
of	O
cultured	O
cells	O
increased	O
RAE	O
-	O
1	O
expression	B-PROC
,	O
resulting	O
in	O
enhanced	O
NK	O
cell	O
-	O
mediated	O
killing	O
through	O
NKG2D	O
recognition	O
.	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
in	O
a	O
viral	O
-	O
induced	O
demyelination	O
model	O
,	O
NK	O
cells	O
contribute	O
to	O
rejection	O
of	O
allogeneic	O
NPCs	O
through	O
an	O
NKG2D	O
signaling	B-PROC
pathway	I-PROC
.	O

Expression	B-PROC
of	O
hamster	O
DPP4	O
containing	O
the	O
five	O
human	O
DPP4	O
amino	O
acids	O
rendered	O
BHK	O
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
,	O
whereas	O
expression	B-PROC
of	O
human	O
DPP4	O
containing	O
the	O
five	O
hamster	O
DPP4	O
amino	O
acids	O
did	O
not	O
.	O

We	O
discuss	O
the	O
clinical	O
condition	O
of	O
Strongyloides	O
hyperinfection	O
syndrome	O
presenting	O
with	O
severe	O
hypoxemia	O
and	O
complicated	O
by	O
severe	O
diffuse	O
alveolar	O
hemorrhage	O
leading	O
to	O
death	B-PROC
.	O

As	O
such	O
,	O
it	O
is	O
unlikely	O
to	O
reflect	O
the	O
transcriptional	B-PROC
complexity	O
of	O
the	O
mouse	O
species	O
.	O

Gene	B-PROC
transcription	I-PROC
is	O
dynamic	O
and	O
condition	O
-	O
specific	O
;	O
therefore	O
,	O
to	O
better	O
understand	O
the	O
mouse	O
transcriptional	B-PROC
response	O
to	O
respiratory	O
virus	B-PROC
infection	I-PROC
,	O
we	O
infected	O
the	O
eight	O
founder	O
strains	O
of	O
the	O
Collaborative	O
Cross	O
with	O
either	O
influenza	O
A	O
virus	O
or	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
sequenced	O
lung	O
RNA	O
samples	O
at	O
2	O
and	O
4	O
days	O
after	O
infection	O
.	O

On	O
the	O
second	O
day	O
postoperative	O
,	O
the	O
patient	O
developed	O
numbness	O
moving	B-PROC
upward	O
from	O
the	O
hands	O
and	O
feet	O
,	O
loss	O
of	O
strength	O
,	O
difficulty	O
swallowing	B-PROC
and	O
respiratory	O
distress	O
.	O

After	O
10	O
days	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
at	O
which	O
the	O
respiratory	O
,	O
hemodynamic	B-PROC
,	O
neurologic	O
and	O
laboratory	O
results	O
returned	O
to	O
normal	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
neurology	O
service	O
.	O

Since	O
many	O
cytoplasmic	O
viruses	O
exploit	O
similar	O
mechanisms	O
of	O
innate	O
immune	B-PROC
evasion	I-PROC
,	O
mechanistic	O
insight	O
into	O
the	O
direct	O
interplay	O
between	O
viral	O
RNA	O
,	O
viral	O
RNA	O
-	O
processing	O
enzymes	O
,	O
cellular	O
sensors	O
and	O
antiviral	O
proteins	O
will	O
be	O
highly	O
relevant	O
to	O
develop	O
novel	O
antiviral	O
targets	O
and	O
to	O
restrict	O
important	O
animal	O
and	O
human	O
infections	O
.	O

Clinical	O
data	O
and	O
laboratory	O
findings	O
including	O
autoantibodies	O
,	O
immunoglobulin	B-PROC
levels	O
as	O
well	O
as	O
number	O
of	O
T	O
,	O
B	O
and	O
NK	O
cells	O
were	O
evaluated	O
.	O

Two	O
cousins	O
of	O
PI	O
had	O
the	O
same	O
hypomorphic	O
splice	O
site	O
mutation	O
leading	O
to	O
a	O
deletion	O
of	O
27	O
amino	O
acids	O
,	O
but	O
normal	O
FOXP3	O
protein	B-PROC
expression	B-PROC
and	O
normal	O
suppressive	O
capacity	O
of	O
T	O
reg	O
in	O
a	O
proliferation	O
inhibition	B-PROC
assay	O
.	O

Overall	O
5	O
,	O
329	O
lncRNAs	O
were	O
differentially	O
expressed	B-PROC
after	O
infection	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
investigate	O
the	O
prevalence	O
and	O
track	O
genetic	O
and	O
antigenic	O
evolutions	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
their	O
prevalence	O
in	O
Guangxi	O
,	O
China	O
since	O
1985	O
,	O
gene	B-PROC
amplification	I-PROC
and	O
sequencing	O
and	O
virus	B-PROC
neutralization	I-PROC
(	O
VN	O
)	O
test	O
on	O
chicken	O
embryo	O
tracheal	O
organ	O
cultures	O
were	O
used	O
in	O
genotyping	O
and	O
serotyping	O
of	O
28	O
IBV	O
isolates	O
during	O
2009	O
-	O
2011	O
in	O
Guangxi	O
.	O

The	O
coronavirus	O
nonstructural	O
integral	O
membrane	O
proteins	O
(	O
nsps	O
)	O
3	O
,	O
4	O
and	O
6	O
,	O
are	O
key	O
players	O
in	O
the	O
formation	B-PROC
of	O
the	O
rearranged	O
membranes	O
.	O

They	O
are	O
the	O
cause	O
of	O
severe	O
problems	O
with	O
kidney	O
disease	O
and	O
reproductive	B-PROC
tract	O
disorders	O
.	O

Severe	O
lung	O
disease	O
in	O
newborn	O
infants	O
and	O
older	O
patients	O
is	O
caused	O
by	O
mutations	O
in	O
genes	O
regulating	O
alveolar	O
epithelial	O
cells	O
and	O
surfactant	B-PROC
homeostasis	I-PROC
.	O

TITLE	O
:	O
Genetic	O
manipulation	O
of	O
outer	O
membrane	B-PROC
permeability	I-PROC
:	O
generating	O
porous	O
heterogeneous	O
catalyst	O
analogs	O
in	O
Escherichia	O
coli	O
.	O

Inflammation	O
-	O
related	O
gene	B-PROC
expression	I-PROC
was	O
detected	O
by	O
real	O
-	O
time	O
PCR	O
,	O
immunohistochemistry	O
and	O
Western	O
blotting	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	O
,	O
interleukin	O
(	O
IL	O
)-	O
1β	O
,	O
IL	O
-	O
6	O
,	O
and	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)-	O
α	O
,	O
were	O
also	O
increased	O
significantly	O
at	O
72	O
h	O
post	O
-	O
infection	O
.	O

Virus	B-PROC
infection	I-PROC
was	O
observed	O
in	O
lung	O
,	O
liver	O
,	O
and	O
brain	O
tissue	O
.	O

Venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
an	O
effective	O
adjunctive	O
therapy	O
and	O
can	O
be	O
used	O
as	O
a	O
life	O
-	O
saving	O
procedure	O
for	O
carefully	O
selected	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
when	O
the	O
limits	O
of	O
standard	O
therapy	O
have	O
been	O
reached	O
.	O

Complications	O
related	O
to	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
included	O
severe	O
bleeding	O
(	O
n	O
=	O
2	O
;	O
6	O
.	O
5	O
%)	O
and	O
mechanical	O
complications	O
of	O
the	O
circuits	O
(	O
n	O
=	O
3	O
;	O
9	O
.	O
7	O
%).	O

ABSTRACT	O
:	O
Programmed	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
(-	O
1PRF	O
)	O
is	O
an	O
mRNA	O
recoding	O
event	O
utilized	O
by	O
cells	O
to	O
enhance	O
the	O
information	O
content	O
of	O
the	O
genome	O
and	O
to	O
regulate	O
gene	B-PROC
expression	I-PROC
.	O

TITLE	O
:	O
Surfactant	O
protein	O
A	O
genetic	O
variants	O
associate	O
with	O
severe	O
respiratory	O
insufficiency	O
in	O
pandemic	O
influenza	O
A	O
virus	B-PROC
infection	I-PROC
.	O

Oseltamivir	O
,	O
anti	O
-	O
infective	O
drugs	O
,	O
methylprednisolone	O
,	O
albumin	O
,	O
and	O
intravenous	O
immunoglobulin	B-PROC
were	O
administered	O
.	O

TITLE	O
:	O
Automatic	O
protective	O
ventilation	O
using	O
the	O
ARDSNet	O
protocol	O
with	O
the	O
additional	O
monitoring	O
of	O
electrical	B-PROC
impedance	I-PROC
tomography	O
.	O

The	O
most	O
appropriate	O
FCoV	O
antibody	B-PROC
test	O
to	O
use	O
depends	O
on	O
the	O
reason	O
for	O
testing	O
:	O
in	O
excluding	O
a	O
diagnosis	O
of	O
FIP	O
,	O
sensitivity	O
,	O
specificity	O
,	O
small	O
sample	O
quantity	O
,	O
rapidity	O
and	O
ability	O
to	O
work	O
in	O
the	O
presence	O
of	O
virus	O
all	O
matter	O
.	O

One	O
hundred	O
and	O
two	O
indoor	O
patients	O
with	O
isolated	O
P	O
vivax	O
malaria	O
were	O
included	O
in	O
this	O
study	O
with	O
exclusion	O
of	O
other	O
causes	O
of	O
fever	B-PROC
including	O
P	O
falciparum	O
malaria	O
.	O

Using	O
the	O
method	O
of	O
GST	O
pull	O
-	O
down	O
with	O
the	O
nucleocapsid	O
(	O
N	O
),	O
N	O
protein	O
was	O
found	O
to	O
interact	O
with	O
swine	O
testes	O
(	O
ST	O
)	O
cells	O
elongation	O
factor	O
1	O
-	O
alpha	O
(	O
EF1A	O
),	O
an	O
essential	O
component	O
of	O
the	O
translational	B-PROC
machinery	O
with	O
an	O
important	O
role	O
in	O
cells	O
.	O

Mechanical	O
ventilation	O
with	O
positive	O
intrathoracic	O
pressure	O
further	O
induces	O
salt	O
and	O
water	O
retention	B-PROC
,	O
while	O
impairing	O
the	O
pathways	B-PROC
designed	O
for	O
edema	O
clearance	O
.	O

The	O
survey	O
was	O
distributed	O
using	O
a	O
commercial	O
website	O
that	O
collected	O
information	O
on	O
center	O
characteristics	O
,	O
the	O
presence	O
of	O
a	O
mechanical	O
ventilator	O
protocol	O
,	O
ventilator	O
settings	O
,	O
and	O
weaning	B-PROC
practices	O
.	O

Primers	O
were	O
designed	O
based	O
on	O
multiple	O
alignment	O
of	O
reference	O
sequences	O
,	O
targeting	B-PROC
the	O
conserved	O
regions	O
of	O
each	O
species	O
of	O
HcoV	O
.	O
Virus	O
strains	O
and	O
nucleic	O
acid	O
preserved	O
in	O
our	O
lab	O
were	O
used	O
as	O
template	O
in	O
developing	O
this	O
automatic	O
-	O
electrophoresis	O
-	O
based	O
one	O
-	O
tube	O
multiplex	O
RT	O
-	O
PCR	O
assay	O
.	O

Adjunctive	O
use	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
INO	O
)	O
is	O
well	O
-	O
defined	O
as	O
a	O
rescue	O
therapy	O
in	O
severe	O
ARDS	O
,	O
but	O
its	O
specific	O
role	O
in	O
intracranial	O
hypertension	O
is	O
somewhat	O
uncertain	O
.	O

However	O
,	O
under	O
prolonged	O
ER	O
stress	O
,	O
UPR	O
can	O
also	O
induce	O
apoptotic	B-PROC
cell	B-PROC
death	I-PROC
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
on	O
coronavirus	O
-	O
induced	O
ER	O
stress	O
and	O
UPR	O
activation	O
,	O
with	O
emphasis	O
on	O
their	O
cross	O
-	O
talking	B-PROC
to	O
apoptotic	O
signaling	B-PROC
.	O

Analysis	O
of	O
WIPI2	O
puncta	O
induced	O
by	O
NSP6	O
suggests	O
that	O
NSP6	O
limits	O
autophagosome	O
diameter	O
at	O
the	O
point	O
of	O
omegasome	O
formation	B-PROC
.	O

The	O
unique	O
features	O
observed	O
in	O
the	O
crystal	O
structure	O
of	O
the	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
)	O
should	O
allow	O
the	O
design	O
of	O
antivirals	O
that	O
would	O
not	O
interfere	O
with	O
host	O
ubiquitin	B-PROC
-	O
specific	O
proteases	O
.	O

To	O
address	O
this	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
different	O
repetitive	O
peptides	O
expressed	B-PROC
by	O
L	O
.	O
casei	O
,	O
specifically	O
the	O
MDP	O
and	O
tuftsin	O
fusion	O
protein	O
(	O
MT	O
)	O
repeated	O
20	O
and	O
40	O
times	O
(	O
20MT	O
and	O
40MT	O
),	O
in	O
mice	O
also	O
expressing	O
the	O
D	O
antigenic	O
site	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
on	O
intestinal	O
and	O
systemic	O
immune	B-PROC
responses	I-PROC
and	O
confirmed	O
the	O
immunoregulation	B-PROC
of	O
these	O
peptides	O
.	O

Increased	O
IgG	O
and	O
IgA	O
resulted	O
in	O
the	O
activation	O
of	O
TGEV	O
-	O
neutralising	O
antibody	B-PROC
activity	I-PROC
in	O
vitro	O
.	O

Notably	O
,	O
treatment	O
of	O
mice	O
with	O
L	O
.	O
casei	O
expressing	O
20MT	O
and	O
40MT	O
enhanced	O
the	O
anti	O
-	O
TGEV	O
antibody	B-PROC
immune	B-PROC
responses	I-PROC
of	O
both	O
the	O
humoral	O
and	O
mucosal	O
immune	O
systems	O
.	O

These	O
molecules	O
inhibit	O
not	O
only	O
HIV	O
integrase	O
catalytic	O
activity	O
,	O
but	O
they	O
also	O
interfere	O
with	O
the	O
function	O
of	O
the	O
RNase	O
H	O
component	O
of	O
the	O
HIV	O
reverse	O
transcriptase	B-PROC
.	O

Of	O
interest	O
,	O
serum	O
miR	O
-	O
125b	O
expression	B-PROC
was	O
also	O
decreased	O
and	O
inversely	O
correlated	O
with	O
the	O
disease	O
severity	O
in	O
patients	O
with	O
ARDS	O
.	O

TITLE	O
:	O
Coronavirus	O
-	O
induced	O
demyelination	O
of	O
neural	O
pathways	B-PROC
triggers	O
neurogenic	O
bladder	O
overactivity	O
in	O
a	O
mouse	O
model	O
of	O
multiple	O
sclerosis	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
induces	O
caspase	B-PROC
-	I-PROC
independent	I-PROC
apoptosis	B-PROC
through	O
activation	O
of	O
mitochondrial	O
apoptosis	B-PROC
-	O
inducing	O
factor	O
.	O

We	O
evaluated	O
the	O
proportion	O
of	O
SARI	O
/	O
ARDS	O
cases	O
and	O
deaths	B-PROC
due	O
to	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
infection	O
and	O
the	O
impact	O
of	O
other	O
respiratory	O
viruses	O
during	O
pandemic	O
and	O
postpandemic	O
period	O
(	O
2009	O
-	O
2011	O
)	O
in	O
northern	O
Italy	O
;	O
additionally	O
we	O
searched	O
for	O
unknown	O
viruses	O
in	O
those	O
cases	O
for	O
which	O
diagnosis	O
remained	O
negative	O
.	O

This	O
review	O
provides	O
insight	O
on	O
the	O
development	B-PROC
of	O
intranasal	O
DNA	O
vaccine	O
for	O
respiratory	O
infections	O
,	O
with	O
special	O
attention	O
paid	O
to	O
the	O
strategies	O
to	O
improve	O
the	O
delivery	O
of	O
DNA	O
vaccines	O
using	O
non	O
-	O
viral	O
delivery	O
agents	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
antiviral	O
activity	O
of	O
new	O
phenylimidazopyridines	O
and	O
N	O
-	O
benzylidenequinolinamines	O
derived	O
by	O
molecular	O
simplification	O
of	O
phenylimidazo	O
[	O
4	O
,	O
5	O
-	O
g	O
]	O
quinolines	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
evaluation	O
of	O
a	O
duplex	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
for	O
detection	O
and	O
differentiation	B-PROC
of	O
virulent	O
and	O
variant	O
strains	O
of	O
porcine	O
epidemic	O
diarrhea	O
viruses	O
from	O
the	O
United	O
States	O
.	O

The	O
lack	O
of	O
assays	O
to	O
easily	O
detect	O
the	O
different	O
steps	O
of	O
entry	O
severely	O
hampers	O
the	O
analysis	O
of	O
this	O
key	O
process	O
in	O
virus	B-PROC
infection	I-PROC
.	O

After	O
controlling	O
for	O
confounding	O
variables	O
,	O
there	O
was	O
no	O
significant	O
association	O
between	O
the	O
volume	O
of	O
IV	O
fluids	O
administered	O
in	O
the	O
first	O
24	O
hours	O
of	O
hospitalization	O
and	O
the	O
development	B-PROC
of	O
ARDS	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
1	O
.	O
05	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
0	O
.	O
95	O
-	O
1	O
.	O
18	O
).	O

The	O
presence	O
of	O
a	O
genetically	O
divergent	O
S1	O
subunit	O
within	O
the	O
NeoCoV	O
spike	O
gene	O
indicated	O
that	O
intraspike	O
recombination	B-PROC
events	O
may	O
have	O
been	O
involved	O
in	O
the	O
emergence	O
of	O
MERS	O
-	O
CoV	O
.	O
NeoCoV	O
constitutes	O
a	O
sister	O
taxon	O
of	O
MERS	O
-	O
CoV	O
,	O
placing	O
the	O
MERS	O
-	O
CoV	O
root	O
between	O
a	O
recently	O
described	O
virus	O
from	O
African	O
camels	O
and	O
all	O
other	O
viruses	O
.	O

The	O
bat	O
virus	O
roots	O
the	O
phylogenetic	O
tree	O
of	O
MERS	O
-	O
CoV	O
,	O
providing	O
evidence	O
for	O
an	O
evolution	B-PROC
of	O
MERS	O
-	O
CoV	O
in	O
camels	O
that	O
preceded	O
that	O
in	O
humans	O
.	O

By	O
ligating	O
head	O
-	O
to	O
-	O
tail	O
viral	O
RNA	O
positive	O
strands	O
and	O
sequencing	O
,	O
we	O
found	O
that	O
(	O
1	O
)	O
the	O
regulation	B-PROC
pattern	O
of	O
coronaviral	O
poly	O
(	O
A	O
)	O
tail	O
length	O
in	O
BCoV	O
-	O
infected	O
hamster	O
kidney	O
-	O
21	O
(	O
BHK	O
-	O
21	O
)	O
cells	O
was	O
similar	O
to	O
that	O
in	O
BCoV	O
-	O
infected	O
HRT	O
-	O
18	O
cells	O
and	O
(	O
2	O
)	O
the	O
poly	O
(	O
A	O
)	O
tail	O
length	O
of	O
wild	O
-	O
type	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
virulent	O
strain	O
IBV	O
-	O
TW1	O
,	O
which	O
is	O
in	O
the	O
genus	O
gammacoronaviruses	O
,	O
varied	O
throughout	O
infection	O
in	O
primary	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	O
and	O
in	O
the	O
tracheas	O
of	O
1	O
-	O
day	O
-	O
old	O
chicks	O
.	O

Efforts	O
to	O
minimize	O
bloodstream	B-PROC
infections	O
during	O
the	O
resuscitation	O
must	O
be	O
increased	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
effects	O
of	O
treatment	O
approach	O
on	O
the	O
outcomes	O
of	O
newborns	O
(	O
birth	B-PROC
weight	O
[	O
BW	O
]	O
<	O
1	O
,	O
000	O
g	O
)	O
with	O
patent	O
ductus	O
arteriosus	O
(	O
PDA	O
),	O
from	O
the	O
Brazilian	O
Neonatal	O
Research	O
Network	O
(	O
BNRN	O
)	O
on	O
:	O
death	B-PROC
,	O
bronchopulmonary	O
dysplasia	O
(	O
BPD	O
),	O
severe	O
intraventricular	O
hemorrhage	O
(	O
IVH	O
III	O
/	O
IV	O
),	O
retinopathy	O
of	O
prematurity	O
requiring	O
surgical	O
(	O
ROPsur	O
),	O
necrotizing	O
enterocolitis	O
requiring	O
surgery	O
(	O
NECsur	O
),	O
and	O
death	B-PROC
/	O
BPD	O
.	O

The	O
conservative	O
approach	O
of	O
PDA	O
was	O
associated	O
to	O
high	O
mortality	O
,	O
the	O
surgical	O
approach	O
to	O
the	O
occurrence	O
of	O
BPD36wks	O
and	O
ROPsur	O
,	O
and	O
the	O
pharmacological	O
treatment	O
was	O
protective	O
for	O
the	O
outcome	O
death	B-PROC
/	O
BPD36wks	O
.	O

IgA	O
antibody	B-PROC
levels	O
were	O
higher	O
than	O
IgG	O
antibody	B-PROC
levels	O
throughout	O
the	O
primary	O
response	O
in	O
tears	O
and	O
were	O
similar	O
in	O
magnitude	O
in	O
plasma	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
ability	O
of	O
virus	O
-	O
specific	O
memory	B-PROC
CD8	O
T	O
cells	O
to	O
mediate	O
protection	O
against	O
infection	O
in	O
the	O
absence	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
memory	B-PROC
CD4	O
T	O
or	O
B	O
cells	O
.	O

Intravenous	O
immunization	O
with	O
peptide	O
-	O
loaded	O
dendritic	O
cells	O
(	O
DCs	O
)	O
followed	O
by	O
intranasal	O
boosting	O
with	O
recombinant	O
vaccinia	O
virus	O
(	O
rVV	O
)	O
encoding	O
S436	O
or	O
S525	O
resulted	O
in	O
accumulation	O
of	O
virus	O
-	O
specific	O
memory	B-PROC
CD8	O
T	O
cells	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BAL	O
),	O
lungs	O
,	O
and	O
spleen	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
proprotein	O
convertases	O
abrogates	O
processing	O
of	O
the	O
middle	O
eastern	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
in	O
infected	O
cells	O
but	O
does	O
not	O
reduce	O
viral	O
infectivity	O
.	O

The	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
(	O
MERS	O
-	O
S	O
)	O
facilitates	O
viral	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
,	O
which	O
depends	O
on	O
activation	O
of	O
MERS	O
-	O
S	O
by	O
cellular	O
proteases	O
.	O

Histological	O
examination	O
of	O
the	O
lung	O
showed	O
alveolar	O
damage	O
,	O
microvascular	O
congestion	O
,	O
microvascular	O
injury	O
,	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
pulmonary	O
edema	O
and	O
necrosis	B-PROC
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

ABSTRACT	O
:	O
We	O
found	O
serologic	O
evidence	O
for	O
the	O
circulation	B-PROC
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
among	O
dromedary	O
camels	O
in	O
Nigeria	O
,	O
Tunisia	O
,	O
and	O
Ethiopia	O
.	O

In	O
disease	O
-	O
endemic	O
areas	O
,	O
murine	O
typhus	O
should	O
be	O
considered	O
for	O
patients	O
with	O
respiratory	O
symptoms	O
and	O
fever	B-PROC
.	O

TITLE	O
:	O
Chimeric	O
influenza	O
-	O
virus	O
-	O
like	O
particles	O
containing	O
the	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
GP5	O
protein	O
and	O
the	O
influenza	O
virus	O
HA	O
and	O
M1	O
proteins	O
.	O

TITLE	O
:	O
Bicaval	O
dual	O
-	O
lumen	O
cannula	O
for	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
:	O
Avalon	O
©	O
cannula	O
in	O
childhood	O
disease	O
.	O

When	O
conservative	O
oxygenation	B-PROC
methods	O
fail	O
,	O
a	O
lifesaving	O
measure	O
is	O
the	O
introduction	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

Here	O
,	O
by	O
insertion	O
of	O
one	O
single	O
catheter	O
in	O
one	O
target	O
vessel	O
,	O
in	O
a	O
majority	O
of	O
cases	O
in	O
the	O
right	O
internal	O
jugular	O
vein	O
,	O
satisfactory	O
oxygenation	B-PROC
of	O
the	O
patient	O
is	O
achieved	O
.	O

According	O
to	O
flow	O
cytometry	O
data	O
,	O
the	O
HL	O
-	O
CZ	O
cells	O
also	O
expressed	B-PROC
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
,	O
a	O
SARS	O
-	O
CoV	O
receptor	O
)	O
and	O
higher	O
levels	O
of	O
the	O
FcγRII	O
receptor	O
.	O

Testing	O
for	O
circulating	O
FIV	O
antibody	B-PROC
and	O
FeLV	O
antigen	O
,	O
a	O
PCR	O
assay	O
for	O
feline	O
coronavirus	O
performed	O
on	O
a	O
sample	O
of	O
peritoneal	O
fluid	O
,	O
and	O
fecal	O
flotation	O
yielded	O
negative	O
results	O
.	O

Our	O
study	O
shows	O
that	O
IAPV	O
is	O
established	O
as	O
a	O
persistent	O
infection	O
in	O
honey	O
bee	O
populations	O
,	O
likely	O
enabled	O
by	O
both	O
horizontal	O
and	O
vertical	O
transmission	O
pathways	B-PROC
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
real	O
-	O
time	O
quantitative	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
to	O
analyze	O
the	O
cis	O
-	O
acting	O
elements	O
on	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
sgmRNA	O
7	O
required	O
for	O
the	O
synthesis	B-PROC
of	O
its	O
(-)-	O
strand	O
counterpart	O
by	O
deletion	O
mutagenesis	B-PROC
.	O

TITLE	O
:	O
Varying	O
antibody	B-PROC
responses	I-PROC
of	O
laying	O
hens	O
housed	O
in	O
an	O
aviary	O
system	O
and	O
in	O
furnished	O
cages	O
.	O

Our	O
data	O
revealed	O
that	O
PEDV	O
entry	O
followed	O
clathrin	B-PROC
-	I-PROC
mediated	I-PROC
endocytosis	I-PROC
and	O
was	O
dependent	O
on	O
a	O
low	O
pH	O
and	O
serine	O
proteolysis	B-PROC
for	O
successful	O
entry	O
into	O
cells	O
.	O

TITLE	O
:	O
The	O
vaccine	O
efficacy	O
of	O
recombinant	O
duck	O
enteritis	O
virus	O
expressing	O
secreted	B-PROC
E	O
with	O
or	O
without	O
PrM	O
proteins	O
of	O
duck	O
tembusu	O
virus	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
Temporal	O
Association	O
between	O
Kawasaki	O
Disease	O
and	O
Viral	B-PROC
Infections	I-PROC
in	O
South	O
Korea	O
.	O

For	O
on	O
-	O
farm	O
detection	O
of	O
PEDV	O
RNA	O
in	O
feed	O
,	O
paint	O
rollers	O
were	O
used	O
to	O
collect	O
material	O
from	O
at	O
-	O
risk	O
feed	O
bins	O
from	O
3	O
clinically	O
affected	O
breeding	B-PROC
herds	O
.	O

Clinical	O
signs	O
of	O
PEDV	O
infection	O
(	O
vomiting	O
and	O
diarrhea	O
)	O
and	O
viral	B-PROC
shedding	I-PROC
were	O
observed	O
in	O
both	O
the	O
Positive	O
control	O
and	O
Treatment	O
group	O
'	O
post	O
-	O
consumption	O
with	O
virus	O
and	O
microscopic	O
lesions	O
detected	O
in	O
intestinal	O
samples	O
No	O
evidence	O
of	O
infection	O
was	O
observed	O
in	O
the	O
Negative	O
controls	O
.	O

RESULTS	O
:	O
For	O
on	O
-	O
farm	O
detection	O
of	O
PEDV	O
RNA	O
in	O
feed	O
,	O
paint	O
rollers	O
were	O
used	O
to	O
collect	O
material	O
from	O
at	O
-	O
risk	O
feed	O
bins	O
from	O
3	O
clinically	O
affected	O
breeding	B-PROC
herds	O
.	O

Age	O
,	O
female	O
sex	O
,	O
and	O
higher	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
were	O
associated	O
with	O
complications	O
.	O

Quantitative	O
PCR	O
studies	O
and	O
fluorescence	O
-	O
activated	O
cell	O
sorting	B-PROC
(	O
FACS	O
)	O
analyses	O
showed	O
that	O
RDS1759	O
selectively	O
inhibited	O
reverse	B-PROC
transcription	B-PROC
in	O
cell	O
-	O
based	O
assays	O
.	O

Some	O
CoV	O
proteins	O
act	O
as	O
antagonists	O
of	O
interferon	O
(	O
IFN	O
)	O
by	O
inhibiting	O
IFN	O
production	O
or	O
signaling	B-PROC
,	O
aspects	O
that	O
are	O
briefly	O
addressed	O
in	O
this	O
review	O
.	O

After	O
CoV	O
infection	O
,	O
potent	O
cytokines	O
relevant	O
in	O
controlling	O
virus	O
infections	O
and	O
priming	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
are	O
also	O
generated	O
.	O

However	O
,	O
an	O
uncontrolled	O
induction	O
of	O
these	O
proinflammatory	O
cytokines	O
can	O
lead	O
to	O
pathogenesis	B-PROC
and	O
disease	O
severity	O
as	O
described	O
for	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
The	O
cellular	O
pathways	B-PROC
mediated	O
by	O
interferon	O
regulatory	O
factor	O
(	O
IRF	O
)-	O
3	O
and	O
-	O
7	O
,	O
activating	O
transcription	B-PROC
factor	O
(	O
ATF	O
)-	O
2	O
/	O
jun	O
,	O
activator	O
protein	O
(	O
AP	O
)-	O
1	O
,	O
nuclear	O
factor	O
kappa	O
-	O
light	O
-	O
chain	O
-	O
enhancer	O
of	O
activated	O
B	O
cells	O
(	O
NF	O
-	O
κB	O
),	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
),	O
are	O
the	O
main	O
drivers	O
of	O
the	O
inflammatory	B-PROC
response	I-PROC
triggered	O
after	O
viral	B-PROC
infections	I-PROC
,	O
with	O
NF	O
-	O
κB	O
pathway	B-PROC
the	O
most	O
frequently	O
activated	O
.	O

Although	O
E	O
protein	O
is	O
not	O
essential	O
for	O
CoV	O
genome	O
replication	O
or	O
subgenomic	O
mRNA	B-PROC
synthesis	I-PROC
,	O
it	O
affects	O
virus	O
morphogenesis	B-PROC
,	O
budding	B-PROC
,	O
assembly	O
,	O
intracellular	O
trafficking	B-PROC
,	O
and	O
virulence	B-PROC
.	O

TITLE	O
:	O
Coronaviruses	O
induce	O
entry	O
-	O
independent	O
,	O
continuous	O
macropinocytosis	B-PROC
.	O

Murine	O
hepatitis	O
virus	O
macropinocytosis	B-PROC
requires	O
a	O
fusogenic	O
virus	O
spike	O
protein	O
and	O
signals	O
through	O
the	O
epidermal	O
growth	B-PROC
factor	O
receptor	O
and	O
the	O
classical	O
macropinocytosis	B-PROC
pathway	B-PROC
.	O

Sweet	B-PROC
syndrome	O
has	O
rare	O
oral	O
manifestations	O
secondary	O
to	O
hematological	O
changes	O
.	O

ABSTRACT	O
:	O
Viral	O
protease	B-PROC
inhibitors	I-PROC
are	O
remarkably	O
effective	O
at	O
blocking	O
the	O
replication	O
of	O
viruses	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
and	O
hepatitis	O
C	O
virus	O
,	O
but	O
they	O
inevitably	O
lead	O
to	O
the	O
selection	O
of	O
inhibitor	O
-	O
resistant	O
mutants	O
,	O
which	O
may	O
contribute	O
to	O
ongoing	O
disease	O
.	O

He	O
was	O
treated	O
with	O
antibiotics	O
,	O
intravenous	O
immunoglobulin	B-PROC
,	O
and	O
oxygen	O
by	O
nasal	O
cannula	O
.	O

Further	O
,	O
M133	O
Tregs	O
inhibited	O
migration	B-PROC
of	O
M133	O
Tconv	O
from	O
the	O
DLN	O
.	O

These	O
cells	O
are	O
more	O
suppressive	O
than	O
bulk	O
Tregs	O
and	O
provide	O
a	O
targeted	B-PROC
approach	O
to	O
ameliorating	O
immunopathological	O
disease	O
in	O
infectious	O
settings	O
.	O

RESULTS	O
:	O
The	O
RT	O
-	O
LAMP	O
assay	O
was	O
capable	O
of	O
detecting	O
as	O
few	O
as	O
3	O
.	O
4	O
copies	O
of	O
MERS	O
-	O
CoV	O
RNA	O
,	O
and	O
was	O
highly	O
specific	O
,	O
with	O
no	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
to	O
other	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Inflammatory	O
and	O
cell	O
-	O
mediated	O
immune	B-PROC
responses	I-PROC
in	O
the	O
respiratory	O
tract	O
of	O
chickens	O
to	O
infection	O
with	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

In	O
conclusion	O
,	O
an	O
early	O
upregulation	B-PROC
of	O
expression	B-PROC
of	O
proinflammatory	O
cytokines	O
such	O
as	O
IL6	O
,	O
IL1β	O
,	O
and	O
IFNγ	O
induced	O
by	O
the	O
M41	O
strain	O
of	O
IBV	O
may	O
be	O
partially	O
implicated	O
in	O
the	O
viral	O
pathogenicity	O
on	O
trachea	O
tissues	O
of	O
nonimmune	O
challenged	O
chickens	O
,	O
in	O
addition	O
to	O
a	O
late	O
induction	O
of	O
a	O
putative	O
protective	O
immune	B-PROC
responses	I-PROC
by	O
this	O
virus	O
through	O
upregulation	B-PROC
of	O
CD8αα	O
and	O
Granzyme	O
homolog	O
A	O
genes	O
in	O
this	O
organ	O
.	O

ABSTRACT	O
:	O
Leukocyte	B-PROC
adhesion	I-PROC
deficiency	O
type	O
1	O
(	O
LAD	O
1	O
-	O
CD18	O
deficiency	O
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
disturbance	O
of	O
phagocyte	O
function	O
associated	O
with	O
less	O
severe	O
cellular	O
and	O
humoral	O
dysfunction	O
.	O

The	O
infections	O
are	O
indolent	O
,	O
necrotic	B-PROC
and	O
recurrent	O
.	O

Nevertheless	O
,	O
its	O
high	O
recombination	B-PROC
rate	O
may	O
result	O
in	O
the	O
loss	O
of	O
the	O
full	O
-	O
length	O
foreign	O
gene	O
,	O
limiting	O
their	O
use	O
as	O
vectors	O
.	O

It	O
is	O
synergistic	O
with	O
neuraminidase	B-PROC
inhibitors	I-PROC
,	O
and	O
combination	O
therapy	O
with	O
oseltamivir	O
is	O
being	O
studied	O
in	O
humans	O
as	O
part	O
of	O
ongoing	O
Phase	O
3	O
clinical	O
development	B-PROC
.	O

However	O
,	O
over	O
the	O
last	O
decade	O
it	O
has	O
become	O
clear	O
that	O
aggressive	B-PROC
fluid	O
resuscitation	O
leading	O
to	O
fluid	O
overload	O
is	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
across	O
a	O
diverse	O
group	O
of	O
patients	O
,	O
including	O
patients	O
with	O
severe	O
sepsis	O
as	O
well	O
as	O
elective	O
surgical	O
and	O
trauma	O
patients	O
and	O
those	O
with	O
pancreatitis	O
.	O

Normal	O
saline	O
(	O
0	O
.	O
9	O
%	O
salt	O
solution	O
)	O
as	O
compared	O
to	O
balanced	O
electrolyte	O
solutions	O
is	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
acute	O
kidney	O
injury	O
and	O
death	B-PROC
.	O

Mean	O
partial	O
oxygen	O
pressure	O
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
was	O
58	O
.	O
1	O
.	O

TITLE	O
:	O
Palmitoylation	B-PROC
of	O
the	O
Alphacoronavirus	O
TGEV	O
spike	O
protein	O
S	O
is	O
essential	O
for	O
incorporation	O
into	O
virus	O
-	O
like	O
particles	O
but	O
dispensable	O
for	O
S	O
-	O
M	O
interaction	O
.	O

This	O
motif	O
is	O
palmitoylated	O
in	O
the	O
Betacoronaviruses	O
MHV	O
and	O
SARS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
demonstrate	O
by	O
metabolic	B-PROC
labeling	O
with	O
[(	O
3	O
)	O
H	O
]-	O
palmitic	O
acid	O
that	O
the	O
S	O
protein	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
),	O
an	O
Alphacoronavirus	O
,	O
is	O
palmitoylated	O
as	O
well	O
.	O

Since	O
the	O
3a	O
protein	O
forms	O
ion	O
channels	O
,	O
we	O
were	O
interested	O
to	O
see	O
any	O
conformational	O
changes	O
occurring	O
in	O
the	O
Cyot3a	O
upon	O
calcium	B-PROC
binding	I-PROC
,	O
using	O
fluorescence	O
spectroscopy	O
and	O
circular	O
dichroism	O
.	O

Here	O
we	O
report	O
that	O
E	O
protein	O
PDZ	O
-	O
binding	O
motif	O
(	O
PBM	O
),	O
a	O
domain	O
involved	O
in	O
protein	O
-	O
protein	O
interactions	O
,	O
is	O
a	O
major	O
determinant	O
of	O
virulence	B-PROC
.	O

Silencing	O
of	O
syntenin	O
using	O
siRNAs	O
led	O
to	O
a	O
decrease	O
in	O
p38	O
MAPK	B-PROC
activation	I-PROC
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
,	O
further	O
reinforcing	O
their	O
functional	O
relationship	O
.	O

Since	O
it	O
has	O
been	O
reported	O
that	O
sepsis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
contribute	O
to	O
brain	O
dysfunction	O
,	O
we	O
investigated	O
the	O
brain	O
-	O
lung	O
crosstalk	B-PROC
using	O
a	O
combined	O
experimental	O
in	O
vitro	O
airway	O
epithelial	O
and	O
brain	O
cell	O
injury	O
model	O
.	O

Levels	O
of	O
brain	O
damage	O
markers	O
S100	O
calcium	B-PROC
binding	I-PROC
protein	O
B	O
and	O
neuron	O
-	O
specific	O
enolase	O
,	O
interleukin	O
-	O
6	O
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
as	O
well	O
as	O
matrix	O
metalloproteinase	O
-	O
9	O
increased	O
significantly	O
after	O
treating	O
brain	O
cells	O
with	O
≥	O
2	O
%	O
conditioned	O
medium	O
.	O

These	O
findings	O
indicate	O
that	O
FTY720	O
mutes	O
effective	O
anti	O
-	O
viral	O
immune	B-PROC
responses	I-PROC
through	O
impacting	O
migration	B-PROC
and	O
accumulation	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
within	O
the	O
CNS	O
during	O
acute	O
viral	O
-	O
induced	O
encephalomyelitis	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
FTY720	O
mutes	O
effective	O
anti	O
-	O
viral	O
immune	B-PROC
responses	I-PROC
through	O
impacting	O
migration	B-PROC
and	O
accumulation	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
within	O
the	O
CNS	O
during	O
acute	O
viral	O
-	O
induced	O
encephalomyelitis	O
.	O

The	O
results	O
from	O
this	O
study	O
provide	O
valuable	O
information	O
for	O
understanding	O
how	O
MERS	O
-	O
CoV	O
PLpro	O
-	O
mediated	O
antagonism	O
of	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
is	O
orchestrated	O
,	O
as	O
well	O
as	O
insight	O
into	O
the	O
design	O
of	O
inhibitors	O
against	O
MERS	O
-	O
CoV	O
PLpro	O
.	O

Under	O
prolonged	O
and	O
irremediable	O
ER	O
stress	O
,	O
however	O
,	O
the	O
UPR	O
can	O
also	O
trigger	O
apoptosis	B-PROC
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
demographics	O
including	O
the	O
median	O
patient	O
age	O
,	O
sex	O
ratio	O
,	O
initial	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
,	O
initial	O
pulmonary	B-PROC
function	I-PROC
and	O
the	O
sources	O
of	O
ARDS	O
.	O

Together	O
,	O
these	O
data	O
support	O
the	O
hypothesis	O
that	O
reduced	O
BDNF	O
signaling	B-PROC
and	O
respiratory	O
dysfunction	O
in	O
RTT	O
are	O
linked	O
,	O
and	O
establish	O
the	O
proof	O
-	O
of	O
-	O
concept	O
that	O
treatment	O
with	O
a	O
small	O
-	O
molecule	O
structural	O
mimetic	O
of	O
a	O
BDNF	O
loop	O
domain	O
and	O
a	O
TrkB	O
partial	O
agonist	O
can	O
acutely	O
reverse	O
abnormal	O
breathing	B-PROC
at	O
rest	O
and	O
in	O
response	O
to	O
behavioral	B-PROC
arousal	O
in	O
symptomatic	O
RTT	O
mice	O
.	O

ABSTRACT	O
:	O
Evolution	B-PROC
of	O
polymerase	O
chain	O
reaction	O
testing	O
for	O
infectious	O
pathogens	O
has	O
occurred	O
concurrent	O
with	O
a	O
focus	O
on	O
value	O
-	O
based	O
medicine	O
.	O

The	O
increase	O
in	O
disease	O
severity	O
in	O
dogs	O
and	O
the	O
emergence	O
of	O
novel	O
CCoVs	O
can	O
be	O
attributed	O
to	O
the	O
high	O
level	O
of	O
recombination	B-PROC
within	O
the	O
spike	O
gene	O
that	O
can	O
occur	O
during	O
infection	O
by	O
more	O
than	O
one	O
CCoV	O
type	O
in	O
the	O
same	O
host	O
.	O

For	O
each	O
test	O
condition	O
,	O
assessments	O
included	O
relative	O
quantification	O
of	O
the	O
inhibition	B-PROC
of	O
intracellular	O
viral	O
genomic	O
RNA	B-PROC
synthesis	I-PROC
by	O
means	O
of	O
real	O
-	O
time	O
,	O
reverse	O
-	O
transcription	B-PROC
PCR	O
analysis	O
;	O
flow	O
cytometric	O
evaluation	O
of	O
the	O
reduction	O
of	O
viral	O
protein	B-PROC
expression	B-PROC
in	O
infected	O
cells	O
;	O
and	O
assessment	O
of	O
virus	B-PROC
replication	I-PROC
inhibition	B-PROC
via	O
titration	O
of	O
extracellular	O
virus	O
with	O
a	O
TCID₅₀	O
infectivity	O
assay	O
.	O

Combinations	O
of	O
siRNAs	O
that	O
targeted	B-PROC
different	O
regions	O
of	O
the	O
viral	O
genome	O
resulted	O
in	O
more	O
effective	O
viral	O
inhibition	B-PROC
than	O
did	O
individual	O
siRNAs	O
that	O
targeted	B-PROC
a	O
single	O
gene	O
.	O

Such	O
an	O
approach	O
may	O
also	O
be	O
useful	O
for	O
identifying	O
patients	O
with	O
severe	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
who	O
may	O
benefit	O
from	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

Probable	O
cases	O
of	O
secondary	O
transmission	O
were	O
identified	O
on	O
the	O
basis	O
of	O
reactivity	O
in	O
two	O
reverse	O
-	O
transcriptase	B-PROC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
with	O
independent	O
RNA	O
extraction	O
from	O
throat	O
swabs	O
or	O
reactivity	O
on	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
against	O
MERS	O
-	O
CoV	O
S1	O
antigen	O
,	O
supported	O
by	O
reactivity	O
on	O
recombinant	O
S	O
-	O
protein	O
immunofluorescence	O
and	O
demonstration	O
of	O
neutralization	O
of	O
more	O
than	O
50	O
%	O
of	O
the	O
infectious	O
virus	O
seed	O
dose	O
on	O
plaque	O
-	O
reduction	O
neutralization	O
testing	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
61	O
-	O
year	O
-	O
old	O
man	O
with	O
past	O
medical	O
history	O
of	O
chronic	O
respiratory	O
failure	O
with	O
emphysema	O
,	O
and	O
a	O
known	O
multiple	O
myeloma	O
(	O
Durie	O
and	O
Salmon	O
stage	O
III	O
B	O
and	O
t	O
(	O
4	O
;	O
14	O
)	O
translocation	B-PROC
).	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
and	O
porcine	O
epidemic	O
diarrhoea	O
virus	B-PROC
infection	I-PROC
induces	O
dramatic	O
changes	O
in	O
the	O
tight	O
junctions	O
and	O
microfilaments	O
of	O
polarized	O
IPEC	O
-	O
J2	O
cells	O
.	O

Finally	O
,	O
the	O
PEDV	O
and	O
TGEV	O
infection	O
affected	O
the	O
MAPK	O
pathway	B-PROC
,	O
and	O
inhibition	B-PROC
of	O
MAPK	O
pathway	B-PROC
regulated	O
the	O
changes	O
of	O
tight	O
junctions	O
and	O
microfilaments	O
of	O
cells	O
.	O

TITLE	O
:	O
Tropism	B-PROC
and	O
replication	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
from	O
dromedary	O
camels	O
in	O
the	O
human	O
respiratory	O
tract	O
:	O
an	O
in	O
-	O
vitro	O
and	O
ex	O
-	O
vivo	O
study	O
.	O

King	O
Faisal	O
University	O
,	O
Egyptian	O
National	O
Research	O
Centre	O
,	O
Hong	O
Kong	O
Food	O
and	O
Health	O
Bureau	O
,	O
National	O
Institute	O
of	O
Allergy	B-PROC
and	O
Infectious	O
Diseases	O
,	O
and	O
European	O
Community	O
Seventh	O
Framework	O
Program	O
.	O

Fever	B-PROC
≥	O
39	O
°	O
C	O
(	O
66	O
.	O
7	O
%),	O
fatigue	O
(	O
64	O
.	O
6	O
%),	O
and	O
purulent	O
sputum	O
(	O
52	O
.	O
1	O
%)	O
was	O
the	O
most	O
common	O
symptoms	O
in	O
viral	O
pneumonia	O
patients	O
.	O

Sera	O
from	O
a	O
cat	O
experimentally	O
infected	O
with	O
type	O
I	O
FCoV	O
was	O
unable	O
to	O
neutralize	O
type	O
II	O
CCoV	O
infection	O
,	O
indicating	O
that	O
cats	O
persistently	O
infected	O
with	O
type	O
I	O
FCoV	O
may	O
be	O
superinfected	O
with	O
type	O
II	O
CCoV	O
.	O
Our	O
previous	O
study	O
reported	O
that	O
few	O
Japanese	O
cats	O
have	O
antibody	B-PROC
against	O
type	O
II	O
FCoV	O
.	O
All	O
of	O
these	O
observations	O
suggest	O
that	O
type	O
II	O
FCoV	O
emerged	O
inside	O
the	O
cat	O
body	O
and	O
is	O
unable	O
to	O
readily	O
spread	O
among	O
cats	O
,	O
indicating	O
that	O
these	O
recombination	B-PROC
events	O
for	O
emergence	O
of	O
pathogenic	O
coronaviruses	O
occur	O
frequently	O
.	O

Among	O
them	O
,	O
twenty	O
-	O
three	O
compounds	O
showed	O
much	O
better	O
anti	O
-	O
HBV	O
activity	O
than	O
caudatin	O
,	O
and	O
eleven	O
compounds	O
significantly	O
inhibited	O
the	O
HBV	O
DNA	B-PROC
replication	I-PROC
with	O
IC50	O
values	O
<	O
10	O
μM	O
.	O
Interestingly	O
,	O
three	O
compounds	O
(	O
22	O
,	O
28	O
,	O
29	O
)	O
exhibited	O
excellent	O
activity	O
against	O
the	O
secretion	B-PROC
of	O
HBsAg	O
(	O
IC50	O
=	O
63	O
.	O
02	O
μM	O
,	O
52	O
.	O
81	O
μM	O
,	O
56	O
.	O
08	O
μM	O
),	O
HBeAg	O
(	O
IC50	O
=	O
204	O
.	O
80	O
μM	O
,	O
173	O
.	O
51	O
μM	O
,	O
70	O
.	O
39	O
μM	O
),	O
along	O
with	O
HBV	O
DNA	B-PROC
replication	I-PROC
(	O
IC50	O
=	O
24	O
.	O
55	O
μM	O
,	O
5	O
.	O
69	O
μM	O
,	O
8	O
.	O
23	O
μM	O
)	O
with	O
lower	O
cytotoxicity	O
.	O

ABSTRACT	O
:	O
CD4	O
T	O
-	O
cell	O
help	O
is	O
not	O
a	O
universal	O
requirement	O
for	O
effective	O
primary	O
CD8	O
T	O
cells	O
but	O
is	O
essential	O
to	O
generate	O
memory	B-PROC
CD8	O
T	O
cells	O
capable	O
of	O
recall	O
responses	O
.	O

By	O
contrast	O
,	O
CD4	O
T	O
cells	O
are	O
essential	O
to	O
prolong	O
primary	O
CD8	O
T	O
-	O
cell	B-PROC
function	I-PROC
in	O
the	O
CNS	O
and	O
imprint	O
memory	B-PROC
CD8	O
T	O
cells	O
for	O
recall	O
responses	O
.	O

However	O
,	O
comparative	O
analysis	O
showed	O
that	O
directed	O
expression	B-PROC
or	O
selective	O
scission	O
of	O
the	O
ACE2	O
protein	O
had	O
no	O
measurable	O
effect	O
on	O
virus	O
adhesion	O
.	O

MERS	O
-	O
CoV	O
infection	O
actively	O
causes	O
disease	O
in	O
environments	O
with	O
low	O
relative	O
humidity	O
(<	O
20	O
%)	O
and	O
high	B-PROC
temperature	I-PROC
(	O
15	O
°	O
C	O
-	O
35	O
°	O
C	O
).	O

TITLE	O
:	O
Emerging	O
novel	O
and	O
antimicrobial	O
-	O
resistant	O
respiratory	O
tract	O
infections	O
:	O
new	O
drug	O
development	B-PROC
and	O
therapeutic	O
options	O
.	O

We	O
report	O
a	O
patient	O
with	O
life	O
-	O
threatening	O
PVL	O
-	O
expressing	O
S	O
.	O
aureus	O
-	O
associated	O
pneumonia	O
who	O
was	O
rescued	O
using	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
implementation	O
of	O
an	O
immunoinformatics	O
-	O
driven	O
approach	O
to	O
systematically	O
search	O
for	O
key	O
determinants	O
of	O
immunity	B-PROC
in	O
newly	O
available	O
genome	O
sequence	O
data	O
and	O
design	O
vaccines	O
.	O

Sequence	O
variations	O
in	O
different	O
genes	O
,	O
especially	O
the	O
S	O
gene	O
and	O
nsp3	O
,	O
in	O
the	O
genomes	O
of	O
CK	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
viruses	O
might	O
contribute	O
to	O
differences	O
in	O
viral	B-PROC
replication	I-PROC
,	O
pathogenicity	O
,	O
antigenicity	O
,	O
immunogenicity	O
,	O
and	O
tissue	B-PROC
tropism	B-PROC
.	O

Without	O
a	O
loss	O
of	O
processivity	O
,	O
the	O
nsp7	O
/	O
nsp8	O
/	O
nsp12	O
complex	O
can	O
associate	O
with	O
nsp14	O
,	O
a	O
bifunctional	O
enzyme	O
bearing	O
3	O
'-	O
5	O
'	O
exoribonuclease	O
and	O
RNA	O
cap	O
N7	O
-	O
guanine	O
methyltransferase	O
activities	O
involved	O
in	O
replication	O
fidelity	O
and	O
5	O
'-	O
RNA	B-PROC
capping	B-PROC
,	O
respectively	O
.	O

The	O
MHV	O
-	O
3	O
infected	O
C5aR	O
(-/-)	O
mice	O
exhibited	O
reduced	O
numbers	O
of	O
infiltrated	O
inflammatory	O
CD11b	O
(+)	O
cells	O
and	O
a	O
reduced	O
expression	B-PROC
of	O
TNF	O
-	O
α	O
and	O
FGL2	O
.	O

ABSTRACT	O
:	O
The	O
pregnant	O
patients	O
are	O
prone	O
to	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	B-PROC
infection	I-PROC
,	O
which	O
may	O
rapidly	O
progress	O
to	O
lower	O
respiratory	O
tract	O
infection	O
and	O
subsequent	O
respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
SARs	O
of	O
indole	O
-	O
based	O
α	O
-	O
amino	O
acids	O
as	O
potent	O
HIV	O
-	O
1	O
non	B-PROC
-	I-PROC
nucleoside	I-PROC
reverse	I-PROC
transcriptase	I-PROC
inhibitors	I-PROC
.	O

The	O
necessary	O
attributes	O
for	O
transfusion	O
transmission	O
were	O
outlined	O
including	O
:	O
presence	O
of	O
the	O
agent	O
in	O
blood	O
during	O
the	O
donor	O
'	O
s	O
asymptomatic	O
phase	O
,	O
the	O
agent	O
'	O
s	O
survival	O
/	O
persistence	O
in	O
blood	O
during	O
processing	O
/	O
storage	B-PROC
,	O
and	O
lastly	O
that	O
the	O
agent	O
must	O
be	O
recognized	O
as	O
responsible	O
for	O
a	O
clinically	O
apparent	O
outcome	O
in	O
at	O
least	O
a	O
proportion	O
of	O
recipients	O
who	O
become	O
infected	O
.	O

ABSTRACT	O
:	O
Chloroplast	O
-	O
based	O
expression	B-PROC
system	O
is	O
promising	O
for	O
the	O
hyper	O
-	O
expression	B-PROC
of	O
plant	O
-	O
derived	O
recombinant	O
therapeutic	O
proteins	O
and	O
vaccines	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
the	O
feasibility	O
of	O
highly	O
expressing	O
SARS	O
subunit	O
vaccine	O
RBD	O
,	O
indicating	O
its	O
potential	O
in	O
subsequent	O
development	B-PROC
of	O
a	O
plant	O
-	O
derived	O
recombinant	O
subunit	O
vaccine	O
and	O
reagents	O
production	O
for	O
antibody	B-PROC
detection	O
in	O
SARS	O
serological	O
tests	O
.	O

The	O
levels	O
of	O
O2	O
content	O
of	O
central	O
venous	O
blood	O
(	O
CcvO2	O
),	O
arterial	O
oxygen	B-PROC
content	I-PROC
(	O
CaO2	O
),	O
alveolar	O
-	O
arterial	O
oxygen	O
pressure	O
difference	O
P	O
(	O
A	O
-	O
a	O
)	O
DO2	O
,	O
ratio	O
of	O
arterial	O
oxygen	O
pressure	O
/	O
alveolar	O
oxygen	O
pressure	O
(	O
PaO2	O
/	O
PaO2	O
),	O
respiratory	O
index	O
(	O
RI	O
)	O
and	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
were	O
determined	O
.	O

The	O
isolation	O
of	O
PEDV	O
in	O
cell	O
culture	O
is	O
the	O
first	O
step	O
toward	O
the	O
development	B-PROC
of	O
an	O
attenuated	O
vaccine	O
,	O
to	O
study	O
the	O
biology	O
of	O
PEDV	O
and	O
to	O
develop	O
in	O
vitro	O
PEDV	O
immunoassays	O
,	O
inactivation	O
assays	O
and	O
screen	O
for	O
PEDV	O
antivirals	O
.	O

We	O
provided	O
the	O
initial	O
evidence	O
supporting	O
this	O
antibody	B-PROC
germline	O
/	O
maturation	B-PROC
hypothesis	O
,	O
which	O
prompted	O
a	O
number	O
of	O
studies	O
to	O
design	O
vaccine	O
immunogens	O
that	O
could	O
bind	O
putative	O
germline	O
predecessors	O
of	O
known	O
bnAbs	O
and	O
to	O
explore	O
complex	O
B	O
cell	O
lineages	O
.	O

TITLE	O
:	O
The	O
genotyping	O
of	O
infectious	O
bronchitis	O
virus	O
in	O
Taiwan	O
by	O
a	O
multiplex	O
amplification	O
refractory	O
mutation	O
system	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
before	O
and	O
after	O
treatment	O
,	O
mean	O
arterial	B-PROC
pressure	I-PROC
(	O
MAP	O
),	O
respiratory	O
index	O
(	O
PaO2	O
/	O
FiO2	O
),	O
hepatic	B-PROC
function	I-PROC
,	O
platelet	O
count	O
,	O
and	O
blood	B-PROC
coagulation	I-PROC
were	O
determined	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
are	O
promising	O
therapeutic	O
cells	O
for	O
preventing	O
apoptosis	B-PROC
and	O
eliminating	O
cellular	O
injury	O
.	O

The	O
anti	B-PROC
-	I-PROC
apoptosis	I-PROC
action	O
of	O
BMSCs	O
was	O
reversed	O
by	O
SB216763	O
,	O
a	O
specific	O
inhibitor	O
of	O
GSK	O
-	O
3β	O
that	O
also	O
activates	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	B-PROC
.	O

The	O
emergence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
2002	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
has	O
resulted	O
in	O
severe	O
human	O
respiratory	O
disease	O
with	O
high	O
death	B-PROC
rates	O
.	O

More	O
than	O
three	O
days	O
of	O
history	O
of	O
fever	B-PROC
,	O
cerebral	O
malaria	O
,	O
PE	O
/	O
ARDS	O
,	O
renal	O
failure	O
,	O
metabolic	B-PROC
acidosis	O
,	O
hyperparasitaemia	O
,	O
leucocytosis	O
and	O
severe	O
thrombocytopaenia	O
were	O
independently	O
associated	O
factors	O
with	O
intensive	O
care	O
requirement	O
.	O

ABSTRACT	O
:	O
To	O
conduct	B-PROC
a	O
country	O
-	O
wide	O
prevalence	O
study	O
of	O
bovine	O
group	O
A	O
rotavirus	O
,	O
coronavirus	O
,	O
Cryptosporidium	O
parvum	O
,	O
Salmonella	O
spp	O
.	O
and	O
enterotoxigenic	O
K99	O
(+)	O
Escherichia	O
coli	O
(	O
K99	O
)	O
in	O
calves	O
on	O
New	O
Zealand	O
dairy	O
farms	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
did	O
not	O
provide	O
evidence	O
of	O
peculiar	O
immune	O
profiles	O
in	O
HB	O
,	O
except	O
for	O
a	O
prevalent	O
Th1	O
profile	O
,	O
that	O
may	O
explain	O
why	O
in	O
our	O
caseload	O
the	O
rate	O
of	O
shedders	O
was	O
lower	O
in	O
HB	O
than	O
in	O
other	O
breeds	B-PROC
.	O

ABSTRACT	O
:	O
WHEN	O
AN	O
ANTIVIRAL	O
IMMUNE	B-PROC
RESPONSE	I-PROC
IS	O
GENERATED	O
,	O
A	O
BALANCE	B-PROC
MUST	O
BE	O
REACHED	O
BETWEEN	O
TWO	O
OPPOSING	O
PATHWAYS	B-PROC
:	O
the	O
production	O
of	O
proinflammatory	O
and	O
cytotoxic	O
effectors	O
that	O
drive	O
a	O
robust	O
antiviral	O
immune	B-PROC
response	I-PROC
to	O
control	O
the	O
infection	O
and	O
regulators	O
that	O
function	O
to	O
limit	O
or	O
blunt	O
an	O
excessive	O
immune	B-PROC
response	I-PROC
to	O
minimize	O
immune	O
-	O
mediated	O
pathology	O
and	O
repair	B-PROC
tissue	I-PROC
damage	O
.	O

Myeloid	O
cells	O
,	O
including	O
monocytes	O
and	O
macrophages	O
,	O
play	O
an	O
important	O
role	O
in	O
this	O
balance	B-PROC
,	O
particularly	O
through	O
the	O
activities	O
of	O
the	O
arginine	O
-	O
hydrolyzing	O
enzymes	O
nitric	O
oxide	O
synthase	O
2	O
(	O
Nos2	O
;	O
iNOS	O
)	O
and	O
arginase	O
1	O
(	O
Arg1	O
).	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
a	O
variety	O
of	O
viral	B-PROC
infections	I-PROC
,	O
including	O
HIV	O
,	O
SARS	O
-	O
CoV	O
,	O
LCMV	O
,	O
HCV	O
,	O
RSV	O
,	O
and	O
others	O
,	O
where	O
myeloid	O
cells	O
influence	O
the	O
control	O
and	O
clearance	O
of	O
the	O
virus	O
from	O
the	O
host	O
,	O
as	O
well	O
as	O
the	O
severity	O
and	O
resolution	O
of	O
tissue	O
damage	O
,	O
via	O
the	O
activities	O
of	O
iNOS	O
and	O
/	O
or	O
Arg1	O
.	O

TITLE	O
:	O
An	O
evaluation	O
of	O
a	O
liquid	O
antimicrobial	O
(	O
Sal	O
CURB	O
®)	O
for	O
reducing	O
the	O
risk	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
of	O
naïve	O
pigs	O
during	O
consumption	O
of	O
contaminated	O
feed	O
.	O

The	O
differing	O
molecular	O
determinants	O
appear	O
to	O
accommodate	O
distinct	O
antiviral	O
mechanisms	O
TRIM56	O
adopts	O
to	O
target	O
different	O
families	O
of	O
viruses	O
;	O
while	O
TRIM56	O
curbs	O
intracellular	O
YFV	O
/	O
DENV2	O
RNA	B-PROC
replication	I-PROC
,	O
it	O
acts	O
at	O
a	O
later	O
step	O
in	O
HCoV	O
-	O
OC43	O
life	O
cycle	O
.	O

These	O
findings	O
will	O
assist	O
with	O
the	O
rapid	O
laboratory	O
diagnosis	O
of	O
enteritis	O
in	O
puppies	O
and	O
highlight	O
the	O
need	O
for	O
continued	O
surveillance	O
for	O
CCoV	O
variants	O
and	O
intestinal	O
viral	B-PROC
diseases	I-PROC
of	O
global	O
significance	O
.	O

The	O
differential	O
IFITM	O
-	O
sensitivity	O
of	O
coronaviruses	O
observed	O
in	O
293T	O
cells	O
afforded	O
the	O
opportunity	O
to	O
investigate	O
whether	O
efficiency	O
of	O
entry	O
inhibition	B-PROC
by	O
IFITMs	O
and	O
endosomal	O
cholesterol	O
accumulation	O
correlate	O
.	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
the	O
emerging	O
MERS	O
-	O
CoV	O
is	O
a	O
target	O
of	O
the	O
antiviral	O
activity	O
of	O
IFITM	O
proteins	O
and	O
demonstrate	O
that	O
mechanisms	O
other	O
than	O
accumulation	O
of	O
endosomal	O
cholesterol	O
can	O
contribute	O
to	O
viral	O
entry	O
inhibition	B-PROC
by	O
IFITMs	O
.	O

All	O
patients	O
achieved	O
neutrophil	O
engraftment	B-PROC
by	O
a	O
median	O
of	O
day	O
18	O
(	O
range	O
:	O
day	O
11	O
-	O
61	O
).	O

TITLE	O
:	O
Insulin	O
upregulates	O
the	O
expression	B-PROC
of	O
epithelial	O
sodium	O
channel	O
in	O
vitro	O
and	O
in	O
a	O
mouse	O
model	O
of	O
acute	O
lung	O
injury	O
:	O
role	O
of	O
mTORC2	O
/	O
SGK1	O
pathway	B-PROC
.	O

Genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
on	O
73	O
cats	O
that	O
died	B-PROC
of	O
FIP	O
after	O
one	O
or	O
more	O
exposures	O
(	O
cases	O
)	O
and	O
34	O
cats	O
that	O
survived	O
(	O
controls	O
)	O
demonstrated	O
four	O
significant	O
associations	O
after	O
100k	O
permutations	O
.	O

RESULTS	O
:	O
Arterial	O
oxygen	B-PROC
tension	I-PROC
(	O
PaO2	O
),	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
as	O
well	O
as	O
dynamic	O
pulmonary	O
compliance	O
were	O
all	O
elevated	O
significantly	O
,	O
whereas	O
peak	O
inspiratory	B-PROC
pressure	O
significantly	O
decreased	O
at	O
6h	O
,	O
12h	O
and	O
24h	O
after	O
CRRT	O
respectively	O
;	O
serum	O
cytokine	O
level	O
and	O
CRP	O
significantly	O
decreased	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Respiratory	O
viruses	O
can	O
cause	O
a	O
wide	O
spectrum	O
of	O
pulmonary	O
diseases	O
,	O
ranging	O
from	O
mild	O
,	O
upper	O
respiratory	O
tract	O
infections	O
to	O
severe	O
and	O
life	O
-	O
threatening	O
lower	O
respiratory	O
tract	O
infections	O
,	O
including	O
the	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
also	O
showed	O
that	O
overexpression	B-PROC
of	O
PDK1	O
(	O
3	O
-	O
phosphoinositide	O
-	O
dependent	O
protein	O
kinase	O
1	O
),	O
the	O
immediate	O
upstream	O
kinase	O
of	O
PKB	O
/	O
Akt	O
,	O
suppressed	O
M	O
-	O
induced	O
apoptosis	B-PROC
.	O

ABSTRACT	O
:	O
The	O
genome	O
of	O
CK	O
/	O
CH	O
/	O
SD09	O
/	O
005	O
,	O
an	O
isolate	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
was	O
characterized	O
to	O
enable	O
the	O
further	O
understanding	O
of	O
the	O
epidemiology	O
and	O
evolution	B-PROC
of	O
IBV	O
in	O
China	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
investigate	O
viral	B-PROC
infections	I-PROC
and	O
the	O
prevalence	O
of	O
influenza	O
-	O
like	O
illness	O
(	O
ILI	O
)	O
in	O
Shijiazhuang	O
,	O
China	O
,	O
in	O
2011	O
and	O
to	O
provide	O
a	O
scientific	O
basis	O
for	O
the	O
diagnosis	O
and	O
control	O
of	O
respiratory	O
tract	O
infections	O
.	O

The	O
ERK	O
-	O
MAPK	O
pathway	B-PROC
is	O
involved	O
in	O
LPS	O
-	O
induced	O
acute	O
lung	O
inflammation	O
.	O

TITLE	O
:	O
Immune	O
biomarkers	O
predictive	O
of	O
respiratory	O
viral	B-PROC
infection	I-PROC
in	O
elderly	O
nursing	B-PROC
home	O
residents	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
if	O
immune	O
phenotypes	O
associated	O
with	O
immunosenescence	O
predict	O
risk	O
of	O
respiratory	O
viral	B-PROC
infection	I-PROC
in	O
elderly	O
nursing	B-PROC
home	O
residents	O
.	O

In	O
multivariable	O
analysis	O
,	O
high	O
T	O
-	O
reg	O
%	O
(	O
HR	O
0	O
.	O
41	O
,	O
95	O
%	O
CI	O
0	O
.	O
20	O
-	O
0	O
.	O
81	O
)	O
and	O
high	O
CMV	O
-	O
reactive	O
CD4	O
+	O
T	O
-	O
cell	O
%	O
(	O
HR	O
1	O
.	O
69	O
,	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
2	O
.	O
78	O
)	O
were	O
predictive	O
of	O
respiratory	O
viral	B-PROC
infection	I-PROC
.	O

This	O
manuscript	O
explores	O
the	O
role	O
of	O
NSP16	O
,	O
a	O
2	O
'	O
O	O
-	O
methyl	O
-	O
transferase	O
(	O
2	O
'	O
O	O
-	O
MTase	O
),	O
in	O
CoV	O
infection	O
and	O
the	O
host	O
immune	B-PROC
response	I-PROC
.	O

Lower	O
tidal	O
volume	O
ventilation	O
appears	O
to	O
be	O
beneficial	O
,	O
but	O
optimal	O
management	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
remains	O
unclear	O
.	O

Enhanced	O
furin	B-PROC
activity	I-PROC
appeared	O
to	O
partially	O
override	O
the	O
low	O
pH	O
-	O
dependent	O
nature	O
of	O
MERS	O
-	O
CoV	O
entry	O
.	O

Using	O
the	O
data	O
of	O
10	O
,	O
000	O
,	O
000	O
simulated	O
patients	O
with	O
predetermined	O
outcomes	O
and	O
costs	O
,	O
an	O
analysis	O
was	O
performed	O
of	O
the	O
ratio	O
between	O
cost	O
increase	O
and	O
years	O
of	O
life	O
gained	O
,	O
adjusted	O
for	O
quality	O
(	O
cost	O
-	O
utility	O
),	O
with	O
survival	O
rates	O
of	O
40	O
and	O
60	O
%	O
for	O
patients	O
using	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Analyzing	O
only	O
patients	O
with	O
severe	O
hypoxemia	O
(	O
i	O
.	O
e	O
.,	O
a	O
ratio	O
of	O
partial	O
oxygen	O
pressure	O
in	O
the	O
blood	O
to	O
the	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
<	O
100	O
mmHg	O
),	O
the	O
increased	O
cost	O
was	O
R	O
$=-	O
5	O
,	O
714	O
.	O
00	O
/	O
272	O
.	O
00	O
,	O
with	O
a	O
cost	O
per	O
six	O
-	O
month	O
quality	O
-	O
adjusted	O
life	O
-	O
year	O
gained	O
of	O
R	O
$=-	O
9	O
,	O
521	O
.	O
00	O
/	O
293	O
.	O
00	O
and	O
a	O
cost	O
of	O
R	O
$=-	O
280	O
.	O
00	O
/	O
7	O
.	O
00	O
per	O
quality	O
-	O
adjusted	O
life	O
-	O
year	O
gained	O
.	O

TITLE	O
:	O
Nucleocapsid	O
phosphorylation	B-PROC
and	O
RNA	O
helicase	O
DDX1	O
recruitment	O
enables	O
coronavirus	O
transition	O
from	O
discontinuous	O
to	O
continuous	O
transcription	B-PROC
.	O

ABSTRACT	O
:	O
Incidence	O
of	O
acute	O
febrile	B-PROC
encephalopathy	O
(	O
AFE	O
)	O
is	O
high	O
in	O
children	O
and	O
associated	O
with	O
high	O
mortality	O
and	O
sequela	O
.	O

One	O
hundred	O
and	O
seventy	O
six	O
children	O
in	O
the	O
age	O
group	O
of	O
one	O
month	O
to	O
12	O
years	O
,	O
presented	O
with	O
fever	B-PROC
≤	O
2wks	O
duration	O
and	O
altered	O
mental	O
status	O
lasting	O
for	O
more	O
than	O
4h	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Among	O
independently	O
significant	O
variables	O
,	O
shock	O
,	O
severe	O
anaemia	O
,	O
bradycardia	O
,	O
Glasgow	O
coma	O
scale	O
(	O
GCS	O
)	O
of	O
less	O
than	O
eight	O
and	O
refractory	O
seizures	O
were	O
found	O
to	O
be	O
significant	O
and	O
other	O
variables	O
like	O
respiratory	O
failure	O
,	O
multiorgan	O
dysfunction	O
syndrome	O
and	O
abnormal	O
coagulation	B-PROC
profile	O
were	O
found	O
insignificant	O
on	O
full	O
model	O
of	O
multivariate	O
regression	O
analysis	O
.	O

It	O
causes	O
two	O
syndromes	O
:	O
hemorrhagic	O
fever	B-PROC
with	O
renal	O
syndrome	O
(	O
HFRS	O
),	O
endemic	O
in	O
Asia	O
and	O
Europe	O
and	O
the	O
Hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	O
),	O
found	O
in	O
the	O
American	O
continent	O
,	O
including	O
Brazil	O
,	O
with	O
high	O
mortality	O
rates	O
.	O

During	O
sepsis	O
,	O
hemodynamic	B-PROC
instability	O
and	O
perpetuation	O
of	O
inflammatory	O
state	O
may	O
result	O
from	O
adrenal	O
insufficiency	O
(	O
AI	O
).	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
review	O
the	O
literature	O
on	O
inhaled	B-PROC
nitric	O
oxide	O
to	O
children	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Lab	O
tests	O
made	O
upon	O
his	O
admission	O
showed	O
hyperbilirubinemia	O
at	O
a	O
level	O
of	O
50	O
mg	O
/	O
dL	O
,	O
severe	O
metabolic	B-PROC
acidosis	O
,	O
thrombocytopenia	O
,	O
creatinine	O
levels	O
of	O
5	O
.	O
6	O
mg	O
/	O
dL	O
and	O
leukocytosis	O
with	O
deviation	O
through	O
metamyelocytes	O
.	O

TITLE	O
:	O
Coronavirus	O
membrane	O
-	O
associated	O
papain	O
-	O
like	O
proteases	O
induce	O
autophagy	B-PROC
through	O
interacting	O
with	O
Beclin1	O
to	O
negatively	O
regulate	O
antiviral	O
innate	B-PROC
immunity	B-PROC
.	O

ABSTRACT	O
:	O
Autophagy	B-PROC
plays	O
important	O
roles	O
in	O
modulating	O
viral	B-PROC
replication	I-PROC
and	O
antiviral	O
immune	B-PROC
response	I-PROC
.	O

These	O
results	O
suggested	O
that	O
coronavirus	O
papain	O
-	O
like	O
protease	O
induces	O
incomplete	O
autophagy	B-PROC
by	O
interacting	O
with	O
Beclin1	O
,	O
which	O
in	O
turn	O
modulates	O
coronavirus	O
replication	O
and	O
antiviral	O
innate	B-PROC
immunity	B-PROC
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
used	O
for	O
patients	O
with	O
severe	O
,	O
potentially	O
reversible	O
,	O
respiratory	O
failure	O
unresponsive	O
to	O
conventional	O
management	O
.	O

Lung	O
histopathological	O
changes	O
in	O
infected	O
mice	O
included	O
diffuse	O
pneumonia	O
,	O
alveolar	O
damage	O
,	O
inflammatory	O
cellular	B-PROC
infiltration	I-PROC
,	O
interstitial	O
and	O
alveolar	O
edema	O
,	O
and	O
hemorrhage	O
.	O

In	O
addition	O
,	O
H9N2	O
viral	B-PROC
infection	I-PROC
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	O
,	O
and	O
a	O
significant	O
increase	O
in	O
interleukin	O
1	O
,	O
interleukin	O
6	O
,	O
tumor	O
necrosis	B-PROC
factor	O
,	O
and	O
interferon	O
in	O
BALF	O
and	O
serum	O
.	O

The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
develop	O
and	O
validate	O
a	O
prediction	O
model	O
to	O
accurately	O
and	O
timely	O
identify	O
patients	O
with	O
severe	O
hypoxemic	O
respiratory	O
failure	O
at	O
high	O
risk	O
of	O
death	B-PROC
,	O
in	O
whom	O
novel	O
rescue	O
strategies	O
can	O
be	O
efficiently	O
evaluated	O
.	O

IAH	O
contributes	O
to	O
multiple	O
physiologic	O
alterations	O
and	O
leads	O
to	O
the	O
development	B-PROC
of	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	O
)	O
that	O
induces	O
multiorgan	O
failure	O
.	O

ABSTRACT	O
:	O
The	O
interactions	O
occurring	O
between	O
a	O
virus	O
and	O
a	O
host	O
cell	O
during	O
a	O
viral	B-PROC
infection	I-PROC
are	O
complex	O
.	O

Therefore	O
,	O
this	O
study	O
provides	O
a	O
solid	O
foundation	O
for	O
further	O
investigation	O
,	O
and	O
will	O
likely	O
help	O
us	O
to	O
better	O
understand	O
the	O
mechanisms	O
of	O
TGEV	O
infection	O
and	O
pathogenesis	B-PROC
.	O

Then	O
based	O
on	O
the	O
gene	B-PROC
expression	I-PROC
,	O
PPI	B-PROC
and	O
signalling	B-PROC
pathways	B-PROC
data	O
,	O
we	O
investigate	O
the	O
comorbidity	O
association	O
of	O
these	O
2	O
infective	O
pathologies	O
with	O
other	O
7	O
diseases	O
(	O
heart	O
failure	O
,	O
kidney	O
disorder	O
,	O
breast	O
cancer	O
,	O
neurodegenerative	O
disorders	O
,	O
bone	O
diseases	O
,	O
Type	O
1	O
and	O
Type	O
2	O
diabetes	O
).	O

Moreover	O
,	O
SARS	O
and	O
HIV	O
infections	O
dysregulate	O
4	O
genes	O
(	O
ANXA3	O
,	O
GNS	O
,	O
HIST1H1C	O
,	O
RASA3	O
)	O
and	O
3	O
genes	O
(	O
HBA1	O
,	O
TFRC	O
,	O
GHITM	O
)	O
respectively	O
that	O
affect	O
the	O
ageing	B-PROC
process	O
.	O

It	O
is	O
notable	O
that	O
HIV	O
and	O
SARS	O
similarly	O
dysregulated	O
11	O
genes	O
and	O
3	O
pathways	B-PROC
.	O

ABSTRACT	O
:	O
Recommendations	O
concerning	O
the	O
management	O
of	O
hemoglobin	O
levels	O
and	O
hematocrit	O
in	O
patients	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
still	O
advise	O
maintenance	O
of	O
a	O
normal	O
hematocrit	O
.	O

We	O
report	O
results	O
for	O
treating	O
acute	O
allergic	O
and	O
non	O
-	O
allergic	O
bronchoconstriction	B-PROC
in	O
sheep	O
using	O
S	O
-	O
1226	O
(	O
a	O
gas	O
mixture	O
containing	O
carbon	O
dioxide	O
and	O
small	O
volumes	O
of	O
nebulized	O
perflubron	O
).	O

Data	O
suggest	O
that	O
activated	O
microglia	O
and	O
inflammatory	O
mediators	O
contribute	O
to	O
a	O
local	O
CNS	O
microenvironment	O
that	O
regulates	O
viral	B-PROC
replication	I-PROC
and	O
IFN	O
-	O
γ	O
production	O
during	O
the	O
acute	O
phase	O
of	O
infection	O
,	O
which	O
in	O
turn	O
can	O
cause	O
phagolysosome	O
maturation	B-PROC
and	O
phagocytosis	B-PROC
of	O
the	O
myelin	O
sheath	O
,	O
leading	O
to	O
demyelination	O
.	O

Infection	O
with	O
novel	O
avian	O
-	O
origin	O
reassortment	O
influenza	O
A	O
(	O
H7N9	O
)	O
virus	O
is	O
characterized	O
by	O
high	O
fever	B-PROC
,	O
cough	O
,	O
and	O
severe	O
respiratory	O
failure	O
and	O
is	O
associated	O
with	O
a	O
high	O
mortality	O
.	O

TITLE	O
:	O
Design	O
of	O
potential	O
RNAi	B-PROC
(	O
miRNA	O
and	O
siRNA	O
)	O
molecules	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
gene	B-PROC
silencing	I-PROC
by	O
computational	O
method	O
.	O

Genetic	O
studies	O
on	O
MERS	O
-	O
CoV	O
have	O
shown	O
that	O
ORF	O
1ab	O
encodes	O
replicase	O
polyproteins	O
and	O
play	O
a	O
foremost	O
role	O
in	O
viral	B-PROC
infection	I-PROC
.	O

Fusion	O
of	O
MHV	O
was	O
severely	O
inhibited	O
by	O
a	O
pan	O
-	O
lysosomal	O
protease	O
inhibitor	O
,	O
while	O
trafficking	B-PROC
of	O
MHV	O
to	O
lysosomes	O
and	O
processing	O
by	O
lysosomal	O
proteases	O
was	O
no	O
longer	O
required	O
when	O
a	O
furin	O
cleavage	B-PROC
site	O
was	O
introduced	O
in	O
the	O
S	O
protein	O
immediately	O
upstream	O
of	O
the	O
fusion	O
peptide	O
.	O

In	O
contrast	O
,	O
MERS	O
-	O
CoV	O
,	O
which	O
contains	O
a	O
minimal	O
furin	O
cleavage	B-PROC
site	O
just	O
upstream	O
of	O
the	O
fusion	O
peptide	O
,	O
was	O
negatively	O
affected	O
by	O
inhibition	B-PROC
of	O
furin	O
,	O
but	O
not	O
of	O
lysosomal	O
proteases	O
.	O

In	O
fact	O
,	O
Ifnβ	O
expression	B-PROC
is	O
delayed	O
with	O
respect	O
to	O
the	O
peak	O
of	O
viral	B-PROC
replication	I-PROC
and	O
the	O
accompanying	O
accumulation	O
of	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
).	O

Furthermore	O
,	O
we	O
provide	O
evidence	O
that	O
accessory	O
proteins	O
3a	O
and	O
3b	O
of	O
IBV	O
modulate	O
the	O
response	O
at	O
the	O
transcriptional	B-PROC
and	O
translational	B-PROC
levels	O
.	O

Taken	O
together	O
,	O
this	O
study	O
provides	O
the	O
first	O
comprehensive	O
analysis	O
of	O
host	O
-	O
virus	O
interactions	O
of	O
a	O
Gammacoronavirus	O
with	O
avian	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

Lipid	O
rafts	O
,	O
enriched	O
in	O
sphingolipids	O
,	O
cholesterol	O
and	O
associated	O
proteins	O
,	O
are	O
special	O
plasma	O
membrane	O
microdomains	O
involved	O
in	O
several	O
processes	O
in	O
viral	B-PROC
infections	I-PROC
.	O

Based	O
on	O
the	O
scene	O
investigation	O
and	O
autopsy	O
findings	O
in	O
this	O
case	O
,	O
the	O
medical	O
examiner	O
determined	O
that	O
the	O
cause	O
of	O
death	B-PROC
was	O
narcotic	O
(	O
Nucynta	O
)	O
intoxication	O
and	O
the	O
manner	O
of	O
death	B-PROC
was	O
undetermined	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
the	O
laboratory	O
-	O
confirmed	O
etiologies	O
of	O
illness	O
among	O
participants	O
in	O
a	O
hospital	O
-	O
based	O
febrile	B-PROC
illness	O
cohort	O
study	O
in	O
northern	O
Tanzania	O
who	O
retrospectively	O
met	O
Integrated	O
Management	O
of	O
Adolescent	O
and	O
Adult	O
Illness	O
District	O
Clinician	O
Manual	O
(	O
IMAI	O
)	O
criteria	O
for	O
septic	O
shock	O
,	O
severe	O
respiratory	O
distress	O
without	O
shock	O
,	O
and	O
severe	O
pneumonia	O
,	O
and	O
compare	O
these	O
etiologies	O
against	O
commonly	O
used	O
antimicrobials	O
,	O
including	O
IMAI	O
recommendations	O
for	O
emergency	O
antibacterials	O
(	O
ceftriaxone	O
or	O
ampicillin	O
plus	O
gentamicin	O
)	O
and	O
IMAI	O
first	O
-	O
line	O
recommendations	O
for	O
severe	O
pneumonia	O
(	O
ceftriaxone	O
and	O
a	O
macrolide	O
).	O

Among	O
423	O
participants	O
hospitalized	O
with	O
febrile	B-PROC
illness	O
,	O
there	O
were	O
25	O
septic	O
shock	O
,	O
37	O
severe	O
respiratory	O
distress	O
without	O
shock	O
,	O
and	O
109	O
severe	O
pneumonia	O
cases	O
.	O

We	O
conclude	O
that	O
amino	O
-	O
acid	O
residues	O
736	O
-	O
761	O
of	O
the	O
S	O
protein	O
carry	O
neutralizing	O
epitopes	O
that	O
may	O
be	O
used	O
in	O
the	O
development	B-PROC
of	O
vaccines	O
and	O
antiviral	O
agents	O
against	O
MERS	O
-	O
CoV	O
.	O

Anticoagulation	B-PROC
,	O
intensive	O
antibiotic	O
therapy	O
assisted	O
by	O
surgery	O
of	O
the	O
primary	O
infection	O
site	O
,	O
and	O
intensive	O
supportive	O
care	O
can	O
reach	B-PROC
remission	O
rates	O
of	O
100	O
%.	O

ABSTRACT	O
:	O
Infection	O
by	O
pathogenic	O
viruses	O
results	O
in	O
rapid	O
epithelial	O
damage	O
and	O
significantly	O
impacts	O
on	O
the	O
condition	O
of	O
the	O
upper	O
respiratory	O
tract	O
,	O
thus	O
the	O
effects	O
of	O
viral	B-PROC
infection	I-PROC
may	O
induce	O
changes	O
in	O
microbiota	O
.	O

Calculations	O
on	O
8a	O
are	O
compared	O
to	O
data	O
derived	O
for	O
a	O
pentameric	O
bundle	O
consisting	O
of	O
the	O
M2	O
helices	O
of	O
the	O
bacterial	O
pentameric	O
ligand	B-PROC
gated	O
ion	O
channel	O
GLIC	O
(	O
3EHZ	O
).	O

ABSTRACT	O
:	O
An	O
elevated	O
physiological	O
dead	B-PROC
space	O
,	O
calculated	O
from	O
measurements	O
of	O
arterial	O
CO2	O
and	O
mixed	O
expired	O
CO2	O
,	O
has	O
proven	O
to	O
be	O
a	O
useful	O
clinical	O
marker	O
of	O
prognosis	O
both	O
for	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
for	O
patients	O
with	O
severe	O
heart	O
failure	O
.	O

There	O
were	O
343	O
critical	O
patients	O
included	O
in	O
this	O
prospective	O
multicenter	O
cohort	O
study	O
,	O
of	O
which	O
163	O
patients	O
who	O
developed	O
ARDS	O
were	O
considered	O
as	O
ARDS	O
group	O
(	O
2	O
case	O
lost	O
to	O
follow	O
-	O
up	O
,	O
and	O
49	O
died	B-PROC
)	O
and	O
180	O
patients	O
who	O
did	O
not	O
developed	O
ARDS	O
regarded	O
as	O
severe	O
control	O
group	O
(	O
1	O
case	O
lost	O
to	O
follow	O
-	O
up	O
,	O
and	O
34	O
died	B-PROC
).	O

Multivariate	O
COX	O
regression	O
analysis	O
showed	O
that	O
old	O
age	O
and	O
septic	O
shock	O
were	O
significantly	O
associated	O
with	O
the	O
increased	O
risk	O
of	O
in	O
28	O
-	O
day	O
death	B-PROC
of	O
ARDS	O
[	O
advanced	O
age	O
:	O
hazard	O
ratio	O
(	O
HR	O
)=	O
1	O
.	O
040	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
018	O
-	O
1	O
.	O
064	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
septic	O
shock	O
:	O
HR	O
=	O
3	O
.	O
209	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
676	O
-	O
6	O
.	O
146	O
,	O
P	O
<	O
0	O
.	O
001	O
].	O

Absence	O
of	O
activating	O
transcription	B-PROC
factor	O
3	O
(	O
ATF3	O
)	O
confers	O
susceptibility	O
to	O
ALI	O
/	O
VILI	O
.	O

TITLE	O
:	O
Tailoring	O
subunit	O
vaccine	O
immunity	B-PROC
with	O
adjuvant	O
combinations	O
and	O
delivery	O
routes	O
using	O
the	O
Middle	O
East	O
respiratory	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
receptor	O
-	O
binding	O
domain	O
as	O
an	O
antigen	O
.	O

We	O
evaluated	O
the	O
induction	O
of	O
RBD	O
-	O
specific	O
humoral	B-PROC
immunity	I-PROC
(	O
total	O
IgG	O
and	O
neutralizing	O
antibodies	O
)	O
and	O
cellular	B-PROC
immunity	I-PROC
(	O
ELISpot	O
assay	O
for	O
IFN	O
-	O
γ	O
spot	O
-	O
forming	O
cells	O
and	O
splenocyte	O
cytokine	B-PROC
production	I-PROC
).	O

Together	O
,	O
these	O
results	O
imply	O
that	O
bats	O
indeed	O
could	O
be	O
among	O
the	O
MERS	O
-	O
CoV	O
host	O
spectrum	O
,	O
and	O
that	O
cellular	O
restriction	O
of	O
MERS	O
-	O
CoV	O
is	O
determined	O
by	O
CD26	O
/	O
DPP4	O
expression	B-PROC
rather	O
than	O
by	O
downstream	O
restriction	O
factors	O
.	O

We	O
analyzed	O
the	O
evolution	B-PROC
of	O
orf9b	O
in	O
concert	O
with	O
orf9a	O
using	O
sequence	O
data	O
of	O
betacoronavirus	O
-	O
lineage	O
b	O
and	O
found	O
that	O
orf9b	O
,	O
which	O
encodes	O
the	O
overprinting	O
protein	O
,	O
evolved	O
largely	O
independent	O
of	O
the	O
overprinted	O
orf9a	O
.	O

Virus	O
-	O
positive	O
exacerbations	O
were	O
associated	O
with	O
a	O
greater	O
increase	O
in	O
markers	O
of	O
systemic	O
and	O
airway	O
inflammation	O
(	O
serum	O
IL	O
-	O
6	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
;	O
sputum	O
IL	O
-	O
1β	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
)	O
compared	O
with	O
virus	O
-	O
negative	O
exacerbations	O
,	O
but	O
the	O
differences	O
in	O
spirometric	O
indexes	O
,	O
quality	O
of	O
life	O
,	O
and	O
bacterial	O
density	O
were	O
unremarkable	O
.	O

Tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)	O
and	O
interferon	O
(	O
IFN	O
)	O
signaling	B-PROC
were	O
not	O
required	O
for	O
effective	O
host	O
control	O
of	O
mutant	O
virus	O
as	O
all	O
N1347A	O
virus	O
-	O
infected	O
mice	O
survived	O
the	O
infection	O
.	O

However	O
,	O
the	O
adaptive	O
immune	O
system	O
was	O
required	O
for	O
protection	O
since	O
N1347A	O
virus	O
was	O
able	O
to	O
cause	O
lethal	O
encephalitis	O
in	O
RAG1	O
(-/-)	O
(	O
recombination	B-PROC
activation	O
gene	O
1	O
knockout	O
)	O
mice	O
although	O
disease	O
onset	O
was	O
modestly	O
delayed	O
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
BAC	O
-	O
based	O
MHV	O
reverse	O
genetics	O
system	O
will	O
be	O
useful	O
for	O
studies	O
of	O
JHMV	O
and	O
expand	O
upon	O
previous	O
studies	O
,	O
showing	O
that	O
the	O
macrodomain	O
is	O
critical	O
for	O
the	O
ability	O
of	O
coronaviruses	O
to	O
evade	O
the	O
immune	O
system	O
and	O
promote	O
viral	O
pathogenesis	B-PROC
.	O

133	O
kPa	O
),	O
lung	O
recruitment	O
maneuver	O
was	O
performed	O
combining	O
incremental	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
.	O

TITLE	O
:	O
Coronavirus	O
nonstructural	O
protein	O
1	O
:	O
Common	O
and	O
distinct	O
functions	O
in	O
the	O
regulation	B-PROC
of	O
host	O
and	O
viral	O
gene	B-PROC
expression	I-PROC
.	O

Therefore	O
,	O
this	O
newly	O
resolved	O
phylogeny	O
can	O
be	O
used	O
to	O
direct	O
future	O
assessments	O
of	O
viral	O
diversity	O
and	O
to	O
elucidate	O
the	O
origin	O
and	O
development	B-PROC
of	O
SARS	O
-	O
like	O
coronaviruses	O
in	O
mammals	O
.	O

No	O
major	O
clinical	O
or	O
technical	O
issues	O
were	O
observed	O
during	O
the	O
transport	B-PROC
.	O

RESULTS	O
:	O
Type	O
II	O
epithelial	B-PROC
cell	I-PROC
proliferation	I-PROC
was	O
significantly	O
more	O
common	O
in	O
cases	O
with	O
a	O
longer	O
time	O
between	O
burn	O
and	O
admission	O
(	O
p	O
<	O
0	O
.	O
02	O
).	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
a	O
large	O
group	O
of	O
enveloped	O
,	O
single	O
-	O
stranded	O
positive	O
-	O
sense	B-PROC
RNA	O
viruses	O
that	O
infect	O
a	O
wide	O
range	O
of	O
avian	O
and	O
mammalian	O
species	O
,	O
including	O
humans	O
.	O

Whereas	O
binding	O
to	O
the	O
host	O
cell	O
receptor	O
is	O
an	O
essential	O
first	O
step	O
in	O
establishing	O
infection	O
,	O
the	O
proteolytic	B-PROC
activation	O
step	O
is	O
often	O
critical	O
for	O
the	O
fusion	O
function	O
of	O
spike	O
,	O
as	O
it	O
allows	O
for	O
controlled	O
release	O
of	O
the	O
fusion	O
peptide	O
into	O
target	O
cellular	O
membranes	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
entry	O
inhibitors	O
targeting	B-PROC
spike	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
replication	O
of	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
was	O
studied	O
in	O
a	O
line	O
of	O
pigs	O
possessing	O
a	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
).	O

ABSTRACT	O
:	O
The	O
simian	O
hemorrhagic	O
fever	B-PROC
virus	O
(	O
SHFV	O
)	O
genome	O
differs	O
from	O
those	O
of	O
other	O
members	O
of	O
the	O
family	O
Arteriviridae	O
in	O
encoding	O
three	O
papain	O
-	O
like	O
one	O
proteases	O
(	O
PLP1α	O
,	O
PLP1β	O
and	O
PLP1γ	O
)	O
at	O
the	O
5	O
'	O
end	O
and	O
two	O
adjacent	O
sets	O
of	O
four	O
minor	O
structural	O
proteins	O
at	O
the	O
3	O
'	O
end	O
.	O

Intermediate	O
precursor	O
and	O
alternative	O
cleavage	B-PROC
products	O
were	O
detected	O
in	O
the	O
in	O
vitro	O
transcription	B-PROC
/	O
translation	B-PROC
reactions	O
but	O
only	O
the	O
three	O
mature	O
nsp1	O
proteins	O
were	O
detected	O
in	O
SHFV	O
-	O
infected	O
MA104	O
cell	O
lysates	O
with	O
SHFV	O
nsp1	O
protein	O
-	O
specific	O
antibodies	O
.	O

ABSTRACT	O
:	O
SHAPE	O
technology	O
was	O
used	O
to	O
analyze	O
RNA	O
secondary	O
structure	O
of	O
the	O
5	O
'	O
most	O
474	O
nts	O
of	O
the	O
MHV	O
-	O
A59	O
genome	O
encompassing	O
the	O
minimal	O
5	O
'	O
cis	O
-	O
acting	O
region	O
required	O
for	O
defective	O
interfering	O
RNA	B-PROC
replication	I-PROC
.	O

We	O
prospectively	O
monitored	O
the	O
course	O
of	O
symptomatic	O
respiratory	O
virus	B-PROC
infection	I-PROC
in	O
18	O
SOT	O
patients	O
(	O
14	O
lung	O
,	O
3	O
liver	O
,	O
and	O
1	O
kidney	O
)	O
using	O
patient	O
self	O
-	O
collected	O
swabs	O
.	O

Self	O
-	O
collected	O
nasal	O
swabs	O
provide	O
a	O
convenient	O
,	O
feasible	O
,	O
and	O
patient	O
-	O
acceptable	O
methodology	O
for	O
longitudinal	O
monitoring	O
of	O
upper	O
respiratory	O
virus	B-PROC
infection	I-PROC
in	O
SOT	O
recipients	O
.	O

CONCLUSIONS	O
:	O
Self	O
-	O
collected	O
nasal	O
swabs	O
provide	O
a	O
convenient	O
,	O
feasible	O
,	O
and	O
patient	O
-	O
acceptable	O
methodology	O
for	O
longitudinal	O
monitoring	O
of	O
upper	O
respiratory	O
virus	B-PROC
infection	I-PROC
in	O
SOT	O
recipients	O
.	O

As	O
of	O
May	O
9	O
,	O
2014	O
,	O
536	O
laboratory	O
-	O
confirmed	O
cases	O
and	O
145	O
deaths	B-PROC
have	O
been	O
reported	O
globally	O
.	O

ALI	O
/	O
ARDS	O
is	O
characterized	O
by	O
diffuse	O
alveolar	O
injury	O
,	O
lung	O
edema	O
formation	B-PROC
,	O
neutrophil	O
-	O
derived	O
inflammation	O
,	O
and	O
surfactant	O
dysfunction	O
.	O

The	O
results	O
also	O
suggest	O
that	O
nsp4	O
glycosylation	B-PROC
serves	O
roles	O
in	O
replication	O
in	O
addition	O
to	O
the	O
organization	O
and	O
stability	O
of	O
MHV	O
-	O
induced	O
double	O
-	O
membrane	O
vesicles	O
.	O

Three	O
viral	O
nonstructural	O
proteins	O
(	O
nsps	O
),	O
nsp3	O
,	O
nsp4	O
,	O
and	O
nsp6	O
,	O
are	O
known	O
to	O
be	O
required	O
for	O
DMV	O
formation	B-PROC
.	O

Passive	B-PROC
immunity	I-PROC
transfer	O
status	O
of	O
the	O
calves	O
,	O
measured	O
both	O
before	O
the	O
onset	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
were	O
non	O
-	O
significant	O
between	O
groups	O
.	O

TITLE	O
:	O
[	O
Pulse	B-PROC
indicator	O
continuous	O
cardiac	O
output	O
measurement	O
-	O
guided	O
treatment	O
aids	O
two	O
pediatric	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

During	O
treatment	O
,	O
the	O
dehydration	O
speed	O
of	O
CVVHDF	O
was	O
set	O
at	O
50	O
ml	O
/	O
h	O
to	O
maintain	O
the	O
balance	B-PROC
of	O
fluid	O
input	O
and	O
output	O
.	O

Two	O
hours	O
after	O
PiCCO	O
monitoring	O
,	O
the	O
oxygenation	B-PROC
index	O
decreased	O
to	O
140	O
mmHg	O
,	O
GEDVI	O
481	O
ml	O
/	O
m²	O
,	O
EVLWI	O
9	O
ml	O
/	O
kg	O
,	O
thus	O
the	O
dehydration	O
speed	O
of	O
CVVHDF	O
was	O
increased	O
(	O
up	O
to	O
100	O
ml	O
/	O
h	O
).	O

PiCCO	O
monitoring	O
can	O
provide	O
real	O
-	O
time	O
surveillance	O
of	O
cardiac	B-PROC
function	I-PROC
,	O
cardiac	O
preload	O
and	O
afterload	O
,	O
and	O
extravascular	O
lung	O
water	O
in	O
pediatric	O
patients	O
with	O
SAP	O
combined	O
with	O
ARDS	O
.	O

To	O
guide	O
fluid	O
management	O
,	O
the	O
cardiac	O
index	O
(	O
CI	O
)	O
was	O
measured	O
to	O
assess	O
cardiac	B-PROC
function	I-PROC
,	O
the	O
global	O
end	O
-	O
diastolic	O
volume	O
index	O
(	O
GEDVI	O
)	O
was	O
used	O
to	O
evaluate	O
cardiac	O
preload	O
,	O
and	O
the	O
extravascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
)	O
was	O
used	O
to	O
evaluate	O
the	O
pulmonary	O
edema	O
.	O

Since	O
there	O
is	O
documented	O
resistance	B-PROC
to	O
the	O
current	O
drugs	O
used	O
against	O
herpesviruses	O
and	O
there	O
is	O
no	O
treatment	O
for	O
equine	O
viral	O
arteritis	O
,	O
it	O
is	O
advisable	O
to	O
search	O
for	O
new	O
antiviral	O
compounds	O
to	O
overcome	O
these	O
infections	O
.	O

Here	O
we	O
show	O
that	O
PLpro	O
also	O
inhibits	O
IRF3	O
activation	O
at	O
a	O
step	O
after	O
phosphorylation	B-PROC
and	O
that	O
this	O
inhibition	B-PROC
is	O
dependent	O
on	O
the	O
de	O
-	O
ubiquitination	B-PROC
(	O
DUB	O
)	O
activity	O
of	O
PLpro	O
.	O

We	O
found	O
that	O
PLpro	O
is	O
able	O
to	O
block	O
the	O
type	O
I	O
IFN	O
induction	O
of	O
a	O
constitutively	O
active	O
IRF3	O
,	O
but	O
does	O
not	O
inhibit	O
IRF3	O
dimerization	O
,	O
nuclear	O
localization	B-PROC
or	O
DNA	O
binding	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
demonstrate	O
an	O
additional	O
mechanism	O
that	O
PLpro	O
is	O
able	O
to	O
inhibit	O
IRF3	O
signaling	B-PROC
.	O

Immunofluorescence	O
assays	O
confirmed	O
a	O
co	O
-	O
localization	B-PROC
between	O
the	O
TGEV	O
S	O
protein	O
and	O
filamin	O
A	O
.	O
Further	O
experiments	O
have	O
to	O
be	O
performed	O
to	O
prove	O
a	O
significant	O
impact	O
of	O
filamin	O
A	O
on	O
TGEV	O
infection	O
.	O

Haemagglutination	B-PROC
inhibition	B-PROC
(	O
HI	O
)	O
NDV	O
antibody	B-PROC
titres	O
were	O
similar	O
across	O
all	O
groups	O
but	O
were	O
above	O
protective	O
titres	O
.	O

METHODS	O
:	O
Three	O
respiratory	O
clinical	O
samples	O
were	O
tested	O
on	O
well	O
-	O
differentiated	B-PROC
pseudostratified	O
tracheobronchial	O
human	O
airway	O
epithelial	O
(	O
HAE	O
)	O
cultures	O
grown	O
at	O
an	O
air	O
-	O
liquid	O
interface	O
,	O
which	O
resemble	O
the	O
airway	O
epithelium	O
.	O

Despite	O
the	O
importance	O
of	O
bats	O
as	O
reservoir	O
hosts	O
of	O
zoonotic	O
and	O
potentially	O
zoonotic	O
agents	O
,	O
virtually	O
nothing	O
is	O
known	O
about	O
the	O
host	O
/	O
virus	O
relationships	O
;	O
principally	O
because	O
few	O
colonies	O
of	O
bats	O
are	O
available	O
for	O
experimental	O
infections	O
,	O
a	O
lack	O
of	O
reagents	O
,	O
methods	O
and	O
expertise	O
for	O
studying	O
bat	O
antiviral	O
responses	O
and	O
immunology	O
,	O
and	O
the	O
difficulty	O
of	O
conducting	B-PROC
meaningful	O
field	O
work	O
.	O

We	O
calculated	O
Systemic	O
Inflammatory	B-PROC
Response	I-PROC
Syndrome	O
criteria	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
,	O
and	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
scores	O
.	O

A	O
promoter	O
variant	O
,	O
fTNFA	O
-	O
421	O
T	O
,	O
was	O
found	O
to	O
be	O
a	O
disease	O
-	O
resistance	B-PROC
allele	O
.	O

ABSTRACT	O
:	O
Aspirin	O
-	O
exacerbated	O
respiratory	O
disease	O
(	O
AERD	O
),	O
also	O
known	O
as	O
Samter	O
'	O
s	O
triad	O
,	O
is	O
a	O
clinical	O
syndrome	O
which	O
consists	O
of	O
aspirin	O
(	O
ASA	O
)	O
intolerance	B-PROC
,	O
chronic	O
rhinosinusitis	O
with	O
nasal	O
polyposis	O
,	O
and	O
intrinsic	O
bronchial	O
asthma	O
(	O
Press	O
Med	O
119	O
:	O
48	O
-	O
51	O
,	O
1922	O
).	O

RESULTS	O
:	O
Seventy	O
-	O
three	O
percent	O
(	O
n	O
=	O
81	O
)	O
claimed	O
symptom	O
improvement	O
after	O
achieving	O
maintenance	O
dosing	O
on	O
the	O
desensitization	B-PROC
protocol	O
.	O

In	O
ARDS	O
patients	O
,	O
the	O
ventilator	O
strategy	O
should	O
be	O
a	O
balance	B-PROC
between	O
muscle	O
paralysis	O
in	O
the	O
most	O
hypoxemic	O
patients	O
and	O
preserved	O
spontaneous	O
breathing	B-PROC
after	O
improvement	O
or	O
from	O
the	O
acute	O
phase	O
in	O
less	O
severe	O
forms	O
.	O

TITLE	O
:	O
Detection	O
of	O
infectious	O
bronchitis	O
virus	O
with	O
the	O
use	O
of	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-PROC
-	O
PCR	O
and	O
correlation	O
with	O
virus	O
detection	O
in	O
embryonated	O
eggs	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
a	O
tool	O
for	O
prediction	O
of	O
the	O
host	O
tropism	B-PROC
of	O
the	O
virus	O
based	O
on	O
the	O
host	O
receptor	O
binding	O
interface	O
.	O

In	O
addition	O
to	O
its	O
function	O
as	O
a	O
structural	O
protein	O
,	O
N	O
protein	O
is	O
involved	O
in	O
cell	O
apoptosis	B-PROC
or	O
cell	B-PROC
-	I-PROC
cycle	I-PROC
regulation	I-PROC
.	O

They	O
died	B-PROC
of	O
massive	O
hemorrhage	O
and	O
meningoencephalitis	O
,	O
and	O
domestic	O
children	O
were	O
diagnosed	O
and	O
treated	O
within	O
two	O
to	O
4	O
weeks	O
after	O
onset	O
,	O
5	O
cases	O
were	O
cured	O
,	O
one	O
case	O
died	B-PROC
of	O
severe	O
pneumonia	O
.	O

Too	O
late	O
a	O
diagnosis	O
or	O
development	B-PROC
of	O
serious	O
complications	O
may	O
lead	O
to	O
death	B-PROC
.	O

To	O
study	O
MxA	O
protein	O
levels	O
in	O
healthy	O
state	O
and	O
during	O
respiratory	O
virus	B-PROC
infection	I-PROC
of	O
young	O
children	O
in	O
an	O
observational	O
prospective	O
cohort	O
.	O

Their	O
inhibition	B-PROC
mechanisms	O
and	O
mutually	O
binding	O
synergistic	O
effect	O
were	O
also	O
investigated	O
.	O

The	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
/	O
inspiratory	B-PROC
oxygen	O
fraction	O
tables	O
are	O
the	O
only	O
methods	O
providing	O
lower	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
lower	O
recruiters	O
and	O
higher	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
higher	O
recruiters	O
.	O

This	O
inevitably	O
hinders	O
understanding	O
of	O
virushost	O
interaction	O
and	O
development	B-PROC
of	O
appropriate	O
countermeasures	O
.	O

We	O
conclude	O
that	O
INO	O
in	O
short	O
-	O
term	O
experiments	O
,	O
in	O
addition	O
to	O
causing	O
selective	O
pulmonary	O
vasodilation	B-PROC
in	O
ventilated	O
lung	O
regions	O
,	O
increases	O
the	O
ET	O
-	O
A	O
/	O
ET	O
-	O
B	O
mRNA	B-PROC
expression	B-PROC
ratio	O
in	O
lung	O
tissue	O
.	O

Here	O
,	O
we	O
report	O
that	O
development	B-PROC
of	O
a	O
transgenic	O
mouse	O
model	O
expressing	O
porcine	O
APN	O
which	O
is	O
susceptible	O
to	O
porcine	O
coronavirus	O
infection	O
.	O

Therefore	O
,	O
targeting	B-PROC
PLpro	O
with	O
antiviral	O
drugs	O
may	O
have	O
an	O
advantage	O
in	O
not	O
only	O
inhibiting	O
viral	B-PROC
replication	I-PROC
but	O
also	O
inhibiting	O
the	O
dysregulation	O
of	O
signaling	B-PROC
cascades	O
in	O
infected	O
cells	O
that	O
may	O
lead	O
to	O
cell	B-PROC
death	I-PROC
in	O
surrounding	O
,	O
uninfected	O
cells	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
identify	O
morphological	O
changes	O
in	O
the	O
lung	O
parenchyma	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
survivors	O
after	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
by	O
high	O
-	O
resolution	O
computed	O
tomography	O
(	O
HRCT	O
)	O
follow	O
-	O
up	O
.	O

Fifteen	O
(	O
88	O
%)	O
patients	O
were	O
hospitalized	O
,	O
nine	O
(	O
53	O
%)	O
required	O
mechanical	O
ventilation	O
,	O
five	O
(	O
29	O
%)	O
required	O
emergent	O
cesarean	O
delivery	O
,	O
and	O
four	O
(	O
24	O
%)	O
died	B-PROC
.	O

Lower	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
(	O
until	O
day	O
7	O
)	O
and	O
lower	O
delivered	O
tidal	O
volume	O
after	O
3	O
days	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
were	O
associated	O
with	O
significantly	O
higher	O
mortality	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
multivariate	O
analysis	O
,	O
higher	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
during	O
the	O
first	O
3	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
were	O
associated	O
with	O
lower	O
mortality	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
75	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
64	O
-	O
0	O
.	O
88	O
;	O
p	O
=	O
0	O
.	O
0006	O
).	O

Then	O
the	O
historical	O
development	B-PROC
of	O
ECLA	O
evidences	O
for	O
ARDS	O
are	O
reviewed	O
.	O

Patients	O
who	O
progressed	O
had	O
acute	O
kidney	O
injury	O
and	O
other	O
severe	O
maternal	O
morbidity	O
,	O
including	O
one	O
case	O
of	O
maternal	B-PROC
death	B-PROC
.	O

Tryptophan	B-PROC
catabolism	B-PROC
is	O
an	O
endogenous	O
mechanism	O
that	O
restricts	O
excessive	O
immune	B-PROC
responses	I-PROC
,	O
thereby	O
preventing	O
immunopathology	O
.	O

Since	O
indoleamine	O
-	O
2	O
,	O
3	O
-	O
dioxygenase	O
(	O
IDO	O
)	O
is	O
the	O
key	O
and	O
rate	O
-	O
limiting	O
enzyme	O
of	O
tryptophan	B-PROC
catabolism	B-PROC
,	O
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
explore	O
whether	O
specific	O
inhibition	B-PROC
of	O
IDO	O
by	O
Levo	O
-	O
1	O
-	O
methyl	O
tryptophan	O
(	O
MT	O
)	O
could	O
affect	O
MHV	O
actions	O
.	O

Herd	O
-	O
level	O
data	O
on	O
production	O
,	O
health	O
and	O
reproduction	B-PROC
were	O
retrieved	O
from	O
VÄXA	O
Sweden	O
and	O
the	O
study	O
herds	O
were	O
representative	O
of	O
the	O
source	O
population	O
.	O

This	O
determined	O
six	O
single	O
-	O
nucleotide	O
polymorphisms	B-PROC
(	O
SNPs	O
)	O
that	O
were	O
associated	O
with	O
antibody	B-PROC
levels	O
against	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
):	O
rsZ2494661	O
,	O
rsZ2494710	O
,	O
rs1211307701	O
,	O
rs1211307711	O
,	O
rs1218289310	O
and	O
rs420701988	O
.	O

IB	O
had	O
two	O
SNPs	O
associated	O
with	O
antibody	B-PROC
levels	O
:	O
rs149988433	O
and	O
rs16170823	O
;	O
both	O
reached	O
chromosome	O
-	O
wide	O
significance	O
levels	O
and	O
they	O
were	O
near	O
the	O
USP7	O
and	O
TRIM27	O
genes	O
,	O
respectively	O
.	O

Identification	O
of	O
PEDV	O
-	O
or	O
TGEV	O
-	O
specific	O
antigenic	O
regions	O
allows	O
the	O
development	B-PROC
of	O
more	O
specific	O
immunoassays	O
for	O
each	O
virus	O
.	O

Moreover	O
,	O
infected	O
Tg	O
(+)	O
mice	O
were	O
able	O
to	O
activate	O
genes	O
encoding	O
for	O
many	O
antiviral	O
and	O
inflammatory	O
mediators	O
within	O
the	O
lungs	O
and	O
brains	O
,	O
coinciding	O
with	O
the	O
high	O
levels	O
of	O
viral	B-PROC
replication	I-PROC
.	O

In	O
this	O
article	O
,	O
we	O
briefly	O
review	O
the	O
definition	O
,	O
epidemiology	O
,	O
and	O
pathophysiology	O
of	O
ARDS	O
and	O
present	O
emerging	O
aspects	O
of	O
ARDS	O
pathophysiology	O
that	O
encompass	O
modulators	O
of	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
,	O
damage	O
signals	O
,	O
and	O
aberrant	O
proteolysis	B-PROC
that	O
may	O
serve	O
as	O
a	O
foundation	O
for	O
future	O
therapeutic	O
targets	O
.	O

TITLE	O
:	O
Combination	O
siRNA	O
therapy	O
against	O
feline	O
coronavirus	O
can	O
delay	O
the	O
emergence	O
of	O
antiviral	O
resistance	B-PROC
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Prone	O
position	O
ventilation	O
has	O
been	O
shown	O
to	O
improve	O
oxygenation	B-PROC
and	O
ventilatory	O
mechanics	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

When	O
stratified	O
by	O
subgroups	O
,	O
a	O
significant	O
decrease	O
was	O
seen	O
in	O
the	O
risk	O
of	O
mortality	O
in	O
patients	O
ventilated	O
with	O
low	O
tidal	O
volume	O
(	O
OR	O
:	O
0	O
.	O
58	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
38	O
to	O
0	O
.	O
87	O
;	O
P	O
=.	O
009	O
,	O
I	O
(	O
2	O
)	O
33	O
%),	O
prolonged	O
pronation	B-PROC
(	O
OR	O
:	O
0	O
.	O
6	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
43	O
to	O
0	O
.	O
83	O
;	O
p	O
=.	O
002	O
,	O
I	O
(	O
2	O
)	O
27	O
%),	O
start	O
within	O
the	O
first	O
48hours	O
of	O
disease	O
evolution	B-PROC
(	O
OR	O
0	O
.	O
49	O
;	O
95	O
%	O
CI	O
0	O
.	O
35	O
to	O
0	O
.	O
68	O
;	O
P	O
=.	O
0001	O
,	O
I	O
(	O
2	O
)	O
0	O
%)	O
and	O
severe	O
hypoxemia	O
(	O
OR	O
:	O
0	O
.	O
51	O
:	O
95	O
%	O
CI	O
:	O
0	O
.	O
36	O
to	O
1	O
.	O
25	O
;	O
P	O
=.	O
0001	O
,	O
I	O
(	O
2	O
)	O
0	O
%).	O

Prone	O
position	O
ventilation	O
is	O
a	O
safe	O
strategy	O
and	O
reduces	O
mortality	O
in	O
patients	O
with	O
severely	O
impaired	O
oxygenation	B-PROC
.	O

The	O
mast	O
cells	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	B-PROC
of	O
lung	O
injury	O
and	O
the	O
increase	O
of	O
vascular	B-PROC
permeability	I-PROC
in	O
mice	O
following	O
the	O
subcutaneous	O
administration	O
of	O
Aah	O
scorpion	O
venom	O
through	O
the	O
NK1	O
receptor	O
.	O

These	O
differentially	O
expressed	B-PROC
proteins	O
were	O
involved	O
in	O
apoptosis	B-PROC
,	O
signal	B-PROC
transduction	I-PROC
,	O
and	O
stress	O
responses	O
.	O

However	O
,	O
receptor	O
binding	O
,	O
endosomal	O
uptake	O
,	O
and	O
probably	O
signaling	B-PROC
via	O
Toll	O
-	O
like	O
receptor	O
7	O
(	O
TLR7	O
)	O
were	O
critical	O
for	O
sensing	O
of	O
MERS	O
-	O
CoV	O
by	O
pDCs	O
.	O

ABSTRACT	O
:	O
Among	O
neonates	O
with	O
Down	O
syndrome	O
(	O
DS	O
)	O
and	O
transient	O
leukemia	O
(	O
TL	O
),	O
hyperleukocytosis	O
(	O
white	O
blood	O
cell	O
[	O
WBC	O
]	O
count	O
>	O
100	O
×	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
is	O
associated	O
with	O
increased	B-PROC
blood	I-PROC
viscosity	I-PROC
,	O
respiratory	O
failure	O
due	O
to	O
pulmonary	O
hypertension	O
,	O
multiorgan	O
failure	O
,	O
and	O
increased	O
risk	O
of	O
early	O
death	B-PROC
.	O

TITLE	O
:	O
Study	O
of	O
viral	O
pathogenesis	B-PROC
in	O
humanized	O
mice	O
.	O

ABSTRACT	O
:	O
Many	O
of	O
the	O
viral	O
pathogens	O
that	O
cause	O
infectious	O
diseases	O
in	O
humans	O
have	O
a	O
highly	O
restricted	O
species	O
tropism	B-PROC
,	O
making	O
the	O
study	O
of	O
their	O
pathogenesis	B-PROC
and	O
the	O
development	B-PROC
of	O
clinical	O
therapies	O
difficult	O
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationship	O
of	O
pyrrolyl	O
diketo	O
acid	O
derivatives	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
integrase	O
and	O
reverse	O
transcriptase	B-PROC
ribonuclease	O
H	O
domain	O
.	O

ABSTRACT	O
:	O
The	O
development	B-PROC
of	O
HIV	O
-	O
1	O
dual	O
inhibitors	O
is	O
a	O
highly	O
innovative	O
approach	O
aimed	O
at	O
reducing	O
drug	O
toxic	O
side	O
effects	O
as	O
well	O
as	O
therapeutic	O
costs	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
validation	O
of	O
a	O
rapid	O
immunochromatographic	O
assay	O
for	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
antigen	O
in	O
dromedary	O
camels	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
efficacy	O
of	O
a	O
novel	O
live	O
-	O
attenuated	O
QX	O
-	O
like	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	O
vaccine	O
in	O
China	O
.	O

In	O
conclusion	O
,	O
the	O
attenuated	O
YX10p90	O
strain	O
exhibited	O
a	O
fine	O
balance	B-PROC
between	O
attenuation	O
and	O
immunogenicity	O
,	O
and	O
should	O
be	O
considered	O
as	O
a	O
candidate	O
vaccine	O
to	O
prevent	O
infection	O
of	O
Chinese	O
QX	O
-	O
like	O
nephropathogenic	O
IBV	O
.	O

These	O
results	O
provide	O
insight	O
into	O
DPP4	O
species	O
-	O
specific	O
differences	O
impacting	O
MERS	O
-	O
CoV	O
host	O
range	O
and	O
may	O
inform	O
MERS	O
-	O
CoV	O
mouse	O
model	O
development	B-PROC
.	O

Using	O
gene	B-PROC
silencing	I-PROC
,	O
the	O
ATP1A1	O
protein	O
was	O
shown	O
to	O
be	O
critical	O
for	O
infection	O
of	O
cells	O
with	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
),	O
and	O
VSV	O
but	O
not	O
with	O
IAV	O
.	O

A	O
total	O
of	O
61	O
compounds	O
including	O
flavonoids	O
,	O
phenylpropanoids	O
,	O
anthraquinones	O
,	O
triterpenoids	O
,	O
iridoids	O
,	O
and	O
other	O
types	O
of	O
compounds	O
were	O
unambiguously	O
or	O
tentatively	O
identified	O
by	O
comparing	O
the	O
retention	B-PROC
times	O
and	O
accurate	O
mass	O
measurement	O
with	O
reference	O
compounds	O
or	O
literature	O
data	O
.	O

MERS	O
is	O
often	O
a	O
lower	O
respiratory	O
tract	O
disease	O
associated	O
with	O
fever	B-PROC
,	O
cough	O
,	O
breathing	B-PROC
difficulties	O
,	O
pneumonia	O
that	O
can	O
progress	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
multiorgan	O
failure	O
and	O
death	B-PROC
among	O
more	O
than	O
a	O
third	O
of	O
those	O
infected	O
.	O

We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
inhibition	B-PROC
of	O
PPV	O
replication	O
in	O
swine	O
testis	O
(	O
ST	O
)	O
cells	O
by	O
LiCl	O
is	O
dose	O
-	O
dependent	O
,	O
and	O
that	O
the	O
antiviral	O
effect	O
of	O
LiCl	O
occurred	O
in	O
the	O
early	O
phase	O
of	O
PPV	O
replication	O
.	O

All	O
proteins	O
oligomerise	O
through	O
covalent	B-PROC
bonds	O
,	O
are	O
N	O
-	O
glycosylated	O
and	O
are	O
maintained	O
in	O
the	O
ER	O
in	O
non	O
-	O
infected	O
but	O
also	O
in	O
CCoV	O
-	O
II	O
infected	O
cells	O
,	O
without	O
any	O
specific	O
retention	B-PROC
signal	O
.	O

However	O
,	O
deletions	O
influence	O
their	O
level	O
of	O
expression	B-PROC
.	O

Our	O
results	O
support	O
previous	O
studies	O
that	O
implicate	O
S	O
protein	O
mutations	O
in	O
the	O
pathogenesis	B-PROC
of	O
FIP	O
.	O

Additional	O
studies	O
need	O
to	O
be	O
performed	O
in	O
which	O
the	O
amount	O
of	O
supplementation	O
is	O
targeted	B-PROC
to	O
a	O
potentially	O
measurable	O
endpoint	O
,	O
e	O
.	O
g	O
.	O
the	O
O	O
-	O
3I	O
.	O

These	O
findings	O
have	O
provided	O
new	O
insight	O
into	O
the	O
potential	O
characteristics	O
of	O
the	O
bat	O
innate	O
immune	O
system	O
against	O
viral	B-PROC
infection	I-PROC
.	O

Infection	O
involved	O
porcine	O
aminpeptidase	O
N	O
(	O
pAPN	O
),	O
a	O
reported	O
cellular	O
receptor	O
for	O
PEDV	O
,	O
transient	O
expression	B-PROC
of	O
pAPN	O
and	O
siRNA	O
targeted	B-PROC
pAPN	O
increased	O
and	O
decreased	O
the	O
infectivity	O
of	O
PEDV	O
in	O
IECs	O
,	O
respectively	O
.	O

TITLE	O
:	O
Rapid	O
detection	O
of	O
equine	O
coronavirus	O
by	O
reverse	B-PROC
transcription	B-PROC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
.	O

However	O
,	O
it	O
is	O
important	O
that	O
the	O
global	O
public	O
health	O
community	O
have	O
access	O
to	O
information	O
on	O
the	O
basic	O
epidemiological	O
features	O
of	O
the	O
outbreak	O
to	O
date	O
,	O
including	O
the	O
basic	O
reproduction	B-PROC
number	O
(	O
R0	O
)	O
and	O
best	O
estimates	O
of	O
case	O
-	O
fatality	O
rates	O
(	O
CFR	O
).	O

Overall	O
case	O
-	O
fatality	O
was	O
40	O
%;	O
depending	O
on	O
the	O
timing	O
of	O
171	O
deaths	B-PROC
unlinked	O
to	O
case	O
data	O
,	O
outbreak	O
CFR	O
could	O
be	O
higher	O
,	O
lower	O
,	O
or	O
equivalent	O
to	O
pre	O
-	O
outbreak	O
CFR	O
.	O

The	O
percentage	O
of	O
FCoV	O
seropositive	O
and	O
seronegative	O
cats	O
that	O
died	B-PROC
in	O
spite	O
of	O
supportive	O
veterinary	O
treatment	O
was	O
33	O
%	O
(	O
21	O
/	O
63	O
)	O
and	O
12	O
%	O
(	O
13	O
/	O
106	O
),	O
respectively	O
.	O

TITLE	O
:	O
Aptamers	O
in	O
diagnostics	O
and	O
treatment	O
of	O
viral	B-PROC
infections	I-PROC
.	O

The	O
second	O
child	O
developed	O
headache	O
,	O
somnolence	O
,	O
agitation	O
,	O
and	O
speech	B-PROC
dysfunction	O
following	O
an	O
upper	O
respiratory	O
tract	O
infection	O
.	O

Since	O
3CLpro	O
is	O
functionally	O
and	O
structurally	O
conserved	O
among	O
these	O
viruses	O
and	O
essential	O
for	O
viral	B-PROC
replication	I-PROC
,	O
3CLpro	O
is	O
considered	O
a	O
potential	O
target	O
for	O
the	O
design	O
of	O
antiviral	O
drugs	O
with	O
broad	O
-	O
spectrum	O
activities	O
against	O
these	O
distinct	O
and	O
highly	O
important	O
viral	B-PROC
infections	I-PROC
.	O

In	O
this	O
study	O
,	O
derivatives	O
of	O
peptidyl	O
compounds	O
targeting	B-PROC
3CLpro	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
activities	O
against	O
FCoV	O
and	O
FCV	O
.	O

However	O
,	O
the	O
thermal	O
stability	O
of	O
the	O
Ubl	O
mutant	O
PLP2	O
was	O
significantly	O
reduced	O
at	O
30	O
°	O
C	O
,	O
thereby	O
reducing	O
the	O
total	O
enzymatic	B-PROC
activity	I-PROC
.	O

Our	O
results	O
identify	O
the	O
coronavirus	O
Ubl	O
domain	O
as	O
a	O
novel	O
modulator	O
of	O
viral	O
protease	O
stability	O
and	O
reveal	O
manipulating	O
the	O
Ubl	O
domain	O
as	O
a	O
new	O
approach	O
for	O
attenuating	O
coronavirus	O
replication	O
and	O
pathogenesis	B-PROC
.	O

Adjustment	O
of	O
PEEP	O
and	O
inspiratory	B-PROC
driving	O
pressures	O
did	O
not	O
worsen	O
oxygenation	B-PROC
and	O
did	O
not	O
affect	O
cardiac	O
output	O
significantly	O
.	O

Adjustment	O
of	O
PEEP	O
and	O
inspiratory	B-PROC
driving	O
pressures	O
did	O
not	O
worsen	O
oxygenation	B-PROC
and	O
did	O
not	O
affect	O
cardiac	O
output	O
significantly	O
.	O

ABSTRACT	O
:	O
Pneumonia	O
is	O
a	O
most	O
common	O
human	O
disease	O
and	O
a	O
leading	O
cause	O
of	O
death	B-PROC
from	O
infectious	O
pathology	O
.	O

It	O
is	O
a	O
multi	O
-	O
domain	O
,	O
multi	O
-	O
functional	O
protein	O
important	O
for	O
viral	B-PROC
replication	I-PROC
and	O
a	O
number	O
of	O
cellular	O
processes	O
.	O

Surprisingly	O
,	O
analysis	O
of	O
the	O
subcellular	O
localization	B-PROC
of	O
the	O
N	O
protein	O
of	O
HCoV	O
-	O
NL63	O
revealed	O
that	O
,	O
differently	O
than	O
homologous	O
proteins	O
from	O
other	O
coronaviral	O
species	O
except	O
for	O
SARS	O
-	O
CoV	O
,	O
it	O
is	O
not	O
present	O
in	O
the	O
nucleus	O
of	O
infected	O
or	O
transfected	O
cells	O
.	O

Furthermore	O
,	O
no	O
significant	O
alteration	O
in	O
cell	B-PROC
cycle	I-PROC
progression	I-PROC
in	O
cells	O
expressing	O
the	O
protein	O
was	O
observed	O
.	O

Antibody	B-PROC
rates	O
of	O
decay	O
were	O
calculated	O
.	O

Vaccination	O
at	O
2	O
or	O
5	O
weeks	O
of	O
age	O
had	O
no	O
effect	O
on	O
the	O
rate	O
of	O
antibody	B-PROC
decay	O
.	O

RESULTS	O
:	O
Of	O
255	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
infection	O
,	O
93	O
died	B-PROC
(	O
case	O
fatality	O
rate	O
,	O
36	O
.	O
5	O
%).	O

Based	O
on	O
the	O
incidence	O
in	O
Saudi	O
Arabia	O
since	O
June	O
2012	O
,	O
the	O
most	O
likely	O
scenario	O
given	O
recent	O
pilgrim	O
numbers	O
is	O
estimated	O
to	O
be	O
one	O
case	O
per	O
Hajj	O
,	O
and	O
three	O
Umrah	O
pilgrims	O
per	O
year	O
,	O
but	O
which	O
could	O
plausibly	O
reach	B-PROC
seven	O
and	O
ten	O
pilgrims	O
respectively	O
.	O

This	O
predisposition	O
is	O
primarily	O
due	O
to	O
high	O
error	O
rate	O
,	O
and	O
limited	O
proofreading	O
capability	O
of	O
the	O
viral	O
polymerase	O
and	O
by	O
recombination	B-PROC
.	O

Here	O
,	O
we	O
describe	O
a	O
method	O
for	O
incorporating	O
a	O
proteinaceous	O
viral	O
receptor	O
,	O
feline	O
aminopeptidase	O
N	O
(	O
fAPN	O
),	O
into	O
SLBs	O
using	O
cell	B-PROC
blebbing	I-PROC
of	O
mammalian	O
cells	O
expressing	O
fAPN	O
in	O
the	O
plasma	O
membrane	O
.	O

In	O
addition	O
,	O
RT	O
-	O
qPCR	O
analysis	O
is	O
used	O
for	O
further	O
transcriptional	B-PROC
profiling	O
of	O
selected	O
genes	O
in	O
infected	O
CRFK	O
cells	O
and	O
Peripheral	O
Blood	O
Mononuclear	O
Cells	O
(	O
PBMCs	O
)	O
from	O
healthy	O
and	O
FIP	O
-	O
diagnosed	O
cats	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
whole	O
genome	O
showed	O
that	O
VicS	O
-	O
v	O
and	O
VicS	O
-	O
del	O
did	O
not	O
cluster	O
with	O
strains	O
from	O
other	O
countries	O
,	O
supporting	O
the	O
hypothesis	O
that	O
Australian	O
IBV	O
strains	O
have	O
been	O
evolving	O
independently	O
for	O
some	O
time	O
,	O
and	O
analyses	O
of	O
individual	O
polymerase	O
peptide	O
and	O
S	O
glycoprotein	O
genes	O
suggested	O
a	O
distant	O
common	O
ancestor	O
with	O
no	O
recent	O
recombination	B-PROC
.	O

This	O
study	O
suggests	O
the	O
potential	O
role	O
of	O
the	O
TM	O
domain	O
in	O
nsp6	O
,	O
the	O
integrity	O
of	O
the	O
S2	O
protein	O
and	O
the	O
B	O
-	O
TRS	O
3	O
,	O
and	O
the	O
putative	O
accessory	O
protein	O
4b	O
,	O
as	O
well	O
as	O
the	O
3	O
'	O
untranslated	O
region	O
,	O
in	O
the	O
virulence	B-PROC
and	O
replication	O
of	O
IBV	O
and	O
has	O
provided	O
a	O
better	O
understanding	O
of	O
relationships	O
between	O
the	O
Australian	O
vaccine	O
strain	O
of	O
IBV	O
and	O
those	O
used	O
elsewhere	O
.	O

The	O
purified	O
whole	O
viral	O
antigen	O
of	O
Sczy3	O
strain	O
was	O
used	O
to	O
immunize	O
BALB	O
/	O
c	O
mice	O
to	O
produce	O
hybridoma	O
-	O
secreting	B-PROC
anti	O
-	O
IBV	O
MAbs	O
.	O

The	O
anti	O
-	O
S1	O
MAbs	O
produced	O
in	O
the	O
present	O
work	O
may	O
be	O
valuable	O
in	O
developing	O
an	O
antigen	O
-	O
capture	O
ELISA	O
test	O
for	O
antigen	O
detection	O
or	O
a	O
competitive	O
ELISA	O
test	O
for	O
antibody	B-PROC
detection	O
or	O
therapeutic	O
medicine	O
for	O
IB	O
in	O
poultry	O
.	O

TITLE	O
:	O
Monoclonal	O
antibody	B-PROC
to	O
N	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Then	O
,	O
female	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
the	O
purified	O
recombinant	O
N	O
protein	O
and	O
one	O
strain	O
of	O
hybridoma	O
cells	O
named	O
2B8	O
secreting	B-PROC
anti	O
-	O
N	O
protein	O
monoclonal	O
antibodies	O
(	O
MAb	O
)	O
was	O
obtained	O
by	O
hybridoma	O
technique	O
.	O

ABSTRACT	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
a	O
rescue	O
treatment	O
for	O
severe	O
hypoxemia	O
in	O
the	O
intensive	O
care	O
unit	O
setting	O
.	O

Patients	O
treated	O
with	O
iNO	O
had	O
significant	O
improvement	O
in	O
oxygenation	B-PROC
:	O
mean	O
(	O
SD	O
)	O
for	O
PaO2	O
increased	O
from	O
60	O
.	O
7	O
(	O
20	O
.	O
2	O
)	O
to	O
72	O
.	O
3	O
(	O
40	O
.	O
6	O
)	O
mm	O
Hg	O
(	O
P	O
=.	O
008	O
),	O
and	O
mean	O
(	O
SD	O
)	O
for	O
ratio	O
of	O
PaO2	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
P	O
:	O
F	O
)	O
increased	O
from	O
62	O
.	O
4	O
(	O
26	O
.	O
1	O
)	O
to	O
73	O
.	O
1	O
(	O
42	O
.	O
6	O
)	O
(	O
P	O
=	O
.	O
03	O
).	O

We	O
developed	O
a	O
simple	O
,	O
reliable	O
MERS	O
-	O
CoV	O
variant	O
typing	O
assay	O
which	O
is	O
crucial	O
in	O
monitoring	O
MERS	O
-	O
CoV	O
circulation	B-PROC
in	O
real	O
time	O
with	O
relatively	O
little	O
investment	O
on	O
location	O
.	O

TITLE	O
:	O
VHL	O
negatively	O
regulates	O
SARS	O
coronavirus	O
replication	O
by	O
modulating	O
nsp16	O
ubiquitination	B-PROC
and	O
stability	O
.	O

ABSTRACT	O
:	O
Eukaryotic	O
cellular	O
and	O
most	O
viral	O
RNAs	O
carry	O
a	O
5	O
'-	O
terminal	O
cap	O
structure	O
,	O
a	O
5	O
'-	O
5	O
'	O
triphosphate	O
linkage	B-PROC
between	O
the	O
5	O
'	O
end	O
of	O
the	O
RNA	O
and	O
a	O
guanosine	O
nucleotide	O
(	O
cap	O
-	O
0	O
).	O

This	O
study	O
provides	O
costs	O
of	O
inadequate	O
breastfeeding	B-PROC
that	O
had	O
not	O
been	O
quantified	O
in	O
Mexico	O
.	O

Among	O
all	O
cases	O
,	O
.	O
9	O
%	O
of	O
Plasmodium	O
falciparum	O
cases	O
resulted	O
in	O
death	B-PROC
and	O
9	O
.	O
3	O
%	O
were	O
classified	O
as	O
severe	O
,	O
whereas	O
.	O
09	O
%	O
of	O
P	O
.	O
vivax	O
cases	O
resulted	O
in	O
death	B-PROC
and	O
1	O
.	O
3	O
%	O
were	O
classified	O
as	O
severe	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
)	O
detecting	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
RNA	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
of	O
cats	O
with	O
and	O
without	O
neurological	O
and	O
/	O
or	O
ocular	B-PROC
signs	O
for	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

Nineteen	O
cats	O
had	O
a	O
definitive	O
histopathological	O
diagnosis	O
of	O
FIP	O
(	O
seven	O
of	O
these	O
with	O
neurological	O
and	O
/	O
or	O
ocular	B-PROC
signs	O
),	O
and	O
15	O
cats	O
had	O
other	O
diseases	O
but	O
similar	O
clinical	O
signs	O
(	O
three	O
of	O
these	O
with	O
neurological	O
and	O
/	O
or	O
ocular	B-PROC
signs	O
).	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
TLS	O
and	O
CS	O
as	O
complications	O
of	O
hemorrhage	O
at	O
the	O
lung	O
metastases	O
of	O
advanced	O
testicular	O
cancer	O
leading	O
to	O
death	B-PROC
.	O

During	O
follow	O
-	O
up	O
,	O
7	O
/	O
34	O
(	O
21	O
%)	O
Rtx	O
-	O
treated	O
ASS	O
patients	O
died	B-PROC
;	O
6	O
/	O
7	O
deaths	B-PROC
were	O
related	O
to	O
infections	O
.	O

Goat	O
anti	O
-	O
turkey	O
IgG	O
(	O
H	O
+	O
L	O
)	O
conjugated	O
with	O
horseradish	O
peroxidase	O
was	O
used	O
as	O
detector	O
antibody	B-PROC
.	O

This	O
RNA	O
motif	O
has	O
high	O
homology	O
in	O
sequence	O
and	O
secondary	O
structure	O
with	O
the	O
gamma	O
interferon	O
-	O
activated	O
inhibitor	O
of	O
translation	B-PROC
(	O
GAIT	O
)	O
element	O
,	O
which	O
is	O
located	O
at	O
the	O
3	O
'	O
end	O
of	O
several	O
mRNAs	O
encoding	O
proinflammatory	O
proteins	O
.	O

The	O
innate	B-PROC
immune	I-PROC
response	I-PROC
is	O
the	O
first	O
line	O
of	O
antiviral	O
defense	O
that	O
culminates	O
with	O
the	O
synthesis	B-PROC
of	O
interferon	O
and	O
proinflammatory	O
cytokines	O
to	O
limit	O
virus	B-PROC
replication	I-PROC
.	O

Moreover	O
,	O
the	O
disruption	O
of	O
the	O
viral	O
GAIT	O
-	O
like	O
RNA	O
motif	O
led	O
to	O
an	O
exacerbated	O
innate	B-PROC
immune	I-PROC
response	I-PROC
triggered	O
by	O
MDA5	O
,	O
indicating	O
that	O
the	O
GAIT	O
-	O
like	O
RNA	O
motif	O
counteracts	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
female	O
patient	O
with	O
preterm	O
labor	B-PROC
,	O
severe	O
viral	O
hepatitis	O
B	O
of	O
acute	O
phase	O
,	O
hepatic	O
encephalopathy	O
stage	O
III	O
and	O
coma	O
.	O

Nonviral	O
gene	O
vector	O
platforms	O
are	O
tailorable	O
and	O
can	O
overcome	O
key	O
limitations	O
intrinsic	O
to	O
virus	O
-	O
mediated	O
delivery	O
;	O
however	O
,	O
lack	O
of	O
clinical	O
efficacy	O
with	O
nonviral	O
systems	O
to	O
date	O
may	O
be	O
attributed	O
to	O
limited	O
gene	O
vector	O
dispersion	O
and	O
transfection	B-PROC
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Ubiquitin	B-PROC
(	O
Ub	B-PROC
)	O
and	O
the	O
Ub	B-PROC
-	O
like	O
(	O
Ubl	O
)	O
modifier	O
interferon	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
participate	O
in	O
the	O
host	B-PROC
defence	I-PROC
of	O
viral	B-PROC
infections	I-PROC
.	O

First	O
,	O
MERS	O
PLpro	O
shows	O
broad	O
linkage	B-PROC
specificity	O
for	O
the	O
cleavage	B-PROC
of	O
polyUb	O
chains	O
,	O
whereas	O
SARS	O
PLpro	O
prefers	O
to	O
cleave	O
Lys48	O
-	O
linked	O
polyUb	O
chains	O
.	O

Host	O
shifts	O
resulted	O
in	O
dramatic	O
variation	O
in	O
virulence	B-PROC
,	O
with	O
benign	O
infections	O
in	O
some	O
species	O
and	O
rapid	O
death	B-PROC
in	O
others	O
.	O

Experimental	O
studies	O
on	O
ARDS	O
have	O
shown	O
that	O
inhibition	B-PROC
of	I-PROC
apoptosis	I-PROC
in	O
the	O
lungs	O
reduces	O
lung	O
epithelial	O
injury	O
.	O

Subgroup	O
analysis	O
by	O
HFOV	O
strategy	O
showed	O
a	O
similar	O
effect	O
in	O
trials	O
with	O
a	O
more	O
strict	O
lung	B-PROC
volume	I-PROC
recruitment	O
strategy	O
,	O
targeting	B-PROC
a	O
very	O
low	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
FiO2	O
),	O
and	O
trials	O
with	O
a	O
less	O
strict	O
lung	B-PROC
volume	I-PROC
recruitment	O
strategy	O
and	O
with	O
a	O
somewhat	O
higher	O
or	O
unspecified	O
target	O
FiO2	O
.	O

Subgroup	O
analyses	O
by	O
age	O
at	O
randomisation	O
,	O
routine	O
surfactant	O
use	O
or	O
not	O
,	O
type	O
of	O
high	O
frequency	O
ventilator	O
(	O
oscillator	O
versus	O
flow	O
interrupter	O
),	O
inspiratory	B-PROC
to	O
expiratory	B-PROC
(	O
I	O
:	O
E	O
)	O
ratio	O
of	O
high	O
frequency	O
ventilator	O
(	O
1	O
:	O
1	O
versus	O
1	O
:	O
2	O
)	O
and	O
CV	O
strategy	O
(	O
lung	O
protective	O
or	O
not	O
)	O
could	O
not	O
sufficiently	O
explain	O
the	O
heterogeneity	O
.	O

TK9	O
,	O
which	O
forms	O
a	O
beta	O
-	O
sheet	O
rich	O
fibril	O
,	O
contains	O
a	O
key	O
sequence	O
motif	O
that	O
may	O
be	O
critical	O
for	O
beta	O
-	O
sheet	O
formation	B-PROC
,	O
thus	O
making	O
it	O
an	O
interesting	O
system	O
to	O
study	O
amyloid	O
fibrillation	O
.	O

Thus	O
,	O
biophysical	O
and	O
NMR	O
experimental	O
results	O
have	O
revealed	O
a	O
molecular	O
level	O
understanding	O
of	O
peptide	O
folding	O
events	O
,	O
as	O
well	O
as	O
the	O
inhibition	B-PROC
of	O
amyloid	O
-	O
protein	O
aggregation	O
are	O
reported	O
.	O

High	O
biodiversity	O
and	O
bird	O
migration	B-PROC
facilitate	O
spread	O
of	O
the	O
pathogen	O
and	O
provide	O
reservoirs	O
for	O
emerging	O
infectious	O
diseases	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
animal	O
models	O
against	O
emerging	O
coronaviruses	O
:	O
From	O
SARS	O
to	O
MERS	O
coronavirus	O
.	O

We	O
intended	O
to	O
demonstrate	O
the	O
incidence	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
detected	O
by	O
PCR	O
and	O
real	O
-	O
time	O
PCR	O
in	O
adult	O
patients	O
with	O
CAP	O
.	O

Clinical	O
severity	O
may	O
be	O
related	O
to	O
MERS	O
-	O
CoV	O
'	O
s	O
ability	O
to	O
infect	O
a	O
broad	O
range	O
of	O
cells	O
with	O
DPP4	O
expression	B-PROC
,	O
evade	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
,	O
and	O
induce	O
cytokine	O
dysregulation	O
.	O

Reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
on	O
respiratory	O
and	O
/	O
or	O
extrapulmonary	O
specimens	O
rapidly	O
establishes	O
diagnosis	O
.	O

High	O
index	O
of	O
suspicion	O
should	O
be	O
kept	O
in	O
acute	O
febrile	B-PROC
illness	O
patients	O
with	O
respiratory	O
symptoms	O
and	O
alveolar	O
hemorrhage	O
.	O

Examined	O
strains	O
had	O
a	O
hemagglutinin	O
polymorphism	B-PROC
associated	O
with	O
enhanced	O
binding	O
to	O
lower	O
respiratory	O
tract	O
receptors	O
.	O

The	O
transcription	B-PROC
factor	O
NF	O
-	O
κB	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
host	O
immune	B-PROC
responses	I-PROC
.	O

Severely	O
ill	O
patients	O
with	O
H7N9	O
had	O
significantly	O
longer	O
interval	O
from	O
onset	O
of	O
illness	O
to	O
neuraminidase	O
inhibitor	O
treatment	O
and	O
to	O
death	B-PROC
.	O

This	O
study	O
experimentally	O
confirmed	O
PDCoV	O
pathogenicity	O
and	O
characterized	O
PDCoV	O
pathogenesis	B-PROC
in	O
neonatal	O
piglets	O
.	O

The	O
diagnosis	O
and	O
treatment	O
was	O
delayed	O
by	O
an	O
average	O
of	O
15	O
days	O
in	O
those	O
patients	O
who	O
died	B-PROC
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
and	O
low	O
-	O
pathogenicity	O
influenza	O
A	O
viruses	O
(	O
LP	O
IAVs	O
)	O
depend	O
on	O
target	O
cell	O
proteases	O
to	O
cleave	O
their	O
viral	O
glycoproteins	O
and	O
prime	O
them	O
for	O
virus	O
-	O
cell	O
membrane	B-PROC
fusion	I-PROC
.	O

Implications	O
of	O
these	O
findings	O
extend	O
to	O
the	O
use	O
of	O
virus	O
entry	O
antagonists	O
,	O
such	O
as	O
protease	B-PROC
inhibitors	I-PROC
,	O
which	O
might	O
be	O
most	O
effective	O
when	O
localized	O
to	O
these	O
microdomains	O
.	O

The	O
structural	O
destruction	O
and	O
disorganization	O
of	O
TJ	O
and	O
AJ	O
were	O
extensive	O
in	O
PEDV	O
-	O
infected	O
pigs	O
at	O
PIDs	O
1	O
-	O
3	O
,	O
but	O
then	O
appeared	O
to	O
reversibly	O
recover	B-PROC
at	O
PID	O
5	O
,	O
as	O
evident	O
by	O
increased	O
numbers	O
of	O
ZO	O
-	O
1	O
-	O
positive	O
epithelial	O
cells	O
and	O
markedly	O
improved	O
appearance	O
of	O
E	O
-	O
Cadherin	O
-	O
positive	O
villous	O
epithelium	O
.	O

Our	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
structurally	O
impaired	O
TJ	O
and	O
AJ	O
in	O
the	O
pathogenesis	B-PROC
of	O
PEDV	O
,	O
potentially	O
leading	O
to	O
secondary	O
bacterial	O
infections	O
.	O

There	O
was	O
a	O
3	O
-	O
fold	O
increase	O
in	O
plasma	O
Tumor	O
Necrosis	B-PROC
Factor	O
-	O
α	O
,	O
a	O
7	O
-	O
fold	O
increase	O
in	O
plasma	O
Interleukin	O
-	O
6	O
and	O
a	O
20	O
-	O
fold	O
increase	O
in	O
lavage	O
fluid	O
Matrix	O
-	O
Metalloprotease	O
-	O
9	O
by	O
HVt	O
but	O
simvastatin	O
reduced	O
these	O
levels	O
to	O
control	O
.	O

Despite	O
lung	O
protective	O
ventilation	O
strategies	O
with	O
maximal	O
F	O
i	O
O2	O
(	O
patients	O
A	O
-	O
D	O
),	O
neuromuscular	B-PROC
blockade	I-PROC
(	O
patients	O
A	O
-	O
D	O
),	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
patients	O
A	O
and	O
D	O
),	O
and	O
prone	O
positioning	O
(	O
patient	O
D	O
),	O
progressive	O
hypoxemia	O
resulted	O
in	O
initiation	O
of	O
venovenous	O
ECMO	O
by	O
hours	O
24	O
-	O
90	O
of	O
mechanical	O
ventilation	O
with	O
subsequent	O
de	O
-	O
escalation	O
of	O
ventilatory	O
support	O
.	O

For	O
efficient	O
virion	B-PROC
assembly	I-PROC
,	O
these	O
proteins	O
must	O
be	O
targeted	B-PROC
to	O
the	O
budding	B-PROC
site	O
and	O
to	O
interact	O
with	O
each	O
other	O
or	O
the	O
ribonucleoprotein	O
.	O

The	O
goal	O
of	O
this	O
review	O
is	O
to	O
summarize	O
recent	O
findings	O
on	O
the	O
mechanism	O
of	O
incorporation	O
of	O
the	O
M	O
and	O
S	O
glycoproteins	O
into	O
the	O
CoV	O
virion	O
,	O
focusing	O
on	O
protein	B-PROC
trafficking	B-PROC
and	O
protein	O
-	O
protein	O
interactions	O
.	O

The	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
ventilator	O
management	O
were	O
essential	O
for	O
this	O
patient	O
'	O
s	O
recovery	O
.	O

Along	O
with	O
progress	O
in	O
MERS	O
animal	O
model	O
development	B-PROC
,	O
these	O
obstacles	O
can	O
be	O
circumvented	O
or	O
at	O
least	O
mitigated	O
.	O

Particularly	O
,	O
S377	O
-	O
588	O
-	O
Fc	O
at	O
1	O
μg	O
elicited	O
strong	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
against	O
both	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
similar	O
to	O
those	O
induced	O
at	O
5	O
and	O
20	O
μg	O
,	O
respectively	O
.	O

Nerve	B-PROC
conduction	B-PROC
studies	O
demonstrated	O
acute	O
motor	O
-	O
sensory	O
axonal	O
neuropathy	O
including	O
both	O
phrenic	O
nerves	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
low	O
tidal	O
volume	O
ventilation	O
and	O
low	O
to	O
moderate	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
levels	O
is	O
a	O
widespread	O
strategy	O
to	O
ventilate	O
patients	O
with	O
non	O
-	O
injured	O
lungs	O
during	O
general	B-PROC
anesthesia	I-PROC
and	O
in	O
intensive	O
care	O
as	O
well	O
with	O
mild	O
to	O
moderate	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Based	O
on	O
the	O
same	O
grounds	O
,	O
RMs	O
have	O
been	O
proposed	O
to	O
improve	O
lung	O
aeration	O
during	O
general	B-PROC
anesthesia	I-PROC
.	O

The	O
aim	O
of	O
this	O
review	O
was	O
to	O
present	O
the	O
clinical	O
evidence	O
supporting	O
the	O
use	O
of	O
RMs	O
in	O
patients	O
with	O
ARDS	O
and	O
during	O
general	B-PROC
anesthesia	I-PROC
and	O
as	O
well	O
their	O
potential	O
biological	O
effects	O
in	O
experimental	O
models	O
of	O
acute	O
lung	O
injury	O
.	O

The	O
patient	O
was	O
successfully	O
weaned	B-PROC
off	O
ECMO	O
and	O
discharged	O
without	O
deterioration	O
of	O
her	O
neurological	O
status	O
.	O

The	O
pathological	O
changes	O
were	O
severe	O
,	O
and	O
general	O
hyperemia	O
,	O
hemorrhage	O
,	O
inflammatory	O
cell	O
infiltration	O
,	O
and	O
necrosis	B-PROC
were	O
evident	O
in	O
the	O
tissues	O
of	O
dead	B-PROC
swine	O
.	O

PCR	O
was	O
used	O
to	O
identify	O
the	O
pathogen	O
and	O
we	O
tested	O
for	O
eight	O
viruses	O
(	O
HEV	O
,	O
Porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
,	O
PCV2	O
,	O
Classical	O
swine	O
fever	B-PROC
virus	O
,	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
,	O
Transmissible	O
gastroenteritis	O
coronavirus	O
,	O
Porcine	O
parvovirus	O
and	O
Pseudorabies	O
virus	O
)	O
that	O
are	O
prevalent	O
in	O
Chinese	O
pig	O
farms	O
.	O

However	O
,	O
pretreatment	O
with	O
c26	O
attenuated	O
the	O
LPS	O
induced	O
increase	O
through	O
ERK	B-PROC
pathway	I-PROC
in	O
vivo	O
.	O

No	O
mixed	O
respiratory	O
virus	B-PROC
infection	I-PROC
was	O
found	O
.	O

It	O
is	O
important	O
to	O
identify	O
alveolar	O
hemorrhage	O
due	O
to	O
sepsis	O
,	O
then	O
separate	O
an	O
autoimmune	O
cause	O
(	O
vasculitis	O
associated	O
with	O
antineutrophil	O
cytoplasmic	O
antibody	B-PROC
,	O
connective	O
tissue	O
disease	O
and	O
Goodpasture	O
'	O
s	O
syndrome	O
)	O
with	O
the	O
search	O
for	O
autoantibodies	O
and	O
biopsies	O
from	O
readily	O
accessible	O
organs	O
,	O
from	O
a	O
non	O
-	O
immune	O
cause	O
,	O
performing	O
echocardiography	O
.	O

The	O
best	O
knowledge	O
of	O
PPE	O
requirements	O
(	O
76	O
%)	O
was	O
found	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
with	O
less	O
knowledge	O
about	O
PPE	O
requirements	O
for	O
anthrax	O
,	O
plague	O
,	O
Ebola	O
virus	B-PROC
disease	I-PROC
(	O
EVD	O
),	O
and	O
smallpox	O
(	O
60	O
%).	O

This	O
deficiency	O
of	O
vitamin	O
D	O
appears	O
to	O
contribute	O
to	O
the	O
development	B-PROC
of	O
the	O
condition	O
,	O
and	O
approaches	O
to	O
correct	O
vitamin	O
D	O
deficiency	O
in	O
patients	O
at	O
risk	O
of	O
ARDS	O
should	O
be	O
developed	O
.	O

This	O
patient	O
also	O
had	O
other	O
complications	O
like	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
kidney	O
injury	O
,	O
and	O
septic	O
shock	O
that	O
required	O
venous	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
.	O

TITLE	O
:	O
An	O
educational	O
programme	O
for	O
nursing	B-PROC
college	O
staff	O
and	O
students	O
during	O
a	O
MERS	O
-	O
coronavirus	O
outbreak	O
in	O
Saudi	O
Arabia	O
.	O

College	O
of	O
Nursing	B-PROC
academic	O
staff	O
developed	O
a	O
programme	O
in	O
response	O
to	O
the	O
educational	O
and	O
emotional	O
needs	O
of	O
participants	O
.	O

After	O
the	O
sessions	O
,	O
faculty	O
,	O
students	O
and	O
staff	O
were	O
asked	O
about	O
what	O
was	O
learned	B-PROC
through	O
the	O
sessions	O
,	O
and	O
what	O
educational	O
needs	O
still	O
needed	O
to	O
be	O
addressed	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	O
6	O
mediates	O
ubiquitin	B-PROC
-	O
dependent	O
proteosomal	O
degradation	O
of	O
N	O
-	O
Myc	O
(	O
and	O
STAT	O
)	O
interactor	O
.	O

For	O
further	O
investigation	O
,	O
we	O
targeted	B-PROC
the	O
IFN	O
signaling	B-PROC
pathway	I-PROC
-	O
mediating	O
protein	O
,	O
N	O
-	O
Myc	O
(	O
and	O
STAT	O
)	O
interactor	O
(	O
Nmi	O
).	O

To	O
test	O
this	O
hypothesis	O
the	O
IBV	O
-	O
specific	B-PROC
immune	B-PROC
response	I-PROC
and	O
immune	O
protection	O
were	O
measured	O
in	O
chicks	O
vaccinated	O
at	O
different	O
ages	O
.	O

This	O
demonstrated	O
a	O
delayed	O
production	O
of	O
IgG	O
and	O
IgA	O
plasma	O
antibodies	O
in	O
the	O
1	O
,	O
7	O
and	O
14	O
-	O
day	O
-	O
old	O
vaccination	O
groups	O
and	O
also	O
lower	O
IgA	O
antibody	B-PROC
levels	O
were	O
observed	O
in	O
plasma	O
of	O
the	O
1	O
-	O
day	O
-	O
old	O
group	O
.	O

Airway	O
pressure	O
release	O
ventilation	O
was	O
the	O
initial	O
choice	O
of	O
treatment	O
reported	O
by	O
most	O
when	O
conventional	O
mechanical	O
ventilation	O
strategy	O
failed	O
followed	O
by	O
inhaled	B-PROC
nitric	O
oxide	O
and	O
prone	O
positioning	O
.	O

Reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
formalin	O
fixed	O
paraffin	O
embedded	O
tissue	O
from	O
the	O
lung	O
,	O
spleen	O
,	O
and	O
kidney	O
was	O
negative	O
for	O
FRSCV	O
and	O
positive	O
for	O
ferret	O
enteric	O
coronavirus	O
(	O
FRECV	O
).	O

This	O
may	O
be	O
due	O
to	O
the	O
progressive	O
changes	O
in	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
and	O
intrinsic	O
properties	O
of	O
the	O
lung	O
that	O
occur	O
during	O
the	O
process	O
of	O
aging	B-PROC
.	O

TITLE	O
:	O
Comparison	O
of	O
Coagulation	B-PROC
Parameters	O
,	O
Anticoagulation	B-PROC
,	O
and	O
Need	O
for	O
Transfusion	O
in	O
Patients	O
on	O
Interventional	O
Lung	O
Assist	O
or	O
Veno	O
-	O
Venous	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
Clinical	O
data	O
on	O
anticoagulation	B-PROC
needs	O
of	O
modern	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
and	O
its	O
impact	O
on	O
coagulation	B-PROC
are	O
scarce	O
.	O

The	O
impact	O
of	O
modern	O
iLA	O
and	O
ECMO	O
systems	O
on	O
coagulation	B-PROC
allows	O
comparatively	O
safe	O
long	O
-	O
term	O
treatment	O
of	O
adult	O
patients	O
with	O
acute	O
respiratory	O
failure	O
.	O

A	O
moderate	O
systemic	O
anticoagulation	B-PROC
seems	O
to	O
be	O
sufficient	O
.	O

TITLE	O
:	O
A	O
cluster	O
-	O
randomised	O
controlled	O
trial	O
to	O
test	O
the	O
efficacy	O
of	O
facemasks	O
in	O
preventing	O
respiratory	O
viral	B-PROC
infection	I-PROC
among	O
Hajj	O
pilgrims	O
.	O

Nursing	B-PROC
workloads	O
should	O
be	O
quantified	O
to	O
facilitate	O
the	O
development	B-PROC
of	O
guidelines	O
for	O
optimum	O
nurse	O
-	O
patient	O
ratio	O
during	O
outbreaks	O
.	O

One	O
such	O
approach	O
(	O
the	O
Buxco	O
platform	O
)	O
performs	O
unrestrained	O
whole	O
body	O
plethysmography	O
on	O
mice	O
which	O
infers	O
thoracic	O
movements	B-PROC
from	O
pressure	O
differences	O
from	O
the	O
act	O
of	O
inhalation	B-PROC
and	O
exhalation	B-PROC
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
)	O
may	O
mediate	O
infection	O
by	O
binding	O
to	O
a	O
cellular	O
neural	O
cell	B-PROC
adhesion	I-PROC
molecule	O
(	O
NCAM	O
).	O

Three	O
fusion	O
proteins	O
(	O
S	O
(	O
1	O
-	O
291	O
),	O
S	O
(	O
277	O
-	O
794	O
)	O
and	O
S	O
(	O
548	O
-	O
868	O
))	O
were	O
screened	O
for	O
their	O
interactions	O
with	O
NCAM	O
by	O
protein	B-PROC
-	I-PROC
protein	I-PROC
interaction	I-PROC
assays	O
.	O

RESULTS	O
:	O
Three	O
fusion	O
proteins	O
(	O
S	O
(	O
1	O
-	O
291	O
),	O
S	O
(	O
277	O
-	O
794	O
)	O
and	O
S	O
(	O
548	O
-	O
868	O
))	O
were	O
screened	O
for	O
their	O
interactions	O
with	O
NCAM	O
by	O
protein	B-PROC
-	I-PROC
protein	I-PROC
interaction	I-PROC
assays	O
.	O

ABSTRACT	O
:	O
During	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
infection	O
,	O
the	O
type	O
I	O
interferon	O
α	O
/	O
β	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
innate	B-PROC
immune	I-PROC
response	I-PROC
is	O
suppressed	O
by	O
EBOV	O
viral	O
protein	O
35	O
(	O
VP35	O
),	O
a	O
validated	O
drug	O
target	O
.	O

Molecular	B-PROC
dynamics	I-PROC
further	O
confirmed	O
ligand	B-PROC
stability	O
and	O
hydrogen	O
bonding	O
networks	O
.	O

TITLE	O
:	O
Comparative	O
pathogenesis	B-PROC
of	O
US	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
strain	O
PC21A	O
in	O
conventional	O
9	O
-	O
day	O
-	O
old	O
nursing	B-PROC
piglets	O
vs	O
.	O
26	O
-	O
day	O
-	O
old	O
weaned	B-PROC
pigs	O
.	O

Twenty	O
-	O
six	O
-	O
day	O
-	O
old	O
weaned	B-PROC
[	O
PEDV	O
-	O
inoculated	O
(	O
n	O
=	O
11	O
);	O
mock	O
(	O
n	O
=	O
9	O
)]	O
and	O
9	O
-	O
day	O
-	O
old	O
nursing	B-PROC
pigs	O
[	O
PEDV	O
-	O
inoculated	O
(	O
n	O
=	O
9	O
);	O
mock	O
(	O
n	O
=	O
11	O
)]	O
were	O
inoculated	O
orally	O
[	O
8	O
.	O
9	O
log10	O
genomic	O
equivalents	O
(	O
GE	O
)/	O
pig	O
]	O
with	O
PC21A	O
strain	O
or	O
mock	O
(	O
MEM	O
).	O

Severe	O
watery	O
diarrhea	O
and	O
atrophic	O
enteritis	O
with	O
moderate	O
to	O
high	O
PEDV	O
RNA	O
titers	O
in	O
feces	O
(	O
7	O
.	O
5	O
-	O
12	O
.	O
2	O
log10	O
GE	O
/	O
ml	O
)	O
and	O
low	O
viral	O
RNA	O
titers	O
in	O
serum	O
(	O
5	O
.	O
6	O
-	O
8	O
.	O
6	O
log10	O
GE	O
/	O
ml	O
)	O
were	O
observed	O
in	O
all	O
inoculated	O
nursing	B-PROC
piglets	O
at	O
PIDs	O
1	O
-	O
5	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
transmission	O
and	O
the	O
immune	B-PROC
response	I-PROC
in	O
growing	O
pigs	O
.	O

To	O
characterize	O
chronic	O
PEDV	O
infection	O
,	O
the	O
duration	O
of	O
infectious	O
virus	O
shedding	O
and	O
development	B-PROC
of	O
protective	O
immunity	B-PROC
was	O
determined	O
.	O

Although	O
live	O
attenuated	O
IB	O
vaccines	O
remarkably	O
induce	O
potent	O
immune	B-PROC
response	I-PROC
,	O
the	O
potential	O
risk	O
of	O
reversion	O
to	O
virulence	B-PROC
,	O
neutralization	O
by	O
the	O
maternal	O
antibodies	O
,	O
and	O
recombination	B-PROC
and	O
mutation	O
events	O
are	O
important	O
concern	O
on	O
their	O
usage	O
.	O

Metabolic	B-PROC
profiling	O
of	O
BAL	O
detected	O
the	O
presence	O
of	O
bacterial	O
substrates	O
suitable	O
for	O
both	O
isolates	O
.	O

The	O
clinical	O
picture	O
of	O
these	O
different	O
pneumonias	O
can	O
be	O
very	O
similar	O
,	O
but	O
viral	B-PROC
infection	I-PROC
is	O
more	O
common	O
in	O
the	O
pediatric	O
and	O
geriatric	O
populations	O
,	O
leukocytes	O
are	O
not	O
generally	O
elevated	O
,	O
fever	B-PROC
is	O
variable	O
,	O
and	O
upper	O
respiratory	O
tract	O
symptoms	O
often	O
occur	O
;	O
procalcitonin	O
levels	O
are	O
not	O
generally	O
affected	O
.	O

The	O
presence	O
of	O
hemodynamic	B-PROC
instability	O
was	O
not	O
different	O
in	O
both	O
groups	O
.	O

We	O
report	O
on	O
a	O
case	O
of	O
in	O
-	O
flight	B-PROC
exposure	O
to	O
an	O
infection	O
with	O
significant	O
public	O
health	O
risks	O
that	O
was	O
successfully	O
resolved	O
using	O
IHR	O
(	O
2005	O
)	O
guidelines	O
.	O

Pulmonary	O
signs	O
and	O
functions	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
perioperative	O
period	O
,	O
and	O
,	O
if	O
necessary	O
,	O
gamma	O
globulin	O
and	O
thymosin	O
should	O
be	O
administered	O
early	O
in	O
the	O
preoperative	O
or	O
postoperative	O
period	O
to	O
enhance	O
immunity	B-PROC
.	O

By	O
substitution	O
of	O
a	O
single	O
amino	O
acid	O
in	O
the	O
S	O
protein	O
,	O
we	O
created	O
a	O
recombinant	O
PEDV	O
with	O
an	O
artificial	O
furin	O
protease	O
cleavage	B-PROC
site	O
N	O
terminal	O
of	O
the	O
putative	O
fusion	O
peptide	O
(	O
PEDV	O
-	O
SFCS	O
).	O

PEDV	O
-	O
SFCS	O
exhibited	O
trypsin	O
-	O
independent	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
and	O
was	O
able	O
to	O
replicate	O
in	O
culture	O
cells	O
independently	O
of	O
trypsin	O
,	O
though	O
to	O
low	O
titer	O
.	O

Analysis	O
of	O
the	O
200	O
to	O
300	O
regulated	O
genes	O
showed	O
that	O
genes	O
for	O
interferon	O
(	O
IFN	O
)	O
and	O
antiviral	O
pathways	B-PROC
are	O
highly	O
upregulated	O
in	O
NDV	O
-	O
infected	O
PVK	O
cells	O
,	O
including	O
genes	O
for	O
beta	O
IFN	O
,	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
ISG15	O
,	O
and	O
IRF1	O
.	O

The	O
association	O
was	O
first	O
described	O
as	O
a	O
syndrome	O
by	O
Cottin	O
in	O
2005	O
,	O
named	O
""""	O
combined	O
pulmonary	O
fibrosis	O
and	O
emphysema	O
(	O
CPFE	O
")"","	O
which	O
is	O
characterized	O
by	O
exertional	O
dyspnea	O
,	O
upper	O
-	O
lobe	O
emphysema	O
and	O
lower	O
-	O
lobe	O
fibrosis	O
,	O
preserved	O
lung	B-PROC
volume	I-PROC
and	O
severely	O
diminished	O
capacity	O
of	O
gas	O
exchange	O
.	O

This	O
program	O
generated	O
47	O
transcriptomic	O
and	O
proteomic	O
datasets	O
from	O
30	O
studies	O
that	O
investigate	O
in	O
vivo	O
and	O
in	O
vitro	O
host	O
responses	O
to	O
viral	B-PROC
infections	I-PROC
.	O

DAD	O
is	O
characterized	O
by	O
hyaline	O
membrane	O
formation	B-PROC
,	O
lung	O
edema	O
,	O
inflammation	O
,	O
hemorrhage	O
and	O
alveolar	O
epithelial	O
cell	O
injury	O
.	O

TITLE	O
:	O
Mixed	O
viral	B-PROC
infections	I-PROC
circulating	O
in	O
hospitalized	O
patients	O
with	O
respiratory	O
tract	O
infections	O
in	O
kuwait	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
host	O
cell	B-PROC
interactions	I-PROC
are	O
most	O
commonly	O
analyzed	O
in	O
cells	O
maintained	O
in	O
vitro	O
as	O
two	O
-	O
dimensional	O
tissue	O
cultures	O
.	O

The	O
outbreak	O
in	O
West	O
Africa	O
of	O
highly	O
contagious	O
Ebola	O
viral	B-PROC
disease	I-PROC
(	O
EVD	B-PROC
)	O
that	O
started	O
in	O
Guinea	O
in	O
December	O
2013	O
,	O
assumed	O
global	O
proportions	O
to	O
become	O
the	O
largest	O
outbreak	O
of	O
EVD	B-PROC
and	O
the	O
most	O
prominent	O
international	O
health	O
concern	O
.	O

Although	O
no	O
approved	O
vaccine	O
for	O
the	O
prevention	O
of	O
EVD	O
currently	O
exists	O
,	O
disease	O
control	O
can	O
be	O
greatly	O
enhanced	O
by	O
timely	O
laboratory	O
confirmation	O
through	O
blood	O
tests	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Five	O
passengers	O
reported	O
respiratory	O
symptoms	O
within	O
14	O
days	O
of	O
the	O
flight	B-PROC
,	O
but	O
all	O
tested	O
were	O
negative	O
for	O
MERS	O
-	O
CoV	O
.	O
Details	O
of	O
non	O
-	O
UK	O
residents	O
were	O
passed	O
on	O
to	O
relevant	O
World	O
Health	O
Organization	O
International	O
Health	O
Regulation	B-PROC
focal	O
points	O
for	O
follow	O
-	O
up	O
,	O
and	O
no	O
further	O
cases	O
were	O
reported	O
back	O
.	O

Typical	O
for	O
these	O
diseases	O
is	O
a	O
natural	O
circulation	B-PROC
between	O
reservoir	O
animals	O
in	O
remote	O
areas	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
supplemental	O
genistein	O
(	O
an	O
isoflavonoid	O
)	O
on	O
performance	O
,	O
lymphoid	O
organs	O
'	O
development	B-PROC
,	O
and	O
cellular	O
and	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
in	O
broiler	O
chicks	O
.	O

Blockade	O
of	O
PI3K	O
/	O
Akt	O
and	O
MEK1	O
/	O
2	O
kinase	O
pathways	B-PROC
completely	O
abrogated	O
lung	O
injury	O
.	O

Epidural	O
analgesia	B-PROC
is	O
standard	O
of	O
care	O
for	O
patients	O
undergoing	O
thoracotomy	O
.	O

Due	O
to	O
hypotension	O
and	O
fluid	O
losses	O
following	O
surgery	O
,	O
he	O
was	O
maintained	O
on	O
intravenous	O
sedato	O
-	O
analgesia	B-PROC
during	O
postoperative	O
mechanical	O
ventilation	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
body	O
temperature	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
,	O
white	O
blood	O
cell	O
(	O
WBC	O
),	O
systolic	O
blood	B-PROC
pressure	I-PROC
(	O
SBP	O
),	O
diastolic	O
blood	B-PROC
pressure	I-PROC
(	O
DBP	O
),	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
),	O
acute	O
respiratory	O
failure	O
,	O
septic	O
shock	O
,	O
hypernatremia	O
,	O
and	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
between	O
the	O
SE	O
and	O
non	O
-	O
SE	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Patients	O
with	O
SE	O
had	O
higher	O
adjusted	O
rates	O
of	O
fever	B-PROC
≥	O
39	O
°	O
C	O
(	O
odds	O
ratio	O
(	O
OR	O
):	O
2	O
.	O
753	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
1	O
.	O
116	O
-	O
6	O
.	O
794	O
;	O
P	O
=	O
0	O
.	O
028	O
)	O
and	O
SIRS	O
≥	O
3	O
items	O
(	O
OR	O
:	O
6	O
.	O
459	O
;	O
95	O
%	O
CI	O
:	O
2	O
.	O
050	O
-	O
20	O
.	O
351	O
;	O
P	O
=	O
0	O
.	O
001	O
).	O

RNA	O
/	O
DNA	O
of	O
influenza	O
A	O
,	O
B	O
,	O
parainfluenza	O
(	O
PI	O
);	O
adeno	O
-,	O
rhino	O
-,	O
RS	O
-	O
viruses	O
,	O
corona	O
-,	O
metapneumo	O
-	O
(	O
MPV	O
)	O
and	O
bocaviruses	O
were	O
detected	O
in	O
nasopharynx	O
smears	O
by	O
PCR	O
with	O
hybridization	B-PROC
-	O
fluorescent	O
detection	O
in	O
real	O
time	O
.	O

RS	O
-	O
virus	B-PROC
infection	I-PROC
at	O
the	O
debut	O
of	O
CAP	O
in	O
children	O
younger	O
than	O
3	O
years	O
in	O
55	O
.	O
5	O
%	O
of	O
cases	O
is	O
associated	O
with	O
the	O
development	B-PROC
of	O
broncho	O
-	O
obstructive	O
syndrome	O
.	O

Tests	O
in	O
the	O
29	O
patients	O
with	O
respiratory	O
dysfunction	O
suggested	O
predominant	O
expiratory	B-PROC
muscle	O
dysfunction	O
,	O
leading	O
to	O
ineffective	O
cough	O
in	O
17	O
patients	O
.	O

Three	O
patients	O
had	O
acute	O
respiratory	O
failure	O
requiring	O
mechanical	O
ventilation	O
;	O
16	O
patients	O
had	O
poor	O
airway	O
clearance	O
,	O
including	O
10	O
with	O
sleep	B-PROC
apnea	O
syndrome	O
,	O
responsible	O
in	O
7	O
for	O
chronic	O
hypercapnia	O
.	O

TITLE	O
:	O
Factors	O
secreted	B-PROC
from	O
dental	O
pulp	O
stem	O
cells	O
show	O
multifaceted	O
benefits	O
for	O
treating	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

Importantly	O
,	O
SHED	O
-	O
CM	O
attenuated	O
the	O
BLM	O
-	O
induced	O
pro	O
-	O
inflammatory	B-PROC
response	I-PROC
and	O
generated	O
an	O
anti	O
-	O
inflammatory	O
/	O
tissue	O
-	O
regenerating	O
environment	O
,	O
accompanied	O
by	O
the	O
induction	O
of	O
anti	O
-	O
inflammatory	O
M2	O
-	O
like	O
lung	O
macrophages	O
.	O

Furthermore	O
,	O
SHED	O
-	O
CM	O
promoted	O
the	O
in	O
vitro	O
differentiation	B-PROC
of	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
into	O
M2	O
-	O
like	O
cells	O
,	O
which	O
expressed	B-PROC
high	O
levels	O
of	O
Arginase1	O
,	O
CD206	O
and	O
Ym	O
-	O
1	O
.	O

Recently	O
,	O
TGF	O
-	O
α	O
/	O
EGFR	O
signaling	B-PROC
has	O
also	O
been	O
shown	O
to	O
regulate	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
in	O
bronchial	O
epithelial	O
cells	O
.	O

Patients	O
with	O
fever	B-PROC
and	O
acute	O
respiratory	O
distress	O
,	O
with	O
or	O
without	O
abnormal	O
CXR	O
,	O
were	O
treated	O
in	O
the	O
hospital	O
until	O
tests	O
proved	O
negative	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
protocol	O
successfully	O
reduced	O
the	O
number	O
of	O
patients	O
who	O
needed	O
to	O
be	O
tested	O
for	O
MERS	O
-	O
CoV	O
from	O
12	O
,	O
563	O
to	O
514	O
,	O
identified	O
seven	O
positive	O
cases	O
,	O
and	O
did	O
not	O
lead	O
to	O
apparent	O
cross	O
infectivity	O
that	O
resulted	O
in	O
serious	O
illness	O
or	O
death	B-PROC
.	O

Randomized	O
and	O
nonrandomized	O
controlled	O
trials	O
,	O
controlled	O
before	O
-	O
and	O
-	O
after	O
studies	O
,	O
concurrent	O
cohort	O
studies	O
,	O
interrupted	O
time	O
series	O
studies	O
,	O
historically	O
controlled	O
studies	O
,	O
cohort	O
studies	O
,	O
cross	O
-	O
sectional	O
studies	O
,	O
and	O
uncontrolled	O
longitudinal	O
studies	O
were	O
included	O
for	O
data	O
synthesis	B-PROC
.	O

Topics	O
included	O
ventilator	O
mode	O
,	O
tidal	O
volume	O
delivery	O
,	O
inspiratory	B-PROC
plateau	O
pressure	O
,	O
high	O
-	O
frequency	O
ventilation	O
,	O
cuffed	O
endotracheal	O
tubes	O
,	O
and	O
gas	O
exchange	O
goals	O
.	O

Moreover	O
,	O
a	O
growing	O
number	O
of	O
studies	O
have	O
investigated	O
the	O
memory	B-PROC
T	O
cell	O
responses	O
in	O
recovered	O
SARS	O
patients	O
.	O

This	O
review	O
covers	O
the	O
available	O
literature	O
on	O
the	O
emerging	O
importance	O
of	O
T	O
cell	O
responses	O
in	O
SARS	O
-	O
CoV	O
infection	O
,	O
particularly	O
on	O
the	O
mapping	O
of	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
,	O
longevity	O
,	O
polyfunctionality	O
and	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
association	O
as	O
well	O
as	O
their	O
potential	O
implications	O
on	O
treatment	O
and	O
vaccine	O
development	B-PROC
.	O

Protein	O
kinases	O
are	O
key	O
regulators	O
of	O
many	O
cellular	O
functions	O
,	O
and	O
the	O
systematic	O
knockdown	O
of	O
their	O
expression	B-PROC
should	O
provide	O
a	O
broad	O
perspective	O
on	O
factors	O
and	O
pathways	B-PROC
promoting	O
or	O
antagonizing	O
coronavirus	O
replication	O
.	O

TITLE	O
:	O
Arterivirus	O
nsp12	O
versus	O
the	O
coronavirus	O
nsp16	O
2	O
'-	O
O	O
-	O
methyltransferase	O
:	O
comparison	O
of	O
the	O
C	O
-	O
terminal	O
cleavage	B-PROC
products	O
of	O
two	O
nidovirus	O
pp1ab	O
polyproteins	O
.	O

Following	O
the	O
detection	O
of	O
PEDV	O
infection	O
in	O
transfected	O
MDCK	O
cells	O
after	O
PEDV	O
challenge	O
,	O
we	O
clearly	O
demonstrated	O
that	O
the	O
SPC	O
subdomain	O
plays	O
a	O
key	O
role	O
in	O
cell	O
entry	O
of	O
PEDV	O
and	O
its	O
expression	B-PROC
permits	O
PEDV	O
growth	B-PROC
in	O
transfected	O
MDCK	O
cells	O
,	O
while	O
virus	O
propagation	O
can	O
be	O
inhibited	O
by	O
anti	O
-	O
SPC	O
serum	O
,	O
indicating	O
that	O
the	O
SPC	O
subdomain	O
appears	O
to	O
be	O
a	O
crucial	O
functional	O
domain	O
in	O
contributing	O
to	O
efficient	O
PEDV	O
infection	O
.	O

In	O
the	O
case	O
of	O
HCoV	O
-	O
NL63	O
the	O
activity	O
was	O
highly	O
promising	O
with	O
an	O
EC50	O
<	O
10	O
μM	O
and	O
a	O
CC50	O
>	O
100	O
μM	O
.	O
As	O
such	O
,	O
these	O
doubly	O
flexible	O
nucleoside	O
analogues	O
are	O
viewed	O
as	O
a	O
novel	O
new	O
class	O
of	O
drug	O
candidates	O
with	O
potential	O
for	O
potent	O
inhibition	B-PROC
of	O
coronaviruses	O
.	O

As	O
of	O
May	O
31	O
,	O
2015	O
,	O
1180	O
laboratory	O
-	O
confirmed	O
cases	O
(	O
483	O
deaths	B-PROC
;	O
40	O
%	O
mortality	O
)	O
have	O
been	O
reported	O
to	O
WHO	O
.	O

TITLE	O
:	O
Oxygenation	B-PROC
and	O
Ventilation	O
.	O

Blockade	O
of	O
C5a	O
signaling	B-PROC
have	O
been	O
implicated	O
in	O
the	O
treatment	O
of	O
ALI	O
induced	O
by	O
highly	O
pathogenic	O
virus	O
.	O

Herein	O
,	O
we	O
review	O
the	O
literature	O
that	O
links	O
C5a	O
and	O
ALI	O
,	O
and	O
review	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
C5a	O
affects	O
ALI	O
during	O
highly	O
pathogenic	O
viral	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Identification	O
and	O
pathogenicity	O
of	O
a	O
variant	O
porcine	O
epidemic	O
diarrhea	O
virus	O
field	O
strain	O
with	O
reduced	O
virulence	B-PROC
.	O

Our	O
results	O
show	O
that	O
the	O
expression	B-PROC
of	O
Mo	O
-	O
DC	O
surface	O
markers	O
such	O
as	O
SWC3a	O
(+)	O
CD1a	O
(+),	O
SWC3a	O
(+)	O
CD80	O
/	O
86	O
(+)	O
and	O
SWC3a	O
(+)	O
SLA	O
-	O
II	O
-	O
DR	O
(+)	O
is	O
increased	O
after	O
infection	O
with	O
CV777	O
for	O
24	O
h	O
.	O
Mo	O
-	O
DCs	O
infected	O
with	O
CV777	O
produce	O
higher	O
levels	O
of	O
IL	O
-	O
12	O
and	O
INF	O
-	O
γ	O
compared	O
to	O
mock	O
-	O
infected	O
Mo	O
-	O
DCs	O
but	O
the	O
expression	B-PROC
profile	O
for	O
IL	O
-	O
10	O
does	O
not	O
change	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
after	O
48	O
h	O
of	O
CV777	O
infection	O
,	O
there	O
is	O
enhancement	O
in	O
the	O
ability	O
of	O
porcine	O
intestinal	O
DCs	O
to	O
sample	O
the	O
antigen	O
and	O
activate	O
T	B-PROC
-	I-PROC
cell	I-PROC
proliferation	I-PROC
in	O
vivo	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
acute	O
kidney	O
injury	O
on	O
outcome	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
under	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
and	O
to	O
analyze	O
the	O
association	O
between	O
prognosis	O
and	O
the	O
time	O
of	O
occurrence	O
of	O
acute	O
kidney	O
injury	O
and	O
renal	O
replacement	O
therapy	O
initiation	O
.	O

Furthermore	O
,	O
the	O
multivariate	O
logistic	O
regression	O
analysis	O
suggests	O
that	O
the	O
necessity	O
of	O
renal	O
replacement	O
therapy	O
prior	O
to	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
insertion	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
mortality	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
77	O
-	O
0	O
.	O
88	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

Recently	O
,	O
we	O
showed	O
that	O
LeTx	O
inactivation	O
of	O
p38	O
MAP	O
kinase	O
signaling	B-PROC
via	O
degradation	O
of	O
MKK3	O
in	O
pulmonary	O
vascular	O
endothelial	O
cells	O
can	O
be	O
linked	O
to	O
compromise	O
of	O
the	O
endothelial	O
permeability	O
barrier	O
.	O

Here	O
we	O
reported	O
that	O
ET	O
-	O
1	O
stimulated	O
expression	B-PROC
of	O
VCAM	O
-	O
1	O
gene	O
on	O
HTSMCs	O
,	O
which	O
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
inhibitors	O
of	O
ET	O
receptors	O
,	O
Src	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
epidermal	O
growth	B-PROC
factor	O
receptor	O
(	O
EGFR	O
),	O
platelet	O
-	O
derived	O
growth	B-PROC
factor	O
receptor	O
(	O
PDGFR	O
),	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
),	O
AKT	O
,	O
MEK1	O
/	O
2	O
,	O
and	O
p300	O
,	O
suggesting	O
the	O
participation	O
of	O
these	O
signaling	B-PROC
components	O
in	O
ET	O
-	O
1	O
-	O
regulated	O
HTSMC	O
responses	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
ET	O
-	O
1	O
promotes	O
occurrence	O
and	O
amplification	O
of	O
pathology	O
-	O
related	O
airway	O
inflammation	O
via	O
enhancing	O
VCAM	O
-	O
1	O
expression	B-PROC
in	O
an	O
ET	O
receptor	O
/	O
Src	O
/	O
MMP	O
/	O
EGFR	O
,	O
PDGFR	O
/	O
PI3K	O
/	O
AKT	O
/	O
p42	O
/	O
p44	O
MAPK	O
/	O
Elk	O
-	O
1	O
/	O
p300	O
pathway	B-PROC
in	O
HTSMCs	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
common	O
variants	O
across	O
the	O
nuclear	O
factor	O
erythroid	O
2	O
-	O
like	O
2	O
(	O
NFE2L2	O
)	O
gene	O
contribute	O
to	O
the	O
development	B-PROC
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
)	O
is	O
the	O
leading	O
cause	O
of	O
death	B-PROC
in	O
children	O
worldwide	O
and	O
a	O
substantial	O
proportion	O
of	O
childhood	O
CAP	O
is	O
caused	O
by	O
viruses	O
.	O

CONCLUSIONS	O
:	O
Although	O
only	O
supportive	O
therapies	O
are	O
administered	O
generally	O
in	O
viral	O
infections	B-PROC
,	I-PROC
viral	I-PROC
investigations	O
are	O
important	O
in	O
terms	O
of	O
determining	O
the	O
measures	O
to	O
be	O
taken	O
by	O
determining	O
the	O
causes	O
as	O
well	O
as	O
in	O
terms	O
of	O
establishing	O
a	O
general	O
database	O
.	O

Multivariable	O
analysis	O
showed	O
that	O
the	O
duration	O
of	O
pre	O
-	O
ECMO	O
ventilation	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
death	B-PROC
(	O
odds	O
ratio	O
[	O
OR	O
],	O
2	O
.	O
25	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
29	O
to	O
3	O
.	O
90	O
;	O
p	O
=	O
0	O
.	O
004	O
),	O
whereas	O
the	O
concomitant	O
use	O
of	O
continuous	O
venovenous	O
hemodialysis	O
(	O
CVVHD	O
)	O
was	O
associated	O
with	O
improved	O
survival	O
(	O
OR	O
,	O
0	O
.	O
55	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
31	O
to	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
038	O
).	O

TITLE	O
:	O
The	O
Nucleocapsid	O
Protein	O
of	O
Coronaviruses	O
Acts	O
as	O
a	O
Viral	O
Suppressor	O
of	O
RNA	B-PROC
Silencing	I-PROC
in	O
Mammalian	O
Cells	O
.	O

However	O
,	O
recent	O
studies	O
provided	O
strong	O
supports	O
that	O
RNAi	B-PROC
is	O
also	O
involved	O
in	O
antiviral	B-PROC
response	I-PROC
in	O
mammalian	O
cells	O
.	O

TITLE	O
:	O
Mild	O
to	O
Moderate	O
,	O
but	O
Not	O
Minimal	O
or	O
Severe	O
,	O
Acute	O
Histologic	O
Chorioamnionitis	O
or	O
Intra	O
-	O
Amniotic	O
Inflammation	O
Is	O
Associated	O
with	O
a	O
Decrease	O
in	O
Respiratory	O
Distress	O
Syndrome	O
of	O
Preterm	O
Newborns	O
without	O
Fetal	B-PROC
Growth	B-PROC
Restriction	O
.	O

To	O
assess	O
the	O
relationship	O
between	O
the	O
severity	O
of	O
acute	O
-	O
HCA	O
or	O
IAI	O
and	O
the	O
development	B-PROC
of	O
RDS	O
in	O
preterm	O
newborns	O
due	O
to	O
preterm	O
labor	B-PROC
and	O
intact	O
membranes	O
(	O
PTL	O
)	O
or	O
preterm	O
premature	O
rupture	O
of	O
membranes	O
(	O
preterm	O
-	O
PROM	O
)	O
without	O
fetal	B-PROC
growth	B-PROC
restriction	O
(	O
FGR	O
).	O

Previous	O
studies	O
have	O
shown	O
that	O
platelet	O
-	O
derived	O
growth	B-PROC
factor	O
(	O
PDGF	O
)	O
and	O
transforming	O
growth	B-PROC
factor	O
β1	O
(	O
TGFβ1	O
)	O
participate	O
in	O
the	O
pathogenesis	B-PROC
of	O
ARDS	O
by	O
stimulation	B-PROC
of	I-PROC
fibroblast	I-PROC
proliferation	I-PROC
,	O
leading	O
to	O
the	O
development	B-PROC
of	O
pulmonary	O
fibrosis	O
.	O

To	O
profile	O
the	O
viruses	O
causing	O
ARI	O
in	O
children	O
admitted	O
to	O
a	O
community	O
-	O
based	O
hospital	O
in	O
central	O
Taiwan	O
,	O
a	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
on	O
children	O
under	O
14	O
years	O
of	O
age	O
that	O
were	O
hospitalized	O
with	O
febrile	B-PROC
ARI	O
.	O

ABSTRACT	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
diagnosed	O
with	O
type	O
B	O
influenza	O
infection	O
and	O
high	O
fever	B-PROC
4	O
days	O
previously	O
was	O
admitted	O
to	O
our	O
hospital	O
.	O

ABSTRACT	O
:	O
Rodent	O
-	O
borne	O
hantaviruses	O
(	O
family	O
Bunyaviridae	O
,	O
genus	O
Hantavirus	O
)	O
cause	O
hantavirus	O
pulmonary	O
syndrome	O
in	O
the	O
Americas	O
and	O
hemorrhagic	O
fever	B-PROC
with	O
renal	O
syndrome	O
in	O
Europe	O
and	O
Asia	O
.	O

We	O
provide	O
a	O
review	O
of	O
risk	O
factors	O
,	O
evidence	O
of	O
infection	O
in	O
HCPs	O
,	O
and	O
prevention	O
strategies	O
with	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
,	O
Ebola	O
virus	B-PROC
disease	I-PROC
(	O
Ebola	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
avian	O
influenza	O
.	O

The	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
(	O
ROC	O
-	O
AUC	O
)	O
for	O
mortality	O
of	O
suPAR	O
(	O
0	O
.	O
62	O
)	O
was	O
lower	O
than	O
the	O
ROC	O
-	O
AUC	O
of	O
the	O
APACHE	O
IV	O
score	O
(	O
0	O
.	O
72	O
,	O
P	O
=	O
0	O
.	O
007	O
),	O
higher	O
than	O
that	O
of	O
the	O
ARDS	O
definition	O
classification	O
(	O
0	O
.	O
53	O
,	O
P	O
=	O
0	O
.	O
005	O
),	O
and	O
did	O
not	O
differ	O
from	O
that	O
of	O
the	O
SOFA	O
score	O
(	O
0	O
.	O
68	O
,	O
P	O
=	O
0	O
.	O
07	O
)	O
and	O
the	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
(	O
0	O
.	O
58	O
,	O
P	O
=	O
0	O
.	O
29	O
).	O

The	O
affected	O
cellular	O
proteins	O
that	O
we	O
identified	O
in	O
this	O
study	O
were	O
classified	O
into	O
the	O
functional	O
groups	O
involved	O
in	O
various	O
cellular	O
processes	O
such	O
as	O
cell	B-PROC
division	I-PROC
,	O
metabolism	B-PROC
,	O
the	O
stress	B-PROC
response	I-PROC
,	O
protein	B-PROC
biosynthesis	I-PROC
and	O
transport	B-PROC
,	O
cytoskeleton	O
networks	O
and	O
cell	B-PROC
communication	I-PROC
.	O

Reovirus	O
binds	O
to	O
cell	O
surface	O
glycans	O
,	O
junctional	O
adhesion	O
molecule	O
A	O
(	O
JAM	O
-	O
A	O
),	O
and	O
the	O
Nogo	O
-	O
1	O
receptor	O
(	O
depending	O
on	O
the	O
cell	O
type	O
)	O
and	O
enters	O
cells	O
by	O
receptor	B-PROC
-	I-PROC
mediated	I-PROC
endocytosis	I-PROC
.	O

Consistent	O
with	O
an	O
inhibition	B-PROC
of	O
viral	O
disassembly	O
,	O
5	O
-	O
NT	O
treatment	O
did	O
not	O
alter	O
infection	O
by	O
in	O
vitro	O
-	O
generated	O
infectious	O
subvirion	O
particles	O
,	O
which	O
bind	O
to	O
JAM	O
-	O
A	O
but	O
bypass	O
a	O
requirement	O
for	O
proteolytic	B-PROC
uncoating	O
in	O
endosomes	O
to	O
infect	O
cells	O
.	O

In	O
conclusion	O
,	O
the	O
neutralizing	O
antigenicity	O
of	O
recombinant	O
S1	O
protein	O
expressed	B-PROC
from	O
mammalian	O
cells	O
was	O
decreased	O
,	O
and	O
was	O
not	O
sufficient	O
to	O
induce	O
neutralizing	O
antibodies	O
.	O

This	O
methodology	O
closely	O
tracked	O
with	O
traditional	O
pathogenesis	B-PROC
metrics	O
,	O
distinguished	O
both	O
virus	O
-	O
and	O
dose	O
-	O
specific	O
responses	O
,	O
and	O
identified	O
long	O
-	O
term	O
respiratory	O
changes	O
following	O
both	O
SARS	O
-	O
CoV	O
and	O
Influenza	O
A	O
Virus	B-PROC
infection	I-PROC
.	O

Immune	B-PROC
responses	I-PROC
and	O
protection	O
efficacy	O
of	O
the	O
vaccination	O
vector	O
were	O
assessed	O
in	O
both	O
mice	O
and	O
pig	O
models	O
.	O

Results	O
from	O
the	O
passive	B-PROC
immunity	I-PROC
protection	O
test	O
of	O
new	O
born	O
piglets	O
demonstrated	O
that	O
the	O
recombinant	O
live	O
-	O
vector	O
vaccine	O
,	O
rSPV	O
-	O
SA	O
,	O
could	O
100	O
%	O
protect	O
piglets	O
from	O
the	O
SPV	O
infection	O
,	O
and	O
there	O
was	O
no	O
significant	O
clinical	O
symptom	O
in	O
the	O
rSPV	O
-	O
SA	O
treatment	O
group	O
during	O
this	O
experiment	O
.	O

All	O
5	O
deaths	B-PROC
were	O
directly	O
attributable	O
to	O
RVI	O
and	O
all	O
5	O
deaths	B-PROC
occurred	O
in	O
patients	O
with	O
a	O
lower	O
respiratory	O
tract	O
infection	O
.	O

Each	O
chicken	O
in	O
the	O
control	O
and	O
infected	O
group	O
was	O
intranasally	O
inoculated	O
with	O
0	O
.	O
2	O
mL	O
sterile	O
physiological	O
saline	O
and	O
virus	O
,	O
respectively	O
,	O
after	O
which	O
serum	O
antioxidant	O
parameters	O
and	O
renal	O
XOD	O
mRNA	B-PROC
expression	B-PROC
in	O
growing	O
layers	O
were	O
evaluated	O
at	O
8	O
,	O
15	O
and	O
22	O
days	O
post	O
-	O
inoculation	O
(	O
dpi	O
).	O

During	O
typical	O
performance	O
of	O
apneic	O
test	O
involving	O
the	O
use	O
of	O
oxygen	O
catheter	O
for	O
apneic	O
oxygenation	B-PROC
we	O
observed	O
severe	O
desaturation	O
with	O
growing	O
hypotension	O
and	O
hemodynamic	B-PROC
destabilization	O
.	O

But	O
with	O
the	O
use	O
of	O
Boussignac	O
CPAP	O
system	O
all	O
necessary	O
tests	O
were	O
successfully	O
completed	O
,	O
confirming	O
the	O
patient	O
'	O
s	O
brain	O
death	B-PROC
,	O
which	O
gave	O
us	O
the	O
opportunity	O
to	O
perform	O
procedures	O
for	O
organ	O
donation	O
.	O

Thus	O
lack	O
of	O
positive	O
end	O
expiratory	B-PROC
pressure	O
during	O
classical	O
performance	O
of	O
apneic	O
test	O
leads	O
to	O
quick	O
desaturation	O
and	O
rapid	O
hemodynamic	B-PROC
deterioration	O
,	O
limiting	O
the	O
observation	O
period	O
below	O
dedicated	O
at	O
least	O
10	O
-	O
minute	O
interval	O
.	O

Accelerated	O
virus	O
control	O
in	O
mice	O
lacking	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	O
-	O
10	O
was	O
associated	O
with	O
limited	O
initial	O
demyelination	O
,	O
but	O
low	O
viral	O
mRNA	O
persistence	O
similar	O
to	O
WT	O
mice	O
and	O
declining	O
antiviral	O
cellular	B-PROC
immunity	I-PROC
.	O

RESULTS	O
:	O
We	O
estimated	O
the	O
incubation	O
period	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
based	O
on	O
a	O
subset	O
of	O
patients	O
with	O
available	O
data	O
on	O
exposure	O
periods	B-PROC
and	O
a	O
separate	O
subset	O
of	O
patients	O
in	O
a	O
putative	O
common	O
source	O
outbreak	O
,	O
and	O
we	O
found	O
associations	O
between	O
shorter	O
incubation	O
period	O
and	O
greater	O
severity	O
in	O
both	O
groups	O
after	O
adjusting	O
for	O
potential	O
confounders	O
.	O

TITLE	O
:	O
A	O
Coronavirus	O
E	O
Protein	O
Is	O
Present	O
in	O
Two	O
Distinct	O
Pools	O
with	O
Different	O
Effects	O
on	O
Assembly	O
and	O
the	O
Secretory	B-PROC
Pathway	I-PROC
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
assemble	O
by	O
budding	B-PROC
into	O
the	O
lumen	O
of	O
the	O
early	O
Golgi	O
complex	O
prior	O
to	O
exocytosis	B-PROC
.	O

The	O
small	O
CoV	O
envelope	O
(	O
E	O
)	O
protein	O
plays	O
roles	O
in	O
assembly	O
,	O
virion	O
release	O
,	O
and	O
pathogenesis	B-PROC
.	O

The	O
E	O
protein	O
from	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
has	O
dramatic	O
effects	O
on	O
the	O
secretory	B-PROC
system	O
which	O
require	O
residues	O
in	O
the	O
HD	O
.	O

During	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infections	O
,	O
signaling	B-PROC
through	O
the	O
adaptor	O
protein	O
Myd88	O
promotes	O
both	O
innate	O
and	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
.	O

According	O
to	O
the	O
mortality	O
occurring	O
in	O
ICU	O
,	O
the	O
patients	O
were	O
divided	O
into	O
death	B-PROC
group	O
and	O
survival	O
group	O
.	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
score	O
,	O
oxygenation	B-PROC
index	O
,	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
the	O
length	O
of	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
stay	O
,	O
incidence	O
of	O
VAP	O
,	O
and	O
28	O
-	O
day	O
mortality	O
5	O
days	O
after	O
treatment	O
were	O
compared	O
between	O
two	O
groups	O
.	O

We	O
did	O
not	O
identify	O
associations	O
between	O
new	O
-	O
onset	O
AF	O
and	O
baseline	O
central	O
venous	B-PROC
pressure	I-PROC
,	O
plasma	O
levels	O
of	O
troponin	O
I	O
,	O
epinephrine	O
,	O
interleukin	O
6	O
,	O
or	O
interleukin	O
8	O
.	O

The	O
results	O
showed	O
that	O
P3	O
infection	O
upregulated	O
the	O
expression	B-PROC
of	O
AvBDs	O
,	O
including	O
AvBD2	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
,	O
while	O
P110	O
infection	O
downregulated	O
the	O
expression	B-PROC
of	O
AvBDs	O
,	O
including	O
AvBD3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
and	O
9	O
in	O
most	O
tissues	O
.	O

Currently	O
South	O
Korea	O
is	O
experiencing	O
the	O
hospital	O
-	O
associated	O
outbreak	O
of	O
MER	O
-	O
CoV	O
that	O
has	O
infected	O
126	O
human	O
cases	O
and	O
13	O
deaths	B-PROC
,	O
as	O
of	O
12	O
June	O
2015	O
,	O
following	O
the	O
return	O
of	O
a	O
MERS	O
infected	O
patient	O
from	O
Middle	O
East	O
.	O

The	O
patient	O
,	O
who	O
presented	O
with	O
fever	B-PROC
,	O
severe	O
pneumonia	O
,	O
leucopenia	O
,	O
and	O
lymphopenia	O
,	O
developed	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
died	B-PROC
on	O
day	O
10	O
after	O
illness	O
onset	O
.	O

RESULTS	O
:	O
The	O
patient	O
,	O
who	O
presented	O
with	O
fever	B-PROC
,	O
severe	O
pneumonia	O
,	O
leucopenia	O
,	O
and	O
lymphopenia	O
,	O
developed	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
died	B-PROC
on	O
day	O
10	O
after	O
illness	O
onset	O
.	O

However	O
,	O
5	O
patients	O
died	B-PROC
,	O
among	O
whom	O
3	O
patients	O
with	O
fulminant	O
NPE	O
(	O
onset	O
within	O
1	O
hour	O
)	O
died	B-PROC
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
complicated	O
with	O
multiple	O
organ	O
failure	O
,	O
and	O
2	O
died	B-PROC
of	O
cerebral	O
hernia	O
.	O

TITLE	O
:	O
A	O
G	O
-	O
quadruplex	O
-	O
binding	O
macrodomain	O
within	O
the	O
""""	O
SARS	O
-	O
unique	O
domain	O
""""	O
is	O
essential	O
for	O
the	O
activity	O
of	O
the	O
SARS	O
-	O
coronavirus	O
replication	O
-	O
transcription	B-PROC
complex	O
.	O

TITLE	O
:	O
Chloroquine	O
rescues	O
A549	O
cells	O
from	O
paraquat	O
-	O
induced	O
death	B-PROC
.	O

We	O
decided	O
to	O
further	O
investigate	O
the	O
evolution	B-PROC
of	O
OAS1	O
in	O
primates	O
by	O
characterizing	O
intra	O
-	O
specific	O
variation	O
in	O
four	O
species	O
commonly	O
used	O
as	O
models	O
in	O
infectious	O
disease	O
research	O
:	O
the	O
rhesus	O
macaque	O
,	O
the	O
cynomolgus	O
macaque	O
,	O
the	O
olive	O
baboon	O
,	O
and	O
the	O
Guinea	O
baboon	O
.	O

The	O
region	O
of	O
the	O
enzyme	O
that	O
directly	O
interacts	O
with	O
viral	O
RNA	O
,	O
the	O
RNA	O
-	O
binding	O
domain	O
,	O
contains	O
a	O
number	O
of	O
polymorphisms	B-PROC
likely	O
to	O
affect	O
the	O
RNA	O
-	O
binding	O
affinity	O
of	O
OAS1	O
.	O

Mutagenesis	B-PROC
studies	O
indicate	O
that	O
both	O
these	O
zinc	O
fingers	O
are	O
essential	O
for	O
the	O
function	O
of	O
nsp14	O
.	O

TITLE	O
:	O
Serious	O
maternal	O
complications	O
after	O
early	O
preterm	O
delivery	O
(	O
24	O
-	O
33	O
weeks	O
'	O
gestation	B-PROC
).	O

Obstetricians	O
need	O
to	O
be	O
prepared	O
to	O
manage	O
potential	O
hemorrhage	O
,	O
infection	O
,	O
and	O
intensive	O
care	O
unit	O
admission	O
for	O
early	O
preterm	O
births	B-PROC
requiring	O
cesarean	O
delivery	O
.	O

HR2P	O
-	O
M2	O
was	O
highly	O
effective	O
in	O
inhibiting	O
MERS	O
-	O
CoV	O
S	O
protein	O
-	O
mediated	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
and	O
infection	O
by	O
pseudoviruses	O
expressing	O
MERS	O
-	O
CoV	O
S	O
protein	O
with	O
or	O
without	O
mutation	O
in	O
the	O
HR1	O
region	O
.	O

Binding	O
of	O
HAdV	O
-	O
B14p1	O
to	O
the	O
apical	O
surface	O
of	O
differentiated	B-PROC
human	O
bronchial	O
epithelial	O
cells	O
and	O
subsequent	O
internalization	O
of	O
HAdV	O
DNA	O
was	O
10	O
fold	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
compared	O
to	O
the	O
less	O
-	O
pneumotropic	O
HAdV	O
-	O
C5	O
one	O
hour	O
after	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
correlation	O
of	O
severity	O
classification	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
by	O
the	O
Berlin	O
definition	O
with	O
extra	O
vascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
)	O
and	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
index	O
(	O
PVPI	O
).	O

Patients	O
who	O
died	B-PROC
were	O
significantly	O
older	O
than	O
the	O
survivors	O
(	O
mean	O
age	O
,	O
57	O
.	O
37	O
±	O
20	O
.	O
42	O
years	O
and	O
44	O
.	O
29	O
±	O
15	O
.	O
53	O
years	O
respectively	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

Sequence	O
analysis	O
showed	O
the	O
circulation	B-PROC
of	O
at	O
least	O
five	O
different	O
virus	O
strains	O
at	O
these	O
premises	O
,	O
suggesting	O
that	O
this	O
location	O
is	O
a	O
driver	O
of	O
MERS	O
-	O
CoV	O
circulation	B-PROC
and	O
a	O
high	O
-	O
risk	O
area	O
for	O
human	O
exposure	O
.	O

The	O
frequent	O
occurrence	O
of	O
a	O
left	O
shift	O
in	O
the	O
absence	O
of	O
a	O
mature	O
neutrophilia	O
complicates	O
the	O
differentiation	B-PROC
of	O
effusive	O
FIP	O
and	O
septic	O
peritonitis	O
.	O

In	O
our	O
study	O
,	O
a	O
5	O
'	O
long	O
terminal	O
repeat	O
/	O
gag	O
region	O
-	O
based	O
reverse	B-PROC
transcription	B-PROC
insulated	O
isothermal	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
iiPCR	O
)	O
was	O
developed	O
to	O
amplify	O
all	O
known	O
FIV	O
strains	O
to	O
facilitate	O
point	O
-	O
of	O
-	O
need	O
FIV	O
diagnosis	O
.	O

The	O
rising	O
tide	O
of	O
sepsis	O
due	O
to	O
bacterial	O
,	O
fungal	O
and	O
viral	B-PROC
infections	I-PROC
cannot	O
be	O
stemmed	O
by	O
current	O
antimicrobial	O
therapies	O
and	O
supportive	O
measures	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
risk	O
-	O
taking	O
behaviour	B-PROC
in	O
epidemic	O
models	O
.	O

Damage	O
control	O
resuscitation	O
(	O
DCR	O
)	O
integrates	O
the	O
main	O
links	O
such	O
as	O
damage	O
control	O
operation	O
and	O
allowable	O
low	O
blood	B-PROC
pressure	I-PROC
(	O
or	O
limited	O
liquid	O
resuscitation	O
)	O
and	O
hemostatic	B-PROC
control	O
resuscitation	O
,	O
was	O
early	O
effective	O
treatment	O
measures	O
for	O
the	O
patients	O
with	O
severe	O
multiple	O
trauma	O
in	O
the	O
pelvic	O
fractures	O
.	O

The	O
inactivated	O
KNU	O
-	O
141112	O
virus	O
was	O
found	O
to	O
mediate	O
potent	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
in	O
immunized	O
guinea	O
pigs	O
.	O

Silencing	O
of	O
TNFR1	O
decreased	O
TNF	O
-	O
α	O
mediated	O
inhibition	B-PROC
of	O
endothelial	O
tube	B-PROC
formation	I-PROC
,	O
as	O
well	O
as	O
TNF	O
-	O
α	O
-	O
induced	O
upregulation	B-PROC
of	O
ICAM	O
-	O
1	O
,	O
VCAM	O
,	O
and	O
E	O
-	O
selection	O
in	O
human	O
lung	O
microvascular	O
endothelial	O
cells	O
.	O

The	O
major	O
aim	O
of	O
our	O
work	O
was	O
to	O
evaluate	O
the	O
ability	O
of	O
CoVs	O
to	O
enter	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
through	O
the	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
(	O
BBB	O
).	O

We	O
report	O
here	O
a	O
MHV	O
strain	O
-	O
specific	O
ability	O
to	O
cross	O
the	O
BBB	O
during	O
acute	O
infection	O
according	O
to	O
their	O
virulence	B-PROC
for	O
liver	O
.	O

Brain	O
invasion	O
was	O
observed	O
only	O
in	O
MHV3	O
-	O
infected	O
mice	O
and	O
correlated	O
with	O
enhanced	O
BBB	O
permeability	O
associated	O
with	O
decreased	O
expression	B-PROC
of	O
zona	O
occludens	O
protein	O
1	O
(	O
ZO	O
-	O
1	O
),	O
VE	O
-	O
cadherin	O
,	O
and	O
occludin	O
,	O
but	O
not	O
claudin	O
-	O
5	O
,	O
in	O
the	O
brain	O
or	O
in	O
cultured	O
BMECs	O
.	O

BBB	O
breakdown	B-PROC
in	O
MHV3	O
infection	O
was	O
not	O
related	O
to	O
production	O
of	O
barrier	O
-	O
dysregulating	O
inflammatory	O
cytokines	O
or	O
chemokines	O
by	O
infected	O
BMECs	O
but	O
rather	O
to	O
a	O
downregulation	B-PROC
of	O
barrier	O
protective	O
beta	O
interferon	O
(	O
IFN	O
-	O
β	O
)	O
production	O
.	O

We	O
further	O
demonstrated	O
that	O
MERS	O
-	O
CoV	O
infection	O
induced	O
apoptosis	B-PROC
in	O
T	O
cells	O
,	O
which	O
involved	O
the	O
activation	O
of	O
both	O
the	O
extrinsic	O
and	O
intrinsic	B-PROC
apoptosis	I-PROC
pathways	B-PROC
.	O

Here	O
,	O
we	O
summarize	O
the	O
progress	O
made	O
in	O
the	O
past	O
decade	O
in	O
understanding	O
the	O
cross	O
-	O
species	O
transmission	O
of	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
by	O
focusing	O
on	O
the	O
features	O
of	O
the	O
S	O
protein	O
,	O
its	O
receptor	O
-	O
binding	O
characteristics	O
,	O
and	O
the	O
cleavage	B-PROC
process	O
involved	O
in	O
priming	O
.	O

The	O
present	O
review	O
aimed	O
to	O
update	O
the	O
clinical	O
information	O
on	O
pharmacodynamics	O
,	O
pharmacokinetics	B-PROC
,	O
adverse	O
effects	O
and	O
drug	B-PROC
interactions	I-PROC
,	O
and	O
to	O
discuss	O
the	O
future	O
directions	O
of	O
alogliptin	O
.	O

Recent	O
studies	O
reveal	O
regulatory	O
roles	O
of	O
Wnt3a	O
and	O
Wnt5a	O
signaling	B-PROC
in	O
inflammatory	O
processes	O
.	O

These	O
findings	O
indicate	O
the	O
major	O
components	O
of	O
Wnt3a	O
and	O
Wnt5a	O
signaling	B-PROC
in	O
the	O
lung	O
are	O
disturbed	O
under	O
endotoxic	O
insult	O
.	O

However	O
,	O
two	O
distinct	O
features	O
were	O
observed	O
in	O
the	O
CCoV	O
-	O
I	O
genome	O
:	O
(	O
i	O
)	O
the	O
presence	O
of	O
an	O
additional	O
ORF	O
between	O
the	O
spike	O
(	O
S	O
)	O
protein	O
gene	O
and	O
ORF3a	O
;	O
(	O
ii	O
)	O
the	O
diversity	O
of	O
the	O
S	O
protein	O
,	O
which	O
is	O
more	O
closely	O
related	O
to	O
that	O
of	O
feline	O
coronavirus	O
type	O
I	O
and	O
presents	O
a	O
furin	O
cleavage	B-PROC
site	O
.	O

TITLE	O
:	O
Oral	O
Ribavirin	O
for	O
the	O
Treatment	O
of	O
Noninfluenza	O
Respiratory	O
Viral	B-PROC
Infections	I-PROC
:	O
A	O
Systematic	O
Review	O
.	O

The	O
mortality	O
rate	O
ranged	O
from	O
0	O
%	O
to	O
31	O
%	O
in	O
malignancy	O
/	O
stem	O
cell	O
transplant	O
recipients	O
treated	O
with	O
oral	O
ribavirin	O
,	O
and	O
1	O
/	O
108	O
(	O
0	O
.	O
9	O
%)	O
ribavirin	O
-	O
treated	O
lung	O
transplant	O
recipients	O
died	B-PROC
at	O
30	O
days	O
.	O

Hemolysis	B-PROC
was	O
the	O
most	O
common	O
adverse	O
reaction	O
,	O
occurring	O
in	O
14	O
%	O
(	O
54	O
/	O
375	O
)	O
of	O
patients	O
.	O

ABSTRACT	O
:	O
Recent	O
,	O
severe	O
outbreaks	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
in	O
Asia	O
and	O
North	O
America	O
highlight	O
the	O
need	O
for	O
well	O
-	O
validated	O
diagnostic	O
tests	O
for	O
the	O
identification	O
of	O
PEDV	O
infected	O
animals	O
and	O
evaluation	O
of	O
their	O
immune	B-PROC
status	I-PROC
to	O
this	O
virus	O
.	O

Genome	O
-	O
wide	O
association	O
(	O
GWA	O
)	O
studies	O
can	O
objectively	O
examine	O
these	O
variations	O
,	O
and	O
help	O
identify	O
important	O
new	O
genes	O
and	O
pathogenetic	O
pathways	B-PROC
for	O
future	O
analysis	O
.	O

An	O
immunoadhesin	O
targeting	B-PROC
the	O
MERS	O
coronavirus	O
is	O
in	O
an	O
early	O
stage	O
of	O
development	B-PROC
.	O

TITLE	O
:	O
Development	B-PROC
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
monitoring	O
and	O
surveillance	O
of	O
antibodies	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
based	O
on	O
a	O
recombinant	O
membrane	O
protein	O
.	O

(	O
1	O
)	O
A	O
43	O
years	O
old	O
male	O
of	O
South	O
Korean	O
nationality	O
was	O
admitted	O
with	O
the	O
complaint	O
of	O
back	O
ache	O
for	O
7	O
days	O
and	O
fever	B-PROC
2	O
days	O
with	O
the	O
following	O
characteristics	O
:	O
back	O
ache	O
7	O
days	O
ago	O
,	O
without	O
fever	B-PROC
or	O
cough	O
or	O
expectoration	O
.	O

We	O
also	O
performed	O
molecular	B-PROC
dynamics	I-PROC
(	O
MD	O
)	O
simulations	O
and	O
the	O
results	O
revealed	O
that	O
NS2B	O
shows	O
the	O
highest	O
structural	O
fluctuations	O
in	O
the	O
complex	O
,	O
thus	O
providing	O
the	O
dynamic	O
basis	O
for	O
the	O
observation	O
on	O
its	O
conformational	O
exchange	O
between	O
open	O
and	O
closed	O
states	O
.	O

The	O
indicators	O
of	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
,	O
pulmonary	B-PROC
circulation	B-PROC
,	I-PROC
blood	B-PROC
gases	I-PROC
,	O
and	O
hemodynamics	B-PROC
as	O
well	O
as	O
APACHE	O
II	O
and	O
ALI	O
scores	O
were	O
detected	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
7	O
.	O

A	O
literature	O
search	O
was	O
undertaken	O
to	O
examine	O
the	O
effects	O
of	O
prone	O
positioning	O
on	O
oxygenation	B-PROC
,	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
ARDS	O
.	O

One	O
SGS	O
patient	O
died	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Nevertheless	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
a	O
life	O
-	O
saving	O
technology	O
in	O
patients	O
with	O
respiratory	O
failure	O
refractory	O
to	O
maximal	O
medical	O
therapy	O
.	O

Our	O
findings	O
offer	O
insight	O
into	O
the	O
evolutionary	O
origin	O
of	O
SARS	O
-	O
CoV	O
ORF8	O
protein	O
,	O
which	O
was	O
likely	O
acquired	O
from	O
SARSr	O
-	O
CoVs	O
of	O
greater	O
horseshoe	O
bats	O
through	O
recombination	B-PROC
.	O

Nitric	O
oxide	O
was	O
administered	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiration	I-PROC
pressure	O
was	O
reduced	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
an	O
ELISA	O
based	O
on	O
a	O
multi	O
-	O
fragment	O
antigen	O
of	O
infectious	O
bronchitis	O
virus	O
for	O
antibodies	O
detection	O
.	O

The	O
risk	O
of	O
MERS	O
death	B-PROC
in	O
Korea	O
was	O
consistent	O
with	O
published	O
CFR	O
.	O

The	O
virus	O
resulted	O
in	O
less	O
than	O
1000	O
infected	O
cases	O
and	O
355	O
deaths	B-PROC
.	O

Using	O
the	O
real	O
-	O
time	O
PCR	O
the	O
virus	O
circulation	B-PROC
has	O
been	O
established	O
for	O
all	O
species	O
common	O
in	O
humans	O
,	O
including	O
three	O
rhinoviruses	O
,	O
HRV	O
A	O
,	O
HRV	O
B	O
,	O
and	O
HRV	O
C	O
,	O
and	O
four	O
coronaviruses	O
,	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
229E	O
,	O
HCoV	O
-	O
OC43	O
,	O
and	O
HCoV	O
-	O
HKU1	O
.	O

More	O
recently	O
,	O
the	O
observation	O
that	O
flexible	O
nucleosides	O
could	O
overcome	O
drug	B-PROC
resistance	B-PROC
spawned	O
a	O
renewed	O
interest	O
in	O
the	O
field	O
of	O
nucleoside	O
drug	O
design	O
.	O

In	O
this	O
study	O
,	O
porcine	O
small	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
),	O
the	O
target	O
cells	O
of	O
PEDV	O
,	O
were	O
used	O
as	O
the	O
infection	O
model	O
in	O
vitro	O
to	O
identify	O
the	O
possible	O
molecular	O
mechanisms	O
of	O
PEDV	O
-	O
inhibition	B-PROC
IFN	O
-	O
β	O
production	O
.	O

To	O
identify	O
the	O
mechanism	O
of	O
PEDV	O
intervention	O
with	O
dsRNA	O
-	O
mediated	O
IFN	O
-	O
β	O
expression	B-PROC
more	O
accurately	O
,	O
the	O
role	O
of	O
individual	O
molecules	O
of	O
RIG	B-PROC
-	I-PROC
I	I-PROC
signaling	B-PROC
pathway	I-PROC
were	O
investigated	O
.	O

Inoculation	O
of	O
early	O
CEK	O
passages	O
into	O
chickens	O
induced	O
higher	O
antibody	B-PROC
levels	O
and	O
CEKp4	O
induced	O
increased	O
respiratory	O
signs	O
compared	O
to	O
CEKp7	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
inhaled	B-PROC
prostacyclin	O
in	O
treating	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Here	O
we	O
offer	O
a	O
multiplexed	O
assay	O
for	O
a	O
panel	O
of	O
respiratory	O
viruses	O
that	O
mitigates	O
these	O
problems	O
by	O
combining	O
several	O
nucleic	O
acid	O
analogs	O
from	O
the	O
emerging	O
field	O
of	O
synthetic	O
biology	O
:	O
(	O
i	O
)	O
self	O
-	O
avoiding	O
molecular	B-PROC
recognition	I-PROC
systems	O
(	O
SAMRSs	O
),	O
which	O
facilitate	O
multiplexing	O
,	O
and	O
(	O
ii	O
)	O
artificially	O
expanded	O
genetic	O
information	O
systems	O
(	O
AEGISs	O
),	O
which	O
enable	O
low	O
-	O
noise	O
PCR	O
.	O

In	O
this	O
case	O
series	O
,	O
seven	O
patients	O
with	O
AlP	O
poisoning	O
suffering	O
from	O
severe	O
metabolic	B-PROC
acidosis	O
and	O
refractory	O
cardiogenic	O
shock	O
with	O
a	O
reduced	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
(<	O
35	O
%)	O
received	O
ECMO	O
treatment	O
.	O

Although	O
the	O
development	B-PROC
of	O
approaches	O
for	O
chicken	O
transcriptome	O
and	O
proteome	O
analyses	O
have	O
greatly	O
helped	O
the	O
understanding	O
of	O
the	O
underlying	O
genetic	O
mechanisms	O
for	O
immunity	B-PROC
,	O
there	O
are	O
still	O
major	O
knowledge	O
gaps	O
,	O
such	O
as	O
the	O
role	O
of	O
mucosal	O
and	O
cellular	O
responses	O
to	O
IBVs	O
.	O

In	O
view	O
of	O
recent	O
reports	O
of	O
emergent	O
IBV	O
variants	O
in	O
many	O
countries	O
,	O
there	O
is	O
renewed	O
interest	O
in	O
a	O
more	O
complete	O
understanding	O
of	O
poultry	O
immune	B-PROC
responses	I-PROC
to	O
both	O
virulent	O
and	O
vaccine	O
strains	O
of	O
IBVs	O
.	O

TITLE	O
:	O
Novel	O
Uses	O
of	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
in	O
Adults	O
.	O

We	O
used	O
recombinant	O
non	O
-	O
structural	O
protein	O
9	O
of	O
the	O
arterivirus	O
equine	O
arteritis	O
virus	O
(	O
EAV	O
)	O
and	O
different	O
biochemical	O
assays	O
,	O
including	O
irreversible	O
labeling	O
with	O
a	O
GTP	O
analog	O
followed	O
by	O
a	O
proteomics	O
analysis	O
,	O
to	O
demonstrate	O
the	O
manganese	O
-	O
dependent	O
covalent	B-PROC
binding	O
of	O
guanosine	O
and	O
uridine	O
phosphates	O
to	O
a	O
lysine	O
/	O
histidine	O
residue	O
.	O

The	O
3	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
were	O
used	O
during	O
20	O
minutes	O
for	O
each	O
one	O
,	O
whereas	O
brain	O
tissue	O
oxygen	O
pressure	O
,	O
oxygen	O
saturation	O
,	O
intracranial	B-PROC
pressure	I-PROC
,	O
and	O
cerebral	O
perfusion	O
pressure	O
were	O
recorded	O
.	O

The	O
several	O
host	O
factors	O
identified	O
in	O
this	O
study	O
may	O
provide	O
directions	O
for	O
future	O
research	O
on	O
targeted	B-PROC
therapeutics	O
.	O

This	O
study	O
presents	O
evidence	O
for	O
a	O
strategy	O
used	O
by	O
MERS	O
-	O
CoV	O
nsp1	O
to	O
inhibit	O
host	O
gene	B-PROC
expression	I-PROC
that	O
has	O
not	O
been	O
described	O
previously	O
for	O
any	O
viral	O
protein	O
.	O

Injured	O
lungs	O
can	O
be	O
partially	O
protected	O
by	O
optimal	O
settings	O
and	O
ventilation	O
modes	O
,	O
using	O
low	O
tidal	O
volume	O
(	O
VT	O
)	O
values	O
and	O
high	O
positive	O
-	O
end	O
expiratory	B-PROC
pressure	O
(	O
PEEP	O
).	O

Detection	O
of	O
viral	O
RNA	O
was	O
performed	O
by	O
using	O
a	O
commercial	O
real	O
-	O
time	O
PCR	O
kit	O
(	O
hCoV	O
-	O
EMC	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
,	O
Fast	O
Track	O
Diagnostics	O
,	O
Luxembourg	O
)	O
targeting	B-PROC
the	O
MERS	O
-	O
CoV	O
E	O
protein	O
(	O
upE	O
),	O
ORF1a	O
and	O
ORF1b	O
gene	O
regions	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
:	O
transmission	O
,	O
virology	O
and	O
therapeutic	O
targeting	B-PROC
to	O
aid	O
in	O
outbreak	O
control	O
.	O

Results	O
define	O
cellular	O
cyclophilin	B-PROC
A	O
as	O
a	O
host	O
target	O
for	O
inhibition	B-PROC
of	O
coronaviruses	O
ranging	O
from	O
relatively	O
mild	O
common	O
cold	B-PROC
to	O
highly	O
pathogenic	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
viruses	O
with	O
the	O
perspective	O
of	O
disclosing	O
non	O
-	O
immunosuppressive	O
cyclosporin	O
A	O
analogs	O
to	O
broadly	O
inactivate	O
the	O
coronavirus	O
family	O
.	O

TITLE	O
:	O
Pulmonary	O
ultrasound	O
and	O
pulse	B-PROC
oximetry	O
versus	O
chest	O
radiography	O
and	O
arterial	O
blood	B-PROC
gas	I-PROC
analysis	O
for	O
the	O
diagnosis	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
pilot	O
study	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
whether	O
pulmonary	O
ultrasound	O
and	O
pulse	B-PROC
oximetry	O
could	O
be	O
used	O
in	O
place	O
of	O
traditional	O
radiographic	O
and	O
oxygenation	B-PROC
evaluation	O
for	O
ARDS	O
.	O

The	O
fact	O
that	O
most	O
of	O
these	O
viral	B-PROC
infections	I-PROC
are	O
asymptomatic	O
in	O
bats	O
has	O
been	O
observed	O
since	O
a	O
long	O
time	O
but	O
the	O
mechanisms	O
of	O
the	O
viral	O
persistence	O
are	O
not	O
clearly	O
understood	O
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
role	O
of	O
bats	O
in	O
the	O
circulation	B-PROC
of	O
these	O
viral	O
zoonoses	O
,	O
epidemiologists	O
must	O
pay	O
attention	O
to	O
some	O
of	O
their	O
biologic	O
properties	O
which	O
are	O
not	O
fully	O
documented	O
,	O
like	O
their	O
extreme	O
longevity	O
,	O
their	O
diet	O
,	O
the	O
population	O
size	O
and	O
the	O
particular	O
densities	O
observed	O
in	O
species	O
with	O
crowded	O
roosting	O
behavior	O
,	O
the	O
population	O
structure	O
and	O
migrations	O
,	O
the	O
hibernation	B-PROC
permitting	O
overwintering	O
of	O
viruses	O
,	O
their	O
particular	O
innate	O
and	O
acquired	B-PROC
immune	I-PROC
response	I-PROC
,	O
probably	O
related	O
at	O
least	O
partially	O
to	O
their	O
ability	O
to	O
fly	O
,	O
allowing	O
persistent	O
virus	O
infections	O
and	O
preventing	O
immunopathological	O
consequences	O
,	O
etc	O
.	O

Calcium	B-PROC
transport	I-PROC
through	O
the	O
E	O
protein	O
IC	O
was	O
the	O
main	O
trigger	O
of	O
this	O
process	O
.	O

Both	O
MERS	O
and	O
SARS	O
nosocomial	O
outbreaks	O
are	O
characterized	O
by	O
early	O
nosocomial	O
super	O
-	O
spreading	O
events	O
,	O
with	O
the	O
reproduction	B-PROC
number	O
dropping	O
below	O
1	O
within	O
three	O
to	O
five	O
disease	O
generations	O
.	O

Moreover	O
,	O
reduced	O
viral	B-PROC
replication	I-PROC
,	O
inflammatory	B-PROC
response	I-PROC
,	O
and	O
virulence	B-PROC
in	O
HCoV	O
-	O
OC43	O
-	O
Δns12	O
.	O
9	O
-	O
infected	O
mice	O
were	O
observed	O
compared	O
to	O
the	O
levels	O
for	O
HCoV	O
-	O
OC43	O
-	O
WT	O
-	O
infected	O
mice	O
.	O

TITLE	O
:	O
CDC	O
'	O
s	O
Early	O
Response	O
to	O
a	O
Novel	O
Viral	B-PROC
Disease	I-PROC
,	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
September	O
2012	O
-	O
May	O
2014	O
.	O

ABSTRACT	O
:	O
To	O
trace	O
evolution	B-PROC
of	O
canine	O
parvovirus	O
-	O
2	O
(	O
CPV	O
-	O
2	O
),	O
a	O
total	O
of	O
201	O
stool	O
samples	O
were	O
collected	O
from	O
dogs	O
with	O
diarrhea	O
in	O
Heilongjiang	O
province	O
of	O
northeast	O
China	O
from	O
May	O
2014	O
to	O
April	O
2015	O
.	O

Recombination	B-PROC
analysis	O
using	O
entire	O
VP2	O
gene	O
indicated	O
possible	O
recombination	B-PROC
events	O
between	O
the	O
identified	O
CPV	O
-	O
2	O
strains	O
and	O
reference	O
strains	O
from	O
China	O
.	O

Increased	O
expiratory	B-PROC
time	O
constant	O
has	O
a	O
direct	O
correlation	O
with	O
the	O
value	O
of	O
airway	B-PROC
resistance	I-PROC
was	O
due	O
not	O
only	O
to	O
the	O
maintenance	O
of	O
optimal	O
parameters	O
for	O
MVV	O
(	O
mechanical	O
voluntary	O
ventilation	O
),	O
but	O
regular	O
lavage	O
of	O
the	O
tracheobronchial	O
tree	O
,	O
which	O
allows	O
to	O
maintain	O
patency	O
of	O
the	O
lower	O
respiratory	O
tract	O
.	O

Plasma	O
BNP	O
level	O
,	O
arterial	O
blood	B-PROC
gases	I-PROC
,	O
serum	O
C	O
-	O
reactive	O
protein	O
level	O
,	O
alveolar	O
-	O
arterial	O
oxygen	B-PROC
tension	I-PROC
difference	O
and	O
oxygenation	B-PROC
index	O
were	O
measured	O
in	O
patients	O
with	O
and	O
without	O
ALI	O
/	O
ARDS	O
within	O
24	O
h	O
of	O
admission	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

The	O
selection	O
of	O
IN	O
strand	O
-	O
transfer	O
drug	O
-	O
resistant	O
HIV	O
strains	O
in	O
patients	O
supports	O
the	O
development	B-PROC
of	O
new	O
agents	O
that	O
are	O
active	O
as	O
allosteric	O
IN	O
inhibitors	O
.	O

In	O
addition	O
,	O
the	O
virulent	O
strain	O
could	O
activate	O
NF	O
-	O
κB	O
pathway	B-PROC
more	O
intensively	O
than	O
the	O
CV777	O
vaccine	O
strain	O
-	O
like	O
isolate	O
,	O
and	O
elicit	O
stronger	O
inflammatory	O
cascades	O
as	O
well	O
.	O

These	O
data	O
might	O
provide	O
new	O
insights	O
for	O
elucidating	O
the	O
specific	O
pathogenesis	B-PROC
of	O
PEDV	O
infection	O
,	O
and	O
pave	O
the	O
way	O
for	O
the	O
development	B-PROC
of	O
effective	O
therapeutic	O
strategies	O
.	O

The	O
primary	O
outcome	O
was	O
a	O
composite	O
of	O
pulmonary	O
complications	O
:	O
(	O
1	O
)	O
ARDS	O
development	B-PROC
and	O
(	O
2	O
)	O
respiratory	O
failure	O
.	O

Multivariate	O
analysis	O
demonstrated	O
an	O
association	O
between	O
the	O
NL	O
group	O
and	O
development	B-PROC
of	O
pulmonary	O
complications	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	O
],	O
2	O
.	O
1	O
;	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
15	O
-	O
3	O
.	O
78	O
).	O

The	O
quick	O
release	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
by	O
the	O
infected	O
macrophages	O
suggests	O
a	O
plausible	O
viral	O
initiation	O
of	O
NLRP3	B-PROC
inflammasome	I-PROC
activation	I-PROC
.	O

Regarding	O
longer	O
time	O
periods	B-PROC
,	O
influenza	O
epidemics	O
occasionally	O
occur	O
very	O
early	O
in	O
the	O
season	O
,	O
as	O
during	O
the	O
2009	O
pandemic	O
.	O

TITLE	O
:	O
Successfully	O
treated	O
severe	O
obstetric	O
sepsis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Neutralizing	O
antibody	B-PROC
titers	O
were	O
detected	O
using	O
the	O
serum	O
neutralization	O
test	O
(	O
SN50	O
).	O

TITLE	O
:	O
Right	O
over	O
left	O
ventricular	O
end	O
-	O
diastolic	O
area	O
relevance	O
to	O
predict	O
hemodynamic	B-PROC
intolerance	B-PROC
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
patients	O
with	O
severe	O
ARDS	O
.	O

The	O
outbreak	O
and	O
spread	O
of	O
these	O
virulent	O
diseases	O
including	O
avian	O
influenza	O
(	O
H1N1	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
Corona	O
virus	O
),	O
cholera	O
(	O
Vibrio	O
cholera	O
),	O
tuberculosis	O
(	O
Mycobacterium	O
tuberculosis	O
),	O
Ebola	O
hemorrhagic	O
fever	B-PROC
(	O
Ebola	O
Virus	O
)	O
and	O
AIDS	O
(	O
HIV	O
-	O
1	O
)	O
necessitate	O
urgent	O
attention	O
to	O
develop	O
diagnostic	O
protocols	O
and	O
assays	O
for	O
rapid	O
detection	O
and	O
screening	O
.	O

TITLE	O
:	O
Dynamics	O
of	O
end	O
expiratory	B-PROC
lung	B-PROC
volume	I-PROC
after	O
changing	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
.	O

ABSTRACT	O
:	O
Apoptosis	B-PROC
has	O
been	O
postulated	O
to	O
play	O
an	O
important	O
role	O
during	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
infection	O
;	O
however	O
,	O
its	O
mechanism	O
is	O
not	O
well	O
characterized	O
.	O

This	O
study	O
is	O
focused	O
on	O
apoptosis	B-PROC
and	O
transcriptional	B-PROC
profiling	O
of	O
FIPV	O
-	O
infected	O
cells	O
following	O
in	O
vitro	O
infection	O
of	O
CRFK	O
cells	O
with	O
FIPV	O
79	O
-	O
1146	O
WSU	O
.	O

131	O
genes	O
from	O
apoptosis	B-PROC
cluster	O
(	O
80	O
down	O
-	O
regulated	O
and	O
51	O
up	O
-	O
regulated	O
)	O
along	O
with	O
increase	O
of	O
apoptosis	B-PROC
,	O
p53	O
,	O
p38	O
MAPK	O
,	O
VEGF	O
and	O
chemokines	O
/	O
cytokines	O
signaling	B-PROC
pathways	B-PROC
were	O
probably	O
involved	O
in	O
apoptosis	B-PROC
process	O
.	O

We	O
investigated	O
the	O
inhibitory	O
effect	O
of	O
the	O
compound	O
by	O
conducting	B-PROC
colorimetry	O
-	O
based	O
ATP	B-PROC
hydrolysis	I-PROC
assay	O
and	O
fluorescence	O
resonance	O
energy	B-PROC
transfer	I-PROC
-	O
based	O
double	O
-	O
stranded	O
DNA	B-PROC
unwinding	I-PROC
assay	O
.	O

We	O
show	O
that	O
IBV	O
is	O
fairly	O
resistant	O
to	O
the	O
antiviral	O
state	O
induced	O
by	O
IFN	O
and	O
identify	O
that	O
viral	O
accessory	O
protein	O
3a	O
is	O
involved	O
in	O
resistance	B-PROC
to	O
IFN	O
,	O
as	O
its	O
absence	O
renders	O
IBV	O
less	O
resistant	O
to	O
IFN	O
treatment	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
resistant	O
to	O
IFN	O
treatment	O
and	O
identify	O
a	O
role	O
for	O
accessory	O
protein	O
3a	O
in	O
the	O
resistance	B-PROC
against	O
the	O
type	O
I	O
IFN	O
response	O
.	O

ABSTRACT	O
:	O
Newcastle	O
disease	O
(	O
ND	O
)	O
and	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
are	O
two	O
major	O
viral	B-PROC
diseases	I-PROC
affecting	O
the	O
respiratory	O
tracts	O
of	O
birds	O
and	O
whose	O
impact	O
on	O
African	O
poultry	O
is	O
still	O
poorly	O
known	O
.	O

Patients	O
under	O
treatment	O
were	O
at	O
a	O
7	O
.	O
8	O
-	O
fold	O
(	O
95	O
%	O
CI	O
,	O
4	O
.	O
0	O
-	O
16	O
.	O
7	O
)	O
significantly	O
higher	O
risk	O
of	O
death	B-PROC
compared	O
to	O
other	O
MERS	O
cases	O
.	O

No	O
difference	O
in	O
complications	O
and	O
outcome	O
is	O
found	O
in	O
treatment	O
regimens	O
of	O
intravenous	O
immunoglobulin	B-PROC
(	O
IVIG	O
)	O
and	O
plasma	O
exchange	O
.	O

Mice	O
deficient	O
in	O
MDA5	O
expression	B-PROC
(	O
MDA5	O
(-/-)	O
mice	O
)	O
experienced	O
more	O
severe	O
disease	O
following	O
MHV	O
infection	O
,	O
with	O
reduced	O
survival	O
,	O
increased	O
spread	O
of	O
virus	O
to	O
additional	O
sites	O
of	O
infection	O
,	O
and	O
more	O
extensive	O
liver	O
damage	O
than	O
did	O
wild	O
-	O
type	O
mice	O
.	O

Production	O
of	O
several	O
proinflammatory	O
cytokines	O
was	O
elevated	O
in	O
MDA5	O
(-/-)	O
mice	O
,	O
suggesting	O
that	O
MDA5	O
may	O
be	O
responsible	O
for	O
keeping	O
pathological	O
inflammatory	B-PROC
responses	I-PROC
in	O
check	O
.	O

TITLE	O
:	O
Plant	O
-	O
derived	O
H7	O
VLP	O
vaccine	O
elicits	O
protective	O
immune	B-PROC
response	I-PROC
against	O
H7N9	O
influenza	O
virus	O
in	O
mice	O
and	O
ferrets	O
.	O

Here	O
,	O
we	O
describe	O
the	O
rapid	O
(	O
19	O
days	O
)	O
development	B-PROC
of	O
a	O
plant	O
-	O
derived	O
VLP	O
vaccine	O
based	O
on	O
the	O
hemagglutinin	O
sequence	O
of	O
influenza	O
H7N9	O
A	O
/	O
Hangzhou	O
/	O
1	O
/	O
2013	O
.	O

There	O
are	O
limited	O
studies	O
on	O
the	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
PED	O
virus	O
(	O
PEDV	O
)	O
in	O
pigs	O
.	O

The	O
aims	O
of	O
our	O
study	O
were	O
to	O
investigate	O
differences	O
in	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
PEDV	O
infection	O
in	O
suckling	O
and	O
weaned	B-PROC
pigs	O
and	O
to	O
examine	O
if	O
disease	O
severity	O
coincides	O
with	O
reduced	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

We	O
review	O
here	O
efforts	O
to	O
develop	O
next	O
-	O
generation	O
vaccines	O
through	O
targeting	B-PROC
these	O
key	O
immunomodulatory	O
genes	O
in	O
influenza	O
virus	O
,	O
coronaviruses	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
measles	O
virus	O
,	O
and	O
mumps	O
virus	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
M	O
protein	O
blocks	O
cell	B-PROC
cycle	I-PROC
progression	I-PROC
at	O
S	B-PROC
-	I-PROC
phase	I-PROC
and	O
its	O
subcellular	O
localization	B-PROC
in	O
the	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

This	O
study	O
investigates	O
the	O
subcellular	O
localization	B-PROC
and	O
function	O
of	O
PEDV	O
M	O
protein	O
through	O
examination	O
of	O
its	O
effects	O
on	O
cell	B-PROC
growth	B-PROC
,	O
cell	B-PROC
cycle	I-PROC
progression	I-PROC
,	O
and	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
expression	B-PROC
.	O

We	O
have	O
previously	O
reported	O
that	O
intraspinal	O
transplantation	O
of	O
mouse	O
NPCs	O
into	O
JHMV	O
-	O
infected	O
animals	O
resulted	O
in	O
selective	O
colonization	O
of	O
demyelinated	O
lesions	O
,	O
preferential	O
differentiation	B-PROC
into	O
oligodendroglia	O
accompanied	O
by	O
axonal	O
preservation	O
,	O
and	O
increased	O
remyelination	B-PROC
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
(	O
IB	O
)	O
is	O
a	O
common	O
,	O
highly	O
contagious	O
,	O
acute	O
,	O
and	O
economically	O
important	O
viral	B-PROC
disease	I-PROC
of	O
chickens	O
caused	O
by	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
,	O
sp	O
.	O
Avian	O
coronavirus	O
).	O

Dilutions	O
with	O
theoretical	O
infectious	O
titers	O
from	O
560	O
to	O
0	O
.	O
0056	O
TCID50	O
/	O
ml	O
together	O
with	O
a	O
medium	O
control	O
were	O
orogastrically	O
inoculated	O
(	O
10ml	O
/	O
pig	O
)	O
into	O
7	O
groups	O
of	O
5	O
-	O
day	O
-	O
old	O
neonatal	O
pigs	O
(	O
n	O
=	O
4	O
per	O
group	O
)	O
and	O
7	O
groups	O
of	O
21	O
-	O
day	O
-	O
old	O
weaned	B-PROC
pigs	O
(	O
n	O
=	O
6	O
per	O
group	O
).	O

In	O
21	O
-	O
day	O
-	O
old	O
pigs	O
,	O
10ml	O
of	O
inoculum	O
with	O
titers	O
560	O
-	O
5	O
.	O
6	O
TCID50	O
/	O
ml	O
(	O
Ct	O
24	O
.	O
2	O
-	O
31	O
.	O
4	O
)	O
resulted	O
in	O
100	O
%	O
infection	O
in	O
each	O
group	O
while	O
10ml	O
of	O
inoculum	O
with	O
titers	O
0	O
.	O
56	O
-	O
0	O
.	O
0056	O
TCID50	O
/	O
ml	O
(	O
Ct	O
values	O
35	O
.	O
3	O
->	O
45	O
)	O
did	O
not	O
establish	O
infection	O
in	O
any	O
pigs	O
under	O
study	O
conditions	O
as	O
determined	O
by	O
clinical	O
signs	O
,	O
PCR	O
,	O
histopathology	O
,	O
immunohistochemistry	O
,	O
and	O
antibody	B-PROC
response	I-PROC
.	O

In	O
contrast	O
to	O
the	O
overwhelming	O
infection	O
seen	O
in	O
the	O
mice	O
challenged	O
with	O
10	O
(	O
5	O
)	O
LD50	O
of	O
MERS	O
-	O
CoV	O
,	O
we	O
were	O
able	O
to	O
recover	B-PROC
infectious	O
virus	O
from	O
these	O
mice	O
only	O
infrequently	O
,	O
although	O
quantitative	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
tests	O
indicated	O
early	O
and	O
persistent	O
lung	O
infection	O
and	O
delayed	O
occurrence	O
of	O
brain	O
infection	O
.	O

When	O
given	O
a	O
high	O
dose	O
of	O
MERS	O
-	O
CoV	O
,	O
our	O
transgenic	O
mice	O
expressing	O
hCD26	O
/	O
DPP4	O
viral	O
receptor	O
uniformly	O
succumbed	O
to	O
death	B-PROC
within	O
6	O
days	O
,	O
making	O
it	O
difficult	O
to	O
evaluate	O
host	O
responses	O
to	O
infection	O
and	O
disease	O
.	O

ABSTRACT	O
:	O
Electrical	B-PROC
impedance	I-PROC
tomography	O
(	O
EIT	O
)	O
is	O
a	O
noninvasive	O
technique	O
used	O
to	O
assess	O
regional	O
gas	O
distribution	O
in	O
the	O
lung	O
.	O

Impedance	B-PROC
distribution	O
in	O
ventral	O
,	O
mid	O
-	O
ventral	O
,	O
mid	O
-	O
dorsal	O
,	O
and	O
dorsal	O
layers	O
before	O
and	O
20	O
min	O
after	O
the	O
start	O
of	O
prone	O
positioning	O
was	O
9	O
,	O
48	O
,	O
44	O
,	O
and	O
0	O
%,	O
and	O
10	O
,	O
25	O
,	O
48	O
,	O
and	O
16	O
%,	O
respectively	O
.	O

TITLE	O
:	O
The	O
early	O
immune	B-PROC
response	I-PROC
to	O
infection	O
of	O
chickens	O
with	O
Infectious	O
Bronchitis	O
Virus	O
(	O
IBV	O
)	O
in	O
susceptible	O
and	O
resistant	O
birds	O
.	O

To	O
select	O
the	O
mode	O
of	O
antimicrobial	O
therapy	O
is	O
most	O
important	O
local	O
monitoring	O
antimicrobial	O
resistance	B-PROC
of	O
pathogens	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
often	O
used	O
in	O
patients	O
with	O
severe	O
respiratory	O
failure	O
to	O
improve	O
oxygenation	B-PROC
and	O
survival	O
.	O

This	O
study	O
demonstrates	O
a	O
constant	O
evolution	B-PROC
of	O
IBV	O
in	O
Iran	O
,	O
demonstrating	O
the	O
need	O
for	O
continuous	O
monitoring	O
and	O
development	B-PROC
of	O
new	O
vaccines	O
based	O
on	O
indigenous	O
viruses	O
.	O

The	O
remaining	O
five	O
IBV	O
isolates	O
,	O
ck	O
/	O
CH	O
/	O
LHB	O
/	O
111172	O
,	O
ck	O
/	O
CH	O
/	O
LSD	O
/	O
111219	O
,	O
ck	O
/	O
CH	O
/	O
LHB	O
/	O
130598	O
,	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
110931	O
,	O
and	O
ck	O
/	O
CH	O
/	O
LHB	O
/	O
130573	O
,	O
were	O
shown	O
to	O
have	O
originated	O
from	O
natural	O
recombination	B-PROC
events	O
between	O
an	O
H120	O
-	O
like	O
vaccine	O
strain	O
and	O
other	O
types	O
of	O
viruses	O
.	O

TITLE	O
:	O
Genetic	B-PROC
polymorphisms	I-PROC
of	O
IL28b	O
gene	O
as	O
predictors	O
of	O
response	O
to	O
dual	O
therapy	O
in	O
genotypes	O
1	O
and	O
4	O
-	O
HCV	O
and	O
HIV	O
/	O
HCV	O
-	O
infected	O
patients	O
.	O

Part	O
2	O
:	O
Design	O
,	O
Synthesis	B-PROC
,	O
and	O
Structure	O
-	O
Activity	O
Relationships	O
of	O
Thiophosphoramide	O
Derivatives	O
as	O
Novel	O
Antiviral	O
and	O
Antifungal	O
Agents	O
.	O

Hence	O
,	O
the	O
role	O
of	O
the	O
RBM	O
is	O
a	O
bi	O
-	O
functional	O
bioactive	O
surface	O
that	O
can	O
be	O
demonstrated	O
by	O
antibodies	O
such	O
as	O
the	O
neutralizing	O
human	O
anti	O
-	O
SARS	O
monoclonal	O
antibody	B-PROC
(	O
mAb	O
)	O
80R	O
which	O
targets	O
the	O
RBM	O
and	O
competes	O
with	O
the	O
ACE2	O
receptor	O
for	O
binding	O
.	O

ABSTRACT	O
:	O
Pathogenic	O
viral	B-PROC
infections	I-PROC
pose	O
major	O
health	O
risks	O
to	O
humans	O
and	O
livestock	O
due	O
to	O
viral	B-PROC
infection	I-PROC
-	O
associated	O
illnesses	O
such	O
as	O
chronic	O
or	O
acute	O
inflammation	O
in	O
crucial	O
organs	O
and	O
systems	O
,	O
malignant	O
and	O
benign	O
lesions	O
.	O

Furthermore	O
,	O
all	O
of	O
the	O
three	O
MAbs	O
reacted	O
with	O
PEDV	O
in	O
the	O
fluorescent	O
antibody	B-PROC
assay	O
.	O

Efforts	O
should	O
be	O
made	O
to	O
establish	O
a	O
methodology	O
for	O
rapid	O
tracking	O
of	O
all	O
possible	O
contacts	O
and	O
elimination	B-PROC
-	O
based	O
identification	O
of	O
the	O
precise	O
modes	O
of	O
transmission	O
.	O

The	O
Type	O
I	O
pattern	O
pathogens	O
had	O
varied	O
trends	O
in	O
disease	O
incidence	O
in	O
the	O
years	O
following	O
the	O
exponential	O
growth	B-PROC
and	O
subsequent	O
decline	O
in	O
the	O
number	O
of	O
citations	O
.	O

Among	O
these	O
,	O
subjects	O
who	O
lost	O
a	O
partner	O
,	O
child	O
,	O
or	O
sibling	O
were	O
older	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
less	O
likely	O
to	O
be	O
working	O
(	O
P	O
=	O
0	O
.	O
032	O
),	O
and	O
more	O
likely	O
to	O
be	O
suffering	O
from	O
hypertension	O
(	O
P	O
=	O
0	O
.	O
021	O
),	O
returned	O
higher	O
scores	O
on	O
the	O
SCI	O
-	O
CG	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
developed	O
the	O
index	O
ACS	O
more	O
frequently	O
between	O
12	O
and	O
48	O
months	O
after	O
the	O
death	B-PROC
than	O
those	O
who	O
lost	O
a	O
parent	O
or	O
another	O
relative	O
(	O
P	O
≤	O
0	O
.	O
0001	O
).	O

ABSTRACT	O
:	O
Inefficiency	O
of	O
RT	O
-	O
PCR	O
can	O
be	O
associated	O
with	O
the	O
suboptimal	O
process	O
of	O
reverse	B-PROC
transcription	B-PROC
as	O
only	O
40	O
-	O
80	O
%	O
of	O
RNA	O
is	O
converted	O
to	O
cDNA	O
.	O

ABSTRACT	O
:	O
Despite	O
tremendous	O
progress	O
made	O
toward	O
elimination	B-PROC
,	O
measles	O
continues	O
to	O
pose	O
a	O
great	O
threat	O
to	O
the	O
health	O
of	O
children	O
in	O
developing	O
countries	O
.	O

A	O
total	O
of	O
7	O
infants	O
developed	O
a	O
secondary	O
bacterial	O
infection	O
,	O
and	O
12	O
infants	O
received	O
mechanical	O
ventilation	O
(	O
5	O
with	O
high	O
-	O
frequency	O
mechanical	O
ventilation	O
and	O
3	O
with	O
mechanical	O
ventilation	O
and	O
NO	O
inhalation	B-PROC
);	O
the	O
average	O
duration	O
of	O
mechanical	O
ventilation	O
was	O
10	O
.	O
08	O
days	O
,	O
and	O
3	O
infants	O
expired	O
.	O

TITLE	O
:	O
How	O
much	O
esophageal	B-PROC
pressure	I-PROC
-	O
guided	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
transpulmonary	O
pressure	O
is	O
sufficient	O
to	O
maintain	O
lung	O
recruitment	O
in	O
lavage	O
-	O
induced	O
lung	O
injury	O
?	O

TITLE	O
:	O
Extracorporeal	O
decarboxylation	O
in	O
patients	O
with	O
severe	O
traumatic	O
brain	O
injury	O
and	O
ARDS	O
enables	O
effective	O
control	O
of	O
intracranial	B-PROC
pressure	I-PROC
.	O

Eight	O
patients	O
developed	O
LRTI	O
,	O
four	O
of	O
whom	O
had	O
severe	O
pneumonia	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
these	O
four	O
patients	O
died	B-PROC
despite	O
receiving	O
intensive	O
care	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
Antiviral	O
Evaluation	O
of	O
Some	O
C	O
(	O
3	O
)-	O
Symmetrical	O
Trialkoxy	O
-	O
Substituted	O
1	O
,	O
3	O
,	O
5	O
-	O
Triazines	O
and	O
Their	O
Molecular	O
Geometry	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
integrin	O
receptor	O
specificity	O
of	O
targeted	B-PROC
liposomes	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
ORF3	O
gene	O
prolongs	O
S	B-PROC
-	I-PROC
phase	I-PROC
,	O
facilitates	O
formation	B-PROC
of	O
vesicles	O
and	O
promotes	O
the	O
proliferation	O
of	O
attenuated	O
PEDV	O
.	O

In	O
2014	O
alone	O
,	O
over	O
3	O
.	O
3	O
billion	O
passengers	O
(	O
a	O
number	O
equivalent	O
to	O
42	O
%	O
of	O
the	O
world	O
population	O
)	O
and	O
50	O
million	O
metric	O
tons	O
of	O
cargo	O
traveled	O
by	O
air	O
from	O
41	O
,	O
000	O
airports	O
and	O
50	O
,	O
000	O
routes	O
worldwide	O
,	O
and	O
significant	O
growth	B-PROC
is	O
anticipated	O
,	O
with	O
passenger	O
numbers	O
expected	O
to	O
reach	B-PROC
5	O
.	O
9	O
billion	O
by	O
2030	O
.	O

The	O
loss	O
of	O
binding	B-PROC
activity	I-PROC
was	O
manifested	O
as	O
a	O
20	O
%	O
decrease	O
in	O
the	O
minimum	O
on	O
-	O
rate	O
accompanied	O
with	O
a	O
70	O
%	O
increase	O
in	O
the	O
maximum	O
off	O
-	O
rate	O
.	O

Our	O
findings	O
provide	O
insight	O
into	O
the	O
development	B-PROC
of	O
new	O
therapeutics	O
that	O
disrupt	O
the	O
interaction	O
between	O
RNA	O
and	O
viral	O
NP	O
in	O
the	O
HCoV	O
.	O
The	O
discovery	O
of	O
the	O
new	O
compound	O
would	O
be	O
an	O
impetus	O
to	O
design	O
novel	O
NP	O
inhibitors	O
against	O
human	O
CoV	O
.	O

No	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
was	O
observed	O
with	O
other	O
viruses	O
.	O

This	O
duplex	O
UNDP	O
-	O
PCR	O
assay	O
could	O
detect	O
TGEV	O
(	O
RNA	O
virus	O
)	O
and	O
PCV2	O
(	O
DNA	O
virus	O
)	O
from	O
large	O
-	O
scale	O
serum	O
samples	O
simultaneously	O
without	O
the	O
need	O
for	O
DNA	O
/	O
RNA	O
extraction	O
,	O
purification	O
and	O
reverse	B-PROC
transcription	B-PROC
of	O
RNA	O
,	O
and	O
showed	O
a	O
significantly	O
increased	O
positive	O
detection	O
rate	O
for	O
PCV2	O
(	O
29	O
%)	O
and	O
TGEV	O
(	O
11	O
.	O
7	O
%)	O
preclinical	O
infection	O
than	O
conventional	O
duplex	O
PCR	O
/	O
RT	O
-	O
PCR	O
.	O

TITLE	O
:	O
Cleavage	B-PROC
of	O
a	O
Neuroinvasive	O
Human	O
Respiratory	O
Virus	O
Spike	O
Glycoprotein	O
by	O
Proprotein	O
Convertases	O
Modulates	O
Neurovirulence	O
and	O
Virus	O
Spread	O
within	O
the	O
Central	O
Nervous	O
System	O
.	O

We	O
identified	O
one	O
predominant	O
mutation	O
at	O
amino	O
acid	O
758	O
(	O
from	O
RRSR	O
↓	O
G758	O
to	O
RRSR	O
↓	O
R758	O
),	O
which	O
introduces	O
a	O
putative	O
furin	O
-	O
like	O
cleavage	B-PROC
(↓)	O
site	O
.	O

Using	O
a	O
molecular	O
cDNA	O
infectious	O
clone	O
to	O
generate	O
a	O
corresponding	O
recombinant	O
virus	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
such	O
point	B-PROC
mutation	I-PROC
in	O
the	O
HCoV	O
-	O
OC43	O
S	O
glycoprotein	O
creates	O
a	O
functional	O
cleavage	B-PROC
site	O
between	O
the	O
S1	O
and	O
S2	O
portions	O
of	O
the	O
S	O
protein	O
.	O

The	O
results	O
indicate	O
that	O
group	O
2b	O
viruses	O
encoding	O
the	O
SHC014	O
spike	O
in	O
a	O
wild	O
-	O
type	O
backbone	O
can	O
efficiently	O
use	O
multiple	O
orthologs	O
of	O
the	O
SARS	O
receptor	O
human	O
angiotensin	O
converting	O
enzyme	O
II	O
(	O
ACE2	O
),	O
replicate	O
efficiently	O
in	O
primary	O
human	O
airway	O
cells	O
and	O
achieve	O
in	O
vitro	O
titers	O
equivalent	O
to	O
epidemic	O
strains	O
of	O
SARS	O
-	O
CoV	O
.	O
Additionally	O
,	O
in	O
vivo	O
experiments	O
demonstrate	O
replication	O
of	O
the	O
chimeric	O
virus	O
in	O
mouse	O
lung	O
with	O
notable	O
pathogenesis	B-PROC
.	O

Respiratory	O
viruses	O
are	O
responsible	O
for	O
more	O
deaths	B-PROC
globally	O
than	O
any	O
other	O
infectious	O
agent	O
.	O

The	O
increase	O
in	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
led	O
to	O
an	O
equivalent	O
increase	O
in	O
the	O
plateau	O
pressure	O
,	O
and	O
lung	O
-	O
protective	O
ventilation	O
was	O
significantly	O
altered	O
during	O
the	O
procedure	O
.	O

Lung	B-PROC
volumes	I-PROC
were	O
measured	O
in	O
computed	O
tomography	O
slices	O
acquired	O
at	O
end	B-PROC
-	I-PROC
expiration	I-PROC
and	O
end	O
-	O
inspiration	B-PROC
.	O

Despite	O
intensive	O
anti	O
-	O
bacterial	O
treatment	O
,	O
she	O
died	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
46	O
days	O
after	O
hospitalization	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
the	O
development	B-PROC
of	O
SARS	O
3CL	O
protease	B-PROC
inhibitors	I-PROC
from	O
a	O
peptide	O
mimic	O
to	O
an	O
aza	O
-	O
decaline	O
scaffold	O
.	O

(	O
18	O
)	O
F	O
-	O
Fluorodeoxyglucose	O
([(	O
18	O
)	O
F	O
]-	O
FDG	O
)-	O
positron	O
emission	O
tomography	O
/	O
computed	O
tomography	O
(	O
PET	O
/	O
CT	O
)	O
as	O
a	O
longitudinal	O
noninvasive	O
approach	O
can	O
be	O
beneficial	O
in	O
providing	O
biomarkers	O
for	O
host	O
immune	B-PROC
response	I-PROC
.	O

[(	O
18	O
)	O
F	O
]-	O
FDG	O
-	O
PET	O
is	O
able	O
to	O
detect	O
subtle	O
changes	O
in	O
host	O
immune	B-PROC
response	I-PROC
to	O
contain	O
a	O
subclinical	O
virus	B-PROC
infection	I-PROC
.	O

Despite	O
equivocal	O
results	O
in	O
sepsis	O
trials	O
,	O
anakinra	O
is	O
effective	O
in	O
treating	O
macrophage	B-PROC
activation	I-PROC
syndrome	O
,	O
a	O
similar	O
entity	O
with	O
fever	B-PROC
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
hepatobiliary	O
dysfunction	O
,	O
cytopenias	O
,	O
and	O
hyperferritinemia	O
.	O

The	O
non	O
-	O
hepatobiliary	O
dysfunction	O
/	O
disseminated	O
intravascular	O
coagulation	B-PROC
group	O
included	O
patients	O
with	O
only	O
hepatobiliary	O
dysfunction	O
,	O
only	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
or	O
neither	O
.	O

In	O
this	O
subgroup	O
analysis	O
,	O
interleukin	O
-	O
1	O
receptor	O
blockade	O
was	O
associated	O
with	O
significant	O
improvement	O
in	O
survival	O
of	O
patients	O
with	O
sepsis	O
and	O
concurrent	O
hepatobiliary	O
dysfunction	O
/	O
disseminated	O
intravascular	O
coagulation	B-PROC
.	O

The	O
Identify	O
-	O
Isolate	O
-	O
Inform	O
(	O
3I	O
)	O
tool	O
,	O
originally	O
conceived	O
for	O
initial	O
detection	O
and	O
management	O
of	O
Ebola	O
virus	B-PROC
disease	I-PROC
patients	O
in	O
the	O
ED	O
and	O
later	O
adjusted	O
for	O
measles	O
,	O
can	O
be	O
adapted	O
for	O
real	O
-	O
time	O
use	O
for	O
any	O
emerging	O
infectious	O
disease	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
)	O
is	O
an	O
emerging	O
disease	O
of	O
pigs	O
that	O
has	O
recently	O
led	O
to	O
large	O
numbers	O
of	O
piglet	O
deaths	B-PROC
in	O
a	O
number	O
of	O
countries	O
of	O
Eastern	O
Asia	O
and	O
The	O
Americas	O
.	O

ABSTRACT	O
:	O
Although	O
the	O
original	O
US	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
was	O
confirmed	O
as	O
highly	O
virulent	O
by	O
multiple	O
studies	O
,	O
the	O
virulence	B-PROC
of	O
spike	O
-	O
insertion	O
deletion	O
(	O
S	O
-	O
INDEL	B-PROC
)	O
PEDV	O
strains	O
is	O
undefined	O
.	O

We	O
aim	O
to	O
determine	O
the	O
viral	O
content	O
of	O
the	O
air	O
emitted	O
by	O
symptomatic	O
inpatients	O
or	O
long	O
-	O
term	O
care	O
residents	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
virus	B-PROC
infection	I-PROC
(	O
emitters	O
),	O
and	O
in	O
the	O
breathing	B-PROC
zones	O
of	O
healthcare	O
workers	O
who	O
attend	O
to	O
them	O
.	O

TITLE	O
:	O
Does	O
Bronchoscopic	O
Evaluation	O
of	O
Inhalation	B-PROC
Injury	O
Severity	O
Predict	O
Outcome	O
?	O

RESULTS	O
:	O
Six	O
males	O
and	O
one	O
female	O
ranging	O
from	O
3	O
months	O
to	O
9	O
years	O
of	O
age	O
presented	O
with	O
status	O
epilepticus	O
preceded	O
by	O
a	O
febrile	B-PROC
illness	O
.	O

We	O
investigated	O
the	O
spatial	O
and	O
cellular	B-PROC
localization	I-PROC
of	O
DPP4	O
to	O
evaluate	O
an	O
association	O
MERS	O
clinical	O
disease	O
.	O

DPP4	O
was	O
rarely	O
detected	O
in	O
the	O
surface	O
epithelium	O
from	O
nasal	O
cavity	O
to	O
conducting	B-PROC
airways	O
with	O
a	O
slightly	O
increased	O
incidence	O
in	O
distal	O
airways	O
.	O

Inactivation	O
of	O
8	O
log10	O
TCID50	O
/	O
ml	O
plasma	O
within	O
30	O
min	O
(	O
8D	O
value	O
<	O
30	O
min	O
)	O
by	O
moderate	O
pH	O
and	O
temperature	O
would	O
denote	O
potential	O
industrial	O
processing	O
conditions	O
that	O
ensure	O
safety	O
towards	O
PEDV	O
while	O
limiting	O
denaturation	B-PROC
of	O
bioactive	O
components	O
.	O

The	O
average	O
number	O
of	O
animals	O
on	O
each	O
operation	O
exhibiting	O
clinical	O
signs	O
(	O
morbidity	O
)	O
and	O
the	O
average	O
number	O
of	O
case	O
fatalities	O
was	O
greatest	O
for	O
suckling	O
and	O
weaned	B-PROC
pigs	O
.	O

To	O
determine	O
whether	O
these	O
mutations	O
lead	O
to	O
changes	O
in	O
antigenicity	O
,	O
as	O
suggested	O
by	O
the	O
failure	O
of	O
PEDV	O
vaccines	O
in	O
China	O
,	O
we	O
first	O
optimized	O
the	O
codons	O
of	O
typical	O
S	O
genes	O
of	O
the	O
CV777	O
vaccine	O
strain	O
(	O
G1	O
subtype	O
)	O
and	O
LNCT2	O
strain	O
(	O
G2	O
subtype	O
)	O
and	O
expressed	B-PROC
the	O
recombinant	O
full	O
-	O
length	O
sequence	O
of	O
the	O
S	O
protein	O
in	O
a	O
eukaryotic	O
expression	B-PROC
system	O
.	O

The	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
index	O
(	O
PVPI	O
)	O
was	O
significantly	O
higher	O
in	O
the	O
PE	O
group	O
than	O
in	O
the	O
non	O
-	O
PE	O
group	O
on	O
Day	O
6	O
(	O
p	O
=	O
0	O
.	O
029	O
)	O
and	O
Day	O
10	O
(	O
p	O
=	O
0	O
.	O
011	O
).	O

However	O
,	O
pretreatment	O
of	O
mice	O
with	O
imatinib	O
increased	O
lung	O
catalase	O
activity	O
and	O
decreased	O
intravenous	O
LPS	O
-	O
induced	O
lung	O
oxidant	O
injury	O
as	O
measured	O
by	O
γ	O
-	O
H2AX	O
,	O
a	O
marker	O
of	O
oxidant	O
-	O
induced	O
DNA	O
damage	O
,	O
lung	O
apoptosis	B-PROC
,	O
and	O
pulmonary	O
edema	O
.	O

In	O
this	O
study	O
,	O
based	O
on	O
the	O
peptide	O
-	O
binding	O
motifs	O
of	O
chicken	O
MHC	B-PROC
I	O
molecules	O
for	O
the	O
BF2	O
*	O
4	O
,	O
BF2	O
*	O
12	O
,	O
BF2	O
*	O
15	O
,	O
and	O
BF2	O
*	O
19	O
haplotypes	O
,	O
potential	O
CTL	O
epitopes	O
were	O
predicted	O
using	O
S1	O
proteins	O
from	O
different	O
IBV	O
strains	O
.	O

Spleen	O
lymphocytes	O
were	O
collected	O
from	O
specific	O
-	O
pathogen	O
free	O
(	O
SPF	O
)	O
chicken	O
that	O
had	O
been	O
immunized	O
with	O
the	O
S1	O
protein	B-PROC
expression	B-PROC
plasmid	O
,	O
pV	O
-	O
S1	O
,	O
and	O
were	O
stimulated	O
by	O
the	O
synthesized	O
peptides	O
.	O

IFN	O
-	O
γ	O
secretion	B-PROC
and	O
CD8	O
(+)	O
T	B-PROC
cell	I-PROC
proliferation	I-PROC
in	O
chickens	O
were	O
tested	O
by	O
ELISpot	O
array	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

Compared	O
with	O
those	O
in	O
pre	O
-	O
RM	O
,	O
pulmonary	O
compliance	O
,	O
oxygenation	B-PROC
index	O
(	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
[	O
PaO2	O
/	O
FiO2	O
])	O
and	O
EVLWI	O
remarkably	O
improved	O
in	O
RM1	O
,	O
RM2	O
,	O
RM3	O
and	O
4	O
hours	O
post	O
-	O
RRM	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

As	O
of	O
August	O
2015	O
,	O
the	O
disease	O
has	O
infected	O
1	O
,	O
400	O
patients	O
,	O
of	O
whom	O
500	O
have	O
died	B-PROC
,	O
yielding	O
a	O
36	O
%	O
mortality	O
rate	O
.	O

Biosafety	O
concerns	O
(	O
such	O
as	O
pollen	O
contamination	O
and	O
immunogenicity	O
of	O
plant	O
-	O
specific	O
glycans	O
)	O
and	O
costly	O
downstream	O
extraction	O
and	O
purification	O
requirements	O
,	O
however	O
,	O
have	O
hampered	O
PMF	O
production	O
from	O
moving	B-PROC
from	O
the	O
laboratory	O
to	O
industrial	O
application	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
used	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

PaO2	O
/	O
FiO2	O
increased	O
from	O
118	O
.	O
4	O
±	O
15	O
.	O
5	O
mm	O
Hg	O
to	O
179	O
.	O
1	O
±	O
72	O
.	O
4	O
mm	O
Hg	O
in	O
the	O
ILIAS	O
group	O
compared	O
with	O
an	O
improvement	O
of	O
oxygenation	B-PROC
from	O
107	O
.	O
1	O
±	O
24	O
.	O
9	O
mm	O
Hg	O
to	O
179	O
.	O
0	O
±	O
45	O
.	O
7	O
mm	O
Hg	O
in	O
the	O
standard	O
ECMO	O
group	O
(	O
P	O
=	O
n	O
.	O
s	O
.).	O

However	O
,	O
hemolysis	B-PROC
was	O
significantly	O
higher	O
in	O
the	O
ILIAS	O
group	O
compared	O
with	O
the	O
conventional	O
ECMO	O
.	O

We	O
noted	O
a	O
marked	O
improvement	O
of	O
right	B-PROC
ventricular	I-PROC
function	I-PROC
with	O
restoration	O
of	O
haemodynamic	O
stability	O
.	O

Adult	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
requiring	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
therapy	O
.	O

The	O
different	O
types	O
of	O
membrane	O
oxygenators	O
and	O
pumps	O
did	O
not	O
significantly	O
alter	O
hemostasis	B-PROC
.	O

In	O
lymphoid	O
tissues	O
,	O
viral	O
RNA	O
and	O
proteins	O
were	O
detected	O
in	O
infected	O
monocytes	O
upon	O
differentiation	B-PROC
into	O
dendritic	O
cells	O
(	O
DCs	O
)	O
within	O
3	O
days	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
present	O
recent	O
progress	O
in	O
the	O
development	B-PROC
of	O
nucleoside	O
HCV	O
NS5B	O
polymerase	O
inhibitors	O
,	O
focusing	O
on	O
lead	O
compounds	O
that	O
hold	O
great	O
promise	O
for	O
medicinal	O
use	O
and	O
their	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
in	O
order	O
to	O
provide	O
guidance	O
for	O
future	O
drug	O
design	O
and	O
discovery	O
.	O

ABSTRACT	O
:	O
To	O
establish	O
a	O
characteristic	O
host	B-PROC
response	I-PROC
to	O
predict	O
the	O
pathogenicity	O
and	O
tissue	B-PROC
tropism	B-PROC
of	O
infectious	O
bronchitis	O
viruses	O
(	O
IBV	O
),	O
we	O
investigated	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
(	O
IIR	O
)	O
and	O
apoptosis	B-PROC
in	O
chicken	O
embryo	O
kidney	O
cells	O
(	O
CEKC	O
)	O
and	O
tracheal	O
organ	O
cultures	O
(	O
TOC	O
)	O
infected	O
with	O
three	O
IBV	O
strains	O
.	O

Elevated	O
IIR	O
is	O
associated	O
with	O
tissue	B-PROC
tropism	B-PROC
of	O
different	O
IBV	O
strains	O
.	O

We	O
also	O
solved	O
the	O
structure	O
of	O
FIPV	O
M	O
(	O
pro	O
)	O
complexed	O
with	O
two	O
inhibitors	O
,	O
delineating	O
the	O
structural	O
view	O
of	O
a	O
dual	O
inhibition	B-PROC
mechanism	O
.	O

Mutations	O
specifically	O
disrupting	O
the	O
cysteine	O
protease	B-PROC
activity	I-PROC
of	O
PEDV	O
nsp5	O
abrogated	O
NEMO	O
cleavage	B-PROC
and	O
the	O
inhibition	B-PROC
of	O
IFN	O
induction	O
.	O

These	O
data	O
show	O
that	O
PEDV	O
nsp5	O
disrupts	O
type	O
I	O
IFN	O
signaling	B-PROC
by	O
cleaving	O
NEMO	O
.	O

The	O
new	O
molecular	O
details	O
and	O
determinants	O
impacting	O
NEMO	O
scission	O
by	O
PEDV	O
nsp5	O
delineated	O
in	O
this	O
study	O
are	O
fundamental	O
to	O
our	O
understanding	O
of	O
critical	O
virus	O
-	O
host	O
interactions	O
that	O
determine	O
PEDV	O
pathogenesis	B-PROC
.	O

TITLE	O
:	O
Chemo	O
-	O
enzymatic	O
synthesis	B-PROC
of	O
site	O
-	O
specific	O
isotopically	O
labeled	O
nucleotides	O
for	O
use	O
in	O
NMR	O
resonance	O
assignment	O
,	O
dynamics	O
and	O
structural	O
characterizations	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
prototype	O
automated	O
microarray	O
that	O
integrates	O
and	O
automates	O
all	O
steps	O
of	O
post	O
-	O
PCR	O
microarray	O
processing	O
for	O
the	O
simultaneous	O
detection	O
and	O
typing	O
of	O
eight	O
bacteria	O
and	O
viruses	O
commonly	O
associated	O
with	O
PRDC	O
is	O
described	O
along	O
with	O
associated	O
multiplex	O
reverse	O
transcriptase	B-PROC
PCR	O
.	O

The	O
user	O
-	O
friendly	O
assay	O
detected	O
and	O
differentiated	B-PROC
between	O
four	O
viruses	O
[	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
influenza	O
A	O
virus	O
,	O
porcine	O
circovirus	O
type	O
2	O
,	O
porcine	O
respiratory	O
corona	O
virus	O
],	O
four	O
bacteria	O
(	O
Mycoplasma	O
hyopneumoniae	O
,	O
Pasteurella	O
multocida	O
,	O
Salmonella	O
enterica	O
serovar	O
Choleraesuis	O
,	O
Streptococcus	O
suis	O
),	O
and	O
further	O
differentiated	B-PROC
between	O
type	O
1	O
and	O
type	O
2	O
PRRSV	O
as	O
well	O
as	O
toxigenic	O
and	O
non	O
-	O
toxigenic	O
P	O
.	O
multocida	O
.	O

RESULTS	O
:	O
For	O
a	O
fixed	O
sequence	O
of	O
stepwise	O
increases	O
in	O
the	O
respiratory	O
rate	O
,	O
corresponding	O
decreases	O
in	O
tidal	O
volume	O
to	O
keep	O
the	O
alveolar	O
minute	O
ventilation	O
and	O
inspiratory	B-PROC
flow	O
constant	O
were	O
calculated	O
according	O
to	O
standard	O
formulae	O
.	O

Overlap	O
syndrome	O
have	O
significantly	O
higher	O
likelihood	O
of	O
obesity	O
and	O
metabolic	B-PROC
syndrome	O
compared	O
to	O
only	O
COPD	O
.	O

In	O
this	O
outbreak	O
investigation	O
,	O
the	O
participation	O
of	O
health	O
-	O
care	O
personnel	O
in	O
conducting	B-PROC
vigorous	O
contact	O
tracing	O
may	O
have	O
reduced	O
the	O
risk	O
of	O
transmission	O
.	O

We	O
compared	O
the	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
network	O
protocol	O
using	O
low	O
levels	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
with	O
open	O
lung	O
approach	O
resulting	O
in	O
moderate	O
to	O
high	O
levels	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
for	O
the	O
management	O
of	O
established	O
moderate	O
/	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

At	O
12	O
-	O
36	O
hours	O
after	O
acute	O
respiratory	O
distress	O
syndrome	O
onset	O
,	O
patients	O
were	O
assessed	O
under	O
standardized	O
ventilator	O
settings	O
(	O
FIO2	O
≥	O
0	O
.	O
5	O
,	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
≥	O
10	O
cm	O
H2O	O
).	O

However	O
,	O
protein	O
interacting	O
with	O
NIMA	O
(	O
Pin1	O
),	O
a	O
member	O
of	O
the	O
parvulin	B-PROC
subfamily	O
of	O
PPIases	O
that	O
differs	O
from	O
Cyps	O
and	O
FKBPs	O
,	O
is	O
essential	O
for	O
various	O
signaling	B-PROC
pathways	B-PROC
.	O

TITLE	O
:	O
Mouse	O
Hepatitis	O
Virus	B-PROC
Infection	I-PROC
Remodels	O
Connexin43	O
-	O
Mediated	O
Gap	O
Junction	O
Intercellular	B-PROC
Communication	I-PROC
In	O
Vitro	O
and	O
In	O
Vivo	O
.	O

After	O
infection	O
,	O
a	O
significant	O
amount	O
of	O
Cx43	O
was	O
retained	O
in	O
endoplasmic	O
reticulum	O
/	O
endoplasmic	O
reticulum	O
Golgi	O
intermediate	O
complex	O
(	O
ER	O
/	O
ERGIC	O
)	O
and	O
GJ	O
plaque	O
formation	B-PROC
was	O
impaired	O
at	O
the	O
cell	O
surface	O
,	O
as	O
evidenced	O
by	O
a	O
reduction	O
of	O
the	O
Triton	O
X	O
-	O
100	O
insoluble	O
fraction	O
of	O
Cx43	O
.	O

MERS	O
-	O
CoV	O
was	O
detected	O
by	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
viable	O
virus	O
was	O
isolated	O
by	O
cultures	O
.	O

Thus	O
,	O
our	O
findings	O
suggested	O
that	O
the	O
S	O
INDEL	B-PROC
strain	O
had	O
different	O
viral	O
dynamics	O
than	O
the	O
NA	O
prototype	O
strain	O
.	O

Biodegradable	O
DNA	O
nanoparticles	O
offer	O
a	O
safe	O
gene	B-PROC
delivery	I-PROC
platform	O
devoid	O
of	O
adverse	O
effects	O
associated	O
with	O
virus	O
-	O
based	O
or	O
synthetic	O
nonbiodegradable	O
systems	O
.	O

These	O
nanoparticles	O
provide	O
a	O
biodegradable	O
DNA	O
nanoparticle	O
platform	O
enabling	O
uniform	O
transgene	O
expression	B-PROC
patterns	O
in	O
vivo	O
and	O
hold	O
promise	O
for	O
the	O
treatment	O
of	O
neurological	O
diseases	O
.	O

We	O
reviewed	O
experimental	O
findings	O
from	O
human	O
primary	O
cells	O
and	O
ex	O
vivo	O
human	O
lung	O
tissues	O
,	O
as	O
well	O
as	O
those	O
from	O
animal	O
studies	O
,	O
so	O
as	O
to	O
understand	O
the	O
pathogenesis	B-PROC
and	O
high	O
case	O
-	O
fatality	O
of	O
MERS	O
.	O

MERS	O
-	O
CoV	O
can	O
also	O
effectively	O
infect	O
human	O
primary	O
T	O
cells	O
and	O
induce	O
massive	O
apoptosis	B-PROC
in	O
these	O
cells	O
.	O

TITLE	O
:	O
Recent	O
insights	O
into	O
the	O
development	B-PROC
of	O
therapeutics	O
against	O
coronavirus	O
diseases	O
by	O
targeting	B-PROC
N	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
advent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
the	O
21st	O
century	O
and	O
the	O
recent	O
outbreak	O
of	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
highlight	O
the	O
importance	O
of	O
coronaviruses	O
(	O
CoVs	O
)	O
as	O
human	O
pathogens	O
,	O
emphasizing	O
the	O
need	O
for	O
development	B-PROC
of	O
novel	O
antiviral	O
strategies	O
to	O
combat	O
acute	O
respiratory	O
infections	O
caused	O
by	O
CoVs	O
.	O

This	O
review	O
aims	O
to	O
provide	O
readers	O
with	O
a	O
concise	O
survey	O
of	O
the	O
structural	O
features	O
of	O
coronavirus	O
N	O
proteins	O
and	O
how	O
these	O
features	O
provide	O
insights	O
into	O
structure	O
-	O
based	O
development	B-PROC
of	O
therapeutics	O
against	O
coronaviruses	O
.	O

Circulation	B-PROC
persisted	O
in	O
multiple	O
healthcare	O
settings	O
over	O
an	O
extended	O
period	O
,	O
underscoring	O
the	O
importance	O
of	O
strengthening	O
MERS	O
-	O
CoV	O
surveillance	O
and	O
infection	O
-	O
control	O
practices	O
.	O

For	O
the	O
limited	O
number	O
of	O
autopsy	O
reports	O
,	O
small	O
animal	O
models	O
are	O
urgently	O
needed	O
to	O
study	O
the	O
mechanisms	O
of	O
MERS	O
-	O
CoV	O
infection	O
and	O
pathogenesis	B-PROC
of	O
the	O
disease	O
and	O
to	O
evaluate	O
the	O
efficacy	O
of	O
therapeutics	O
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

RESULTS	O
:	O
Among	O
the	O
received	O
data	O
sets	O
,	O
three	O
employed	O
an	O
in	O
-	O
house	O
-	O
developed	O
real	O
-	O
time	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
assay	O
and	O
the	O
others	O
applied	O
various	O
commercial	O
rRT	O
-	O
PCR	O
kits	O
.	O

Twenty	O
-	O
five	O
percent	O
of	O
patients	O
were	O
treated	O
with	O
neuromuscular	B-PROC
blockade	I-PROC
,	O
10	O
.	O
1	O
%	O
received	O
inhaled	B-PROC
pulmonary	O
vasodilators	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
was	O
initiated	O
in	O
2	O
.	O
6	O
%.	O

We	O
found	O
that	O
IL	B-PROC
-	I-PROC
17	I-PROC
level	O
was	O
elevated	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
of	O
ALI	O
mice	O
.	O

Of	O
note	O
,	O
blockade	O
of	O
IL	B-PROC
-	I-PROC
17	I-PROC
effectively	O
inhibited	O
the	O
lung	O
inflammation	O
and	O
alleviated	O
ALI	O
severity	O
.	O

Finally	O
,	O
we	O
confirmed	O
the	O
clinical	O
relevance	O
and	O
found	O
that	O
IL	B-PROC
-	I-PROC
17	I-PROC
expression	B-PROC
was	O
elevated	O
and	O
associated	O
with	O
the	O
disease	O
severity	O
in	O
patients	O
with	O
ARDS	O
.	O

Gastrointestinal	O
symptoms	O
among	O
fattening	O
pigs	O
were	O
generally	O
mild	O
,	O
quickly	O
resolving	O
and	O
did	O
not	O
lead	O
to	O
death	B-PROC
.	O

For	O
the	O
confirmed	O
cases	O
and	O
death	B-PROC
cases	O
,	O
the	O
median	O
ages	O
were	O
55	O
years	O
and	O
70	O
years	O
respectively	O
,	O
and	O
the	O
cases	O
and	O
deaths	B-PROC
in	O
males	O
accounted	O
for	O
60	O
%	O
and	O
67	O
%	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Thus	O
,	O
monitoring	O
of	O
bovine	O
coronavirus	O
in	O
Ireland	O
is	O
important	O
as	O
the	O
current	O
isolates	O
in	O
circulation	B-PROC
in	O
the	O
south	O
of	O
Ireland	O
may	O
be	O
diverging	O
from	O
the	O
available	O
vaccine	O
strain	O
,	O
which	O
may	O
have	O
implications	O
regarding	O
future	O
BCoV	O
vaccine	O
efficacy	O
.	O

We	O
characterize	O
nonspecific	O
protein	O
adsorption	O
(	O
corona	O
formation	B-PROC
)	O
to	O
membrane	O
-	O
wrapped	O
nanoparticles	O
with	O
core	O
diameters	O
of	O
approximately	O
35	O
and	O
80	O
nm	O
and	O
its	O
effect	O
on	O
the	O
GM3	O
-	O
mediated	O
targeting	B-PROC
efficacy	O
as	O
a	O
function	O
of	O
surface	O
charge	O
through	O
combined	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
.	O

We	O
hypothesised	O
that	O
'	O
failure	O
to	O
rescue	O
'	O
(	O
death	B-PROC
after	O
a	O
complication	O
during	O
an	O
in	O
-	O
hospital	O
stay	O
)	O
may	O
be	O
responsible	O
for	O
part	O
of	O
this	O
variation	O
.	O

The	O
median	O
incubation	O
period	O
was	O
five	O
days	O
,	O
while	O
the	O
median	O
period	O
from	O
symptom	O
onset	O
to	O
death	B-PROC
was	O
12	O
.	O
5	O
days	O
.	O

There	O
were	O
six	O
deaths	B-PROC
(	O
2	O
.	O
4	O
%)	O
and	O
out	O
of	O
them	O
four	O
presented	O
with	O
impaired	O
consciousness	O
(	O
66	O
.	O
6	O
%).	O

RESULTS	O
:	O
Out	O
of	O
254	O
children	O
admitted	O
with	O
dengue	O
fever	B-PROC
,	O
non	O
-	O
severe	O
dengue	O
and	O
severe	O
dengue	O
were	O
seen	O
in	O
62	O
.	O
6	O
%	O
and	O
37	O
.	O
4	O
%	O
respectively	O
.	O

Using	O
specific	O
inhibitors	O
or	O
small	O
-	O
interfering	O
RNA	O
,	O
we	O
confirmed	O
that	O
indirubin	O
derivatives	O
can	O
suppress	O
H9N2	O
-	O
induced	O
cytokines	O
production	O
through	O
MAPKs	O
and	O
STAT3	O
signaling	B-PROC
pathways	B-PROC
.	O

TITLE	O
:	O
High	O
sensitive	O
and	O
direct	O
fluorescence	O
detection	O
of	O
single	O
viral	O
DNA	O
sequences	O
by	O
integration	B-PROC
of	O
double	O
strand	O
probes	O
onto	O
microgels	O
particles	O
.	O

Upon	O
sensing	O
double	O
-	O
stranded	O
RNA	O
,	O
OAS	O
produces	O
2	O
',	O
5	O
'-	O
oligoadenylates	O
(	O
2	O
-	O
5A	O
),	O
which	O
activate	O
RNase	O
L	O
.	O
Murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
[	O
MHV	O
])	O
nonstructural	O
protein	O
2	O
(	O
ns2	O
)	O
is	O
a	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-PROC
(	O
PDE	O
)	O
that	O
cleaves	O
2	O
-	O
5A	O
,	O
thereby	O
antagonizing	O
RNase	O
L	O
activation	O
.	O

Thus	O
,	O
activation	O
of	O
RNase	O
L	O
does	O
not	O
require	O
virus	O
-	O
induced	O
IFN	O
but	O
rather	O
correlates	O
with	O
adequate	O
levels	O
of	O
basal	O
Oas	O
gene	B-PROC
expression	I-PROC
,	O
maintained	O
by	O
basal	O
IFN	O
signaling	B-PROC
.	O

Lung	O
injury	O
scores	O
became	O
more	O
severe	O
with	O
increased	O
dose	O
and	O
time	O
of	O
exposure	O
to	O
LPS	O
without	O
reaching	B-PROC
the	O
level	O
of	O
hyaline	O
membranes	O
formation	B-PROC
.	O

Co	O
-	O
infection	O
caused	O
significantly	O
higher	O
rates	O
of	O
breathing	B-PROC
difficulties	O
,	O
cough	O
,	O
and	O
sore	O
throat	O
than	O
those	O
of	O
single	O
infection	O
with	O
HCoV	O
-	O
NL63	O
and	O
influenza	O
A	O
/	O
H1N1	O
.	O

Newer	O
technology	O
that	O
delinks	O
oxygenation	B-PROC
and	O
ventilation	O
by	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
may	O
lead	O
to	O
ultra	O
-	O
lung	O
protective	O
ventilation	O
,	O
avoidance	O
of	O
endotracheal	O
intubation	O
in	O
some	O
situations	O
,	O
and	O
ambulatory	O
therapies	O
as	O
a	O
bridge	O
to	O
lung	O
transplantation	O
.	O

Compound	O
showed	O
selective	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
thanks	O
to	O
its	O
ability	O
to	O
inhibit	O
the	O
reverse	O
transcriptase	B-PROC
.	O

Stiffening	O
correlated	O
with	O
the	O
cytokines	O
interleukin	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
8	O
,	O
tumor	O
necrosis	B-PROC
factor	O
TNF	O
-	O
α	O
,	O
and	O
IL	O
-	O
10	O
but	O
not	O
with	O
interferon	O
-	O
γ	O
,	O
transforming	O
growth	B-PROC
factor	O
-	O
β	O
,	O
IL	O
-	O
6	O
,	O
or	O
IL	B-PROC
-	I-PROC
17	I-PROC
.	O

In	O
contrast	O
,	O
the	O
measurements	O
of	O
integrin	O
expression	B-PROC
(	O
CD11b	O
,	O
CD11a	O
,	O
CD18	O
,	O
CD49d	O
)	O
and	O
leukocyte	O
-	O
endothelium	O
adhesion	O
showed	O
a	O
weak	O
and	O
slow	O
response	O
after	O
incubation	O
with	O
the	O
sera	O
of	O
patients	O
with	O
ARDS	O
(	O
several	O
hours	O
),	O
suggesting	O
a	O
lesser	O
role	O
of	O
leukocyte	O
adhesiveness	O
compared	O
with	O
leukocyte	O
stiffness	O
in	O
early	O
ARDS	O
.	O

The	O
three	O
patients	O
who	O
died	B-PROC
had	O
a	O
comorbid	O
medical	O
condition	O
.	O

The	O
FR	O
(-	O
9	O
.	O
6	O
%),	O
RR	O
(+	O
9	O
.	O
8	O
%),	O
TB	O
(-	O
1	O
.	O
6	O
),	O
BA	O
(-	O
1	O
.	O
1	O
),	O
WPL	O
(-	O
1	O
.	O
1	O
),	O
sows	O
mated	B-PROC
by	O
7	O
days	O
after	O
weaning	B-PROC
(-	O
6	O
.	O
9	O
%),	O
WFSI	O
(+	O
0	O
.	O
8	O
days	O
),	O
NPDs	O
(+	O
6	O
.	O
9	O
days	O
)	O
and	O
sow	O
culling	O
rate	O
(+	O
7	O
.	O
2	O
%)	O
were	O
significantly	O
different	O
between	O
the	O
1	O
-	O
year	O
pre	O
-	O
PEDV	O
outbreak	O
period	O
and	O
the	O
post	O
-	O
PEDV	O
outbreak	O
period	O
.	O

Collectively	O
,	O
these	O
findings	O
illustrate	O
that	O
sustained	O
CXCL1	O
expression	B-PROC
amplifies	O
the	O
severity	O
of	O
white	O
matter	O
damage	O
and	O
that	O
neutrophils	O
can	O
contribute	O
to	O
this	O
process	O
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
neurologic	O
disease	O
.	O

PEDV	O
nsp1	O
did	O
not	O
interfere	O
the	O
IRF3	O
phosphorylation	B-PROC
and	O
nuclear	B-PROC
translocation	B-PROC
but	O
interrupted	O
the	O
enhanceosome	O
assembly	O
of	O
IRF3	O
and	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
by	O
degrading	O
CBP	O
.	O

Children	O
eligible	O
for	O
enrollment	O
in	O
this	O
study	O
were	O
aged	O
24	O
-	O
59	O
months	O
and	O
presented	O
with	O
acute	O
respiratory	O
symptoms	O
and	O
fever	B-PROC
.	O

Naso	O
-	O
and	O
oropharyngeal	O
swabs	O
were	O
collected	O
and	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
performed	O
to	O
identify	O
the	O
respiratory	O
viruses	O
involved	O
.	O

Ten	O
patients	O
(	O
2	O
%)	O
were	O
diagnosed	O
with	O
pneumonia	O
,	O
and	O
six	O
of	O
these	O
tested	O
positive	O
for	O
viral	B-PROC
infection	I-PROC
(	O
4	O
HRV	O
,	O
1	O
RSV	O
,	O
and	O
1	O
AdV	O
).	O

TITLE	O
:	O
Deciphering	O
MERS	O
-	O
CoV	O
Evolution	B-PROC
in	O
Dromedary	O
Camels	O
.	O

Further	O
research	O
is	O
needed	O
to	O
assess	O
the	O
role	O
of	O
viruses	O
in	O
the	O
pathogenesis	B-PROC
of	O
respiratory	O
symptoms	O
and	O
their	O
potential	O
role	O
in	O
the	O
severity	O
of	O
the	O
symptoms	O
.	O

Results	O
were	O
analysed	O
using	O
a	O
narrative	O
synthesis	B-PROC
.	O

Our	O
study	O
showed	O
an	O
acceptable	O
agreement	O
of	O
P	O
(	O
tcCO2	O
)	O
monitoring	O
with	O
arterial	O
blood	B-PROC
gas	I-PROC
analysis	O
.	O

Particularly	O
,	O
the	O
host	O
pathogen	O
recognition	O
receptors	O
and	O
the	O
signal	B-PROC
transduction	I-PROC
pathways	I-PROC
to	O
mount	O
an	O
effective	O
antiviral	B-PROC
response	I-PROC
against	O
SARS	O
and	O
MERS	O
coronavirus	O
infection	O
are	O
discussed	O
.	O

Thus	O
,	O
antibodies	O
targeting	B-PROC
the	O
HA	O
stem	O
can	O
reduce	O
the	O
severity	O
of	O
ARDS	O
and	O
show	O
promise	O
as	O
agents	O
for	O
controlling	O
pulmonary	O
complications	O
in	O
influenza	O
.	O

Clinical	O
symptoms	O
of	O
ML	O
II	O
are	O
severe	O
psychomotor	O
delay	O
and	O
dysostosis	O
multiplex	O
;	O
death	B-PROC
usually	O
occurs	O
by	O
5	O
-	O
8	O
years	O
of	O
age	O
from	O
cardiopulmonary	O
complications	O
.	O

TITLE	O
:	O
Extensive	O
Positive	O
Selection	O
Drives	O
the	O
Evolution	B-PROC
of	O
Nonstructural	O
Proteins	O
in	O
Lineage	O
C	O
Betacoronaviruses	O
.	O

TITLE	O
:	O
Activity	O
and	O
biophysical	O
inhibition	B-PROC
resistance	B-PROC
of	O
a	O
novel	O
synthetic	O
lung	O
surfactant	O
containing	O
Super	O
-	O
Mini	O
-	O
B	O
DATK	O
peptide	O
.	O

In	O
vivo	O
pulmonary	O
activity	O
of	O
S	O
-	O
MB	O
DATK	O
surfactant	O
was	O
measured	O
in	O
ventilated	O
rabbits	O
with	O
surfactant	O
deficiency	O
/	O
dysfunction	O
induced	O
by	O
repeated	O
lung	O
lavages	O
that	O
resulted	O
in	O
arterial	O
PO2	B-PROC
values	O
<	O
100	O
mmHg	O
.	O

Enzymatic	O
studies	O
showed	O
that	O
RMNC6	O
interferes	O
with	O
efavirenz	O
(	O
an	O
approved	O
NNRTI	O
)	O
in	O
its	O
binding	O
to	O
the	O
RT	O
polymerase	O
domain	O
,	O
although	O
NNRTI	O
resistance	B-PROC
-	O
associated	O
mutations	O
such	O
as	O
K103N	O
,	O
Y181C	O
and	O
Y188L	O
had	O
a	O
minor	O
impact	O
on	O
RT	O
susceptibility	O
to	O
RMNC6	O
.	O

In	O
addition	O
,	O
antibody	B-PROC
neutralization	O
assay	O
and	O
shRNA	O
knockdown	O
experiments	O
indicated	O
a	O
vital	O
role	O
of	O
vimentin	O
in	O
cell	O
binding	O
and	O
uptake	O
of	O
SARS	O
-	O
CoV	O
VLPs	O
and	O
the	O
viral	O
spike	O
protein	O
.	O

Among	O
them	O
46	O
patients	O
survived	O
,	O
and	O
40	O
patients	O
died	B-PROC
.	O

The	O
following	O
clinical	O
data	O
were	O
significantly	O
higher	O
in	O
the	O
death	B-PROC
group	O
than	O
those	O
in	O
the	O
survival	O
group	O
,	O
namely	O
body	O
temperature	O
(	O
centigrade	O
:	O
38	O
.	O
67	O
±	O
1	O
.	O
18	O
vs	O
.	O
37	O
.	O
74	O
±	O
1	O
.	O
18	O
,	O
t	O
=	O
-	O
3	O
.	O
627	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
pulse	B-PROC
(	O
bpm	O
:	O
130	O
.	O
65	O
±	O
15	O
.	O
72	O
vs	O
.	O
107	O
.	O
26	O
±	O
19	O
.	O
61	O
,	O
t	O
'	O
=	O
-	O
6	O
.	O
133	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
the	O
ratio	O
of	O
concomitant	O
chronic	O
lung	O
disease	O
[	O
45	O
.	O
0	O
%	O
(	O
18	O
/	O
40	O
)	O
vs	O
.	O
13	O
.	O
0	O
%	O
(	O
6	O
/	O
46	O
),	O
χ	O
(	O
2	O
)	O
=	O
10	O
.	O
860	O
,	O
P	O
=	O
0	O
.	O
001	O
],	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
[	O
FiO2	O
:	O
0	O
.	O
495	O
(	O
0	O
.	O
410	O
,	O
0	O
.	O
600	O
)	O
vs	O
.	O
0	O
.	O
380	O
(	O
0	O
.	O
290	O
,	O
0	O
.	O
500	O
),	O
Z	O
=	O
-	O
3	O
.	O
265	O
,	O
P	O
=	O
0	O
.	O
001	O
],	O
APACHE	O
II	O
score	O
(	O
25	O
.	O
80	O
±	O
5	O
.	O
07	O
vs	O
.	O
16	O
.	O
39	O
±	O
5	O
.	O
12	O
,	O
t	O
=-	O
8	O
.	O
540	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
CURB	O
-	O
65	O
score	O
[	O
3	O
(	O
3	O
,	O
4	O
)	O
vs	O
.	O
2	O
(	O
1	O
,	O
2	O
),	O
Z	O
=	O
-	O
5	O
.	O
562	O
,	O
P	O
=	O
0	O
.	O
000	O
],	O
MODS	O
score	O
(	O
8	O
.	O
15	O
±	O
2	O
.	O
49	O
vs	O
.	O
4	O
.	O
35	O
±	O
2	O
.	O
01	O
,	O
t	O
=	O
-	O
7	O
.	O
832	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
international	O
normalized	O
ratio	O
[	O
INR	O
:	O
1	O
.	O
22	O
(	O
1	O
.	O
08	O
,	O
1	O
.	O
31	O
)	O
vs	O
.	O
1	O
.	O
07	O
(	O
1	O
.	O
00	O
,	O
1	O
.	O
10	O
),	O
Z	O
=	O
-	O
4	O
.	O
231	O
,	O
P	O
=	O
0	O
.	O
000	O
],	O
and	O
activated	O
partial	O
thromboplastin	O
time	O
[	O
APTT	O
(	O
s	O
):	O
33	O
.	O
80	O
(	O
32	O
.	O
13	O
,	O
38	O
.	O
75	O
)	O
vs	O
.	O
28	O
.	O
50	O
(	O
25	O
.	O
70	O
,	O
36	O
.	O
00	O
),	O
Z	O
=	O
-	O
3	O
.	O
482	O
,	O
P	O
=	O
0	O
.	O
000	O
].	O

""""	O
Oxygenation	B-PROC
parameters	O
were	O
collected	O
at	O
H0	O
,	O
H2	O
,	O
and	O
H14	O
.	O

The	O
normal	O
aspect	O
of	O
the	O
anterobasal	O
regions	O
was	O
significantly	O
associated	O
with	O
the	O
oxygenation	B-PROC
response	O
(	O
P	O
=	O
.	O
0436	O
),	O
with	O
a	O
positive	O
predictive	O
value	O
equal	O
to	O
or	O
near	O
100	O
%.	O

Only	O
7	O
of	O
133	O
acute	O
respiratory	O
distress	O
syndrome	O
cases	O
met	O
criteria	O
for	O
engraftment	B-PROC
syndrome	O
and	O
15	O
for	O
diffuse	O
alveolar	O
hemorrhage	O
.	O

These	O
findings	O
highlight	O
the	O
need	O
to	O
better	O
understand	O
the	O
risk	O
factors	O
underlying	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
this	O
population	O
,	O
thereby	O
facilitating	O
the	O
development	B-PROC
of	O
effective	O
prevention	O
strategies	O
.	O

These	O
findings	O
suggest	O
that	O
CRP	O
may	O
be	O
used	O
as	O
an	O
early	O
indicator	O
to	O
identify	O
high	O
-	O
risk	O
patients	O
,	O
to	O
assess	O
disease	O
progression	O
,	O
and	O
to	O
determine	O
the	O
development	B-PROC
of	O
hypercytokinemia	O
.	O

According	O
to	O
the	O
severity	O
,	O
patients	O
were	O
divided	O
into	O
three	O
groups	O
(	O
Mild	O
group	O
,	O
Moderate	O
group	O
and	O
Severe	O
group	O
);	O
the	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
system	O
II	O
score	O
(	O
APACHE	O
II	O
),	O
the	O
lung	O
injury	O
score	O
(	O
LIS	O
),	O
the	O
pulse	B-PROC
contour	O
curve	O
continuous	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
and	O
other	O
clinical	O
indicators	O
were	O
respectively	O
monitored	O
in	O
the	O
period	O
of	O
24	O
,	O
48	O
,	O
72	O
hrs	O
after	O
admission	O
;	O
then	O
the	O
correlation	O
of	O
EVLWI	O
,	O
PVPI	O
and	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
among	O
groups	O
were	O
analyzed	O
;	O
According	O
to	O
the	O
prognosis	O
,	O
patients	O
were	O
divided	O
into	O
the	O
survival	O
group	O
and	O
the	O
death	B-PROC
group	O
,	O
both	O
given	O
the	O
univariate	O
and	O
multivariate	O
Logistic	O
regression	O
analysis	O
;	O
EVLWI	O
,	O
PVPI	O
,	O
APACHE	O
II	O
score	O
,	O
LIS	O
and	O
lactic	O
acid	O
were	O
admitted	O
into	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
,	O
and	O
the	O
prognosis	O
was	O
evaluated	O
respectively	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
effect	O
of	O
mehanical	O
ventilation	O
(	O
MV	O
)	O
guided	O
by	O
transpulmonary	O
pressure	O
(	O
Ptp	O
)	O
on	O
respiratory	B-PROC
mechanics	I-PROC
and	O
gas	O
exchange	O
in	O
severe	O
acute	O
pancreatitis	O
patient	O
with	O
intraabdominal	O
hypertension	O
.	O

We	O
also	O
limited	O
tidal	O
volume	O
to	O
keep	O
Ptp	O
at	O
less	O
than	O
25	O
cm	O
of	O
water	O
at	O
end	O
inspiration	B-PROC
.	O

Compared	O
with	O
baseline	O
,	O
lung	B-PROC
compliance	I-PROC
(	O
CL	O
)	O
(	O
48	O
.	O
1	O
±	O
10	O
.	O
3	O
)	O
cmH2O	O
vs	O
(	O
25	O
.	O
7	O
±	O
6	O
.	O
4	O
)	O
cmH2O	O
and	O
oxygenation	B-PROC
index	O
(	O
PaO2	O
/	O
FiO2	O
)	O
(	O
235	O
±	O
48	O
)	O
mmHg	O
vs	O
(	O
160	O
±	O
35	O
)	O
mmHg	O
improved	O
obviously	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
dead	B-PROC
space	O
fraction	O
(	O
VD	O
/	O
VT	O
)	O
(	O
0	O
.	O
48	O
±	O
0	O
.	O
07	O
)	O
vs	O
(	O
0	O
.	O
59	O
±	O
0	O
.	O
06	O
)	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
but	O
Ccw	O
and	O
respiratory	O
compliance	O
(	O
Cr	O
)	O
didn	O
'	O
t	O
improve	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

Since	O
pain	O
,	O
agitation	O
and	O
delirium	O
compromise	O
respiratory	B-PROC
function	I-PROC
they	O
should	O
also	O
be	O
regarded	O
during	O
noninvasive	O
ventilation	O
and	O
during	O
ventilator	O
weaning	B-PROC
.	O

Healthy	O
birds	O
from	O
the	O
two	O
lines	O
showed	O
significant	O
differences	O
in	O
expression	B-PROC
profiles	O
for	O
subsets	O
of	O
adaptive	O
and	O
innate	B-PROC
immunity	B-PROC
-	O
related	O
genes	O
,	O
whereas	O
comparison	O
of	O
the	O
IBV	O
-	O
infected	O
birds	O
from	O
the	O
two	O
lines	O
showed	O
differences	O
in	O
expression	B-PROC
of	O
immunity	B-PROC
-	O
related	O
genes	O
involved	O
in	O
T	B-PROC
cell	I-PROC
activation	I-PROC
and	O
proliferation	O
.	O

Two	O
cats	O
showed	O
mild	O
clinical	O
signs	O
,	O
faecal	O
shedding	O
of	O
infectious	O
virus	O
from	O
4	O
dpi	O
,	O
a	O
cell	O
-	O
associated	O
viraemia	O
at	O
inconsistent	O
time	O
points	O
from	O
5	O
dpi	O
,	O
a	O
highly	O
neutralising	O
antibody	B-PROC
response	I-PROC
from	O
9	O
dpi	O
,	O
and	O
no	O
major	O
abnormalities	O
in	O
leukocyte	O
numbers	O
.	O

Two	O
groups	O
of	O
NHPs	O
were	O
treated	O
with	O
either	O
a	O
human	O
anti	O
-	O
MERS	O
monoclonal	O
antibody	B-PROC
3B11	O
-	O
N	O
or	O
E410	O
-	O
N	O
,	O
an	O
anti	O
-	O
HIV	O
antibody	B-PROC
.	O

3B11	O
-	O
N	O
treated	O
subjects	O
developed	O
significantly	O
reduced	O
lung	O
pathology	O
when	O
compared	O
to	O
infected	O
,	O
untreated	O
subjects	O
,	O
indicating	O
that	O
this	O
antibody	B-PROC
may	O
be	O
a	O
suitable	O
MERS	O
-	O
CoV	O
treatment	O
.	O

The	O
model	O
set	O
corresponds	O
to	O
sentinel	O
surveillance	O
complemented	O
by	O
the	O
universal	O
notification	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
investigating	O
outbreaks	O
,	O
deaths	B-PROC
,	O
and	O
unusual	O
events	O
and	O
monitoring	O
hospitalization	O
and	O
mortality	O
in	O
an	O
expanded	O
surveillance	O
.	O

To	O
date	O
,	O
about	O
one	O
in	O
three	O
people	O
died	B-PROC
as	O
a	O
result	O
of	O
MERS	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
pathogenicity	O
differences	O
of	O
the	O
US	O
PEDV	O
prototype	O
and	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
strains	O
in	O
conventional	O
neonatal	O
piglets	O
under	O
experimental	O
infections	O
.	O

Compared	O
with	O
pigs	O
inoculated	O
with	O
the	O
three	O
US	O
PEDV	O
prototype	O
isolates	O
,	O
pigs	O
inoculated	O
with	O
the	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
isolate	O
had	O
significantly	O
diminished	O
clinical	O
signs	O
,	O
virus	O
shedding	O
in	O
faeces	O
,	O
gross	O
lesions	O
in	O
small	O
intestines	O
,	O
caeca	O
and	O
colons	O
,	O
histopathological	O
lesions	O
in	O
small	O
intestines	O
,	O
and	O
immunohistochemistry	O
staining	O
in	O
ileum	O
.	O

A	O
27	O
-	O
year	O
-	O
old	O
male	O
patient	O
was	O
suffering	O
from	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
community	O
-	O
acquired	O
pneumonia	O
and	O
acute	O
myocarditis	O
with	O
circulatory	B-PROC
shock	O
.	O

TITLE	O
:	O
Molecular	O
mechanisms	O
of	O
coronavirus	O
RNA	B-PROC
capping	B-PROC
and	O
methylation	B-PROC
.	O

The	O
injection	O
of	O
a	O
lentiviral	O
vector	O
carrying	O
a	O
minigene	O
encoding	O
for	O
a	O
FXN	O
-	O
specific	O
short	O
hairpin	O
ribonucleic	O
acid	O
(	O
shRNA	O
)	O
into	O
the	O
mouse	O
cerebellar	O
cortex	O
triggers	O
a	O
FXN	O
deficit	O
which	O
is	O
accompanied	O
by	O
significant	O
apoptosis	B-PROC
of	O
granule	O
neurons	O
as	O
well	O
as	O
loss	O
of	O
calbindin	O
in	O
Purkinje	O
cells	O
.	O

The	O
model	O
was	O
designed	O
to	O
capture	O
a	O
)	O
any	O
signal	O
of	O
the	O
serial	O
interval	O
distribution	O
in	O
the	O
initial	O
stochastic	O
phase	O
b	O
)	O
the	O
growth	B-PROC
rate	O
of	O
the	O
exponential	O
phase	O
and	O
c	O
)	O
the	O
unique	O
combination	O
of	O
R0	O
and	O
Tg	O
that	O
generates	O
a	O
specific	O
shape	O
of	O
peak	O
incidence	O
when	O
the	O
susceptible	O
portion	O
of	O
a	O
small	O
population	O
is	O
depleted	O
.	O

Therefore	O
,	O
we	O
developed	O
a	O
demonstrator	O
with	O
an	O
integrated	O
control	O
algorithm	O
to	O
keep	O
continuously	O
measured	O
peripheral	B-PROC
oxygen	I-PROC
saturation	I-PROC
and	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
constant	O
by	O
automatically	O
adjusting	O
extracorporeal	O
blood	O
and	O
gas	O
flow	O
.	O

With	O
decreasing	O
inspiratory	B-PROC
oxygen	O
concentration	O
,	O
extracorporeal	O
oxygen	O
uptake	O
increased	O
from	O
68	O
±	O
25	O
to	O
154	O
±	O
34	O
mL	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
reducing	O
respiratory	O
rate	O
resulted	O
in	O
increasing	O
extracorporeal	O
carbon	O
dioxide	O
elimination	B-PROC
from	O
71	O
±	O
37	O
to	O
92	O
±	O
37	O
mL	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

We	O
previously	O
reported	O
the	O
preparation	O
of	O
a	O
feline	O
TNF	O
-	O
alpha	O
(	O
fTNF	O
-	O
alpha	O
)-	O
neutralizing	O
mouse	O
monoclonal	O
antibody	B-PROC
(	O
anti	O
-	O
fTNF	O
-	O
alpha	O
mAb	O
).	O

These	O
results	O
strongly	O
suggested	O
that	O
the	O
anti	O
-	O
fTNF	O
-	O
alpha	O
antibody	B-PROC
is	O
effective	O
for	O
the	O
treatment	O
of	O
FIP	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
clinical	O
course	O
and	O
outcomes	O
of	O
liver	B-PROC
functions	I-PROC
in	O
children	O
with	O
dengue	O
viral	B-PROC
infection	I-PROC
-	O
caused	O
acute	O
liver	O
failure	O
(	O
ALF	O
),	O
the	O
records	O
of	O
patients	O
aged	O
<	O
15	O
years	O
attending	O
our	O
institution	O
during	O
1989	O
-	O
2011	O
were	O
reviewed	O
.	O

This	O
was	O
followed	O
by	O
quercitrin	O
which	O
could	O
inhibit	O
DENV	O
-	O
2	O
but	O
not	O
MHV	O
,	O
whereas	O
rutin	O
did	O
not	O
exert	B-PROC
any	O
inhibitory	O
effect	O
on	O
either	O
virus	O
.	O

These	O
organotypic	O
human	O
airway	O
cultures	O
represent	O
a	O
universal	O
platform	O
to	O
study	O
respiratory	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
by	O
offering	O
more	O
detailed	O
insights	O
compared	O
to	O
cell	O
lines	O
.	O

A	O
recombinant	O
form	O
of	O
the	O
7b	O
protein	O
was	O
expressed	B-PROC
as	O
a	O
fusion	O
protein	O
in	O
Escherichia	O
coli	O
,	O
purified	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
and	O
used	O
as	O
immunogen	O
.	O

TITLE	O
:	O
Automatically	O
quantifying	O
the	O
scientific	O
quality	O
and	O
sensationalism	O
of	O
news	O
records	O
mentioning	O
pandemics	O
:	O
validating	O
a	O
maximum	O
entropy	O
machine	O
-	O
learning	B-PROC
model	O
.	O

Therapies	O
that	O
expedite	O
IFN	O
I	O
induction	O
as	O
well	O
as	O
interventions	O
that	O
antagonize	O
immunoevasive	O
virus	O
proteins	O
are	O
thus	O
promising	O
candidates	O
for	O
immune	B-PROC
modulation	I-PROC
.	O

TITLE	O
:	O
Classification	O
of	O
Extrapulmonary	O
Manifestations	O
Due	O
to	O
Mycoplasma	O
pneumoniae	O
Infection	O
on	O
the	O
Basis	O
of	O
Possible	O
Pathogenesis	B-PROC
.	O

Blocking	O
the	O
secretion	B-PROC
of	O
M	O
protein	O
by	O
brefeldin	O
A	O
(	O
BFA	O
)	O
failed	O
to	O
reverse	O
the	O
M	O
-	O
mediated	O
IFN	O
-	O
β	O
induction	O
.	O

Except	O
negative	O
result	O
of	O
antibody	B-PROC
test	O
in	O
the	O
well	O
-	O
known	O
""""	O
acute	O
window	O
phase	O
""","	O
in	O
rare	O
cases	O
,	O
patients	O
do	O
not	O
develop	O
HIV	O
antibodies	O
despite	O
demonstrable	O
infection	O
.	O

This	O
case	O
underscores	O
the	O
importance	O
of	O
plasma	O
RNA	O
test	O
in	O
conjunction	O
with	O
HIV	O
antibody	B-PROC
test	O
for	O
some	O
rare	O
patients	O
with	O
HIV	O
infection	O
who	O
present	O
with	O
severe	O
immunodeficiency	O
and	O
opportunistic	O
infections	O
or	O
malignancy	O
.	O

In	O
this	O
issue	O
of	O
Cell	O
Host	O
&	O
Microbe	O
,	O
Channappanavar	O
et	O
al	O
.	O
(	O
2016	O
)	O
use	O
a	O
SARS	O
-	O
coronavirus	O
animal	O
model	O
to	O
describe	O
how	O
rapid	O
and	O
robust	O
virus	B-PROC
replication	I-PROC
with	O
delayed	O
IFN	O
-	O
I	O
can	O
lead	O
to	O
lung	O
immunopathology	O
,	O
with	O
fatal	O
outcomes	O
.	O

Using	O
mice	O
infected	O
with	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)-	O
CoV	O
,	O
we	O
show	O
that	O
robust	O
virus	B-PROC
replication	I-PROC
accompanied	O
by	O
delayed	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
signaling	B-PROC
orchestrates	O
inflammatory	B-PROC
responses	I-PROC
and	O
lung	O
immunopathology	O
with	O
diminished	O
survival	O
.	O

In	O
contrast	O
,	O
we	O
observed	O
that	O
some	O
mutants	O
were	O
more	O
sensitive	O
to	O
3	O
/	O
11	O
or	O
CD81	O
-	O
LEL	O
inhibition	B-PROC
.	O

With	O
the	O
emerging	O
development	B-PROC
of	O
monoclonal	O
antibodies	O
as	O
therapeutics	O
,	O
the	O
potential	O
implications	O
of	O
antibody	B-PROC
-	O
dependent	O
enhancement	O
of	O
disease	O
were	O
also	O
addressed	O
.	O

There	O
are	O
no	O
typical	O
clinical	O
features	O
of	O
malaria	O
;	O
even	O
fever	B-PROC
is	O
not	O
invariably	O
present	O
.	O

Primaquine	O
(	O
for	O
eradication	O
of	O
P	O
.	O
vivax	O
or	O
P	O
.	O
ovale	O
hypnozoites	O
)	O
is	O
contraindicated	O
in	O
pregnancy	O
and	O
when	O
breastfeeding	B-PROC
(	O
until	O
the	O
G6PD	O
status	O
of	O
child	O
is	O
known	O
);	O
after	O
initial	O
treatment	O
for	O
these	O
infections	O
a	O
pregnant	O
woman	O
should	O
take	O
weekly	O
chloroquine	O
prophylaxis	O
until	O
after	O
delivery	O
or	O
cessation	O
of	O
breastfeeding	B-PROC
when	O
hypnozoite	O
eradication	O
can	O
be	O
considered	O
.	O

Among	O
the	O
5550	O
patients	O
admitted	O
during	O
the	O
study	O
periods	B-PROC
,	O
663	O
(	O
11	O
.	O
9	O
%)	O
had	O
SARI	O
.	O

We	O
identified	O
several	O
risk	O
factors	O
for	O
in	O
-	O
hospital	O
death	B-PROC
that	O
may	O
be	O
useful	O
for	O
risk	O
stratification	O
in	O
these	O
patients	O
.	O

Here	O
,	O
we	O
show	O
that	O
TIE2	O
gene	B-PROC
expression	I-PROC
may	O
constitute	O
a	O
novel	O
vascular	O
barrier	O
control	O
mechanism	O
in	O
diverse	O
infections	O
.	O

TITLE	O
:	O
Human	O
polyclonal	O
immunoglobulin	B-PROC
G	O
from	O
transchromosomic	O
bovines	O
inhibits	O
MERS	O
-	O
CoV	O
in	O
vivo	O
.	O

The	O
SARS	O
-	O
CoV	O
M	O
chimera	O
exhibited	O
a	O
conditional	O
growth	B-PROC
defect	O
that	O
was	O
partially	O
suppressed	O
by	O
mutations	O
in	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
.	O

Of	O
>	O
70	O
TRIMs	O
,	O
TRIM56	O
is	O
a	O
restriction	O
factor	O
of	O
several	O
positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
including	O
three	O
members	O
of	O
the	O
family	O
Flaviviridae	O
(	O
yellow	O
fever	B-PROC
virus	O
,	O
dengue	O
virus	O
,	O
and	O
bovine	O
viral	O
diarrhea	O
virus	O
)	O
and	O
a	O
human	O
coronavirus	O
(	O
OC43	O
),	O
and	O
this	O
ability	O
invariably	O
depends	O
upon	O
the	O
E3	O
ligase	O
activity	O
of	O
TRIM56	O
.	O

Moreover	O
,	O
expression	B-PROC
of	O
this	O
short	O
C	O
-	O
terminal	O
segment	O
curtailed	O
the	O
replication	O
of	O
influenza	O
viruses	O
as	O
effectively	O
as	O
that	O
of	O
full	O
-	O
length	O
TRIM56	O
.	O

After	O
3	O
-	O
6	O
hours	O
of	O
induction	O
of	O
ALI	O
by	O
IV	O
endotoxin	O
and	O
mechanical	O
ventilation	O
(	O
MV	O
),	O
young	O
female	O
piglets	O
were	O
allocated	O
to	O
five	O
groups	O
(	O
n	O
=	O
5	O
):	O
ALI	O
-	O
MV	O
,	O
ALI	O
treated	O
with	O
MV	O
;	O
ALI	O
-	O
EC	O
,	O
ALI	O
treated	O
with	O
both	O
MV	O
and	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
;	O
ALI	O
-	O
EC	O
-	O
T	O
,	O
ALI	O
-	O
EC	O
protocol	O
plus	O
intratracheal	O
type	O
II	O
alveolar	O
epithelial	O
cell	O
transplant	O
;	O
CON	O
-	O
MV	O
,	O
healthy	O
animals	O
treated	O
with	O
MV	O
;	O
and	O
CON	O
-	O
EC	O
-	O
T	O
,	O
healthy	O
animals	O
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Conclusions	O
and	O
relevance	O
Once	O
the	O
clinical	O
disease	O
of	O
FIP	O
develops	O
in	O
a	O
cat	O
,	O
it	O
always	O
leads	O
to	O
death	B-PROC
,	O
and	O
most	O
of	O
the	O
cats	O
are	O
euthanased	O
within	O
a	O
few	O
days	O
or	O
weeks	O
.	O

In	O
addition	O
,	O
the	O
antibody	B-PROC
treatment	O
induced	O
a	O
marked	O
reduction	O
in	O
the	O
number	O
of	O
the	O
infected	O
cells	O
at	O
24	O
hours	O
post	O
inoculation	O
,	O
without	O
changing	O
the	O
infected	O
cell	O
numbers	O
during	O
the	O
initial	O
phase	O
of	O
infection	O
.	O

Particulate	O
substances	O
in	O
smoke	O
,	O
toxic	O
and	O
harmful	O
gas	O
,	O
and	O
chemical	O
substances	O
act	O
together	O
would	O
rapidly	O
induce	O
the	O
occurrence	O
of	O
dramatic	O
pathophysiologic	O
reaction	O
in	O
the	O
respiratory	O
tract	O
,	O
resulting	O
in	O
acute	O
injury	O
to	O
the	O
respiratory	O
tract	O
,	O
thus	O
inducing	O
serious	O
injury	O
to	O
it	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
leading	O
to	O
death	B-PROC
of	O
the	O
victims	O
.	O

The	O
availability	O
of	O
recombinant	O
N	O
and	O
M	O
proteins	O
from	O
plants	O
opens	O
the	O
way	O
to	O
further	O
evaluation	O
of	O
their	O
potential	O
utility	O
for	O
the	O
development	B-PROC
of	O
diagnostic	O
and	O
protection	O
/	O
therapy	O
tools	O
to	O
be	O
quickly	O
manufactured	O
,	O
at	O
low	O
cost	O
and	O
with	O
minimal	O
risk	O
,	O
to	O
face	O
potential	O
new	O
highly	O
infectious	O
SARS	O
-	O
CoV	O
outbreaks	O
.	O

ABSTRACT	O
:	O
A	O
clinical	O
trial	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	B-PROC
)	O
as	O
an	O
alternative	O
ventilator	O
tool	O
is	O
being	O
performed	O
as	O
a	O
new	O
indication	O
for	O
ECMO	B-PROC
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
of	O
awake	O
ECMO	O
to	O
increase	O
the	O
success	O
rate	O
of	O
weaning	B-PROC
patients	O
from	O
ECMO	O
and	O
ventilator	O
care	O
during	O
treatment	O
of	O
postoperative	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Awake	O
ECMO	O
was	O
a	O
useful	O
weaning	B-PROC
strategy	O
after	O
severe	O
postoperative	O
ARDS	O
,	O
as	O
it	O
avoids	O
long	O
-	O
duration	O
use	O
of	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
ROS	O
-	O
activated	O
calcium	B-PROC
signaling	I-PROC
mechanisms	O
regulating	O
endothelial	O
barrier	O
function	O
.	O

ABSTRACT	O
:	O
Increased	B-PROC
vascular	I-PROC
permeability	I-PROC
is	O
a	O
common	O
pathogenic	O
feature	O
in	O
many	O
inflammatory	O
diseases	O
.	O

The	O
reproduction	B-PROC
number	O
,	O
that	O
is	O
,	O
the	O
average	O
number	O
of	O
secondary	O
cases	O
produced	O
by	O
a	O
single	O
primary	O
case	O
,	O
was	O
estimated	O
as	O
a	O
function	O
of	O
time	O
and	O
according	O
to	O
different	O
types	O
of	O
hosts	O
.	O

Budesonide	O
was	O
given	O
orally	O
at	O
a	O
daily	O
dose	O
of	O
0	O
.	O
25	O
g	O
,	O
and	O
salmeterol	O
was	O
inhaled	B-PROC
at	O
a	O
dose	O
of	O
4	O
.	O
5	O
µg	O
for	O
3	O
times	O
per	O
day	O
.	O

One	O
patient	O
died	B-PROC
of	O
heart	O
failure	O
during	O
the	O
treatment	O
,	O
the	O
other	O
6	O
patients	O
were	O
alive	O
and	O
the	O
pulmonary	B-PROC
function	I-PROC
parameters	O
including	O
FEV1	O
,	O
FEV1	O
/	O
FVC	B-PROC
,	O
PaO2	O
and	O
AaDO2	O
were	O
significantly	O
improved	O
after	O
6	O
months	O
as	O
compared	O
with	O
the	O
baseline	O
parameters	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Clarification	O
of	O
Interaction	O
Mechanism	O
of	O
Mouse	O
Hepatitis	O
Virus	O
(	O
MHV	O
)	O
N	O
and	O
nsp3	O
Protein	O
with	O
Homology	O
Modeling	O
and	O
Protein	O
-	O
Protein	O
Docking	B-PROC
Analysis	O
.	O

Positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
with	O
lung	O
recruitment	O
maneuvers	O
has	O
also	O
been	O
found	O
to	O
be	O
helpful	O
.	O

We	O
hypothesized	O
that	O
endothelial	O
activation	O
biomarkers	O
would	O
be	O
differentially	O
expressed	B-PROC
in	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
patients	O
with	O
ARDS	O
compared	O
with	O
healthy	O
volunteers	O
,	O
and	O
that	O
biomarker	O
concentrations	O
would	O
be	O
associated	O
with	O
ARDS	O
severity	O
.	O

TITLE	O
:	O
Sharing	O
experiences	O
from	O
a	O
reference	O
laboratory	O
in	O
the	O
public	O
health	O
response	O
for	O
Ebola	O
viral	B-PROC
disease	I-PROC
,	O
MERS	O
-	O
CoV	O
and	O
H7N9	O
influenza	O
virus	O
investigations	O
.	O

TITLE	O
:	O
Early	O
prediction	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
eligibility	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
adults	O
.	O

TITLE	O
:	O
Spatial	O
Configuration	O
and	O
Three	O
-	O
Dimensional	O
Conformation	O
Directed	O
Design	O
,	O
Synthesis	B-PROC
,	O
Antiviral	O
Activity	O
,	O
and	O
Structure	O
-	O
Activity	O
Relationships	O
of	O
Phenanthroindolizidine	O
Analogues	O
.	O

No	O
consensus	O
was	O
found	O
regarding	O
the	O
use	O
of	O
oral	O
versus	O
inhaled	B-PROC
RBV	O
,	O
or	O
the	O
use	O
of	O
IVIG	O
.	O

A	O
20	O
-	O
year	O
-	O
old	O
girl	O
from	O
Pakistan	O
presented	O
for	O
acute	O
fatigue	O
,	O
fever	B-PROC
,	O
and	O
cough	O
with	O
a	O
chest	O
X	O
-	O
ray	O
displayed	O
the	O
micronodular	O
interstitial	O
disease	O
.	O

Additionally	O
,	O
lipid	O
rafts	O
act	O
as	O
signal	O
platforms	O
for	O
the	O
EGFR	O
-	O
associated	O
signaling	B-PROC
cascade	I-PROC
and	O
correlate	O
with	O
the	O
adhesion	O
of	O
TGEV	O
.	O

Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
known	O
to	O
cause	O
severe	O
acute	O
respiratory	O
illness	O
associated	O
with	O
a	O
high	O
risk	O
of	O
mortality	O
Various	O
factors	O
may	O
have	O
contributed	O
to	O
the	O
successful	O
outcome	O
of	O
this	O
patient	O
such	O
as	O
young	O
age	O
,	O
presentation	O
during	O
the	O
last	O
stages	O
of	O
pregnancy	O
,	O
and	O
possible	O
differences	O
in	O
immune	B-PROC
response	I-PROC
.	O

All	O
patients	O
experienced	O
significant	O
improvements	O
in	O
arterial	O
oxygenation	B-PROC
on	O
VV	O
-	O
ECMO	O
.	O

TITLE	O
:	O
Prophylaxis	O
With	O
a	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
Specific	O
Human	O
Monoclonal	O
Antibody	B-PROC
Protects	O
Rabbits	O
From	O
MERS	O
-	O
CoV	O
Infection	O
.	O

m336	O
was	O
administered	O
to	O
rabbits	O
intravenously	O
or	O
intranasally	O
before	O
infection	O
with	O
MERS	O
-	O
CoV	O
.	O
Prophylaxis	O
with	O
m336	O
resulted	O
in	O
a	O
reduction	O
of	O
pulmonary	O
viral	O
RNA	O
titers	O
by	O
40	O
-	O
9000	O
-	O
fold	O
,	O
compared	O
with	O
an	O
irrelevant	O
control	O
antibody	B-PROC
with	O
little	O
to	O
no	O
inflammation	O
or	O
viral	O
antigen	O
detected	O
.	O

In	O
this	O
study	O
,	O
some	O
analogues	O
of	O
MAS0	O
were	O
rationally	O
selected	O
by	O
docking	B-PROC
studies	O
and	O
evaluated	O
in	O
vitro	O
for	O
their	O
ability	O
to	O
disrupt	O
dimeric	O
assembly	O
.	O

Structural	O
analysis	O
,	O
consistent	O
with	O
biochemical	O
inhibition	B-PROC
results	O
,	O
reveals	O
the	O
molecular	O
mechanism	O
of	O
enzyme	B-PROC
inhibition	I-PROC
at	O
the	O
highly	O
conservative	O
substrate	O
-	O
recognition	O
pocket	O
.	O

TITLE	O
:	O
Guillain	O
-	O
Barré	O
Syndrome	O
outbreak	O
associated	O
with	O
Zika	O
virus	B-PROC
infection	I-PROC
in	O
French	O
Polynesia	O
:	O
a	O
case	O
-	O
control	O
study	O
.	O

Patients	O
with	O
Guillain	O
-	O
Barré	O
syndrome	O
had	O
electrophysiological	O
findings	O
compatible	O
with	O
acute	O
motor	O
axonal	O
neuropathy	O
(	O
AMAN	O
)	O
type	O
,	O
and	O
had	O
rapid	O
evolution	B-PROC
of	O
disease	O
(	O
median	O
duration	O
of	O
the	O
installation	O
and	O
plateau	O
phases	O
was	O
6	O
[	O
IQR	O
4	O
-	O
9	O
]	O
and	O
4	O
days	O
[	O
3	O
-	O
10	O
],	O
respectively	O
).	O

Treatment	O
with	O
intravenous	O
immunoglobulin	B-PROC
or	O
plasma	O
exchange	O
is	O
the	O
optimal	O
management	O
approach	O
,	O
alongside	O
supportive	O
care	O
.	O

After	O
establishment	O
of	O
mice	O
model	O
,	O
we	O
observed	O
the	O
clinical	O
signs	O
of	O
disease	O
,	O
virus	B-PROC
replication	I-PROC
,	O
immunopathogenesis	O
and	O
antibody	B-PROC
response	I-PROC
.	O

In	O
summary	O
,	O
the	O
MERS	O
-	O
CoV	O
infected	O
mice	O
model	O
were	O
established	O
prior	O
transduction	B-PROC
with	O
DPP4	O
,	O
and	O
the	O
level	O
of	O
DPP4	O
influenced	O
the	O
clinical	O
signs	O
of	O
disease	O
,	O
virus	B-PROC
replication	I-PROC
and	O
antibody	B-PROC
response	I-PROC
in	O
this	O
model	O
.	O

ABSTRACT	O
:	O
Ebola	O
virus	B-PROC
infection	I-PROC
can	O
cause	O
severe	O
hemorrhagic	O
fever	B-PROC
with	O
a	O
high	O
mortality	O
in	O
humans	O
.	O

The	O
development	B-PROC
of	O
additional	O
effective	O
anti	O
-	O
Ebola	O
therapeutic	O
agents	O
is	O
therefore	O
quite	O
urgent	O
.	O

Two	O
CD8	O
(+)	O
T	O
cell	O
responses	O
targeting	B-PROC
the	O
SARS	O
-	O
CoV	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
were	O
characterized	O
by	O
determining	O
their	O
HLA	O
restriction	O
and	O
minimal	O
T	O
cell	O
epitope	O
regions	O
.	O

All	O
patients	O
who	O
were	O
admitted	O
to	O
our	O
medical	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
who	O
are	O
positive	O
for	O
H1N1	O
viral	B-PROC
infection	I-PROC
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
requiring	O
invasive	O
mechanical	O
ventilation	O
in	O
prone	O
position	O
were	O
included	O
in	O
our	O
prospective	O
observational	O
study	O
.	O

Recombination	B-PROC
analysis	O
indicated	O
that	O
strain	O
GD	O
was	O
a	O
chimera	O
whose	O
putative	O
parental	O
strains	O
belonged	O
to	O
the	O
QX	O
-	O
and	O
TW	O
-	O
type	O
subgroups	O
.	O

Coronavirus	O
RNA	B-PROC
synthesis	I-PROC
is	O
connected	O
with	O
the	O
formation	B-PROC
of	O
double	O
-	O
membrane	O
vesicles	O
and	O
convoluted	O
membranes	O
.	O

Hypothermia	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
short	O
-	O
term	O
mortality	O
,	O
whereas	O
patients	O
with	O
fever	B-PROC
were	O
associated	O
with	O
a	O
lower	O
risk	O
compared	O
to	O
those	O
with	O
normothermia	O
.	O

Compared	O
to	O
normothermic	O
patients	O
,	O
the	O
adjusted	O
hazard	O
ratio	O
of	O
30	O
-	O
day	O
mortality	O
among	O
hypothermic	O
patients	O
was	O
1	O
.	O
62	O
(	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
2	O
.	O
49	O
)	O
and	O
0	O
.	O
74	O
(	O
95	O
%	O
CI	O
0	O
.	O
58	O
-	O
0	O
.	O
94	O
)	O
among	O
patients	O
with	O
fever	B-PROC
.	O

Child	O
was	O
diagnosed	O
as	O
GBS	O
and	O
treated	O
with	O
intravenous	O
immunoglobulin	B-PROC
.	O

The	O
inbreeding	B-PROC
experiment	O
began	O
with	O
a	O
genetically	O
related	O
parental	O
(	O
P	O
)	O
population	O
consisting	O
of	O
three	O
toms	O
and	O
four	O
queens	O
identified	O
from	O
among	O
the	O
survivors	O
of	O
the	O
earlier	O
study	O
and	O
belonging	O
to	O
a	O
closely	O
related	O
subgroup	O
(	O
B	O
).	O

The	O
common	O
genetic	O
factor	O
associated	O
with	O
this	O
diminished	O
resistance	B-PROC
was	O
a	O
loss	B-PROC
of	I-PROC
heterozygosity	I-PROC
.	O

The	O
rapid	O
development	B-PROC
of	O
bilateral	O
consolidations	O
within	O
10	O
days	O
after	O
illness	O
onset	O
were	O
the	O
most	O
common	O
radiographic	O
finding	O
,	O
usually	O
accompanied	O
by	O
adjacent	O
ground	O
glass	O
opacities	O
and	O
pleural	O
effusions	O
.	O

To	O
evaluate	O
PEDV	O
viability	O
over	O
time	O
,	O
ingredients	O
were	O
organized	O
into	O
1	O
of	O
4	O
batches	O
of	O
samples	O
,	O
each	O
batch	O
representing	O
a	O
specific	O
segment	O
of	O
transport	B-PROC
.	O

TITLE	O
:	O
Disseminated	O
tuberculosis	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
lacking	O
granuloma	B-PROC
formation	I-PROC
in	O
the	O
lung	O
.	O

TITLE	O
:	O
Avian	O
Influenza	O
Viruses	O
,	O
Inflammation	O
,	O
and	O
CD8	O
(+)	O
T	O
Cell	O
Immunity	B-PROC
.	O

Ongoing	O
circulation	B-PROC
of	O
H5N1	O
and	O
H7N9	O
viruses	O
in	O
wild	O
birds	O
and	O
poultry	O
,	O
and	O
their	O
ability	O
to	O
infect	O
humans	O
emphasizes	O
their	O
epidemic	O
and	O
pandemic	O
potential	O
and	O
poses	O
a	O
public	O
health	O
threat	O
.	O

It	O
is	O
,	O
thus	O
,	O
imperative	O
to	O
understand	O
the	O
host	O
immune	B-PROC
responses	I-PROC
to	O
the	O
AIVs	O
so	O
we	O
can	O
control	O
severe	O
influenza	O
disease	O
caused	O
by	O
H5N1	O
or	O
H7N9	O
and	O
rationally	O
design	O
new	O
immunotherapies	O
and	O
vaccines	O
.	O

Importantly	O
,	O
available	O
SARS	O
monoclonal	O
antibodies	O
offered	O
success	O
in	O
limiting	O
viral	B-PROC
infection	I-PROC
absent	O
from	O
available	O
vaccine	O
approaches	O
.	O

A	O
mathematical	O
model	O
for	O
MERS	O
-	O
CoV	O
transmission	O
dynamics	O
is	O
used	O
to	O
estimate	O
the	O
transmission	O
rates	O
in	O
two	O
periods	B-PROC
due	O
to	O
the	O
implementation	O
of	O
intensive	O
interventions	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
porcine	O
neonatal	O
Fc	O
receptor	O
(	O
pFcRn	O
)	O
was	O
expressed	B-PROC
in	O
a	O
model	O
of	O
normal	O
porcine	O
intestinal	O
epithelial	O
cells	O
(	O
IPEC	O
-	O
J2	O
)	O
as	O
well	O
as	O
in	O
kidney	O
cells	O
(	O
PK	O
-	O
15	O
),	O
and	O
pFcRn	O
was	O
mainly	O
distributed	O
in	O
the	O
apical	O
side	O
of	O
the	O
polarized	O
IPEC	O
-	O
J2	O
cells	O
.	O

We	O
also	O
showed	O
that	O
pFcRn	O
mediated	O
bidirectional	O
IgG	O
transport	B-PROC
across	O
polarized	O
IPEC	O
-	O
J2	O
cells	O
and	O
bound	O
to	O
IgG	O
in	O
a	O
pH	O
-	O
dependent	O
manner	O
.	O

The	O
development	B-PROC
of	O
a	O
framework	O
for	O
graduate	O
competencies	O
in	O
PH	O
was	O
perceived	O
to	O
be	O
a	O
top	O
priority	O
.	O

The	O
issue	O
was	O
addressed	O
by	O
comparing	O
the	O
effects	O
on	O
lung	B-PROC
function	I-PROC
of	O
CMV	O
and	O
HFJV	O
in	O
two	O
rabbit	O
models	O
of	O
neonatal	O
acute	O
lung	O
injury	O
:	O
repetitive	O
saline	O
lung	O
lavage	O
(	O
LAV	O
)	O
and	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	O
)	O
induced	O
by	O
intratracheal	O
meconium	O
instillation	O
.	O

We	O
recommend	O
against	O
the	O
routine	O
use	O
of	O
other	O
drugs	O
,	O
including	O
corticosteroids	O
,	O
beta2	O
agonists	O
,	O
statins	O
,	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
or	O
prostanoids	O
in	O
adults	O
with	O
ARDS	O
(	O
strong	O
recommendations	O
:	O
low	O
-	O
to	O
high	O
-	O
quality	O
evidence	O
).	O

TITLE	O
:	O
Microbiological	O
characterization	O
of	O
a	O
newly	O
established	O
pig	O
breed	B-PROC
,	O
Aachen	O
Minipigs	O
.	O

ABSTRACT	O
:	O
The	O
proteasome	B-PROC
inhibitor	O
bortezomib	O
is	O
indicated	O
for	O
use	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
(	O
MM	O
)	O
patients	O
.	O

One	O
of	O
the	O
driving	O
features	O
in	O
the	O
pathogenesis	B-PROC
of	O
ARDS	O
is	O
the	O
accumulation	O
of	O
fluid	O
in	O
the	O
alveoli	O
,	O
which	O
causes	O
severe	O
pulmonary	O
edema	O
and	O
impaired	O
oxygen	O
uptake	O
.	O

Inhibition	B-PROC
of	O
the	O
TRAIL	O
signaling	B-PROC
pathway	I-PROC
has	O
been	O
shown	O
to	O
improve	O
lung	O
injury	O
after	O
influenza	O
infection	O
,	O
and	O
future	O
studies	O
will	O
be	O
needed	O
to	O
determine	O
if	O
blocking	O
this	O
pathway	B-PROC
is	O
a	O
viable	O
option	O
in	O
the	O
treatment	O
of	O
ARDS	O
.	O

In	O
patients	O
recovering	O
from	O
ARDS	O
undergoing	O
ECMO	O
,	O
the	O
amount	O
of	O
carbon	O
dioxide	O
removed	O
by	O
the	O
artificial	O
lung	O
may	O
influence	O
spontaneous	O
breathing	B-PROC
.	O

ABSTRACT	O
:	O
Endothelial	O
Specific	O
Molecule	O
-	O
1	O
or	O
endocan	O
is	O
a	O
novel	O
biomarker	O
associated	O
with	O
the	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
response	O
to	O
a	O
systemic	O
inflammatory	O
state	O
such	O
as	O
trauma	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
inhibited	O
by	O
71	O
%	O
(	O
55	O
-	O
94	O
)	O
fibrocyte	O
differentiation	B-PROC
compared	O
to	O
saline	O
control	O
.	O

Ventilated	O
controls	O
'	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
was	O
a	O
less	O
potent	O
inhibitor	O
(	O
51	O
%	O
[	O
23	O
-	O
66	O
%]	O
of	O
inhibition	B-PROC
),	O
whereas	O
non	O
-	O
ventilated	O
controls	O
'	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
had	O
no	O
effect	O
on	O
fibrocyte	O
differentiation	B-PROC
.	O

Patients	O
with	O
ARDS	O
treated	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
also	O
benefit	O
from	O
prone	O
positioning	O
;	O
however	O
,	O
the	O
procedure	O
is	O
associated	O
with	O
a	O
possible	O
higher	O
risk	O
of	O
serious	O
adverse	O
events	O
.	O

A	O
specific	O
mutation	O
within	O
zinc	O
finger	O
1	O
(	O
ZF	O
-	O
C	O
)	O
led	O
to	O
production	O
of	O
a	O
viable	O
virus	O
with	O
growth	B-PROC
and	O
viral	O
RNA	B-PROC
synthesis	I-PROC
kinetics	O
similar	O
to	O
that	O
of	O
the	O
parental	O
virus	O
.	O

The	O
expression	B-PROC
of	O
beta	O
interferon	O
(	O
IFN	O
-	O
β	O
),	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
),	O
and	O
interferon	O
-	O
stimulated	O
genes	O
in	O
cells	O
infected	O
with	O
mutant	O
rTGEV	O
-	O
ZF	O
-	O
C	O
was	O
reduced	O
compared	O
to	O
the	O
levels	O
seen	O
with	O
the	O
parental	O
virus	O
.	O

Overall	O
,	O
our	O
data	O
revealed	O
a	O
potential	O
role	O
for	O
CoV	O
nsp14	O
in	O
modulation	O
of	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

CoVs	O
have	O
evolved	O
several	O
mechanisms	O
to	O
counteract	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
at	O
different	O
levels	O
,	O
but	O
the	O
role	O
of	O
CoV	O
-	O
encoded	O
ribonucleases	O
in	O
preventing	O
activation	O
of	O
the	O
dsRNA	O
-	O
induced	O
antiviral	B-PROC
response	I-PROC
has	O
not	O
been	O
described	O
to	O
date	O
.	O

We	O
expect	O
to	O
see	O
further	O
pathophysiological	O
data	O
and	O
the	O
development	B-PROC
of	O
novel	O
treatments	O
for	O
SAD	O
now	O
that	O
reliable	O
and	O
consistent	O
definitions	O
of	O
SAD	O
have	O
been	O
established	O
.	O

The	O
recombinant	O
Lactobacillus	O
elicited	O
specific	O
systemic	O
and	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
.	O

However	O
,	O
during	O
TGEV	O
infection	O
,	O
the	O
systemic	O
and	O
local	O
immune	B-PROC
responses	I-PROC
switched	O
from	O
Th1	O
to	O
Th2	O
-	O
based	O
immune	B-PROC
responses	I-PROC
.	O

Activated	O
RNase	O
L	O
cleaves	O
viral	O
and	O
host	O
single	O
-	O
stranded	O
RNA	O
(	O
ssRNA	O
),	O
which	O
leads	O
to	O
translational	B-PROC
arrest	O
and	O
subsequent	O
cell	B-PROC
death	I-PROC
,	O
preventing	O
viral	B-PROC
replication	I-PROC
and	O
spread	O
.	O

Here	O
we	O
report	O
that	O
MERS	O
-	O
CoV	O
,	O
a	O
lineage	O
CBetacoronavirus	O
,	O
and	O
related	O
bat	O
CoV	O
NS4b	O
accessory	O
proteins	O
have	O
phosphodiesterase	B-PROC
(	O
PDE	O
)	O
activity	O
and	O
antagonize	O
OAS	O
-	O
RNase	O
L	O
by	O
enzymatically	O
degrading	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
),	O
activators	O
of	O
RNase	O
L	O
.	O
This	O
is	O
a	O
novel	O
function	O
for	O
NS4b	O
,	O
which	O
has	O
previously	O
been	O
reported	O
to	O
antagonize	O
IFN	O
signaling	B-PROC
.	O

Our	O
report	O
may	O
offer	O
a	O
potential	O
target	O
for	O
therapeutic	O
intervention	O
if	O
NS4b	O
proves	O
to	O
be	O
critical	O
to	O
pathogenesis	B-PROC
inin	O
vivomodels	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

This	O
dynamic	O
nature	O
of	O
coronaviruses	O
may	O
facilitate	O
cross	O
-	O
species	O
transmission	O
and	O
shifts	O
in	O
tissue	O
or	O
cell	O
tropism	B-PROC
in	O
a	O
host	O
,	O
resulting	O
in	O
substantial	O
change	O
in	O
virulence	B-PROC
.	O

Selective	O
autophagy	B-PROC
of	O
mitochondria	O
(	O
mitophagy	B-PROC
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
quality	O
control	O
of	O
mitochondria	O
and	O
maintenance	O
of	O
cell	O
homeostasis	B-PROC
.	O

Furthermore	O
,	O
TGEV	O
replication	O
was	O
inhibited	O
when	O
autophagy	B-PROC
was	O
activated	O
by	O
rapamycin	O
.	O

The	O
antiviral	B-PROC
response	I-PROC
of	O
autophagy	B-PROC
was	O
confirmed	O
by	O
using	O
siRNA	O
to	O
reduce	O
the	O
expression	B-PROC
of	O
gene	O
p300	O
,	O
which	O
otherwise	O
inhibits	O
autophagy	B-PROC
.	O

Thus	O
,	O
the	O
FPs	O
of	O
3	O
different	O
lineages	O
of	O
β	O
-	O
CoVs	O
are	O
conserved	O
in	O
location	O
within	O
the	O
S	O
glycoproteins	O
and	O
in	O
their	O
functions	O
,	O
although	O
their	O
amino	O
acid	O
sequences	O
have	O
diverged	O
significantly	O
during	O
CoV	O
evolution	B-PROC
.	O

The	O
disease	O
rapidly	O
progressed	O
to	O
severe	O
pneumonia	O
,	O
multiple	O
organ	O
dysfunctions	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
the	O
patient	O
died	B-PROC
on	O
6	O
February	O
.	O

On	O
initial	O
evaluation	O
,	O
he	O
complained	O
of	O
dyspnea	O
and	O
was	O
afebrile	O
with	O
a	O
pulse	B-PROC
rate	I-PROC
,	O
blood	B-PROC
pressure	I-PROC
,	O
and	O
respiratory	O
rate	O
of	O
105	O
beats	O
/	O
min	O
,	O
112	O
/	O
98mmHg	O
,	O
and	O
28	O
breath	O
/	O
min	O
,	O
respectively	O
.	O

Thus	O
,	O
vaccination	O
with	O
S1	O
subunit	O
vaccine	O
failed	O
to	O
provide	O
complete	O
protection	O
to	O
suckling	O
piglets	O
after	O
challenge	O
exposure	O
,	O
and	O
further	O
improvements	O
are	O
needed	O
for	O
the	O
development	B-PROC
of	O
a	O
subunit	O
vaccine	O
that	O
fully	O
protects	O
against	O
PEDV	O
infection	O
.	O

Thirty	O
minutes	O
after	O
the	O
start	O
of	O
the	O
transfusion	O
,	O
bradycardia	O
and	O
dyspnea	O
appeared	O
,	O
quickly	O
followed	O
by	O
chills	O
,	O
nausea	O
,	O
vomiting	O
,	O
headache	O
,	O
and	O
hyperthermia	B-PROC
.	O

Three	O
groups	O
of	O
PEDV	O
-	O
negative	O
,	O
3	O
-	O
week	O
-	O
old	O
pigs	O
(	O
five	O
pigs	O
per	O
group	O
)	O
were	O
inoculated	O
orally	O
with	O
a	O
U	O
.	O
S	O
.	O
PEDV	O
prototype	O
isolate	O
(	O
previously	O
isolated	O
in	O
our	O
lab	O
),	O
an	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
isolate	O
or	O
virus	O
-	O
negative	O
culture	O
medium	O
.	O

These	O
data	O
indicate	O
that	O
the	O
antibodies	O
against	O
U	O
.	O
S	O
.	O
PEDV	O
prototype	O
and	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
strains	O
cross	O
-	O
reacted	O
and	O
cross	O
-	O
neutralized	O
both	O
strains	O
in	O
vitro	O
.	O

However	O
,	O
less	O
is	O
known	O
about	O
the	O
effect	O
of	O
ECLS	O
on	O
hemodynamic	B-PROC
measurements	O
.	O

In	O
the	O
present	O
work	O
,	O
the	O
influence	O
of	O
single	O
-	O
site	O
low	O
-	O
flow	O
veno	O
-	O
venous	O
ECLS	O
(	O
LFVV	O
-	O
ECLS	O
)	O
on	O
hemodynamic	B-PROC
monitoring	O
by	O
transpulmonary	O
thermodilution	O
(	O
TPTD	O
)	O
was	O
prospectively	O
investigated	O
.	O

TITLE	O
:	O
Does	O
Circulating	O
Antibody	B-PROC
Play	O
a	O
Role	O
in	O
the	O
Protection	O
of	O
Piglets	O
against	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
?	O

The	O
data	O
were	O
evaluated	O
for	O
the	O
effects	O
of	O
systemic	O
PEDV	O
antibody	B-PROC
levels	O
on	O
growth	B-PROC
,	O
body	O
temperature	O
,	O
fecal	O
shedding	O
,	O
survival	O
,	O
and	O
antibody	B-PROC
response	I-PROC
.	O

When	O
combined	O
with	O
previous	O
literature	O
on	O
PEDV	O
,	O
it	O
can	O
be	O
concluded	O
that	O
both	O
systemic	O
antibodies	O
and	O
maternal	O
secretory	B-PROC
IgA	O
in	O
milk	O
contribute	O
to	O
the	O
protection	O
of	O
the	O
neonatal	O
pig	O
against	O
PEDV	O
infections	O
.	O

We	O
could	O
not	O
verify	O
the	O
virus	O
itself	O
by	O
in	O
situ	O
hybridization	B-PROC
and	O
confocal	O
microscopy	O
(	O
MERS	O
-	O
CoV	O
co	O
-	O
stained	O
with	O
dipeptidyl	O
peptidase	O
4	O
).	O

The	O
viremic	O
status	O
,	O
urinary	O
virus	O
excretion	B-PROC
,	O
and	O
timely	O
kidney	O
biopsy	O
results	O
should	O
be	O
investigated	O
with	O
thorough	O
precautions	O
to	O
reveal	O
the	O
direct	O
effects	O
of	O
MERS	O
-	O
CoV	O
with	O
respect	O
to	O
renal	O
complications	O
.	O

TITLE	O
:	O
Assessment	O
of	O
the	O
effects	O
of	O
inspiratory	B-PROC
load	O
on	O
right	B-PROC
ventricular	I-PROC
function	I-PROC
.	O

Pulse	B-PROC
pressure	I-PROC
variations	O
,	O
central	O
venous	B-PROC
pressure	I-PROC
and	O
especially	O
echocardiography	O
may	O
monitor	O
RV	O
function	O
in	O
abnormal	O
clinical	O
situations	O
.	O

CONCLUSIONS	O
:	O
Our	O
experience	O
showed	O
that	O
NAVA	O
improved	O
not	O
only	O
patient	O
-	O
ventilator	O
synchrony	O
but	O
also	O
regional	O
ventilation	O
distribution	O
in	O
an	O
acute	O
respiratory	O
distress	O
patient	O
with	O
sustained	O
low	O
lung	B-PROC
compliance	I-PROC
.	O

Arterial	O
blood	B-PROC
gas	I-PROC
and	O
ventilator	O
setting	O
on	O
Days	O
0	O
and	O
1	O
were	O
obtained	O
.	O

Inhospital	O
complications	O
,	O
including	O
single	O
/	O
multiple	O
organ	O
failure	O
,	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
,	O
sepsis	O
,	O
pneumonia	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
showed	O
no	O
significant	O
differences	O
.	O

This	O
result	O
indicated	O
that	O
the	O
functional	O
constraints	O
on	O
F	O
and	O
N	O
genes	O
prevent	O
dramatic	O
aminoacid	O
changes	O
,	O
and	O
indicated	O
that	O
the	O
evolution	B-PROC
of	O
HMPV	O
was	O
slow	O
.	O

In	O
this	O
study	O
,	O
coronavirus	O
sequences	O
were	O
detected	O
using	O
a	O
nested	O
RT	O
-	O
PCR	O
targeting	B-PROC
440	O
bp	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
in	O
six	O
of	O
79	O
fecal	O
samples	O
collected	O
from	O
an	O
urban	O
colony	O
of	O
E	O
.	O
helvum	O
in	O
Ibadan	O
,	O
Nigeria	O
.	O

ABSTRACT	O
:	O
Porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
(	O
PRRS	O
)	O
and	O
porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
)	O
are	O
two	O
diseases	O
costly	O
to	O
the	O
U	O
.	O
S	O
.	O
swine	O
industry	O
.	O

Several	O
decades	O
of	O
advances	O
in	O
acute	O
management	O
and	O
treatment	O
,	O
as	O
well	O
as	O
better	O
understanding	O
of	O
approaches	O
to	O
ventilation	O
,	O
oxygenation	B-PROC
,	O
and	O
surfactant	O
regulation	B-PROC
have	O
contributed	O
to	O
improvements	O
in	O
patient	O
recovery	O
.	O

Using	O
the	O
equine	O
arteritis	O
virus	O
(	O
EAV	O
)	O
model	O
system	O
and	O
electron	O
tomography	O
,	O
we	O
present	O
new	O
data	O
regarding	O
the	O
biogenesis	B-PROC
of	O
arterivirus	O
-	O
induced	O
DMVs	O
and	O
uncover	O
numerous	O
putative	O
intermediates	O
in	O
DMV	O
formation	B-PROC
.	O

We	O
generated	O
cell	O
lines	O
that	O
can	O
be	O
induced	O
to	O
express	O
specific	O
EAV	O
replicase	O
proteins	O
and	O
showed	O
that	O
DMVs	O
induced	O
by	O
the	O
transmembrane	O
proteins	O
nsp2	O
and	O
nsp3	O
form	O
an	O
RVN	O
and	O
are	O
comparable	O
in	O
topology	O
and	O
architecture	O
to	O
those	O
formed	O
during	O
viral	B-PROC
infection	I-PROC
.	O

Utilizing	O
direct	O
medical	O
oversight	O
and	O
real	O
-	O
time	O
technical	O
support	O
from	O
the	O
clinical	O
department	O
,	O
each	O
patient	O
underwent	O
a	O
thorough	O
bedside	O
evaluation	O
,	O
transport	B-PROC
ventilator	O
trial	O
,	O
and	O
transfer	O
to	O
a	O
transport	B-PROC
stretcher	O
either	O
with	O
the	O
endotracheal	O
tube	O
secured	O
by	O
an	O
anesthesia	O
pillow	O
or	O
overhanging	O
the	O
stretcher	O
.	O

The	O
median	O
transport	B-PROC
time	O
was	O
36	O
minutes	O
(	O
IQR	O
19	O
,	O
51	O
).	O

There	O
were	O
no	O
deaths	B-PROC
or	O
major	O
incidents	O
(	O
tube	O
dislodgement	O
or	O
line	O
displacement	O
)	O
during	O
patient	O
transport	B-PROC
.	O

The	O
methods	O
herein	O
described	O
for	O
rapid	O
development	B-PROC
of	O
a	O
highly	O
protective	O
SARS	O
vaccine	O
are	O
equally	O
suited	O
to	O
rapid	O
development	B-PROC
of	O
vaccines	O
against	O
other	O
fatal	O
human	O
coronavirus	O
infections	O
,	O
e	O
.	O
g	O
.,	O
the	O
MERS	O
coronavirus	O
.	O

TITLE	O
:	O
A	O
comparison	O
of	O
clinical	O
efficacy	O
between	O
high	O
frequency	O
oscillatory	O
ventilation	O
and	O
conventional	O
ventilation	O
with	O
lung	B-PROC
volume	I-PROC
recruitment	O
in	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
efficacy	O
of	O
lung	B-PROC
volume	I-PROC
recruitment	O
maneuver	O
(	O
LVRM	O
)	O
with	O
high	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
on	O
oxygenation	B-PROC
,	O
hemodynamic	B-PROC
alteration	O
,	O
and	O
clinical	O
outcomes	O
when	O
compared	O
to	O
conventional	O
mechanical	O
ventilation	O
(	O
CV	O
)	O
in	O
children	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Hemodynamic	B-PROC
and	O
serious	O
complications	O
were	O
not	O
significantly	O
affected	O
after	O
LVRM	O
.	O

Although	O
the	O
etiology	O
of	O
the	O
disease	O
is	O
well	O
defined	O
,	O
the	O
underling	O
pathogenesis	B-PROC
is	O
still	O
incompletely	O
understood	O
.	O

The	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
),	O
one	O
of	O
the	O
primary	O
cardiovascular	O
regulatory	O
systems	O
,	O
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
inflammatory	O
lung	O
disease	O
.	O

In	O
an	O
attempt	O
to	O
summarize	O
current	O
literature	O
findings	O
and	O
progress	O
made	O
in	O
uncovering	O
the	O
role	O
of	O
ACE2	O
in	O
inflammatory	O
lung	O
disease	O
,	O
this	O
review	O
will	O
focus	O
on	O
recent	O
studies	O
examining	O
pulmonary	O
ACE2	O
biology	O
,	O
its	O
roles	O
in	O
inflammatory	O
lung	O
disease	O
pathogenesis	B-PROC
and	O
possible	O
underlying	O
mechanisms	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
vaccine	O
candidates	O
in	O
development	B-PROC
:	O
The	O
current	O
landscape	O
.	O

Sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
results	O
showed	O
that	O
rNPs	O
of	O
CCoV	O
and	O
CRCoV	O
were	O
expressed	B-PROC
efficiently	O
and	O
isolated	O
with	O
a	O
final	O
purity	O
of	O
over	O
95	O
%.	O

The	O
samples	O
were	O
tested	O
by	O
viral	O
culture	O
with	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
using	O
MERS	O
-	O
CoV	O
Spike	O
antibody	B-PROC
,	O
and	O
electron	O
microscopy	O
(	O
EM	O
).	O

Expression	B-PROC
of	O
MERS	O
-	O
CoV	O
M	O
protein	O
suppressed	O
type	O
I	O
IFN	O
expression	B-PROC
in	O
response	O
to	O
Sendai	O
virus	B-PROC
infection	I-PROC
or	O
poly	O
(	O
I	O
:	O
C	O
)	O
induction	O
.	O

We	O
also	O
found	O
higher	O
levels	O
of	O
those	O
mediators	O
were	O
associated	O
with	O
poor	O
survival	O
rates	O
in	O
patients	O
with	O
lung	O
cancer	O
and	O
involved	O
in	O
the	O
process	O
of	O
the	O
epithelial	B-PROC
mesenchymal	I-PROC
transition	I-PROC
of	O
alveolar	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
having	O
a	O
severe	O
effect	O
on	O
the	O
pig	O
breeding	B-PROC
industry	O
in	O
central	O
China	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
macro	O
and	O
the	O
microcirculatory	O
effects	O
of	O
prone	O
positioning	O
and	O
emphasize	O
which	O
hemodynamic	B-PROC
variables	O
can	O
be	O
monitored	O
when	O
this	O
therapy	O
is	O
applied	O
.	O

This	O
results	O
in	O
an	O
increase	O
in	O
cardiac	O
output	O
only	O
in	O
patients	O
with	O
preload	O
reserve	O
,	O
emphasizing	O
the	O
important	O
role	O
of	O
preload	O
in	O
the	O
hemodynamic	B-PROC
effects	O
of	O
prone	O
positioning	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
method	O
for	O
the	O
swift	O
generation	O
of	O
a	O
human	O
-	O
derived	O
monoclonal	O
antibody	B-PROC
,	O
known	O
as	O
LCA60	O
,	O
as	O
a	O
treatment	O
for	O
MERS	O
infections	O
.	O

It	O
is	O
critical	O
for	O
future	O
pathogenic	O
and	O
antigenic	O
studies	O
,	O
as	O
well	O
as	O
for	O
the	O
development	B-PROC
of	O
effective	O
preventive	O
and	O
control	O
vaccines	O
against	O
PEDV	O
.	O

To	O
characterize	O
the	O
inflammatory	B-PROC
response	I-PROC
developed	O
against	O
this	O
virus	O
,	O
lesions	O
from	O
4	O
naturally	O
infected	O
ferrets	O
were	O
examined	O
.	O

The	O
extent	O
and	O
distribution	O
of	O
viral	O
antigen	O
expression	B-PROC
was	O
also	O
assessed	O
.	O

FRSCV	O
was	O
expressed	B-PROC
in	O
G	O
,	O
G	O
-	O
NL	O
,	O
G	O
-	O
N	O
,	O
and	O
DG	O
,	O
with	O
decreasing	O
numbers	O
of	O
immunoreactive	O
cells	O
.	O

However	O
,	O
the	O
translation	B-PROC
of	O
this	O
physiological	O
model	O
in	O
a	O
clinical	O
perspective	O
is	O
not	O
straightforward	O
because	O
our	O
model	O
of	O
acute	O
and	O
severe	O
hemorrhage	O
is	O
not	O
strictly	O
equivalent	O
to	O
a	O
progressive	O
hypovolemia	O
,	O
as	O
could	O
be	O
obtained	O
in	O
ICU	O
by	O
diuretic	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
factors	O
before	O
therapy	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
),	O
except	O
pH	O
,	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	B-PROC
pressure	I-PROC
(	O
MAP	O
)	O
between	O
the	O
ECMO	O
survival	O
group	O
and	O
the	O
ECMO	O
non	O
-	O
survival	O
group	O
.	O

Peak	O
testing	O
occurred	O
following	O
the	O
annual	O
Hajj	O
season	O
and	O
in	O
other	O
periods	B-PROC
of	O
raised	O
national	O
awareness	O
.	O

No	O
heparin	O
was	O
used	O
for	O
at	O
least	O
4	O
days	O
in	O
this	O
group	O
with	O
activated	O
coagulation	B-PROC
time	O
(	O
ACT	O
)	O
approximating	O
170	O
seconds	O
by	O
the	O
3	O
(	O
rd	O
)	O
and	O
4	O
(	O
th	O
)	O
day	O
.	O

miRNAs	O
can	O
regulate	O
inflammation	O
pathways	B-PROC
by	O
targeting	B-PROC
specific	O
molecules	O
and	O
modulate	O
immune	B-PROC
response	I-PROC
in	O
the	O
process	O
of	O
lung	O
injury	O
and	O
repair	B-PROC
.	O

Recombination	B-PROC
was	O
confirmed	O
by	O
detecting	O
putative	O
breakpoints	O
of	O
Lineage	O
1	O
coronaviruses	O
in	O
M	O
.	O
fuliginosus	O
and	O
M	O
.	O
pusillus	O
(	O
Wu	O
et	O
al	O
.,	O
2015	O
),	O
which	O
supported	O
the	O
results	O
of	O
topological	O
and	O
phylogenetic	O
analyses	O
.	O

To	O
conduct	B-PROC
a	O
nationwide	O
survey	O
of	O
critical	O
care	O
physicians	O
in	O
the	O
United	O
States	O
regarding	O
accepted	O
definitions	O
and	O
management	O
strategies	O
for	O
severe	O
and	O
refractory	O
hypoxemia	O
.	O

TITLE	O
:	O
Effect	O
of	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
Use	O
on	O
Sedative	O
Requirements	O
in	O
Patients	O
with	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

The	O
parameters	O
were	O
set	O
as	O
follows	O
:	O
temperature	O
34	O
degrees	O
C	O
,	O
flow	O
rate	O
20	O
L	O
/	O
min	O
,	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
FiO2	O
)	O
0	O
.	O
50	O
.	O

RESULTS	O
:	O
A	O
43	O
-	O
year	O
old	O
male	O
was	O
admitted	O
to	O
negative	O
pressure	O
isolation	O
intensive	O
care	O
unit	O
with	O
the	O
complaint	O
of	O
back	O
ache	O
for	O
7	O
days	O
and	O
fever	B-PROC
for	O
2	O
days	O
.	O

Each	O
observed	O
indicator	O
was	O
analyzed	O
by	O
univariate	O
analysis	O
,	O
and	O
factors	O
leading	O
to	O
death	B-PROC
were	O
further	O
analyzed	O
by	O
logistic	O
regression	O
.	O

Risk	O
factors	O
of	O
severe	O
trauma	O
patients	O
were	O
sorted	B-PROC
,	O
from	O
which	O
the	O
meaningful	O
indicators	O
were	O
included	O
to	O
calculate	O
the	O
warning	O
score	O
of	O
death	B-PROC
.	O

When	O
the	O
cut	O
-	O
off	O
value	O
of	O
warning	O
score	O
of	O
death	B-PROC
was	O
1	O
.	O
5	O
,	O
the	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predict	O
value	O
(+	O
PV	O
),	O
negative	O
predict	O
value	O
(-	O
PV	O
),	O
positive	O
likelihood	O
ratio	O
(+	O
LR	O
),	O
negative	O
likelihood	O
ratio	O
(-	O
LR	O
),	O
and	O
Youden	O
index	O
was	O
75	O
.	O
00	O
%,	O
85	O
.	O
40	O
%,	O
50	O
.	O
0	O
%,	O
94	O
.	O
6	O
%,	O
5	O
.	O
16	O
,	O
0	O
.	O
29	O
,	O
and	O
0	O
.	O
605	O
,	O
respectively	O
.	O

The	O
central	O
venous	B-PROC
pressure	I-PROC
(	O
CVP	O
),	O
central	O
venous	B-PROC
oxygen	I-PROC
saturation	I-PROC
(	O
ScvO₂	O
),	O
blood	O
lactate	O
(	O
Lac	O
),	O
and	O
the	O
monitor	O
of	O
other	O
parameters	O
of	O
patients	O
in	O
late	O
group	O
were	O
consummated	O
late	O
.	O

TITLE	O
:	O
Reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
assays	O
for	O
the	O
differentiation	B-PROC
of	O
various	O
US	O
porcine	O
epidemic	O
diarrhea	O
virus	O
strains	O
.	O

ABSTRACT	O
:	O
Concurrently	O
,	O
several	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
variants	O
are	O
circulating	O
in	O
US	O
swine	O
farms	O
,	O
including	O
the	O
original	O
US	O
and	O
the	O
spike	O
insertion	O
-	O
deletion	O
(	O
S	O
-	O
INDEL	B-PROC
)	O
strains	O
.	O

Two	O
hundred	O
sixty	O
-	O
one	O
patients	O
(	O
60	O
.	O
3	O
%)	O
received	O
lung	O
protective	O
ventilation	O
,	O
but	O
most	O
patients	O
were	O
ventilated	O
with	O
a	O
low	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
,	O
high	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
strategy	O
.	O

The	O
review	O
includes	O
verotoxin	O
-	O
producing	O
Escherichia	O
coli	O
O104	O
:	O
H4	O
infections	O
,	O
MERS	O
-	O
CoV	O
infections	O
,	O
Ebola	O
virus	B-PROC
disease	I-PROC
,	O
malaria	O
,	O
dengue	O
fever	B-PROC
,	O
West	O
Nile	O
fever	B-PROC
,	O
chikungunya	O
and	O
cholera	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
a	O
subunit	O
vaccine	O
for	O
PEDV	O
,	O
we	O
cloned	O
two	O
different	O
fragments	O
of	O
S	O
protein	O
and	O
expressed	B-PROC
as	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)-	O
tagged	O
fusion	O
proteins	O
,	O
namely	O
rGST	O
-	O
COE	O
and	O
rGST	O
-	O
S1D	O
,	O
in	O
E	O
.	O
coli	O
.	O

In	O
this	O
study	O
,	O
soluble	O
production	O
of	O
recombinant	O
spike	O
protein	O
of	O
PEDV	O
,	O
rGST	O
-	O
COE	O
and	O
rGST	O
-	O
S1D	O
,	O
were	O
achieved	O
by	O
using	O
TF	O
chaperone	O
co	O
-	O
expression	B-PROC
system	O
.	O

As	O
there	O
are	O
no	O
epidemiological	O
studies	O
of	O
positive	O
rate	O
of	O
SFTSV	O
antibody	B-PROC
in	O
people	O
living	O
in	O
endemic	O
areas	O
in	O
Japan	O
,	O
a	O
field	O
study	O
was	O
performed	O
.	O

TITLE	O
:	O
Comparative	O
and	O
kinetic	O
analysis	O
of	O
viral	B-PROC
shedding	I-PROC
and	O
immunological	O
responses	O
in	O
MERS	O
patients	O
representing	O
a	O
broad	O
spectrum	O
of	O
disease	O
severity	O
.	O

Robust	O
induction	O
of	O
various	O
chemokines	O
with	O
differential	O
kinetics	O
was	O
more	O
prominent	O
in	O
patients	O
that	O
recovered	O
from	O
pneumonia	O
than	O
in	O
patients	O
with	O
mild	O
febrile	B-PROC
illness	O
or	O
deceased	B-PROC
patients	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
Monoclonal	O
Antibody	B-PROC
and	O
Diagnostic	O
Test	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Using	O
Cell	O
-	O
Free	O
Synthesized	O
Nucleocapsid	O
Antigen	O
.	O

The	O
preparation	O
and	O
purification	O
of	O
native	O
viral	O
antigens	O
in	O
conventional	O
cell	O
-	O
based	O
protein	B-PROC
expression	B-PROC
systems	O
are	O
often	O
accompanied	O
by	O
technical	O
hardships	O
.	O

Optimal	O
management	O
remains	O
unknown	O
,	O
including	O
the	O
roles	O
of	O
adjunctive	O
corticosteroids	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O
We	O
conducted	O
a	O
retrospective	O
chart	O
review	O
of	O
patients	O
with	O
ARDS	O
caused	O
by	O
blastomycosis	O
,	O
managed	O
in	O
intensive	O
care	O
units	O
in	O
Manitoba	O
,	O
Canada	O
,	O
from	O
1992	O
to	O
2014	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
PDCoV	O
infection	O
fails	O
to	O
induce	O
,	O
and	O
even	O
remarkably	O
inhibits	O
,	O
Sendai	O
virus	O
-	O
or	O
poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
IFN	O
-	O
β	O
production	O
by	O
impeding	O
the	O
activation	O
of	O
transcription	B-PROC
factors	O
NF	O
-	O
κB	O
and	O
IRF3	O
.	O

Diagnosis	O
was	O
confirmed	O
in	O
all	O
patients	O
using	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
on	O
respiratory	O
samples	O
.	O

After	O
adjustment	O
for	O
the	O
severity	O
of	O
illness	O
and	O
the	O
degree	O
of	O
organ	O
dysfunction	O
,	O
the	O
need	O
for	O
vasopressors	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
death	B-PROC
in	O
the	O
ICU	O
(	O
odds	O
ratio	O
=	O
18	O
.	O
33	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
11	O
-	O
302	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
04	O
).	O

In	O
this	O
study	O
,	O
weaned	B-PROC
piglets	O
were	O
inoculated	O
with	O
an	O
early	O
European	O
isolate	O
(	O
Br1	O
/	O
87	O
)	O
or	O
faecal	O
/	O
intestinal	O
suspensions	O
derived	O
from	O
pigs	O
infected	O
with	O
a	O
recent	O
European	O
strain	O
of	O
PEDV	O
(	O
from	O
Germany	O
)	O
or	O
a	O
US	O
strain	O
of	O
PEDV	O
.	O

TITLE	O
:	O
SARS	O
Coronavirus	O
Papain	O
-	O
Like	O
Protease	O
Inhibits	O
the	O
TLR7	B-PROC
Signaling	B-PROC
Pathway	I-PROC
through	O
Removing	O
Lys63	O
-	O
Linked	O
Polyubiquitination	B-PROC
of	O
TRAF3	O
and	O
TRAF6	O
.	O

Western	O
blot	O
analysis	O
with	O
anti	O
-	O
Lys48	O
and	O
anti	O
-	O
Lys63	O
ubiquitin	B-PROC
antibodies	O
indicated	O
the	O
SARS	O
-	O
CoV	O
PLPro	O
removed	O
Lys63	O
-	O
linked	O
ubiquitin	B-PROC
chains	O
of	O
TRAF3	O
and	O
TRAF6	O
,	O
but	O
not	O
Lys48	O
-	O
linked	O
ubiquitin	B-PROC
chains	O
in	O
un	O
-	O
treated	O
and	O
treated	O
cells	O
.	O

TITLE	O
:	O
[	O
Development	B-PROC
of	O
peptidic	O
MERS	O
-	O
CoV	O
entry	O
inhibitors	O
].	O

Moreover	O
,	O
the	O
reverse	O
genetics	O
system	O
we	O
constructed	O
will	O
be	O
helpful	O
for	O
study	O
of	O
the	O
pathogenesis	B-PROC
of	O
this	O
group	O
of	O
viruses	O
and	O
to	O
develop	O
therapeutics	O
for	O
future	O
control	O
of	O
emerging	O
SARS	O
-	O
like	O
infections	O
.	O

The	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
is	O
essential	O
for	O
the	O
coronaviral	O
life	O
cycle	O
and	O
is	O
an	O
appealing	O
target	O
for	O
the	O
development	B-PROC
of	O
therapeutics	O
.	O

ABSTRACT	O
:	O
Gram	O
-	O
negative	O
pathogen	O
-	O
induced	O
nosocomial	O
infections	O
and	O
resistance	B-PROC
are	O
a	O
most	O
serious	O
menace	O
to	O
global	O
public	O
health	O
.	O

He	O
admitted	O
to	O
our	O
hospital	O
with	O
the	O
complaints	O
of	O
sensation	B-PROC
of	I-PROC
cold	I-PROC
,	O
shivering	O
and	O
fever	B-PROC
.	O

He	O
had	O
sudden	O
onset	O
of	O
fever	B-PROC
,	O
headache	O
,	O
nausea	O
and	O
vomiting	O
and	O
impaired	O
consciousness	O
.	O

TITLE	O
:	O
Resolution	O
acute	O
respiratory	O
distress	O
syndrome	O
through	O
reversing	O
the	O
imbalance	O
of	O
Treg	O
/	O
Th17	O
by	O
targeting	B-PROC
the	O
cAMP	O
signaling	B-PROC
pathway	I-PROC
.	O

TITLE	O
:	O
Surveillance	O
and	O
response	O
systems	O
for	O
elimination	B-PROC
of	O
tropical	O
diseases	O
:	O
summary	O
of	O
a	O
thematic	O
series	O
in	O
Infectious	O
Diseases	O
of	O
Poverty	O
.	O

There	O
are	O
five	O
scoping	O
reviews	O
,	O
a	O
commentary	O
,	O
a	O
letter	O
to	O
the	O
editor	O
,	O
an	O
opinion	O
piece	O
and	O
an	O
editorial	O
pertaining	O
to	O
the	O
theme	O
""""	O
Elimination	B-PROC
of	O
tropical	O
disease	O
through	O
surveillance	O
and	O
response	O
"""."	O

A	O
successful	O
policy	O
implementation	O
process	O
in	O
Ontario	O
has	O
helped	O
to	O
move	B-PROC
public	O
health	O
towards	O
the	O
new	O
vision	B-PROC
.	O

Factors	O
and	O
related	O
components	O
that	O
were	O
most	O
clearly	O
linked	O
to	O
the	O
OPHS	O
policy	O
implementation	O
were	O
:	O
attributes	O
of	O
the	O
innovation	O
itself	O
;	O
adoption	O
by	O
individuals	O
;	O
diffusion	O
and	O
dissemination	O
;	O
the	O
outer	O
context	O
-	O
interorganizational	O
networks	O
and	O
collaboration	O
;	O
the	O
inner	O
setting	O
-	O
implementation	O
processes	O
and	O
routinization	O
;	O
and	O
,	O
linkage	B-PROC
at	O
the	O
design	O
and	O
implementation	O
stage	O
.	O

Pregnant	O
sows	O
were	O
immunized	O
intramuscularly	O
with	O
the	O
inactivated	O
adjuvanted	O
monovalent	O
vaccine	O
at	O
six	O
and	O
three	O
weeks	O
prior	O
to	O
farrowing	B-PROC
.	O

The	O
administration	O
of	O
the	O
inactivated	O
vaccine	O
to	O
sows	O
greatly	O
increased	O
the	O
survival	O
rate	O
of	O
piglets	O
challenged	O
with	O
the	O
virulent	O
strain	O
,	O
from	O
0	O
%	O
to	O
approximately	O
92	O
%	O
(	O
22	O
/	O
24	O
),	O
and	O
significantly	O
reduced	O
diarrhea	O
severity	O
including	O
viral	B-PROC
shedding	I-PROC
in	O
feces	O
.	O

We	O
show	O
that	O
(	O
i	O
)	O
common	O
principles	O
pertaining	O
to	O
the	O
stereochemistry	B-PROC
of	O
protein	O
-	O
carbohydrate	O
interactions	O
were	O
at	O
the	O
core	O
of	O
the	O
transition	O
in	O
lectin	O
ligand	B-PROC
and	O
esterase	O
substrate	O
specificity	O
;	O
(	O
ii	O
)	O
in	O
consequence	O
,	O
the	O
switch	O
in	O
O	O
-	O
Ac	O
-	O
Sia	O
specificity	O
could	O
be	O
readily	O
accomplished	O
via	O
convergent	O
intramolecular	O
coevolution	O
with	O
only	O
modest	O
architectural	O
changes	O
in	O
lectin	O
and	O
esterase	O
domains	O
;	O
and	O
(	O
iii	O
)	O
a	O
single	O
,	O
inconspicuous	O
Ala	O
-	O
to	O
-	O
Ser	O
substitution	O
in	O
the	O
catalytic	O
site	O
was	O
key	O
to	O
the	O
emergence	O
of	O
the	O
type	O
II	O
HEs	O
.	O

TITLE	O
:	O
Different	O
pattern	O
of	O
viral	B-PROC
infections	I-PROC
and	O
clinical	O
outcomes	O
in	O
patient	O
with	O
acute	O
exacerbation	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
with	O
pneumonia	O
.	O

TITLE	O
:	O
Relationship	O
between	O
different	O
enteric	O
viral	B-PROC
infections	I-PROC
and	O
the	O
occurrence	O
of	O
diarrhea	O
in	O
broiler	O
flocks	O
in	O
Jordan	O
.	O

After	O
MERS	O
-	O
CoV	O
infections	O
occurred	O
in	O
an	O
extended	O
family	O
in	O
Saudi	O
Arabia	O
in	O
2014	O
,	O
relatives	O
were	O
tested	O
by	O
using	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
and	O
serologic	O
methods	O
.	O

Risk	O
factors	O
for	O
household	O
transmission	O
included	O
sleeping	B-PROC
in	O
an	O
index	O
patient	O
'	O
s	O
room	O
and	O
touching	O
respiratory	O
secretions	O
from	O
an	O
index	O
patient	O
.	O

Antibody	B-PROC
longevity	O
was	O
more	O
variable	O
in	O
patients	O
who	O
had	O
experienced	O
milder	O
disease	O
.	O

TITLE	O
:	O
Receptor	O
Interacting	O
Protein	O
3	O
-	O
Mediated	O
Necroptosis	B-PROC
Promotes	O
Lipopolysaccharide	O
-	O
Induced	O
Inflammation	O
and	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Mice	O
.	O

Viral	B-PROC
infection	I-PROC
was	O
detected	O
by	O
multiplex	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
with	O
primers	O
specific	O
to	O
the	O
subtypes	O
HCoV	O
-	O
229E	O
/	O
NL63	O
and	O
OC43	O
/	O
HKU1	O
.	O

TITLE	O
:	O
Recognition	O
of	O
Lys48	O
-	O
Linked	O
Di	O
-	O
ubiquitin	B-PROC
and	O
Deubiquitinating	B-PROC
Activities	O
of	O
the	O
SARS	O
Coronavirus	O
Papain	O
-	O
like	O
Protease	O
.	O

Inhaled	B-PROC
nitric	O
oxide	O
might	O
improve	O
outcomes	O
in	O
a	O
subset	O
of	O
patients	O
with	O
postoperative	O
pulmonary	O
hypertension	O
who	O
had	O
cardiac	O
surgery	O
;	O
however	O
,	O
it	O
has	O
not	O
been	O
shown	O
to	O
provide	O
long	O
-	O
term	O
benefit	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Pulmonary	B-PROC
function	I-PROC
tests	O
performed	O
at	O
six	O
months	O
were	O
normal	O
and	O
the	O
CT	O
scan	O
showed	O
complete	O
regression	O
of	O
pulmonary	O
injuries	O
.	O

TITLE	O
:	O
Immune	B-PROC
evasion	I-PROC
of	O
porcine	O
enteric	O
coronaviruses	O
and	O
viral	O
modulation	O
of	O
antiviral	O
innate	O
signaling	B-PROC
.	O

Accumulating	O
evidence	O
however	O
suggests	O
that	O
IFN	O
induction	O
and	O
signaling	B-PROC
in	O
the	O
intestinal	O
epithelial	O
cells	O
differ	O
from	O
other	O
epithelial	O
cells	O
,	O
largely	O
due	O
to	O
distinct	O
features	O
of	O
the	O
gut	O
epithelial	O
mucosal	O
surface	O
and	O
commensal	O
microflora	O
,	O
and	O
it	O
appears	O
that	O
type	O
III	O
interferon	O
(	O
IFN	O
-	O
λ	O
)	O
plays	O
a	O
key	O
role	O
to	O
maintain	O
the	O
antiviral	O
state	O
in	O
the	O
gut	O
.	O

We	O
also	O
highlight	O
areas	O
of	O
particular	O
relevance	O
to	O
PEDV	O
pathogenesis	B-PROC
and	O
disease	O
that	O
have	O
benefited	O
from	O
reverse	O
genetics	O
studies	O
and	O
pressing	O
questions	O
that	O
await	O
resolution	O
by	O
such	O
studies	O
.	O

Identifying	O
factors	O
that	O
influence	O
lactogenic	O
immunity	B-PROC
and	O
the	O
gut	O
-	O
mammary	O
-	O
sIgA	O
axis	O
may	O
lead	O
to	O
improved	O
vaccine	O
regimens	O
for	O
PEDV	O
and	O
other	O
enteric	O
pathogens	O
in	O
gestating	O
swine	O
and	O
improved	O
overall	O
herd	B-PROC
immunity	I-PROC
,	O
swine	O
health	O
and	O
industry	O
productivity	O
.	O

TITLE	O
:	O
Factors	O
influencing	O
emergency	O
nurses	O
'	O
ethical	O
problems	O
during	O
the	O
outbreak	O
of	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Whenever	O
there	O
has	O
been	O
a	O
worldwide	O
contagious	O
disease	O
outbreak	O
,	O
there	O
have	O
been	O
reports	O
of	O
infection	O
and	O
death	B-PROC
of	O
healthcare	O
workers	O
.	O

The	O
clinical	O
course	O
of	O
the	O
disease	O
ranges	O
from	O
asymptomatic	O
infection	O
to	O
severe	O
lower	O
respiratory	O
tract	O
illness	O
with	O
multiorgan	O
involvement	O
and	O
death	B-PROC
.	O

TITLE	O
:	O
Sentinel	O
surveillance	O
for	O
influenza	O
among	O
severe	O
acute	O
respiratory	O
infection	O
and	O
acute	O
febrile	B-PROC
illness	O
inpatients	O
at	O
three	O
hospitals	O
in	O
Ghana	O
.	O

The	O
school	O
leadership	O
conducted	O
ongoing	O
risk	O
assessment	O
and	O
developed	O
contingency	O
plans	O
to	O
balance	B-PROC
student	O
safety	O
and	O
continuity	O
in	O
medical	O
education	O
.	O

TITLE	O
:	O
Feline	O
Coronavirus	O
3c	O
Protein	O
:	O
A	O
Candidate	O
for	O
a	O
Virulence	B-PROC
Marker	O
?	O

TITLE	O
:	O
Structural	O
and	O
mutational	O
analysis	O
of	O
the	O
interaction	O
between	O
the	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
and	O
human	O
ubiquitin	B-PROC
.	O

Through	O
sitedirected	O
mutagenesis	B-PROC
,	O
we	O
demonstrate	O
that	O
conserved	O
Asp165	O
and	O
non	O
-	O
conserved	O
Asp164	O
are	O
important	O
for	O
the	O
catalytic	O
activities	O
of	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
).	O

The	O
enzyme	O
appears	O
not	O
to	O
be	O
optimized	O
for	O
catalytic	O
efficiency	O
;	O
thus	O
,	O
replacement	O
of	O
Phe269	O
by	O
Tyr	O
leads	O
to	O
increased	O
peptidolytic	O
and	O
deubiquitinating	B-PROC
activities	O
.	O

The	O
respiratory	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
survival	O
prediction	O
(	O
RESP	O
)	O
score	O
and	O
simplified	O
acute	O
physiology	O
score	O
(	O
SAPS	O
)	O
II	O
score	O
also	O
showed	O
fair	O
prediction	O
ability	O
with	O
AUC	O
of	O
0	O
.	O
79	O
(	O
95	O
%	O
CI	O
0	O
.	O
65	O
-	O
0	O
.	O
89	O
)	O
and	O
AUC	O
of	O
0	O
.	O
78	O
(	O
95	O
%	O
CI	O
0	O
.	O
64	O
-	O
0	O
.	O
88	O
),	O
respectively	O
.	O

In	O
multivariate	O
logistic	O
regression	O
models	O
,	O
TAPSE	O
maintained	O
a	O
significant	O
association	O
with	O
mortality	O
independent	O
of	O
age	O
,	O
pH	O
,	O
PaO2	O
∶	O
FiO2	O
ratios	O
,	O
positive	O
end	O
expiratory	B-PROC
pressure	O
,	O
PCO2	O
,	O
serum	O
bicarbonate	O
,	O
plateau	O
pressures	O
,	O
driving	O
pressures	O
,	O
APACHE	O
II	O
,	O
SAPS	O
II	O
,	O
and	O
SOFA	O
scores	O
.	O

RESULTS	O
:	O
The	O
patients	O
transported	O
by	O
HEMS	O
had	O
a	O
significantly	O
faster	O
median	O
transport	B-PROC
time	O
(	O
1	O
.	O
3	O
versus	O
1	O
.	O
7	O
h	O
,	O
p	O
<	O
0	O
.	O
01	O
),	O
faster	O
time	O
to	O
meeting	O
criteria	O
for	O
severe	O
sepsis	O
or	O
septic	O
shock	O
(	O
1	O
.	O
2	O
versus	O
2	O
.	O
9	O
h	O
,	O
p	O
<	O
0	O
.	O
01	O
),	O
a	O
higher	O
SOFA	O
score	O
(	O
9	O
versus	O
7	O
,	O
p	O
<	O
0	O
.	O
01	O
),	O
higher	O
incidence	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
38	O
versus	O
18	O
%,	O
p	O
=	O
0	O
.	O
013	O
),	O
higher	O
need	O
for	O
invasive	O
mechanical	O
ventilation	O
(	O
60	O
versus	O
41	O
%	O
p	O
=	O
0	O
.	O
014	O
),	O
higher	O
ICU	O
mortality	O
(	O
13	O
.	O
3	O
versus	O
4	O
.	O
1	O
%,	O
p	O
=	O
0	O
.	O
024	O
),	O
and	O
an	O
increased	O
hospital	O
mortality	O
(	O
17	O
versus	O
30	O
%,	O
p	O
=	O
0	O
.	O
04	O
)	O
when	O
compared	O
to	O
those	O
transported	O
by	O
ground	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
VV	O
-	O
ECMO	O
)	O
is	O
a	O
therapeutic	O
option	O
in	O
the	O
management	O
of	O
the	O
most	O
severe	O
forms	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

If	O
hypoxemia	O
occurs	O
during	O
VV	O
-	O
ECMO	O
,	O
collecting	O
oxygenation	B-PROC
parameters	O
and	O
a	O
clear	O
step	O
-	O
by	O
-	O
step	O
algorithm	O
could	O
guide	O
specific	O
intervention	O
to	O
improve	O
oxygenation	B-PROC
.	O

Participants	O
(	O
n	O
=	O
249	O
)	O
were	O
nursing	B-PROC
students	O
in	O
their	O
third	O
or	O
fourth	O
year	O
of	O
the	O
programme	O
who	O
were	O
engaged	O
in	O
clinical	O
practice	O
for	O
eight	O
hours	O
per	O
day	O
at	O
the	O
tertiary	O
hospitals	O
with	O
Middle	O
East	O
respiratory	O
syndrome	O
patients	O
.	O

MHV3	O
in	O
vitro	O
infection	O
of	O
macrophagic	O
cells	O
induced	O
rapid	O
and	O
higher	O
viral	B-PROC
replication	I-PROC
and	O
/	O
or	O
interleukin	O
-	O
6	O
induction	O
in	O
comparison	O
to	O
MHV	O
-	O
A59	O
,	O
and	O
depended	O
on	O
viral	B-PROC
activation	I-PROC
of	O
TLR2	O
and	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

Mass	O
vaccination	O
is	O
conducted	O
in	O
Morocco	O
using	O
a	O
vaccine	O
against	O
Massachusetts	O
,	O
which	O
is	O
the	O
most	O
dominant	O
serotype	O
;	O
however	O
no	O
information	O
about	O
the	O
pathogenesis	B-PROC
and	O
tissue	O
distribution	O
of	O
the	O
Moroccan	O
Italy	O
02	O
genotype	O
was	O
reported	O
.	O

The	O
infected	O
birds	O
appeared	O
lethargic	O
,	O
reluctant	O
to	O
move	B-PROC
,	O
with	O
specific	O
respiratory	O
clinical	O
signs	O
and	O
macroscopic	O
lesions	O
.	O

The	O
nucleoprotein	O
of	O
PDCoV	O
was	O
expressed	B-PROC
as	O
a	O
recombinant	O
protein	O
and	O
purified	O
for	O
use	O
as	O
an	O
antigen	O
to	O
immunize	O
mice	O
for	O
polyclonal	O
,	O
hyperimmune	O
sera	O
and	O
monoclonal	O
antibody	B-PROC
(	O
mAb	O
)	O
production	O
.	O

An	O
indirect	O
fluorescent	O
antibody	B-PROC
(	O
IFA	O
)	O
test	O
was	O
also	O
developed	O
using	O
cell	O
culture	O
adapted	O
PDCoV	O
for	O
comparative	O
purposes	O
.	O

Many	O
viruses	O
inhibit	O
protein	B-PROC
synthesis	I-PROC
by	O
their	O
host	O
cell	O
to	O
enhance	O
virus	B-PROC
replication	I-PROC
and	O
to	O
antagonize	O
antiviral	O
defense	O
mechanisms	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
can	O
cause	O
serious	O
disease	O
and	O
even	O
death	B-PROC
in	O
neonatal	O
piglets	O
,	O
resulting	O
in	O
serious	O
damage	O
to	O
the	O
swine	O
industry	O
worldwide	O
.	O

In	O
this	O
study	O
,	O
a	O
nanoparticle	O
-	O
assisted	O
polymerase	O
chain	O
reaction	O
(	O
nanoparticle	O
-	O
assisted	O
RT	O
-	O
PCR	O
)	O
assay	O
targeting	B-PROC
the	O
ORF3	O
of	O
PEDV	O
was	O
developed	O
to	O
distinguish	O
PEDV	O
field	O
strains	O
from	O
attenuated	O
strains	O
by	O
using	O
a	O
specific	O
pair	O
of	O
primers	O
.	O

Alternatively	O
,	O
infiltration	O
of	O
activated	O
cells	O
of	O
the	O
immune	O
system	O
may	O
be	O
detrimental	O
,	O
as	O
these	O
cells	O
can	O
contribute	O
to	O
neuropathology	O
that	O
may	O
result	O
in	O
long	O
-	O
term	O
cellular	O
damage	O
or	O
death	B-PROC
.	O

TITLE	O
:	O
[	O
Visual	O
Detection	O
of	O
Human	O
Coronavirus	O
NL63	O
by	O
Reverse	B-PROC
Transcription	B-PROC
Loop	O
-	O
Mediated	O
Isothermal	O
Amplification	O
].	O

Female	O
BALB	O
/	O
C	O
mice	O
were	O
immunized	O
with	O
individual	O
polypeptide	O
-	O
KLH	O
,	O
and	O
the	O
total	O
IgG	O
was	O
detected	O
by	O
ELISA	O
as	O
well	O
as	O
the	O
cellular	O
mediated	O
immunity	B-PROC
(	O
CMI	O
)	O
was	O
analyzed	O
using	O
ELIs	O
-	O
pot	O
assay	O
.	O

This	O
review	O
summarizes	O
their	O
structural	O
characteristics	O
and	O
classification	O
,	O
as	O
well	O
as	O
the	O
biosynthesis	B-PROC
starting	O
in	O
the	O
chloroplast	O
,	O
and	O
their	O
supposed	O
biological	O
activity	O
associated	O
with	O
plant	O
defense	O
mechanisms	O
are	O
also	O
discussed	O
.	O

In	O
the	O
present	O
article	O
we	O
have	O
described	O
about	O
risk	O
factors	O
,	O
chance	O
of	O
infection	O
,	O
and	O
prevention	O
methods	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
),	O
human	O
coronaviruses	O
(	O
CoVs	O
)	O
frequently	O
cause	O
a	O
normal	O
cold	B-PROC
which	O
is	O
mild	O
and	O
self	O
-	O
restricting	O
.	O

Insight	O
from	O
successful	O
approaches	O
of	O
targeting	B-PROC
viral	O
ncRNA	O
in	O
HIV	O
,	O
HCV	O
,	O
SARS	O
CoV	O
,	O
and	O
influenza	O
A	O
will	O
provide	O
a	O
basis	O
for	O
the	O
future	O
exploration	O
of	O
RNA	O
targets	O
for	O
therapeutic	O
intervention	O
in	O
other	O
viral	O
pathogens	O
which	O
create	O
urgent	O
,	O
unmet	O
medical	O
needs	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
adaptation	B-PROC
of	O
an	O
embryo	O
-	O
attenuated	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
Arkansas	O
Delmarva	O
Poultry	O
Industry	O
(	O
ArkDPI	O
)-	O
derived	O
vaccine	O
to	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	O
shifted	O
the	O
virus	O
population	O
towards	O
homogeneity	O
in	O
spike	O
(	O
S	O
)	O
and	O
nonstructural	O
protein	O
genes	O
.	O

There	O
were	O
no	O
lesions	O
in	O
the	O
respiratory	O
system	O
,	O
and	O
no	O
IBV	O
antigen	O
was	O
detected	O
in	O
trachea	O
,	O
lung	O
,	O
air	O
sac	B-PROC
,	O
conjunctiva	O
,	O
and	O
cecal	O
tonsils	O
.	O

The	O
results	O
suggest	O
a	O
broader	O
tissue	B-PROC
tropism	B-PROC
of	O
this	O
isolate	O
,	O
which	O
might	O
be	O
related	O
to	O
the	O
mutations	O
in	O
the	O
S1	O
gene	O
.	O

TITLE	O
:	O
Frequent	O
Respiratory	O
Viral	B-PROC
Infections	I-PROC
in	O
Children	O
with	O
Febrile	B-PROC
Neutropenia	O
-	O
A	O
Prospective	O
Follow	O
-	O
Up	O
Study	O
.	O

TITLE	O
:	O
Remyelination	B-PROC
Is	O
Correlated	O
with	O
Regulatory	O
T	O
Cell	O
Induction	O
Following	O
Human	O
Embryoid	O
Body	O
-	O
Derived	O
Neural	O
Precursor	O
Cell	O
Transplantation	O
in	O
a	O
Viral	O
Model	O
of	O
Multiple	O
Sclerosis	O
.	O

TITLE	O
:	O
Single	O
-	O
dose	O
treatment	O
with	O
a	O
humanized	O
neutralizing	O
antibody	B-PROC
affords	O
full	O
protection	O
of	O
a	O
human	O
transgenic	O
mouse	O
model	O
from	O
lethal	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
coronavirus	O
infection	O
.	O

APE	O
manifestation	O
is	O
significantly	O
more	O
often	O
sleep	B-PROC
-	O
related	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
OSA	O
compared	O
to	O
subjects	O
with	O
an	O
apnea	O
-	O
hypopnea	O
index	O
≤	O
15	O
/	O
h	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Cellular	O
protection	O
against	O
oxidative	O
stress	O
and	O
xenobiotics	O
is	O
mainly	O
conferred	O
by	O
Nrf2	O
,	O
a	O
transcription	B-PROC
factor	O
that	O
promotes	O
the	O
expression	B-PROC
of	O
genes	O
that	O
regulate	O
oxidative	O
stress	O
,	O
xenobiotic	B-PROC
metabolism	I-PROC
and	O
excretion	B-PROC
,	O
inflammation	O
,	O
apoptosis	B-PROC
,	O
autophagy	B-PROC
,	O
and	O
cellular	O
bioenergetics	B-PROC
.	O

This	O
study	O
suggests	O
that	O
Euphorbia	O
characias	O
extracts	O
represent	O
a	O
good	O
source	O
of	O
natural	O
bioactive	O
compounds	O
which	O
could	O
be	O
useful	O
for	O
pharmaceutical	O
application	O
as	O
well	O
as	O
in	O
food	O
system	O
for	O
the	O
prevention	O
of	O
the	O
growth	B-PROC
of	O
food	O
-	O
borne	O
bacteria	O
and	O
to	O
extend	O
the	O
shelf	O
-	O
life	O
of	O
processed	O
foods	O
.	O

We	O
propose	O
a	O
simple	O
sampling	O
strategy	O
to	O
enrich	O
in	O
especially	O
dangerous	O
pathogens	O
with	O
a	O
low	O
background	O
for	O
molecular	O
diagnostics	O
by	O
targeting	B-PROC
blood	O
-	O
borne	O
pathogens	O
in	O
the	O
healthiest	O
age	O
groups	O
.	O

Here	O
we	O
review	O
the	O
current	O
data	O
on	O
PEDV	O
entry	O
into	O
its	O
host	O
cell	O
,	O
including	O
therein	O
our	O
new	O
observations	O
regarding	O
the	O
functional	O
role	O
of	O
the	O
sialic	O
acid	O
binding	B-PROC
activity	I-PROC
of	O
the	O
S	O
protein	O
in	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Consortia	O
'	O
s	O
critical	O
role	O
in	O
developing	O
medical	O
countermeasures	O
for	O
re	O
-	O
emerging	O
viral	B-PROC
infections	I-PROC
:	O
a	O
USA	O
perspective	O
.	O

The	O
challenge	O
is	O
how	O
to	O
take	O
this	O
academic	O
virology	O
knowledge	O
into	O
a	O
drug	O
discovery	O
and	O
development	B-PROC
domain	O
.	O

Acute	O
haemodialysis	O
performed	O
due	O
to	O
refractory	O
metabolic	B-PROC
acidosis	O
.	O

Recombination	B-PROC
analysis	O
determined	O
that	O
these	O
strains	O
belonged	O
to	O
four	O
groups	O
,	O
which	O
originated	O
from	O
independent	O
recombination	B-PROC
events	O
between	O
the	O
QX	O
and	O
793B	O
IBV	O
genotypes	O
.	O

An	O
association	O
with	O
microcephaly	O
and	O
other	O
birth	B-PROC
defects	O
as	O
well	O
as	O
Guillain	O
-	O
Barre	O
Syndrome	O
has	O
led	O
to	O
a	O
World	O
Health	O
Organization	O
declaration	O
of	O
Zika	O
virus	O
as	O
a	O
Public	O
Health	O
Emergency	O
of	O
International	O
Concern	O
in	O
February	O
2016	O
.	O

After	O
an	O
incubation	O
period	O
of	O
2	O
-	O
7	O
days	O
,	O
symptomatic	O
patients	O
develop	O
rapid	O
onset	O
fever	B-PROC
,	O
maculopapular	O
rash	O
,	O
arthralgia	O
,	O
and	O
conjunctivitis	O
,	O
often	O
associated	O
with	O
headache	O
and	O
myalgias	O
.	O

The	O
identify	O
-	O
isolate	O
-	O
inform	O
(	O
3I	O
)	O
tool	O
,	O
originally	O
conceived	O
for	O
initial	O
detection	O
and	O
management	O
of	O
Ebola	O
virus	B-PROC
disease	I-PROC
patients	O
in	O
the	O
ED	O
,	O
and	O
later	O
adjusted	O
for	O
measles	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
,	O
can	O
be	O
adapted	O
for	O
real	O
-	O
time	O
use	O
for	O
any	O
emerging	O
infectious	O
disease	O
.	O

Of	O
the	O
identified	O
pre	O
-	O
ECMO	O
factors	O
,	O
advanced	O
age	O
,	O
a	O
long	O
duration	O
of	O
ventilation	O
before	O
ECMO	O
,	O
a	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
underlying	O
lung	O
disease	O
,	O
and	O
pulmonary	O
barotrauma	O
prior	O
to	O
ECMO	O
were	O
associated	O
with	O
unsuccessful	O
weaning	B-PROC
from	O
ECMO	O
.	O

Finally	O
,	O
she	O
gave	O
birth	B-PROC
to	O
a	O
healthy	O
boy	O
at	O
38	O
weeks	O
of	O
gestation	B-PROC
.	O

Thus	O
the	O
role	O
of	O
these	O
hosts	O
on	O
the	O
evolution	B-PROC
and	O
spread	O
of	O
CoVs	O
currently	O
deserve	O
the	O
attention	O
of	O
emerging	O
diseases	O
surveillance	O
programs	O
.	O

TITLE	O
:	O
Hyperleptinemia	O
is	O
associated	O
with	O
impaired	O
pulmonary	O
host	B-PROC
defense	I-PROC
.	O

Remarkable	O
beneficial	O
effects	O
of	O
IL	O
-	O
6	O
blockade	O
therapy	O
using	O
a	O
humanized	O
anti	O
-	O
IL	O
-	O
6	O
receptor	O
antibody	B-PROC
,	O
tocilizumab	O
were	O
recently	O
observed	O
in	O
patients	O
with	O
cytokine	O
release	O
syndrome	O
complicated	O
by	O
T	O
-	O
cell	O
engaged	O
therapy	O
.	O

Sleep	B-PROC
disturbance	O
questionnaire	O
for	O
patients	O
with	O
ACS	O
hospitalized	O
in	O
coronary	O
care	O
unit	O
(	O
CCU	O
)	O
was	O
identified	O
in	O
5	O
dimensions	O
and	O
assessed	O
for	O
validity	O
and	O
reliability	O
.	O

In	O
APRV	O
group	O
ventilation	O
central	O
venous	O
pressure	O
(	O
CVP	O
)	O
and	O
systemic	O
circulation	B-PROC
resistance	B-PROC
index	O
(	O
SVRI	O
)	O
were	O
reduced	O
,	O
but	O
cardiac	O
index	O
(	O
CI	O
)	O
increased	O
,	O
and	O
at	O
the	O
same	O
time	O
lac	O
and	O
oxygen	O
saturation	O
of	O
central	O
venous	O
blood	O
(	O
ScvO2	O
)	O
were	O
improved	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
/	O
or	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
prone	O
positioning	O
is	O
a	O
therapeutic	O
intervention	O
to	O
improve	O
oxygenation	B-PROC
.	O

CONCLUSIONS	O
:	O
The	O
use	O
of	O
thin	O
soft	O
silicone	O
foam	O
dressings	O
may	O
prevent	O
the	O
development	B-PROC
of	O
facial	O
deep	O
tissue	O
injuries	O
in	O
patients	O
receiving	O
prolonged	O
pronation	B-PROC
therapy	O
.	O

This	O
study	O
uses	O
Affymetrix	O
microarray	O
analysis	O
to	O
compare	O
differential	O
spinal	O
cord	O
mRNA	O
levels	O
between	O
mice	O
infected	O
with	O
demyelinating	O
and	O
non	O
-	O
demyelinating	O
strains	O
of	O
MHV	O
to	O
identify	O
host	O
immune	O
genes	O
expressed	B-PROC
in	O
this	O
demyelinating	O
disease	O
model	O
.	O

Etiology	O
of	O
acute	O
respiratory	O
failure	O
was	O
acute	O
exacerbation	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
in	O
29	O
patients	O
,	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
4	O
patients	O
,	O
severe	O
kyphoscoliosis	O
in	O
2	O
patients	O
,	O
interstitial	O
lung	O
disease	O
(	O
ILD	O
)	O
in	O
4	O
patients	O
,	O
lung	O
contusion	O
with	O
pneumonia	O
in	O
1	O
patient	O
,	O
thoracoplasty	O
in	O
1	O
patient	O
and	O
difficult	O
weaning	B-PROC
in	O
4	O
patients	O
.	O

Mean	O
expiratory	B-PROC
positive	O
airway	O
pressure	O
(	O
EPAP	O
)	O
was	O
5	O
.	O
8	O
cm	O
H2O	O
(	O
range	O
4	O
to	O
8	O
cm	O
H2O	O
).	O

Mesenchymal	O
stromal	O
/	O
stem	O
cells	O
(	O
MSCs	O
)	O
are	O
adult	O
multi	O
-	O
progenitor	O
cells	O
that	O
can	O
modulate	O
the	O
immune	B-PROC
response	I-PROC
and	O
enhance	O
repair	B-PROC
of	O
damaged	O
tissue	O
and	O
thus	O
may	O
provide	O
a	O
therapeutic	O
option	O
for	O
ARDS	O
.	O

MSCs	O
appear	O
to	O
exert	B-PROC
their	O
effects	O
via	O
multiple	O
mechanisms	O
-	O
some	O
are	O
cell	B-PROC
interaction	I-PROC
dependent	O
whereas	O
others	O
are	O
paracrine	B-PROC
dependent	O
resulting	O
from	O
both	O
soluble	O
secreted	B-PROC
products	O
and	O
microvesicles	O
/	O
exosomes	O
derived	O
from	O
the	O
cells	O
.	O

Strategies	O
to	O
further	O
enhance	O
the	O
efficacy	O
of	O
MSCs	O
,	O
such	O
as	O
by	O
overexpressing	O
anti	O
-	O
inflammatory	O
or	O
pro	O
-	O
repair	B-PROC
molecules	O
,	O
are	O
also	O
being	O
investigated	O
.	O

Development	B-PROC
of	O
a	O
scoring	O
system	O
with	O
national	O
characteristics	O
might	O
be	O
warranted	O
.	O

ABSTRACT	O
:	O
In	O
the	O
present	O
study	O
,	O
the	O
replication	O
kinetics	O
of	O
nephropathogenic	O
(	O
B1648	O
)	O
and	O
respiratory	O
(	O
Massachusetts	O
-	O
M41	O
)	O
IBV	O
strains	O
were	O
compared	O
in	O
vitro	O
in	O
respiratory	O
mucosa	O
explants	O
and	O
blood	O
monocytes	O
(	O
KUL01	O
(+)	O
cells	O
),	O
and	O
in	O
vivo	O
in	O
chickens	O
to	O
understand	O
why	O
some	O
IBV	O
strains	O
have	O
a	O
kidney	O
tropism	B-PROC
.	O

Post	B-PROC
translational	B-PROC
modification	I-PROC
of	O
TRPV4	O
by	O
kinases	O
and	O
other	O
signalling	B-PROC
molecules	O
can	O
modulate	O
TRPV4	O
opening	O
in	O
response	O
to	O
stimuli	O
such	O
as	O
mechanical	O
and	O
hyposmolarity	O
and	O
there	O
is	O
an	O
emerging	O
area	O
of	O
research	O
implicating	O
TRPV4	O
as	O
a	O
transducer	O
of	O
these	O
signals	O
as	O
opposed	O
to	O
a	O
direct	O
sensor	O
of	O
the	O
stimuli	O
.	O

In	O
respiratory	B-PROC
function	I-PROC
,	O
TRPV4	O
is	O
involved	O
in	O
cystic	O
fibrosis	O
,	O
cilary	O
beat	O
frequency	O
,	O
bronchoconstriction	B-PROC
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
pulmonary	O
hypertension	O
,	O
acute	O
lung	O
injury	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
cough	O
.	O

Death	B-PROC
-	O
associated	O
exposure	O
factors	O
were	O
age	O
,	O
ISS	O
,	O
APACHE	O
Ⅱ	O
score	O
,	O
urea	O
volume	O
on	O
the	O
first	O
day	O
,	O
platelet	O
count	O
,	O
albumin	O
,	O
and	O
blood	O
sodium	O
.	O

TITLE	O
:	O
Destabilized	O
SMC5	O
/	O
6	O
complex	O
leads	O
to	O
chromosome	B-PROC
breakage	I-PROC
syndrome	O
with	O
severe	O
lung	O
disease	O
.	O

Impairments	O
in	O
chromosome	O
maintenance	O
are	O
linked	O
to	O
rare	O
chromosome	B-PROC
breakage	I-PROC
disorders	O
.	O

ABSTRACT	O
:	O
The	O
Ebola	O
virus	B-PROC
disease	I-PROC
outbreak	O
in	O
West	O
Africa	O
and	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
outbreak	O
in	O
the	O
Republic	O
of	O
Korea	O
have	O
given	O
huge	O
impacts	O
in	O
different	O
aspects	O
.	O

In	O
the	O
perspective	O
of	O
global	O
health	O
,	O
it	O
will	O
be	O
helpful	O
to	O
peruse	O
lessons	O
learned	B-PROC
from	O
the	O
Ebola	O
outbreak	O
in	O
West	O
Africa	O
and	O
MERS	O
outbreak	O
in	O
Korea	O
.	O

Onset	O
of	O
apneas	O
during	O
SPS	O
should	O
be	O
considered	O
as	O
a	O
signal	O
of	O
possible	O
progression	O
toward	O
acute	O
respiratory	O
failure	O
and	O
sudden	O
death	B-PROC
,	O
and	O
should	O
lead	O
to	O
ICU	O
admission	O
for	O
continuous	O
monitoring	O
.	O

The	O
second	O
experiment	O
examined	O
the	O
specific	O
antibody	B-PROC
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
in	O
pullet	O
chicks	O
following	O
vaccination	O
against	O
IBV	O
at	O
d	O
1	O
.	O

In	O
Hospital	O
B	O
,	O
the	O
median	O
incubation	O
period	O
was	O
shorter	O
(	O
4	O
.	O
6	O
days	O
vs	O
.	O
10	O
.	O
8	O
days	O
),	O
the	O
median	O
time	O
to	O
pneumonia	O
development	B-PROC
was	O
faster	O
(	O
3	O
days	O
vs	O
.	O
6	O
days	O
)	O
and	O
mortality	O
was	O
higher	O
(	O
70	O
%	O
vs	O
.	O
30	O
.	O
8	O
%)	O
than	O
in	O
Hospital	O
A	O
.	O
MERS	O
-	O
CoV	O
isolates	O
from	O
11	O
cases	O
formed	O
a	O
single	O
monophyletic	O
clade	O
,	O
with	O
the	O
closest	O
similarity	O
to	O
strains	O
from	O
Riyadh	O
.	O

Median	O
incubation	O
periods	B-PROC
tended	O
to	O
be	O
longer	O
over	O
time	O
as	O
the	O
disease	O
generation	O
progressed	O
:	O
6	O
.	O
16	O
days	O
(	O
95	O
%	O
CI	O
,	O
5	O
.	O
38	O
-	O
6	O
.	O
97	O
),	O
7	O
.	O
68	O
days	O
(	O
95	O
%	O
CI	O
,	O
7	O
.	O
04	O
-	O
8	O
.	O
44	O
),	O
and	O
7	O
.	O
95	O
days	O
(	O
95	O
%	O
CI	O
,	O
6	O
.	O
25	O
-	O
9	O
.	O
88	O
)	O
in	O
the	O
first	O
,	O
second	O
,	O
and	O
third	O
generations	O
,	O
respectively	O
.	O

In	O
lung	O
tissue	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
monocyte	O
chemo	O
attractant	B-PROC
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
and	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
was	O
elevated	O
in	O
both	O
C5	O
-/-	O
mice	O
and	O
wildtype	O
littermates	O
(	O
wt	O
),	O
whereas	O
caspase	O
-	O
3	O
was	O
reduced	O
in	O
lungs	O
after	O
DH	O
in	O
C5	O
-/-	O
mice	O
.	O

Accelerating	O
the	O
development	B-PROC
of	O
a	O
preventive	O
vaccine	O
requires	O
a	O
better	O
understanding	O
of	O
MERS	O
epidemiology	O
,	O
transmission	O
,	O
and	O
pathogenesis	B-PROC
in	O
humans	O
and	O
animals	O
.	O

ABSTRACT	O
:	O
Two	O
topics	O
that	O
have	O
attracted	O
recent	O
attention	O
in	O
the	O
field	O
of	O
autophagy	B-PROC
concern	O
the	O
source	O
of	O
the	O
membrane	O
that	O
is	O
used	O
to	O
form	O
the	O
autophagosome	O
during	O
macroautophagy	B-PROC
and	O
the	O
role	O
of	O
noncanonical	O
autophagic	O
pathways	B-PROC
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	B-PROC
)	O
use	O
is	O
perceived	O
to	O
cause	O
thrombocytopenia	O
(	O
T	O
),	O
but	O
the	O
role	O
of	O
non	O
-	O
ECMO	B-PROC
factors	O
in	O
the	O
development	B-PROC
of	O
T	O
remains	O
unclear	O
.	O

Using	O
two	O
murine	O
ALI	O
models	O
and	O
cells	O
culture	O
,	O
we	O
examined	O
the	O
presence	O
of	O
sCD74	O
in	O
circulation	B-PROC
and	O
alveolar	O
space	O
and	O
preliminarily	O
assessed	O
the	O
biological	B-PROC
function	I-PROC
of	O
sCD74	O
.	O

However	O
,	O
overexpression	B-PROC
of	O
pAPN	O
in	O
porcine	O
CPK	O
cells	O
(	O
CPK	O
-	O
pAPN	O
cells	O
)	O
slightly	O
increased	O
the	O
production	O
of	O
PEDV	O
,	O
and	O
the	O
increased	O
replication	O
in	O
CPK	O
-	O
pAPN	O
cells	O
was	O
inhibited	O
by	O
bestatin	O
,	O
an	O
inhibitor	O
of	O
the	O
protease	B-PROC
activity	I-PROC
of	O
aminopeptidase	O
N	O
.	O
These	O
results	O
suggest	O
that	O
pAPN	O
is	O
not	O
a	O
functional	O
receptor	O
for	O
PEDV	O
,	O
but	O
promotes	O
the	O
infection	O
of	O
PEDV	O
through	O
its	O
protease	B-PROC
activity	I-PROC
.	O

Since	O
the	O
development	B-PROC
of	O
the	O
first	O
viral	O
infectious	O
clone	O
system	O
for	O
the	O
poliovirus	O
,	O
novel	O
strategies	O
of	O
viral	O
genome	O
construction	O
have	O
allowed	O
for	O
the	O
assembly	O
of	O
viral	O
genomes	O
across	O
the	O
identified	O
viral	O
families	O
.	O

In	O
addition	O
,	O
a	O
partial	O
co	O
-	O
localization	B-PROC
of	O
TGEV	O
spike	O
proteins	O
with	O
authentic	O
host	O
cell	O
β	O
-	O
tubulin	O
was	O
observed	O
.	O

Immunity	B-PROC
resulting	O
from	O
disease	O
in	O
childhood	O
is	O
incomplete	O
and	O
reinfection	O
with	O
HPIV	O
accounts	O
for	O
15	O
%	O
of	O
respiratory	O
illnesses	O
in	O
adults	O
.	O

Several	O
novel	O
drugs	O
including	O
DAS181	O
appear	O
promising	O
in	O
efforts	O
to	O
treat	O
severe	O
disease	O
in	O
immunocompromised	O
patients	O
,	O
and	O
vaccines	O
to	O
decrease	O
the	O
burden	O
of	O
disease	O
in	O
young	O
children	O
are	O
in	O
development	B-PROC
.	O

Studies	O
showed	O
that	O
immunoglobulin	B-PROC
of	O
egg	O
yolk	O
(	O
IgY	O
)	O
from	O
immunized	O
hens	O
has	O
been	O
identified	O
to	O
be	O
a	O
convenient	O
source	O
for	O
specific	O
antibodies	O
for	O
using	O
in	O
immunotherapy	O
and	O
immunodiagnostic	O
to	O
limit	O
the	O
infections	O
.	O

This	O
higher	O
replication	O
and	O
proinflammatory	O
activation	O
in	O
LSECs	O
by	O
the	O
virulent	O
MHV3	O
strain	O
was	O
associated	O
with	O
a	O
specific	O
activation	O
of	O
TLR2	O
signaling	B-PROC
by	O
the	O
virus	O
.	O

Disrupting	O
the	O
interaction	O
between	O
CEACAM5	O
and	O
MERS	O
-	O
CoV	O
spike	O
with	O
anti	O
-	O
CEACAM5	O
antibody	B-PROC
,	O
recombinant	O
CEACAM5	O
protein	O
,	O
or	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
knockdown	O
of	O
CEACAM5	O
significantly	O
inhibited	O
the	O
entry	O
of	O
MERS	O
-	O
CoV	O
.	O
Recombinant	O
expression	B-PROC
of	O
CEACAM5	O
did	O
not	O
render	O
nonpermissive	O
baby	O
hamster	O
kidney	O
(	O
BHK21	O
)	O
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
identification	O
of	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecule	O
5	O
(	O
CEACAM5	O
)	O
as	O
a	O
novel	O
cell	O
surface	O
binding	O
target	O
of	O
MERS	O
-	O
CoV	O
advanced	O
our	O
knowledge	O
on	O
the	O
cell	O
binding	O
biology	O
of	O
MERS	O
-	O
CoV	O
.	O
Importantly	O
,	O
CEACAM5	O
could	O
potentiate	O
the	O
entry	O
of	O
MERS	O
-	O
CoV	O
by	O
functioning	O
as	O
an	O
attachment	O
factor	O
.	O

In	O
this	O
regard	O
,	O
CEACAM5	O
could	O
serve	O
as	O
a	O
novel	O
target	O
,	O
in	O
addition	O
to	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
in	O
the	O
development	B-PROC
of	O
antiviral	O
strategies	O
for	O
MERS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
To	O
report	O
clinical	O
,	O
virological	O
,	O
and	O
epidemiological	O
features	O
of	O
the	O
first	O
death	B-PROC
caused	O
by	O
a	O
H5N6	O
avian	O
influenza	O
virus	O
in	O
Yunnan	O
Province	O
,	O
China	O
.	O

The	O
case	O
was	O
described	O
in	O
clinical	O
expression	B-PROC
,	O
chest	O
radiography	O
,	O
blood	O
test	O
and	O
treatment	O
.	O

A	O
total	O
of	O
1425	O
patients	O
with	O
confirmed	O
CAD	O
starting	O
rehabilitation	O
were	O
screened	O
for	O
SDB	O
using	O
cardiorespiratory	O
polygraphy	O
(	O
n	O
=	O
921	O
)	O
or	O
polygraphy	O
plus	O
pulse	B-PROC
oximetry	O
(	O
n	O
=	O
484	O
).	O

This	O
study	O
aimed	O
at	O
determining	O
the	O
role	O
of	O
the	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-PROC
(	O
CCL	O
)	O
2	O
and	O
CCL7	O
in	O
ARDS	O
.	O

Moreover	O
,	O
CCL2	O
and	O
CCL7	O
synergised	O
with	O
CXCL8	O
to	O
promote	O
neutrophil	B-PROC
migration	I-PROC
.	O

However	O
,	O
although	O
protective	O
immune	B-PROC
responses	I-PROC
could	O
be	O
induced	O
by	O
recombinant	O
S1	O
protein	O
,	O
the	O
protection	O
rate	O
in	O
chickens	O
was	O
still	O
low	O
(<	O
50	O
%).	O

After	O
immunization	O
,	O
animals	O
vaccinated	O
with	O
fusion	O
proteins	O
rS1	O
-	O
HA2	O
and	O
rS1	O
-	O
H3	O
(	O
TM	O
)	O
demonstrated	O
stronger	O
robust	O
humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
than	O
that	O
of	O
rS1	O
and	O
inactivated	O
M41	O
vaccine	O
.	O

TITLE	O
:	O
Therapeutic	O
potential	O
of	O
recombinant	O
thrombomodulin	O
for	O
lung	O
injury	O
after	O
pneumonectomy	O
via	O
inhibition	B-PROC
of	O
high	O
-	O
mobility	O
group	O
box	O
1	O
in	O
mice	O
.	O

This	O
was	O
a	O
retrospective	O
review	O
of	O
moderate	O
to	O
severe	O
ARDS	O
patients	O
who	O
were	O
prescribed	O
>	O
12	O
hours	O
of	O
continuous	O
infusion	O
cisatracurium	O
between	O
January	O
1	O
,	O
2013	O
,	O
and	O
December	O
31	O
,	O
2014	O
,	O
with	O
a	O
PaO	B-PROC
A	O
total	O
of	O
378	O
patients	O
were	O
screened	O
for	O
inclusion	O
,	O
with	O
107	O
evaluable	O
patients	O
meeting	O
criteria	O
at	O
baseline	O
.	O

TITLE	O
:	O
p53	O
down	O
-	O
regulates	O
SARS	O
coronavirus	O
replication	O
and	O
is	O
targeted	B-PROC
by	O
the	O
SARS	O
-	O
unique	O
domain	O
and	O
PLpro	O
via	O
E3	O
ubiquitin	B-PROC
ligase	O
RCHY1	O
.	O

The	O
significance	O
of	O
these	O
findings	O
is	O
that	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
p53	O
as	O
a	O
major	O
player	O
in	O
antiviral	O
innate	B-PROC
immunity	B-PROC
provides	O
a	O
long	O
-	O
sought	O
explanation	O
for	O
delayed	O
activities	O
of	O
respective	O
genes	O
.	O

We	O
addressed	O
this	O
problem	O
by	O
using	O
the	O
-	O
1	O
PRF	O
stimulation	O
pseudoknot	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
PK	O
)	O
to	O
build	O
a	O
ligand	B-PROC
-	O
dependent	O
-	O
1	O
PRF	O
stimulator	O
.	O

Similarly	O
,	O
CCE	O
helps	O
in	O
identifying	O
patients	O
at	O
high	O
risk	O
of	O
ventilator	O
weaning	B-PROC
failure	O
,	O
depicts	O
the	O
mechanisms	O
of	O
weaning	B-PROC
pulmonary	O
edema	O
in	O
those	O
patients	O
who	O
fail	O
a	O
spontaneous	O
breathing	B-PROC
trial	O
,	O
and	O
guides	O
tailored	O
therapeutic	O
strategy	O
.	O

In	O
all	O
these	O
clinical	O
settings	O
,	O
CCE	O
provides	O
unparalleled	O
information	O
on	O
both	O
the	O
efficacy	O
and	O
tolerance	B-PROC
of	O
therapeutic	O
changes	O
.	O

TITLE	O
:	O
Role	O
of	O
Inhaled	B-PROC
Nitric	O
Oxide	O
in	O
the	O
Management	O
of	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

ABSTRACT	O
:	O
We	O
explored	O
the	O
feasibility	O
of	O
collecting	O
convalescent	O
plasma	O
for	O
passive	O
immunotherapy	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
by	O
using	O
ELISA	O
to	O
screen	O
serum	O
samples	O
from	O
443	O
potential	O
plasma	O
donors	O
:	O
196	O
patients	O
with	O
suspected	O
or	O
laboratory	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
infection	O
,	O
230	O
healthcare	O
workers	O
,	O
and	O
17	O
household	O
contacts	O
exposed	O
to	O
MERS	O
-	O
CoV	O
.	O
ELISA	O
-	O
reactive	O
samples	O
were	O
further	O
tested	O
by	O
indirect	O
fluorescent	O
antibody	B-PROC
and	O
microneutralization	O
assays	O
.	O

Next	O
,	O
we	O
showed	O
that	O
feline	O
venous	O
ECs	O
become	O
activated	O
when	O
exposed	O
to	O
supernatant	O
from	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)-	O
infected	O
monocytes	O
,	O
as	O
indicated	O
by	O
increased	O
adhesion	O
molecule	O
expression	B-PROC
.	O

TITLE	O
:	O
Identification	O
of	O
Nafamostat	O
as	O
a	O
Potent	O
Inhibitor	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
S	O
Protein	O
-	O
Mediated	O
Membrane	B-PROC
Fusion	I-PROC
Using	O
the	O
Split	O
-	O
Protein	O
-	O
Based	O
Cell	B-PROC
-	I-PROC
Cell	I-PROC
Fusion	I-PROC
Assay	O
.	O

As	O
compared	O
to	O
inoculation	O
with	O
free	O
proteins	O
,	O
vaccination	O
with	O
the	O
sVLPs	O
showed	O
enhanced	O
lymphatic	O
antigen	O
delivery	O
,	O
stronger	O
antibody	B-PROC
titers	O
,	O
increased	O
splenic	O
T	O
-	O
cell	O
response	O
,	O
and	O
reduced	O
infection	O
-	O
associated	O
symptoms	O
in	O
an	O
avian	O
model	O
of	O
coronavirus	O
infection	O
.	O

TITLE	O
:	O
TGEV	O
infection	O
up	O
-	O
regulates	O
FcRn	O
expression	B-PROC
via	O
activation	O
of	O
NF	O
-	O
κB	O
signaling	B-PROC
.	O

Since	O
RNA	O
packaging	O
impacts	O
on	O
several	O
essential	O
functions	O
of	O
retroviral	O
replication	O
such	O
as	O
RNA	O
dimerization	O
,	O
translation	B-PROC
and	O
recombination	B-PROC
events	O
,	O
there	O
are	O
many	O
studies	O
that	O
require	O
the	O
determination	O
of	O
RNA	O
packaging	O
efficiency	O
and	O
/	O
or	O
RNA	O
packaging	O
ability	O
.	O

This	O
review	O
focuses	O
on	O
the	O
different	O
approaches	O
available	O
to	O
monitor	O
RNA	O
packaging	O
:	O
Northern	O
blot	O
analysis	O
,	O
ribonuclease	O
protection	O
assay	O
and	O
quantitative	O
reverse	O
transcriptase	B-PROC
-	O
coupled	O
polymerase	O
chain	O
reaction	O
as	O
well	O
as	O
the	O
most	O
recent	O
RNA	O
imaging	O
and	O
sequencing	O
technologies	O
.	O

The	O
results	O
showed	O
that	O
biological	O
characteristics	O
of	O
R	O
-	O
H120	O
-	O
Beaudette	O
-	O
p65	O
(	O
S	O
),	O
such	O
as	O
replication	O
kinetics	O
in	O
embryonated	O
chicken	O
eggs	O
(	O
ECEs	O
)	O
and	O
embryo	O
virulence	B-PROC
,	O
were	O
similar	O
to	O
those	O
of	O
H120	O
.	O

The	O
PEDV	O
S	O
was	O
inserted	O
into	O
the	O
ORFV121	O
gene	O
locus	O
,	O
an	O
immunomodulatory	O
gene	O
that	O
inhibits	O
activation	O
of	O
the	O
NF	O
-	O
κB	O
signalling	B-PROC
pathway	B-PROC
and	O
contributes	O
to	O
ORFV	O
virulence	B-PROC
in	O
the	O
natural	O
host	O
.	O

The	O
PI3K	O
/	O
Akt	O
pathway	B-PROC
is	O
an	O
important	O
cellular	O
pathway	B-PROC
that	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
virus	B-PROC
replication	I-PROC
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
PI3K	O
/	O
Akt	O
/	O
GSK	O
-	O
3α	O
/	O
β	O
signaling	B-PROC
pathway	I-PROC
is	O
activated	O
by	O
PEDV	O
and	O
functions	O
in	O
inhibiting	O
PEDV	O
replication	O
.	O

Time	O
from	O
hospitalisation	O
to	O
isolation	O
decreased	O
in	O
periods	B-PROC
of	O
high	O
public	O
health	O
attention	O
(	O
2	O
.	O
33	O
±	O
0	O
.	O
34	O
vs	O
.	O
6	O
.	O
44	O
±	O
0	O
.	O
97	O
days	O
during	O
baseline	O
attention	O
).	O

Differential	O
plasma	O
expression	B-PROC
of	O
pulmonary	O
surfactant	O
associated	O
protein	O
A	O
,	O
apolipoprotein	B-PROC
A1	O
,	O
and	O
deleted	O
in	O
malignant	O
brain	O
tumors	O
1	O
protein	O
(	O
DMBT1	O
)	O
was	O
verified	O
in	O
plasma	O
samples	O
.	O

No	O
therapeutics	O
or	O
vaccines	O
are	O
approved	O
for	O
MERS	O
;	O
thus	O
,	O
development	B-PROC
of	O
novel	O
therapies	O
is	O
needed	O
.	O

CONCLUSIONS	O
:	O
HFOV	O
with	O
high	O
level	O
of	O
mPaw	O
increases	O
transpulmonary	O
pressures	O
without	O
improvement	O
in	O
oxygenation	B-PROC
.	O

Piglets	O
2	O
-	O
4	O
days	O
of	O
age	O
and	O
their	O
dams	O
were	O
administered	O
an	O
oronasal	O
PDCoV	O
inoculum	O
with	O
a	O
quantitative	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
(	O
qRT	O
)-	O
PCR	O
quantification	O
cycle	O
(	O
Cq	O
)	O
value	O
of	O
22	O
that	O
was	O
generated	O
from	O
a	O
field	O
sample	O
having	O
100	O
%	O
nucleotide	O
identity	O
to	O
USA	O
/	O
Illinois121	O
/	O
2014	O
determined	O
by	O
metagenomic	O
sequencing	O
and	O
testing	O
negative	O
for	O
other	O
enteric	O
disease	O
agents	O
using	O
standard	O
assays	O
.	O

Lactobacillus	O
plantarum	O
-	O
Biocenol	O
(	O
TM	O
)	O
LP96	O
(	O
CCM	O
7512	O
),	O
Lactobacillus	O
fermentum	O
-	O
Biocenol	O
(	O
TM	O
)	O
LF99	O
(	O
CCM	O
7514	O
)	O
and	O
flaxseed	O
(	O
rich	O
in	O
n	O
-	O
3	O
polyunsaturated	O
fatty	O
acids	O
)	O
were	O
administered	O
to	O
36	O
conventional	O
piglets	O
from	O
a	O
problematic	O
breed	B-PROC
with	O
confirmed	O
presence	O
of	O
enterotoxigenic	O
Escherichia	O
coli	O
and	O
Coronavirus	O
.	O

(	O
2	O
)	O
The	O
differences	O
of	O
occurrence	O
rates	O
of	O
hypotension	O
,	O
vomiting	O
,	O
abdominal	O
tenderness	O
,	O
muscle	B-PROC
tension	I-PROC
,	O
positive	O
peritoneal	O
irritation	O
,	O
decreased	O
bowel	O
sounds	O
,	O
liver	O
enlargement	O
,	O
seizures	O
and	O
unconsciousness	O
among	O
the	O
three	O
groups	O
were	O
statistically	O
significant	O
(	O
χ	O
(	O
2	O
)=	O
32	O
.	O
264	O
,	O
12	O
.	O
071	O
,	O
13	O
.	O
959	O
,	O
7	O
.	O
979	O
,	O
13	O
.	O
774	O
,	O
12	O
.	O
459	O
,	O
9	O
.	O
443	O
,	O
40	O
.	O
805	O
,	O
99	O
.	O
183	O
,	O
P	O
<	O
0	O
.	O
05	O
for	O
all	O
these	O
comparisons	O
).	O

Nineteen	O
mechanically	O
ventilated	O
patients	O
underwent	O
six	O
consecutive	O
ventilatory	O
conditions	O
:	O
three	O
on	O
volume	O
assist	O
-	O
control	O
(	O
VC	O
)	O
mode	O
,	O
each	O
with	O
set	O
Vt	O
of	O
6	O
,	O
7	O
.	O
5	O
,	O
and	O
9	O
ml	O
/	O
kg	O
,	O
and	O
three	O
on	O
adaptive	O
pressure	O
-	O
control	O
(	O
APC	O
)	O
mode	O
,	O
with	O
those	O
same	O
set	O
Vts	O
and	O
matching	O
inspiratory	B-PROC
times	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
estimate	O
in	O
population	O
of	O
free	O
-	O
living	O
wild	O
boar	O
in	O
the	O
Czech	O
Republic	O
the	O
prevalence	O
of	O
enteric	O
viral	O
pathogens	O
,	O
namely	O
rotavirus	O
groups	O
A	O
and	O
C	O
(	O
RVA	O
and	O
RVC	O
),	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
and	O
members	O
of	O
family	O
Coronaviridae	O
(	O
transmissible	O
gastroenteritis	O
virus	O
-	O
TGEV	O
,	O
porcine	O
epidemic	O
diarrhea	O
virus	O
-	O
PEDV	O
,	O
porcine	O
respiratory	O
coronavirus	O
-	O
PRCV	O
,	O
and	O
porcine	O
hemagglutination	B-PROC
encephalomyelitis	O
virus	O
-	O
PHEV	O
)	O
and	O
Picornaviridae	O
,(	O
teschovirus	O
A	O
-	O
PTV	O
,	O
sapelovirus	O
A	O
-	O
PSV	O
,	O
and	O
enterovirus	O
G	O
-	O
EV	O
-	O
G	O
).	O

Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
)	O
Ⅱ	O
,	O
Ⅲ	O
,	O
Ⅳ	O
,	O
Simplified	O
Acute	O
Physiology	O
Score	O
Ⅱ	O
(	O
SAPS	O
)	O
Ⅱ	O
,	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
),	O
ECMO	O
net	O
,	O
PRedicting	O
dEath	B-PROC
for	O
SEvere	O
ARDS	O
on	O
VVECMO	O
(	O
PRESERVE	O
),	O
and	O
Respiratory	O
ECMO	O
Survival	O
Prediction	O
(	O
RESP	O
)	O
scores	O
were	O
collected	O
within	O
6	O
hours	O
before	O
VV	O
-	O
ECMO	O
support	O
.	O

ABSTRACT	O
:	O
A	O
recent	O
individual	O
patient	O
data	O
(	O
IPD	O
)	O
meta	O
-	O
analysis	O
suggested	O
that	O
patients	O
with	O
moderate	O
or	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
benefit	O
from	O
higher	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
ventilation	O
strategies	O
.	O

We	O
found	O
that	O
for	O
patients	O
with	O
PaO2	O
/	O
FiO2	O
below	O
150	O
mm	O
Hg	O
,	O
but	O
above	O
100	O
mm	O
Hg	O
or	O
an	O
oxygenation	B-PROC
index	O
above	O
12	O
(	O
moderate	O
ARDS	O
),	O
higher	O
PEEP	O
reduces	O
hospital	O
mortality	O
,	O
but	O
the	O
beneficial	O
effect	O
appears	O
to	O
level	O
off	O
for	O
patients	O
with	O
very	O
severe	O
ARDS	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
for	O
patients	O
with	O
PaO2	O
/	O
FiO2	O
below	O
150	O
mm	O
Hg	O
,	O
but	O
above	O
100	O
mm	O
Hg	O
or	O
an	O
oxygenation	B-PROC
index	O
above	O
12	O
(	O
moderate	O
ARDS	O
),	O
higher	O
PEEP	O
reduces	O
hospital	O
mortality	O
,	O
but	O
the	O
beneficial	O
effect	O
appears	O
to	O
level	O
off	O
for	O
patients	O
with	O
very	O
severe	O
ARDS	O
.	O

Adult	O
patients	O
were	O
randomized	O
within	O
24	O
hours	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
onset	O
to	O
receive	O
either	O
intravenous	O
midazolam	O
or	O
inhaled	B-PROC
sevoflurane	O
for	O
48	O
hours	O
.	O

In	O
a	O
prospective	O
multicentre	O
epidemiological	O
study	O
,	O
93	O
infants	O
were	O
included	O
in	O
the	O
DS	O
cohort	O
and	O
68	O
matched	O
by	O
sex	O
and	O
data	O
of	O
birth	B-PROC
(±	O
1	O
week	O
)	O
and	O
were	O
followed	O
up	O
to	O
1	O
year	O
of	O
age	O
and	O
during	O
a	O
complete	O
RSV	O
season	O
.	O

TITLE	O
:	O
Intravascular	O
haemolysis	B-PROC
with	O
haemoglobinuria	O
in	O
a	O
splenectomized	O
patient	O
with	O
severe	O
Plasmodium	O
knowlesi	O
malaria	O
.	O

The	O
structure	O
reveals	O
the	O
complete	O
architecture	O
of	O
the	O
fusion	O
machinery	O
including	O
the	O
triggering	O
loop	O
and	O
the	O
C	O
-	O
terminal	O
domains	O
,	O
which	O
contribute	O
to	O
anchoring	B-PROC
the	O
trimer	O
to	O
the	O
viral	O
membrane	O
.	O

All	O
chickens	O
tested	O
for	O
avian	O
influenza	O
and	O
Newcastle	O
disease	O
viruses	O
using	O
real	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
were	O
negative	O
.	O

We	O
report	O
4	O
cases	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
from	O
influenza	O
in	O
need	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
evaluation	O
at	O
a	O
tertiary	O
care	O
center	O
,	O
transported	O
by	O
ground	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
are	O
at	O
risk	O
of	O
the	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Plasma	O
proinflammatory	O
markers	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
and	O
anti	O
-	O
inflammatory	O
marker	O
IL	O
-	O
10	O
were	O
associated	O
with	O
the	O
development	B-PROC
of	O
ARDS	O
(	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
1	O
.	O
55	O
,	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
14	O
,	O
2	O
.	O
11	O
,	O
P	O
=	O
0	O
.	O
005	O
for	O
IL	O
-	O
6	O
;	O
adjusted	O
HR	O
=	O
1	O
.	O
32	O
,	O
CI	O
=	O
1	O
.	O
10	O
,	O
1	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
003	O
for	O
IL	O
-	O
8	O
).	O

Subclones	O
of	O
this	O
cell	O
line	O
expressed	B-PROC
both	O
epithelial	O
and	O
fibroblast	O
markers	O
to	O
varying	O
extents	O
.	O

The	O
chance	O
of	O
catch	O
-	O
up	O
growth	B-PROC
may	O
decrease	O
the	O
number	O
of	O
pervious	O
""""	O
diagnosed	O
""""	O
microcephaly	O
.	O

Non	O
-	O
celiac	O
gluten	O
sensitivity	O
(	O
NCGS	O
)	O
is	O
a	O
syndrome	O
diagnosed	O
in	O
patients	O
responsive	O
to	O
gluten	O
-	O
free	O
diet	O
after	O
ruling	O
out	O
celiac	O
disease	O
and	O
wheat	O
allergy	B-PROC
.	O

We	O
observed	O
important	O
seasonal	O
differences	O
,	O
with	O
circulation	B-PROC
of	O
Human	O
Metapneumoviruses	O
,	O
RSV	O
A	O
and	O
B	O
and	O
coronavirus	O
only	O
during	O
summer	O
;	O
whereas	O
parainfluenza	O
viruses	O
were	O
identified	O
only	O
during	O
winter	O
.	O

The	O
use	O
of	O
dexmedetomidine	O
to	O
facilitate	O
extubation	O
in	O
children	O
intolerant	O
of	O
an	O
awake	O
,	O
intubated	O
state	O
may	O
abbreviate	O
ventilator	O
weaning	B-PROC
.	O

TITLE	O
:	O
Activated	O
GL7	O
ABSTRACT	O
:	O
Central	O
nervous	O
system	O
(	O
CNS	O
)	O
inflammation	O
associated	O
with	O
viral	B-PROC
infection	I-PROC
and	O
autoimmune	O
disease	O
results	O
in	O
the	O
accumulation	O
of	O
B	O
cells	O
in	O
various	O
differentiation	B-PROC
stages	O
.	O

Investigation	O
of	O
the	O
temporal	O
dynamics	O
of	O
B	B-PROC
cell	I-PROC
activation	I-PROC
in	O
draining	O
cervical	O
lymph	O
nodes	O
(	O
CLN	O
)	O
and	O
the	O
CNS	O
revealed	O
that	O
peak	O
CNS	O
infiltration	O
of	O
early	O
activated	O
,	O
unswitched	O
IgD	O

The	O
selection	O
of	O
drug	B-PROC
resistance	B-PROC
viral	O
strains	O
is	O
however	O
a	O
still	O
open	O
issue	O
requiring	O
constant	O
efforts	O
to	O
identify	O
new	O
anti	O
-	O
HIV	O
-	O
1	O
drugs	O
.	O

To	O
characterize	O
potential	O
for	O
interspecies	O
transmission	O
associated	O
with	O
feeding	B-PROC
behavior	I-PROC
,	O
we	O
also	O
analyzed	O
cytochrome	B-PROC
B	O
sequences	O
from	O
fecal	O
samples	O
to	O
identify	O
prey	O
species	O
and	O
found	O
that	O
domestic	O
cattle	O
(	O
Bos	O
taurus	O
)	O
made	O
up	O
the	O
majority	O
of	O
blood	O
meals	O
.	O

Using	O
the	O
purified	O
NS6	O
from	O
an	O
Escherichia	O
coli	O
expression	B-PROC
system	O
,	O
we	O
obtained	O
two	O
anti	O
-	O
NS6	O
monoclonal	O
antibodies	O
that	O
could	O
detect	O
the	O
predicted	O
NS6	O
in	O
cells	O
infected	O
with	O
PDCoV	O
or	O
transfected	O
with	O
NS6	O
-	O
expressing	O
plasmids	O
.	O

Recent	O
technological	O
developments	O
in	O
single	O
particle	O
cryo	O
-	O
electron	O
microscopy	O
allowed	O
us	O
to	O
determine	O
the	O
first	O
structure	O
of	O
a	O
coronavirus	O
S	O
glycoprotein	O
trimer	O
which	O
provided	O
a	O
framework	O
to	O
understand	O
the	O
mechanisms	O
of	O
viral	O
entry	O
and	O
suggested	O
potential	O
inhibition	B-PROC
strategies	O
for	O
this	O
family	O
of	O
viruses	O
.	O

Average	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
prior	O
to	O
cannulation	O
was	O
74	O
(	O
range	O
23	O
-	O
122	O
).	O

Severe	O
lung	O
injury	O
with	O
a	O
reproducible	O
deterioration	O
of	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
and	O
hemodynamics	B-PROC
can	O
be	O
induced	O
in	O
anesthetized	O
pigs	O
using	O
repeated	O
lung	O
lavages	O
with	O
warmed	O
0	O
.	O
9	O
%	O
saline	O
(	O
50	O
ml	O
/	O
kg	O
body	O
weight	O
).	O

Using	O
mAb	O
5E8	O
,	O
we	O
observed	O
that	O
the	O
N	O
protein	O
was	O
expressed	B-PROC
in	O
the	O
cytoplasm	O
during	O
TGEV	O
replication	O
and	O
that	O
the	O
protein	O
could	O
be	O
immunoprecipitated	O
from	O
TGEV	O
-	O
infected	O
PK	O
-	O
15	O
cells	O
.	O

Overall	O
,	O
the	O
rate	O
of	O
fever	B-PROC
in	O
confirmed	O
viral	O
respiratory	O
infections	O
in	O
adult	O
HCWs	O
was	O
23	O
·	O
4	O
%	O
(	O
37	O
/	O
158	O
).	O

TITLE	O
:	O
Neutrophils	O
promote	O
alveolar	O
epithelial	O
regeneration	B-PROC
by	O
enhancing	O
type	O
II	O
pneumocyte	O
proliferation	O
in	O
a	O
model	O
of	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

As	O
neutrophil	O
depletion	O
itself	O
may	O
alter	O
the	O
cytokine	O
response	O
,	O
we	O
questioned	O
the	O
contribution	O
of	O
neutrophils	O
to	O
alveolar	O
epithelial	O
repair	B-PROC
in	O
neutropenic	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)-/-	O
mice	O
.	O

A	O
respiratory	O
or	O
enteric	O
virus	O
was	O
detected	O
in	O
72	O
.	O
9	O
%	O
of	O
children	O
with	O
febrile	B-PROC
seizures	O
and	O
in	O
51	O
.	O
4	O
%	O
of	O
healthy	O
controls	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
determine	O
knowledge	O
,	O
attitude	O
and	O
practice	O
of	O
airborne	O
and	O
droplet	O
isolation	O
precautions	O
among	O
Dental	O
Health	O
Professionals	O
(	O
DHPs	O
)	O
(	O
dental	O
students	O
,	O
interns	O
,	O
practitioners	O
and	O
auxiliaries	O
)	O
during	O
the	O
outbreak	O
of	O
MERS	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	O
),	O
corona	O
virus	B-PROC
infection	I-PROC
in	O
Riyadh	O
city	O
,	O
Saudi	O
Arabia	O
.	O

TITLE	O
:	O
The	O
Emulsified	O
PFC	O
Oxycyte	O
ABSTRACT	O
:	O
Perfluorocarbons	O
(	O
PFCs	O
)	O
can	O
transport	B-PROC
50	O
times	O
more	O
oxygen	O
than	O
human	O
plasma	O
.	O

Their	O
properties	O
may	O
be	O
advantageous	O
in	O
preservation	O
of	O
tissue	B-PROC
viability	I-PROC
in	O
oxygen	O
-	O
deprived	O
states	O
,	O
such	O
as	O
in	O
acute	O
lung	O
injury	O
.	O

15	O
.	O
3	O
%	O
(	O
69	O
/	O
450	O
)	O
needed	O
intensive	O
care	O
and	O
1	O
.	O
6	O
%	O
(	O
7	O
/	O
450	O
)	O
died	B-PROC
.	O

As	O
the	O
mechanistic	O
pathway	B-PROC
for	O
this	O
ability	O
is	O
not	O
fully	O
known	O
,	O
we	O
extended	O
previous	O
studies	O
on	O
influenza	O
virus	O
tropism	B-PROC
in	O
cultured	O
human	O
pulmonary	O
endothelial	O
cells	O
.	O

ORFs	O
located	O
in	O
the	O
3	O
'-	O
terminal	O
one	O
-	O
third	O
of	O
the	O
genome	O
encode	O
structural	O
and	O
accessory	O
proteins	O
and	O
are	O
expressed	B-PROC
from	O
a	O
set	O
of	O
5	O
'	O
leader	O
-	O
containing	O
subgenomic	O
mRNAs	O
that	O
are	O
synthesized	O
by	O
a	O
process	O
called	O
discontinuous	O
transcription	B-PROC
.	O

TITLE	O
:	O
Feline	O
Coronaviruses	O
:	O
Pathogenesis	B-PROC
of	O
Feline	O
Infectious	O
Peritonitis	O
.	O

The	O
development	B-PROC
of	O
attenuated	O
virus	O
vaccines	O
to	O
combat	O
infections	O
caused	O
by	O
highly	O
pathogenic	O
CoVs	O
was	O
largely	O
based	O
on	O
the	O
identification	O
and	O
characterization	O
of	O
viral	O
virulence	B-PROC
proteins	O
that	O
,	O
for	O
example	O
,	O
interfere	O
with	O
the	O
innate	O
and	O
adaptive	B-PROC
immune	I-PROC
response	I-PROC
or	O
are	O
involved	O
in	O
interactions	O
with	O
specific	O
cell	O
types	O
,	O
such	O
as	O
macrophages	O
,	O
dendritic	O
and	O
epithelial	O
cells	O
,	O
and	O
T	O
lymphocytes	O
,	O
thereby	O
modulating	O
antiviral	O
host	O
responses	O
and	O
viral	O
pathogenesis	B-PROC
and	O
potentially	O
resulting	O
in	O
deleterious	O
side	O
effects	O
following	O
vaccination	O
.	O

Coronavirus	O
replicase	O
functions	O
include	O
more	O
or	O
less	O
universal	O
activities	O
of	O
plus	O
-	O
stranded	O
RNA	O
viruses	O
,	O
like	O
an	O
RNA	O
polymerase	O
(	O
nsp12	O
)	O
and	O
helicase	O
(	O
nsp13	O
),	O
but	O
also	O
a	O
number	O
of	O
rare	O
or	O
even	O
unique	O
domains	O
involved	O
in	O
mRNA	B-PROC
capping	B-PROC
(	O
nsp14	O
,	O
nsp16	O
)	O
and	O
fidelity	O
control	O
(	O
nsp14	O
).	O

Fifteen	O
patients	O
(	O
60	O
.	O
0	O
%)	O
developed	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
14	O
(	O
56	O
%)	O
died	B-PROC
of	O
the	O
ARDS	O
or	O
multiorgan	O
failure	O
.	O

The	O
administration	O
of	O
intravenous	O
immunoglobulins	O
seems	O
to	O
reinforce	O
the	O
immune	B-PROC
response	I-PROC
to	O
the	O
infection	O
in	O
particular	O
in	O
patients	O
with	O
inadequate	O
levels	O
of	O
antibodies	O
and	O
when	O
an	O
enriched	O
IgM	O
preparation	O
has	O
been	O
used	O
;	O
however	O
,	O
more	O
studies	O
are	O
needed	O
to	O
determinate	O
their	O
impact	O
on	O
outcome	O
and	O
to	O
define	O
the	O
population	O
that	O
will	O
receive	O
more	O
benefit	O
.	O

Purchase	O
of	O
livestock	O
was	O
an	O
additional	O
risk	O
factor	O
for	O
BCoV	O
seropositivity	O
,	O
included	O
in	O
the	O
model	O
as	O
in	O
-	O
degree	O
,	O
which	O
was	O
defined	O
as	O
the	O
number	O
of	O
incoming	O
movements	B-PROC
from	O
individual	O
herds	O
,	O
through	O
animal	O
purchase	O
,	O
over	O
a	O
period	O
of	O
five	O
years	O
.	O

Among	O
the	O
COPD	O
exacerbations	O
,	O
viral	B-PROC
infection	I-PROC
was	O
detected	O
in	O
78	O
episodes	O
(	O
28	O
.	O
1	O
%)	O
from	O
67	O
subjects	O
.	O

Moreover	O
,	O
female	O
subjects	O
are	O
at	O
significantly	O
higher	O
risk	O
for	O
viral	B-PROC
infections	I-PROC
in	O
COPD	O
exacerbations	O
.	O

Microproteinuria	O
has	O
been	O
associated	O
with	O
the	O
presence	O
of	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
as	O
well	O
as	O
trauma	O
,	O
although	O
its	O
association	O
with	O
AP	O
is	O
not	O
well	O
understood	O
.	O

The	O
α1	O
-	O
microglobulin	O
/	O
creatinine	O
ratio	O
upon	O
presentation	O
with	O
AP	O
is	O
related	O
to	O
inflammation	O
and	O
predicts	O
development	B-PROC
of	O
organ	O
failure	O
.	O

A	O
PCR	O
targeting	B-PROC
a	O
portion	O
of	O
ORF1a	O
of	O
python	O
nidoviruses	O
was	O
used	O
to	O
detect	O
nidoviruses	O
in	O
diagnostic	O
samples	O
from	O
live	O
boas	O
and	O
pythons	O
.	O

The	O
treatment	O
group	O
had	O
significant	O
improvement	O
in	O
the	O
ratio	O
of	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
in	O
arterial	O
blood	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
and	O
lung	O
injury	O
score	O
(	O
p	O
=	O
0	O
.	O
01	O
),	O
and	O
similar	O
timing	O
to	O
removal	O
of	O
vital	O
organ	O
support	O
(	O
HR	O
0	O
.	O
74	O
,	O
95	O
%	O
CI	O
0	O
.	O
51	O
-	O
1	O
.	O
07	O
;	O
p	O
=	O
0	O
.	O
107	O
).	O

Thus	O
,	O
in	O
addition	O
to	O
recombination	B-PROC
and	O
mutation	O
,	O
HCoV	O
genomes	O
evolve	O
through	O
gene	O
gains	O
and	O
losses	O
.	O

ABSTRACT	O
:	O
Resistance	B-PROC
to	O
respiratory	O
pathogens	O
,	O
including	O
coronavirus	O
-	O
induced	O
infection	O
and	O
clinical	O
illness	O
in	O
chickens	O
has	O
been	O
correlated	O
with	O
the	O
B	O
(	O
MHC	B-PROC
)	O
complex	O
and	O
differential	O
ex	O
vivo	O
macrophage	O
responses	O
.	O

Additional	O
factors	O
are	O
also	O
knowingly	O
associated	O
with	O
worse	O
outcomes	O
:	O
higher	O
values	O
of	O
ICU	O
severity	O
score	O
,	O
presence	O
of	O
severe	O
sepsis	O
,	O
and	O
lower	O
ratio	O
of	O
arterial	O
oxygen	B-PROC
tension	I-PROC
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
.	O

TITLE	O
:	O
Discovery	O
of	O
novel	O
piperidine	O
-	O
substituted	O
indolylarylsulfones	O
as	O
potent	O
HIV	O
NNRTIs	O
via	O
structure	O
-	O
guided	O
scaffold	O
morphing	O
and	O
fragment	O
rearrangement	B-PROC
.	O

By	O
mutagenesis	B-PROC
analysis	O
,	O
it	O
was	O
found	O
that	O
(	O
i	O
)	O
the	O
hexamer	O
AGUAAA	O
and	O
poly	O
(	O
A	O
)	O
tail	O
are	O
two	O
important	O
elements	O
responsible	O
for	O
synthesis	B-PROC
of	O
the	O
coronavirus	O
poly	O
(	O
A	O
)	O
tail	O
and	O
may	O
function	O
in	O
concert	O
to	O
accomplish	O
polyadenylation	B-PROC
and	O
(	O
ii	O
)	O
the	O
function	O
of	O
the	O
hexamer	O
AGUAAA	O
in	O
coronaviral	O
polyadenylation	B-PROC
is	O
position	O
dependent	O
.	O

Our	O
results	O
provide	O
the	O
first	O
genetic	O
evidence	O
to	O
gain	O
insight	O
into	O
coronaviral	O
polyadenylation	B-PROC
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
at	O
the	O
Animal	O
-	O
Human	O
Interface	O
:	O
Inputs	O
on	O
Exposure	O
Pathways	B-PROC
from	O
an	O
Expert	O
-	O
Opinion	O
Elicitation	O
.	O

Experts	O
believed	O
that	O
dromedary	O
camels	O
play	O
the	O
largest	O
role	O
in	O
MERS	O
-	O
CoV	O
infection	O
of	O
other	O
dromedaries	O
;	O
however	O
,	O
they	O
also	O
indicated	O
a	O
significant	O
influence	O
of	O
the	O
season	O
(	O
i	O
.	O
e	O
.	O
calving	O
or	O
weaning	B-PROC
periods	B-PROC
)	O
on	O
transmission	O
risk	O
.	O

High	O
antibody	B-PROC
prevalence	O
(>	O
90	O
%)	O
was	O
only	O
found	O
to	O
FHV	O
-	O
1	O
and	O
FIV	O
in	O
lions	O
.	O

Our	O
results	O
emphasize	O
the	O
need	O
for	O
a	O
comprehensive	O
,	O
multispecies	O
approach	O
to	O
disease	O
monitoring	O
and	O
the	O
development	B-PROC
of	O
coordinated	O
management	O
strategies	O
for	O
subpopulations	O
likely	O
to	O
be	O
connected	O
in	O
transboundary	O
initiatives	O
.	O

We	O
demonstrate	O
that	O
LPS	O
induced	O
Nur77	O
expression	B-PROC
and	O
nuclear	B-PROC
export	I-PROC
in	O
A549	O
cells	O
.	O

In	O
vivo	O
,	O
LPS	O
induced	O
Nur77	O
expression	B-PROC
in	O
lung	O
in	O
ARDS	O
rats	O
.	O

For	O
the	O
aHUS	O
the	O
initial	O
management	O
is	O
supportive	O
and	O
similar	O
to	O
the	O
approach	O
for	O
STEC	O
-	O
HUS	O
;	O
currently	O
we	O
have	O
moved	O
from	O
the	O
historic	O
plasma	O
therapy	O
to	O
new	O
therapeutic	O
approaches	O
,	O
first	O
of	O
all	O
eculizumab	O
,	O
a	O
monoclonal	O
antibody	B-PROC
that	O
blocks	O
the	O
C5	O
cascade	O
.	O

Further	O
work	O
is	O
needed	O
to	O
explore	O
potential	O
pathogen	O
interactions	O
and	O
their	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
PTB	O
.	O

To	O
learn	B-PROC
from	O
our	O
experience	O
,	O
we	O
described	O
the	O
critical	O
care	O
response	O
to	O
the	O
outbreak	O
.	O

In	O
all	O
documented	O
cases	O
of	O
bleeding	O
a	O
bolus	O
and	O
infusion	O
of	O
heparin	O
was	O
administered	O
,	O
aiming	O
for	O
an	O
activated	O
clotting	B-PROC
time	O
(	O
ACT	O
)	O
target	O
longer	O
than	O
150	O
seconds	O
.	O

TITLE	O
:	O
Design	O
and	O
Rationale	O
of	O
the	O
Reevaluation	O
of	O
Systemic	O
Early	O
Neuromuscular	B-PROC
Blockade	I-PROC
Trial	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

ABSTRACT	O
:	O
Neuromuscular	B-PROC
blockade	I-PROC
(	O
NMB	O
)	O
has	O
been	O
shown	O
to	O
improve	O
outcome	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
adults	O
,	O
challenging	O
maintaining	O
spontaneous	O
breathing	B-PROC
when	O
there	O
is	O
severe	O
lung	O
injury	O
.	O

We	O
tested	O
in	O
a	O
prospective	O
physiological	O
study	O
the	O
hypothesis	O
that	O
continuous	O
administration	O
of	O
NMB	O
agents	O
in	O
mechanically	O
ventilated	O
children	O
with	O
severe	O
acute	O
hypoxemic	O
respiratory	O
failure	O
(	O
AHRF	O
)	O
improves	O
the	O
oxygenation	B-PROC
index	O
without	O
a	O
redistribution	O
of	O
tidal	O
volume	O
V	O
Oxygenation	B-PROC
index	O
,	O
PaO	B-PROC
Twenty	O
-	O
two	O
patients	O
were	O
studied	O
(	O
N	O
=	O
18	O
met	O
the	O
criteria	O
for	O
pediatric	O
ARDS	O
).	O

Subgroup	O
analysis	O
showed	O
that	O
OI	O
decreased	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
PaO	B-PROC
NMB	O
resulted	O
in	O
an	O
improved	O
oxygenation	B-PROC
index	O
in	O
pediatric	O
patients	O
with	O
AHRF	O
.	O

Upon	O
detecting	O
viral	O
dsRNA	O
,	O
PKR	O
phosphorylates	O
eIF2α	O
,	O
leading	O
to	O
the	O
inhibition	B-PROC
of	O
cellular	O
and	O
viral	O
translation	B-PROC
and	O
the	O
formation	B-PROC
of	O
stress	O
granules	O
(	O
SGs	O
),	O
which	O
are	O
increasingly	O
recognized	O
as	O
platforms	O
for	O
antiviral	O
signaling	B-PROC
pathways	B-PROC
.	O

It	O
is	O
unknown	O
whether	O
cellular	O
infection	O
by	O
MERS	O
-	O
CoV	O
activates	O
the	O
stress	B-PROC
response	I-PROC
pathway	B-PROC
or	O
whether	O
the	O
virus	O
has	O
evolved	O
strategies	O
to	O
suppress	O
this	O
infection	O
-	O
limiting	O
pathway	B-PROC
.	O

MERS	O
-	O
CoV	O
p4a	O
represents	O
the	O
first	O
coronavirus	O
stress	B-PROC
response	I-PROC
antagonist	B-PROC
described	O
.	O

ABSTRACT	O
:	O
For	O
infectious	O
diseases	O
caused	O
by	O
highly	O
pathogenic	O
agents	O
(	O
e	O
.	O
g	O
.,	O
Ebola	O
/	O
Lassa	O
fever	B-PROC
virus	O
,	O
SARS	O
-/	O
MERS	O
-	O
CoV	O
,	O
pandemic	O
influenza	O
virus	O
)	O
which	O
have	O
the	O
potential	O
to	O
spread	O
over	O
several	O
continents	O
within	O
only	O
a	O
few	O
days	O
,	O
international	O
Health	O
Protection	O
Authorities	O
have	O
taken	O
appropriate	O
measures	O
to	O
limit	O
the	O
consequences	O
of	O
a	O
possible	O
spread	O
.	O

The	O
viral	B-PROC
infections	I-PROC
have	O
been	O
reported	O
in	O
more	O
than	O
1700	O
humans	O
,	O
ranging	O
from	O
asymptomatic	O
or	O
mild	O
cases	O
to	O
severe	O
pneumonia	O
with	O
a	O
mortality	O
rate	O
of	O
40	O
%.	O

In	O
particular	O
,	O
52	O
.	O
4	O
%	O
of	O
patients	O
with	O
viral	B-PROC
infection	I-PROC
had	O
a	O
concurrent	O
bacterial	O
infection	O
,	O
and	O
rhinovirus	O
was	O
the	O
most	O
common	O
virus	O
in	O
mixed	O
infections	O
(	O
40	O
/	O
55	O
).	O

ABSTRACT	O
:	O
The	O
discovery	O
of	O
potent	O
and	O
pan	O
-	O
genotypic	O
HCV	O
NS5A	O
inhibitors	O
faces	O
many	O
challenges	O
including	O
the	O
significant	O
diversity	O
among	O
genotypes	O
,	O
substantial	O
potency	O
shift	O
conferred	O
on	O
some	O
key	O
resistance	B-PROC
-	O
associated	O
variants	O
,	O
inconsistent	O
SARs	O
between	O
different	O
genotypes	O
and	O
mutants	O
,	O
and	O
the	O
lacking	O
of	O
models	O
of	O
inhibitor	O
/	O
protein	O
complexes	O
for	O
rational	O
inhibitor	O
design	O
.	O

Several	O
sites	O
of	O
recombination	B-PROC
were	O
scattered	O
throughout	O
the	O
genome	O
suggesting	O
that	O
the	O
Sudan	O
-	O
QX	O
-	O
like	O
strain	O
emerged	O
as	O
a	O
unique	O
recombinant	O
from	O
multiple	O
recombination	B-PROC
events	O
of	O
parental	O
viruses	O
from	O
4	O
/	O
91	O
,	O
H120	O
and	O
ITA	O
/	O
90254	O
/	O
2005	O
genotypes	O
.	O

Porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
and	O
equine	O
arteritis	O
virus	O
are	O
two	O
major	O
members	O
of	O
the	O
arterivirus	O
family	O
.	O

Given	O
that	O
the	O
strain	O
OC43	O
is	O
neurovirulent	O
in	O
mice	O
and	O
induces	O
neuronal	B-PROC
cell	B-PROC
death	I-PROC
,	O
we	O
explored	O
the	O
neuronal	O
response	O
to	O
infection	O
by	O
characterizing	O
the	O
activation	O
of	O
RCD	O
.	O

Our	O
results	O
revealed	O
that	O
classical	O
apoptosis	B-PROC
associated	O
with	O
the	O
Bax	O
protein	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
HCoV	O
-	O
OC43	O
-	O
induced	O
neuronal	B-PROC
cell	B-PROC
death	I-PROC
and	O
that	O
RIP1	O
and	O
MLKL	O
,	O
two	O
cellular	O
proteins	O
usually	O
associated	O
with	O
necroptosis	B-PROC
(	O
an	O
RCD	O
back	O
-	O
up	O
system	O
when	O
apoptosis	B-PROC
is	O
not	O
adequately	O
induced	O
),	O
both	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
process	O
.	O

Babesia	O
-	O
infected	O
individuals	O
had	O
a	O
regenerative	O
response	O
of	O
the	O
erythrocytic	O
lineage	O
,	O
an	O
active	O
inflammatory	B-PROC
response	I-PROC
and	O
hepatic	B-PROC
function	I-PROC
impairment	O
.	O

In	O
sum	O
,	O
FRCs	B-PROC
act	O
as	O
an	O
'	O
on	O
-	O
demand	O
'	O
immunological	O
'	O
rheostat	O
'	O
by	O
restraining	O
activation	O
of	O
group	O
1	O
ILCs	O
and	O
thereby	O
preventing	O
immunopathological	O
damage	O
in	O
the	O
intestine	O
.	O

Data	O
regarding	O
demographic	O
,	O
underlying	O
conditions	O
,	O
arterial	O
blood	B-PROC
gases	I-PROC
and	O
clinical	O
outcomes	O
were	O
collected	O
and	O
analyzed	O
.	O

ABSTRACT	O
:	O
For	O
patients	O
with	O
a	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
represents	O
a	O
life	O
-	O
saving	O
measure	O
.	O

This	O
cleavage	B-PROC
motif	O
is	O
present	O
in	O
the	O
majority	O
of	O
cell	O
culture	O
-	O
adapted	O
PEDV	O
strains	O
but	O
is	O
missing	O
in	O
emerging	O
field	O
isolates	O
.	O

Growth	B-PROC
retardation	O
in	O
recombinant	O
PEDV	O
carrying	O
uncleavable	O
N	O
suggests	O
a	O
replication	O
advantage	O
provided	O
by	O
the	O
cleavage	B-PROC
event	O
,	O
at	O
least	O
in	O
the	O
cell	O
culture	O
system	O
.	O

GILZ	O
protein	O
and	O
gene	B-PROC
expression	I-PROC
was	O
quantified	O
in	O
blood	O
neutrophils	O
,	O
along	O
with	O
markers	O
of	O
inflammation	O
(	O
CRP	O
,	O
extracellular	O
DNA	O
)	O
or	O
its	O
resolution	O
(	O
Annexin	O
A1	O
).	O

Contrary	O
to	O
some	O
markers	O
of	O
inflammation	O
or	O
its	O
resolution	O
,	O
the	O
levels	O
of	O
gilz	O
gene	B-PROC
expression	I-PROC
were	O
related	O
to	O
ARDS	O
severity	O
.	O

RESULTS	O
:	O
Neutrophil	O
GILZ	O
expression	B-PROC
was	O
detected	O
at	O
the	O
transcriptional	B-PROC
and	O
/	O
or	O
translational	B-PROC
level	O
in	O
9	O
/	O
17	O
ARDS	O
patients	O
(	O
in	O
particular	O
7	O
/	O
10	O
severe	O
ARDS	O
)	O
and	O
in	O
2	O
/	O
14	O
ventilated	O
controls	O
.	O

Studies	O
report	O
decreased	O
nosocomial	O
transmission	O
when	O
aggressive	B-PROC
infection	O
control	O
measures	O
are	O
implemented	O
with	O
more	O
success	O
using	O
a	O
multicomponent	O
approach	O
.	O

Hip	O
width	O
,	O
hip	O
height	O
,	O
body	O
length	O
,	O
heart	O
girth	O
,	O
and	O
body	O
weight	O
were	O
measured	O
at	O
birth	B-PROC
and	O
weaning	B-PROC
.	O

These	O
results	O
indicate	O
that	O
free	O
-	O
access	O
acidified	O
milk	O
replacer	O
feeding	O
tended	O
to	O
support	O
improved	O
health	O
,	O
and	O
greater	O
body	O
weight	O
gain	O
and	O
structural	O
growth	B-PROC
during	O
the	O
preweaning	O
period	O
;	O
these	O
effects	O
did	O
not	O
persist	O
in	O
the	O
postweaning	O
period	O
.	O

The	O
growth	B-PROC
advantage	O
observed	O
before	O
weaning	B-PROC
in	O
the	O
ACD	O
calves	O
likely	O
disappeared	O
due	O
to	O
the	O
weaning	B-PROC
methods	O
used	O
.	O

This	O
tremendously	O
limits	O
the	O
capacity	O
to	O
conduct	B-PROC
viral	O
genomic	O
research	O
,	O
particularly	O
the	O
application	O
of	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
).	O

The	O
process	O
generates	O
barcoded	O
DNA	O
amplicons	O
that	O
range	O
in	O
length	O
from	O
300	O
to	O
1	O
,	O
000	O
bp	O
,	O
which	O
cannot	O
be	O
used	O
to	O
rescue	O
a	O
virus	O
and	O
are	O
stable	O
to	O
transport	B-PROC
at	O
room	O
temperature	O
.	O

Our	O
findings	O
suggested	O
that	O
GLTSCR2	O
contributed	O
to	O
efficient	O
viral	B-PROC
replication	I-PROC
,	O
and	O
GLTSCR2	O
should	O
be	O
considered	O
as	O
a	O
potential	O
target	O
for	O
therapeutic	O
control	O
of	O
viral	B-PROC
infection	I-PROC
.	O

It	O
has	O
been	O
confirmed	O
that	O
T	O
-	O
cell	O
immunity	B-PROC
plays	O
an	O
important	O
role	O
in	O
recovery	O
from	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
results	O
showed	O
that	O
antibody	B-PROC
against	O
CCoV	O
-	O
II	O
was	O
present	O
in	O
87	O
dogs	O
(	O
43	O
.	O
3	O
%).	O

The	O
precise	O
anti	O
-	O
DENV	O
replication	O
mechanism	O
of	O
celastrol	O
was	O
clarified	O
using	O
specific	O
RNA	B-PROC
silencing	I-PROC
and	O
specific	O
inhibitor	O
.	O

In	O
the	O
adjusted	O
analysis	O
,	O
a	O
statistically	O
significant	O
relationship	O
between	O
PEEP	O
and	O
ICP	O
and	O
PEEP	O
and	O
CPP	O
was	O
found	O
only	O
among	O
observations	O
occurring	O
during	O
periods	B-PROC
of	O
severe	O
lung	O
injury	O
.	O

Our	O
data	O
demonstrate	O
that	O
infection	O
with	O
TGEV	O
resulted	O
in	O
increased	O
glucose	B-PROC
uptake	I-PROC
and	O
augmented	O
expression	B-PROC
of	O
EGFR	O
,	O
SGLT1	O
and	O
GLUT2	O
.	O

Moreover	O
,	O
inhibition	B-PROC
studies	O
showed	O
that	O
EGFR	O
modulated	O
glucose	B-PROC
uptake	I-PROC
in	O
control	O
and	O
TGEV	O
infected	O
cells	O
.	O

Electroencephalogram	O
ruled	O
out	O
brain	O
death	B-PROC
diagnosis	O
as	O
a	O
paradoxical	O
sleep	B-PROC
trace	O
was	O
recorded	O
.	O

ECLS	O
in	O
critical	O
CS	O
as	O
a	O
bridge	O
to	O
implantation	B-PROC
of	O
the	O
Berlin	O
Heart	O
Excor	O
ventricular	O
assist	O
device	O
is	O
safe	O
and	O
is	O
associated	O
with	O
improvement	O
in	O
end	O
-	O
organ	O
function	O
leading	O
to	O
similar	O
excellent	O
early	O
and	O
long	O
-	O
term	O
survival	O
and	O
incidences	O
of	O
major	O
complications	O
as	O
in	O
patients	O
without	O
the	O
need	O
for	O
preoperative	O
ECLS	O
support	O
.	O

Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
(	O
QSAR	O
)	O
and	O
molecular	O
docking	B-PROC
are	O
both	O
used	O
to	O
compare	O
the	O
performance	O
of	O
the	O
selected	O
nucleotide	O
inhibitors	O
to	O
their	O
parent	O
nucleotides	O
and	O
Ribavirin	O
.	O

Based	O
on	O
this	O
novel	O
design	O
,	O
simple	O
agglutination	B-PROC
tests	O
of	O
the	O
IgG	O
antibodies	O
of	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
nucleoprotein	O
(	O
NP	O
)	O
and	O
Middle	O
East	O
Respiratory	O
Virus	O
(	O
MERS	O
)	O
NP	O
in	O
rabbit	O
sera	O
were	O
successfully	O
developed	O
by	O
conjugating	O
the	O
S	O
.	O
aureus	O
nanobioparticles	O
with	O
two	O
fusion	O
proteins	O
EBOV	O
NP	O
-	O
CBD	O
and	O
MERS	O
NP	O
-	O
CBD	O
,	O
respectively	O
.	O

First	O
,	O
the	O
time	O
interval	O
between	O
mechanical	O
ventilator	O
support	O
and	O
ECMO	O
implantation	B-PROC
was	O
shorter	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
acute	O
oesophageal	O
necrosis	B-PROC
(	O
AEN	O
)	O
and	O
non	O
-	O
occlusive	O
mesenteric	O
ischaemia	O
in	O
an	O
otherwise	O
healthy	O
30	O
-	O
year	O
-	O
old	O
man	O
with	O
cocaine	O
and	O
alcohol	O
abuse	O
.	O

ABSTRACT	O
:	O
Obesity	O
worsens	O
asthma	O
control	O
partly	O
through	O
enhanced	O
airway	O
neutrophilia	O
,	O
altered	O
lung	O
mechanics	O
and	O
comorbidities	O
,	O
including	O
obstructive	O
sleep	B-PROC
apnea	O
syndrome	O
,	O
gastroesophageal	O
reflux	O
disease	O
and	O
depression	O
.	O

In	O
acute	O
asthma	O
,	O
IL	B-PROC
-	I-PROC
17	I-PROC
expression	B-PROC
,	O
like	O
most	O
other	O
clinical	O
measures	O
,	O
was	O
similar	O
among	O
lean	O
,	O
overweight	O
and	O
obese	O
groups	O
,	O
but	O
was	O
higher	O
in	O
acute	O
versus	O
stable	O
asthma	O
subjects	O
,	O
with	O
sputum	O
IL	B-PROC
-	I-PROC
17	I-PROC
correlating	O
positively	O
with	O
sputum	O
neutrophils	O
and	O
negatively	O
with	O
FEV	O
IL	B-PROC
-	I-PROC
17	I-PROC
contributes	O
to	O
worse	O
disease	O
control	O
in	O
obese	O
asthma	O
through	O
enhancing	O
airway	O
neutrophilia	O
and	O
depression	O
,	O
and	O
may	O
implicate	O
in	O
asthma	O
exacerbations	O
.	O

TITLE	O
:	O
Passive	O
immunotherapy	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
infection	O
with	O
equine	O
immunoglobulin	B-PROC
or	O
immunoglobulin	B-PROC
fragments	O
in	O
a	O
mouse	O
model	O
.	O

Although	O
membrane	B-PROC
fusion	I-PROC
has	O
been	O
broadly	O
studied	O
,	O
there	O
are	O
still	O
major	O
gaps	O
in	O
the	O
molecular	O
details	O
of	O
lipid	O
rearrangements	O
in	O
the	O
bilayer	O
during	O
fusion	O
peptide	O
-	O
membrane	O
interactions	O
.	O

Eligible	O
articles	O
reported	O
clinical	O
outcomes	O
,	O
especially	O
severe	O
complications	O
or	O
death	B-PROC
associated	O
with	O
MERS	O
.	O

The	O
heterogeneity	O
for	O
the	O
risk	O
of	O
death	B-PROC
and	O
severe	O
manifestations	O
was	O
substantially	O
high	O
among	O
the	O
studies	O
,	O
and	O
varying	O
study	O
designs	O
was	O
one	O
of	O
the	O
underlying	O
reasons	O
for	O
this	O
heterogeneity	O
.	O

A	O
statistical	O
estimation	O
of	O
the	O
risk	O
of	O
MERS	O
death	B-PROC
and	O
identification	O
of	O
risk	O
factors	O
must	O
be	O
conducted	O
,	O
particularly	O
considering	O
the	O
study	O
design	O
and	O
potential	O
biases	O
associated	O
with	O
case	O
detection	O
and	O
diagnosis	O
.	O

According	O
to	O
the	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
P	O
/	O
F	O
ratio	O
)	O
at	O
7	O
days	O
,	O
patients	O
were	O
classified	O
into	O
PPP	O
-	O
positive	O
(	O
P	O
/	O
F	O
ratio	O
>	O
300	O
)	O
and	O
PPP	O
-	O
negative	O
groups	O
;	O
also	O
,	O
the	O
patients	O
were	O
classified	O
into	O
survival	O
and	O
nonsurvival	O
groups	O
according	O
to	O
28	O
-	O
day	O
mortality	O
.	O

Concurrently	O
,	O
the	O
frequency	O
of	O
occurrence	O
of	O
the	O
wild	O
type	O
at	O
the	O
two	O
positions	O
was	O
only	O
6	O
.	O
5	O
%	O
±	O
1	O
.	O
7	O
%	O
on	O
average	O
,	O
supporting	O
the	O
hypothesis	O
that	O
selection	O
pressure	O
exerted	B-PROC
by	O
the	O
host	O
immune	B-PROC
response	I-PROC
played	O
a	O
critical	O
role	O
in	O
shaping	O
genetic	O
variants	O
and	O
their	O
interaction	O
in	O
human	O
MERS	O
-	O
CoVs	O
during	O
the	O
outbreak	O
.	O

As	O
an	O
alternative	O
to	O
chicks	O
,	O
this	O
study	O
used	O
an	O
in	O
vitro	O
infection	O
model	O
to	O
identify	O
single	O
-	O
nucleotide	O
polymorphisms	B-PROC
(	O
SNPs	O
)	O
within	O
the	O
part	O
-	O
S1	O
gene	O
of	O
two	O
live	O
infectious	O
bronchitis	O
virus	O
vaccine	O
strains	O
(	O
793B	O
and	O
Massachusetts	O
)	O
following	O
single	O
or	O
dual	O
inoculation	O
onto	O
tracheal	O
organ	O
cultures	O
.	O

The	O
influence	O
of	O
the	O
increased	O
SNP	O
and	O
hydrophobic	O
properties	O
of	O
the	O
translated	O
proteins	O
on	O
the	O
vaccine	O
viruses	O
'	O
virulence	B-PROC
is	O
unknown	O
.	O

However	O
,	O
the	O
mechanism	O
underlying	O
the	O
regulation	B-PROC
of	O
coronavirus	O
replication	O
by	O
CsA	O
is	O
unknown	O
.	O

TITLE	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
and	O
the	O
risk	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
propensity	O
-	O
matched	O
cohort	O
study	O
.	O

ABSTRACT	O
:	O
The	O
coordinated	O
recognition	O
of	O
virus	O
-	O
derived	O
T	O
cell	O
epitopes	O
and	O
MHC	B-PROC
molecules	O
by	O
T	O
cells	O
plays	O
a	O
pivotal	O
role	O
in	O
cellular	B-PROC
immunity	I-PROC
-	O
mediated	O
virus	O
clearance	O
.	O

In	O
particular	O
,	O
the	O
study	O
investigates	O
whether	O
the	O
U	O
-	O
shaped	O
curve	O
becomes	O
a	O
J	O
-	O
shaped	O
curve	O
due	O
to	O
the	O
interaction	O
between	O
medical	O
vulnerability	O
and	O
labor	B-PROC
market	O
vulnerability	O
after	O
an	O
outbreak	O
,	O
assuming	O
that	O
the	O
relative	O
vulnerability	O
in	O
the	O
labor	B-PROC
market	O
by	O
age	O
shows	O
a	O
U	O
curve	O
with	O
peaks	O
for	O
the	O
young	O
group	O
and	O
middle	O
aged	O
and	O
old	O
aged	O
groups	O
using	O
the	O
Economically	O
Active	O
Population	O
Survey	O
.	O

Prompt	O
recognition	O
and	O
initiation	O
of	O
immunotherapy	O
including	O
intravenous	O
immunoglobulin	B-PROC
or	O
plasmapheresis	O
,	O
together	O
with	O
supportive	O
care	O
including	O
treatment	O
of	O
underlying	O
infections	O
and	O
physical	O
therapy	O
,	O
can	O
improve	O
outcomes	O
in	O
both	O
myasthenic	O
crisis	O
and	O
GBS	O
.	O

TITLE	O
:	O
Differential	O
Cell	O
Count	O
and	O
CRP	O
Level	O
in	O
Blood	O
as	O
Predictors	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
in	O
Acute	O
Febrile	B-PROC
Patients	O
during	O
Nosocomial	O
Outbreak	O
.	O

Simple	O
laboratory	O
data	O
such	O
as	O
complete	O
blood	O
counts	O
(	O
CBC	O
)	O
with	O
differential	O
count	O
could	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
MERS	O
and	O
triage	O
at	O
the	O
initial	O
presentation	O
of	O
acute	O
febrile	B-PROC
patients	O
in	O
outbreak	O
setting	O
.	O

Following	O
vaccination	O
,	O
swabs	O
and	O
tissues	O
collected	O
at	O
intervals	O
were	O
pooled	O
and	O
RNA	O
was	O
extracted	O
for	O
detection	O
of	O
IBV	O
by	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
.	O

Single	O
nucleotide	O
polymorphisms	B-PROC
,	O
amino	O
acid	O
variations	O
and	O
hydrophobicity	O
changes	O
were	O
identified	O
and	O
recorded	O
for	O
each	O
sampling	O
point	O
.	O

Survival	O
has	O
steadily	O
improved	O
for	O
a	O
decade	O
,	O
reaching	B-PROC
up	O
to	O
65	O
%	O
at	O
hospital	O
discharge	O
in	O
the	O
most	O
recent	O
cohorts	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
widely	O
used	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
myocarditis	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
treatment	O
on	O
the	O
formation	B-PROC
of	O
arterivirus	O
-	O
induced	O
membrane	O
structures	O
.	O

IB	O
virus	O
primarily	O
affects	O
respiratory	O
tract	O
,	O
but	O
strains	O
differ	O
in	O
their	O
tropism	B-PROC
for	O
such	O
other	O
target	O
organs	O
as	O
kidneys	O
and	O
alimentary	O
tract	O
.	O

Although	O
the	O
epidemic	O
was	O
unprecedented	O
,	O
the	O
world	O
had	O
previously	O
experienced	O
several	O
acute	O
public	O
health	O
emergencies	O
requiring	O
global	O
coordination	B-PROC
.	O

Pregnant	O
multiparous	O
sows	O
and	O
their	O
litters	O
were	O
allocated	O
to	O
one	O
of	O
3	O
treatment	O
groups	O
:	O
Group	O
1	O
-	O
6	O
serum	O
antibody	B-PROC
-	O
negative	O
sows	O
and	O
a	O
subset	O
(	O
n	O
=	O
11	O
)	O
of	O
their	O
piglets	O
.	O

However	O
,	O
when	O
combined	O
with	O
previous	O
PEDV	O
literature	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
optimal	O
protection	O
to	O
piglets	O
will	O
be	O
provided	O
by	O
dams	O
able	O
to	O
deliver	O
sufficient	O
lactogenic	O
immunity	B-PROC
,	O
both	O
humoral	O
and	O
cellular	O
,	O
to	O
their	O
offspring	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
genome	O
-	O
wide	O
differences	O
between	O
dead	B-PROC
and	O
recovered	O
suckling	O
piglets	O
from	O
commercial	O
farms	O
after	O
PED	O
outbreaks	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
membrane	O
(	O
M	O
)	O
protein	O
acts	O
as	O
a	O
dominant	O
immunogen	O
and	O
is	O
a	O
major	O
player	O
in	O
virus	B-PROC
assembly	I-PROC
.	O

TITLE	O
:	O
Hepatitis	O
E	O
Virus	B-PROC
Infection	I-PROC
after	O
Platelet	O
Transfusion	O
in	O
an	O
Immunocompetent	O
Trauma	O
Patient	O
.	O

All	O
these	O
results	O
suggest	O
that	O
these	O
two	O
novel	O
epitopes	O
and	O
their	O
cognate	O
MAbs	O
could	O
serve	O
as	O
the	O
basis	O
for	O
the	O
development	B-PROC
of	O
precise	O
diagnostic	O
assays	O
for	O
PEDV	O
.	O

There	O
was	O
much	O
improvement	O
with	O
airway	O
pressure	O
release	O
ventilation	O
mode	O
of	O
ventilation	O
,	O
but	O
the	O
child	O
succumbed	O
to	O
death	B-PROC
due	O
to	O
pulmonary	O
hemorrhage	O
.	O

It	O
was	O
found	O
that	O
the	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
TNF	O
-	O
The	O
study	O
found	O
that	O
,	O
as	O
a	O
potential	O
treatment	O
,	O
MSCs	O
could	O
work	O
on	O
multiple	O
S1P	O
related	O
genes	O
simultaneously	O
.	O

Activated	O
platelets	O
,	O
neutrophils	O
,	O
endothelial	O
cells	O
,	O
neutrophil	O
extracellular	O
traps	O
,	O
microparticles	O
,	O
and	O
coagulation	B-PROC
proteases	O
,	O
participate	O
in	O
the	O
complex	O
process	O
of	O
immunothrombosis	O
,	O
which	O
is	O
a	O
key	O
event	O
in	O
ARDS	O
pathophysiology	O
.	O

A	O
comparison	O
of	O
predicted	O
protein	O
sequences	O
also	O
demonstrated	O
the	O
existence	O
of	O
two	O
clade	O
A	O
lineages	O
with	O
unique	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
,	O
A1	O
(	O
EMC	O
/	O
2012	O
and	O
Jordan	O
-	O
N3	O
/	O
2012	O
)	O
and	O
A2	O
(	O
D998	O
/	O
15	O
and	O
NRCE	O
-	O
HKU205	O
),	O
circulating	O
in	O
humans	O
and	O
camels	O
,	O
respectively	O
.	O

TITLE	O
:	O
A	O
camel	O
-	O
derived	O
MERS	O
-	O
CoV	O
with	O
a	O
variant	O
spike	O
protein	B-PROC
cleavage	I-PROC
site	O
and	O
distinct	O
fusion	O
activation	O
properties	O
.	O

We	O
show	O
that	O
NRCE	O
-	O
HKU205	O
has	O
more	O
limited	O
fusion	O
activation	O
properties	O
possibly	O
resulting	O
in	O
more	O
restricted	O
viral	O
tropism	B-PROC
and	O
may	O
represent	O
an	O
intermediate	O
in	O
the	O
complex	O
pattern	O
of	O
MERS	O
-	O
CoV	O
ecology	O
and	O
evolution	B-PROC
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
,	O
PaO₂	O
/	O
FiO₂	O
<	O
100	O
on	O
PEEP	O
≥	O
5	O
cm	O
H₂O	O
)	O
is	O
treated	O
using	O
controlled	O
mechanical	O
ventilation	O
(	O
CMV	O
),	O
recently	O
combined	O
with	O
muscle	B-PROC
relaxation	I-PROC
for	O
48	O
h	O
and	O
prone	O
positioning	O
.	O

However	O
,	O
conditionalities	O
are	O
stringent	O
:	O
upfront	O
circulatory	B-PROC
optimization	O
,	O
upright	O
positioning	O
,	O
lowered	O
VO₂	O
,	O
lowered	O
acidotic	O
and	O
hypercapnic	O
drives	O
,	O
sedation	O
without	O
ventilatory	O
depression	O
and	O
without	O
lowered	O
muscular	O
tone	O
.	O

The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
present	O
the	O
details	O
of	O
the	O
development	B-PROC
of	O
a	O
population	O
pharmacokinetic	O
(	O
PK	O
)	O
model	O
,	O
an	O
empirical	O
population	O
placebo	O
response	O
model	O
,	O
and	O
the	O
exploration	O
of	O
a	O
PK	O
/	O
pharmacodynamic	O
(	O
PD	O
)	O
model	O
of	O
dilmapimod	O
.	O

ABSTRACT	O
:	O
The	O
lipid	O
kinase	O
phosphatidylinositol	O
4	O
-	O
kinase	O
IIIβ	O
(	O
PI4KB	O
)	O
is	O
an	O
essential	O
host	O
factor	O
for	O
many	O
positive	O
-	O
sense	B-PROC
single	O
-	O
stranded	O
RNA	O
(+	O
RNA	O
)	O
viruses	O
including	O
human	O
pathogens	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
coxsackie	O
viruses	O
,	O
and	O
rhinoviruses	O
.	O

15	O
min	O
,	O
with	O
eventual	O
administration	O
of	O
vasopressors	O
according	O
to	O
an	O
arterial	O
blood	B-PROC
pressure	I-PROC
.	O

The	O
lavage	O
procedure	O
was	O
repeated	O
until	O
the	O
paO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
index	O
after	O
stabilization	O
remained	O
below	O
100	O
at	O
PEEP	O
5	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
In	O
33	O
pigs	O
we	O
have	O
achieved	O
the	O
desired	O
degree	O
of	O
severe	O
ARDS	O
(	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)<	O
100	O
).	O

We	O
will	O
underline	O
how	O
a	O
holistic	O
framework	O
of	O
respiratory	O
and	O
hemodynamic	B-PROC
support	O
should	O
be	O
provided	O
to	O
patients	O
with	O
ARDS	O
,	O
aiming	O
to	O
ensure	O
adequate	O
gas	O
exchange	O
by	O
promoting	O
lung	O
recruitment	O
while	O
minimizing	O
the	O
risk	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

The	O
mechanism	O
of	O
nuclear	B-PROC
translocation	B-PROC
,	O
and	O
whether	O
N	O
protein	O
associates	O
with	O
particular	O
nucleolar	O
components	O
,	O
is	O
unknown	O
.	O

Furthermore	O
,	O
overexpression	B-PROC
of	O
NPM1	O
promoted	O
PEDV	O
growth	B-PROC
,	O
while	O
knockdown	O
of	O
NPM1	O
suppressed	O
PEDV	O
growth	B-PROC
.	O

Adapted	O
to	O
growth	B-PROC
in	O
avian	O
cells	O
MVA	O
lost	O
the	O
ability	O
to	O
replicate	O
in	O
mammalian	O
hosts	O
and	O
lacks	O
many	O
of	O
the	O
genes	O
orthopoxviruses	O
use	O
to	O
conquer	O
their	O
host	O
(	O
cell	O
)	O
environment	O
.	O

Further	O
studies	O
by	O
complete	O
genomic	O
analysis	O
showed	O
that	O
strain	O
ck	O
/	O
CH	O
/	O
LGX	O
/	O
111119	O
may	O
have	O
originated	O
from	O
recombination	B-PROC
events	O
involving	O
LX4	O
genotype	O
IBVs	O
and	O
an	O
as	O
-	O
yet	O
-	O
unidentified	O
IBV	O
donating	O
a	O
S1	O
gene	O
,	O
or	O
from	O
the	O
result	O
of	O
accumulation	O
of	O
mutations	O
and	O
selections	O
,	O
especially	O
in	O
the	O
S1	O
gene	O
,	O
from	O
a	O
LX4	O
genotype	O
virus	O
.	O

In	O
addition	O
,	O
few	O
of	O
these	O
viruses	O
experienced	O
recombination	B-PROC
with	O
those	O
of	O
the	O
vaccine	O
strains	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
genome	O
.	O

Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
,	O
the	O
monitoring	O
of	O
barometric	O
whole	O
body	O
plethysmography	O
for	O
pulmonary	B-PROC
function	I-PROC
tests	O
in	O
non	O
-	O
anesthetized	O
ricin	O
-	O
treated	O
pigs	O
.	O

TITLE	O
:	O
The	O
First	O
Infant	O
Death	B-PROC
Associated	O
With	O
Human	O
Coronavirus	O
NL63	O
Infection	O
.	O

ABSTRACT	O
:	O
The	O
continued	O
emergence	O
and	O
spread	O
of	O
infectious	O
agents	O
is	O
of	O
great	O
concern	O
,	O
and	O
systems	O
biology	O
approaches	O
to	O
infectious	O
disease	O
research	O
can	O
advance	O
our	O
understanding	O
of	O
host	O
-	O
pathogen	O
relationships	O
and	O
facilitate	O
the	O
development	B-PROC
of	O
new	O
therapies	O
and	O
vaccines	O
.	O

A	O
logistic	O
regression	O
analysis	O
found	O
that	O
the	O
overall	O
sensitive	O
group	O
with	O
high	O
sensitivity	O
had	O
higher	O
stress	O
levels	O
(	O
17	O
.	O
80	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
13	O
.	O
77	O
to	O
23	O
.	O
00	O
),	O
higher	O
reliability	O
on	O
preventive	O
behaviors	B-PROC
(	O
5	O
.	O
81	O
;	O
95	O
%	O
CI	O
,	O
4	O
.	O
84	O
to	O
6	O
.	O
98	O
),	O
higher	O
practice	O
of	O
preventive	O
behaviors	B-PROC
(	O
4	O
.	O
53	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
83	O
to	O
5	O
.	O
37	O
)	O
and	O
higher	O
practice	O
of	O
hand	O
washing	O
(	O
2	O
.	O
71	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
13	O
to	O
3	O
.	O
43	O
)	O
during	O
the	O
outbreak	O
period	O
,	O
compared	O
to	O
the	O
non	O
-	O
sensitive	O
group	O
.	O

Infection	O
sensitivity	O
of	O
community	O
residents	O
during	O
the	O
MERS	O
outbreak	O
correlated	O
with	O
gender	O
,	O
age	O
,	O
occupation	O
,	O
and	O
health	O
behaviors	B-PROC
.	O

Sandwich	O
immunoassay	O
formation	B-PROC
was	O
influenced	O
by	O
whether	O
the	O
strip	O
was	O
run	O
in	O
corona	O
forming	O
conditions	O
,	O
i	O
.	O
e	O
.,	O
in	O
human	O
serum	O
.	O

TITLE	O
:	O
Viral	O
-	O
induced	O
suppression	B-PROC
of	O
self	O
-	O
reactive	O
T	O
cells	O
:	O
Lessons	O
from	O
neurotropic	O
coronavirus	O
-	O
induced	O
demyelination	O
.	O

TITLE	O
:	O
The	O
relationship	O
between	O
liver	O
-	O
kidney	O
impairment	O
and	O
viral	O
load	O
after	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	B-PROC
infection	I-PROC
in	O
embryonic	O
chickens	O
.	O

These	O
patients	O
received	O
mechanical	O
ventilation	O
for	O
more	O
than	O
12	O
h	O
during	O
1	O
-	O
month	O
periods	B-PROC
in	O
1998	O
,	O
2004	O
,	O
and	O
2010	O
.	O

Although	O
IPEC	O
-	O
J2	O
cells	O
responded	O
to	O
both	O
IFN	O
-	O
alpha	O
and	O
lambda	O
,	O
transcriptional	B-PROC
profiling	O
of	O
ISGs	O
(	O
specifically	O
ISG15	O
,	O
OASL	O
,	O
MxA	O
,	O
and	O
IFITMs	O
)	O
differed	O
when	O
induced	O
by	O
either	O
IFN	O
-	O
alpha	O
or	O
rpIFN	O
-	O
L	O
.	O
Therefore	O
,	O
our	O
data	O
provide	O
the	O
experimental	O
evidence	O
that	O
porcine	O
IFN	O
-	O
L	O
suppresses	O
PEDV	O
infection	O
of	O
IPEC	O
-	O
J2	O
cells	O
,	O
which	O
may	O
offer	O
a	O
promising	O
therapeutic	O
for	O
combating	O
PED	O
in	O
piglets	O
.	O

Recombination	B-PROC
analysis	O
revealed	O
that	O
three	O
recombination	B-PROC
events	O
could	O
be	O
found	O
in	O
the	O
genome	O
of	O
CK	O
/	O
CH	O
/	O
2010	O
/	O
JT	O
-	O
1	O
at	O
positions	O
24709	O
-	O
365	O
,	O
17160	O
-	O
19811	O
and	O
21136	O
-	O
21770	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
polyphenols	O
from	O
Broussonetia	O
papyrifera	O
as	O
coronavirus	O
protease	B-PROC
inhibitors	I-PROC
.	O

Cellular	B-PROC
infiltration	I-PROC
,	O
cholangiohepatitis	O
and	O
focal	O
necrosis	B-PROC
in	O
the	O
liver	O
were	O
also	O
found	O
.	O

ABSTRACT	O
:	O
Cecal	O
infarction	O
is	O
an	O
uncommon	O
lesion	O
in	O
calves	O
that	O
results	O
in	O
localized	O
peritonitis	O
and	O
,	O
on	O
occasion	O
,	O
perforation	O
with	O
secondary	O
diffuse	O
peritonitis	O
and	O
death	B-PROC
.	O

We	O
found	O
that	O
the	O
isolate	O
was	O
better	O
adapted	O
to	O
growth	B-PROC
in	O
IECs	O
than	O
in	O
Vero	O
cells	O
,	O
and	O
the	O
titer	O
of	O
the	O
IEC	O
cultures	O
was	O
10	O

Herein	O
we	O
demonstrated	O
that	O
infection	O
of	O
macrophages	O
with	O
lentiviral	O
particles	O
pseudotyped	O
with	O
MERS	O
-	O
CoV	O
S	O
glycoprotein	O
results	O
in	O
suppression	B-PROC
of	O
macrophage	O
responses	O
since	O
it	O
reduced	O
the	O
capacity	O
of	O
macrophages	O
to	O
produce	O
TNFα	O
and	O
IL	O
-	O
6	O
in	O
naive	O
and	O
LPS	O
-	O
activated	O
THP	O
-	O
1	O
macrophages	O
and	O
augmented	O
LPS	O
-	O
induced	O
production	O
of	O
the	O
immunosuppressive	O
cytokine	O
IL	O
-	O
10	O
.	O

These	O
findings	O
support	O
a	O
DPP4	O
-	O
mediated	O
suppressive	O
action	O
of	O
MERS	O
-	O
CoV	O
in	O
macrophages	O
and	O
suggest	O
a	O
potential	O
target	O
for	O
effective	O
elimination	B-PROC
of	O
its	O
pathogenicity	O
.	O

High	O
immune	B-PROC
responses	I-PROC
require	O
further	O
study	O
in	O
animal	O
models	O
,	O
such	O
as	O
human	O
receptor	O
-	O
expressing	O
mice	O
,	O
non	O
-	O
human	O
primates	O
,	O
and	O
camels	O
.	O

Areas	O
covered	O
:	O
This	O
article	O
reviews	O
the	O
epidemiology	O
,	O
clinical	O
impact	O
and	O
therapeutic	O
options	O
for	O
respiratory	O
virus	B-PROC
infection	I-PROC
in	O
both	O
children	O
and	O
adults	O
with	O
CF	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
corona	O
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
novel	O
positive	O
sense	B-PROC
singlestranded	O
ribonucleic	O
acid	O
virus	O
of	O
the	O
genus	O
Beta	O
corona	O
virus	O
.	O

Compared	O
with	O
patients	O
who	O
avoided	O
ETI	O
,	O
those	O
who	O
failed	O
NIV	O
or	O
had	O
a	O
DNI	O
order	O
and	O
died	B-PROC
were	O
more	O
likely	O
to	O
have	O
acute	O
leukemia	O
(	O
84	O
%	O
vs	O
61	O
%;	O
P	O
=	O
.	O
02	O
)	O
and	O
at	O
baseline	O
had	O
higher	O
Paco	O
Two	O
-	O
thirds	O
of	O
patients	O
with	O
HM	O
and	O
respiratory	O
failure	O
failed	O
NIV	O
and	O
required	O
ETI	O
,	O
and	O
had	O
high	O
subsequent	O
mortality	O
.	O

TITLE	O
:	O
Neurovirulent	O
Murine	O
Coronavirus	O
JHM	O
.	O
SD	O
Uses	O
Cellular	O
Zinc	O
Metalloproteases	O
for	O
Virus	O
Entry	O
and	O
Cell	B-PROC
-	I-PROC
Cell	I-PROC
Fusion	I-PROC
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
of	O
veterinary	O
and	O
medical	O
importance	O
and	O
include	O
highly	O
pathogenic	O
zoonotic	O
viruses	O
,	O
such	O
as	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
They	O
are	O
known	O
to	O
efficiently	O
evade	O
early	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
,	O
manifesting	O
in	O
almost	O
negligible	O
expression	B-PROC
of	O
type	O
-	O
I	O
interferons	O
(	O
IFN	O
-	O
I	O
).	O

Although	O
antiviral	O
therapy	O
is	O
available	O
for	O
some	O
respiratory	O
viral	B-PROC
infections	I-PROC
,	O
further	O
research	O
is	O
needed	O
to	O
determine	O
which	O
groups	O
of	O
patients	O
would	O
benefit	O
.	O

Primary	O
duodenal	O
ulcers	O
are	O
rare	O
in	O
children	O
but	O
stress	O
induced	O
ulceration	O
in	O
stomach	O
occurs	O
more	O
often	O
in	O
neonatal	O
period	O
due	O
to	O
birth	B-PROC
asphyxia	O
,	O
prolonged	O
labour	B-PROC
,	O
cesarean	O
deliveries	O
,	O
instrumentations	O
,	O
respiratory	O
distress	O
syndrome	O
and	O
sepsis	O
.	O

The	O
arteriviruses	O
have	O
significantly	O
smaller	O
genomes	O
and	O
form	O
an	O
intriguing	O
package	O
with	O
the	O
coronaviruses	O
to	O
analyse	O
viral	O
RdRp	O
evolution	B-PROC
and	O
function	O
.	O

TITLE	O
:	O
Nursery	O
pig	O
growth	B-PROC
performance	O
and	O
tissue	O
accretion	O
modulation	O
due	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
or	O
porcine	O
deltacoronavirus	O
challenge	O
.	O

Our	O
findings	O
suggest	O
that	O
there	O
is	O
a	O
need	O
for	O
development	B-PROC
of	O
effective	O
strategies	O
to	O
train	O
medical	O
students	O
in	O
correct	O
use	O
of	O
PPE	O
.	O

We	O
'	O
ve	O
demonstrated	O
that	O
the	O
group	O
vaccinated	O
with	O
Ma5	O
and	O
4	O
/	O
91	O
strain	O
simultaneously	O
developed	O
the	O
most	O
desirable	O
immunity	B-PROC
which	O
reflects	O
the	O
level	O
of	O
CD8	O

TITLE	O
:	O
Hemodynamic	B-PROC
effects	O
of	O
lung	O
recruitment	O
maneuvers	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Multiple	O
clinical	O
variables	O
were	O
recorded	O
and	O
analyzed	O
,	O
including	O
arterial	O
oxygenation	B-PROC
,	O
cardiac	O
output	O
,	O
peripheral	O
oxygen	O
delivery	O
and	O
alveolar	O
strain	O
.	O

In	O
South	O
Korea	O
,	O
a	O
well	O
-	O
established	O
ECMO	O
interhospital	O
transport	B-PROC
system	O
is	O
lacking	O
due	O
to	O
limited	O
resources	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
case	O
of	O
severe	O
swine	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	B-PROC
infection	I-PROC
in	O
an	O
immunocompetent	O
middle	O
-	O
aged	O
man	O
in	O
October	O
2016	O
in	O
Italy	O
who	O
had	O
only	O
indirect	O
exposure	O
to	O
pigs	O
.	O

The	O
detection	O
rate	O
of	O
PEDV	O
was	O
71	O
.	O
2	O
%	O
(	O
146	O
/	O
205	O
)	O
by	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
is	O
a	O
zoonotic	O
viral	B-PROC
disease	I-PROC
that	O
can	O
be	O
transmitted	O
from	O
dromedaries	O
to	O
human	O
beings	O
.	O

VV	O
ECMO	O
was	O
associated	O
with	O
less	O
gastrointestinal	O
bleeding	O
and	O
hemolysis	B-PROC
,	O
but	O
overall	O
rates	O
of	O
bleeding	O
,	O
stroke	O
,	O
and	O
renal	O
failure	O
were	O
similar	O
.	O

These	O
characteristics	O
of	O
HCoV	O
-	O
OC43	O
may	O
affect	O
viral	B-PROC
replication	I-PROC
dynamics	O
,	O
receptor	O
binding	O
,	O
antigenicity	O
,	O
evolution	B-PROC
,	O
transmission	O
,	O
and	O
clinical	O
illness	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	B-PROC
)	O
is	O
performed	O
as	O
an	O
acceptable	O
life	O
-	O
saving	O
bridging	O
procedure	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O
To	O
patients	O
with	O
avian	O
influenza	O
A	O
(	O
H7N9	O
)-	O
associated	O
ARDS	O
,	O
ECMO	B-PROC
could	O
be	O
adopted	O
as	O
a	O
feasible	O
therapeutic	O
solution	O
.	O

The	O
method	O
is	O
specific	O
exclusively	O
to	O
ASFV	O
DNA	O
without	O
cross	O
-	O
reactions	O
with	O
cDNA	O
of	O
classical	O
swine	O
fever	B-PROC
virus	O
(	O
CSFV	O
),	O
porcine	O
reproductive	B-PROC
respiratory	O
syndrome	O
(	O
PRRSV	O
)	O
or	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

ABSTRACT	O
:	O
Lungs	O
are	O
easily	O
damaged	O
by	O
the	O
inflammatory	B-PROC
responses	I-PROC
induced	O
after	O
extensive	O
burns	O
.	O

Cell	O
-	O
mediated	O
immune	O
(	O
CMI	O
)	O
related	O
genes	O
presented	O
also	O
lower	O
levels	O
of	O
expression	B-PROC
in	O
tracheal	O
samples	O
from	O
birds	O
challenged	O
with	O
B	O
isolate	O
at	O
1dpi	O
.	O

Risk	O
factors	O
for	O
new	O
multiple	O
organ	O
dysfunction	O
syndrome	O
were	O
moderate	O
/	O
severe	O
lung	O
injury	O
and	O
neuromuscular	B-PROC
blockade	I-PROC
.	O

In	O
Saudi	O
Arabia	O
recent	O
significant	O
hospital	O
outbreaks	O
,	O
including	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
have	O
resulted	O
from	O
lack	O
of	O
,	O
or	O
breakdown	B-PROC
in	O
,	O
infection	O
prevention	O
and	O
control	O
procedures	O
.	O

TITLE	O
:	O
Identification	O
and	O
evaluation	O
of	O
potent	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
3CL	O
ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
acute	O
respiratory	O
illness	O
with	O
fever	B-PROC
,	O
cough	O
and	O
shortness	O
of	O
breath	O
.	O

TITLE	O
:	O
Simultaneous	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
,	O
and	O
related	O
bat	O
coronaviruses	O
by	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
PCR	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
duplex	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
method	O
for	O
the	O
simultaneous	O
detection	O
of	O
these	O
viruses	O
.	O

The	O
current	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kits	O
for	O
IBV	O
specific	O
antibody	B-PROC
detection	O
are	O
mostly	O
based	O
on	O
the	O
whole	O
virion	O
,	O
and	O
few	O
serological	O
tests	O
based	O
on	O
nonstructural	O
proteins	O
of	O
IBV	O
have	O
been	O
developed	O
.	O

During	O
the	O
treatment	O
process	O
,	O
the	O
variations	O
in	O
dynamic	O
lung	B-PROC
compliance	I-PROC
,	O
oxygenation	B-PROC
index	O
,	O
hemodynamics	B-PROC
,	O
and	O
urine	O
volume	O
per	O
hour	O
at	O
different	O
times	O
(	O
Baseline	O
,	O
0	O
,	O
2	O
,	O
4	O
,	O
and	O
6	O
h	O
)	O
were	O
recorded	O
.	O

The	O
first	O
prone	O
session	O
significantly	O
increased	O
PaO	B-PROC
CONCLUSIONS	O
:	O
Prone	O
position	O
of	O
ARDS	O
patients	O
after	O
abdominal	O
surgery	O
was	O
not	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
surgical	O
complication	O
.	O

These	O
results	O
suggested	O
that	O
during	O
mouse	O
pneumonia	O
,	O
changes	O
in	O
the	O
expression	B-PROC
of	O
gene	O
clusters	O
and	O
the	O
complex	O
interactions	O
among	O
genes	O
lead	O
to	O
significant	O
changes	O
in	O
function	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
different	O
testing	O
modalities	O
available	O
for	O
the	O
ongoing	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
epidemic	O
including	O
cell	O
culture	O
,	O
nucleic	O
acid	O
amplification	O
,	O
antigen	O
detection	O
,	O
and	O
antibody	B-PROC
detection	O
assays	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
PDCoV	O
nsp5	O
significantly	O
inhibited	O
IFN	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
promoter	O
activity	O
and	O
transcription	B-PROC
of	O
IFN	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
),	O
suggesting	O
that	O
PDCoV	O
nsp5	O
also	O
suppresses	O
IFN	O
signaling	B-PROC
.	O

The	O
results	O
of	O
our	O
study	O
demonstrate	O
that	O
PDCoV	O
nsp5	O
antagonizes	O
type	O
I	O
IFN	O
signaling	B-PROC
by	O
cleaving	O
STAT2	O
and	O
provides	O
structural	O
insights	O
for	O
comprehending	O
the	O
cleavage	B-PROC
mechanism	O
of	O
PDCoV	O
nsp5	O
,	O
revealing	O
a	O
potential	O
new	O
function	O
for	O
PDCoV	O
nsp5	O
in	O
type	O
I	O
IFN	O
signaling	B-PROC
.	O

This	O
increased	O
flexibility	O
could	O
be	O
important	O
for	O
the	O
downstream	O
effects	O
of	O
the	O
interaction	O
with	O
other	O
proteins	O
and	O
the	O
inhibition	B-PROC
of	O
the	O
innate	B-PROC
immunity	B-PROC
.	O

These	O
conserved	O
CoV	O
residues	O
were	O
associated	O
with	O
lower	O
deubiquitinating	B-PROC
activity	O
and	O
render	O
MERS	O
CoV	O
Plpro	O
with	O
less	O
potent	O
deubiquitinating	B-PROC
potential	O
.	O

The	O
number	O
of	O
residues	O
and	O
total	O
interactions	O
with	O
ubiquitin	B-PROC
were	O
lower	O
for	O
the	O
MERS	O
CoV	O
Plpro	O
than	O
for	O
the	O
SARS	O
CoV	O
.	O
These	O
factors	O
contribute	O
to	O
the	O
lower	O
deubiquitinating	B-PROC
actions	O
of	O
MERS	O
CoV	O
NSP3	O
and	O
its	O
subsequently	O
lower	O
interaction	O
with	O
the	O
host	O
immune	O
system	O
.	O

Tidal	O
volume	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
had	O
no	O
impact	O
on	O
mortality	O
.	O

We	O
identified	O
a	O
driving	O
pressure	O
cut	O
-	O
off	O
value	O
of	O
19	O
cm	O
H2O	O
where	O
an	O
ordinal	O
increment	O
was	O
accompanied	O
by	O
an	O
increment	O
of	O
risk	O
of	O
death	B-PROC
.	O

In	O
patients	O
treated	O
with	O
umifenovir	O
(	O
provided	O
that	O
it	O
was	O
administered	O
in	O
the	O
first	O
48	O
hours	O
after	O
disease	O
onset	O
),	O
the	O
duration	O
of	O
fever	B-PROC
and	O
frequency	O
of	O
complications	O
proved	O
to	O
be	O
lower	O
than	O
those	O
in	O
patients	O
who	O
did	O
not	O
receive	O
antiviral	O
therapy	O
.	O

Umifenovir	O
therapy	O
substantially	O
reduces	O
the	O
duration	O
of	O
fever	B-PROC
and	O
risk	O
of	O
complications	O
,	O
especially	O
in	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
infection	O
.	O

ABSTRACT	O
:	O
Using	O
an	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	B-PROC
(	O
RT	O
)-	O
associated	O
RNase	O
H	O
inhibition	B-PROC
assay	O
as	O
lead	O
,	O
bioguided	O
fractionation	O
of	O
the	O
dichloromethane	O
extract	O
of	O
the	O
Ocimum	O
sanctum	O
leaves	O
led	O
to	O
the	O
isolation	O
of	O
five	O
triterpenes	O
(	O
1	O
-	O
5	O
)	O
along	O
with	O
three	O
3	O
-	O
methoxy	O
-	O
4	O
-	O
hydroxy	O
phenyl	O
derivatives	O
(	O
6	O
-	O
8	O
).	O

However	O
,	O
our	O
results	O
did	O
not	O
indicate	O
that	O
any	O
of	O
these	O
viruses	O
are	O
involved	O
in	O
the	O
development	B-PROC
of	O
PTA	O
.	O

Development	B-PROC
of	O
anti	O
-	O
FN	O
antibodies	O
in	O
FN	O
-	O
positive	O
patients	O
with	O
PTA	O
.	O

Furthermore	O
,	O
cultures	O
made	O
from	O
PTA	O
aspirates	O
should	O
include	O
a	O
selective	O
FN	O
-	O
agar	O
plate	O
in	O
order	O
to	O
identify	O
growth	B-PROC
of	O
this	O
bacterium	O
.	O

ABSTRACT	O
:	O
The	O
third	O
meeting	O
of	O
WHO	O
'	O
s	O
Product	O
Development	B-PROC
for	O
Vaccines	O
Advisory	O
Committee	O
(	O
PDVAC	O
)	O
was	O
held	O
in	O
June	O
2016	O
,	O
with	O
a	O
remit	O
to	O
revisit	O
the	O
pathogen	O
areas	O
for	O
which	O
significant	O
progress	O
has	O
occurred	O
since	O
recommendations	O
from	O
the	O
2015	O
meeting	O
,	O
as	O
well	O
as	O
to	O
consider	O
new	O
advances	O
in	O
the	O
development	B-PROC
of	O
vaccines	O
against	O
other	O
pathogens	O
.	O

Clinical	O
signs	O
included	O
right	O
head	O
tilt	O
and	O
circling	O
,	O
depression	O
alternated	O
with	O
excitability	O
,	O
fever	B-PROC
and	O
lateral	O
strabismus	O
.	O

ABSTRACT	O
:	O
Immune	B-PROC
response	I-PROC
of	O
gilts	O
following	O
single	O
and	O
double	O
infection	O
with	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
at	O
gilt	O
acclimatization	B-PROC
and	O
prepartum	O
were	O
investigated	O
.	O

A	O
reliability	O
test	O
was	O
performed	O
on	O
the	O
levels	O
of	O
MERS	O
-	O
related	O
worry	O
during	O
key	O
outbreak	O
periods	B-PROC
.	O

The	O
reliability	O
test	O
results	O
on	O
MERS	O
-	O
related	O
worry	O
scores	O
during	O
key	O
outbreak	O
periods	B-PROC
showed	O
consistent	O
scores	O
during	O
each	O
period	O
.	O

Hospital	O
course	O
was	O
complicated	O
with	O
acute	O
kidney	O
injury	O
and	O
metabolic	B-PROC
acidosis	O
.	O

ABSTRACT	O
:	O
Viral	B-PROC
infections	I-PROC
are	O
leading	O
causes	O
of	O
both	O
upper	O
and	O
lower	O
airway	O
acute	O
illness	O
in	O
all	O
age	O
groups	O
of	O
healthy	O
persons	O
,	O
and	O
have	O
also	O
been	O
implicated	O
in	O
the	O
acute	O
exacerbations	O
of	O
chronic	O
respiratory	O
disorders	O
like	O
asthma	O
and	O
COPD	O
.	O

The	O
virus	O
growth	B-PROC
kinetics	O
in	O
cell	O
culture	O
,	O
virulence	B-PROC
in	O
neonatal	O
pigs	O
and	O
the	O
whole	O
genomic	O
sequences	O
of	O
selected	O
passages	O
were	O
examined	O
.	O

TITLE	O
:	O
Effects	O
of	O
early	O
administration	O
of	O
acetazolamide	O
on	O
the	O
duration	O
of	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
or	O
obesity	O
-	O
hypoventilation	O
syndrome	O
with	O
metabolic	B-PROC
alkalosis	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
comorbidities	O
,	O
baseline	O
characteristics	O
or	O
arterial	O
blood	B-PROC
gases	I-PROC
at	O
inclusion	O
.	O

It	O
remains	O
to	O
be	O
determined	O
if	O
primary	O
closure	O
and	O
subsequent	O
tensioning	O
or	O
scar	O
tissue	O
of	O
the	O
GE	O
mucosa	O
results	O
in	O
further	O
complications	O
related	O
to	O
restricted	O
epiglottic	O
movement	B-PROC
.	O

TITLE	O
:	O
Induction	O
of	O
Atypical	O
Autophagy	B-PROC
by	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	O
Virus	O
Contributes	O
to	O
Viral	B-PROC
Replication	I-PROC
.	O

Suppression	B-PROC
of	O
autophagy	B-PROC
by	O
3	O
-	O
MA	O
increased	O
viral	B-PROC
replication	I-PROC
,	O
compared	O
with	O
the	O
mock	O
treatment	O
,	O
while	O
promoting	O
of	O
autophagy	B-PROC
by	O
rapamycin	O
reduced	O
PHEV	O
replication	O
.	O

Serological	O
data	O
suggest	O
that	O
lineage	O
A	O
betacoronavirus	O
infections	O
are	O
commonly	O
infecting	O
horses	O
in	O
Saudi	O
Arabia	O
and	O
Oman	O
but	O
antibody	B-PROC
cross	O
-	O
reactivities	O
between	O
these	O
viruses	O
do	O
not	O
permit	O
us	O
to	O
use	O
serological	O
data	O
alone	O
to	O
identify	O
which	O
coronaviruses	O
are	O
causing	O
these	O
infections	O
.	O

Host	O
inosine	O
-	O
5	O
'-	O
monophosphate	O
dehydrogenase	O
(	O
IMPDH	O
)	O
involved	O
in	O
the	O
synthesis	B-PROC
of	O
guanine	O
nucleotides	O
,	O
is	O
known	O
to	O
be	O
a	O
potential	O
target	O
to	O
inhibit	O
the	O
replication	O
of	O
viruses	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
further	O
confirmed	O
that	O
N30	O
provided	O
a	O
strong	O
inhibition	B-PROC
on	O
the	O
replication	O
of	O
respiratory	O
syncytial	O
virus	O
,	O
coronavirus	O
,	O
enterovirus	O
71	O
and	O
a	O
diverse	O
strains	O
of	O
coxsackie	O
B	O
virus	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
thus	O
provide	O
important	O
information	O
regarding	O
the	O
underlying	O
evolution	B-PROC
mechanisms	O
of	O
coronaviruses	O
.	O

To	O
this	O
end	O
,	O
we	O
used	O
increasing	O
doses	O
of	O
commercial	O
ArkDPI	O
vaccine	O
to	O
vaccinate	O
100	O
commercial	O
broiler	O
chicks	O
at	O
day	O
of	O
hatch	B-PROC
,	O
using	O
a	O
commercial	O
hatchery	O
spray	O
cabinet	O
.	O

Thus	O
,	O
the	O
minimum	O
infectious	O
dose	O
for	O
the	O
ArkDPI	O
vaccine	O
using	O
a	O
hatchery	O
spray	O
cabinet	O
appears	O
to	O
be	O
dependent	O
on	O
the	O
amount	O
of	O
this	O
minor	O
subpopulation	O
reaching	B-PROC
the	O
chicks	O
.	O

Here	O
,	O
we	O
describe	O
the	O
development	B-PROC
of	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
reverse	O
genetics	O
system	O
for	O
PEDV	O
based	O
on	O
two	O
recent	O
Chinese	O
field	O
isolates	O
,	O
namely	O
CHM2013	O
and	O
BJ2011C	O
.	O

TITLE	O
:	O
DNA	O
vaccine	O
encoding	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
S1	O
protein	O
induces	O
protective	O
immune	B-PROC
responses	I-PROC
in	O
mice	O
.	O

Furthermore	O
,	O
the	O
IBV	O
replicase	O
-	O
encoded	O
PLP	O
,	O
including	O
the	O
downstream	O
transmembrane	O
(	O
TM	O
)	O
domain	O
,	O
is	O
a	O
DUB	O
enzyme	O
and	O
dramatically	O
reduced	O
the	O
level	O
of	O
Ub	O
-	O
conjugated	O
proteins	O
,	O
while	O
processing	O
both	O
K48	O
-	O
and	O
K63	O
-	O
linked	O
polyubiquitin	B-PROC
chains	O
.	O

In	O
the	O
lymph	O
nodes	O
and	O
spleen	O
,	O
ERag	O
is	O
mainly	O
produced	O
by	O
fibroblastic	O
reticular	O
cells	O
(	O
FRCs	B-PROC
),	O
which	O
play	O
a	O
key	O
role	O
in	O
nursing	B-PROC
the	O
ERfibs	O
to	O
form	O
a	O
fibroblastic	O
reticular	O
network	O
(	O
FRN	O
).	O

Inhibition	B-PROC
of	O
STAT3	O
phosphorylation	B-PROC
by	O
S3I	O
-	O
201	O
abrogated	O
the	O
antiviral	O
ability	O
of	O
mpIL	O
-	O
22	O
and	O
the	O
mpIL	O
-	O
22	O
-	O
induced	O
expression	B-PROC
of	O
BD	O
-	O
2	O
,	O
IL	O
-	O
18	O
,	O
and	O
IFN	O
-	O
λ	O
.	O

Together	O
,	O
mpIL	O
-	O
22	O
inhibited	O
the	O
infection	O
of	O
PoRV	O
and	O
enteric	O
coronaviruses	O
,	O
and	O
up	O
-	O
regulated	O
the	O
expression	B-PROC
of	O
antimicrobial	O
genes	O
in	O
IPEC	O
-	O
J2	O
,	O
which	O
were	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
STAT3	O
signal	B-PROC
pathway	I-PROC
.	O

TITLE	O
:	O
Outcome	O
and	O
Management	O
of	O
Refractory	O
Respiratory	O
Failure	O
With	O
Timely	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
:	O
Single	O
-	O
Center	O
Experience	O
With	O
Legionella	O
Pneumonia	O
.	O

Diagnosis	O
for	O
rabies	O
and	O
leptospirosis	O
were	O
cited	O
as	O
the	O
capacities	O
most	O
in	O
need	O
of	O
development	B-PROC
.	O

Moreover	O
,	O
autophagy	B-PROC
was	O
confirmed	O
to	O
benefit	O
PEDV	O
replication	O
by	O
using	O
autophagy	B-PROC
regulators	O
and	O
RNA	B-PROC
interference	I-PROC
.	O

Furthermore	O
,	O
autophagy	B-PROC
might	O
be	O
associated	O
with	O
the	O
expression	B-PROC
of	O
inflammatory	O
cytokines	O
and	O
have	O
a	O
positive	O
feedback	O
loop	O
with	O
the	O
NF	O
-	O
κB	O
signaling	B-PROC
pathway	I-PROC
during	O
PEDV	O
infection	O
.	O

He	O
could	O
be	O
successfully	O
treated	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
and	O
therapeutic	O
plasma	O
exchange	O
.	O

This	O
suggested	O
a	O
possible	O
recombination	B-PROC
event	O
between	O
the	O
Thai	O
and	O
the	O
newly	O
described	O
Chinese	O
strain	O
.	O

Samples	O
from	O
other	O
bat	O
species	O
were	O
negative	O
for	O
these	O
viruses	O
,	O
indicating	O
that	O
the	O
least	O
horseshoe	O
bat	O
represents	O
one	O
of	O
the	O
natural	O
reservoirs	O
and	O
mixers	O
for	O
strains	O
of	O
CoVs	O
and	O
has	O
a	O
pivotal	O
role	O
in	O
the	O
evolution	B-PROC
and	O
dissemination	O
of	O
these	O
viruses	O
.	O

Furthermore	O
,	O
both	O
HCoV	O
-	O
229E	O
replication	O
and	O
IL	O
-	O
1	O
were	O
shown	O
to	O
upregulate	O
a	O
small	O
set	O
of	O
genes	O
encoding	O
immunomodulatory	O
factors	O
that	O
bind	O
p65	O
at	O
promoters	O
and	O
require	O
IKKβ	O
activity	O
and	O
p65	O
for	O
expression	B-PROC
.	O

We	O
hypothesize	O
that	O
alveolar	O
stretch	O
activates	O
the	O
integrated	O
stress	B-PROC
response	I-PROC
(	O
ISR	O
)	O
pathway	B-PROC
and	O
that	O
the	O
chemical	O
inhibition	B-PROC
of	O
this	O
pathway	B-PROC
mitigates	O
alveolar	O
barrier	O
disruption	O
during	O
stretch	O
and	O
mechanical	O
ventilation	O
.	O

Chemical	O
inhibition	B-PROC
of	O
protein	O
kinase	O
RNA	O
-	O
like	O
endoplasmic	O
reticulum	O
kinase	O
,	O
an	O
upstream	O
regulator	O
of	O
the	O
pathway	B-PROC
,	O
resulted	O
in	O
decreased	O
injury	O
signaling	B-PROC
and	O
improved	O
barrier	O
function	O
after	O
prolonged	O
cyclic	O
stretch	O
and	O
injurious	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Swine	O
and	O
poultry	O
viruses	O
,	O
such	O
as	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
and	O
highly	O
pathogenic	O
avian	O
influenza	O
virus	O
(	O
HPAIV	O
),	O
are	O
economically	O
important	O
pathogens	O
that	O
can	O
spread	O
via	O
aerosols	O
.	O

HIV	O
-	O
1	O
IN	O
and	O
Reverse	O
Transcriptase	B-PROC
-	O
associated	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
active	O
sites	O
show	O
structural	O
homologies	O
,	O
with	O
the	O
presence	O
of	O
two	O
Mg	O
(	O
II	O
)	O
cofactors	O
,	O
hence	O
it	O
seems	O
possible	O
to	O
inhibit	O
both	O
enzymes	O
by	O
means	O
of	O
chelating	B-PROC
ligands	O
with	O
analogous	O
structural	O
features	O
.	O

PEDV	O
RNA	O
was	O
detected	O
from	O
rectal	O
swabs	O
of	O
experimentally	O
infected	O
(	O
INF	O
)	O
and	O
sentinel	O
pigs	O
by	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
).	O

Specific	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
screening	O
found	O
four	O
RVA	O
strains	O
.	O

Interestingly	O
,	O
the	O
lack	O
of	O
a	O
strictly	O
controlled	O
and	O
well	O
balanced	O
IFN	O
/	O
TRAIL	O
signaling	B-PROC
response	O
has	O
not	O
only	O
been	O
implicated	O
in	O
viral	B-PROC
infection	I-PROC
but	O
might	O
furthermore	O
be	O
an	O
important	O
determinant	O
of	O
disease	O
progression	O
in	O
bacterial	O
superinfections	O
and	O
in	O
chronic	O
respiratory	O
illness	O
.	O

Seropositivity	O
rates	O
were	O
higher	O
in	O
large	O
/	O
medium	O
herds	O
(≥	O
51	O
camels	O
)	O
than	O
small	O
herds	O
(	O
p	O
=	O
0	O
.	O
061	O
),	O
in	O
camels	O
raised	O
for	O
meat	O
or	O
milk	O
than	O
for	O
transport	B-PROC
(	O
p	O
=	O
0	O
.	O
01	O
),	O
and	O
in	O
nomadic	O
or	O
sedentary	O
herds	O
than	O
in	O
herds	O
with	O
a	O
mix	O
of	O
these	O
lifestyles	O
(	O
p	O
<	O
0	O
.	O
005	O
).	O

TITLE	O
:	O
Brazilian	O
strain	O
of	O
bovine	O
respiratory	O
coronavirus	O
is	O
derived	O
from	O
dual	O
enteric	O
and	O
respiratory	O
tropism	B-PROC
.	O

In	O
this	O
article	O
,	O
we	O
summarize	O
pulmonary	O
fibrotic	O
changes	O
observed	O
after	O
a	O
SARS	O
-	O
CoV	O
infection	O
,	O
discuss	O
the	O
extent	O
to	O
which	O
other	O
respiratory	O
viruses	O
induce	O
fibrosis	O
,	O
describe	O
available	O
animal	O
models	O
to	O
study	O
the	O
development	B-PROC
of	O
SARS	O
-	O
CoV	O
induced	O
fibrosis	O
and	O
review	O
evidence	O
that	O
pulmonary	O
fibrosis	O
is	O
caused	O
by	O
a	O
hyperactive	O
host	B-PROC
response	I-PROC
to	O
lung	O
injury	O
mediated	O
by	O
epidermal	O
growth	B-PROC
factor	O
receptor	O
(	O
EGFR	O
)	O
signaling	B-PROC
.	O

We	O
summarize	O
work	O
from	O
our	O
group	O
and	O
others	O
indicating	O
that	O
inhibiting	O
EGFR	O
signaling	B-PROC
may	O
prevent	O
an	O
excessive	O
fibrotic	O
response	O
to	O
SARS	O
-	O
CoV	O
and	O
other	O
respiratory	O
viral	B-PROC
infections	I-PROC
and	O
propose	O
directions	O
for	O
future	O
research	O
.	O

We	O
conclude	O
that	O
allosteric	O
inhibition	B-PROC
of	O
APN	O
functions	O
occurs	O
by	O
ligand	B-PROC
suppression	B-PROC
of	O
ectodomain	O
motions	O
necessary	O
for	O
catalysis	O
and	O
virus	O
cell	O
entry	O
,	O
as	O
validated	O
by	O
locking	O
APN	O
with	O
disulfides	O
.	O

ABSTRACT	O
:	O
The	O
development	B-PROC
of	O
simple	O
fluorescent	O
and	O
colorimetric	O
assays	O
that	O
enable	O
point	O
-	O
of	O
-	O
care	O
DNA	O
and	O
RNA	O
detection	O
has	O
been	O
a	O
topic	O
of	O
significant	O
research	O
because	O
of	O
the	O
utility	O
of	O
such	O
assays	O
in	O
resource	O
limited	O
settings	O
.	O

,	O
there	O
are	O
still	O
no	O
licensed	O
treatments	O
for	O
Ebola	O
virus	B-PROC
disease	I-PROC
(	O
EVD	O
),	O
significant	O
progress	O
was	O
made	O
during	O
the	O
West	O
Africa	O
outbreak	O
.	O

TITLE	O
:	O
Overactive	O
Epidermal	O
Growth	B-PROC
Factor	O
Receptor	B-PROC
Signaling	B-PROC
Leads	O
to	O
Increased	O
Fibrosis	O
after	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

Prospective	O
hypothermia	O
treatment	O
in	O
eight	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
with	O
PaO2	O
/	O
FIO2	O
less	O
than	O
150	O
receiving	O
neuromuscular	B-PROC
blockade	I-PROC
.	O

Results	O
support	O
conducting	B-PROC
a	O
randomized	O
clinical	O
trial	O
of	O
hypothermia	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
the	O
feasibility	O
of	O
studying	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
receiving	O
neuromuscular	B-PROC
blockade	I-PROC
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
may	O
serve	O
as	O
rescue	O
therapy	O
in	O
refractory	O
acute	O
respiratory	O
distress	O
syndrome	O
but	O
has	O
not	O
been	O
assessed	O
in	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
recipients	O
.	O

ABSTRACT	O
:	O
Venovenous	O
(	O
VV	O
)	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
be	O
a	O
life	O
-	O
saving	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	O
lung	O
failure	O
refractory	O
to	O
conventional	O
therapy	O
.	O

Moreover	O
,	O
Taiwan	O
CDC	O
will	O
continue	O
to	O
implement	O
the	O
IHR	O
(	O
2005	O
)	O
and	O
to	O
promote	O
a	O
global	O
community	O
working	O
together	O
to	O
fight	O
shared	O
risks	O
and	O
to	O
reach	B-PROC
the	O
goal	O
of	O
""""	O
One	O
World	O
,	O
One	O
Health	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
DE	O
as	O
adjuvant	O
in	O
an	O
Ark	O
-	O
DPI	O
live	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccine	O
after	O
ocular	B-PROC
or	O
spray	O
application	O
.	O

Finally	O
,	O
we	O
confirmed	O
through	O
our	O
observations	O
that	O
Ark	O
vaccines	O
administered	O
by	O
hatchery	O
spray	O
cabinet	O
elicit	O
weaker	O
immune	B-PROC
responses	I-PROC
and	O
protection	O
against	O
an	O
IBV	O
homologous	O
challenge	O
compared	O
to	O
the	O
same	O
vaccine	O
delivered	O
via	O
ocular	B-PROC
route	O
.	O

All	O
animals	O
reached	O
a	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
ratio	O
of	O
less	O
than	O
150	O
mm	O
Hg	O
within	O
3	O
hours	O
after	O
start	O
of	O
the	O
LPS	O
infusion	O
.	O

Oxygenation	B-PROC
and	O
compliance	O
in	O
the	O
control	O
animals	O
continued	O
to	O
decline	O
during	O
the	O
4	O
-	O
hour	O
in	O
vivo	O
perfusion	O
period	O
,	O
and	O
3	O
of	O
the	O
4	O
animals	O
died	B-PROC
of	O
severe	O
hypoxia	O
within	O
4	O
hours	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
encode	O
multifunctional	O
papain	O
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
that	O
have	O
the	O
ability	O
to	O
process	O
the	O
viral	O
polyprotein	O
to	O
facilitate	O
RNA	B-PROC
replication	I-PROC
and	O
antagonize	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

Two	O
patients	O
with	O
chronic	O
diseases	O
and	O
H1N1	O
infection	O
died	B-PROC
secondary	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
classified	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
based	O
on	O
an	O
oxygen	B-PROC
partial	I-PROC
pressure	I-PROC
/	O
oxygen	O
inspired	B-PROC
fraction	O
ratio	O
<	O
100	O
,	O
although	O
the	O
Berlin	O
classification	O
is	O
limited	O
in	O
considering	O
patients	O
with	O
severe	O
hypoxemia	O
managed	O
exclusively	O
with	O
noninvasive	O
ventilation	O
.	O

The	O
possible	O
complications	O
of	O
using	O
noninvasive	O
positive	O
-	O
pressure	O
mechanical	O
ventilation	O
in	O
cases	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
include	O
delays	O
in	O
orotracheal	O
intubation	O
,	O
which	O
is	O
performed	O
in	O
cases	O
of	O
poor	O
clinical	O
condition	O
and	O
with	O
high	O
support	O
pressure	O
levels	O
,	O
and	O
deep	O
inspiratory	B-PROC
efforts	O
,	O
generating	O
high	O
tidal	O
volumes	O
and	O
excessive	O
transpulmonary	O
pressures	O
,	O
which	O
contribute	O
to	O
ventilation	O
-	O
related	O
lung	O
injury	O
.	O

However	O
,	O
the	O
mechanisms	O
by	O
which	O
alcohol	O
sensitizes	O
the	O
lung	O
to	O
development	B-PROC
of	O
this	O
disease	O
are	O
poorly	O
understood	O
.	O

Aerosolized	O
tobramycin	O
inhalation	B-PROC
solution	O
(	O
TIS	O
)	O
240	O
mg	O
was	O
administered	O
daily	O
for	O
14	O
days	O
in	O
addition	O
to	O
systemic	O
antibiotics	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
evaluation	O
of	O
phenylisoserine	O
derivatives	O
for	O
the	O
SARS	O
-	O
CoV	O
3CL	O
protease	O
inhibitor	O
.	O

ABSTRACT	O
:	O
Synthesis	B-PROC
and	O
evaluation	O
of	O
new	O
scaffold	O
phenylisoserine	O
derivatives	O
connected	O
with	O
the	O
essential	O
functional	O
groups	O
against	O
SARS	O
CoV	O
3CL	O
protease	O
are	O
described	O
.	O

ABSTRACT	O
:	O
From	O
2002	O
to	O
2003	O
,	O
a	O
global	O
pandemic	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
spread	O
to	O
5	O
continents	O
and	O
caused	O
8000	O
respiratory	O
infections	O
and	O
800	O
deaths	B-PROC
.	O

By	O
contrast	O
with	O
influenza	O
viruses	O
,	O
little	O
is	O
known	O
about	O
the	O
contemporaneous	O
global	O
diversity	O
of	O
these	O
viruses	O
,	O
and	O
the	O
relevance	O
of	O
such	O
for	O
development	B-PROC
of	O
pharmaceutical	O
interventions	O
.	O

This	O
study	O
aimed	O
to	O
validate	O
the	O
EGFR	O
'	O
s	O
role	O
in	O
ALI	O
and	O
investigated	O
the	O
effects	O
of	O
EGFR	O
inhibition	B-PROC
on	O
lipopolysaccharides	O
(	O
LPS	O
)-	O
induced	O
ALI	O
in	O
rats	O
.	O

In	O
a	O
cohort	O
of	O
82	O
VV	O
-	O
ECMO	O
patients	O
(	O
PRedicting	O
dEath	B-PROC
for	O
SEvere	O
ARDS	O
on	O
VV	O
-	O
ECMO	O
[	O
PRESERVE	O
]	O
score	O
:	O
4	O
,	O
Interquartile	O
range	O
[	O
IQR	O
]:	O
3	O
-	O
5	O
,	O
Respiratory	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
Survival	O
Prediction	O
[	O
RESP	O
]	O
score	O
:	O
2	O
,	O
IQR	O
:	O
2	O
-	O
4	O
),	O
76	O
(	O
92	O
.	O
7	O
%)	O
patients	O
received	O
at	O
least	O
1	O
unit	O
of	O
packed	O
red	O
blood	O
cells	O
(	O
PRBCs	O
)	O
during	O
the	O
intensive	O
care	O
unit	O
stay	O
related	O
to	O
ECMO	O
(	O
median	O
PRBC	O
/	O
d	O
156	O
mL	O
,	O
IQR	O
:	O
93	O
-	O
218	O
;	O
median	O
ECMO	O
duration	O
14	O
days	O
,	O
IQR	O
:	O
8	O
-	O
22	O
).	O

To	O
research	O
the	O
immunogenicity	O
differences	O
of	O
PEDV	O
G1	O
and	O
G2	O
genotype	O
strains	O
and	O
obtain	O
a	O
neutralizing	O
monoclonal	O
antibody	B-PROC
(	O
mAb	O
),	O
we	O
inoculated	O
specific	O
-	O
pathogen	O
-	O
free	O
BALB	O
/	O
c	O
mice	O
with	O
a	O
newly	O
emerged	O
strain	O
,	O
PEDV	O
-	O
LNCT2	O
.	O

To	O
understand	O
the	O
substrate	O
specificity	O
of	O
APN	O
for	O
the	O
development	B-PROC
of	O
targeted	B-PROC
inhibitors	O
,	O
we	O
used	O
a	O
global	O
substrate	O
profiling	O
method	O
to	O
determine	O
the	O
P1	O
-	O
P4	O
'	O
amino	O
acid	O
preferences	O
.	O

The	O
low	O
pathogenic	O
CoVs	O
infect	O
the	O
upper	O
respiratory	O
tract	O
and	O
cause	O
mild	O
,	O
cold	B-PROC
-	O
like	O
respiratory	O
illness	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
16	O
-	O
year	O
-	O
old	O
girl	O
who	O
was	O
diagnosed	O
with	O
acute	O
leukaemia	O
and	O
a	O
marked	O
leucocytosis	O
>	O
200	O
×	O
10	O
Mark	O
hypophosphatemia	O
and	O
hypokalemia	O
may	O
be	O
presenting	O
electrolyte	O
abnormalities	O
in	O
a	O
patient	O
with	O
acute	O
leukaemia	O
,	O
and	O
these	O
may	O
be	O
indicators	O
of	O
aggressive	B-PROC
tumour	O
genesis	O
.	O

TITLE	O
:	O
Zero	O
Transmission	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
:	O
Lessons	O
Learned	B-PROC
From	O
Thailand	O
.	O

It	O
might	O
partially	O
explain	O
the	O
pathogenesis	B-PROC
of	O
acute	O
mountain	O
sickness	O
,	O
a	O
treatable	O
disease	O
characterized	O
by	O
severe	O
hyperventilation	O
secondary	O
to	O
the	O
hypoxia	O
of	O
high	O
altitude	O
exposure	O
.	O

Moreover	O
,	O
following	O
stimulation	O
with	O
LPS	O
,	O
p47phox	O
was	O
expressed	B-PROC
at	O
lower	O
levels	O
in	O
miR	O
-	O
19	O
-	O
deficient	O
murine	O
pulmonary	O
inflammatory	O
cells	O
than	O
in	O
those	O
in	O
wild	O
-	O
type	O
rats	O
.	O

A	O
retrospective	O
study	O
of	O
children	O
with	O
HCoV	O
detected	O
by	O
reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
performed	O
for	O
a	O
community	O
cohort	O
and	O
a	O
children	O
'	O
s	O
hospital	O
in	O
the	O
same	O
community	O
from	O
January	O
2013	O
to	O
December	O
2014	O
.	O

Obesity	O
affects	O
the	O
respiratory	B-PROC
function	I-PROC
.	O

Anesthesia	O
and	O
surgery	O
can	O
profoundly	O
impair	O
respiratory	B-PROC
function	I-PROC
,	O
increasing	O
the	O
risk	O
of	O
postoperative	O
respiratory	O
complications	O
and	O
acute	O
respiratory	O
failure	O
.	O

Infection	O
of	O
macrophages	O
with	O
N15m1	O
,	O
which	O
expresses	O
an	O
unstable	O
nsp15	O
,	O
or	O
N15m3	O
,	O
which	O
expresses	O
a	O
catalysis	O
-	O
deficient	O
nsp15	O
,	O
activated	O
MDA5	O
,	O
PKR	O
,	O
and	O
the	O
OAS	O
/	O
RNase	O
L	O
system	O
,	O
resulting	O
in	O
an	O
early	O
,	O
robust	O
induction	O
of	O
type	O
I	O
IFN	O
,	O
PKR	O
-	O
mediated	O
apoptosis	B-PROC
,	O
and	O
RNA	B-PROC
degradation	I-PROC
.	O

ECMO	O
and	O
non	O
-	O
ECMO	O
survivors	O
showed	O
similar	O
pulmonary	B-PROC
function	I-PROC
,	O
morphological	O
abnormalities	O
,	O
resting	O
arterial	O
blood	B-PROC
gas	I-PROC
values	O
,	O
and	O
6	O
-	O
min	O
walking	O
distance	O
.	O

Our	O
studies	O
showed	O
that	O
IL	O
-	O
33	O
administration	O
in	O
a	O
MHV	O
-	O
3	O
infection	O
promoted	O
survival	O
during	O
FH	O
,	O
with	O
a	O
significant	O
reduction	O
in	O
FGL2	O
expression	B-PROC
and	O
liver	O
inflammation	O
.	O

Changing	O
breeding	B-PROC
strategies	O
towards	O
selection	O
of	O
chickens	O
with	O
a	O
more	O
general	O
and	O
broad	O
disease	B-PROC
resistance	I-PROC
or	O
robustness	O
may	O
therefore	O
improve	O
the	O
overall	O
health	O
status	O
,	O
animal	O
welfare	O
,	O
and	O
food	O
security	O
in	O
the	O
poultry	O
production	O
.	O

The	O
current	O
study	O
indicates	O
that	O
considerable	O
differences	O
in	O
immunocompetence	B-PROC
may	O
exist	O
between	O
commercial	O
layer	O
lines	O
used	O
in	O
organic	O
production	O
.	O

These	O
results	O
indicate	O
the	O
continuing	O
evolution	B-PROC
of	O
IBV	O
field	O
strains	O
by	O
genetic	B-PROC
drift	I-PROC
and	O
by	O
genetic	B-PROC
recombination	I-PROC
leading	O
to	O
outbreaks	O
in	O
the	O
vaccinated	O
chicken	O
populations	O
in	O
Egypt	O
.	O

GLS	O
-	O
5300	O
,	O
a	O
prophylactic	O
DNA	O
-	O
plasmid	O
vaccine	O
encoding	O
S	O
protein	O
,	O
is	O
the	O
first	O
MERS	O
-	O
CoV	O
vaccine	O
to	O
be	O
tested	O
in	O
humans	O
,	O
while	O
monoclonal	O
antibody	B-PROC
,	O
m336	O
has	O
given	O
promising	O
results	O
in	O
animal	O
models	O
and	O
has	O
potential	O
for	O
use	O
in	O
outbreak	O
situations	O
.	O

This	O
study	O
might	O
contribute	O
to	O
an	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
PEDV	O
infection	O
and	O
aid	O
in	O
the	O
development	B-PROC
of	O
effective	O
preventive	O
and	O
control	O
vaccines	O
.	O

Using	O
this	O
method	O
,	O
recombinant	O
CoVs	O
can	O
be	O
rapidly	O
generated	O
and	O
used	O
to	O
investigate	O
host	O
range	O
,	O
gene	B-PROC
function	I-PROC
,	O
pathogenesis	B-PROC
,	O
and	O
candidate	O
therapeutics	O
for	O
emerging	O
and	O
preemergent	O
CoVs	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

RESULTS	O
:	O
Immunohistochemical	O
studies	O
have	O
suggested	O
that	O
over	O
-	O
expression	B-PROC
of	O
GPC3	O
is	O
associated	O
with	O
a	O
poorer	O
prognosis	O
for	O
hepatocellular	O
carcinoma	O
patients	O
.	O

Six	O
participants	O
died	B-PROC
,	O
one	O
(	O
2	O
%)	O
from	O
the	O
plasma	O
plus	O
standard	O
care	O
group	O
and	O
five	O
(	O
10	O
%)	O
from	O
the	O
standard	O
care	O
group	O
(	O
HR	O
0	O
·	O
19	O
[	O
95	O
%	O
CI	O
0	O
·	O
02	O
-	O
1	O
·	O
65	O
],	O
p	O
=	O
0	O
·	O
093	O
).	O

TITLE	O
:	O
TMPRSS2	O
and	O
MSPL	O
Facilitate	O
Trypsin	O
-	O
Independent	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	B-PROC
Replication	I-PROC
in	O
Vero	O
Cells	O
.	O

The	O
patients	O
in	O
the	O
obstetric	O
causes	O
group	O
showed	O
significant	O
improvement	O
after	O
delivery	O
in	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
the	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
and	O
peak	O
inspiratory	B-PROC
pressure	O
decrease	O
.	O

Alignment	O
and	O
comparison	O
of	O
full	O
-	O
length	O
sequences	O
of	O
PEDVPT	O
-	O
P5	O
and	O
PEDVPT	O
-	O
P96	O
revealed	O
23	O
nucleotide	O
changes	O
and	O
resultant	O
19	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
in	O
non	O
-	O
structure	O
proteins	O
2	O
,	O
3	O
,	O
4	O
,	O
9	O
,	O
14	O
,	O
15	O
,	O
spike	O
,	O
open	O
reading	O
frame	O
3	O
(	O
ORF3	O
),	O
and	O
membrane	O
proteins	O
with	O
no	O
detectable	O
deletion	O
or	O
insertion	O
.	O

A	O
retrospective	O
study	O
of	O
patients	O
admitted	O
at	O
Indira	O
Gandhi	O
Medical	O
College	O
Hospital	O
,	O
Shimla	O
with	O
snake	O
bite	B-PROC
-	O
induced	O
AKI	O
from	O
July	O
2003	O
to	O
June	O
2016	O
.	O

Coagulation	B-PROC
defect	O
was	O
seen	O
in	O
89	O
%	O
patients	O
.	O

A	O
variety	O
of	O
viral	O
DUBs	O
(	O
vDUBs	O
),	O
including	O
the	O
MERS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
,	O
are	O
responsible	O
for	O
cleaving	O
the	O
viral	O
replicase	O
polyproteins	O
during	O
replication	O
,	O
and	O
are	O
thereby	O
critical	O
components	O
of	O
the	O
viral	B-PROC
replication	I-PROC
cycle	I-PROC
.	O

She	O
developed	O
severe	O
acute	O
kidney	O
injury	O
with	O
acute	O
tubular	O
necrosis	B-PROC
,	O
subnephrotic	O
ranged	O
proteinuria	O
and	O
tubulointerstitial	O
nephritis	O
for	O
which	O
she	O
underwent	O
haemodialysis	O
three	O
times	O
along	O
with	O
other	O
measures	O
of	O
resuscitation	O
.	O

Case	O
1	O
showed	O
delayed	O
symptom	O
development	B-PROC
after	O
a	O
four	O
-	O
day	O
asymptomatic	O
period	O
,	O
Case	O
2	O
experienced	O
a	O
20	O
-	O
day	O
incubation	O
period	O
,	O
and	O
Case	O
3	O
exhibited	O
persistent	O
viral	B-PROC
shedding	I-PROC
without	O
clinical	O
deterioration	O
.	O

The	O
main	O
causes	O
of	O
respiratory	O
failure	O
were	O
pneumonia	O
(	O
mostly	O
viral	O
)	O
and	O
ARDS	O
;	O
60	O
%	O
of	O
patients	O
with	O
respiratory	O
failure	O
were	O
successfully	O
weaned	B-PROC
from	O
ECMO	O
,	O
and	O
51	O
%	O
in	O
total	O
were	O
released	O
from	O
intensive	O
care	O
;	O
71	O
%	O
of	O
patients	O
treated	O
with	O
VA	O
-	O
ECMO	O
were	O
successfully	O
weaned	B-PROC
,	O
and	O
58	O
%	O
in	O
total	O
were	O
released	O
from	O
intensive	O
care	O
.	O

Neutrophils	O
are	O
poorly	O
studied	O
with	O
respect	O
to	O
viral	B-PROC
infection	I-PROC
,	O
and	O
specifically	O
to	O
respiratory	O
viral	B-PROC
disease	I-PROC
.	O

TITLE	O
:	O
Broad	O
-	O
spectrum	O
inhibition	B-PROC
of	O
common	O
respiratory	O
RNA	O
viruses	O
by	O
a	O
pyrimidine	O
synthesis	B-PROC
inhibitor	O
with	O
involvement	O
of	O
the	O
host	O
antiviral	B-PROC
response	I-PROC
.	O

Cx43	O
is	O
mainly	O
expressed	B-PROC
by	O
astrocytes	O
in	O
the	O
CNS	O
and	O
forms	O
gap	O
junction	O
intercellular	O
communications	O
between	O
astrocytes	O
-	O
astrocytes	O
(	O
Cx43	O
-	O
Cx43	O
)	O
and	O
between	O
astrocytes	O
-	O
oligodendrocytes	O
(	O
Cx43	O
-	O
Cx47	O
).	O

Patients	O
with	O
high	O
-	O
grade	O
INH	O
had	O
worse	O
pulmonary	O
dysfunction	O
,	O
worse	O
oxygenation	B-PROC
indices	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
plasma	O
carboxyhemoglobin	O
(	O
COHgb	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
on	O
admission	O
,	O
increased	O
fluid	O
requirements	O
(	O
P	O
<	O
0	O
.	O
01	O
at	O
24	O
hours	O
;	O
P	O
=	O
0	O
.	O
04	O
at	O
48	O
hours	O
),	O
MODS	O
(	O
P	O
=	O
0	O
.	O
04	O
),	O
pneumonia	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
P	O
=	O
0	O
.	O
01	O
at	O
48	O
hours	O
),	O
fewer	O
28	O
-	O
day	O
ventilator	O
-	O
free	O
days	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
greater	O
ventilator	O
dependence	O
(	O
P	O
=	O
0	O
.	O
03	O
),	O
and	O
longer	O
length	O
of	O
stay	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Serum	O
Cytokine	O
Profiles	O
Differentiating	O
Hemorrhagic	O
Fever	B-PROC
with	O
Renal	O
Syndrome	O
and	O
Hantavirus	O
Pulmonary	O
Syndrome	O
.	O

ABSTRACT	O
:	O
Hantavirus	O
infection	O
is	O
an	O
acute	O
zoonosis	O
that	O
clinically	O
manifests	O
in	O
two	O
primary	O
forms	O
,	O
hemorrhagic	O
fever	B-PROC
with	O
renal	O
syndrome	O
(	O
HFRS	O
)	O
and	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	O
).	O

Importantly	O
,	O
cell	O
damage	O
due	O
to	O
virus	B-PROC
replication	I-PROC
,	O
or	O
subsequent	O
tissue	B-PROC
repair	I-PROC
,	O
has	O
not	O
been	O
documented	O
.	O

Furthermore	O
,	O
HPS	O
was	O
strictly	O
characterized	O
by	O
the	O
upregulation	B-PROC
of	O
cytokine	O
levels	O
,	O
in	O
contrast	O
to	O
HFRS	O
where	O
cases	O
were	O
distinguished	O
by	O
a	O
dichotomy	O
in	O
serum	O
cytokine	O
levels	O
.	O

RV1B	O
infection	O
caused	O
numerous	O
gene	B-PROC
expression	I-PROC
changes	O
,	O
but	O
the	O
differential	O
effect	O
peaked	O
at	O
12	O
hours	O
post	O
-	O
infection	O
.	O

MHV	O
-	O
1	O
had	O
comparatively	O
few	O
effects	O
on	O
host	O
gene	B-PROC
expression	I-PROC
.	O

ABSTRACT	O
:	O
Despite	O
the	O
fact	O
that	O
there	O
had	O
been	O
multiple	O
small	O
outbreaks	O
of	O
Ebola	O
Virus	B-PROC
Disease	I-PROC
,	O
when	O
a	O
large	O
outbreak	O
occurred	O
in	O
2014	O
there	O
were	O
no	O
vaccines	O
or	O
drugs	O
available	O
for	O
use	O
.	O

In	O
order	O
to	O
be	O
better	O
prepared	O
for	O
future	O
outbreaks	O
of	O
known	O
human	O
pathogens	O
,	O
platform	O
technologies	O
to	O
accelerate	O
vaccine	O
development	B-PROC
should	O
be	O
employed	O
,	O
allowing	O
vaccine	O
developers	O
to	O
take	O
advantage	O
of	O
detailed	O
knowledge	O
of	O
the	O
vaccine	O
platform	O
and	O
facilitating	O
rapid	O
progress	O
to	O
clinical	O
trials	O
and	O
eventually	O
to	O
vaccine	O
stockpiles	O
.	O

TITLE	O
:	O
ChAdOx1	O
and	O
MVA	O
based	O
vaccine	O
candidates	O
against	O
MERS	O
-	O
CoV	O
elicit	O
neutralising	O
antibodies	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
in	O
mice	O
.	O

The	O
syndrome	O
ranges	O
from	O
asymptomatic	O
and	O
mild	O
cases	O
to	O
severe	O
pneumonia	O
and	O
death	B-PROC
.	O

A	O
single	O
dose	O
of	O
ChAdOx1	O
MERS	O
with	O
tPA	O
elicited	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
as	O
well	O
as	O
neutralising	O
antibodies	O
that	O
were	O
boosted	O
to	O
a	O
significantly	O
higher	O
level	O
by	O
MVA	O
MERS	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
Antibody	B-PROC
Responses	I-PROC
1	O
Year	O
after	O
Symptom	O
Onset	O
,	O
South	O
Korea	O
,	O
2015	O
.	O

This	O
study	O
evaluated	O
the	O
performance	O
of	O
an	O
insulated	O
isothermal	O
PCR	O
(	O
iiPCR	O
)	O
that	O
detects	O
proviral	O
DNA	O
,	O
and	O
a	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
iiPCR	O
that	O
detects	O
both	O
viral	O
RNA	O
and	O
proviral	O
DNA	O
,	O
for	O
FeLV	O
detection	O
at	O
the	O
PON	O
.	O

Major	O
advances	O
in	O
the	O
study	O
of	O
the	O
molecular	O
biology	O
of	O
IBV	O
have	O
resulted	O
from	O
the	O
development	B-PROC
of	O
reverse	O
genetics	O
systems	O
for	O
the	O
highly	O
attenuated	O
,	O
cell	O
culture	O
-	O
adapted	O
,	O
IBV	O
strain	O
Beaudette	O
.	O

As	O
a	O
result	O
of	O
the	O
outbreak	O
in	O
South	O
Korea	O
,	O
186	O
infections	O
were	O
reported	O
,	O
and	O
36	O
patients	O
died	B-PROC
.	O

The	O
basic	O
reproduction	B-PROC
number	O
of	O
an	O
epidemic	O
is	O
defined	O
as	O
the	O
average	O
number	O
of	O
secondary	O
cases	O
that	O
an	O
infected	O
subject	O
produces	O
over	O
its	O
infectious	O
period	O
in	O
a	O
susceptible	O
and	O
uninfected	O
population	O
.	O

It	O
is	O
worth	O
comparing	O
with	O
the	O
basic	O
reproductive	B-PROC
number	O
of	O
the	O
2014	O
Ebola	O
outbreak	O
in	O
West	O
Africa	O
including	O
Guinea	O
,	O
Sierra	O
Leone	O
,	O
and	O
Liberia	O
,	O
which	O
had	O
values	O
of	O
1	O
.	O
5	O
-	O
2	O
.	O
5	O
.	O

It	O
is	O
worth	O
comparing	O
with	O
the	O
basic	O
reproductive	B-PROC
number	O
of	O
the	O
2014	O
Ebola	O
outbreak	O
in	O
West	O
Africa	O
including	O
Guinea	O
,	O
Sierra	O
Leone	O
,	O
and	O
Liberia	O
,	O
which	O
had	O
values	O
of	O
1	O
.	O
5	O
-	O
2	O
.	O
5	O
.	O

Although	O
the	O
typical	O
genome	O
structure	O
of	O
NS1	O
-	O
NP1	O
-	O
VP1	O
/	O
VP2	O
was	O
observed	O
in	O
DBoV1	O
and	O
DBoV2	O
,	O
no	O
phospholipase	O
A2	O
motif	O
and	O
associated	O
calcium	B-PROC
binding	I-PROC
site	O
were	O
observed	O
in	O
the	O
predicted	O
VP1	O
sequences	O
for	O
any	O
of	O
the	O
18	O
sequenced	O
DBoV2	O
,	O
and	O
no	O
start	O
codons	O
were	O
found	O
for	O
their	O
VP1	O
.	O

ARDS	O
is	O
defined	O
by	O
the	O
patient	O
'	O
s	O
oxygen	O
in	O
arterial	O
blood	O
(	O
PaO2	O
)	O
to	O
the	O
fraction	O
of	O
the	O
oxygen	O
in	O
the	O
inspired	B-PROC
air	O
(	O
FiO2	O
).	O

TITLE	O
:	O
Sedation	O
Management	O
in	O
Children	O
Supported	O
on	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
for	O
Acute	O
Respiratory	O
Failure	O
.	O

Sixty	O
-	O
one	O
Randomized	O
Evaluation	O
of	O
Sedation	O
Titration	O
for	O
Respiratory	O
Failure	O
patients	O
(	O
5	O
%)	O
with	O
moderate	O
/	O
severe	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
were	O
supported	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
including	O
29	O
managed	O
per	O
Randomized	O
Evaluation	O
of	O
Sedation	O
Titration	O
for	O
Respiratory	O
Failure	O
protocol	O
.	O

Median	O
opioid	O
and	O
benzodiazepine	O
doses	O
on	O
the	O
day	O
of	O
cannulation	O
,	O
0	O
.	O
15	O
mg	O
/	O
kg	O
/	O
hr	O
(	O
3	O
.	O
7	O
mg	O
/	O
kg	O
/	O
d	O
)	O
and	O
0	O
.	O
11	O
mg	O
/	O
kg	O
/	O
hr	O
(	O
2	O
.	O
8	O
mg	O
/	O
kg	O
/	O
d	O
),	O
increased	O
by	O
36	O
%	O
and	O
58	O
%,	O
respectively	O
,	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
day	O
3	O
.	O

However	O
,	O
cSP	O
-	O
A	O
expression	B-PROC
in	O
the	O
respiratory	O
tract	O
of	O
chickens	O
after	O
viral	O
co	O
-	O
infection	O
remains	O
unclear	O
.	O

The	O
mechanism	O
of	O
the	O
downregulation	B-PROC
of	O
SP	O
-	O
A	O
expression	B-PROC
level	O
will	O
be	O
addressed	O
in	O
future	O
.	O

Phylogenetic	O
analysis	O
,	O
network	O
tree	O
,	O
similarity	O
plot	O
analysis	O
,	O
Recombination	B-PROC
Detection	O
Program	O
4	O
(	O
RDP4	O
)	O
and	O
sequence	O
comparison	O
revealed	O
that	O
12	O
of	O
the	O
20	O
isolates	O
were	O
likely	O
the	O
reisolated	O
vaccine	O
virus	O
.	O

TGEV	O
PUR	O
46	O
-	O
MAD	B-PROC
is	O
a	O
commonly	O
used	O
TGEV	O
strain	O
that	O
is	O
known	O
to	O
be	O
attenuated	O
.	O

The	O
antibody	B-PROC
,	O
named	O
PC10	O
,	O
was	O
demonstrated	O
to	O
target	O
the	O
conformational	O
epitope	O
of	O
PEDV	O
spike	O
protein	O
,	O
specifically	O
bind	O
to	O
the	O
infected	O
cells	O
of	O
PEDV	O
genogroup	O
1	O
and	O
2	O
strains	O
,	O
and	O
potently	O
neutralize	O
PEDV	O
infection	O
.	O

TITLE	O
:	O
Discovery	O
of	O
unsymmetrical	O
aromatic	O
disulfides	O
as	O
novel	O
inhibitors	O
of	O
SARS	O
-	O
CoV	O
main	O
protease	O
:	O
Chemical	O
synthesis	B-PROC
,	O
biological	O
evaluation	O
,	O
molecular	O
docking	B-PROC
and	O
3D	O
-	O
QSAR	O
study	O
.	O

This	O
paper	O
reviewed	O
recent	O
related	O
studies	O
,	O
summarized	O
the	O
prevalence	O
,	O
pathogenesis	B-PROC
and	O
diagnostic	O
approaches	O
of	O
ACP	O
in	O
ARDS	O
,	O
especially	O
echocardiography	O
which	O
was	O
considered	O
as	O
a	O
cornerstone	O
for	O
ACP	O
diagnosis	O
,	O
and	O
elucidated	O
the	O
beneficial	O
effects	O
of	O
right	O
ventricular	O
protective	O
ventilatory	O
strategy	O
and	O
prone	O
-	O
positioning	O
on	O
the	O
pulmonary	O
vasculature	O
and	O
right	O
heart	O
,	O
in	O
order	O
to	O
provide	O
a	O
novel	O
idea	O
for	O
the	O
therapy	O
of	O
ACP	O
in	O
ARDS	O
.	O

While	O
preload	O
optimization	O
is	O
crucial	O
in	O
its	O
management	O
,	O
dynamic	O
fluid	O
responsiveness	O
indices	O
lack	O
reliability	O
,	O
and	O
there	O
is	O
no	O
consensus	O
on	O
target	O
central	O
venous	B-PROC
pressure	I-PROC
(	O
CVP	O
).	O

Blood	O
samples	O
were	O
collected	O
for	O
analysis	O
of	O
oxidative	O
parameters	O
and	O
specific	O
antibody	B-PROC
titers	O
,	O
and	O
splenocytes	O
were	O
prepared	O
for	O
lymphocyte	O
proliferative	O
assay	O
.	O

Enhanced	O
immune	B-PROC
responses	I-PROC
,	O
such	O
as	O
lymphocyte	B-PROC
proliferation	I-PROC
induced	O
by	O
concanavalin	O
A	O
and	O
lipopolysaccharides	O
,	O
and	O
serum	O
Newcastle	O
disease	O
virus	O
-	O
and	O
infectious	O
bronchitis	O
virus	O
-	O
specific	O
antibodies	O
were	O
also	O
observed	O
in	O
chickens	O
injected	O
with	O
or	O
without	O
cyclophosphamide	O
.	O

To	O
develop	O
a	O
radiological	O
metric	O
of	O
injurious	O
inflation	O
derived	O
from	O
matched	O
inspiratory	B-PROC
and	O
expiratory	B-PROC
CT	O
scans	O
,	O
calibrate	O
it	O
in	O
a	O
model	O
of	O
experimental	O
lung	O
injury	O
,	O
and	O
test	O
it	O
in	O
patients	O
with	O
ARDS	O
.	O

TITLE	O
:	O
Different	O
residues	O
in	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
determine	O
cleavage	B-PROC
and	O
activation	O
by	O
the	O
host	O
cell	O
protease	O
TMPRSS2	O
.	O

Although	O
R667	O
was	O
required	O
for	O
SARS	O
S	O
cleavage	B-PROC
by	O
TMPRSS2	O
,	O
this	O
residue	O
was	O
dispensable	O
for	O
TMPRSS2	O
-	O
mediated	O
S	O
protein	B-PROC
activation	I-PROC
.	O

In	O
fact	O
,	O
by	O
virtue	O
of	O
its	O
numerous	O
active	O
metabolites	O
,	O
H	O
.	O
indicus	O
was	O
able	O
to	O
inhibit	O
not	O
only	O
the	O
RT	O
-	O
associated	O
RNase	O
H	O
function	O
,	O
but	O
also	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNA	B-PROC
-	I-PROC
dependent	I-PROC
DNA	I-PROC
polymerase	I-PROC
activity	I-PROC
and	O
the	O
cellular	O
α	O
-	O
glucosidase	O
.	O

ABSTRACT	O
:	O
Although	O
shrews	O
are	O
one	O
of	O
the	O
largest	O
groups	O
of	O
mammals	O
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
the	O
evolution	B-PROC
and	O
transmission	O
of	O
viral	O
pathogens	O
,	O
including	O
coronaviruses	O
(	O
CoVs	O
).	O

TITLE	O
:	O
Argatroban	O
for	O
Heparin	O
-	O
Induced	O
Thrombocytopenia	O
during	O
Venovenous	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
with	O
Continuous	O
Venovenous	O
Hemofiltration	O
.	O

ABSTRACT	O
:	O
Patients	O
receiving	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
are	O
at	O
risk	O
of	O
circuit	O
thrombosis	O
due	O
to	O
constant	O
contact	O
between	O
blood	O
and	O
the	O
extracorporeal	O
components	O
.	O

NF	O
-	O
κB	O
activation	O
is	O
a	O
common	O
pro	O
-	O
inflammatory	B-PROC
response	I-PROC
of	O
host	O
cells	O
to	O
viral	B-PROC
infection	I-PROC
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
(	O
i	O
)	O
find	O
an	O
effective	O
combination	O
treatment	O
for	O
coronaviral	O
infections	O
through	O
targeting	B-PROC
of	O
the	O
virus	O
per	O
se	O
and	O
cellular	O
NF	O
-	O
κB	O
activity	O
;	O
and	O
(	O
ii	O
)	O
to	O
study	O
the	O
underling	O
mechanisms	O
.	O

Next	O
to	O
a	O
role	O
in	O
basic	O
virus	B-PROC
replication	I-PROC
or	O
virus	B-PROC
assembly	I-PROC
,	O
many	O
of	O
the	O
coronavirus	O
proteins	O
expressed	B-PROC
in	O
the	O
infected	O
cell	O
contribute	O
to	O
the	O
coronavirus	O
-	O
host	O
interplay	O
.	O

Besides	O
avoiding	O
patients	O
death	B-PROC
from	O
hypoxemia	O
,	O
this	O
technique	O
can	O
also	O
prevent	O
further	O
progression	O
of	O
the	O
lung	O
damage	O
due	O
to	O
artificial	O
ventilation	O
.	O

Putative	O
factors	O
related	O
to	O
increased	O
survival	O
include	O
patients	O
retrieval	O
after	O
connecting	O
them	O
to	O
ECMO	O
,	O
and	O
less	O
intensive	O
anticoagulation	B-PROC
protocols	O
.	O

It	O
is	O
a	O
common	O
belief	O
that	O
overwhelming	O
immune	B-PROC
response	I-PROC
contributes	O
to	O
the	O
severe	O
illness	O
.	O

Alone	O
,	O
resveratrol	O
does	O
not	O
inhibit	O
HIV	O
-	O
1	O
infection	O
of	O
activated	O
T	O
cells	O
,	O
but	O
it	O
does	O
synergize	O
with	O
nucleoside	B-PROC
reverse	I-PROC
transcriptase	I-PROC
inhibitors	I-PROC
in	O
these	O
cells	O
to	O
inhibit	O
reverse	B-PROC
transcription	B-PROC
.	O

ABSTRACT	O
:	O
Emerging	O
viral	B-PROC
infections	I-PROC
are	O
difficult	O
to	O
control	O
because	O
heterogeneous	O
members	O
periodically	O
cycle	O
in	O
and	O
out	O
of	O
humans	O
and	O
zoonotic	O
hosts	O
,	O
complicating	O
the	O
development	B-PROC
of	O
specific	O
antiviral	O
therapies	O
and	O
vaccines	O
.	O

The	O
International	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
Network	O
recommends	O
regionalization	B-PROC
of	O
extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
to	O
high	O
-	O
volume	O
centers	O
and	O
development	B-PROC
of	O
mobile	O
ECLS	O
teams	O
to	O
rescue	O
patients	O
with	O
severe	O
acute	O
respiratory	O
disease	O
.	O

We	O
conducted	O
a	O
retrospective	O
study	O
of	O
all	O
consecutive	O
patients	O
presenting	O
for	O
ECLS	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
from	O
outside	O
hospitals	O
through	O
our	O
mobile	O
ECLS	O
program	O
associated	O
with	O
hemodynamic	B-PROC
instability	O
from	O
January	O
1	O
,	O
2015	O
,	O
until	O
December	O
31	O
,	O
2015	O
.	O

The	O
formation	B-PROC
of	O
a	O
mobile	O
ECLS	O
program	O
is	O
a	O
complex	O
undertaking	O
that	O
took	O
2	O
years	O
of	O
planning	O
to	O
develop	O
.	O

Development	B-PROC
of	O
criteria	O
for	O
ECLS	O
implementation	O
can	O
guide	O
appropriate	O
resources	O
utilization	O
and	O
may	O
prevent	O
their	O
use	O
in	O
patients	O
with	O
little	O
to	O
no	O
chance	O
of	O
survival	O
.	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
the	O
nsp14	O
protein	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
virus	B-PROC
replication	I-PROC
as	O
it	O
methylates	O
the	O
RNA	O
cap	O
structure	O
at	O
the	O
N7	O
position	O
of	O
the	O
guanine	O
.	O

The	O
occurrence	O
of	O
ACO	O
was	O
defined	O
as	O
a	O
positive	O
response	O
to	O
a	O
bronchodilator	O
(	O
an	O
increase	O
in	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
1	O
second	O
[	O
FEV1	O
]	O
of	O
12	O
%	O
and	O
200	O
mL	O
).	O

The	O
sows	O
were	O
categorized	O
into	O
six	O
groups	O
based	O
on	O
the	O
period	O
in	O
which	O
they	O
were	O
exposed	O
to	O
PED	O
virus	O
:	O
between	O
days	O
0	O
-	O
30	O
(	O
G1	O
),	O
31	O
-	O
60	O
(	O
G2	O
),	O
61	O
-	O
90	O
(	O
G3	O
),	O
or	O
after	O
91	O
days	O
of	O
pregnancy	O
(	O
G4	O
),	O
during	O
lactation	B-PROC
(	O
L	O
),	O
and	O
after	O
weaning	B-PROC
(	O
W	O
).	O

The	O
sows	O
of	O
the	O
G4	O
and	O
L	O
groups	O
had	O
the	O
fewest	O
piglets	O
weaned	B-PROC
(	O
4	O
.	O
8	O
±	O
0	O
.	O
4	O
,	O
and	O
4	O
.	O
0	O
±	O
0	O
.	O
3	O
pigs	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
greatest	O
pre	O
-	O
weaning	B-PROC
mortality	O
(	O
33	O
.	O
1	O
±	O
4	O
.	O
8	O
%,	O
and	O
39	O
.	O
7	O
±	O
4	O
.	O
1	O
%,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Co	O
-	O
circulation	B-PROC
of	O
three	O
clusters	O
of	O
793	O
/	O
B	O
-	O
like	O
avian	O
infectious	O
bronchitis	O
virus	O
genotypes	O
in	O
Iranian	O
chicken	O
flocks	O
.	O

Clinical	O
signs	O
were	O
limited	O
to	O
the	O
respiratory	O
tract	O
in	O
all	O
challenged	O
groups	O
and	O
varied	O
from	O
mild	O
to	O
moderate	O
mouth	O
breathing	B-PROC
to	O
severe	O
respiratory	O
signs	O
with	O
snorting	O
sound	O
and	O
extended	O
head	O
.	O

Viral	O
propagation	O
was	O
confirmed	O
in	O
Vero	O
cells	O
based	O
on	O
cytopathic	O
effect	O
,	O
immunofluorescence	O
assay	O
,	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
electron	O
microscopic	O
analyses	O
.	O

Traveling	O
plays	O
an	O
important	O
role	O
in	O
transmitting	O
infections	O
such	O
as	O
Zika	O
virus	B-PROC
infection	I-PROC
,	O
Ebola	O
,	O
avian	O
flu	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Chikungunya	O
,	O
and	O
dengue	O
fever	B-PROC
and	O
is	O
the	O
principal	O
reason	O
for	O
the	O
epidemics	O
of	O
these	O
types	O
of	O
infections	O
on	O
a	O
global	O
scale	O
.	O

Enrolled	O
children	O
fulfilled	O
the	O
following	O
criteria	O
:	O
(	O
1	O
)	O
PICU	O
admission	O
;	O
(	O
2	O
)	O
age	O
of	O
1	O
month	O
to	O
16	O
years	O
;	O
(	O
3	O
)	O
diagnosis	O
of	O
infectious	O
pneumonia	O
and	O
respiratory	O
virus	B-PROC
infection	I-PROC
;	O
and	O
(	O
4	O
)	O
development	B-PROC
of	O
severe	O
ARDS	O
within	O
72	O
h	O
after	O
PICU	O
admission	O
.	O

Limiting	O
such	O
behaviour	B-PROC
by	O
rapidly	O
identifying	O
and	O
isolating	O
cases	O
and	O
avoiding	O
high	O
-	O
risk	O
contacts	O
effectively	O
stopped	O
further	O
transmission	O
.	O

Three	O
patients	O
presented	O
sequels	O
and	O
one	O
patient	O
died	B-PROC
.	O

The	O
percentage	O
of	O
gilts	O
that	O
displayed	O
natural	O
estrus	B-PROC
by	O
220days	O
of	O
age	O
was	O
low	O
but	O
not	O
different	O
among	O
dietary	O
treatments	O
(	O
low	O
27	O
.	O
7	O
%,	O
medium	O
31	O
.	O
0	O
%	O
and	O
high	O
37	O
.	O
7	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
1201	O
).	O

The	O
present	O
study	O
aimed	O
to	O
identify	O
the	O
potential	O
roles	O
of	O
miRNAs	O
in	O
the	O
pathogenesis	B-PROC
and	O
progression	O
of	O
ARDS	O
.	O

The	O
miRNA	O
expression	B-PROC
profile	O
of	O
the	O
GSE57223	O
dataset	O
was	O
downloaded	O
from	O
the	O
Gene	B-PROC
Expression	I-PROC
Omnibus	O
database	O
.	O

GO	O
and	O
pathway	B-PROC
analyses	O
were	O
performed	O
for	O
the	O
co	O
‑	O
regulated	O
target	O
genes	O
of	O
significant	O
miRNAs	O
in	O
MFSN	O
.	O

ABSTRACT	O
:	O
TAFRO	O
syndrome	O
is	O
a	O
distinct	O
idiopathic	O
multicentric	O
Castleman	O
disease	O
characterized	O
by	O
the	O
association	O
of	O
thrombocytopenia	O
,	O
anasarca	O
,	O
fever	B-PROC
,	O
reticulin	O
fibrosis	O
,	O
and	O
organomegaly	O
.	O

Following	O
the	O
MERS	O
outbreak	O
,	O
there	O
was	O
an	O
increase	O
in	O
overall	O
ED	O
visits	O
by	O
febrile	B-PROC
patients	O
and	O
the	O
proportion	O
of	O
visits	O
by	O
febrile	B-PROC
patients	O
,	O
relative	O
to	O
total	O
ED	O
attendances	O
.	O

However	O
,	O
programs	O
to	O
provide	O
vaccines	O
against	O
emerging	O
diseases	O
must	O
allow	O
alternative	O
clinical	O
development	B-PROC
paths	O
to	O
licensure	O
,	O
without	O
the	O
requirement	O
to	O
carry	O
out	O
large	O
scale	O
field	O
efficacy	O
studies	O
.	O

The	O
conservative	O
LFM	O
group	O
included	O
patients	O
with	O
at	O
least	O
2	O
consecutive	O
days	O
with	O
a	O
negative	O
fluid	B-PROC
balance	I-PROC
between	O
day	O
3	O
and	O
day	O
7	O
;	O
other	O
patients	O
were	O
allocated	O
to	O
the	O
liberal	O
LFM	O
group	O
.	O

The	O
dysregulation	O
of	O
EPCR	O
and	O
TM	O
in	O
the	O
lung	O
,	O
especially	O
in	O
those	O
with	O
increased	O
levels	O
of	O
hemozoin	O
,	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
malaria	O
-	O
associated	O
ARDS	O
through	O
an	O
apoptotic	O
pathway	B-PROC
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
being	O
used	O
more	O
often	O
as	O
a	O
bridge	O
to	O
transplantation	O
(	O
BTT	O
)	O
in	O
patients	O
with	O
acutely	O
decompensated	O
end	O
-	O
stage	O
lung	O
disease	O
in	O
Korea	O
.	O

We	O
demonstrated	O
that	O
binding	O
of	O
nsp4	O
with	O
nsp3	O
is	O
essential	O
for	O
membrane	O
rearrangement	B-PROC
and	O
identified	O
amino	O
acid	O
residues	O
in	O
nsp4	O
responsible	O
for	O
the	O
interaction	O
with	O
nsp3	O
.	O

TITLE	O
:	O
SARS	O
,	O
MERS	O
and	O
other	O
Viral	O
Lung	O
Infections	O
ABSTRACT	O
:	O
Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
infection	O
has	O
an	O
estimated	O
global	O
incidence	O
of	O
33	O
million	O
cases	O
in	O
children	O
younger	O
than	O
5	O
years	O
,	O
with	O
10	O
%	O
requiring	O
hospital	O
admission	O
and	O
up	O
to	O
199	O
,	O
000	O
dying	B-PROC
of	O
the	O
disease	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
,	O
as	O
the	O
major	O
immunity	B-PROC
-	O
eliciting	O
antigen	O
,	O
has	O
previously	O
been	O
used	O
for	O
serological	O
testing	O
and	O
has	O
been	O
found	O
to	O
correlate	O
significantly	O
with	O
the	O
results	O
of	O
the	O
serum	O
neutralization	O
(	O
SN	O
)	O
test	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
glycosylation	B-PROC
also	O
acts	O
as	O
a	O
determinant	O
of	O
permissivity	O
for	O
ferret	O
,	O
hamster	O
,	O
and	O
guinea	O
pig	O
DPP4	O
.	O

Due	O
to	O
worsening	O
clinical	O
condition	O
and	O
unavailability	O
of	O
a	O
deceased	B-PROC
donor	O
organ	O
,	O
ABO	O
-	O
incompatible	O
LDLT	O
was	O
considered	O
.	O

TITLE	O
:	O
Genetic	O
characteristics	O
,	O
pathogenicity	O
,	O
and	O
immunogenicity	O
associated	O
with	O
cell	O
adaptation	B-PROC
of	O
a	O
virulent	O
genotype	O
2b	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Animal	O
inoculation	O
studies	O
revealed	O
that	O
the	O
virulence	B-PROC
of	O
both	O
S	O
DEL2	O
/	O
ORF3	O
and	O
S	O
DEL5	O
/	O
ORF3	O
viruses	O
with	O
a	O
large	O
46	O
-	O
nt	O
deletion	O
in	O
the	O
intergenic	O
portion	O
of	O
S	O
and	O
ORF3	O
was	O
remarkably	O
diminished	O
,	O
indicating	O
viral	O
attenuation	O
in	O
the	O
natural	O
host	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
the	O
cell	O
-	O
attenuated	O
S	O
DEL2	O
/	O
ORF3	O
and	O
S	O
DEL5	O
/	O
ORF3	O
strains	O
are	O
promising	O
candidates	O
for	O
the	O
development	B-PROC
of	O
a	O
safe	O
and	O
effective	O
live	O
PEDV	O
vaccine	O
.	O

The	O
development	B-PROC
of	O
novel	O
vaccines	O
based	O
on	O
the	O
emerging	O
Vietnamese	O
strains	O
may	O
be	O
contributive	O
to	O
the	O
control	O
of	O
the	O
current	O
PED	O
outbreaks	O
.	O

The	O
odds	O
of	O
dying	B-PROC
from	O
the	O
disease	O
was	O
found	O
to	O
increase	O
as	O
age	O
increased	O
beyond	O
25	O
years	O
and	O
was	O
much	O
higher	O
for	O
individuals	O
with	O
any	O
underlying	O
comorbidities	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
uncover	O
the	O
significance	O
of	O
macrophage	O
infection	O
of	O
IBV	O
in	O
the	O
pathogenesis	B-PROC
of	O
IBV	O
infection	O
in	O
chickens	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
specifically	O
designed	O
to	O
detect	O
FCoV	O
spike	O
gene	B-PROC
mutations	I-PROC
at	O
two	O
nucleotide	O
positions	O
.	O

Effusion	O
and	O
/	O
or	O
serum	O
/	O
plasma	O
samples	O
were	O
examined	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
targeting	B-PROC
the	O
two	O
FCoV	O
spike	O
gene	O
fusion	O
peptide	O
mutations	O
M1058	O
L	O
and	O
S1060A	O
using	O
an	O
allelic	O
discrimination	O
approach	O
.	O

TITLE	O
:	O
Evolution	B-PROC
and	O
Emergence	O
of	O
Pathogenic	O
Viruses	O
:	O
Past	O
,	O
Present	O
,	O
and	O
Future	O
.	O

The	O
causative	O
agent	O
,	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
an	O
RNA	O
virus	O
with	O
great	O
ability	O
for	O
mutation	O
and	O
recombination	B-PROC
;	O
thus	O
,	O
capable	O
of	O
generating	O
new	O
virus	O
strains	O
that	O
are	O
difficult	O
to	O
control	O
.	O

We	O
previously	O
reported	O
that	O
type	O
I	O
FCoV	O
is	O
closely	O
associated	O
with	O
cholesterol	O
throughout	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
U18666A	O
,	O
the	O
cholesterol	B-PROC
synthesis	I-PROC
and	O
transport	B-PROC
inhibitor	O
,	O
shows	O
antiviral	O
effects	O
against	O
type	O
I	O
FCoV	O
.	O
U18666A	O
induced	O
cholesterol	O
accumulation	O
in	O
cells	O
and	O
inhibited	O
type	O
I	O
FCoV	O
replication	O
.	O

U18666A	O
or	O
other	O
cholesterol	B-PROC
transport	B-PROC
inhibitor	O
may	O
be	O
considered	O
as	O
the	O
antiviral	O
drug	O
for	O
the	O
treatment	O
of	O
cats	O
with	O
FIP	O
.	O

Poor	O
immune	B-PROC
response	I-PROC
coupled	O
with	O
primary	O
cryptosporidial	O
infections	O
predispose	O
neonatal	O
calves	O
to	O
multiple	O
secondary	O
infections	O
resulting	O
in	O
their	O
deaths	B-PROC
.	O

One	O
case	O
of	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
was	O
treated	O
with	O
methylprednisolone	O
pulse	B-PROC
therapy	O
(	O
10mg	O
/	O
kg	O
/	O
d	O
)	O
for	O
the	O
first	O
three	O
days	O
and	O
followed	O
by	O
systemic	O
steroid	O
therapy	O
,	O
he	O
successfully	O
decannulated	O
10days	O
later	O
and	O
discharged	O
with	O
a	O
favorable	O
quality	O
of	O
life	O
.	O

We	O
applied	O
methylprednisolone	O
pulse	B-PROC
therapy	O
(	O
10mg	O
/	O
kg	O
/	O
d	O
)	O
for	O
three	O
days	O
and	O
other	O
supportive	O
therapies	O
,	O
the	O
girl	O
survived	O
through	O
complicated	O
with	O
oxygen	O
dependence	O
.	O

Patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	O
severe	O
acute	O
respiratory	O
infection	O
had	O
more	O
severe	O
hypoxemic	O
respiratory	O
failure	O
(	O
PaO2	O
/	O
FIO2	O
:	O
106	O
[	O
66	O
,	O
160	O
]	O
vs	O
176	O
[	O
104	O
,	O
252	O
];	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
more	O
frequent	O
nonrespiratory	O
organ	O
failure	O
(	O
nonrespiratory	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
:	O
6	O
[	O
4	O
,	O
9	O
]	O
vs	O
5	O
[	O
3	O
,	O
7	O
];	O
p	O
=	O
0	O
.	O
002	O
),	O
thus	O
required	O
more	O
frequently	O
invasive	O
mechanical	O
ventilation	O
(	O
85	O
.	O
2	O
%	O
vs	O
73	O
.	O
0	O
%;	O
p	O
<	O
0	O
.	O
001	O
),	O
oxygen	O
rescue	O
therapies	O
(	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
5	O
.	O
8	O
%	O
vs	O
0	O
.	O
9	O
%;	O
p	O
=	O
0	O
.	O
003	O
),	O
vasopressor	O
support	O
(	O
79	O
.	O
4	O
%	O
vs	O
55	O
.	O
0	O
%;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
renal	O
replacement	O
therapy	O
(	O
48	O
.	O
8	O
%	O
vs	O
22	O
.	O
1	O
%;	O
p	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Persistent	O
Transmissible	O
Gastroenteritis	O
Virus	B-PROC
Infection	I-PROC
Enhances	O
Enterotoxigenic	O
Escherichia	O
coli	O
K88	O
Adhesion	O
by	O
Promoting	O
Epithelial	B-PROC
-	I-PROC
Mesenchymal	I-PROC
Transition	I-PROC
in	O
Intestinal	O
Epithelial	O
Cells	O
.	O

One	O
should	O
consider	O
APT	O
when	O
signs	O
of	O
pulmonary	O
failure	O
occur	O
during	O
brief	O
periods	B-PROC
of	O
amiodarone	O
therapy	O
especially	O
after	O
thoracic	O
surgery	O
.	O

Respiratory	O
failure	O
caused	O
by	O
neuromuscular	O
weakness	O
is	O
considered	O
as	O
more	O
critical	O
than	O
lung	O
disease	O
because	O
its	O
development	B-PROC
may	O
be	O
insidious	O
or	O
subtle	O
until	O
sudden	O
decompensation	O
leads	O
to	O
life	O
threatening	O
hypoxia	O
.	O

These	O
GI	O
-	O
29	O
viral	O
genomes	O
are	O
still	O
evolving	O
and	O
diverging	O
,	O
particularly	O
in	O
the	O
3	O
'	O
region	O
,	O
although	O
we	O
cannot	O
rule	O
out	O
the	O
possibility	O
of	O
recombination	B-PROC
events	O
occurring	O
.	O

Cell	O
imaging	O
revealed	O
intracellular	O
peptide	O
aggregates	O
,	O
consistent	O
with	O
their	O
endocytosis	B-PROC
into	O
compartments	O
where	O
CoV	O
entry	O
takes	O
place	O
.	O

The	O
experimental	O
infection	O
model	O
has	O
established	O
a	O
foundation	O
for	O
further	O
studies	O
on	O
vaccine	O
development	B-PROC
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
describe	O
the	O
possibility	O
of	O
using	O
Electrical	B-PROC
Impedance	I-PROC
Tomography	O
(	O
EIT	O
)	O
as	O
a	O
treatment	O
monitoring	O
tool	O
in	O
the	O
ICU	O
.	O

Swabs	O
from	O
trachea	O
and	O
nasal	O
tract	O
along	O
with	O
tissue	O
samples	O
of	O
spleen	O
and	O
lung	O
from	O
dead	B-PROC
animals	O
were	O
found	O
positive	O
for	O
PPR	O
virus	O
based	O
on	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
using	O
H	O
gene	O
and	O
partial	O
N	O
gene	O
-	O
specific	O
primers	O
.	O

ABSTRACT	O
:	O
Clinical	O
and	O
radiographic	O
characteristics	O
of	O
a	O
subset	O
of	O
South	O
East	O
Asian	O
temporomandibular	O
disorder	O
(	O
TMD	O
)	O
patients	O
with	O
comorbid	O
upper	O
airway	B-PROC
resistance	I-PROC
syndrome	O
(	O
UARS	O
)	O
were	O
documented	O
in	O
a	O
multi	O
-	O
center	O
prospective	O
series	O
of	O
86	O
patients	O
(	O
26	O
men	O
and	O
60	O
women	O
/	O
mean	O
age	O
35	O
.	O
7	O
years	O
).	O

The	O
US	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
'	O
s	O
(	O
CDC	O
'	O
s	O
)	O
Global	O
Disease	O
Detection	O
Operations	O
Center	O
(	O
GDDOC	O
)	O
was	O
created	O
in	O
2007	O
to	O
serve	O
as	O
CDC	O
'	O
s	O
platform	O
dedicated	O
to	O
conducting	B-PROC
worldwide	O
event	O
-	O
based	O
surveillance	O
,	O
which	O
is	O
now	O
highlighted	O
as	O
part	O
of	O
the	O
""""	O
detect	O
""""	O
element	O
of	O
the	O
Global	O
Health	O
Security	O
Agenda	O
(	O
GHSA	O
).	O

Here	O
we	O
use	O
structure	O
-	O
based	O
design	O
to	O
develop	O
a	O
generalizable	O
strategy	O
for	O
retaining	O
coronavirus	O
S	O
proteins	O
in	O
the	O
antigenically	O
optimal	O
prefusion	O
conformation	O
and	O
demonstrate	O
that	O
our	O
engineered	O
immunogen	O
is	O
able	O
to	O
elicit	O
high	O
neutralizing	O
antibody	B-PROC
titers	O
against	O
MERS	O
-	O
CoV	O
.	O
We	O
also	O
determined	O
high	O
-	O
resolution	O
structures	O
of	O
the	O
trimeric	O
MERS	O
-	O
CoV	O
S	O
ectodomain	O
in	O
complex	O
with	O
G4	O
,	O
a	O
stem	O
-	O
directed	O
neutralizing	O
antibody	B-PROC
.	O

Previously	O
reported	O
surviving	O
patients	O
in	O
China	O
and	O
Taiwan	O
required	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
and	O
other	O
invasive	O
modalities	O
.	O

The	O
remaining	O
SAD	O
mice	O
had	O
mild	O
lung	O
histological	O
changes	O
in	O
room	O
air	O
with	O
an	O
altered	O
respiratory	O
pattern	O
,	O
seizures	O
,	O
and	O
a	O
high	O
rate	O
of	O
death	B-PROC
in	O
response	B-PROC
to	I-PROC
hypoxia	I-PROC
.	O

Similar	O
to	O
NPCs	O
derived	O
from	O
striatum	O
of	O
day	O
1	O
postnatal	O
GFP	O
-	O
transgenic	O
mice	O
(	O
GFP	O
-	O
NPCs	O
),	O
iPSC	O
-	O
derived	O
NPCs	O
(	O
iPSC	O
-	O
NPCs	O
)	O
are	O
able	O
to	O
differentiate	O
into	O
terminal	O
neural	O
cell	O
types	O
and	O
express	O
MHC	B-PROC
class	O
I	O
and	O
II	O
in	O
response	O
to	O
IFN	O
-	O
γ	O
treatment	O
.	O

At	O
14	O
,	O
28	O
,	O
and	O
42	O
days	O
after	O
the	O
first	O
vaccination	O
,	O
serum	O
anti	O
-	O
IBV	O
antibody	B-PROC
titers	O
;	O
peripheral	O
lymphocyte	B-PROC
proliferation	I-PROC
;	O
and	O
the	O
mRNA	B-PROC
expression	B-PROC
of	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
α	O
in	O
the	O
spleen	O
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
the	O
cell	O
counting	O
kit	O
-	O
8	O
(	O
CCK	O
-	O
8	O
),	O
and	O
real	O
time	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
),	O
respectively	O
.	O

ABSTRACT	O
:	O
In	O
acute	O
hypoxemic	O
respiratory	O
failure	O
(	O
AHRF	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
,	O
spontaneous	O
breathing	B-PROC
is	O
associated	O
with	O
multiple	O
physiologic	O
benefits	O
:	O
it	O
prevents	O
muscles	O
atrophy	O
,	O
avoids	O
paralysis	O
,	O
decreases	O
sedation	O
needs	O
and	O
is	O
associated	O
with	O
improved	O
hemodynamics	B-PROC
.	O

These	O
results	O
suggested	O
that	O
high	O
-	O
dose	O
pulses	O
of	O
methylprednisolone	O
might	O
cause	O
long	O
-	O
term	O
systemic	O
damage	O
associated	O
with	O
serum	O
metabolic	B-PROC
alterations	O
.	O

The	O
results	O
showed	O
that	O
some	O
cells	O
were	O
able	O
to	O
survive	O
the	O
infection	O
,	O
as	O
demonstrated	O
by	O
continued	O
tdTomato	O
expression	B-PROC
after	O
virus	O
antigen	O
could	O
no	O
longer	O
be	O
detected	O
.	O

Most	O
notably	O
,	O
interneurons	O
in	O
the	O
olfactory	B-PROC
bulb	O
,	O
which	O
are	O
known	O
to	O
be	O
inhibitory	O
,	O
represented	O
a	O
large	O
fraction	O
of	O
the	O
surviving	O
cells	O
.	O

The	O
mean	O
serum	O
anti	O
-	O
BCV	O
antibody	B-PROC
abundance	O
at	O
weaning	B-PROC
for	O
a	O
group	O
of	O
calves	O
was	O
inversely	O
related	O
with	O
the	O
subsequent	O
incidence	O
of	O
BRD	O
in	O
that	O
group	O
;	O
however	O
,	O
the	O
serum	O
anti	O
-	O
BCV	O
antibody	B-PROC
abundance	O
at	O
weaning	B-PROC
for	O
individual	O
calves	O
was	O
not	O
predictive	O
of	O
which	O
calves	O
would	O
develop	O
BRD	O
after	O
feedlot	O
entry	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
Results	O
indicated	O
that	O
serum	O
anti	O
-	O
BCV	O
antibody	B-PROC
abundance	O
as	O
determined	O
with	O
ELISA	O
were	O
not	O
associated	O
with	O
BCV	O
shedding	O
or	O
risk	O
of	O
BRD	O
in	O
individual	O
beef	O
calves	O
from	O
birth	B-PROC
through	O
the	O
first	O
5	O
weeks	O
after	O
feedlot	O
entry	O
.	O

TITLE	O
:	O
Prolonged	O
Shedding	O
of	O
Human	O
Coronavirus	O
in	O
Hematopoietic	O
Cell	O
Transplant	O
Recipients	O
:	O
Risk	O
Factors	O
and	O
Viral	O
Genome	O
Evolution	B-PROC
.	O

Differences	O
in	O
clinical	O
outcomes	O
after	O
development	B-PROC
of	O
isolated	O
RF	O
in	O
comparison	O
to	O
other	O
forms	O
of	O
OF	O
were	O
determined	O
using	O
independent	O
t	O
and	O
Mann	O
-	O
Whitney	O
Among	O
500	O
patients	O
with	O
acute	O
pancreatitis	O
,	O
111	O
patients	O
developed	O
persistent	O
OF	O
:	O
mean	O
age	O
was	O
54	O
years	O
,	O
and	O
75	O
(	O
67	O
.	O
6	O
%)	O
were	O
male	O
.	O

No	O
differences	O
in	O
demographics	O
,	O
etiology	O
of	O
acute	O
pancreatitis	O
,	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
scores	O
,	O
or	O
development	B-PROC
of	O
pancreatic	O
necrosis	B-PROC
were	O
seen	O
between	O
patients	O
with	O
isolated	O
RF	O
CONCLUSIONS	O
:	O
Among	O
patients	O
with	O
SAP	O
per	O
the	O
Revised	O
Atlanta	O
Classification	O
,	O
approximately	O
15	O
%	O
develop	O
isolated	O
RF	O
.	O

Although	O
there	O
have	O
been	O
several	O
studies	O
on	O
the	O
pathogenesis	B-PROC
of	O
coronaviruses	O
in	O
humans	O
and	O
surrogate	O
animals	O
,	O
there	O
is	O
little	O
information	O
on	O
the	O
interactions	O
of	O
these	O
viruses	O
with	O
their	O
natural	O
bat	O
hosts	O
.	O

The	O
IL	O
-	O
17A	O
levels	O
were	O
significantly	O
correlated	O
with	O
those	O
of	O
IL	O
-	O
4	O
,	O
IL	O
-	O
25	O
,	O
IL	O
-	O
10	O
,	O
and	O
IFN	O
-	O
γ	O
in	O
patients	O
with	O
uncontrolled	O
asthma	O
,	O
and	O
the	O
patients	O
with	O
the	O
highest	O
levels	O
of	O
all	O
the	O
above	O
cytokines	O
were	O
refractory	O
to	O
high	O
-	O
dose	O
of	O
inhaled	B-PROC
corticosteroid	O
therapy	O
and	O
have	O
a	O
history	O
of	O
acute	O
exacerbation	O
within	O
1	O
year	O
,	O
requiring	O
systemic	O
steroid	O
therapy	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
inhibits	O
the	O
host	O
typeⅠinterferon	O
and	O
cellular	O
antiviral	B-PROC
response	I-PROC
,	O
but	O
its	O
inhibition	B-PROC
mechanism	O
is	O
unclear	O
,	O
and	O
the	O
roles	O
of	O
PEDV	O
nonstructural	O
proteins	O
in	O
regulating	O
typeⅠinterferon	O
responses	O
have	O
been	O
seldom	O
studied	O
.	O

ELISA	O
results	O
showed	O
that	O
nsp1	O
significantly	O
inhibited	O
the	O
expression	B-PROC
of	O
IFN	O
-	O
β	O
in	O
protein	O
level	O
.	O

This	O
change	O
resulted	O
in	O
weaker	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
,	O
smaller	O
plaque	O
morphology	O
,	O
higher	O
virus	O
titer	O
and	O
serious	O
microfilament	O
condensation	O
.	O

Otherwise	O
,	O
a	O
novel	O
variation	O
(	O
16	O
-	O
20	O
aa	O
deletion	O
and	O
an	O
L25P	O
mutation	O
)	O
in	O
the	O
transmembrane	O
domain	O
of	O
the	O
E	O
protein	O
affected	O
multiple	O
infection	O
processes	O
,	O
including	O
up	B-PROC
-	I-PROC
regulation	B-PROC
of	O
the	O
production	O
of	O
the	O
ER	O
stress	O
indicator	O
GRP78	O
,	O
improving	O
the	O
expression	B-PROC
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
,	O
and	O
promoting	O
apoptosis	B-PROC
.	O

However	O
,	O
options	O
are	O
limited	O
for	O
ARDS	O
patients	O
who	O
fail	O
to	O
wean	B-PROC
from	O
ECMO	O
.	O

We	O
analysed	O
the	O
post	O
-	O
mortem	O
histopathological	O
findings	O
and	O
investigated	O
localisation	B-PROC
of	O
viral	O
particles	O
in	O
the	O
pulmonary	O
and	O
extrapulmonary	O
tissue	O
by	O
transmission	O
electron	O
microscopic	O
examination	O
in	O
a	O
33	O
-	O
year	O
-	O
old	O
male	O
patient	O
of	O
T	O
cell	O
lymphoma	O
,	O
who	O
acquired	O
MERS	O
-	O
CoV	O
infection	O
.	O

All	O
samples	O
were	O
collected	O
within	O
45	O
min	O
from	O
death	B-PROC
to	O
reduce	O
tissue	O
decomposition	O
and	O
artefact	O
.	O

Site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
experiments	O
showed	O
that	O
,	O
with	O
respect	O
to	O
wt	O
RT	O
,	O
V108A	O
substitution	O
strongly	O
reduced	O
A15	O
IC50	O
values	O
(	O
12	O
.	O
6	O
-	O
fold	O
for	O
RNase	O
H	O
inhibition	B-PROC
and	O
4	O
.	O
7	O
-	O
fold	O
for	O
RDDP	O
),	O
while	O
substitution	O
A502F	O
caused	O
a	O
9	O
.	O
0	O
-	O
fold	O
increase	O
in	O
its	O
IC50	O
value	O
for	O
RNase	O
H	O
,	O
not	O
affecting	O
the	O
RDDP	O
inhibition	B-PROC
,	O
reinforcing	O
the	O
hypothesis	O
of	O
a	O
dual	O
-	O
site	O
inhibition	B-PROC
.	O

However	O
,	O
the	O
effect	O
of	O
protective	O
ventilation	O
on	O
bacterial	O
growth	B-PROC
during	O
early	O
pneumonia	O
in	O
non	O
-	O
injured	O
lungs	O
is	O
not	O
extensively	O
studied	O
.	O

We	O
analyzed	O
responses	O
from	O
209	O
respondents	O
(	O
53	O
%),	O
mostly	O
from	O
academic	O
centers	O
(	O
63	O
%);	O
41	O
%	O
respondents	O
provide	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
to	O
adults	O
exclusively	O
.	O

TITLE	O
:	O
Neurologic	O
Injury	O
With	O
Severe	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Patients	O
Undergoing	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
:	O
A	O
Single	O
-	O
Center	O
Retrospective	O
Analysis	O
.	O

The	O
""""	O
immune	O
paralysis	O
""""	O
post	O
-	O
sepsis	O
still	O
remains	O
a	O
rigorous	O
challenge	O
for	O
curing	O
sepsis	O
,	O
our	O
study	O
may	O
aid	O
in	O
the	O
development	B-PROC
of	O
new	O
therapeutic	O
strategies	O
to	O
this	O
problem	O
.	O

TITLE	O
:	O
A	O
multi	O
-	O
faceted	O
approach	O
of	O
a	O
nursing	B-PROC
led	O
education	O
in	O
response	O
to	O
MERS	O
-	O
CoV	O
infection	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
within	O
Italy	O
QX	O
circulation	B-PROC
reconstruction	O
showed	O
a	O
much	O
more	O
intricate	O
connection	O
network	O
among	O
different	O
locations	O
,	O
evidencing	O
the	O
difficulty	O
in	O
controlling	O
IBV	O
spread	O
especially	O
in	O
highly	O
densely	O
poultry	O
populated	O
areas	O
.	O

TITLE	O
:	O
Virulence	B-PROC
of	O
current	O
German	O
PEDV	O
strains	O
in	O
suckling	O
pigs	O
and	O
investigation	O
of	O
protective	O
effects	O
of	O
maternally	O
derived	O
antibodies	O
.	O

Interestingly	O
,	O
an	O
increased	O
transcription	B-PROC
of	O
type	O
I	O
interferon	O
including	O
interferon	O
-	O
α	O
and	O
β	O
was	O
observed	O
in	O
infected	O
cells	O
compared	O
to	O
mock	O
infected	O
cells	O
.	O

The	O
aim	O
of	O
the	O
study	O
is	O
to	O
assess	O
the	O
evolution	B-PROC
of	O
malaria	O
cases	O
in	O
the	O
area	O
as	O
well	O
as	O
its	O
clinical	O
management	O
over	O
the	O
10	O
years	O
of	O
its	O
implementation	O
.	O

In	O
the	O
absence	O
of	O
IL	O
-	O
18	O
,	O
mice	O
had	O
elevated	O
viral	B-PROC
replication	I-PROC
and	O
poor	O
survival	O
,	O
and	O
this	O
protective	O
effect	O
of	O
IL	O
-	O
18	O
was	O
found	O
to	O
be	O
due	O
to	O
promotion	O
of	O
interferon	O
gamma	O
production	O
in	O
αβ	O
T	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
inflammasome	O
signaling	B-PROC
is	O
largely	O
protective	O
during	O
murine	O
coronavirus	O
infection	O
,	O
in	O
large	O
part	O
due	O
to	O
the	O
pro	O
-	O
inflammatory	O
effects	O
of	O
IL	O
-	O
18	O
.	O

We	O
also	O
characterized	O
the	O
antigenicity	O
,	O
pathogenesis	B-PROC
,	O
tissue	B-PROC
tropism	B-PROC
and	O
spreading	O
of	O
three	O
IBV	O
isolates	O
by	O
experimental	O
infection	O
of	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
and	O
contact	O
sentinel	O
birds	O
.	O

The	O
immune	B-PROC
evasion	I-PROC
mechanism	O
including	O
type	O
1	O
interferon	O
and	O
protein	O
kinase	O
R	O
-	O
mediated	O
antiviral	O
stress	O
responses	O
has	O
been	O
recently	O
attributed	O
to	O
the	O
involvement	O
of	O
MERS	O
-	O
CoV	O
protein	O
4a	O
(	O
p4a	O
)	O
that	O
masks	O
the	O
viral	O
dsRNA	O
.	O

Conclusions	O
and	O
relevance	O
GC376	O
showed	O
promise	O
in	O
treating	O
cats	O
with	O
certain	O
presentations	O
of	O
FIP	O
and	O
has	O
opened	O
the	O
door	O
to	O
targeted	B-PROC
antiviral	O
drug	O
therapy	O
.	O

TITLE	O
:	O
Elucidation	O
of	O
Bacterial	O
Pneumonia	O
-	O
Causing	O
Pathogens	O
in	O
Patients	O
with	O
Respiratory	O
Viral	B-PROC
Infection	I-PROC
.	O

TITLE	O
:	O
A	O
Novel	O
Chemical	O
Compound	O
for	O
Inhibition	B-PROC
of	O
SARS	O
Coronavirus	O
Helicase	O
.	O

Once	O
the	O
""""	O
two	O
event	O
model	O
""""	O
was	O
accepted	O
,	O
it	O
became	O
clear	O
that	O
patients	O
although	O
initially	O
resuscitated	O
,	O
but	O
in	O
a	O
vulnerable	O
condition	O
,	O
have	O
a	O
high	O
risk	O
that	O
a	O
secondary	O
aggression	B-PROC
(	O
for	O
example	O
,	O
surgical	O
interventions	O
)	O
would	O
precipitate	O
a	O
state	O
of	O
hyperinflammation	O
and	O
early	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
).	O

Targeted	B-PROC
DNA	O
sequencing	O
was	O
performed	O
on	O
243	O
(	O
34	O
.	O
9	O
%)	O
patients	O
.	O

Vaccination	O
of	O
swine	O
with	O
rSPV	O
-	O
St	O
elicited	O
a	O
robust	O
antibody	B-PROC
response	I-PROC
specific	O
for	O
the	O
homologous	O
PEDV	O
SQ2014	O
.	O

The	O
new	O
test	O
is	O
based	O
on	O
the	O
analysis	O
of	O
virus	O
-	O
elicited	O
immunoglobulin	B-PROC
G	O
(	O
IgG	O
)	O
antibody	B-PROC
present	O
in	O
the	O
protein	O
corona	O
of	O
a	O
gold	O
nanoparticle	O
surface	O
upon	O
mixing	O
the	O
gold	O
nanoparticles	O
with	O
blood	O
sera	O
.	O

When	O
used	O
together	O
with	O
the	O
traditional	O
serology	O
testing	O
,	O
the	O
nanoparticle	O
test	O
can	O
determine	O
clearly	O
whether	O
a	O
positive	O
serology	O
response	O
is	O
due	O
to	O
a	O
recent	O
or	O
historical	O
viral	B-PROC
infection	I-PROC
.	O

The	O
probability	O
for	O
severe	O
illness	O
originated	O
from	O
delayed	O
utilization	O
of	O
health	O
services	O
,	O
delayed	O
prescription	O
of	O
neuraminidase	B-PROC
inhibitors	I-PROC
(	O
NAIs	O
)	O
and	O
inappropriate	O
use	O
of	O
antibiotics	O
was	O
assessed	O
.	O

As	O
part	O
of	O
its	O
viral	O
genome	O
,	O
MERS	O
-	O
CoV	O
encodes	O
a	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
that	O
has	O
been	O
observed	O
to	O
act	O
as	O
a	O
deubiquitinase	B-PROC
and	O
deISGylase	O
to	O
antagonize	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
immune	O
pathways	B-PROC
.	O

The	O
task	O
force	O
was	O
unable	O
to	O
reach	B-PROC
agreement	O
on	O
a	O
single	O
test	O
that	O
can	O
reliably	O
diagnose	O
CIRCI	O
,	O
although	O
delta	O
cortisol	O
(	O
change	O
in	O
baseline	O
cortisol	O
at	O
60	O
min	O
of	O
<	O
9	O
µg	O
/	O
dl	O
)	O
after	O
cosyntropin	O
(	O
250	O
µg	O
)	O
administration	O
and	O
a	O
random	O
plasma	O
cortisol	O
of	O
<	O
10	O
µg	O
/	O
dl	O
may	O
be	O
used	O
by	O
clinicians	O
.	O

Recombination	B-PROC
detection	O
suggested	O
that	O
both	O
XM1	O
-	O
2	O
and	O
XM2	O
-	O
4	O
are	O
inter	O
-	O
subgroup	O
recombinants	O
with	O
breakpoints	O
within	O
ORF1b	O
.	O

We	O
present	O
a	O
case	O
of	O
the	O
successful	O
use	O
of	O
ECMO	O
to	O
treat	O
acute	O
respiratory	O
failure	O
secondary	O
to	O
staphylococcal	O
sepsis	O
in	O
an	O
adolescent	O
CF	O
patient	O
with	O
previously	O
normal	O
lung	B-PROC
function	I-PROC
.	O

Her	O
post	O
-	O
ECMO	O
course	O
was	O
notable	O
for	O
severe	O
airflow	B-PROC
obstruction	O
,	O
hypoxemia	O
,	O
deconditioning	O
,	O
and	O
growth	B-PROC
failure	O
.	O

TITLE	O
:	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	O
Virus	O
Enters	O
Neuro	O
-	O
2a	O
Cells	O
via	O
Clathrin	B-PROC
-	I-PROC
Mediated	I-PROC
Endocytosis	I-PROC
in	O
a	O
Rab5	O
-,	O
Cholesterol	O
-,	O
and	O
pH	O
-	O
Dependent	O
Manner	O
.	O

These	O
two	O
lines	O
will	O
be	O
used	O
as	O
an	O
animal	O
model	O
in	O
subsequent	O
experiments	O
to	O
understand	O
the	O
mechanisms	O
by	O
which	O
the	O
immune	O
system	O
in	O
chickens	O
generates	O
resistance	B-PROC
to	O
infectious	O
bronchitis	O
virus	O
.	O

TITLE	O
:	O
Infectious	O
Bronchitis	O
Virus	O
S2	O
of	O
4	O
/	O
91	O
Expressed	B-PROC
from	O
Recombinant	O
Virus	O
Does	O
Not	O
Protect	O
Against	O
Ark	O
-	O
Type	O
Challenge	O
.	O

Therefore	O
,	O
we	O
evaluated	O
the	O
protective	O
capabilities	O
of	O
the	O
S2	O
protein	O
of	O
IBV	O
4	O
/	O
91	O
expressed	B-PROC
from	O
rLS	O
.	O

Neither	O
the	O
addition	O
of	O
inspiratory	B-PROC
pauses	O
or	O
the	O
alveolar	O
recruitment	O
maneuver	O
followed	O
by	O
decremental	O
PEEP	O
titration	O
resulted	O
in	O
further	O
reductions	O
in	O
VT	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
clinical	O
significance	O
of	O
mechanical	O
ventilation	O
on	O
ischemic	O
-	O
reperfusion	O
injury	O
caused	O
by	O
lung	O
chest	O
trauma	O
as	O
well	O
as	O
vascular	B-PROC
endothelial	I-PROC
growth	B-PROC
factor	I-PROC
(	O
VEGF	O
)	O
expression	B-PROC
levels	O
in	O
peripheral	O
blood	O
.	O

TITLE	O
:	O
Respiratory	B-PROC
mechanics	I-PROC
to	O
understand	O
ARDS	O
and	O
guide	O
mechanical	O
ventilation	O
.	O

Some	O
species	O
of	O
mosquitoes	O
belonging	O
to	O
the	O
genus	O
Culex	O
have	O
been	O
implicated	O
as	O
having	O
major	O
roles	O
in	O
the	O
transmission	O
of	O
arboviruses	O
such	O
as	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
Saint	O
Louis	O
encephalitis	O
virus	O
,	O
and	O
Western	O
equine	O
encephalitis	O
virus	O
.	O

HELLP	O
syndrome	O
is	O
a	O
life	O
-	O
threatening	O
condition	O
frequently	O
associated	O
with	O
severe	O
preeclampsia	O
-	O
eclampsia	O
and	O
is	O
characterized	O
by	O
three	O
hallmark	O
features	O
of	O
hemolysis	B-PROC
,	O
elevated	O
liver	O
enzymes	O
and	O
low	O
platelets	O
.	O

The	O
data	O
of	O
this	O
survey	O
also	O
provided	O
valuable	O
information	O
about	O
the	O
replication	O
of	O
IBD	O
vaccines	O
and	O
subsequent	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
)	O
antibody	B-PROC
responses	I-PROC
under	O
field	O
conditions	O
.	O

TITLE	O
:	O
Lianqinjiedu	O
decoction	O
attenuates	O
LPS	O
-	O
induced	O
inflammation	O
and	O
acute	O
lung	O
injury	O
in	O
rats	O
via	O
TLR4	O
/	O
NF	O
-	O
κB	O
pathway	B-PROC
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
pneumonia	O
.	O

We	O
will	O
also	O
distinguish	O
dynamic	O
(	O
tidal	O
volume	O
)	O
from	O
static	O
strain	O
(	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
and	O
mean	O
airway	O
pressure	O
)	O
and	O
will	O
discuss	O
their	O
roles	O
in	O
inducing	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Here	O
we	O
present	O
a	O
novel	O
reverse	O
genetics	O
system	O
for	O
MERS	O
-	O
CoV	O
that	O
involves	O
maintenance	O
of	O
the	O
full	O
-	O
length	O
viral	O
genome	O
as	O
a	O
cDNA	O
copy	O
inserted	O
in	O
a	O
bacterial	O
artificial	O
chromosome	O
amenable	O
to	O
manipulation	O
by	O
homologue	O
recombination	B-PROC
,	O
based	O
on	O
the	O
bacteriophage	O
λ	O
Red	O
recombination	B-PROC
system	O
.	O

Measurement	O
of	O
syndecan	O
-	O
1	O
levels	O
in	O
sepsis	O
patients	O
might	O
be	O
useful	O
for	O
identifying	O
patients	O
at	O
high	O
risk	O
of	O
organ	O
dysfunction	O
and	O
mortality	O
as	O
well	O
as	O
those	O
who	O
could	O
benefit	O
from	O
therapies	O
targeted	B-PROC
at	O
protecting	O
or	O
restoring	O
the	O
glycocalyx	O
.	O

Here	O
,	O
we	O
have	O
solved	O
3D	O
structure	O
,	O
dynamics	O
and	O
micelle	O
localization	B-PROC
of	O
a	O
64	O
-	O
residue	O
long	O
fusion	O
peptide	O
or	O
LFP	O
in	O
DPC	O
detergent	O
micelles	O
by	O
NMR	O
methods	O
.	O

TITLE	O
:	O
Antibody	B-PROC
response	I-PROC
to	O
equine	O
coronavirus	O
in	O
horses	O
inoculated	O
with	O
a	O
bovine	O
coronavirus	O
vaccine	O
.	O

TITLE	O
:	O
Is	O
Systemic	O
Inflammatory	B-PROC
Response	I-PROC
Syndrome	O
Relevant	O
to	O
Pulmonary	O
Complications	O
and	O
Mortality	O
in	O
Multiply	O
Injured	O
Children	O
?	O

Only	O
3	O
OI	O
patients	O
developed	O
the	O
criteria	O
for	O
ARDS	O
,	O
and	O
only	O
3	O
patients	O
with	O
orthopaedic	O
injuries	O
died	B-PROC
,	O
2	O
died	B-PROC
within	O
24	O
hours	O
of	O
presentation	O
and	O
1	O
within	O
48	O
hours	O
,	O
all	O
had	O
severe	O
brain	O
trauma	O
.	O

Here	O
,	O
we	O
determined	O
the	O
expression	B-PROC
of	O
MERS	O
-	O
CoV	O
receptor	O
,	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPP4	O
),	O
in	O
lung	O
tissues	O
of	O
smokers	O
without	O
airflow	B-PROC
limitation	O
and	O
COPD	O
patients	O
in	O
comparison	O
to	O
nonsmoking	O
individuals	O
(	O
never	O
-	O
smokers	O
).	O

Additionally	O
,	O
we	O
found	O
that	O
both	O
DPP4	O
mRNA	O
and	O
protein	B-PROC
expression	B-PROC
were	O
inversely	O
correlated	O
with	O
lung	B-PROC
function	I-PROC
and	O
diffusing	O
capacity	O
parameters	O
.	O

The	O
recombination	B-PROC
detection	O
program	O
subsequently	O
identified	O
the	O
major	O
parent	O
(	O
S5011	O
strain	O
)	O
and	O
minor	O
parent	O
(	O
HKU15	O
-	O
44	O
strain	O
)	O
of	O
the	O
two	O
Vietnam	O
PDCoV	O
strains	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
A	O
rapid	O
bio	O
-	O
optical	O
sensor	O
for	O
diagnosing	O
Q	O
fever	B-PROC
in	O
clinical	O
specimens	O
.	O

This	O
study	O
indicated	O
that	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
could	O
be	O
used	O
as	O
an	O
efficient	O
adjuvant	O
and	O
delivery	O
carrier	O
for	O
further	O
development	B-PROC
of	O
mucosal	O
vaccines	O
and	O
drugs	O
and	O
could	O
have	O
an	O
immense	O
application	O
potential	O
in	O
medicine	O
.	O

TITLE	O
:	O
Influenza	O
virus	O
but	O
not	O
MERS	O
coronavirus	O
circulation	B-PROC
in	O
Iran	O
,	O
2013	O
-	O
2016	O
:	O
Comparison	O
between	O
pilgrims	O
and	O
general	O
population	O
.	O

The	O
vascular	B-PROC
endothelial	I-PROC
growth	B-PROC
factor	I-PROC
-	O
A	O
(	O
VEGF	O
-	O
A	O
)	O
and	O
the	O
placental	O
growth	B-PROC
factor	O
(	O
PlGF	O
)	O
are	O
vascular	B-PROC
permeability	I-PROC
factors	O
and	O
may	O
be	O
involved	O
in	O
the	O
disruption	O
of	O
the	O
alveolar	O
-	O
capillary	O
membrane	O
,	O
leading	O
to	O
alveolar	O
edema	O
.	O

Notably	O
,	O
codon	O
1020	O
was	O
positively	O
selected	O
among	O
B	O
and	O
B5	O
strains	O
,	O
and	O
can	O
distinguish	O
between	O
clade	O
A	O
(	O
Q1020	O
)	O
and	O
B	O
(	O
R1020	O
/	O
H1020	O
)	O
strains	O
,	O
suggesting	O
that	O
this	O
residue	O
may	O
play	O
a	O
role	O
in	O
the	O
evolution	B-PROC
of	O
S	O
protein	O
during	O
divergence	O
of	O
different	O
lineages	O
.	O

Further	O
characterization	O
of	O
these	O
and	O
other	O
uncharacterized	O
sites	O
may	O
reveal	O
novel	O
aspects	O
of	O
N	O
-	O
linked	O
glycosylation	B-PROC
in	O
coronavirus	O
replication	O
and	O
pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
The	O
cleavage	B-PROC
products	O
from	O
coronavirus	O
polyproteins	O
,	O
known	O
as	O
the	O
non	O
-	O
structural	O
proteins	O
(	O
nsps	O
),	O
are	O
believed	O
to	O
make	O
up	O
the	O
major	O
components	O
of	O
the	O
viral	B-PROC
replication	I-PROC
/	O
transcription	B-PROC
complex	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
are	O
positive	O
-	O
sense	B-PROC
RNA	O
viruses	O
that	O
infect	O
numerous	O
mammalian	O
and	O
avian	O
species	O
and	O
are	O
capable	O
of	O
causing	O
severe	O
and	O
lethal	O
disease	O
in	O
humans	O
.	O

Challenges	O
to	O
successful	O
development	B-PROC
include	O
incomplete	O
understanding	O
of	O
viral	B-PROC
transmission	I-PROC
,	O
pathogenesis	B-PROC
and	O
immune	B-PROC
response	I-PROC
(	O
in	O
particular	O
at	O
the	O
mucosal	O
level	O
),	O
no	O
optimal	O
animal	O
challenge	O
models	O
,	O
lack	O
of	O
standardized	O
immunological	O
assays	O
,	O
and	O
insufficient	O
sustainable	O
funding	O
.	O

Müller	O
cell	B-PROC
proliferation	I-PROC
was	O
present	O
within	O
lesions	O
of	O
retinal	O
detachment	O
.	O

TITLE	O
:	O
CD59	O
association	O
with	O
infectious	O
bronchitis	O
virus	O
particles	O
protects	O
against	O
antibody	B-PROC
-	O
dependent	O
complement	O
-	O
mediated	O
lysis	B-PROC
.	O

ABSTRACT	O
:	O
CD59	O
protein	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
terminal	O
pathway	B-PROC
of	O
the	O
complement	O
system	O
by	O
binding	O
to	O
the	O
C8	O
/	O
C9	O
factors	O
.	O

Finally	O
,	O
our	O
data	O
provide	O
a	O
structural	O
framework	O
for	O
understanding	O
the	O
mode	O
of	O
neutralization	O
of	O
antibodies	O
targeting	B-PROC
the	O
fusion	O
machinery	O
and	O
for	O
engineering	O
next	O
-	O
generation	O
subunit	O
vaccines	O
or	O
inhibitors	O
against	O
this	O
medically	O
important	O
virus	O
family	O
.	O

Ventilator	O
modes	O
and	O
adequate	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
settings	O
play	O
a	O
major	O
role	O
in	O
these	O
strategies	O
.	O

Food	O
allergies	B-PROC
are	O
a	O
growing	O
public	O
health	O
concern	O
-	O
allergic	B-PROC
reactions	I-PROC
can	O
result	O
in	O
anaphylactic	O
shock	O
,	O
which	O
can	O
prove	O
fatal	O
in	O
minutes	O
-	O
thus	O
,	O
the	O
ability	O
to	O
test	O
foods	O
for	O
common	O
allergens	O
,	O
rapidly	O
and	O
locally	O
,	O
before	O
ingestion	O
,	O
would	O
improve	O
food	O
safety	O
for	O
those	O
with	O
allergies	B-PROC
.	O

Many	O
different	O
vaccination	O
protocols	O
are	O
applied	O
in	O
the	O
same	O
region	O
and	O
even	O
in	O
consecutive	O
cycles	O
on	O
the	O
same	O
farm	O
in	O
order	O
to	O
find	O
the	O
perfect	O
balance	B-PROC
between	O
costs	O
and	O
benefits	O
.	O

The	O
present	O
work	O
compared	O
the	O
different	O
vaccine	O
strains	O
(	O
Mass	O
-	O
like	O
or	O
B48	O
,	O
and	O
1	O
/	O
96	O
)	O
kinetics	O
both	O
in	O
field	O
conditions	O
and	O
in	O
a	O
21	O
-	O
day	O
-	O
long	O
experimental	O
trial	O
in	O
broilers	O
,	O
monitoring	O
the	O
viral	B-PROC
replication	I-PROC
by	O
upper	O
respiratory	O
tract	O
swabbing	O
and	O
vaccine	O
specific	O
real	O
time	O
reverse	B-PROC
transcription	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
quantification	O
.	O

ABSTRACT	O
:	O
Ten	O
reference	O
genes	O
were	O
investigated	O
for	O
normalisation	O
of	O
candidate	O
target	O
gene	B-PROC
expression	I-PROC
data	O
in	O
the	O
shell	O
gland	O
and	O
spleen	O
of	O
laying	O
hens	O
challenged	O
with	O
two	O
strains	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

TITLE	O
:	O
The	O
effect	O
of	O
a	O
novel	O
extracorporeal	O
cytokine	O
hemoadsorption	O
device	O
on	O
IL	O
-	O
6	O
elimination	B-PROC
in	O
septic	O
patients	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

Significant	O
IL	O
-	O
6	O
elimination	B-PROC
,	O
averaging	O
between	O
5	O
and	O
18	O
%	O
per	O
blood	O
pass	O
throughout	O
the	O
entire	O
treatment	O
period	O
was	O
recorded	O
.	O

TITLE	O
:	O
The	O
impact	O
of	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
on	O
cytokine	O
levels	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
prospective	O
,	O
observational	O
study	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
now	O
a	O
recognized	O
revolutionary	O
technology	O
,	O
which	O
has	O
emerged	O
as	O
a	O
life	O
-	O
saving	O
therapeutic	O
option	O
for	O
patients	O
with	O
potentially	O
reversible	O
severe	O
respiratory	O
failure	O
who	O
fail	O
to	O
respond	O
positively	O
with	O
the	O
conventional	O
ventilation	O
therapy	O
.	O

TITLE	O
:	O
Targeting	B-PROC
and	O
Enrichment	O
of	O
Viral	O
Pathogen	O
by	O
Cell	O
Membrane	O
Cloaked	O
Magnetic	O
Nanoparticles	O
for	O
Enhanced	O
Detection	O
.	O

In	O
viral	B-PROC
infections	I-PROC
,	O
viruses	O
exploit	O
receptor	O
-	O
ligand	B-PROC
interactions	O
to	O
latch	O
onto	O
cellular	O
exterior	O
prior	O
to	O
subsequent	O
entry	O
and	O
invasion	O
.	O

Paired	O
With	O
12	O
-	O
year	O
follow	O
-	O
up	O
,	O
significant	O
improvements	O
on	O
VAS	O
(	O
6	O
.	O
81	O
of	O
pre	O
-	O
treatment	O
vs	O
3	O
.	O
94	O
of	O
12	O
-	O
year	O
post	O
-	O
treatment	O
)	O
and	O
Harris	O
score	O
(	O
74	O
.	O
54	O
of	O
pre	O
-	O
treatment	O
vs	O
80	O
.	O
14	O
of	O
12	O
-	O
year	O
post	O
-	O
treatment	O
)	O
were	O
observed	O
(	O
all	O
The	O
combined	O
treatment	O
may	O
delay	O
or	O
discontinue	O
the	O
development	B-PROC
of	O
ONFH	O
in	O
post	O
-	O
SARS	O
patients	O
.	O

LCMS	O
/	O
MS	O
coupled	O
to	O
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantification	O
(	O
iTRAQ	O
)	O
is	O
used	O
to	O
profile	O
expressed	B-PROC
proteins	O
in	O
IPEC	O
-	O
J2	O
cells	O
infected	O
by	O
TGEV	O
alone	O
,	O
ETEC	O
K88	O
alone	O
,	O
and	O
by	O
both	O
agents	O
together	O
.	O

Although	O
several	O
studies	O
have	O
investigated	O
the	O
molecular	O
aspects	O
and	O
host	O
immune	B-PROC
response	I-PROC
to	O
PEDV	O
,	O
there	O
are	O
little	O
data	O
on	O
the	O
impact	O
of	O
PEDV	O
on	O
pig	O
intestinal	O
physiology	O
.	O

TITLE	O
:	O
Genetic	O
and	O
biological	O
characterization	O
of	O
a	O
Porcine	O
Reproductive	B-PROC
and	O
Respiratory	O
Syndrome	O
Virus	O
2	O
(	O
PRRSV	O
-	O
2	O
)	O
causing	O
significant	O
clinical	O
disease	O
in	O
the	O
field	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
biological	O
evaluation	O
of	O
NH	O
ABSTRACT	O
:	O
Neuraminidase	B-PROC
inhibitors	I-PROC
can	O
deter	O
nascent	O
viruses	O
from	O
infecting	O
intact	O
cells	O
by	O
preventing	O
their	O
release	O
from	O
host	O
cells	O
.	O

TITLE	O
:	O
VSIG4	O
inhibits	O
proinflammatory	O
macrophage	B-PROC
activation	I-PROC
by	O
reprogramming	O
mitochondrial	O
pyruvate	B-PROC
metabolism	I-PROC
.	O

Three	O
samples	O
with	O
high	O
antibody	B-PROC
levels	O
tested	O
negative	O
by	O
qRT	O
-	O
PCR	O
,	O
whereas	O
18	O
qRT	O
-	O
PCR	O
positive	O
effusions	O
contained	O
no	O
or	O
low	O
-	O
titre	O
antibodies	O
.	O

CSF	O
antibody	B-PROC
was	O
detected	O
in	O
28	O
cats	O
,	O
which	O
were	O
divided	O
into	O
2	O
groups	O
;	O
15	O
with	O
CSF	O
titer	O
of	O
1	O
:	O
80	O
or	O
lower	O
and	O
13	O
with	O
CSF	O
titer	O
of	O
1	O
:	O
640	O
or	O
higher	O
.	O

The	O
replication	O
of	O
MERS	O
-	O
CoV	O
is	O
mediated	O
by	O
ORF	O
1ab	O
and	O
viral	O
gene	O
activity	O
can	O
be	O
modulated	O
by	O
RNAi	B-PROC
approach	O
.	O

Results	O
from	O
the	O
French	O
confidential	O
enquiry	O
into	O
maternal	B-PROC
deaths	B-PROC
,	O
2010	O
-	O
2012	O
].	O

RESULTS	O
:	O
The	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
were	O
significantly	O
lower	O
in	O
the	O
drug	O
-	O
associated	O
ARDS	O
group	O
than	O
in	O
the	O
non	O
-	O
drug	O
-	O
associated	O
ARDS	O
group	O
(	O
median	O
(	O
IQR	O
):	O
18	O
.	O
0	O
(	O
16	O
.	O
5	O
-	O
21	O
.	O
0	O
)	O
vs	O
23	O
.	O
0	O
(	O
18	O
.	O
0	O
-	O
26	O
.	O
0	O
),	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
the	O
arterial	O
oxygen	B-PROC
tension	I-PROC
/	O
fractional	O
inspired	B-PROC
oxygen	O
ratio	O
was	O
higher	O
(	O
148	O
.	O
0	O
(	O
114	O
.	O
1	O
-	O
177	O
.	O
5	O
)	O
vs	O
101	O
.	O
0	O
(	O
71	O
.	O
5	O
-	O
134	O
.	O
0	O
),	O
p	O
=	O
0	O
.	O
003	O
).	O

With	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
a	O
massive	O
infusion	O
of	O
propofol	O
successfully	O
suppressed	O
status	O
epilepticus	O
,	O
and	O
both	O
the	O
circulatory	B-PROC
collapse	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
gradually	O
improved	O
;	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
propofol	O
treatments	O
were	O
then	O
terminated	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
without	O
further	O
disabilities	O
.	O

TITLE	O
:	O
A	O
lethal	O
case	O
of	O
mamushi	O
(	O
ABSTRACT	O
:	O
We	O
report	O
a	O
lethal	O
case	O
of	O
a	O
mamushi	O
(	O
The	O
patient	O
died	B-PROC
35	O
days	O
after	O
the	O
bite	B-PROC
.	O

An	O
autopsy	O
revealed	O
widespread	O
necrosis	B-PROC
of	O
the	O
ileum	O
,	O
colon	O
,	O
and	O
liver	O
.	O

This	O
report	O
supplies	O
useful	O
clinical	O
information	O
on	O
the	O
treatment	O
of	O
severe	O
mamushi	O
bite	B-PROC
cases	O
,	O
and	O
severe	O
abdominal	O
symptoms	O
,	O
such	O
as	O
ileus	O
and	O
melena	O
,	O
may	O
be	O
a	O
lethal	O
sign	O
.	O

Our	O
results	O
revealed	O
up	O
to	O
13	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
among	O
vaccines	O
and	O
some	O
of	O
them	O
were	O
localized	O
in	O
regions	O
of	O
the	O
S1	O
glycoprotein	O
that	O
play	O
a	O
role	O
in	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
.	O

Though	O
these	O
vaccines	O
have	O
shown	O
efficacy	O
,	O
some	O
have	O
side	O
effects	O
including	O
viral	B-PROC
shedding	I-PROC
.	O

Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
infectious	O
agents	O
in	O
chickens	O
,	O
and	O
in	O
chicken	O
cells	O
,	O
it	O
can	O
be	O
recognized	O
by	O
MDA5	O
to	O
activate	O
interferon	B-PROC
production	I-PROC
.	O

However	O
,	O
the	O
absence	O
of	O
RIG	O
-	O
I	O
in	O
chickens	O
raises	O
the	O
question	O
of	O
whether	O
this	O
protein	O
influences	O
the	O
antiviral	O
immune	B-PROC
response	I-PROC
against	O
IBV	O
infection	O
.	O

We	O
also	O
found	O
that	O
IBV	O
can	O
cleave	O
MAVS	O
,	O
an	O
adaptor	O
protein	O
downstream	O
of	O
RIG	O
-	O
I	O
and	O
MDA5	O
that	O
acts	O
as	O
a	O
platform	O
for	O
antiviral	O
innate	B-PROC
immunity	B-PROC
at	O
an	O
early	O
stage	O
of	O
infection	O
.	O

Metabolic	B-PROC
abnormalities	O
include	O
hypoglycemia	O
,	O
hyponatremia	O
and	O
lactic	O
acidosis	O
.	O

Aggressive	B-PROC
fluid	O
boluses	O
may	O
not	O
be	O
appropriate	O
in	O
children	O
.	O

However	O
,	O
at	O
24	O
hours	O
,	O
cigarette	O
smoke	O
exposure	O
was	O
associated	O
with	O
increased	O
impairment	O
in	O
platelet	B-PROC
aggregation	I-PROC
,	O
reflecting	O
a	O
statistically	O
significant	O
decline	O
in	O
platelet	B-PROC
aggregation	I-PROC
over	O
the	O
initial	O
24	O
hours	O
after	O
trauma	O
.	O

The	O
relationship	O
between	O
this	O
decline	O
in	O
platelet	B-PROC
aggregation	I-PROC
and	O
ARDS	O
differed	O
by	O
cigarette	O
smoke	O
exposure	O
status	O
,	O
suggesting	O
that	O
impaired	O
platelet	B-PROC
activation	I-PROC
differentially	O
affects	O
the	O
risk	O
of	O
ARDS	O
in	O
those	O
with	O
cigarette	O
smoke	O
exposure	O
(	O
arachidonic	O
acid	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
005	O
,	O
collagen	O
p	O
for	O
interaction	O
:	O
0	O
.	O
02	O
,	O
adenosine	O
diphosphate	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
05	O
).	O

Cigarette	O
smoke	O
-	O
exposed	O
patients	O
are	O
more	O
likely	O
to	O
develop	O
impaired	O
platelet	B-PROC
aggregation	I-PROC
over	O
the	O
first	O
24	O
hours	O
of	O
admission	O
,	O
which	O
may	O
contribute	O
to	O
their	O
increased	O
risk	O
of	O
ARDS	O
.	O

Cigarette	O
smoke	O
-	O
exposed	O
patients	O
are	O
more	O
likely	O
to	O
develop	O
impaired	O
platelet	B-PROC
aggregation	I-PROC
over	O
the	O
first	O
24	O
hours	O
of	O
admission	O
,	O
which	O
may	O
contribute	O
to	O
their	O
increased	O
risk	O
of	O
ARDS	O
.	O

This	O
study	O
did	O
not	O
provide	O
evidence	O
that	O
recombination	B-PROC
can	O
directly	O
alter	O
the	O
antigenicity	O
,	O
virulence	B-PROC
,	O
replication	O
,	O
shedding	O
,	O
and	O
tissue	B-PROC
tropism	B-PROC
of	O
a	O
virus	O
,	O
but	O
it	O
did	O
show	O
that	O
recombination	B-PROC
events	O
are	O
likely	O
to	O
be	O
major	O
determinants	O
of	O
viral	O
evolution	B-PROC
.	O

Finally	O
,	O
elimination	B-PROC
of	O
peripheral	O
Ly6G	O
+	O
neutrophils	O
and	O
pharmacological	O
blockade	O
of	O
the	O
miR	O
-	O
223	O
-	O
NLRP3	O
-	O
IL	O
-	O
1β	O
signalling	B-PROC
axis	O
could	O
alleviate	O
MTD	O
-	O
induced	O
ALI	O
.	O

In	O
summary	O
,	O
miR	O
-	O
223	O
is	O
essential	O
for	O
regulating	O
the	O
pathogenesis	B-PROC
of	O
DAMP	O
-	O
induced	O
ALI	O
.	O

However	O
,	O
the	O
causes	O
of	O
death	B-PROC
in	O
11	O
patients	O
who	O
died	B-PROC
within	O
30	O
days	O
were	O
generally	O
not	O
related	O
to	O
the	O
procedural	O
complications	O
,	O
but	O
related	O
to	O
the	O
serious	O
clinical	O
status	O
before	O
PCI	O
.	O

We	O
demonstrated	O
that	O
human	O
primary	O
intestinal	O
epithelial	O
cells	O
,	O
small	O
intestine	O
explants	O
,	O
and	O
intestinal	O
organoids	O
were	O
highly	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
and	O
can	O
sustain	O
robust	O
viral	B-PROC
replication	I-PROC
.	O

All	O
the	O
11	O
DMD	O
patients	O
carried	O
out	O
-	O
of	O
-	O
frame	O
DMD	O
gene	B-PROC
mutations	I-PROC
.	O

Moving	B-PROC
from	O
the	O
nondependent	O
to	O
the	O
dependent	O
lung	O
regions	O
,	O
the	O
not	O
inflated	O
lung	O
tissue	O
significantly	O
increased	O
,	O
while	O
the	O
well	O
inflated	O
tissue	O
decreased	O
(	O
ρ	O
=	O
0	O
.	O
96	O
-	O
1	O
.	O
00	O
,	O

TITLE	O
:	O
Prevention	O
and	O
treatment	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
:	O
Presentations	O
on	O
antivirals	O
,	O
traditional	O
therapies	O
and	O
host	O
-	O
directed	O
interventions	O
at	O
the	O
5th	O
ISIRV	O
Antiviral	O
Group	O
conference	O
.	O

Coronavirus	O
RNA	B-PROC
synthesis	I-PROC
is	O
thought	O
to	O
be	O
associated	O
with	O
replication	O
organelles	O
(	O
ROs	O
)	O
consisting	O
of	O
modified	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
membranes	O
.	O

We	O
have	O
now	O
expressed	B-PROC
MERS	O
-	O
CoV	O
replicase	O
self	O
-	O
cleaving	O
polyprotein	O
fragments	O
encompassing	O
nsp3	O
-	O
4	O
or	O
nsp3	O
-	O
6	O
,	O
as	O
well	O
as	O
coexpressed	O
nsp3	O
and	O
nsp4	O
of	O
either	O
MERS	O
-	O
CoV	O
or	O
SARS	O
-	O
CoV	O
,	O
to	O
characterize	O
the	O
membrane	O
structures	O
induced	O
.	O

These	O
findings	O
provide	O
important	O
insight	O
into	O
the	O
biogenesis	B-PROC
of	O
coronavirus	O
DMVs	O
,	O
establish	O
strong	O
similarities	O
with	O
other	O
nidoviruses	O
(	O
specifically	O
,	O
the	O
arteriviruses	O
),	O
and	O
highlight	O
possible	O
general	O
principles	O
in	O
viral	O
DMV	O
formation	B-PROC
.	O

TITLE	O
:	O
Astragalus	O
polysaccharides	O
inhibit	O
avian	O
infectious	O
bronchitis	O
virus	B-PROC
infection	I-PROC
by	O
regulating	O
viral	B-PROC
replication	I-PROC
.	O

Viral	O
titers	O
were	O
calculated	O
by	O
using	O
the	O
plaque	O
formation	B-PROC
assay	O
,	O
and	O
the	O
cytotoxicity	O
of	O
APS	O
was	O
tested	O
by	O
utilizing	O
a	O
Cell	O
Counting	O
Kit	O
-	O
8	O
assay	O
.	O

We	O
also	O
found	O
that	O
the	O
decreased	O
viral	B-PROC
replication	I-PROC
after	O
APS	O
treatment	O
was	O
associated	O
with	O
reduced	O
mRNA	O
levels	O
of	O
the	O
cytokines	O
IL	O
-	O
1B	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
TNF	O
-	O
α	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
small	O
-	O
molecule	O
viral	O
inhibitors	O
targeting	B-PROC
various	O
stages	O
of	O
the	O
life	O
cycle	O
of	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
.	O

TITLE	O
:	O
Immune	B-PROC
responses	I-PROC
in	O
influenza	O
A	O
virus	O
and	O
human	O
coronavirus	O
infections	O
:	O
an	O
ongoing	O
battle	O
between	O
the	O
virus	O
and	O
host	O
.	O

Recent	O
studies	O
in	O
virology	O
and	O
immunology	O
have	O
improved	O
our	O
understanding	O
of	O
the	O
role	O
of	O
the	O
immune	O
system	O
in	O
protection	O
and	O
in	O
the	O
pathogenesis	B-PROC
of	O
these	O
infections	O
and	O
of	O
co	O
-	O
evolution	B-PROC
of	O
viruses	O
and	O
their	O
hosts	O
.	O

Lactobacillus	O
casei	O
delivering	O
the	O
COE	O
antigen	O
of	O
PEDV	O
conjugated	O
with	O
a	O
M	O
cell	O
-	O
targeting	B-PROC
peptide	O
Co1	O
as	O
an	O
immune	O
adjuvant	O
is	O
a	O
promising	O
oral	O
vaccine	O
candidate	O
for	O
PEDV	O
.	O

After	O
34	O
days	O
,	O
the	O
patient	O
was	O
weaned	B-PROC
from	O
mechanical	O
ventilation	O
and	O
was	O
discharged	O
to	O
the	O
pulmonary	O
ward	O
,	O
followed	O
by	O
complete	O
recovery	O
.	O

To	O
study	O
the	O
possible	O
immune	B-PROC
evasion	I-PROC
of	O
the	O
type	O
III	O
IFN	O
response	O
by	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
a	O
line	O
of	O
porcine	O
intestinal	O
epithelial	O
cells	O
was	O
developed	O
as	O
a	O
cell	O
model	O
for	O
PEDV	O
replication	O
.	O

The	O
peroxisome	O
is	O
the	O
innate	O
antiviral	O
signaling	B-PROC
platform	O
for	O
the	O
activation	O
of	O
IRF1	O
-	O
mediated	O
IFN	O
-	O
λ	O
production	O
,	O
and	O
the	O
numbers	O
of	O
peroxisomes	O
were	O
found	O
to	O
be	O
decreased	O
in	O
PEDV	O
-	O
infected	O
cells	O
.	O

PEDV	O
nsp1	O
blocked	O
the	O
nuclear	B-PROC
translocation	B-PROC
of	O
IRF1	O
and	O
reduced	O
the	O
number	O
of	O
peroxisomes	O
to	O
suppress	O
IRF1	O
-	O
mediated	O
type	O
III	O
IFNs	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
a	O
technique	O
used	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
severe	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
ADP	O
-	O
ribosylation	O
is	O
a	O
common	O
post	B-PROC
-	I-PROC
translational	B-PROC
modification	I-PROC
,	O
although	O
how	O
it	O
modulates	O
RNA	O
virus	B-PROC
infection	I-PROC
is	O
not	O
well	O
understood	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
a	O
novel	O
post	O
-	O
translation	B-PROC
modification	O
of	O
the	O
CoV	O
N	O
protein	O
that	O
may	O
play	O
a	O
regulatory	O
role	O
for	O
this	O
important	O
structural	O
protein	O
.	O

An	O
AHT	O
animal	O
model	O
was	O
developed	O
on	O
12	O
-	O
day	O
-	O
old	O
mice	O
subjected	O
to	O
90	O
°	O
head	O
extension	O
-	O
flexion	B-PROC
sagittal	O
shaking	O
repeated	O
30	O
,	O
60	O
,	O
80	O
and	O
100	O
times	O
.	O

Acute	O
oxygen	O
desaturation	O
was	O
observed	O
by	O
pulse	B-PROC
oximetry	O
during	O
respiratory	O
and	O
cardiac	O
suppression	B-PROC
.	O

There	O
was	O
a	O
severe	O
reduction	O
in	O
cerebral	O
blood	B-PROC
perfusion	I-PROC
immediately	O
after	O
the	O
trauma	O
that	O
did	O
not	O
significantly	O
improve	O
within	O
24	O
h	O
.	O
The	O
injured	O
mice	O
began	O
to	O
experience	O
reversible	O
sensorimotor	O
function	O
at	O
9	O
days	O
postinjury	O
(	O
dpi	O
),	O
which	O
had	O
completely	O
recovered	O
at	O
28	O
dpi	O
.	O

We	O
previously	O
reported	O
that	O
clinical	O
isolates	O
of	O
HCoV	O
-	O
229E	O
preferred	O
cell	O
-	O
surface	O
TMPRSS2	O
to	O
endosomal	O
cathepsin	O
for	O
cell	O
entry	O
,	O
and	O
that	O
they	O
acquired	O
the	O
ability	O
to	O
use	O
cathepsin	O
L	O
by	O
repeated	O
passage	O
in	O
cultured	O
cells	O
and	O
were	O
then	O
able	O
to	O
enter	O
cells	O
via	O
the	O
endosomal	O
pathway	B-PROC
.	O

ABSTRACT	O
:	O
Stridor	O
presenting	O
soon	O
after	O
birth	B-PROC
due	O
to	O
bilateral	O
abductor	O
vocal	O
cord	O
paralysis	O
(	O
VCP	O
)	O
is	O
rare	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
use	O
of	O
PP	O
in	O
ARDS	O
patients	O
(	O
primary	O
endpoint	O
),	O
the	O
physiological	B-PROC
effects	I-PROC
of	O
PP	O
,	O
and	O
the	O
reasons	O
for	O
not	O
using	O
it	O
(	O
secondary	O
endpoints	O
).	O

TITLE	O
:	O
Prevalence	O
of	O
sleep	B-PROC
apnea	O
at	O
the	O
acute	O
phase	O
of	O
ischemic	O
stroke	O
with	O
or	O
without	O
thrombolysis	O
.	O

CONCLUSIONS	O
:	O
Sleep	B-PROC
apnea	O
was	O
present	O
in	O
the	O
vast	O
majority	O
of	O
ischemic	O
stroke	O
patients	O
.	O

ABSTRACT	O
:	O
The	O
longitudinal	O
pattern	O
of	O
lung	B-PROC
function	I-PROC
in	O
children	O
with	O
sickle	O
cell	O
anemia	O
(	O
SCA	O
)	O
has	O
shown	O
a	O
decrease	O
in	O
FEV	O

In	O
this	O
study	O
ATII	O
cells	O
(	O
2	O
.	O
5	O
×	O
10	O
ATII	O
cell	O
transplantation	O
promoted	O
recovery	O
of	O
lung	B-PROC
function	I-PROC
,	O
decrease	O
mortality	O
and	O
lung	O
inflammation	O
of	O
the	O
animals	O
with	O
ALI	O
.	O

The	O
primary	O
mechanisms	O
for	O
benefit	O
were	O
paracrine	B-PROC
effects	O
of	O
prostaglandin	O
E	O
CONCLUSIONS	O
:	O
ATII	O
cells	O
and	O
their	O
secreted	B-PROC
molecules	O
have	O
shown	O
an	O
ability	O
to	O
resolve	O
ALI	O
,	O
thereby	O
highlighting	O
a	O
potential	O
novel	O
therapeutic	O
target	O
.	O

TITLE	O
:	O
Activation	O
of	O
the	O
c	O
-	O
Jun	O
NH	O
ABSTRACT	O
:	O
Mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
are	O
conserved	O
protein	O
kinases	O
that	O
regulate	O
a	O
variety	O
of	O
important	O
cellular	O
signaling	B-PROC
pathways	B-PROC
.	O

Knockdown	O
of	O
clathrin	O
expression	B-PROC
by	O
siRNA	O
drastically	O
abrogated	O
the	O
infection	O
of	O
VSVΔG	O
-	O
MERS	O
in	O
Vero	O
cells	O
.	O

Evaluation	O
revealed	O
evidence	O
of	O
bilateral	O
central	O
retinal	O
artery	O
occlusion	B-PROC
and	O
bilateral	O
ischemic	O
optic	O
neuropathy	O
.	O

Both	O
central	O
retinal	O
artery	O
occlusion	B-PROC
and	O
ischemic	O
optic	O
neuropathy	O
have	O
been	O
reported	O
in	O
cases	O
of	O
severe	O
hypotension	O
,	O
blood	O
loss	O
,	O
and	O
prone	O
positioning	O
,	O
most	O
often	O
postoperatively	O
after	O
spinal	O
surgery	O
.	O

The	O
more	O
common	O
major	O
BCCE	O
abnormality	O
found	O
was	O
severe	O
ACP	O
(	O
28	O
.	O
2	O
%),	O
followed	O
by	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
<	O
40	O
%	O
(	O
16	O
.	O
2	O
%).	O

TITLE	O
:	O
Alveolar	O
injury	O
and	O
regeneration	B-PROC
following	O
deletion	O
of	O
ABCA3	O
.	O

Compared	O
with	O
severe	O
pneumonia	O
without	O
ARDS	O
development	B-PROC
,	O
patients	O
with	O
ARDS	O
development	B-PROC
had	O
shorter	O
disease	O
duration	O
before	O
admission	O
,	O
higher	O
lung	O
injury	O
score	O
(	O
LIS	O
),	O
serum	O
fibrinogen	O
(	O
FiB	O
),	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
),	O
lower	O
Marshall	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
score	O
and	O
proportion	O
of	O
cardiovascular	O
and	O
gastrointestinal	O
diseases	O
,	O
but	O
similar	O
mortality	O
.	O

MDMA	O
-	O
induced	O
hyponatremia	O
is	O
hypothesized	O
to	O
result	O
from	O
enhanced	O
serotonergic	O
activity	O
and	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
release	O
in	O
the	O
brain	O
leading	O
to	O
hyperthermia	B-PROC
-	O
induced	O
polydipsia	O
and	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
(	O
SIADH	O
)	O
secretion	B-PROC
.	O

TITLE	O
:	O
Physiological	O
and	O
molecular	O
triggers	O
for	O
SARS	O
-	O
CoV	O
membrane	B-PROC
fusion	I-PROC
and	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
.	O

The	O
patient	O
was	O
successfully	O
weaned	B-PROC
from	O
ECMO	O
by	O
reference	O
to	O
EAdi	O
.	O

This	O
is	O
the	O
first	O
case	O
report	O
to	O
suggest	O
that	O
EAdi	O
monitoring	O
might	O
be	O
useful	O
for	O
ARDS	O
patients	O
during	O
ECMO	O
weaning	B-PROC
.	O

ACS	O
in	O
SCD	O
is	O
defined	O
as	O
the	O
presence	O
of	O
fever	B-PROC
and	O
/	O
or	O
new	O
respiratory	O
symptoms	O
accompanied	O
by	O
the	O
presence	O
of	O
a	O
new	O
pulmonary	O
infiltrate	O
on	O
chest	O
X	O
-	O
ray	O
.	O

In	O
our	O
body	O
,	O
fat	O
is	O
transported	O
by	O
lipoproteins	O
,	O
intriguing	O
supramolecular	O
nanostructures	O
that	O
have	O
important	O
roles	O
in	O
cell	B-PROC
function	I-PROC
,	O
lipid	B-PROC
metabolism	I-PROC
,	O
and	O
disease	O
.	O

The	O
integration	B-PROC
of	O
different	O
hydrophobic	O
and	O
amphiphilic	O
imaging	O
labels	O
,	O
including	O
chelated	O
radioisotopes	O
and	O
paramagnetic	O
or	O
fluorescent	O
lipids	O
,	O
renders	O
HDL	O
nanobiologics	O
suitable	O
for	O
diagnostic	O
purposes	O
.	O

Baseline	O
characteristics	O
,	O
acute	O
kidney	O
injury	O
stage	O
,	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
),	O
intermittent	O
hemodialysis	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
survival	O
,	O
and	O
renal	O
recovery	O
(	O
defined	O
as	O
dialysis	O
independence	O
)	O
were	O
evaluated	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
was	O
instituted	O
in	O
17	O
patients	O
;	O
15	O
of	O
these	O
patients	O
required	O
CRRT	O
.	O

However	O
,	O
the	O
relative	O
contribution	O
of	O
memory	B-PROC
CD8	O
T	O
cells	O
in	O
providing	O
protection	O
against	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
infection	O
is	O
currently	O
unclear	O
.	O

These	O
results	O
demonstrate	O
that	O
in	O
contrast	O
to	O
other	O
respiratory	O
viruses	O
,	O
RSV	O
-	O
specific	O
memory	B-PROC
CD8	O
T	O
cells	O
can	O
induce	O
lethal	O
immunopathology	O
despite	O
mediating	O
enhanced	O
viral	O
clearance	O
.	O

Herein	O
,	O
we	O
summarize	O
the	O
current	O
updates	O
on	O
the	O
characteristics	O
of	O
human	O
T	O
-	O
cell	O
immunological	O
responses	O
against	O
recently	O
emerged	O
or	O
re	O
-	O
emerged	O
viruses	O
,	O
and	O
emphasize	O
the	O
necessity	O
for	O
timely	O
investigation	O
on	O
the	O
T	O
-	O
cell	O
features	O
of	O
these	O
viral	B-PROC
diseases	I-PROC
,	O
which	O
may	O
provide	O
beneficial	O
recommendations	O
for	O
clinical	O
diagnosis	O
and	O
vaccine	O
development	B-PROC
.	O

Through	O
the	O
construction	O
of	O
recombinant	O
IBV	O
expressing	O
proteins	O
8a	O
,	O
8b	O
and	O
8ab	O
encoded	O
by	O
SARS	O
-	O
CoV	O
ORF8	O
,	O
we	O
demonstrate	O
that	O
expression	B-PROC
of	O
8b	O
and	O
8ab	O
enables	O
the	O
corresponding	O
recombinant	O
viruses	O
to	O
partially	O
overcome	O
the	O
inhibitory	O
actions	O
of	O
IFN	O
activation	O
to	O
achieve	O
higher	O
replication	O
efficiencies	O
in	O
cells	O
.	O

This	O
counteracting	O
effect	O
was	O
partially	O
mediated	O
by	O
protein	O
8b	O
/	O
8ab	O
-	O
induced	O
degradation	O
of	O
IRF3	O
in	O
a	O
ubiquitin	B-PROC
-	O
proteasome	B-PROC
-	O
dependent	O
manner	O
.	O

In	O
severe	O
ARDS	O
,	O
the	O
ventilatable	O
parenchyma	O
is	O
strongly	O
reduced	O
in	O
size	O
('	O
baby	O
lung	O
');	O
its	O
resting	O
volume	O
could	O
be	O
as	O
low	O
as	O
300	O
mL	O
,	O
and	O
the	O
total	O
inspiratory	B-PROC
capacity	O
could	O
be	O
reached	O
with	O
a	O
tidal	O
volume	O
of	O
750	O
-	O
900	O
mL	O
,	O
thus	O
generating	O
lethal	O
stress	O
and	O
strain	O
in	O
the	O
lung	O
.	O

The	O
determinants	O
of	O
mechanical	O
power	O
are	O
not	O
only	O
the	O
tidal	O
volume	O
,	O
but	O
also	O
respiratory	O
rate	O
,	O
inspiratory	B-PROC
flow	O
,	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
).	O

We	O
also	O
observed	O
that	O
gene	B-PROC
function	I-PROC
,	O
evolution	B-PROC
time	O
and	O
the	O
different	O
host	O
species	O
of	O
the	O
virus	O
all	O
contributed	O
to	O
the	O
bias	O
of	O
MERS	O
-	O
CoV	O
,	O
to	O
some	O
extent	O
.	O

Our	O
study	O
provides	O
the	O
first	O
glimpse	O
of	O
the	O
virus	O
evolution	B-PROC
in	O
one	O
longitudinally	O
observed	O
bat	O
population	O
cohort	O
and	O
underlines	O
the	O
surveillance	O
and	O
pre	O
-	O
warning	O
of	O
potential	O
interspecies	O
transmittable	O
viruses	O
in	O
bats	O
.	O

Coronavirus	O
EndoU	O
is	O
encoded	O
within	O
the	O
sequence	O
of	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
15	O
,	O
which	O
was	O
initially	O
identified	O
as	O
a	O
component	O
of	O
the	O
viral	B-PROC
replication	I-PROC
complex	O
.	O

The	O
gender	O
,	O
age	O
,	O
onset	O
to	O
diagnosis	O
time	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
oxygenation	B-PROC
index	O
(	O
PaO	B-PROC
There	O
was	O
no	O
significant	O
difference	O
in	O
gender	O
,	O
age	O
,	O
onset	O
to	O
diagnosis	O
time	O
,	O
APACHE	O
II	O
score	O
,	O
PaO	B-PROC
Early	O
bundle	O
therapy	O
has	O
a	O
significant	O
effect	O
on	O
severe	O
human	O
infection	O
by	O
avian	O
influenza	O
H7N9	O
,	O
which	O
can	O
improve	O
the	O
prognosis	O
and	O
reduce	O
the	O
mortality	O
of	O
patients	O
.	O

As	O
a	O
strong	O
stressor	O
during	O
sepsis	O
,	O
the	O
severe	O
infectious	O
state	O
of	O
the	O
body	O
triggers	O
serious	O
stress	B-PROC
reaction	I-PROC
.	O

The	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
cortical	O
(	O
HPA	O
)	O
axis	O
and	O
sympathetic	O
-	O
adrenal	O
medulla	O
axis	O
were	O
activated	O
and	O
participated	O
the	O
initiation	O
and	O
progression	O
of	O
the	O
stress	B-PROC
response	I-PROC
through	O
the	O
production	O
of	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
),	O
glucocorticoid	O
(	O
GC	O
),	O
epinephrine	O
and	O
norepinephrine	O
(	O
NE	O
).	O

ABSTRACT	O
:	O
Despite	O
being	O
still	O
invasive	O
and	O
challenging	O
,	O
technical	O
improvement	O
has	O
resulted	O
in	O
broader	O
and	O
more	O
frequent	O
application	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
),	O
to	O
prevent	O
hypoxemia	O
and	O
to	O
reduce	O
invasiveness	O
of	O
mechanical	O
ventilation	O
(	O
MV	O
).	O

Moreover	O
,	O
in	O
P	O
.	O
berghei	O
NK65	O
infected	O
mice	O
,	O
increased	O
lipid	B-PROC
peroxidation	I-PROC
,	O
accumulation	O
of	O
triglycerides	O
,	O
impairment	O
of	O
anti	O
-	O
oxidant	O
enzymes	O
and	O
higher	O
collagen	O
deposition	O
were	O
detected	O
.	O

Despite	O
lung	O
protective	O
ventilation	O
,	O
prone	O
position	O
and	O
neuromuscular	B-PROC
blockade	I-PROC
,	O
refractory	O
respiratory	O
failure	O
of	O
unknown	O
etiology	O
supervened	O
(	O
ratio	O
of	O
arterial	O
oxygen	B-PROC
partial	I-PROC
pressure	I-PROC
to	O
fractional	O
inspired	B-PROC
oxygen	O
46	O
-	O
130	O
)	O
and	O
ECMO	O
was	O
initiated	O
after	O
3	O
-	O
7	O
days	O
of	O
mechanical	O
ventilation	O
.	O

CFs	O
had	O
an	O
inhibitory	O
effect	O
on	O
injury	O
repair	B-PROC
in	O
ALI	O
/	O
ARDS	O
mice	O
model	O
.	O

In	O
both	O
PCV	O
and	O
PSV	O
,	O
peak	O
transpulmonary	O
pressure	O
was	O
lower	O
,	O
whereas	O
E	O
-	O
cadherin	O
tissue	O
expression	B-PROC
,	O
which	O
is	O
related	O
to	O
epithelial	O
integrity	O
,	O
was	O
higher	O
at	O
PEEP	O
=	O
5	O
cmH2O	O
than	O
at	O
PEEP	O
=	O
2	O
cmH2O	O
.	O

In	O
PSV	O
,	O
PEEP	O
=	O
5	O
cmH2O	O
compared	O
with	O
PEEP	O
=	O
2	O
cmH2O	O
was	O
associated	O
with	O
significantly	O
reduced	O
diffuse	O
alveolar	O
damage	O
score	O
[	O
median	O
(	O
interquartile	O
range	O
),	O
11	O
(	O
8	O
.	O
5	O
to	O
13	O
.	O
5	O
)	O
vs	O
.	O
23	O
(	O
19	O
to	O
26	O
),	O
P	O
=	O
0	O
.	O
005	O
]	O
and	O
expressions	O
of	O
IL	O
-	O
6	O
and	O
CINC	O
-	O
1	O
(	O
P	O
=	O
0	O
.	O
02	O
for	O
both	O
),	O
whereas	O
surfactant	O
protein	O
-	O
B	O
mRNA	B-PROC
expression	B-PROC
increased	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

These	O
findings	O
indicate	O
that	O
UTI	O
ameliorates	O
LPS	O
-	O
induced	O
ALI	O
by	O
attenuating	O
the	O
TLR4	O
/	O
NF	O
-	O
κB	O
pathway	B-PROC
activation	O
.	O

Polymerase	O
chain	O
reaction	O
was	O
the	O
most	O
sensitive	O
method	O
for	O
detecting	O
viral	B-PROC
infection	I-PROC
.	O

Our	O
findings	O
indicate	O
the	O
need	O
to	O
develop	O
prophylactic	O
polyvalent	O
or	O
polyvirus	O
(	O
including	O
RV	O
,	O
EnV	O
,	O
IfV	O
and	O
RSV	O
)	O
vaccines	O
that	O
produce	O
herd	B-PROC
immunity	I-PROC
and	O
reduce	O
the	O
healthcare	O
burden	O
associated	O
with	O
virus	O
-	O
induced	O
asthma	O
exacerbations	O
.	O

TITLE	O
:	O
Safety	O
and	O
tolerability	O
of	O
a	O
novel	O
,	O
polyclonal	O
human	O
anti	O
-	O
MERS	O
coronavirus	O
antibody	B-PROC
produced	O
from	O
transchromosomic	O
cattle	O
:	O
a	O
phase	O
1	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
single	O
-	O
dose	O
-	O
escalation	O
study	O
.	O

The	O
findings	O
of	O
our	O
study	O
suggest	O
that	O
dietary	O
RP	O
and	O
VE	O
additives	O
can	O
interact	O
and	O
modulate	O
the	O
humoral	B-PROC
immunity	I-PROC
of	O
broilers	O
,	O
but	O
not	O
sufficiently	O
to	O
improve	O
antibody	B-PROC
titers	O
against	O
specific	O
virus	O
during	O
a	O
42	O
-	O
day	O
production	O
cycle	O
.	O

Our	O
results	O
highlighted	O
the	O
importance	O
of	O
monitoring	O
virus	O
circulation	B-PROC
in	O
wildlife	O
,	O
especially	O
bats	O
,	O
in	O
the	O
context	O
of	O
intense	O
human	O
-	O
wildlife	O
interfaces	O
in	O
order	O
to	O
strengthen	O
prevention	O
measures	O
among	O
local	O
populations	O
and	O
to	O
implement	O
sentinel	O
surveillance	O
in	O
sites	O
with	O
high	O
zoonotic	O
diseases	O
transmission	O
potential	O
.	O

ABSTRACT	O
:	O
This	O
single	O
-	O
center	O
case	O
series	O
investigated	O
the	O
effect	O
of	O
almitrine	O
infusion	O
on	O
PaO2	O
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
FIO2	O
)	O
in	O
25	O
patients	O
on	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Utilizing	O
a	O
systems	O
-	O
based	O
approach	O
,	O
we	O
examined	O
differential	O
regulation	B-PROC
of	O
IFN	O
-	O
γ	O
-	O
dependent	O
genes	O
following	O
infection	O
with	O
robust	O
respiratory	O
viruses	O
including	O
influenza	O
viruses	O
[	O
A	O
/	O
influenza	O
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
(	O
H5N1	O
-	O
VN1203	O
)	O
and	O
A	O
/	O
influenza	O
/	O
California	O
/	O
04	O
/	O
2009	O
(	O
H1N1	O
-	O
CA04	O
)]	O
and	O
coronaviruses	O
[	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
(	O
MERS	O
-	O
CoV	O
)].	O

Most	O
of	O
the	O
patients	O
(	O
88	O
.	O
1	O
%)	O
had	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
,	O
and	O
the	O
median	O
PaO	B-PROC
CONCLUSIONS	O
:	O
The	O
outcome	O
of	O
ARDS	O
in	O
patients	O
with	O
hematological	O
malignancies	O
is	O
associated	O
with	O
the	O
severity	O
of	O
the	O
underlying	O
diseases	O
,	O
the	O
presence	O
of	O
multidrug	O
-	O
resistance	B-PROC
pathogens	O
,	O
and	O
the	O
amount	O
of	O
transfusion	O
;	O
however	O
,	O
strict	O
application	O
of	O
low	O
tidal	O
volume	O
ventilation	O
may	O
improve	O
the	O
outcome	O
of	O
these	O
patients	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

We	O
compared	O
GCV	O
-	O
induced	O
injury	O
and	O
repair	B-PROC
in	O
SPC	O
-	O
TK	O
mice	O
that	O
have	O
normal	O
endogenous	O
SPC	O
expression	B-PROC
with	O
SPC	O
-	O
TK	O
/	O
SPC	O
-	O
KO	O
mice	O
lacking	O
SPC	O
expression	B-PROC
.	O

TITLE	O
:	O
Receptor	O
Usage	O
of	O
a	O
Novel	O
Bat	O
Lineage	O
C	O
Betacoronavirus	O
Reveals	O
Evolution	B-PROC
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
Related	O
Coronavirus	O
Spike	O
Proteins	O
for	O
Human	O
Dipeptidyl	O
Peptidase	O
4	O
Binding	O
.	O

As	O
expected	O
,	O
administration	O
of	O
GBT1118	O
to	O
mice	O
significantly	O
increased	O
the	O
oxygen	B-PROC
affinity	I-PROC
of	O
hemoglobin	O
.	O

ABSTRACT	O
:	O
Patients	O
who	O
develop	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
despite	O
full	O
medical	O
management	O
may	O
require	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
VV	O
ECMO	O
)	O
to	O
support	O
respiratory	B-PROC
function	I-PROC
.	O

Acute	O
,	O
life	O
-	O
threatening	O
but	O
potentially	O
reversible	O
organ	O
dysfunction	O
is	O
its	O
hallmark	O
,	O
and	O
unresolving	O
organ	O
dysfunction	O
is	O
the	O
dominant	O
cause	O
of	O
death	B-PROC
in	O
critical	O
illness	O
.	O

In	O
addition	O
,	O
the	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMMs	O
)	O
from	O
Gal	O
-	O
3KO	O
mice	O
exhibited	O
reduced	O
oligomerization	O
of	O
apoptosis	B-PROC
-	O
associated	O
speck	O
-	O
like	O
proteins	O
containing	O
caspase	O
-	O
associated	O
recruitment	O
domains	O
and	O
secreted	B-PROC
less	O
IL	O
-	O
1β	O
compared	O
with	O
BMMs	O
from	O
WT	O
mice	O
.	O

Hence	O
,	O
targeted	B-PROC
RNA	O
recombination	B-PROC
based	O
on	O
virulent	O
IBV	O
provides	O
opportunities	O
for	O
the	O
development	B-PROC
of	O
a	O
next	O
generation	O
of	O
rationally	O
designed	O
live	O
attenuated	O
IBV	O
vaccines	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
if	O
PEDV	O
could	O
be	O
detected	O
in	O
semen	O
from	O
infected	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
boars	O
inoculated	O
with	O
a	O
PEDV	O
US	O
non	O
-	O
InDel	B-PROC
strain	O
suggesting	O
venereal	O
transmission	O
may	O
occur	O
.	O

RESULTS	O
:	O
By	O
suggesting	O
methods	O
to	O
evaluate	O
the	O
field	O
epidemiologist	O
system	O
and	O
training	O
programs	O
and	O
by	O
suggesting	O
ways	O
for	O
the	O
Korea	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
to	O
conduct	B-PROC
evaluations	O
on	O
its	O
own	O
,	O
the	O
present	O
study	O
provides	O
supporting	O
evidence	O
for	O
improvement	O
of	O
systems	O
for	O
training	O
of	O
experts	O
in	O
epidemiological	O
investigations	O
.	O

A	O
better	O
understanding	O
of	O
the	O
specific	O
role	O
of	O
microglia	O
in	O
responding	O
to	O
viral	B-PROC
infection	I-PROC
is	O
complicated	O
by	O
the	O
presence	O
of	O
nonmicroglial	O
myeloid	O
cells	O
with	O
potentially	O
overlapping	O
function	O
in	O
the	O
healthy	O
brain	O
and	O
by	O
the	O
rapid	O
infiltration	O
of	O
hematopoietic	O
myeloid	O
cells	O
into	O
the	O
brain	O
in	O
diseased	O
states	O
.	O

The	O
essential	O
virulence	B-PROC
,	O
infected	O
host	O
and	O
external	O
environmental	O
factors	O
required	O
for	O
invasive	O
GAS	O
infections	O
have	O
not	O
yet	O
been	O
determined	O
.	O

Topics	O
addressed	O
include	O
the	O
bacteriological	O
,	O
virological	O
and	O
immunological	O
mechanisms	O
impacting	O
invasion	O
upon	O
superinfection	O
on	O
top	O
of	O
underlying	O
influenza	O
virus	B-PROC
infection	I-PROC
by	O
GAS	O
and	O
other	O
bacteria	O
(	O
i	O
.	O
e	O
.,	O
Streptococcus	O
pneumoniae	O
and	O
Staphylococcus	O
aureus	O
).	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
PEDV	O
infection	O
stimulated	O
epidermal	O
growth	B-PROC
factor	O
receptor	O
(	O
EGFR	O
)	O
activation	O
,	O
which	O
has	O
been	O
linked	O
to	O
not	O
only	O
anticancer	O
therapeutics	O
,	O
but	O
also	O
antiviral	O
signaling	B-PROC
.	O

Therefore	O
,	O
we	O
determined	O
whether	O
EGFR	O
activation	O
affected	O
PEDV	O
infection	O
by	O
using	O
an	O
activator	O
or	O
overexpression	B-PROC
assay	O
.	O

Respiratory	O
specimens	O
were	O
collected	O
from	O
patients	O
and	O
tested	O
for	O
eight	O
respiratory	O
viruses	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
or	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Patients	O
with	O
BAIT	O
generally	O
present	O
with	O
acute	O
ocular	B-PROC
pain	O
,	O
photophobia	O
,	O
and	O
red	O
eyes	O
.	O

TITLE	O
:	O
Expression	B-PROC
profile	O
and	O
promoter	O
analysis	O
of	O
HEPIS	O
.	O

Patients	O
in	O
intensive	O
care	O
units	O
were	O
eligible	O
if	O
they	O
were	O
intubated	O
and	O
mechanically	O
ventilated	O
and	O
had	O
ARDS	O
as	O
defined	O
by	O
a	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
concentration	O
(	O
Patients	O
were	O
randomised	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
enteral	O
simvastatin	O
80	O
mg	O
or	O
identical	O
placebo	O
tablets	O
once	O
daily	O
for	O
up	O
to	O
28	O
days	O
.	O

One	O
patient	O
died	B-PROC
from	O
Haemophilus	O
influenzae	O
co	O
-	O
infection	O
.	O

Characterized	O
by	O
a	O
rapid	O
onset	O
of	O
diarrhea	O
in	O
pigs	O
of	O
all	O
ages	O
,	O
morbidity	O
can	O
reach	B-PROC
up	O
to	O
100	O
%	O
whereas	O
mortality	O
is	O
variable	O
.	O

Then	O
,	O
the	O
effects	O
of	O
PGE2	O
on	O
the	O
expression	B-PROC
of	O
innate	O
antiviral	O
factors	O
in	O
cultured	O
uterine	O
mucosal	O
cells	O
were	O
examined	O
.	O

These	O
results	O
suggest	O
that	O
the	O
expression	B-PROC
of	O
viral	O
RNA	O
-	O
recognition	O
receptors	O
,	O
AvBDs	O
,	O
CATHs	O
,	O
and	O
IFNs	O
and	O
PGE2	O
are	O
induced	O
by	O
the	O
IBV	O
antigen	O
,	O
and	O
that	O
the	O
expression	B-PROC
of	O
a	O
different	O
set	O
of	O
AvBDs	O
is	O
also	O
induced	O
by	O
PGE2	O
in	O
the	O
cultured	O
uterine	O
mucosal	O
cells	O
.	O

TITLE	O
:	O
Highly	O
convergent	O
synthesis	B-PROC
and	O
antiviral	O
activity	O
of	O
(	O
E	O
)-	O
but	O
-	O
2	O
-	O
enyl	O
nucleoside	O
phosphonoamidates	O
.	O

Genome	O
-	O
wide	O
analysis	O
of	O
differentially	O
expressed	B-PROC
genes	O
(	O
DEGs	O
)	O
was	O
performed	O
in	O
Vero	O
E6	O
cells	O
post	O
-	O
PEDV	O
infection	O
.	O

Like	O
SARS	O
previously	O
and	O
Zika	O
recently	O
,	O
the	O
Ebola	O
crisis	O
in	O
2015	O
showed	O
how	O
vulnerable	O
the	O
world	O
is	O
to	O
these	O
epidemics	O
,	O
with	O
over	O
11	O
,	O
000	O
people	O
dying	B-PROC
in	O
the	O
outbreak	O
.	O

The	O
prevalence	O
of	O
Chinese	O
non	O
-	O
S	O
-	O
INDEL	B-PROC
strains	O
may	O
be	O
responsible	O
for	O
the	O
immunization	O
failure	O
by	O
using	O
currently	O
available	O
commercial	O
vaccines	O
(	O
based	O
on	O
attenuated	O
CV777	O
strain	O
),	O
and	O
the	O
development	B-PROC
of	O
novel	O
vaccines	O
based	O
on	O
these	O
newly	O
identified	O
PEDV	O
variants	O
may	O
contribute	O
to	O
the	O
control	O
of	O
PED	O
outbreaks	O
in	O
China	O
.	O

Importantly	O
,	O
we	O
discovered	O
that	O
the	O
lipoxin	O
pathway	B-PROC
could	O
be	O
a	O
potent	O
modulator	O
of	O
NET	O
formation	B-PROC
,	O
and	O
that	O
mice	O
deficient	O
in	O
the	O
lipoxin	O
receptor	O
(	O
Fpr2	O
-/-)	O
produced	O
excess	O
NETs	O
leading	O
to	O
increased	O
lung	O
injury	O
and	O
mortality	O
.	O

In	O
most	O
acute	O
respiratory	O
distress	O
syndrome	O
trials	O
,	O
it	O
is	O
unknown	O
whether	O
reported	O
deaths	B-PROC
are	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
or	O
the	O
underlying	O
disease	O
,	O
unrelated	O
to	O
the	O
specific	O
intervention	O
tested	O
.	O

We	O
investigated	O
the	O
causes	O
of	O
death	B-PROC
after	O
contracting	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
a	O
large	O
cohort	O
.	O

Twenty	O
-	O
three	O
percent	O
of	O
deaths	B-PROC
occurred	O
from	O
refractory	O
hypoxemia	O
due	O
to	O
nonresolving	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Pathophysiology	O
is	O
mainly	O
characterized	O
by	O
granulocyte	O
infiltration	O
of	O
the	O
lung	O
thereby	O
inducing	O
interstitial	O
and	O
intra	O
-	O
alveolar	O
lung	O
edema	O
with	O
surfactant	O
depletion	O
and	O
atelectasis	O
formation	B-PROC
.	O

COE	O
fused	O
to	O
the	O
flanking	O
C	O
'/	O
N	O
'	O
terminal	O
of	O
rSF	O
yielded	O
rSF	O
-	O
COE	O
-	O
C	O
and	O
rSF	O
-	O
COE	O
-	O
N	O
.	O
As	O
a	O
result	O
,	O
rSF	O
-	O
COE	O
-	O
3D	O
could	O
significantly	O
improve	O
COE	O
specific	O
antibody	B-PROC
production	I-PROC
including	O
serum	O
IgG	O
,	O
serum	O
IgA	O
,	O
mucosal	O
IgA	O
and	O
PEDV	O
neutralizing	O
antibody	B-PROC
.	O

By	O
day	O
28	O
,	O
fewer	O
patients	O
died	B-PROC
before	O
achieving	O
extubation	O
(	O
15	O
.	O
7	O
%	O
vs	O
25	O
.	O
3	O
%	O
and	O
risk	O
ratio	O
,	O
0	O
.	O
62	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
34	O
-	O
1	O
.	O
13	O
),	O
more	O
achieved	O
successful	O
extubation	O
(	O
71	O
.	O
9	O
%	O
vs	O
49	O
.	O
5	O
%	O
and	O
risk	O
ratio	O
,	O
1	O
.	O
45	O
;	O
CI	O
,	O
1	O
.	O
14	O
-	O
1	O
.	O
85	O
),	O
time	O
to	O
successful	O
extubation	O
was	O
shorter	O
(	O
hazard	O
ratio	O
,	O
2	O
.	O
05	O
;	O
CI	O
,	O
1	O
.	O
42	O
-	O
2	O
.	O
96	O
),	O
and	O
more	O
were	O
discharged	O
alive	O
from	O
the	O
ICU	O
(	O
65	O
.	O
2	O
%	O
vs	O
48	O
.	O
3	O
%;	O
risk	O
ratio	O
,	O
1	O
.	O
35	O
;	O
CI	O
,	O
1	O
.	O
04	O
-	O
1	O
.	O
75	O
).	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
for	O
a	O
multitrauma	O
patient	O
with	O
ARDS	O
:	O
A	O
case	O
report	O
and	O
literature	O
review	O
.	O

Functional	O
morphology	O
and	O
thermoregulatory	O
effectors	O
differences	O
between	O
dogs	O
and	O
humans	O
may	O
require	O
special	O
heatstroke	O
protective	O
adaptations	B-PROC
in	O
dogs	O
,	O
however	O
,	O
the	O
risk	O
factors	O
for	O
developing	O
heatstroke	O
are	O
similar	O
in	O
both	O
.	O

TITLE	O
:	O
Predictors	O
of	O
long	O
-	O
term	O
adherence	O
to	O
continuous	O
positive	O
airway	O
pressure	O
in	O
patients	O
with	O
obstructive	O
sleep	B-PROC
apnoea	O
and	O
acute	O
coronary	O
syndrome	O
.	O

TITLE	O
:	O
Lung	B-PROC
volumes	I-PROC
and	O
lung	B-PROC
volume	I-PROC
recruitment	O
in	O
ARDS	O
:	O
a	O
comparison	O
between	O
supine	O
and	O
prone	O
position	O
.	O

Some	O
of	O
the	O
taxa	O
showing	O
differences	O
in	O
abundance	O
between	O
uninfected	O
piglets	O
and	O
piglets	O
infected	O
with	O
PEDV	O
were	O
associated	O
with	O
cellular	O
transport	B-PROC
and	O
catabolism	B-PROC
,	O
energy	B-PROC
metabolism	B-PROC
,	O
the	O
biosynthesis	B-PROC
of	O
other	O
secondary	O
metabolites	O
,	O
and	O
amino	B-PROC
acid	I-PROC
metabolism	I-PROC
as	O
determined	O
through	O
the	O
prediction	O
of	O
microbial	O
function	O
based	O
on	O
the	O
bacterial	O
16S	O
rRNA	O
gene	O
.	O

ABSTRACT	O
:	O
Hyperventilation	O
syndrome	O
(	O
HVS	O
)	O
sometimes	O
occurs	O
in	O
patients	O
under	O
stressful	O
conditions	O
and	O
may	O
provoke	O
severe	O
complications	O
such	O
as	O
myocardial	O
infarction	O
and	O
death	B-PROC
.	O

Therefore	O
,	O
understanding	O
the	O
relationship	O
between	O
the	O
molecular	O
regulation	B-PROC
of	O
immune	O
cells	O
and	O
the	O
pulmonary	O
microenvironment	O
is	O
critical	O
for	O
disease	O
management	O
.	O

Knowledge	O
about	O
age	O
-	O
specific	O
pattern	O
of	O
CoV	O
infection	O
in	O
P	O
.	O
lylei	O
,	O
prevalence	O
,	O
and	O
viral	B-PROC
shedding	I-PROC
at	O
roosts	O
and	O
foraging	O
sites	O
may	O
have	O
an	O
impact	O
on	O
infection	O
-	O
age	O
-	O
structure	O
model	O
to	O
control	O
CoV	O
outbreak	O
.	O

Whether	O
viral	O
reactivation	O
during	O
parturition	B-PROC
period	O
or	O
stress	O
is	O
responsible	O
in	O
maintaining	O
transmission	O
in	O
the	O
bat	O
colony	O
needs	O
to	O
be	O
explored	O
.	O

Seventy	O
-	O
seven	O
patients	O
had	O
short	O
duration	O
AKI	O
(	O
1	O
-	O
2	O
days	O
),	O
47	O
medium	O
duration	O
AKI	O
(	O
3	O
-	O
7	O
days	O
),	O
87	O
persistent	O
AKI	O
(>	O
7	O
days	O
)	O
and	O
38	O
died	B-PROC
during	O
their	O
AKI	O
episode	O
.	O

TITLE	O
:	O
Whole	O
transcriptome	O
analysis	O
reveals	O
differential	B-PROC
gene	B-PROC
expression	I-PROC
profile	O
reflecting	O
macrophage	O
polarization	O
in	O
response	O
to	O
influenza	O
A	O
H5N1	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Metalloprotease	O
ADAM17	O
regulates	O
porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
by	O
modifying	O
aminopeptidase	O
N	O
.	O
ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
a	O
causative	O
agent	O
of	O
porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
).	O

TITLE	O
:	O
Pathogenicity	O
and	O
Viral	B-PROC
Shedding	I-PROC
of	O
MERS	O
-	O
CoV	O
in	O
Immunocompromised	O
Rhesus	O
Macaques	O
.	O

Pteropus	O
medius	O
is	O
widespread	O
in	O
Asia	O
and	O
appears	O
to	O
excrete	B-PROC
group	O
D	O
coronaviruses	O
,	O
which	O
are	O
hitherto	O
confined	O
to	O
bats	O
;	O
however	O
,	O
these	O
findings	O
may	O
have	O
public	O
health	O
implications	O
in	O
the	O
future	O
.	O

In	O
pigs	O
,	O
the	O
newly	O
emerged	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
and	O
re	O
-	O
emerged	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
reported	O
in	O
the	O
US	O
and	O
Asia	O
,	O
as	O
well	O
as	O
the	O
discovery	O
of	O
novel	O
CoVs	O
in	O
wild	O
bats	O
or	O
birds	O
,	O
has	O
necessitated	O
development	B-PROC
of	O
improved	O
detection	O
and	O
control	O
measures	O
for	O
these	O
CoVs	O
.	O

A	O
multiplex	O
TaqMan	O
real	O
-	O
time	O
PCR	O
method	O
was	O
developed	O
for	O
the	O
detection	O
and	O
differentiation	B-PROC
of	O
four	O
antigenic	O
types	O
of	O
CPV	O
.	O

In	O
this	O
study	O
,	O
a	O
70	O
-	O
nm	O
nano	O
silicon	O
particle	O
was	O
applied	O
with	O
inactivated	O
TGEV	O
vaccine	O
in	O
mice	O
,	O
and	O
its	O
immune	O
-	O
enhancing	O
effects	O
and	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
investigated	O
.	O

Human	O
metapneumovirus	O
was	O
detected	O
by	O
direct	O
immunofluorescence	O
and	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
.	O

hMPV	O
was	O
further	O
detected	O
in	O
several	O
cases	O
of	O
SARS	O
and	O
it	O
was	O
the	O
only	O
virus	O
detected	O
in	O
three	O
deaths	B-PROC
.	O

TITLE	O
:	O
Identification	O
of	O
H209	O
as	O
Essential	O
for	O
pH	O
8	O
-	O
Triggered	O
Receptor	O
-	O
Independent	O
Syncytium	B-PROC
Formation	I-PROC
by	O
S	O
Protein	O
of	O
Mouse	O
Hepatitis	O
Virus	O
A59	O
.	O

PR40	O
infected	O
animals	O
showed	O
an	O
early	O
and	O
marked	O
reduction	O
of	O
pro	O
-	O
inflammatory	O
CD172α	O
+	O
CD14	O
+	O
CD16	O
+	O
and	O
CD14	O
+	O
CD163	O
+	O
monocytes	O
and	O
TCRγδ	O
+	O
CD8α	O
+/	O
CD8α	O
-	O
lymphocytes	O
when	O
pigs	O
were	O
most	O
infected	O
,	O
possibly	O
due	O
to	O
a	O
recruitment	O
sustaining	O
an	O
acute	B-PROC
inflammatory	I-PROC
response	I-PROC
in	O
target	O
tissues	O
.	O

Further	O
studies	O
showed	O
that	O
TGEV	O
nsp7	O
protein	O
had	O
no	O
effect	O
on	O
GRP78	O
expression	B-PROC
,	O
could	O
not	O
induce	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
activate	O
NF	O
-	O
κB	O
activity	O
.	O

TITLE	O
:	O
Neuromuscular	B-PROC
blockade	I-PROC
is	O
associated	O
with	O
the	O
attenuation	O
of	O
biomarkers	O
of	O
epithelial	O
and	O
endothelial	O
injury	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Fever	B-PROC
accompanying	O
vaso	O
-	O
occlusive	O
crisis	O
is	O
a	O
common	O
presentation	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
and	O
carries	O
a	O
broad	O
differential	O
diagnosis	O
.	O

ABSTRACT	O
:	O
Respiratory	O
virus	B-PROC
infection	I-PROC
(	O
RVI	B-PROC
)	O
in	O
pediatric	O
solid	O
organ	O
transplant	O
(	O
SOT	O
)	O
recipients	O
poses	O
a	O
significant	O
risk	O
;	O
however	O
,	O
the	O
epidemiology	O
and	O
effects	O
of	O
an	O
RVI	B-PROC
after	O
pediatric	O
SOT	O
in	O
the	O
era	O
of	O
current	O
molecular	O
diagnostic	O
assays	O
are	O
unclear	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
US	O
-	O
like	O
and	O
Asian	O
non	O
-	O
S	O
INDEL	B-PROC
strains	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
that	O
circulated	O
in	O
Japan	O
during	O
2013	O
-	O
2016	O
and	O
PEDVs	O
collected	O
from	O
recurrent	O
outbreaks	O
.	O

For	O
one	O
sample	O
genotyping	O
was	O
not	O
possible	O
despite	O
high	O
viral	O
load	O
,	O
and	O
two	O
samples	O
were	O
negative	O
for	O
FCoV	O
.	O
As	O
none	O
of	O
the	O
control	O
animals	O
showed	O
FCoV	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
previously	O
demonstrated	O
in	O
cats	O
with	O
FIP	O
,	O
it	O
can	O
be	O
presumed	O
that	O
the	O
substitution	O
M1058L	O
correlates	O
with	O
the	O
presence	O
of	O
FIP	O
.	O

Although	O
triggered	O
by	O
a	O
pathogen	O
,	O
pneumonia	O
often	O
results	O
from	O
dysregulations	O
of	O
host	B-PROC
defense	I-PROC
that	O
likely	O
precede	O
infection	O
.	O

The	O
expression	B-PROC
of	O
viral	O
RNA	O
and	O
protein	O
of	O
PEDV	O
in	O
Vero	O
cells	O
was	O
suppressed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
LiCl	O
.	O

We	O
found	O
that	O
imatinib	O
and	O
two	O
specific	O
Abl	O
kinase	B-PROC
inhibitors	I-PROC
,	O
GNF2	O
and	O
GNF5	O
,	O
reduce	O
IBV	O
titres	O
by	O
blocking	O
the	O
first	O
round	O
of	O
virus	B-PROC
infection	I-PROC
.	O

Studying	O
the	O
effects	O
of	O
Abl	O
kinase	B-PROC
inhibitors	I-PROC
on	O
IBV	O
will	O
be	O
useful	O
in	O
identifying	O
the	O
host	O
cell	O
pathways	B-PROC
required	O
for	O
coronavirus	O
infection	O
.	O

After	O
treatment	O
,	O
the	O
homocysteine	O
and	O
methylmalonic	O
acid	O
levels	O
were	O
normalized	O
but	O
hemolysis	B-PROC
and	O
acute	O
kidney	O
failure	O
persisted	O
.	O

This	O
includes	O
molecules	O
with	O
very	O
broad	O
antiviral	O
spectrum	O
such	O
as	O
ribavirin	O
and	O
T	O
-	O
705	O
(	O
favipiravir	O
),	O
and	O
others	O
targeting	B-PROC
more	O
specifically	O
one	O
or	O
a	O
few	O
virus	O
families	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
structure	O
(	O
s	O
)	O
and	O
function	O
(	O
s	O
)	O
of	O
respiratory	O
virus	O
polymerases	O
will	O
likely	O
support	O
the	O
discovery	O
and	O
development	B-PROC
of	O
novel	O
nucleoside	O
analogs	O
.	O

ABSTRACT	O
:	O
Idiopathic	O
pulmonary	O
fibrosis	O
(	O
IPF	O
)	O
is	O
a	O
fibrotic	O
lung	O
disease	O
characterized	O
by	O
progressive	O
loss	O
of	O
lung	B-PROC
function	I-PROC
and	O
poor	O
prognosis	O
.	O

By	O
the	O
mentioned	O
case	O
there	O
is	O
sepsis	O
-	O
induced	O
polyorganic	O
insufficiency	O
with	O
underlying	O
severe	O
somatic	O
pathological	O
condition	O
,	O
with	O
violation	O
of	O
hemodynamics	B-PROC
.	O

The	O
smaller	O
size	O
of	O
the	O
medulla	O
in	O
the	O
coronavirus	O
-	O
infected	O
birds	O
may	O
lead	O
to	O
a	O
lower	O
number	O
of	O
B	O
lymphocytes	O
and	O
bursal	O
secretory	B-PROC
dendritic	O
cells	O
,	O
which	O
negatively	O
affects	O
the	O
reactivity	O
and	O
efficacy	O
of	O
the	O
immune	O
system	O
.	O

An	O
acute	O
exacerbation	O
(	O
AE	O
)	O
of	O
pre	O
-	O
existing	O
IP	O
triggered	O
by	O
an	O
infection	O
was	O
suspected	O
,	O
and	O
the	O
treatment	O
with	O
antibiotics	O
and	O
corticosteroid	O
pulse	B-PROC
therapy	O
improved	O
her	O
general	O
condition	O
and	O
chest	O
radiological	O
findings	O
.	O

Because	O
some	O
auto	O
-	O
antibodies	O
associated	O
with	O
acute	O
/	O
subacute	O
onset	O
IP	O
have	O
recently	O
become	O
available	O
in	O
clinic	O
,	O
we	O
examined	O
those	O
including	O
anti	O
-	O
aminoacyl	O
tRNA	O
synthetase	O
(	O
ARS	O
)	O
antibodies	O
,	O
and	O
found	O
that	O
she	O
was	O
positive	O
for	O
anti	O
-	O
PL	O
-	O
7	O
antibody	B-PROC
.	O

Molecular	O
understanding	O
of	O
the	O
pathogenic	O
contributors	O
to	O
ARDS	O
has	O
improved	O
,	O
but	O
the	O
molecular	O
-	O
associated	O
treatments	O
are	O
still	O
under	O
development	B-PROC
.	O

All	O
six	O
isolated	O
compounds	O
have	O
been	O
evaluated	O
firstly	O
for	O
the	O
inhibition	B-PROC
of	O
both	O
Human	O
Immunodeficiency	O
Virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Reverse	O
Transcriptase	B-PROC
(	O
RT	O
)-	O
associated	O
DNA	O
Polymerase	O
(	O
RDDP	O
)	O
and	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
activities	O
,	O
for	O
the	O
inhibition	B-PROC
of	O
HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
in	O
biochemical	O
assays	O
,	O
and	O
also	O
for	O
their	O
effect	O
on	O
viral	B-PROC
replication	I-PROC
.	O

This	O
suggests	O
that	O
Chinese	O
Ark	O
-	O
type	O
isolates	O
are	O
derived	O
from	O
the	O
Jilin	O
vaccine	O
,	O
and	O
have	O
diverged	O
and	O
evolved	O
independently	O
by	O
point	B-PROC
mutations	I-PROC
since	O
introduction	O
into	O
China	O
.	O

Pathogenicity	O
testing	O
showed	O
that	O
Chinese	O
Ark	O
viruses	O
had	O
comparable	O
virulence	B-PROC
to	O
that	O
of	O
the	O
Massachusetts	O
-	O
type	O
M41	O
strain	O
,	O
although	O
they	O
had	O
lower	O
affinity	O
for	O
the	O
kidneys	O
of	O
chickens	O
than	O
the	O
M41	O
strain	O
had	O
.	O

Quantitation	O
of	O
the	O
challenge	O
pathogens	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
-	O
PCR	O
determined	O
that	O
MGC	O
was	O
shed	O
in	O
much	O
higher	O
titers	O
from	O
the	O
trachea	O
than	O
MG	O
,	O
when	O
co	O
-	O
infected	O
with	O
IBV	O
.	O

In	O
addition	O
,	O
its	O
infection	O
leads	O
to	O
reduced	O
fertility	B-PROC
and	O
hatchability	O
in	O
layer	O
birds	O
.	O

ABSTRACT	O
:	O
Infectious	O
diseases	O
caused	O
by	O
enveloped	O
viruses	O
,	O
such	O
as	O
influenza	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
cause	O
thousands	O
of	O
deaths	B-PROC
and	O
billions	O
of	O
dollars	O
of	O
economic	O
losses	O
per	O
year	O
.	O

TITLE	O
:	O
Resiquimod	O
enhances	O
mucosal	O
and	O
systemic	O
immunity	B-PROC
against	O
avian	O
infectious	O
bronchitis	O
virus	O
vaccine	O
in	O
the	O
chicken	O
.	O

Patient	O
samples	O
showed	O
severe	O
surfactant	O
inhibition	B-PROC
even	O
in	O
the	O
absence	O
of	O
elevated	O
cholesterol	O
levels	O
.	O

However	O
,	O
treatment	O
with	O
APN	O
-	O
specific	O
antibody	B-PROC
and	O
inhibitors	O
did	O
not	O
completely	O
block	O
PDCoV	O
infection	O
in	O
IPI	O
-	O
2I	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

We	O
also	O
discuss	O
the	O
evolution	B-PROC
and	O
variation	O
of	O
PDCoV	O
S1	O
-	O
CTD	O
based	O
on	O
structure	O
information	O
,	O
providing	O
clues	O
to	O
explain	O
the	O
usage	O
of	O
pAPN	O
by	O
PDCoV	O
.	O
Taken	O
together	O
,	O
the	O
results	O
presented	O
herein	O
reveal	O
that	O
pAPN	O
is	O
likely	O
not	O
a	O
critical	O
functional	O
receptor	O
for	O
PDCoV	O
,	O
although	O
it	O
is	O
involved	O
in	O
PDCoV	O
infection	O
.	O

TITLE	O
:	O
Macrophage	O
Polarization	O
Favors	O
Epithelial	O
Repair	B-PROC
During	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

ABSTRACT	O
:	O
Alveolar	O
macrophage	O
polarization	O
and	O
role	O
on	O
alveolar	O
repair	B-PROC
during	O
human	O
acute	O
respiratory	O
distress	O
syndrome	O
remain	O
unclear	O
.	O

These	O
results	O
suggest	O
that	O
macrophage	O
polarization	O
may	O
be	O
an	O
important	O
step	O
for	O
epithelial	O
repair	B-PROC
and	O
acute	O
respiratory	O
distress	O
syndrome	O
recovery	O
.	O

TITLE	O
:	O
A	O
novel	O
mechanism	O
of	O
RNase	O
L	O
inhibition	B-PROC
:	O
Theiler	O
'	O
s	O
virus	O
L	O
*	O
protein	O
prevents	O
2	O
-	O
5A	O
from	O
binding	O
to	O
RNase	O
L	O
.	O
ABSTRACT	O
:	O
The	O
OAS	O
/	O
RNase	O
L	O
pathway	B-PROC
is	O
one	O
of	O
the	O
best	O
-	O
characterized	O
effector	O
pathways	B-PROC
of	O
the	O
IFN	O
antiviral	B-PROC
response	I-PROC
.	O

The	O
mortality	O
was	O
higher	O
among	O
patients	O
with	O
qSOFA	O
>	O
3	O
,	O
mean	O
arterial	O
blood	B-PROC
pressure	I-PROC
<	O
60	O
mmHg	O
,	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
at	O
presentation	O
.	O

Systolic	O
blood	B-PROC
pressure	I-PROC
(	O
BP	B-PROC
)	O
was	O
<	O
120	O
mm	O
Hg	O
in	O
68	O
and	O
BP	B-PROC
was	O
not	O
recordable	O
in	O
four	O
patients	O
.	O

Only	O
fecal	O
score	O
and	O
breed	B-PROC
size	O
had	O
an	O
effect	O
on	O
fecal	O
S100A12	O
concentrations	O
in	O
multivariate	O
analysis	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

Previously	O
,	O
we	O
demonstrated	O
that	O
isolated	O
paramyxovirus	O
fusion	O
protein	O
TMDs	O
associate	O
in	O
a	O
monomer	O
-	O
trimer	O
equilibrium	B-PROC
,	O
using	O
sedimentation	O
equilibrium	B-PROC
analytical	O
ultracentrifugation	O
.	O

ABSTRACT	O
:	O
Epidemiological	O
models	O
of	O
the	O
spread	O
of	O
pathogens	O
in	O
livestock	O
populations	O
primarily	O
focus	O
on	O
direct	O
contact	O
between	O
farms	O
based	O
on	O
animal	O
movement	B-PROC
data	O
,	O
and	O
in	O
some	O
cases	O
,	O
local	O
spatial	O
spread	O
based	O
on	O
proximity	O
between	O
premises	O
.	O

By	O
modifying	O
the	O
likelihood	O
of	O
each	O
transmission	O
mechanism	O
and	O
fitting	O
this	O
model	O
to	O
observed	O
epidemiological	O
dynamics	O
,	O
our	O
results	O
suggest	O
that	O
between	O
-	O
farm	O
transmission	O
was	O
primarily	O
driven	O
by	O
direct	O
mechanisms	O
related	O
to	O
animal	O
movement	B-PROC
and	O
indirect	O
mechanisms	O
related	O
to	O
local	O
spatial	O
spread	O
based	O
on	O
geographic	O
proximity	O
.	O

ABSTRACT	O
:	O
Obstructive	O
sleep	B-PROC
apnea	O
(	O
OSA	O
)	O
might	O
influence	O
disease	O
severity	O
in	O
acute	O
pulmonary	O
embolism	O
(	O
PE	O
).	O

253	O
survivors	O
of	O
acute	O
PE	O
were	O
evaluated	O
for	O
sleep	B-PROC
-	O
disordered	O
breathing	B-PROC
by	O
portable	O
monitoring	O
and	O
nocturnal	O
polysomnography	O
.	O

TITLE	O
:	O
Recovery	O
of	O
pulmonary	B-PROC
functions	I-PROC
,	O
exercise	O
capacity	O
,	O
and	O
quality	O
of	O
life	O
after	O
pulmonary	O
rehabilitation	O
in	O
survivors	O
of	O
ARDS	O
due	O
to	O
severe	O
influenza	O
A	O
(	O
H1N1	O
)	O
pneumonitis	O
.	O

Data	O
of	O
spirometry	O
,	O
total	O
lung	B-PROC
capacity	I-PROC
(	O
TLC	O
),	O
diffusing	O
capacity	O
of	O
carbon	O
monoxide	O
(	O
DL	O
Nine	O
survivors	O
of	O
H1N1	O
-	O
ARDS	O
in	O
the	O
study	O
period	O
were	O
included	O
.	O

In	O
this	O
Review	O
,	O
we	O
provide	O
a	O
comprehensive	O
update	O
and	O
synthesis	B-PROC
of	O
the	O
latest	O
available	O
data	O
on	O
the	O
epidemiology	O
,	O
determinants	O
,	O
and	O
risk	O
factors	O
of	O
primary	O
,	O
household	O
,	O
and	O
nosocomial	O
transmission	O
of	O
MERS	O
-	O
CoV	O
,	O
and	O
suggest	O
measures	O
to	O
reduce	O
risk	O
of	O
transmission	O
.	O

TITLE	O
:	O
Cryo	O
-	O
EM	O
structure	O
of	O
infectious	O
bronchitis	O
coronavirus	O
spike	O
protein	O
reveals	O
structural	O
and	O
functional	O
evolution	B-PROC
of	O
coronavirus	O
spike	O
proteins	O
.	O

Probiotics	O
with	O
or	O
without	O
flaxseed	O
were	O
fed	O
to	O
weanling	O
gilts	O
starting	O
10	O
days	O
before	O
and	O
lasting	O
up	O
until	O
14	O
days	O
after	O
weaning	B-PROC
.	O

The	O
blood	O
samples	O
for	O
the	O
levels	O
of	O
steroid	O
hormones	O
and	O
insulin	B-PROC
-	I-PROC
like	I-PROC
growth	B-PROC
factor	I-PROC
I	O
(	O
IGF	O
-	O
I	O
)	O
were	O
assessed	O
using	O
immunoassays	O
and	O
the	O
levels	O
of	O
fatty	O
acids	O
were	O
assessed	O
using	O
gas	O
chromatography	O
.	O

While	O
some	O
viruses	O
simply	O
cause	O
symptoms	O
of	O
the	O
common	O
cold	B-PROC
,	O
many	O
respiratory	O
viruses	O
induce	O
severe	O
bronchiolitis	O
,	O
pneumonia	O
,	O
and	O
even	O
death	B-PROC
following	O
infection	O
.	O

However	O
,	O
the	O
mucosal	O
antibody	B-PROC
response	I-PROC
to	O
many	O
respiratory	O
viruses	O
is	O
not	O
long	O
-	O
lasting	O
and	O
declines	O
with	O
age	O
.	O

TITLE	O
:	O
miR	O
-	O
146a	O
-	O
5p	O
promotes	O
replication	O
of	O
infectious	O
bronchitis	O
virus	O
by	O
targeting	B-PROC
IRAK2	O
and	O
TNFRSF18	O
.	O

TITLE	O
:	O
Passive	B-PROC
immunity	I-PROC
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
following	O
immunization	O
of	O
pregnant	O
gilts	O
with	O
a	O
recombinant	O
orf	O
virus	O
vector	O
expressing	O
the	O
spike	O
protein	O
.	O

TITLE	O
:	O
Right	O
ventricular	O
dysfunction	O
during	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
Inappropriate	O
use	O
of	O
antibiotics	O
increases	O
resistance	B-PROC
and	O
reduces	O
their	O
effectiveness	O
.	O

This	O
relationship	O
indicates	O
that	O
interventions	O
aimed	O
at	O
reducing	O
influenza	O
cases	O
in	O
addition	O
to	O
effort	B-PROC
to	O
discourage	O
the	O
prescription	O
of	O
antibiotics	O
by	O
physicians	O
may	O
help	O
to	O
decrease	O
unnecessary	O
antibiotic	O
consumption	O
.	O

METHODS	O
/	O
DESIGN	O
:	O
The	O
""""	O
REstricted	O
versus	O
Liberal	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
patients	O
without	O
ARDS	O
""""	O
trial	O
(	O
RELAx	O
)	O
is	O
a	O
national	O
,	O
multicenter	O
,	O
randomized	O
controlled	O
,	O
noninferiority	O
trial	O
in	O
adult	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
with	O
uninjured	O
lungs	O
who	O
are	O
expected	O
not	O
to	O
be	O
extubated	O
within	O
24	O
h	O
.	O
RELAx	O
will	O
run	O
in	O
13	O
ICUs	O
in	O
the	O
Netherlands	O
to	O
enroll	O
980	O
patients	O
under	O
invasive	O
ventilation	O
.	O

Thus	O
,	O
heterologous	O
prime	O
-	O
boost	O
may	O
induce	O
longer	O
-	O
lasting	O
immune	B-PROC
responses	I-PROC
against	O
MERS	O
-	O
CoV	O
because	O
of	O
an	O
appropriate	O
balance	B-PROC
of	O
Th1	O
/	O
Th2	O
responses	O
.	O

However	O
,	O
members	O
of	O
this	O
family	O
recognize	O
different	O
cellular	O
receptors	O
and	O
exploit	O
different	O
entry	O
routes	O
,	O
what	O
affects	O
their	O
species	O
specificity	O
and	O
virulence	B-PROC
.	O

ABSTRACT	O
:	O
This	O
report	O
describes	O
the	O
successful	O
use	O
of	O
a	O
new	O
intervention	O
to	O
improve	O
respiratory	B-PROC
mechanics	I-PROC
and	O
gas	O
exchange	O
in	O
a	O
relatively	O
homogeneous	O
group	O
of	O
infants	O
with	O
severe	O
bronchiolitis	O
-	O
induced	O
PARDS	O
after	O
failure	O
of	O
conventional	O
treatment	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
the	O
case	O
of	O
an	O
RSV	O
-	O
associated	O
death	B-PROC
of	O
a	O
child	O
who	O
was	O
born	O
at	O
full	O
-	O
term	O
and	O
developed	O
normally	O
up	O
to	O
the	O
age	O
of	O
2	O
years	O
old	O
.	O

MERS	O
-	O
CoV	O
sub	O
-	O
genomic	O
mRNA	O
was	O
detected	O
by	O
reverse	B-PROC
transcription	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
MERS	O
-	O
CoV	O
genomic	O
RNA	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Clinical	O
characteristics	O
that	O
could	O
affect	O
imaging	O
,	O
such	O
as	O
patient	O
age	O
and	O
immune	B-PROC
status	I-PROC
,	O
seasonal	O
variation	O
and	O
community	O
outbreaks	O
,	O
and	O
pathogenesis	B-PROC
,	O
are	O
also	O
discussed	O
.	O

TITLE	O
:	O
Early	O
Pulmonary	O
Interstitial	O
Emphysema	O
in	O
Preterm	O
Neonates	O
-	O
Respiratory	O
Management	O
and	O
Case	O
Report	O
in	O
Nonventilated	O
Very	O
Low	O
Birth	B-PROC
Weight	O
Twins	O
.	O

We	O
present	O
a	O
case	O
of	O
pneumoperitoneum	O
in	O
an	O
extremely	O
preterm	O
infant	O
with	O
severe	O
growth	B-PROC
restriction	O
.	O

TITLE	O
:	O
Discovery	O
and	O
Sequence	O
Analysis	O
of	O
Four	O
Deltacoronaviruses	O
from	O
Birds	O
in	O
the	O
Middle	O
East	O
Reveal	O
Interspecies	O
Jumping	O
with	O
Recombination	B-PROC
as	O
a	O
Potential	O
Mechanism	O
for	O
Avian	O
-	O
to	O
-	O
Avian	O
and	O
Avian	O
-	O
to	O
-	O
Mammalian	O
Transmission	O
.	O

The	O
antisera	O
raised	O
against	O
the	O
Korean	O
prototype	O
2014	O
G2b	O
strain	O
efficiently	O
neutralized	O
KNU	O
-	O
1705	O
virus	B-PROC
infection	I-PROC
,	O
suggesting	O
antigenic	O
homology	O
between	O
the	O
2014	O
and	O
2017	O
PEDV	O
strains	O
.	O

PCR	O
SuperArray	O
analysis	O
showed	O
that	O
the	O
reduction	O
of	O
virus	B-PROC
replication	I-PROC
was	O
associated	O
with	O
a	O
greater	O
induction	O
of	O
interferon	O
stimulated	O
genes	O
.	O

Abdominal	O
ultrasonography	O
confirmed	O
the	O
presence	O
of	O
a	O
soft	O
-	O
tissue	O
structure	O
,	O
with	O
a	O
moderate	O
blood	B-PROC
supply	I-PROC
and	O
mesenteric	O
lymphadenopathy	O
.	O

We	O
analysed	O
the	O
proteolytic	B-PROC
processing	I-PROC
of	O
the	O
HCoV	O
-	O
229E	O
spike	O
protein	O
by	O
trypsin	O
-	O
like	O
serine	O
proteases	O
leading	O
to	O
activation	O
of	O
the	O
fusion	O
process	O
.	O

Education	O
was	O
protective	O
from	O
post	O
-	O
intensive	O
care	O
syndrome	O
problems	O
and	O
frailty	O
predictive	O
of	O
the	O
development	B-PROC
of	O
post	O
-	O
intensive	O
care	O
syndrome	O
problems	O
.	O

TITLE	O
:	O
Versatile	O
Electrochemiluminescence	O
Assays	O
for	O
PEDV	O
Antibody	B-PROC
Based	O
on	O
Rolling	O
Circle	O
Amplification	O
and	O
Ru	O
-	O
DNA	O
Nanotags	O
.	O

ABSTRACT	O
:	O
The	O
sensitive	O
and	O
accurate	O
detection	O
methods	O
for	O
PEDV	O
antibody	B-PROC
have	O
practical	O
significance	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
PEDV	O
.	O

Additionally	O
,	O
proteins	O
3a	O
and	O
E	O
have	O
a	O
PDZ	O
-	O
binding	O
motif	O
(	O
PBM	O
),	O
which	O
can	O
potentially	O
bind	O
over	O
400	O
cellular	O
proteins	O
which	O
contain	O
a	O
PDZ	O
domain	O
,	O
making	O
them	O
potentially	O
important	O
for	O
the	O
control	O
of	O
cell	B-PROC
function	I-PROC
.	O

Therefore	O
,	O
dominance	O
of	O
the	O
IC	O
and	O
PBM	O
of	O
protein	O
E	O
over	O
those	O
of	O
protein	O
3a	O
was	O
demonstrated	O
in	O
the	O
induction	O
of	O
pathogenesis	B-PROC
in	O
mice	O
.	O

A	O
focused	O
set	O
of	O
thienyl	O
chalcone	O
derivaties	O
II	O
-	O
VI	O
was	O
screened	O
for	O
selected	O
viruses	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
Herpes	O
simplex	O
virus	O
1	O
(	O
HSV	O
-	O
1	O
),	O
Human	O
cytomegalovirus	O
(	O
HCMV	O
),	O
Dengue	O
virus	O
2	O
(	O
DENV2	O
),	O
Influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
,	O
MERS	O
coronavirus	O
,	O
Poliovirus	O
1	O
(	O
PV	O
1	O
),	O
Rift	O
Valley	O
fever	B-PROC
(	O
RVF	O
),	O
Tacaribe	O
virus	O
(	O
TCRV	O
),	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEE	O
)	O
and	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
using	O
the	O
National	O
Institute	O
of	O
Allergy	B-PROC
and	O
Infectious	O
Diseases	O
(	O
NIAID	O
)'	O
s	O
Division	O
of	O
Microbiology	O
and	O
Infectious	O
Diseases	O
(	O
DMID	O
)	O
antiviral	O
screening	O
program	O
.	O

Additionally	O
,	O
a	O
cyclopropylquinoline	O
derivative	O
IV	O
has	O
been	O
screened	O
for	O
60	O
human	O
cancer	O
cell	O
lines	O
using	O
the	O
Development	B-PROC
Therapeutics	O
Program	O
(	O
DTP	O
)	O
of	O
NCI	O
.	O

TITLE	O
:	O
Monkey	O
viral	O
pathology	O
in	O
the	O
Sukhum	O
colony	O
and	O
modeling	O
human	O
viral	B-PROC
infections	I-PROC
.	O

Among	O
6218	O
patients	O
with	O
nonmissing	O
outcome	O
status	O
in	O
the	O
combined	O
cohort	O
,	O
643	O
(	O
10	O
%)	O
died	B-PROC
.	O

When	O
assessed	O
among	O
hospitalized	O
adults	O
with	O
suspected	O
infection	O
in	O
9	O
LMIC	O
cohorts	O
,	O
the	O
qSOFA	O
score	O
identified	O
infected	O
patients	O
at	O
risk	O
of	O
death	B-PROC
beyond	O
that	O
explained	O
by	O
baseline	O
factors	O
.	O

p53	O
protein	O
exists	O
in	O
a	O
wide	O
variety	O
of	O
animal	O
cells	O
,	O
which	O
is	O
involved	O
in	O
cell	B-PROC
cycle	I-PROC
regulation	I-PROC
,	O
apoptosis	B-PROC
,	O
cell	B-PROC
differentiation	I-PROC
and	O
other	O
biological	O
functions	O
.	O

Neutralizing	O
antibodies	O
targeting	B-PROC
the	O
spike	O
of	O
MERS	O
-	O
CoV	O
have	O
been	O
shown	O
to	O
be	O
a	O
therapeutic	O
option	O
for	O
treatment	O
of	O
lethal	O
disease	O
.	O

For	O
guidelines	O
,	O
the	O
methods	O
for	O
development	B-PROC
were	O
incompletely	O
reported	O
;	O
WHO	O
'	O
s	O
quality	O
assurance	O
process	O
was	O
rarely	O
used	O
;	O
systematic	O
or	O
other	O
evidence	O
reviews	O
were	O
infrequently	O
referenced	O
;	O
external	O
peer	O
review	O
was	O
not	O
performed	O
;	O
and	O
they	O
scored	O
poorly	O
with	O
AGREE	O
II	O
,	O
particularly	O
for	O
rigour	O
of	O
development	B-PROC
and	O
editorial	O
independence	O
.	O

A	O
45	O
-	O
year	O
-	O
old	O
female	O
with	O
a	O
clear	O
medical	O
history	O
presented	O
with	O
fever	B-PROC
,	O
cough	O
,	O
and	O
headache	O
.	O

Participants	O
expressed	B-PROC
that	O
they	O
need	O
to	O
be	O
supported	O
while	O
caring	O
for	O
suspected	O
or	O
infected	O
patients	O
.	O

These	O
findings	O
extend	O
the	O
known	O
range	O
of	O
MERS	O
-	O
CoV	O
circulation	B-PROC
in	O
Middle	O
Eastern	O
camels	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
decade	O
,	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
vvECMO	O
)	O
has	O
been	O
increasingly	O
utilized	O
in	O
respiratory	O
failure	O
in	O
patients	O
.	O

The	O
inhibitory	O
effect	O
on	O
virus	O
spread	O
is	O
due	O
to	O
an	O
inhibition	B-PROC
of	O
the	O
DEAD	B-PROC
-	O
box	O
RNA	O
helicase	O
eIF4A	O
,	O
which	O
is	O
required	O
to	O
unwind	O
structured	O
5	O
'-	O
untranslated	O
regions	O
(	O
UTRs	O
).	O

Interestingly	O
,	O
in	O
parallel	O
silvestrol	O
affects	O
the	O
activity	O
of	O
the	O
antiviral	O
major	O
vault	O
protein	O
(	O
MVP	O
)	O
by	O
translocation	B-PROC
from	O
the	O
cytoplasm	O
to	O
the	O
perinuclear	O
membrane	O
.	O

We	O
present	O
here	O
the	O
case	O
of	O
a	O
five	O
-	O
year	O
-	O
old	O
girl	O
,	O
known	O
to	O
have	O
thoracolumbar	O
myelomeningocele	O
(	O
for	O
which	O
she	O
underwent	O
a	O
surgical	O
procedure	O
in	O
infancy	O
),	O
secondary	O
hydrocephalus	O
(	O
with	O
a	O
ventriculoperitoneal	O
shunt	O
)	O
and	O
flaccid	O
paralysis	O
,	O
who	O
was	O
admitted	O
in	O
our	O
hospital	O
with	O
prolonged	O
fever	B-PROC
syndrome	O
,	O
productive	O
cough	O
,	O
severe	O
dyspnea	O
and	O
perioral	O
cyanosis	O
.	O

TITLE	O
:	O
Could	O
Heme	O
Oxygenase	B-PROC
-	O
1	O
Be	O
a	O
New	O
Target	O
for	O
Therapeutic	O
Intervention	O
in	O
Malaria	O
-	O
Associated	O
Acute	O
Lung	O
Injury	O
/	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
?	O

Patients	O
with	O
AKI	O
had	O
significantly	O
lower	O
PaO	B-PROC
AKI	O
is	O
common	O
in	O
children	O
with	O
ARF	O
.	O

Our	O
study	O
shows	O
for	O
the	O
first	O
time	O
that	O
ACGs	O
inhibit	O
acute	O
inflammation	O
and	O
apoptosis	B-PROC
by	O
suppressing	O
activation	O
of	O
TLR4	O
/	O
TRPC6	O
signaling	B-PROC
pathway	I-PROC
in	O
a	O
murine	O
model	O
of	O
ALI	O
.	O

Meanwhile	O
,	O
recombinant	O
protein	B-PROC
expression	B-PROC
was	O
induced	O
by	O
isopropy1	O
-	O
β	O
-	O
galactopyranoside	O
(	O
IPTG	O
).	O

After	O
denaturation	B-PROC
and	O
renaturation	O
of	O
inclusion	O
bodies	O
,	O
the	O
S1	O
protein	O
was	O
obtained	O
by	O
using	O
purified	O
recombinant	O
S1	O
protein	O
in	O
immunized	O
female	O
BALB	O
/	O
c	O
mice	O
.	O

The	O
development	B-PROC
of	O
a	O
detection	O
method	O
for	O
this	O
virus	O
that	O
can	O
lead	O
to	O
rapid	O
and	O
accurate	O
diagnosis	O
would	O
be	O
significant	O
.	O

She	O
died	B-PROC
4	O
weeks	O
after	O
admission	O
due	O
to	O
hospital	O
-	O
acquired	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
probably	O
due	O
to	O
the	O
high	O
dose	O
of	O
steroids	O
.	O

Previous	O
literature	O
suggests	O
that	O
the	O
TGEV	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
plays	O
a	O
significant	O
role	O
in	O
viral	O
transcriptional	B-PROC
process	O
,	O
however	O
,	O
there	O
is	O
a	O
need	O
to	O
examine	O
other	O
functions	O
of	O
TGEV	O
N	O
protein	O
in	O
the	O
porcine	O
intestinal	O
epithelial	O
cell	O
(	O
IEC	O
)	O
which	O
is	O
the	O
target	O
cell	O
of	O
TGEV	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
degradation	O
,	O
subcellular	O
localisation	B-PROC
,	O
and	O
function	O
of	O
TGEV	O
N	O
protein	O
by	O
examining	O
its	O
effects	O
on	O
cycle	O
progression	O
,	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
,	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
expression	B-PROC
,	O
and	O
cell	B-PROC
survival	I-PROC
.	O

TITLE	O
:	O
Detection	O
of	O
Respiratory	O
Viruses	O
in	O
Deceased	B-PROC
Persons	O
,	O
Spain	O
,	O
2017	O
.	O

ABSTRACT	O
:	O
During	O
the	O
2016	O
-	O
17	O
influenza	O
season	O
in	O
Spain	O
,	O
we	O
tested	O
specimens	O
from	O
57	O
elderly	O
deceased	B-PROC
persons	O
for	O
respiratory	O
viruses	O
.	O

Only	O
7	O
%	O
of	O
participants	O
had	O
received	O
a	O
diagnosis	O
of	O
infection	O
with	O
the	O
detected	O
virus	O
before	O
death	B-PROC
.	O

Although	O
FHS	O
-	O
1	O
cells	O
lost	O
the	O
expression	B-PROC
of	O
MHC	B-PROC
class	O
II	O
and	O
CD163	O
,	O
our	O
findings	O
indicate	O
that	O
FHS	O
-	O
1	O
is	O
a	O
feline	O
HS	O
cell	O
line	O
that	O
retains	O
functional	O
properties	O
of	O
dendritic	O
cells	O
/	O
macrophages	O
in	O
terms	O
of	O
phagocytic	O
and	O
antigen	O
uptake	O
/	O
processing	O
activities	O
.	O

A	O
panzootic	O
starting	O
in	O
2010	O
renewed	O
interest	O
in	O
the	O
development	B-PROC
of	O
a	O
universal	O
vaccine	O
toward	O
PEDV	O
.	O

Genetically	O
modified	O
new	O
vaccine	O
candidates	O
were	O
able	O
to	O
elicit	O
a	O
strong	O
antibody	B-PROC
(	O
Ab	O
)	O
response	O
to	O
the	O
YSNIGVCK	O
epitope	O
,	O
which	O
correlated	O
with	O
an	O
increased	O
ability	O
to	O
neutralize	O
the	O
CO	O
strain	O
of	O
PEDV	O
.	O

TITLE	O
:	O
Epidemiology	O
,	O
drug	B-PROC
resistance	B-PROC
,	O
and	O
pathophysiology	O
of	O
ABSTRACT	O
:	O
Malaria	O
,	O
caused	O
by	O
the	O
protozoan	O
parasites	O
of	O
the	O
genus	O
Plasmodium	O
,	O
is	O
a	O
major	O
health	O
problem	O
in	O
many	O
countries	O
of	O
the	O
world	O
.	O

Despite	O
exhibiting	O
low	O
parasite	O
biomass	O
in	O
infected	O
people	O
due	O
to	O
parasite	O
'	O
s	O
specificity	O
to	O
infect	O
only	O
reticulocytes	O
,	O
P	O
.	O
vivax	O
infection	O
triggers	O
higher	O
inflammatory	B-PROC
responses	I-PROC
and	O
exacerbated	O
clinical	O
symptoms	O
than	O
P	O
.	O
falciparum	O
,	O
such	O
as	O
fever	B-PROC
and	O
chills	O
.	O

TITLE	O
:	O
Selective	O
Management	O
of	O
Multiple	O
Bronchopleural	O
Fistulae	O
in	O
a	O
Pediatric	O
Patient	O
on	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
:	O
A	O
Multidisciplinary	O
Approach	O
.	O

The	O
development	B-PROC
of	O
multiple	O
BPFs	O
precluded	O
lung	O
recruitment	O
necessary	O
to	O
wean	B-PROC
from	O
ECMO	O
.	O

The	O
success	O
of	O
this	O
intervention	O
enabled	O
positive	O
pressure	O
ventilator	O
support	O
and	O
rehabilitation	O
required	O
for	O
weaning	B-PROC
from	O
ECMO	O
support	O
.	O

ABSTRACT	O
:	O
GBF1	O
has	O
emerged	O
as	O
a	O
host	O
factor	O
required	O
for	O
the	O
replication	O
of	O
positive	O
-	O
sense	B-PROC
single	O
-	O
stranded	O
RNA	O
viruses	O
of	O
different	O
families	O
,	O
but	O
its	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
is	O
still	O
unknown	O
.	O

However	O
,	O
using	O
siRNA	O
or	O
CRISPR	O
-	O
Cas9	O
technologies	O
,	O
it	O
was	O
seen	O
that	O
the	O
depletion	O
of	O
Arf1	O
,	O
Arf3	O
,	O
Arf4	O
or	O
Arf5	O
had	O
no	O
impact	O
on	O
viral	B-PROC
replication	I-PROC
.	O

However	O
,	O
the	O
characteristics	O
of	O
immune	O
memory	B-PROC
in	O
patients	O
who	O
have	O
recovered	O
from	O
H7N9	O
infection	O
are	O
not	O
well	O
understood	O
.	O

H7N9	O
-	O
specific	O
antibody	B-PROC
concentrations	O
declined	O
over	O
time	O
,	O
and	O
protective	O
antibodies	O
persisted	O
longer	O
in	O
severely	O
ill	O
patients	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
patients	O
presenting	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
than	O
in	O
patients	O
with	O
mild	O
disease	O
.	O

We	O
emphasize	O
that	O
recurrent	O
febrile	B-PROC
episodes	O
,	O
prolonged	O
neutropenia	O
,	O
and	O
underlying	O
gastrointestinal	O
mucosal	O
damage	O
require	O
extreme	O
caution	O
due	O
to	O
the	O
possibility	O
of	O
breakthrough	O
infection	O
caused	O
by	O
new	O
fungal	O
pathogens	O
during	O
empirical	O
therapy	O
with	O
caspofungin	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
endothelial	O
cells	O
'	O
(	O
ECs	O
)	O
injury	O
and	O
apoptotic	O
death	B-PROC
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
pathogenesis	B-PROC
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
regardless	O
of	O
epithelial	O
damage	O
.	O

Treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
),	O
an	O
inhibitor	O
of	O
mitochondrial	B-PROC
permeability	I-PROC
transition	I-PROC
pore	O
(	O
MPTP	O
)	O
opening	O
,	O
significantly	O
suppressed	O
PDCoV	O
-	O
triggered	O
apoptosis	B-PROC
and	O
viral	B-PROC
replication	I-PROC
.	O

However	O
,	O
in	O
the	O
case	O
of	O
super	O
-	O
infection	O
,	O
the	O
second	O
virus	O
,	O
either	O
AIV	O
or	O
IBV	O
,	O
induced	O
a	O
decrease	O
in	O
the	O
growth	B-PROC
of	O
the	O
first	O
inoculated	O
virus	O
.	O

RESULTS	O
:	O
Quantitative	O
results	O
of	O
AIV	O
and	O
IBV	O
co	O
-	O
infection	O
showed	O
that	O
interferences	O
between	O
the	O
two	O
viruses	O
yielded	O
decreased	O
viral	O
growth	B-PROC
.	O

However	O
,	O
in	O
the	O
case	O
of	O
super	O
-	O
infection	O
,	O
the	O
second	O
virus	O
,	O
either	O
AIV	O
or	O
IBV	O
,	O
induced	O
a	O
decrease	O
in	O
the	O
growth	B-PROC
of	O
the	O
first	O
inoculated	O
virus	O
.	O

ABSTRACT	O
:	O
Binge	O
drinking	B-PROC
and	O
continued	O
alcohol	O
use	O
in	O
large	O
amounts	O
are	O
associated	O
with	O
many	O
health	O
problems	O
but	O
there	O
are	O
very	O
few	O
studies	O
on	O
the	O
effects	O
of	O
alcohol	O
intake	O
on	O
the	O
function	O
of	O
lung	O
,	O
the	O
effects	O
of	O
ethanol	O
on	O
lung	O
diseases	O
,	O
and	O
links	O
between	O
alcohol	O
consumption	O
and	O
lung	O
cancer	O
.	O

Using	O
a	O
murine	O
model	O
of	O
demyelination	O
induced	O
by	O
a	O
gliatropic	O
coronavirus	O
,	O
in	O
which	O
BMDM	O
are	O
redundant	O
for	O
demyelination	O
,	O
we	O
herein	O
characterize	O
gene	B-PROC
expression	I-PROC
profiles	O
of	O
BMDM	O
versus	O
microglia	O
associated	O
with	O
demyelination	O
.	O

However	O
,	O
data	O
are	O
scarce	O
on	O
the	O
differences	O
in	O
tonsillar	O
virus	O
infections	O
and	O
immune	B-PROC
responses	I-PROC
between	O
patients	O
with	O
tonsillar	O
hypertrophy	O
or	O
recurrent	O
tonsillitis	O
.	O

TITLE	O
:	O
Interleukin	O
1	O
receptor	O
antagonist	B-PROC
(	O
IL1RA	O
)	O
gene	B-PROC
polymorphism	I-PROC
and	O
levels	O
associated	O
with	O
adverse	O
outcome	O
in	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
in	O
children	O
:	O
A	O
hospital	O
-	O
based	O
study	O
in	O
India	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
analyze	O
the	O
Variable	O
Number	O
of	O
Tandem	O
Repeats	O
(	O
VNTRs	O
)	O
of	O
IL1RA	O
gene	B-PROC
polymorphism	I-PROC
and	O
ELISA	O
test	O
to	O
detect	O
serum	O
levels	O
of	O
IL1RA	O
.	O

In	O
conclusion	O
,	O
dietary	O
yeast	O
nucleotides	O
supplementation	O
can	O
help	O
birds	O
to	O
mount	O
a	O
faster	O
and	O
stronger	O
antibody	B-PROC
response	I-PROC
to	O
IBV	O
vaccine	O
.	O

Recent	O
data	O
indicate	O
that	O
dromedaries	O
represent	O
an	O
important	O
source	O
of	O
infection	O
,	O
although	O
information	O
regarding	O
viral	O
cell	O
tropism	B-PROC
and	O
pathogenesis	B-PROC
is	O
sparse	O
.	O

The	O
results	O
showed	O
that	O
the	O
IBV	O
-	O
specific	O
antibody	B-PROC
levels	O
and	O
the	O
percentages	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
were	O
higher	O
in	O
the	O
rHBM	O
-	O
S1	O
-	O
N	O
vaccinated	O
birds	O
compared	O
to	O
birds	O
vaccinated	O
with	O
the	O
rHBM	O
-	O
S1	O
and	O
rHBM	O
-	O
N	O
vaccines	O
.	O

Thus	O
,	O
the	O
recombinant	O
baculovirus	O
co	O
-	O
expressing	O
S1	O
and	O
N	O
proteins	O
could	O
serve	O
as	O
a	O
potential	O
IBV	O
vaccine	O
and	O
this	O
demonstrates	O
that	O
the	O
bivalent	O
subunit	O
vaccine	O
including	O
the	O
S1	O
and	O
N	O
proteins	O
might	O
be	O
a	O
strategy	O
for	O
the	O
development	B-PROC
of	O
an	O
IBV	O
subunit	O
vaccine	O
.	O

Babesiosis	O
'	O
prevalence	O
and	O
presentation	O
have	O
earned	O
it	O
the	O
monikers	O
""""	O
malaria	O
of	O
the	O
northeast	O
""""	O
and	O
""""	O
Nantucket	O
fever	B-PROC
"""."	O

The	O
modality	O
of	O
treatment	O
depends	O
on	O
patient	O
'	O
s	O
clinical	O
course	O
and	O
hemodynamic	B-PROC
stability	O
,	O
although	O
spleen	O
conserving	O
strategy	O
should	O
be	O
considered	O
first	O
whenever	O
possible	O
.	O

In	O
patients	O
requiring	O
mechanical	O
ventilation	O
after	O
severe	O
trauma	O
,	O
lung	O
microbiome	O
enrichment	O
with	O
gut	O
-	O
associated	O
microbes	O
was	O
found	O
to	O
correlate	O
with	O
the	O
development	B-PROC
of	O
ARDS	O
.	O

All	O
the	O
compounds	O
showed	O
no	O
inhibition	B-PROC
of	O
cytochrome	B-PROC
P450	I-PROC
enzymes	O
,	O
no	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
permeability	O
and	O
no	O
toxic	O
structure	O
in	O
medicinal	O
chemistry	O
profile	O
.	O

All	O
the	O
compounds	O
are	O
not	O
a	O
substrate	O
of	O
P	B-PROC
-	I-PROC
glycoprotein	I-PROC
.	O

For	O
endocan	O
blood	O
values	O
>	O
5	O
.	O
36	O
ng	O
/	O
mL	O
,	O
the	O
adjusted	O
OR	O
for	O
development	B-PROC
of	O
ARDS	O
at	O
72	O
h	O
was	O
of	O
0	O
.	O
001	O
(	O
95	O
%	O
CI	O
0	O
-	O
0	O
.	O
215	O
;	O
p	O
=	O
0	O
.	O
011	O
).	O

CONCLUSIONS	O
:	O
The	O
development	B-PROC
of	O
posttraumatic	O
ARDS	O
is	O
associated	O
with	O
higher	O
health	O
care	O
costs	O
.	O

For	O
validation	O
,	O
we	O
tested	O
a	O
MERS	O
-	O
CoV	O
strain	O
(	O
hCoVEMC	O
),	O
clinical	O
specimens	O
from	O
patients	O
with	O
fever	B-PROC
in	O
Shanghai	O
,	O
and	O
specimens	O
from	O
the	O
first	O
imported	O
MERS	O
case	O
in	O
China	O
.	O

Examination	O
revealed	O
diminished	O
bilateral	O
vesicular	O
breath	O
sounds	O
,	O
fever	B-PROC
,	O
intense	O
yellow	O
tracheal	O
secretions	O
,	O
a	O
respiratory	O
rate	O
of	O
24	O
/	O
minute	O
,	O
a	O
heart	O
rate	O
of	O
123	O
/	O
minute	O
,	O
and	O
blood	B-PROC
pressure	I-PROC
of	O
75	O
/	O
55	O
mmHg	O
.	O

A	O
subsequent	O
improvement	O
in	O
the	O
respiratory	O
parameters	O
and	O
vital	O
functions	O
resulted	O
in	O
weaning	B-PROC
from	O
ventilator	O
8	O
days	O
after	O
the	O
onset	O
of	O
the	O
ARDS	O
and	O
transfer	O
to	O
the	O
surgery	O
ward	O
14	O
days	O
after	O
pneumonectomy	O
.	O

TITLE	O
:	O
Better	O
horizontal	O
transmission	O
of	O
a	O
US	O
non	O
-	O
InDel	B-PROC
strain	O
compared	O
with	O
a	O
French	O
InDel	B-PROC
strain	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
.	O

ABSTRACT	O
:	O
From	O
the	O
severe	O
porcine	O
epidemic	O
diarrhoea	O
(	O
PED	O
)	O
epidemics	O
that	O
struck	O
in	O
2013	O
in	O
the	O
United	O
States	O
of	O
America	O
and	O
other	O
countries	O
of	O
North	O
and	O
South	O
America	O
,	O
two	O
types	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
were	O
isolated	O
,	O
namely	O
the	O
InDel	B-PROC
and	O
the	O
non	O
-	O
InDel	B-PROC
strains	O
.	O

Although	O
viral	O
RNA	O
was	O
detected	O
in	O
air	O
samples	O
with	O
both	O
strains	O
,	O
the	O
indirect	O
contact	O
pigs	O
remained	O
free	O
from	O
infection	O
with	O
the	O
InDel	B-PROC
strain	O
in	O
contrast	O
to	O
the	O
non	O
-	O
InDel	B-PROC
group	O
in	O
which	O
airborne	O
transmission	O
occurred	O
in	O
the	O
indirect	O
contact	O
pigs	O
.	O

The	O
results	O
show	O
that	O
the	O
virus	O
hijacks	O
caveolin	B-PROC
-	I-PROC
dependent	I-PROC
endocytosis	I-PROC
to	O
enter	O
cells	O
via	O
endocytic	O
internalization	O
.	O

On	O
day	O
28	O
,	O
serum	O
immunoglobulin	B-PROC
(	O
Ig	O
)	O
A	O
and	O
IgG	O
were	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
6	O
%	O
FVW	O
group	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
fed	O
groups	O
.	O

Serum	O
cytokine	O
interleukin	O
(	O
IL	O
)-	O
2	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
both	O
the	O
4	O
%	O
and	O
6	O
%	O
FVW	O
grousp	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
;	O
IL	O
-	O
4	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
FVW	O
groups	O
than	O
in	O
the	O
control	O
group	O
;	O
and	O
IL	O
-	O
6	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
6	O
%	O
FVW	O
group	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
.	O

CONCLUSIONS	O
:	O
FVW	O
at	O
the	O
6	O
%	O
level	O
can	O
be	O
used	O
as	O
a	O
potential	O
phytogenic	O
feed	O
stuff	O
in	O
growing	O
layer	O
hen	O
rations	O
with	O
respect	O
to	O
improving	O
the	O
immune	B-PROC
response	I-PROC
without	O
affecting	O
normal	O
weight	O
gain	O
.	O

ABSTRACT	O
:	O
Sepsis	O
is	O
one	O
of	O
the	O
ten	O
leading	O
causes	O
of	O
death	B-PROC
in	O
developed	O
and	O
developing	O
countries	O
.	O

The	O
fundamental	O
role	O
of	O
nuclear	O
signalling	B-PROC
in	O
the	O
progres	O
-	O
sion	O
and	O
resolution	O
of	O
sepsis	O
was	O
established	O
with	O
a	O
new	O
class	O
of	O
cell	O
-	O
penetrating	O
nuclear	B-PROC
transport	B-PROC
modifiers	O
(	O
NTMs	O
).	O

NTMs	O
target	O
the	O
translocation	B-PROC
of	O
proinflammatory	O
and	O
metabolic	B-PROC
transcription	B-PROC
factors	O
to	O
the	O
cell	O
'	O
s	O
nucleus	O
while	O
also	O
enhancing	O
bacterial	O
clearance	O
in	O
experimental	O
polymicrobial	O
sepsis	O
models	O
.	O

Previously	O
,	O
groups	O
had	O
targeted	B-PROC
conserved	O
coronavirus	O
proteins	O
as	O
a	O
strategy	O
to	O
generate	O
live	O
attenuated	O
vaccine	O
strains	O
against	O
current	O
and	O
future	O
CoVs	O
.	O

Finally	O
,	O
we	O
show	O
that	O
HA	O
activation	O
by	O
the	O
TMPRSS11A	O
-	O
related	O
enzymes	O
human	O
airway	O
tryptase	O
and	O
DESC1	O
,	O
but	O
not	O
TMPRSS11A	O
itself	O
,	O
is	O
blocked	O
by	O
the	O
cellular	O
serine	O
protease	O
inhibitor	O
hepatocyte	B-PROC
growth	B-PROC
factor	I-PROC
activator	O
inhibitor	O
type	O
-	O
1	O
(	O
HAI	O
-	O
1	O
).	O

TITLE	O
:	O
The	O
US	O
Military	O
Commitment	O
to	O
Vaccine	O
Development	B-PROC
:	O
A	O
Century	O
of	O
Successes	O
and	O
Challenges	O
.	O

Although	O
preventive	O
measures	O
and	O
the	O
development	B-PROC
of	O
drugs	O
have	O
provided	O
some	O
relief	O
from	O
the	O
burden	O
of	O
malaria	O
,	O
dengue	O
,	O
and	O
HIV	O
,	O
the	O
US	O
military	O
continues	O
to	O
fund	O
research	O
and	O
development	B-PROC
of	O
prophylactic	O
vaccines	O
that	O
will	O
contribute	O
to	O
force	O
health	O
protection	O
and	O
global	O
health	O
.	O

TITLE	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
mitigates	O
need	O
for	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
a	O
patient	O
with	O
refractory	O
acute	O
hypoxemic	O
respiratory	O
failure	O
due	O
to	O
cardiac	O
and	O
pulmonary	O
shunts	O
.	O

In	O
South	O
Korea	O
,	O
the	O
incidence	O
of	O
PEDV	O
has	O
continued	O
despite	O
nationwide	O
use	O
of	O
attenuated	O
and	O
inactivated	O
vaccines	O
,	O
raising	O
questions	O
regarding	O
the	O
current	O
vaccines	O
'	O
efficacy	O
and	O
the	O
need	O
for	O
new	O
vaccine	O
development	B-PROC
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
(	O
PEDV	O
)	O
has	O
raised	O
growing	O
concerns	O
in	O
the	O
pig	O
-	O
breeding	B-PROC
industry	O
because	O
it	O
has	O
caused	O
significant	O
economic	O
losses	O
.	O

We	O
conclude	O
that	O
the	O
recombinant	O
baculovirus	O
expressed	B-PROC
IBV	O
N	O
protein	O
could	O
serve	O
as	O
a	O
useful	O
diagnostic	O
antigen	O
for	O
detection	O
of	O
IBV	O
infections	O
in	O
chickens	O
by	O
ELISA	O
.	O

Methods	O
for	O
growth	B-PROC
and	O
preparation	O
of	O
Streptococcus	O
pneumoniae	O
are	O
provided	O
as	O
methods	O
to	O
assess	O
lung	O
inflammation	O
and	O
injury	O
.	O

This	O
syndrome	O
is	O
a	O
clinical	O
diagnosis	O
based	O
on	O
the	O
recurrent	O
occurrence	O
of	O
tachycardia	O
,	O
hypertension	O
,	O
diaphoresis	O
,	O
tachypnea	O
,	O
and	O
occasionally	O
high	O
fever	B-PROC
and	O
dystonic	O
postures	O
.	O

The	O
maximum	O
sequential	O
organ	O
failure	O
assessment	O
score	O
and	O
highest	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
were	O
lower	O
in	O
2016	O
than	O
in	O
2009	O
(	O
Respiratory	O
management	O
for	O
influenza	O
-	O
associated	O
acute	O
respiratory	O
failure	O
using	O
ECMO	O
was	O
significantly	O
changed	O
in	O
2016	O
compared	O
with	O
2009	O
in	O
Japan	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
Qingfeihuayutongfu	O
prescription	O
on	O
oxygenation	B-PROC
and	O
pulmonary	O
fibrosis	O
in	O
patients	O
with	O
sepsis	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

As	O
time	O
went	O
on	O
,	O
PaO	B-PROC

Our	O
study	O
aimed	O
to	O
examine	O
associations	O
between	O
hand	O
-	O
washing	O
education	O
and	O
self	O
-	O
reported	O
hand	O
-	O
washing	O
behaviors	B-PROC
among	O
Korean	O
adults	O
during	O
the	O
year	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
outbreak	O
.	O

However	O
,	O
the	O
role	O
of	O
HO	O
-	O
1	O
activation	O
in	O
the	O
development	B-PROC
of	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
during	O
sepsis	O
remains	O
unknown	O
.	O

TITLE	O
:	O
Cyclophilins	O
and	O
cyclophilin	B-PROC
inhibitors	O
in	O
nidovirus	O
replication	O
.	O

TITLE	O
:	O
StatPearls	O
ABSTRACT	O
:	O
Hypersensitivity	B-PROC
reactions	I-PROC
(	O
HR	O
)	O
are	O
immune	B-PROC
responses	I-PROC
that	O
are	O
exaggerated	O
or	O
inappropriate	O
against	O
an	O
antigen	O
or	O
allergen	O
.	O

In	O
addition	O
,	O
dec	O
-	O
RVKR	O
-	O
CMK	O
inhibited	O
not	O
only	O
the	O
enzymatic	B-PROC
activity	I-PROC
of	O
furin	O
but	O
also	O
those	O
of	O
cathepsin	O
L	O
,	O
cathepsin	O
B	O
,	O
trypsin	O
,	O
papain	O
,	O
and	O
TMPRSS2	O
.	O

TITLE	O
:	O
Immune	B-PROC
responses	I-PROC
induced	O
by	O
recombinant	O
Lactobacillus	O
plantarum	O
expressing	O
the	O
spike	O
protein	O
derived	O
from	O
transmissible	O
gastroenteritis	O
virus	O
in	O
piglets	O
.	O

Cyclophosphamide	O
pulse	B-PROC
therapy	O
was	O
initiated	O
with	O
subsequent	O
clinical	O
and	O
radiological	O
improvement	O
,	O
allowing	O
the	O
patient	O
to	O
be	O
discharged	O
.	O

Surprisingly	O
,	O
combination	O
therapy	O
did	O
not	O
reduce	O
the	O
production	O
of	O
cytokines	O
and	O
chemokines	O
in	O
the	O
lungs	O
,	O
demonstrating	O
that	O
inflammatory	O
cells	O
,	O
rather	O
than	O
hypercytokinemia	O
,	O
are	O
the	O
direct	O
target	O
of	O
these	O
compounds	O
and	O
primary	O
cause	O
of	O
ARDS	O
-	O
related	O
death	B-PROC
.	O

TITLE	O
:	O
To	O
accelerate	O
the	O
Zika	O
beat	O
:	O
Candidate	O
design	O
for	O
RNA	B-PROC
interference	I-PROC
-	O
based	O
therapy	O
.	O

Perhaps	O
more	O
importantly	O
,	O
acidified	O
autophagosomes	O
(	O
known	O
as	O
amphisomes	O
)	O
provide	O
havens	O
for	O
maturation	B-PROC
of	O
new	O
viral	O
particles	O
into	O
infectious	O
viruses	O
.	O

Persistent	O
high	O
fever	B-PROC
was	O
resistant	O
to	O
intravenous	O
immunoglobulin	B-PROC
and	O
pulse	B-PROC
steroid	O
therapy	O
.	O

In	O
conclusion	O
;	O
leptospirosis	O
may	O
cause	O
thrombocytopenia	O
-	O
associated	O
multiple	O
organ	O
failure	O
,	O
persistent	O
high	O
fever	B-PROC
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Aim	O
of	O
our	O
study	O
was	O
assessment	O
of	O
developmental	O
outcome	O
of	O
neonates	O
with	O
respiratory	O
distress	O
syndrome	O
,	O
evaluation	O
of	O
the	O
impact	O
of	O
RDS	O
on	O
child	O
'	O
s	O
health	O
,	O
growth	B-PROC
and	O
neurodevelopment	B-PROC
at	O
2	O
years	O
of	O
age	O
.	O

Both	O
structural	O
and	O
accessory	O
HCoV	O
-	O
OC43	O
proteins	O
are	O
able	O
to	O
inhibit	O
antiviral	B-PROC
response	I-PROC
elements	O
in	O
HEK	O
-	O
293	O
cells	O
,	O
and	O
to	O
block	O
the	O
activation	O
of	O
different	O
antiviral	O
signaling	B-PROC
pathways	B-PROC
.	O

CONCLUSIONS	O
:	O
Both	O
structural	O
and	O
accessory	O
HCoV	O
-	O
OC43	O
proteins	O
are	O
able	O
to	O
inhibit	O
antiviral	B-PROC
response	I-PROC
elements	O
in	O
HEK	O
-	O
293	O
cells	O
,	O
and	O
to	O
block	O
the	O
activation	O
of	O
different	O
antiviral	O
signaling	B-PROC
pathways	B-PROC
.	O

Cardiac	O
glycosides	O
not	O
only	O
inhibit	O
the	O
pump	O
function	O
of	O
Na	O
,	O
K	O
-	O
ATPase	O
but	O
also	O
activate	O
intracellular	B-PROC
signal	B-PROC
transduction	I-PROC
pathways	I-PROC
,	O
which	O
are	O
important	O
in	O
many	O
biological	B-PROC
processes	I-PROC
.	O

Limiting	O
disease	O
may	O
require	O
the	O
development	B-PROC
of	O
virus	O
-	O
directed	O
and	O
host	O
-	O
directed	O
therapeutic	O
strategies	O
due	O
to	O
the	O
acute	O
etiology	O
of	O
hCoV	O
infections	O
.	O

ABSTRACT	O
:	O
Viral	O
infectious	O
diseases	O
are	O
a	O
global	O
health	O
concern	O
,	O
as	O
is	O
evident	O
by	O
recent	O
outbreaks	O
of	O
the	O
middle	O
east	O
respiratory	O
syndrome	O
,	O
Ebola	O
virus	B-PROC
disease	I-PROC
,	O
and	O
re	O
-	O
emerging	O
zika	O
,	O
dengue	O
,	O
and	O
chikungunya	O
fevers	B-PROC
.	O

An	O
84	O
-	O
year	O
-	O
old	O
man	O
underwent	O
reperfusion	O
therapy	O
for	O
acute	O
left	O
internal	O
carotid	O
artery	O
occlusion	B-PROC
;	O
complete	O
reperfusion	O
was	O
achieved	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
Lactobacillus	O
plantarum	O
(	O
L	O
.	O
plantarum	O
)	O
to	O
anchor	O
the	O
expression	B-PROC
of	O
TGEV	O
antigen	O
(	O
S	O
)	O
to	O
dendritic	O
cells	O
(	O
DCs	O
)	O
via	O
dendritic	O
cell	O
-	O
targeting	B-PROC
peptides	O
(	O
DCpep	O
).	O

TITLE	O
:	O
Immune	B-PROC
Responses	I-PROC
to	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
During	O
the	O
Acute	O
and	O
Convalescent	O
Phases	O
of	O
Human	O
Infection	O
.	O

Probability	O
of	O
introduction	O
through	O
animal	O
purchase	O
was	O
calculated	O
by	O
using	O
real	O
animal	O
movement	B-PROC
data	O
and	O
herd	O
prevalence	O
in	O
the	O
region	O
of	O
the	O
source	O
herd	O
.	O

TITLE	O
:	O
Design	O
,	O
Synthesis	B-PROC
,	O
and	O
SAR	O
of	O
C	O
-	O
3	O
Benzoic	O
Acid	O
,	O
C	O
-	O
17	O
Triterpenoid	O
Derivatives	O
.	O

Identification	O
of	O
the	O
HIV	O
-	O
1	O
Maturation	B-PROC
Inhibitor	O
4	O
-((	O
1	O
R	O
,	O
3a	O
S	O
,	O
5a	O
R	O
,	O
5b	O
R	O
,	O
7a	O
R	O
,	O
11a	O
S	O
,	O
11b	O
R	O
,	O
13a	O
R	O
,	O
13b	O
R	O
)-	O
3a	O
-((	O
2	O
-(	O
1	O
,	O
1	O
-	O
Dioxidothiomorpholino	O
)	O
ethyl	O
)	O
amino	O
)-	O
5a	O
,	O
5b	O
,	O
8	O
,	O
8	O
,	O
11a	O
-	O
pentamethyl	O
-	O
1	O
-(	O
prop	O
-	O
1	O
-	O
en	O
-	O
2	O
-	O
yl	O
)-	O
2	O
,	O
3	O
,	O
3a	O
,	O
4	O
,	O
5	O
,	O
5a	O
,	O
5b	O
,	O
6	O
,	O
7	O
,	O
7a	O
,	O
8	O
,	O
11	O
,	O
11a	O
,	O
11b	O
,	O
12	O
,	O
13	O
,	O
13a	O
,	O
13b	O
-	O
octadecahydro	O
-	O
1	O
H	O
-	O
cyclopenta	O
[	O
a	O
]	O
chrysen	O
-	O
9	O
-	O
yl	O
)	O
benzoic	O
Acid	O
(	O
GSK3532795	O
,	O
BMS	O
-	O
955176	O
).	O

The	O
impact	O
of	O
SG	O
formation	B-PROC
on	O
virus	B-PROC
replication	I-PROC
varies	O
among	O
different	O
viruses	O
,	O
and	O
the	O
significance	O
of	O
SGs	O
in	O
coronavirus	O
(	O
CoV	O
)	O
replication	O
is	O
largely	O
unknown	O
.	O

The	O
MERS	O
-	O
CoV	O
4a	O
accessory	O
protein	O
is	O
known	O
to	O
inhibit	O
SG	O
formation	B-PROC
in	O
cells	O
in	O
which	O
it	O
was	O
expressed	B-PROC
by	O
binding	O
to	O
double	O
-	O
stranded	O
RNAs	O
and	O
inhibiting	O
protein	O
kinase	O
R	O
(	O
PKR	O
)-	O
mediated	O
phosphorylation	B-PROC
of	O
the	O
α	O
subunit	O
of	O
eukaryotic	O
initiation	O
factor	O
2	O
(	O
eIF2α	O
).	O

Rather	O
,	O
it	O
was	O
due	O
to	O
the	O
inefficient	O
translation	B-PROC
of	O
viral	O
proteins	O
,	O
which	O
was	O
caused	O
by	O
high	O
levels	O
of	O
PKR	O
-	O
mediated	O
eIF2α	O
phosphorylation	B-PROC
and	O
likely	O
by	O
the	O
confinement	O
of	O
various	O
factors	O
that	O
are	O
required	O
for	O
translation	B-PROC
in	O
the	O
SGs	O
.	O

The	O
full	O
-	O
length	O
genome	O
of	O
the	O
G2b	O
Taiwan	O
PEDV	O
-	O
Pintung	O
52	O
(	O
PEDV	O
-	O
PT	O
)	O
strain	O
and	O
its	O
intestinal	O
tropism	B-PROC
by	O
evaluating	O
the	O
pathological	O
changes	O
in	O
the	O
original	O
PEDV	O
-	O
PT	O
infected	O
field	O
piglet	O
and	O
orally	O
inoculation	O
of	O
either	O
10	O
,	O
10	O

Most	O
of	O
the	O
outbreaks	O
were	O
in	O
farrow	O
-	O
to	O
-	O
finish	O
,	O
farrow	O
-	O
to	O
-	O
wean	B-PROC
and	O
finisher	O
farms	O
.	O

Our	O
results	O
suggest	O
that	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
can	O
provide	O
a	O
safe	O
and	O
effective	O
alternative	O
to	O
lung	O
-	O
protective	O
mechanical	O
ventilation	O
in	O
carefully	O
selected	O
patients	O
.	O

Docking	B-PROC
studies	O
of	O
these	O
molecules	O
revealed	O
their	O
high	O
affinity	O
binding	O
to	O
several	O
amino	O
acids	O
of	O
HIV	O
-	O
1	O
RT	O
which	O
are	O
less	O
sensitive	O
to	O
point	B-PROC
mutations	I-PROC
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
Biological	O
Evaluation	O
of	O
Reniochalistatins	O
A	O
-	O
E	O
and	O
a	O
Reniochalistatin	O
E	O
Analogue	O
.	O

Structural	O
comparisons	O
suggested	O
that	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
retains	O
a	O
prefusion	O
architecture	O
after	O
trypsin	O
cleavage	B-PROC
into	O
the	O
S1	O
and	O
S2	O
subunits	O
and	O
acidic	O
pH	O
treatment	O
.	O

This	O
study	O
reports	O
development	B-PROC
and	O
initial	O
validation	O
of	O
two	O
independent	O
highly	O
sensitive	O
and	O
specific	O
multiplex	O
PCR	O
-	O
electronic	O
microarray	O
assays	O
,	O
one	O
for	O
the	O
detection	O
and	O
differentiation	B-PROC
of	O
pathogens	O
of	O
the	O
BRDC	O
and	O
the	O
other	O
for	O
detection	O
and	O
differentiation	B-PROC
of	O
pathogens	O
of	O
the	O
BED	O
.	O

Importantly	O
,	O
the	O
mortality	O
rate	O
of	O
inoculated	O
-	O
newborn	O
piglets	O
was	O
100	O
%	O
and	O
half	O
of	O
the	O
cohabiting	O
piglets	O
died	B-PROC
.	O

TITLE	O
:	O
Cerebral	O
toxoplasmosis	O
in	O
a	O
cat	O
with	O
feline	O
leukemia	O
and	O
feline	O
infectious	O
peritonitis	O
viral	B-PROC
infections	I-PROC
.	O

The	O
T	O
cell	O
chemoattractant	O
chemokine	O
CXCL10	O
(	O
interferon	O
-	O
inducible	O
protein	O
10	O
kDa	O
,	O
IP	O
-	O
10	O
)	O
is	O
prominently	O
expressed	B-PROC
in	O
both	O
stages	O
of	O
disease	O
,	O
and	O
serves	O
to	O
attract	O
activated	O
T	O
and	O
B	O
lymphocytes	O
expressing	O
CXC	O
chemokine	O
receptor	O
3	O
(	O
CXCR3	O
),	O
the	O
receptor	O
for	O
CXCL10	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
likely	O
originated	O
in	O
bats	O
and	O
passed	O
to	O
humans	O
through	O
dromedary	O
camels	O
;	O
however	O
,	O
the	O
genetic	O
mechanisms	O
underlying	O
cross	O
-	O
species	O
adaptation	B-PROC
remain	O
poorly	O
understood	O
.	O

To	O
better	O
understand	O
the	O
species	O
adaptability	O
of	O
MERS	O
-	O
CoV	O
,	O
we	O
identified	O
a	O
suboptimal	O
species	O
-	O
derived	O
variant	O
of	O
DPP4	O
to	O
study	O
viral	O
adaption	B-PROC
.	O

TITLE	O
:	O
The	O
Endonucleolytic	O
RNA	O
Cleavage	B-PROC
Function	O
of	O
nsp1	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Promotes	O
the	O
Production	O
of	O
Infectious	O
Virus	O
Particles	O
in	O
Specific	O
Human	O
Cell	O
Lines	O
.	O

A	O
Novel	O
Pathway	B-PROC
in	O
Pediatric	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

To	O
test	O
for	O
an	O
association	O
between	O
MMP	O
pathway	B-PROC
proteins	O
and	O
inflammation	O
,	O
endothelial	O
dysfunction	O
,	O
and	O
clinical	O
outcomes	O
.	O

Within	O
PPs	O
,	O
Dendritic	O
cells	O
(	O
DCs	O
)	O
can	O
uptake	O
antigens	O
from	O
the	O
gut	O
lumen	O
by	O
extending	O
dendrites	O
into	O
epithelium	O
,	O
and	O
process	O
it	O
and	O
then	O
present	O
to	O
lymphocytes	O
,	O
which	O
effectively	O
antigen	O
produces	O
an	O
immune	B-PROC
response	I-PROC
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
be	O
a	O
lifesaving	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
proportions	O
of	O
γδ	O
T	O
cells	O
in	O
blood	O
,	O
spleen	O
and	O
liver	O
,	O
and	O
cytokines	O
secreted	B-PROC
by	O
hepatic	O
γδ	O
T	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

The	O
proportions	O
of	O
γδ	O
T	O
cells	O
in	O
blood	O
,	O
spleen	O
and	O
liver	O
were	O
significantly	O
increased	O
post	O
MHV	O
-	O
3	O
infection	O
,	O
while	O
those	O
of	O
the	O
early	O
activating	O
molecule	O
CD69	O
-	O
expressing	O
γδ	O
T	O
cells	O
and	O
productions	O
of	O
cytokines	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
α	O
)	O
and	O
interferon	O
-	O
γ	O
(	O
IFN	O
-	O
γ	O
)	O
increased	O
remarkably	O
in	O
the	O
liver	O
.	O

These	O
highly	O
activated	O
liver	O
γδ	O
T	O
cells	O
were	O
cytotoxic	O
to	O
MHV	O
-	O
3	O
-	O
infected	O
hepatocytes	O
in	O
vitro	O
and	O
this	O
effect	O
of	O
liver	O
γδ	O
T	O
cells	O
against	O
hepatocytes	O
might	O
involve	O
the	O
TNF	O
-	O
α	O
and	O
IFN	O
-	O
γ	O
pathway	B-PROC
.	O

To	O
explore	O
the	O
effect	O
of	O
PERK	O
inhibition	B-PROC
on	O
VILI	O
,	O
we	O
ventilated	O
live	O
rats	O
and	O
compared	O
lung	O
injury	O
parameters	O
to	O
non	O
-	O
ventilated	O
controls	O
.	O

RESULTS	O
:	O
Our	O
studies	O
revealed	O
increased	O
PERK	O
-	O
specific	O
ER	O
stress	O
signaling	B-PROC
in	O
response	O
to	O
overstretch	O
.	O

While	O
the	O
two	O
proteins	O
display	O
strong	O
structural	O
conservation	O
and	O
the	O
mechanisms	O
underlying	O
membrane	B-PROC
fusion	I-PROC
are	O
similar	O
,	O
they	O
share	O
no	O
sequence	O
similarity	O
.	O

Treatment	O
with	O
endocytosis	B-PROC
inhibitors	O
did	O
not	O
affect	O
syncytium	B-PROC
formation	I-PROC
by	O
infected	O
cells	O
.	O

TITLE	O
:	O
Modulation	O
of	O
the	O
immune	B-PROC
response	I-PROC
by	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

rRT	O
-	O
PCR	O
results	O
with	O
virus	O
titration	O
in	O
ECEs	O
revealed	O
a	O
significant	O
increase	O
in	O
H9N2	O
AIV	O
titer	O
with	O
extension	O
in	O
the	O
period	O
of	O
viral	B-PROC
shedding	I-PROC
in	O
Groups	O
1	O
and	O
5	O
.	O

These	O
papers	O
were	O
then	O
peer	O
-	O
reviewed	O
by	O
external	O
reviewers	O
to	O
provide	O
the	O
editorial	O
team	O
with	O
an	O
enlightened	O
vision	B-PROC
to	O
select	O
the	O
best	O
papers	O
.	O

We	O
obtained	O
samples	O
with	O
nylon	O
swabs	O
from	O
the	O
glans	O
penis	O
,	O
corona	O
,	O
inner	O
layer	O
of	O
the	O
prepuce	O
and	O
penile	O
body	O
and	O
detected	O
different	O
types	O
of	O
HPV	O
infection	O
using	O
the	O
Hybribio	O
HPV	O
typing	O
kit	O
,	O
PCR	O
and	O
membrane	O
hybridization	B-PROC
.	O

Mortality	O
rate	O
of	O
patients	O
with	O
ARDS	O
was	O
extremely	O
high	O
(	O
80	O
%),	O
especially	O
for	O
severe	O
ARDS	O
patients	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
deaths	B-PROC
were	O
mostly	O
due	O
to	O
multiple	O
organ	O
failure	O
.	O

TITLE	O
:	O
Viral	B-PROC
infection	I-PROC
in	O
community	O
acquired	O
pneumonia	O
patients	O
with	O
fever	B-PROC
:	O
a	O
prospective	O
observational	O
study	O
.	O

An	O
enrolment	O
system	O
was	O
established	O
for	O
monitoring	O
the	O
CAP	O
patients	O
with	O
fever	B-PROC
.	O

TITLE	O
:	O
Novel	O
coronavirus	O
-	O
like	O
particles	O
targeting	B-PROC
cells	O
lining	O
the	O
respiratory	O
tract	O
.	O

TITLE	O
:	O
Clinical	O
and	O
Epidemiologic	O
Patterns	O
of	O
Chikungunya	O
Virus	B-PROC
Infection	I-PROC
and	O
Coincident	O
Arboviral	O
Disease	O
in	O
a	O
School	O
Cohort	O
in	O
Haiti	O
,	O
2014	O
-	O
2015	O
.	O

We	O
show	O
that	O
SARS	O
3a	O
interacts	O
with	O
Receptor	O
Interacting	O
Protein	O
3	O
(	O
Rip3	O
),	O
which	O
augments	O
the	O
oligomerization	O
of	O
SARS	O
3a	O
helping	O
drive	O
necrotic	B-PROC
cell	B-PROC
death	I-PROC
.	O

Using	O
this	O
joint	O
analysis	O
of	O
the	O
molecular	O
function	O
and	O
phylogeny	O
,	O
our	O
results	O
suggested	O
that	O
SARS	O
-	O
CoV	O
-	O
cpsR	O
-	O
19	O
could	O
play	O
a	O
role	O
in	O
SARS	O
-	O
CoV	O
infection	O
or	O
pathogenesis	B-PROC
.	O

Inhibition	B-PROC
of	O
coiled	O
coil	O
-	O
mediated	O
interactions	O
using	O
bioactive	O
peptides	O
that	O
replicate	O
an	O
α	O
-	O
helical	O
chain	O
from	O
the	O
viral	O
fusion	O
machinery	O
has	O
significant	O
antiviral	O
potential	O
.	O

ABSTRACT	O
:	O
Positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
such	O
as	O
coronaviruses	O
,	O
induce	O
cellular	O
membrane	O
rearrangements	O
during	O
replication	O
to	O
form	O
replication	O
organelles	O
allowing	O
for	O
efficient	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

Although	O
fatalities	O
from	O
septicemia	O
after	O
uterine	O
artery	O
embolization	O
have	O
been	O
reported	O
,	O
aseptic	O
inflammatory	B-PROC
responses	I-PROC
to	O
uterine	O
degeneration	O
can	O
also	O
lead	O
to	O
multiorgan	O
failure	O
.	O

Here	O
we	O
characterize	O
replication	O
kinetics	O
and	O
plaque	O
formation	B-PROC
of	O
a	O
model	O
type	O
I	O
strain	O
FIPV	O
Black	O
in	O
Fcwf	O
-	O
4	O
cells	O
established	O
at	O
Cornell	O
University	O
(	O
Fcwf	O
-	O
4	O
CU	O
).	O

Samples	O
from	O
two	O
dead	B-PROC
piglets	O
and	O
two	O
euthanized	O
affected	O
piglets	O
were	O
collected	O
for	O
gross	O
and	O
histopathological	O
examinations	O
.	O

Current	O
ongoing	O
trials	O
include	O
the	O
use	O
of	O
mesenchymal	O
stem	O
cells	O
,	O
vitamin	O
C	O
,	O
re	O
-	O
evaluation	O
of	O
neuromuscular	B-PROC
blockade	I-PROC
,	O
and	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
.	O

In	O
1980	O
,	O
smallpox	O
,	O
responsible	O
for	O
300	O
million	O
–	O
500	O
million	O
deaths	B-PROC
in	O
the	O
twentieth	O
century	O
,	O
was	O
declared	O
to	O
be	O
the	O
first	O
disease	O
eradicated	O
from	O
the	O
planet	O
following	O
a	O
global	O
immunization	O
campaign	O
led	O
by	O
the	O
WHO	O
.	O

Acute	O
myocardial	O
infarction	O
,	O
seizures	O
,	O
hallucinations	O
,	O
hyperthermia	B-PROC
,	O
and	O
movement	B-PROC
disorders	O
are	O
among	O
the	O
possible	O
adverse	O
effects	O
.	O

High	O
antibody	B-PROC
responses	I-PROC
were	O
detected	O
in	O
chickens	O
immunized	O
with	O
IBV	O
-	O
Flagellin	O
-	O
SAPN	O
.	O

Logistic	O
regression	O
analysis	O
showed	O
that	O
AKI	O
was	O
the	O
independent	O
risk	O
factor	O
for	O
death	B-PROC
in	O
elderly	O
patients	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
8	O
.	O
449	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
=	O
2	O
.	O
347	O
-	O
30	O
.	O
410	O
,	O
P	O
=	O
0	O
.	O
001	O
].	O

TITLE	O
:	O
Salvage	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
induction	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
acute	O
leukemia	O
patients	O
:	O
A	O
case	O
series	O
.	O

Four	O
cases	O
of	O
acute	O
myelogenous	O
leukemia	O
with	O
respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
treated	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
while	O
undergoing	O
induction	O
chemotherapy	O
were	O
identified	O
.	O

The	O
recirculation	O
fraction	O
and	O
arterial	B-PROC
oxygen	I-PROC
saturation	I-PROC
and	O
pressure	O
(	O
SaO	O
In	O
the	O
lower	O
inferior	O
vena	O
cava	O
drainage	O
cannula	O
position	O
,	O
the	O
recirculation	O
fraction	O
was	O
the	O
lowest	O
.	O

In	O
the	O
lower	O
inferior	O
vena	O
cava	O
,	O
upper	O
inferior	O
vena	O
cava	O
,	O
and	O
right	O
atrium	O
drainage	O
cannula	O
positions	O
at	O
3	O
L	O
/	O
min	O
,	O
SaO	O
With	O
respect	O
to	O
blood	O
oxygenation	B-PROC
,	O
the	O
optimal	O
position	O
for	O
the	O
drainage	O
cannula	O
was	O
the	O
upper	O
inferior	O
vena	O
cava	O
.	O

Therefore	O
,	O
rapid	O
diagnosis	O
and	O
immune	B-PROC
status	I-PROC
determination	O
are	O
critical	O
for	O
controlling	O
IBV	O
outbreaks	O
.	O

Two	O
microarray	O
assays	O
,	O
which	O
were	O
rapid	O
,	O
specific	O
,	O
sensitive	O
,	O
and	O
relatively	O
simple	O
,	O
were	O
developed	O
for	O
the	O
detection	O
of	O
an	O
antibody	B-PROC
against	O
IBV	O
.	O

Moreover	O
,	O
our	O
findings	O
verified	O
the	O
significantly	O
enhanced	O
PEDV	O
-	O
specific	O
IgA	O
antibody	B-PROC
titers	O
in	O
small	O
intestinal	O
and	O
lung	O
in	O
the	O
mice	O
immunized	O
with	O
PEDV	O
vaccine	O
and	O
CVC1303	O
.	O

CONCLUSIONS	O
:	O
Compound	O
adjuvant	O
CVC1303	O
could	O
effectively	O
improve	O
the	O
PEDV	O
-	O
specific	O
immune	B-PROC
responses	I-PROC
and	O
mucosal	O
immune	O
,	O
which	O
provided	O
an	O
experimental	O
basis	O
for	O
the	O
further	O
clinical	O
application	O
of	O
new	O
adjuvant	O
CVC1303	O
and	O
the	O
development	B-PROC
of	O
improvement	O
on	O
the	O
mucosal	B-PROC
immune	I-PROC
response	I-PROC
.	O

This	O
prospective	O
multicenter	O
study	O
,	O
entitled	O
""""	O
Viral	O
etiological	O
causes	O
of	O
febrile	B-PROC
seizures	O
for	O
respiratory	O
pathogens	O
(	O
EFES	O
Study	O
")"""	O
examined	O
representative	O
populations	O
in	O
eight	O
different	O
cities	O
in	O
Turkey	O
between	O
March	O
1	O
,	O
2016	O
and	O
April	O
1	O
,	O
2017	O
.	O

ABSTRACT	O
:	O
Electrical	B-PROC
impedance	I-PROC
tomography	O
(	O
EIT	O
)	O
has	O
been	O
used	O
to	O
guide	O
mechanical	O
ventilation	O
in	O
ICU	O
patients	O
with	O
lung	O
collapse	O
.	O

These	O
results	O
illuminate	O
the	O
relationship	O
between	O
TGEV	O
infection	O
and	O
nutrient	B-PROC
absorption	I-PROC
,	O
and	O
further	O
our	O
understanding	O
of	O
the	O
mechanisms	O
of	O
TGEV	O
infection	O
.	O

During	O
infection	O
,	O
MERS	O
-	O
CoV	O
regulates	O
several	O
host	O
cellular	O
processes	O
including	O
antiviral	B-PROC
response	I-PROC
genes	O
.	O

Mucosal	B-PROC
immunity	I-PROC
is	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
PEDV	O
control	O
and	O
mucosal	O
delivery	O
of	O
vaccines	O
induces	O
mucosal	B-PROC
immunity	I-PROC
more	O
efficiently	O
than	O
parenteral	O
vaccination	O
.	O

Overall	O
,	O
our	O
results	O
indicate	O
that	O
the	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
might	O
serve	O
as	O
an	O
effective	O
way	O
to	O
induce	O
PEDV	O
-	O
specific	O
mucosal	B-PROC
immunity	I-PROC
in	O
pigs	O
against	O
PEDV	O
.	O

Another	O
important	O
finding	O
is	O
that	O
recombination	B-PROC
events	O
occurred	O
between	O
the	O
predominant	O
GI	O
-	O
19	O
lineage	O
and	O
the	O
commonly	O
used	O
4	O
/	O
91	O
vaccine	O
,	O
which	O
gave	O
rise	O
to	O
distinct	O
IBV	O
isolates	O
.	O

ABSTRACT	O
:	O
Spontaneous	O
breathing	B-PROC
efforts	O
during	O
mechanical	O
ventilation	O
can	O
lead	O
to	O
patient	O
self	O
-	O
inflicted	O
lung	O
injury	O
(	O
P	O
-	O
SILI	O
).	O

Further	O
studies	O
revealed	O
that	O
TA	O
-	O
dampened	O
inflammatory	B-PROC
responses	I-PROC
by	O
downregulating	O
the	O
LPS	O
-	O
induced	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
expression	B-PROC
and	O
inhibiting	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
1	O
/	O
2	O
and	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activation	O
.	O

For	O
severe	O
hypoxemia	O
,	O
first	O
-	O
line	O
treatment	O
adjuncts	O
include	O
high	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
strategies	O
,	O
recruitment	O
maneuvers	O
,	O
neuromuscular	B-PROC
blockade	I-PROC
,	O
and	O
prone	O
positioning	O
.	O

Results	O
indicated	O
that	O
AIF	O
translocated	O
from	O
the	O
mitochondria	O
to	O
nucleus	O
during	O
TGEV	O
infection	O
,	O
and	O
the	O
AIF	O
inhibitor	O
,	O
N	O
-	O
phenylmaleimide	O
(	O
NP	O
),	O
significantly	O
attenuated	O
the	O
apoptosis	B-PROC
.	O

In	O
addition	O
,	O
the	O
translocation	B-PROC
of	O
AIF	O
was	O
inhibited	O
by	O
Veliparib	O
(	O
ABT	O
-	O
888	O
),	O
an	O
inhibitor	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
).	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
p53	O
-	O
and	O
ROS	O
-	O
mediated	O
AIF	B-PROC
pathway	I-PROC
and	O
caspase	O
-	O
dependent	O
pathway	B-PROC
were	O
involved	O
in	O
TGEV	O
-	O
induced	O
apoptosis	B-PROC
.	O

The	O
blood	O
samples	O
were	O
assessed	O
for	O
the	O
antibodies	O
against	O
NDV	O
and	O
AIV	O
by	O
haemagglutination	B-PROC
inhibition	B-PROC
test	O
,	O
and	O
against	O
IBV	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Moreover	O
,	O
purified	O
lysosomal	O
extracts	O
from	O
bat	O
cells	O
cleave	O
cell	O
surface	O
-	O
expressed	B-PROC
coronavirus	O
spikes	O
more	O
efficiently	O
than	O
their	O
counterparts	O
from	O
human	O
cells	O
.	O

TITLE	O
:	O
TRAIL	O
(	O
CD253	O
)	O
Sensitizes	O
Human	O
Airway	O
Epithelial	O
Cells	O
to	O
Toxin	O
-	O
Induced	O
Cell	B-PROC
Death	I-PROC
.	O

ABSTRACT	O
:	O
Inhalation	B-PROC
of	O
ricin	O
toxin	O
is	O
associated	O
with	O
the	O
onset	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
characterized	O
by	O
hemorrhage	O
,	O
inflammatory	O
exudates	O
,	O
and	O
tissue	O
edema	O
,	O
as	O
well	O
as	O
the	O
nearly	O
complete	O
destruction	O
of	O
the	O
lung	O
epithelium	O
.	O

The	O
Research	O
and	O
Development	B-PROC
(	O
R	O
&	O
D	O
)	O
Blueprint	O
is	O
a	O
World	O
Health	O
Organization	O
initiative	O
to	O
reduce	O
the	O
time	O
between	O
the	O
declaration	O
of	O
a	O
public	O
health	O
emergency	O
and	O
the	O
availability	O
of	O
effective	O
diagnostic	O
tests	O
,	O
vaccines	O
,	O
and	O
treatments	O
that	O
can	O
save	O
lives	O
and	O
avert	O
a	O
public	O
health	O
crisis	O
.	O

Therefore	O
,	O
the	O
time	O
interval	O
between	O
arrival	O
to	O
the	O
CCU	O
and	O
switching	O
to	O
spontaneous	O
ventilation	O
(	O
SV	O
)	O
is	O
not	O
focused	O
on	O
normalizing	O
the	O
different	O
factors	O
involved	O
in	O
the	O
pathophysiology	O
of	O
ARDS	O
:	O
fever	B-PROC
,	O
low	O
cardiac	O
output	O
,	O
systemic	O
acidosis	O
,	O
peripheral	O
shutdown	O
(	O
local	O
acidosis	O
),	O
supine	O
position	O
,	O
hypocapnia	O
(	O
generated	O
by	O
hyperpnea	O
and	O
tachypnea	O
),	O
sympathetic	O
activation	O
,	O
inflammation	O
and	O
agitation	O
.	O

The	O
stabilization	O
of	O
the	O
acute	O
cardio	O
-	O
ventilatory	O
distress	O
should	O
primarily	O
itemize	O
the	O
pathophysiological	O
conditions	O
:	O
fever	B-PROC
control	O
,	O
improved	O
micro	O
-	O
circulation	B-PROC
and	O
normalized	O
local	O
acidosis	O
,	O
'	O
upright	O
'	O
position	O
,	O
minimized	O
hypercapnia	O
,	O
sympathetic	O
de	O
-	O
activation	O
(	O
normalized	O
sympathetic	O
activity	O
toward	O
baseline	O
levels	O
resulting	O
in	O
improved	O
micro	O
-	O
circulation	B-PROC
with	O
alpha	O
-	O
2	O
agonists	O
administered	O
immediately	O
following	O
optimized	O
circulation	B-PROC
and	O
endotracheal	O
intubation	O
),	O
lowered	O
inflammation	O
and	O
'	O
cooperative	O
'	O
sedation	O
without	O
respiratory	O
depression	O
evoked	O
by	O
alpha	O
-	O
2	O
agonists	O
.	O

TITLE	O
:	O
Molecular	O
evolution	B-PROC
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
and	O
porcine	O
deltacoronavirus	O
strains	O
in	O
Central	O
China	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
(	O
IB	O
)	O
is	O
an	O
acute	O
,	O
highly	O
contagious	O
,	O
and	O
economically	O
important	O
viral	B-PROC
disease	I-PROC
of	O
chickens	O
.	O

TITLE	O
:	O
Detection	O
of	O
neutralizing	O
antibody	B-PROC
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
subclinically	O
infected	O
finishing	O
pigs	O
.	O

In	O
recent	O
years	O
,	O
the	O
rapid	O
spread	O
of	O
severe	O
infections	O
such	O
as	O
HIV	O
,	O
SARS	O
,	O
Ebola	O
,	O
and	O
Zika	O
have	O
highlighted	O
the	O
dire	O
need	O
for	O
global	O
preparedness	O
for	O
pandemics	O
,	O
which	O
necessitates	O
the	O
extremely	O
rapid	O
development	B-PROC
and	O
comprehensive	O
distribution	O
of	O
vaccines	O
against	O
potentially	O
previously	O
unknown	O
pathogens	O
.	O

TITLE	O
:	O
The	O
influence	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
on	O
pig	O
small	O
intestine	O
mucosal	O
epithelial	O
cell	B-PROC
function	I-PROC
.	O

PED	O
is	O
characterized	O
by	O
watery	O
diarrhea	O
,	O
dehydration	O
,	O
weight	O
loss	O
,	O
vomiting	O
and	O
death	B-PROC
.	O

Moreover	O
,	O
inoculation	O
with	O
iPEDVPT	O
-	O
P96	O
elicited	O
comparable	O
levels	O
of	O
anti	O
-	O
PEDV	O
specific	O
plasma	O
IgG	O
and	O
fecal	O
/	O
salivary	O
IgA	O
,	O
neutralizing	O
antibody	B-PROC
titers	O
,	O
and	O
similar	O
but	O
less	O
effective	O
immunoprotection	O
against	O
the	O
virulent	O
PEDVPT	O
-	O
P5	O
challenge	O
compared	O
to	O
the	O
parental	O
PEDVPT	O
-	O
P96	O
.	O

The	O
successful	O
development	B-PROC
of	O
the	O
iPEDVPT	O
-	O
P96	O
cDNA	O
clone	O
could	O
allow	O
for	O
the	O
manipulation	O
of	O
the	O
viral	O
genome	O
to	O
study	O
viral	O
pathogenesis	B-PROC
and	O
facilitate	O
the	O
rapid	O
development	B-PROC
of	O
effective	O
vaccines	O
.	O

Diseases	O
like	O
West	O
Nile	O
fever	B-PROC
,	O
Hendra	O
,	O
VS	O
,	O
VEE	O
,	O
EEE	O
,	O
JE	O
,	O
Rabies	O
have	O
the	O
potential	O
for	O
spread	O
and	O
ability	O
to	O
cause	O
disease	O
in	O
human	O
.	O

ABSTRACT	O
:	O
Evaluation	O
of	O
people	O
returning	O
from	O
trips	O
abroad	O
with	O
fever	B-PROC
is	O
an	O
important	O
skill	O
for	O
all	O
general	O
physicians	O
given	O
the	O
increasing	O
trend	O
in	O
foreign	O
travel	O
.	O

Our	O
study	O
suggest	O
that	O
MERS	O
patients	O
with	O
radiographic	O
score	O
>	O
10	O
on	O
day	O
10	O
from	O
viral	O
exposure	O
require	O
aggressive	B-PROC
therapy	O
with	O
careful	O
surveillance	O
and	O
follow	O
-	O
up	O
evaluation	O
.	O

Consideration	O
of	O
limitations	O
of	O
the	O
latter	O
protocols	O
may	O
prevent	O
clinicians	O
from	O
reaching	B-PROC
premature	O
conclusions	O
regarding	O
the	O
prediction	O
of	O
EVLW	O
.	O

Do	O
our	O
life	O
history	O
traits	O
make	O
us	O
susceptible	O
to	O
generating	O
damaging	O
immune	B-PROC
responses	I-PROC
to	O
RNA	O
viruses	O
or	O
does	O
the	O
physiology	O
of	O
bats	O
make	O
them	O
particularly	O
tolerant	O
or	O
resistant	O
?	O

As	O
with	O
the	O
outcome	O
of	O
human	O
infection	O
,	O
intranasal	O
infection	O
of	O
C57BL	O
/	O
6J	O
mice	O
with	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
results	O
in	O
high	O
-	O
titer	O
virus	B-PROC
replication	I-PROC
within	O
the	O
lung	O
,	O
induction	O
of	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
and	O
immune	O
cell	O
infiltration	O
within	O
the	O
lung	O
.	O

Because	O
of	O
instability	O
of	O
hemodynamic	B-PROC
status	O
,	O
modified	O
David	O
-	O
Komeda	O
operation	O
with	O
double	O
patch	O
was	O
performed	O
in	O
the	O
subacute	O
phase	O
of	O
VSP	O
.	O

Although	O
we	O
found	O
a	O
high	O
rate	O
of	O
MERS	O
-	O
CoV	O
antibody	B-PROC
positive	O
dromedaries	O
(	O
75	O
.	O
62	O
%)	O
in	O
Pakistan	O
,	O
no	O
neutralizing	O
antibodies	O
were	O
detected	O
in	O
humans	O
with	O
and	O
without	O
contact	O
to	O
camels	O
.	O

TITLE	O
:	O
Economic	O
Evaluation	O
of	O
Venovenous	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
for	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

We	O
assessed	O
the	O
cost	O
-	O
utility	O
of	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
adults	O
compared	O
with	O
standard	O
lung	O
protective	O
ventilation	O
from	O
the	O
perspective	O
of	O
the	O
healthcare	O
system	O
.	O

Based	O
on	O
current	O
data	O
,	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
cost	O
-	O
effective	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
also	O
observed	O
that	O
overexpression	B-PROC
of	O
miR	O
-	O
22	O
led	O
to	O
a	O
reduction	O
of	O
p	O
-	O
IκB	O
-	O
α	O
and	O
accumulation	O
of	O
p65	O
in	O
nucleus	O
in	O
TGEV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
.	O

In	O
contrast	O
,	O
inhibition	B-PROC
of	O
miR	O
-	O
22	O
had	O
the	O
opposite	O
effects	O
.	O

The	O
data	O
revealed	O
that	O
differentially	O
expressed	B-PROC
mRNAs	O
and	O
ncRNAs	O
were	O
primarily	O
enriched	O
in	O
inflammation	O
-	O
related	O
pathways	B-PROC
and	O
ssc_circ_009380	O
promoted	O
activation	O
of	O
NF	O
-	O
κB	O
pathway	B-PROC
by	O
binding	O
miR	O
-	O
22	O
during	O
TGEV	O
-	O
induced	O
inflammation	O
.	O

Patients	O
with	O
acute	O
hypoxemic	O
respiratory	O
failure	O
(	O
arterial	O
oxygen	B-PROC
tension	I-PROC
/	O
pressure	O
[	O
Pa	O
Among	O
738	O
patients	O
reviewed	O
,	O
110	O
(	O
15	O
%)	O
had	O
consensus	O
-	O
ARDS	O
,	O
100	O
(	O
14	O
%)	O
had	O
disagreement	O
,	O
and	O
528	O
(	O
72	O
%)	O
did	O
not	O
have	O
ARDS	O
.	O

RESULTS	O
:	O
The	O
presence	O
of	O
PAstV	O
and	O
PSaV	O
was	O
studied	O
in	O
411	O
rectal	O
swabs	O
collected	O
from	O
healthy	O
(	O
n	O
=	O
251	O
)	O
and	O
diarrheic	O
(	O
n	O
=	O
160	O
)	O
pigs	O
of	O
different	O
age	O
categories	O
:	O
suckling	O
(	O
n	O
=	O
143	O
),	O
weaned	B-PROC
(	O
n	O
=	O
147	O
)	O
and	O
fattening	O
(	O
n	O
=	O
121	O
)	O
animals	O
on	O
farms	O
in	O
Slovakia	O
.	O

Development	B-PROC
of	O
new	O
vaccines	O
and	O
antimicrobial	O
therapies	O
remains	O
a	O
priority	O
,	O
including	O
the	O
need	O
to	O
expedite	O
clinical	O
trials	O
using	O
new	O
methodologies	O
.	O

TITLE	O
:	O
Novel	O
natural	O
non	O
-	O
nucleoside	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-PROC
identified	O
by	O
shape	O
-	O
and	O
structure	O
-	O
based	O
virtual	O
screening	O
techniques	O
.	O

Viral	B-PROC
infection	I-PROC
was	O
predominant	O
in	O
the	O
pediatric	O
environment	O
(	O
90	O
.	O
8	O
%,	O
P	O
<	O
0	O
.	O
001	O
),	O
male	O
patients	O
(	O
88	O
.	O
0	O
%),	O
and	O
spring	O
(	O
93	O
.	O
8	O
%).	O

Six	O
of	O
the	O
8	O
horses	O
(	O
75	O
%)	O
exhibited	O
mild	O
,	O
clinical	O
disease	O
with	O
soft	O
,	O
formed	O
manure	O
;	O
1	O
horse	O
exhibited	O
transient	O
pyrexia	B-PROC
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
the	O
S2	O
subunit	O
of	O
the	O
avirulent	O
Beau	O
-	O
R	O
strain	O
is	O
responsible	O
for	O
its	O
extended	O
cellular	B-PROC
tropism	B-PROC
for	O
Vero	O
cells	O
.	O

In	O
addition	O
,	O
YQFM	O
increased	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
phosphorylation	B-PROC
and	O
dramatically	O
suppressed	O
the	O
PM	O
-	O
stimulated	O
expression	B-PROC
of	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
),	O
MyD88	O
,	O
autophagy	B-PROC
-	O
related	O
protein	O
LC3Ⅱand	O
Beclin	O
1	O
as	O
well	O
as	O
autophagy	B-PROC
.	O

It	O
has	O
been	O
listed	O
by	O
the	O
WHO	O
and	O
the	O
Coalition	O
for	O
Epidemic	O
Preparedness	O
Innovations	O
(	O
CEPI	O
)	O
as	O
an	O
important	O
target	O
for	O
vaccine	O
development	B-PROC
.	O

Analysis	O
of	O
patients	O
with	O
and	O
without	O
spontaneous	O
breathing	B-PROC
,	O
defined	O
by	O
the	O
mode	O
of	O
mechanical	O
ventilation	O
and	O
by	O
actual	O
respiratory	O
rate	O
compared	O
with	O
set	O
respiratory	O
rate	O
during	O
the	O
first	O
48	O
hours	O
of	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
MicroRNA	O
-	O
221	O
-	O
5p	O
Inhibits	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	B-PROC
Replication	I-PROC
by	O
Targeting	B-PROC
Genomic	O
Viral	O
RNA	O
and	O
Activating	O
the	O
NF	O
-	O
κB	O
Pathway	B-PROC
.	O

Previous	O
studies	O
reported	O
miRNA	O
involvement	O
in	O
viral	B-PROC
infection	I-PROC
;	O
however	O
,	O
their	O
role	O
in	O
regulating	O
PEDV	O
infection	O
remains	O
unknown	O
.	O

Evaluating	O
for	O
LRTI	O
risk	O
factors	O
found	O
in	O
this	O
study	O
may	O
identify	O
patients	O
who	O
require	O
closer	O
surveillance	O
and	O
aggressive	B-PROC
supportive	O
care	O
when	O
infected	O
with	O
HCoV	O
.	O

Our	O
focus	O
is	O
on	O
platelet	O
-	O
endothelial	O
cell	B-PROC
adhesion	I-PROC
molecule	O
-	O
1	O
,	O
which	O
contributes	O
to	O
the	O
maintenance	O
and	O
restoration	O
of	O
vascular	O
integrity	O
following	O
barrier	O
disruption	O
.	O

ABSTRACT	O
:	O
Emerging	O
and	O
re	O
-	O
emerging	O
zoonotic	O
viral	B-PROC
diseases	I-PROC
are	O
major	O
threats	O
to	O
global	O
health	O
,	O
economic	O
stability	O
,	O
and	O
national	O
security	O
.	O

Vaccines	O
are	O
key	O
for	O
reducing	O
coronaviral	O
disease	O
burden	O
;	O
however	O
,	O
the	O
utility	O
of	O
live	O
-	O
attenuated	O
vaccines	O
is	O
limited	O
by	O
risks	O
of	O
reversion	O
or	O
repair	B-PROC
.	O

Transforming	O
Growth	B-PROC
Factor	O
-	O
β1	O
(	O
TGF	O
-	O
β1	O
)	O
is	O
involved	O
in	O
collagen	O
production	O
and	O
lung	O
repair	B-PROC
.	O

The	O
process	O
of	O
withdrawing	O
mechanical	O
ventilation	O
,	O
referred	O
to	O
as	O
weaning	B-PROC
from	O
MV	O
,	O
may	O
cause	O
worsening	O
of	O
lung	O
injury	O
by	O
spontaneous	O
ventilation	O
.	O

We	O
also	O
reviewed	O
new	O
treatments	O
(	O
modes	O
of	O
mechanical	O
ventilation	O
,	O
neuromuscular	O
blocker	O
use	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
)	O
that	O
could	O
be	O
considered	O
in	O
weaning	B-PROC
ARDS	O
patients	O
from	O
MV	O
.	O

Cell	O
apoptosis	B-PROC
induced	O
by	O
PEDV	O
or	O
overexpression	B-PROC
non	O
-	O
structural	O
or	O
structural	O
proteins	O
was	O
measured	O
by	O
the	O
flow	O
cytometry	O
assay	O
.	O

Overexpression	B-PROC
of	O
S1	O
Spike	O
protein	O
of	O
PEDV	O
SM98	O
strain	O
effectively	O
induced	O
host	O
cell	O
apoptosis	B-PROC
,	O
while	O
the	O
expression	B-PROC
of	O
the	O
other	O
non	O
-	O
structure	O
proteins	O
(	O
Nsp1	O
-	O
16	O
)	O
and	O
structural	O
proteins	O
(	O
M	O
,	O
N	O
,	O
E	O
,	O
S2	O
and	O
ORF3	O
)	O
has	O
no	O
or	O
less	O
effect	O
on	O
cell	O
apoptosis	B-PROC
.	O

TITLE	O
:	O
Deletion	O
of	O
both	O
the	O
Tyrosine	O
-	O
Based	O
Endocytosis	B-PROC
Signal	O
and	O
the	O
Endoplasmic	O
Reticulum	O
Retrieval	O
Signal	O
in	O
the	O
Cytoplasmic	O
Tail	O
of	O
Spike	O
Protein	O
Attenuates	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
in	O
Pigs	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
they	O
also	O
exerted	B-PROC
proviral	O
effects	O
.	O

Right	O
heart	O
catheterization	O
confirmed	O
these	O
findings	O
with	O
a	O
mean	O
pulmonary	O
arterial	B-PROC
pressure	I-PROC
of	O
61	O
mmHg	O
.	O

TITLE	O
:	O
Diagnosis	O
of	O
non	O
-	O
effusive	O
feline	O
infectious	O
peritonitis	O
by	O
reverse	O
transcriptase	B-PROC
quantitative	O
PCR	O
from	O
mesenteric	O
lymph	O
node	O
fine	O
-	O
needle	O
aspirates	O
.	O

Since	O
2012	O
,	O
the	O
World	O
Health	O
Organization	O
has	O
been	O
informed	O
of	O
2220	O
laboratory	O
-	O
confirmed	O
cases	O
resulting	O
in	O
at	O
least	O
790	O
deaths	B-PROC
.	O

MERS	O
-	O
CoV	O
is	O
now	O
included	O
on	O
the	O
WHO	O
list	O
of	O
priority	O
blueprint	O
diseases	O
for	O
which	O
there	O
which	O
is	O
an	O
urgent	O
need	O
for	O
accelerated	O
research	O
and	O
development	B-PROC
as	O
they	O
have	O
the	O
potential	O
to	O
cause	O
a	O
public	O
health	O
emergency	O
while	O
there	O
is	O
an	O
absence	O
of	O
efficacious	O
drugs	O
and	O
/	O
or	O
vaccines	O
.	O

Attention	O
is	O
given	O
to	O
recommended	O
treatments	O
and	O
progress	O
towards	O
vaccine	O
development	B-PROC
.	O

Here	O
,	O
we	O
used	O
mutagenic	O
analysis	O
and	O
MERS	O
-	O
S	O
-	O
bearing	O
vectors	O
to	O
study	O
the	O
contribution	O
of	O
specific	O
cleavage	B-PROC
sites	O
to	O
S	O
protein	O
-	O
driven	O
entry	O
.	O

In	O
keeping	O
with	O
a	O
previous	O
study	O
,	O
pre	O
-	O
cleavage	B-PROC
at	O
the	O
S1	O
/	O
S2	O
motif	O
(	O
RSVR	O
)	O
was	O
important	O
although	O
not	O
essential	O
for	O
subsequent	O
MERS	O
-	O
S	O
activation	O
by	O
TMPRSS2	O
,	O
and	O
indirect	O
evidence	O
was	O
obtained	O
that	O
this	O
motif	O
is	O
processed	O
by	O
a	O
protease	O
depending	O
on	O
an	O
intact	O
RXXR	O
motif	O
,	O
most	O
likely	O
furin	O
.	O

These	O
findings	O
suggest	O
that	O
cleavage	B-PROC
at	O
S2	O
'	O
is	O
carried	O
out	O
by	O
proteases	O
recognizing	O
a	O
single	O
arginine	O
,	O
most	O
likely	O
TMPRSS2	O
and	O
cathepsin	O
L	O
.	O
Finally	O
,	O
mutation	O
of	O
the	O
proposed	O
cathepsin	O
L	O
site	O
did	O
not	O
impact	O
viral	O
entry	O
and	O
double	O
mutation	O
of	O
S1	O
/	O
S2	O
and	O
S2	O
'	O
site	O
was	O
compatible	O
with	O
cathepsin	O
L	O
-	O
but	O
not	O
TMPRSS2	O
-	O
dependent	O
host	O
cell	O
entry	O
,	O
indicating	O
that	O
cathepsin	O
L	O
can	O
process	O
the	O
S	O
protein	O
at	O
auxiliary	O
sites	O
.	O

The	O
most	O
frequent	O
clinical	O
manifestations	O
described	O
in	O
these	O
patients	O
are	O
febrile	B-PROC
or	O
afebrile	O
seizures	O
,	O
status	O
epilepticus	O
,	O
encephalopathies	O
and	O
encephalitis	O
.	O

TITLE	O
:	O
Primary	O
and	O
Repeated	O
Respiratory	O
Viral	B-PROC
Infections	I-PROC
Among	O
Infants	O
in	O
Rural	O
Nepal	O
.	O

Risk	O
factors	O
for	O
initial	O
and	O
repeated	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
young	O
infants	O
in	O
resource	O
-	O
limited	O
settings	O
have	O
not	O
been	O
well	O
described	O
.	O

We	O
tested	O
nasal	O
swabs	O
of	O
infants	O
with	O
respiratory	O
illness	O
for	O
multiple	O
respiratory	O
viruses	O
by	O
using	O
a	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
assay	O
.	O

The	O
major	O
cause	O
of	O
myocarditis	O
in	O
the	O
paediatric	O
population	O
is	O
viral	B-PROC
infection	I-PROC
,	O
including	O
coxsackievirus	O
B3	O
,	O
adenovirus	O
,	O
herpesvirus	O
,	O
parvovirus	O
,	O
influenza	O
A	O
and	O
B	O
,	O
and	O
hepatitis	O
.	O

Further	O
characterization	O
of	O
the	O
enterovirus	O
group	O
was	O
carried	O
out	O
using	O
PCR	O
with	O
primers	O
targeting	B-PROC
the	O
VP4	O
/	O
VP2	O
gene	O
,	O
followed	O
by	O
sequencing	O
.	O

The	O
differences	O
of	O
demographic	O
indexes	O
(	O
gender	O
,	O
age	O
),	O
time	O
of	O
admission	O
,	O
type	O
of	O
injury	O
,	O
atrial	O
fibrillation	O
,	O
trachea	O
cannula	O
,	O
multiple	O
injury	O
,	O
open	O
injury	O
,	O
shock	O
,	O
surgery	O
,	O
blood	O
transfusion	O
,	O
central	O
venous	O
indwelling	O
catheter	O
,	O
infection	O
,	O
and	O
blood	O
routine	O
indexes	O
[	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
red	O
blood	O
cell	O
count	O
(	O
RBC	O
),	O
platelet	O
count	O
(	O
PLT	O
),	O
plateletcytocrit	O
(	O
PCT	O
),	O
hematocrit	O
(	O
Hct	O
)],	O
biochemical	O
indexes	O
[	O
total	O
bilirubin	O
(	O
TBil	O
),	O
albumin	O
(	O
Alb	O
),	O
serum	O
creatinine	O
(	O
SCr	O
),	O
blood	O
sodium	O
,	O
blood	O
calcium	O
,	O
blood	O
potassium	O
,	O
blood	O
glucose	O
],	O
arterial	O
blood	B-PROC
gas	I-PROC
analysis	O
indexes	O
[	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO	O
A	O
total	O
of	O
303	O
patients	O
with	O
severe	O
trauma	O
,	O
including	O
223	O
males	O
and	O
80	O
females	O
,	O
were	O
enrolled	O
.	O

There	O
were	O
305	O
deaths	B-PROC
(	O
9	O
.	O
6	O
%),	O
mainly	O
among	O
the	O
elderly	O
,	O
with	O
an	O
average	O
age	O
of	O
(	O
71	O
.	O
10	O
±	O
16	O
.	O
08	O
)	O
years	O
old	O
.	O

We	O
gathered	O
data	O
from	O
47	O
patients	O
with	O
dengue	O
fever	B-PROC
using	O
a	O
10	O
-	O
GHz	O
Doppler	O
radar	O
system	O
at	O
the	O
National	O
Hospital	O
of	O
Tropical	O
Diseases	O
(	O
NHTD	O
)	O
in	O
Hanoi	O
,	O
Vietnam	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
reveals	O
that	O
neboviruses	O
circulate	O
widely	O
in	O
dairy	O
cows	O
in	O
China	O
and	O
exhibit	O
a	O
unique	O
evolution	B-PROC
of	O
RdRp	O
.	O

Prevalence	O
of	O
OSA	O
is	O
high	O
in	O
patients	O
with	O
MPS	O
IVA	O
,	O
underlying	O
the	O
importance	O
of	O
a	O
systematic	O
screening	O
for	O
sleep	B-PROC
-	O
disordered	O
breathing	B-PROC
.	O

CPAP	O
and	O
NIV	O
are	O
efficient	O
and	O
well	O
accepted	O
for	O
treating	O
sleep	B-PROC
-	O
disordered	O
breathing	B-PROC
.	O

We	O
recruited	O
ventilated	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
(	O
ratio	O
of	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
to	O
fractional	O
inspired	B-PROC
oxygen	O
<	O
27	O
kPa	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
[	O
PEEP	O
]	O
≥	O
8	O
cm	O
H	O
From	O
March	O
24	O
,	O
2014	O
,	O
to	O
Feb	O
9	O
,	O
2017	O
we	O
screened	O
1038	O
patients	O
,	O
of	O
whom	O
60	O
were	O
eligible	O
for	O
and	O
received	O
treatment	O
.	O

One	O
patient	O
in	O
the	O
MSC	O
group	O
died	B-PROC
within	O
24	O
h	O
of	O
MSC	O
infusion	O
,	O
but	O
death	B-PROC
was	O
judged	O
to	O
be	O
probably	O
unrelated	O
.	O

However	O
,	O
NMBAs	O
have	O
no	O
effect	O
on	O
reduction	O
of	O
oxygenation	B-PROC
at	O
24	O
hours	O
(	O
WMD	O
,	O
26	O
.	O
83	O
;	O
95	O
%	O
CI	O
,	O
-	O
5	O
.	O
89	O
to	O
59	O
.	O
55	O
;	O
p	O
=	O
0	O
.	O
108	O
;	O
I	O
=	O
82	O
.	O
4	O
%;	O
4	O
trials	O
,	O
447	O
patients	O
),	O
and	O
plateau	O
pressure	O
(	O
WMD	O
,	O
0	O
.	O
43	O
;	O
95	O
%	O
CI	O
,	O
-	O
0	O
.	O
46	O
to	O
1	O
.	O
31	O
;	O
p	O
=	O
0	O
.	O
345	O
;	O
4	O
trials	O
,	O
455	O
patients	O
)	O
as	O
well	O
as	O
positive	O
end	O
expiratory	B-PROC
pressure	O
(	O
WMD	O
,	O
0	O
.	O
10	O
;	O
95	O
%	O
CI	O
,	O
-	O
0	O
.	O
47	O
to	O
0	O
.	O
67	O
;	O
p	O
=	O
0	O
.	O
73	O
;	O
4	O
trials	O
,	O
455	O
patients	O
)	O
at	O
48	O
hours	O
.	O

We	O
characterized	O
its	O
growth	B-PROC
kinetics	O
and	O
pathogenicity	O
in	O
embryonated	O
eggs	O
,	O
and	O
its	O
tropism	B-PROC
and	O
persistence	O
in	O
different	O
tissues	O
from	O
chickens	O
;	O
then	O
,	O
we	O
evaluated	O
pathogenicity	O
by	O
using	O
a	O
new	O
premature	O
reproductive	B-PROC
tract	O
pathogenicity	O
model	O
.	O

Patients	O
with	O
immunodeficiency	O
(	O
e	O
.	O
g	O
.	O
SCID	O
with	O
T	O
and	O
B	O
cell	O
deficiency	O
)	O
are	O
particularly	O
susceptible	O
to	O
the	O
development	B-PROC
of	O
severe	O
ARDS	O
.	O

RAG2	O
CONCLUSIONS	O
:	O
Following	O
LPS	O
instillation	O
,	O
lung	O
mechanics	O
deteriorate	O
within	O
the	O
first	O
4	O
days	O
and	O
recover	B-PROC
towards	O
day	O
10	O
.	O

Considered	O
the	O
lack	O
of	O
therapy	O
for	O
EVD	O
,	O
restoring	O
the	O
immune	O
activation	O
is	O
a	O
promising	O
approach	O
for	O
drug	O
development	B-PROC
.	O

To	O
trace	O
the	O
evolution	B-PROC
of	O
type	O
I	O
and	O
II	O
feline	O
coronavirus	O
in	O
China	O
,	O
115	O
samples	O
of	O
ascetic	O
fluid	O
from	O
FIP	O
-	O
suspected	O
cats	O
and	O
54	O
fecal	O
samples	O
from	O
clinically	O
healthy	O
cats	O
were	O
collected	O
from	O
veterinary	O
hospitals	O
in	O
China	O
.	O

Principally	O
,	O
the	O
serotypes	O
are	O
identified	O
by	O
virus	B-PROC
neutralization	I-PROC
(	O
VN	O
)	O
tests	O
.	O

The	O
data	O
are	O
useful	O
for	O
the	O
development	B-PROC
of	O
new	O
vaccine	O
strategies	O
.	O

Keywords	O
:	O
avian	O
infectious	O
bronchitis	O
;	O
Iran	O
;	O
virus	B-PROC
neutralization	I-PROC
.	O

The	O
results	O
showed	O
that	O
the	O
IFN	O
-	O
β	O
expression	B-PROC
and	O
production	O
were	O
notably	O
inhibited	O
in	O
p53	O
-/-	O
PK	O
-	O
15	O
cells	O
compared	O
with	O
that	O
in	O
WT	O
PK	O
-	O
15	O
cells	O
at	O
early	O
stage	O
of	O
TGEV	O
infection	O
.	O

TITLE	O
:	O
[	O
Reye	O
syndrome	O
and	O
sudden	O
death	B-PROC
symptoms	O
after	O
oral	O
administration	O
of	O
nimesulide	O
due	O
to	O
upper	O
respiratory	O
tract	O
infection	O
in	O
a	O
boy	O
].	O

An	O
empirical	O
systemic	O
anticoagulation	B-PROC
protocol	O
(	O
heparin	O
intravenous	O
infusion	O
)	O
was	O
initiated	O
when	O
autopsy	O
of	O
patients	O
with	O
severe	O
hypoxemia	O
confirmed	O
multiple	O
primary	O
pulmonary	O
thrombi	O
and	O
emboli	O
.	O

In	O
multivariate	O
analysis	O
,	O
adjusting	O
for	O
H1N1	O
status	O
,	O
patients	O
without	O
empirical	O
systemic	O
anticoagulation	B-PROC
were	O
33	O
times	O
more	O
likely	O
to	O
have	O
any	O
VTE	O
compared	O
with	O
those	O
treated	O
with	O
empirical	O
systemic	O
heparin	O
anticoagulation	B-PROC
(	O
P	O
=	O
.	O
01	O
).	O

In	O
an	O
effort	B-PROC
to	O
enhance	O
respiratory	O
virus	O
surveillance	O
in	O
Singapore	O
,	O
our	O
team	O
conducted	O
a	O
pilot	O
study	O
employing	O
a	O
noninvasive	O
bioaerosol	O
sampling	O
method	O
to	O
detect	O
respiratory	O
viruses	O
in	O
Singapore	O
'	O
s	O
Mass	O
Rapid	O
Transit	O
(	O
MRT	O
)	O
network	O
.	O

In	O
the	O
present	O
case	O
,	O
no	O
casual	O
genetic	B-PROC
mutations	I-PROC
known	O
to	O
be	O
involved	O
in	O
humans	O
with	O
PVOD	O
and	O
PAH	O
were	O
found	O
.	O

Newborn	O
animals	O
and	O
humans	O
have	O
only	O
limited	O
immunity	B-PROC
upon	O
birth	B-PROC
,	O
but	O
their	O
immune	O
functions	O
are	O
expected	O
to	O
develop	O
within	O
weeks	O
to	O
months	O
and	O
eventually	O
to	O
reach	B-PROC
a	O
maturity	O
that	O
will	O
provide	O
full	O
protection	O
.	O

Despite	O
the	O
importance	O
of	O
immune	O
activity	O
in	O
animal	O
and	O
human	O
health	O
management	O
,	O
there	O
is	O
no	O
convenient	O
test	O
available	O
that	O
allows	O
for	O
rapid	O
assessment	O
of	O
the	O
state	O
of	O
immune	B-PROC
function	I-PROC
in	O
nonlaboratory	O
settings	O
.	O

Here	O
we	O
report	O
an	O
extremely	O
simple	O
and	O
rapid	O
blood	O
test	O
that	O
may	O
be	O
used	O
in	O
point	O
-	O
of	O
-	O
care	O
clinics	O
or	O
field	O
settings	O
to	O
evaluate	O
the	O
humoral	O
immune	B-PROC
status	I-PROC
of	O
animals	O
.	O

Although	O
variant	O
IBV	O
isolates	O
with	O
major	O
genetic	O
differences	O
have	O
been	O
subjected	O
to	O
comparative	O
studies	O
,	O
it	O
is	O
unknown	O
whether	O
minor	O
genetic	O
differences	O
in	O
IBV	O
variants	O
within	O
a	O
serotype	O
are	O
different	O
in	O
terms	O
of	O
pathogenesis	B-PROC
and	O
eliciting	O
host	O
responses	O
.	O

Meanwhile	O
,	O
the	O
loss	O
of	O
TRIM8	O
markedly	O
lessened	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
α	O
expression	B-PROC
in	O
lung	O
tissues	O
of	O
LPS	O
-	O
challenged	O
mice	O
,	O
and	O
reduced	O
NF	O
-	O
κB	O
phosphorylation	B-PROC
.	O

TITLE	O
:	O
Profile	O
analysis	O
of	O
circRNAs	O
induced	O
by	O
porcine	O
endemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
in	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
functional	O
annotation	O
analysis	O
revealed	O
that	O
the	O
parent	O
genes	O
of	O
differentially	O
expressed	B-PROC
circRNAs	O
might	O
be	O
associated	O
with	O
host	B-PROC
response	I-PROC
to	O
PEDV	O
infection	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
Conventional	O
RT	O
-	O
PCR	O
Assay	O
for	O
Rapid	O
Detection	O
of	O
Porcine	O
Deltacoronavirus	O
with	O
the	O
Same	O
Detection	O
Limit	O
as	O
a	O
SYBR	O
Green	O
-	O
Based	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
Assay	O
.	O

ABSTRACT	O
:	O
Adequate	O
oxygenation	B-PROC
is	O
one	O
of	O
the	O
primary	O
goals	O
of	O
mechanical	O
ventilation	O
.	O

Maintenance	O
of	O
adequate	O
oxygenation	B-PROC
and	O
prevention	O
of	O
hypoxemia	O
are	O
the	O
primary	O
goals	O
for	O
the	O
battlefield	O
casualty	O
,	O
but	O
military	O
operations	O
have	O
unique	O
concerns	O
.	O

The	O
SpO2	O
to	O
SaO2	B-PROC
difference	O
was	O
≤	O
4	O
%	O
throughout	O
the	O
evaluation	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
beginning	O
of	O
the	O
2000s	O
,	O
globalization	O
has	O
accelerated	O
because	O
of	O
the	O
development	B-PROC
of	O
transportation	O
systems	O
that	O
allow	O
for	O
human	O
and	O
material	O
exchanges	O
throughout	O
the	O
world	O
.	O

In	O
particular	O
,	O
avian	O
influenza	O
virus	O
(	O
AIV	O
)	O
is	O
highly	O
infectious	O
and	O
causes	O
economic	O
,	O
health	O
,	O
ethnical	O
,	O
and	O
social	O
problems	O
to	O
human	O
beings	O
,	O
which	O
has	O
necessitated	O
the	O
development	B-PROC
of	O
an	O
ultrasensitive	O
and	O
selective	O
rapid	O
-	O
detection	O
system	O
of	O
AIV	O
.	O

TITLE	O
:	O
[	O
Etiological	O
structure	O
of	O
influenza	O
and	O
other	O
ARVI	O
in	O
St	O
.	O
Petersburg	O
during	O
epidemic	O
seasons	O
2012	O
-	O
2016	O
.]	O
ABSTRACT	O
:	O
The	O
etiological	O
structure	O
of	O
influenza	O
and	O
other	O
acute	O
respiratory	O
viral	B-PROC
infections	I-PROC
including	O
their	O
rate	O
of	O
incidence	O
in	O
St	O
.	O
Petersburg	O
and	O
Leningrad	O
region	O
during	O
4	O
epidemic	O
seasons	O
has	O
been	O
studied	O
.	O

ANCA	O
is	O
a	O
disease	O
-	O
labeled	O
antibody	B-PROC
of	O
AAV	O
,	O
and	O
myeloperoxidase	O
(	O
MPO	O
)	O
and	O
proteinase	B-PROC
3	O
are	O
the	O
main	O
targeted	B-PROC
antigens	O
of	O
ANCA	O
.	O

Overlapping	O
peptides	O
spanning	O
the	O
whole	O
MERS	O
-	O
CoV	O
N	O
polypeptide	O
were	O
used	O
to	O
identify	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
I	O
/	O
II	O
-	O
restricted	O
T	O
cell	O
responses	O
in	O
BALB	O
/	O
c	O
mice	O
immunized	O
with	O
MVA	O
-	O
MERS	O
-	O
N	O
.	O
We	O
have	O
identified	O
a	O
H2	O
-	O
d	O
restricted	O
decamer	O
peptide	O
epitope	O
in	O
the	O
MERS	O
-	O
N	O
protein	O
with	O
CD8	O
+	O
T	O
cell	O
antigenicity	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
lung	B-PROC
compliance	I-PROC
,	O
the	O
applied	O
PEEP	O
and	O
the	O
plateau	O
pressures	O
across	O
trimesters	O
.	O

A	O
56	O
-	O
year	O
-	O
old	O
female	O
patient	O
(	O
case	O
1	O
)	O
and	O
a	O
78	O
-	O
year	O
-	O
old	O
female	O
patient	O
(	O
case	O
2	O
)	O
were	O
admitted	O
because	O
of	O
fever	B-PROC
,	O
cough	O
,	O
chest	O
tightness	O
and	O
shortness	O
of	O
breath	O
.	O

TITLE	O
:	O
Innate	B-PROC
Immune	I-PROC
Responses	I-PROC
and	O
Viral	O
-	O
Induced	O
Neurologic	O
Disease	O
.	O

In	O
this	O
review	O
,	O
we	O
have	O
summarized	O
some	O
of	O
the	O
recent	O
advancements	O
made	O
in	O
the	O
area	O
of	O
nucleic	O
acid	O
based	O
therapeutics	O
and	O
highlighted	O
the	O
emerging	O
roles	O
of	O
nucleic	O
acids	O
in	O
the	O
management	O
of	O
some	O
of	O
the	O
severe	O
respiratory	O
viral	B-PROC
infections	I-PROC
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
provides	O
a	O
circulatory	B-PROC
and	O
/	O
or	O
respiratory	O
assistance	O
in	O
case	O
of	O
refractory	O
cardiogenic	O
shock	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
is	O
enteropathogenic	O
coronavirus	O
that	O
causes	O
diarrhea	O
in	O
pigs	O
,	O
and	O
is	O
associated	O
with	O
high	O
morbidity	O
and	O
mortality	O
in	O
sucking	B-PROC
piglets	O
.	O

The	O
TGEV	O
membrane	O
(	O
M	O
)	O
protein	O
is	O
a	O
decisive	O
protein	O
for	O
the	O
proliferation	O
of	O
viral	O
proteins	O
,	O
and	O
is	O
associated	O
with	O
virus	B-PROC
assembly	I-PROC
and	O
budding	B-PROC
.	O

Due	O
to	O
clot	O
formation	B-PROC
,	O
an	O
oxygenator	O
change	O
-	O
out	O
was	O
necessary	O
shortly	O
after	O
initiation	O
.	O

ABSTRACT	O
:	O
ICAM	O
-	O
1	O
plays	O
a	O
critical	O
role	O
in	O
the	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Current	O
Understanding	O
of	O
Humoral	B-PROC
Immunity	I-PROC
to	O
Enterovirus	O
D68	O
.	O

We	O
aimed	O
to	O
characterize	O
viral	B-PROC
replication	I-PROC
and	O
pathogenesis	B-PROC
in	O
neonatal	O
gnotobiotic	O
pigs	O
infected	O
simultaneously	O
with	O
the	O
two	O
types	O
of	O
PEDV	O
using	O
two	O
recombinant	O
PEDVs	O
:	O
icPC22A	O
and	O
its	O
S1	O
NTD	O
-	O
del	O
form	O
icPC22A	O
-	O
S1Δ197	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
induces	O
TLR3	O
,	O
IL	O
-	O
12	O
,	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
and	O
PKR	O
mRNA	B-PROC
expression	B-PROC
in	O
infected	O
Peyer	O
'	O
s	O
patches	O
in	O
vivo	O
.	O

TITLE	O
:	O
Effect	O
of	O
route	O
of	O
inoculation	O
on	O
innate	O
and	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
to	O
porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
in	O
suckling	O
pigs	O
.	O

ABSTRACT	O
:	O
The	O
effects	O
of	O
route	O
of	O
administration	O
on	O
systemic	O
and	O
gut	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
induced	O
by	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
in	O
suckling	O
pigs	O
were	O
investigated	O
.	O

TITLE	O
:	O
Spotted	O
fever	B-PROC
rickettsioses	O
causing	O
myocarditis	O
and	O
ARDS	O
:	O
a	O
case	O
from	O
Sri	O
Lanka	O
.	O

Deceased	B-PROC
patients	O
underwent	O
autopsy	O
.	O

Although	O
9	O
-	O
O	O
-	O
acetylation	B-PROC
of	O
sialic	O
acids	O
on	O
multiple	O
hematopoietic	O
lineages	O
was	O
lost	O
,	O
there	O
were	O
no	O
obvious	O
defects	O
in	O
hematopoiesis	B-PROC
.	O

The	O
incidence	O
of	O
admission	O
due	O
to	O
AMI	O
during	O
an	O
acute	O
viral	B-PROC
infection	I-PROC
was	O
six	O
times	O
as	O
high	O
during	O
the	O
7	O
days	O
after	O
laboratory	O
confirmation	O
of	O
influenza	O
infection	O
as	O
during	O
the	O
control	O
interval	O
(	O
10	O
-	O
fold	O
in	O
influenza	O
B	O
,	O
5	O
-	O
fold	O
in	O
influenza	O
A	O
,	O
3	O
.	O
5	O
-	O
fold	O
in	O
respiratory	O
syncytial	O
virus	O
and	O
2	O
.	O
7	O
-	O
fold	O
for	O
all	O
other	O
viruses	O
).	O

Clinical	O
features	O
of	O
MERS	O
range	O
from	O
asymptomatic	O
or	O
mild	O
disease	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multi	O
-	O
organ	O
failure	O
resulting	O
in	O
death	B-PROC
,	O
especially	O
in	O
individuals	O
with	O
underlying	O
comorbidities	O
.	O

Available	O
immunosuppressive	O
antivirals	O
are	O
directed	O
to	O
control	O
an	O
often	O
exaggerated	O
pro	O
-	O
inflammatory	B-PROC
response	I-PROC
that	O
gives	O
rise	O
to	O
complex	O
clinical	O
conditions	O
such	O
as	O
lymphocytopenia	O
.	O

Using	O
mutagenesis	B-PROC
and	O
reverse	O
genetics	O
,	O
we	O
reveal	O
that	O
this	O
ncRNA	O
is	O
a	O
subgenomic	O
RNA	O
generated	O
by	O
discontinuous	O
transcription	B-PROC
mechanism	O
.	O

ABSTRACT	O
:	O
The	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
vulnerable	O
to	O
several	O
viral	B-PROC
infections	I-PROC
including	O
herpes	O
viruses	O
,	O
arboviruses	O
and	O
HIV	O
to	O
name	O
a	O
few	O
.	O

There	O
is	O
lack	O
of	O
data	O
on	O
the	O
management	O
of	O
severe	O
dengue	O
infection	O
during	O
labor	B-PROC
.	O

All	O
had	O
thrombocytopenia	O
at	O
the	O
moment	O
labor	B-PROC
started	O
.	O

We	O
then	O
characterized	O
this	O
mouse	O
model	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
expression	B-PROC
profile	O
of	O
hDPP4	O
in	O
these	O
mice	O
was	O
almost	O
equivalent	O
to	O
that	O
in	O
human	O
tissues	O
,	O
including	O
kidney	O
and	O
lung	O
;	O
however	O
,	O
hDPP4	O
was	O
overexpressed	O
in	O
murine	O
CD3	O
-	O
positive	O
cells	O
within	O
peripheral	O
blood	O
and	O
lymphoid	O
tissues	O
.	O

ABSTRACT	O
:	O
Intensive	O
care	O
unit	O
-	O
acquired	O
weakness	O
is	O
characterised	O
by	O
severe	O
impairment	O
of	O
muscle	B-PROC
function	I-PROC
that	O
often	O
arises	O
after	O
prolonged	O
mechanical	O
ventilation	O
,	O
difficult	O
weaning	B-PROC
,	O
and	O
severe	O
sepsis	O
.	O

Most	O
common	O
presenting	O
complaints	O
were	O
fever	B-PROC
and	O
colic	O
and	O
were	O
similar	O
across	O
groups	O
.	O

However	O
,	O
when	O
the	O
C5a	O
-	O
C5aR1	O
axis	O
was	O
blocked	O
by	O
an	O
anti	O
-	O
C5aR1	O
antibody	B-PROC
(	O
Ab	O
),	O
expression	B-PROC
of	O
caspase	O
-	O
1	O
and	O
IL	O
-	O
1β	O
fell	O
.	O

Of	O
them	O
,	O
3	O
reported	O
comorbidities	O
including	O
immunosuppression	B-PROC
and	O
1	O
patient	O
had	O
worse	O
outcome	O
,	O
requiring	O
ICU	O
admission	O
.	O

Tidal	O
volume	O
,	O
based	O
on	O
both	O
actual	O
body	O
weight	O
and	O
ideal	O
body	O
weight	O
,	O
was	O
not	O
associated	O
with	O
either	O
increased	O
mortality	O
or	O
decreased	O
probability	O
of	O
extubation	O
after	O
adjusting	O
for	O
oxygenation	B-PROC
index	O
in	O
the	O
whole	O
cohort	O
,	O
whereas	O
associations	O
between	O
higher	O
tidal	O
volume	O
and	O
poor	O
outcomes	O
were	O
seen	O
in	O
subgroup	O
analyses	O
in	O
overweight	O
children	O
and	O
in	O
severe	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

Ubiquitin	B-PROC
-	O
like	O
interferon	O
-	O
stimulated	O
gene	O
product	O
15	O
(	O
ISG15	O
)	O
is	O
a	O
key	O
modulator	O
of	O
these	O
interferon	O
responses	O
.	O

ABSTRACT	O
:	O
The	O
study	O
objective	O
was	O
to	O
compare	O
titration	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
with	O
electrical	B-PROC
impedance	I-PROC
tomography	O
(	O
EIT	O
)	O
and	O
with	O
ventilator	O
-	O
embedded	O
pressure	O
-	O
volume	O
loop	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Hypersensitivity	B-PROC
reactions	I-PROC
to	O
this	O
drug	O
involve	O
a	O
wide	O
range	O
of	O
symptoms	O
of	O
various	O
importance	O
for	O
patient	O
management	O
.	O

Frequencies	O
≥	O
8	O
Hz	O
and	O
high	O
∆	O
P	O
This	O
is	O
the	O
first	O
study	O
reporting	O
the	O
feasibility	O
of	O
an	O
alternative	O
,	O
individualized	O
,	O
physiology	O
-	O
based	O
open	O
-	O
lung	O
HFOV	O
strategy	O
targeting	B-PROC
high	O
F	O
and	O
high	O
∆	O
P	O
RESULTS	O
:	O
Data	O
from	O
115	O
non	O
-	O
cardiac	O
patients	O
were	O
analysed	O
,	O
of	O
whom	O
53	O
had	O
moderate	O
-	O
to	O
-	O
severe	O
paediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PARDS	O
).	O

Here	O
,	O
serum	O
-	O
derived	O
EVs	O
from	O
severe	O
TBI	O
patients	O
were	O
analyzed	O
for	O
particle	O
size	O
,	O
concentration	O
,	O
origin	O
,	O
and	O
levels	O
of	O
the	O
inflammasome	O
component	O
,	O
an	O
apoptosis	B-PROC
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
caspase	O
-	O
recruiting	O
domain	O
(	O
ASC	O
).	O

The	O
pipeline	O
has	O
been	O
validated	O
on	O
human	O
immunodeficiency	O
virus	O
,	O
human	O
parainfluenza	O
virus	O
1	O
-	O
4	O
,	O
human	O
metapneumovirus	O
,	O
human	O
coronaviruses	O
(	O
229E	O
/	O
OC43	O
/	O
NL63	O
/	O
HKU1	O
/	O
SARS	O
/	O
MERS	O
),	O
human	O
enteroviruses	O
/	O
rhinoviruses	O
,	O
measles	O
virus	O
,	O
mumps	O
virus	O
,	O
Hepatitis	O
A	O
-	O
E	O
Virus	O
,	O
Chikungunya	O
virus	O
,	O
dengue	O
virus	O
,	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
as	O
well	O
the	O
human	O
polyomaviruses	O
BK	O
/	O
JC	O
/	O
MCV	O
,	O
human	O
adenoviruses	O
,	O
and	O
human	O
papillomaviruses	O
.	O

Whether	O
these	O
are	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
human	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
could	O
be	O
a	O
potential	O
therapeutic	O
target	O
is	O
unknown	O
.	O

In	O
conclusion	O
,	O
we	O
analyzed	O
the	O
genetic	O
variation	O
and	O
pathogenicity	O
of	O
the	O
emerging	O
PEDV	O
isolates	O
of	O
China	O
,	O
indicating	O
that	O
G2	O
variant	O
PEDV	O
strains	O
as	O
the	O
main	O
prevalent	O
strains	O
that	O
may	O
mutate	B-PROC
continually	O
.	O

It	O
is	O
predicted	O
that	O
the	O
inherent	O
genetic	O
diversity	O
of	O
CoVs	O
caused	O
by	O
accumulation	O
of	O
point	B-PROC
mutations	I-PROC
and	O
high	O
frequency	O
of	O
homologous	B-PROC
recombination	B-PROC
is	O
the	O
principal	O
determinant	O
of	O
these	O
competences	O
.	O

The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
the	O
development	B-PROC
of	O
ARDS	O
.	O

TITLE	O
:	O
A	O
3	O
-	O
Year	O
Retrospective	O
Study	O
of	O
the	O
Epidemiology	O
of	O
Acute	O
Respiratory	O
Viral	B-PROC
Infections	I-PROC
in	O
Pediatric	O
Patients	O
With	O
Cancer	O
Undergoing	O
Chemotherapy	O
.	O

Our	O
second	O
aim	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
viral	B-PROC
infections	I-PROC
on	O
delaying	O
the	O
patients	O
'	O
chemotherapy	O
or	O
radiotherapy	O
.	O

Natural	O
initial	O
enteric	O
FCoV	O
infection	O
may	O
remain	O
subclinical	O
,	O
or	O
result	O
in	O
mild	O
enteric	O
signs	O
or	O
the	O
development	B-PROC
of	O
FIP	O
;	O
cats	O
may	O
also	O
carry	O
the	O
virus	O
systemically	O
with	O
no	O
adverse	O
effect	O
.	O

Higher	O
expression	B-PROC
levels	O
in	O
FIP	O
were	O
found	O
for	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
2	O
,	O
4	O
and	O
8	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
characterized	O
by	O
an	O
acute	B-PROC
inflammatory	I-PROC
response	I-PROC
in	O
the	O
lung	O
parenchyma	O
leading	O
to	O
severe	O
hypoxemia	O
.	O

Accordingly	O
,	O
the	O
full	O
genome	O
sequence	O
was	O
retrieved	O
from	O
the	O
UK	O
rat	O
coronavirus	O
,	O
along	O
with	O
partial	O
genome	O
sequences	O
from	O
the	O
UK	O
field	O
vole	O
and	O
Poland	O
-	O
resident	O
bank	O
vole	O
CoVs	O
,	O
and	O
a	O
short	O
conserved	O
ORF1b	O
fragment	O
from	O
the	O
French	O
rabbit	O
CoV	O
.	O
Genome	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
despite	O
their	O
diverse	O
geographic	O
origins	O
,	O
all	O
rodent	O
alpha	O
-	O
CoVs	O
formed	O
a	O
single	O
monophyletic	O
group	O
and	O
shared	O
similar	O
features	O
,	O
such	O
as	O
the	O
same	O
gene	O
constellations	O
,	O
a	O
recombinant	O
beta	O
-	O
CoV	O
spike	O
gene	O
,	O
and	O
similar	O
core	O
transcriptional	B-PROC
regulatory	O
sequences	O
(	O
TRS	O
).	O

TITLE	O
:	O
Development	B-PROC
and	O
application	O
of	O
an	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
using	O
recombinant	O
S1	O
for	O
serological	O
testing	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

This	O
rS1	O
-	O
ELISA	O
was	O
then	O
applied	O
to	O
antibody	B-PROC
detection	O
in	O
inactivated	O
PEDV	O
vaccinated	O
pigs	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
presence	O
of	O
unilateral	O
or	O
bilateral	O
diaphragmatic	O
paralysis	O
of	O
undetermined	O
aetiology	O
,	O
it	O
seems	O
relevant	O
to	O
perform	O
Lyme	O
serology	O
in	O
the	O
blood	O
and	O
,	O
in	O
positive	O
cases	O
,	O
to	O
follow	O
up	O
with	O
a	O
lumbar	O
puncture	O
in	O
order	O
to	O
detect	O
intrathecal	O
IgG	O
synthesis	B-PROC
.	O

Host	O
-	O
based	O
antiviral	O
agents	O
target	O
host	O
cellular	O
machineries	O
essential	O
for	O
viral	B-PROC
infections	I-PROC
or	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
interfere	O
with	O
viral	O
pathogenesis	B-PROC
.	O

Although	O
the	O
two	O
antibodies	O
studied	O
blocked	O
attachment	O
to	O
the	O
host	O
cell	O
receptor	O
,	O
only	O
the	O
anti	O
-	O
SARS	O
-	O
CoV	O
S	O
antibody	B-PROC
triggered	O
fusogenic	O
conformational	O
changes	O
via	O
receptor	O
functional	O
mimicry	O
.	O

These	O
results	O
provide	O
a	O
structural	O
framework	O
for	O
understanding	O
coronavirus	O
neutralization	O
by	O
human	O
antibodies	O
and	O
shed	O
light	O
on	O
activation	O
of	O
coronavirus	O
membrane	B-PROC
fusion	I-PROC
,	O
which	O
takes	O
place	O
through	O
a	O
receptor	O
-	O
driven	O
ratcheting	O
mechanism	O
.	O

ABSTRACT	O
:	O
Tension	O
pneumoperitoneum	O
is	O
a	O
severe	O
and	O
rare	O
form	O
of	O
pneumoperitoneum	O
with	O
concomitant	O
hemodynamic	B-PROC
instability	O
and	O
respiratory	O
failure	O
.	O

This	O
analysis	O
provides	O
key	O
initial	O
evidence	O
of	O
an	O
environmental	O
component	O
contributing	O
to	O
the	O
development	B-PROC
of	O
primary	O
MERS	O
-	O
CoV	O
infections	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
Evaluation	O
of	O
a	O
Multiplexed	O
Immunoassay	O
for	O
Simultaneous	O
Detection	O
of	O
Serum	O
IgG	O
Antibodies	O
to	O
Six	O
Human	O
Coronaviruses	O
.	O

However	O
,	O
accumulating	O
evidence	O
indicates	O
that	O
spontaneous	O
effort	B-PROC
may	O
cause	O
or	O
worsen	O
lung	O
and	O
diaphragm	O
injury	O
,	O
especially	O
if	O
the	O
ARDS	O
is	O
severe	O
or	O
spontaneous	O
effort	B-PROC
is	O
vigorous	O
.	O

Prior	O
adenovirus	O
or	O
influenza	O
virus	B-PROC
infection	I-PROC
conferred	O
cross	O
-	O
protection	O
against	O
subsequent	O
FRI	O
episodes	O
relative	O
to	O
prior	O
infection	O
due	O
to	O
other	O
circulating	O
viruses	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
vvECMO	O
)	O
has	O
not	O
unequivocally	O
been	O
shown	O
to	O
improve	O
survival	O
.	O

TITLE	O
:	O
Severe	O
thoracic	O
trauma	O
caused	O
left	O
pneumonectomy	O
complicated	O
by	O
right	O
traumatic	O
wet	O
lung	O
,	O
reversed	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
-	O
a	O
case	O
report	O
.	O

In	O
most	O
cases	O
,	O
when	O
the	O
patients	O
'	O
vital	O
signs	O
have	O
been	O
stabilized	O
,	O
the	O
repair	B-PROC
can	O
be	O
performed	O
.	O

Thus	O
,	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
V	O
-	O
V	O
ECMO	O
)	O
was	O
initiated	O
;	O
upon	O
improvement	O
of	O
oxygenation	B-PROC
,	O
the	O
patient	O
received	O
an	O
exploratory	O
thoracotomy	O
.	O

Samples	O
were	O
tested	O
using	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reactions	O
and	O
microarray	O
.	O

Single	O
-	O
chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
antibodies	O
effectively	O
inhibit	O
virus	B-PROC
infection	I-PROC
and	O
could	O
be	O
a	O
potential	O
therapeutic	O
reagent	O
for	O
preventing	O
disease	O
.	O

TITLE	O
:	O
HIPK1	O
Interference	O
Attenuates	O
Inflammation	O
and	O
Oxidative	O
Stress	O
of	O
Acute	O
Lung	O
Injury	O
via	O
Autophagy	B-PROC
.	O

It	O
is	O
usually	O
caused	O
by	O
A	O
young	O
Romanian	O
male	O
presented	O
with	O
fever	B-PROC
and	O
rigors	O
,	O
mild	O
tachypnea	O
,	O
hypoxia	O
,	O
sore	O
throat	O
,	O
decayed	O
teeth	O
,	O
and	O
tenderness	O
of	O
the	O
left	O
carotid	O
triangle	O
.	O

ABSTRACT	O
:	O
Nod	O
-	O
like	O
receptor	O
family	O
,	O
pyrin	O
domain	O
-	O
containing	O
3	O
(	O
NLRP3	O
)	O
regulates	O
the	O
secretion	B-PROC
of	O
proinflammatory	O
cytokines	O
interleukin	O
1	O
beta	O
(	O
IL	O
-	O
1β	O
)	O
and	O
IL	O
-	O
18	O
.	O

While	O
cells	O
uninfected	O
or	O
infected	O
with	O
a	O
lentivirus	O
expressing	O
a	O
3a	O
protein	O
defective	O
in	O
ion	O
channel	O
activity	O
expressed	B-PROC
NLRP3	O
uniformly	O
throughout	O
the	O
cytoplasm	O
,	O
NLRP3	O
was	O
redistributed	O
to	O
the	O
perinuclear	O
space	O
in	O
cells	O
infected	O
with	O
a	O
lentivirus	O
expressing	O
the	O
3a	O
protein	O
.	O

The	O
IBV	O
single	O
-	O
stranded	O
RNA	O
genome	O
has	O
high	O
rates	O
of	O
mutation	O
and	O
recombination	B-PROC
that	O
generate	O
a	O
notorious	O
virus	O
variability	O
.	O

Molecular	O
diagnostics	O
can	O
improve	O
management	O
of	O
febrile	B-PROC
episodes	O
and	O
reduce	O
antibiotic	O
use	O
.	O

To	O
find	O
correlates	O
of	O
IBV	O
-	O
vaccine	O
-	O
induced	O
protection	O
,	O
hence	O
,	O
we	O
employed	O
a	O
flow	O
cytometric	O
assay	O
to	O
quantify	O
peripheral	O
leucocyte	O
subsets	O
and	O
expression	B-PROC
of	O
cell	O
surface	O
markers	O
of	O
six	O
different	O
non	O
-	O
vaccinated	O
and	O
vaccinated	O
Major	B-PROC
Histocompatibility	I-PROC
Complex	I-PROC
(	O
MHC	B-PROC
)	O
haplotypes	O
.	O

Non	O
-	O
vaccinated	O
and	O
vaccinated	O
MHC	B-PROC
haplotypes	O
presented	O
differential	O
leucocyte	O
composition	O
and	O
IBV	O
viral	O
load	O
.	O

Fourteen	O
patients	O
were	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
and	O
six	O
patients	O
died	B-PROC
(	O
five	O
premature	O
deaths	B-PROC
).	O

Here	O
,	O
we	O
show	O
that	O
enhanced	O
inflammatory	O
cytokine	B-PROC
production	I-PROC
in	O
response	B-PROC
to	I-PROC
lipopolysaccharide	I-PROC
(	O
LPS	O
)	O
is	O
due	O
to	O
increased	O
TGF	O
-	O
β	O
-	O
activated	O
kinase	O
-	O
1	O
(	O
TAK1	O
)	O
phosphorylation	B-PROC
with	O
subsequent	O
activation	O
of	O
nuclear	O
factor	O
-	O
κB	O
(	O
NF	O
-	O
κB	O
).	O

We	O
created	O
decision	O
trees	O
to	O
model	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
from	O
ICU	O
admission	O
through	O
death	B-PROC
(	O
societal	O
perspective	O
)	O
and	O
hospital	O
discharge	O
(	O
hospital	O
perspective	O
).	O

We	O
discovered	O
92	O
pathways	B-PROC
that	O
were	O
significantly	O
different	O
between	O
ARDS	O
and	O
control	O
groups	O
,	O
including	O
57	O
pathways	B-PROC
linked	O
to	O
metabolism	B-PROC
.	O

TITLE	O
:	O
Incidence	O
of	O
hospitalisation	O
for	O
severe	O
complications	O
of	O
influenza	O
virus	B-PROC
infection	I-PROC
in	O
Japanese	O
patients	O
between	O
2012	O
and	O
2016	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
using	O
routinely	O
collected	O
administrative	O
data	O
.	O

TITLE	O
:	O
Chemical	O
synthesis	B-PROC
,	O
crystal	O
structure	O
,	O
versatile	O
evaluation	O
of	O
their	O
biological	O
activities	O
and	O
molecular	O
simulations	O
of	O
novel	O
pyrithiobac	O
derivatives	O
.	O

The	O
viral	B-PROC
infection	I-PROC
surveillance	O
method	O
using	O
metagenomics	O
technology	O
enables	O
the	O
monitoring	O
of	O
multiple	O
viral	B-PROC
infections	I-PROC
,	O
which	O
allows	O
the	O
detection	O
of	O
main	O
infectious	O
viruses	O
.	O

TITLE	O
:	O
Enhanced	O
Ability	O
of	O
Oligomeric	O
Nanobodies	O
Targeting	B-PROC
MERS	O
Coronavirus	O
Receptor	O
-	O
Binding	O
Domain	O
.	O

We	O
generated	O
two	O
oligomeric	O
Nbs	O
by	O
linking	O
two	O
or	O
three	O
monomeric	O
Nbs	O
(	O
Mono	O
-	O
Nbs	O
)	O
targeting	B-PROC
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
and	O
compared	O
their	O
RBD	O
-	O
binding	O
affinity	O
,	O
RBD	O
⁻	O
receptor	O
binding	O
inhibition	B-PROC
,	O
stability	O
,	O
and	O
neutralizing	O
and	O
cross	O
-	O
neutralizing	O
activity	O
against	O
MERS	O
-	O
CoV	O
.	O
Relative	O
to	O
Mono	O
-	O
Nb	O
,	O
dimeric	O
Nb	O
(	O
Di	O
-	O
Nb	O
)	O
and	O
trimeric	O
Nb	O
(	O
Tri	O
-	O
Nb	O
)	O
had	O
significantly	O
greater	O
ability	O
to	O
bind	O
MERS	O
-	O
CoV	O
RBD	O
proteins	O
with	O
or	O
without	O
mutations	O
in	O
the	O
RBD	O
,	O
thereby	O
potently	O
blocking	O
RBD	O
⁻	O
MERS	O
-	O
CoV	O
receptor	O
binding	O
.	O

Areas	O
covered	O
:	O
This	O
manuscript	O
provides	O
an	O
in	O
-	O
depth	O
overview	O
of	O
the	O
pathogenesis	B-PROC
,	O
clinical	O
characteristics	O
,	O
current	O
toxicity	O
management	O
strategies	O
,	O
and	O
future	O
perspectives	O
pertaining	O
to	O
CRS	O
and	O
neurotoxicity	O
.	O

ABSTRACT	O
:	O
A	O
7	O
-	O
month	O
-	O
old	O
male	O
baby	O
presented	O
to	O
the	O
pediatric	O
hematology	O
unit	O
for	O
investigations	O
of	O
recurrent	O
episodes	O
of	O
neutropenia	O
associated	O
with	O
fever	B-PROC
and	O
respiratory	O
distress	O
.	O

Lower	O
induction	B-PROC
of	I-PROC
apoptosis	I-PROC
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
CARD	O
(	O
ASC	O
)	O
speck	O
formation	B-PROC
and	O
secretion	B-PROC
of	O
interleukin	O
-	O
1β	O
in	O
response	O
to	O
both	O
'	O
sterile	O
'	O
stimuli	O
and	O
infection	O
with	O
multiple	O
zoonotic	O
viruses	O
including	O
influenza	O
A	O
virus	O
(-	O
single	O
-	O
stranded	O
(	O
ss	O
)	O
RNA	O
),	O
Melaka	O
virus	O
(	O
PRV3M	O
,	O
double	O
-	O
stranded	O
RNA	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(+	O
ssRNA	O
)	O
was	O
observed	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
glutamine	B-PROC
metabolism	I-PROC
accelerates	O
resolution	O
of	O
acute	O
lung	O
injury	O
.	O

Due	O
to	O
their	O
high	O
metabolic	B-PROC
needs	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
and	O
lymphocytes	O
rely	O
upon	O
glutamine	B-PROC
metabolism	I-PROC
to	O
support	O
activation	O
and	O
function	O
.	O

Additionally	O
,	O
during	O
times	O
of	O
physiologic	O
stress	O
,	O
nearly	O
all	O
cells	O
,	O
including	O
fibroblasts	O
and	O
epithelial	O
cells	O
,	O
require	O
glutamine	B-PROC
metabolism	I-PROC
.	O

These	O
data	O
contribute	O
to	O
our	O
understanding	O
of	O
how	O
glutamine	B-PROC
metabolism	I-PROC
regulates	O
lung	O
inflammation	O
and	O
repair	B-PROC
,	O
and	O
identifies	O
a	O
novel	O
target	O
for	O
future	O
therapies	O
for	O
ARDS	O
and	O
other	O
inflammatory	O
lung	O
diseases	O
.	O

TITLE	O
:	O
Early	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
infants	O
with	O
cystic	O
fibrosis	O
.	O

Past	O
viral	B-PROC
infection	I-PROC
was	O
associated	O
with	O
elevated	O
neutrophil	O
concentrations	O
and	O
bacterial	O
isolates	O
in	O
BAL	O
fluid	O
,	O
including	O
recovery	O
of	O
classic	O
CF	O
bacterial	O
pathogens	O
.	O

Early	O
viral	B-PROC
infections	I-PROC
appear	O
to	O
contribute	O
to	O
initiation	O
of	O
lower	O
airway	O
inflammation	O
in	O
infants	O
with	O
CF	O
.	O

Oxygenation	B-PROC
was	O
improved	O
obviously	O
after	O
treatment	O
,	O
ventilator	O
support	O
conditions	O
could	O
be	O
obviously	O
reduced	O
,	O
including	O
3	O
-	O
6	O
mL	O
/	O
kg	O
of	O
the	O
small	O
tidal	O
volume	O
,	O
8	O
-	O
10	O
cmH	O

In	O
addition	O
,	O
the	O
immunologic	O
effect	O
of	O
CAV	O
provokedthe	O
development	B-PROC
of	O
clinical	O
signs	O
of	O
LPAI	O
-	O
H9N2	O
and	O
IB	O
virus	O
infections	O
.	O

Taken	O
together	O
,	O
the	O
data	O
presented	O
in	O
this	O
study	O
indicate	O
that	O
GIIa	O
strain	O
-	O
based	O
inactivated	O
vaccine	O
candidates	O
are	O
more	O
promising	O
than	O
GIIb	O
-	O
based	O
candidates	O
for	O
the	O
development	B-PROC
of	O
an	O
effective	O
vaccine	O
against	O
the	O
current	O
highly	O
virulent	O
pandemic	O
PEDV	O
strains	O
.	O

Subsequently	O
,	O
she	O
improved	O
clinically	O
and	O
was	O
successfully	O
weaned	B-PROC
from	O
ECMO	O
.	O

Our	O
findings	O
reveal	O
a	O
mechanism	O
responsible	O
for	O
virus	O
-	O
mediated	O
ALI	O
,	O
define	O
a	O
pathological	O
consequence	O
of	O
viral	O
specific	O
antibody	B-PROC
response	I-PROC
,	O
and	O
provide	O
a	O
potential	O
target	O
for	O
treatment	O
of	O
SARS	O
-	O
CoV	O
or	O
other	O
virus	O
-	O
mediated	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Viral	O
respiratory	O
and	O
intestinal	O
infections	O
are	O
the	O
most	O
common	O
causes	O
of	O
canine	O
viral	B-PROC
illness	I-PROC
.	O

The	O
second	O
outcomes	O
were	O
to	O
determine	O
the	O
risk	O
factors	O
of	O
mortality	O
of	O
ARDS	O
in	O
leptospirosis	O
and	O
to	O
describe	O
the	O
cases	O
requiring	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
(	O
ECMO	O
).	O

Protection	O
in	O
alpaca	O
correlates	O
with	O
high	O
serum	O
neutralizing	O
antibody	B-PROC
titers	O
.	O

We	O
restructure	O
the	O
original	O
data	O
into	O
run	O
-	O
off	O
triangle	O
data	O
,	O
where	O
the	O
cells	O
contain	O
the	O
numbers	O
of	O
cured	O
patients	O
,	O
deceased	B-PROC
patients	O
,	O
and	O
patients	O
still	O
having	O
the	O
disease	O
at	O
a	O
given	O
combination	O
of	O
calendar	O
and	O
disease	O
-	O
duration	O
times	O
.	O

We	O
demonstrated	O
that	O
PEDV	O
N	O
expression	B-PROC
positively	O
affected	O
both	O
recovery	O
of	O
PEDV	O
from	O
infectious	O
clones	O
and	O
PEDV	O
propagation	O
in	O
cell	O
culture	O
.	O

Compared	O
to	O
Vero	O
E6	O
cells	O
,	O
Vero	O
E6	O
cells	O
expressing	O
PEDV	O
N	O
could	O
accelerate	O
growth	B-PROC
of	O
a	O
slow	O
-	O
growing	O
PEDV	O
strain	O
to	O
higher	O
peak	O
titers	O
by	O
12	O
hours	O
or	O
enhance	O
the	O
yield	O
of	O
a	O
vaccine	O
candidate	O
strain	O
by	O
two	O
orders	O
of	O
magnitude	O
.	O

Lower	O
median	O
peak	O
inspiratory	B-PROC
pressure	O
and	O
median	O
dynamic	O
driving	O
pressure	O
were	O
observed	O
in	O
the	O
extended	O
group	O
24	O
hours	O
after	O
ECMO	O
support	O
.	O

To	O
study	O
the	O
receptor	B-PROC
interactions	I-PROC
as	O
a	O
determinant	O
for	O
tropism	B-PROC
and	O
pathogenicity	O
,	O
recombinant	O
S1	O
proteins	O
were	O
produced	O
and	O
analyzed	O
by	O
glycan	O
and	O
tissue	O
arrays	O
.	O

ABSTRACT	O
:	O
Due	O
to	O
the	O
inconsistent	O
development	B-PROC
of	O
enteric	O
signs	O
associated	O
with	O
ECoV	O
infection	O
in	O
adult	O
horses	O
,	O
many	O
practitioners	O
collect	O
nasal	O
secretions	O
rather	O
than	O
feces	O
for	O
the	O
molecular	O
diagnostic	O
work	O
-	O
up	O
of	O
such	O
horses	O
.	O

However	O
,	O
activation	O
of	O
the	O
ER	B-PROC
stress	I-PROC
response	I-PROC
was	O
significantly	O
reduced	O
in	O
cells	O
infected	O
with	O
rN3D	O
/	O
N6D	O
,	O
correlated	O
with	O
a	O
lower	O
level	O
of	O
apoptosis	B-PROC
and	O
reduced	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

The	O
incidence	O
of	O
cannula	O
-	O
related	O
venous	O
thrombosis	O
after	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
high	O
.	O

In	O
general	O
,	O
camels	O
only	O
show	O
minor	O
clinical	O
signs	O
of	O
disease	O
after	O
being	O
infected	O
with	O
MERS	O
-	O
CoV	O
.	O
Serological	O
evidence	O
of	O
MERS	O
-	O
CoV	O
in	O
camels	O
has	O
been	O
found	O
in	O
20	O
countries	O
,	O
with	O
molecular	O
evidence	O
for	O
virus	O
circulation	B-PROC
in	O
13	O
countries	O
.	O

High	O
fever	B-PROC
,	O
rigors	O
,	O
headache	O
,	O
pain	O
and	O
prostration	O
start	O
abruptly	O
,	O
2	O
-	O
18	O
days	O
after	O
infection	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
long	O
-	O
term	O
outcomes	O
of	O
ARDS	O
patients	O
treated	O
with	O
or	O
without	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

One	O
year	O
after	O
discharge	O
,	O
survivors	O
underwent	O
pulmonary	B-PROC
function	I-PROC
tests	O
,	O
computed	O
tomography	O
of	O
the	O
chest	O
,	O
and	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
questionnaires	O
.	O

Eighty	O
-	O
four	O
patients	O
(	O
34	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
50	O
non	O
-	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
)	O
were	O
studied	O
;	O
both	O
groups	O
had	O
similar	O
characteristics	O
at	O
baseline	O
,	O
but	O
comorbidity	O
was	O
more	O
common	O
in	O
non	O
-	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
23	O
of	O
50	O
vs	O
.	O
4	O
of	O
34	O
,	O
46	O
%	O
vs	O
.	O
12	O
%,	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
severity	O
of	O
hypoxemia	O
was	O
greater	O
in	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
median	O
PaO2	O
/	O
FIO2	O
72	O
[	O
interquartile	O
range	O
,	O
50	O
to	O
103	O
]	O
vs	O
.	O
114	O
[	O
87	O
to	O
133	O
]	O
mm	O
Hg	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
respiratory	O
compliance	O
worse	O
.	O

Despite	O
more	O
severe	O
respiratory	O
failure	O
at	O
admission	O
,	O
1	O
-	O
yr	O
survival	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
patients	O
was	O
not	O
different	O
from	O
that	O
of	O
non	O
-	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
patients	O
;	O
each	O
group	O
had	O
almost	O
full	O
recovery	O
of	O
lung	B-PROC
function	I-PROC
,	O
but	O
non	O
-	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
patients	O
had	O
greater	O
impairment	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

Although	O
Brazil	O
has	O
18	O
%	O
of	O
global	O
avian	O
species	O
diversity	O
,	O
studies	O
regarding	O
the	O
presence	O
of	O
avian	O
viral	B-PROC
diseases	I-PROC
in	O
wild	O
birds	O
in	O
South	O
America	O
are	O
scarce	O
.	O

Oropharyngeal	O
and	O
cloacal	O
swabs	O
were	O
obtained	O
and	O
placed	O
together	O
in	O
vials	O
containing	O
VTM	O
transport	B-PROC
medium	O
collected	O
in	O
different	O
regions	O
of	O
Brazil	O
between	O
2006	O
and	O
2013	O
.	O

Fourteen	O
days	O
after	O
the	O
aforementioned	O
therapy	O
,	O
the	O
patient	O
began	O
to	O
recover	B-PROC
and	O
she	O
was	O
discharged	O
on	O
day	O
81	O
postoperatively	O
.	O

There	O
are	O
a	O
few	O
species	O
of	O
rodent	O
-	O
infective	O
malaria	O
parasites	O
,	O
and	O
mice	O
infected	O
with	O
such	O
parasites	O
are	O
now	O
widely	O
used	O
for	O
screening	O
candidate	O
drugs	O
and	O
vaccines	O
and	O
for	O
studying	O
host	O
immune	B-PROC
responses	I-PROC
and	O
pathogenesis	B-PROC
associated	O
with	O
disease	O
-	O
related	O
complications	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
shedding	O
and	O
antibody	B-PROC
responses	I-PROC
are	O
not	O
fully	O
understood	O
,	O
particularly	O
in	O
relation	O
to	O
underlying	O
medical	O
conditions	O
,	O
clinical	O
manifestations	O
,	O
and	O
mortality	O
.	O

These	O
findings	O
should	O
be	O
considered	O
in	O
the	O
development	B-PROC
of	O
infection	O
control	O
policies	O
,	O
vaccines	O
,	O
and	O
antibody	B-PROC
therapeutics	O
.	O

As	O
such	O
,	O
they	O
are	O
the	O
excellent	O
surrogates	O
of	O
native	O
virions	O
for	O
studying	O
viral	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
.	O

Liver	O
suture	O
was	O
performed	O
,	O
but	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO2	O
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
,	O
50	O
)	O
necessitated	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Endovascular	O
aneurysm	O
repair	B-PROC
of	O
aortic	O
dissection	O
and	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
were	O
performed	O
.	O

TITLE	O
:	O
Respiratory	O
Management	O
in	O
Smoke	O
Inhalation	B-PROC
Injury	O
.	O

TITLE	O
:	O
Host	O
Determinants	O
of	O
MERS	O
-	O
CoV	O
Transmission	O
and	O
Pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
as	O
salvage	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
gaining	O
greater	O
acceptance	O
among	O
trauma	O
intensivists	O
.	O

To	O
date	O
,	O
the	O
only	O
proven	O
route	O
of	O
transmission	O
is	O
the	O
faecal	O
-	O
oral	O
route	O
,	O
but	O
a	O
possible	O
localisation	B-PROC
of	O
FCoV	O
in	O
the	O
reproductive	B-PROC
tract	O
of	O
tom	O
cats	O
is	O
of	O
concern	O
,	O
owing	O
to	O
the	O
involvement	O
of	O
the	O
male	O
reproductive	B-PROC
tract	O
during	O
FIP	O
and	O
to	O
the	O
presence	O
of	O
reproduction	B-PROC
disorders	O
in	O
FCoV	O
-	O
endemic	O
feline	O
catteries	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
presence	O
and	O
localisation	B-PROC
of	O
FCoV	O
in	O
semen	O
and	O
/	O
or	O
in	O
the	O
reproductive	B-PROC
tract	O
of	O
tom	O
cats	O
,	O
and	O
its	O
possible	O
association	O
with	O
seroconversion	O
and	O
viraemic	O
phase	O
.	O

Taken	O
together	O
,	O
this	O
shRNAs	O
expression	B-PROC
system	O
not	O
only	O
is	O
proved	O
to	O
be	O
a	O
novel	O
approach	O
for	O
studying	O
functions	O
of	O
various	O
genes	O
synchronously	O
,	O
but	O
also	O
developed	O
to	O
test	O
aspects	O
of	O
a	O
potential	O
therapeutic	O
option	O
for	O
treatment	O
and	O
prevention	O
of	O
multiple	O
SECoV	O
infections	O
.	O

Pathologies	O
with	O
similar	O
meaning	O
and	O
possibly	O
similar	O
clinical	O
course	O
cannot	O
,	O
actually	O
,	O
be	O
differentiated	B-PROC
;	O
they	O
may	O
accompany	O
other	O
injuries	O
to	O
the	O
trunk	O
,	O
skull	O
or	O
extremities	O
,	O
which	O
,	O
alone	O
,	O
are	O
associated	O
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
solitary	O
chemosensory	O
cells	O
in	O
the	O
distal	O
lung	O
after	O
severe	O
influenza	O
injury	O
.	O

As	O
during	O
infection	O
by	O
other	O
viruses	O
,	O
host	O
sensing	O
of	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
induces	O
several	O
antiviral	O
pathways	B-PROC
.	O

NS4a	O
has	O
been	O
previously	O
characterized	O
as	O
a	O
dsRNA	O
binding	O
protein	O
,	O
while	O
NS4b	O
is	O
a	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-PROC
with	O
structural	O
and	O
enzymatic	O
similarity	O
to	O
NS2	O
encoded	O
by	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Here	O
,	O
we	O
report	O
genetic	O
analysis	O
of	O
a	O
ts	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
tsNC11	O
,	O
focusing	O
on	O
the	O
role	O
of	O
mutations	O
in	O
the	O
macrodomain	O
(	O
MAC	O
)	O
and	O
the	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
domain	O
of	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
),	O
a	O
component	O
of	O
the	O
viral	B-PROC
replication	I-PROC
complex	O
.	O

Viral	B-PROC
replication	I-PROC
kinetics	O
and	O
efficiency	O
-	O
of	O
-	O
plating	O
analysis	O
performed	O
at	O
permissive	O
and	O
nonpermissive	O
temperatures	O
revealed	O
that	O
changes	O
in	O
the	O
macrodomain	O
alone	O
were	O
both	O
necessary	O
and	O
sufficient	O
for	O
the	O
ts	O
phenotype	O
.	O

Jaundice	O
can	O
reflect	O
the	O
course	O
of	O
disease	O
or	O
be	O
caused	O
by	O
treatment	O
(	O
e	O
.	O
g	O
.	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)),	O
thus	O
can	O
be	O
difficult	O
to	O
differentiate	O
.	O

ABSTRACT	O
:	O
Enteric	O
viral	B-PROC
diseases	I-PROC
of	O
swine	O
are	O
one	O
of	O
the	O
most	O
frequent	O
disorders	O
causing	O
huge	O
economic	O
losses	O
in	O
pork	O
production	O
.	O

Thus	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
reveal	O
the	O
course	O
of	O
sRAGE	O
levels	O
over	O
the	O
first	O
three	O
posttraumatic	O
weeks	O
,	O
focusing	O
on	O
the	O
severity	O
of	O
thoracic	O
trauma	O
and	O
the	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
/	O
or	O
pneumonia	O
.	O

By	O
analyzing	O
simulated	O
outbreaks	O
under	O
various	O
contact	O
tracing	O
scenarios	O
,	O
we	O
demonstrate	O
that	O
contact	O
data	O
significantly	O
improves	O
our	O
ability	O
to	O
reconstruct	O
transmission	O
trees	O
,	O
even	O
under	O
realistic	O
limitations	O
on	O
the	O
coverage	O
of	O
the	O
contact	O
tracing	O
effort	B-PROC
and	O
the	O
amount	O
of	O
non	O
-	O
infectious	O
mixing	O
between	O
cases	O
.	O

Ketamine	O
treatment	O
was	O
initiated	O
at	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
h	O
continuous	O
infusion	O
on	O
the	O
day	O
of	O
admission	O
for	O
pain	O
control	O
and	O
required	O
up	O
-	O
titration	O
to	O
2	O
mg	O
/	O
kg	O
/	O
h	O
by	O
intensive	O
care	O
unit	O
day	O
4	O
for	O
bronchodilation	B-PROC
.	O

These	O
antibodies	O
belong	O
to	O
six	O
distinct	O
epitope	O
groups	O
and	O
interfere	O
with	O
the	O
three	O
critical	O
entry	O
functions	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
:	O
sialic	O
acid	O
binding	O
,	O
receptor	O
binding	O
and	O
membrane	B-PROC
fusion	I-PROC
.	O

Collectively	O
,	O
these	O
antibodies	O
offer	O
new	O
ways	O
to	O
gain	O
humoral	O
protection	O
in	O
humans	O
against	O
the	O
emerging	O
MERS	O
-	O
CoV	O
by	O
targeting	B-PROC
different	O
spike	O
protein	O
epitopes	O
and	O
functions	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nonstructural	O
protein	O
1	O
(	O
nsp1	O
)	O
is	O
a	O
key	O
factor	O
in	O
virus	O
-	O
induced	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
host	O
gene	B-PROC
expression	I-PROC
.	O

Here	O
,	O
we	O
report	O
a	O
previously	O
undetected	O
mechanism	O
by	O
which	O
nsp1	O
exploits	O
the	O
nuclear	O
pore	O
complex	O
and	O
disrupts	O
the	O
nuclear	O
-	O
cytoplasmic	B-PROC
transport	B-PROC
of	O
biomolecules	O
.	O

ABSTRACT	O
:	O
Equine	O
arteritis	O
virus	O
(	O
EAV	O
)	O
and	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
represent	O
two	O
members	O
of	O
the	O
family	O

ABSTRACT	O
:	O
The	O
4a	O
and	O
4b	O
proteins	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
have	O
been	O
described	O
for	O
their	O
antagonism	O
on	O
host	O
innate	B-PROC
immunity	B-PROC
.	O

ABSTRACT	O
:	O
A	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
rection	O
(	O
mRT	O
-	O
PCR	O
)	O
was	O
developed	O
for	O
simultaneous	O
detection	O
of	O
four	O
RNA	O
viruses	O
in	O
swine	O
.	O

Both	O
medium	O
and	O
high	O
MP	O
doses	O
improved	O
coagulation	B-PROC
and	O
fibrinolysis	B-PROC
conditions	O
compared	O
with	O
low	O
-	O
dose	O
MP	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
determine	O
the	O
feasibility	O
of	O
using	O
oligodeoxynucleotides	O
with	O
unmethylated	O
cytosine	O
-	O
guanine	O
dinucleotide	O
sequences	O
(	O
CpG	O
ODN	O
)	O
as	O
an	O
immunity	B-PROC
protection	O
strategy	O
for	O
a	O
mouse	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

CMV	O
-	O
related	O
FS	O
appeared	O
to	O
be	O
similar	O
to	O
H	O
.	O
influenzae	O
-	O
and	O
C	O
.	O
jejuni	O
-	O
related	O
FS	O
regarding	O
anti	O
-	O
GQ1b	O
antibody	B-PROC
-	O
mediated	O
pathogenesis	B-PROC
,	O
as	O
opposed	O
to	O
CMV	O
-	O
related	O
GBS	O
.	O

A	O
series	O
of	O
studies	O
have	O
shown	O
that	O
25HC	O
activity	O
in	O
hosts	O
plays	O
a	O
vital	O
role	O
in	O
inhibiting	O
viral	B-PROC
infection	I-PROC
.	O

Our	O
results	O
showed	O
that	O
PEDV	O
infection	O
downregulated	O
the	O
expression	B-PROC
of	O
CH25H	O
in	O
Vero	O
cells	O
.	O

The	O
overall	O
MERS	O
-	O
CoV	O
antibody	B-PROC
seroprevalence	O
was	O
80	O
.	O
5	O
%,	O
whereas	O
the	O
overall	O
viral	O
RNA	O
prevalence	O
was	O
2	O
.	O
4	O
%.	O

The	O
field	O
of	O
obstetrics	O
and	O
gynecology	O
has	O
come	O
a	O
long	O
way	O
since	O
Mendelson	O
’	O
s	O
time	O
,	O
as	O
the	O
use	O
of	O
general	B-PROC
anesthesia	I-PROC
is	O
now	O
infrequent	O
for	O
laboring	O
women	O
,	O
and	O
neuraxial	O
analgesia	B-PROC
is	O
the	O
standard	O
of	O
care	O
for	O
modern	O
practice	O
.	O

During	O
Mendelson	O
’	O
s	O
time	O
,	O
the	O
induction	O
of	O
general	B-PROC
anesthesia	I-PROC
was	O
not	O
limited	O
to	O
parturients	O
undergoing	O
a	O
cesarean	O
section	O
but	O
was	O
also	O
the	O
method	O
for	O
spontaneous	O
or	O
operative	O
vaginal	O
deliveries	O
.	O

Opaque	O
rubber	O
masks	O
that	O
can	O
conceal	O
regurgitation	O
and	O
vomitus	O
have	O
been	O
replaced	O
with	O
clear	O
plastic	O
masks	O
and	O
ingestion	O
of	O
solid	O
food	O
has	O
been	O
discouraged	O
during	O
labor	B-PROC
.	O

TITLE	O
:	O
Dynamic	O
multi	O
-	O
outcome	O
prediction	O
after	O
injury	O
:	O
Applying	O
adaptive	O
machine	O
learning	B-PROC
for	O
precision	O
medicine	O
in	O
trauma	O
.	O

ABSTRACT	O
:	O
Surfactin	O
has	O
antiviral	O
activity	O
against	O
various	O
enveloped	O
viruses	O
by	O
inhibiting	O
viral	O
membrane	B-PROC
fusion	I-PROC
.	O

The	O
important	O
factors	O
impelling	O
the	O
recovery	O
are	O
found	O
using	O
machine	O
learning	B-PROC
.	O

Thus	O
,	O
the	O
present	O
review	O
comprehensively	O
and	O
critically	O
illustrates	O
the	O
recent	O
aspects	O
on	O
the	O
epidemiology	O
of	O
the	O
virus	O
,	O
the	O
structural	O
and	O
functional	O
features	O
of	O
the	O
viral	O
genome	O
,	O
viral	O
entry	O
and	O
transmission	O
,	O
major	O
mechanisms	O
of	O
pathogenesis	B-PROC
and	O
associated	O
virulent	O
factors	O
,	O
current	O
animal	O
models	O
,	O
detection	O
methods	O
and	O
novel	O
strategies	O
for	O
the	O
development	B-PROC
of	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
review	O
further	O
illustrates	O
the	O
molecular	O
and	O
computational	O
virtual	O
screening	O
platforms	O
which	O
provide	O
insights	O
for	O
the	O
identification	O
of	O
putative	O
drug	O
targets	O
and	O
novel	O
lead	O
molecules	O
toward	O
the	O
development	B-PROC
of	O
therapeutic	O
remedies	O
.	O

This	O
Council	O
would	O
strengthen	O
the	O
global	O
health	O
system	O
by	O
improving	O
collaboration	O
and	O
coordination	B-PROC
across	O
organizations	O
(	O
e	O
.	O
g	O
.,	O
the	O
WHO	O
,	O
Gavi	O
,	O
CEPI	O
,	O
national	O
centers	O
for	O
disease	O
control	O
,	O
pharmaceutical	O
manufacturers	O
,	O
etc	O
.);	O
filling	O
in	O
knowledge	O
gaps	O
with	O
respect	O
to	O
(	O
for	O
example	O
)	O
infectious	O
disease	O
surveillance	O
,	O
research	O
and	O
development	B-PROC
needs	O
,	O
financing	O
models	O
,	O
supply	O
chain	O
logistics	O
,	O
and	O
the	O
social	O
and	O
economic	O
impacts	O
of	O
potential	O
threats	O
;	O
and	O
making	O
high	O
-	O
level	O
,	O
evidence	O
-	O
based	O
recommendations	O
for	O
managing	O
global	O
risks	O
associated	O
with	O
infectious	O
disease	O
.	O

Hemodynamics	B-PROC
remained	O
adequate	O
without	O
intervention	O
.	O

The	O
expression	B-PROC
of	O
visfatin	O
was	O
evaluated	O
in	O
ALI	O
patients	O
and	O
mouse	O
sepsis	O
models	O
.	O

No	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
with	O
other	O
porcine	O
infectious	O
viruses	O
was	O
observed	O
.	O

The	O
ratio	O
of	O
partial	O
pressure	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
was	O
225	O
.	O

All	O
of	O
the	O
patients	O
were	O
initially	O
hypoxic	O
and	O
some	O
had	O
PaO	B-PROC

The	O
differential	O
expressed	B-PROC
genes	O
were	O
associated	O
with	O
appetite	B-PROC
decrease	O
and	O
weight	O
loss	O
of	O
PDCoV	O
-	O
affected	O
piglets	O
.	O

Despite	O
mechanical	O
ventilation	O
,	O
he	O
developed	O
severe	O
pulmonary	O
inflammation	O
with	O
a	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
and	O
died	B-PROC
5	O
days	O
later	O
.	O

ABSTRACT	O
:	O
Besides	O
fatigue	O
,	O
many	O
Q	O
fever	B-PROC
fatigue	O
syndrome	O
(	O
QFS	O
)	O
patients	O
also	O
complain	O
of	O
frequently	O
recurring	O
upper	O
respiratory	O
tract	O
infections	O
with	O
severe	O
symptoms	O
.	O

QFS	O
patients	O
showed	O
diminished	O
cytokine	O
responses	O
to	O
various	O
stimuli	O
compared	O
to	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
,	O
likely	O
due	O
to	O
epigenetic	O
remodeling	O
and	O
long	B-PROC
-	I-PROC
term	I-PROC
memory	I-PROC
as	O
a	O
result	O
from	O
the	O
acute	O
Q	O
fever	B-PROC
infection	O
.	O

While	O
SARS	O
was	O
a	O
wake	B-PROC
-	O
up	O
-	O
call	O
to	O
strengthen	O
infection	O
prevention	O
and	O
control	O
capacity	O
in	O
health	O
care	O
settings	O
and	O
led	O
to	O
the	O
formation	B-PROC
of	O
the	O
Public	O
Health	O
Agency	O
of	O
Canada	O
,	O
it	O
also	O
strengthened	O
our	O
Federal	O
/	O
Provincial	O
/	O
Territorial	O
(	O
FPT	O
)	O
senior	O
-	O
level	O
governance	O
and	O
led	O
to	O
agreements	O
for	O
pan	O
-	O
Canadian	O
mutual	O
aid	O
and	O
infectious	O
disease	O
information	O
sharing	O
.	O

As	O
we	O
move	B-PROC
forward	O
,	O
it	O
will	O
be	O
important	O
to	O
explore	O
the	O
design	O
of	O
scalable	O
or	O
modular	O
emergency	O
response	O
strategies	O
and	O
structures	O
that	O
are	O
socio	O
-	O
culturally	O
appropriate	O
and	O
employ	O
evidence	O
-	O
based	O
strategic	O
risk	O
communications	O
that	O
continue	O
to	O
be	O
critical	O
,	O
especially	O
given	O
the	O
volume	O
and	O
spread	O
of	O
misinformation	O
.	O

The	O
most	O
robust	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
was	O
induced	O
after	O
the	O
animal	O
had	O
been	O
vaccinated	O
with	O
the	O
membrane	O
-	O
fused	O
RBD	O
(	O
rAd5	O
-	O
RBD	O
-	O
G	O
).	O

The	O
most	O
significant	O
cellular	B-PROC
immune	I-PROC
response	I-PROC
was	O
induced	O
after	O
vaccination	O
of	O
the	O
animals	O
with	O
the	O
full	O
-	O
length	O
S	O
(	O
rAd5	O
-	O
S	O
).	O

However	O
,	O
the	O
effects	O
of	O
VIP	O
on	O
the	O
activation	O
of	O
murine	O
fibroblast	O
and	O
expression	B-PROC
of	O
IL	B-PROC
-	I-PROC
17	I-PROC
receptor	O
(	O
IL	O
-	O
17R	O
)	O
in	O
ARDS	O
remain	O
unclear	O
.	O

In	O
detail	O
,	O
VIP	O
reduced	O
the	O
hydroxyproline	O
content	O
and	O
col3a1	O
messenger	O
RNA	O
induced	O
by	O
LPS	O
in	O
NIH3T3	O
cells	O
,	O
as	O
well	O
as	O
the	O
expression	B-PROC
of	O
α	O
-	O
smooth	O
muscle	O
actin	O
.	O

As	O
the	O
first	O
,	O
in	O
vivo	O
,	O
RNAseq	O
analysis	O
of	O
piglets	O
and	O
PEDV	O
infection	O
,	O
our	O
study	O
provides	O
knowledge	O
about	O
the	O
transcriptomics	O
of	O
intestinal	O
mucosa	O
in	O
PEDV	O
-	O
infected	O
piglets	O
,	O
from	O
which	O
a	O
complex	O
molecular	O
pathways	B-PROC
and	O
pathogenesis	B-PROC
-	O
related	O
biological	B-PROC
processes	I-PROC
are	O
involved	O
in	O
PEDV	O
interaction	O
with	O
piglet	O
intestinal	O
mucosa	O
.	O

UBXN1	O
overexpression	B-PROC
significantly	O
increased	O
the	O
viral	O
copy	O
number	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
infections	O
induce	O
apoptosis	B-PROC
in	O
Vero	O
cells	O
via	O
a	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)/	O
p53	O
,	O
but	O
not	O
p38	O
MAPK	O
and	O
SAPK	O
/	O
JNK	O
signalling	B-PROC
pathways	B-PROC
.	O

ABSTRACT	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
a	O
selective	O
pulmonary	O
vasodilator	O
with	O
limited	O
indications	O
in	O
adults	O
.	O

Nuclear	O
DNA	O
encoded	O
genes	O
that	O
are	O
involved	O
in	O
mitochondrial	B-PROC
biogenesis	B-PROC
,	O
fission	O
and	O
function	O
were	O
studied	O
in	O
the	O
shell	O
gland	O
of	O
the	O
oviduct	O
undergoing	O
virus	B-PROC
multiplication	I-PROC
.	O

The	O
expression	B-PROC
levels	O
of	O
citrate	O
synthase	O
(	O
CS	O
),	O
cytochrome	B-PROC
C	I-PROC
,	O
somatic	O
(	O
CYC	O
,	O
S	O
)	O
and	O
sodium	O
-	O
potassium	O
adenosine	O
triphosphatase	O
(	O
Na	O

CONCLUSIONS	O
:	O
Current	O
findings	O
showed	O
a	O
correlation	O
between	O
IAP	O
hospitalised	O
patients	O
in	O
ICU	O
and	O
shock	O
,	O
SIRS	O
,	O
APACHE	O
II	O
,	O
central	O
venous	B-PROC
oxygen	I-PROC
saturation	I-PROC
and	O
GCS	O
.	O

We	O
sought	O
to	O
determine	O
the	O
distribution	O
of	O
influenza	O
virus	O
RNA	O
emitted	O
into	O
the	O
air	O
by	O
participants	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
,	O
and	O
whether	O
these	O
emissions	O
had	O
the	O
potential	O
to	O
reach	B-PROC
healthcare	O
workers	O
'	O
breathing	B-PROC
zones	O
.	O

To	O
analyze	O
lipid	B-PROC
peroxidation	I-PROC
we	O
used	O
a	O
spectrophotometric	O
determination	O
of	O
diene	O
conjugates	O
.	O

The	O
ceruloplasmin	B-PROC
activity	I-PROC
and	O
the	O
transferrin	O
saturation	O
in	O
blood	O
plasma	O
by	O
iron	O
were	O
determined	O
by	O
G	O
.	O
Babenko	O
'	O
s	O
method	O
.	O

Conclusions	O
:	O
Changes	O
in	O
antioxidant	O
system	O
happend	O
due	O
to	O
the	O
activation	O
of	O
lipid	B-PROC
peroxidation	I-PROC
,	O
and	O
because	O
of	O
the	O
inability	O
to	O
neutralize	O
toxic	O
metabolites	O
in	O
the	O
children	O
`	O
body	O
the	O
intoxication	O
syndrome	O
developed	O
.	O

CONCLUSIONS	O
:	O
Conclusions	O
:	O
Changes	O
in	O
antioxidant	O
system	O
happend	O
due	O
to	O
the	O
activation	O
of	O
lipid	B-PROC
peroxidation	I-PROC
,	O
and	O
because	O
of	O
the	O
inability	O
to	O
neutralize	O
toxic	O
metabolites	O
in	O
the	O
children	O
`	O
body	O
the	O
intoxication	O
syndrome	O
developed	O
.	O

ABSTRACT	O
:	O
Disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
)	O
associated	O
with	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
plays	O
pivotal	O
roles	O
in	O
severe	O
sepsis	O
.	O

Logistic	O
regression	O
analyses	O
after	O
propensity	O
score	O
adjustment	O
for	O
potential	O
confounders	O
confirmed	O
a	O
significant	O
association	O
between	O
DIC	O
and	O
MODS	O
and	O
hospital	O
death	B-PROC
in	O
the	O
patients	O
with	O
severe	O
sepsis	O
.	O

This	O
study	O
aimed	O
to	O
describe	O
secondary	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	O
among	O
healthcare	O
workers	O
and	O
to	O
identify	O
risk	O
factors	O
for	O
death	B-PROC
.	O

A	O
transthoracic	O
echocardiogram	O
showed	O
wall	O
motion	O
abnormalities	O
with	O
low	O
-	O
normal	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
.	O

Airway	O
pressure	O
release	O
ventilation	O
offers	O
an	O
alternative	O
approach	O
to	O
maximize	O
lung	O
recruitment	O
and	O
oxygenation	B-PROC
,	O
but	O
clinical	O
trials	O
have	O
not	O
demonstrated	O
a	O
survival	O
benefit	O
of	O
this	O
mode	O
over	O
conventional	O
ventilation	O
strategies	O
.	O

An	O
EriCoV	O
-	O
specific	O
BRYT	O
-	O
Green	O
®	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
PCR	O
assay	O
was	O
used	O
to	O
test	O
351	O
samples	O
of	O
faeces	O
or	O
distal	O
large	O
intestinal	O
tract	O
contents	O
collected	O
from	O
casualty	O
or	O
dead	B-PROC
hedgehogs	O
from	O
a	O
wide	O
area	O
across	O
GB	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
potential	O
predictors	O
for	O
ARDS	O
development	B-PROC
in	O
patients	O
with	O
SP	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
enters	O
cells	O
via	O
two	O
pathways	B-PROC
:	O
A	O
protease	O
-	O
mediated	O
one	O
at	O
the	O
cell	O
surface	O
and	O
another	O
facilitated	O
by	O
cathepsins	O
in	O
the	O
endosome	O
.	O

Providers	O
should	O
also	O
be	O
vigilant	O
for	O
rare	O
but	O
highly	O
pathogenic	O
emerging	O
infections	O
such	O
as	O
Ebola	O
virus	B-PROC
disease	I-PROC
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
).	O

And	O
the	O
individuals	O
with	O
different	O
viral	B-PROC
infection	I-PROC
varied	O
significantly	O
in	O
terms	O
of	O
clinical	O
profiles	O
.	O

And	O
the	O
individuals	O
with	O
different	O
viral	B-PROC
infection	I-PROC
varied	O
significantly	O
in	O
terms	O
of	O
clinical	O
profiles	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
is	O
a	O
highly	O
infectious	O
disease	O
of	O
the	O
domestic	O
chicken	O
of	O
all	O
ages	O
and	O
type	O
,	O
affecting	O
the	O
respiratory	O
,	O
renal	O
and	O
reproductive	B-PROC
systems	O
.	O

Viral	O
RNA	O
was	O
extracted	O
from	O
pooled	O
tissue	O
samples	O
(	O
trachea	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
liver	O
)	O
and	O
tested	O
for	O
Avian	O
influenza	O
virus	O
(	O
AIV	O
),	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
by	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

In	O
order	O
to	O
determine	O
the	O
prevalence	O
of	O
IBV	O
serotype	O
(	O
s	O
)	O
in	O
the	O
flock	O
,	O
serum	O
samples	O
were	O
screened	O
by	O
hemagglutination	B-PROC
-	O
inhibition	B-PROC
(	O
HI	O
)	O
test	O
using	O
IBV	O
antigens	O
and	O
antisera	O
(	O
Arkansas	O
,	O
Connecticut	O
,	O
and	O
Massachusetts	O
).	O

Unfortunately	O
,	O
to	O
date	O
,	O
there	O
is	O
no	O
effective	O
approved	O
treatment	O
or	O
vaccine	O
for	O
MERS	O
-	O
CoV	O
.	O
Thus	O
,	O
there	O
are	O
urgent	O
needs	O
for	O
the	O
development	B-PROC
of	O
novel	O
MERS	O
-	O
CoV	O
therapies	O
as	O
well	O
as	O
vaccines	O
to	O
help	O
minimize	O
the	O
spread	O
of	O
the	O
virus	O
from	O
infected	O
patients	O
,	O
thereby	O
mitigating	O
the	O
risk	O
of	O
any	O
potential	O
pandemics	O
.	O

We	O
believe	O
this	O
study	O
will	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
that	O
enhance	O
the	O
MERS	O
-	O
CoV	O
immune	B-PROC
response	I-PROC
and	O
subsequently	O
contribute	O
to	O
the	O
control	O
of	O
MERS	O
-	O
CoV	O
infections	O
.	O

TITLE	O
:	O
Oxygen	O
delivery	O
,	O
carbon	O
dioxide	O
removal	O
,	O
energy	B-PROC
transfer	I-PROC
to	O
lungs	O
and	O
pulmonary	O
hypertension	O
behavior	O
during	O
venous	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
:	O
a	O
mathematical	O
modeling	O
approach	O
.	O

Venous	O
-	O
venous	O
-	O
ECMO	O
support	O
potentially	O
relieves	O
hypoxic	O
pulmonary	O
vasoconstriction	B-PROC
.	O

TITLE	O
:	O
Porcine	O
Reproductive	B-PROC
and	O
Respiratory	O
Syndrome	O
Virus	O
nsp11	O
Antagonizes	O
Type	O
I	O
Interferon	O
Signaling	B-PROC
by	O
Targeting	B-PROC
IRF9	O
.	O

The	O
B	O
cell	O
receptor	O
(	O
BCR	O
)	O
is	O
involved	O
in	O
inducing	O
the	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
.	O

Fifteen	O
cat	O
litters	O
were	O
mixed	O
and	O
incubated	O
with	O
FCoV	O
,	O
centrifuged	O
and	O
the	O
supernatants	O
tested	O
in	O
vitro	O
for	O
the	O
ability	O
to	O
prevent	O
virus	B-PROC
infection	I-PROC
of	O
cell	O
culture	O
.	O

To	O
test	O
applicability	O
of	O
in	O
vitro	O
results	O
to	O
real	O
life	O
,	O
virus	O
load	O
was	O
measured	O
in	O
two	O
households	O
in	O
a	O
double	O
crossover	O
study	O
of	O
four	O
Fuller	O
'	O
s	O
earth	O
-	O
based	O
cat	O
litters	O
by	O
testing	O
rectal	O
swabs	O
using	O
FCoV	O
reverse	O
transcriptase	B-PROC
quantitative	O
PCR	O
.	O

ABSTRACT	O
:	O
ADP	O
-	O
ribosylation	O
is	O
a	O
ubiquitous	O
post	O
-	O
translational	B-PROC
addition	O
of	O
either	O
monomers	O
or	O
polymers	O
of	O
ADP	O
-	O
ribose	O
to	O
target	O
proteins	O
by	O
ADP	O
-	O
ribosyltransferases	O
,	O
usually	O
by	O
interferon	O
-	O
inducible	O
diphtheria	O
toxin	O
-	O
like	O
enzymes	O
known	O
as	O
PARPs	O
.	O

In	O
summary	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
macrodomain	O
is	O
required	O
to	O
prevent	O
PARP	O
-	O
mediated	O
inhibition	B-PROC
of	O
coronavirus	O
replication	O
and	O
enhancement	O
of	O
interferon	B-PROC
production	I-PROC
.	O

However	O
,	O
the	O
patient	O
finally	O
developed	O
multiorgan	O
failure	O
(	O
MOF	O
)	O
complicated	O
by	O
refractory	O
hypoxemia	O
due	O
to	O
progressive	O
lung	O
fibrosis	O
and	O
died	B-PROC
36	O
days	O
after	O
admission	O
.	O

TITLE	O
:	O
FORMATION	B-PROC
OF	O
EXCESSIVE	O
AMOUNT	O
OF	O
ENDOGENOUS	O
CARBON	O
MONOXIDE	O
AND	O
INCREASE	O
OF	O
CARBOXYLATED	O
HEMOGLOBIN	O
CONTENT	O
IN	O
PATIENTS	O
WITH	O
POLYTRAUMA	O
.	O

Nonsurvivors	O
had	O
a	O
more	O
intense	O
inflammatory	B-PROC
response	I-PROC
than	O
did	O
survivors	O
at	O
48	O
h	O
(	O
C	O
-	O
reactive	O
protein	O
:	O
31	O
.	O
0	O
±	O
17	O
.	O
5	O
vs	O
.	O
14	O
.	O
6	O
±	O
8	O
.	O
9	O
mg	O
/	O
dl	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
as	O
well	O
as	O
a	O
more	O
positive	O
fluid	B-PROC
balance	I-PROC
.	O

TITLE	O
:	O
Characteristics	O
of	O
the	O
Life	O
Cycle	O
of	O
Porcine	O
Deltacoronavirus	O
(	O
PDCoV	O
)	O
In	O
Vitro	O
:	O
Replication	O
Kinetics	O
,	O
Cellular	O
Ultrastructure	O
and	O
Virion	O
Morphology	O
,	O
and	O
Evidence	O
of	O
Inducing	O
Autophagy	B-PROC
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
establish	O
the	O
basic	O
,	O
in	O
vitro	O
characteristics	O
of	O
the	O
life	O
cycle	O
such	O
as	O
replication	O
kinetics	O
,	O
cellular	O
ultrastructure	O
,	O
virion	O
morphology	O
,	O
and	O
induction	O
of	O
autophagy	B-PROC
of	O
PDCoV	O
.	O
Time	O
-	O
course	O
analysis	O
of	O
viral	O
subgenomic	O
and	O
genomic	O
RNA	O
loads	O
and	O
infectious	O
titers	O
indicated	O
that	O
one	O
replication	O
cycle	O
of	O
PDCoV	O
takes	O
5	O
to	O
6	O
h	O
.	O
Electron	O
microscopy	O
showed	O
that	O
PDCoV	O
infection	O
induced	O
the	O
membrane	O
rearrangements	O
with	O
double	O
-	O
membrane	O
vesicles	O
and	O
large	O
virion	O
-	O
containing	O
vacuoles	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
alveolar	O
macrophages	O
phagocytosis	B-PROC
on	O
prognosis	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
abdominal	O
infection	O
:	O
a	O
multicenter	O
study	O
].	O

There	O
was	O
no	O
significant	O
difference	O
in	O
gender	O
between	O
the	O
survival	O
group	O
and	O
the	O
death	B-PROC
group	O
[	O
male	O
(	O
case	O
):	O
8	O
vs	O
.	O
6	O
,	O
P	O
>	O
0	O
.	O
05	O
].	O

Binary	O
Logistic	O
regression	O
analysis	O
showed	O
that	O
neutral	O
red	O
phagocytosis	B-PROC
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0	O
.	O
596	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
=	O
0	O
.	O
212	O
-	O
0	O
.	O
997	O
]	O
and	O
alkaline	O
phosphatase	O
activity	O
(	O
OR	O
=	O
0	O
.	O
573	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
339	O
-	O
0	O
.	O
968	O
)	O
were	O
the	O
influencing	O
factors	O
of	O
prognosis	O
(	O
both	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
Twenty	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
with	O
8	O
in	O
the	O
death	B-PROC
group	O
and	O
12	O
in	O
the	O
survival	O
group	O
.	O

Blood	B-PROC
gases	I-PROC
and	O
ventilator	O
settings	O
24	O
hours	O
prior	O
to	O
and	O
48	O
hours	O
after	O
HFOV	O
in	O
survivors	O
and	O
nonsurvivors	O
were	O
evaluated	O
.	O

At	O
90	O
days	O
,	O
213	O
patients	O
(	O
42	O
.	O
5	O
%)	O
in	O
the	O
intervention	O
group	O
and	O
216	O
(	O
42	O
.	O
8	O
%)	O
in	O
the	O
control	O
group	O
had	O
died	B-PROC
before	O
hospital	O
discharge	O
(	O
between	O
-	O
group	O
difference	O
,	O
-	O
0	O
.	O
3	O
percentage	O
points	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
6	O
.	O
4	O
to	O
5	O
.	O
9	O
;	O
P	O
=	O
0	O
.	O
93	O
).	O

However	O
emergence	O
of	O
antiviral	O
T	O
cell	O
responses	O
after	O
a	O
second	O
exposure	O
to	O
FIPV	O
,	O
implicated	O
cellular	B-PROC
immunity	I-PROC
in	O
the	O
control	O
of	O
FIPV	O
infection	O
and	O
disease	O
progression	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
the	O
imperative	O
and	O
auxiliary	O
roles	O
glycans	O
play	O
,	O
and	O
how	O
specific	O
oligosaccharide	O
structures	O
facilitate	O
these	O
functions	O
during	O
viral	O
pathogenesis	B-PROC
.	O

TITLE	O
:	O
Recombinant	O
vesicular	O
stomatitis	O
virus	O
expressing	O
the	O
spike	O
protein	O
of	O
genotype	O
2b	O
porcine	O
epidemic	O
diarrhea	O
virus	O
:	O
A	O
platform	O
for	O
vaccine	O
development	B-PROC
against	O
emerging	O
epidemic	O
isolates	O
.	O

As	O
a	O
result	O
;	O
postmortem	O
microbiological	O
diagnosis	O
with	O
autopsy	O
and	O
histopathological	O
detection	O
of	O
the	O
patients	O
who	O
are	O
thought	O
to	O
have	O
respiratory	O
tract	O
infection	O
will	O
also	O
determine	O
the	O
infectious	O
agents	O
causing	O
death	B-PROC
.	O

TITLE	O
:	O
The	O
viral	O
protein	O
corona	O
directs	O
viral	O
pathogenesis	B-PROC
and	O
amyloid	O
aggregation	O
.	O

This	O
review	O
summarizes	O
the	O
available	O
data	O
on	O
the	O
epidemiology	O
and	O
evolution	B-PROC
of	O
respiratory	O
viruses	O
.	O

We	O
conducted	O
a	O
literature	O
review	O
of	O
camel	O
-	O
borne	O
zoonotic	O
diseases	O
and	O
found	O
that	O
the	O
majority	O
of	O
publications	O
(	O
65	O
%)	O
focused	O
on	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
brucellosis	O
,	O
Echinococcus	O
granulosus	O
,	O
and	O
Rift	O
Valley	O
fever	B-PROC
.	O

However	O
,	O
we	O
contend	O
that	O
other	O
camel	O
-	O
borne	O
diseases	O
such	O
as	O
Yersinia	O
pestis	O
,	O
Coxiella	O
burnetii	O
,	O
and	O
Crimean	O
-	O
Congo	O
hemorrhagic	O
fever	B-PROC
are	O
just	O
as	O
important	O
to	O
include	O
in	O
surveillance	O
efforts	O
.	O

He	O
was	O
referred	O
for	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
due	O
to	O
severe	O
hypoxia	O
and	O
pulmonary	O
haemorrhage	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
CCoV	O
,	O
designated	O
HLJ	O
-	O
073	O
,	O
from	O
a	O
dead	B-PROC
6	O
-	O
week	O
-	O
old	O
male	O
Pekingese	O
with	O
gross	O
lesions	O
and	O
diarrhea	O
.	O

In	O
total	O
,	O
915	O
out	O
of	O
2336	O
adult	O
patients	O
with	O
viral	B-PROC
infection	I-PROC
were	O
enrolled	O
in	O
the	O
analysis	O
,	O
with	O
influenza	O
virus	O
(	O
28	O
.	O
4	O
%)	O
the	O
most	O
frequently	O
detected	O
virus	O
,	O
followed	O
by	O
respiratory	O
syncytial	O
virus	O
(	O
3	O
.	O
6	O
%),	O
adenovirus	O
(	O
3	O
.	O
3	O
%),	O
human	O
coronavirus	O
(	O
3	O
.	O
0	O
%),	O
parainfluenza	O
virus	O
(	O
2	O
.	O
2	O
%),	O
human	O
rhinovirus	O
(	O
1	O
.	O
8	O
%)	O
and	O
human	O
metapneumovirus	O
(	O
1	O
.	O
5	O
%).	O

TITLE	O
:	O
ATN	O
-	O
161	O
reduces	O
virus	O
proliferation	O
in	O
PHEV	O
-	O
infected	O
mice	O
by	O
inhibiting	O
the	O
integrin	O
α5β1	O
-	O
FAK	O
signaling	B-PROC
pathway	I-PROC
.	O

Heavier	O
smoking	O
dampened	O
maternal	O
heart	O
rate	O
variability	O
across	O
gestation	B-PROC
and	O
potentiated	O
reactivity	O
to	O
buprenorphine	O
at	O
24	O
and	O
36	O
weeks	O
.	O

Sirtuin	O
1	O
(	O
SIRT1	O
)	O
and	O
nuclear	O
factor	O
(	O
erythroid	O
-	O
derived	O
2	O
)-	O
like	O
2	O
(	O
Nrf2	O
)	O
expression	B-PROC
was	O
increased	O
by	O
NBP	O
in	O
lung	O
of	O
LPS	O
-	O
treated	O
mice	O
.	O

Subsequent	O
challenge	O
of	O
the	O
recipient	O
transduced	O
mice	O
by	O
the	O
intra	O
-	O
nasal	O
route	O
with	O
a	O
clinical	O
isolate	O
of	O
the	O
MERS	O
-	O
CoV	O
resulted	O
in	O
a	O
significantly	O
reduced	O
viral	O
load	O
in	O
their	O
lungs	O
,	O
compared	O
with	O
transduced	O
mice	O
receiving	O
a	O
negative	O
control	O
antibody	B-PROC
.	O

Other	O
findings	O
during	O
the	O
initial	O
evaluation	O
of	O
the	O
patient	O
may	O
include	O
a	O
lack	O
of	O
acute	O
cardiac	O
disease	O
or	O
inappropriate	O
fluid	B-PROC
balance	I-PROC
,	O
flat	O
neck	O
veins	O
,	O
and	O
the	O
absence	O
of	O
peripheral	O
edema	O
.	O

The	O
levels	O
of	O
EVLWI	O
,	O
Ang	O
-	O
2	O
and	O
PaO	B-PROC
ΔEVLWI	O
and	O
ΔAng	O
-	O
2	O
can	O
be	O
used	O
as	O
independent	O
risk	O
factors	O
for	O
28	O
-	O
day	O
mortality	O
of	O
severe	O
multiple	O
trauma	O
patients	O
with	O
ARDS	O
,	O
and	O
the	O
predictive	O
value	O
of	O
ΔEVLWI	O
was	O
better	O
than	O
Ang	O
-	O
2	O
and	O
APACHE	O
II	O
.	O

Dynamic	O
observation	O
of	O
EVLWI	O
could	O
improve	O
the	O
accuracy	O
of	O
death	B-PROC
forecasting	O
for	O
severe	O
multiple	O
trauma	O
patients	O
with	O
ARDS	O
.	O

The	O
levels	O
of	O
EVLWI	O
,	O
Ang	O
-	O
2	O
and	O
PaO	B-PROC

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
considered	O
to	O
be	O
a	O
pulmonary	O
manifestation	O
of	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
),	O
often	O
occurring	O
as	O
a	O
complication	O
of	O
disease	O
,	O
and	O
worsening	O
the	O
prognosis	O
of	O
patients	O
.	O

The	O
inflammatory	O
factors	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	B-PROC
of	O
traumatic	O
ARDS	O
.	O

Its	O
earliest	O
manifestation	O
is	O
hypoxemia	O
due	O
to	O
deposition	O
of	O
fat	O
globules	O
in	O
pulmonary	B-PROC
circulation	B-PROC
which	O
can	O
progress	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
the	O
treatment	O
of	O
which	O
is	O
mainly	O
supportive	O
.	O

We	O
found	O
that	O
SARS	O
-	O
CoV	O
S	O
colocalized	O
with	O
both	O
BST2	O
and	O
reduced	O
cell	O
surface	O
BST2	O
,	O
suggesting	O
an	O
association	O
between	O
SARS	O
-	O
CoV	O
S	O
and	O
BST2	O
that	O
targets	O
the	O
lysosomal	O
degradation	O
pathway	B-PROC
.	O

The	O
high	O
prevalence	O
of	O
active	O
infection	O
measured	O
in	O
juveniles	O
and	O
at	O
sites	O
where	O
dromedary	O
populations	O
mix	O
should	O
guide	O
further	O
investigation	O
-	O
particularly	O
of	O
dromedary	O
movement	B-PROC
-	O
and	O
inform	O
vaccination	O
strategy	O
design	O
and	O
evaluation	O
through	O
mathematical	O
modelling	O
.	O

Blood	B-PROC
gas	I-PROC
exchange	O
variations	O
before	O
and	O
after	O
surfactant	O
use	O
were	O
recorded	O
.	O

The	O
increased	O
antibody	B-PROC
was	O
capable	O
of	O
neutralizing	O
NDV	O
and	O
IBV	O
.	O

More	O
importantly	O
GSLS	O
-	O
Se	O
was	O
found	O
to	O
promote	O
early	O
production	O
and	O
prolong	O
the	O
duration	O
of	O
the	O
antibody	B-PROC
responses	I-PROC
.	O

Convergent	O
or	O
divergent	O
approaches	O
have	O
been	O
used	O
for	O
the	O
synthesis	B-PROC
of	O
these	O
compounds	O
.	O

RSV	O
,	O
adenovirus	O
,	O
FluA	O
,	O
and	O
coinfections	O
were	O
identified	O
in	O
14	O
%,	O
14	O
%,	O
5	O
%,	O
and	O
15	O
%	O
of	O
children	O
with	O
viral	B-PROC
infection	I-PROC
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
outbreak	O
was	O
caused	O
by	O
a	O
coronavirus	O
(	O
CoV	O
)	O
named	O
the	O
SARS	O
-	O
CoV	O
.	O
SARS	O
pathology	O
is	O
propagated	O
both	O
by	O
direct	O
cytotoxic	O
effects	O
of	O
the	O
virus	O
and	O
aberrant	O
activation	O
of	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

ORF8b	O
triggers	O
cell	B-PROC
death	I-PROC
consistent	O
with	O
pyroptotic	O
cell	B-PROC
death	I-PROC
in	O
macrophages	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
reveals	O
the	O
mechanism	O
of	O
PDCoV	O
inducing	O
apoptosis	B-PROC
.	O

Daily	O
injections	O
of	O
Clenbuterol	O
(	O
1	O
mg	O
/	O
kg	O
for	O
21	O
days	O
)	O
or	O
vehicle	O
control	O
were	O
also	O
carried	O
out	O
to	O
assess	O
the	O
effects	O
of	O
AAV	O
-	O
Pck2	O
overexpression	B-PROC
on	O
the	O
anabolic	O
response	O
to	O
a	O
beta	O
-	O
adrenergic	O
agonist	O
.	O

When	O
skeletal	O
muscle	O
growth	B-PROC
was	O
induced	O
by	O
daily	O
administration	O
of	O
Clenbuterol	O
(	O
for	O
21	O
days	O
),	O
overexpression	B-PROC
of	O
AAV	O
-	O
Pck2	O
had	O
no	O
effect	O
on	O
the	O
growth	B-PROC
response	O
,	O
nor	O
did	O
it	O
alter	O
the	O
expression	B-PROC
of	O
Phosphoserine	O
Aminotransferase	O
-	O
1	O
(	O
Psat1	O
)	O
or	O
Asparagine	O
Synthetase	O
(	O
Asns	O
)	O
mRNA	O
or	O
the	O
Clenbuterol	O
-	O
induced	O
decreases	O
in	O
MyHC	O
IIa	O
and	O
IIx	O
mRNA	B-PROC
expression	B-PROC
(	O
p	O
=	O
0	O
.	O
0065	O
and	O
p	O
=	O
0	O
.	O
0267	O
respectively	O
).	O

Hence	O
,	O
contrary	O
to	O
the	O
original	O
hypothesis	O
,	O
AAV	O
-	O
Pck2	O
overexpression	B-PROC
reduced	O
TA	O
muscle	O
weights	O
and	O
did	O
not	O
mimic	O
or	O
alter	O
the	O
muscle	O
hypertrophic	O
effects	O
of	O
the	O
beta	O
-	O
adrenergic	O
agonist	O
,	O
Clenbuterol	O
.	O

The	O
majority	O
of	O
MBL	O
-	O
positive	O
EACs	O
express	O
the	O
CD83	O
antigen	O
,	O
providing	O
evidence	O
that	O
coronavirus	O
infection	O
facilitated	O
the	O
maturation	B-PROC
of	O
dendritic	O
cell	O
precursors	O
.	O

Surprisingly	O
,	O
co	O
-	O
localisation	B-PROC
of	O
MBL	O
and	O
CD83	O
was	O
not	O
detectable	O
in	O
the	O
CT	O
.	O

ABSTRACT	O
:	O
Like	O
all	O
coronaviruses	O
,	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
possesses	O
a	O
long	O
,	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	B-PROC
RNA	O
genome	O
(∼	O
27	O
kb	O
)	O
and	O
has	O
a	O
complex	O
replication	O
strategy	O
that	O
includes	O
the	O
production	O
of	O
a	O
nested	O
set	O
of	O
subgenomic	O
mRNAs	O
(	O
sgmRNAs	O
).	O

Cellular	O
genes	O
and	O
gene	B-PROC
networks	I-PROC
differentially	O
expressed	B-PROC
during	O
virus	B-PROC
infection	I-PROC
were	O
also	O
identified	O
,	O
giving	O
insights	O
into	O
the	O
host	O
cell	O
response	O
to	O
IBV	O
infection	O
.	O

CONCLUSIONS	O
:	O
Smoke	O
inhalation	B-PROC
injury	O
leads	O
to	O
early	O
development	B-PROC
of	O
shunt	O
,	O
V	O
/	O
Q	O
mismatch	O
,	O
lung	O
consolidation	O
,	O
and	O
diffuse	O
alveolar	O
damage	O
.	O

Anesthetized	O
female	O
Yorkshire	O
pigs	O
(	O
n	O
=	O
14	O
)	O
received	O
smoke	O
inhalation	B-PROC
injury	O
(	O
SII	O
)	O
and	O
40	O
%	O
total	O
body	O
surface	O
area	O
thermal	O
burns	O
.	O

Measurements	O
of	O
PaO2	O
-	O
to	O
-	O
FiO2	O
ratio	O
(	O
PFR	O
),	O
peak	O
inspiratory	B-PROC
pressure	O
(	O
PIP	O
),	O
dynamic	O
compliance	O
,	O
airway	B-PROC
resistance	I-PROC
,	O
and	O
OCT	O
bronchoscopy	O
were	O
performed	O
at	O
baseline	O
,	O
postinjury	O
,	O
24	O
hours	O
,	O
48	O
hours	O
,	O
72	O
hours	O
after	O
injury	O
.	O

The	O
results	O
suggested	O
that	O
the	O
public	O
'	O
s	O
preventive	O
(	O
hand	O
hygiene	O
)	O
and	O
avoidance	O
(	O
avoiding	O
hospitals	O
even	O
when	O
sick	O
)	O
behaviors	B-PROC
that	O
were	O
frequently	O
practiced	O
during	O
the	O
pandemic	O
were	O
influenced	O
by	O
their	O
social	O
determinants	O
both	O
direct	O
and	O
indirect	O
pathways	B-PROC
.	O

Enhanced	O
surveillance	O
and	O
early	O
detection	O
can	O
be	O
useful	O
in	O
the	O
diagnosis	O
,	O
treatment	O
,	O
and	O
prevention	O
of	O
AFRS	O
,	O
as	O
well	O
as	O
for	O
guiding	O
the	O
development	B-PROC
of	O
appropriate	O
public	O
health	O
strategies	O
.	O

CONCLUSIONS	O
:	O
Inhaled	B-PROC
streptokinase	O
serves	O
as	O
rescue	O
therapy	O
in	O
patients	O
with	O
severe	O
ARDS	O
with	O
improving	O
oxygenation	B-PROC
and	O
lung	O
mechanics	O
more	O
quickly	O
than	O
heparin	O
or	O
conventional	O
management	O
.	O

ABSTRACT	O
:	O
Avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
responsible	O
of	O
significant	O
economic	O
losses	O
for	O
poultry	O
industry	O
around	O
the	O
world	O
,	O
through	O
evolution	B-PROC
of	O
its	O
pathogenicity	O
,	O
inadequacy	O
of	O
vaccines	O
,	O
and	O
virus	O
evasion	O
.	O

In	O
this	O
study	O
,	O
reverse	O
-	O
transcription	B-PROC
LAMP	O
(	O
RT	O
-	O
LAMP	O
)	O
was	O
combined	O
with	O
lateral	O
flow	O
dipstick	O
(	O
LFD	O
)	O
forming	O
a	O
novel	O
detection	O
tool	O
which	O
could	O
simultaneously	O
detect	O
IBV	O
and	O
NDV	O
visually	O
.	O

TITLE	O
:	O
Emerging	O
infectious	O
disease	O
laboratory	O
and	O
diagnostic	O
preparedness	O
to	O
accelerate	O
vaccine	O
development	B-PROC
.	O

ABSTRACT	O
:	O
Rapid	O
vaccine	O
development	B-PROC
in	O
response	O
to	O
an	O
outbreak	O
of	O
a	O
new	O
emerging	O
infectious	O
disease	O
(	O
EID	O
)	O
is	O
a	O
goal	O
targeted	B-PROC
by	O
public	O
health	O
agencies	O
worldwide	O
.	O

Here	O
we	O
review	O
emerging	O
infectious	O
disease	O
biological	O
standards	O
development	B-PROC
,	O
vaccine	O
clinical	O
assay	O
development	B-PROC
and	O
trial	O
execution	O
with	O
the	O
recent	O
experiences	O
of	O
MERS	O
-	O
CoV	O
and	O
Zika	O
virus	O
as	O
examples	O
.	O

There	O
is	O
great	O
need	O
to	O
establish	O
,	O
in	O
advance	O
,	O
the	O
standardized	O
reagents	O
,	O
sample	O
panels	O
,	O
controls	O
,	O
and	O
assays	O
to	O
support	O
the	O
rapid	O
advancement	O
of	O
vaccine	O
development	B-PROC
efforts	O
in	O
response	O
to	O
EID	O
outbreaks	O
.	O

We	O
compared	O
the	O
expression	B-PROC
of	O
six	O
tight	O
junction	O
proteins	O
(	O
ZO	O
-	O
1	O
,	O
ZO	O
-	O
2	O
,	O
Occludin	O
,	O
Claudin	O
-	O
1	O
,	O
Claudin	O
-	O
4	O
,	O
and	O
Claudin	O
-	O
5	O
)	O
between	O
seven	O
-	O
day	O
-	O
old	O
piglets	O
infected	O
with	O
PEDV	O
and	O
normal	O
piglets	O
,	O
as	O
well	O
as	O
in	O
PEDV	O
-	O
infected	O
porcine	O
intestinal	O
epithelial	O
cells	O
(	O
IPEC	O
-	O
J2	O
).	O

The	O
expression	B-PROC
of	O
Claudin	O
-	O
5	O
in	O
the	O
jejunum	O
was	O
significantly	O
lower	O
in	O
PEDV	O
-	O
infected	O
piglets	O
than	O
in	O
the	O
normal	O
animals	O
(	O
p	O
⟨	O
0	O
.	O
01	O
).	O

In	O
this	O
review	O
,	O
we	O
will	O
describe	O
some	O
of	O
the	O
novel	O
therapeutics	O
currently	O
under	O
development	B-PROC
for	O
the	O
treatment	O
of	O
these	O
infections	O
.	O

An	O
inadequate	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
output	O
flow	O
was	O
observed	O
,	O
possibly	O
because	O
of	O
severe	O
polycythemia	O
and	O
hyperviscosity	O
.	O

Management	O
with	O
acute	O
normovolemic	O
hemodilution	O
corrected	O
both	O
the	O
biologic	O
and	O
hemodynamic	B-PROC
parameters	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
acute	O
normovolemic	O
hemodilution	O
to	O
improve	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
outflow	O
.	O

Outcome	O
measures	O
included	O
blood	B-PROC
gas	I-PROC
criteria	O
and	O
oxygenation	B-PROC
state	O
at	O
ARDS	O
onset	O
,	O
mechanical	O
ventilation	O
duration	O
,	O
length	O
of	O
stay	O
in	O
the	O
ICU	O
and	O
in	O
the	O
hospital	O
,	O
ventilation	O
-	O
free	O
time	O
and	O
mortality	O
rate	O
until	O
28	O
days	O
postburn	O
.	O

TITLE	O
:	O
Microarray	O
analysis	O
of	O
infectious	O
bronchitis	O
virus	B-PROC
infection	I-PROC
of	O
chicken	O
primary	O
dendritic	O
cells	O
.	O

Interestingly	O
,	O
inactivated	O
IBV	O
was	O
better	O
able	O
than	O
IBV	O
to	O
induce	O
DC	O
maturation	B-PROC
and	O
activate	O
lymphocytes	O
.	O

Our	O
research	O
suggests	O
a	O
new	O
mechanism	O
to	O
explain	O
why	O
IBV	O
actively	O
blocks	O
innate	O
responses	O
needed	O
for	O
inducing	O
immune	O
gene	B-PROC
expression	I-PROC
and	O
also	O
provides	O
insight	O
into	O
the	O
pathogenic	O
mechanisms	O
of	O
avian	O
IBV	O
.	O

RESULTS	O
:	O
First	O
,	O
we	O
found	O
that	O
IBV	O
stimulation	O
did	O
not	O
enhance	O
the	O
maturation	B-PROC
ability	O
of	O
avian	O
DCs	O
.	O

Endocan	O
is	O
a	O
circulating	O
proteoglycan	O
that	O
binds	O
to	O
the	O
leukocyte	O
integrin	O
leukocyte	O
functional	O
antigen	O
-	O
1	O
and	O
blocks	O
its	O
interaction	O
with	O
its	O
endothelial	O
ligand	B-PROC
,	O
ICAM	O
-	O
1	O
.	O

In	O
vitro	O
,	O
endocan	O
inhibited	O
human	O
leukocyte	O
transendothelial	B-PROC
migration	I-PROC
as	O
well	O
as	O
ICAM	O
-	O
1	O
-	O
dependent	O
migration	B-PROC
but	O
had	O
a	O
very	O
mild	O
effect	O
on	O
ICAM	O
-	O
1	O
-	O
dependent	O
adhesion	O
.	O

Two	O
groups	O
of	O
colonies	O
were	O
set	O
in	O
a	O
Eucalyptus	O
grandis	O
plantation	O
at	O
the	O
beginning	O
of	O
the	O
flowering	B-PROC
period	O
(	O
autumn	O
),	O
replicating	O
a	O
natural	O
scenario	O
with	O
a	O
nutritionally	O
poor	O
food	O
source	O
.	O

Porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
increased	O
the	O
proportion	O
of	O
harmful	O
bacteria	O
and	O
decreased	O
the	O
proportion	O
of	O
beneficial	O
bacteria	O
in	O
the	O
cecal	O
mucosa	O
and	O
contents	O
of	O
suckling	O
piglets	O
.	O

The	O
number	O
of	O
dead	B-PROC
piglets	O
per	O
sow	O
(	O
DP	O
/	O
S	O
)	O
was	O
calculated	O
as	O
the	O
number	O
of	O
dead	B-PROC
suckling	O
piglets	O
during	O
TAC	O
divided	O
by	O
the	O
sow	O
inventory	O
.	O

Farms	O
that	O
fixed	O
the	O
hours	O
staff	O
worked	O
in	O
farrowing	B-PROC
barn	O
had	O
lower	O
DP	O
/	O
S	O
than	O
the	O
other	O
farms	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
addition	O
,	O
CXCL5	O
neutralizing	O
antibody	B-PROC
effectively	O
alleviated	O
inflammatory	B-PROC
response	I-PROC
,	O
diffuse	O
alveolar	O
damage	O
,	O
and	O
pulmonary	O
edema	O
,	O
and	O
decreased	O
the	O
expression	B-PROC
levels	O
of	O
MMP2	O
and	O
MMP9	O
compared	O
to	O
LPS	O
-	O
induced	O
ARDS	O
.	O

CONCLUSIONS	O
We	O
found	O
that	O
CXCL5	O
/	O
CXCR2	O
accelerated	O
the	O
progression	O
of	O
ARDS	O
,	O
partly	O
by	O
upregulation	B-PROC
of	O
MMP2	O
and	O
MMP9	O
in	O
lung	O
tissues	O
with	O
the	O
release	O
of	O
inflammatory	O
factors	O
.	O

TITLE	O
:	O
Biochemical	O
Analysis	O
of	O
Coronavirus	O
Spike	O
Glycoprotein	O
Conformational	O
Intermediates	O
during	O
Membrane	B-PROC
Fusion	I-PROC
.	O

Our	O
model	O
proposes	O
a	O
key	O
mechanism	O
for	O
membrane	B-PROC
fusion	I-PROC
of	O
enveloped	O
viruses	O
.	O

Porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
strain	O
responsible	O
for	O
the	O
outbreak	O
was	O
of	O
the	O
S	O
-	O
INDEL	B-PROC
genotype	O
,	O
much	O
the	O
same	O
as	O
other	O
European	O
PEDV	O
strains	O
.	O

The	O
International	O
Society	O
on	O
Thrombosis	O
and	O
Haemostasis	B-PROC
overt	O
DIC	O
score	O
was	O
calculated	O
after	O
subtracting	O
the	O
fibrinogen	O
component	O
.	O

On	O
day	O
1	O
,	O
2	O
-	O
3	O
and	O
4	O
-	O
5	O
after	O
admission	O
the	O
following	O
pituitary	O
axes	O
were	O
assessed	O
:	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
,	O
hypothalamic	O
-	O
pituitary	O
-	O
thyroid	O
,	O
somatotroph	O
,	O
prolactin	B-PROC
and	O
copeptin	O
.	O

TITLE	O
:	O
Correlation	O
analysis	O
between	O
mechanical	O
power	O
,	O
transforming	O
growth	B-PROC
factor	O
-	O
β1	O
,	O
and	O
connective	O
tissue	B-PROC
growth	B-PROC
factor	O
levels	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
and	O
their	O
clinical	O
significance	O
in	O
pulmonary	O
structural	O
remodeling	O
.	O

Alanine	O
replacement	O
of	O
the	O
motif	O
I	O
residues	O
(	O
AA	O
-	O
E	O
-	O
D	O
;	O
four	O
nucleotide	O
substitutions	O
)	O
in	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
yields	O
viable	O
mutants	O
with	O
impaired	O
replication	O
and	O
fitness	O
,	O
increased	O
mutation	O
rates	O
,	O
and	O
attenuated	O
virulence	B-PROC

This	O
study	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
white	O
blood	O
cell	O
counts	O
and	O
haptoglobin	O
(	O
Hp	O
)	O
and	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
levels	O
in	O
post	O
-	O
weaned	B-PROC
calves	O
with	O
diarrhea	O
caused	O
by	O
BCoV	O
and	O
those	O
that	O
recovered	O
from	O
diarrhea	O
.	O

Post	O
-	O
weaned	B-PROC
calves	O
with	O
diarrhea	O
had	O
a	O
significantly	O
higher	O
Hp	O
concentration	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
diarrhea	O
-	O
recovered	O
calves	O
.	O

Nonetheless	O
,	O
there	O
was	O
no	O
significant	O
change	O
in	O
deaths	B-PROC
after	O
emergency	O
care	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
alphacoronavirus	O
nsp1	O
is	O
an	O
essential	O
virulence	B-PROC
determinant	O
,	O
providing	O
a	O
potential	O
paradigm	O
for	O
the	O
development	B-PROC
of	O
a	O
new	O
attenuated	O
vaccine	O
based	O
on	O
modified	O
nsp1	O
.	O

The	O
binding	O
mode	O
of	O
the	O
shortlisted	O
peptides	O
was	O
measured	O
based	O
on	O
the	O
number	O
of	O
clusters	O
which	O
forms	O
in	O
a	O
protein	O
-	O
peptide	O
docking	B-PROC
using	O
Piper	O
.	O

TITLE	O
:	O
IFN	O
-	O
I	O
response	O
timing	O
relative	O
to	O
virus	B-PROC
replication	I-PROC
determines	O
MERS	O
coronavirus	O
infection	O
outcomes	O
.	O

When	O
transmission	O
-	O
based	O
PPE	O
ensembles	O
are	O
not	O
appropriate	O
,	O
HCP	O
must	O
recognize	O
the	O
transmission	O
pathway	B-PROC
of	O
the	O
disease	O
and	O
anticipate	O
the	O
exposures	O
to	O
select	O
PPE	O
.	O

The	O
treatment	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
using	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
an	O
example	O
of	O
these	O
considerations	O
.	O

However	O
,	O
the	O
implementation	O
of	O
this	O
therapy	O
means	O
an	O
immense	O
effort	B-PROC
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
and	O
re	O
-	O
emergence	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
underscore	O
the	O
urgent	O
need	O
for	O
the	O
development	B-PROC
of	O
novel	O
,	O
safe	O
,	O
and	O
effective	O
vaccines	O
against	O
the	O
prevailing	O
strain	O
.	O

Among	O
25	O
randomized	O
clinical	O
trials	O
evaluating	O
9	O
interventions	O
,	O
2686	O
of	O
7743	O
patients	O
(	O
34	O
.	O
6	O
%)	O
died	B-PROC
within	O
28	O
days	O
.	O

Compared	O
with	O
lung	O
protective	O
ventilation	O
alone	O
,	O
prone	O
positioning	O
and	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
were	O
associated	O
with	O
significantly	O
lower	O
28	O
-	O
day	O
mortality	O
(	O
prone	O
positioning	O
:	O
risk	O
ratio	O
,	O
0	O
.	O
69	O
;	O
95	O
%	O
credible	O
interval	O
,	O
0	O
.	O
48	O
-	O
0	O
.	O
99	O
;	O
low	O
quality	O
of	O
evidence	O
;	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
:	O
risk	O
ratio	O
,	O
0	O
.	O
60	O
;	O
95	O
%	O
credible	O
interval	O
,	O
0	O
.	O
38	O
-	O
0	O
.	O
93	O
;	O
moderate	O
quality	O
of	O
evidence	O
).	O

TITLE	O
:	O
Intraoperative	O
Visible	O
Air	O
Bubbling	O
Recorded	O
as	O
a	O
Sign	O
of	O
Massive	O
Venous	O
Air	O
Embolism	O
During	O
Prone	O
Position	O
Surgery	O
for	O
Extensive	O
Ossification	B-PROC
of	O
Spinal	O
Ligaments	O
:	O
A	O
Case	O
Report	O
with	O
a	O
Video	O
Clip	O
.	O

Although	O
the	O
adjuvanticity	B-PROC
of	O
RNA	O
has	O
been	O
reported	O
,	O
a	O
systematic	O
and	O
overall	O
investigation	O
on	O
its	O
efficacy	O
is	O
lacking	O
.	O

Recombination	B-PROC
analysis	O
gave	O
an	O
evidence	O
for	O
distinct	O
patterns	O
of	O
origin	O
for	O
the	O
studied	O
isolate	O
providing	O
another	O
example	O
of	O
intra	O
-	O
genotypic	O
recombination	B-PROC
among	O
IBVs	O
and	O
the	O
first	O
example	O
of	O
recombination	B-PROC
within	O
the	O
GI	O
-	O
13	O
lineage	O
in	O
the	O
Egyptian	O
field	O
.	O

Surprisingly	O
,	O
we	O
uncovered	O
aberrant	O
viral	O
RNA	O
transcription	B-PROC
of	O
rC3663	O
in	O
A72	O
cells	O
.	O

The	O
deubiquitination	B-PROC
of	O
Nsp3	O
domains	O
and	O
its	O
effect	O
on	O
IκBα	O
and	O
p65	O
were	O
analyzed	O
by	O
western	O
blotting	O
.	O

Individual	O
TGEV	O
protein	O
screening	O
revealed	O
the	O
high	O
potential	O
of	O
non	O
-	O
structural	O
protein	O
3	O
(	O
Nsp3	O
)	O
to	O
inhibit	O
NF	O
-	O
κB	O
signaling	B-PROC
,	O
and	O
leading	O
to	O
the	O
downregulation	B-PROC
of	O
the	O
NF	O
-	O
κB	O
-	O
induced	O
cytokine	B-PROC
production	I-PROC
.	O

Furthermore	O
,	O
the	O
amino	O
acid	O
residues	O
at	O
positions	O
590	O
-	O
1	O
,	O
215	O
in	O
Nsp3	O
were	O
demonstrated	O
to	O
inhibit	O
the	O
degradation	O
of	O
IκBα	O
by	O
inhibiting	O
the	O
IκBα	O
ubiquitination	B-PROC
.	O

The	O
clinical	O
spectrum	O
of	O
SCARs	O
comprises	O
Stevens	O
-	O
Johnson	O
syndrome	O
,	O
toxic	O
epidermal	O
necrolysis	O
,	O
DRESS	O
(	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
)	O
(	O
also	O
known	O
as	O
drug	O
hypersensitivity	B-PROC
syndrome	O
or	O
drug	O
-	O
induced	O
hypersensitivity	B-PROC
syndrome	O
)	O
and	O
acute	O
generalised	O
exanthematous	O
pustulosis	O
.	O

ABSTRACT	O
:	O
Interferon	O
gamma	O
(	O
IFN	O
-	O
γ	O
)	O
is	O
best	O
known	O
for	O
its	O
ability	O
to	O
regulate	O
host	O
immune	B-PROC
responses	I-PROC
;	O
however	O
,	O
its	O
direct	O
antiviral	O
activity	O
is	O
less	O
well	O
studied	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
TGEV	O
elevated	O
the	O
expression	B-PROC
of	O
poIRF1	O
and	O
IFN	O
-	O
γ	O
in	O
infected	O
small	O
intestines	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Plasma	O
and	O
bronchoalveolar	O
lavage	O
soluble	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
,	O
plasma	O
interleukin	O
-	O
6	O
,	O
and	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
were	O
sampled	O
preextracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
after	O
12	O
hours	O
at	O
each	O
step	O
.	O

During	O
stable	O
visits	O
,	O
rhinovirus	O
accounted	O
for	O
54	O
.	O
2	O
%	O
of	O
all	O
viral	B-PROC
infections	I-PROC
,	O
followed	O
by	O
coronavirus	O
(	O
20	O
.	O
5	O
%).	O

TITLE	O
:	O
Personalised	O
mechanical	O
ventilation	O
tailored	O
to	O
lung	O
morphology	O
versus	O
low	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
for	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
France	O
(	O
the	O
LIVE	O
study	O
):	O
a	O
multicentre	O
,	O
single	O
-	O
blind	O
,	O
randomised	O
controlled	O
trial	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
hypericin	O
against	O
infectious	O
bronchitis	O
virus	O
induced	O
apoptosis	B-PROC
and	O
reactive	O
oxygen	O
species	O
in	O
chicken	O
embryo	O
kidney	O
cells	O
.	O

To	O
investigate	O
the	O
inhibition	B-PROC
effect	O
of	O
HY	O
on	O
IBV	O
infection	O
in	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	O
,	O
3	O
different	O
experimental	O
designs	O
:	O
pre	O
-	O
treatment	O
of	O
cells	O
prior	O
to	O
IBV	O
infection	O
,	O
direct	O
treatment	O
of	O
IBV	O
-	O
infected	O
cells	O
,	O
and	O
pre	O
-	O
treatment	O
of	O
IBV	O
prior	O
to	O
cell	O
infection	O
were	O
used	O
.	O

Hsp90	O
inhibitors	O
are	O
anticancer	O
compounds	O
,	O
associated	O
with	O
strong	O
anti	O
-	O
inflammatory	B-PROC
responses	I-PROC
in	O
the	O
endothelium	O
.	O

Immunoglobulin	B-PROC
levels	O
were	O
examined	O
and	O
immunophenotyping	O
was	O
performed	O
.	O

On	O
the	O
contrary	O
,	O
our	O
data	O
revealed	O
changes	O
in	O
peripheral	O
cell	O
populations	O
,	O
the	O
most	O
important	O
being	O
the	O
decrease	O
in	O
the	O
T	O
-	O
cluster	O
of	O
differentiation	B-PROC
(	O
CD	O
)	O
8	O

In	O
addition	O
to	O
a	O
lack	O
of	O
reported	O
resistance	B-PROC
,	O
the	O
benefits	O
of	O
PVP	O
-	O
I	O
include	O
an	O
excellent	O
safety	O
profile	O
and	O
a	O
broad	O
spectrum	O
of	O
effect	O
due	O
to	O
its	O
multimodal	O
action	O
.	O

The	O
medical	O
records	O
of	O
infants	O
were	O
reviewed	O
retrospectively	O
and	O
multiple	O
factors	O
that	O
may	O
be	O
associated	O
with	O
the	O
development	B-PROC
of	O
ROP	O
were	O
collected	O
manually	O
.	O

Taken	O
together	O
,	O
MERS	O
-	O
CoV	O
accessory	O
proteins	O
are	O
involved	O
in	O
viral	O
escape	O
of	O
NF	O
-	O
κB	O
-	O
mediated	O
antiviral	O
immune	B-PROC
responses	I-PROC
.	O

TITLE	O
:	O
Clinical	O
Profile	O
and	O
Outcome	O
of	O
Dengue	O
Fever	B-PROC
in	O
Multidisciplinary	O
Intensive	O
Care	O
Unit	O
of	O
a	O
Tertiary	O
Level	O
Hospital	O
in	O
India	O
.	O

Clinical	O
Profile	O
and	O
Outcome	O
of	O
Dengue	O
Fever	B-PROC
in	O
Multidisciplinary	O
Intensive	O
Care	O
Unit	O
of	O
a	O
Tertiary	O
Level	O
Hospital	O
in	O
India	O
.	O

Acute	O
renal	O
injury	O
with	O
hypoperfusion	O
state	O
due	O
to	O
toxicity	O
at	O
cellular	O
level	O
,	O
redox	B-PROC
cycling	O
and	O
intracellular	O
reactive	O
oxidative	O
stress	O
generation	O
may	O
also	O
cause	O
death	B-PROC
in	O
early	O
stages	O
in	O
paraquat	O
poisoning	O
despite	O
optimal	O
management	O
.	O

Chlamydia	O
psittaci	O
has	O
not	O
previously	O
been	O
associated	O
with	O
the	O
development	B-PROC
of	O
neonatal	O
respiratory	O
disease	O
.	O

The	O
sub	O
-	O
epidemic	O
wave	O
model	O
outperforms	O
simpler	O
growth	B-PROC
models	O
in	O
short	O
-	O
term	O
forecasts	O
based	O
on	O
performance	O
metrics	O
that	O
account	O
for	O
the	O
uncertainty	O
of	O
the	O
predictions	O
namely	O
the	O
mean	O
interval	O
score	O
(	O
MIS	O
)	O
and	O
the	O
coverage	O
of	O
the	O
95	O
%	O
prediction	O
interval	O
.	O

The	O
ratio	O
of	O
carbohydrates	O
and	O
fat	O
is	O
particularly	O
important	O
for	O
burn	O
patients	O
,	O
as	O
an	O
essential	O
fatty	O
acid	O
deficiency	O
can	O
contribute	O
to	O
poor	O
wound	B-PROC
healing	I-PROC
.	O

These	O
patients	O
also	O
experienced	O
shorter	O
hospital	O
length	O
of	O
stay	O
and	O
shorter	O
wound	B-PROC
healing	I-PROC
times	O
,	O
as	O
well	O
as	O
lower	O
spleen	O
and	O
kidney	O
weights	O
,	O
lower	O
urinary	O
nitrogen	O
losses	O
,	O
improved	O
nitrogen	O
balance	B-PROC
,	O
higher	O
insulin	O
levels	O
,	O
higher	O
insulin	B-PROC
-	I-PROC
like	I-PROC
growth	B-PROC
factor	I-PROC
-	O
1	O
,	O
lower	O
cortisol	O
,	O
and	O
less	O
muscle	O
protein	B-PROC
breakdown	I-PROC
.	O

The	O
evidence	O
available	O
to	O
date	O
supports	O
the	O
clinical	O
use	O
of	O
nutrition	B-PROC
support	O
providing	O
≤	O
15	O
%	O
fat	O
and	O
≥	O
60	O
%	O
carbohydrate	O
for	O
critically	O
ill	O
burn	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
renal	O
status	O
and	O
fluid	B-PROC
balance	I-PROC
parameters	O
between	O
the	O
non	O
-	O
survivors	O
and	O
survivors	O
in	O
the	O
2013	O
-	O
2016	O
cohort	O
.	O

Of	O
note	O
,	O
MDA5	O
protein	O
levels	O
were	O
significantly	O
down	O
-	O
regulated	O
by	O
ORF8b	O
and	O
co	O
-	O
expression	B-PROC
of	O
ORF4a	O
and	O
ORF4b	O
.	O

Currently	O
,	O
there	O
are	O
no	O
effective	O
treatments	O
or	O
vaccines	O
available	O
to	O
control	O
PDCoV	O
.	O
To	O
study	O
the	O
potential	O
of	O
RNA	B-PROC
interference	I-PROC
(	O
RNAi	B-PROC
)	O
as	O
a	O
strategy	O
against	O
PDCoV	O
infection	O
,	O
two	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)-	O
expressing	O
plasmids	O
(	O
pGenesil	O
-	O
M	O
and	O
pGenesil	O
-	O
N	O
)	O
that	O
targeted	B-PROC
the	O
M	O
and	O
N	O
genes	O
of	O
PDCoV	O
were	O
constructed	O
and	O
transfected	O
separately	O
into	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	O
,	O
which	O
were	O
then	O
infected	O
with	O
PDCoV	O
strain	O
HB	O
-	O
BD	O
.	O

The	O
median	O
time	O
to	O
evaluation	O
by	O
occupational	O
,	O
physical	O
,	O
and	O
speech	B-PROC
therapy	O
was	O
universally	O
decreased	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
year	O
following	O
the	O
initiation	O
of	O
the	O
mPATH	O
team	O
,	O
we	O
observed	O
earlier	O
time	O
to	O
occupational	O
,	O
physical	O
,	O
and	O
speech	B-PROC
therapist	O
evaluation	O
,	O
decreased	O
length	O
of	O
stay	O
,	O
and	O
cost	O
savings	O
in	O
severe	O
traumatic	O
brain	O
and	O
spinal	O
cord	O
injury	O
patients	O
requiring	O
tracheostomy	O
compared	O
with	O
our	O
historical	O
control	O
.	O

The	O
combined	O
expression	B-PROC
of	O
miR	O
-	O
126	O
,	O
miR	O
-	O
27a	O
,	O
miR	O
-	O
146a	O
,	O
and	O
miR	O
-	O
155	O
predicted	O
ARDS	O
with	O
an	O
area	O
under	O
the	O
curve	O
of	O
0	O
.	O
909	O
(	O
95	O
%	O
CI	O
0	O
.	O
815	O
-	O
1	O
).	O

TITLE	O
:	O
A	O
Novel	O
Bacterium	O
-	O
Like	O
Particle	O
Vaccine	O
Displaying	O
the	O
MERS	O
-	O
CoV	O
Receptor	O
-	O
Binding	O
Domain	O
Induces	O
Specific	O
Mucosal	O
and	O
Systemic	O
Immune	B-PROC
Responses	I-PROC
in	O
Mice	O
.	O

The	O
development	B-PROC
of	O
prophylactics	O
and	O
therapeutics	O
is	O
urgently	O
needed	O
to	O
prevent	O
and	O
control	O
MERS	O
-	O
CoV	O
infections	O
.	O

For	O
pigs	O
of	O
group	O
III	O
,	O
the	O
RM	O
protocol	O
used	O
was	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
of	O
25	O
cmH	O

TITLE	O
:	O
Identification	O
of	O
Diverse	O
Bat	O
Alphacoronaviruses	O
and	O
Betacoronaviruses	O
in	O
China	O
Provides	O
New	O
Insights	O
Into	O
the	O
Evolution	B-PROC
and	O
Origin	O
of	O
Coronavirus	O
-	O
Related	O
Diseases	O
.	O

Viruses	O
are	O
mainly	O
transmitted	O
by	O
aerosol	O
inhalation	B-PROC
and	O
can	O
cause	O
a	O
wide	O
spectrum	O
of	O
symptoms	O
,	O
ranging	O
from	O
mild	O
signs	O
of	O
a	O
cold	B-PROC
to	O
severe	O
respiratory	O
failure	O
requiring	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Due	O
to	O
their	O
ability	O
to	O
inhibit	O
viral	O
DNA	O
or	O
RNA	B-PROC
replication	I-PROC
,	O
nucleoside	O
analogues	O
have	O
been	O
used	O
for	O
decades	O
as	O
potent	O
antiviral	O
therapeutics	O
.	O

ABSTRACT	O
:	O
One	O
Health	O
(	O
OH	O
)	O
is	O
a	O
collaborative	O
effort	B-PROC
to	O
attain	O
optimal	O
health	O
for	O
people	O
,	O
animals	O
and	O
the	O
environment	O
.	O

Here	O
,	O
the	O
authors	O
analyzed	O
pediatric	O
GSWHs	O
from	O
a	O
population	O
-	O
based	O
sample	O
to	O
identify	O
predictors	O
of	O
prolonged	O
hospitalization	O
,	O
morbidity	O
,	O
and	O
death	B-PROC
.	O

TITLE	O
:	O
Myocardial	O
calcification	B-PROC
in	O
a	O
patient	O
with	O
B	O
-	O
lymphoblastic	O
leukemia	O
accompanied	O
by	O
tumor	O
lysis	B-PROC
syndrome	O
.	O

A	O
50	O
-	O
year	O
-	O
old	O
man	O
with	O
hyperthermia	B-PROC
and	O
general	O
malaise	O
presented	O
to	O
our	O
hospital	O
and	O
was	O
clinically	O
diagnosed	O
with	O
B	O
-	O
lymphoblastic	O
leukemia	O
(	O
B	O
-	O
ALL	O
)	O
and	O
febrile	B-PROC
neutropenia	O
accompanied	O
by	O
septic	O
shock	O
.	O

ABSTRACT	O
:	O
A	O
35	O
-	O
year	O
-	O
old	O
male	O
patient	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
complains	O
of	O
fever	B-PROC
,	O
dyspnea	O
and	O
petechiae	O
.	O

In	O
an	O
outpatient	O
follow	O
up	O
,	O
lung	B-PROC
function	I-PROC
was	O
fully	O
recovered	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
is	O
a	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	B-PROC
RNA	O
virus	O
that	O
belongs	O
to	O
the	O
Coronaviridae	O
.	O

Overexpression	B-PROC
of	O
exogenous	O
G3BP1	O
,	O
on	O
the	O
other	O
hand	O
,	O
lowered	O
virus	B-PROC
replication	I-PROC
by	O
100	O
-	O
fold	O
compared	O
to	O
vector	O
control	O
.	O

TITLE	O
:	O
Summit	O
proceedings	O
:	O
Biomedical	O
countermeasure	O
development	B-PROC
for	O
emerging	O
vector	O
-	O
borne	O
viral	B-PROC
diseases	I-PROC
.	O

Increasing	O
populations	O
,	O
urbanization	O
,	O
deforestation	O
,	O
climate	O
change	O
,	O
anti	O
-	O
vaccination	O
movements	B-PROC
,	O
war	O
,	O
and	O
international	O
travel	O
are	O
some	O
of	O
the	O
contributing	O
factors	O
to	O
this	O
trend	O
.	O

Whole	O
genome	O
sequence	O
analysis	O
revealed	O
frequent	O
recombination	B-PROC
events	O
among	O
HAdV	O
-	O
C	O
genomes	O
.	O

Chinese	O
medicine	O
has	O
a	O
holistic	O
view	O
of	O
the	O
human	O
body	O
,	O
and	O
emphasizes	O
individualization	O
based	O
on	O
body	B-PROC
balance	I-PROC
and	O
mind	O
-	O
body	O
interaction	O
and	O
employs	O
herbal	O
medicines	O
and	O
acupuncture	O
.	O

The	O
critical	O
importance	O
of	O
using	O
PPE	O
properly	O
is	O
highlighted	O
by	O
2	O
potentially	O
fatal	O
viral	B-PROC
infections	I-PROC
,	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
and	O
Ebola	O
virus	O
,	O
where	O
HCP	O
became	O
infected	O
while	O
caring	O
for	O
patients	O
due	O
to	O
errors	O
in	O
the	O
use	O
of	O
PPE	O
.	O

Through	O
fine	O
epitope	O
mapping	O
of	O
mAb	O
3E9	O
using	O
a	O
panel	O
of	O
eukaryotic	O
-	O
expressed	B-PROC
polypeptides	O
with	O
GFP	O
-	O
tags	O
,	O
we	O
identified	O
the	O
motif	O

ABSTRACT	O
:	O
Middle	O
Eastern	O
respiratory	O
syndrome	O
,	O
an	O
emerging	O
viral	B-PROC
infection	I-PROC
with	O
a	O
global	O
case	O
fatality	O
rate	O
of	O
35	O
.	O
5	O
%,	O
caused	O
major	O
outbreaks	O
first	O
in	O
2012	O
and	O
2015	O
,	O
though	O
new	O
cases	O
are	O
continuously	O
reported	O
around	O
the	O
world	O
.	O

Nanobodies	O
have	O
been	O
used	O
in	O
the	O
clinic	O
to	O
overcome	O
these	O
problems	O
because	O
of	O
the	O
advantages	O
of	O
their	O
easy	O
expression	B-PROC
and	O
high	O
level	O
of	O
stability	O
.	O

The	O
mandatory	O
vaccines	O
required	O
to	O
secure	O
the	O
visa	O
include	O
the	O
quadrivalent	O
meningococcal	O
vaccine	O
for	O
all	O
pilgrims	O
,	O
while	O
yellow	O
fever	B-PROC
,	O
and	O
poliomyelitis	O
vaccines	O
are	O
required	O
for	O
pilgrims	O
coming	O
from	O
countries	O
endemic	O
or	O
with	O
disease	O
activity	O
.	O

Despite	O
the	O
importance	O
of	O
the	O
spike	O
protein	O
in	O
viral	O
entry	O
and	O
host	O
immune	B-PROC
responses	I-PROC
,	O
high	O
-	O
resolution	O
structural	O
information	O
concerning	O
this	O
large	O
macromolecular	O
machine	O
has	O
been	O
difficult	O
to	O
obtain	O
.	O

The	O
cat	O
initially	O
presented	O
as	O
underweight	O
,	O
despite	O
a	O
good	O
appetite	B-PROC
,	O
and	O
a	O
complete	O
blood	O
count	O
showed	O
non	O
-	O
regenerative	O
anemia	O
.	O

TITLE	O
:	O
A	O
Breath	O
Close	O
To	O
Death	B-PROC
:	O
A	O
Case	O
Report	O
Of	O
Idiosyncratic	O
Reaction	O
To	O
Welding	O
Fumes	O
.	O

This	O
review	O
aimed	O
to	O
provide	O
a	O
clear	O
knowledge	O
on	O
the	O
recent	O
development	B-PROC
of	O
indoles	O
as	O
anti	O
-	O
cancer	O
agents	O
,	O
such	O
as	O
myeloid	O
cell	O
leukemia	O
-	O
1	O
(	O
Mcl	O
-	O
1	O
)	O
inhibitors	O
,	O
proviral	O
insertion	O
site	O
in	O
moloney	O
murine	O
leukemia	O
virus	O
(	O
Pim	O
)	O
inhibitors	O
,	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitors	O
,	O
silent	O
mating	B-PROC
type	O
information	O
regulation	B-PROC
2	O
homolog	O
(	O
SIRT	O
)	O
inhibitors	O
and	O
tubulin	O
inhibitors	O
,	O
and	O
made	O
an	O
insight	O
into	O
the	O
corresponding	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
).	O

Highresolution	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
initially	O
identified	O
48	O
protein	O
spots	O
which	O
were	O
differentially	O
expressed	B-PROC
in	O
the	O
presence	O
of	O
NS7	O
.	O

We	O
hypothesized	O
that	O
VT	O
could	O
be	O
reduced	O
down	O
to	O
4	O
ml	O
/	O
kg	O
,	O
with	O
clinically	O
significant	O
decrease	O
in	O
driving	O
pressure	O
,	O
without	O
the	O
need	O
for	O
extracorporeal	O
CO	O
We	O
conducted	O
a	O
non	O
-	O
experimental	O
before	O
-	O
and	O
-	O
after	O
multicenter	O
study	O
on	O
35	O
ARDS	O
patients	O
with	O
PaO	B-PROC
From	O
inclusion	O
to	O
day	O
2	O
,	O
driving	O
pressure	O
decreased	O
significantly	O
from	O
12	O
[	O
9	O
-	O
15	O
]	O
to	O
8	O
[	O
6	O
-	O
11	O
]	O
cmH	O
Ultra	O
-	O
low	O
tidal	O
volume	O
ventilation	O
may	O
be	O
applied	O
in	O
approximately	O
2	O
/	O
3	O
of	O
moderately	O
severe	O
-	O
to	O
-	O
severe	O
ARDS	O
patients	O
,	O
with	O
a	O
4	O
cmH	O
RESULTS	O
:	O
From	O
inclusion	O
to	O
day	O
2	O
,	O
driving	O
pressure	O
decreased	O
significantly	O
from	O
12	O
[	O
9	O
-	O
15	O
]	O
to	O
8	O
[	O
6	O
-	O
11	O
]	O
cmH	O
CONCLUSIONS	O
:	O
Ultra	O
-	O
low	O
tidal	O
volume	O
ventilation	O
may	O
be	O
applied	O
in	O
approximately	O
2	O
/	O
3	O
of	O
moderately	O
severe	O
-	O
to	O
-	O
severe	O
ARDS	O
patients	O
,	O
with	O
a	O
4	O
cmH	O

This	O
may	O
indicate	O
δ	O
-	O
CoV	O
emerging	O
status	O
and	O
incomplete	O
adaptation	B-PROC
to	O
new	O
host	O
species	O
limiting	O
its	O
spread	O
.	O

We	O
will	O
search	O
the	O
following	O
electronic	O
databases	O
of	O
Ovid	O
MEDLINE	O
,	O
EMBASE	O
,	O
Web	O
of	O
Science	O
,	O
Cochrane	O
Library	O
,	O
Scopus	O
,	O
Cumulative	O
Index	O
to	O
Nursing	B-PROC
and	O
Allied	O
Health	O
Literature	O
,	O
the	O
Allied	O
and	O
Complementary	O
Medicine	O
Database	O
,	O
Chinese	O
Biomedical	O
Literature	O
Database	O
,	O
China	O
National	O
Knowledge	O
Infrastructure	O
,	O
and	O
WANGFANG	O
from	O
inception	O
to	O
the	O
present	O
without	O
language	O
restriction	O
.	O

A	O
systematic	O
review	O
and	O
data	O
synthesis	B-PROC
will	O
be	O
carried	O
out	O
of	O
randomized	O
controlled	O
trials	O
of	O
BP	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
SP	O
and	O
ARDS	O
.	O

Furthermore	O
,	O
GHRH	O
antagonists	O
supported	O
the	O
integrity	O
of	O
endothelial	O
barrier	O
,	O
while	O
GHRH	O
and	O
GHRH	O
agonists	O
had	O
the	O
contrary	O
effects	O
,	O
as	O
reflected	O
in	O
measurements	O
of	O
transendothelial	O
resistance	B-PROC
.	O

The	O
most	O
common	O
cause	O
of	O
death	B-PROC
was	O
worsening	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
two	O
[	O
2	O
%]	O
vs	O
two	O
[	O
4	O
%]	O
patients	O
).	O

Although	O
our	O
study	O
did	O
not	O
have	O
the	O
precision	O
to	O
rule	O
out	O
a	O
small	O
,	O
clinically	O
relevant	O
effect	O
,	O
the	O
benefit	O
is	O
insufficient	O
to	O
justify	O
the	O
use	O
of	O
immune	O
plasma	O
for	O
treating	O
patients	O
with	O
severe	O
influenza	O
A	O
.	O
National	O
Institute	O
of	O
Allergy	B-PROC
and	O
Infectious	O
Diseases	O
of	O
the	O
National	O
Institutes	O
of	O
Health	O
(	O
Bethesda	O
,	O
MD	O
,	O
USA	O
).	O

Samples	O
were	O
bacteriologically	O
cultured	O
and	O
tested	O
by	O
PCR	O
for	O
E	O
.	O
coli	O
virulence	B-PROC
factors	O
genes	O
,	O
C	O
.	O
perfringens	O
types	O
A	O
and	O
C	O
toxins	O
(	O
Cpα	O
,	O
Cpβ	O
,	O
Cpβ2	O
)	O
and	O
C	O
.	O
difficile	O
toxins	O
(	O
TcdA	O
,	O
TcdB	O
).	O

However	O
,	O
there	O
are	O
some	O
MERS	O
vaccines	O
in	O
the	O
preclinical	O
stage	O
of	O
development	B-PROC
.	O

Despite	O
good	O
herd	B-PROC
immunity	I-PROC
with	O
overall	O
seroprevalence	O
of	O
>	O
95	O
%	O
against	O
measles	O
,	O
major	O
outbreaks	O
of	O
measles	O
occurred	O
among	O
HKIA	O
staff	O
having	O
daily	O
contact	O
with	O
many	O
international	O
pssengers	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
serves	O
multiple	O
functions	O
in	O
viral	B-PROC
replication	I-PROC
,	O
transcription	B-PROC
,	O
and	O
assembly	O
of	O
the	O
viral	O
genome	O
complex	O
.	O

Many	O
,	O
if	O
not	O
all	O
,	O
viruses	O
,	O
including	O
the	O
respiratory	O
viruses	O
listed	O
above	O
,	O
suppress	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
gain	O
a	O
window	O
of	O
opportunity	O
for	O
efficient	O
virus	B-PROC
replication	I-PROC
and	O
setting	O
-	O
up	O
of	O
the	O
infection	O
.	O

The	O
affected	O
innate	B-PROC
immune	I-PROC
response	I-PROC
also	O
impacts	O
subsequent	O
adaptive	O
responses	O
,	O
and	O
therefore	O
viral	O
innate	O
immune	B-PROC
evasion	I-PROC
often	O
undermines	O
fully	O
protective	O
immunity	B-PROC
.	O

Furthermore	O
,	O
viral	O
protease	O
-	O
mediated	O
immune	B-PROC
evasion	I-PROC
and	O
viral	O
manipulation	O
of	O
the	O
ubiquitin	B-PROC
system	O
will	O
be	O
addressed	O
.	O

To	O
produce	O
MERS	O
-	O
CoV	O
-	O
like	O
particles	O
(	O
MERS	O
-	O
CoV	O
-	O
LPs	O
),	O
the	O
coexpression	O
of	O
spike	O
proteins	O
was	O
performed	O
in	O
Bm5	O
cells	O
and	O
envelope	O
(	O
E	O
)	O
and	O
membrane	O
(	O
M	O
)	O
proteins	O
secreted	B-PROC
E	O
and	O
M	O
proteins	O
extracellularly	O
,	O
suggesting	O
that	O
MERS	O
-	O
CoV	O
-	O
LPs	O
may	O
be	O
formed	O
.	O

ABSTRACT	O
:	O
Recent	O
nosocomial	O
transmission	O
events	O
of	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
,	O
including	O
Ebola	O
virus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
,	O
Nipah	O
virus	O
,	O
and	O
Crimean	O
-	O
Congo	O
hemorrhagic	O
fever	B-PROC
orthonairovirus	O
,	O
have	O
highlighted	O
the	O
risk	O
of	O
nosocomial	O
transmission	O
of	O
emerging	O
viruses	O
in	O
health	O
-	O
care	O
settings	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
Nebulizable	O
CDR	O
-	O
Modified	O
MERS	O
-	O
CoV	O
Neutralizing	O
Human	O
Antibody	B-PROC
.	O

In	O
summary	O
,	O
we	O
generated	O
a	O
MERS	O
-	O
CoV	O
neutralizing	O
human	O
antibody	B-PROC
that	O
is	O
reactive	O
to	O
recombinant	O
MERS	O
-	O
CoV	O
S	O
RBD	O
protein	O
for	O
delivery	O
via	O
a	O
pulmonary	O
route	O
by	O
introducing	O
stabilizing	O
mutations	O
into	O
five	O
CDRs	O
.	O

We	O
then	O
used	O
comprehensive	O
preinfection	O
immunophenotyping	O
to	O
identify	O
global	O
baseline	O
immune	O
correlates	O
of	O
protection	O
from	O
mortality	O
to	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Improved	O
inference	O
of	O
time	O
-	O
varying	O
reproduction	B-PROC
numbers	O
during	O
infectious	O
disease	O
outbreaks	O
.	O

The	O
bases	O
for	O
these	O
controversies	O
is	O
likely	O
due	O
to	O
both	O
host	O
factors	O
(	O
e	O
.	O
g	O
.,	O
differences	O
in	O
GC	O
resistance	B-PROC
and	O
susceptibility	O
to	O
adverse	O
effects	O
)	O
and	O
different	O
phenotypes	O
of	O
any	O
one	O
disease	O
state	O
;	O
e	O
.	O
g	O
.,	O
different	O
pathogenesis	B-PROC
and	O
pathogens	O
under	O
the	O
rubric	O
of	O
""""	O
sepsis	O
.	O

For	O
syndromic	O
diagnosis	O
,	O
several	O
multiplex	O
nucleic	O
acid	O
amplification	O
tests	O
have	O
been	O
developed	O
for	O
clinics	O
,	O
of	O
which	O
SureX	O
13	O
Respiratory	O
Pathogen	O
Multiplex	O
Kit	O
(	O
ResP	O
)	O
can	O
simultaneously	O
detect	O
13	O
pathogens	O
directly	O
from	O
airway	O
secretion	B-PROC
specimens	O
.	O

Owing	O
to	O
the	O
severity	O
of	O
the	O
condition	O
,	O
conventional	O
methods	O
of	O
oxygenation	B-PROC
are	O
often	O
insufficient	O
.	O

TITLE	O
:	O
Bedside	O
troubleshooting	O
during	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

ABSTRACT	O
:	O
In	O
this	O
review	O
,	O
we	O
discuss	O
common	O
difficulties	O
that	O
clinicians	O
may	O
encounter	O
while	O
managing	O
patients	O
treated	O
with	O
venovenous	O
(	O
VV	O
)	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

Such	O
lung	O
-	O
protective	O
ventilation	O
seeks	O
to	O
avoid	O
barotrauma	O
(	O
by	O
monitoring	O
transpulmonary	O
pressure	O
),	O
volutrauma	O
(	O
by	O
reducing	O
excessive	O
tidal	O
volume	O
to	O
promote	O
lung	O
rest	O
),	O
atelectotrauma	O
[	O
by	O
maintaining	O
adequate	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)],	O
and	O
oxygen	O
toxicity	O
(	O
by	O
decreasing	O
ventilator	O
oxygen	O
levels	O
when	O
PEEP	O
is	O
adequate	O
).	O

Other	O
effects	O
of	O
opioids	O
include	O
respiratory	O
depression	O
,	O
decreased	O
gastrointestinal	B-PROC
motility	B-PROC
,	O
sedation	O
,	O
nausea	O
,	O
vomiting	O
,	O
constipation	O
and	O
intestinal	O
bloating	O
.	O

Specialized	O
opioid	B-PROC
antagonists	I-PROC
can	O
be	O
used	O
to	O
reverse	O
unwanted	O
opioid	O
effects	O
,	O
such	O
as	O
constipation	O
in	O
patients	O
with	O
chronic	O
pain	O
on	O
long	O
-	O
term	O
opioids	O
.	O

The	O
clinical	O
syndrome	O
resembles	O
acute	O
hepatic	O
necrosis	B-PROC
and	O
liver	O
failure	O
,	O
but	O
is	O
rapidly	O
reversible	O
and	O
rarely	O
the	O
primary	O
cause	O
of	O
death	B-PROC
from	O
overdose	O
.	O

In	O
HCoV	O
-	O
229E	O
,	O
its	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
shows	O
extensive	O
sequence	O
variation	O
but	O
how	O
S	O
-	O
protein	B-PROC
function	I-PROC
is	O
maintained	O
is	O
not	O
understood	O
.	O

ABSTRACT	O
:	O
Some	O
coronaviruses	O
(	O
CoVs	O
)	O
have	O
an	O
extra	O
furin	O
cleavage	B-PROC
site	O
(	O
RRKR	O
/	O
S	O
,	O
furin	O
-	O
S2	O
'	O
site	O
)	O
upstream	O
of	O
the	O
fusion	O
peptide	O
in	O
the	O
spike	O
protein	O
,	O
which	O
plays	O
roles	O
in	O
virion	O
adsorption	O
and	O
fusion	O
.	O

To	O
elucidate	O
the	O
evolution	B-PROC
of	O
MERS	O
-	O
CoV	O
-	O
related	O
viruses	O
and	O
their	O
interspecies	O
transmission	O
pathway	B-PROC
,	O
samples	O
were	O
collected	O
from	O
different	O
mammals	O
in	O
China	O
.	O

TITLE	O
:	O
Potentially	O
fatal	O
electrolyte	O
imbalance	O
caused	O
by	O
severe	O
hydrofluoric	O
acid	O
burns	O
combined	O
with	O
inhalation	B-PROC
injury	O
:	O
A	O
case	O
report	O
.	O

Retinoic	O
acid	O
-	O
inducible	O
gene	O
-	O
I	O
(	O
RIG	O
-	O
I	O
)	O
and	O
MDA5	O
both	O
belong	O
to	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
family	O
,	O
and	O
RIG	O
-	O
I	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
anti	O
-	O
DEV	O
signaling	B-PROC
pathway	I-PROC
.	O

We	O
confirmed	O
that	O
DEV	O
infection	O
was	O
significantly	O
suppressed	O
in	O
MDA5	O
-	O
overexpressing	O
DEF	O
cells	O
,	O
while	O
knockdown	O
of	O
MDA5	O
by	O
siRNA	O
markedly	O
enhanced	O
DEV	O
growth	B-PROC
.	O

In	O
the	O
uninfected	O
turkeys	O
,	O
the	O
higher	O
by	O
40	O
%	O
(	O
than	O
recommended	O
by	O
NRC	O
)	O
level	O
of	O
Met	O
in	O
the	O
feeds	O
had	O
a	O
positive	O
effect	O
on	O
humoral	B-PROC
immunity	I-PROC
parameters	O
.	O

Clinicopathological	O
assessment	O
showed	O
that	O
two	O
of	O
the	O
variants	O
caused	O
high	O
fatality	O
rates	O
of	O
67	O
%	O
and	O
20	O
%	O
in	O
one	O
-	O
day	O
-	O
old	O
SPF	O
chicks	O
,	O
and	O
all	O
the	O
variants	O
possessed	O
multiorgan	O
tropisms	B-PROC
,	O
including	O
trachea	O
,	O
proventriculus	O
and	O
urogenital	O
tissues	O
.	O

Meanwhile	O
,	O
we	O
found	O
that	O
the	O
differentially	O
expressed	B-PROC
lncRNA	O
TCONS_00058367	O
might	O
lead	O
to	O
a	O
reduction	O
of	O
phosphorylation	B-PROC
of	O
transcription	B-PROC
factor	O
p65	O
(	O
p	O
-	O
p65	O
)	O
in	O
TGEV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
by	O
negatively	O
regulating	O
its	O
antisense	O
gene	O
promyelocytic	O
leukemia	O
(	O
PML	O
).	O

The	O
AuNP	O
-	O
adjuvanted	O
protein	O
induced	O
a	O
strong	O
IgG	O
response	O
but	O
failed	O
to	O
improve	O
vaccine	O
efficacy	O
or	O
to	O
reduce	O
eosinophilic	O
infiltration	O
because	O
of	O
highly	O
allergic	O
inflammatory	B-PROC
responses	I-PROC
.	O

Whereas	O
similar	O
virus	O
titers	O
were	O
observed	O
in	O
the	O
control	O
animals	O
and	O
the	O
animals	O
immunized	O
with	O
S	O
protein	O
with	O
or	O
without	O
AuNPs	O
,	O
Type	O
1	O
interferon	O
and	O
pro	O
-	O
inflammatory	B-PROC
responses	I-PROC
were	O
moderate	O
in	O
the	O
mice	O
treated	O
with	O
S	O
protein	O
with	O
and	O
without	O
AuNPs	O
.	O

The	O
findings	O
of	O
this	O
study	O
will	O
support	O
the	O
development	B-PROC
of	O
vaccines	O
against	O
severe	O
pneumonia	O
-	O
associated	O
coronaviruses	O
.	O

Reported	O
adverse	O
effects	O
of	O
methadone	O
include	O
constipation	O
,	O
respiratory	O
depression	O
,	O
dizziness	O
,	O
nausea	O
,	O
vomiting	O
,	O
itching	O
,	O
sweating	O
,	O
rhabdomyolysis	O
,	O
QT	O
prolongation	O
,	O
and	O
orthostatic	B-PROC
hypotension	O
.	O

Here	O
,	O
we	O
show	O
that	O
AhR	O
is	O
activated	O
in	O
cells	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
coronavirus	O
(	O
CoV	O
),	O
and	O
contributes	O
to	O
the	O
upregulation	B-PROC
of	O
downstream	O
effector	O
TCDD	O
-	O
inducible	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
TiPARP	O
)	O
during	O
infection	O
.	O

Of	O
these	O
,	O
all	O
but	O
one	O
patient	O
had	O
inhalation	B-PROC
injury	O
,	O
burn	O
percentage	O
of	O
TBSA	O
was	O
37	O
±	O
23	O
%,	O
ABSI	O
score	O
was	O
8	O
.	O
4	O
±	O
2	O
,	O
and	O
R	O
-	O
Baux	O
-	O
score	O
was	O
98	O
±	O
21	O
.	O

Spiked	O
units	O
were	O
then	O
treated	O
with	O
amotosalen	O
/	O
UVA	O
to	O
inactivate	O
MERS	O
-	O
CoV	O
.	O
Infectious	O
and	O
genomic	O
viral	O
titres	O
were	O
quantified	O
by	O
plaque	O
assay	O
and	O
quantitative	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
).	O

This	O
infectious	O
single	O
-	O
stranded	O
,	O
positive	O
(+)	O
sense	B-PROC
RNA	O
virus	O
enters	O
the	O
host	O
by	O
binding	O
to	O
dipeptidyl	O
-	O
peptide	O
receptors	O
.	O

Furthermore	O
,	O
docking	B-PROC
analyses	O
revealed	O
that	O
the	O
predicted	O
peptides	O
engaged	O
in	O
strong	O
bonding	O
with	O
the	O
HLA	O
-	O
B7	O
allele	O
.	O

ABSTRACT	O
:	O
We	O
hypothesized	O
that	O
the	O
recent	O
change	O
of	O
sepsis	O
definition	O
by	O
sepsis	O
-	O
3	O
would	O
facilitate	O
the	O
measurement	O
of	O
timing	O
of	O
sepsis	O
for	O
trauma	O
patients	O
presenting	O
with	O
initial	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
.	O

PARDS	O
severity	O
varied	O
widely	O
in	O
the	O
first	O
24	O
hours	O
;	O
52	O
.	O
4	O
%	O
of	O
patients	O
showed	O
an	O
improvement	O
,	O
35	O
.	O
4	O
%	O
showed	O
no	O
change	O
,	O
and	O
12	O
.	O
2	O
%	O
either	O
showed	O
progression	O
of	O
PARDS	O
or	O
died	B-PROC
.	O

In	O
cases	O
where	O
patients	O
are	O
refractory	O
to	O
conventional	O
therapy	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
should	O
be	O
considered	O
.	O

TITLE	O
:	O
Feline	O
coronavirus	O
with	O
and	O
without	O
spike	O
gene	B-PROC
mutations	I-PROC
detected	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCRs	O
in	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
.	O

We	O
report	O
a	O
case	O
of	O
altered	O
pharmacokinetics	B-PROC
,	O
insufficient	O
liposomal	O
amphotericin	O
B	O
and	O
isavuconazole	O
levels	O
,	O
and	O
the	O
need	O
for	O
escalated	O
doses	O
during	O
ECMO	O
in	O
a	O
patient	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
pulmonary	O
blastomycosis	O
.	O

We	O
report	O
on	O
a	O
case	O
of	O
severe	O
acute	O
lung	O
injury	O
secondary	O
to	O
inhalation	B-PROC
of	O
cannabis	O
oil	O
via	O
a	O
vape	O
pen	O
,	O
and	O
propose	O
a	O
new	O
term	O
that	O
describes	O
lung	O
injury	O
related	O
to	O
vaping	O
.	O

This	O
study	O
clearly	O
suggests	O
that	O
the	O
government	O
,	O
especially	O
the	O
municipal	O
government	O
at	O
the	O
provincial	O
level	O
,	O
should	O
increase	O
financial	O
investment	O
in	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDCs	O
)	O
with	O
worse	O
resource	O
allocation	O
in	O
their	O
jurisdiction	O
through	O
various	O
ways	O
of	O
compensation	B-PROC
and	O
incentives	O
,	O
enhance	O
their	O
infrastructure	O
,	O
and	O
improve	O
the	O
salary	O
of	O
personnel	O
in	O
these	O
institutions	O
,	O
to	O
attract	O
more	O
public	O
health	O
professionals	O
to	O
these	O
institutions	O
.	O

The	O
clinical	O
complications	O
in	O
severe	O
malaria	O
cases	O
included	O
thrombocytopenia	O
(	O
50	O
.	O
7	O
%),	O
metabolic	B-PROC
acidosis	O
(	O
30	O
.	O
1	O
%),	O
severe	O
anaemia	O
(	O
26	O
.	O
0	O
%),	O
jaundice	O
(	O
21	O
.	O
9	O
%),	O
hepatic	O
dysfunction	O
(	O
15	O
.	O
1	O
%),	O
acute	O
renal	O
failure	O
(	O
6	O
.	O
8	O
%),	O
haematuria	O
(	O
8	O
.	O
2	O
%),	O
hypotension	O
(	O
9	O
.	O
6	O
%),	O
cerebral	O
malaria	O
(	O
1	O
.	O
4	O
%)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
1	O
.	O
4	O
%).	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
share	O
tropism	B-PROC
for	O
swine	O
intestinal	O
epithelial	O
cells	O
.	O

Whether	O
mixing	O
of	O
viral	O
components	O
during	O
co	O
-	O
infection	O
alters	O
pathogenic	O
outcomes	O
or	O
viral	B-PROC
replication	I-PROC
is	O
not	O
known	O
.	O

Despite	O
partial	O
interchangeability	O
in	O
nucleocapsid	O
oligomerization	O
and	O
viral	O
RNA	B-PROC
synthesis	I-PROC
,	O
endogenous	O
PEDV	O
N	O
cannot	O
be	O
replaced	O
in	O
the	O
production	O
of	O
infectious	O
PEDV	O
particles	O
.	O

However	O
,	O
there	O
is	O
a	O
lack	O
of	O
early	O
signs	O
suggesting	O
right	O
ventricular	O
systolic	O
and	O
diastolic	O
dysfunction	O
prior	O
to	O
acute	O
cor	O
pulmonale	O
development	B-PROC
.	O

Sacubitril	O
/	O
valsartan	O
was	O
added	O
to	O
optimal	O
medical	O
therapy	O
after	O
hemodynamic	B-PROC
stabilization	O
allowing	O
progressive	O
clinical	O
,	O
laboratoristic	O
,	O
and	O
echocardiographic	O
improvement	O
.	O

PLpro	O
acts	O
as	O
a	O
protease	O
and	O
processes	O
the	O
large	O
coronavirus	O
polyprotein	O
for	O
virus	B-PROC
replication	I-PROC
.	O

TITLE	O
:	O
Mortalin	O
restricts	O
porcine	O
epidemic	O
diarrhea	O
virus	O
entry	O
by	O
downregulating	O
clathrin	B-PROC
-	I-PROC
mediated	I-PROC
endocytosis	I-PROC
.	O

Mortalin	O
protein	O
is	O
involved	O
in	O
a	O
variety	O
of	O
cellular	O
functions	O
and	O
plays	O
a	O
role	O
in	O
viral	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Host	O
population	O
size	O
,	O
density	O
,	O
immune	B-PROC
status	I-PROC
,	O
age	O
structure	O
,	O
and	O
contact	O
rates	O
are	O
critical	O
elements	O
of	O
virus	O
epidemiology	O
.	O

Physical	O
examination	O
revealed	O
oliguria	O
,	O
suppurated	O
tonsils	O
,	O
poor	O
hemoglobin	O
saturation	O
,	O
alert	O
consciousness	O
,	O
normal	O
neurological	O
signs	O
and	O
reflexes	B-PROC
,	O
hypertension	O
,	O
and	O
tachypnea	O
.	O

TITLE	O
:	O
Enhancement	O
of	O
antigen	O
-	O
specific	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
and	O
protein	O
solubility	O
through	O
conjugation	B-PROC
of	O
bacterial	O
flagellin	O
,	O
ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
)	O
is	O
a	O
highly	O
contagious	O
enteric	O
swine	O
disease	O
.	O

S0	O
,	O
a	O
truncated	O
region	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
spike	O
protein	O
,	O
has	O
been	O
suggested	O
as	O
a	O
candidate	O
antigen	O
for	O
PED	O
subunit	O
vaccines	O
;	O
however	O
,	O
poor	O
solubility	O
problems	O
when	O
the	O
protein	O
is	O
expressed	B-PROC
in	O

The	O
former	O
triggers	O
the	O
release	O
inflammatory	O
cytokines	O
and	O
the	O
latter	O
promotes	O
exocytosis	B-PROC
of	O
unusually	O
large	O
von	O
Willebrand	O
factor	O
multimers	O
(	O
ULVWF	O
)	O
and	O
platelet	B-PROC
activation	I-PROC
.	O

DIT	O
is	O
a	O
hemostatic	B-PROC
disease	O
due	O
to	O
lone	O
activation	O
of	O
ULVWF	O
path	O
without	O
activated	O
tissue	O
factor	O
path	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
comparison	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
based	O
on	O
recombinant	O
trimeric	O
full	O
-	O
length	O
and	O
truncated	O
spike	O
proteins	O
for	O
detecting	O
antibodies	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Outbreaks	O
of	O
EIDs	O
,	O
like	O
the	O
2013	O
-	O
2016	O
Ebola	O
outbreak	O
in	O
West	O
Africa	O
or	O
the	O
current	O
Ebola	O
outbreak	O
in	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
(	O
DRC	O
),	O
have	O
not	O
only	O
put	O
populations	O
in	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
(	O
LMIC	O
)	O
at	O
risk	O
in	O
terms	O
of	O
morbidity	O
and	O
mortality	O
,	O
but	O
they	O
also	O
have	O
had	O
a	O
significant	O
impact	O
on	O
economic	O
growth	B-PROC
in	O
affected	O
regions	O
and	O
beyond	O
.	O

Vaccination	O
against	O
influenza	O
will	O
lead	O
to	O
lower	O
infection	O
rates	O
and	O
fewer	O
complications	O
,	O
even	O
if	O
the	O
vaccine	O
is	O
poorly	O
matched	O
to	O
circulating	O
viral	O
strains	O
,	O
with	O
maternal	O
vaccination	O
offering	O
infants	O
protection	O
via	O
antibody	B-PROC
transmission	O
through	O
the	O
placenta	O
and	O
breast	O
milk	O
.	O

ABSTRACT	O
:	O
It	O
is	O
unclear	O
whether	O
multiple	O
respiratory	O
viral	B-PROC
infections	I-PROC
are	O
associated	O
with	O
more	O
severe	O
bronchiolitis	O
requiring	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
admission	O
.	O

We	O
aimed	O
to	O
identify	O
the	O
association	O
between	O
multiple	O
respiratory	O
viral	B-PROC
infections	I-PROC
and	O
PICU	O
admission	O
among	O
infants	O
with	O
bronchiolitis	O
.	O

Multivariable	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
fit	O
the	O
association	O
between	O
multiple	O
respiratory	O
viral	B-PROC
infections	I-PROC
(≥	O
2	O
strains	O
)	O
and	O
PICU	O
admission	O
.	O

In	O
the	O
multivariable	O
logistic	O
regression	O
analysis	O
,	O
bronchiolitis	O
with	O
multiple	O
viral	B-PROC
infections	I-PROC
was	O
associated	O
with	O
higher	O
odds	O
of	O
PICU	O
admission	O
(	O
adjusted	O
odds	O
ratio	O
:	O
2	O
.	O
56	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
17	O
-	O
5	O
.	O
57	O
,	O
P	O
=	O
0	O
.	O
02	O
).	O

CONCLUSIONS	O
:	O
Early	O
FO	O
≥	O
5	O
%	O
has	O
been	O
linked	O
to	O
adverse	O
postoperative	O
outcomes	O
in	O
pediatric	O
patients	O
undergoing	O
repair	B-PROC
for	O
ALCAPA	O
.	O

ABSTRACT	O
:	O
Human	O
embryo	O
lung	O
cellular	O
protein	O
interacting	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nonstructural	O
protein	O
-	O
10	O
(	O
HEPIS	O
)	O
is	O
expressed	B-PROC
at	O
varying	O
levels	O
in	O
multiple	O
organs	O
and	O
breast	O
cancer	O
cell	O
lines	O
.	O

Complications	O
were	O
observed	O
in	O
1	O
%	O
(	O
n	O
=	O
6	O
)	O
of	O
all	O
pronation	B-PROC
maneuvers	O
(	O
vomit	O
,	O
2	O
%;	O
respiratory	O
device	O
removal	O
,	O
0	O
.	O
4	O
%).	O

However	O
,	O
there	O
are	O
several	O
complications	O
attributed	O
to	O
extracorporeal	O
circulation	B-PROC
.	O

Our	O
previous	O
work	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
viruses	O
argued	O
that	O
bats	O
already	O
harbor	O
CoVs	O
with	O
the	O
ability	O
to	O
infect	O
humans	O
without	O
adaptation	B-PROC
.	O

Experimental	O
studies	O
found	O
that	O
higher	O
PEEP	O
strategy	O
can	O
be	O
effective	O
to	O
reduce	O
lung	O
injury	O
from	O
spontaneous	O
effort	B-PROC
while	O
maintaining	O
some	O
muscle	O
activity	O
.	O

Crucial	O
to	O
halting	O
PDCoV	O
transmission	O
and	O
infection	O
is	O
the	O
development	B-PROC
of	O
effective	O
therapies	O
and	O
vaccines	O
.	O

Based	O
on	O
these	O
findings	O
,	O
CTD	O
may	O
be	O
a	O
promising	O
target	O
for	O
development	B-PROC
of	O
an	O
effective	O
vaccine	O
against	O
PDCoV	O
infection	O
in	O
pigs	O
.	O

As	O
of	O
September	O
2019	O
,	O
2468	O
laboratory	O
-	O
confirmed	O
cases	O
with	O
851	O
associated	O
deaths	B-PROC
have	O
occurred	O
with	O
a	O
case	O
fatality	O
rate	O
of	O
34	O
.	O
4	O
%,	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
.	O

Outcomes	O
are	O
reported	O
including	O
the	O
hospital	O
mortality	O
,	O
ECMO	O
-	O
related	O
complications	O
and	O
physiological	O
data	O
on	O
weaning	B-PROC
from	O
invasive	O
ventilation	O
.	O

At	O
hatch	B-PROC
,	O
birds	O
were	O
inoculated	O
with	O
QX	O
vaccine	O
or	O
its	O
virulent	O
progenitor	O
IBV	O
-	O
D388	O
,	O
and	O
postmortem	O
swabs	O
and	O
tissues	O
were	O
collected	O
each	O
day	O
up	O
to	O
eight	O
days	O
post	O
infection	O
to	O
assess	O
viral	B-PROC
replication	I-PROC
and	O
morphological	O
changes	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
how	O
a	O
neutralizing	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
),	O
which	O
targets	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronavirus	O
spike	O
,	O
mediates	O
viral	O
entry	O
using	O
pseudovirus	O
entry	O
and	O
biochemical	O
assays	O
.	O

The	O
nucleotide	O
and	O
amino	O
acid	O
sequences	O
of	O
MERS	O
-	O
CoV	O
Spike	O
protein	O
gene	O
were	O
used	O
to	O
analyze	O
the	O
recombination	B-PROC
,	O
genetic	O
diversity	O
and	O
phylogenetic	O
relationship	O
with	O
selected	O
sequences	O
from	O
Saudi	O
Arabia	O
.	O

The	O
minor	O
recombination	B-PROC
events	O
were	O
identified	O
in	O
eight	O
different	O
sequences	O
at	O
various	O
hotspots	O
in	O
both	O
human	O
and	O
camel	O
samples	O
using	O
recombination	B-PROC
detection	O
programme	O
.	O

Downregulation	B-PROC
of	O
miR	O
-	O
142a	O
-	O
3p	O
by	O
an	O
miRNA	O
inhibitor	O
led	O
to	O
a	O
significant	O
repression	O
of	O
viral	O
proliferation	O
,	O
implying	O
that	O
it	O
acts	O
as	O
a	O
positive	O
regulator	O
of	O
PHEV	O
proliferation	O
.	O

Knockdown	O
of	O
Rab3a	O
expression	B-PROC
by	O
transfection	B-PROC
with	O
an	O
miR	O
-	O
142a	O
-	O
3p	O
mimic	O
or	O
Rab3a	O
siRNA	O
significantly	O
increased	O
PHEV	O
replication	O
in	O
N2a	O
cells	O
.	O

Conversely	O
,	O
the	O
use	O
of	O
an	O
miR	O
-	O
142a	O
-	O
3p	O
inhibitor	O
or	O
overexpression	B-PROC
of	O
Rab3a	O
resulted	O
in	O
a	O
marked	O
restriction	O
of	O
viral	O
production	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

This	O
amplifying	O
step	O
may	O
be	O
one	O
of	O
the	O
missing	O
links	O
in	O
the	O
pathogenesis	B-PROC
of	O
this	O
enigmatic	O
disease	O
.	O

Basic	O
reproductive	B-PROC
number	O
was	O
0	O
.	O
9	O
.	O

This	O
study	O
used	O
targeted	B-PROC
molecular	O
techniques	O
,	O
serological	O
assays	O
and	O
next	O
generation	O
sequencing	O
to	O
characterise	O
adenoviruses	O
,	O
coronaviruses	O
and	O
paramyxoviruses	O
from	O
11	O
species	O
of	O
insectivorous	O
bats	O
within	O
the	O
South	O
West	O
Botanical	O
Province	O
of	O
Western	O
Australia	O
.	O

TITLE	O
:	O
Diabetes	O
Mellitus	O
,	O
Hypertension	O
,	O
and	O
Death	B-PROC
among	O
32	O
Patients	O
with	O
MERS	O
-	O
CoV	O
Infection	O
,	O
Saudi	O
Arabia	O
.	O

Growth	B-PROC
kinetics	O
studies	O
suggest	O
that	O
rPDCoV	O
-	O
ΔNS7	O
could	O
replicate	O
similarly	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
PDCoV	O
,	O
whereas	O
rPDCoV	O
-	O
ΔNS6	O
-	O
GFP	O
exhibited	O
a	O
substantial	O
reduction	O
of	O
viral	O
titer	O

TITLE	O
:	O
Design	O
and	O
synthesis	B-PROC
of	O
novel	O
Imidazo	O
[	O
2	O
,	O
1	O
-	O
b	O
]	O
thiazole	O
derivatives	O
as	O
potent	O
antiviral	O
and	O
antimycobacterial	O
agents	O
.	O

Pretreatment	O
with	O
recombinant	O
porcine	O
IL	O
-	O
11	O
(	O
pIL	O
-	O
11	O
)	O
was	O
found	O
to	O
suppress	O
PEDV	O
replication	O
in	O
Vero	O
E6	O
cells	O
,	O
while	O
IL	O
-	O
11	O
knockdown	O
promoted	O
viral	B-PROC
infection	I-PROC
.	O

Our	O
data	O
suggest	O
that	O
IL	O
-	O
11	O
is	O
a	O
newfound	O
PEDV	O
-	O
inducible	O
cytokine	O
,	O
and	O
its	O
production	O
enhances	O
the	O
anti	B-PROC
-	I-PROC
apoptosis	I-PROC
ability	O
of	O
epithelial	O
cells	O
against	O
PEDV	O
infection	O
.	O

Pregnant	O
women	O
developed	O
pneumonia	O
more	O
often	O
than	O
other	O
women	O
in	O
the	O
reproductive	B-PROC
period	O
,	O
but	O
without	O
statistical	O
significance	O
(	O
81	O
.	O
8	O
%	O
vs	O
.	O
65	O
.	O
7	O
%,	O
p	O
=	O
0	O
.	O
330	O
,	O
OR	O
(	O
95	O
%	O
CI	O
)	O
2	O
.	O
35	O
(	O
0	O
.	O
47	O
-	O
11	O
.	O
80	O
)).	O

Gestational	O
week	O
of	O
pregnancy	O
,	O
the	O
etiology	O
of	O
pneumonia	O
and	O
comorbidity	O
were	O
not	O
found	O
to	O
be	O
risk	O
factors	O
for	O
death	B-PROC
(	O
p	O
=	O
0	O
.	O
128	O
,	O
p	O
=	O
0	O
.	O
499	O
and	O
p	O
=	O
1	O
.	O
000	O
,	O
respectively	O
).	O

All	O
tested	O
samples	O
which	O
were	O
originally	O
found	O
negative	O
for	O
influenza	O
A	O
H1N1	O
virus	O
were	O
also	O
found	O
to	O
be	O
negative	O
for	O
MERS	O
-	O
CoV	O
.	O
These	O
results	O
suggest	O
that	O
circulation	B-PROC
of	O
MERS	O
-	O
CoV	O
was	O
uncommon	O
among	O
patients	O
with	O
acute	O
respiratory	O
symptoms	O
in	O
Western	O
Saudi	O
Arabia	O
between	O
2010	O
and	O
2012	O
.	O

As	O
the	O
results	O
,	O
12	O
pathogens	O
(	O
5	O
virus	O
and	O
7	O
bacteria	O
)	O
were	O
detected	O
and	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
virus	O
US	O
strain	O
,	O
Mycoplasma	O
hyorhinis	O
,	O
Haemophilus	O
parasuis	O
,	O
and	O
porcine	O
cytomegalovirus	O
were	O
detected	O
at	O
high	O
frequency	O
.	O

The	O
deficiencies	O
are	O
three	O
-	O
fold	O
:	O
(	O
1	O
)	O
specialties	O
are	O
excessively	O
institutionalized	O
,	O
(	O
2	O
)	O
students	O
engage	O
in	O
passive	O
learning	B-PROC
and	O
memorization	O
,	O
and	O
(	O
3	O
)	O
passing	O
one	O
written	O
national	O
examination	O
serves	O
as	O
the	O
means	O
of	O
granting	O
permanent	O
physician	O
qualification	O
.	O

ABSTRACT	O
:	O
Chaige	O
Jieji	O
Decoction	O
recorded	O
in	O
Six	O
Books	O
of	O
Exogenous	O
Febrile	B-PROC
Disease	O
could	O
be	O
used	O
to	O
treat	O
exterior	O
syndrome	O
due	O
to	O
wind	O
-	O
cold	B-PROC
and	O
heat	O
caused	O
by	O
stagnation	O
.	O

Following	O
receptor	O
interaction	O
,	O
the	O
virus	O
can	O
utilize	O
diverse	O
host	O
proteases	O
for	O
cleavage	B-PROC
activation	O
of	O
virus	O
-	O
host	O
cell	O
membrane	B-PROC
fusion	I-PROC
and	O
subsequent	O
genome	O
delivery	O
.	O

Analysis	O
of	O
coronavirus	O
spike	O
proteins	O
by	O
western	O
blot	O
allows	O
the	O
visualization	O
and	O
assessment	O
of	O
proteolytic	B-PROC
processing	I-PROC
by	O
endogenous	O
or	O
exogenous	O
proteases	O
.	O

Here	O
,	O
we	O
present	O
a	O
method	O
based	O
on	O
western	O
blot	O
analysis	O
to	O
investigate	O
spike	O
protein	O
proteolytic	B-PROC
cleavage	B-PROC
by	O
transient	O
transfection	B-PROC
of	O
HEK	O
-	O
293	O
T	O
cells	O
allowing	O
expression	B-PROC
of	O
the	O
spike	O
protein	O
of	O
the	O
highly	O
pathogenic	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
cellular	O
trypsin	O
-	O
like	O
transmembrane	O
serine	O
protease	O
,	O
matriptase	O
.	O

Such	O
analysis	O
enables	O
the	O
characterization	O
of	O
cleavage	B-PROC
patterns	O
produced	O
by	O
a	O
host	O
protease	O
on	O
a	O
coronavirus	O
spike	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
emergence	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
,	O
more	O
than	O
2280	O
confirmed	O
human	O
infections	O
and	O
800	O
associated	O
deaths	B-PROC
had	O
been	O
reported	O
to	O
the	O
World	O
Health	O
Organization	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
Mouse	O
-	O
Adapted	O
MERS	O
Coronavirus	O
.	O

An	O
animal	O
model	O
that	O
supports	O
MERS	O
-	O
CoV	O
infection	O
and	O
causes	O
severe	O
lung	O
disease	O
is	O
useful	O
to	O
study	O
pathogenesis	B-PROC
and	O
evaluate	O
therapies	O
and	O
vaccines	O
.	O

ABSTRACT	O
:	O
Innate	O
immune	O
cells	O
play	O
a	O
vital	O
role	O
in	O
mounting	O
an	O
effective	O
host	B-PROC
response	I-PROC
to	O
a	O
variety	O
of	O
pathogen	O
challenges	O
.	O

Animal	O
models	O
are	O
often	O
required	O
to	O
study	O
viral	B-PROC
infections	I-PROC
and	O
therapies	O
,	O
especially	O
during	O
an	O
initial	O
outbreak	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
IPEC	O
-	O
J2	O
cells	O
as	O
a	O
model	O
to	O
explore	O
potential	O
evasion	O
strategies	O
employed	O
by	O
SADS	O
-	O
CoV	O
.	O
Our	O
results	O
showed	O
that	O
SADS	O
-	O
CoV	O
infection	O
failed	O
to	O
induce	O
IFN	O
-	O
β	O
production	O
,	O
and	O
inhibited	O
poly	O
(	O
I	O
:	O
C	O
)	O
and	O
Sendai	O
virus	O
(	O
SeV	O
)-	O
triggered	O
IFN	O
-	O
β	O
expression	B-PROC
.	O

TITLE	O
:	O
Comparative	O
therapeutic	O
efficacy	O
of	O
remdesivir	O
and	O
combination	O
lopinavir	O
,	O
ritonavir	O
,	O
and	O
interferon	O
beta	O
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
a	O
severe	O
respiratory	O
disease	O
associated	O
with	O
more	O
than	O
2468	O
human	O
infections	O
and	O
over	O
851	O
deaths	B-PROC
in	O
27	O
countries	O
since	O
2012	O
.	O

Therapeutic	O
LPV	O
/	O
RTV	O
-	O
IFNb	O
improves	O
pulmonary	B-PROC
function	I-PROC
but	O
does	O
not	O
reduce	O
virus	B-PROC
replication	I-PROC
or	O
severe	O
lung	O
pathology	O
.	O

Although	O
BCoV	O
(	O
P	O
=	O
0	O
.	O
032	O
)	O
and	O
BoRVA	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
were	O
significantly	O
associated	O
with	O
diarrhea	O
in	O
pre	O
-	O
weaned	B-PROC
calves	O
,	O
BNoV	O
and	O
BToV	O
showed	O
no	O
association	O
.	O

They	O
are	O
proposed	O
to	O
form	O
stacking	O
interactions	O
with	O
polypurine	O
sequences	O
in	O
the	O
5	O
'-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
selected	O
mRNAs	O
,	O
thereby	O
clamping	O
the	O
RNA	O
substrate	O
onto	O
eIF4A	O
and	O
causing	O
inhibition	B-PROC
of	O
the	O
translation	B-PROC
initiation	I-PROC
complex	O
.	O

Since	O
virus	B-PROC
replication	I-PROC
relies	O
on	O
the	O
host	O
translation	B-PROC
machinery	O
,	O
it	O
is	O
not	O
surprising	O
that	O
the	O
rocaglate	O
Silvestrol	O
has	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
.	O

CR	O
-	O
31	O
-	O
B	O
(-)	O
inhibited	O
the	O
replication	O
of	O
corona	O
-,	O
Zika	O
-,	O
Lassa	O
-,	O
Crimean	O
Congo	O
hemorrhagic	O
fever	B-PROC
viruses	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
hepatitis	O
E	O
virus	O
(	O
HEV	O
)	O
at	O
non	O
-	O
cytotoxic	O
low	O
nanomolar	O
concentrations	O
.	O

Moreover	O
,	O
thermodynamic	O
destabilization	O
of	O
the	O
HEV	O
5	O
'-	O
UTR	O
led	O
to	O
reduced	O
translational	B-PROC
inhibition	I-PROC
by	O
Silvestrol	O
,	O
suggesting	O
differences	O
between	O
rocaglates	O
in	O
their	O
mode	O
of	O
action	O
,	O
most	O
probably	O
by	O
engaging	O
Silvestrol	O
'	O
s	O
additional	O
dioxane	O
moiety	O
.	O

Lnc	O
-	O
MALAT1	O
expression	B-PROC
and	O
inflammatory	O
cytokines	O
levels	O
were	O
detected	O
using	O
real	O
-	O
time	O
qPCR	O
and	O
ELISA	O
assay	O
respectively	O
.	O

ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
is	O
a	O
porcine	O
enteropathogenic	O
coronavirus	O
that	O
causes	O
watery	O
diarrhea	O
,	O
vomiting	O
,	O
and	O
frequently	O
death	B-PROC
in	O
piglets	O
,	O
causing	O
serious	O
economic	O
losses	O
to	O
the	O
pig	O
industry	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
presence	O
of	O
the	O
M1030L	O
or	O
S1032A	O
mutations	O
in	O
FeCV	O
derived	O
from	O
stool	O
samples	O
from	O
a	O
selected	O
group	O
of	O
healthy	O
cats	O
from	O
households	O
and	O
shelters	O
and	O
determine	O
how	O
many	O
of	O
these	O
cats	O
excrete	B-PROC
FeCV	O
.	O

The	O
fusion	O
protein	O
LTB	O
-	O
COE	O
was	O
successfully	O
expressed	B-PROC
by	O
the	O
recombinant	O
adenovirus	O
in	O
HEK293	O
cells	O
,	O
and	O
the	O
immunogenicity	O
of	O
the	O
vaccine	O
candidate	O
was	O
assessed	O
in	O
BALB	O
/	O
c	O
mice	O
and	O
piglets	O
.	O

Moreover	O
,	O
a	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immune	I-PROC
response	I-PROC
was	O
promoted	O
in	O
immunized	O
mice	O
,	O
and	O
the	O
neutralizing	O
antibody	B-PROC
inhibited	O
both	O
the	O
vaccine	O
strain	O
and	O
the	O
emerging	O
PEDV	O
isolate	O
.	O

Herein	O
we	O
investigated	O
the	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
of	O
newly	O
synthesized	O
sixteen	O
halogenated	O
triazole	O
compounds	O
through	O
the	O
inhibition	B-PROC
of	I-PROC
helicase	I-PROC
activity	I-PROC
using	O
the	O
FRET	O
assay	O
.	O

Of	O
the	O
2220	O
reported	O
cases	O
,	O
1408	O
cases	O
,	O
including	O
451	O
MERS	O
-	O
CoV	O
deaths	B-PROC
,	O
were	O
analyzed	O
.	O

The	O
secondary	O
outcomes	O
were	O
the	O
ratio	O
of	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
the	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
PaO2	O
/	O
FIO2	O
),	O
total	O
positive	O
end	O
expiratory	B-PROC
pressure	O
(	O
PEEP	O
),	O
plateau	O
pressure	O
(	O
Pplat	O
),	O
days	O
free	O
of	O
ventilator	O
at	O
day	O
28	O
,	O
barotrauma	O
and	O
ICU	O
-	O
acquired	O
weakness	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
a	O
core	O
component	O
of	O
PDCoV	O
,	O
is	O
essential	O
for	O
virus	B-PROC
replication	I-PROC
and	O
is	O
a	O
significant	O
candidate	O
in	O
the	O
development	B-PROC
of	O
diagnostics	O
for	O
PDCoV	O
.	O
In	O
this	O
study	O
,	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
were	O
generated	O
and	O
tested	O
for	O
reactivity	O
with	O
three	O
truncations	O
of	O
the	O
full	O
protein	O
(	O
N1	O
,	O
N2	O
,	O
N3	O
)	O
that	O
contained	O
partial	O
overlaps	O
;	O
of	O
the	O
five	O
monoclonals	O
chosen	O
tested	O
,	O
each	O
reacted	O
with	O
only	O
the	O
N3	O
truncation	O
.	O

Two	O
polymorphisms	B-PROC
(	O
K267E	O
and	O
A291P	O
)	O
were	O
analyzed	O
in	O
the	O
context	O
of	O
authentic	O
MERS	O
-	O
CoV	O
and	O
were	O
found	O
to	O
attenuate	O
viral	B-PROC
replication	I-PROC
.	O

We	O
identified	O
severe	O
AOSD	O
-	O
related	O
complications	O
,	O
including	O
macrophage	B-PROC
activation	I-PROC
syndrome	O
(	O
4	O
.	O
7	O
%)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
12	O
.	O
3	O
%).	O

TITLE	O
:	O
Correlation	O
of	O
plasma	O
suPAR	O
expression	B-PROC
with	O
disease	O
risk	O
and	O
severity	O
as	O
well	O
as	O
prognosis	O
of	O
sepsis	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
results	O
show	O
that	O
the	O
rabies	O
virus	O
vector	O
-	O
based	O
vaccine	O
can	O
induce	O
remarkably	O
earlier	O
antibody	B-PROC
response	I-PROC
and	O
higher	O
levels	O
of	O
cellular	B-PROC
immunity	I-PROC
than	O
the	O
GEM	O
particles	O
vector	O
.	O

For	O
the	O
11	O
sera	O
from	O
hybrid	O
camels	O
in	O
Dubai	O
tested	O
with	O
the	O
S	O
-	O
ELISA	O
and	O
neutralization	O
antibody	B-PROC
test	O
,	O
6	O
(	O
55	O
%)	O
and	O
9	O
(	O
82	O
%),	O
respectively	O
,	O
were	O
positive	O
for	O
MERS	O
-	O
CoV	O
antibodies	O
.	O

All	O
the	O
6	O
serum	O
samples	O
that	O
were	O
positive	O
for	O
the	O
S	O
-	O
ELISA	O
were	O
also	O
positive	O
with	O
the	O
neutralization	O
antibody	B-PROC
test	O
.	O

There	O
was	O
a	O
strong	O
correlation	O
between	O
the	O
antibody	B-PROC
levels	O
detected	O
by	O
S	O
-	O
ELISA	O
and	O
neutralizing	O
antibody	B-PROC
titers	O
,	O
with	O
a	O
Spearman	O
coefficient	O
of	O
0	O
.	O
6262	O
(	O

TITLE	O
:	O
Coronavirus	O
infections	O
and	O
immune	B-PROC
responses	I-PROC
.	O

In	O
addition	O
,	O
dual	O
-	O
luciferase	O
reporter	O
assays	O
revealed	O
that	O
ubiquitin	B-PROC
-	O
specific	O
protease	O
47	O
(	O
USP47	O
),	O
a	O
deubiquitinase	B-PROC
-	O
encoding	O
gene	O
,	O
was	O
a	O
target	O
for	O
gga	O
-	O
miR	O
-	O
30d	O
.	O

TITLE	O
:	O
Increased	O
mobilization	O
of	O
mesenchymal	O
stem	O
cells	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
undergoing	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

In	O
severe	O
forms	O
of	O
ARDS	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
often	O
the	O
last	O
option	O
for	O
life	O
support	O
.	O

Serum	O
concentrations	O
of	O
vascular	B-PROC
endothelial	I-PROC
growth	B-PROC
factor	I-PROC
(	O
VEGF	O
)	O
and	O
angiopoietin	O
2	O
(	O
Ang2	O
)	O
were	O
determined	O
.	O

Common	O
symptoms	O
at	O
onset	O
of	O
illness	O
were	O
fever	B-PROC
(	O
40	O
[	O
98	O
%]	O
of	O
41	O
patients	O
),	O
cough	O
(	O
31	O
[	O
76	O
%]),	O
and	O
myalgia	O
or	O
fatigue	O
(	O
18	O
[	O
44	O
%]);	O
less	O
common	O
symptoms	O
were	O
sputum	B-PROC
production	I-PROC
(	O
11	O
[	O
28	O
%]	O
of	O
39	O
),	O
headache	O
(	O
three	O
[	O
8	O
%]	O
of	O
38	O
),	O
haemoptysis	O
(	O
two	O
[	O
5	O
%]	O
of	O
39	O
),	O
and	O
diarrhoea	O
(	O
one	O
[	O
3	O
%]	O
of	O
38	O
).	O

The	O
median	O
age	O
of	O
the	O
people	O
who	O
died	B-PROC
was	O
75	O
(	O
range	O
48	O
-	O
89	O
)	O
years	O
.	O

With	O
a	O
mean	O
serial	O
interval	O
of	O
7	O
.	O
5	O
days	O
(	O
95	O
%	O
CI	O
,	O
5	O
.	O
3	O
to	O
19	O
),	O
the	O
basic	O
reproductive	B-PROC
number	O
was	O
estimated	O
to	O
be	O
2	O
.	O
2	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
4	O
to	O
3	O
.	O
9	O
).	O

The	O
first	O
case	O
presented	O
with	O
a	O
febrile	B-PROC
respiratory	O
infection	O
with	O
persistent	O
symptoms	O
despite	O
antibiotic	O
treatment	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
close	O
coordination	B-PROC
between	O
clinicians	O
and	O
public	O
health	O
authorities	O
at	O
the	O
local	O
,	O
state	O
,	O
and	O
federal	O
levels	O
,	O
as	O
well	O
as	O
the	O
need	O
for	O
rapid	O
dissemination	O
of	O
clinical	O
information	O
related	O
to	O
the	O
care	O
of	O
patients	O
with	O
this	O
emerging	O
infection	O
.	O

Putative	O
recombination	B-PROC
was	O
investigated	O
by	O
RDP4	O
and	O
Simplot	O
v3	O
.	O
5	O
.	O
1	O
and	O
discordant	O
phylogenetic	O
clustering	O
in	O
individual	O
genomic	O
fragments	O
was	O
confirmed	O
by	O
phylogenetic	O
analysis	O
using	O
maximum	O
likelihood	O
and	O
Bayesian	O
methods	O
.	O

ABSTRACT	O
:	O
Launched	O
at	O
Davos	O
in	O
January	O
2017	O
with	O
funding	O
from	O
sovereign	O
investors	O
and	O
philanthropic	O
institutions	O
,	O
the	O
Coalition	O
for	O
Epidemic	O
Preparedness	O
Innovations	O
(	O
CEPI	O
)	O
is	O
an	O
innovative	O
partnership	O
between	O
public	O
,	O
private	O
,	O
philanthropic	O
,	O
and	O
civil	O
organisations	O
whose	O
mission	O
is	O
to	O
stimulate	O
,	O
finance	O
and	O
co	O
-	O
ordinate	O
vaccine	O
development	B-PROC
against	O
diseases	O
with	O
epidemic	O
potential	O
in	O
cases	O
where	O
market	O
incentives	O
fail	O
.	O

As	O
an	O
entity	O
largely	O
supported	O
by	O
public	O
funds	O
,	O
ensuring	O
equitable	O
access	O
to	O
vaccines	O
whose	O
development	B-PROC
it	O
supports	O
in	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
is	O
CEPI	O
'	O
s	O
primary	O
focus	O
.	O

Samples	O
were	O
tested	O
for	O
MERS	O
-	O
CoV	O
S1	O
-	O
specific	O
antibodies	O
(	O
Abs	O
)	O
by	O
ELISA	O
and	O
confirmed	O
by	O
testing	O
for	O
neutralizing	O
Abs	O
(	O
nAbs	O
)	O
using	O
both	O
pseudotyped	O
and	O
live	O
virus	B-PROC
neutralization	I-PROC
assays	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
CoVs	O
)	O
are	O
enveloped	O
viruses	O
with	O
a	O
positive	O
-	O
sense	B-PROC
single	O
-	O
stranded	O
RNA	O
genome	O
.	O

The	O
respiratory	O
ArTH	O
predictive	O
tool	O
assigns	O
one	O
point	O
for	O
each	O
of	O
the	O
following	O
:	O
apnea	O
-	O
hypopnea	O
index	O
(	O
AHI	O
)	O
<	O
30	O
/	O
h	O
,	O
nadir	O
oxygen	O
saturation	O
(	O
SaO	O
Our	O
results	O
reconfirmed	O
the	O
association	O
between	O
moderate	O
-	O
to	O
-	O
severe	O
sleep	B-PROC
apnea	O
syndrome	O
and	O
WUS	O
(	O
OR	O
2	O
.	O
879	O
,	O
95	O
%	O
CI	O
1	O
.	O
17	O
-	O
7	O
.	O
089	O
,	O
p	O
=	O
0	O
.	O
021	O
).	O

A	O
mechanistic	O
understanding	O
of	O
the	O
impact	O
of	O
bats	O
'	O
virus	O
hosting	O
capacities	O
,	O
including	O
uniquely	O
constitutive	O
immune	O
pathways	B-PROC
,	O
on	O
cellular	O
-	O
scale	O
viral	O
dynamics	O
is	O
needed	O
to	O
elucidate	O
zoonotic	O
emergence	O
.	O

The	O
patient	O
'	O
s	O
evolution	B-PROC
was	O
complicated	O
by	O
a	O
massive	O
epistaxis	O
,	O
in	O
the	O
context	O
of	O
thrombocytopenia	O
which	O
required	O
plasma	O
,	O
thrombocyte	O
,	O
and	O
erythrocyte	O
substitutes	O
.	O

Her	O
evolution	B-PROC
was	O
favorable	O
,	O
the	O
treatment	O
being	O
successful	O
in	O
remission	O
induction	O
.	O

However	O
,	O
none	O
of	O
the	O
deaths	B-PROC
occurred	O
during	O
the	O
isolation	O
period	O
,	O
and	O
no	O
differences	O
were	O
observed	O
in	O
patient	O
survival	O
rate	O
according	O
to	O
different	O
isolation	O
strategies	O
.	O

Recombinant	O
camel	O
IFN	O
-	O
α1	O
induced	O
the	O
mRNA	B-PROC
expression	B-PROC
of	O
interferon	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
camel	O
kidney	O
cells	O
.	O

TITLE	O
:	O
Neuromuscular	B-PROC
blockade	I-PROC
in	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O

Diffuse	O
alveolar	O
hemorrhage	O
from	O
Goodpasture	O
'	O
s	O
Syndrome	O
has	O
manifested	O
following	O
inhalation	B-PROC
of	O
hydrocarbons	O
and	O
following	O
smoking	O
.	O

However	O
,	O
pre	O
-	O
existing	O
pulmonary	O
disease	O
and	O
immunosuppression	B-PROC
were	O
associated	O
with	O
severe	O
PARDS	O
(	O
12	O
/	O
20	O
[	O
60	O
.	O
0	O
%]	O
vs	O
19	O
/	O
65	O
[	O
29	O
.	O
2	O
%];	O
P	O
=	O
.	O
017	O
),	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
use	O
(	O
5	O
/	O
20	O
[	O
25	O
.	O
0	O
%]	O
vs	O
3	O
/	O
65	O
[	O
4	O
.	O
6	O
%];	O
P	O
=	O
.	O
016	O
)	O
and	O
reduced	O
ventilator	O
free	O
days	O
(	O
VFD	O
)	O
(	O
15	O
[	O
0	O
,	O
19	O
]	O
vs	O
21	O
[	O
6	O
,	O
23	O
];	O
P	O
=	O
.	O
039	O
),	O
compared	O
with	O
those	O
without	O
them	O
.	O

Patients	O
with	O
pulmonary	O
comorbidities	O
and	O
immunosuppression	B-PROC
had	O
a	O
more	O
severe	O
course	O
of	O
PARDS	O
compared	O
with	O
others	O
.	O

However	O
,	O
pre	O
-	O
existing	O
pulmonary	O
disease	O
and	O
immunosuppression	B-PROC
were	O
associated	O
with	O
severe	O
PARDS	O
(	O
12	O
/	O
20	O
[	O
60	O
.	O
0	O
%]	O
vs	O
19	O
/	O
65	O
[	O
29	O
.	O
2	O
%];	O
P	O
=	O
.	O
017	O
),	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
use	O
(	O
5	O
/	O
20	O
[	O
25	O
.	O
0	O
%]	O
vs	O
3	O
/	O
65	O
[	O
4	O
.	O
6	O
%];	O
P	O
=	O
.	O
016	O
)	O
and	O
reduced	O
ventilator	O
free	O
days	O
(	O
VFD	O
)	O
(	O
15	O
[	O
0	O
,	O
19	O
]	O
vs	O
21	O
[	O
6	O
,	O
23	O
];	O
P	O
=	O
.	O
039	O
),	O
compared	O
with	O
those	O
without	O
them	O
.	O

Here	O
,	O
we	O
focus	O
on	O
advances	O
in	O
research	O
and	O
development	B-PROC
of	O
fast	O
diagnosis	O
methods	O
,	O
as	O
well	O
as	O
potential	O
prophylactics	O
and	O
therapeutics	O
to	O
prevent	O
or	O
treat	O
2019	O
-	O
nCoV	O
infection	O
.	O

Severe	O
lung	O
injury	O
,	O
disruption	O
of	O
alveolar	O
-	O
capillary	O
barrier	O
with	O
the	O
loss	O
of	O
zonula	O
occluden	O
(	O
ZO	O
)-	O
1	O
and	O
up	O
-	O
regulated	O
expression	B-PROC
of	O
Nox2	O
in	O
AECs	O
were	O
exhibited	O
in	O
ARDS	O
mice	O
.	O

Although	O
little	O
is	O
known	O
about	O
the	O
virus	O
,	O
an	O
examination	O
of	O
the	O
genome	O
sequence	O
shows	O
strong	O
homology	O
with	O
its	O
better	O
-	O
studied	O
cousin	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
spike	O
protein	O
used	O
for	O
host	O
cell	O
infection	O
shows	O
key	O
nonsynonymous	O
mutations	O
that	O
might	O
hamper	O
the	O
efficacy	O
of	O
previously	O
developed	O
therapeutics	O
but	O
remains	O
a	O
viable	O
target	O
for	O
the	O
development	B-PROC
of	O
biologics	O
and	O
macrocyclic	O
peptides	O
.	O

According	O
to	O
current	O
observations	O
,	O
2019	O
-	O
nCoV	O
is	O
weaker	O
than	O
SARS	O
in	O
pathogenesis	B-PROC
,	O
but	O
has	O
stronger	O
transmission	O
competence	O
;	O
it	O
'	O
s	O
mechanism	O
of	O
cross	O
-	O
species	O
spread	O
might	O
be	O
related	O
with	O
angiotensin	O
-	O
converting	O
enzyme	O
Ⅱ	O
(	O
ACE2	O
),	O
which	O
is	O
consistent	O
with	O
the	O
receptor	O
SARS	O
-	O
CoV	O
.	O
After	O
the	O
outbreak	O
of	O
this	O
disease	O
,	O
Chinese	O
scientists	O
invested	O
a	O
lot	O
of	O
energy	O
to	O
carry	O
out	O
research	O
by	O
developing	O
rapid	O
diagnostic	O
reagents	O
,	O
identifying	O
the	O
characters	O
of	O
the	O
pathogen	O
,	O
screening	O
out	O
clinical	O
drugs	O
that	O
may	O
inhibit	O
the	O
virus	O
,	O
and	O
are	O
rapidly	O
developing	O
vaccines	O
.	O

Fever	B-PROC
,	O
cough	O
,	O
myalgia	O
,	O
weakness	O
,	O
dyspnea	O
and	O
imagings	O
may	O
be	O
helpful	O
for	O
the	O
early	O
detection	O
of	O
novel	O
coronavirus	O
pneumonia	O
.	O

Materials	O
and	O
MethodsFifty	O
-	O
one	O
patients	O
(	O
25	O
men	O
and	O
26	O
women	O
;	O
age	O
range	O
16	O
-	O
76	O
years	O
)	O
with	O
laboratory	O
-	O
confirmed	O
2019	O
-	O
nCoV	O
infection	O
by	O
using	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
underwent	O
thin	O
-	O
section	O
CT	O
.	O

Cases	O
have	O
also	O
been	O
reported	O
in	O
26	O
locations	O
outside	O
of	O
mainland	O
China	O
,	O
including	O
documentation	O
of	O
some	O
person	O
-	O
to	O
-	O
person	O
transmission	O
and	O
one	O
death	B-PROC
(	O
2	O
).	O

Supportive	O
treatment	O
and	O
oseltamivir	O
did	O
not	O
prevent	O
the	O
development	B-PROC
of	O
chronic	O
renal	O
failure	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
its	O
most	O
advanced	O
form	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
severe	O
inflammatory	O
pulmonary	O
process	O
triggered	O
by	O
varieties	O
of	O
pathophysiological	O
factors	O
,	O
among	O
which	O
apoptosis	B-PROC
of	O
pulmonary	O
endothelial	O
cells	O
plays	O
a	O
critical	O
role	O
in	O
the	O
progression	O
of	O
ALI	O
/	O
ARDS	O
.	O

The	O
results	O
showed	O
that	O
RUS	O
could	O
attenuate	O
LPS	O
-	O
induced	O
lung	O
injury	O
and	O
pulmonary	O
endothelial	O
apoptosis	B-PROC
significantly	O
.	O

And	O
we	O
observed	O
that	O
RUS	O
inhibited	O
the	O
activation	O
of	O
TLR4	O
/	O
MYD88	O
/	O
NF	O
-	O
κB	O
pathway	B-PROC
in	O
pulmonary	O
endothelium	O
after	O
LPS	O
treatment	O
.	O

EIC	O
mutations	O
were	O
also	O
implicated	O
in	O
regulating	O
IBV	O
-	O
induced	O
apoptosis	B-PROC
,	O
induction	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
and	O
viral	O
pathogenicity	O

It	O
identifies	O
key	O
behavioural	O
risk	O
factors	O
that	O
can	O
be	O
targeted	B-PROC
for	O
development	B-PROC
of	O
tailored	O
risk	O
-	O
mitigation	O
strategies	O
to	O
reduce	O
the	O
threat	O
of	O
novel	O
zoonoses	O
.	O

Fundación	O
Mutua	O
Madrileña	O
,	O
Instituto	O
de	O
Salud	O
Carlos	O
III	O
,	O
The	O
European	O
Regional	O
Development	B-PROC
'	O
s	O
Funds	O
,	O
Asociación	O
Científica	O
Pulmón	O
y	O
Ventilación	O
Mecánica	O
.	O

Six	O
patients	O
underwent	O
lung	O
and	O
airway	O
imaging	O
at	O
four	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
in	O
a	O
cohort	O
trial	O
.	O

The	O
estimations	O
based	O
on	O
likelihood	O
and	O
model	O
analysis	O
show	O
that	O
the	O
control	O
reproduction	B-PROC
number	O
may	O
be	O
as	O
high	O
as	O
6	O
.	O
47	O
(	O
95	O
%	O
CI	O
5	O
.	O
71	O
-	O
7	O
.	O
23	O
).	O

Focusing	O
on	O
two	O
betacoronaviruses	O
,	O
murine	O
JHM	O
-	O
CoV	O
and	O
human	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
we	O
found	O
that	O
virus	O
particle	O
binding	O
to	O
cells	O
was	O
mediated	O
by	O
sialic	O
acids	O
;	O
however	O
,	O
the	O
transmembrane	O
protein	O
receptors	O
were	O
required	O
for	O
a	O
subsequent	O
virus	B-PROC
infection	I-PROC
.	O

However	O
,	O
sialic	O
acids	O
sufficiently	O
facilitated	O
the	O
later	O
stages	O
of	O
virus	O
spread	O
through	O
cell	O
-	O
cell	O
membrane	B-PROC
fusion	I-PROC
,	O
without	O
requiring	O
protein	O
receptors	O
.	O

Overall	O
,	O
these	O
findings	O
reveal	O
roles	O
for	O
sialic	O
acids	O
in	O
virus	O
-	O
cell	O
binding	O
,	O
viral	O
spike	O
protein	O
-	O
directed	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
,	O
and	O
resultant	O
spread	O
of	O
CoV	O
infections	O
.	O

TITLE	O
:	O
Preliminary	O
prediction	O
of	O
the	O
basic	O
reproduction	B-PROC
number	O
of	O
the	O
Wuhan	O
novel	O
coronavirus	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
To	O
estimate	O
the	O
basic	O
reproduction	B-PROC
number	O
of	O
the	O
Wuhan	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
).	O

Based	O
on	O
the	O
susceptible	O
-	O
exposed	O
-	O
infected	O
-	O
removed	O
(	O
SEIR	O
)	O
compartment	O
model	O
and	O
the	O
assumption	O
that	O
the	O
infectious	O
cases	O
with	O
symptoms	O
occurred	O
before	O
26	O
January	O
,	O
2020	O
are	O
resulted	O
from	O
free	O
propagation	O
without	O
intervention	O
,	O
we	O
estimate	O
the	O
basic	O
reproduction	B-PROC
number	O
of	O
2019	O
-	O
nCoV	O
according	O
to	O
the	O
reported	O
confirmed	O
cases	O
and	O
suspected	O
cases	O
,	O
as	O
well	O
as	O
the	O
theoretical	O
estimated	O
number	O
of	O
infected	O
cases	O
by	O
other	O
research	O
teams	O
,	O
together	O
with	O
some	O
epidemiological	O
determinants	O
learned	B-PROC
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Further	O
investigation	O
revealed	O
these	O
cases	O
to	O
result	O
from	O
infection	O
with	O
a	O
newly	O
identified	O
coronavirus	O
,	O
termed	O
the	O
2019	O
-	O
nCoV	O
.	O
The	O
infection	O
moved	O
rapidly	O
through	O
China	O
,	O
spread	O
to	O
Thailand	O
and	O
Japan	O
,	O
extended	O
into	O
adjacent	O
countries	O
through	O
infected	O
persons	O
travelling	O
by	O
air	O
,	O
eventually	O
reaching	B-PROC
multiple	O
countries	O
and	O
continents	O
.	O

Due	O
to	O
immaturity	O
of	O
immune	B-PROC
function	I-PROC
and	O
the	O
possibility	O
of	O
mother	O
-	O
fetal	O
vertical	O
transmission	O
,	O
neonates	O
are	O
particularly	O
susceptible	O
to	O
2019	O
-	O
nCoV	O
.	O
The	O
perinatal	O
-	O
neonatal	O
departments	O
should	O
cooperate	O
closely	O
and	O
take	O
integrated	O
approaches	O
,	O
and	O
the	O
neonatal	O
intensive	O
care	O
unit	O
should	O
prepare	O
the	O
emergency	O
plan	O
for	O
2019	O
-	O
nCoV	O
infection	O
as	O
far	O
as	O
possible	O
,	O
so	O
as	O
to	O
ensure	O
the	O
optimal	O
management	O
and	O
treatment	O
of	O
potential	O
victims	O
.	O

Therapeutic	O
remdesivir	O
treatment	O
initiated	O
12	O
h	O
postinoculation	O
also	O
provided	O
a	O
clear	O
clinical	O
benefit	O
,	O
with	O
a	O
reduction	O
in	O
clinical	O
signs	O
,	O
reduced	O
virus	B-PROC
replication	I-PROC
in	O
the	O
lungs	O
,	O
and	O
decreased	O
presence	O
and	O
severity	O
of	O
lung	O
lesions	O
.	O

A	O
RV	O
global	O
LSS	O
value	O
>	O
-	O
13	O
.	O
7	O
%	O
differentiated	B-PROC
patients	O
with	O
a	O
TAPSE	O
<	O
vs	O
>	O
12	O
mm	O
with	O
a	O
sensitivity	O
of	O
88	O
%	O
and	O
a	O
specificity	O
of	O
83	O
%.	O

Regarding	O
clinical	O
outcomes	O
,	O
mortality	O
and	O
cumulative	O
incidence	O
of	O
weaning	B-PROC
from	O
MV	O
at	O
day	O
28	O
were	O
not	O
different	O
in	O
patients	O
with	O
normal	O
versus	O
abnormal	O
STE	O
-	O
derived	O
parameters	O
.	O

The	O
binding	O
of	O
COVID	O
-	O
19	O
and	O
ACE2	O
resulted	O
in	O
the	O
exhaustion	O
of	O
ACE2	O
,	O
and	O
then	O
ACE2	O
/	O
Ang	O
(	O
1	O
-	O
7	O
)/	O
Mas	O
receptor	O
pathway	B-PROC
was	O
inhibited	O
.	O

Gene	O
Ontology	O
(	O
GO	O
)	O
and	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
analysis	O
revealed	O
that	O
these	O
lncRNAs	O
might	O
be	O
involved	O
in	O
numerous	O
biological	B-PROC
processes	I-PROC
.	O

The	O
KEGG	O
analysis	O
of	O
the	O
co	O
-	O
expressed	B-PROC
genes	O
showed	O
that	O
these	O
differentially	O
expressed	B-PROC
lncRNAs	O
were	O
enriched	O
in	O
pathways	B-PROC
related	O
to	O
metabolism	B-PROC
and	O
TNF	O
signaling	B-PROC
.	O

Our	O
study	O
provided	O
comprehensive	O
information	O
about	O
lncRNAs	O
that	O
would	O
be	O
a	O
useful	O
resource	O
for	O
studying	O
the	O
pathogenesis	B-PROC
of	O
and	O
designing	O
antiviral	O
therapy	O
for	O
PDCoV	O
infection	O
.	O

TITLE	O
:	O
The	O
Effects	O
of	O
Social	O
Media	O
Use	O
on	O
Preventive	O
Behaviors	B-PROC
during	O
Infectious	O
Disease	O
Outbreaks	O
:	O
The	O
Mediating	O
Role	O
of	O
Self	O
-	O
relevant	O
Emotions	O
and	O
Public	O
Risk	O
Perception	O
.	O

Using	O
data	O
collected	O
during	O
the	O
2015	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
in	O
South	O
Korea	O
,	O
this	O
study	O
explores	O
the	O
relationships	O
among	O
social	O
media	O
use	O
,	O
risk	O
perception	O
,	O
and	O
preventive	O
behaviors	B-PROC
by	O
examining	O
the	O
mediating	O
role	O
of	O
two	O
self	O
-	O
relevant	O
emotions	O
:	O
fear	O
and	O
anger	O
.	O

TITLE	O
:	O
Can	O
Chinese	O
Medicine	O
Be	O
Used	O
for	O
Prevention	O
of	O
Corona	O
Virus	B-PROC
Disease	I-PROC
2019	O
(	O
COVID	O
-	O
19	O
)?	O

The	O
primary	O
outcome	O
was	O
a	O
score	O
combining	O
death	B-PROC
and	O
number	O
of	O
ventilator	O
-	O
free	O
days	O
at	O
day	O
28	O
(	O
score	O
ranged	O
from	O
-	O
1	O
for	O
death	B-PROC
to	O
27	O
if	O
the	O
patient	O
was	O
off	O
ventilator	O
on	O
the	O
first	O
day	O
).	O

The	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
are	O
a	O
major	O
class	O
of	O
innate	O
immune	O
pattern	O
recognition	O
receptors	O
that	O
have	O
a	O
key	O
role	O
in	O
immune	B-PROC
response	I-PROC
and	O
defense	O
against	O
various	O
infections	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
targeting	B-PROC
driving	O
pressure	O
may	O
improve	O
the	O
safety	O
of	O
ventilation	O
strategies	O
for	O
ARDS	O
patients	O
.	O

Collectively	O
,	O
the	O
results	O
of	O
our	O
study	O
indicate	O
that	O
necroptosis	B-PROC
is	O
an	O
important	O
mechanism	B-PROC
of	I-PROC
cell	B-PROC
death	I-PROC
in	O
ARDS	O
and	O
the	O
inhibition	B-PROC
of	O
necroptosis	B-PROC
may	O
be	O
a	O
therapeutic	O
intervention	O
for	O
ARDS	O
.	O

Consumption	O
of	O
30	O
g	O
dry	O
beef	O
can	O
fully	O
meet	O
daily	O
physiological	O
needs	O
of	O
the	O
healthy	O
70	O
-	O
kg	O
adult	O
human	O
for	O
taurine	O
and	O
carnosine	O
,	O
and	O
can	O
also	O
provide	O
large	O
amounts	O
of	O
creatine	O
,	O
anserine	O
and	O
4	O
-	O
hydroxyproline	O
to	O
improve	O
human	O
nutrition	B-PROC
and	O
health	O
,	O
including	O
metabolic	B-PROC
,	O
retinal	O
,	O
immunological	O
,	O
muscular	O
,	O
cartilage	O
,	O
neurological	O
,	O
and	O
cardiovascular	O
health	O
.	O

Conventional	O
coagulation	B-PROC
results	O
and	O
outcomes	O
of	O
183	O
consecutive	O
patients	O
with	O
confirmed	O
NCP	O
in	O
Tongji	O
hospital	O
were	O
retrospectively	O
analyzed	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
panel	O
and	O
chest	O
CT	O
scan	O
should	O
be	O
conducted	O
for	O
patients	O
with	O
fever	B-PROC
(>	O
37	O
.	O
3	O
℃),	O
travel	O
history	O
to	O
Hubei	O
Province	O
within	O
14	O
days	O
,	O
or	O
contact	O
history	O
with	O
residents	O
from	O
Wuhan	O
district	O
within	O
14	O
days	O
.	O

We	O
modeled	O
epidemic	O
growth	B-PROC
either	O
from	O
a	O
single	O
index	O
case	O
with	O
illness	O
onset	O
on	O
8	O
December	O
,	O
2019	O
(	O
Scenario	O
1	O
),	O
or	O
using	O
the	O
growth	B-PROC
rate	O
fitted	O
along	O
with	O
the	O
other	O
parameters	O
(	O
Scenario	O
2	O
)	O
based	O
on	O
data	O
from	O
20	O
exported	O
cases	O
reported	O
by	O
24	O
January	O
2020	O
.	O

During	O
the	O
COVID	O
-	O
19	O
outbreak	O
period	O
,	O
it	O
should	O
be	O
carefully	O
differentiated	B-PROC
for	O
fever	B-PROC
and	O
respiratory	O
symptoms	O
for	O
lung	O
cancer	O
patients	O
receiving	O
anti	O
-	O
tumor	O
treatment	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
risk	O
of	O
COVID	O
-	O
19	O
.	O

Comprehensive	O
measures	O
and	O
suggestions	O
for	O
protection	O
and	O
disinfection	O
are	O
put	O
forward	O
from	O
perspectives	O
of	O
functional	O
areas	O
in	O
key	O
places	O
,	O
such	O
as	O
hotels	O
,	O
mobile	O
cabin	O
hospitals	O
,	O
passenger	O
transport	B-PROC
stations	O
and	O
public	O
transport	B-PROC
facilities	O
,	O
environment	O
and	O
facilities	O
,	O
personal	O
protection	O
,	O
operation	O
management	O
system	O
,	O
etc	O
.,	O
so	O
as	O
to	O
provide	O
technical	O
support	O
for	O
the	O
prevention	O
and	O
control	O
of	O
new	O
respiratory	O
infectious	O
diseases	O
.	O

Among	O
patients	O
with	O
pneumonia	O
caused	O
by	O
SARS	O
-	O
CoV	O
-	O
2	O
(	O
novel	O
coronavirus	O
pneumonia	O
or	O
Wuhan	O
pneumonia	O
),	O
fever	B-PROC
was	O
the	O
most	O
common	O
symptom	O
,	O
followed	O
by	O
cough	O
.	O

The	O
virus	O
knowledge	O
is	O
limited	O
and	O
especially	O
about	O
COVID	O
-	O
2019	O
pathogenesis	B-PROC
.	O

Although	O
colorectal	O
surgery	O
is	O
not	O
a	O
front	O
-	O
line	O
subject	O
in	O
the	O
fight	O
against	O
the	O
epidemic	O
,	O
but	O
in	O
this	O
special	O
situation	O
,	O
now	O
it	O
is	O
a	O
difficult	O
task	O
that	O
with	O
the	O
premise	O
of	O
how	O
to	O
maximize	O
the	O
protection	O
for	O
patients	O
and	O
their	O
families	O
,	O
health	O
of	O
medical	O
staff	O
,	O
and	O
the	O
safety	O
of	O
wards	O
and	O
hospitals	O
,	O
we	O
can	O
provide	O
the	O
highest	O
quality	O
medical	O
services	O
to	O
ensure	O
the	O
orderly	O
development	B-PROC
of	O
previous	O
clinical	O
work	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
role	O
of	O
host	O
factors	O
during	O
pregnancy	O
on	O
antiviral	O
immunity	B-PROC
and	O
their	O
implications	O
for	O
generating	O
protective	O
lactogenic	O
immunity	B-PROC
in	O
suckling	O
neonates	O
.	O

TITLE	O
:	O
The	O
SARS	O
,	O
MERS	O
and	O
novel	O
coronavirus	O
(	O
COVID	O
-	O
19	O
)	O
epidemics	O
,	O
the	O
newest	O
and	O
biggest	O
global	O
health	O
threats	O
:	O
what	O
lessons	O
have	O
we	O
learned	B-PROC
?	O

Acute	O
cor	O
pulmonale	O
is	O
usually	O
secondary	O
to	O
an	O
acute	O
respiratory	O
distress	O
syndrome	O
or	O
to	O
a	O
pulmonary	O
embolism	O
but	O
it	O
can	O
also	O
be	O
seen	O
in	O
primary	O
lactic	O
acidosis	O
,	O
a	O
vaso	O
-	O
occlusive	O
crisis	O
in	O
a	O
patient	O
with	O
sickle	O
cell	O
anaemia	O
,	O
severe	O
acute	O
asthma	O
,	O
and	O
entry	O
of	O
air	O
or	O
injected	O
crushed	O
tablets	O
into	O
the	O
circulation	B-PROC
.	O

TITLE	O
:	O
Lessons	O
learned	B-PROC
from	O
the	O
2019	O
-	O
nCoV	O
epidemic	O
on	O
prevention	O
of	O
future	O
infectious	O
diseases	O
.	O

Here	O
,	O
we	O
systematically	O
investigated	O
the	O
role	O
of	O
trypsin	O
in	O
PDCoV	O
replication	O
including	O
cell	O
entry	O
,	O
cell	O
-	O
to	O
-	O
cell	O
membrane	B-PROC
fusion	I-PROC
and	O
virus	O
release	O
.	O

The	O
case	O
stresses	O
the	O
need	O
for	O
healthcare	O
personnel	O
to	O
perform	O
thorough	O
anamnesis	B-PROC
in	O
pregnant	O
women	O
in	O
farming	O
areas	O
and	O
to	O
advise	O
them	O
to	O
avoid	O
contact	O
with	O
small	O
ruminants	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
one	O
of	O
the	O
causes	O
of	O
the	O
common	O
cold	B-PROC
,	O
exacerbates	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
bronchial	O
asthma	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
a	O
combination	O
of	O
three	O
drugs	O
(	O
glycopyrronium	O
,	O
formoterol	O
,	O
and	O
budesonide	O
)	O
exerted	B-PROC
additive	O
inhibitory	O
effects	O
on	O
viral	O
titers	O
and	O
cytokine	B-PROC
production	I-PROC
.	O

Here	O
,	O
we	O
co	O
-	O
expressed	B-PROC
the	O
MERS	O
-	O
CoV	O
nonstructural	O
proteins	O
nsp5	O
,	O
nsp7	O
,	O
nsp8	O
,	O
and	O
nsp12	O
(	O
RdRp	O
)	O
in	O
insect	O
cells	O
as	O
a	O
part	O
a	O
polyprotein	O
to	O
study	O
the	O
mechanism	O
of	O
inhibition	B-PROC
of	O
MERS	O
-	O
CoV	O
RdRp	O
by	O
RDV	O
.	O

Once	O
incorporated	O
at	O
position	O
i	O
,	O
the	O
inhibitor	O
caused	O
RNA	B-PROC
synthesis	I-PROC
arrest	O
at	O
position	O
i	O
+	O
3	O
.	O

TITLE	O
:	O
High	O
expression	B-PROC
of	O
ACE2	O
receptor	O
of	O
2019	O
-	O
nCoV	O
on	O
the	O
epithelial	O
cells	O
of	O
oral	O
mucosa	O
.	O

TITLE	O
:	O
[	O
Management	O
of	O
corona	O
virus	B-PROC
disease	I-PROC
-	O
19	O
(	O
COVID	O
-	O
19	O
):	O
the	O
Zhejiang	O
experience	O
].	O

ABSTRACT	O
:	O
The	O
current	O
epidemic	O
situation	O
of	O
corona	O
virus	B-PROC
disease	I-PROC
-	O
19	O
(	O
COVID	O
-	O
19	O
)	O
still	O
remained	O
severe	O
.	O

The	O
epidemic	O
of	O
novel	O
coronavirus	O
pneumonia	O
poses	O
new	O
challenges	O
to	O
diagnosis	O
and	O
treatment	O
of	O
the	O
patients	O
with	O
digestive	B-PROC
system	O
malignancies	O
.	O

Based	O
on	O
the	O
fully	O
understanding	O
of	O
the	O
characteristics	O
of	O
digestive	B-PROC
system	O
tumors	O
,	O
we	O
should	O
change	O
the	O
treatment	O
strategy	O
and	O
adopt	O
more	O
reasonable	O
treatment	O
strategy	O
timely	O
during	O
the	O
epidemic	O
period	O
to	O
minimize	O
the	O
adverse	O
effects	O
of	O
the	O
epidemic	O
of	O
novel	O
coronavirus	O
pneumonia	O
on	O
the	O
treatment	O
.	O

The	O
probable	O
number	O
of	O
new	O
cases	O
for	O
the	O
next	O
ten	O
days	O
would	O
gradually	O
increase	O
,	O
and	O
the	O
estimated	O
cumulative	O
cases	O
would	O
reach	B-PROC
1514	O
(	O
1384	O
-	O
1656	O
)	O
at	O
the	O
tenth	O
day	O
in	O
the	O
future	O
.	O

Many	O
nanoparticles	O
(	O
NPs	O
)	O
can	O
inhibit	O
the	O
biological	O
functions	O
of	O
tumours	O
by	O
modulating	O
tumour	O
-	O
associated	O
inflammation	O
,	O
which	O
provokes	O
angiogenesis	B-PROC
and	O
tumour	O
growth	B-PROC
.	O

Third	O
,	O
ascertainment	O
bias	O
and	O
risk	O
of	O
death	B-PROC
among	O
all	O
those	O
infected	O
would	O
be	O
smaller	O
when	O
estimated	O
using	O
shorter	O
virus	O
detection	O
windows	O
and	O
less	O
sensitive	O
diagnostic	O
laboratory	O
tests	O
.	O

TITLE	O
:	O
Structural	O
Basis	O
for	O
Inhibiting	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	B-PROC
Replication	I-PROC
with	O
the	O
3C	O
-	O
Like	O
Protease	O
Inhibitor	O
GC376	O
.	O

There	O
are	O
no	O
commercial	O
drugs	O
targeting	B-PROC
coronaviruses	O
(	O
CoVs	O
),	O
and	O
few	O
studies	O
on	O
anti	O
-	O
PEDV	O
inhibitors	O
.	O

TITLE	O
:	O
Emergence	O
of	O
Novel	O
Coronavirus	O
2019	O
-	O
nCoV	O
:	O
Need	O
for	O
Rapid	O
Vaccine	O
and	O
Biologics	O
Development	B-PROC
.	O

ABSTRACT	O
:	O
Thousands	O
of	O
medical	O
workers	O
in	O
the	O
Military	O
support	O
Hubei	O
medical	O
team	O
are	O
exerting	B-PROC
themselves	O
in	O
many	O
hospitals	O
in	O
Hubei	O
Province	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
risk	O
of	O
transmission	O
of	O
2019	O
-	O
nCoV	O
through	O
human	O
passenger	O
air	O
flight	B-PROC
from	O
four	O
major	O
cities	O
of	O
China	O
(	O
Wuhan	O
,	O
Beijing	O
,	O
Shanghai	O
and	O
Guangzhou	O
)	O
to	O
the	O
passengers	O
'	O
destination	O
countries	O
.	O

Increased	O
public	O
health	O
response	O
including	O
early	O
case	O
recognition	O
,	O
isolation	O
of	O
identified	O
case	O
,	O
contract	O
tracing	O
and	O
targeted	B-PROC
airport	O
screening	O
,	O
public	O
awareness	O
and	O
vigilance	O
of	O
health	O
workers	O
will	O
help	O
mitigate	O
the	O
force	O
of	O
further	O
spread	O
to	O
naïve	O
countries	O
.	O

We	O
evaluated	O
ARDS	O
incidence	O
,	O
and	O
determined	O
ARDS	O
severity	O
from	O
arterial	O
blood	B-PROC
gas	I-PROC
analysis	O
.	O

As	O
the	O
delay	O
is	O
small	O
,	O
the	O
decision	O
to	O
control	O
travel	O
volume	O
through	O
restrictions	O
on	O
freedom	O
of	O
movement	B-PROC
should	O
be	O
balanced	O
between	O
the	O
resulting	O
estimated	O
epidemiological	O
impact	O
and	O
predicted	O
economic	O
fallout	O
.	O

Most	O
of	O
the	O
infected	O
patients	O
have	O
mild	O
symptoms	O
including	O
fever	B-PROC
,	O
fatigue	O
and	O
cough	O
.	O

But	O
in	O
severe	O
cases	O
,	O
patients	O
can	O
progress	O
rapidly	O
and	O
develop	O
to	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
septic	O
shock	O
,	O
metabolic	B-PROC
acidosis	O
and	O
coagulopathy	O
.	O

X	O
-	O
ray	O
crystallography	O
and	O
small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
showed	O
that	O
5	O
-	O
benzyloxygramine	O
stabilizes	O
the	O
N	O
-	O
NTD	O
dimers	O
through	O
simultaneous	O
hydrophobic	B-PROC
interactions	I-PROC
with	O
both	O
partners	O
,	O
resulting	O
in	O
abnormal	O
N	O
protein	B-PROC
oligomerization	I-PROC
that	O
was	O
further	O
confirmed	O
in	O
the	O
cell	O
.	O

There	O
have	O
been	O
2	O
,	O
462	O
associated	O
deaths	B-PROC
worldwide	O
;	O
no	O
deaths	B-PROC
have	O
been	O
reported	O
in	O
the	O
United	O
States	O
.	O

The	O
main	O
clinical	O
manifestations	O
of	O
the	O
patients	O
were	O
fever	B-PROC
and	O
cough	O
,	O
which	O
accounted	O
for	O
63	O
cases	O
(	O
78	O
.	O
75	O
%)	O
and	O
51	O
cases	O
(-	O
63	O
.	O
75	O
%)	O
respectively	O
.	O

According	O
to	O
the	O
latest	O
data	O
,	O
a	O
total	O
of	O
813	O
deaths	B-PROC
occurred	O
in	O
China	O
mainland	O
,	O
with	O
the	O
mortality	O
reaching	B-PROC
approximately	O
2	O
.	O
2	O
%.	O

Several	O
laboratory	O
protocols	O
for	O
confirmation	O
of	O
suspected	O
2019	O
-	O
nCoV	O
cases	O
using	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
have	O
been	O
published	O
.	O

Hemodynamics	B-PROC
need	O
be	O
closely	O
monitored	O
and	O
different	O
types	O
of	O
shock	O
should	O
be	O
distinguished	O
.	O

Fever	B-PROC
,	O
cough	O
and	O
expectoration	O
were	O
the	O
most	O
common	O
symptoms	O
,	O
14	O
patients	O
had	O
decreased	O
oxygen	O
saturation	O
,	O
33	O
had	O
leukopenia	O
,	O
53	O
had	O
lymphopenia	O
,	O
and	O
82	O
had	O
elevated	O
C	O
-	O
reactive	O
protein	O
.	O

Network	O
pharmacology	O
analysis	O
predicted	O
that	O
the	O
general	O
in	O
vivo	O
roles	O
of	O
these	O
26	O
herbal	O
plants	O
were	O
related	O
to	O
regulating	O
viral	B-PROC
infection	I-PROC
,	O
immune	O
/	O
inflammation	O
reactions	O
and	O
hypoxia	O
response	O
.	O

TITLE	O
:	O
Autophagy	B-PROC
Protects	O
Against	O
Developing	O
Increased	O
Lung	O
Permeability	O
and	O
Hypoxemia	O
by	O
Down	O
Regulating	O
Inflammasome	O
Activity	O
and	O
IL	O
-	O
1β	O
in	O
LPS	O
Plus	O
Mechanical	O
Ventilation	O
-	O
Induced	O
Acute	O
Lung	O
Injury	O
.	O

Autophagy	B-PROC
is	O
a	O
key	O
regulator	O
of	O
inflammasome	O
activation	O
in	O
macrophages	O
.	O

This	O
might	O
be	O
due	O
to	O
the	O
biological	O
characteristics	O
of	O
2019	O
-	O
nCoV	O
,	O
and	O
might	O
also	O
be	O
related	O
to	O
the	O
basic	O
disease	O
,	O
clinical	O
status	O
,	O
glucocorticoid	O
using	O
,	O
sample	O
sampling	O
,	O
processing	O
and	O
detecting	O
of	O
patients	O
,	O
and	O
some	O
even	O
related	O
to	O
the	O
re	O
-	O
infection	O
or	O
secondary	O
bacterial	O
virus	B-PROC
infection	I-PROC
.	O

The	O
effects	O
of	O
cluster	O
of	O
differentiation	B-PROC
4	O
(	O
CD4	O
)+	O
T	O
lymphocytes	O
,	O
inflammatory	O
indicators	O
,	O
and	O
glucocorticoid	O
treatment	O
on	O
viral	O
nucleic	O
acid	O
clearance	O
were	O
analyzed	O
.	O

For	O
all	O
the	O
78	O
patients	O
,	O
fever	B-PROC
was	O
the	O
most	O
common	O
initial	O
symptom	O
,	O
and	O
the	O
maximum	O
body	O
temperature	O
at	O
admission	O
was	O
significantly	O
higher	O
in	O
the	O
progression	O
group	O
than	O
in	O
the	O
improvement	O
/	O
stabilization	O
group	O
(	O
38	O
.	O
2	O
[	O
37	O
.	O
8	O
,	O
38	O
.	O
6	O
]	O
vs	O
.	O
37	O
.	O
5	O
[	O
37	O
.	O
0	O
,	O
38	O
.	O
4	O
]°	O
C	O
,	O
U	O
=	O
2	O
.	O
057	O
,	O
P	O
=	O
0	O
.	O
027	O
).	O

Data	O
on	O
population	O
migration	B-PROC
from	O
Wuhan	O
city	O
and	O
Hubei	O
province	O
were	O
extracted	O
from	O
Baidu	O
Qianxi	O
,	O
and	O
their	O
correlation	O
with	O
the	O
number	O
of	O
cases	O
was	O
analyzed	O
.	O

However	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
associated	O
with	O
a	O
coagulopathy	O
characterized	O
by	O
thromboembolic	O
and	O
hemorrhagic	O
complications	O
.	O

Bleeding	O
requiring	O
blood	O
product	O
application	O
occurred	O
in	O
three	O
of	O
10	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
patients	O
and	O
in	O
four	O
of	O
eight	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
patients	O
.	O

In	O
-	O
hospital	O
mortality	O
was	O
30	O
%	O
for	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
37	O
.	O
5	O
%	O
for	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
patients	O
.	O

The	O
underlying	O
factors	O
of	O
the	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
-	O
associated	O
coagulopathy	O
differ	O
between	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
patients	O
and	O
are	O
best	O
diagnosed	O
by	O
a	O
combination	O
of	O
point	O
-	O
of	O
-	O
care	O
and	O
conventional	O
coagulation	B-PROC
and	O
platelet	O
analyses	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
an	O
effort	B-PROC
to	O
compile	O
and	O
analyze	O
epidemiological	O
outbreak	O
information	O
on	O
COVID	O
-	O
19	O
based	O
on	O
the	O
several	O
open	O
datasets	O
on	O
2019	O
-	O
nCoV	O
provided	O
by	O
the	O
Johns	O
Hopkins	O
University	O
,	O
World	O
Health	O
Organization	O
,	O
Chinese	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
National	O
Health	O
Commission	O
,	O
and	O
DXY	O
.	O

ABSTRACT	O
:	O
Currently	O
there	O
is	O
no	O
effective	O
antiviral	O
therapy	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
,	O
which	O
frequently	O
leads	O
to	O
fatal	O
inflammatory	B-PROC
responses	I-PROC
and	O
acute	O
lung	O
injury	O
.	O

TITLE	O
:	O
Small	O
Molecule	O
Inhibitors	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Fusion	O
by	O
Targeting	B-PROC
Cavities	O
on	O
Heptad	O
Repeat	O
Trimers	O
.	O

Two	O
patients	O
died	B-PROC
of	O
SARS	O
,	O
and	O
78	O
were	O
enrolled	O
in	O
this	O
study	O
from	O
August	O
2003	O
to	O
March	O
2018	O
.	O

Indications	O
of	O
pulmonary	B-PROC
function	I-PROC
testing	O
should	O
be	O
followed	O
strictly	O
.	O

Cleaning	O
and	O
disinfection	O
procedures	O
for	O
environment	O
and	O
equipment	O
in	O
pulmonary	B-PROC
function	I-PROC
testing	O
laboratory	O
should	O
be	O
paid	O
more	O
attention	O
.	O

CONCLUSIONS	O
:	O
SARS	O
-	O
CoV	O
-	O
2	O
evolves	O
in	O
vivo	O
after	O
infection	O
,	O
which	O
may	O
affect	O
its	O
virulence	B-PROC
,	O
infectivity	O
,	O
and	O
transmissibility	O
.	O

Although	O
NK	O
cells	O
are	O
often	O
considered	O
as	O
a	O
uniform	O
cell	O
population	O
,	O
several	O
phenotypic	O
and	O
functionally	O
distinct	O
NK	O
cells	O
subsets	O
exist	O
in	O
healthy	O
individuals	O
,	O
that	O
are	O
differentially	O
affected	O
by	O
ageing	B-PROC
or	O
by	O
apparently	O
innocuous	O
viruses	O
such	O
as	O
cytomegalovirus	O
(	O
CMV	O
).	O

In	O
addition	O
,	O
further	O
alterations	O
in	O
the	O
expression	B-PROC
of	O
activating	O
and	O
inhibitory	O
receptors	O
are	O
found	O
in	O
NK	O
cells	O
from	O
cancer	O
patients	O
,	O
likely	O
because	O
of	O
their	O
interaction	O
with	O
tumour	O
cells	O
.	O

ABSTRACT	O
:	O
Several	O
reports	O
have	O
demonstrated	O
similar	O
effects	O
on	O
oxygenation	B-PROC
between	O
inhaled	B-PROC
epoprostenol	O
(	O
iEPO	O
)	O
compared	O
to	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Previous	O
studies	O
directly	O
comparing	O
oxygenation	B-PROC
and	O
clinical	O
outcomes	O
between	O
iEPO	O
and	O
iNO	O
exclusively	O
in	O
an	O
adult	O
ARDS	O
patient	O
population	O
utilized	O
a	O
weight	O
-	O
based	O
dosing	O
strategy	O
.	O

NS7b	O
and	O
NS8	O
have	O
previously	O
been	O
shown	O
to	O
affect	O
immune	B-PROC
response	I-PROC
signaling	B-PROC
in	O
the	O
SARS	O
-	O
CoV	O
experimental	O
model	O
.	O

The	O
continuous	O
evolution	B-PROC
of	O
coronaviruses	O
was	O
further	O
highlighted	O
with	O
the	O
emergence	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
CoV	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
in	O
2012	O
.	O

While	O
human	O
strains	O
of	O
Coronavirus	O
are	O
associated	O
with	O
about	O
15	O
%	O
of	O
cases	O
of	O
the	O
common	O
cold	B-PROC
,	O
the	O
SARS	O
-	O
CoV	O
-	O
2	O
may	O
present	O
with	O
varying	O
degrees	O
of	O
severity	O
,	O
from	O
flu	O
-	O
like	O
symptoms	O
to	O
death	B-PROC
.	O

TITLE	O
:	O
[	O
Screening	O
and	O
management	O
of	O
asymptomatic	O
infection	O
of	O
corona	O
virus	B-PROC
disease	I-PROC
2019	O
(	O
COVID	O
-	O
19	O
)].	O

And	O
there	O
are	O
also	O
negatives	O
trials	O
as	O
following	O
:	O
individual	O
mechanical	O
ventilation	O
,	O
maximal	O
recruitment	O
open	O
lung	O
ventilation	O
or	O
early	O
neuromuscular	B-PROC
blockade	I-PROC
for	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
,	O
N95	O
respirators	O
preventing	O
influenza	O
,	O
flexible	O
family	O
visit	O
program	O
against	O
delirium	O
or	O
early	O
sedation	O
with	O
dexmedetomidine	O
to	O
mechanically	O
ventilated	O
patients	O
,	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
diary	O
or	O
nurse	O
-	O
led	O
preventive	O
psychological	O
intervention	O
against	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
in	O
patients	O
with	O
mechanical	O
ventilation	O
,	O
recombinant	O
human	O
soluble	O
thrombomodulin	O
(	O
rhsTM	O
)	O
in	O
patients	O
with	O
sepsis	O
-	O
associated	O
coagulopathy	O
,	O
and	O
so	O
on	O
.	O

Autopsy	O
revealed	O
a	O
golden	O
-	O
brown	O
heavy	O
liver	O
with	O
massive	O
hepatic	O
necrosis	B-PROC
and	O
sinusoidal	O
congestion	O
.	O

TITLE	O
:	O
Radiation	O
induced	O
apoptosis	B-PROC
and	O
pulmonary	O
fibrosis	O
:	O
curcumin	O
an	O
effective	O
intervention	O
?	O

The	O
prevalence	O
of	O
bacterial	O
and	O
viral	B-PROC
infections	I-PROC
continue	O
to	O
increase	O
,	O
because	O
of	O
the	O
acquisition	O
of	O
rhinovirus	O
,	O
coronaviruses	O
(	O
229E	O
,	O
HKU1	O
,	O
OC43	O
),	O
influenza	O
A	O
H1N1	O
,	O
Streptococcus	O
pneumoniae	O
,	O
Haemophilus	O
influenzae	O
and	O
Staphylococcus	O
aureus	O
during	O
Hajj	O
.	O

The	O
spike	O
protein	O
of	O
coronavirus	O
GX_P2V	O
shares	O
92	O
.	O
2	O
%	O
amino	O
acid	O
identity	O
with	O
that	O
of	O
2019	O
-	O
nCoV	O
isolate	O
Wuhan	O
-	O
hu	O
-	O
1	O
,	O
and	O
uses	O
ACE2	O
as	O
the	O
receptor	O
for	O
infection	O
just	O
like	O
2019	O
-	O
nCoV	O
.	O
Three	O
drugs	O
-	O
cepharanthine	O
(	O
CEP	O
),	O
selamectin	O
and	O
mefloquine	O
hydrochloride	O
exhibited	O
complete	O
inhibition	B-PROC
of	O
cytopathic	O
effects	O
in	O
cell	O
culture	O
at	O
10	O
μmol	O
/	O
L	O
.	O
CEP	O
demonstrated	O
the	O
most	O
potent	O
inhibition	B-PROC
of	O
GX_P2V	O
infection	O
,	O
with	O
a	O
concentration	O
for	O
50	O
%	O
of	O
maximal	O
effect	O
[	O
EC50	O
]	O
of	O
0	O
.	O
98	O
μmol	O
/	O
L	O
.	O
The	O
viral	O
RNA	O
yield	O
in	O
cells	O
treated	O
with	O
10	O
μmol	O
/	O
L	O
CEP	O
was	O
15	O
,	O
393	O
-	O
fold	O
lower	O
than	O
in	O
cells	O
without	O
CEP	O
treatment	O
([	O
6	O
.	O
48	O
±	O
0	O
.	O
02	O
]	O
×	O
10vs	O
.	O

Furthermore	O
,	O
we	O
found	O
CEP	O
has	O
potent	O
antiviral	O
activities	O
against	O
both	O
viral	O
entry	O
(	O
1	O
.	O
00	O
±	O
0	O
.	O
37	O
vs	O
.	O
0	O
.	O
46	O
±	O
0	O
.	O
12	O
,	O
t	O
=	O
2	O
.	O
42	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
viral	B-PROC
replication	I-PROC
(	O
1	O
.	O
00	O
±	O
0	O
.	O
43	O
vs	O
.	O
[	O
6	O
.	O
18	O
±	O
0	O
.	O
95	O
]	O
×	O
10	O
,	O
t	O
=	O
3	O
.	O
98	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
StatPearls	O
ABSTRACT	O
:	O
According	O
to	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
),	O
viral	B-PROC
diseases	I-PROC
continue	O
to	O
emerge	O
and	O
represent	O
a	O
serious	O
issue	O
to	O
public	O
health	O
.	O

They	O
are	O
a	O
large	O
family	O
of	O
single	O
-	O
stranded	O
RNA	O
viruses	O
(+	O
ssRNA	O
)	O
that	O
can	O
be	O
isolated	O
in	O
different	O
animal	O
species	O
.[	O
1	O
]	O
For	O
reasons	O
yet	O
to	O
be	O
explained	O
,	O
these	O
viruses	O
can	O
cross	O
species	O
barriers	O
and	O
can	O
cause	O
,	O
in	O
humans	O
,	O
illness	O
ranging	O
from	O
the	O
common	O
cold	B-PROC
to	O
more	O
severe	O
diseases	O
such	O
as	O
MERS	O
and	O
SARS	O
.	O

Respiratory	O
tract	O
specimens	O
were	O
negative	O
by	O
reverse	B-PROC
transcription	B-PROC
PCR	O
.	O

Antibody	B-PROC
levels	O
measured	O
in	O
both	O
assays	O
correlated	O
strongly	O
with	O
virus	O
-	O
neutralizing	O
antibody	B-PROC
titers	O
,	O
proving	O
their	O
use	O
for	O
serologic	O
confirmatory	O
diagnosis	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
.	O

Clinically	O
,	O
the	O
first	O
symptom	O
in	O
the	O
neonates	O
was	O
shortness	O
of	O
breath	O
(	O
n	O
=	O
6	O
),	O
but	O
other	O
initial	O
symptoms	O
such	O
as	O
fever	B-PROC
(	O
n	O
=	O
2	O
),	O
thrombocytopenia	O
accompanied	O
by	O
abnormal	O
liver	B-PROC
function	I-PROC
(	O
n	O
=	O
2	O
),	O
rapid	O
heart	O
rate	O
(	O
n	O
=	O
1	O
),	O
vomiting	O
(	O
n	O
=	O
1	O
),	O
and	O
pneumothorax	O
(	O
n	O
=	O
1	O
)	O
were	O
observed	O
.	O

The	O
EU	O
/	O
EEA	O
is	O
moving	B-PROC
towards	O
the	O
'	O
limited	O
sustained	O
transmission	O
'	O
phase	O
.	O

Fever	B-PROC
was	O
present	O
in	O
all	O
of	O
the	O
case	O
series	O
available	O
,	O
flanked	O
by	O
cough	O
,	O
dyspnoea	O
,	O
myalgia	O
and	O
fatigue	O
.	O

ABSTRACT	O
:	O
The	O
human	O
FcγRs	O
interact	O
with	O
antigen	O
-	O
complexed	O
IgG	O
ligands	O
to	O
both	O
activate	O
and	O
modulate	O
a	O
powerful	O
network	O
of	O
inflammatory	O
host	O
-	O
protective	O
effector	O
functions	O
that	O
are	O
key	O
to	O
the	O
normal	O
physiology	O
of	O
immune	B-PROC
resistance	I-PROC
to	O
pathogens	O
.	O

The	O
most	O
common	O
symptoms	O
were	O
fever	B-PROC
and	O
cough	O
.	O

Liver	B-PROC
function	I-PROC
damage	O
is	O
more	O
frequent	O
in	O
NCOVID	O
-	O
19	O
than	O
NON	O
-	O
NCOVID	O
-	O
19	O
patients	O
.	O

These	O
containment	O
measures	O
are	O
necessary	O
to	O
optimize	O
the	O
quality	O
of	O
care	O
provided	O
to	O
COVID	O
-	O
19	O
patients	O
and	O
to	O
reduce	O
the	O
risk	O
of	O
viral	B-PROC
transmission	I-PROC
to	O
other	O
patients	O
or	O
healthcare	O
workers	O
.	O

The	O
compounds	O
are	O
made	O
publicly	O
available	O
for	O
further	O
characterization	O
and	O
development	B-PROC
by	O
scientific	O
community	O
.	O

In	O
poultry	O
,	O
the	O
genetic	O
diversity	O
,	O
evolution	B-PROC
,	O
distribution	O
,	O
and	O
taxonomy	O
of	O
CoVs	O
dominant	O
in	O
birds	O
other	O
than	O
chickens	O
remain	O
enigmatic	O
.	O

Most	O
of	O
those	O
who	O
died	B-PROC
had	O
limitations	O
placed	O
on	O
treatment	O
prior	O
to	O
death	B-PROC
.	O

It	O
has	O
been	O
known	O
since	O
the	O
2003	O
SARS	O
epidemic	O
that	O
the	O
receptor	O
critical	O
for	O
SARS	O
-	O
CoV	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
is	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

To	O
confirm	O
the	O
result	O
,	O
we	O
discovered	O
that	O
theaflavin	O
has	O
lower	O
binding	O
energy	O
of	O
-	O
8	O
.	O
8	O
kcal	O
/	O
mol	O
when	O
it	O
docks	O
in	O
the	O
catalytic	O
pocket	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
RdRp	O
by	O
using	O
the	O
Blind	O
Docking	B-PROC
server	O
.	O

In	O
this	O
study	O
,	O
we	O
retrieved	O
95	O
full	O
-	O
length	O
genomic	O
sequences	O
of	O
SARAS	O
-	O
CoV	O
-	O
2	O
strains	O
from	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
and	O
GISAID	O
databases	O
,	O
established	O
the	O
reference	O
sequence	O
by	O
conducting	B-PROC
multiple	O
sequence	O
alignment	O
and	O
phylogenetic	O
analyses	O
,	O
and	O
analyzed	O
sequence	O
variations	O
along	O
the	O
SARS	O
-	O
CoV	O
-	O
2	O
genome	O
.	O

ABSTRACT	O
:	O
With	O
an	O
increasing	O
number	O
of	O
Coronavirus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
cases	O
outside	O
of	O
Hubei	O
,	O
emergency	O
departments	O
(	O
EDs	O
)	O
and	O
fever	B-PROC
clinics	O
are	O
facing	O
challenges	O
posed	O
by	O
the	O
large	O
number	O
of	O
admissions	O
of	O
patients	O
suspected	O
to	O
have	O
COVID	O
-	O
19	O
.	O

In	O
bivariate	O
Cox	O
regression	O
analysis	O
,	O
risk	O
factors	O
associated	O
with	O
the	O
development	B-PROC
of	O
ARDS	O
and	O
progression	O
from	O
ARDS	O
to	O
death	B-PROC
included	O
older	O
age	O
(	O
hazard	O
ratio	O
[	O
HR	O
],	O
3	O
.	O
26	O
;	O
95	O
%	O
CI	O
2	O
.	O
08	O
-	O
5	O
.	O
11	O
;	O
and	O
HR	O
,	O
6	O
.	O
17	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
26	O
-	O
11	O
.	O
67	O
,	O
respectively	O
),	O
neutrophilia	O
(	O
HR	O
,	O
1	O
.	O
14	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
09	O
-	O
1	O
.	O
19	O
;	O
and	O
HR	O
,	O
1	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
17	O
,	O
respectively	O
),	O
and	O
organ	O
and	O
coagulation	B-PROC
dysfunction	O
(	O
eg	O
,	O
higher	O
lactate	O
dehydrogenase	O
[	O
HR	O
,	O
1	O
.	O
61	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
44	O
-	O
1	O
.	O
79	O
;	O
and	O
HR	O
,	O
1	O
.	O
30	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
11	O
-	O
1	O
.	O
52	O
,	O
respectively	O
]	O
and	O
D	O
-	O
dimer	O
[	O
HR	O
,	O
1	O
.	O
03	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
04	O
;	O
and	O
HR	O
,	O
1	O
.	O
02	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
04	O
,	O
respectively	O
]).	O

Computed	O
tomography	O
scans	O
of	O
patients	O
helped	O
monitor	O
the	O
changes	O
continuously	O
,	O
which	O
could	O
timely	O
provide	O
the	O
information	O
of	O
the	O
evolution	B-PROC
of	O
the	O
disease	O
or	O
therapeutic	O
effect	O
to	O
clinicians	O
.	O

Moreover	O
,	O
lung	O
cells	O
that	O
have	O
ACE2	O
expression	B-PROC
may	O
be	O
the	O
main	O
target	O
cells	O
during	O
2019	O
-	O
nCoV	O
infection	O
.	O

The	O
longest	O
observed	O
duration	O
of	O
viral	B-PROC
shedding	I-PROC
in	O
survivors	O
was	O
37	O
days	O
.	O

Prolonged	O
viral	B-PROC
shedding	I-PROC
provides	O
the	O
rationale	O
for	O
a	O
strategy	O
of	O
isolation	O
of	O
infected	O
patients	O
and	O
optimal	O
antiviral	O
interventions	O
in	O
the	O
future	O
.	O

Overall	O
,	O
potential	O
RT	O
-	O
PCR	O
vulnerabilities	O
include	O
general	O
preanalytical	O
issues	O
such	O
as	O
identification	O
problems	O
,	O
inadequate	O
procedures	O
for	O
collection	O
,	O
handling	O
,	O
transport	B-PROC
and	O
storage	B-PROC
of	O
the	O
swabs	O
,	O
collection	O
of	O
inappropriate	O
or	O
inadequate	O
material	O
(	O
for	O
quality	O
or	O
volume	O
),	O
presence	O
of	O
interfering	O
substances	O
,	O
manual	O
errors	O
,	O
as	O
well	O
as	O
specific	O
aspects	O
such	O
as	O
sample	O
contamination	O
and	O
testing	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O

Compared	O
with	O
general	O
COVID	O
-	O
19	O
patients	O
(	O
45	O
.	O
2	O
%),	O
refractory	O
patients	O
had	O
an	O
older	O
age	O
,	O
male	O
sex	O
,	O
more	O
underlying	O
comorbidities	O
,	O
lower	O
incidence	O
of	O
fever	B-PROC
,	O
higher	O
levels	O
of	O
maximum	O
temperature	O
among	O
fever	B-PROC
cases	O
,	O
higher	O
incidence	O
of	O
breath	O
shortness	O
and	O
anorexia	O
,	O
severer	O
disease	O
assessment	O
on	O
admission	O
,	O
high	O
levels	O
of	O
neutrophil	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
lower	O
levels	O
of	O
platelets	O
and	O
albumin	O
,	O
and	O
higher	O
incidence	O
of	O
bilateral	O
pneumonia	O
and	O
pleural	O
effusion	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
Compared	O
with	O
general	O
COVID	O
-	O
19	O
patients	O
(	O
45	O
.	O
2	O
%),	O
refractory	O
patients	O
had	O
an	O
older	O
age	O
,	O
male	O
sex	O
,	O
more	O
underlying	O
comorbidities	O
,	O
lower	O
incidence	O
of	O
fever	B-PROC
,	O
higher	O
levels	O
of	O
maximum	O
temperature	O
among	O
fever	B-PROC
cases	O
,	O
higher	O
incidence	O
of	O
breath	O
shortness	O
and	O
anorexia	O
,	O
severer	O
disease	O
assessment	O
on	O
admission	O
,	O
high	O
levels	O
of	O
neutrophil	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
lower	O
levels	O
of	O
platelets	O
and	O
albumin	O
,	O
and	O
higher	O
incidence	O
of	O
bilateral	O
pneumonia	O
and	O
pleural	O
effusion	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Analysis	O
of	O
recombination	B-PROC
confirmed	O
that	O
TGEV	O
JS2012	O
is	O
a	O
natural	O
recombinant	O
strain	O
between	O
Miller	O
M6	O
and	O
Purdue	O
115	O
.	O

All	O
5	O
deaths	B-PROC
occurred	O
in	O
the	O
SpO2	O
<	O
90	O
%	O
group	O
.	O

Older	O
patients	O
or	O
those	O
with	O
underlying	O
comorbidities	O
are	O
at	O
higher	O
risk	O
of	O
death	B-PROC
.	O

Calculating	O
the	O
composition	O
of	O
host	O
specific	O
slow	O
codons	O
and	O
slow	O
di	O
-	O
codons	O
in	O
the	O
viral	O
protein	O
coding	O
sequences	O
can	O
predict	O
the	O
order	O
of	O
viral	B-PROC
protein	I-PROC
synthesis	I-PROC
rates	O
between	O
different	O
virus	O
strains	O
.	O

Several	O
mechanisms	O
for	O
this	O
activity	O
have	O
been	O
suggested	O
including	O
:	O
SUMOylation	B-PROC
inhibition	B-PROC
;	O
blocking	O
formation	B-PROC
of	O
the	O
E1	O
-	O
SUMO	O
intermediate	O
;	O
inhibition	B-PROC
of	O
fatty	O
acid	O
synthase	O
;	O
non	O
-	O
specific	O
SIRT	O
inhibition	B-PROC
;	O
and	O
activation	O
of	O
protein	O
phosphatase	O
type	O
-	O
2C	O
.	O

Here	O
we	O
report	O
that	O
GA	O
inhibits	O
Herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
by	O
inhibition	B-PROC
of	O
both	O
fusion	O
and	O
viral	B-PROC
protein	I-PROC
synthesis	I-PROC
.	O

Thus	O
,	O
in	O
light	O
of	O
the	O
strong	O
effect	O
of	O
GA	O
on	O
viral	B-PROC
infection	I-PROC
,	O
even	O
after	O
the	O
infection	O
begins	O
,	O
it	O
may	O
potentially	O
be	O
used	O
to	O
treat	O
acute	O
infections	O
(	O
e	O
.	O
g	O
.	O
Coronavirus	O
,	O
EBOV	O
,	O
ZIKV	O
,	O
IAV	O
and	O
measles	O
),	O
and	O
also	O
topically	O
for	O
the	O
successful	O
treatment	O
of	O
active	O
lesions	O
(	O
e	O
.	O
g	O
.	O
HSV	O
-	O
1	O
,	O
HSV	O
-	O
2	O
and	O
varicella	O
-	O
zoster	O
virus	O
(	O
VZV	O
)).	O

This	O
analysis	O
reveals	O
that	O
unlike	O
coronavirus	O
infections	O
of	O
pregnant	O
women	O
caused	O
by	O
SARS	O
and	O
MERS	O
,	O
in	O
these	O
38	O
pregnant	O
women	O
COVID	O
-	O
19	O
did	O
not	O
lead	O
to	O
maternal	B-PROC
deaths	B-PROC
.	O

Consequently	O
,	O
many	O
countries	O
have	O
implemented	O
flight	B-PROC
restrictions	O
to	O
China	O
.	O

A	O
significantly	O
decreased	O
growth	B-PROC
rate	O
and	O
increased	O
doubling	O
time	O
of	O
cases	O
was	O
observed	O
,	O
which	O
is	O
most	O
likely	O
due	O
to	O
Chinese	O
lockdown	O
measures	O
.	O

ABSTRACT	O
:	O
While	O
the	O
Western	O
world	O
now	O
takes	O
on	O
a	O
viral	O
pandemic	O
,	O
the	O
news	O
-	O
cycle	O
and	O
constant	O
reminders	O
to	O
wash	O
your	O
hands	O
and	O
avoid	O
touching	O
your	O
face	O
might	O
drive	O
anyone	O
to	O
reach	B-PROC
in	O
the	O
fridge	O
for	O
a	O
beer	O
.	O

It	O
is	O
believed	O
that	O
these	O
proteins	O
should	O
be	O
useful	O
for	O
further	O
structure	O
-	O
based	O
virtual	O
screening	O
and	O
related	O
computer	O
-	O
aided	O
drug	O
development	B-PROC
and	O
vaccine	O
design	O
.	O

By	O
using	O
a	O
least	O
-	O
square	O
-	O
based	O
method	O
with	O
Poisson	O
noise	O
,	O
we	O
estimate	O
that	O
the	O
basic	O
reproduction	B-PROC
number	O
for	O
the	O
epidemic	O
in	O
Japan	O
is	O
R	O
0	O
=	O
2	O
.	O

TITLE	O
:	O
A	O
Sequence	O
Homology	O
and	O
Bioinformatic	O
Approach	O
Can	O
Predict	O
Candidate	O
Targets	O
for	O
Immune	B-PROC
Responses	I-PROC
to	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

Due	O
to	O
the	O
extensive	O
spread	O
and	O
high	O
transmission	O
ability	O
of	O
the	O
COVID	O
-	O
19	O
,	O
there	O
is	O
a	O
possibility	O
of	O
virus	O
infections	O
among	O
malaria	O
cases	O
during	O
the	O
medical	O
care	O
-	O
seeking	O
behaviors	B-PROC
and	O
among	O
healthcare	O
professionals	O
during	O
clinical	O
diagnosis	O
and	O
treatment	O
,	O
sample	O
collection	O
and	O
testing	O
and	O
epidemiological	O
surveys	O
.	O

The	O
child	O
evolved	O
to	O
refractory	O
hypoxemia	O
and	O
hypercapnia	O
,	O
requiring	O
high	O
parameters	O
of	O
mechanical	O
pulmonary	B-PROC
ventilation	I-PROC
and	O
use	O
of	O
vasoactive	O
agents	O
.	O

PLP2	O
acts	O
as	O
a	O
protease	O
that	O
cleaves	O
the	O
viral	O
replicase	O
polyprotein	O
,	O
and	O
a	O
deubiquitinating	B-PROC
(	O
DUB	O
)	O
enzyme	O
which	O
removes	O
ubiquitin	B-PROC
moieties	O
from	O
ubiquitin	B-PROC
-	O
conjugated	O
proteins	O
.	O

A	O
history	O
of	O
atopic	O
disease	O
has	O
been	O
identified	O
as	O
one	O
of	O
risk	O
factors	O
for	O
the	O
development	B-PROC
of	O
OMA	O
.	O

Effectiveness	O
of	O
these	O
measures	O
was	O
assessed	O
by	O
calculating	O
the	O
7	O
-	O
day	O
moving	B-PROC
average	O
of	O
the	O
interval	O
from	O
symptom	O
onset	O
to	O
isolation	O
in	O
hospital	O
or	O
quarantine	O
,	O
which	O
indicated	O
significant	O
decreasing	O
trends	O
for	O
both	O
local	O
and	O
imported	O
COVID	O
-	O
19	O
cases	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
lung	O
support	O
is	O
increasingly	O
implemented	O
worldwide	O
in	O
clinical	O
practice	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
is	O
required	O
when	O
mechanical	O
ventilation	O
is	O
unable	O
to	O
establish	O
sufficient	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
or	O
if	O
the	O
respirator	O
settings	O
are	O
persistent	O
elevated	O
with	O
an	O
increased	O
risk	O
for	O
ventilator	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

The	O
presence	O
of	O
thrombocytopenia	O
,	O
anemia	O
,	O
metabolic	B-PROC
acidosis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multi	O
-	O
organ	O
dysfunction	O
involving	O
liver	O
,	O
kidneys	O
,	O
and	O
brain	O
created	O
an	O
image	O
of	O
advanced	O
severe	O
malaria	O
.	O

Laboratory	O
findings	O
revealed	O
normal	O
or	O
increased	O
whole	O
blood	O
counts	O
(	O
7	O
/	O
8	O
),	O
increased	O
C	O
-	O
reactive	O
protein	O
,	O
procalcitonin	O
and	O
lactate	O
dehydrogenase	O
(	O
6	O
/	O
8	O
),	O
and	O
abnormal	O
liver	B-PROC
function	I-PROC
(	O
4	O
/	O
8	O
).	O

TITLE	O
:	O
Social	O
Capital	O
and	O
Sleep	B-PROC
Quality	O
in	O
Individuals	O
Who	O
Self	O
-	O
Isolated	O
for	O
14	O
Days	O
During	O
the	O
Coronavirus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
Outbreak	O
in	O
January	O
2020	O
in	O
China	O
.	O

In	O
Patient	O
1	O
,	O
he	O
died	B-PROC
6	O
days	O
after	O
being	O
admitted	O
to	O
the	O
PICU	O
on	O
the	O
28th	O
day	O
from	O
onset	O
.	O

ABSTRACT	O
:	O
The	O
seasonal	O
cycle	O
of	O
respiratory	O
viral	B-PROC
diseases	I-PROC
has	O
been	O
widely	O
recognized	O
for	O
thousands	O
of	O
years	O
,	O
as	O
annual	O
epidemics	O
of	O
the	O
common	O
cold	B-PROC
and	O
influenza	O
disease	O
hit	O
the	O
human	O
population	O
like	O
clockwork	O
in	O
the	O
winter	O
season	O
in	O
temperate	O
regions	O
.	O

We	O
further	O
discuss	O
determinants	O
of	O
host	B-PROC
response	I-PROC
in	O
the	O
seasonality	O
of	O
respiratory	O
viruses	O
by	O
highlighting	O
recent	O
studies	O
in	O
the	O
field	O
.	O

ABSTRACT	O
:	O
In	O
2014	O
,	O
the	O
worst	O
outbreak	O
of	O
Ebola	O
virus	B-PROC
disease	I-PROC
(	O
EVD	O
)	O
emerged	O
in	O
sub	O
-	O
Saharan	O
Africa	O
(	O
SSA	O
)	O
causing	O
fear	O
and	O
panic	O
.	O

The	O
laboratory	O
results	O
showed	O
that	O
compared	O
to	O
the	O
normal	O
values	O
,	O
the	O
patients	O
'	O
lymphocytes	O
were	O
reduced	O
(	O
4	O
[	O
80	O
%]	O
patients	O
),	O
and	O
liver	B-PROC
function	I-PROC
ALT	O
and	O
AST	O
(	O
2	O
[	O
40	O
%]	O
patients	O
,	O
2	O
[	O
40	O
%]	O
patients	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
4	O
[	O
80	O
%]	O
patients	O
)	O
were	O
increased	O
when	O
admitted	O
to	O
hospital	O
.	O

All	O
patients	O
were	O
given	O
antiviral	O
therapy	O
(	O
including	O
oseltamivir	O
),	O
oxygen	O
inhalation	B-PROC
,	O
and	O
antibiotics	O
.	O

Both	O
Pangolin	O
-	O
CoV	O
and	O
RaTG13	O
lost	O
the	O
putative	O
furin	O
recognition	O
sequence	O
motif	O
at	O
S1	O
/	O
S2	O
cleavage	B-PROC
site	O
that	O
can	O
be	O
observed	O
in	O
the	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

This	O
Special	O
Feature	O
highlights	O
the	O
unique	O
circumstances	O
and	O
challenges	O
of	O
cancer	O
treatment	O
amidst	O
this	O
global	O
pandemic	O
,	O
and	O
the	O
importance	O
of	O
organizational	O
structure	O
,	O
preparation	O
,	O
agility	O
,	O
and	O
a	O
shared	O
vision	B-PROC
for	O
continuing	O
to	O
provide	O
cancer	O
treatment	O
to	O
patients	O
in	O
the	O
face	O
of	O
uncertainty	O
and	O
rapid	O
change	O
.	O

ABSTRACT	O
:	O
A	O
46	O
-	O
year	O
-	O
old	O
woman	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
2	O
-	O
day	O
fever	B-PROC
and	O
cough	O
at	O
seven	O
days	O
after	O
returning	O
from	O
Macau	O
.	O

Singapore	O
'	O
s	O
health	O
ministry	O
has	O
responded	O
with	O
enhanced	O
surveillance	O
of	O
COVID	O
-	O
19	O
for	O
all	O
suspected	O
pneumonia	O
cases	O
,	O
further	O
increasing	O
the	O
volume	O
of	O
testing	O
via	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
PCR	O
,	O
as	O
well	O
as	O
samples	O
necessitating	O
stringent	O
infectious	O
control	O
.	O

False	O
negative	O
results	O
can	O
be	O
achieved	O
and	O
failure	O
to	O
quarantine	O
the	O
infected	O
patient	O
would	O
be	O
a	O
major	O
setback	O
in	O
containing	O
the	O
viral	B-PROC
transmission	I-PROC
.	O

RESULTS	O
:	O
The	O
median	O
duration	O
of	O
IgM	O
and	O
IgA	O
antibody	B-PROC
detection	O
were	O
5	O
days	O
(	O
IQR	O
3	O
-	O
6	O
),	O
while	O
IgG	O
was	O
detected	O
on	O
14	O
days	O
(	O
IQR	O
10	O
-	O
18	O
)	O
after	O
symptom	O
onset	O
,	O
with	O
a	O
positive	O
rate	O
of	O
85	O
.	O
4	O
%,	O
92	O
.	O
7	O
%	O
and	O
77	O
.	O
9	O
%	O
respectively	O
.	O

Studies	O
were	O
identified	O
using	O
large	O
-	O
circulation	B-PROC
international	O
journals	O
found	O
in	O
two	O
electronic	O
databases	O
:	O
Scopus	O
and	O
Embase	O
.	O

We	O
found	O
that	O
macrophages	O
frequently	O
communicate	O
with	O
the	O
CoVs	O
targets	O
through	O
chemokine	O
and	O
phagocytosis	B-PROC
signaling	B-PROC
,	O
highlighting	O
the	O
importance	O
of	O
tissue	O
macrophages	O
in	O
immune	O
defense	O
and	O
immune	O
pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
outbreak	O
that	O
started	O
in	O
Wuhan	O
,	O
Hubei	O
province	O
,	O
China	O
in	O
December	O
2019	O
has	O
now	O
extended	O
across	O
the	O
globe	O
with	O
>	O
100	O
,	O
000	O
cases	O
and	O
3	O
,	O
000	O
deaths	B-PROC
reported	O
in	O
93	O
countries	O
as	O
of	O
7	O
March	O
2020	O
.	O

Four	O
common	O
coronaviruses	O
are	O
in	O
current	O
circulation	B-PROC
and	O
cause	O
millions	O
of	O
cases	O
worldwide	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
on	O
PTMs	O
of	O
CoV	O
proteins	O
,	O
with	O
an	O
emphasis	O
on	O
their	O
impact	O
on	O
viral	B-PROC
replication	I-PROC
and	O
pathogenesis	B-PROC
.	O

TITLE	O
:	O
STAT3	O
roles	O
in	O
viral	B-PROC
infection	I-PROC
:	O
antiviral	O
or	O
proviral	O
?	O

In	O
an	O
optimistic	O
scenario	O
of	O
the	O
basic	O
reproduction	B-PROC
number	O
(	O
R00	O
)	O
being	O
1	O
.	O
5	O
,	O
and	O
asymptomatic	O
infections	O
lacking	O
any	O
infectiousness	O
,	O
such	O
measures	O
would	O
reduce	O
the	O
cumulative	O
incidence	O
by	O
62	O
per	O
cent	O
.	O

The	O
review	O
showed	O
that	O
children	O
have	O
so	O
far	O
accounted	O
for	O
1	O
-	O
5	O
%	O
of	O
diagnosed	O
COVID	O
-	O
19	O
cases	O
,	O
they	O
often	O
have	O
milder	O
disease	O
than	O
adults	O
and	O
deaths	B-PROC
have	O
been	O
extremely	O
rare	O
.	O

We	O
review	O
research	O
suggesting	O
that	O
repeated	O
media	O
exposure	O
to	O
community	O
crisis	O
can	O
lead	O
to	O
increased	O
anxiety	O
,	O
heightened	O
stress	O
responses	O
that	O
can	O
lead	O
to	O
downstream	O
effects	O
on	O
health	O
,	O
and	O
misplaced	O
health	O
-	O
protective	O
and	O
help	O
-	O
seeking	O
behaviors	B-PROC
that	O
can	O
overburden	O
health	O
care	O
facilities	O
and	O
tax	O
available	O
resources	O
.	O

In	O
fact	O
,	O
viral	O
elimination	B-PROC
in	O
the	O
feces	O
may	O
be	O
more	O
prolonged	O
than	O
viral	O
identification	O
in	O
respiratory	O
tract	O
secretions	O
.	O

Approaching	O
to	O
treat	O
severe	O
respiratory	O
disease	O
in	O
infants	O
and	O
children	O
,	O
the	O
risks	O
related	O
to	O
the	O
development	B-PROC
of	O
atelectasis	O
starting	O
invasive	O
or	O
non	O
-	O
invasive	O
ventilation	O
support	O
and	O
the	O
risk	O
of	O
oxygen	O
toxicity	O
must	O
be	O
taken	O
into	O
serious	O
consideration	O
.	O

The	O
twin	O
girls	O
,	O
aged	O
1	O
year	O
and	O
2	O
months	O
,	O
were	O
admitted	O
on	O
January	O
29	O
,	O
2020	O
due	O
to	O
fever	B-PROC
for	O
one	O
day	O
and	O
cough	O
and	O
sneezing	O
for	O
two	O
days	O
respectively	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
disease	O
is	O
an	O
emerging	O
infection	O
caused	O
by	O
a	O
novel	O
coronavirus	O
that	O
is	O
moving	B-PROC
rapidly	O
.	O

Enhanced	O
TCB	O
incorporates	O
the	O
necessary	O
adaptations	B-PROC
.	O

A	O
second	O
adaptation	B-PROC
involves	O
enhancing	O
the	O
checkpoint	B-PROC
hand	O
disinfection	O
and	O
gowning	O
up	O
with	O
Personal	O
Protective	O
Equipment	O
deployed	O
in	O
traditional	O
TCB	O
.	O

While	O
many	O
countries	O
have	O
implemented	O
flight	B-PROC
restrictions	O
to	O
China	O
,	O
an	O
increasing	O
number	O
of	O
cases	O
with	O
or	O
without	O
travel	O
background	O
to	O
China	O
are	O
confirmed	O
daily	O
.	O

TITLE	O
:	O
Lianhuaqingwen	O
exerts	B-PROC
anti	O
-	O
viral	O
and	O
anti	O
-	O
inflammatory	O
activity	O
against	O
novel	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
).	O

The	O
median	O
radiograph	O
score	O
was	O
2	O
.	O
0	O
and	O
there	O
'	O
s	O
negative	O
correlation	O
between	O
the	O
score	O
and	O
oxygenation	B-PROC
index	O
(	O
ρ	O
=-	O
0	O
.	O
657	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
is	O
of	O
global	O
concern	O
and	O
might	O
have	O
emerged	O
from	O
RNA	O
recombination	B-PROC
among	O
existing	O
coronaviruses	O
.	O

Collectively	O
,	O
for	O
the	O
first	O
time	O
our	O
results	O
exhibit	O
the	O
emergence	O
of	O
human	O
2019	O
-	O
nCoV	O
is	O
closely	O
related	O
to	O
predecessor	O
SARS	O
-	O
CoV	O
and	O
provide	O
the	O
evidence	O
that	O
2019	O
-	O
nCoV	O
uses	O
various	O
novel	O
glycosylation	B-PROC
sites	O
as	O
SARS	O
-	O
CoV	O
and	O
may	O
have	O
a	O
potential	O
to	O
become	O
pandemic	O
owing	O
its	O
antigenic	O
discrepancy	O
.	O

Further	O
,	O
demonstration	O
of	O
novel	O
Cytotoxic	O
T	O
lymphocyte	O
epitopes	O
may	O
impart	O
opportunities	O
for	O
the	O
development	B-PROC
of	O
peptide	O
based	O
vaccine	O
for	O
the	O
prevention	O
of	O
2019	O
-	O
nCoV	O
.	O

Two	O
critical	O
cases	O
(	O
8	O
%)	O
were	O
given	O
invasive	O
mechanical	O
ventilation	O
,	O
corticosteroids	O
,	O
and	O
immunoglobulin	B-PROC
.	O

The	O
team	O
formulated	O
various	O
measures	O
,	O
such	O
as	O
reconfiguration	O
of	O
the	O
radiology	O
department	O
,	O
personal	O
protection	O
and	O
staff	O
training	O
,	O
standardized	O
imaging	O
examination	O
procedures	O
for	O
fever	B-PROC
patients	O
and	O
common	O
patients	O
,	O
and	O
so	O
on	O
.	O

RESULTS	O
:	O
From	O
January	O
21	O
to	O
March	O
9	O
,	O
3	O
,	O
083	O
people	O
underwent	O
fever	B-PROC
-	O
CT	O
examinations	O
.	O

Furthermore	O
,	O
he	O
observes	O
the	O
significant	O
abnormality	O
of	O
coagulation	B-PROC
function	O
and	O
proposes	O
that	O
the	O
early	O
intravenous	O
immunoglobulin	B-PROC
and	O
low	O
molecular	O
weight	O
heparin	O
anticoagulation	B-PROC
therapy	O
are	O
very	O
important	O
.	O

The	O
study	O
may	O
be	O
beneficial	O
for	O
the	O
surveillance	O
of	O
the	O
genome	B-PROC
mutation	I-PROC
of	O
coronavirus	O
in	O
the	O
field	O
.	O

Our	O
study	O
enrolled	O
109	O
COVID	O
-	O
19	O
patients	O
who	O
died	B-PROC
during	O
hospitalization	O
and	O
116	O
recovered	O
patients	O
.	O

The	O
patients	O
in	O
the	O
death	B-PROC
group	O
had	O
more	O
complications	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
89	O
.	O
9	O
%	O
vs	O
.	O
7	O
.	O
6	O
%,	O
χ	O
=	O
148	O
.	O
105	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
acute	O
cardiac	O
injury	O
(	O
59	O
.	O
6	O
%	O
vs	O
.	O
0	O
.	O
8	O
%,	O
χ	O
=	O
93	O
.	O
222	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
acute	O
kidney	O
injury	O
(	O
18	O
.	O
3	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
23	O
.	O
257	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
shock	O
(	O
11	O
.	O
9	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
14	O
.	O
618	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
)	O
(	O
6	O
.	O
4	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
7	O
.	O
655	O
,	O
P	O
=	O
0	O
.	O
006	O
).	O

Despite	O
intensive	O
care	O
,	O
the	O
patient	O
'	O
s	O
hypoxia	O
continued	O
to	O
worsen	O
and	O
he	O
died	B-PROC
on	O
day	O
7	O
.	O

TITLE	O
:	O
Unrevealing	O
sequence	O
and	O
structural	O
features	O
of	O
novel	O
coronavirus	O
using	O
ABSTRACT	O
:	O
Direct	O
-	O
acting	O
antivirals	O
are	O
effective	O
tools	O
to	O
control	O
viral	B-PROC
infections	I-PROC
.	O

Deferment	O
or	O
cancellation	O
of	O
such	O
mass	O
gatherings	O
may	O
exert	B-PROC
an	O
extraordinary	O
economic	O
loss	O
to	O
the	O
host	O
nation	O
.	O

In	O
these	O
uncertain	O
times	O
,	O
it	O
is	O
up	O
to	O
intergovernmental	O
organizations	O
to	O
be	O
the	O
voice	B-PROC
of	O
reason	O
.	O

Although	O
increased	O
dead	B-PROC
-	O
space	O
ventilation	O
(	O
V	O
Forty	O
-	O
two	O
consecutive	O
patients	O
with	O
early	O
moderate	O
and	O
severe	O
ARDS	O
were	O
included	O
.	O

The	O
experience	O
and	O
lessons	O
learned	B-PROC
should	O
be	O
a	O
valuable	O
asset	O
for	O
international	O
health	O
community	O
to	O
contain	O
the	O
ongoing	O
COVID	O
-	O
19	O
epidemic	O
around	O
the	O
world	O
.	O

We	O
summarized	O
the	O
effective	O
intervention	O
and	O
prevention	O
measures	O
in	O
the	O
fields	O
of	O
public	O
health	O
response	O
,	O
clinical	O
management	O
,	O
and	O
research	O
development	B-PROC
in	O
China	O
,	O
which	O
may	O
provide	O
vital	O
lessons	O
for	O
the	O
global	O
response	O
.	O

